﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Li, J
   He, JQ
   Zhang, X
   Li, JK
   Zhao, PQ
   Fei, P
AF Li, Jing
   He, Jiaqi
   Zhang, Xiang
   Li, Jiakai
   Zhao, Peiquan
   Fei, Ping
TI TSP1 ameliorates age-related macular degeneration by regulating the
   STAT3-iNOS signaling pathway
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Age-related macular degeneration; CNV; TSP1; Tubule formation
ID ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE PRODUCTION; OXIDATIVE STRESS;
   CD47; THROMBOSPONDIN-1; ALPHA; CELLS; ANGIOGENESIS; PATHOGENESIS;
   INFLAMMATION
AB Age-related macular degeneration is a progressive ocular disease that is the leading cause of vision loss among elderly. AMD usually is divided into two types: wet and dry AMD, which is linked with inflammation. Choroidal Neovascularization (CNV) formation or wet AMD is also associated with oxidative stress. Previously, TSP1 has been shown to have a significant alleviating effect on CNV in TSP1 knockout (TSP1(-/-)) mice. However, the mechanism by which TSP1 ameliorates CNV remains unclear. Here we report that TSP1 reduces nitric oxide production to prevent cells from forming tubes formation and reduced the levels of vascular endothelial growth factor (VEGF) and lipid peroxides (LPO) during oxidative stress. We measured RF/6A cell viability by CCK-8 assay and apoptosis by flow cytometry. RF/6A cell were transfected with TSP1 and STAT3 overexpression, and then the mRNA and protein levels of TSP1 and also the signal pathways were detected by qRT-PCR and Western blot analysis. Migration assays were performed using a transwell system. Co-Immunoprecipitation was used to analyze the binding relationship between CD47 and SHP-2. The results show that overexpression of TSP1 alleviated the damage of oxidative stress to RF/6A cells including increased cell activity and migration, decreased apoptosis and reduced migration compared to the control group. SHP-2 was activated by TSP1 through its receptor CD47 and STAT3 phosphorylation was reduced by activation of SHP-2, thereby blocking STAT3-iNOS pathway and reducing NO concentration in RF/6A cells ultimately protecting them from oxidative stress. Finally, the CNV mice model confirmed that TSP1 overexpression could protect the mice against CNV in vivo, modified the antioxidants levels and decreased the expression of TNF-alpha and IL-6 under laser irradiation. These results indicate a potential mechanism of TSP1 to slow down formation of CNV in wet AMD, which may bring hope for new treatment strategies.
C1 [Li, Jing; Zhang, Xiang; Li, Jiakai; Zhao, Peiquan; Fei, Ping] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Ophthalmol, Sch Med, Shanghai 200092, Peoples R China.
   [He, Jiaqi] Fudan Univ, Dept Gen Surg, Huadong Hosp, Shanghai 201104, Peoples R China.
C3 Shanghai Jiao Tong University; Fudan University
RP Zhao, PQ; Fei, P (通讯作者)，Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Ophthalmol, Sch Med, Shanghai 200092, Peoples R China.
EM zhaopeiquan@xinhuamed.com.cn; feiping@xinhuamed.com.cn
OI He, Jiaqi/0000-0003-2276-3298
FU National Natural Science Foundation of China [81770963, 81500725,
   81570829]; Shanghai Shen Kang Hospital Development Center Program
   [16CR4017A]; Program for Shanghai Outstanding Academic Leader
FX This study was supported by the National Natural Science Foundation of
   China (81770963, 81500725, 81570829); Shanghai Shen Kang Hospital
   Development Center Program (16CR4017A); Program for Shanghai Outstanding
   Academic Leader.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alblas J, 2005, MOL CELL BIOL, V25, P7181, DOI 10.1128/MCB.25.16.7181-7192.2005
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083
   Armstrong LC, 2003, MATRIX BIOL, V22, P63, DOI 10.1016/S0945-053X(03)00005-2
   Barclay AN, 2014, ANNU REV IMMUNOL, V32, P25, DOI 10.1146/annurev-immunol-032713-120142
   Borsotti P, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12319
   Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Camacho P, 2018, OPHTHALMIC RES, V59, P212, DOI 10.1159/000484349
   Cheng SB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170016
   Cherian DA, 2019, J PHARM BIOALLIED SC, V11, pS297, DOI [10.4103/JPBS.JPBS_17_19, 10.4103/jpbs.JPBS_17_19]
   Csanyi G, 2017, ANTIOXID REDOX SIGN, V26, P886, DOI 10.1089/ars.2016.6834
   de Vries HE, 2002, J IMMUNOL, V168, P5832, DOI 10.4049/jimmunol.168.11.5832
   DeCicco-Skinner KL, 2014, JOVE-J VIS EXP, DOI 10.3791/51312
   Farnoodian M, 2018, J OPHTHAL VIS RES, V13, P470, DOI 10.4103/jovr.jovr_67_18
   Fujioka Y, 1996, MOL CELL BIOL, V16, P6887
   Gao Q, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.155
   Hai Long, 2018, Cell Physiol Biochem, V51, P2925, DOI 10.1159/000496044
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   Heun Y, 2017, MOL THER, V25, P1616, DOI 10.1016/j.ymthe.2017.04.007
   Housset M, 2015, J OCUL PHARMACOL TH, V31, P406, DOI 10.1089/jop.2015.0023
   Isenberg JS, 2006, J BIOL CHEM, V281, P26069, DOI 10.1074/jbc.M605040200
   Jayachandran A, 2014, ONCOTARGET, V5, P5782, DOI 10.18632/oncotarget.2164
   Jiang J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046058
   Lawler PR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006627
   Liu ZJ, 2015, CIRC RES, V117, P129, DOI 10.1161/CIRCRESAHA.117.305262
   Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007
   Lu L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.174
   Maruko I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159439
   Murata Y, 2014, METHODS, V65, P254, DOI 10.1016/j.ymeth.2013.09.016
   Puram SV, 2012, J NEUROSCI, V32, P7806, DOI 10.1523/JNEUROSCI.3243-11.2012
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Sick E, 2012, BRIT J PHARMACOL, V167, P1415, DOI 10.1111/j.1476-5381.2012.02099.x
   Uhlmann S, 2001, MICROVASC RES, V62, P179, DOI 10.1006/mvre.2001.2334
   Vulovic TSS, 2016, INT J OPHTHALMOL-CHI, V9, P1138, DOI 10.18240/ijo.2016.08.09
   Wada M, 2001, CURR EYE RES, V23, P226, DOI 10.1076/ceyr.23.3.226.5467
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Xing CH, 2009, J NEUROSCI RES, V87, P2571, DOI 10.1002/jnr.22076
   Yang HD, 2019, HEPATOLOGY, V70, P1262, DOI 10.1002/hep.30657
   Zhan CD, 2004, J HYPERTENS, V22, P2025, DOI 10.1097/00004872-200410000-00027
   Zhang EE, 2004, P NATL ACAD SCI USA, V101, P16064, DOI 10.1073/pnas.0405041101
NR 42
TC 9
Z9 10
U1 2
U2 16
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD MAR 1
PY 2020
VL 388
IS 1
AR 111811
DI 10.1016/j.yexcr.2019.111811
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA KO0BS
UT WOS:000515211600005
PM 31899207
DA 2022-11-30
ER

PT J
AU Ferrone, PJ
   Anwar, F
   Naysan, J
   Chaudhary, K
   Fastenberg, D
   Graham, K
   Deramo, V
AF Ferrone, Philip J.
   Anwar, Farihah
   Naysan, Jonathan
   Chaudhary, Khurram
   Fastenberg, David
   Graham, Kenneth
   Deramo, Vincent
TI Early initial clinical experience with intravitreal aflibercept for wet
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; BEVACIZUMAB
AB Background Age-related macular degeneration (AMD) is a degenerative process that leads to severe vision loss. Wet AMD is defined by choroidal neovascularisation, leading to the accumulation of subretinal fluid (SRF), macular oedema (ME), and pigment epithelium detachments (PED). Purpose To evaluate the initial clinical experience of conversion from bevacizumab or ranibizumab to aflibercept in wet AMD patients.
   Methods Records of 250 consecutive wet AMD patients were retrospectively reviewed. Of 250 patients, 29 were naive (with no previous treatment), and 221 were previously treated with bevacizumab (1/3) or ranibizumab (2/3). On average, converted patients received 14 injections every 6 weeks on a treat-and-extend regimen with Avastin or Lucentis before being converted to aflibercept every 7 weeks on average (no loading dose) for three doses. For the purposes of this study, we concentrated on the patients converted to aflibercept since the number of naive patients was too small to draw any conclusion from. Snellen (as logMar) visual acuities, and optical coherence tomography (OCT) were compared predrug and postdrug conversion.
   Results Converted patients did not show a significant difference in visual acuity or average OCT thickness from preconversion values; however, small improvements in ME (p=0.0001), SRF (p=0.0001), and PED (p=0.008) grading were noted on average after conversion to aflibercept.
   Conclusions No significant difference in visual outcome or average OCT thickness was observed when switched from bevacizumab or ranibizumab q6 week to aflibercept 7-week dosing, on average. Mild anatomic improvements did occur in converted patients with regard to ME, SRF and PED improvement, on average, after conversion to aflibercept, and aflibercept was injected less frequently. No serious adverse reactions, including ocular infections or inflammation, as well as ocular and systemic effects were noted.
C1 [Ferrone, Philip J.; Fastenberg, David; Graham, Kenneth; Deramo, Vincent] Isl Vitreoretinal Consultants, Great Neck, NY USA.
   [Ferrone, Philip J.] Columbia Univ, New York, NY USA.
   [Anwar, Farihah; Naysan, Jonathan; Chaudhary, Khurram] North Shore Long Isl Jewish, Dept Ophthalmol, Great Neck, NY USA.
C3 Columbia University; Northwell Health
RP Ferrone, PJ (通讯作者)，Long Isl Vitreoretinal Consultants, 600 Northern Blvd,Suite 216, Great Neck, NY 11021 USA.
EM p_ferrone@hotmail.com
FU Regeneron; Genentech
FX This work was supported by Regeneron and Genentech.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fardad A, WET AGE RELATED MACU
   Gass MD., 1987, STERIOSCOPIC ATLAS M, P60
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Jager MD, 2008, NEW ENGL J MED, V358, P606
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart M, 2013, US OPHTHALMIC REV, V6, P58
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 14
TC 22
Z9 22
U1 0
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2014
VL 98
SU 1
BP 17
EP 21
DI 10.1136/bjophthalmol-2013-304474
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI4MX
UT WOS:000336840600005
PM 24795335
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Dimitrov, PN
   Robman, LD
   Varsamidis, M
   Aung, KZ
   Makeyeva, G
   Busija, L
   Vingrys, AJ
   Guymer, RH
AF Dimitrov, Peter N.
   Robman, Liubov D.
   Varsamidis, Mary
   Aung, Khin Zaw
   Makeyeva, Galina
   Busija, Lucy
   Vingrys, Algis J.
   Guymer, Robyn H.
TI Relationship between Clinical Macular Changes and Retinal Function in
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BRUCHS MEMBRANE CHANGE; DARK-ADAPTATION; BLOOD-FLOW; SEVERITY SCALE;
   HIGH-RISK; MACULOPATHY; FLICKER; EYES; ROD; CLASSIFICATION
AB PURPOSE. The aim of this study was to investigate the relationship between clinical macular changes and retinal function in age-related macular degeneration (AMD).
   METHODS. We recruited 357 participants with visual acuity of better than 20/60 in the study eye, including 64 individuals with normal fundi and 293 AMD participants classified into 12 subgroups based upon the International Classification and Grading System. Visual function in the study eye was assessed using two steady-state tests (achromatic 14 Hz flicker [F14Hz] and isoluminant blue color [BCT]) and two adaptation measurements (cone photo-stress recovery rate [CRR] and rod dark adaptation recovery rate [RRR]). The groups were compared on their average psychophysical measurements and ranked according to functional deficiency.
   RESULTS. Both adaptation parameters were significantly abnormal when only hard and/or intermediate drusen were evident (compared to controls, P < 0.023) and yielded considerably worse outcomes in cases with more advanced fundus changes (P < 0.001), but provided limited ability to discriminate between these cases (linear trend, CRR t = 0.68, P = 0.50 and RRR t = 1.76, P = 0.08). Steady-state measurements, however, declined gradually along the entire hierarchy of fundus changes (linear trend, F14Hz t = 10.16, P < 0.001 and BCT t = 11.19, P < 0.001) with F14Hz being able to detect significant functional change as early as in the intermediate drusen group, when compared to controls (P = 0.003).
   CONCLUSIONS. Steady state thresholds (F14Hz and BCT) and clinical signs showed significant concordance across the spectrum of early AMD fundus changes. This suggests that these tests may be an effective tool for monitoring progression of AMD to supplement clinical grading. (Invest Ophthalmol Vis Sci. 2012;53:5213-5220) DOI:10.1167/iovs.11-8958
C1 [Dimitrov, Peter N.; Robman, Liubov D.; Varsamidis, Mary; Aung, Khin Zaw; Makeyeva, Galina; Busija, Lucy; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Dimitrov, Peter N.; Vingrys, Algis J.] Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic 3002, Australia.
   [Busija, Lucy] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; Royal Melbourne
   Hospital; University of Melbourne
RP Dimitrov, PN (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM dimitrov@unimelb.edu.au
RI Busija, Lucy/Y-6064-2019
OI Busija, Lucy/0000-0001-7464-9089; Vingrys, Algis/0000-0001-5920-4604;
   Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) Project [350224];
   Australian Research Council Linkage Project [ARC-LP0211474]; NHMRC CCRE;
   NHMRC practitioner fellowship; RVEEH Wagstaff Fellowship; RVEEH Research
   Committee; Macular Vision Loss Support Society of Australia; Melbourne
   Centre for Epidemiology, Biostatistics, and Health Services Research;
   Centre for Research Excellence in Translational Neuroscience
FX Supported by grants from National Health and Medical Research Council
   (NHMRC) Project Grant 350224 (RHG, AJV), Australian Research Council
   Linkage Project (ARC-LP0211474), NHMRC CCRE, NHMRC practitioner
   fellowship (RHG), RVEEH Wagstaff Fellowship (LDR), RVEEH Research
   Committee and the Macular Vision Loss Support Society of Australia.
   Postdoctoral fellowship jointly funded by the Melbourne Centre for
   Epidemiology, Biostatistics, and Health Services Research and Centre for
   Research Excellence in Translational Neuroscience. CERA receives
   Operational Infrastructure Support from the Victorian Government.
CR Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Beirne RO, 2006, INVEST OPHTH VIS SCI, V47, P4624, DOI 10.1167/iovs.05-1227
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AC, 1991, EYE, V5, P1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Formaz F, 1997, CURR EYE RES, V16, P1252, DOI 10.1076/ceyr.16.12.1252.5021
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Garhofer G, 2004, VISION RES, V44, P833, DOI 10.1016/j.visres.2003.11.013
   GITTINGS NS, 1986, EXP GERONTOL, V21, P423, DOI 10.1016/0531-5565(86)90047-1
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Pianta MJ, 2000, J PHYSIOL-LONDON, V528, P591, DOI 10.1111/j.1469-7793.2000.00591.x
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Shakoor A, 2006, INVEST OPHTH VIS SCI, V47, P4962, DOI 10.1167/iovs.06-0291
   Stanga P. E., 2001, International Ophthalmology, V23, P191, DOI 10.1023/A:1014476430078
   SUNNESS JS, 1989, APPL OPTICS, V28, P1158, DOI 10.1364/AO.28.001158
   TAYLOR HR, 1989, AUST NZ J OPHTHALMOL, V17, P81, DOI 10.1111/j.1442-9071.1989.tb00492.x
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 44
TC 37
Z9 38
U1 0
U2 17
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2012
VL 53
IS 9
BP 5213
EP 5220
DI 10.1167/iovs.11-8958
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004QE
UT WOS:000308695400016
PM 22714893
OA Green Published
DA 2022-11-30
ER

PT J
AU Huynh, N
   Nicholson, BP
   Agron, E
   Clemons, TE
   Bressler, SB
   Rosenfeld, PJ
   Chew, EY
AF Nancy Huynh
   Nicholson, Benjamin P.
   Agron, Elvira
   Clemons, Traci E.
   Bressler, Susan B.
   Rosenfeld, Philip J.
   Chew, Emily Y.
CA Age-Related Eye Dis Study 2 Res Gr
TI Visual Acuity after Cataract Surgery in Patients with Age-Related
   Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID HIGH-DOSE SUPPLEMENTATION; BEAVER DAM EYE; CLINICAL-TRIAL;
   BETA-CAROTENE; UNITED-STATES; VISION LOSS; VITAMIN-C; DISEASE;
   RANIBIZUMAB; RISK
AB Objective: To evaluate visual acuity outcomes after cataract surgery in persons with varying degrees of severity of age-related macular degeneration (AMD).
   Design: Cohort study.
   Participants: A total of 1232 eyes of 793 participants who underwent cataract surgery during the Age-Related Eye Disease Study 2, a prospective, multicenter, randomized controlled trial of nutritional supplements for treatment of AMD.
   Methods: Preoperative and postoperative characteristics of participants who underwent cataract extraction during the 5-year trial were analyzed. Both clinical data and standardized red-reflex lens and fundus photographs were obtained at baseline and annually. Photographs were graded by a centralized reading center for cortical and posterior subcapsular lens opacities and for AMD severity. Cataract surgery was documented at annual study visits or by history during the 6-month telephone calls. Analyses were conducted using multivariate repeated-measures regression.
   Main Outcome Measures: Change in best-corrected visual acuity (BCVA) after cataract surgery compared with preoperative BCVA.
   Results: Adjusting for age at time of surgery, gender, interval between preoperative and postoperative visits, and type and severity of cataract, the mean changes in visual acuity were as follows: eyes with mild AMD (n = 30) gained 11.2 letters (95% confidence interval [CI], 6.9-15.5), eyes with moderate AMD (n = 346) gained 11.1 letters (95% CI, 9.1-13.2), eyes with severe AMD (n = 462) gained 8.7 letters (95% CI, 6.7-10.7), eyes with noncentral geographic atrophy (n = 70) gained 8.9 letters (95% CI, 5.8-12.1), and eyes with advanced AMD (central geographic atrophy, neovascular disease, or both; n = 324) gained 6.8 letters (95% CI, 4.9-8.8). The visual acuity gain across all AMD severity groups was statistically significant from preoperative values (P < 0.0001). Conclusions: Mean visual acuities improved significantly after cataract surgery across varying degrees of AMD severity. (C) 2014 by the American Academy of Ophthalmology.
C1 [Nancy Huynh; Nicholson, Benjamin P.; Agron, Elvira; Chew, Emily Y.] NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
   [Bressler, Susan B.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; Johns Hopkins University; Johns Hopkins
   Medicine; Bascom Palmer Eye Institute; University of Miami
RP Chew, EY (通讯作者)，NEI, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020
FU Research to Prevent Blindness, Inc., New York, New York; National Eye
   Institute, National Institutes of Health, Bethesda, Maryland
   [HHS-N-260-2005-00007-C]; Administrative Data Base (ADB)
   [N01-EY-5-0007]; EMMES Corporation; Jaeb Center; Allergan, Bausch Lomb;
   Bayer Healthcare; Genentech, Lumenis, Inc.; Notal Vision Ltd; Novartis;
   Regeneron; Thrombogenics; Sanofi-Aventis
FX The author(s) have made the following disclosure(s): Susan B. Bressler:
   Consultante-GlaxoSmithKline; Financial support-EMMES Corporation, the
   Jaeb Center, Allergan, Bausch & Lomb, Bayer Healthcare, Genentech,
   Lumenis, Inc., Notal Vision Ltd, Novartis, Regeneron, Thrombogenics,
   Sanofi-Aventis; Lecturere-Providers of continuing medical education
   materials; these grants are negotiated and administered by the School of
   Medicine, which receives the grants through the Office of Research
   Administration ( individual investigators who participate in such
   sponsored projects are not compensated directly by the sponsor but may
   receive salary or other support from the institution to support their
   effort on the projects). Philip J. Rosenfeld: Consultante-Oraya,
   Novartis, Chengdu Kanghong Biotech, Acucela, Thrombogenics, Canon;
   Financial support- Carl Zeiss Meditec, Alexion, Potentia,
   GlaxoSmithKline; Lecturer-Carl Zeiss Meditec, Allergan, Topcon.;
   Supported by Research to Prevent Blindness, Inc., New York, New York
   (Physician-Scientist grant to S. B. B.); the National Eye Institute,
   National Institutes of Health, Bethesda, Maryland (contract no.:
   HHS-N-260-2005-00007-C; Administrative Data Base (ADB) contract no.:
   N01-EY-5-0007). The sponsor and funding organization participated in the
   design and conduct of the study; collection, management, analysis, and
   interpretation of data; and the preparation, review, and approval of the
   manuscript.
CR Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Monestam E, 2012, J CATARACT REFR SURG, V38, P409, DOI 10.1016/j.jcrs.2011.09.041
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Tseng VL, 2012, JAMA-J AM MED ASSOC, V308, P493, DOI 10.1001/jama.2012.9014
NR 28
TC 27
Z9 27
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2014
VL 121
IS 6
BP 1229
EP 1236
DI 10.1016/j.ophtha.2013.12.035
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ0KG
UT WOS:000337339100015
OA Green Accepted
DA 2022-11-30
ER

PT J
AU McCarty, CA
   Fuchs, MJ
   Lamb, A
   Conway, P
AF McCarty, Catherine A.
   Fuchs, Michael J.
   Lamb, Allan
   Conway, Pat
TI How Do Patients Respond to Genetic Testing for Age-related Macular
   Degeneration?
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; RISK; PROGRESSION; PREDICTION; SMOKING;
   MOTIVATION; BLINDNESS; VARIANT; TRIALS; CANCER
AB SIGNIFICANCE The American Academy of Ophthalmology currently recommends against routine genetic testing for complex diseases such as age-related macular degeneration (AMD). The results of this study demonstrate that patients are very interested in predictive genetic testing for AMD, find the information useful, and make behavioral changes as a result of the information.
   PURPOSE The goal of this project was to conduct a pilot AMD genomic medicine study.
   METHODS Eligible patients were aged 50 to 65 years with no personal history of AMD. DNA samples were genotyped for five single-nucleotide polymorphisms (SNPs) in the CFH gene, one SNP in the ARMS-2 gene, one SNP in the C3 gene, and one SNP in the mitochondrial ND2 gene. A risk score was calculated utilizing a model based on odds ratios, lifetime risk of advanced AMD and known population prevalence of genotype, haplotype, and smoking risk. The study optometrist provided the patient's risk score and counseling for personal protective behaviors. Telephone interviews were conducted 1 to 3 months after the counseling visit.
   RESULTS One hundred one subjects (85%) participated in the genetic testing; 78 (77.2%) were female. Follow-up interviews were conducted with 94 participants (93.1%). More than half (n = 48) of the participants said that they were motivated to participate in the study because they had a family member with AMD or another eye or genetic disorder. Despite low risk levels, many participants reported making changes as a result of the genetic testing. Twenty-seven people reported making specific changes, including wearing sunglasses and brimmed hat and taking vitamin supplements. Another 16 people said that they were already doing the recommended activities, including wearing glasses, quitting smoking, and/or taking vitamins.
   CONCLUSIONS Interest in genetic testing for future risk of AMD was high in this population and resulted in support to continue current health behaviors or incentive to improve behaviors related to eye health.
C1 [McCarty, Catherine A.] Univ Minnesota, Sch Med, Duluth, MN 55812 USA.
   [McCarty, Catherine A.; Lamb, Allan; Conway, Pat] Essentia Hlth, Essentia Inst Rural Hlth, Duluth, MN 55805 USA.
   [Fuchs, Michael J.] Essentia Hlth, Dept Optometry, Duluth, MN USA.
C3 University of Minnesota System; University of Minnesota Duluth
RP McCarty, CA (通讯作者)，Univ Minnesota, Sch Med, Duluth, MN 55812 USA.; McCarty, CA (通讯作者)，Essentia Hlth, Essentia Inst Rural Hlth, Duluth, MN 55805 USA.
EM cathy@d.umn.edu
FU National Human Genome Research Institute [5U01HG006389]; NATIONAL HUMAN
   GENOME RESEARCH INSTITUTE [U01HG006389] Funding Source: NIH RePORTER
FX Grant no. 5U01HG006389 from the National Human Genome Research
   Institute.
CR Au CPY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0071-6
   Bailey JNC, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030031
   Brown Gary C, 2015, Int J Retina Vitreous, V1, P19, DOI 10.1186/s40942-015-0016-5
   Buitendijk GHS, 2014, INVEST OPHTH VIS SCI, V55, P6167, DOI 10.1167/iovs.14-15142
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chao S, 2008, ALZ DIS ASSOC DIS, V22, P94, DOI 10.1097/WAD.0b013e31815a9dcc
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gollust SE, 2012, PUBLIC HEALTH GENOM, V15, P22, DOI 10.1159/000327296
   Graves KD, 2013, GENOMICS, V102, P123, DOI 10.1016/j.ygeno.2013.04.002
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa S, 2011, EYE, V25, P1170, DOI 10.1038/eye.2011.143
   Hollands GJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1102
   Janz NK, 2007, OPHTHALMOLOGY, V114, P2213, DOI 10.1016/j.ophtha.2007.02.014
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   McCarty CA, 1996, AUST NZ J OPHTHALMOL, V24, P3, DOI 10.1111/j.1442-9071.1996.tb01544.x
   Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42
   Rennie CA, 2012, EYE, V26, P109, DOI 10.1038/eye.2011.256
   Sanderson SC, 2009, CANCER EPIDEM BIOMAR, V18, P1953, DOI 10.1158/1055-9965.EPI-08-0620
   Sanfilippo PG, 2015, CLIN EXP OPHTHALMOL, V43, P578, DOI 10.1111/ceo.12508
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sood A, 2009, MAYO CLIN PROC, V84, P243, DOI 10.1016/S0025-6196(11)61141-5
   Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI 10.1111/nhs.12048
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
NR 31
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAR
PY 2018
VL 95
IS 3
BP 166
EP 170
DI 10.1097/OPX.0000000000001188
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY1EH
UT WOS:000426554100002
PM 29424826
OA Green Published
DA 2022-11-30
ER

PT J
AU Heo, TY
   Kim, KM
   Min, HK
   Gu, SM
   Kim, JH
   Yun, J
   Min, JK
AF Heo, Tae-Young
   Kim, Kyoung Min
   Min, Hyun Kyu
   Gu, Sun Mi
   Kim, Jae Hyun
   Yun, Jaesuk
   Min, Jung Kee
TI Development of a Deep-Learning-Based Artificial Intelligence Tool for
   Differential Diagnosis between Dry and Neovascular Age-Related Macular
   Degeneration
SO DIAGNOSTICS
LA English
DT Article
DE age-related macular degeneration; class activation map; convolutional
   neural network; cross-validation; retina
AB The use of deep-learning-based artificial intelligence (AI) is emerging in ophthalmology, with AI-mediated differential diagnosis of neovascular age-related macular degeneration (AMD) and dry AMD a promising methodology for precise treatment strategies and prognosis. Here, we developed deep learning algorithms and predicted diseases using 399 images of fundus. Based on feature extraction and classification with fully connected layers, we applied the Visual Geometry Group with 16 layers (VGG16) model of convolutional neural networks to classify new images. Image-data augmentation in our model was performed using Keras ImageDataGenerator, and the leave-one-out procedure was used for model cross-validation. The prediction and validation results obtained using the AI AMD diagnosis model showed relevant performance and suitability as well as better diagnostic accuracy than manual review by first-year residents. These results suggest the efficacy of this tool for early differential diagnosis of AMD in situations involving shortages of ophthalmology specialists and other medical devices.
C1 [Heo, Tae-Young; Kim, Kyoung Min] Chungbuk Natl Univ, Dept Informat & Stat, Chungdae Ro 1, Cheongju 28644, Chungbuk, South Korea.
   [Min, Hyun Kyu; Gu, Sun Mi; Yun, Jaesuk; Min, Jung Kee] Chungbuk Natl Univ, Coll Pharm, 194-31 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea.
   [Min, Hyun Kyu; Gu, Sun Mi; Yun, Jaesuk; Min, Jung Kee] Chungbuk Natl Univ, Med Res Ctr, 194-31 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea.
   [Kim, Jae Hyun; Min, Jung Kee] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Ophthalmol, 877 Bangeojinsunhwando Ro, Ulsan 44033, South Korea.
C3 Chungbuk National University; Chungbuk National University; Chungbuk
   National University; University of Ulsan; Ulsan University Hospital
RP Yun, J; Min, JK (通讯作者)，Chungbuk Natl Univ, Coll Pharm, 194-31 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea.; Yun, J; Min, JK (通讯作者)，Chungbuk Natl Univ, Med Res Ctr, 194-31 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea.; Min, JK (通讯作者)，Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Ophthalmol, 877 Bangeojinsunhwando Ro, Ulsan 44033, South Korea.
EM theo@cbnu.ac.kr; ganaam12002@naver.com; gusrb4785@naver.com;
   g09010327@nate.com; rururara2002@naver.com; jyun@chungbuk.ac.kr;
   jkmin@uuh.ulsan.kr
OI heo, tae-young/0000-0002-0505-5559; Min, Jung Kee/0000-0002-8006-8560
FU National Research Foundation of Korea (NRF) - Korean government (MSIT)
   [2017R1C1B5017929]; Chungbuk National University
FX L This work was supported by a National Research Foundation of Korea
   (NRF) grant, funded by the Korean government (MSIT) (No.
   2017R1C1B5017929), and a research grant from the Chungbuk National
   University in 2019 and 2020.
CR Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Baltruschat IM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42294-8
   Bernardes R, 2011, OPHTHALMOLOGICA, V226, P161, DOI 10.1159/000329597
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Coudray N, 2018, NAT MED, V24, P1559, DOI 10.1038/s41591-018-0177-5
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Hall Anthony, 2011, Community Eye Health, V24, P5
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Levine AB, 2019, TRENDS CANCER, V5, P157, DOI 10.1016/j.trecan.2019.02.002
   Ly A, 2018, CLIN EXP OPTOM, V101, P172, DOI 10.1111/cxo.12624
   Mathews SM, 2018, COMPUT BIOL MED, V99, P53, DOI 10.1016/j.compbiomed.2018.05.013
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Tan JH, 2018, FUTURE GENER COMP SY, V87, P127, DOI 10.1016/j.future.2018.05.001
   Tremolada G, 2012, EXP DIABETES RES, DOI 10.1155/2012/728325
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 20
TC 13
Z9 13
U1 0
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD MAY
PY 2020
VL 10
IS 5
AR 261
DI 10.3390/diagnostics10050261
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LZ1XJ
UT WOS:000541022500005
PM 32354098
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kumar, JB
   Wai, KM
   Ehlers, JP
   Singh, RP
   Rachitskaya, AV
AF Kumar, Jaya B.
   Wai, Karen M.
   Ehlers, Justin P.
   Singh, Rishi P.
   Rachitskaya, Aleksandra V.
TI Subfoveal choroidal thickness as a prognostic factor in exudative
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE choroid; treatment Medical; macula
ID OPTICAL COHERENCE TOMOGRAPHY; RANIBIZUMAB INJECTIONS; VISUAL-ACUITY;
   EYES
AB Aims To investigate the relationship between subfoveal choroidal thickness (SFCT), visual acuity (VA), optical coherence tomography (OCT) features and total anti-vascular endothelial growth factor (VEGF) treatments to determine whether SFCT serves as a prognostic factor in age-related macular degeneration (AMD). Methods This is a retrospective case series of 62 consecutive treatment-naive patients with exudative AMD followed for 1 year and treated with treat-and-extend or pro re nata anti-VEGF protocols. SFCT was measured at three locations using Cirrus HD-OCT (the foveal centre and 500 um nasal and temporal to the fovea) at presentation, 3, 6 and 12 months. Demographic characteristics, OCT imaging biomarkers and VA were recorded. Results Mean SFCT at baseline was 187 mu m (range: 70-361 mu m). There was a trend of decreasing SFCT at 1 year (173 mu m) compared with 3 months (175 mu m) and baseline (188 mu m) (p=0.2). There was no correlation between baseline SFCT and presence of subretinal fluid (p=0.2), intraretinal fluid (p=0.6) or subretinal hyper-reflective material (p=0.4) at baseline. The mean number of injections at 1 year was 6.6 (range: 2-12). Increased SFCT at baseline showed statistically significant correlation with a higher number of intravitreal injections at 1 year (p=0.004). Eyes with SFCT>1 SD above the mean required 50% more injections compared with others. There was no association between SFCT on presentation with baseline and 1 year VA (p=0.7 and p=0.2). Conclusions SFCT in naive patients with exudative AMD may be an important prognostic tool in determining treatment burden. Patients with thicker subfoveal choroid may require increased intravitreal injections.
C1 [Kumar, Jaya B.; Ehlers, Justin P.; Singh, Rishi P.; Rachitskaya, Aleksandra V.] Cleveland Clin, Dept Ophthalmol, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Wai, Karen M.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
C3 Cleveland Clinic Foundation; Case Western Reserve University
RP Rachitskaya, AV (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM rachita@ccf.org
OI Kumar, Jaya/0000-0002-7312-9134
FU Research to Prevent Blindness, Inc
FX This study was supported in part by an Unrestricted Grant from The
   Research to Prevent Blindness, Inc, awarded to the Cole Eye Institute.
CR Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Goldenberg D, 2012, OPHTHAL SURG LAS IM, V43, P296, DOI 10.3928/15428877-20120426-02
   Hernandez-Martinez P, 2017, EUR J OPHTHALMOL, V27, P196, DOI 10.5301/ejo.5000860
   Ho J, 2011, OPHTHALMOLOGY, V118, P2001, DOI 10.1016/j.ophtha.2011.02.049
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Karapetyan A, 2016, RETINA-J RET VIT DIS, V36, P82, DOI 10.1097/IAE.0000000000000654
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kim YK, 2016, RETINA-J RET VIT DIS, V36, P1516, DOI 10.1097/IAE.0000000000000952
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0B013E31822F5678, 10.1097/IAE.0b013e31822f5678]
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Unlu C, 2017, INT OPHTHALMOL, V37, P147, DOI 10.1007/s10792-016-0242-3
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   You JY, 2012, CURR EYE RES, V37, P438, DOI 10.3109/02713683.2011.647227
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
NR 28
TC 10
Z9 10
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2019
VL 103
IS 7
BP 918
EP 921
DI 10.1136/bjophthalmol-2018-312625
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IF4HJ
UT WOS:000473042100009
PM 30150279
DA 2022-11-30
ER

PT J
AU Dolz-Marco, R
   Balaratnasingam, C
   Messinger, JD
   Li, ML
   Ferrara, D
   Freund, KB
   Curcio, CA
AF Dolz-Marco, Rosa
   Balaratnasingam, Chandrakumar
   Messinger, Jeffrey D.
   Li, Miaoling
   Ferrara, Daniela
   Freund, K. Bailey
   Curcio, Christine A.
TI The Border of Macular Atrophy in Age-Related Macular Degeneration: A
   Clinicopathologic Correlation
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC
   ATROPHY; END-POINTS; FUNDUS AUTOFLUORESCENCE; GRADING SYSTEM; EYE
   DISEASE; PROGRESSION; NEOVASCULARIZATION; EVOLUTION
AB PURPOSE: To correlate in vivo imaging to histology in an eye with macular atrophy owing to age-related macular degeneration (AMD; complete retinal pigment epithelium [RPE] and outer retinal atrophy [cRORA]) to evaluate the utility of new optical coherence tomography (OCT) suggested by previous histology.
   DESIGN: Case study with clinicopathologic correlation.
   METHODS: In vivo eye-tracked cross-sectional OCT scans at 13 and 8 months before death were compared to postmortem histopathology. On OCT, the atrophy border was identified as either the descent of the external limiting membrane (ELM) toward the Bruch membrane (BrM) (representing gliosis) or the presence of choroidal hypertransmission (representing lack of shadowing by RPE). Thicknesses of RPE, basal laminar deposit (BLamD), and BrM were measured at 500 and 100 mu m on the nonatrophic and atrophic sides of these borders, on in vivo eye-tracked OCT and histology matched to the same location.
   RESULTS: In all OCT scans, the ELM descent was visible. The RPE-BLamD band significantly thickened toward it (P<.005), over time (P=.015 and P=.043, at 500 and 100 mu m, respectively). On OCT, the ELM descent delineated a smaller atrophic area than did hypertransmission. RPE-BLamD thicknesses manually measured on OCT overestimated histologic thicknesses. BrM visibility varied with RPE status.
   CONCLUSION: Visible on OCT, the ELM descent is a histopathologic atrophy border supporting new terminology of cRORA, whereas hypertransmission reveals RPE degeneration. RPE-BLamD thickening across the macula, toward the atrophy and over time is confirmed. The presence of gliosis and thick RPE-BLamD suggests that macular atrophy is a late stage in disease progression, encouraging anatomic endpoints at earlier AMD stages than atrophy enlargement. ((C) 2018 Elsevier Inc. All rights reserved.)
C1 [Dolz-Marco, Rosa; Balaratnasingam, Chandrakumar; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Dolz-Marco, Rosa; Balaratnasingam, Chandrakumar; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Dolz-Marco, Rosa] Oftalvist Clin, Unit Macula, Valencia, Spain.
   [Balaratnasingam, Chandrakumar] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA, Australia.
   [Balaratnasingam, Chandrakumar] Sir Charles Gairdner Hosp, Perth, WA, Australia.
   [Messinger, Jeffrey D.; Li, Miaoling; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Li, Miaoling] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China.
   [Ferrara, Daniela] Genentech Inc, San Francisco, CA USA.
   [Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Lions Eye Institute; University of Western Australia;
   University of Western Australia; University of Alabama System;
   University of Alabama Birmingham; Sun Yat Sen University; Roche Holding;
   Genentech; Columbia University; New York University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, EyeSight Fdn Alabama Vis Res Labs, Sch Med, 1670 Univ Blvd Room 360, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; Dolz-Marco,
   Rosa/0000-0002-2963-2541; Curcio, Christine/0000-0001-9769-1538
FU HOFFMAN LAROCHE; MACULA FOUNDATION INC, NEW YORK, New York, USA;
   LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and
   Throat Hospital, New York, New York, USA; Department of Ophthalmology at
   UAB from EyeSight Foundation of Alabama; Research to Prevent Blindness;
   Heidelberg Engineering
FX THIS WORK WAS SUPPORTED BY HOFFMAN LAROCHE AND THE MACULA FOUNDATION
   INC, NEW YORK, New York, USA (authors R.D.M., K.B.F., C.A.C., M.L.,
   J.D.M.) and the LuEsther T. Mertz Retinal Research Center, Manhattan
   Eye, Ear, and Throat Hospital, New York, New York, USA (authors R.D.M.,
   K.B.F.), and support from the Department of Ophthalmology at UAB from
   EyeSight Foundation of Alabama, Research to Prevent Blindness, and
   Heidelberg Engineering (authors C.A.C., M.L., J.D.M.). The funding
   organizations had no role in the design or execution of this research.
CR [Anonymous], 2011, CTGTAC M 52
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brader HS, 2011, INVEST OPHTH VIS SCI, V52, P9218, DOI 10.1167/iovs.11-7493
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Curcio C, 2017, INVEST OPHTH VIS SCI, V58
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Dolz-Marco R, 2016, INVEST OPHTH VIS SCI, V57, P6440, DOI 10.1167/iovs.16-20265
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, pBIO61
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Omri S, 2010, CLIN OPHTHALMOL, V4, P183
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P1735, DOI 10.1097/IAE.0000000000000553
   Ross DH, 2015, INVEST OPHTH VIS SCI, V56, P4166, DOI 10.1167/iovs.14-15256
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Wagner A, 2018, OPHTHALMOLOGE, DOI [10.1007/s00347-017-0638-0, DOI 10.1007/S00347-017-0638-0.2018.01.08]
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
NR 51
TC 22
Z9 22
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2018
VL 193
BP 166
EP 177
DI 10.1016/j.ajo.2018.06.020
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GS9SU
UT WOS:000444068100021
PM 29981740
DA 2022-11-30
ER

PT J
AU VanderBeek, BL
   Zacks, DN
   Talwar, N
   Nan, B
   Stein, JD
AF VanderBeek, Brian L.
   Zacks, David N.
   Talwar, Nidhi
   Nan, Bin
   Stein, Joshua D.
TI ROLE OF STATINS IN THE DEVELOPMENT AND PROGRESSION OF AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; claims database; statins; serum LDL;
   serum HDL; serum trigylcerides
ID CHOLESTEROL-LOWERING MEDICATIONS; RISK-FACTORS; 5-YEAR INCIDENCE;
   CARDIOVASCULAR-DISEASE; EYE DISEASE; MACULOPATHY; PREVENTION; HEALTH;
   RANIBIZUMAB; ASSOCIATION
AB Purpose: To determine if statins are associated with the development or progression of age-related macular degeneration (AMD).
   Methods: A large, national insurance claims database was reviewed to identify individuals aged 60 years or older who were enrolled for >= 2 years and had >= 1 visits to an eye provider. Prescription claims for statins within a 24-month look-back period and outpatient lipid laboratory values were also reviewed. Cox regression analysis was used to determine whether statin use was associated with the development of nonexudative or exudative AMD or progressing from nonexudative to exudative AMD.
   Results: Of the 107,007 beneficiaries eligible for the nonexudative AMD analysis, 4,647 incident cases of nonexudative AMD occurred. Seven hundred and ninety-two incident cases of exudative AMD were found among the 113,111 beneficiaries eligible for the exudative AMD analysis. Of the 10,743 beneficiaries with known nonexudative AMD eligible for the progression model, 404 progressed to exudative AMD during their time in the plan. After multivariable analysis, statin use was not associated with the development of nonexudative AMD (P > 0.05). Statin use of >12 months was associated with an increased hazard for developing exudative AMD (P < 0.005). Among those taking statins, only enrollees with the highest lipid levels had an increased hazard of developing exudative AMD (P, 0.05).
   Conclusion: In those with elevated lipid levels, >1 year of statin use was associated with an increased hazard for exudative AMD. Lipid status influences the relationship between statins and the risk of AMD. Because of a number of limitations in study design, these observations warrant further study and should not be the rationale for any changes in the use of statins to treat dyslipidemias. RETINA 33:414-422, 2013
C1 [VanderBeek, Brian L.; Zacks, David N.; Talwar, Nidhi; Stein, Joshua D.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   [Nan, Bin] Univ Michigan, Dept Biostat, Sch Publ Hlth, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP VanderBeek, BL (通讯作者)，Univ Michigan, Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM blbeek@med.umich.edu
RI Zacks, David/I-4394-2013
OI Zacks, David/0000-0001-8592-5165; Stein, Joshua/0000-0003-2937-6987;
   VanderBeek, Brian L./0000-0003-4953-118X
FU National Eye Institute [EY019511]; Blue Cross Blue Shield of Michigan
   Foundation; University of Michigan Anthony Adamis Research Award;
   NATIONAL EYE INSTITUTE [K12EY015398, K23EY019511] Funding Source: NIH
   RePORTER
FX Supported by National Eye Institute K23 Mentored Clinician Scientist
   Award (JDS; EY019511), Blue Cross Blue Shield of Michigan Foundation
   (JDS), University of Michigan Anthony Adamis Research Award (JDS).
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2010, PRESCRIPTION DRUG SA
   [Anonymous], 1998, N ENGL J MED, V339, P1349
   [Anonymous], 2006, PHYS INT CLASSIFICAT
   [Anonymous], 2006, PHYS INT CLASSIFICAT, V2
   Beebe M, 2006, CURRENT PROCEDURAL T
   Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Butt AL, 2011, OPHTHALMOLOGY
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Little RJ., 2019, STAT ANAL MISSING DA, VVolume 793
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Taylor HR, 2001, BRIT J OPHTHALMOL, V85, P261, DOI 10.1136/bjo.85.3.261
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
NR 45
TC 33
Z9 35
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2013
VL 33
IS 2
BP 414
EP 422
DI 10.1097/IAE.0b013e318276e0cf
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 081TI
UT WOS:000314344800022
PM 23314233
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Dey, N
   Hong, S
   Ach, T
   Koutalos, Y
   Curcio, CA
   Smith, RT
   Gerig, G
AF Dey, Neel
   Hong, Sungmin
   Ach, Thomas
   Koutalos, Yiannis
   Curcio, Christine A.
   Smith, R. Theodore
   Gerig, Guido
TI Tensor decomposition of hyperspectral images to study autofluorescence
   in age-related macular degeneration
SO MEDICAL IMAGE ANALYSIS
LA English
DT Article
DE Non-negative tensor decompositions; Unsupervised machine learning;
   Hyperspectral fluorescence microscopy imaging; Functional data analysis;
   Age-related macular degeneration
ID INDEPENDENT COMPONENT ANALYSIS; RETINAL-PIGMENT EPITHELIUM; BLIND SOURCE
   SEPARATION; MATRIX FACTORIZATION; FUNCTIONAL DATA; LEAST-SQUARES;
   PARAFAC; SPECTROSCOPY; LIPOFUSCIN; RECOVERY
AB Autofluorescence is the emission of light by naturally occurring tissue components on the absorption of incident light. Autofluorescence within the eye is associated with several disorders, such as Age-related Macular Degeneration (AMD) which is a leading cause of central vision loss. Its pathogenesis is incompletely understood, but endogenous fluorophores in retinal tissue might play a role. Hyperspectral fluorescence microscopy of ex-vivo retinal tissue can be used to determine the fluorescence emission spectra of these fluorophores. Comparisons of spectra in healthy and diseased tissues can provide important insights into the pathogenesis of AMD. However, the spectrum from each pixel of the hyperspectral image is a superposition of spectra from multiple overlapping tissue components. As spectra cannot be negative, there is a need for a non-negative blind source separation model to isolate individual spectra. We propose a tensor formulation by leveraging multiple excitation wavelengths to excite the tissue sample. Arranging images from different excitation wavelengths as a tensor, a non-negative tensor decomposition can be performed to recover a provably unique low-rank model with factors representing emission and excitation spectra of these materials and corresponding abundance maps of autofluorescent substances in the tissue sample. We iteratively impute missing values common in fluorescence measurements using Expectation-Maximization and use L-2 regularization to reduce ill-posedness. Further, we present a framework for performing group hypothesis testing on hyperspectral images, finding significant differences in spectra between AMD and control groups in the peripheral macula. In the absence of ground truth, i.e. molecular identification of fluorophores, we provide a rigorous validation of chosen methods on both synthetic and real images where fluorescence spectra are known. These methodologies can be applied to the study of other pathologies presenting autofluorescence that can be captured by hyperspectral imaging. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Dey, Neel; Hong, Sungmin; Gerig, Guido] NYU, Dept Comp Sci & Engn, Tandon Sch Engn, New York, NY 10003 USA.
   [Ach, Thomas] Univ Hosp Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   [Koutalos, Yiannis] Med Univ South Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Sch Med, Birmingham, AL USA.
   [Smith, R. Theodore] Icahn Sch Med, Dept Ophthalmol, Mt Sinai, NY USA.
C3 New York University; New York University Tandon School of Engineering;
   University of Wurzburg; Medical University of South Carolina; University
   of Alabama System; University of Alabama Birmingham; Icahn School of
   Medicine at Mount Sinai
RP Dey, N (通讯作者)，NYU, Dept Comp Sci & Engn, Tandon Sch Engn, New York, NY 10003 USA.
EM neel.dey@nyu.edu
RI Ach, Thomas/AAE-7870-2021
OI Ach, Thomas/0000-0001-6583-8283; Gerig, Guido/0000-0002-9547-6233; Dey,
   Neel/0000-0003-1427-6406; smith, theodore/0000-0002-1693-943X
FU NIH [R01EY015520, R01 EY027948]; Macula Foundation; EyeSight Foundation
   of Alabama; International Retinal Research Foundation; Research to
   Prevent Blindness; Dr. Werner Jackstadt Foundation; IZKF Wiirzburg;
   NATIONAL EYE INSTITUTE [R01EY027948, R01EY015520] Funding Source: NIH
   RePORTER
FX For this study, the authors acknowledge support from NIH R01 EY027948.
   Christine A. Curcio (CAC) and Roland Theodore Smith are additionally
   funded by NIH R01EY015520. CAC also acknowledges support from the Macula
   Foundation, the EyeSight Foundation of Alabama, the International
   Retinal Research Foundation, and Research to Prevent Blindness. Thomas
   Ach acknowledges support from the Dr. Werner Jackstadt Foundation and
   IZKF Wiirzburg. We thank Martin Hammer and Zsolt Ablonczy for their
   helpful comments and advice while conducting this study. We thank
   Yuehong Tong and Jeffrey D. Messinger for preparing and capturing some
   of the images used in this study. We thank Kejun Huang for making
   available the original implementation of AOADMM and our reviewers for
   greatly improving the quality of our manuscript. Finally, we gratefully
   acknowledge NSF MRI-1229185 for HPC services and infrastructure and NIH
   R01 EY006109 for tissue collection.
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Anandkumar A, 2014, J MACH LEARN RES, V15, P2773
   Andersson CA, 2000, CHEMOMETR INTELL LAB, V52, P1, DOI 10.1016/S0169-7439(00)00071-X
   Bader B. W., 2015, MATLAB TENSOR TOOLBO
   Ben Ami T, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.3.5
   Bharath HN, 2017, IEEE J BIOMED HEALTH, V21, P1124, DOI 10.1109/JBHI.2016.2583539
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Bioucas-Dias JM, 2012, IEEE J-STARS, V5, P354, DOI 10.1109/JSTARS.2012.2194696
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Boyd S, 2011, TRENDS MACH LEARN, V3, P1, DOI DOI 10.1561/2200000016
   Bro R, 2003, J CHEMOMETR, V17, P274, DOI 10.1002/cem.801
   CARROLL JD, 1970, PSYCHOMETRIKA, V35, P283, DOI 10.1007/BF02310791
   Cichocki A, 2015, IEEE SIGNAL PROC MAG, V32, P145, DOI 10.1109/MSP.2013.2297439
   COMON P, 1994, SIGNAL PROCESS, V36, P287, DOI 10.1016/0165-1684(94)90029-9
   Cong FY, 2015, J NEUROSCI METH, V248, P59, DOI 10.1016/j.jneumeth.2015.03.018
   Crouch RK, 2015, PROG MOL BIOL TRANSL, V134, P449, DOI 10.1016/bs.pmbts.2015.06.005
   Curcio C.A, 2013, RETINA PHILADELPHIA, V33
   Dobigeon N, 2016, DATA HANDL SCI TECHN, V30, P185, DOI 10.1016/B978-0-444-63638-6.00006-1
   Duchi J, 2008, P 25 INT C MACH LEAR, P272
   Galeano J, 2015, BIOMED OPT EXPRESS, V6, P1589, DOI 10.1364/BOE.6.001589
   Gao L, 2015, J BIOPHOTONICS, V8, P441, DOI 10.1002/jbio.201400051
   Geng XJ, 2012, NEUROIMAGE, V61, P542, DOI 10.1016/j.neuroimage.2012.03.057
   Gobinet Cyril, 2004, 2004 12th European Signal Processing Conference (EUSIPCO), P1095
   Hall P, 2006, ANN STAT, V34, P1493, DOI 10.1214/009053606000000272
   Harshman R.A., 1970, FOUNDATIONS PARAFAC
   HASTAD J, 1990, J ALGORITHMS, V11, P644, DOI 10.1016/0196-6774(90)90014-6
   Heylen R, 2014, IEEE J-STARS, V7, P1844, DOI 10.1109/JSTARS.2014.2320576
   Hillar CJ, 2013, J ACM, V60, DOI 10.1145/2512329
   Hitchcock F.L., 1927, STUD APPL MATH, V6, P164, DOI [10.1002/sapm192761164, DOI 10.1002/SAPM192761164]
   Hotelling H, 1933, J EDUC PSYCHOL, V24, P417, DOI 10.1037/h0071325
   Huang KJ, 2016, IEEE T SIGNAL PROCES, V64, P5052, DOI 10.1109/TSP.2016.2576427
   Ikoma H, 2014, OPT EXPRESS, V22, P19469, DOI 10.1364/OE.22.019469
   JOHRI A, 2014, INVEST OPHTH VIS SCI, V55
   KASHA M, 1950, DISCUSS FARADAY SOC, P14, DOI 10.1039/df9500900014
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Keshava N, 2002, IEEE SIGNAL PROC MAG, V19, P44, DOI 10.1109/79.974727
   Kiers HAL, 1997, PSYCHOMETRIKA, V62, P251, DOI 10.1007/BF02295279
   Kim H, 2008, SIAM J MATRIX ANAL A, V30, P713, DOI 10.1137/07069239X
   Kolda TG, 2009, SIAM REV, V51, P455, DOI 10.1137/07070111X
   Kolda Tamara G, 2006, MULTILINEAR OPERATOR
   Kroonenberg P. M, 2007, MISSING DATA MULTIWA, P143
   Kruskal J, 1989, RANK DECOMPOSITION U, DOI [10.1002/bimj.4710330518, DOI 10.1002/BIMJ.4710330518]
   Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, V205, P235
   Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, P3, DOI DOI 10.1007/978-0-387-46312-4
   Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565
   Lee H, 2010, IEEE SIGNAL PROC LET, V17, P4, DOI 10.1109/LSP.2009.2027163
   Lin CJ, 2007, IEEE T NEURAL NETWOR, V18, P1589, DOI 10.1109/TNN.2007.895831
   Liu J, 2013, IEEE T PATTERN ANAL, V35, P208, DOI 10.1109/TPAMI.2012.39
   Liu KF, 2013, INT CONF ACOUST SPEE, P6635, DOI 10.1109/ICASSP.2013.6638945
   Moller A, 2016, J CHEMOMETR, V30, P715, DOI 10.1002/cem.2849
   Montcuquet AS, 2011, IEEE T BIO-MED ENG, V58, P2554, DOI 10.1109/TBME.2011.2159382
   Morup M, 2009, J CHEMOMETR, V23, P352, DOI 10.1002/cem.1223
   Nascimento JMP, 2005, IEEE T GEOSCI REMOTE, V43, P175, DOI 10.1109/TGRS.2004.839806
   Neher RA, 2009, BIOPHYS J, V96, P3791, DOI 10.1016/j.bpj.2008.10.068
   Norris JL, 2013, CHEM REV, V113, P2309, DOI 10.1021/cr3004295
   PAATERO P, 1994, ENVIRONMETRICS, V5, P111, DOI 10.1002/env.3170050203
   Pomann GM, 2016, J R STAT SOC C-APPL, V65, P395, DOI 10.1111/rssc.12130
   Pu Y, 2011, TECHNOL CANCER RES T, V10, P113, DOI 10.7785/tcrt.2012.500186
   Ramsay J.O., 2007, APPL FUNCTIONAL DATA
   Roxbury D, 2015, SCI REP-UK, V5, DOI 10.1038/srep14167
   Rui Li, 2017, Medical Image Computing and Computer Assisted Intervention - MICCAI 2017. 20th International Conference. Proceedings: LNCS 10435, P125, DOI 10.1007/978-3-319-66179-7_15
   Saeys W, 2008, J CHEMOMETR, V22, P335, DOI 10.1002/cem.1129
   Sajda P, 2003, PROC SPIE, V5207, P321, DOI 10.1117/12.504676
   SCHOLZ FW, 1987, J AM STAT ASSOC, V82, P918, DOI 10.2307/2288805
   Schultz T, 2008, IEEE T VIS COMPUT GR, V14, P1635, DOI 10.1109/TVCG.2008.128
   Smilde A., 2005, MULTIWAY ANAL APPL C
   Smith RT, 2014, BIOMED OPT EXPRESS, V5, P4171, DOI 10.1364/BOE.5.004171
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   STEPHENS MA, 1974, J AM STAT ASSOC, V69, P730, DOI 10.2307/2286009
   Suhling Klaus, 2015, Medical Photonics, V27, P3, DOI 10.1016/j.medpho.2014.12.001
   Tomasi G, 2005, CHEMOMETR INTELL LAB, V75, P163, DOI 10.1016/j.chemolab.2004.07.003
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   Tucker Ledyard R., 1964, CONTRIBUTIONS MATH P
   Wang W., 2013, ARXIV13091541
   Waters JC, 2009, J CELL BIOL, V185, P1135, DOI 10.1083/jcb.200903097
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woolfe F, 2011, IEEE T IMAGE PROCESS, V20, P1085, DOI 10.1109/TIP.2010.2079810
   Yao F, 2003, BIOMETRICS, V59, P676, DOI 10.1111/1541-0420.00078
   Zhang ZM, 2014, PROC CVPR IEEE, P3842, DOI 10.1109/CVPR.2014.485
   Zhu HT, 2011, NEUROIMAGE, V56, P1412, DOI 10.1016/j.neuroimage.2011.01.075
NR 80
TC 8
Z9 8
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1361-8415
EI 1361-8423
J9 MED IMAGE ANAL
JI Med. Image Anal.
PD AUG
PY 2019
VL 56
BP 96
EP 109
DI 10.1016/j.media.2019.05.009
PG 14
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications; Engineering, Biomedical; Radiology,
   Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Radiology, Nuclear Medicine & Medical
   Imaging
GA IP9NC
UT WOS:000480375900008
PM 31203169
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lommatzsch, A
   Heimes, B
   Gutfleisch, M
   Spital, G
   Zeimer, M
   Pauleikhoff, D
AF Lommatzsch, A.
   Heimes, B.
   Gutfleisch, M.
   Spital, G.
   Zeimer, M.
   Pauleikhoff, D.
TI Serous pigment epithelial detachment in age-related macular
   degeneration: comparison of different treatments
SO EYE
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium detachment;
   photodynamic therapy; ranibizumab; bevacizumab; pegaptanib
ID RETINAL ANGIOMATOUS PROLIFERATION; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; INDOCYANINE GREEN ANGIOGRAPHY; OPTICAL COHERENCE
   TOMOGRAPHY; PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB;
   TRIAMCINOLONE ACETONIDE; TEAR; PEGAPTANIB; PATHOGENESIS
AB Aims To investigate the therapeutic effects of different treatments on serous pigment epithelium detachment (PED) in age-related macular degeneration (AMD).
   Methods A total of 328 patients suffering from serous PED in AMD were retrospectively analysed. We treated only patients with documented visual deterioration: 86 patients with bevacizumab, 128 with ranibizumab, 60 with pegaptanib, and 54 with photodynamic therapy (PDT) combined with intravitreal triamcinolone acetonide (IVTA). Best-corrected vision was determined in the logarithm of the minimal angle of resolution (logMAR). We also analysed morphological findings such as full foveal thickness by optical coherence tomography (OCT), manually calculated height of PED as measured by OCT, and fluorescence angiography.
   Results The mean follow-up was 42.4 weeks. The best-corrected visual acuity of 0.78 logMAR before treatment could be improved by about 0.066 logMAR after treatment. Retinal thickness decreased in all patients with PED, in the mean by about 64.06 mu m, and the mean value of the manually calculated height decreased by about 0.98 units. All functional and morphological results proved to be significantly better after injection of ranibizumab and bevacizumab than after pegaptanib and the combined treatment with PDT and IVTA. In all, 41 (12.5%) of our patients developed a tear of the retinal pigment epithelium (RPE).
   Conclusion The therapeutic results were significantly better in patients treated with bevacizumab and ranibizumab than in those treated with pegaptanib or with a combination of PDT and IVTA. Even with treatment, tears of the RPE or only a partial flattening of the PED always indicated a worse prognosis in eyes with exudative AMD than in eyes with classic choroidal neovascularization. Eye (2009) 23, 2163-2168; doi:10.1038/eye.2008.425; published online 6 February 2009
C1 [Lommatzsch, A.; Heimes, B.; Gutfleisch, M.; Spital, G.; Zeimer, M.; Pauleikhoff, D.] St Francis Hosp Muenster, Dept Ophthalmol, D-48145 Munster, Germany.
C3 St. Franziskus-Hospital
RP Lommatzsch, A (通讯作者)，St Francis Hosp Muenster, Dept Ophthalmol, Hohenzollernring 74, D-48145 Munster, Germany.
EM Albrecht.lommatzsch@web.de
OI Gutfleisch, Matthias/0000-0002-2001-5838; Heimes-Bussmann,
   Britta/0000-0003-3898-1679
CR Ahlers C, 2006, GRAEF ARCH CLIN EXP, V244, P1233, DOI 10.1007/s00417-006-0418-z
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2006, OPHTHAL SURG LAS IM, V37, P455, DOI 10.3928/15428877-20061101-02
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bird A C, 1983, Trans Ophthalmol Soc N Z, V35, P73
   Bird AC, 2005, J FR OPHTALMOL, V28, P984, DOI 10.1016/S0181-5512(05)81128-3
   BIRD AC, 1991, EYE, V5, P1
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Costagliola C, 2007, AM J OPHTHALMOL, V144, P449, DOI 10.1016/j.ajo.2007.05.025
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   GELISKEN F, 2008, EYE
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Gomez-Ulla F, 2006, OPTOMETRY VISION SCI, V83, P546, DOI 10.1097/01.opx.0000230279.95171.71
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Jaissle GB, 2005, KLIN MONATSBL AUGENH, V222, P390, DOI 10.1055/s-2005-858231
   Joeres S, 2007, GRAEF ARCH CLIN EXP, V245, P1597, DOI 10.1007/s00417-007-0580-y
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Krebs I, 2006, GRAEF ARCH CLIN EXP, V244, P863, DOI 10.1007/s00417-005-0155-8
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Lai TYY, 2007, GRAEF ARCH CLIN EXP, V245, P1877, DOI 10.1007/s00417-007-0679-1
   Lee WK, 2007, JPN J OPHTHALMOL, V51, P216, DOI 10.1007/s10384-006-0430-1
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pece A, 2007, RETINA-J RET VIT DIS, V27, P342, DOI 10.1097/01.iae.0000239253.78495.8c
   Sallet G, 1996, GRAEF ARCH CLIN EXP, V234, P25, DOI 10.1007/BF00186515
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Spital G, 2000, OPHTHALMOLOGE, V97, P173, DOI 10.1007/s003470050509
   Truong SN, 2007, RETINA-J RET VIT DIS, V27, P915, DOI 10.1097/IAE.0b013e31805468fd
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 44
TC 53
Z9 57
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD DEC
PY 2009
VL 23
IS 12
BP 2163
EP 2168
DI 10.1038/eye.2008.425
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 530JK
UT WOS:000272585500003
PM 19197318
OA Bronze
DA 2022-11-30
ER

PT J
AU Schmidt, S
   Hauser, MA
   Scott, WK
   Postel, EA
   Agarwal, A
   Gallins, P
   Wong, F
   Chen, YS
   Spencer, K
   Schnetz-Boutaud, N
   Haines, JL
   Pericak-Vance, MA
AF Schmidt, S
   Hauser, MA
   Scott, WK
   Postel, EA
   Agarwal, A
   Gallins, P
   Wong, F
   Chen, YS
   Spencer, K
   Schnetz-Boutaud, N
   Haines, JL
   Pericak-Vance, MA
TI Cigarette smoking strongly modifies the association of LOC387715 and
   age-related macular degeneration
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENETIC ASSOCIATION; GENOMEWIDE-SCAN; CHOROIDAL
   NEOVASCULARIZATION; LINKAGE DISEQUILIBRIUM; GEOGRAPHIC ATROPHY; PARENTAL
   GENOTYPES; EXTENDED FAMILIES; CHROMOSOME 10Q26; GRADING SYSTEM
AB We used iterative association mapping to identify a susceptibility gene for age-related macular degeneration (AMD) on chromosome 10q26, which is one of the most consistently implicated linkage regions for this disorder. We employed linkage analysis methods, followed by family-based and case-control association analyses, using two independent data sets. To identify statistically the most likely AMD-susceptibility allele, we used the Genotype-IBD Sharing Test (GIST) and conditional haplotype analysis. To incorporate the two most important known AMD risk factors-smoking and the Y402H variant of the complement factor H gene (CFH) - we used logistic regression modeling to test for gene-gene and gene-environment interactions in the case-control data set and used the ordered-subset analysis to account for genetic linkage heterogeneity in the family-based data set. Our results strongly implicate a coding change (Ala69Ser) in the LOC387715 gene as the second major identified AMD-susceptibility allele, confirming earlier suggestions. This variant's effect on AMD is statistically independent of CFH and is of similar magnitude to the effect of Y402H. The overall effect is driven primarily by a strong association in smokers, since we observed significant evidence for a statistical interaction between the LOC387715 variant and a history of cigarette smoking. This gene-environment interaction is supported by statistically independent family-based and case-control analysis methods. We estimate that CFH, LOC387715, and cigarette smoking together explain 61% of the population-attributable risk (PAR) of AMD. The adjusted PAR percentage estimates are 20% for smoking, 36% for LOC387715, and 43% for CFH. We demonstrate, for the first time, that a genetic susceptibility coupled with a modifiable lifestyle factor such as cigarette smoking confers a significantly higher risk of AMD than either factor alone.
C1 Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Duke Eye Ctr, Durham, NC 27710 USA.
   Vanderbilt Univ, Med Ctr, Dept Ophthalmol, Nashville, TN USA.
   Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
C3 Duke University; Duke University; Vanderbilt University; Vanderbilt
   University
RP Schmidt, S (通讯作者)，Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27710 USA.
EM silke.schmidt@duke.edu
RI Haines, Jonathan/C-3374-2012; Scott, William/A-7593-2009
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NCRR NIH HHS [RR 00095, M01 RR000095] Funding Source: Medline; NEI NIH
   HHS [U10 EY012118, EY015216, EY12118, R01 EY012118, R03 EY015216]
   Funding Source: Medline; NIA NIH HHS [P60 AG011268, AG11268] Funding
   Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R03EY015216,
   U10EY012118, R01EY012118] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [P60AG011268] Funding Source: NIH RePORTER
CR Abecasis GR, 2005, AM J HUM GENET, V77, P754, DOI 10.1086/497345
   Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boyles AL, 2005, HUM HERED, V59, P220, DOI 10.1159/000087122
   BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hauser ER, 2004, GENET EPIDEMIOL, V27, P53, DOI 10.1002/gepi.20000
   Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592
   Li C, 2004, AM J HUM GENET, V74, P418, DOI 10.1086/381712
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Martin ER, 2003, AM J HUM GENET, V73, P1016, DOI 10.1086/378779
   North BV, 2005, HUM HERED, V59, P79, DOI 10.1159/000085222
   Oliveira SA, 2005, AM J HUM GENET, V77, P252, DOI 10.1086/432588
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SCHMIDT M, 2005, STAT APPL GENET MOL, P4
   Schmidt S, 2000, MOL VIS, V6, P287
   SCOTT WK, 2005, AM SOC HUM GEN 55 AN
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Xu H, 2005, BIOINFORMATICS, V21, P4181, DOI 10.1093/bioinformatics/bti682
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 44
TC 259
Z9 271
U1 0
U2 8
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAY
PY 2006
VL 78
IS 5
BP 852
EP 864
DI 10.1086/503822
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 032EH
UT WOS:000236756200010
PM 16642439
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Espallargues, M
   Czoski-Murray, CJ
   Bansback, NJ
   Carlton, J
   Lewis, GM
   Hughes, LA
   Brand, CS
   Brazier, JE
AF Espallargues, M
   Czoski-Murray, CJ
   Bansback, NJ
   Carlton, J
   Lewis, GM
   Hughes, LA
   Brand, CS
   Brazier, JE
TI The impact of age-related macular degeneration on health status utility
   values
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL FUNCTION; FUNCTIONAL IMPAIRMENT; CLINICAL-TRIAL;
   INDEX; VF-14; SF-36; ACUITY; SF-6D
AB PURPOSE. To estimate health status utility values in patients with age-related macular degeneration (ARMD) associated with visual impairments, by using preference-based measures of health.
   METHOD. This was a cross-sectional study involving patients with unilateral or bilateral ARMD who attended a large teaching hospital. Patients underwent visual tests ( near and distant visual acuity [VA] and contrast sensitivity [ CS]) and completed health status questionnaires including the Index of Visual Function (VF)-14 and three preference-based measures ( the Health Utilities Index Mark III [HUI-3], the EuroQoL Health Questionnaire [EQ-5D], and the Short Form 6D Health Status Questionnaire [SF-6D]) and the time tradeoff (TTO). The mean health status is presented for five groups, defined according to the VA in the better-seeing eye and for four CS groups.
   RESULTS. Two hundred nine patients were recruited with substantial loss of visual function as obtained by visual tests ( mean decimal VA in the better-seeing eye: 0.2) and self-report ( mean VF-14 score: 41.5). The mean ( +/- SD) utilities were 0.34 +/- 0.28 for HUI-3, 0.66 +/- 0.14 for SF-6D, 0.72 +/- 0.22 for EQ-5D, and 0.64 +/- 0.31 for TTO. The HUI-3 had the highest correlation with VA and CS (0.40 and - 0.34), followed by TTO (0.25 and - 0.21). Across the VA and CS groups, only HUI3 and TTO had a significant linear trend ( P < 0.05). In a regression model with CS and VA as explanatory variables, only the coefficient on CS was statistically significant.
   CONCLUSIONS. ARMD is associated with a substantial impact on patients' health status, but this was not reflected in two of the generic preference-based measures used. The HUI-3 seems to be the instrument of choice for use in economic evaluations in which community data are needed. It may be more appropriate to base economic models on CS or some combination of CS and VA rather than on VA alone.
C1 Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.
   Catalan Hlth Serv, Catalan Agcy Hlth Technol Assessment & Res, Catalan, Spain.
   Sheffield Teaching Hosp NHS Trust, Dept Orthopt, Sheffield, S Yorkshire, England.
   Sheffield Teaching Hosp NHS Trust, Dept Ophthalmol, Sheffield, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield; University of
   Sheffield
RP Brazier, JE (通讯作者)，Univ Sheffield, Sch Hlth & Related Res, Regent Court,30 Regent St, Sheffield S1 4DA, S Yorkshire, England.
EM j.e.brazier@sheffield.ac.uk
RI Carlton, Jill/N-3225-2019; brazier, john e/B-1936-2008; Carlton,
   Jill/E-6673-2010
OI Carlton, Jill/0000-0002-9373-7663; Carlton, Jill/0000-0002-9373-7663;
   Czoski Murray, Carolyn/0000-0001-7742-2883; Brazier,
   John/0000-0001-8645-4780; Bansback, Nick/0000-0002-1510-3462
CR Alonso J, 1997, OPHTHALMOLOGY, V104, P799, DOI 10.1016/S0161-6420(97)30230-9
   Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8
   Brazier J, 1999, J Health Serv Res Policy, V4, P174
   Brazier J, 1999, HEALTH TECHNOL ASSES, V3, P1, DOI [DOI 10.1177/135581969900400310, DOI 10.3310/hta3090]
   BRAZIER J, 2004, HLTH EC DECISION SCI, V504
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   *CAN COORD OFF HLT, 1997, GUID EC EV PHARM
   CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005
   Commonwealth Department of Health and Ageing, 2002, GUID PHARM IND PREP
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Dolan P, 1996, J HEALTH ECON, V15, P209, DOI 10.1016/0167-6296(95)00038-0
   Drummond MF., 2015, METHODS EC EVALUATIO, V4
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006
   FLETCHER A, 1992, BRIT MED J, V305, P1146
   Gold MR., 1996, COST EFFECTIVENESS H
   Hatoum HT, 2004, VALUE HEALTH, V7, P602, DOI 10.1111/j.1524-4733.2004.75011.x
   Kind P, 1998, BMJ-BRIT MED J, V316, P736, DOI 10.1136/bmj.316.7133.736
   Marra CA, 2004, MED CARE, V42, P1125, DOI 10.1097/00005650-200411000-00012
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   NICE, 2004, GUID METH TECHN APPR
   O'Brien BJ, 2003, HEALTH ECON, V12, P975, DOI 10.1002/hec.789
   O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Porter T, 2001, Insight, V26, P40, DOI 10.1067/min.2001.113403
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Valderas JM, 2004, QUAL LIFE RES, V13, P35, DOI 10.1023/B:QURE.0000015298.09085.b0
   Walters SJ, 2001, AGE AGEING, V30, P337, DOI 10.1093/ageing/30.4.337
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   *ZIEK, 1999, DUTCH GUID PHARM RES
NR 35
TC 120
Z9 120
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2005
VL 46
IS 11
BP 4016
EP 4023
DI 10.1167/iovs.05-0072
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 977MH
UT WOS:000232807400012
PM 16249475
DA 2022-11-30
ER

PT J
AU Litts, KM
   Zhang, YH
   Freund, KB
   Curcio, CA
AF Litts, Katie M.
   Zhang, Yuhua
   Freund, K. Bailey
   Curcio, Christine A.
TI OPTICAL COHERENCE TOMOGRAPHY AND HISTOLOGY OF AGE-RELATED MACULAR
   DEGENERATION SUPPORT MITOCHONDRIA AS REFLECTIVITY SOURCES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE photoreceptors; Muller cells; age-related macular degeneration; outer
   retinal tubulation; ellipsoid; myoid; inner segments; reflectivity;
   optical coherence tomography; histology; transmission electron
   microscopy; adaptive optics
ID OUTER RETINAL TUBULATION; SCANNING LASER OPHTHALMOSCOPY; DOMINANT
   RETINITIS-PIGMENTOSA; PHOTORECEPTOR INNER SEGMENTS; HUMAN CONE
   PHOTORECEPTORS; MEDIATED DARK-ADAPTATION; GEOGRAPHIC ATROPHY; ADAPTIVE
   OPTICS; LIGHT-SCATTERING; MULLER CELLS
AB Purpose: Widespread adoption of optical coherence tomography has revolutionized the diagnosis and management of retinal disease. If the cellular and subcellular sources of reflectivity in optical coherence tomography can be identified, the value of this technology will be advanced even further toward precision medicine, mechanistic thinking, and molecular discovery. Four hyperreflective outer retinal bands are created by the exquisite arrangement of photoreceptors, Muller cells, retinal pigment epithelium, and Bruch membrane. Because of massed effects of these axially compartmentalized and transversely aligned cells, reflectivity can be localized to the subcellular level. This review focuses on the second of the four bands, called ellipsoid zone in a consensus clinical lexicon, with the central thesis that mitochondria in photoreceptor inner segments are a major independent reflectivity source in this band, because of Mie scattering and waveguiding.
   Methods: We review the evolution of Band 2 nomenclature in published literature and discuss the origins of imaging signals from photoreceptor mitochondria that could make these organelles visible in vivo.
   Results: Our recent data pertain to outer retinal tubulation, a unique neurodegenerative and gliotic structure with a highly reflective border, prominent in late age-related macular degeneration. High-resolution histology and multimodal imaging of outer retinal tubulation together provide evidence that inner segment mitochondria undergoing fission and translocation toward the nucleus provide the reflectivity signal.
   Conclusion: Our data support adoption of the ellipsoid zone nomenclature. Identifying subcellular signal sources will newly inform clinical.
C1 [Litts, Katie M.; Zhang, Yuhua; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35294 USA.
   [Litts, Katie M.] Med Coll Wisconsin, Dept Ophthalmol & Visual Sci, Milwaukee, WI 53226 USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
C3 University of Alabama System; University of Alabama Birmingham; Medical
   College of Wisconsin; Vitreous Retina Macula Consultants of New York
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, EyeSight Fdn,Alabama Vis Res Labs, 1670 Univ Blvd Room 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Litts, Katie M/AAK-1564-2021; Freund, K. Bailey/V-7488-2018
OI Litts, Katie M/0000-0001-6707-8273; Freund, K.
   Bailey/0000-0002-7888-9773
FU Vision Science Graduate Program at UAB; International Retina Research
   Foundation [EY021903, EY024378]; EyeSight Foundation of Alabama; Macula
   Foundation; International Retinal Research Foundation; Research to
   Prevent Blindness, Inc; National Eye Institute [EY06109, P30 EY003039];
   Arnold and Mabel Beckman Initiative for Macular Research; Edward N. and
   Della L. Thome Memorial Foundation; Genentech/Roche; Heidelberg
   Engineering; NATIONAL EYE INSTITUTE [R21EY021903, R01EY024378,
   P30EY003039, R01EY006109] Funding Source: NIH RePORTER
FX This article substantively reviews PhD dissertation research that was
   supported by the Vision Science Graduate Program at UAB (K.M.L.). Y.
   Zhang is supported by EY021903, EY024378, International Retina Research
   Foundation, and the EyeSight Foundation of Alabama. The Eye Donor
   Project and K. B. Freund's participation are supported by the Macula
   Foundation. C. A. Curcio is supported by International Retinal Research
   Foundation, unrestricted funds to the Department of Ophthalmology from
   Research to Prevent Blindness, Inc, and EyeSight Foundation of Alabama.
   Acquisition of donor eyes for AMD research was supported by National Eye
   Institute (EY06109, P30 EY003039), International Retinal Research
   Foundation, and the Arnold and Mabel Beckman Initiative for Macular
   Research. The Project MACULA website was supported by these and
   additionally by the Edward N. and Della L. Thome Memorial Foundation.;
   K. B. Freund is a Consultant to Genentech, Optos, Optovue, Heidelberg
   Engineering, and Spark Therapeutics; Research support from
   Genentech/Roche. C. A. Curcio is a Consultant to Novartis; Research
   support from Genentech/Roche, Heidelberg Engineering.
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Anger EM, 2004, EXP EYE RES, V78, P1117, DOI 10.1016/j.exer.2004.01.011
   [Anonymous], 2008, TECHNOLOGY APPL
   [Anonymous], 2007, SPECTRALIS OPERATING
   Bagheri N, 2012, ADV EXP MED BIOL, V723, P479, DOI 10.1007/978-1-4614-0631-0_60
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   BEAUVOIT B, 1995, ANAL BIOCHEM, V226, P167, DOI 10.1006/abio.1995.1205
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bohren CF., 1998, ABSORPTION SCATTERIN, DOI [DOI 10.1002/9783527618156, 10.1002/9783527618156]
   Bonilha VL, 2015, EXP EYE RES, V139, P22, DOI 10.1016/j.exer.2015.07.014
   BORWEIN B, 1980, AM J ANAT, V159, P125, DOI 10.1002/aja.1001590202
   Brown NH, 2009, GRAEF ARCH CLIN EXP, V247, P1069, DOI 10.1007/s00417-009-1044-3
   Burns SA, 1997, J OPT SOC AM A, V14, P2033, DOI 10.1364/JOSAA.14.002033
   BURNS SA, 1995, J OPT SOC AM A, V12, P2329, DOI 10.1364/JOSAA.12.002329
   Burris C, 2002, J COMP NEUROL, V453, P100, DOI 10.1002/cne.10397
   CAMERON DA, 1991, NATURE, V353, P161, DOI 10.1038/353161a0
   Cameron JR, 2016, NEUROLOGY, V87, P1960, DOI 10.1212/WNL.0000000000003301
   Cense B, 2004, OPT EXPRESS, V12, P2435, DOI 10.1364/OPEX.12.002435
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Chauhan DS, 1999, INVEST OPHTH VIS SCI, V40, P2332
   Chen TC, 2006, AM J OPHTHALMOL, V141, P1165, DOI 10.1016/j.ajo.2006.01.086
   Cruz-Herranz A, 2016, NEUROLOGY, V86, P2303, DOI 10.1212/WNL.0000000000002774
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   DeRamus ML, 2017, SCI REP-UK, V7, DOI 10.1038/srep42545
   Distler C, 1996, VISION RES, V36, P2381, DOI 10.1016/0042-6989(96)00005-3
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Drasdo N, 2007, VISION RES, V47, P2901, DOI 10.1016/j.visres.2007.01.007
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   ENOCH JM, 1963, J OPT SOC AM, V53, P71, DOI 10.1364/JOSA.53.000071
   Farhat G, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3600770
   FARISS RN, 1990, EXP EYE RES, V51, P473, DOI 10.1016/0014-4835(90)90160-V
   Fernandez EJ, 2008, OPT EXPRESS, V16, P11083, DOI 10.1364/OE.16.011083
   FLANNERY JG, 1989, INVEST OPHTH VIS SCI, V30, P191
   Fujinami K, 2013, AM J OPHTHALMOL, V156, P487, DOI 10.1016/j.ajo.2013.05.003
   Genead MA, 2011, INVEST OPHTH VIS SCI, V52, P7298, DOI 10.1167/iovs.11-7762
   Ghazi NG, 2006, AM J OPHTHALMOL, V141, P719, DOI 10.1016/j.ajo.2005.10.019
   Gin TJ, 2017, INVEST OPHTH VIS SCI, V58, P2079, DOI 10.1167/iovs.16-20105
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang YJ, 1998, INVEST OPHTH VIS SCI, V39, P2405
   Iriyama Aya, 2013, Retina, V33, P1462, DOI 10.1097/IAE.0b013e31828221ae
   IWASAKI M, 1988, INVEST OPHTH VIS SCI, V29, P671
   Jacob J, 2015, AM J OPHTHALMOL, V159, P118, DOI 10.1016/j.ajo.2014.09.043
   JOHNSON LV, 1991, INVEST OPHTH VIS SCI, V32, P1951
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jonnal RS, 2015, INVEST OPHTH VIS SCI, V56, P2507, DOI 10.1167/iovs.15-16756
   Jonnal RS, 2014, INVEST OPHTH VIS SCI, V55, P7904, DOI 10.1167/iovs.14-14907
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Kashani AH, 2015, RETINA-J RET VIT DIS, V35, P2323, DOI 10.1097/IAE.0000000000000811
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Knabe W, 1997, VISION RES, V37, P267, DOI 10.1016/S0042-6989(96)00199-X
   Krebs W., 1991, PRIMATE RETINA CHORO
   LATIES AM, 1971, INVEST OPHTH VISUAL, V10, P69
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Litts KM, 2017, RETINA-J RET VIT DIS, V37, P978, DOI 10.1097/IAE.0000000000001265
   Litts KM, 2016, INVEST OPHTH VIS SCI, V57, P2647, DOI 10.1167/iovs.16-19262
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Liu ZL, 2015, BIOMED OPT EXPRESS, V6, P3378, DOI 10.1364/BOE.6.003378
   Lu RW, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.6.060504
   Lujan BJ, 2015, RETINA-J RET VIT DIS, V35, P1511, DOI 10.1097/IAE.0000000000000527
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   MacAskill AF, 2010, TRENDS CELL BIOL, V20, P102, DOI 10.1016/j.tcb.2009.11.002
   Meadway A, 2013, OPT EXPRESS, V21, P29792, DOI 10.1364/OE.21.029792
   Miller DT, 1996, VISION RES, V36, P1067, DOI 10.1016/0042-6989(95)00225-1
   Mitamura Y, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/518170
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Mulvey CS, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3259363
   Osterberg G, 1935, Acta Ophthalmol., V13, P11
   Ouyang YL, 2013, GRAEF ARCH CLIN EXP, V251, P2311, DOI 10.1007/s00417-013-2308-5
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Pasternack RM, 2011, CYTOM PART A, V79A, P137, DOI 10.1002/cyto.a.21011
   Pasternack RM, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3467501
   Polyak S., 1957, VERTEBRATE VISUAL SY
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   Powner MB, 2013, OPHTHALMOLOGY, V120, P2344, DOI 10.1016/j.ophtha.2013.04.013
   Putnam NM, 2010, OPT EXPRESS, V18, P24902, DOI 10.1364/OE.18.024902
   Quinten M., 2011, OPTICAL PROPERTIES N
   Reidel B, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002469
   REME CE, 1977, INVEST OPHTH VIS SCI, V16, P815
   Roorda A, 2015, ANNU REV VIS SCI, V1, P19, DOI 10.1146/annurev-vision-082114-035357
   Roorda A, 2002, J VISION, V2, P404, DOI 10.1167/2.5.4
   Ross DH, 2015, INVEST OPHTH VIS SCI, V56, P4166, DOI 10.1167/iovs.14-15256
   ROWE MP, 1994, J OPT SOC AM A, V11, P55, DOI 10.1364/JOSAA.11.000055
   Rueda EM, 2016, MOL VIS, V22, P847
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Scoles D, 2014, INVEST OPHTH VIS SCI, V55, P4244, DOI 10.1167/iovs.14-14542
   Sharma R, 2016, INVEST OPHTH VIS SCI, V57, P632, DOI 10.1167/iovs.15-17961
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Spaide RF, 2015, INVEST OPHTH VIS SCI, V56, P2505, DOI 10.1167/iovs.15-16456
   Spaide RF, 2012, OPHTHALMOLOGY, V119, P2203, DOI 10.1016/j.ophtha.2012.09.009
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   STEINBERG RH, 1977, PHILOS T ROY SOC B, V277, P459, DOI 10.1098/rstb.1977.0028
   Stone J, 2008, BRAIN RES, V1189, P58, DOI 10.1016/j.brainres.2007.10.083
   Sun LW, 2016, PLOS ONE, V11
   Suzuki W, 2013, INVEST OPHTH VIS SCI, V54, P6345, DOI 10.1167/iovs.13-12381
   Toth CA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1425, DOI 10.1001/archopht.1997.01100160595012
   TUCKER GS, 1986, INVEST OPHTH VIS SCI, V27, P708
   Tulvatana W, 1999, ARCH OPHTHALMOL-CHIC, V117, P399, DOI 10.1001/archopht.117.3.399
   Tychinsky V, 2009, J BIOPHOTONICS, V2, P494, DOI 10.1002/jbio.200910042
   UGA S, 1973, INVEST OPHTH VISUAL, V12, P434
   van de Hulst HC, 1981, LIGHT SCATTERING SMA
   Wang L. V., 2012, BIOMEDICAL OPTICS PR
   Williams DR, 2011, VISION RES, V51, P1379, DOI 10.1016/j.visres.2011.05.002
   WILLIAMS DS, 1990, J COMP NEUROL, V295, P155, DOI 10.1002/cne.902950113
   Wilson JD, 2005, OPT LETT, V30, P2442, DOI 10.1364/OL.30.002442
   Wilson JD, 2005, BIOPHYS J, V88, P2929, DOI 10.1529/biophysj.104.054528
   Wilson JD, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2437765
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Wolff B, 2011, ACTA OPHTHALMOL, V89, pE496, DOI 10.1111/j.1755-3768.2011.02144.x
   Wong IY, 2012, CURR OPIN OPHTHALMOL, V23, P210, DOI 10.1097/ICU.0b013e3283524162
   Wu ZC, 2013, OPHTHALMOLOGY, V120, P1307, DOI 10.1016/j.ophtha.2012.12.047
   Xue KM, 2016, INVEST OPHTH VIS SCI, V57, P3674, DOI 10.1167/iovs.15-18364
   YAMADA E, 1969, ARCH OPHTHALMOL-CHIC, V82, P151
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zhang TJ, 2015, AM J OPHTHALMOL, V160, P290, DOI 10.1016/j.ajo.2015.04.034
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zheng JY, 2008, BIOPHYS J, V94, P286, DOI 10.1529/biophysj.107.104323
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 137
TC 42
Z9 43
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2018
VL 38
IS 3
BP 445
EP 461
DI 10.1097/IAE.0000000000001946
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2AB
UT WOS:000440619200006
PM 29210936
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zheng, YL
   Hijazi, MHA
   Coenen, F
AF Zheng, Yalin
   Hijazi, Mohd Hanafi Ahmad
   Coenen, Frans
TI Automated "Disease/No Disease" Grading of Age-Related Macular
   Degeneration by an Image Mining Approach
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID DIABETIC-RETINOPATHY; SD-OCT; SEGMENTATION; DRUSEN; DIAGNOSIS; IMPACT
AB PURPOSE. To describe and evaluate an automated grading system for age-related macular degeneration (AMD) by color fundus photography.
   METHODS. An automated "disease/no disease'' grading system for AMD was developed based on image-mining techniques. First, image preprocessing was performed to normalize color and nonuniform illumination of the fundus images to define a region of interest and to identify and remove pixels belonging to retinal vessels. To represent images for the prediction task, a graph-based image representation using quadtrees was then adopted. Next, a graph-mining technique was applied to the generated graphs to extract relevant features (in the form of frequent subgraphs) from images of both AMD and healthy volunteers. Features of the training data were then fed into a classifier generator for training purposes before employing the trained classifiers to classify new "unseen'' images.
   RESULTS. The algorithm was evaluated on two publically available fundus-image datasets comprising 258 images (160 AMD and 98 normal). Ten-fold cross validation was used. The experiments produced a best specificity of 100% and a best sensitivity of 99.4% with an overall accuracy of 99.6%. Our approach outperformed previous approaches reported in the literature.
   CONCLUSIONS. This study has demonstrated a proof-of-concept, image-mining technique for automated AMD grading. This technique has the potential to be further developed as an automated grading tool for future whole-scale AMD screening programs. (Invest Ophthalmol Vis Sci. 2012;53:8310-8318) DOI:10.1167/iovs.12-9576
C1 [Zheng, Yalin] Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, Liverpool L69 3GA, Merseyside, England.
   [Hijazi, Mohd Hanafi Ahmad; Coenen, Frans] Univ Liverpool, Dept Comp Sci, Liverpool L69 3GA, Merseyside, England.
   [Zheng, Yalin] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Hijazi, Mohd Hanafi Ahmad] Univ Malaysia Sabah, Sch Engn & Informat Technol, Sabah, Malaysia.
C3 University of Liverpool; University of Liverpool; Royal Liverpool &
   Broadgreen University Hospitals NHS Trust; Royal Liverpool University
   Hospital; University of Liverpool; Universiti Malaysia Sabah
RP Zheng, YL (通讯作者)，Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, 3rd Floor,UCD Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.
EM yalin.zheng@liv.ac.uk
RI Zheng, Yalin/N-6432-2017; Hijazi, Mohd Hanafi Ahmad/I-5702-2015
OI Zheng, Yalin/0000-0002-7873-0922; Hijazi, Mohd Hanafi
   Ahmad/0000-0003-0431-8967
FU Ministry of Higher Education Malaysia; Foundation for the Prevention of
   Blindness
FX Supported by the Ministry of Higher Education Malaysia (MHAH) and
   Foundation for the Prevention of Blindness (YZ). The authors alone are
   responsible for the content and writing of the paper.; The authors thank
   the Ministry of Higher Education Malaysia for their financial support,
   and the Foundation for the Prevention of Blindness for their support.
CR Abramoff MD, 2010, EXPERT REV MED DEVIC, V7, P287, DOI 10.1586/ERD.09.76
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Barriga ES, 2009, COMP MED SY, P339
   Ben Sbeh Z, 2001, IEEE T MED IMAGING, V20, P1321, DOI 10.1109/42.974927
   Brandon L, 2003, LECT NOTES COMPUT SC, V2878, P618
   Buderer NMF, 1996, ACAD EMERG MED, V3, P895, DOI 10.1111/j.1553-2712.1996.tb03538.x
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Chang Y-W, 2008, CAUSATION PREDICTION, P53
   Chaum E, 2008, RETINA-J RET VIT DIS, V28, P1463, DOI 10.1097/IAE.0b013e31818356dd
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Domingos P, 1997, MACH LEARN, V29, P103, DOI 10.1023/A:1007413511361
   Elsayed A, 2010, KNOWL-BASED SYST, V23, P330, DOI 10.1016/j.knosys.2009.11.008
   Fan RE, 2008, J MACH LEARN RES, V9, P1871
   Fleming AD, 2011, CURR DIABETES REV, V7, P246, DOI 10.2174/157339911796397802
   Foracchia M, 2005, MED IMAGE ANAL, V9, P179, DOI 10.1016/j.media.2004.07.001
   Gonzalez RC, 2008, DIGITAL IMAGE PROCES
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hijazi MHA, 2010, P INT JOINT C NEUR N, P3501
   Hijazi MHA, 2012, KNOWL-BASED SYST, V29, P83, DOI 10.1016/j.knosys.2011.07.002
   Hijazi MHA, 2010, LECT NOTES ARTIF INT, V6171, P197, DOI 10.1007/978-3-642-14400-4_16
   Holz F.G., 2007, ATLAS FUNDUS AUTOFLU, V1st ed.
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Jiang CT, 2009, APPLICATIONS AND INNOVATIONS IN INTELLIGENT SYSTEMS XVI, P63, DOI 10.1007/978-1-84882-215-3_5
   Karnon J, 2008, HEALTH TECHNOL ASSES, V12, P2
   Karnon J, 2008, Health Technol Assess, V12, piii
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   SAMET H, 1984, COMPUT SURV, V16, P187, DOI 10.1145/356924.356930
   Soares JVB, 2006, IEEE T MED IMAGING, V25, P1214, DOI 10.1109/TMI.2006.879967
   ter Haar F., 2005, THESIS UTRECHT U UTR
   Wilson JMG, 1968, PUBLIC HLTH PAPERS, P26
   Witten I. H., 2005, DATA MINING PRACTICA
   Zuiderveld K., 1994, GRAPHICS GEMS, VIV, P474, DOI [10.1016/b978-0-12-336156-1.50061-6, DOI 10.1016/B978-0-12-336156-1.50061-6]
NR 43
TC 52
Z9 54
U1 0
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2012
VL 53
IS 13
BP 8310
EP 8318
DI 10.1167/iovs.12-9576
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064EX
UT WOS:000313056000054
PM 23150624
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Joo, JH
   Kim, H
   Shin, JH
   Moon, SW
AF Joo, Jin-Ho
   Kim, Hyejee
   Shin, Jae-Ho
   Moon, Sang Woong
TI Aqueous humor cytokine levels through microarray analysis and a
   sub-analysis based on optical coherence tomography in wet age-related
   macular degeneration patients
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE AMD; Aqueous humor; Cytokine; OCT
ID CHOROIDAL NEOVASCULARIZATION; GROWTH-FACTOR; VITREOUS LEVELS; MOUSE
   MODEL; EXPRESSION; MCP-1; INFLAMMATION; CHEMOKINES; OUTCOMES; EDEMA
AB Background To identify disease-specific cytokine and growth factor profile differences in the aqueous humor between wet age-related macular degeneration (AMD) patients and age-matched controls and to correlate their levels with the optical coherence tomography (OCT) findings. Methods Aqueous humors were obtained from 13 wet AMD eyes and 10 control eyes. Twenty cytokines and growth factors were measured using a RayBio antibody microarray technology in wet AMD and control eyes. Results The samples obtained from wet AMD patients exhibited a significantly increased expression of MCP-1, MIP-1 alpha, MIP-1 beta, and vascular endothelial growth factor (VEGF). Subretinal fluid (SRF) patients showed significantly lower levels of proinflammatory cytokines, such as IL-1 alpha and GM-CSF, than those without SRF. Pigment epithelial detachments (PED) patients showed lower levels of inflammatory cytokines, such as GM-CSF, IFN-gamma, and TNF-alpha, than those without PED. Subretinal tissue (SRT) patients showed a higher level of IFN-gamma than those without SRT. Compared with the controls, type 1 macular neovascularization (MNV) patients showed increased levels of MCP-1, MIP-1 alpha, and MIP-1 beta, but not VEGF (p = 0.083). However, type 2 MNV patients showed increased levels of MCP-1 and VEGF (p = 0.040 and p = 0.040). Conclusion Inflammatory cytokines varied according to the type of AMD- and OCT-based parameters. Our observation of low levels of VEGF in patients with type 1 MNV implies that the inhibition of VEGF alone appears to be insufficient treatment for these patients and that cytokines such as MCP-1, MIP-1 alpha, and MIP-1 beta should be modulated. And the presence of SRF in MNV may be associated with a positive prognosis because we found relatively low levels of proinflammatory cytokines.
C1 [Joo, Jin-Ho; Shin, Jae-Ho; Moon, Sang Woong] Kyung Hee Univ Hosp Gangdong, Dept Ophthalmol, 892 Dongnam Ro, Seoul, South Korea.
   [Kim, Hyejee] Barunbit EYE Clin, Seoul, South Korea.
C3 Kyung Hee University; Kyung Hee University Hospital
RP Moon, SW (通讯作者)，Kyung Hee Univ Hosp Gangdong, Dept Ophthalmol, 892 Dongnam Ro, Seoul, South Korea.
EM ophmoon@gmail.com
FU National Research Foundation of Korea (NRF) - Ministry of Science and
   ICT [2018M3A9E8078812]; Kyung Hee University [KHU-20191225]
FX This research was supported by the National Research Foundation of Korea
   (NRF), funded by the Ministry of Science and ICT (2018M3A9E8078812) and
   Kyung Hee University (KHU-20191225).
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Butler DC, 2020, J FORENSIC SCI, V65, P508, DOI 10.1111/1556-4029.14178
   Clark WL, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-018-1012-y
   DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Folgar FA, 2014, OPHTHALMOLOGY, V121, P1956, DOI 10.1016/j.ophtha.2014.04.020
   Foxman EF, 2002, J IMMUNOL, V168, P2483, DOI 10.4049/jimmunol.168.5.2483
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Invernizzi A, 2019, AM J OPHTHALMOL, V204, P105, DOI 10.1016/j.ajo.2019.03.001
   Ishikawa K, 2010, INVEST OPHTH VIS SCI, V51, P4307, DOI 10.1167/iovs.09-4605
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Katsura Y, 2005, DIABETES CARE, V28, P2252, DOI 10.2337/diacare.28.9.2252
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Li R, 2009, AM J PHYSIOL-CELL PH, V297, pC1452, DOI 10.1152/ajpcell.00255.2009
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   O'Hayre M, 2008, BIOCHEM J, V409, P635, DOI 10.1042/BJ20071493
   ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3649
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   Sophie R, 2015, OPHTHALMOLOGY, V122, P1395, DOI 10.1016/j.ophtha.2015.02.036
   Sridhar P, 1999, MOL CELL BIOL, V19, P4219
   Steinle NC, 2021, OPHTHALMOL RETINA, V5, P141, DOI 10.1016/j.oret.2020.07.003
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Suzuki M, 2007, MOL VIS, V13, P772
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Wallace CA, 2013, INVEST OPHTH VIS SCI, V54, P722, DOI 10.1167/iovs.12-10602
   Wang C, 2022, OPHTHALMIC RES, V65, P68, DOI 10.1159/000513588
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yang Q, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030509
   Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P19, DOI 10.1089/jop.2006.22.19
NR 36
TC 2
Z9 2
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 18
PY 2021
VL 21
IS 1
AR 399
DI 10.1186/s12886-021-02152-6
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XA1HY
UT WOS:000720408500001
PM 34794403
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Modjtahedi, BS
   Fong, DS
   Jorgenson, E
   Van Den Eeden, SK
   Quinn, V
   Slezak, JM
AF Modjtahedi, Bobeck S.
   Fong, Donald S.
   Jorgenson, Eric
   Van Den Eeden, Stephen K.
   Quinn, Virginia
   Slezak, Jeffrey M.
TI The Relationship Between Nonsteroidal Anti-inflammatory Drug Use and
   Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; LOW-DOSE ASPIRIN; C-REACTIVE PROTEIN; OXIDATIVE
   STRESS; ENDOTHELIAL DYSFUNCTION; ACETYLSALICYLIC-ACID; INFLAMMATORY
   MARKERS; ASSOCIATION; EXPRESSION; BIOMARKERS
AB PURPOSE: To describe the relationship between the incidence of age-related macular degeneration (AMD) and nonsteroidal anti,inflammatory drug (NSAIDs) use.
   DESIGN: Prospective cohort study.
   METHODS: This study consisted of participants in the California Men's Health Study. Those who completed surveys in 2002-2003 and 2006 were included. Men who self-reported use of aspirin, ibuprofen, naproxen, valdecoxib, celecoxib, and/or rofecoxib at least 3 days per week were considered NSAID users. Patients were categorized as non-users, former users, new users, or longer-term users based on survey responses. NSAID use was also categorized by type: any NSAIDs, aspirin, and/or non-aspirin NSAIDs. Age, race/ethnicity, smoking status, education, income, alcohol use, and Charlson comorbidity index score were included in the multivariate analysis as risk factors for AMD.
   RESULTS: A total of 51 371 men were included. Average follow-up time was 7.4 years. There were 292 (0.6%) and 1536 (3%) cases of exudative and nonexudative AMD, respectively. Longer-term use of any NSAID was associated with lower risk of exudative AMD (hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.50-0.96, P = .029). New users of any NSAIDs (HR = 0.79,95% CI 0.68-0.93, P = .0039) and aspirin (HR = 0.82, 95% CI 0.70-0.97, P = .018) had a lower risk of nonexudative AMD, although this trend did not persist in longer term users. The relationship between exudative or nonexudative AMD and the remaining categories of NSAID use were not significant.
   CONCLUSION: The overall impact of NSAIDs on AMD incidence is small; however, the lower risk of exudative AMD in longer-term NSAID users may point to a protective effect and deserves further study as a possible mechanism to modulate disease risk. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Modjtahedi, Bobeck S.; Fong, Donald S.] Southern Calif Permanente Med Grp, Dept Ophthalmol, Baldwin Park, CA 91706 USA.
   [Modjtahedi, Bobeck S.; Fong, Donald S.] Kaiser Permanente Southern Calif, Eye Monitoring Ctr, 1011 Baldwin Pk Blvd, Baldwin Pk, CA 91706 USA.
   [Fong, Donald S.; Quinn, Virginia; Slezak, Jeffrey M.] Southern Calif Permanente Med Grp, Dept Res & Evaluat, Pasadena, CA USA.
   [Jorgenson, Eric; Van Den Eeden, Stephen K.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA.
C3 Permanente Medical Groups; Kaiser Permanente; Permanente Medical Groups;
   Kaiser Permanente
RP Modjtahedi, BS (通讯作者)，Southern Calif Permanente Med Grp, Dept Ophthalmol, Baldwin Park, CA 91706 USA.; Modjtahedi, BS (通讯作者)，Kaiser Permanente Southern Calif, Eye Monitoring Ctr, 1011 Baldwin Pk Blvd, Baldwin Pk, CA 91706 USA.
EM BobModj@gmail.com
FU Allergan; ThromboGenics; NightstaRx
FX DONALD S. FONG: RESEARCH SUPPORT from Allergan, ThromboGenics, and
   NightstaRx. The following authors have no financial disclosures: Bobeck
   S. Modjtahedi, Eric Jorgenson, Stephen K. Van Den Eeden, Virginia Quinn,
   and Jeffrey M. Slezak. The authors attest that they meet the current
   ICMJE criteria for authorship.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   [Anonymous], 1989, NEW ENGL J MED, V321, P129, DOI DOI 10.1056/NEJM198907203210301
   Asanuma M, 2001, J NEUROCHEM, V76, P1895, DOI 10.1046/j.1471-4159.2001.00205.x
   Basivireddy J, 2002, BIOCHEM PHARMACOL, V64, P339, DOI 10.1016/S0006-2952(02)01067-5
   Beyer I, 2012, CELL STRESS CHAPERON, V17, P255, DOI 10.1007/s12192-011-0304-4
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2014, EXPERT OPIN DRUG SAF, V13, P421, DOI 10.1517/14740338.2014.889680
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dumont I, 2000, AM J PHYSIOL-HEART C, V278, pH60, DOI 10.1152/ajpheart.2000.278.1.H60
   Dumont I, 1998, AM J PHYSIOL-REG I, V275, pR1812, DOI 10.1152/ajpregu.1998.275.6.R1812
   Ely Luisa Scheer, 2014, Inflammation & Allergy Drug Targets, V13, P323
   Enger SM, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-172
   Feldman M, 2001, J AM COLL CARDIOL, V37, P2036, DOI 10.1016/S0735-1097(01)01289-X
   Gao XR, 2009, J PHARM PHARMACOL, V61, P1505, DOI 10.1211/jpp/61.11.0010
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Hetzel S, 2013, J CARDIOVASC PHARM T, V18, P217, DOI 10.1177/1074248413482753
   Hovens MMC, 2008, DIABETES OBES METAB, V10, P668, DOI 10.1111/j.1463-1326.2007.00794.x
   Kacprzak D, 2015, ARCH MED SCI, V11, P494, DOI 10.5114/aoms.2014.41960
   Kahawita SK, 2014, CAN J OPHTHALMOL, V49, P35, DOI 10.1016/j.jcjo.2013.07.016
   Kast R. E., 2006, Inflammopharmacology, V14, P256, DOI 10.1007/s10787-006-1532-6
   Kast RE, 2000, BIOMED PHARMACOTHER, V54, P168, DOI 10.1016/S0753-3322(00)89050-2
   Keles S, 2014, CLIN OPHTHALMOL, V8, P1573, DOI 10.2147/OPTH.S66160
   Kim SJ, 2010, SURV OPHTHALMOL, V55, P108, DOI 10.1016/j.survophthal.2009.07.005
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kuhs KAL, 2015, CANCER EPIDEM BIOMAR, V24, P825, DOI 10.1158/1055-9965.EPI-14-1363
   Li L, 2015, J CLIN PHARM THER, V40, P144, DOI 10.1111/jcpt.12241
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   LopezFarre A, 1996, CIRCULATION, V94, P83, DOI 10.1161/01.CIR.94.1.83
   LOPEZFARRE A, 1995, CIRCULATION, V91, P2080, DOI 10.1161/01.CIR.91.7.2080
   Maity P, 2009, J BIOL CHEM, V284, P3058, DOI 10.1074/jbc.M805329200
   Maniglia FP, 2016, INFLAMMATION, V39, P243, DOI 10.1007/s10753-015-0244-8
   Muroi C, 2014, NEUROCRIT CARE, V20, P240, DOI 10.1007/s12028-013-9930-2
   Naito Y, 2006, REDOX REP, V11, P243, DOI 10.1179/135100006X155021
   Huong NQ, 2011, BIOL PHARM BULL, V34, P1856, DOI 10.1248/bpb.34.1856
   Pohle T, 2001, ALIMENT PHARM THER, V15, P677, DOI 10.1046/j.1365-2036.2001.00975.x
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Rainsford K. D., 2009, Inflammopharmacology, V17, P275, DOI 10.1007/s10787-009-0016-x
   SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240
   Sen H., 2007, INVEST OPHTHALMOL VI, V48, P2166
   Serebruany V, 2011, THROMB HAEMOSTASIS, V105, P81, DOI 10.1160/TH10-05-0316
   Sobrin L, 2013, AM J OPHTHALMOL, V156, P213, DOI 10.1016/j.ajo.2013.04.023
   Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169
   Tassone EJ, 2015, ACTA DIABETOL, V52, P249, DOI 10.1007/s00592-014-0629-4
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Totan Yϋksel, 2015, J Ophthalmic Vis Res, V10, P151, DOI 10.4103/2008-322X.163765
   Vaucher J, 2014, CYTOKINE, V66, P95, DOI 10.1016/j.cyto.2014.01.003
   Wilkinson BL, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.06.014
   Wu Yan, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P59
   Ye J, 2014, INVEST OPHTH VIS SCI, V55, P2687, DOI 10.1167/iovs.13-13206
   Yiannakopoulou EC, 2015, EUR J CANCER PREV, V24, P416, DOI 10.1097/CEJ.0000000000000098
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 56
TC 11
Z9 11
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2018
VL 188
BP 111
EP 122
DI 10.1016/j.ajo.2018.01.012
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB9LV
UT WOS:000429396200018
PM 29360460
DA 2022-11-30
ER

PT J
AU Droege, KM
   Muether, PS
   Hermann, MM
   Caramoy, A
   Viebahn, U
   Kirchhof, B
   Fauser, S
AF Droege, Katharina M.
   Muether, Philipp S.
   Hermann, Manuel M.
   Caramoy, Albert
   Viebahn, Ulrike
   Kirchhof, Bernd
   Fauser, Sascha
TI Adherence to ranibizumab treatment for neovascular age-related macular
   degeneration in real life
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Ranibizumab; Adherence
AB To identify factors and problems influencing treatment adherence in patients undergoing anti-VEGF therapy for neovascular age-related macular degeneration (AMD) under real-life conditions.
   Cross-sectional study was conducted of 95 patients receiving ranibizumab therapy on a pro re nata (PRN) regimen with monthly controls in a tertiary health care clinic. Monthly controls included best corrected visual acuity, slit-lamp examination and spectral-domain optical coherence tomography. Adherence was measured using Kaplan-Meier time-to-discontinuation analysis. Patients were asked to respond to a 16-item questionnaire covering items such as anxiety, subjective benefit, and financial issues of therapy.
   Forty-two men and 53 women were included. After a mean follow-up time of 675 days (range 63-1008), adherence was 81.1 % (77/95). The mean number of follow-up visits was 19 (3-30), the mean number of intravitreal injections was ten (3-23). Seven patients withdrew from treatment due to subjective dissatisfaction with benefit. Other reasons for loss to follow-up were death in one case, serious general disease in three patients, and treatment options closer to home in five cases. Two patients cancelled further follow-up after treatment cessation due to terminal fibrosis. 62.1 % of patients were afraid of a negative examination result, whereas 19.0 % were afraid of intravitreal injections. A major problem was travel to and from the hospital (46.3 %), with 61.5 % of patients requiring escort.
   Despite necessary monthly visits, patients showed a high adherence to therapy. The major problem was travel to and from the hospital. From the patients' point of view, anxiety of a negative examination result was more pronounced than fear of intraocular injections, which would be an argument for continuous injections rather than for a PRN regimen.
C1 [Droege, Katharina M.; Muether, Philipp S.; Hermann, Manuel M.; Caramoy, Albert; Viebahn, Ulrike; Kirchhof, Bernd; Fauser, Sascha] Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50924 Cologne, Germany.
C3 University of Cologne
RP Fauser, S (通讯作者)，Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50924 Cologne, Germany.
EM sfauser@gmx.net
FU Koeln Fortune Program, Faculty of Medicine, University of Cologne
FX This study was supported by the Koeln Fortune Program, Faculty of
   Medicine, University of Cologne. The data was presented in part at the
   ARVO annual meeting 2011 [33]. The authors did not receive support from
   non-profit organizations.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Heimann H, 2011, OPHTHALMOLOGE, V108, P575, DOI 10.1007/s00347-011-2383-0
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Muether PS, 2012, GRAEFES ARCH CLIN EX
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
NR 8
TC 71
Z9 73
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2013
VL 251
IS 5
BP 1281
EP 1284
DI 10.1007/s00417-012-2177-3
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131EW
UT WOS:000317976300005
PM 23086225
DA 2022-11-30
ER

PT J
AU Shen, JJ
   Wang, R
   Wang, LL
   Lyu, CF
   Liu, S
   Xie, GT
   Zeng, HL
   Chen, LY
   Shen, MQ
   Gao, X
   Lin, HD
   Yuan, YZ
AF Shen, Jing-Jing
   Wang, Rui
   Wang, Li-Long
   Lyu, Chuan-Feng
   Liu, Shuo
   Xie, Guo-Tong
   Zeng, Hai-Luan
   Chen, Ling-Yan
   Shen, Min-Qian
   Gao, Xin
   Lin, Huan-Dong
   Yuan, Yuan-Zhi
TI Image enhancement of color fundus photographs for age-related macular
   degeneration: the Shanghai Changfeng Study
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; image enhancement; image optimization;
   retina
ID RETINAL IMAGES; CONTRAST; CAMERA
AB AIM: To develop and evaluate a new fundus image optimization software based on red, green, blue channels (RGB) for the evaluation of age-related macular degeneration (AMD) in the Chinese population.
   METHODS: Fundus images that were diagnosed as AMD from the Shanghai Changfeng Study database were analyzed to develop a standardized optimization procedure. Image brightness, contrast, and color balance were measured. Differences between central lesion area and normal retinal area under different image brightness, contrast, and color balance were observed. The optimal optimization parameters were determined based on the visual system to avoid image distortion. A paired-sample diagnostic test was used to evaluate the enhancement software. Fundus optical coherence tomography (OCT) was used as the gold standard. Diagnostic performances were compared between original images and optimized images using McNemar's test.
   RESULTS: A fundus image optimization procedure was developed using 86 fundus images of 74 subjects diagnosed with AMD. By observing gray-scale images, choroid can be best displayed in red channel and retina in green channel was found. There was limited information in blue channel. Totally 104 participants were included in the paired sample diagnostic test to assess the performance of the optimization software. After the image enhancement, sensitivity increased from 74% to 88% (P=0.008), specificity decreased slightly from 88% to 84% (P=0.500), and Youden index increased by 0.11.
   CONCLUSION: The standardized image optimization software increases diagnostic sensitivity and may help ophthalmologists in AMD diagnosis and screening.
C1 [Shen, Jing-Jing; Shen, Min-Qian; Yuan, Yuan-Zhi] Fudan Univ, Zhongshan Hosp, Dept Ophthalmol, Shanghai 200032, Peoples R China.
   [Shen, Jing-Jing; Shen, Min-Qian; Yuan, Yuan-Zhi] Fudan Univ, Ctr Evidence Based Med, Shanghai 200032, Peoples R China.
   [Wang, Rui; Wang, Li-Long; Lyu, Chuan-Feng; Liu, Shuo; Xie, Guo-Tong] Pingan Technol Shenzhen Co Ltd, Shenzhen 518029, Peoples R China.
   [Zeng, Hai-Luan; Chen, Ling-Yan; Gao, Xin; Lin, Huan-Dong] Fudan Univ, Zhongshan Hosp, Dept Endocrinol & Metab, Shanghai 200032, Peoples R China.
   [Zeng, Hai-Luan; Chen, Ling-Yan; Gao, Xin; Lin, Huan-Dong] Fudan Inst Metab Dis, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Yuan, YZ (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Ophthalmol, Shanghai 200032, Peoples R China.; Lin, HD (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Endocrinol & Metab, Shanghai 200032, Peoples R China.
EM lin.huandong@zs-hospital.sh.cn; yuan.yuanzhi@zs-hospital.sh.cn
CR Cao LC, 2020, MED BIOL ENG COMPUT, V58, P483, DOI 10.1007/s11517-019-02106-7
   De Bats F, 2014, OPHTHALMOLOGICA, V231, P172, DOI 10.1159/000356695
   Gao X, 2010, EUR J EPIDEMIOL, V25, P885, DOI 10.1007/s10654-010-9525-6
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Jain S, 2006, EYE, V20, P471, DOI 10.1038/sj.eye.6701916
   Jin K, 2018, ACTA OPHTHALMOL, V96, pE320, DOI 10.1111/aos.13573
   Liang JZ, 1997, J OPT SOC AM A, V14, P2873, DOI 10.1364/JOSAA.14.002873
   Lin HD, 2017, EUR J EPIDEMIOL, V32, P159, DOI 10.1007/s10654-016-0219-6
   Massin P, 2003, DIABETIC MED, V20, P635, DOI 10.1046/j.1464-5491.2003.01002.x
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Olson JA, 2003, DIABETIC MED, V20, P528, DOI 10.1046/j.1464-5491.2003.00969.x
   Philip S, 2005, BRIT J OPHTHALMOL, V89, P891, DOI 10.1136/bjo.2004.051334
   Scanlon PH, 2003, DIABETIC MED, V20, P467, DOI 10.1046/j.1464-5491.2003.00954.x
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Tsikata E, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.3
   Wu L, 2019, EUR J EPIDEMIOL, V34, P939, DOI 10.1007/s10654-019-00543-0
   Xiong L, 2017, COMPUT METH PROG BIO, V143, P137, DOI 10.1016/j.cmpb.2017.02.026
   Zhou M, 2018, IEEE T BIO-MED ENG, V65, P521, DOI 10.1109/TBME.2017.2700627
NR 20
TC 1
Z9 1
U1 2
U2 3
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2022
VL 15
IS 2
BP 268
EP 275
DI 10.18240/ijo.2022.02.12
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZU9ER
UT WOS:000770141800012
PM 35186687
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kang, HM
   Lee, SJ
   Kim, CG
   Chung, EJ
   Koh, HJ
AF Kang, Hae Min
   Lee, Sung Jun
   Kim, Chul Gu
   Chung, Eun Jee
   Koh, Hyoung Jun
TI Gas-mediated vitreomacular adhesion release with intravitral ranibizumab
   injections for exudative age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE lAge-related macular degeneration; Perfluoropropane; Posterior vitreous
   detachment; Vitreomacular adhesion; Vitreomacular traction
ID OPTICAL COHERENCE TOMOGRAPHY; SUBMACULAR HEMORRHAGE; INTERFACE;
   OCRIPLASMIN; TRACTION; OUTCOMES; THERAPY; RISK; HOLE
AB To evaluate the efficiency of gas-assisted vitreomacular adhesion (VMA) release combined with intravitreal ranibizumab injections for exudative age-related macular degeneration (AMD) patients.
   This prospective, interventional case series included a total of 23 eyes of 22 patients. The eyes were treated with intravitreal injection of 0.3 mL of perfluoropropane (C3F8) gas and concomitant intravitreal ranibizumab injection to stimulate VMA release. After three initial loading injections, additional intravitreal ranibizumab injections were performed pro re nata. Over a 12-month period, monthly examinations were performed for best-corrected visual acuity (BCVA, logMAR; logarithm of the minimum angle resolution), optical coherence tomography, and dilated fundus examinations.
   After gas injection, 22 eyes (95.7 %) showed complete VMA release at 1 week. Complete VMA was achieved in all eyes at 2 months after VMA release, without serious ocular adverse events except one patient who developed a retinal tear. Mean BCVA was 0.61 +/- 0.37 logMAR (20/81 Snellen equivalents) at baseline and 0.46 +/- 0.30 logMAR (20/57 Snellen equivalents) at 12 months (P = 0.135). Mean central macular thickness was 357.9 +/- 128.6 mu m at baseline and 245.6 +/- 60.0 mu m at 12 months (P = 0.188). Mean numbers of intravitreal ranibizumab injections were 4.8 +/- 2.4 times during 12 months (4 to 8 injections).
   Gas-assisted VMA release can be used as an efficient alternative for exudative AMD patients with obvious VMA.
C1 [Kang, Hae Min] Catholic Kwandong Univ, Dept Ophthalmol, Int St Marys Hosp, Inchon, South Korea.
   [Lee, Sung Jun] Yonsei Bon Ophthalmol Clin, Seoul, South Korea.
   [Kim, Chul Gu] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol,Myung Gok Eye Res Inst, Seoul, South Korea.
   [Chung, Eun Jee] Natl Hlth Insurance Corp, Dept Ophthalmol, Ilsan Hosp, Goyang, South Korea.
   [Kang, Hae Min; Koh, Hyoung Jun] Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, 134 Shinchon Dong, Seoul 120752, South Korea.
C3 Catholic Kwandong University; Konyang University; Konyang University
   Hospital; NHIS Ilsan Hospital; Yonsei University; Yonsei University
   Health System
RP Koh, HJ (通讯作者)，Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, 134 Shinchon Dong, Seoul 120752, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516
FU Novartis Korea
FX Novartis Korea provided financial support in the form of $59,000 (USD).
   The sponsor had no role in the design or conduct of this study.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   CHAN CK, 1995, OPHTHALMOLOGY, V102, P757, DOI 10.1016/S0161-6420(95)30958-X
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Fujikawa M, 2013, RETINA-J RET VIT DIS, V33, P1908, DOI 10.1097/IAE.0b013e318287d99d
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gandorfer A, 2009, DEV OPHTHALMOL, V44, P1, DOI 10.1159/000223938
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Houston SK, 2015, RETINA, V35, P757
   Jorge R, 2006, AM J OPHTHALMOL, V142, P869, DOI 10.1016/j.ajo.2006.05.062
   Kim YM, 2011, RETINA-J RET VIT DIS, V31, P2123, DOI 10.1097/IAE.0B013E31822F5720
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Mori K, 2007, OPHTHALMOLOGY, V114, P127, DOI 10.1016/j.ophtha.2006.07.001
   Novack RL, 2015, OPHTHALMOLOGY, V122, P796, DOI 10.1016/j.ophtha.2014.10.006
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rodrigues IA, 2013, AM J OPHTHALMOL, V155, P270, DOI 10.1016/j.ajo.2012.08.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119
   Shultz RW, 2011, SEMIN OPHTHALMOL, V26, P361, DOI 10.3109/08820538.2011.585368
   Stalmans P, 2013, RETINA-J RET VIT DIS, V33, P2003, DOI 10.1097/IAE.0b013e3182993ef8
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   Stefanini FR, 2014, CLIN OPHTHALMOL, V8, P847, DOI 10.2147/OPTH.S32274
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tsui I, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/354979
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
NR 38
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2016
VL 254
IS 9
BP 1681
EP 1692
DI 10.1007/s00417-015-3257-y
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DU2HQ
UT WOS:000382032300003
PM 26743753
DA 2022-11-30
ER

PT J
AU Yoon, KD
   Yamamoto, K
   Ueda, K
   Zhou, JL
   Sparrow, JR
AF Yoon, Kee Dong
   Yamamoto, Kazunori
   Ueda, Keiko
   Zhou, Jilin
   Sparrow, Janet R.
TI A Novel Source of Methylglyoxal and Glyoxal in Retina: Implications for
   Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; GLYCATION END-PRODUCTS; FACTOR-H POLYMORPHISM;
   BRUCHS MEMBRANE; LIPOFUSCIN FLUOROPHORE; ALPHA-OXOALDEHYDES; OXIDATIVE
   STRESS; A2E; RPE; PROTEINS
AB Aging of retinal pigment epithelial (RPE) cells of the eye is marked by accumulations of bisretinoid fluorophores; two of the compounds within this lipofuscin mixture are A2E and all-trans-retinal dimer. These pigments are implicated in pathological mechanisms involved in some vision-threatening disorders including age-related macular degeneration (AMD). Studies have shown that bisretinoids are photosensitive compounds that undergo photooxidation and photodegradation when irradiated with short wavelength visible light. Utilizing ultra performance liquid chromatography (UPLC) with electrospray ionization mass spectrometry (ESI-MS) we demonstrate that photodegradation of A2E and all-trans-retinal dimer generates the dicarbonyls glyoxal (GO) and methylglyoxal (MG), that are known to modify proteins by advanced glycation endproduct (AGE) formation. By extracellular trapping with aminoguanidine, we established that these oxo-aldehydes are released from irradiated A2E-containing RPE cells. Enzyme-linked immunosorbant assays (ELISA) revealed that the substrate underlying A2E-containing RPE was AGE-modified after irradiation. This AGE deposition was suppressed by prior treatment of the cells with aminoguanidine. AGE-modification causes structural and functional impairment of proteins. In chronic diseases such as diabetes and atherosclerosis, MG and GO modify proteins by non-enzymatic glycation and oxidation reactions. AGE-modified proteins are also components of drusen, the sub-RPE deposits that confer increased risk of AMD onset. These results indicate that photodegraded RPE bisretinoid is likely to be a previously unknown source of MG and GO in the eye.
C1 [Yoon, Kee Dong; Yamamoto, Kazunori; Ueda, Keiko; Zhou, Jilin; Sparrow, Janet R.] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Sparrow, Janet R.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
C3 Columbia University; Columbia University
RP Yoon, KD (通讯作者)，Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
EM jrs88@columbia.edu
FU National Institutes of Health [EY12951, P30EY019007]; Research to
   Prevent Blindness to the Department of Ophthalmology; National Research
   Foundation of Korea [NRF-2009-352-E00060]; NATIONAL EYE INSTITUTE
   [P30EY019007, R01EY012951] Funding Source: NIH RePORTER
FX Supported by National Institutes of Health grants EY12951 (JRS) and
   P30EY019007; and a grant from Research to Prevent Blindness to the
   Department of Ophthalmology. KDY was supported in part by National
   Research Foundation of Korea (NRF-2009-352-E00060). KDY is currently at
   the Catholic University of Korea. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abordo EA, 1999, BIOCHEM PHARMACOL, V58, P641, DOI 10.1016/S0006-2952(99)00132-X
   Ahmed N, 2002, BIOCHEM J, V364, P15, DOI 10.1042/bj3640015
   Alderson NL, 2004, DIABETOLOGIA, V47, P1385, DOI 10.1007/s00125-004-1474-8
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dobler D, 2006, DIABETES, V55, P1961, DOI 10.2337/db05-1634
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farboud B, 1999, MOL VIS, V5, pU1
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grey AC, 2011, INVEST OPHTH VIS SCI, V52, P3926, DOI 10.1167/iovs.10-7020
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Kim SR, 2010, VISION RES, V50, P729, DOI 10.1016/j.visres.2009.09.015
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Nawa A, 2010, LIFE SCI, V86, P402, DOI 10.1016/j.lfs.2010.01.009
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x
   Price CL, 2009, TRENDS ENDOCRIN MET, V20, P312, DOI 10.1016/j.tem.2009.03.010
   Rabbani N, 2008, BIOCHEM SOC T, V36, P1045, DOI 10.1042/BST0361045
   Rabbani N, 2008, ANN NY ACAD SCI, V1126, P124, DOI 10.1196/annals.1433.043
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Roy S, 2011, MOL VIS, V17, P3166
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Thornalley PJ, 2000, BIOCHEM PHARMACOL, V60, P55, DOI 10.1016/S0006-2952(00)00287-2
   Wang W, 1998, PHARMACOL REV, V50, P335
   Wolff DJ, 1997, ARCH BIOCHEM BIOPHYS, V338, P73, DOI 10.1006/abbi.1996.9811
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yamamoto K, 2011, INVEST OPHTH VIS SCI, V52, P9084, DOI 10.1167/iovs.11-8632
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 47
TC 60
Z9 63
U1 1
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 19
PY 2012
VL 7
IS 7
AR e41309
DI 10.1371/journal.pone.0041309
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 981GZ
UT WOS:000306956300077
PM 22829938
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Duvvari, MR
   Paun, CC
   Buitendijk, GHS
   Saksens, NTM
   Volokhina, EB
   Ristau, T
   Schoenmaker-Koller, FE
   van de Ven, JPH
   Groenewoud, JMM
   van den Heuvel, LPWJ
   Hofman, A
   Fauser, S
   Uitterlinden, AG
   Klaver, CCW
   Hoyng, CB
   de Jong, EK
   den Hollander, AI
AF Duvvari, Maheswara R.
   Paun, Codrut C.
   Buitendijk, Gabrielle H. S.
   Saksens, Nicole T. M.
   Volokhina, Elena B.
   Ristau, Tina
   Schoenmaker-Koller, Frederieke E.
   van de Ven, Johannes P. H.
   Groenewoud, Joannes M. M.
   van den Heuvel, Lambertus P. W. J.
   Hofman, Albert
   Fauser, Sascha
   Uitterlinden, Andre G.
   Klaver, Caroline C. W.
   Hoyng, Carel B.
   de Jong, Eiko K.
   den Hollander, Anneke I.
TI Analysis of Rare Variants in the C3 Gene in Patients with Age-Related
   Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID HIGH-RISK; COMPLEMENT ACTIVATION; MUTATION; ALLELES; CONFERS; CELLS;
   CFH; DNA
AB Age-related macular degeneration (AMD) is a progressive retinal disorder affecting over 33 million people worldwide. Genome-wide association studies (GWASs) for AMD identified common variants at 19 loci accounting for 15-65% of the heritability and it has been hypothesized that the missing heritability may be attributed to rare variants with large effect sizes. Common variants in the complement component 3 (C3) gene have been associated with AMD and recently a rare C3 variant (Lys155Gln) was identified which exerts a large effect on AMD susceptibility independent of the common variants. To explore whether additional rare variants in the C3 gene are associated with AMD, we sequenced all coding exons in 84 unrelated AMD cases. Subsequently, we genotyped all identified variants in 1474 AMD cases and 2258 controls. Additionally, because of the known genetic overlap between AMD and atypical hemolytic uremic syndrome (aHUS), we genotyped two recurrent aHUS-associated C3 mutations in the entire cohort. Overall, we identified three rare variants (Lys65Gln (P = 0.04), Arg735Trp (OR = 17.4, 95% CI = 2.2-136; P = 0.0003), and Ser1619Arg (OR = 5.2, 95% CI = 1.0-25; P = 0.05) at the C3 locus that are associated with AMD in our EUGENDA cohort. However, the Arg735Trp and Ser1619Arg variants were not found to be associated with AMD in the Rotterdam Study. The Lys65Gln variant was only identified in patients from Nijmegen, the Netherlands, and thus may represent a region-specific AMD risk variant.
C1 [Duvvari, Maheswara R.; Paun, Codrut C.; Saksens, Nicole T. M.; Schoenmaker-Koller, Frederieke E.; van de Ven, Johannes P. H.; Hoyng, Carel B.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Duvvari, Maheswara R.; Paun, Codrut C.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, NL-6525 ED Nijmegen, Netherlands.
   [Buitendijk, Gabrielle H. S.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; Hofman, Albert; Uitterlinden, Andre G.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Volokhina, Elena B.; van den Heuvel, Lambertus P. W. J.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat Nephrol, NL-6525 ED Nijmegen, Netherlands.
   [Ristau, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Dept Vitreoretinal Surg, Cologne, Germany.
   [Groenewoud, Joannes M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth & Evidence, NL-6525 ED Nijmegen, Netherlands.
   [Hofman, Albert; Uitterlinden, Andre G.] Netherlands Consortium Hlth Aging, Netherlands Genom Initiat, The Hague, Netherlands.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; Radboud University Nijmegen; University of Cologne; Radboud
   University Nijmegen; Erasmus University Rotterdam; Erasmus MC; Radboud
   University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
EM Anneke.denHollander@radboudumc.nl
RI Groenewoud, Hans JMM/R-3588-2017; van den Heuvel,
   Lambertus/AAM-1772-2021; de Jong, Eiko/P-3407-2015; van den Heuvel,
   L.P.W.J./H-8044-2014; Hollander, Anneke den/N-4911-2014; Hoyng,
   C.B./H-8050-2014; Volokhina, Elena/L-4725-2015; Klaver, Caroline
   C.W./A-2013-2016
OI Groenewoud, Hans JMM/0000-0002-4974-150X; van den Heuvel,
   Lambertus/0000-0003-3917-6727; de Jong, Eiko/0000-0001-6520-0407; van
   den Heuvel, L.P.W.J./0000-0003-3917-6727; Volokhina,
   Elena/0000-0002-4294-8460; Klaver, Caroline/0000-0002-2355-5258
FU Netherlands Organization for Scientific Research [016.096.309];
   Foundation Fighting Blindness USA [C-GE-0811-0548-RAD04]
FX This study was supported by the Netherlands Organization for Scientific
   Research (Vidi Innovational Research Award 016.096.309 to AIDH) and the
   Foundation Fighting Blindness USA (grant C-GE-0811-0548-RAD04 to AIDH).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   de Carvalho JER, 2013, INVEST OPHTH VIS SCI, V54, P6489, DOI 10.1167/iovs.13-12374
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066
   Fremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grove ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068095
   Haynes T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3312
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hofman A, 2011, EUR J EPIDEMIOL, V26, P657, DOI 10.1007/s10654-011-9610-5
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   International Council of Ophthalmology, GLOB EC COST VIS IMP
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Miller E., 2012, CHARACTERIZATION COM
   NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Roumenina LT, 2012, BLOOD, V119, P4182, DOI 10.1182/blood-2011-10-383281
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2013, FARADAY DISCUSS, V161, P9, DOI 10.1039/c2fd90045a
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Volokhina E, 2012, PEDIATR NEPHROL, V27, P1519, DOI 10.1007/s00467-012-2183-z
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 31
TC 33
Z9 33
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 15
PY 2014
VL 9
IS 4
AR e94165
DI 10.1371/journal.pone.0094165
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AI5PW
UT WOS:000336922600049
PM 24736606
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Cheung, N
   Tay, WT
   Cheung, GCM
   Wang, JJ
   Mitchell, P
   Wong, TY
AF Cheung, Ning
   Tay, Wan-Ting
   Cheung, Gemmy C. M.
   Wang, Jie-Jin
   Mitchell, Paul
   Wong, Tien Y.
TI Is aspirin intake associated with early age-related macular
   degeneration? The Singapore Indian Eye Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ATHEROSCLEROSIS RISK; MACULOPATHY; POPULATION; PREVALENCE
AB Background/aims To examine the relationship between aspirin intake and early age-related macular degeneration (AMD) among an Asian population.
   Methods A population based cross sectional study of 3207 ethnic Indians aged 40 years or older residing in Singapore. AMD signs were graded from retinal images following the modified Wisconsin grading system. Information on aspirin intake was obtained from a standardised questionnaire.
   Results The prevalence of early AMD was 5.6%. Aspirin use was reported by 11.4% of participants. Early AMD signs were present among 10.9% of aspirin users and 4.9% of non-aspirin users (p<0.001). After adjusting for potential confounders, including age, smoking and previous cataract surgery, aspirin use was associated with early AMD (OR 1.50; 95% CI: 1.01 to 2.22). The association weakened and was not significant after additional adjustment for cardiovascular disease (OR 1.38; 95% CI 0.89 to 2.14). In stratified analysis, aspirin use was significantly associated with early AMD in participants with (adjusted OR 2.64, 95% CI 1.31 to 5.36) but not without (OR 0.73; 95% CI 0.36 to 1.51) a history of cardiovascular disease (interaction term, p=0.011).
   Conclusions Aspirin intake overall was not associated with early AMD in this sample of Asian Indians, but in those with a history of cardiovascular disease the association between aspirin intake and early AMD might warrant further investigation.
C1 [Cheung, Ning; Tay, Wan-Ting; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Ning] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Cheung, Ning; Wong, Tien Y.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Cheung, Gemmy C. M.] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Wang, Jie-Jin; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Westmead, NSW 2145, Australia.
C3 National University of Singapore; Singapore National Eye Center; Chinese
   University of Hong Kong; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; Singapore
   National Eye Center; University of Sydney
RP Wong, TY (通讯作者)，Natl Univ Singapore, Singapore Eye Res Inst, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM ophwty@nus.edu.sg
RI Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; Wong, Tien
   Yin/AAC-9724-2020; wang, jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; Wong, Tien Yin/0000-0002-8448-1264;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU National Medical Research Council, Singapore [NMRC/STaR/0003/2008];
   National Health and Medical Research Council (NHMRC), Australia [52993,
   475617]
FX This work was funded by grants from the National Medical Research
   Council (NMRC/STaR/0003/2008), Singapore, and the National Health and
   Medical Research Council (NHMRC, 52993, 475617), Australia.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pan CW, 2011, INVEST OPHTH VIS SCI, V52, P6636, DOI 10.1167/iovs.10-7148
   Pan CW, 2011, INVEST OPHTH VIS SCI, V52, P3166, DOI 10.1167/iovs.10-6210
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014
NR 21
TC 15
Z9 15
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2013
VL 97
IS 6
BP 785
EP 788
DI 10.1136/bjophthalmol-2012-302253
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 148TU
UT WOS:000319271300024
PM 23486919
DA 2022-11-30
ER

PT J
AU Decanini, A
   Nordgaard, CL
   Feng, X
   Ferrington, DA
   Olsen, TW
AF Decanini, Alejandra
   Nordgaard, Curtis L.
   Feng, Xiao
   Ferrington, Deborah A.
   Olsen, Timothy W.
TI Changes in select redox proteins of the retinal pigment epithelium in
   age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMBINED PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB AVASTIN;
   OXIDATIVE STRESS; VISUAL IMPAIRMENT; ANTIOXIDANT ENZYMES; GRADING
   SYSTEM; ZINC INTAKE; MACULOPATHY; PREVALENCE; RISK
AB center dot PURPOSE: To examine changes of select reductionoxidation (redox) sensitive proteins from human donor retinal pigment epithelium (RPE) at four stages of age-related macular degeneration (AMD).
   center dot DESIGN: Experimental study.
   center dot METHODS: Human donor eyes were obtained from the Minnesota Lions Eye Bank and graded using the Minne, sota Grading System (MGS) into four stages that correspond to stages defined by the age-related eye disease study (AREDS). Protein content in RPE homogenates was measured using Western immunoblotting with proteinspecific antibodies.
   center dot RESULTS: The content of several antioxidant enzymes and specific proteins that facilitate refolding or degradation of oxidatively damaged proteins increased significantly in MGS stage 3. These proteins are involved in the primary (copper-zinc superoxide dismutase [CuZnSOD], manganese superoxide dismutase [MnSOD], and catalase) and secondary (heat shock protein [HSP] 27, HSP 90, and proteasome) defense against oxidative damage. Additionally, the insulin pro-survival receptor exhibited disease-related upregulation.
   center dot CONCLUSIONS: The pattern of protein changes identi, fied in human donor tissue graded using the MGS support the role of oxidative mechanisms in the pathogenesis and progression of AMD. The MGS uses nearly identical clinical definitions and grading criteria of AMD that are used in the AREDS, so our results apply to clinical and epiderniologic studies using similar definitions. Results from our protein analysis of human donor tissue helps to explain altered oxidative stress regulation and cell suvival pathways that occur in progressive stages of AMD.
C1 Univ Minnesota, Dept Ophthalmol, Retina Chair, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities
RP Olsen, TW (通讯作者)，Univ Minnesota, Dept Ophthalmol, Retina Chair, MMC 493,420 Delaware St SE, Minneapolis, MN 55455 USA.
EM olsen010@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU NATIONAL EYE INSTITUTE [R03EY014176] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [R01AG025392] Funding Source: NIH RePORTER;
   NEI NIH HHS [R03 EY014176-01A1, EY014176, R03 EY014176] Funding Source:
   Medline; NIA NIH HHS [AG025392, R01 AG025392, R01 AG025392-01] Funding
   Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Arrigo AP, 2005, ANTIOXID REDOX SIGN, V7, P414, DOI 10.1089/ars.2005.7.414
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Chondrogianni N, 2005, J BIOL CHEM, V280, P11840, DOI 10.1074/jbc.M413007200
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Ding QX, 2003, FEBS LETT, V546, P228, DOI 10.1016/S0014-5793(03)00582-9
   Eleuteri AM, 2002, PROTEINS, V48, P169, DOI 10.1002/prot.10101
   Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Fiorenza MT, 2004, BIOL REPROD, V70, P1606, DOI 10.1095/biolreprod.103.024877
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Hipkiss AR, 2006, EXP GERONTOL, V41, P464, DOI 10.1016/j.exger.2006.03.004
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jomary C, 2006, INVEST OPHTH VIS SCI, V47, P1620, DOI 10.1167/iovs.05-1176
   Kapphahn RJ, 2003, BIOCHEMISTRY-US, V42, P15310, DOI 10.1021/bi034774e
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Marques C, 2006, FASEB J, V20, P741, DOI 10.1096/fj.05-5080fje
   MICELI MV, 1994, EXP EYE RES, V59, P271, DOI 10.1006/exer.1994.1108
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703
   Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Salceda R, 1999, NEUROCHEM INT, V35, P301, DOI 10.1016/S0197-0186(99)00072-8
   Santos SD, 2004, NEUROSCIENCE, V126, P657, DOI 10.1016/j.neuroscience.2004.03.023
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   St Clair DK, 2002, METHOD ENZYMOL, V349, P306, DOI 10.1016/S0076-6879(02)49345-7
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5
NR 72
TC 118
Z9 127
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2007
VL 143
IS 4
BP 607
EP 615
DI 10.1016/j.ajo.2006.12.006
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 154WE
UT WOS:000245537800007
PM 17280640
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Eperjesi, F
   Fowler, CW
   Evans, BJW
AF Eperjesi, F
   Fowler, CW
   Evans, BJW
TI The effects of coloured light filter overlays on reading rates in
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE age-related macular degeneration; reading rate; coloured light filter
   overlays; light filters
ID LOW-VISION; CHROMATIC ABERRATION; LENSES; SPEED; PERFORMANCE; CLASSROOM;
   DISEASE; EYE
AB Purpose: To determine the effect of coloured light filter overlays on reading rates for people with age-related macular degeneration (AMD).
   Method: Using a prospective clinical trial design, we examined the null hypothesis that coloured light filter overlays do not improve reading rates in AMD when compared to a clear filter. Reading rates for 12 subjects with non-exudative AMD, associated with a relative scotoma and central fixation (mean age 81 years, SD 5.07 years) were determined using the Rate of Reading Test (printed, nonsense, lower case sans serif, stationary text) with 10 different, coloured light filter overlays (Intuitive Overlays(R); figures in brackets are percentage transmission values); rose (78%), pink (78%), purple (67%), aqua (81%), blue (74%), lime-green (86%), mint-green (85%), yellow (93%), orange (83%) and grey (71%). A clear overlay (Roscolene #00) (360 cdm-2) with 100% transmittance was used as a control.
   Results: ANOVA indicated that there was no statistically significant difference in reading rates with the coloured light filter overlays compared to the clear filter. Furthermore, chi-squared analysis indicated that the rose, purple and blue filters had a significantly poorer overall ranking in terms of reading rates compared to the other coloured and clear light filters.
   Conclusion: Coloured light filter overlays are unlikely to provide a clinically significant improvement in reading rates for people with non-exudative AMD associated with a relative scotoma and central fixation.
C1 Aston Univ, Sch Life & Hlth Sci, Neurosci Res Inst, Birmingham B4 7ET, W Midlands, England.
   Birmingham Focus Blindness, Low Vis Ctr, Birmingham, W Midlands, England.
   Inst Optometry, London, England.
   City Univ London, Dept Optometry & Visual Sci, London, England.
C3 Aston University; University of London; University College London; City
   University London
RP Eperjesi, F (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Neurosci Res Inst, Birmingham B4 7ET, W Midlands, England.
EM f.eperjesi@aston.ac.uk
RI Eperjesi, Frank/A-9275-2013
OI Eperjesi, Frank/0000-0003-4358-0095
CR AHN SJ, 1995, VISION RES, V35, P1939, DOI 10.1016/0042-6989(94)00294-V
   Armstrong RA, 2002, OPHTHAL PHYSL OPT, V22, P248, DOI 10.1046/j.1475-1313.2002.00020.x
   BEDFORD RE, 1957, J OPT SOC AM, V47, P564
   Bennett A.G., 1989, CLIN VISUAL OPTICS, V2nd ed.
   Bouldoukian J, 2002, OPHTHAL PHYSL OPT, V22, P55, DOI 10.1046/j.1475-1313.2002.00002.x
   Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   CAMPBELL FW, 1967, J PHYSIOL-LONDON, V192, P345, DOI 10.1113/jphysiol.1967.sp008304
   CHYLACK LT, 1988, ARCH OPHTHALMOL-CHIC, V106, P330
   Elliott DB, 2001, INVEST OPHTH VIS SCI, V42, P1945
   Eperjesi F, 2004, OPHTHAL PHYSL OPT, V24, P17, DOI 10.1046/j.1475-1313.2003.00157.x
   Eperjesi F, 2002, OPHTHAL PHYSL OPT, V22, P68, DOI 10.1046/j.1475-1313.2002.00004.x
   FRENNESSON IC, 1993, DOC OPHTHALMOL, V84, P135, DOI 10.1007/BF01206248
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   HELLINGER G, 1983, J VISUAL IMPAIR BLIN, V77, P449
   HOEFT WW, 1981, AM J OPTOM PHYS OPT, V58, P841
   Jeanes R, 1997, BRIT J PSYCHOL, V88, P531
   LAND EH, 1977, SCI AM, V237, P108, DOI 10.1038/scientificamerican1277-108
   Langagergaard U, 2003, ACTA OPHTHALMOL SCAN, V81, P455, DOI 10.1034/j.1600-0420.2003.00142.x
   LEGGE GE, 1986, J OPT SOC AM A, V3, P40, DOI 10.1364/JOSAA.3.000040
   Lynch D, 1984, OPTOMETRIC MONTHLY, V75, P36
   Maino J H, 1986, J Am Optom Assoc, V57, P532
   MORRISSETTE DL, 1984, AM J OPTOM PHYS OPT, V61, P704
   Provines W F, 1997, J Am Optom Assoc, V68, P353
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Scott L, 2002, OPHTHAL PHYSL OPT, V22, P156, DOI 10.1046/j.1475-1313.2002.00009.x
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   TUPPER B, 1985, ANN OPHTHALMOL, V17, P67
   WHITAKER D, 1993, OPTOMETRY VISION SCI, V70, P963, DOI 10.1097/00006324-199311000-00014
   WILKINS A, 1994, OPHTHAL PHYSL OPT, V14, P97, DOI 10.1111/j.1475-1313.1994.tb00567.x
   Wilkins A. J., 1995, VISUAL STRESS
   Wilkins AJ, 1996, OPHTHAL PHYSL OPT, V16, P491, DOI 10.1016/0275-5408(96)00028-2
   Wolffsohn JS, 2002, OPHTHAL PHYSL OPT, V22, P300, DOI 10.1046/j.1475-1313.2002.00036.x
   ZIGMAN S, 1990, OPTOMETRY VISION SCI, V67, P100, DOI 10.1097/00006324-199002000-00007
NR 33
TC 17
Z9 18
U1 0
U2 12
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD DEC
PY 2004
VL 82
IS 6
BP 695
EP 700
DI 10.1111/j.1600-0420.2004.00371.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 884NT
UT WOS:000226093000011
PM 15606466
OA Bronze
DA 2022-11-30
ER

PT J
AU Flores-Moreno, I
   Arias-Barquet, L
   Rubio-Caso, MJ
   Ruiz-Moreno, JM
   Duker, JS
   Caminal, JM
AF Flores-Moreno, Ignacio
   Arias-Barquet, Luis
   Rubio-Caso, Marcos J.
   Ruiz-Moreno, Jose M.
   Duker, Jay S.
   Caminal, Josep M.
TI En face swept-source optical coherence tomography in neovascular
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Choroid; Macula; Imaging
ID CHOROIDAL THICKNESS; SPECTRAL-DOMAIN; HIGH MYOPIA; EYES; VOLUME
AB Purpose To describe en face swept-source optical coherence tomography (SS-OCT) findings in the retinal pigment epithelium (RPE) and choroid and to correlate them with fluorescein angiography (FA) and/or indocyanine green angiography (ICGA) in neovascular age-related macular degeneration (AMD).
   Methods Thirty-eight eyes with the recent diagnosis of neovascular AMD were imaged using an SS-OCT system. En face images were obtained at RPE, choriocapillaris, Sattler's layer and Haller's layer level. Analysis of the images and correlation with colour fundus photographs, FA, ICGA in selected cases, were made.
   Results En face images at RPE level revealed changes in all eyes. The neovascular complex appeared hyper-reflective in 9 of 38 eyes (23.7%), and in 29 of 38 eyes (76.3%), it was hyporeflective. The choriocapillaris en face image showed pathological changes in all eyes as well, and in 20 out of 38 eyes (52.6%), the alterations were hyper-reflective, while 18 of 38 eyes (47.4%) showed hyporeflective changes. Twenty (52.6%) eyes and 19 (50.0%) had a hyper-reflective lesion in Sattler's layer and Haller's layer, respectively, and 15 (39.4%) cases showed a hyporeflective lesion in both layers. No differences were found between the neovascular complex area, horizontal and vertical diameters, measured in the en face image and FA (p=0.171, p=0.061, p=0.133, respectively). Hyporeflective changes were predominant at RPE level and hyper-reflective at choriocapillaris, Sattler's and Haller's layers.
   Conclusions En face SS-OCT is a rapid, non-invasive, high-resolution, promising technology, which allows a complementary study to angiography of neovascular AMD. There is a correlation between angiography and en face SS-OCT images in neovascular AMD.
C1 [Flores-Moreno, Ignacio; Arias-Barquet, Luis; Rubio-Caso, Marcos J.; Caminal, Josep M.] Bellvitge Univ Hospital, Dept Ophthalmol, Barcelona 08907, Spain.
   [Ruiz-Moreno, Jose M.] Univ Castilla La Mancha, Dept Ophthalmol, Albacete, Spain.
   [Duker, Jay S.] Tufts Med Ctr, New England Eye Ctr, Boston, MA USA.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge
   University Hospital; Universidad de Castilla-La Mancha; Tufts Medical
   Center
RP Flores-Moreno, I (通讯作者)，Bellvitge Univ Hospital, Dept Ophthalmol, Feixa Llarga S-N, Barcelona 08907, Spain.
EM i_floresmoreno@hotmail.com
RI Ruiz-Moreno, José M/E-4644-2016; Rubio Caso, Marcos Javier/L-6866-2013
OI Rubio Caso, Marcos Javier/0000-0002-7072-9855; Ruiz-Moreno, Jose
   M/0000-0001-9636-0788; Caminal, JM/0000-0001-9563-0344
FU Spanish Ministry of Health, Instituto de Salud Carlos III, Red Tematica
   de Investigacion Cooperativa en Salud "Patologia ocular del
   envejecimiento, calidad visual y calidad de vida" [RD07/0062/0019,
   RD07/0062/0010]; Spanish Vitreo-Retinal Society "Programa de formacion
   de expertos en retina de la Sociedad Espanola de Retina y Vitreo
   (PERF-SERV)"; Research to Prevent Blindness
FX This study has been supported in part by a grant of the Spanish Ministry
   of Health, Instituto de Salud Carlos III, Red Tematica de Investigacion
   Cooperativa en Salud "Patologia ocular del envejecimiento, calidad
   visual y calidad de vida" (RD07/0062/0019 and RD07/0062/0010) and by a
   grant of the Spanish Vitreo-Retinal Society "Programa de formacion de
   expertos en retina de la Sociedad Espanola de Retina y Vitreo
   (PERF-SERV)". This study has been supported in part by a Research to
   Prevent Blindness. Unrestricted Grant to the New England Eye
   Center/Department of Ophthalmology, Tufts University School of Medicine
   and the Massachusetts Lions Clubs.
CR Casaroli-Marano R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/346360
   Copete S, 2014, BRIT J OPHTHALMOL, V98, P334, DOI 10.1136/bjophthalmol-2013-303904
   Ellabban AA, 2012, AM J OPHTHALMOL, V153, P1133, DOI 10.1016/j.ajo.2011.12.013
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Flores-Moreno I, 2013, AM J OPHTHALMOL, V155, P314, DOI 10.1016/j.ajo.2012.07.015
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Itakura H, 2014, INVEST OPHTH VIS SCI, V55, P1447, DOI 10.1167/iovs.13-13496
   Ohsugi H, 2014, AM J OPHTHALMOL, V158, P162, DOI 10.1016/j.ajo.2014.02.054
   Park HYL, 2014, AM J OPHTHALMOL, V157, P876, DOI 10.1016/j.ajo.2014.01.007
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
NR 11
TC 19
Z9 19
U1 0
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2015
VL 99
IS 9
BP 1260
EP 1267
DI 10.1136/bjophthalmol-2014-306422
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ2VL
UT WOS:000360460000023
PM 25722493
DA 2022-11-30
ER

PT J
AU Yiu, G
   Vuong, VS
   Tran, S
   Migacz, J
   Cunefare, D
   Farsiu, S
   Khandelwal, N
   Agrawal, R
   Cheung, CMG
AF Yiu, Glenn
   Vuong, Vivian S.
   Tran, Steven
   Migacz, Justin
   Cunefare, David
   Farsiu, Sina
   Khandelwal, Neha
   Agrawal, Rupesh
   Cheung, Chui Ming Gemmy
TI Vascular Response to Sildenafil Citrate in Aging and Age-Related Macular
   Degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CHOROIDAL BLOOD-FLOW; GROWTH-FACTOR THERAPY; THICKNESS MEASUREMENTS;
   CARDIOVASCULAR EVENTS; INTRAOCULAR-PRESSURE; ARTERIAL STIFFNESS; VIAGRA;
   EYES; CIRCULATION; PERFUSION
AB Age-related macular degeneration (AMD) - the leading cause of vision loss in the elderly - share many risks factors as atherosclerosis, which exhibits loss of vascular compliance resulting from aging and oxidative stress. Here, we attempt to explore choroidal and retinal vascular compliance in patients with AMD by evaluating dynamic vascular changes using live ocular imaging following treatment with oral sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor and potent vasodilator. Enhanced-depth imaging optical coherence tomography (EDI-OCT) and OCT angiography (OCT-A) were performed on 46 eyes of 23 subjects, including 15 patients with non-exudative AMD in one eye and exudative AMD in the fellow eye, and 8 age-matched control subjects. Choroidal thickness, choroidal vascularity, and retinal vessel density were measured across the central macula at 1 and 3 hours after a 100 mg oral dose of sildenafil citrate. Baseline choroidal thickness was 172.1 +/- 60.0 mu m in non-exudative AMD eyes, 196.4 +/- 89.8 mu m in exudative AMD eyes, and 207.4 +/- 77.7 mu m in control eyes, with no difference between the 3 groups (P = 0.116). After sildenafil, choroidal thickness increased by 6.0% to 9.0% at 1 and 3 hours in all groups (P = 0.001-0.014). Eyes from older subjects were associated with choroidal thinning at baseline (P = 0.005) and showed less choroidal expansion at 1 hour and 3 hours after sildenafil (P = 0.001) regardless of AMD status (P = 0.666). The choroidal thickening appeared to be primarily attributed to expansion of the stroma rather than luminal component. Retinal vascular density remained unchanged after sildenafil in all 3 groups (P =0.281-0.587). Together, our studies suggest that vascular response of the choroid to sildenafil decreases with age, but is not affected by the presence of non-exudative or exudative AMD, providing insight into changes in vessel compliance in aging and AMD.
C1 [Yiu, Glenn; Vuong, Vivian S.; Migacz, Justin] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Tran, Steven] Rosalind Franklin Univ Med & Sci, N Chicago, IL USA.
   [Cunefare, David; Farsiu, Sina] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
   [Khandelwal, Neha; Agrawal, Rupesh] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.
   [Agrawal, Rupesh; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
C3 University of California System; University of California Davis;
   Rosalind Franklin University Medical & Science; Duke University; Tan
   Tock Seng Hospital; National University of Singapore; Singapore National
   Eye Center
RP Yiu, G (通讯作者)，Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
EM gyiu@ucdavis.edu
RI Yiu, Glenn/AAF-2858-2020
OI Yiu, Glenn/0000-0003-3061-3310; Agrawal, Rupesh/0000-0002-6662-5850;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU NIH [K08 EY026101, UL1TR000002]; E. Matilda Ziegler Foundation for the
   Blind; Barr Foundation for Retinal Research; Alcon Research Institute;
   ARVO Foundation; California National Primate Resarch Center;
   CITRIS/Banatao Insitute; Macula Society; National Center for Advancing
   Translational Sciences;  [P30 EY005722]; NATIONAL EYE INSTITUTE
   [K08EY026101, P30EY005722] Funding Source: NIH RePORTER
FX We thank Gregory Hoffmeyer (Carl Zeiss Meditec) for assistance with
   image processing, and Thomas Barnes, Jeffrey Caspar, Lawrence Morse, Ala
   Moshiri, Paul Nefedov, and Susanna Park (UC Davis) for assistance with
   patient recruitment. GY is supported by NIH K08 EY026101, the E. Matilda
   Ziegler Foundation for the Blind, Barr Foundation for Retinal Research,
   Alcon Research Institute, ARVO Foundation, California National Primate
   Resarch Center, CITRIS/Banatao Insitute, and the Macula Society. VV is
   supported by the National Center for Advancing Translational Sciences
   and NIH UL1TR000002. SF is funded in part by P30 EY005722. No funding
   organizations had any role in the design or conduct of this research.
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the funding agencies.
CR Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Agrawal R, 2017, ACTA OPHTHALMOL, V95, pe770, DOI 10.1111/aos.13442
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Al-Ali BM, 2015, MINERVA UROL NEFROL, V67, P11
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V191, P23, DOI 10.1016/j.ajo.2018.03.038
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2002, AM J OPHTHALMOL, V133, P809, DOI 10.1016/S0002-9394(02)01391-0
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim DY, 2013, ACTA OPHTHALMOL, V91, P183, DOI 10.1111/j.1755-3768.2011.02305.x
   Kohn JC, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00112
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Metelitsina TI, 2006, EXP EYE RES, V83, P128, DOI 10.1016/j.exer.2005.11.012
   Metelitsina TI, 2005, EXP EYE RES, V81, P159, DOI 10.1016/j.exer.2005.01.017
   Moisseiev E, 2017, ACTA OPHTHALMOL, V95, pE242, DOI 10.1111/aos.12926
   Niblack W, 1986, ADV COMPUTER GRAPHIC
   Pache M, 2002, BRIT J OPHTHALMOL, V86, P156, DOI 10.1136/bjo.86.2.156
   Pemp B, 2012, ACTA OPHTHALMOL, V90, P139, DOI 10.1111/j.1755-3768.2010.01878.x
   Polska E, 2007, INVEST OPHTH VIS SCI, V48, P3768, DOI 10.1167/iovs.07-0307
   Pomeranz HD, 2016, J NEURO-OPHTHALMOL, V36, P193, DOI 10.1097/WNO.0000000000000299
   Schmidl D, 2016, INVEST OPHTH VIS SCI, V57, P5705, DOI 10.1167/iovs.16-20225
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Snyder K, 2018, JAMA OPHTHALMOL, V136, P1008, DOI 10.1001/jamaophthalmol.2018.2650
   Sugiura T, 2017, J ATHEROSCLER THROMB, V24, P1186, DOI 10.5551/jat.39289
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Todorich B, 2014, EXPERT REV CLIN PHAR, V7, P375, DOI 10.1586/17512433.2014.890047
   Vance SK, 2011, RETINA-J RET VIT DIS, V31, P332, DOI 10.1097/IAE.0b013e3181eef0ae
   Vlachopoulos C, 2014, HYPERTENSION, V64, P672, DOI 10.1161/HYPERTENSIONAHA.114.03369
   Vuong VS, 2016, AM J OPHTHALMOL, V169, P104, DOI 10.1016/j.ajo.2016.06.023
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Wong SS, 2017, AM J OPHTHALMOL, V184, P108, DOI 10.1016/j.ajo.2017.10.005
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yajima T, 2000, AM J OPHTHALMOL, V129, P675, DOI 10.1016/S0002-9394(00)00375-5
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Yiu G, 2014, AM J OPHTHALMOL, V158, P745, DOI 10.1016/j.ajo.2014.06.006
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
NR 47
TC 13
Z9 14
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 25
PY 2019
VL 9
AR 5049
DI 10.1038/s41598-019-41509-2
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HQ1HV
UT WOS:000462149800004
PM 30911094
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Longo, A
   Casuccio, A
   Pani, L
   Avitabile, T
   Cillino, S
   Uva, MG
   Bonfiglio, V
   Russo, A
   Parisi, G
   Cennamo, G
   Furino, C
   Parravano, M
   Xoxi, E
   Reibaldi, M
AF Longo, Antonio
   Casuccio, Alessandra
   Pani, Luca
   Avitabile, Teresio
   Cillino, Salvatore
   Uva, Maurizio G.
   Bonfiglio, Vincenza
   Russo, Andrea
   Parisi, Guglielmo
   Cennamo, Gilda
   Furino, Claudio
   Parravano, Mariacristina
   Xoxi, Entela
   Reibaldi, Michele
TI Association of neovascular age-related macular degeneration with month
   and season of birth in Italy
SO AGING-US
LA English
DT Article
DE neovascular age-related macular degeneration; neovascular AMD;
   anti-VEGF; season of birth; month of birth
ID VITAMIN-D DEFICIENCY; 25-HYDROXYVITAMIN D; MULTIPLE-SCLEROSIS;
   HYPOVITAMINOSIS D; RISK; DISEASE
AB In order to investigate the influence of season and month of birth on the risk of neovascular age-related macular degeneration (n-AMD) in Italy, we evaluated the month birth and sex of all patients, recorded in the anti-vascular endothelial growth factor (VEGF) monitoring registry of the Italian Medicines Agency, born between 1925-1944, who received intravitreal anti-VEGF injections for n-AMD between January 1, 2013 and July 29, 2015. The numbers of all births in Italy in the same years, extracted from the Italian National Institute of Statistics, were used to calculate the expected number of n-AMD cases. Overall, 45,845 patients (19,207 men, 26,638 women) received intravitreal anti-VEGF for n-AMD; in the same years, 20,140,426 people (10,334,262 male, 9,806,164 female) were born in Italy. Comparing the observed number of n-AMD cases with the expected number of n-AMD cases in each season, we found that the season-specific risk for n-AMD was 2.5% higher for those born in summer (OR= 1.03, Bonferroni-corrected P= 0.008) and 3% lower for those born in winter (OR= 0.96, Bonferroni-corrected P= 0.0004). When considering the month of birth, the risk of n-AMD was 5.9% lower for people born in January (OR= 0.93, Bonferroni-corrected P= 0.0012). The factors causing such differences should be determined.
C1 [Longo, Antonio; Avitabile, Teresio; Uva, Maurizio G.; Bonfiglio, Vincenza; Russo, Andrea; Parisi, Guglielmo; Reibaldi, Michele] Azienda Policlin Vittorio Emanuele, Catania, Italy.
   [Casuccio, Alessandra] Univ Palermo, Dept Sci Hlth Promot, Palermo, Italy.
   [Casuccio, Alessandra] Univ Palermo, Dept Mother Child Care, Palermo, Italy.
   [Pani, Luca; Xoxi, Entela] Italian Med Agcy, Rome, Italy.
   [Cillino, Salvatore] Univ Palermo, Eye Clin, Palermo, Italy.
   [Cennamo, Gilda] Univ Naples Federico II, Eye Clin, Naples, Italy.
   [Furino, Claudio] Univ Bari, Eye Clin, Bari, Italy.
   [Parravano, Mariacristina] Fdn GB Bietti, IRCCS, Rome, Italy.
C3 Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Presidio
   Ferraotto; University of Palermo; University of Palermo; University of
   Palermo; University of Naples Federico II; Universita degli Studi di
   Bari Aldo Moro; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Longo, A (通讯作者)，Azienda Policlin Vittorio Emanuele, Catania, Italy.
EM ant-longo@libero.it
RI Parisi, Guglielmo/AAC-3933-2022; Longo, Antonio/AAC-6092-2022; Reibaldi,
   Michele/AAL-1113-2021; casuccio, alessandra/B-1730-2013; Avitabile,
   Teresio/AAC-6076-2022; Pani, Luca/AAM-9467-2020
OI Parisi, Guglielmo/0000-0003-0795-618X; casuccio,
   alessandra/0000-0002-5676-9535; Pani, Luca/0000-0001-9273-2839; LONGO,
   Antonio/0000-0002-9525-1800; Xoxi, Entela/0000-0003-0904-9225
CR Bodnar LM, 2007, J NUTR, V137, P2437, DOI 10.1093/jn/137.11.2437
   Boland MR, 2015, J AM MED INFORM ASSN, V22, P1042, DOI 10.1093/jamia/ocv046
   Cadario F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129586
   Carrillo-Vico A, 2013, INT J MOL SCI, V14, P8638, DOI 10.3390/ijms14048638
   Chabas JF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065034
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cui XY, 2007, INT J DEV NEUROSCI, V25, P227, DOI 10.1016/j.ijdevneu.2007.03.006
   Disanto G, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-69
   Dobson R, 2013, J NEUROL NEUROSUR PS, V84, P427, DOI 10.1136/jnnp-2012-303934
   Fiddes B, 2014, J NEUROL, V261, P1851, DOI 10.1007/s00415-014-7241-y
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Harvey L, 2010, J STEROID BIOCHEM, V121, P239, DOI 10.1016/j.jsbmb.2010.03.050
   Hewison M, 2012, CLIN ENDOCRINOL, V76, P315, DOI 10.1111/j.1365-2265.2011.04261.x
   Holmes VA, 2009, BRIT J NUTR, V102, P876, DOI 10.1017/S0007114509297236
   Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Kahn HS, 2009, DIABETES CARE, V32, P2010, DOI 10.2337/dc09-0891
   Kasahara AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065785
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mandel Y, 2008, OPHTHALMOLOGY, V115, P686, DOI 10.1016/j.ophtha.2007.05.040
   McMahon G, 2009, OPHTHALMOLOGY, V116, P468, DOI 10.1016/j.ophtha.2008.10.004
   Montilla S, 2015, INT J TECHNOL ASSESS, V31, P210, DOI 10.1017/S0266462315000446
   Ramagopalan SV, 2010, GENOME RES, V20, P1352, DOI 10.1101/gr.107920.110
   Rasmussen KM, 2001, ANNU REV NUTR, V21, P73, DOI 10.1146/annurev.nutr.21.1.73
   REIBALDI M, AM J OPHTHALMOL, V161, P78, DOI DOI 10.1016/J.AJ0.2015.09.031
   Romagnoli E, 1999, BRIT J NUTR, V81, P133, DOI 10.1017/S0007114599000264
   Salzer J, 2010, ACTA NEUROL SCAND, V121, P20, DOI 10.1111/j.1600-0404.2009.01181.x
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Simpson S, 2010, ANN NEUROL, V68, P193, DOI 10.1002/ana.22043
   Soilu-Hanninen M, 2008, J NEUROL NEUROSUR PS, V79, P152, DOI 10.1136/jnnp.2006.105320
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xoxi E, 2012, PHARM PROGRAMMING, V5, P57, DOI [10.1179/ 1757092112Z.0000000009, DOI 10.1179/1757092112Z.0000000009]
   Yu SH, 2011, J IMMUNOL, V186, P1384, DOI 10.4049/jimmunol.1002545
NR 34
TC 3
Z9 3
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JAN
PY 2017
VL 9
IS 1
BP 147
EP 155
DI 10.18632/aging.101137
PG 9
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA EK8JW
UT WOS:000394170800012
PM 27997361
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Altinisik, M
   Kurt, E
   Sonmezer, P
   Kayikcioglu, O
   Ilker, SS
AF Altinisik, Muhammed
   Kurt, Emin
   Sonmezer, Pinar
   Kayikcioglu, Ozcan
   Ilker, Suleyman Sami
TI A comparative study of type 1 neovascularization: Neovascular
   age-related macular degeneration versus pachychoroid neovasculopathy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Choroidal neovascularization; neovascular age-related macular
   degeneration; optical coherence tomography angiography; quiescent
   neovascularization; pachychoroid neovasculopathy
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION
AB Purpose: This study aimed to compare type 1 choroidal neovascularization (CNV) characteristics in eyes with pachychoroid neovasculopathy (PNV) and neovascular age-related macular degeneration (nAMD) using optical coherence tomography angiography (OCTA). Methods: Treatment naive 23 eyes of 23 patients with PNV and 24 eyes of 24 patients with nAMD were evaluated. The height of pigment epithelial detachment (PED) and the central macular thickness were determined. OCTA sensitivity, CNV area, morphological patterns, and retinal superficial capillary plexus vessel density (SCP-VD) values were compared. The frequency of quiescent CNV, subretinal hyperreflective exudation (SHE), subretinal/intraretinal fluid, serous PED, double-layer sign (DLS), and pachyvessels were noted. Results: CNV was detected on OCTA in 83.3% of nAMD eyes and 91.3% of PNV eyes (p = 0.66). Indistinct pattern was more common (74% vs 50%) and the CNV area (mm(2)) was smaller in PNV (0.77 +/- 0.54 vs 1.57 +/- 1.43) but did not reach significant levels (p = 0.27 and 0.33 respectively). SCP-VD was similar between the groups (p = 0.38). Statistically significant differences were found between groups in age and subfoveal choroidal thickness (p < 0.05). DLS and pachyvessels were found to be more frequently in PNV (p < 0.05). However, both groups had similar rates of quiescent CNV, SHE, subretinal/intraretinal fluid, and serous PED (p > 0.05). Conclusion: Morphological features, area, and activation findings of type 1 CNV may play a limited role in differentiating nAMD and PNV cases.
C1 [Altinisik, Muhammed; Kurt, Emin; Sonmezer, Pinar; Kayikcioglu, Ozcan; Ilker, Suleyman Sami] Manisa Celal Bayar Univ, Ophthalmol Dept, Manisa, Turkey.
C3 Celal Bayar University
RP Altinisik, M (通讯作者)，Manisa Celal Bayar Univ, Sch Med, Ophthalmol Dept, TR-45140 Manisa, Turkey.
EM dr.maltinisik@gmail.com
OI Altinisik, Muhammed/0000-0003-0239-0180
CR Arf S, 2020, JPN J OPHTHALMOL, V64, P257, DOI 10.1007/s10384-020-00730-7
   Baek J., 2019, SCI REP-UK, V9, P1
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Bicer O, 2020, OSLI RETINA, V51, P640, DOI 10.3928/23258160-20201104-06
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Forte R, 2020, BRIT J OPHTHALMOL, V104, P1057, DOI 10.1136/bjophthalmol-2019-315189
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lee SC, 2020, AM J OPHTHALMOL, V212, P7, DOI 10.1016/j.ajo.2019.11.031
   Lupidi M, 2018, EUR J OPHTHALMOL, V28, P349, DOI 10.1177/1120672118766807
   Maruyama-Inoue M, 2018, GRAEF ARCH CLIN EXP, V256, P2089, DOI 10.1007/s00417-018-4121-7
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miere A, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3751702
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Souedan V, 2018, INT OPHTHALMOL, V38, P1051, DOI 10.1007/s10792-017-0559-6
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamamoto Y, 2003, JPN J OPHTHALMOL, V47, P53, DOI 10.1016/S0021-5155(02)00632-9
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
NR 29
TC 1
Z9 1
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL
PY 2022
VL 32
IS 4
BP 2404
EP 2411
AR 11206721211037828
DI 10.1177/11206721211037828
EA AUG 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3B9CF
UT WOS:000684361400001
PM 34374308
DA 2022-11-30
ER

PT J
AU Markun, S
   Dishy, A
   Neuner-Jehle, S
   Rosemann, T
   Frei, A
AF Markun, Stefan
   Dishy, Avraham
   Neuner-Jehle, Stefan
   Rosemann, Thomas
   Frei, Anja
TI The Chronic Care for Wet Age Related Macular Degeneration (CHARMED)
   Study: A Randomized Controlled Trial
SO PLOS ONE
LA English
DT Article
ID CHRONIC ILLNESS CARE; RANIBIZUMAB; EYE; MANAGEMENT; SETTINGS; MODEL
AB Background
   In real life, outcomes in wet age related macular degeneration (W-AMD) continue to fall behind the results from randomized controlled trials. The aim of this trial was to assess if outcomes can be improved by an intervention in healthcare organization following recommendations of the Chronic Care Model (CCM).
   Methods
   Multi-centered randomized controlled clinical trial. The multifaceted intervention consisted in reorganization of care (delivery by trained chronic care coaches, using reminder systems, performing structured follow-up, empowering patients in self-monitoring and giving decision-support). In the control usual care was continued. Main outcome measures were changes in ETDRS visual acuity, optical coherence tomography (OCT) macular retinal thickness and quality of life (NEI VFQ-25 questionnaire).
   Results
   169 consecutive patients in Swiss ophthalmology centers were included. Mean ETDRS baseline visual acuity of eyes with W-AMD was 57.8 (+/- 18.7). After 12 months, the between-group difference in mean change of ETDRS visual acuity was -4.8 (95% CI: -10.8 to + 1.2, p = 0.15); difference in mean change of OCT was + 14.0 (95% CI -39.6 to 67.6, p = 0.60); difference in mean change of NEI VFQ-25 composite score mean change was + 2.1 (95% CI: -1.3 to + 5.5, p = 0.19).
   Conclusions
   The intervention aiming at improving chronic care was not associated with favorable outcomes within 12 months. Other approaches need to be tested to close the evidence-performance gap in W-AMD.
C1 [Markun, Stefan; Neuner-Jehle, Stefan; Rosemann, Thomas; Frei, Anja] Univ Zurich, Univ Zurich Hosp, Inst Primary Care, Zurich, Switzerland.
   [Dishy, Avraham] Cantonal Hosp Aarau, Dept Ophthalmol, Aarau, Switzerland.
   [Frei, Anja] Univ Zurich, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital; Kantonsspital Aarau AG
   (KSA); University of Zurich
RP Markun, S (通讯作者)，Univ Zurich, Univ Zurich Hosp, Inst Primary Care, Zurich, Switzerland.
EM stefan.markun@usz.ch
RI Neuner-Jehle, Stefan/W-3094-2019
OI Frei, Anja/0000-0002-7134-1000; Markun, Stefan/0000-0003-3317-0957;
   Neuner-Jehle, Stefan/0000-0002-6260-8148
FU non-commercial foundation Zukunft Hausarzt, Zurcher Stiftung zur
   Forderung der Hausarztmedizin, Zurich
FX This trial was supported by the non-commercial foundation Zukunft
   Hausarzt, Zurcher Stiftung zur Forderung der Hausarztmedizin, Zurich.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adams SG, 2007, ARCH INTERN MED, V167, P551, DOI 10.1001/archinte.167.6.551
   Bonomi AE, 2002, HEALTH SERV RES, V37, P791, DOI 10.1111/1475-6773.00049
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Epping-Jordan JE, 2001, INNOVATIVE CARE CHRO
   Frei A, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-221
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Glasgow RE, 2005, MED CARE, V43, P436, DOI 10.1097/01.mlr.0000160375.47920.8c
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Markun S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108536
   Moullec G, 2012, RESP MED, V106, P1211, DOI 10.1016/j.rmed.2012.06.001
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stellefson M, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.120180
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64
   Woltmann E, 2012, AM J PSYCHIAT, V169, P790, DOI 10.1176/appi.ajp.2012.11111616
NR 26
TC 4
Z9 5
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 16
PY 2015
VL 10
IS 11
AR e0143085
DI 10.1371/journal.pone.0143085
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CW5XP
UT WOS:000365070700133
PM 26569501
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Vaghefi, E
   Hill, S
   Kersten, HM
   Squirrell, D
AF Vaghefi, Ehsan
   Hill, Sophie
   Kersten, Hannah M.
   Squirrell, David
TI Multimodal Retinal Image Analysis via Deep Learning for the Diagnosis of
   Intermediate Dry Age-Related Macular Degeneration: A Feasibility Study
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AUTOMATED DRUSEN DETECTION; GEOGRAPHIC ATROPHY; QUANTIFICATION;
   MACULOPATHY; PROGRESSION; PREVALENCE; VALIDATION; PREDICTION; SYSTEM;
   AMD
AB Background and Objective. To determine if using a multi-input deep learning approach in the image analysis of optical coherence tomography (OCT), OCT angiography (OCT-A), and colour fundus photographs increases the accuracy of a CNN to diagnose intermediate dry age-related macular degeneration (AMD). Patients and Methods. Seventy-five participants were recruited and divided into three cohorts: young healthy (YH), old healthy (OH), and patients with intermediate dry AMD. Colour fundus photography, OCT, and OCT-A scans were performed. The convolutional neural network (CNN) was trained on multiple image modalities at the same time. Results. The CNN trained using OCT alone showed a diagnostic accuracy of 94%, whilst the OCT-A trained CNN resulted in an accuracy of 91%. When multiple modalities were combined, the CNN accuracy increased to 96% in the AMD cohort. Conclusions. Here we demonstrate that superior diagnostic accuracy can be achieved when deep learning is combined with multimodal image analysis.
C1 [Vaghefi, Ehsan; Kersten, Hannah M.] Univ Auckland, Sch Optometry & Vis Sci, Auckland, New Zealand.
   [Vaghefi, Ehsan] Univ Auckland, Auckland Bioengn Inst, Auckland, New Zealand.
   [Hill, Sophie; Squirrell, David] Univ Auckland, Dept Ophthalmol, Auckland, New Zealand.
C3 University of Auckland; University of Auckland; University of Auckland
RP Vaghefi, E (通讯作者)，Univ Auckland, Sch Optometry & Vis Sci, Auckland, New Zealand.; Vaghefi, E (通讯作者)，Univ Auckland, Auckland Bioengn Inst, Auckland, New Zealand.
EM e.vaghefi@auckland.ac.nz
OI Vaghefi, Ehsan/0000-0002-9482-3168
FU Ministry of Business, Innovation and Education (MBIE) Endeavour Fast
   Start Fund [UOAX1805]
FX This research was funded by the Ministry of Business, Innovation and
   Education (MBIE) Endeavour Fast Start Fund (UOAX1805).
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Acharya UR, 2017, J COMPUT SCI-NETH, V20, P41, DOI 10.1016/j.jocs.2017.03.005
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Bahdanau D., 2015, P INT C LEARN REPR I
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Castelvecchi D, 2016, NATURE, V537, P20, DOI 10.1038/538020a
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Cho K, 2015, IEEE T MULTIMEDIA, V17, P1875, DOI 10.1109/TMM.2015.2477044
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gao XT, 2015, IEEE T BIO-MED ENG, V62, P2693, DOI 10.1109/TBME.2015.2444389
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Krause J, 2018, OPHTHALMOLOGY, V125, P1264, DOI 10.1016/j.ophtha.2018.01.034
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Ly A, 2018, INVEST OPHTH VIS SCI, V59, P1790, DOI 10.1167/iovs.17-23076
   Mansour RF, 2018, BIOMED ENG LETT, V8, P41, DOI 10.1007/s13534-017-0047-y
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Schmitz-Valckenberg S, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.3
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Serrano-Aguilar P, 2012, BRIT J OPHTHALMOL, V96, P503, DOI 10.1136/bjophthalmol-2011-300660
   Sivagnanavel V, 2005, BRIT J OPHTHALMOL, V89, P554, DOI 10.1136/bjo.2004.046813
   Smieliauskas F, 2014, J MED SCREEN, V21, P207, DOI 10.1177/0969141314548055
   Sun WW, 2017, PROC SPIE, V10420, DOI 10.1117/12.2282522
   Tan JH, 2018, FUTURE GENER COMP SY, V87, P127, DOI 10.1016/j.future.2018.05.001
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang W., 2019, 2 STREAM CNN LOSSE P
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
   Zhao R, 2017, BIOMED OPT EXPRESS, V8, P5049, DOI 10.1364/BOE.8.005049
   Zheng YJ, 2013, I S BIOMED IMAGING, P1448
NR 43
TC 13
Z9 13
U1 1
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JAN 13
PY 2020
VL 2020
AR 7493419
DI 10.1155/2020/7493419
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KG4OV
UT WOS:000509926200001
PM 32411434
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Borrone, R
   Saravia, M
   Bar, D
AF Borrone, R.
   Saravia, M.
   Bar, D.
TI Age-related maculopathy and diabetes
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related maculopathy; Age-related macular degeneration; Diabetes;
   Diabetic retinopathy
ID BLUE MOUNTAINS EYE; BEAVER-DAM EYE; MACULAR DEGENERATION; RISK-FACTORS;
   RETINOPATHY; PREVALENCE; SYSTEM
AB PURPOSE. To compare the prevalence of age-related maculopathy (ARM) in a sample of diabetic patients with the general population.
   METHODS. Binocular indirect ophthalmoscopy, biomicroscopy, and fluorescein angiography, Retrospective prevalence study; descriptive-observational case-control type. Two different groups were analyzed from a sample of 1000 consecutive files of diabetic patients: 1) 65 to 74 years old (n = 263) and 2) 75 years and older (n = 199). Prevalence was compared to that of the general population in a control group and the following epidemiologic studies: Beaver Dam Eye Study, Framingham Eye Study, Blue Mountains Study, and Rotterdam Eye Study.
   RESULTS. In diabetic patients aged 75 or older, prevalence of ARM was as follows: early lesions 2.51% (5/199), late lesions (ARMD) 2.51% (5/199). In comparison, the risk in patients 75 or older is as follows: control group (ARMD): OR 4.79, 95% Cl 1.778-12.033, p (Fisher) 0.0005; Beaver Dam Eye Study (ARMD): OR 2.93, 95% CI 1.152-7.450, p (Fisher): 0; Blue Mountains Eye Study (ARMD): OR 3.06, 95% Cl 1.208-7.754, p (Fisher): 0; Framingham Eye Study (ARM): OR 6.73, 95% CI 3.041-14.880, p (Fisher): 0; Rotterdam Eye Study: p (Fisher) 0.133.
   CONCLUSIONS. 1) A lower prevalence of ARM was found in the sample of diabetic patients aged 75 or older than in the general population (with the exception of the Rotterdam study). 2) Prevalence of ARM was even lower in diabetic patients presenting diabetic retinopathy, whether or not they had been treated with photocoagulation. 3) In diabetic patients, the exudative form was more frequent than the atrophic form, in an inverse ratio to that of the general population. (Eur J Ophthalmol 2008; 18: 949-54)
C1 [Borrone, R.; Saravia, M.; Bar, D.] Univ Buenos Aires, Sch Med, Diabet Sect, Dept Ophthalmol,Retina Ctr, Buenos Aires, DF, Argentina.
C3 University of Buenos Aires
RP Borrone, R (通讯作者)，Coronel Diaz 2333,Piso 2 D, RA-1425 Buenos Aires, DF, Argentina.
EM rborrone@intramed.net.ar
CR ALGAN M, 1990, INVEST OPHTHALMOL VI, V31
   Benson WE, 1988, DIABETES ITS OCULAR, P64
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GRANGE JD, 1995, RETINOPATHIE DIABETI, P393
   HIVELA H, 1996, OPHTHALMOLOGY, V103, P871
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Kvanta A, 2006, ACTA OPHTHALMOL SCAN, V84, P282, DOI 10.1111/j.1600-0420.2006.00659.x
   LEIBOWITZ HM, 1980, SURV OPHTHALMOL, V24, pS335
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Varma R, 2006, AM J OPHTHALMOL, V141, P539, DOI 10.1016/j.ajo.2005.11.038
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Zylbermann R, 1997, EYE, V11, P872, DOI 10.1038/eye.1997.224
NR 22
TC 17
Z9 17
U1 0
U2 2
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2008
VL 18
IS 6
BP 949
EP 954
DI 10.1177/112067210801800615
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 405TD
UT WOS:000263246200015
PM 18988167
DA 2022-11-30
ER

PT J
AU Pham, QTM
   Ahn, S
   Shin, J
   Song, SJ
AF Pham, Quang T. M.
   Ahn, Sangil
   Shin, Jitae
   Song, Su Jeong
TI Generating future fundus images for early age-related macular
   degeneration based on generative adversarial networks
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE Age related macular degeneration; Fundus image; Generative adversarial
   network (GAN)
AB Background and objective: Age-related macular degeneration (AMD) is one of the most common diseases that can lead to blindness worldwide. Recently, various fundus image analyzing studies are done using deep learning methods to classify fundus images to aid diagnosis and monitor AMD disease progression. But until now, to the best of our knowledge, no attempt was made to generate future synthesized fundus images that can predict AMD progression. In this paper, we developed a deep learning model using fundus images for AMD patients with different time elapses to generate synthetic future fundus images.
   Method: We exploit generative adversarial networks (GANs) with additional drusen masks to maintain the pathological information. The dataset included 8196 fundus images from 1263 AMD patients. A proposed GAN-based model, called Multi-Modal GAN (MuMo-GAN), was trained to generate synthetic predicted-future fundus images.
   Results: The proposed deep learning model indicates that the additional drusen masks can help to learn the AMD progression. Our model can generate future fundus images with appropriate pathological features. The drusen development over time is depicted well. Both qualitative and quantitative experiments show that our model is more efficient to monitor the AMD disease as compared to other studies.
   Conclusion: This study could help individualized risk prediction for AMD patients. Compared to existing methods, the experimental results show a significant improvement in terms of tracking the AMD stage in both image-level and pixel-level. (C) 2022 Elsevier B.V. All rights reserved.
C1 [Pham, Quang T. M.; Ahn, Sangil; Shin, Jitae] Sungkyunkwan Univ, Dept Elect & Comp Engn, Suwon 16419, South Korea.
   [Song, Su Jeong] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Ophthalmol, Sch Med, Seoul 03181, South Korea.
   [Song, Su Jeong] Sungkyunkwan Univ, Biomed Inst Convergence BICS, Suwon 16419, South Korea.
C3 Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU);
   Sungkyunkwan University (SKKU)
RP Shin, J (通讯作者)，Sungkyunkwan Univ, Dept Elect & Comp Engn, Suwon 16419, South Korea.; Song, SJ (通讯作者)，Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Ophthalmol, Sch Med, Seoul 03181, South Korea.; Song, SJ (通讯作者)，Sungkyunkwan Univ, Biomed Inst Convergence BICS, Suwon 16419, South Korea.
EM jtshin@skku.edu; sjsong7@gmail.com
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2020R1F1A1065626]; MSIT (Ministry of Science and ICT), Korea, under the
   ITRC (Information Technology Research Center) support program
   [IITP-2021-2018-0-01798]; Biomedical Institute for Convergence (BICS),
   Sungkyunkwan University
FX This work was partly supported by the National Research Foundation of
   Korea(NRF) grant funded bythe Korea government(MSIT) (No.
   2020R1F1A1065626) and was partly supported by the MSIT (Ministry of
   Science and ICT), Korea, under the ITRC (Information Technology Research
   Center) support program (IITP-2021-2018-0-01798) supervised by the IITP
   (Institute for Information & communications Technology Promotion). It
   was also partly supported by the research fund from Biomedical Institute
   for Convergence (BICS), Sungkyunkwan University.
CR Chen LCE, 2018, LECT NOTES COMPUT SC, V11211, P833, DOI 10.1007/978-3-030-01234-2_49
   Fu Huazhu, 2018, IEEE Trans Med Imaging, V37, P2493, DOI 10.1109/TMI.2018.2837012
   Fu HZ, 2018, IEEE T MED IMAGING, V37, P1597, DOI 10.1109/TMI.2018.2791488
   Goodfellow I, 2020, COMMUN ACM, V63, P139, DOI 10.1145/3422622
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Hensel M, 2017, ADV NEUR IN, V30
   Isola P, 2017, PROC CVPR IEEE, P5967, DOI 10.1109/CVPR.2017.632
   Kamran Sharif Amit, 2020, Advances in Visual Computing. 15th International Symposium, ISVC 2020. Proceedings. Lecture Notes in Computer Science (LNCS 12510), P125, DOI 10.1007/978-3-030-64559-5_10
   Kamran SA, 2021, INT C COMP VIS WORKS, P3228
   Kamran SA, 2021, INT C PATT RECOG, P9122, DOI 10.1109/ICPR48806.2021.9412428
   Karras T, 2019, PROC CVPR IEEE, P4396, DOI 10.1109/CVPR.2019.00453
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mao XD, 2017, IEEE I CONF COMP VIS, P2813, DOI 10.1109/ICCV.2017.304
   Niu ZX, 2016, PROC CVPR IEEE, P4920, DOI 10.1109/CVPR.2016.532
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Pham QTM, 2020, ELECTRONICS-SWITZ, V9, DOI 10.3390/electronics9101617
   Ren XX, 2021, SIGNAL IMAGE VIDEO P, V15, P895, DOI 10.1007/s11760-020-01812-2
   Ren XX, 2018, IEEE ACCESS, V6, P2952, DOI 10.1109/ACCESS.2017.2786271
   Rezaei M., 2017, BRAINLES MICCAI
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Shim SH, 2016, OPHTHAL EPIDEMIOL, V23, P80, DOI 10.3109/09286586.2015.1129425
   Taigman Y, 2016, ABS161102200
   Tavakkoli A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78696-2
   Wang CY, 2018, IEEE T IMAGE PROCESS, V27, P4066, DOI 10.1109/TIP.2018.2836316
   Yan F, 2018, MICCAI
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
NR 27
TC 3
Z9 3
U1 6
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD APR
PY 2022
VL 216
AR 106648
DI 10.1016/j.cmpb.2022.106648
PG 9
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Medical Informatics
GA YY3IO
UT WOS:000754684800010
PM 35131605
DA 2022-11-30
ER

PT J
AU Costagliola, C
   Romano, MR
   Rinaldi, M
   dell'Omo, R
   Chiosi, F
   Menzione, M
   Semeraro, F
AF Costagliola, Ciro
   Romano, Mario R.
   Rinaldi, Michele
   dell'Omo, Roberto
   Chiosi, Flavia
   Menzione, Massimo
   Semeraro, Francesco
TI Low fluence rate photodynamic therapy combined with intravitreal
   bevacizumab for neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR VEGF; CHOROIDAL NEOVASCULARIZATION; PIGMENT EPITHELIUM;
   VERTEPORFIN; COMBINATION; EXPRESSION; INJECTION; AVASTIN
AB Aims To report the efficacy and safety of intravitreal bevacizumab (IVB) alone versus IVB plus low-fluence photodynamic therapy (PDT) in age-related macular degeneration (AMD) patients and to verify the occurrence of a synergistic effect of the combined approach on visual acuity, size and morphology of lesion, as well as on the treatment rate.
   Method Prospective comparative interventional study on 85 patients with treatment-naive classic, or predominantly classic, subfoveal choroidal neovascularisation secondary to AMD. Patients were randomly assigned to group 1 ( IVB injections) and group 2 ( IVB plus low fluence PDT). In group 2, the PDT with verteporfin was delivered with a low fluence rate ( 300 mW/cm(2) for 83 s, 25 J/cm(2)). The follow-up was scheduled at 1, 3, 6, 9 and 12 months.
   Results The eye without recurrence received a mean of 2.8 ( group 1) versus 1.4 ( group 2) IVB injections, whereas the eyes with recurrence received a mean of 3.2 ( group 1) versus 2.2 ( group 2) IVB injections. The difference in reinjection rate between the two groups was statistically significant (p = 0.03, ANOVA test). Visual acuity improvement was not statistically significant between the two groups (p - 0.31).
   Conclusion The combination of IVB with low fluence PDT for the treatment of classic or predominantly classic neovascular AMD works in a synergistic fashion with a significant reduction in IVB reinjections rate.
C1 [Costagliola, Ciro; Romano, Mario R.; dell'Omo, Roberto] Univ Molise, Dipartimento Sci Salute, I-86100 Campobasso, Italy.
   [Romano, Mario R.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Rinaldi, Michele; Chiosi, Flavia; Menzione, Massimo] Univ Naples 2, Dipartimento Oftalmol, Naples, Italy.
   [Semeraro, Francesco] Univ Brescia, Dipartimento Oftalmol, Brescia, Italy.
C3 University of Molise; Royal Liverpool & Broadgreen University Hospitals
   NHS Trust; Royal Liverpool University Hospital; University of Liverpool;
   Universita della Campania Vanvitelli; University of Brescia
RP Romano, MR (通讯作者)，Univ Molise, Dipartimento Sci Salute, Via F De Sanctis, I-86100 Campobasso, Italy.
EM romanomario@email.it
RI dell'Omo, Roberto/K-7328-2016; Romano, Mario R/I-8320-2012; Semeraro,
   Francesco fs/K-8667-2016; Costagliola, Ciro/G-5707-2012
OI dell'Omo, Roberto/0000-0002-7663-8874; Semeraro, Francesco
   fs/0000-0002-2275-4917; Costagliola, Ciro/0000-0001-8477-6188
CR Ahmadieh H, 2008, EUR J OPHTHALMOL, V18, P297, DOI 10.1177/112067210801800222
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Dewi NA, 2008, JPN J OPHTHALMOL, V52, P277, DOI 10.1007/s10384-008-0551-9
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Krebs I, 2009, ACTA OPHTHALMOL, V87, P611, DOI 10.1111/j.1755-3768.2008.01312.x
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Ohtaki H, 2006, ACTA NEUROCHIR SUPPL, V96, P283
   Rouvas AA, 2008, GRAEF ARCH CLIN EXP, V246, P315, DOI 10.1007/s00417-007-0669-3
   Ruiz-Oliva F, 2002, OPHTHALMOLOGY, V109, P1043, DOI 10.1016/S0161-6420(02)00972-7
   Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136/bjo.2008.137885
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
NR 18
TC 30
Z9 31
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2010
VL 94
IS 2
BP 180
EP 184
DI 10.1136/bjo.2009.159343
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 552WR
UT WOS:000274325500010
PM 19965822
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Bao, LL
   Bian, J
   Yan, YJ
   Zhang, LJ
   O'Shea, DF
   Chen, ZL
AF Bao, Lei-Lei
   Bian, Jun
   Yan, Yi-Jia
   Zhang, Li-Jun
   O'Shea, Donal F.
   Chen, Zhi-Long
TI In vitro and in vivo evaluation of a pyropheophorbide-a derivative as a
   potential photosensitizer for age-related macular degeneration
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE MEP; Photosensitizer; Photodynamic therapy; Age - related macular
   degeneration; Choroidal neovascularization
ID PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; SINGLET OXYGEN;
   VERTEPORFIN; MECHANISM; MEMBRANE; DRUG; PDT
AB Photodynamic therapy (PDT) has been demonstrated to be an effective and safe treatment for subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The photosensitizer is crucial factor in the efficacy of PDT. In this study, the physicochemical properties and the biological activity of a pyropheophorbide-a derivative, 2-(1-methoxyethyl)-2-devinylpyropheophorbide-a (MEP) had been evaluated in vivo and in vitro. MEP had a characteristic long wavelength absorption peak at 664 nm and the singlet oxygen quantum yield was determined as 0.38. In vitro, MEP showed low dark cytotoxicity and high photocytotoxicity, reducing the cell viability in a drug dose - dependent and light dose - dependent manner. In vivo, MEP could selectively localize to experimental CNV in BN rats, resulting in occlusion of CNV with minimal damage to retina tissues. The results indicate that MEP has the perspective to be developed as a safe and effective photosensitizer in PDT for AMD. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Bao, Lei-Lei; Bian, Jun] 411 Hosp, Shanghai 200081, Peoples R China.
   [Yan, Yi-Jia; Zhang, Li-Jun; Chen, Zhi-Long] Donghua Univ, Dept Pharmaceut Sci & Technol, Coll Chem & Biol, Shanghai 201620, Peoples R China.
   [O'Shea, Donal F.] Royal Coll Surgeons Ireland, Dept Pharmaceut & Med Chem, 123 St Stephens Green, Dublin 2, Ireland.
C3 Donghua University; Royal College of Surgeons - Ireland
RP Chen, ZL (通讯作者)，Donghua Univ, Dept Pharmaceut Sci & Technol, Coll Chem & Biol, Shanghai 201620, Peoples R China.; O'Shea, DF (通讯作者)，Royal Coll Surgeons Ireland, Dept Pharmaceut & Med Chem, 123 St Stephens Green, Dublin 2, Ireland.
EM donalfoshea@rcsi.ie; zlchen1967@qq.com
RI Chen, Zhi-long/AGF-6157-2022; O'Shea, Donal/H-2057-2013
OI O'Shea, Donal/0000-0003-0594-4193
FU National Natural Science Foundation of China [21402236, 21372042,
   81301878]; Foundation of Shanghai Government [15XD1523400, 14140903500,
   15431904100, 14ZR1439900, 14ZR1439800, 15ZR1439900, 16ZR1400600,
   15411960400]; Foundation of Songjiang Government [14SJGGYY08, 15SJGG45]
FX This work was supported by National Natural Science Foundation of China
   (No. 21402236, 21372042, 81301878), Foundation of Shanghai Government
   (No. 15XD1523400, 14140903500, 15431904100, 14ZR1439900, 14ZR1439800,
   15ZR1439900, 16ZR1400600, 15411960400) and Foundation of Songjiang
   Government (No. 14SJGGYY08, 15SJGG45).
CR Altaf A, 2014, INT J PHOTOENERGY, V2014, DOI 10.1155/2014/570506
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Chan WM, 2010, GRAEF ARCH CLIN EXP, V248, P613, DOI 10.1007/s00417-010-1307-z
   Debefve E, 2009, PHOTOCHEM PHOTOBIOL, V85, P1400, DOI 10.1111/j.1751-1097.2009.00604.x
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gushchina OI, 2015, J PHOTOCH PHOTOBIO B, V153, P76, DOI 10.1016/j.jphotobiol.2015.09.007
   Hayashi K, 2008, AM J OPHTHALMOL, V145, P518, DOI 10.1016/j.ajo.2007.10.032
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11872
   Lange N, 2001, INVEST OPHTH VIS SCI, V42, P38
   Li BH, 2008, J INNOV OPT HEAL SCI, V1, P141, DOI 10.1142/S1793545808000169
   Li TH, 2015, PHOTOCH PHOTOBIO SCI, V14, P972, DOI 10.1039/c4pp00412d
   Liu J, 2011, J BIOL CHEM, V286, P20991, DOI 10.1074/jbc.M111.226266
   MacDonald IJ, 1999, PHOTOCHEM PHOTOBIOL, V70, P789, DOI 10.1111/j.1751-1097.1999.tb08284.x
   Mataix Jorge, 2012, AGE RELATED MACULAR, P161
   Matroule JY, 2001, ONCOGENE, V20, P4070, DOI 10.1038/sj.onc.1204546
   Matsumura N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039890
   Messmer KJ, 2001, ANN PHARMACOTHER, V35, P1593
   Nishiwaki H, 2002, PHOTOCHEM PHOTOBIOL, V75, P149, DOI 10.1562/0031-8655(2002)075<0149:LTPOOR>2.0.CO;2
   Nordgren Rick N., 2014, WORLD J OPHTHALMOL, V4, P130
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   O'Connor AE, 2012, INT J CANCER, V130, P705, DOI 10.1002/ijc.26073
   Ohr M, 2012, THER ADV CHRONIC DIS, V3, P153, DOI 10.1177/2040622312446007
   Ozdemir H, 2006, AM J OPHTHALMOL, V141, P574, DOI 10.1016/j.ajo.2005.09.031
   Parodi MB, 2007, ACTA OPHTHALMOL SCAN, V85, P50, DOI 10.1111/j.1600-0420.2006.00738.x
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Ruck A, 2005, PHOTODIAGN PHOTODYN, V2, P79, DOI 10.1016/S1572-1000(05)00006-2
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Senge MO, 2012, PHOTODIAGN PHOTODYN, V9, P170, DOI 10.1016/j.pdpdt.2011.10.001
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sheu SJ, 2008, J CHIN MED ASSOC, V71, P135, DOI 10.1016/S1726-4901(08)70005-4
   Singh SP, 2014, PHOTODIAGN PHOTODYN, V11, P156, DOI 10.1016/j.pdpdt.2014.02.011
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   van den Berg Hubert, 2001, SEMIN OPHTHALMOL, V16
   van den Bergh H, 2004, J FR OPHTALMOL, V27, P75, DOI 10.1016/S0181-5512(04)96097-4
   von Buelow M, 2007, ACTA OPHTHALMOL SCAN, V85, P114, DOI 10.1111/j.1600-0420.2006.00825.x
   Zhang LJ, 2015, J INNOV OPT HEAL SCI, V8, DOI 10.1142/S1793545815400039
   Zoltan T, 2007, ANAL CHEM INSIGHTS, V2, P111
NR 39
TC 2
Z9 2
U1 1
U2 17
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD APR
PY 2017
VL 88
BP 1220
EP 1226
DI 10.1016/j.biopha.2017.01.167
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EM7YJ
UT WOS:000395528000143
DA 2022-11-30
ER

PT J
AU Ibrahim, NMS
   Hashem, HA
   Helal, AY
AF Ibrahim, Neveen Mostafa Sabra
   Hashem, Hisham Aly
   Helal, Ahmed Youssef
TI Evaluation of the acute effect of Sildenafil citrate on visual function
   in patients with early -stage age related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Sildenafil citrate; visual function; age related macular degeneration
ID INTRAOCULAR-PRESSURE; VIAGRA; SAFETY
AB AIM: To assess the effect of a single dose of Sildenafil citrate on the visual function in men with early-stage age related macular degeneration(AMD).
   METHODS: Forty men (mean age 71, range from 55-86 years)with early-stage AMD were prospectively randomized to receive either placebo or Sildenafil citrate (Viagra; Pfizer Inc, New York, NY) 100mg as a single oral dose. Subjects underwent visual acuity, Amsler grid and color discrimination in each eye before and at specific intervals within 9 hours after dosing.
   RESULTS: Compared with placebo, no pattern of errors were evident in any visual function test following Sildenafil administration. No statistically or clinically relevant changes from baseline were observed in visual acuity or color discrimination. No clinically relevant changes were observed in the Amsler grid. Sildenafil treatment was associated with transient mild or moderate headache and flushing.
   CONCLUSION: A single 100mg dose of Sildenafil was well tolerated and produced no significant acute visual effects in a sample of men with early-stage AMD.
C1 [Ibrahim, Neveen Mostafa Sabra] Res Inst Ophthalmol, Dept Physiol Opt, Giza, Egypt.
   [Hashem, Hisham Aly; Helal, Ahmed Youssef] Res Inst Ophthalmol, Dept Ophthalmol, Giza, Egypt.
C3 Egyptian Knowledge Bank (EKB); General Organization of Teaching
   Hospitals & Institutes (GOTHI); Research Institute of Ophthalmology
   (RIO); Egyptian Knowledge Bank (EKB); General Organization of Teaching
   Hospitals & Institutes (GOTHI); Research Institute of Ophthalmology
   (RIO)
RP Ibrahim, NMS (通讯作者)，Res Inst Ophthalmol, Dept Physiol Opt, Giza, Egypt.
EM neveen_sabra@rayacontactcenter.com
CR Ballard SA, 1998, J UROLOGY, V159, P2164, DOI 10.1016/S0022-5347(01)63299-3
   Birch DG, 2002, AM J OPHTHALMOL, V133, P665, DOI 10.1016/S0002-9394(02)01338-7
   Cunningham AV, 2001, J NEURO-OPHTHALMOL, V21, P22, DOI 10.1097/00041327-200103000-00006
   Egan R, 2000, ARCH OPHTHALMOL-CHIC, V118, P291
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fraunfelder FT, 2001, DRUG INDUCED OCULAR, P367
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   Grunwald JE, 2001, AM J OPHTHALMOL, V132, P872, DOI 10.1016/S0002-9394(01)01268-5
   Jagle H, 2004, AM J OPHTHALMOL, V137, P842, DOI 10.1016/j.ajo.2003.11.081
   Kretschmann U, 1999, INVEST OPHTH VIS SCI, V40, pS766
   Laties A EP, 1998, OPHTHALMIC RES, V30, P177
   Luu JK, 2001, AM J OPHTHALMOL, V132, P388, DOI 10.1016/S0002-9394(01)01052-2
   Marmor MF, 1999, SURV OPHTHALMOL, V44, P153, DOI 10.1016/S0039-6257(99)00079-X
   Morales A, 1998, INT J IMPOT RES, V10, P69, DOI 10.1038/sj.ijir.3900354
   Moreland RB, 1998, LIFE SCI, V62, pPL309, DOI 10.1016/S0024-3205(98)00158-1
   Sadovsky R, 2001, INT J CLIN PRACT, V55, P115
   SIEGEL RL, 2000, OCULAR SURG NEWS, V18, P5
   Vobig MA, 1999, LANCET, V353, P1442, DOI 10.1016/S0140-6736(05)75965-1
   Yajima T, 2000, AM J OPHTHALMOL, V129, P675, DOI 10.1016/S0002-9394(00)00375-5
   Zrenner E, 2000, INVEST OPHTH VIS SCI, V41, pS592
NR 20
TC 0
Z9 0
U1 0
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2008
VL 1
IS 1
BP 70
EP 73
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V13KV
UT WOS:000207666600018
DA 2022-11-30
ER

PT J
AU Parravano, M
   Oddone, F
   Boccassini, B
   Menchini, F
   Chiaravalloti, A
   Schiavone, M
   Varano, M
AF Parravano, Mariacristina
   Oddone, Francesco
   Boccassini, Barbara
   Menchini, Francesca
   Chiaravalloti, Adele
   Schiavone, Mauro
   Varano, Monica
TI Reproducibility of Macular Thickness Measurements Using Cirrus SD-OCT in
   Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; ULTRAHIGH-RESOLUTION; RETINAL THICKNESS;
   HIGH-SPEED; STRATUS; REPEATABILITY; RANIBIZUMAB; DIAGNOSIS; PATHOLOGY;
   EDEMA
AB PURPOSE. To assess the test-retest variability of central and sectorial macular thickness measurements obtained by Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA) in neovascular age-related macular degeneration (nAMD).
   METHODS. Macular thickness measurements of nine standard ETDRS subfields were obtained and analyzed. The repeatability of macular thickness measurements by Cirrus HD-OCT was assessed by examining the intrasession within subject standard deviation (Sw), coefficient of repeatability (CR), and coefficient of variation (CV), before and after eyes with retinal segmentation errors were excluded.
   RESULTS. Forty-nine nAMD eyes of 49 consecutive patients were included in the study. The CR for the central macular subfield was 42.4 mu m (10.5%) and ranged from 12.1 mu m (3.7%) for the outer nasal to 41.8 mu m (11.4%) for the inner nasal subfields. In a secondary analysis, eyes affected by erroneous detection of inner and outer retinal boundaries (6/49, 12.24%) were excluded. The revised coefficient of repeatability for the central macular subfield was 26.1 mu m (8.1%) and ranged from 10.3 mu m (3.8%) for the outer superior to 30.2 mu m (8.3%) for the inner nasal subfields.
   CONCLUSIONS. Overall, the test-retest variability of Cirrus HD-OCT is good for the central and sectorial macular subfields, with a low incidence of scan artifacts. (Invest Ophthalmol Vis Sci. 2010;51:4788 - 4791) DOI:10.1167/iovs.09-4976
C1 [Parravano, Mariacristina; Oddone, Francesco; Boccassini, Barbara; Chiaravalloti, Adele; Varano, Monica] Fdn GB Bietti IRCCS, I-00198 Rome, Italy.
   [Menchini, Francesca] Univ Udine, Dept Ophthalmol, Azienda Osped, I-33100 Udine, Italy.
   [Schiavone, Mauro] Azienda Osped San Giovanni Addolorata, Dept Ophthalmol 1, Rome, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; University of Udine
RP Parravano, M (通讯作者)，Fdn GB Bietti IRCCS, Via Livenza 3, I-00198 Rome, Italy.
EM criparra@tin.it
RI Varano, Monica/K-8573-2016; Oddone, Francesco/K-8876-2016
OI Oddone, Francesco/0000-0002-2504-0004; Varano,
   Monica/0000-0002-6530-1563
CR BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bland M, 2006, SHOULD I CALCULATE S
   Chen YL, 2009, OPT EXPRESS, V17, P4046, DOI 10.1364/OE.17.004046
   Danis RP, 2008, ARCH OPHTHALMOL-CHIC, V126, P45, DOI 10.1001/archopht.126.1.45
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Ghazi NG, 2009, AM J OPHTHALMOL, V148, P90, DOI 10.1016/j.ajo.2009.02.017
   Haouchine B, 2004, AM J OPHTHALMOL, V138, P732, DOI 10.1016/j.ajo.2004.06.088
   Ho J, 2009, OPHTHALMOLOGY, V116, P1960, DOI 10.1016/j.ophtha.2009.03.034
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X
   Keane PA, 2009, BRIT J OPHTHALMOL, V93, P1461, DOI 10.1136/bjo.2008.155846
   Kiernan DF, 2009, AM J OPHTHALMOL, V147, P267, DOI 10.1016/j.ajo.2008.08.018
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   Krebs I, 2009, INVEST OPHTH VIS SCI, V50, P995, DOI 10.1167/iovs.08-2617
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Legarreta JE, 2008, OPHTHAL SURG LAS IM, V39, pS43, DOI 10.3928/15428877-20080715-02
   Leitgeb RA, 2004, OPT EXPRESS, V12, P2156, DOI 10.1364/OPEX.12.002156
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Menke MN, 2008, BRIT J OPHTHALMOL, V92, P1492, DOI 10.1136/bjo.2008.141242
   MENKE NM, ACTA OPHTHALMOL
   Otani T, 1999, AM J OPHTHALMOL, V127, P688, DOI 10.1016/S0002-9394(99)00033-1
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Polito A, 2005, ARCH OPHTHALMOL-CHIC, V123, P1330, DOI 10.1001/archopht.123.10.1330
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P420
   Sanchez-Tocino H, 2002, INVEST OPHTH VIS SCI, V43, P1588
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
NR 30
TC 31
Z9 31
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2010
VL 51
IS 9
BP 4788
EP 4791
DI 10.1167/iovs.09-4976
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 645YS
UT WOS:000281502700058
PM 20435585
DA 2022-11-30
ER

PT J
AU Kara, S
   Gencer, B
   Ersan, I
   Arikan, S
   Kocabiyik, O
   Tufan, HA
   Comez, A
AF Kara, Selcuk
   Gencer, Baran
   Ersan, Ismail
   Arikan, Sedat
   Kocabiyik, Omer
   Tufan, Hasan Ali
   Comez, ArzuTaskiran
TI Repeatability of contrast sensitivity testing in patients with
   age-related macular degeneration, glaucoma, and cataract
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration; Contrast sensitivity; Glaucoma; Age effect;
   Re-producibility of results
ID VISUAL-ACUITY; PARVOCELLULAR PATHWAYS; LAMELLAR KERATOPLASTY; QUALITY;
   EYES; LIFE; ASSOCIATION; ABILITY; DESIGN; LASIK
AB Purpose: To analyze the intrasession and intersession repeatability of contrast sensitivity (CS) measurements in patients with glaucoma, cataract, or age-related macular degeneration (AMD) and healthy controls.
   Methods: CS measurements were performed using the OPTEC-Functional Vision Analyzer (FVA), which uses a standardized and closed (view-in) system. Measurements for patients with glaucoma, cataract, or AMD and healthy controls were repeated within 30 minutes (intrasession) and during two sessions (intersession), separated by one week to one month. Test-retest reliability and correlation were measured using the intraclass correlation coefficient (ICC) and coefficient of repeatability (COR).
   Results: Ninety subjects (90 eyes) with visual acuity of 0.17 logMAR or higher in the cataract group or 0.00 logMAR in the other groups were included. During the first session, the ICC values were 0.87, 0.90, 0.76, and 0.69, and COR values were 0.24, 0.20, 0.38, and 0.25 for the control, glaucoma, cataract, and AMD groups, respectively. The reliability scores significantly improved during the second session, except in the glaucoma group. There was an acceptable floor effect and no ceiling effect at higher frequencies in the glaucoma and AMD groups.
   Conclusion: In subjects with good visual acuity, the FVA system is useful for evaluating CS and demonstrates good repeatability, as shown by ICC and COR. Because there is no ceiling effect, this system is beneficial for evaluation of early changes in CS, particularly in patients with glaucoma or AMD.
C1 [Kara, Selcuk; Gencer, Baran; Ersan, Ismail; Arikan, Sedat; Kocabiyik, Omer; Tufan, Hasan Ali; Comez, ArzuTaskiran] Canakkale Onsekiz Mart Univ, Dept Ophthalmol, Fac Med, Canakkale, Turkey.
C3 Canakkale Onsekiz Mart University
RP Kara, S (通讯作者)，Canakkale Onsekiz Mart Univ, Tip Fak, Goz Hastaliklari AD, TR-17000 Canakkale, Turkey.
EM selckara@gmail.com
RI Kara, Selcuk/C-8315-2015; Comez, Arzu Taskiran/B-3482-2014
OI Kara, Selcuk/0000-0002-8017-2173; Comez, Arzu
   Taskiran/0000-0001-8048-8146
CR Ansari EA, 2002, BRIT J OPHTHALMOL, V86, P1131, DOI 10.1136/bjo.86.10.1131
   Armstrong RA, 2011, OPHTHAL PHYSL OPT, V31, P123, DOI 10.1111/j.1475-1313.2010.00815.x
   Aslam T, 2014, GRAEF ARCH CLIN EXP, V252, P201, DOI 10.1007/s00417-013-2421-5
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Browne C, 2012, EYE, V26, P1295, DOI 10.1038/eye.2012.137
   Buhren J, 2006, OPTOMETRY VISION SCI, V83, P290, DOI 10.1097/01.opx.0000216100.93302.2d
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Faria BM, 2015, RETINA-J RET VIT DIS, V35, P1465, DOI 10.1097/IAE.0000000000000474
   Gertnere J, 2013, GRAEF ARCH CLIN EXP, V251, P1437, DOI 10.1007/s00417-012-2220-4
   Ginsburg AR, 2006, CURR OPIN OPHTHALMOL, V17, P19, DOI 10.1097/01.icu.0000192520.48411.fa
   Ginsburg Arthur P., 2003, International Ophthalmology Clinics, V43, P5
   Haughom B, 2013, ACTA OPHTHALMOL, V91, P176, DOI 10.1111/j.1755-3768.2011.02323.x
   Hawkins AS, 2003, J GLAUCOMA, V12, P134, DOI 10.1097/00061198-200304000-00008
   Haymes SA, 2006, INVEST OPHTH VIS SCI, V47, P2739, DOI 10.1167/iovs.05-1419
   Hohberger B, 2007, GRAEF ARCH CLIN EXP, V245, P1805, DOI 10.1007/s00417-007-0662-x
   Hong YT, 2010, J CATARACT REFR SURG, V36, P547, DOI 10.1016/j.jcrs.2009.10.048
   Karakus SH, 2013, EYE, V27, P612, DOI 10.1038/eye.2013.24
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Klein J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128681
   Lahav K, 2011, ARCH OPHTHALMOL-CHIC, V129, P16, DOI 10.1001/archophthalmol.2010.332
   Li JH, 2014, INT J OPHTHALMOL-CHI, V7, P100, DOI 10.3980/j.issn.2222-3959.2014.01.18
   LUNDH BL, 1985, ACTA OPHTHALMOL, V63, P487
   McKendrick AM, 2007, INVEST OPHTH VIS SCI, V48, P2115, DOI 10.1167/iovs.06-1208
   Miller D, 2014, OPHTHALMOLOGY, P38
   Nielsen E, 2012, ACTA OPHTHALMOL, V90, P756, DOI 10.1111/j.1755-3768.2011.02218.x
   Onal Sumru, 2008, International Ophthalmology, V28, P407, DOI 10.1007/s10792-007-9169-z
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P2621, DOI 10.1167/iovs.08-2407
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Richman J, 2013, J CATARACT REFR SURG, V39, P1100, DOI 10.1016/j.jcrs.2013.05.001
   Richman J, 2010, ARCH OPHTHALMOL-CHIC, V128, P1576, DOI 10.1001/archophthalmol.2010.275
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Sari ES, 2012, BRIT J OPHTHALMOL, V96, P1063, DOI 10.1136/bjophthalmol-2011-301349
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   SHAFFER R N, 1960, Trans Am Acad Ophthalmol Otolaryngol, V64, P112
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Sun H, 2008, VISION RES, V48, P2633, DOI 10.1016/j.visres.2008.04.008
   Thayaparan K, 2007, BRIT J OPHTHALMOL, V91, P749, DOI 10.1136/bjo.2006.109280
   Wei H, 2012, BRIT J OPHTHALMOL, V96, P735, DOI 10.1136/bjophthalmol-2011-300093
   Yenice O, 2007, EYE, V21, P218, DOI 10.1038/sj.eye.6702251
   Zhang J, 2013, INT J OPHTHALMOL-CHI, V6, P498, DOI 10.3980/j.issn.2222-3959.2013.04.17
NR 40
TC 6
Z9 7
U1 0
U2 7
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD SEP-OCT
PY 2016
VL 79
IS 5
BP 323
EP 327
DI 10.5935/0004-2749.20160092
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EH0DA
UT WOS:000391431500011
PM 27982213
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ornek, N
   Ornek, K
   Aydin, S
   Yilmaz, M
   Olmez, Y
AF Ornek, Nurgul
   Ornek, Kemal
   Aydin, Suleyman
   Yilmaz, Musa
   Olmez, Yasar
TI Serum vascular endothelial growth factor receptor-2 and adropin levels
   in age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE vascular endothelial growth factor receptor-2; adropin; age-related
   macular degeneration
ID C-REACTIVE PROTEIN; SURVIVAL FACTOR; NEOVASCULARIZATION; DYSFUNCTION;
   INHIBITION; RELEVANCE; VEGFR2
AB AIM: To investigate the serum levels of vascular endothelial growth factor receptor-2 (VEGFR-2) and adropin in age-related macular degeneration (AMD) patients.
   METHODS: Ninety-eight AMD patients were included in the study. Seventy-eight age - and sex-matched healthy volunteers were recruited as the control group. Fundus florescein angiography and optical coherence tomography were performed to assess the posterior segment details. Serum VEGFR-2 and adropin levels were measured using enzyme-linked immunosorbent assays and compared between the study groups.
   RESULTS: AMD group had significantly increased fovea! retinal thickness, serum LDL and HDL levels and significantly decreased subfoveal choroidal thickness (P = 0.01, 0.047, 0.025 and <0.001, respectively). Serum VEGFR-2 level revealed a significant decrease in AMD patients compared to controls (26.48 +/- 6.44 vs 30.42 +/- 7.92 ng/mL, P<0.001). There was an insignificant increase in serum adropin level in AMD patients (6.17 +/- 1-3.19 vs 5.79 +/- 2.71 ng/mL, P=0.4). Serum level of VEGFR-2 in AMD patients had a significant negative correlation with fovea! retinal thickness (r=-0.226, P=0.025) and a significant positive correlation with subfoveal choroidal thickness (r=0.2, P=0.048).
   CONCLUSION: The current study demonstrated that the decreased serum VEGFR-2 level may be considered in the development of AMD. Adropin does not seem to play a role in the pathogenesis of AMD.
C1 [Ornek, Nurgul; Ornek, Kemal; Olmez, Yasar] Kirikkale Univ, Sch Med, Dept Ophthalmol, TR-71450 Yahsihan, Kirikkale, Turkey.
   [Aydin, Suleyman; Yilmaz, Musa] Firat Univ, Sch Med, Dept Biochem, TR-23300 Elazig, Turkey.
C3 Kirikkale University; Firat University
RP Ornek, K (通讯作者)，Kirikkale Univ, Sch Med, Dept Ophthalmol, TR-71450 Yahsihan, Kirikkale, Turkey.
EM kemalornek@hotmail.com
RI Örnek, Nurgül/V-1751-2018; Örnek, Kemal/AFL-3613-2022
OI Örnek, Nurgül/0000-0003-3068-1831; 
CR Acobi J, 2004, CIRCULATION, V110, P2424
   Anand A, 2013, OXID MED CELL LONGEV, V2013, DOI DOI 10.1155/2013/365046
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Celik A, 2013, CARDIOVASC THER, V31, P174, DOI 10.1111/1755-5922.12025
   Deanfield JE, 2007, CIRCULATION, V115, P1285, DOI 10.1161/CIRCULATIONAHA.106.652859
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Gozal D, 2013, J PEDIATR-US, V163, P1122, DOI 10.1016/j.jpeds.2013.05.040
   Igarashi J, 2008, BBA-MOL CELL BIOL L, V1781, P489, DOI 10.1016/j.bbalip.2008.06.008
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kumar KG, 2008, CELL METAB, V8, P468, DOI 10.1016/j.cmet.2008.10.011
   Lien S., 2008, V181, P131
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lovren F, 2010, CIRCULATION, V122, pS185, DOI 10.1161/CIRCULATIONAHA.109.931782
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Roeckl W, 1998, EXP CELL RES, V241, P161, DOI 10.1006/excr.1998.4039
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Swendeman S, 2008, CIRC RES, V103, P916, DOI 10.1161/CIRCRESAHA.108.184416
   Sydorova M, 2005, OPHTHALMIC RES, V37, P188, DOI 10.1159/000086594
   Szentirmai O, 2008, J NEUROSURG, V108, P979, DOI 10.3171/JNS/2008/108/5/0979
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Uehara H, 2015, AM J OPHTHALMOL, V159, P92, DOI 10.1016/j.ajo.2014.09.036
   Waldner MJ, 2010, J EXP MED, V207, P2855, DOI 10.1084/jem.20100438
   Wu LZ, 2014, CLIN CHEM LAB MED, V52, P751, DOI 10.1515/cclm-2013-0844
NR 32
TC 4
Z9 5
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2016
VL 9
IS 4
BP 556
EP 560
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DJ5UW
UT WOS:000374276600013
PM 27162728
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU McKibbin, M
   Papastefanou, V
   Matthews, B
   Cook, H
   Downey, L
AF McKibbin, M.
   Papastefanou, V.
   Matthews, B.
   Cook, H.
   Downey, L.
TI Ranibizumab monotherapy for sub-foveal haemorrhage secondary to
   choroidal neovascularisation in age-related macular degeneration
SO EYE
LA English
DT Article
DE ranibizumab; sub-foveal haemorrhage; age-related macular degeneration
ID TISSUE-PLASMINOGEN ACTIVATOR; SUBMACULAR HEMORRHAGE; INTRAVITREAL
   BEVACIZUMAB; PNEUMATIC DISPLACEMENT; SUBRETINAL HEMORRHAGE; INJECTION;
   GAS; MANAGEMENT
AB Purpose In a retrospective review, the functional effects of intra-vitreal ranibizumab monotherapy in patients with sub-foveal haemorrhage secondary to choroidal neovascularisation (CNV) in age-related macular degeneration (ARMD) are reported.
   Patients and methods Twelve eyes of 12 patients were treated with intra-vitreal ranibizumab (0.5 mg in 0.05 ml) in accordance with current practice. Follow-up was arranged at monthly intervals. Eleven patients completed 6 months and seven completed 12 months of follow-up. Duration of haemorrhage, lesion size, ETDRS letter score at baseline, and follow-up were analysed.
   Results The mean time for complete clearance of sub-retinal haemorrhage was 4.7 months (range 3-7 months). After 6 months, visual acuity was stable or improved in 7 of 11 eyes and the mean change in ETDRS letter score was +7.6 letters (P>0.05). After 12 months, visual acuity was stable or improved in five of seven eyes and the mean change in ETDRS letter score was +7.3 letters (P>0.05). For the seven cases with 12 months of follow-up, a mean of six injections were given. Two patients had a decrease in acuity of 415 ETDRS letters during follow-up. No other local or systemic side-effects were reported.
   Conclusions Intra-vitreal ranibizumab monotherapy may be an effective treatment for subfoveal haemorrhage secondary to CNV in ARMD. Eye (2010) 24, 994-998; doi: 10.1038/eye.2009.271; published online 13 November 2009
C1 [McKibbin, M.; Papastefanou, V.; Matthews, B.] St James Univ Hosp, Dept Ophthalmol, Eye Clin, Leeds LS9 7TF, W Yorkshire, England.
   [Cook, H.; Downey, L.] Hull & E Yorkshire Eye Hosp, Hull Royal Infirm, Kingston Upon Hull, N Humberside, England.
C3 Saint James's University Hospital; University of Hull
RP McKibbin, M (通讯作者)，St James Univ Hosp, Dept Ophthalmol, Eye Clin, Leeds LS9 7TF, W Yorkshire, England.
EM martin.mckibbin@leedsth.nhs.uk
RI PAPASTEFANOU, VASILIOS/AAN-9779-2020
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Holz FG, 2009, INVEST OPHTHALMOL VI, P50
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
NR 15
TC 23
Z9 23
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD JUN
PY 2010
VL 24
IS 6
BP 994
EP 998
DI 10.1038/eye.2009.271
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 608YX
UT WOS:000278623000009
PM 19911016
OA Bronze
DA 2022-11-30
ER

PT J
AU Rudnisky, CJ
   Liu, C
   Ng, M
   Weis, E
   Tennant, MTS
AF Rudnisky, Christopher J.
   Liu, Conrad
   Ng, Mancho
   Weis, Ezekiel
   Tennant, Matthew T. S.
TI INTRAVITREAL BEVACIZUMAB ALONE VERSUS COMBINED VERTEPORFIN PHOTODYNAMIC
   THERAPY AND INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN
   AGE-RELATED MACULAR DEGENERATION Visual Acuity After 1 Year of Follow-Up
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE Avastin; bevacizumab; photodynamic therapy/PDT; choroidal
   neovascularization/CNV; age-related macular degeneration/AMD
ID TRIAMCINOLONE; RANIBIZUMAB
AB Purpose: The purpose of the study was to compare the mean change in visual acuity between bevacizumab and combined bevacizumab and photodynamic therapy for the treatment of choroidal neovascularization from age-related macular degeneration after 12 months of follow-up.
   Methods: This study included a retrospective cohort of patients with untreated choroidal neovascularization. The generalized estimating equation was used to account for the correlation between eyes and to construct multivariate models to control for confounding factors of visual acuity change.
   Results: One hundred and thirty-nine eyes treated with bevacizumab were compared with 236 eyes that received bevacizumab and photodynamic therapy (combination treatment). The monotherapy eyes showed an improvement of 0.101 +/- 0.619 logarithm of minimum angle of resolution units (5.05 letters) after a mean follow-up of 409.6 days versus 0.096 +/- 0.611 (4.8 letters) after a mean follow-up of 416.7 days with combination therapy; there was no difference between the groups (P = 0.970). The monotherapy eyes received 3.32 +/- 1.71 injections versus 3.14 +/- 1.52 injections in the combination therapy group (P = 0.665). The multivariate analysis did not show any difference between groups at the end of the study period in terms of visual improvement, worsening, stabilization, or the number of bevacizumab injections used.
   Conclusion: Long-term visual outcomes for the treatment of choroidal neovascularization in age-related macular degeneration are not improved with the addition of photodynamic therapy to bevacizumab nor are fewer injections needed. RETINA 30: 548-554, 2010
C1 [Rudnisky, Christopher J.; Liu, Conrad; Ng, Mancho; Weis, Ezekiel; Tennant, Matthew T. S.] Univ Alberta, Dept Ophthalmol, Edmonton, AB T6G 2M7, Canada.
C3 University of Alberta
RP Rudnisky, CJ (通讯作者)，Royal Alexandra Hosp, Room 2316,10240 Kingsway Ave, Edmonton, AB T5H 3V9, Canada.
EM crudnisk@ualberta.ca
OI Weis, Ezekiel/0000-0002-6862-0850
FU Health and Quality Assurance Council
FX Supported by the Health and Quality Assurance Council.
CR AVERY RL, 2006, OPHTHALMOLOGY, V113
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, pe55
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KRUEGER DE, 1980, SURV OPHTHALMOL, V24, P614, DOI 10.1016/0039-6257(80)90122-8
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
NR 20
TC 10
Z9 10
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2010
VL 30
IS 4
BP 548
EP 554
DI 10.1097/IAE.0b013e3181bcf1b8
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 608AE
UT WOS:000278548900003
PM 20386095
DA 2022-11-30
ER

PT J
AU Acevedo-Jake, A
   Shi, SY
   Siddiqui, Z
   Sanyal, S
   Schur, R
   Kaja, S
   Yuan, AL
   Kumar, VA
AF Acevedo-Jake, Amanda
   Shi, Siyu
   Siddiqui, Zain
   Sanyal, Sreya
   Schur, Rebecca
   Kaja, Simon
   Yuan, Alex
   Kumar, Vivek A.
TI Preclinical Efficacy of Pro- and Anti-Angiogenic Peptide Hydrogels to
   Treat Age-Related Macular Degeneration
SO BIOENGINEERING-BASEL
LA English
DT Article
DE wet age-related macular degeneration; pro-angiogenic; anti-angiogenic;
   hydrogel; biomaterials; tissue regeneration; multi-functional scaffolds
AB Pro-angiogenic and anti-angiogenic peptide hydrogels were evaluated against the standard of care wet age-related macular degeneration (AMD) therapy, Aflibercept (Eylea(R)). AMD was modeled in rats (laser-induced choroidal neovascularization (CNV) model), where the contralateral eye served as the control. After administration of therapeutics, vasculature was monitored for 14 days to evaluate leakiness. Rats were treated with either a low or high concentration of anti-angiogenic peptide hydrogel (0.02 wt% 8 rats, 0.2 wt% 6 rats), or a pro-angiogenic peptide hydrogel (1.0 wt% 7 rats). As controls, six rats were treated with commercially available Aflibercept and six with sucrose solution (vehicle control). Post lasering, efficacy was determined over 14 days via fluorescein angiography (FA) and spectral-domain optical coherence tomography (SD-OCT). Before and after treatment, the average areas of vascular leak per lesion were evaluated as well as the overall vessel leakiness. Unexpectedly, treatment with pro-angiogenic peptide hydrogel showed significant, immediate improvement in reducing vascular leak; in the short term, the pro-angiogenic peptide performed better than anti-angiogenic peptide hydrogel and was comparable to Aflibercept. After 14 days, both the pro-angiogenic and anti-angiogenic peptide hydrogels show a trend of improvement, comparable to Aflibercept. Based on our results, both anti-angiogenic and pro-angiogenic peptide hydrogels may prove good therapeutics in the future to treat wet AMD over a longer-term treatment period.
C1 [Acevedo-Jake, Amanda; Siddiqui, Zain; Kumar, Vivek A.] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.
   [Shi, Siyu] Stanford Univ, Stanford Sch Med, Stanford, CA 94305 USA.
   [Sanyal, Sreya; Kumar, Vivek A.] New Jersey Inst Technol, Dept Biol, Newark, NJ 07102 USA.
   [Schur, Rebecca; Yuan, Alex] Cleveland Clin, Lerner Coll Med, Cole Eye Inst, Cleveland Hts, OH 44195 USA.
   [Kaja, Simon] Experimentica Ltd, Res & Dev Div, Kuopio 70211, Finland.
   [Kaja, Simon] Loyola Univ Chicago, Dept Ophthalmol, Maywood, IL 60153 USA.
   [Kumar, Vivek A.] New Jersey Inst Technol, Dept Chem Engn, Newark, NJ 07102 USA.
   [Kumar, Vivek A.] Rutgers Sch Dent Med, Dept Restorat Dent, Newark, NJ 07102 USA.
C3 New Jersey Institute of Technology; Stanford University; New Jersey
   Institute of Technology; Case Western Reserve University; Cleveland
   Clinic Foundation; Loyola University Chicago; New Jersey Institute of
   Technology; Rutgers State University New Brunswick; Rutgers State
   University Medical Center
RP Kumar, VA (通讯作者)，New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.; Kumar, VA (通讯作者)，New Jersey Inst Technol, Dept Biol, Newark, NJ 07102 USA.; Kumar, VA (通讯作者)，New Jersey Inst Technol, Dept Chem Engn, Newark, NJ 07102 USA.; Kumar, VA (通讯作者)，Rutgers Sch Dent Med, Dept Restorat Dent, Newark, NJ 07102 USA.
EM mauvocado@gmail.com; siyushi@stanford.edu; zs67@njit.edu;
   ss3742@njit.edu; SCHURR@ccf.org; kaja@experimentica.com; yuana@ccf.org;
   vak@njit.edu
RI Schur, Rebecca/ABE-2442-2022
OI Kumar, Vivek/0000-0001-7536-9281
FU NJIT startup funds; National Eye Institute NIH [R15 EY029504]; National
   Science Foundation [NSF IIP 1903617]; NJIT Undergraduate Research and
   Innovation (URI) program; New Jersey Health Foundation
FX We would like to thank NJIT startup funds (for V.A.K.) as well as the
   NJIT Undergraduate Research and Innovation (URI) program. V.A.K.
   acknowledges support from the National Eye Institute NIH R15 EY029504,
   National Science Foundation NSF IIP 1903617, the NJIT Undergraduate
   Research and Innovation (URI) program, and the New Jersey Health
   Foundation.
CR Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Aulisa L, 2009, BIOMACROMOLECULES, V10, P2694, DOI 10.1021/bm900634x
   Bakota EL, 2013, BIOMACROMOLECULES, V14, P1370, DOI 10.1021/bm4000019
   Bakota EL, 2011, BIOMACROMOLECULES, V12, P82, DOI 10.1021/bm1010195
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Carrejo NC, 2018, ACS BIOMATER SCI ENG, V4, P1386, DOI 10.1021/acsbiomaterials.8b00031
   Chen LX, 2020, AM J PHYSIOL-HEART C, V318, pH519, DOI 10.1152/ajpheart.00473.2019
   Chen XT, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0235-6
   Daien V, 2018, OPHTHALMOLOGY, V125, P66, DOI 10.1016/j.ophtha.2017.07.005
   Dong H, 2007, J AM CHEM SOC, V129, P12468, DOI 10.1021/ja072536r
   Drury JL, 2005, J BIOMECH ENG-T ASME, V127, P220, DOI 10.1115/1.1865194
   Ebneter A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119046
   Garweg JG, 2018, GRAEF ARCH CLIN EXP, V256, P823, DOI 10.1007/s00417-018-3907-y
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Grzybowski A, 2018, OPHTHALMOLOGICA, V239, P181, DOI 10.1159/000486145
   Hammer JA, 2020, ANN BIOMED ENG, V48, P1885, DOI 10.1007/s10439-019-02407-w
   Harbour V, 2020, ACS APPL BIO MATER, V3, P8978, DOI 10.1021/acsabm.0c01229
   Honnegowda T.M., 2015, PLAST AESTHET RES, V2, P243, DOI [10.4103/2347-9264.165438, DOI 10.4103/2347-9264.165438]
   Hu CC, 2019, TECHNOL HEALTH CARE, V27, pS153, DOI 10.3233/THC-199015
   Kim KK, 2020, J MATER CHEM B, V8, P945, DOI 10.1039/c9tb02250c
   Kumar VA, 2016, BIOMATERIALS, V98, P113, DOI 10.1016/j.biomaterials.2016.04.032
   Kumar VA, 2016, EXP BIOL MED, V241, P899, DOI 10.1177/1535370216640941
   Kumar VA, 2015, ACS BIOMATER SCI ENG, V1, P1300, DOI 10.1021/acsbiomaterials.5b00356
   Kumar VA, 2015, BIOMATERIALS, V52, P71, DOI 10.1016/j.biomaterials.2015.01.079
   Kumar VA, 2015, ACS NANO, V9, P860, DOI 10.1021/nn506544b
   Leach DG, 2019, ACS BIOMATER SCI ENG, V5, P6755, DOI 10.1021/acsbiomaterials.9b01447
   Leach DG, 2018, BIOMATERIALS, V163, P67, DOI 10.1016/j.biomaterials.2018.01.035
   Li IC, 2017, J AM CHEM SOC, V139, P8044, DOI 10.1021/jacs.7b04655
   Li JL, 2019, SOFT MATTER, V15, P1704, DOI 10.1039/c8sm02573h
   Lopez-Silva TL, 2021, BIOMATERIALS, V265, DOI 10.1016/j.biomaterials.2020.120401
   Lopez-Silva TL, 2020, BIOMATERIALS, V231, DOI 10.1016/j.biomaterials.2019.119667
   Lopez-Silva TL, 2019, ACS BIOMATER SCI ENG, V5, P977, DOI 10.1021/acsbiomaterials.8b01348
   Ma XT, 2020, BIOACT MATER, V5, P124, DOI 10.1016/j.bioactmat.2020.01.005
   Moore AN, 2018, BIOMATERIALS, V161, P154, DOI 10.1016/j.biomaterials.2018.01.033
   Moore AN, 2017, ACCOUNTS CHEM RES, V50, P714, DOI 10.1021/acs.accounts.6b00553
   Nguyen PK, 2018, ACS APPL BIO MATER, V1, P865, DOI 10.1021/acsabm.8b00283
   Nguyen PK, 2018, ACS OMEGA, V3, P5980, DOI 10.1021/acsomega.8b00347
   Ourradi K, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0602-1
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pugliese R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124261
   Pugliese R, 2019, BIOMATER SCI-UK, V7, P76, DOI 10.1039/c8bm00825f
   Pugliese R, 2018, NANO RES, V11, P586, DOI 10.1007/s12274-017-1834-6
   Radvar E, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201800221
   Ragauskas S., 2018, J VIS EXP, V131, pe56173
   Roberts S, 2018, NAT MATER, V17, P1154, DOI 10.1038/s41563-018-0182-6
   Sarkar B, 2021, CHEM ENG J, V408, DOI 10.1016/j.cej.2020.127295
   Sarkar B, 2019, ACS BIOMATER SCI ENG, V5, P4657, DOI 10.1021/acsbiomaterials.9b00967
   Sarkar B, 2018, BIOMACROMOLECULES, V19, P3597, DOI 10.1021/acs.biomac.8b01137
   Seah I, 2020, EYE, V34, P1341, DOI 10.1038/s41433-020-0770-y
   Siddiqui Z, 2021, ACTA BIOMATER, V126, P109, DOI 10.1016/j.actbio.2021.03.001
   Tang JD, 2019, J AM CHEM SOC, V141, P4886, DOI 10.1021/jacs.8b13363
   Van Hove AH, 2015, J CONTROL RELEASE, V217, P191, DOI 10.1016/j.jconrel.2015.09.005
   Wang K, 2018, J BIOMED MATER RES A, V106, P2795, DOI 10.1002/jbm.a.36450
   Wickremasinghe NC, 2015, ACS BIOMATER SCI ENG, V1, P845, DOI 10.1021/acsbiomaterials.5b00210
   Wickremasinghe NC, 2014, BIOMACROMOLECULES, V15, P3587, DOI 10.1021/bm500856c
   Yu Y, 2019, BIOENG TRANSL MED, V4, DOI 10.1002/btm2.10128
   Zeng L, 2019, BIOMIMETICS-BASEL, V4, DOI 10.3390/biomimetics4020036
NR 59
TC 1
Z9 1
U1 6
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2306-5354
J9 BIOENGINEERING-BASEL
JI Bioengineering-Basel
PD DEC
PY 2021
VL 8
IS 12
AR 190
DI 10.3390/bioengineering8120190
PG 12
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA XX4UU
UT WOS:000736293500001
PM 34940343
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yamashiro, K
   Hosoda, Y
   Miyake, M
   Takahashi, A
   Ooto, S
   Tsujikawa, A
AF Yamashiro, Kenji
   Hosoda, Yoshikatsu
   Miyake, Masahiro
   Takahashi, Ayako
   Ooto, Sotaro
   Tsujikawa, Akitaka
TI Hypothetical pathogenesis of age-related macular degeneration and
   pachychoroid diseases derived from their genetic characteristics
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; Genetic association; Pachychoroid
   disease; Pathogenesis
ID COMPLEMENT-FACTOR-H; CENTRAL SEROUS CHORIORETINOPATHY; GENOME-WIDE
   ASSOCIATION; CHOROIDAL THICKNESS; 10-YEAR INCIDENCE; VARIANTS; RISK;
   SUSCEPTIBILITY; MACULOPATHY; PROGRESSION
AB Genetic studies have investigated the pathogenesis of age-related macular degeneration (AMD). The pachychoroid concept has recently garnered attention as a possible explanation for AMD pathogenesis; the genetic characteristics of pachychoroid diseases have also been elucidated. In this review, we summarize previously reported genetic characteristics of AMD and pachychoroid diseases, and analyze these data to understand the pathogenesis of AMD and pachychoroid diseases. Previous studies show thatVIPR2and theCFHI62V A allele promote development of pachychoroid and central serous chorioretinopathy (CSC), while theCFHI62V G allele promotes development of drusen, pachychoroid neovasculopathy (PCN/PNV), and AMD.ARMS2/HTRA1also promotes development of drusen, PCN/PNV, and AMD.TNFRSF10AandGATA5are associated with CSC but not with pachychoroid, andTNFRSF10Ais associated with AMD that includes PCN/PNV. These genetic characteristics suggest the following mechanisms of developing AMD and pachychoroid diseases.VIPR2and theCFHI62V A allele promote pachychoroid development, which can result in CSC development. TheCFHI62V G allele promotes a common step during PCN/PNV and AMD development induced by pachychoroid or drusen, such as damage of Bruch's membrane or retinal pigment epithelium (RPE).ARMS2/HTRA1also promotes damage of Bruch's membrane or RPE, while the association with drusen formation is stronger inARMS2/HTRA1than inCFH.TNFRSF10AandGATA5promote blood-retinal-barrier breakdown to induce CSC, which could lead to PCN/PNV development. Furthermore, recently reported genetic associations with the natural course of CSC suggest the importance of reconsidering the subtype classification of CSC. These associations would enable the development of personalized/precision medicine for CSC and.
C1 [Yamashiro, Kenji; Hosoda, Yoshikatsu; Miyake, Masahiro; Takahashi, Ayako; Ooto, Sotaro; Tsujikawa, Akitaka] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
   [Yamashiro, Kenji] Japanese Red Cross Otsu Hosp, Dept Ophthalmol, Otsu, Shiga, Japan.
C3 Kyoto University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.; Yamashiro, K (通讯作者)，Japanese Red Cross Otsu Hosp, Dept Ophthalmol, Otsu, Shiga, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
OI Yamashiro, Kenji/0000-0001-9354-8558
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Bailey JNC, 2013, HUM MOL GENET, V22, pR59, DOI 10.1093/hmg/ddt396
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Breukink MB, 2015, INVEST OPHTH VIS SCI, V56, P5608, DOI 10.1167/iovs.15-17343
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31109-x
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cho SC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57747-8
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   GASS JDM, 1967, AM J OPHTHALMOL, V64, P612
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Higasa K, 2016, J HUM GENET, V61, P547, DOI 10.1038/jhg.2016.12
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Hosoda Y, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0712-z
   Hosoda Y, 2019, OPHTHALMOL RETINA, V3, P985, DOI 10.1016/j.oret.2019.05.025
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Miki A, 2018, INVEST OPHTH VIS SCI, V59, P5542, DOI 10.1167/iovs.18-25497
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyake M, 2015, JPN J OPHTHALMOL, V59, P273, DOI 10.1007/s10384-015-0394-0
   Mohabati D, 2019, RETINA-J RET VIT DIS, V39, P2303, DOI 10.1097/IAE.0000000000002333
   Moschos MM, 2016, RETINA-J RET VIT DIS, V36, P402, DOI 10.1097/IAE.0000000000000693
   Nakai S, 2019, JPN J OPHTHALMOL, V63, P389, DOI 10.1007/s10384-019-00683-6
   Nakata I, 2015, SCI REP-UK, V5, DOI 10.1038/srep09345
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Ryoo NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209276
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Schellevis RL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43152-3
   Schellevis RL, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.576
   Schellevis RL, 2018, JAMA OPHTHALMOL, V136, P1128, DOI 10.1001/jamaophthalmol.2018.3190
   Schubert C, 2014, HUM MUTAT, V35, P859, DOI 10.1002/humu.22551
   Shiragami C, 2018, AM J OPHTHALMOL, V193, P80, DOI 10.1016/j.ajo.2018.06.009
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Tagawa M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73303-w
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   van Dijk EHC, 2017, JAMA OPHTHALMOL, V135, P446, DOI 10.1001/jamaophthalmol.2017.0245
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoneyama S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64301-z
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 66
TC 8
Z9 8
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2020
VL 64
IS 6
BP 555
EP 567
DI 10.1007/s10384-020-00773-w
EA OCT 2020
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH8VD
UT WOS:000574735800001
PM 33006732
DA 2022-11-30
ER

PT J
AU Edwards, MM
   McLeod, DS
   Bhutto, IA
   Villalonga, MB
   Seddon, JM
   Lutty, GA
AF Edwards, Malia M.
   McLeod, D. Scott
   Bhutto, Imran A.
   Villalonga, Mercedes B.
   Seddon, Johanna M.
   Lutty, Gerard A.
TI Idiopathic preretinal glia in aging and age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Astrocytes; Epiretinal membranes;
   Muller cells; Glia
ID POSTERIOR VITREOMACULAR ADHESION; EXPERIMENTAL RETINAL-DETACHMENT;
   EPIRETINAL MEMBRANE FORMATION; PROLIFERATIVE VITREORETINOPATHY;
   EXPRESSION; ASTROCYTES; CELL; PATHOGENESIS; MIGRATION; PATHOLOGY
AB During analysis of glia in wholemount aged human retinas, frequent projections onto the vitreal surface of the inner limiting membrane (ILM) were noted. The present study characterized these preretinal glial structures. The amount of glial cells on the vitreal side of the ILM was compared between eyes with age related macular degeneration (AMD) and age-matched control eyes. Retinal wholemounts were stained for markers of retinal astrocytes and activated Muller cells (glial fibrillary acidic protein, GFAP), Muller cells (vimentin, glutamine synthetase) and microglia/hyalocytes (IBA-1). Retinal vessels were labeled with UEA lectin. Images were collected using a Zeiss LSM 710 confocal microscope. Retinas were then cryopreserved. Laminin labeling of cryosections determined the location of glial structures in relation to the ILM. All retinas investigated herein had varied amounts of preretinal glia. These glial structures were classified into three groups based on size: sprouts, blooms, and membranes. The simplest of the glial structures observed were focal sprouts of singular GFAP-positive cells or processes on the vitreal surface of the ILM. The intermediate structures observed, glial blooms, were created by multiple cells/processes exiting from a single point and extending along the vitreoretinal surface. The most extensive structures, glial membranes, consisted of compact networks of cells and processes. Preretinal glia were observed in all areas of the retina but they were most prominent over large vessels. While all glial blooms and membranes contained vimentin and GFAP-positive cells, these proteins did not always co-localize. Many areas had no preretinal GFAP but had numerous vimentin only glial sprouts. In double labeled glial sprouts, vimentin staining extended beyond that of GFAP. Hyalocytes and microglia were detected along with glial sprouts, blooms, and membranes. They did not, however, concentrate in the retina below these structures. Cross sectional analysis identified small breaks in the ILM above large retinal vessels through which glial cells exited the retina. Preretinal glial structures of varied sizes are a common occurrence in aged retinas and, in most cases, are subclinical. While all retinal glia are found in blooms, vimentin labeling suggests that Muller cells form the leading edge. All retinas investigated from eyes with active choroidal neovascularization (CNV) had extensive glial membranes on the vitreal surface of the ILM. Although these structures may be benign, they may exert traction on the retina as they spread along the vitreoretinal interface. In cases with CNV, glial cells in the vitreous could bind intravitreally injected anti vascular endothelial growth factor. These preretinal glial structures indicate the remodeling of both astrocytes and Muller cells in aged retinas, in particular those with advanced AMD. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Edwards, Malia M.; McLeod, D. Scott; Bhutto, Imran A.; Lutty, Gerard A.] Johns Hopkins Univ Hosp, Dept Ophthalmol, Wilmer Eye Inst, 400 N Broadway, Baltimore, MD 21287 USA.
   [Villalonga, Mercedes B.; Seddon, Johanna M.] Tufts Univ, Sch Med, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol,Tufts Med Ctr, 800 Washington St 450, Boston, MA 02111 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Tufts Medical Center;
   Tufts University
RP Edwards, MM (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Eye Inst, M023 Smith Bldg,400 North Broadway, Baltimore, MD 21287 USA.
EM medwar28@jhmi.edu; dmcleod1@jhmi.edu; ibhutto1@jhmi.edu;
   MVillalonga@tuftsmedicalcenter.org; jseddon@tuftsmedicalcenter.org;
   glutty@jhmi.edu
FU NEI/NIH [EY009357, EY016151, EY01765, EY013309]; Tufts Macular
   Degeneration Research Fund; Beckman Foundation; NATIONAL EYE INSTITUTE
   [P30EY001765, R01EY011309, R01EY009357, R01EY016151] Funding Source: NIH
   RePORTER
FX This research was supported by funding from the NEI/NIH EY009357,
   EY016151 (GL) and EY01765 (Wilmer), NEI/NIH EY013309 (JMS), RPB (Wilmer
   and Tufts), Tufts Macular Degeneration Research Fund (JMS), and the
   Beckman Foundation (GL and JS). The authors are grateful to Charles
   Eberhart, M.D. and Rachel E. Silver, MPH for assistance with acquisition
   of postmortem eyes. The authors also wish to thank Adam Wenick, M.D.,
   PhD for discussion and assistance with clinical interpretation. Finally,
   the authors are deeply indebted to the eye donors and their families for
   making this study possible.
CR Blasiak Janusz, 2013, Front Biosci (Schol Ed), V5, P412
   Bringmann A, 2009, GRAEF ARCH CLIN EXP, V247, P865, DOI 10.1007/s00417-009-1082-x
   Charteris DG, 2002, EYE, V16, P369, DOI 10.1038/sj.eye.6700194
   Edwards MM, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-60
   Fisher SK, 2003, VISION RES, V43, P887, DOI 10.1016/S0042-6989(02)00680-6
   Fisher SK, 2005, PROG RETIN EYE RES, V24, P395, DOI 10.1016/j.preteyeres.2004.10.004
   Foos R.Y., 1972, AM ACAD OPHTHALMOL O, V76, P480
   FOOS RY, 1972, INVEST OPHTH VISUAL, V11, P801
   FOOS RY, 1977, INVEST OPHTH VIS SCI, V16, P416
   FOOS RY, 1974, A GRAEF ARCH KLIN EX, V189, P231, DOI 10.1007/BF02384852
   Garcia-Ramirez M, 2007, DIABETOLOGIA, V50, P1294, DOI 10.1007/s00125-007-0627-y
   Garweg JG, 2013, SURV OPHTHALMOL, V58, P321, DOI 10.1016/j.survophthal.2012.12.004
   GASS JDM, 1988, ARCH OPHTHALMOL-CHIC, V106, P629, DOI 10.1001/archopht.1988.01060130683026
   Gnanaguru G, 2013, DEVELOPMENT, V140, P2050, DOI 10.1242/dev.087817
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Halfter W, 2001, DEV BIOL, V238, P79, DOI 10.1006/dbio.2001.0396
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Kim SH, 2006, J COLLOID INTERF SCI, V295, P84, DOI 10.1016/j.jcis.2005.07.056
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Koyama T, 2011, J AM COLL SURGEONS, V212, P340, DOI 10.1016/j.jamcollsurg.2010.10.017
   Koyama Y, 2014, J NEUROCHEM, V130, P759, DOI 10.1111/jnc.12770
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019
   Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930
   Kuhrt H, 1997, J BRAIN RES, V38, P223
   Kwok AKH, 2005, CLIN EXP OPHTHALMOL, V33, P379, DOI 10.1111/j.1442-9071.2005.01015.x
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   LEWIS GP, 1994, AM J OPHTHALMOL, V118, P368, DOI 10.1016/S0002-9394(14)72962-9
   Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Pedler C, 1961, Br J Ophthalmol, V45, P423, DOI 10.1136/bjo.45.6.423
   Provis JM, 2000, INVEST OPHTH VIS SCI, V41, P2827
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010
   SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119
   Sebag J, 1989, VITREOUS STRUCTURE F
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sethi CS, 2005, INVEST OPHTH VIS SCI, V46, P329, DOI 10.1167/iovs.03-0518
   SPENCER LM, 1970, ARCH OPHTHALMOL-CHIC, V84, P557, DOI 10.1001/archopht.1970.00990040559001
   Suk K, 2012, CELL ADHES MIGR, V6, P160, DOI 10.4161/cam.20251
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Wang MY, 2009, RETINA-J RET VIT DIS, V29, P644, DOI 10.1097/IAE.0b013e31819e0d92
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   WIZNIA RA, 1986, AM J OPHTHALMOL, V102, P196, DOI 10.1016/0002-9394(86)90144-3
   Wong WT, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00022
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yoshida M, 2007, RETINA-J RET VIT DIS, V27, P169, DOI 10.1097/01.iae.0000224940.79223.fb
NR 50
TC 30
Z9 32
U1 0
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2016
VL 150
SI SI
BP 44
EP 61
DI 10.1016/j.exer.2015.07.016
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DX5BR
UT WOS:000384395300005
PM 26220834
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Shona, O
   Gupta, B
   Vemala, R
   Sivaprasad, S
AF Shona, Olajumoke
   Gupta, Bhaskar
   Vemala, Roopa
   Sivaprasad, Sobha
TI Visual acuity outcomes in ranibizumab-treated neovascular age-related
   macular degeneration; stratified by baseline vision
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   lucentis; ranibizumab; vision
AB P>Background:
   Ranibizumab (Lucentis, Novartis, Basel, Switzerland) is currently indicated for use in neovascular age-related macular degeneration (NVAMD). This study assessed the real-life outcomes based on baseline visual acuity when treated with intravitreal ranibizumab on a three + pro re nata (PRN) dosing schedule for NVAMD.
   Design:
   This retrospective chart-review was conducted at King's College Hospital. The patients were stratified into three groups based on baseline Early treatment diabetic retinopathy study (ETDRS) letters: 27 with poor visual acuity (24-34 letters), 33 with intermediate visual acuity (35-54 letters) and 27 with good visual acuity (>==55 letters).
   Methods:
   All patients received a three + PRN dosing schedule of ranibizumab injections (0.5 mg per 0.05 mL) based on changes in visual acuity and macular thickness on optical coherence tomography (OCT) and all patients completed 12-month follow up.
   Main Outcome Measures:
   The mean change in visual acuity at 12 months in the three groups.
   Results:
   Mean gain in ETDRS letters at 12 months was +14.00 (P < 0.0001), +7.10 (P = 0.012) and +2.85 (P = 0.19), and mean number of injections was 5.30, 6.12 and 5.70 in the poor, intermediate and good baseline vision group, respectively, over the 12- month follow-up period.
   Conclusions:
   Poor baseline visual acuity (24-34 ETDRS letters) is a predictor of maximum gain in visual acuity. However, eyes with better baseline visual acuity (55 letters) had a better final visual acuity.
C1 [Shona, Olajumoke; Gupta, Bhaskar; Vemala, Roopa; Sivaprasad, Sobha] Kings Coll Hosp London, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Gupta, Bhaskar/0000-0002-2122-3559
FU Novartis; Pfizer; Allergan
FX Sobha Sivaprasad has received research and travel grants from Novartis,
   Pfizer and Allergan.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 5
TC 24
Z9 24
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2011
VL 39
IS 1
BP 5
EP 8
DI 10.1111/j.1442-9071.2010.02424.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 719WJ
UT WOS:000287241900003
PM 21040311
OA Bronze
DA 2022-11-30
ER

PT J
AU Sabour-Pickett, S
   Beatty, S
   Connolly, E
   Loughman, J
   Stack, J
   Howard, A
   Klein, R
   Klein, BE
   Meuer, SM
   Myers, CE
   Akuffo, KO
   Nolan, JM
AF Sabour-Pickett, Sarah
   Beatty, Stephen
   Connolly, Eithne
   Loughman, James
   Stack, Jim
   Howard, Alan
   Klein, Ronald
   Klein, Barbara E.
   Meuer, Stacy M.
   Myers, Chelsea E.
   Akuffo, Kwadwo O.
   Nolan, John M.
TI SUPPLEMENTATION WITH THREE DIFFERENT MACULAR CAROTENOID FORMULATIONS IN
   PATIENTS WITH EARLY AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE lutein; zeaxanthin; meso-zeaxanthin; age-related macular degeneration;
   visual performance
ID PIGMENT OPTICAL-DENSITY; CONTRAST SENSITIVITY; SERUM CONCENTRATIONS;
   SPATIAL PROFILE; VISUAL FUNCTION; CLINICAL-TRIAL; RISK-FACTORS; HUMAN
   RETINA; VITAMIN-C; ZEAXANTHIN
AB Purpose: To investigate the impact of three different macular carotenoid formulations on macular pigment optical density and visual performance in subjects with early age-related macular degeneration.
   Methods: Fifty-two subjects were supplemented and followed for 12 months, 17 of them were in intervention Group 1 (20 mg/day lutein and 2 mg/day zeaxanthin); 21 in Group 2 (10 mg/day meso-zeaxanthin, 10 mg/day lutein, and 2 mg/day zeaxanthin); and 14 in Group 3 (17 mg/day meso-zeaxanthin, 3 mg/day lutein, and 2 mg/day zeaxanthin). The macular pigment optical density was measured using customized heterochromatic flicker photometry, and visual function was assessed using corrected distance visual acuity and by letter contrast sensitivity.
   Results: A statistically significant increase in the macular pigment optical density was observed at all measured eccentricities in Group 2 (P <= 0.005) and in Group 3 (P < 0.05, for all), but only at 1.75 degrees in Group 1 (P = 0.018). Statistically significant (P < 0.05) improvements in letter contrast sensitivity were seen at all spatial frequencies (except 1.2 cycles per degree) in Group 3, and at low spatial frequencies in Groups 1 and 2.
   Conclusion: Augmentation of the macular pigment optical density across its spatial profile and enhancements in contrast sensitivity were best achieved after supplementation with a formulation containing high doses of meso-zeaxanthin in combination with lutein and zeaxanthin.
C1 [Sabour-Pickett, Sarah; Loughman, James] Dublin Inst Technol, Sch Phys, Dept Optometry, Dublin, Ireland.
   [Sabour-Pickett, Sarah; Beatty, Stephen; Connolly, Eithne; Stack, Jim; Akuffo, Kwadwo O.; Nolan, John M.] Waterford Inst Technol, Macular Pigment Res Grp, Waterford, Ireland.
   [Sabour-Pickett, Sarah; Beatty, Stephen; Connolly, Eithne; Nolan, John M.] Whitfield Clin, Inst Eye Surg, Waterford, Ireland.
   [Sabour-Pickett, Sarah; Beatty, Stephen; Connolly, Eithne; Nolan, John M.] Whitfield Clin, Inst Vis Res, Waterford, Ireland.
   [Loughman, James] Univ KwaZulu Natal, Fac Hlth Sci, African Vis Res Inst, Durban, South Africa.
   [Howard, Alan] Howard Fdn, Cambridge, England.
   [Klein, Ronald; Klein, Barbara E.; Meuer, Stacy M.; Myers, Chelsea E.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Technological University Dublin; South East Technological University
   (SETU); University of Kwazulu Natal; University of Wisconsin System;
   University of Wisconsin Madison
RP Nolan, JM (通讯作者)，WIT, Macular Pigment Res Grp, Carriganore House,West Campus, Waterford, Ireland.
EM jmnolan@wit.ie
RI Akuffo, Kwadwo Owusu/J-2036-2019; Nolan, John/N-4921-2014
OI Akuffo, Kwadwo Owusu/0000-0001-6683-249X; Nolan,
   John/0000-0002-5503-7084; Loughman, James/0000-0003-3130-8991
FU Howard Foundation, Cambridge, United Kingdom; European Research Council
FX Supported by a grant from The Howard Foundation, Cambridge CB22 5LA,
   United Kingdom. The principal investigator (J.M.N.) is currently funded
   by the European Research Council.
CR Akuffo KO, 2014, OPHTHAL EPIDEMIOL, V21, P111, DOI 10.3109/09286586.2014.888085
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002
   Billsten HH, 2003, PHOTOCHEM PHOTOBIOL, V78, P138, DOI 10.1562/0031-8655(2003)078<0138:PPOXIC>2.0.CO;2
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Connolly EE, 2011, INVEST OPHTH VIS SCI, V52, P9207, DOI 10.1167/iovs.11-8025
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Engles M, 2007, INVEST OPHTH VIS SCI, V48, P2922, DOI 10.1167/iovs.06-0883
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Graham I, 2007, EUR J CARDIOV PREV R, V14, pS1, DOI 10.1097/01.hjr.0000277983.23934.c9
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelliher C, 2006, BRIT J OPHTHALMOL, V90, P367, DOI 10.1136/bjo.2005.075861
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Landrum JT, 1999, METHOD ENZYMOL, V299, P457
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Loane E, 2007, CURR EYE RES, V32, P555, DOI 10.1080/02713680701418405
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   MAOKA T, 1986, COMP BIOCHEM PHYS B, V83, P121, DOI 10.1016/0305-0491(86)90341-X
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2012, EXP EYE RES, V101, P9, DOI 10.1016/j.exer.2012.05.006
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   San Giovanni JP, 2005, INVEST OPHTH VIS SCI, V46, P2382
   Sasamoto Y, 2011, GRAEF ARCH CLIN EXP, V249, P1847, DOI 10.1007/s00417-011-1780-z
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sparrow J M, 1997, Ophthalmic Epidemiol, V4, P49
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2007, OPTOMETRY VISION SCI, V84, P859, DOI 10.1097/OPX.0b013e3181559c2b
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   WHO, 2006, DEF DIAGN DIAB MELL
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
NR 67
TC 34
Z9 35
U1 1
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2014
VL 34
IS 9
BP 1757
EP 1766
DI 10.1097/IAE.0000000000000174
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO8UL
UT WOS:000341630400010
PM 24887490
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Puell, MC
   Palomo-Alvarez, C
   Barrio, AR
   Gomez-Sanz, FJ
   Perez-Carrasco, MJ
AF Puell, Maria C.
   Palomo-Alvarez, Catalina
   Barrio, Ana R.
   Gomez-Sanz, Fernando J.
   Jesus Perez-Carrasco, Maria
TI Relationship between macular pigment and visual acuity in eyes with
   early age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE visual acuity; macular pigment optical density; age-related macular
   degeneration
ID OPTICAL-DENSITY; SPATIAL-DISTRIBUTION; OLDER SUBJECTS; CAROTENOIDS;
   MACULOPATHY; LUTEIN; SUPPLEMENTATION; SENSITIVITY; CATARACT;
   CLASSIFICATION
AB Abstract.
   Purpose: Today the extent to which MP impacts visual function in early AMD remains unclear. This study examines the relationship between macular pigment optical density (MPOD) and high-contrast visual acuity (HC-VA) and low-contrast visual acuity (LC-VA) in eyes with early age-related macular degeneration (AMD).
   Methods: Measurements were made in 22 subjects with early AMD and 27 healthy control subjects. Distance best-corrected VA was measured using HC (96%) and LC (10%) Bailey-Lovie logMAR letter charts under photopic luminance conditions. MPOD was determined at the fovea through apparent motion photometry using the cathode ray tube-based Metropsis psychophysical vision test (Cambridge Research Systems).
   Results: No significant differences in foveal MPOD were detected between the control eyes (0.30 +/- 0.24 log units) and eyes with early AMD (0.27 +/- 0.15 log units). Neither were differences detected between the two groups in mean HC- and LC-VA. Foveal MPOD showed significant correlation with both photopic HC-VA (r = -0.47, p = 0.0008) and LC-VA (r = -0.46, p = 0.0008) such that as MPOD increased, photopic HC-VA and LC-VA improved (lower logMAR values).
   Conclusions: Low MP levels were related to worse visual function in both healthy eyes and eyes with early AMD. Our findings provide direction for future studies designed to improve retinal function through the use of oral supplements known to increase MP levels, especially in eyes with AMD and a low MPOD.
C1 [Puell, Maria C.; Palomo-Alvarez, Catalina; Barrio, Ana R.; Jesus Perez-Carrasco, Maria] Univ Complutense, Appl Vis Res Grp, Madrid 28037, Spain.
   [Gomez-Sanz, Fernando J.] Hosp Henares, Madrid, Spain.
C3 Complutense University of Madrid
RP Puell, MC (通讯作者)，Univ Complutense, Sch Opt & Optometry, Av Arcos de Jalon 118, Madrid 28037, Spain.
EM puellma@fis.ucm.es
RI Puell, MarÃa/ABE-2972-2021; Barrio, Ana/J-7246-2017
OI Palomo-Alvarez, Catalina/0000-0003-2110-678X
FU Fundacion de Investigacion Medica Mutua Madrilena [FMM-02538/2008, GR
   58/08]
FX This research was supported by a grant from Fundacion de Investigacion
   Medica Mutua Madrilena FMM-02538/2008 Principal investigator: Puell MC
   and Banco Santander-Universidad Complutense de Madrid GR 58/08,
   Principal investigator: Puell MC.
CR Abadi RV, 1996, OPHTHAL PHYSL OPT, V16, P455, DOI 10.1046/j.1475-1313.1996.96000129.x
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anstis SM, 1983, COLOUR VISION PSYCHO, P66
   Bahrami Hossein, 2006, BMC Ophthalmol, V6, P23, DOI 10.1186/1471-2415-6-23
   Barbur JL, 2010, OPHTHAL PHYSL OPT, V30, P470, DOI 10.1111/j.1475-1313.2010.00748.x
   Bartlett H, 2011, BRIT J OPHTHALMOL, V95, P662, DOI 10.1136/bjo.2009.178137
   Bartlett H, 2010, BRIT J OPHTHALMOL, V94, P753, DOI 10.1136/bjo.2009.175901
   Bartlett HE, 2008, CLIN NUTR, V27, P218, DOI 10.1016/j.clnu.2008.01.003
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P1338
   de Kinkelder R, 2011, EYE, V25, P105, DOI 10.1038/eye.2010.164
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Hagen S, 2010, ACTA OPHTHALMOL, V88, P207, DOI 10.1111/j.1755-3768.2008.01418.x
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Kanis MJ, 2008, INVEST OPHTH VIS SCI, V49, P2077, DOI 10.1167/iovs.07-1181
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Loughman J, 2012, ACTA OPHTHALMOL, V90, pe90, DOI 10.1111/j.1755-3768.2011.02294.x
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Lovie-Kitchin JE, 1989, CLIN EXP OPTOM, V72, P79
   Moreland JD, 2001, COLOR RES APPL, V26, pS261, DOI 10.1002/1520-6378(2001)26:1+<::AID-COL56>3.0.CO;2-6
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Nolan JM, 2009, INVEST OPHTH VIS SCI, V50, P4777, DOI 10.1167/iovs.08-3277
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Perez-Carrasco MJ, 2009, ACTA OPHTHALMOL, V87
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Raphael S, 2011, J VISION, V11, DOI 10.1167/11.9.14
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   Renzi LM, 2010, EXP EYE RES, V91, P896, DOI 10.1016/j.exer.2010.09.015
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Tsika C, 2011, ACTA OPHTHALMOL, V89, pE573, DOI 10.1111/j.1755-3768.2011.02170.x
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
NR 55
TC 18
Z9 18
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2013
VL 91
IS 4
BP E298
EP E303
DI 10.1111/aos.12067
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF0FE
UT WOS:000334387500010
PM 23575039
DA 2022-11-30
ER

PT J
AU Zhu, DH
   Deng, XM
   Xu, J
   Hinton, DR
AF Zhu, DanHong
   Deng, Xuemei
   Xu, Jing
   Hinton, David R.
TI What determines the switch between atrophic and neovascular forms of age
   related macular degeneration? the role of BMP4 induced senescence
SO AGING-US
LA English
DT Article
DE BMP4; age related macular degeneration; senescence, retinal pigment
   epithelial cell; oxidative stress
ID RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC ATROPHY; LIFE-SPAN; CELLULAR
   SENESCENCE; CELLS; CANCER; PATHOGENESIS; PATHWAY; P53; INTERLEUKIN-8
AB Age-related macular degeneration (AMD), the leading cause of blindness in the elderly, targets the retinal pigment epithelium (RPE), a monolayer of cells at the back of the eye. As AMD progresses, it can develop into two distinct forms of late AMD: "dry," atrophic AMD, characterized by RPE senescence and geographic RPE loss, and "wet," neovascular AMD, characterized by RPE activation with abnormal growth of choroidal vessels. The genetic and molecular pathways that lead to these diverse phenotypes are currently under investigation. We have found that bone morphogenetic protein-4 (BMP4) is differentially expressed in atrophic and neovascular AMD. In atrophic AMD, BMP4 is highly expressed in RPE, and mediates oxidative stress induced RPE senescence in vitro via Smad and p38 pathways. In contrast, in neovascular AMD lesions, BMP4 expression in RPE is low, possibly a result of local expression of pro-inflammatory mediators. Thus, BMP4 may be involved in the molecular switch determining which phenotypic pathway is taken in the progression of AMD.
C1 [Zhu, DanHong; Deng, Xuemei; Hinton, David R.] Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
   [Zhu, DanHong; Deng, Xuemei; Xu, Jing; Hinton, David R.] Univ So Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA 90089 USA.
   [Hinton, David R.] Univ So Calif, Dept Ophthalmol, Keck Sch Med, Los Angeles, CA 90089 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Hinton, DR (通讯作者)，Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM DHinton@doheny.org
FU National Institutes of Health [EY01545, EY03040]; Arnold and Mabel
   Beckman Foundation; NATIONAL EYE INSTITUTE [P30EY003040, R01EY001545]
   Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health grants EY01545
   and EY03040 and by the Arnold and Mabel Beckman Foundation.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chretien A, 2008, FREE RADICAL BIO MED, V44, P1732, DOI 10.1016/j.freeradbiomed.2008.01.026
   Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Demidenko ZN, 2009, CELL CYCLE, V8, P1888, DOI 10.4161/cc.8.12.8606
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Frippiat C, 2001, J BIOL CHEM, V276, P2531, DOI 10.1074/jbc.M006809200
   Fukuda N, 2006, ONCOGENE, V25, P3509, DOI 10.1038/sj.onc.1209393
   Goczalik IM, 2005, J NEUROIMMUNOL, V161, P49, DOI 10.1016/j.jneuroim.2004.12.004
   Gonzalez A, 2008, CIRC RES, V102, P597, DOI 10.1161/CIRCRESAHA.107.165464
   Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   KILL IR, 1994, J CELL SCI, V107, P571
   Kirkwood TBL, 2002, NATURE, V419, P794, DOI 10.1038/419794a
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   Martin GM, 2007, MECH AGEING DEV, V128, P9, DOI 10.1016/j.mad.2006.11.003
   Martin-Ruiz C, 2004, J BIOL CHEM, V279, P17826, DOI 10.1074/jbc.M311980200
   Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Su DM, 2009, J BIOL CHEM, V284, P12153, DOI 10.1074/jbc.M807930200
   Takebayashi-Suzuki K, 2003, DEVELOPMENT, V130, P3929, DOI 10.1242/dev.00615
   Trousse F, 2001, J NEUROSCI, V21, P1292
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yokouchi Y, 1996, DEVELOPMENT, V122, P3725
   YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zdanov S, 2006, ANN NY ACAD SCI, V1067, P210, DOI 10.1196/annals.1354.025
   ZENDER L, 2009, AGING, V1, P1
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
   Zhu NL, 2007, GENE, V393, P70, DOI 10.1016/j.gene.2007.01.016
NR 37
TC 33
Z9 37
U1 1
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD AUG
PY 2009
VL 1
IS 8
BP 740
EP 745
DI 10.18632/aging.100078
PG 6
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 579US
UT WOS:000276401800007
PM 20157553
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Axer-Siegel, R
   Ehrlich, R
   Yassur, Y
   Rosenblatt, I
   Kramer, M
   Priel, E
   Benjamini, Y
   Weinberger, D
AF Axer-Siegel, R
   Ehrlich, R
   Yassur, Y
   Rosenblatt, I
   Kramer, M
   Priel, E
   Benjamini, Y
   Weinberger, D
TI Photodynamic therapy for age-related macular degeneration in a clinical
   setting: Visual results and angiographic patterns
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; ANASTOMOSES; VERTEPORFIN
AB PURPOSE: To evaluate the visual outcome of patients with subfoveal choroidal neovascularization due to age-related macular degeneration, who received photodynamic therapy (PTD) in a clinical setting and to identify potential predictive visual and angiographic factors.
   DESIGN: Interventional case series.
   METHODS: The study included 74 patients with subfoveal choroidal neovascularization who underwent PDT from January 2000 to March 2001 and completed at least 1 year follow-up. All patients received verteporfin PDT and were followed clinically, with fluorescein angiography (74 eyes), and with indocyanine green angiography (65 eyes). A review of the medical records and angiograms was performed.
   RESULTS: Mean follow,up was 15.6 months. Patients received a mean of 3.4 treatments per year. Sixty-six percent lost less than 3 Snellen lines of visual acuity. Three patients (4%) experienced profound visual acuity loss to finger counting. Final visual acuity was positively correlated with lesion size and visual acuity at presentation. Visual outcome was worse in the presence of cystoid macular edema. On indocyanine green angiography, a round hypofluorescent spot was seen at the site of the PDT, with maintenance of medium and large choroidal vessels.
   CONCLUSION: Smaller lesion size and better visual acuity at presentation were good predictive signs, whereas cystoid macular edema was found to be a poor prognostic sign for visual outcome following PDT. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Rabin Med Ctr, Dept Ophthalmol, IL-49100 Petah Tiqwa, Israel.
   Mor Inst Med Data, Bnei Braq, Israel.
   Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   Tel Aviv Univ, Sackler Fac Exact Sci, Dept Stat, IL-69978 Tel Aviv, Israel.
C3 Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine;
   Tel Aviv University
RP Axer-Siegel, R (通讯作者)，Rabin Med Ctr, Dept Ophthalmol, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.
EM seegs@netvision.net.il
RI Benjamini, Yoav/C-4219-2008
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2002, OPHTHALMOLOGY, V109, P1726, DOI 10.1016/S0161-6420(02)01149-1
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1991, ARCH OPHTHALMOL-CHIC, V109, P211, DOI 10.1001/archopht.1991.01080020057043
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Flower RW, 1998, RETINA-J RET VIT DIS, V18, P260, DOI 10.1097/00006982-199803000-00012
   Flower RW, 1999, RETINA-J RET VIT DIS, V19, P365
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   GREGOR Z, 1977, BR J OPHTHALMOL, V90, P206
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   SOUBRANE G, 1988, J FR OPHTALMOL, V11, P711
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
NR 24
TC 46
Z9 48
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2004
VL 137
IS 2
BP 258
EP 264
DI 10.1016/j.ajo.2003.08.009
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 776ZB
UT WOS:000189148300006
PM 14962414
OA Green Published
DA 2022-11-30
ER

PT J
AU Matsuura, T
   Kaneko, H
   Takayama, K
   Shibata, R
   Kataoka, K
   Ito, S
   Tsunekawa, T
   Shimizu, H
   Suzumura, A
   Namba, R
   Ito, Y
   Murohara, T
   Terasaki, H
AF Matsuura, Toshiyuki
   Kaneko, Hiroki
   Takayama, Kei
   Shibata, Rei
   Kataoka, Keiko
   Ito, Seina
   Tsunekawa, Taichi
   Shimizu, Hideyuki
   Suzumura, Ayana
   Namba, Rina
   Ito, Yasuki
   Murohara, Toyoaki
   Terasaki, Hiroko
TI Diacron reactive oxygen metabolites and biological antioxidant potential
   tests for patients with age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Diacron reactive oxygen metabolites;
   Biological antioxidant potential; Oxidative stress; Choroidal
   neovascularization
ID EPITHELIAL-CELLS IMPLICATIONS; D-ROMS TEST; OXIDATIVE STRESS;
   PATHOGENESIS; AFLIBERCEPT; RISK; VEGF
AB Background Previously, we showed that serum malondialdehyde (MDA) was significantly higher in patients with neovascular age-related macular degeneration (nAMD) than in those without AMD. The Diacron reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) tests are known markers of oxidative stress. The aim of this study was to use d-ROMs and BAP tests to evaluate changes in systemic oxidative stress in patients with nAMD. Methods Blood serum samples were collected from 34 patients with nAMD (mean age: 76.5 +/- 7.7 years; 22 men) and 20 control subjects (mean age: 62.9 +/- 14.0 years; 10 men), and d-ROMs and BAP tests were examined. Results In men, the mean level of d-ROMs for the nAMD patients was significantly higher than that for the controls (312.0 +/- 52.4 vs. 275.1 +/- 45.5 U.CARR, respectively; P < .05). There was a significant correlation between d-ROM level and CNV lesion area in the male nAMD group (r = .42, P = .05). There were no significant differences in mean BAP test results between the nAMD patients and controls for either sex (men: 2241 +/- 549 vs. 2136 +/- 246 mu mol/L; women: 2263 +/- 292 vs. 2335 +/- 161 mu mol/L). Conclusion The d-ROMs test may provide a useful indicator of nAMD in men but not in women.
C1 [Matsuura, Toshiyuki; Kaneko, Hiroki; Kataoka, Keiko; Ito, Seina; Tsunekawa, Taichi; Shimizu, Hideyuki; Suzumura, Ayana; Namba, Rina; Ito, Yasuki; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
   [Takayama, Kei] Natl Def Med Coll, Dept Ophthalmol, Saitama, Japan.
   [Shibata, Rei] Nagoya Univ, Grad Sch Med, Dept Adv Cardiovasc Therapeut, Nagoya, Aichi, Japan.
   [Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi, Japan.
C3 Nagoya University; National Defense Medical College - Japan; Nagoya
   University; Nagoya University
RP Kaneko, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM h-kaneko@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/AHA-2461-2022; Ito, Yasuki/M-4876-2014; Kataoka,
   Keiko/B-2806-2016
OI Kaneko, Hiroki/0000-0003-0731-6465; Ito, Yasuki/0000-0001-9219-9261;
   Kataoka, Keiko/0000-0002-8795-6536
FU Ministry of Education, Culture, Sports, Science and Technology [17
   K16964]
FX This work was partially supported by Grants-in-Aid for Young Scientist B
   (K.T.; 17 K16964) from the Ministry of Education, Culture, Sports,
   Science and Technology (http://www.jsps.go.jp/): purchasing assay
   reagents Japan Foundation for Applied Enzymology (K.T.): purchasing
   assay reagents.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Babizhayev MA, 2015, CELL BIOCHEM BIOPHYS, V71, P1425, DOI 10.1007/s12013-014-0365-y
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Carratelli M, 2001, INT J CLIN PHARM RES, V21, P79
   Cesarone MR, 1999, INT ANGIOL, V18, P127
   Colombini F, 2016, FREE RADICAL RES, V50, P447, DOI 10.3109/10715762.2015.1136063
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Dani C, 2003, ARCH DIS CHILD-FETAL, V88, pF119, DOI 10.1136/fn.88.2.F119
   Dolgin E, 2017, NAT BIOTECHNOL, V35, P1000, DOI 10.1038/nbt1117-1000
   Du Hongjun, 2016, Open J Ophthalmol, V6, P43
   Gerardi G, 2002, CLIN CHEM LAB MED, V40, P104, DOI 10.1515/CCLM.2002.019
   Ippolito S, 2002, ITALIAN J BIOCH, V51, P129
   Ito F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020454
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Matsuura T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9548767
   Nojima J., 2010, JPN J MED TECH, V59, P199
   Rahman Irfan, 2002, Current Drug Targets - Inflammation and Allergy, V1, P291, DOI 10.2174/1568010023344607
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Takayama K, 2017, GRAEF ARCH CLIN EXP, V255, P449, DOI 10.1007/s00417-016-3468-x
   Takayama K, 2017, RETINA-J RET VIT DIS, V37, P553, DOI 10.1097/IAE.0000000000001225
   Takayama K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8694641
   Takayama K, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004978
   Trotti R, 2001, HAEMATOLOGICA, V86, P85
   Yagi K, 1981, J APPL BIOCHEM, V3, P58
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 32
TC 1
Z9 1
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD FEB 18
PY 2020
VL 20
IS 1
AR 56
DI 10.1186/s12886-020-01334-y
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KQ9BZ
UT WOS:000517217200002
PM 32070305
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Klein, BEK
   Mcelroy, JA
   Klein, R
   Howard, KP
   Lee, KE
AF Klein, Barbara E. K.
   Mcelroy, Jane A.
   Klein, Ronald
   Howard, Kerri P.
   Lee, Kristine E.
TI Nitrate-nitrogen levels in rural drinking water: Is there an association
   with age-related macular degeneration?
SO JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART A-TOXIC/HAZARDOUS
   SUBSTANCES & ENVIRONMENTAL ENGINEERING
LA English
DT Article
DE Disease; epidemiology; personal exposure; population-based studies
ID VISUAL-ACUITY; POPULATION; EXPOSURE; PATHOGENESIS; GROUNDWATER;
   HEMOGLOBIN; WISCONSIN; RETINA; DRUSEN; PERIOD
AB We examined the association of nitrate-nitrogen exposure from rural private drinking water and incidence of age-related macular degeneration (AMD). All participants in the Beaver Dam Eye Study (53916 improvement plan code) completed a questionnaire and had an ocular examination including standardized, graded fundus photographs at five examinations. Only information from rural residents in that study are included in this report. Data from an environmental monitoring study with probabilistic-based agro-chemical sampling, including nitrate-nitrogen, of rural private drinking water were available. Incidence of early AMD was associated with elevated nitrate-nitrogen levels in rural private drinking water supply (10.0% for low, 19.2% for medium, and 26.1% for high nitrate-nitrogen level in the right eye). The odds ratios (ORs) were 1.77 (95% confidence interval [CI]: 1.12-2.78) for medium and 2.88 (95% CI: 1.59-5.23) for high nitrate-nitrogen level. Incidence of late AMD was increased for those with medium or high levels of nitrate-nitrogen compared to low levels (2.3% for low and 5.1% for the medium or high nitrate-nitrogen level, for the right eye). The OR for medium or high nitrate-nitrogen groups was 2.80 (95% CI: 1.07-7.31) compared to the low nitrate-nitrogen group.
C1 [Klein, Barbara E. K.; Klein, Ronald; Howard, Kerri P.; Lee, Kristine E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Mcelroy, Jane A.] Univ Missouri, Sch Med, Dept Family & Community Med, Columbia, MO USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Missouri System; University of Missouri Columbia
RP Klein, BEK (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 North Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM kleinb@epi.ophth.wisc.edu
OI Klein, Ronald/0000-0002-4428-6237; McElroy, Jane/0000-0001-7518-747X
FU National Institutes of Health [EY06594]; National Eye Institute;
   Research to Prevent Blindness; NATIONAL EYE INSTITUTE [U10EY006594]
   Funding Source: NIH RePORTER
FX Technical editing and writing assistance was provided by Mary Kay
   Aprison, BS and Heidi M. G. Christian, BA. This research was supported
   by National Institutes of Health grant EY06594 (Drs. B. E. K. Klein, R.
   Klein). The National Eye Institute provided funding for entire study
   including collection and analyses of data. Additional support was
   provided by Research to Prevent Blindness. The content of this report is
   solely the responsibility of the authors and does not necessarily
   reflect the official views of the National Eye Institute or the National
   Institutes of Health.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chern L., 1999, NITRATE GROUNDWATER, P1
   CHILVERS C, 1984, INT J EPIDEMIOL, V13, P324, DOI 10.1093/ije/13.3.324
   CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Gulis G, 2002, ENVIRON RES, V88, P182, DOI 10.1006/enrs.2002.4331
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hebels DGAJ, 2009, TOXICOL SCI, V108, P290, DOI 10.1093/toxsci/kfp035
   International Agenecy for Research on Cancer, 2010, IARC MONOGRAPHS EVAL, V94, P43
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   JOHNSON CJ, 1990, AM J IND MED, V18, P449, DOI 10.1002/ajim.4700180416
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   KLENK DC, 1982, CLIN CHEM, V28, P2088
   LeMasters G., 1997, 26A WISC DEP AGR TRA, P1
   McElroy JA, 2008, J WATER HEALTH, V6, P399, DOI 10.2166/wh.2008.048
   MOLLER H, 1989, INT J EPIDEMIOL, V18, P206, DOI 10.1093/ije/18.1.206
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okabe A., 2009, SPATIAL TESSELLATION, DOI [DOI 10.1002/9780470317013, 10.1002/9780470317013.ch2]
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shaban H, 2002, BIOL CHEM, V383, P537, DOI 10.1515/BC.2002.054
   Sibson R., 1981, INTERPRETING MULTIVA, P21, DOI DOI 10.1002/ADVS.201700552
   Slein M. W., 1963, METHOD ENZYMAT AN, P117
   SPALDING RF, 1993, J ENVIRON QUAL, V22, P392, DOI 10.2134/jeq1993.00472425002200030002x
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Uffink G. J. M., 2003, 703717011 RIVM NAT I, P1
   VANDEZANDE JC, 2002, ASP APPL BIOL DAN CR, P1
   Vineis P, 2004, INT J EPIDEMIOL, V33, P945, DOI 10.1093/ije/dyh277
   Ward MH, 2005, ENVIRON HEALTH PERSP, V113, P1607, DOI 10.1289/ehp.8043
   Winyard PG, 2011, BIOCHEM SOC T, V39, P1226, DOI 10.1042/BST0391226
   Wisconsin Department of Agriculture Trade and Consumer Protection, 2010, 15 YEARS DATCP EXC W
   Yoshizawa K, 2009, MOL VIS, V15, P2919
   Zeman C, 2011, J ENVIRON HEALTH, V74, P8
NR 38
TC 10
Z9 10
U1 0
U2 62
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1093-4529
EI 1532-4117
J9 J ENVIRON SCI HEAL A
JI J. Environ. Sci. Health Part A-Toxic/Hazard. Subst. Environ. Eng.
PD DEC 6
PY 2013
VL 48
IS 14
BP 1757
EP 1763
DI 10.1080/10934529.2013.823323
PG 7
WC Engineering, Environmental; Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Environmental Sciences & Ecology
GA 212QX
UT WOS:000323999000001
PM 24007430
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lin, CH
   Liao, WM
   Liang, JW
   Chen, PH
   Ko, CE
   Yang, CH
   Lu, CK
AF Lin, Cheng-Hung
   Liao, Wei-Ming
   Liang, Jing-Wen
   Chen, Po-Han
   Ko, Cheng-En
   Yang, Chih-Hao
   Lu, Cheng-Kai
TI Denoising Performance Evaluation of Automated Age-Related Macular
   Degeneration Detection on Optical Coherence Tomography Images
SO IEEE SENSORS JOURNAL
LA English
DT Article
DE Diseases; Feature extraction; Support vector machines; Wiener filters;
   Sensors; Optical filters; Artificial Intelligence (AI); age-related
   macular degeneration (AMD); optical coherence tomography (OCT)
ID SPECKLE; CLASSIFICATION; REDUCTION
AB Automated detection of eye diseases using artificial intelligence techniques on optical coherence tomography (OCT) images is widely researched in the field of ophthalmology. Such detections are usually performed with the aid of computers. Using high-level simulations, this study investigates and evaluates three automated age-related macular degeneration (AMD) detection flows in terms of computation time and detection accuracy for future hardware-accelerated designs of intelligent and portable OCT systems. In this study, a block-matching and 3-Dimension filter (BM3DF), a hybrid median filter (HMF), and an adaptive wiener filter (AWF) are used to denoise the OCT images. Support vector machine (SVM), AlexNet, GoogLeNet, and Inception-ResNet are employed for AMD detection. Moreover, Local binary patterns, linear configuration patterns, and transfer learning techniques are used to extract image features. Simulation results reveal that machine-learning-based automated AMD detection realizes a high detection accuracy of 95.91% accompanied by low computation time when using the HMF rather than the BM3DF. When considering deep-learning-based automated AMD detection, the combination of HMF and Inception-ResNet achieves the highest detection accuracy of 98.64% but is accompanied by a dramatic increase in computation time. However, only AlexNet achieves a detection accuracy of 96.40%, accompanied by low computation time. In this study, the tradeoffs between the computation time and detection accuracy have been revealed by comparing the denoising methods for the distinct automated AMD detections.
C1 [Lin, Cheng-Hung; Liao, Wei-Ming; Liang, Jing-Wen; Chen, Po-Han; Ko, Cheng-En; Yang, Chih-Hao] Yuan Ze Univ, Dept Elect Engn, Jhongli 32003, Taiwan.
   [Lin, Cheng-Hung; Yang, Chih-Hao] Yuan Ze Univ, Biomed Engn Res Ctr, Jhongli 32003, Taiwan.
   [Lu, Cheng-Kai] Univ Teknol PETRONAS, Dept Elect & Elect Engn, Seri Iskandar 32610, Perak, Malaysia.
C3 Yuan Ze University; Yuan Ze University; Universiti Teknologi Petronas
RP Lin, CH (通讯作者)，Yuan Ze Univ, Dept Elect Engn, Jhongli 32003, Taiwan.; Lu, CK (通讯作者)，Univ Teknol PETRONAS, Dept Elect & Elect Engn, Seri Iskandar 32610, Perak, Malaysia.
EM chlin@saturnyzu.edu.tw; chengkai.lu@utp.edu.my
OI Lu, ChengKai/0000-0002-5819-0754; Lin, Cheng-Hung/0000-0001-8373-2271
FU Ministry of Science and Technology, Taiwan [MOST 107-2221-E-155-057,
   MOST 108-2221-E-155-046, 015LC0-002]
FX This work was supported in part by the Ministry of Science and
   Technology, Taiwan, under Grant MOST 107-2221-E-155-057 and Grant MOST
   108-2221-E-155-046; and in part by the YUTP-Fundamental Research Grant
   under Grant 015LC0-002.
CR Ahonen T, 2006, IEEE T PATTERN ANAL, V28, P2037, DOI 10.1109/TPAMI.2006.244
   Alsaih K, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0352-9
   Alsaih K, 2016, IEEE ENG MED BIO, P1344, DOI 10.1109/EMBC.2016.7590956
   Azlan NAN, 2020, IEEE SENS J, V20, P13094, DOI 10.1109/JSEN.2020.3002559
   Chantraine G, 2018, PALGRAVE STUD PRISON, P1, DOI 10.1007/978-3-319-64358-8_1
   Chen QA, 2010, SIGNAL PROCESS, V90, P2778, DOI 10.1016/j.sigpro.2010.03.016
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Dabov K, 2007, IEEE T IMAGE PROCESS, V16, P2080, DOI 10.1109/TIP.2007.901238
   Dalal N., 2005, CVPR
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Garcia D., HYBRID MEDIAN FILTER
   Guo G.Z. Yimo, 2011, P BRIT MACH VIS C, P119
   Guo Y., LINEAR CONFIGURATION
   Jolliffe IT., 1986, J MARKETING RES, DOI 10.1007/978-1-4757-1904-8
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Ko CE, 2019, 2019 IEEE INTERNATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE CIRCUITS AND SYSTEMS (AICAS 2019), P199, DOI 10.1109/AICAS.2019.8771609
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Kugelman J, 2018, BIOMED OPT EXPRESS, V9, P5759, DOI 10.1364/BOE.9.005759
   Lemaitre G., 2015, OPHTHALMIC MEDICAL I, P9
   Lim JS, 1990, 2 DIMENSIONAL SIGNAL
   Liu YY, 2011, MED IMAGE ANAL, V15, P748, DOI 10.1016/j.media.2011.06.005
   Maggioni M., IMAGE VIDEO DENOISIN
   Mirza S, 2005, OPT ENG, V44, DOI 10.1117/1.1886749
   NIEMINEN A, 1987, IEEE T PATTERN ANAL, V9, P74, DOI 10.1109/TPAMI.1987.4767873
   Ojala T, 2002, IEEE T PATTERN ANAL, V24, P971, DOI 10.1109/TPAMI.2002.1017623
   Oliver A, 2007, LECT NOTES COMPUT SC, V4791, P286
   Ozcan A, 2007, J OPT SOC AM A, V24, P1901, DOI 10.1364/JOSAA.24.001901
   Panigrahi S., 2021, IEEE T KNOWL DATA EN, V194, P781, DOI [10.1109/TKDE.2009.191, 10.1007/978-981-15-5971-6_83, DOI 10.1109/TKDE.2009.191]
   Rakesh MR., 2013, INT J ADV RES ELECT, V2, P5117
   Schmitt JM, 1999, J BIOMED OPT, V4, P95, DOI 10.1117/1.429925
   Shadkam N., 2012, P 20 IR C EL ENG ICE, P934
   Shakher C, 2002, OPT ENG, V41, P176, DOI 10.1117/1.1420192
   Sharma A, 2008, OPT LASER ENG, V46, P42, DOI 10.1016/j.optlaseng.2007.07.004
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Su TY, 2018, IEEE SENS J, V18, P6857, DOI 10.1109/JSEN.2018.2850940
   Szegedy C., 2015, IEEE C COMP VIS PATT, P1, DOI DOI 10.1109/CVPR.2015.7298594
   Szegedy C, 2017, AAAI CONF ARTIF INTE, P4278
   Tang SN, 2018, IEICE ELECTRON EXPR, V15, DOI 10.1587/elex.15.20171128
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   Wu Jiang, 2008, V446, P1, DOI 10.1007/978-1-60327-084-7_1
   Zhang Hao, 2016, Journal of Shanghai Jiaotong University (Science), V21, P173, DOI 10.1007/s12204-016-1709-0
NR 42
TC 5
Z9 5
U1 4
U2 19
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1530-437X
EI 1558-1748
J9 IEEE SENS J
JI IEEE Sens. J.
PD JAN 1
PY 2021
VL 21
IS 1
BP 790
EP 801
DI 10.1109/JSEN.2020.3014254
PG 12
WC Engineering, Electrical & Electronic; Instruments & Instrumentation;
   Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Instruments & Instrumentation; Physics
GA PC8AG
UT WOS:000597216600085
DA 2022-11-30
ER

PT J
AU Eter, N
   Vogel, A
   Inhetvin-Hutter, C
   Spitznas, M
AF Eter, N
   Vogel, A
   Inhetvin-Hutter, C
   Spitznas, M
TI Short-term reaction of choroidal neovascularization and choriocapillaris
   to photodynamic therapy in age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; control
   intervals; photodynamic therapy
ID RANDOMIZED CLINICAL-TRIALS; VERTEPORFIN
AB PURPOSE. To identify the number of primary angiographic nonresponders to photodynamic therapy (PDT) with verteporfin, to determine the rate and speed of reperfusion of choroidal neovascularization (CNV) within a short observation period of only 5 weeks, and to examine the reaction of the underlying choroidal vessels.
   METHODS. PDT according to the TAP regimen was carried out in 36 eyes with subfoveal classic CNV secondary to age-related macular degeneration. The response to PDT was examined 1 (T-1) and 5 (T-2) weeks following treatment. At all visits distant visual acuity was measured and both fluorescein and indocyanine green angiography was carried out.
   RESULTS. One week after treatment (T-1), complete closure of classic CNV had not been achieved in 17% of eyes (primary angiographic nonresponders). At T-2, 91% of eyes showed reperfusion of the CNV In 83% of the primary angiographic nonresponders the CNV size was larger than before treatment. Choroidal shadowing was present in 82% at T-1 and in 48% at T-2.
   CONCLUSIONS. Primary angiographic PDT nonresponders are relatively rare; however, in contrast to former reports, they exist and can be identified by follow-up examination 1 week after PDT Recurrence of leakage occurred earlier than expected and may require closer follow-up and earlier retreatment than recommended by the TAP trial.
C1 Univ Bonn, Med Ctr, Dept Ophthalmol, D-53105 Bonn, Germany.
C3 University of Bonn
RP Eter, N (通讯作者)，Univ Bonn, Med Ctr, Dept Ophthalmol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Hager A, 1999, OPHTHALMOLOGE, V96, P291, DOI 10.1007/s003470050408
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Michels S, 2000, KLIN MONATSBL AUGENH, V217, P94, DOI 10.1055/s-2000-10391
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Stur M, 2001, INVEST OPHTH VIS SCI, V42, pS442
NR 10
TC 1
Z9 1
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD OCT
PY 2003
VL 13
IS 8
BP 687
EP 692
DI 10.1177/112067210301300804
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 739HK
UT WOS:000186338900004
PM 14620172
DA 2022-11-30
ER

PT J
AU Zeng, YY
   Yin, XJ
   Chen, CZ
   Xing, YQ
AF Zeng, Yuyang
   Yin, Xiujuan
   Chen, Changzheng
   Xing, Yiqiao
TI Identification of Diagnostic Biomarkers and Their Correlation with
   Immune Infiltration in Age-Related Macular Degeneration
SO DIAGNOSTICS
LA English
DT Article
DE age-related macular degeneration; complement C1S; adrenomedullin; IER5L;
   immune cell infiltration
ID TUMOR MICROENVIRONMENT
AB Age-related macular degeneration (AMD) is a progressive neurodegenerative disease of the central retina, with no suitable biomarkers for early diagnosis and treatment. This study aimed to find potential diagnostic biomarker candidates for AMD and investigate their immune-related roles in this pathology. Weight gene correlation analysis was first performed based on data from the Gene Expression Omnibus database and 20 hub genes were identified. The functional enrichment analyses showed that the innate immune response, inflammatory response, and complement activation were key pathways associated with AMD. Complement C1s (C1S), adrenomedullin (ADM), and immediate early response 5 like (IER5L) were identified as the crucial genes with favorable diagnostic values for AMD by using LASSO analysis and multiple logistic regression. Furthermore, a 3-gene model was constructed and proved to be of good diagnostic and predictive performance for AMD (AUC = 0.785, 0.840, and 0.810 in training, test, and validation set, respectively). Finally, CIBERSORT was used to evaluate the infiltration of immune cells in AMD tissues. The results showed that the NK cells, CD4 memory T cell activation, and macrophage polarization may be involved in the AMD process. C1S, ADM, and IER5L were correlated with the infiltration of the above immune cells. In conclusion, our study suggests that C1S, ADM, and IER5L are promising diagnostic biomarker candidates for AMD and may regulate the infiltration of immune cells in the occurrence and progression of AMD.
C1 [Zeng, Yuyang; Chen, Changzheng; Xing, Yiqiao] Wuhan Univ, Ctr Eye, Renmin Hosp, 238 Jiefang Rd, Wuhan 430060, Peoples R China.
   [Yin, Xiujuan] Wuhan Univ, State Key Lab Virol, Frontier Sci Ctr Immunol & Metab, Coll Life Sci, Wuhan 430072, Peoples R China.
C3 Wuhan University; Wuhan University
RP Chen, CZ; Xing, YQ (通讯作者)，Wuhan Univ, Ctr Eye, Renmin Hosp, 238 Jiefang Rd, Wuhan 430060, Peoples R China.
EM yuyangz@whu.edu.cn; Y18702772142@163.com; chenchangzheng@whu.edu.cn;
   Yiqiao_xing57@whu.edu.cn
OI Xing, Yiqiao/0000-0001-5534-1951
CR Almitairi JOM, 2018, P NATL ACAD SCI USA, V115, P768, DOI 10.1073/pnas.1718709115
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Asano Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep19174
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Bi KW, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00424
   Bohmig GA, 2018, TRANSPLANTATION, V102, P1837, DOI 10.1097/TP.0000000000002267
   Chakravarthy U, 2020, JAMA-J AM MED ASSOC, V324, P794, DOI 10.1001/jama.2020.5576
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Deng YJ, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10030171
   Ferrero H, 2018, MOL NEUROBIOL, V55, P8799, DOI 10.1007/s12035-018-1031-y
   Fricke TR, 2018, BRIT J OPHTHALMOL, V102, P855, DOI 10.1136/bjophthalmol-2017-311266
   Ge PL, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109228
   Gil-Martinez M, 2020, CURR MED CHEM, V27, P583, DOI 10.2174/0929867326666190726121711
   Iesato Y, 2016, PROG RETIN EYE RES, V52, P112, DOI 10.1016/j.preteyeres.2016.01.001
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Lee IS, 2021, GASTRIC CANCER, V24, P655, DOI 10.1007/s10120-021-01155-y
   Li HY, 2020, AGING-US, V12, P20471, DOI 10.18632/aging.103861
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Liu XJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03222-1
   Lueck K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58296-w
   McMenamin PG, 2019, PROG RETIN EYE RES, V70, P85, DOI 10.1016/j.preteyeres.2018.12.002
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Ueda T, 2019, CELL SIGNAL, V55, P81, DOI 10.1016/j.cellsig.2018.12.012
   Uehiro N, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0788-z
   Wang ZX, 2019, PROG RETIN EYE RES, V70, P110, DOI 10.1016/j.preteyeres.2018.11.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Wu QW, 2019, MOL IMMUNOL, V114, P243, DOI 10.1016/j.molimm.2019.07.028
   Zhao XW, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-020-02698-x
NR 36
TC 1
Z9 1
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD JUN
PY 2021
VL 11
IS 6
AR 1079
DI 10.3390/diagnostics11061079
PG 15
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SX8RL
UT WOS:000665464700001
PM 34204836
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dong, HT
   Zhang, JX
   Li, QM
   Li, FZ
AF Dong, H. T.
   Zhang, J. X.
   Li, Q. M.
   Li, F. Z.
TI Clinical study of the correlation between complement factor H
   polymorphism and age-related macular degeneration
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Liver-kidney yin deficiency type; Y402H polymorphism; Age-related
   macular degeneration; CFH gene
ID RISK; ASSOCIATION; CFH; RANIBIZUMAB; GENES; ARMS2
AB This study aimed to investigate the correlation between age-related macular degeneration (AMD) of the liver-kidney yin-deficiency type and complement factor H (CFH) polymorphism, and to determine whether the C allele of the T1277C (Y402H) variant is a risk factor for this condition. We performed a case-control investigation of 60 patients with liver-kidney yin-deficiency AMD and 60 normal control subjects. Peripheral blood was collected from each participant for DNA extraction. Following amplification by polymerase chain reaction, the DNA samples were sequenced, and polymorphism of the CFH gene was examined. Data were analyzed with the chi-square test, with P < 0.05 signifying statistical significance. The frequency of the C allele was significantly higher in the wet than in the dry AMD group (P = 0.044). In addition, the TC and CC genotypes were markedly more common in the former than in the control group (P = 0.013), and there was a significant difference in the distribution of the T and C alleles between wet AMD patients and control subjects ( P < 0.05). Based on this, we conclude that liver-kidney yin-deficiency AMD is associated with the C allele and TC and CC genotypes of the CFH Y402H polymorphism. Among patients with this condition, CFH genotypes were normally distributed. The principal CFH genotypes that induce liver-kidney yin-deficiency AMD are the mutant homozygote CC and heterozygote TC forms. Moreover, C allele carriers are at higher risk of developing this disease.
C1 [Dong, H. T.; Zhang, J. X.; Li, Q. M.; Li, F. Z.] Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, Zhengzhou, Peoples R China.
C3 Zhengzhou University
RP Li, QM (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, Zhengzhou, Peoples R China.
EM donghongtao211@163.com
FU National Science Foundation of China [U1304812]
FX Research supported by the National Science Foundation of China
   (#U1304812).
CR Abbas RO, 2013, OPHTHALMIC GENET, V34, P209, DOI 10.3109/13816810.2012.762934
   Apte RS, 2008, EXPERT OPIN PHARMACO, V9, P499, DOI [10.1517/14656566.9.3.499, 10.1517/14656566.9.3.499 ]
   Atmaca L, 2011, INT J OPHTHALMOL-CHI, V4, P73, DOI 10.3980/j.issn.2222-3959.2011.01.17
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Michels S, 2005, KLIN MONATSBL AUGENH, V222, P480, DOI 10.1055/s-2005-858315
   Mulder DJ, 2010, BRIT J OPHTHALMOL, V94, P622, DOI 10.1136/bjo.2009.162990
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schramm K, 2014, ACTA OPHTHALMOL, V92, P465, DOI 10.1111/aos.12326
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shyong Mong-Ping, 2005, J Chin Med Assoc, V68, P419
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Soubrane G, 2003, J FR OPHTALMOL, V26, P876
   Tanaka K, 2011, MOL VIS, V17, P2751
   Trouw LA, 2011, CLIN EXP IMMUNOL, V166, P333, DOI 10.1111/j.1365-2249.2011.04482.x
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Yucel D, 2012, OPHTHALMIC GENET, V33, P144, DOI 10.3109/13816810.2012.660225
   [仲路 Zhong Lu], 2011, [南京中医药大学学报, Journal of Nanjing University of Traditional Chinese Medicine], V27, P516
NR 26
TC 0
Z9 0
U1 0
U2 2
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2016
VL 15
IS 3
AR 15038457
DI 10.4238/gmr.15038457
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DY1VA
UT WOS:000384881300053
PM 27706724
OA Bronze
DA 2022-11-30
ER

PT J
AU Souayah, N
   Khella, SL
AF Souayah, Nizar
   Khella, Sami L.
TI A prospective double-blind, placebo-controlled study of thalidomide
   sensory symptoms in an elderly population with age-related macular
   degeneration
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Article
DE Macular degeneration; Neurotoxicity; Sensory symptoms; Thalidomide
   tremor
ID PERIPHERAL NEUROPATHY
AB We aimed to determine the incidence of sensory symptoms (SS) that complicate thalidomide treatment of patients with age-related macular degeneration. In a double-blind prospective study, 38 patients were randomized to receive either thalidomide (100 mg twice per day) or placebo for 1 year. They were then followed for another year off drug. The SS (numbness, tingling, pins and needles) occurred in nine patients who took thalidomide (9/18; 50%) and in four who took placebo (4/20; 20%). Symptom severity was correlated with the time of onset, but not with cumulative dose. Five patients partially improved when the thalidomide was withdrawn, and three patients developed tremor with the neuropathy. The SS occurred shortly after thalidomide was introduced and we concluded that older patients with macular degeneration should be carefully screened for risk factors of peripheral neuropathy before thalidomide is used in their treatment. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Souayah, Nizar] Univ Med & Dent New Jersey, Dept Neurol, Newark, NJ 07101 USA.
   [Khella, Sami L.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center; University of Pennsylvania
RP Souayah, N (通讯作者)，Univ Med & Dent New Jersey, Dept Neurol, 90 Bergen St,DOC 8100, Newark, NJ 07101 USA.
EM souayani@umdnj.edu
RI Souayah, Nizar/B-5556-2017
OI Souayah, Nizar/0000-0003-3873-3448
CR Alonso-Navarro H, 2008, CLIN NEUROPHARMACOL, V31, P241, DOI 10.1097/WNF.0b013e3181585b71
   Chiruka S, 2005, AM J HEMATOL, V78, P81, DOI 10.1002/ajh.20216
   FULLERTON PM, 1961, BRIT MED J, V5256, P855
   Hughes RAC, 2002, BRIT MED J, V324, P466, DOI 10.1136/bmj.324.7335.466
   Isoardo G, 2004, ACTA NEUROL SCAND, V109, P188, DOI 10.1034/j.1600-0404.2003.00203.x
   Molloy FM, 2001, MUSCLE NERVE, V24, P1050, DOI 10.1002/mus.1109
   SHESKIN J, 1980, INT J DERMATOL, V19, P318, DOI 10.1111/j.1365-4362.1980.tb00342.x
   WULFF CH, 1985, BRIT J DERMATOL, V112, P475, DOI 10.1111/j.1365-2133.1985.tb02323.x
   ZIEGLER D, 1995, DIABETOLOGIA, V38, P1425, DOI 10.1007/BF00400603
NR 9
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-5868
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD MAY
PY 2010
VL 17
IS 5
BP 571
EP 573
DI 10.1016/j.jocn.2009.09.017
PG 3
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 583YB
UT WOS:000276715300007
PM 20223672
DA 2022-11-30
ER

PT J
AU Biswas, S
   Lin, SL
AF Biswas, Swati
   Lin, Shili
TI Logistic Bayesian LASSO for Identifying Association with Rare Haplotypes
   and Application to Age-Related Macular Degeneration
SO BIOMETRICS
LA English
DT Article
DE Combination of common SNPs; Complement factor H gene; GWAS; Missing
   heritability; Rare variants; Regularization; Retrospective likelihood
ID FACTOR-H POLYMORPHISM; RISK; INFERENCE; VARIANT; CFH
AB Rare variants have been heralded as key to uncovering missing heritability in complex diseases. These variants can now be genotyped using next-generation sequencing technologies; nonetheless, rare haplotypes may also result from combination of common single nucleotide polymorphisms available from genome-wide association studies (GWAS). The National Eye Institutes data on age-related macular degeneration (AMD) is such an example. Studies on AMD had identified potential rare variants; however, due to lack of appropriate statistical tools, effects of individual rare haplotypes were never studied. Here we develop a method for identifying association with rare haplotypes for casecontrol design. A logistic regression based retrospective likelihood is formulated and is regularized using logistic Bayesian LASSO (LBL). In particular, we penalize the regression coefficients using appropriate priors to weed out unassociated haplotypes, making it possible for the rare associated ones to stand out. We applied LBL to the AMD data and identified common and rare haplotypes in the complement factor H gene, gaining insights into rare variants contributions to AMD beyond the current literature. This analysis also demonstrates the richness of GWAS data for mapping rare haplotypesa potential largely unexplored. Additionally, we conducted simulations to investigate the performance of LBL and compare it with Hapassoc. Our results show that LBL is much more powerful in identifying rare associated haplotypes when the false positive rates for both approaches are kept the same.
C1 [Biswas, Swati] Univ N Texas Hlth Sci Ctr, Sch Publ Hlth, Dept Biostat, Ft Worth, TX 76107 USA.
   [Lin, Shili] Ohio State Univ, Dept Stat, Columbus, OH 43210 USA.
C3 University of North Texas System; University of North Texas Health
   Science Center; University System of Ohio; Ohio State University
RP Biswas, S (通讯作者)，Univ N Texas Hlth Sci Ctr, Sch Publ Hlth, Dept Biostat, Ft Worth, TX 76107 USA.
EM swati.biswas@unthsc.edu
FU National Eye Institute [N01-EY-0-2127]; NATIONAL EYE INSTITUTE
   [N01EY002127] Funding Source: NIH RePORTER
FX The AMD dataset was obtained from the AREDS database found at
   http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
   bin/study.cgi?study_id=phs000001.v2.p1 through dbGaP accession number
   phs000001.v2.p1. Funding support for AREDS was provided by the National
   Eye Institute (N01-EY-0-2127). We thank the AREDS participants and the
   AREDS Research Group for their valuable contribution to this research.
   We also thank Dr Pankaj Choudhary for his insightful discussion on the
   convergence of the Markov chain and Ms Meng Wang for carefully testing
   our software. We are also thankful to the two anonymous reviewers for
   constructive comments and suggestions, which led to improvement and
   clearer presentation of the article.
CR Berger JO., 1985, STAT DECISION THEORY
   Burkett K, 2006, J STAT SOFTW, V16, P1
   Clark AG, 2004, GENET EPIDEMIOL, V27, P321, DOI 10.1002/gepi.20025
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Gelman A, 2013, BAYESIAN DATA ANAL, V3rd, DOI DOI 10.1201/B16018
   Gorlov IP, 2008, AM J HUM GENET, V82, P100, DOI 10.1016/j.ajhg.2007.09.006
   Guo Wei, 2009, BMC Proc, V3 Suppl 7, pS32
   Guo W, 2009, GENET EPIDEMIOL, V33, P308, DOI 10.1002/gepi.20382
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li JH, 2011, BIOINFORMATICS, V27, P516, DOI 10.1093/bioinformatics/btq688
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li Y, 2007, AM J HUM GENET, V80, P705, DOI 10.1086/513205
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Park T, 2008, J AM STAT ASSOC, V103, P681, DOI 10.1198/016214508000000337
   PRENTICE RL, 1979, BIOMETRIKA, V66, P403, DOI 10.1093/biomet/66.3.403
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raftery AE, 1996, MARKOV CHAIN MONTE C, P163
   Satten GA, 2004, GENET EPIDEMIOL, V27, P192, DOI 10.1002/gepi.20020
   Schaid DJ, 2004, GENET EPIDEMIOL, V27, P317, DOI 10.1002/gepi.20046
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Tzeng JY, 2010, J BIOPHARM STAT, V20, P334, DOI 10.1080/10543400903572787
   Weir B.S., 1996, GENETIC DATA ANAL
   Yi NJ, 2008, GENETICS, V179, P1045, DOI 10.1534/genetics.107.085589
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Ziegler A., 2010, STAT APPROACH GENETI
NR 28
TC 26
Z9 27
U1 1
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-341X
EI 1541-0420
J9 BIOMETRICS
JI Biometrics
PD JUN
PY 2012
VL 68
IS 2
BP 587
EP 597
DI 10.1111/j.1541-0420.2011.01680.x
PG 11
WC Biology; Mathematical & Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology; Mathematics
GA 964KA
UT WOS:000305691900028
PM 21955118
DA 2022-11-30
ER

PT J
AU Du, HJ
   Sun, XF
   Guma, M
   Luo, J
   Ouyang, H
   Zhang, XH
   Zeng, J
   Quach, J
   Nguyen, DH
   Shaw, PX
   Karin, M
   Zhang, K
AF Du, Hongjun
   Sun, Xufang
   Guma, Monica
   Luo, Jing
   Ouyang, Hong
   Zhang, Xiaohui
   Zeng, Jing
   Quach, John
   Nguyen, Duy H.
   Shaw, Peter X.
   Karin, Michael
   Zhang, Kang
TI JNK inhibition reduces apoptosis and neovascularization in a murine
   model of age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID ACTIVATION; ATHEROSCLEROSIS; ANGIOGENESIS; INFLAMMATION; TARGETS
AB Age-related macular degeneration (AMD) is the leading cause of registered blindness among the elderly and affects over 30 million people worldwide. It is well established that oxidative stress, inflammation, and apoptosis play critical roles in pathogenesis of AMD. In advanced wet AMD, although, most of the severe vision loss is due to bleeding and exudation of choroidal neovascularization (CNV), and it is well known that vascular endothelial growth factor (VEGF) plays a pivotal role in the growth of the abnormal blood vessels. VEGF suppression therapy improves visual acuity in AMD patients. However, there are unresolved issues, including safety and cost. Here we show that mice lacking c-Jun N-terminal kinase 1 (JNK1) exhibit decreased inflammation, reduced CNV, lower levels of choroidal VEGF, and impaired choroidal macrophage recruitment in a murine model of wet AMD (laser-induced CNV). Interestingly, we also detected a substantial reduction in choroidal apoptosis of JNK1-deficient mice. Intravitreal injection of a pan-caspase inhibitor reduced neovascularization in the laser-induced CNV model, suggesting that apoptosis plays a role in laser-induced pathological angiogenesis. Intravitreal injection of a specific JNK inhibitor decreased choroidal VEGF expression and reduced pathological CNV. These results suggest that JNK1 plays a key role in linking oxidative stress, inflammation, macrophage recruitment apoptosis, and VEGF production in wet AMD and pharmacological JNK inhibition offers a unique and alternative avenue for prevention and treatment of AMD.
C1 [Du, Hongjun] Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Peoples R China.
   [Du, Hongjun; Sun, Xufang; Luo, Jing; Ouyang, Hong; Zhang, Xiaohui; Zeng, Jing; Quach, John; Nguyen, Duy H.; Shaw, Peter X.; Zhang, Kang] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Du, Hongjun; Sun, Xufang; Luo, Jing; Ouyang, Hong; Zhang, Xiaohui; Zeng, Jing; Quach, John; Nguyen, Duy H.; Shaw, Peter X.; Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Du, Hongjun; Zhang, Xiaohui; Zhang, Kang] W China Hosp, Mol Med Res Ctr, Chengdu 610064, Peoples R China.
   [Du, Hongjun; Zhang, Xiaohui; Zhang, Kang] W China Hosp, Dept Ophthalmol, State Key Lab Biotherapy, Chengdu 610064, Peoples R China.
   [Du, Hongjun; Zhang, Xiaohui; Zhang, Kang] Sichuan Univ, Chengdu 610064, Peoples R China.
   [Sun, Xufang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan 430030, Peoples R China.
   [Guma, Monica; Karin, Michael] Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, Sch Med, La Jolla, CA 92093 USA.
   [Guma, Monica; Karin, Michael] Univ Calif San Diego, Dept Pharmacol, Sch Med, La Jolla, CA 92093 USA.
   [Guma, Monica] Univ Calif San Diego, Dept Pathol, Sch Med, La Jolla, CA 92093 USA.
   [Zhang, Kang] Vet Adm Healthcare Syst, La Jolla, CA 92161 USA.
C3 Air Force Military Medical University; University of California System;
   University of California San Diego; University of California System;
   University of California San Diego; Sichuan University; Sichuan
   University; Sichuan University; Huazhong University of Science &
   Technology; University of California System; University of California
   San Diego; University of California System; University of California San
   Diego; University of California System; University of California San
   Diego
RP Karin, M (通讯作者)，Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, Sch Med, La Jolla, CA 92093 USA.
EM karinoffice@ucsd.edu; kang.zhang@gmail.com
RI Nguyen, Duy/HDO-8098-2022; Zhang, Kang/Y-2740-2019; Quach,
   John/AAS-9482-2021
OI Zhang, Kang/0000-0002-4549-1697; guma, monica/0000-0003-1951-9411;
   Ouyang, Hong/0000-0002-7622-7733; Luo, Jing/0000-0002-8905-9388
FU 973 Program [2011CB510200, 2013CB967504]; National Institutes of Health
   [ES00451, ES006376, EY018660, EY021374, EY019270, EY014428]; Superfund
   Research Program [ES010337]; VA Merit Award; Arthritis Foundation; King
   Abdulaziz City for Science and Technology-University of California San
   Diego Center of Excellence in Nanomedicine; Burroughs Wellcome Fund
   Clinical Scientist Award in Translational Research; NATIONAL EYE
   INSTITUTE [R01EY019270, R01EY018660, R01EY014428, R01EY021374] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH
   SCIENCES [P42ES010337, R01ES006376] Funding Source: NIH RePORTER
FX We thank Guy Hughes and members of K.Z. and M. K. laboratories for their
   assistance and helpful discussions. This work is supported in part from
   973 Program Grants 2011CB510200 and 2013CB967504; National Institutes of
   Health Grants ES00451, ES006376, EY018660, EY021374, EY019270, and
   EY014428; Superfund Research Program Grant ES010337; and VA Merit Award,
   the Arthritis Foundation, the King Abdulaziz City for Science and
   Technology-University of California San Diego Center of Excellence in
   Nanomedicine, and the Burroughs Wellcome Fund Clinical Scientist Award
   in Translational Research.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Guma M, 2009, P NATL ACAD SCI USA, V106, P8760, DOI 10.1073/pnas.0902659106
   Hara R, 2010, CURR EYE RES, V35, P1012, DOI 10.3109/02713683.2010.500112
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 30
TC 47
Z9 56
U1 0
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 5
PY 2013
VL 110
IS 6
BP 2377
EP 2382
DI 10.1073/pnas.1221729110
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 093RQ
UT WOS:000315209800083
PM 23341606
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Chakravarthy, U
   Harding, SP
   Rogers, CA
   Downes, SM
   Lotery, AJ
   Wordsworth, S
   Reeves, BC
AF Chakravarthy, Usha
   Harding, Simon P.
   Rogers, Chris A.
   Downes, Susan M.
   Lotery, Andrew J.
   Wordsworth, Sarah
   Reeves, Barnaby C.
CA IVAN Study Investigators
TI Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; DIABETIC-RETINOPATHY; AVASTIN; DESIGN
AB Purpose: To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD).
   Design: Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial is registered (ISRCTN92166560).
   Participants: People >50 years of age with untreated nAMD in the study eye who read >= 25 letters on the Early Treatment Diabetic Retinopathy Study chart.
   Methods: We randomized participants to 4 groups: ranibizumab or bevacizumab, given either every month (continuous) or as needed (discontinuous), with monthly review.
   Main Outcome Measures: The primary outcome is at 2 years; this paper reports a prespecified interim analysis at 1 year. The primary efficacy and safety outcome measures are distance visual acuity and arteriothrombotic events or heart failure. Other outcome measures are health-related quality of life, contrast sensitivity, near visual acuity, reading index, lesion morphology, serum vascular endothelial growth factor (VEGF) levels, and costs.
   Results: Between March 27, 2008 and October 15, 2010, we randomized and treated 610 participants. One year after randomization, the comparison between bevacizumab and ranibizumab was inconclusive (bevacizumab minus ranibizumab -1.99 letters, 95% confidence interval [CI], -4.04 to 0.06). Discontinuous treatment was equivalent to continuous treatment (discontinuous minus continuous -0.35 letters; 95% CI, -2.40 to 1.70). Foveal total thickness did not differ by drug, but was 9% less with continuous treatment (geometric mean ratio [GMR], 0.91; 95% CI, 0.86 to 0.97; P = 0.005). Fewer participants receiving bevacizumab had an arteriothrombotic event or heart failure (odds ratio [OR], 0.23; 95% CI, 0.05 to 1.07; P = 0.03). There was no difference between drugs in the proportion experiencing a serious systemic adverse event (OR, 1.35; 95% CI, 0.80 to 2.27; P = 0.25). Serum VEGF was lower with bevacizumab (GMR, 0.47; 95% CI, 0.41 to 0.54; P<0.0001) and higher with discontinuous treatment (GMR, 1.23; 95% CI, 1.07 to 1.42; P = 0.004). Continuous and discontinuous treatment costs were 9656 pound and 6398 pound per patient per year for ranibizumab and 1654 pound and 1509 pound for bevacizumab; bevacizumab was less costly for both treatment regimens (P<0.0001).
   Conclusions: The comparison of visual acuity at 1 year between bevacizumab and ranibizumab was inconclusive. Visual acuities with continuous and discontinuous treatment were equivalent. Other outcomes are consistent with the drugs and treatment regimens having similar efficacy and safety.
   Financial Disclosure(s): Proprietary or commercial disclosures may be found after the references. Ophthalmology 2012;xx:xxx (C) 2012 by the American Academy of Ophthalmology.
C1 [Chakravarthy, Usha] Queens Univ Belfast, Inst Clin Sci, Belfast, Antrim, North Ireland.
   [Harding, Simon P.] Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, Liverpool L69 3BX, Merseyside, England.
   [Rogers, Chris A.; Reeves, Barnaby C.] Univ Bristol, Sch Clin Sci, Clin Trials & Evaluat Unit, Bristol, Avon, England.
   [Downes, Susan M.] Oxford Univ Hosp NHS Trust, Oxford, England.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England.
   [Wordsworth, Sarah] Univ Oxford, Hlth Econ Res Ctr, Oxford, England.
C3 Queens University Belfast; University of Liverpool; University of
   Bristol; Oxford University Hospitals NHS Foundation Trust; University of
   Southampton; University of Oxford
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Inst Clin Sci, Belfast, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Steel, David H W/I-8053-2015; Quhill, Hibba/AAX-6874-2021; Aslam,
   Tariq/A-8532-2016
OI Steel, David H W/0000-0001-8734-3089; Quhill, Hibba/0000-0002-3857-3168;
   Wordsworth, Sarah/0000-0002-2361-3040; Dakin, Helen/0000-0003-3255-748X;
   Bishop, Paul/0000-0001-7937-7932; Gibson, Jonathan
   M/0000-0002-9281-5244; Harding, Simon/0000-0003-4676-1158; Lotery,
   Andrew/0000-0001-5541-4305; Maishman, Rachel/0000-0002-5052-5951;
   Chakravarthy, Usha/0000-0002-2606-3734; DE SALVO,
   Gabriella/0000-0002-1185-6942; Russell-Hermanns,
   Dawn/0000-0001-6080-3663; Aslam, Tariq/0000-0002-9739-7280; Young,
   Ian/0000-0003-3890-3152
FU Novartis; National Institute for Health Research (NIHR) Health
   Technology Assessment (HTA) [07/36/01]; MRC [G0800800] Funding Source:
   UKRI; Medical Research Council [G0800800] Funding Source: researchfish;
   National Institute for Health Research [07/36/01, NF-SI-0507-10094]
   Funding Source: researchfish
FX Usha Chakravarthy, Principal Investigator, trials sponsored by Novartis,
   the manufacturers of ranibizumab, and attendance at advisory boards for
   Allergan, Bausch & Lomb, and Bayer; Andrew J. Lotery, Principal
   Investigator, trials sponsored by Novartis, the manufacturers of
   ranibizumab; Honoraria, Novartis; Attended Advisory Board Meetings,
   Novartis, Bayer. Simon P. Harding, Principal Investigator, trials
   sponsored by Novartis, the manufacturers of ranibizumab; Susan M.
   Downes, Honoraria, Novartis.; This project was funded by the National
   Institute for Health Research (NIHR) Health Technology Assessment (HTA)
   program (project number 07/36/01). The trial was designed, conducted,
   analyzed, and interpreted independently of the funding sources. The
   writing committee had full access to the data and is responsible for
   submitting the publication. The views and opinions expressed are those
   of the authors and do not necessarily reflect those of the HTA
   programme, NIHR, the UK National Health Service or the Department of
   Health.
CR [Anonymous], 2011, UNIT COSTS HLTH SOCI, V91, P129
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown H., 2015, APPL MIXED MODELS ME
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Davidovic SP, 2012, EUR J OPHTHALMO 0216
   Department of Health, 2011, NSRC4 NHS TRUSTS PCT
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   National Institute for Clinical Excellence, 2004, GUID METH TECHN APPR
   NHS Information Centre, 2011, NHS STAFF EARN JAN M
   NHS. National Institute for Health and Clinical Excellence, TECHN APPR TA155 MAC
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2012, AM J OPHTHALMOL, V153, P327, DOI 10.1016/j.ajo.2011.07.005
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Tufail A, 2010, BMJ-BRIT MED J, V340, pc2459
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
NR 25
TC 590
Z9 598
U1 2
U2 60
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2012
VL 119
IS 7
DI 10.1016/j.ophtha.2012.04.015
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 968UQ
UT WOS:000306011000022
PM 22578446
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Cheng, YW
   Chiou, GCY
AF Cheng, Yu-Wen
   Chiou, George C. Y.
TI Antioxidant effect of hydralazine on retinal pigment epithelial cells
   and its potential use in the therapy of age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); reactive oxygen species (ROS);
   tert-butyl hydroxyperoxide (t-BHP)
ID TERT-BUTYL HYDROPEROXIDE; OXIDATIVE STRESS; CHEMICAL HYPOXIA;
   FREE-RADICALS; DAMAGE; GLUTATHIONE; MECHANISM
AB AIM: To investigate the antioxidant effect of hydralazine under hypoxia-induced damage on retinal pigment epithelial (ARPE-19) cells and the role of reactive oxygen species (ROS) in this effect.
   METHODS: Human retinal pigment epithelial (hRPE) cells were used to investigate the effect of hydralazine on oxidative stress, including tert-butyl hydroxyperoxide (t-BHP), H2O2, sodium azide (NaN3), and hypoxia induced cell damage. Cell viability was determined by MTV assay.
   RESULTS: When ARPE-19 cells were treated with oxidative stress induced by ROS, hydralazine showed concentration-dependent protection against t-BHP, H2O2 and hypoxia induced cell damage but not NaN3. Nitric oxide (NO) was not involved in this effect.
   CONCLUSION: Hydralazine showed antioxidant potential against oxidative stress induced damage in ARPE-19 cells. These effects might be caused through scavenger of ROS. Thus, hydralazine could be used for the treatment of age-related macular degeneration (AMD).
C1 [Cheng, Yu-Wen; Chiou, George C. Y.] Texas A&M Syst Hlth Sci Ctr, Coll Med, Inst Ocular Pharmacol, College Stn, TX 77843 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center
RP Chiou, GCY (通讯作者)，Texas A&M Syst Hlth Sci Ctr, Coll Med, Inst Ocular Pharmacol, College Stn, TX 77843 USA.
EM Chiou@medicine.tamhsc.edu
FU Institute of Ocular Pharmacology, Texas A&M University Health Science
   Center, USA; Stroke Center of Taipei Medical University, Taipei, Taiwan,
   China
FX We thank the support in part from the Institute of Ocular Pharmacology,
   Texas A&M University Health Science Center, USA and Stroke Center of
   Taipei Medical University, Taipei, Taiwan, China.
CR ALARCONSEGOVIA D, 1967, MEDICINE, V46, P1, DOI 10.1097/00005792-196701000-00001
   Alfa M., 2006, TOXICOL APPL PHARM, V212, P110
   Augustin AJ, 1996, GRAEF ARCH CLIN EXP, V234, P58, DOI 10.1007/BF00186520
   AZUMA J, 1987, EUR J PHARMACOL, V135, P137, DOI 10.1016/0014-2999(87)90605-4
   BASINGER SF, 1983, BIOCH EYE, P256
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   BOULTON M, 1991, PROGR RETINAL RES, P65
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHARTERIS DG, 1992, OPHTHALMOLOGY, V99, P1364
   Cui K, 2004, PROG NEURO-PSYCHOPH, V28, P771, DOI 10.1016/j.pnpbp.2004.05.023
   Daiber A, 2005, BIOCHEM BIOPH RES CO, V338, P1865, DOI 10.1016/j.bbrc.2005.10.106
   DAIBER A, 2005, AM J CARDIOL, V10, P25
   DAVIES MJ, 1989, BIOCHEM J, V257, P603, DOI 10.1042/bj2570603
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619
   EMERIT J, 1998, HDB FREE RADICAL ANT
   FANTONE JC, 1985, HUM PATHOL, V16, P973, DOI 10.1016/S0046-8177(85)80273-2
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Gibson GE, 2005, NEUROBIOL AGING, V26, P575, DOI 10.1016/j.neurobiolaging.2004.07.017
   Grammatopoulos T, 2002, MOL BRAIN RES, V99, P114, DOI 10.1016/S0169-328X(02)00101-8
   Grammatopoulos TN, 2004, NEUROSCI RES, V50, P299, DOI 10.1016/j.neures.2004.07.010
   GURNEY AM, 1995, BRIT J PHARMACOL, V114, P238, DOI 10.1111/j.1476-5381.1995.tb14931.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HARPER FH, 1992, CURR EYE RES, V11, P129, DOI 10.3109/02713689208999522
   HERTING RL, 1967, MED CLIN N AM, V51, P25, DOI 10.1016/S0025-7125(16)33080-2
   Hix S, 2000, CHEM RES TOXICOL, V13, P1056, DOI 10.1021/tx000130l
   Klein L, 2003, AM J CARDIOL, V91, p18F, DOI 10.1016/S0002-9149(02)03336-2
   KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lima CF, 2006, LIFE SCI, V79, P2056, DOI 10.1016/j.lfs.2006.06.042
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Martin C, 2001, BIOCHEM PHARMACOL, V62, P705, DOI 10.1016/S0006-2952(01)00704-3
   MCCORD JM, 1985, NEW ENGL J MED, V312, P159
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NEWSOME DA, 1990, INVEST OPHTH VIS SCI, V31, P2508
   Pesakhov S, 2007, BBA-BIOMEMBRANES, V1768, P590, DOI 10.1016/j.bbamem.2006.12.016
   RUSH GF, 1985, TOXICOL APPL PHARM, V78, P473, DOI 10.1016/0041-008X(85)90255-8
   RYAN SJ, 2001, RETINA, V4, P1039
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Steinberg R.H., 1979, RETINAL PIGMENT EPIT, P205
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   SWANSON RA, 1992, NEUROSCI LETT, V147, P143, DOI 10.1016/0304-3940(92)90580-Z
   THOMPSON JA, 1986, PROG CARDIOVASC DIS, V28, P449, DOI 10.1016/0033-0620(86)90027-7
   VAMING T, 1996, J NEUROSCI RES, V44, P40
   VanderZee J, 1996, FREE RADICAL BIO MED, V20, P199, DOI 10.1016/0891-5849(95)02031-4
   Vecsei L, 2001, J NEURAL TRANSM, V108, P273, DOI 10.1007/s007020170072
NR 48
TC 1
Z9 1
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2009
VL 2
IS 1
BP 19
EP 24
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664BK
UT WOS:000282933700005
DA 2022-11-30
ER

PT J
AU Kang, D
   Yoon, EG
   Nam, KT
   Yun, C
AF Kang, Dongwan
   Yoon, Eun Gyu
   Nam, Ki Tae
   Yun, Cheolmin
TI Chorioretinal thickness and retinal pigment epithelial degeneration of
   fellow eyes in patients with unilateral neovascular age-related macular
   degeneration with subretinal drusenoid deposits
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Neovascularization; Subretinal
   drusenoid deposit; Retinal pigment epithelium
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR PSEUDODRUSEN; CHOROIDAL
   NEOVASCULARIZATION; GEOGRAPHIC ATROPHY; LAYER THICKNESS; PREVALENCE;
   MORPHOLOGY; SYSTEM
AB Background We sought to investigate the chorioretinal thickness and retinal pigment epithelial (RPE) degenerative features of eyes with early age-related macular degeneration (AMD) and subretinal drusenoid deposits (SDDs) according to the presence of macular neovascularization (MNV) in the fellow eyes. Methods We classified 70 eyes into two groups of 47 eyes with non-neovascular AMD and 23 eyes with neovascular AMD, respectively, according to the presence of MNV in the fellow eyes. The mean macular retinal, ganglion cell-inner plexiform layer (GCIPL), and choroidal thickness values and RPE features of the 6-mm-diameter zone were compared. RPE degeneration was defined as a lesion with an incomplete RPE and outer retinal atrophy (iRORA) or attenuated RPE reflectivity with diffuse basal laminar deposits, which was defined as when the eye showed an attenuated RPE line with granular features and mixed reflectivity in combination with sub-RPE deposits with a lesion >= 1,000 mu m in length. Results Mean retinal, GCIPL, and choroidal thickness values (286.69 +/- 15.02 mu m, 64.36 +/- 4.21 mu m, and 156.11 +/- 33.10 mu m) of the neovascular AMD group were greater than those (278.61 +/- 13.96 mu m, 61.44 +/- 4.63 mu m, and 133.59 +/- 34.33 mu m) of the non-neovascular AMD group (all P < 0.05). RPE degeneration was more prevalent in the neovascular AMD group (65.2%) than the non-neovascular AMD group (38.3%; P = 0.034). Greater mean GCIPL and choroidal thickness values and the presence of RPE degeneration were associated with type 3 MNV in fellow eyes (all P < 0.05). Conclusions Different degenerative features according to MNV in fellow eyes of patients with AMD and SDDs suggest that variable degenerative features might be present during disease progression and have an association with the phenotype.
C1 [Kang, Dongwan; Yoon, Eun Gyu; Nam, Ki Tae; Yun, Cheolmin] Korea Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Yun, C (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
EM yuncheolmin@gmail.com
FU National Research Foundation of Korea (NRF) - Korean government (MSIT)
   [NRF-2021R1C1C1011685]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Korean government (MSIT) (NRF-2021R1C1C1011685).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Baek J, 2016, INVEST OPHTH VIS SCI, V57, P1500, DOI 10.1167/iovs.15-18837
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Chen L, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.1.33
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Etheridge T, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.2.39
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Jang S, 2020, RETINA-J RET VIT DIS, V40, P686, DOI 10.1097/IAE.0000000000002528
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim JH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041145
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martins A, 2018, OPHTHALMIC RES, V59, P88, DOI 10.1159/000481262
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Nam KT, 2021, RETINA-J RET VIT DIS, V41, P1686, DOI 10.1097/IAE.0000000000003100
   Nam KT, 2020, RETINA-J RET VIT DIS, V40, P2270, DOI 10.1097/IAE.0000000000002758
   Nittala MG, 2019, OPHTHALMOL RETINA, V3, P112, DOI 10.1016/j.oret.2018.09.017
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P1451, DOI 10.1097/IAE.0000000000002412
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   THOMSON RJ, 2022, RETINA-J RET VIT DIS, V42, P1311, DOI 10.1097/IAE.0000000000003460
   Wu ZC, 2022, PROG RETIN EYE RES, V88, DOI 10.1016/j.preteyeres.2021.101017
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zhang YH, 2022, INVEST OPHTH VIS SCI, V63, DOI 10.1167/iovs.63.2.32
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 46
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 14
PY 2022
VL 22
IS 1
AR 304
DI 10.1186/s12886-022-02518-4
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2X7SR
UT WOS:000825400000003
PM 35836149
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, CY
   Chen, HC
   Huang, JY
   Lai, CC
   Lin, HY
   Yang, SF
   Wu, WC
AF Lee, Chia-Yi
   Chen, Hung-Chi
   Huang, Jing-Yang
   Lai, Chi-Chun
   Lin, Hung-Yu
   Yang, Shun-Fa
   Wu, Wei-Chi
TI Increased probability of mood disorders after age-related macular
   degeneration: a population-based cohort study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DEPRESSION PREVENTION TRIAL; QUALITY-OF-LIFE; VISUAL IMPAIRMENT;
   PREVALENCE; ANXIETY; VISION; SYMPTOMS; RISK; EYE; RANIBIZUMAB
AB We aim to investigate the association of mood disorders with age-related macular degeneration (AMD). This retrospective cohort study used data from 2000 and 2016 from National Health Insurance Research Database (NHIRD) in Taiwan. Patients with AMD diagnosis formed the exposed group, and an age- and sex-matched group without AMD served as the nonexposed group. Main outcomes were the incidence of mood disorders including psychological counseling, behavior therapy, sleep or anxiety-related disorders, and major depressive disorders (MDDs) in the exposed and non-exposed groups. The Cox proportional hazard regression analysis was used to evaluate the incidence and adjusted hazard ratio (aHR) of mood disorders. A total of 5916 and 11,832 individuals with and without AMD were enrolled into the exposed and nonexposed groups. There were 1017 (17.19%) and 1366 (11.54%) episodes of mood disorders occurred in the exposed and nonexposed groups, respectively. The aHRs of any psychological counseling, behavioral therapy, sleep or anxiety-related disorders, and MDD were significantly higher in patients with AMD than in those without AMD (all P < 0.05). Besides, patients with dry-AMD, participants aged 50-70 years, and women with AMD had a higher incidence of mood disorders (all P < 0.05) than did non-AMD individuals, patients > 70 years, and women without AMD. In conclusion, AMD occurrence leads to an increased rate of mood disorders, particularly among those with dry-AMD, middle aged participants (aged 50-70), and women.
C1 [Lee, Chia-Yi; Lin, Hung-Yu; Yang, Shun-Fa] Chung Shan Med Univ, Inst Med, 110,Sec 1,Chien Kuo N Rd, Taichung 40201, Taiwan.
   [Lee, Chia-Yi] Nobel Eye Inst, Taipei, Taiwan.
   [Lee, Chia-Yi] Jen Ai Hosp, Dept Ophthalmol, Dali Branch, Taichung, Taiwan.
   [Chen, Hung-Chi; Wu, Wei-Chi] Chang Gung Mem Hosp, Dept Ophthalmol, 5 Fuxing St, Taoyuan, Taiwan.
   [Chen, Hung-Chi; Lai, Chi-Chun; Wu, Wei-Chi] Chang Gung Univ, Dept Med, Coll Med, Taoyuan, Taiwan.
   [Chen, Hung-Chi] Chang Gung Mem Hosp, Ctr Tissue Engn, Linkou, Taiwan.
   [Huang, Jing-Yang; Yang, Shun-Fa] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
   [Lai, Chi-Chun] Chang Gung Mem Hosp, Dept Ophthalmol, Keelung, Taiwan.
   [Lin, Hung-Yu] Show Chwan Mem Hosp, Dept Ophthalmol, Changhua, Taiwan.
   [Lin, Hung-Yu] Chung Shan Med Univ, Dept Optometry, Taichung, Taiwan.
C3 Chung Shan Medical University; Chang Gung Memorial Hospital; Chang Gung
   University; Chang Gung Memorial Hospital; Chung Shan Medical University;
   Chung Shan Medical University Hospital; Chang Gung Memorial Hospital;
   Show Chwan Memorial Hospital; Chung Shan Medical University
RP Yang, SF (通讯作者)，Chung Shan Med Univ, Inst Med, 110,Sec 1,Chien Kuo N Rd, Taichung 40201, Taiwan.; Wu, WC (通讯作者)，Chang Gung Mem Hosp, Dept Ophthalmol, 5 Fuxing St, Taoyuan, Taiwan.; Wu, WC (通讯作者)，Chang Gung Univ, Dept Med, Coll Med, Taoyuan, Taiwan.; Yang, SF (通讯作者)，Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
EM ysf@csmu.edu.tw; weichi666@gmail.com
FU Chang Gung Memorial Hospital Research Grants [CMRPG3I0071-3,
   CMRPG3L0151]; Ministry of Science and Technology Research Grant [MOST
   109-2314-B-182A-019-MY3]
FX This study was supported by Chang Gung Memorial Hospital Research Grants
   (CMRPG3I0071-3 and CMRPG3L0151), and Ministry of Science and Technology
   Research Grant (MOST 109-2314-B-182A-019-MY3) to Wu WC. The sponsors had
   no role in the design or conduct of this research.
CR Avenevoli S, 2015, J AM ACAD CHILD PSY, V54, P37, DOI 10.1016/j.jaac.2014.10.010
   Bentley SM, 2014, MED CLIN N AM, V98, P981, DOI 10.1016/j.mcna.2014.06.013
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brody BL, 2006, J AM GERIATR SOC, V54, P1557, DOI 10.1111/j.1532-5415.2006.00881.x
   Canuto A, 2018, AM J GERIAT PSYCHIAT, V26, P174, DOI 10.1016/j.jagp.2017.08.015
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chen SP, 2017, JAMA OPHTHALMOL, V135, P963, DOI 10.1001/jamaophthalmol.2017.2838
   Chong EW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137322
   Chung SD, 2017, ACTA OPHTHALMOL, V95, pe800, DOI 10.1111/aos.13281
   Chung SD, 2015, ACTA OPHTHALMOL, V93, pE176, DOI 10.1111/aos.12478
   Cimarolli VR, 2018, ARCH GERONTOL GERIAT, V78, P249, DOI 10.1016/j.archger.2018.07.009
   Cosh S, 2018, INT J GERIATR PSYCH, V33, P598, DOI 10.1002/gps.4827
   Das J, 2018, NEUROSCI BIOBEHAV R, V90, P104, DOI 10.1016/j.neubiorev.2018.04.005
   de Kruif M, 2016, J AFFECT DISORDERS, V206, P174, DOI 10.1016/j.jad.2016.07.040
   Deemer AD, 2017, INVEST OPHTH VIS SCI, V58, P1514, DOI 10.1167/iovs.16-20001
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Giloyan A, 2015, AGING MENT HEALTH, V19, P175, DOI 10.1080/13607863.2014.920298
   Gutzmann H, 2015, Z GERONTOL GERIATR, V48, P305, DOI 10.1007/s00391-015-0898-8
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hernandez-Moreno L, 2021, CLIN REHABIL, V35, P1341, DOI 10.1177/0269215521997991
   Hillerer KM, 2019, FRONT NEUROENDOCRIN, V55, DOI 10.1016/j.yfrne.2019.100796
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kessing LV, 2012, CURR OPIN PSYCHIATR, V25, P457, DOI 10.1097/YCO.0b013e328356c368
   Khoo K, 2019, QUAL LIFE RES, V28, P2017, DOI 10.1007/s11136-019-02165-1
   Krebber AMH, 2014, PSYCHO-ONCOLOGY, V23, P121, DOI 10.1002/pon.3409
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Long JM, 2019, CELL, V179, P312, DOI 10.1016/j.cell.2019.09.001
   Loriaut P, 2014, OPHTHALMIC RES, V52, P212, DOI 10.1159/000362881
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Newhouse A, 2014, HEART FAIL CLIN, V10, P295, DOI 10.1016/j.hfc.2013.10.004
   Obeid S, 2018, ENCEPHALE, V44, P397, DOI 10.1016/j.encep.2017.10.010
   Parravano M, 2021, JAMA OPHTHALMOL, V139, P753, DOI 10.1001/jamaophthalmol.2021.1557
   Pondorfer SG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51769-7
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   Rodrigues PFS, 2018, J EXP CHILD PSYCHOL, V176, P140, DOI 10.1016/j.jecp.2018.07.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Silva LMP, 2019, OCUL IMMUNOL INFLAMM, V27, P99, DOI 10.1080/09273948.2017.1370551
   Somers A, 2016, ACTA OPHTHALMOL, V94, pe312, DOI 10.1111/aos.12848
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Thompson AE, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0440-0
   Tu HP, 2017, PSYCHOSOMATICS, V58, P151, DOI 10.1016/j.psym.2016.11.007
   Tyrer P, 2006, LANCET, V368, P2156, DOI 10.1016/S0140-6736(06)69865-6
   Varadaraj V, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.14
   Vu KV, 2021, ACTA OPHTHALMOL, V99, pE547, DOI 10.1111/aos.14635
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   Wongrakpanich S, 2016, AGING DIS, V7, P763, DOI 10.14336/AD.2016.0515
   Wu N, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen-2020-046194
   Yamada Y, 2016, J GERONTOL A-BIOL, V71, P117, DOI 10.1093/gerona/glv036
   Zheng YJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46453
NR 55
TC 0
Z9 0
U1 3
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 8
PY 2022
VL 12
IS 1
AR 15222
DI 10.1038/s41598-022-19429-5
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 4L1LH
UT WOS:000852396300021
PM 36075924
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, JJ
   Mitsuhashi, T
   Matsuo, T
   Yorifuji, T
   Hamada, J
   Liu, YY
AF Zhang, Jingjing
   Mitsuhashi, Toshiharu
   Matsuo, Toshihiko
   Yorifuji, Takashi
   Hamada, Jun
   Liu, Yangyang
TI Alcohol Consumption and Age-related Macular Degeneration: A Systematic
   Review and Dose-response Meta-analysis
SO CURRENT EYE RESEARCH
LA English
DT Review
DE Alcohol consumption; age-related macular degeneration; dose-response;
   meta-analysis; observational study
ID RISK-FACTORS; GENERAL-POPULATION; PREVALENCE; MACULOPATHY; DRINKING;
   SMOKING; LIFE
AB Purpose: To perform a systematic review on the association between alcohol consumption and risk of age-related macular degeneration (AMD) using a meta-analytical approach. Method: Systematic literature research was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines. Both categorical and dose-response meta-analysis was performed separately for early and late AMD. A fixed-effect model was used to calculate pooled effect estimates with 95% confidence interval (CI). Result: Seven studies were included in the analysis with 4,566 and 440 cases of early and late AMD, respectively. Compared to the nondrinkers or occasional drinkers, the pooled effect estimates for early AMD with moderate (1.19, 95% CI [1.03-1.37]) and heavy (1.24, [1.10-1.39]) alcohol consumption, but not light (0.95, [0.90-1.06]) alcohol consumption, were statistically significant. However, the pooled effect estimates for late AMD with light (1.03, [0.79-1.33]), moderate (1.13, [0.83-1.55]), and heavy (0.98, [0.63-1.53]) alcohol consumption were found to be insignificant. A linear dose-response relationship was established (P < .05) between alcohol consumption and risk of early AMD, and the pooled effect estimate for an increase in alcohol consumption of 10 g/day was 1.14 (1.08-1.21). Conclusion: Moderate and heavy alcohol consumption could increase the risk of early AMD, but not late AMD, with a linear dose-response relationship.
C1 [Zhang, Jingjing; Matsuo, Toshihiko] Okayama Univ, Grad Sch Interdisciplinary Sci & Engn Hlth Syst, Dept Regenerat & Reconstruct Med Ophthalmol, Okayama, Japan.
   [Mitsuhashi, Toshiharu] Okayama Univ, Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan.
   [Yorifuji, Takashi; Liu, Yangyang] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Epidemiol, Okayama, Japan.
   [Hamada, Jun] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hlth Econ & Policy, Okayama, Japan.
C3 Okayama University; Okayama University; Okayama University; Okayama
   University
RP Liu, YY (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Epidemiol, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
EM yangyang_liu1986@yahoo.co.jp
OI Liu, Yangyang/0000-0002-7916-2875; Zhang, Jingjing/0000-0002-3170-9894
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Alkerwi A, 2009, ATHEROSCLEROSIS, V204, P624, DOI 10.1016/j.atherosclerosis.2008.10.036
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BERLIN JA, 1993, EPIDEMIOLOGY, V4, P218, DOI 10.1097/00001648-199305000-00005
   Boekhoorn SS, 2008, ARCH OPHTHALMOL-CHIC, V126, P834, DOI 10.1001/archopht.126.6.834
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Dinu M, 2019, EUR J NUTR, V58, P2123, DOI 10.1007/s00394-018-1771-5
   Downer B, 2015, AM J ALZHEIMERS DIS, V30, P364, DOI 10.1177/1533317514549411
   Feunekes GIJ, 1999, AM J EPIDEMIOL, V150, P105
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Gandini S, 2018, EUR J NUTR, V57, P2323, DOI 10.1007/s00394-018-1613-5
   GLYNN RJ, 1985, AM J PUBLIC HEALTH, V75, P1413, DOI 10.2105/AJPH.75.12.1413
   Gu SY, 2016, PHARMACOECONOMICS, V34, P751, DOI 10.1007/s40273-016-0395-y
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jin ZC, 2014, ANN RHEUM DIS, V73, P1962, DOI 10.1136/annrheumdis-2013-203323
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   Mathenge W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001393
   Mirand AL, 1996, AM J PUBLIC HEALTH, V86, P978, DOI 10.2105/AJPH.86.7.978
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Orsini N, 2012, AM J EPIDEMIOL, V175, P66, DOI 10.1093/aje/kwr265
   Piermarocchi S, 2016, OPHTHALMIC RES, V55, P111, DOI 10.1159/000441795
   REED TE, 1985, SOC BIOL, V32, P195
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P5228, DOI 10.1167/iovs.14-14299
   SEITZ HK, 1993, GUT, V34, P1433, DOI 10.1136/gut.34.10.1433
   Shim SH, 2016, OPHTHAL EPIDEMIOL, V23, P80, DOI 10.3109/09286586.2015.1129425
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   Wang DC, 2019, CURR EYE RES, V44, P657, DOI 10.1080/02713683.2019.1576907
   Wickremasinghe SS, 2009, EXPERT REV OPHTHALMO, V4, P79, DOI 10.1586/17469899.4.1.79
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood AM, 2018, LANCET, V391, P1513, DOI 10.1016/S0140-6736(18)30134-X
NR 38
TC 1
Z9 1
U1 2
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD DEC 2
PY 2021
VL 46
IS 12
BP 1900
EP 1907
DI 10.1080/02713683.2021.1942070
EA JUL 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA XV0SU
UT WOS:000668772400001
PM 34115943
DA 2022-11-30
ER

PT J
AU Cymerman, RM
   Skolnick, AH
   Cole, WJ
   Nabati, C
   Curcio, CA
   Smith, RT
AF Cymerman, Rachel M.
   Skolnick, Adam H.
   Cole, William J.
   Nabati, Camellia
   Curcio, Christine A.
   Smith, R. Theodore
TI Coronary Artery Disease and Reticular Macular Disease, a Subphenotype of
   Early Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; coronary artery disease; reticular
   macular disease; reticular pseudo-drusen
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC
   ATROPHY; CARDIOVASCULAR-DISEASE; SOFT DRUSEN; PSEUDODRUSEN; RISK; EYES;
   PREVALENCE; MACULOPATHY
AB Purpose: Reticular macular disease (RMD) is the highest risk form of early age-related macular degeneration and also specifically confers decreased longevity. However, because RMD requires advanced retinal imaging for adequate detection of its characteristic subretinal drusenoid deposits (SDD), it has not yet been completely studied with respect to coronary artery disease (CAD), the leading cause of death in the developed world. Because CAD appears in middle age, our purpose was to screen patients aged 45-80 years, documented either with or without CAD, to determine if CAD is associated with RMD.Design: A prospective cohort study of patients with documented CAD status and no known retinal disease in a clinical practice setting at one institution.Subjects and Controls: A number of 76 eyes from 38 consecutive patients (23 with documented CAD, 15 controls documented without CAD; 47.4% female; mean age 66.7 years).Methods: Patients were imaged with near-infrared reflectance/spectral domain optical coherence tomography and assessed in masked fashion by two graders for the presence of SDD lesions of RMD and soft drusen.Main Outcome Measures: Presence or absence of RMD/SDD and soft drusen.Results: RMD was more frequent in patients with CAD versus those without (Relative Risk [RR] = 2.1, CI = 1.08-3.95, P = 0.03). There was no association of CAD with soft drusen.Conclusions: A specific relationship between CAD and RMD suggests common systemic causes for both and warrants further study.
C1 [Cymerman, Rachel M.; Skolnick, Adam H.; Cole, William J.; Nabati, Camellia; Smith, R. Theodore] NYU, Dept Ophthalmol, Sch Med, 462 First Ave NBV 5N18, New York, NY 10016 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35294 USA.
C3 New York University; University of Alabama System; University of Alabama
   Birmingham
RP Smith, RT (通讯作者)，NYU, Dept Ophthalmol, Sch Med, 462 First Ave NBV 5N18, New York, NY 10016 USA.
EM Theodore.Smith@nyumc.org
OI smith, theodore/0000-0002-1693-943X
FU Foundation Fighting Blindness, Columbia, MD; National Institutes of
   Health/National Eye Institute, Bethesda, MD [R01 EY015520, R01 EY06109];
   Research to Prevent Blindness, New York, NY; EyeSight Foundation of
   Alabama; NATIONAL EYE INSTITUTE [R01EY015520, R01EY006109] Funding
   Source: NIH RePORTER
FX This work was supported by an individual investigator research award
   from the Foundation Fighting Blindness, Columbia, MD (RTS); National
   Institutes of Health/National Eye Institute, Bethesda, MD, [grant number
   R01 EY015520] (RTS) and [grant number R01 EY06109] (CC); unrestricted
   funds from Research to Prevent Blindness, New York, NY (RTS, CC); and
   EyeSight Foundation of Alabama (CC). The funding organizations had no
   role in the design or conduct of this research.
CR Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Saito Y, 1998, RETINA-J RET VIT DIS, V18, P103, DOI 10.1097/00006982-199818020-00002
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2012, OPHTHALMOLOGY, V119, P2203, DOI 10.1016/j.ophtha.2012.09.009
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ARCH INTERN MED, V166, P2388, DOI 10.1001/archinte.166.21.2388
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P482, DOI 10.1097/IAE.0b013e3181f056ce
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 37
TC 18
Z9 18
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD NOV
PY 2016
VL 41
IS 11
BP 1482
EP 1488
DI 10.3109/02713683.2015.1128552
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC2GR
UT WOS:000387928300014
PM 27159771
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Maller, J
   George, S
   Purcell, S
   Fagerness, J
   Altshuler, D
   Daly, MJ
   Seddon, JM
AF Maller, Julian
   George, Sarah
   Purcell, Shaun
   Fagerness, Jes
   Altshuler, David
   Daly, Mark J.
   Seddon, Johanna M.
TI Common variation in three genes, including a noncoding variant in CFH,
   strongly influences risk of age-related macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; BODY-MASS INDEX; FAMILIAL AGGREGATION; EXTENDED
   FAMILIES; GENOMEWIDE-SCAN; MACULOPATHY; ASSOCIATION; SUSCEPTIBILITY;
   HAPLOTYPE; POLYMORPHISM
AB Age-related macular degeneration (AMD) is a common, late-onset disease with seemingly typical complexity: recurrence ratios for siblings of an affected individual are three- to sixfold higher than in the general population, and family-based analysis has resulted in only modestly significant evidence for linkage. In a case-control study drawn from a US-based population of European descent, we have identified a previously unrecognized common, noncoding variant in CFH, the gene encoding complement factor H, that substantially increases the influence of this locus on AMD, and we have strongly replicated the associations of four other previously reported common alleles in three genes ( P values ranging from 10(-6) to 10(-70)). Despite excellent power to detect epistasis, we observed purely additive accumulation of risk from alleles at these genes. We found no differences in association of these loci with major phenotypic categories of advanced AMD. Genotypes at these five common SNPs define a broad spectrum of interindividual disease risk and explain about half of the classical sibling risk of AMD in our study population.
C1 Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Epidemiol Unit, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.
   MIT, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Massachusetts General Hospital; Harvard University;
   Massachusetts Institute of Technology (MIT); Broad Institute; Harvard
   University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Harvard University; Harvard Medical School
RP Seddon, JM (通讯作者)，Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Epidemiol Unit, 243 Charles St, Boston, MA 02114 USA.
EM mjdaly@chgr.mgh.harvard.edu; johanna_seddon@meei.harvard.edu
RI maller, julian B/A-9323-2009; Daly, Mark J/B-2453-2017; Altshuler, David
   M/A-4476-2009
OI Daly, Mark J/0000-0002-0949-8752; Altshuler, David
   M/0000-0002-7250-4107; Maller, Julian/0000-0002-1565-9559
FU NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020278] Funding Source: NIH
   RePORTER; NCRR NIH HHS [U54 RR020278] Funding Source: Medline; NEI NIH
   HHS [EY11309] Funding Source: Medline
CR Cordell HJ, 2006, GENET EPIDEMIOL, V30, P259, DOI 10.1002/gepi.20142
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher R. A., 1919, Transactions of the Royal Society of Edinburgh, V52
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sham PC, 2004, BEHAV GENET, V34, P207, DOI 10.1023/B:BEGE.0000013734.39266.a3
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
NR 28
TC 468
Z9 502
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD SEP
PY 2006
VL 38
IS 9
BP 1055
EP 1059
DI 10.1038/ng1873
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 078OC
UT WOS:000240112100024
PM 16936732
DA 2022-11-30
ER

PT J
AU Tarita-Nistor, L
   Gonzalez, EG
   Markowitz, SN
   Lillakas, L
   Steinbach, MJ
AF Tarita-Nistor, Luminita
   Gonzalez, Esther G.
   Markowitz, Samuel N.
   Lillakas, Linda
   Steinbach, Martin J.
TI Increased role of peripheral vision in self-induced motion in patients
   with age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CIRCULAR VECTION; STIMULUS ECCENTRICITY; VISUAL IMPAIRMENT; PERCEPTION;
   FIXATION; ACUITY
AB PURPOSE. The contribution of peripheral vision in inducing self-motion (vection) was investigated in people with bilateral age-related macular degeneration (AMD).
   METHODS. Eleven patients with bilateral AMD and dense central scotomas with no islands of functional central retina and 12 age-matched control subjects were exposed to random-dot patterns projected on a large screen. The dots either moved from left to right, inducing linear vection, or rotated about the roll axis, inducing roll vection. Latency, total vection time, and objective and subjective measures of tilt were recorded.
   RESULTS. The patients with AMD experienced shorter latencies than did the age-matched control participants, but the total vection time in both conditions and tilt during roll vection were the same in both groups. There was a positive correlation between objective tilt and subjective measures of tilt in the AMD, but not in the age-matched control group. There was a negative relationship between absolute scotoma size and latency.
   CONCLUSIONS. Two main conclusions were drawn. First, the role of peripheral vision in inducing vection is enhanced in people with bilateral central vision loss. Second, people with bilateral AMD adapt successfully to a moving environment ( they do not experience vection longer, nor do they tilt more) and are more aware of their postural position than are age-matched control subjects.
C1 [Tarita-Nistor, Luminita; Gonzalez, Esther G.; Lillakas, Linda; Steinbach, Martin J.] Toronto Western Hosp, Vis Sci Res Program, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada.
   [Tarita-Nistor, Luminita; Gonzalez, Esther G.; Lillakas, Linda; Steinbach, Martin J.] York Univ, Ctr Vis Res, Toronto, ON M3J 2R7, Canada.
   [Gonzalez, Esther G.; Markowitz, Samuel N.; Steinbach, Martin J.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; York University - Canada; University of Toronto
RP Steinbach, MJ (通讯作者)，Toronto Western Hosp, Vis Sci Res Program, Toronto Western Res Inst, 399 Bathurst St,MP 6-302, Toronto, ON M5T 2S8, Canada.
EM mjs@yorku.ca
CR Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   BRANDT T, 1973, EXP BRAIN RES, V16, P476, DOI 10.1007/BF00234474
   Carrasco M, 2003, NAT NEUROSCI, V6, P699, DOI 10.1038/nn1079
   CHEUNG BSK, 1990, EXP BRAIN RES, V81, P391
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   EDWARDS MG, 1999, OPHTHALMOLOGY
   Fushiki H, 1999, J VESTIBUL RES-EQUIL, V9, P287
   HELD R, 1975, VISION RES, V15, P357, DOI 10.1016/0042-6989(75)90083-8
   HOWARD I, HDB PERCEPTION HUMAN, V1
   HOWARD IP, 1989, PERCEPTION, V18, P657, DOI 10.1068/p180657
   Nakamura S, 1998, PERCEPT MOTOR SKILL, V87, P659, DOI 10.2466/pms.1998.87.2.659
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Palmisano S, 1998, PERCEPTION, V27, P1067, DOI 10.1068/p271067
   POST RB, 1986, AM J OPTOM PHYS OPT, V63, P104
   POST RB, 1986, AM J OPTOM PHYS OPT, V63, P94
   POST RB, 1988, PERCEPTION, V17, P737, DOI 10.1068/p170737
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   SEKULER R, 2002, PERCEPTION, P133
   TABACHNICK BG, 2001, USING MULTIVARIATE S, P67
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Tarita-Nistor L, 2006, VISION RES, V46, P2487, DOI 10.1016/j.visres.2006.01.035
   Tarita-Nistor L, 2006, J VESTIBUL RES-EQUIL, V16, P265
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   WOLFE JM, 2006, SENSATION PERCEPTION, P55
NR 24
TC 16
Z9 17
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2008
VL 49
IS 7
BP 3253
EP 3258
DI 10.1167/iovs.07-1290
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318WR
UT WOS:000257124000062
PM 18390642
DA 2022-11-30
ER

PT J
AU Ismayilov, AS
   Esen, E
   Sizmaz, S
   Demircan, AN
AF Ismayilov, Ayna Sariyeva
   Esen, Ebru
   Sizmaz, Selcuk
   Demircan, Ayse Nihal
TI Aflibercept therapy in eyes with neovascular age-related macular
   degeneration and its effect on choroidal thickness
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE aflibercept; central macular thickness; choroidal thickness; neovascular
   age-related macular degeneration
ID VEGF TRAP-EYE; INTRAVITREAL INJECTION; TREATMENT-NAIVE; GROWTH-FACTOR;
   RANIBIZUMAB; EFFICACY
AB Background The purpose of this study was to investigate changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) and subfoveal choroidal thickness (SCT) after intravitreal aflibercept injections for neovascular age-related macular degeneration (NV-AMD). Methods Eighty-nine eyes (48 treatment naive, 41 resistant) were included in this prospective study. All patients were treated with three consecutive monthly injections then every two months as required. BCVA, CMT and SCT were recorded and compared within and between the two groups. Results The mean increase in BCVA after injections was 0.18 +/- 0.34 logMAR in the naive group (p = 0.01) and 0.092 +/- 0.38 logMAR in the resistant group (p = 0.131). The mean decrease in CMT was 200.3 +/- 216.1 mu m in the naive group and 183.3 +/- 203.4 mu m in the resistant group (p < 0.001 for both). The mean decrease in SCT was 22.1 +/- 62.0 mu m in the naive group (p = 0.014). The mean change in SCT was 22.28 +/- 74.05 mu m in the resistant group; this was not statistically significant (p = 0.061). Conclusion BCVA, CMT and SCT decreased significantly after intravitreal aflibercept injections in naive patients with NV-AMD. Despite anatomic success, functional improvement was not reached and SCT did not significantly decrease after intravitreal aflibercept injections in resistant patients.
C1 [Ismayilov, Ayna Sariyeva; Esen, Ebru; Sizmaz, Selcuk; Demircan, Ayse Nihal] Cukurova Univ, Fac Med, Dept Ophthalmol, Adana, Turkey.
C3 Cukurova University
RP Ismayilov, AS (通讯作者)，Cukurova Univ, Fac Med, Dept Ophthalmol, Adana, Turkey.
EM sariyevaayna@hotmail.com
RI Ismayilov, Ayna Sariyeva/AAV-4831-2021
CR Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Cheung CMG, 2014, EYE, V28, P1148, DOI 10.1038/eye.2014.105
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Hirakata T, 2016, CLIN OPHTHALMOL, V10, P969, DOI 10.2147/OPTH.S101596
   Kaya F, 2017, J FR OPHTALMOL, V40, P832, DOI 10.1016/j.jfo.2017.04.014
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Maringe E, 2016, J FR OPHTALMOL, V39, P255, DOI 10.1016/j.jfo.2015.10.009
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Stewart MW, 2013, EXPERT REV CLIN PHAR, V6, P103, DOI [10.1586/ECP.12.81, 10.1586/ecp.12.81]
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
NR 22
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD NOV
PY 2019
VL 102
IS 6
BP 617
EP 620
DI 10.1111/cxo.12877
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JH5OX
UT WOS:000492819000013
PM 30793798
DA 2022-11-30
ER

PT J
AU Yanik, O
   Demirel, S
   Batioglu, F
   Ozmert, E
AF Yanik, Ozge
   Demirel, Sibel
   Batioglu, Figen
   ozmert, Emin
TI Natural course of acquired vitelliform lesions associated with pigment
   epithelial detachments in dry age related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; medical therapies; techniques
   of retinal examination; retinal pathology; research
ID CHOROIDAL NEOVASCULARIZATION
AB Purpose: To describe the natural history of acquired vitelliform lesions (AVLs) associated with different types of pigment epithelial detachments (PEDs) in dry age-related macular degeneration. Methods: A retrospective review of clinical examination and multimodal imaging data of patients with AVLs associated with PED(s) was performed. Results: This study included 25 eyes of 17 patients. The mean age of patients was 67.2 +/- 9.7 (47-83) years. The mean follow-up time was 32.6 +/- 16.2 (12-66) months, excluding four patients (five eyes) that were lost to follow-up. The mean logMAR BCVA was 0.21 +/- 0.16 at baseline and 0.38 +/- 0.28 at final visit (p = 0.016). At the end of the follow-up period, PEDs enlarged in eight eyes (40%) and were unchanged in two eyes (10%). Spontaneous resolution of the central PED(s) with AVLs was seen in four (20%) eyes. Rupture of the PED(s) occurred in four eyes (20%), with two developing central foveolar atrophy afterwards. Overall, central foveolar atrophy was seen ultimately in four eyes (20%). Conclusion: It seems that high PED size may be a risk factor for PED rupture during follow-up. 1/3 of the eyes ended up with unfavorable anatomical outcome.
C1 [Yanik, Ozge; Demirel, Sibel; Batioglu, Figen; ozmert, Emin] Ankara Univ, Dept Ophthalmol, Sch Med, Ankara, Turkey.
C3 Ankara University
RP Demirel, S (通讯作者)，Ankara Univ, Dept Ophthalmol, Sch Med, Vehbi Koc Eye Hosp, Mamak St, TR-06100 Ankara, Turkey.
EM drsibeldemireltr@yahoo.com.tr
RI Yanık Odabaş, Özge/AAO-6777-2020; DEMIREL, SIBEL/GQH-3232-2022
OI Yanık Odabaş, Özge/0000-0002-1822-8703; DEMIREL,
   SIBEL/0000-0002-2477-9974
CR Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   Bastos RR, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/6037537
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Lima LH, 2012, RETINA-J RET VIT DIS, V32, P647, DOI 10.1097/IAE.0b013e31823fb847
   Lupidi M, 2015, INVEST OPHTH VIS SCI, V56, P7638, DOI 10.1167/iovs.15-17603
   Morillo M J, 2014, Arch Soc Esp Oftalmol, V89, P165, DOI 10.1016/j.oftal.2012.09.029
   Saito M, 2014, AM J OPHTHALMOL, V157, P355, DOI 10.1016/j.ajo.2013.10.009
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
NR 15
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2021
VL 31
IS 6
BP 3133
EP 3141
AR 1120672121990566
DI 10.1177/1120672121990566
EA JAN 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XA5GJ
UT WOS:000679160300001
PM 33506698
DA 2022-11-30
ER

PT J
AU Broadhead, GK
   Grigg, JR
   McCluskey, P
   Hong, T
   Schlub, TE
   Chang, AA
AF Broadhead, Geoffrey K.
   Grigg, John R.
   McCluskey, Peter
   Hong, Thomas
   Schlub, Timothy E.
   Chang, Andrew A.
TI Saffron therapy for the treatment of mild/moderate age-related macular
   degeneration: a randomised clinical trial
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Clinical trials; Age-related macular degeneration; Saffron;
   Electroretinogram; Nutritional supplementation
ID HIGH-DOSE SUPPLEMENTATION; MULTIFOCAL ELECTRORETINOGRAPHY;
   BETA-CAROTENE; ISCEV STANDARD; VISUAL-ACUITY; VISION LOSS; VITAMIN-C;
   LUTEIN; NEUROPROTECTION; RANIBIZUMAB
AB PurposeTo assess the efficacy and safety of oral saffron, a natural antioxidant, in treating mild/moderate age-related macular degeneration (AMD).MethodsRandomised, double-blinded, placebo-controlled crossover trial of 100 adults (>50years) with mild/moderate AMD and vision >20/70 Snellen equivalent in at least one eye. Exclusion criteria included confounding visual lesions, or significant gastrointestinal disease impairing absorption. Participants were given oral saffron supplementation (20mg/day) for 3months or placebo for 3months, followed by crossover for 3months. Participants already consuming Age-Related Eye Diseases Study (AREDS) supplements or equivalent maintained these. Primary outcomes included changes in best-corrected visual acuity (BCVA) and changes in multifocal electroretinogram (mfERG) response density and latency. Secondary outcomes included safety outcomes and changes in mfERG and BCVA amongst participants on AREDS supplements.ResultsMean BCVA improved 0.69 letters (p=0.001) and mean-pooled mfERG latency reduced 0.17ms (p=0.04) on saffron compared to placebo. Amongst participants on AREDS supplements, mean BCVA improved 0.73 letters p=0.006) and mean-pooled mfERG response density improved 2.8% (p=0.038). There was no significant difference in adverse event occurrence (p>0.10).ConclusionSaffron supplementation modestly improved visual function in participants with AMD, including those using AREDS supplements. Given the chronic nature of AMD, longer-term supplementation may produce greater benefits.
C1 [Broadhead, Geoffrey K.; Grigg, John R.; McCluskey, Peter; Chang, Andrew A.] Univ Sydney, Save Sight Inst, 8 Macquarie St, Sydney, NSW 2000, Australia.
   [Broadhead, Geoffrey K.; Hong, Thomas; Chang, Andrew A.] Sydney Inst Vis Sci, Sydney, NSW, Australia.
   [Broadhead, Geoffrey K.; Hong, Thomas; Chang, Andrew A.] Sydney Retina Clin & Day Surg, Sydney, NSW, Australia.
   [Schlub, Timothy E.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney
RP Chang, AA (通讯作者)，Univ Sydney, Save Sight Inst, 8 Macquarie St, Sydney, NSW 2000, Australia.; Chang, AA (通讯作者)，Sydney Inst Vis Sci, Sydney, NSW, Australia.; Chang, AA (通讯作者)，Sydney Retina Clin & Day Surg, Sydney, NSW, Australia.
EM achang@sydneyretina.com.au
RI McCluskey, Peter J/H-7607-2013
OI McCluskey, Peter J/0000-0002-8177-1637; Schlub,
   Timothy/0000-0001-7746-9649
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Akhondzadeh S, 2010, PSYCHOPHARMACOLOGY, V207, P637, DOI 10.1007/s00213-009-1706-1
   Ambrosio L, 2015, DOC OPHTHALMOL, V131, P125, DOI 10.1007/s10633-015-9507-9
   Bathaie SZ, 2010, CRIT REV FOOD SCI, V50, P761, DOI 10.1080/10408390902773003
   Berrow EJ, 2013, BRIT J NUTR, V109, P2008, DOI 10.1017/S0007114512004187
   Bisti S, 2014, VISUAL NEUROSCI, V31, P355, DOI 10.1017/S0952523814000108
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen L, 2015, OPHTHALMIC RES, V54, P157, DOI 10.1159/000439026
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Ishizuka F, 2013, EUR J PHARMACOL, V703, P1, DOI [10.1016/j.ephar.2013.02.007, 10.1016/j.ejphar.2013.02.007]
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Mohamadpour AH, 2013, IRAN J BASIC MED SCI, V16, P39
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Purushothuman S, 2013, J PARKINSON DIS, V3, P77, DOI 10.3233/JPD-130173
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schleicher M, 2013, NUTRIENTS, V5, P2405, DOI 10.3390/nu5072405
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Yang SS, 2016, DOC OPHTHALMOL, V132, P17, DOI 10.1007/s10633-016-9523-4
   Yavas GF, 2014, DOC OPHTHALMOL, V129, P167, DOI 10.1007/s10633-014-9460-z
NR 33
TC 29
Z9 29
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2019
VL 257
IS 1
BP 31
EP 40
DI 10.1007/s00417-018-4163-x
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HG7BD
UT WOS:000455142000004
PM 30343354
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Bhargava, M
   Laude, A
   Koh, ACH
   Xiang, L
   Wong, D
   Niang, T
   Lim, TH
   Gopal, L
   Wong, TY
AF Cheung, Chui Ming G.
   Bhargava, Mayuri
   Laude, Augustinus
   Koh, Adrian C. H.
   Xiang, Li
   Wong, Doric
   Niang, Thet
   Lim, Tock Han
   Gopal, Lingam
   Wong, Tien Y.
TI Asian age-related macular degeneration phenotyping study: rationale,
   design and protocol of a prospective cohort study
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); epidemiology; retina
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; FACTOR-H POLYMORPHISM; PHOTODYNAMIC
   THERAPY; EYE DISEASES; INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB;
   VERTEPORFIN; PREVALENCE; VISION; EPIDEMIOLOGY
AB Background: Current knowledge of the phenotypic characteristics (e.g. clinical features, risk factors, natural history and treatment response) of age-related macular degeneration (AMD) in Asians remains limited. This report summarizes the rationale and study design of a prospective observational study of Asian neovascular AMD, including polypoidal choroidovasculopathy variant. Design: The Asian AMD phenotyping study is a prospective, observational clinical study of Asian patients with neovascular AMD or polypoidal choroidovasculopathy in three tertiary eye centres in Singapore. Participants: The study aims to recruit 500 consecutive patients from the retinal clinics of three tertiary eye centres in Singapore. Methods: Standardized examination procedures include interviews, a comprehensive eye examination, digital photography of the retina, fundus fluorescein and indocyanine green angiography and spectral domain optical coherence tomography using a standardized protocol. Blood samples were collected for biochemical analyses and stored for genetic and proteomic studies. Main Outcome Measures: The aim of the study was to build a comprehensive database of clinical, angiographic, functional and natural history data of Asian AMD over a 12-month follow-up period. Results: This article discusses the methodology and design of this prospective multi-centred study. Conclusion: This study will provide in-depth longitudinal data of the evolution of clinical features, risk factors, natural history and treatment pattern and response of Asian AMD and polypoidal choroidovasculopathy, allowing unique insights into pathogenesis and the design of new treatment strategies.
C1 [Cheung, Chui Ming G.; Bhargava, Mayuri; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Bhargava, Mayuri; Niang, Thet; Gopal, Lingam; Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Laude, Augustinus; Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp, Dept Ophthalmol, Inst Eye, Singapore, Singapore.
   [Koh, Adrian C. H.] Camden Med Ctr, Singapore, Singapore.
   [Wong, Tien Y.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Tan Tock Seng Hospital; Centre for Eye
   Research Australia; Royal Victorian Eye & Ear Hospital; University of
   Melbourne
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Wong, Damon/0000-0003-4601-9121;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU National Medical Research Council [NMRC/NIG/1003/2009]
FX Funding sources: National Medical Research Council grant:
   NMRC/NIG/1003/2009.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2004, NAT HLTH SURV
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2011, AM J OPHTHALMOL, V152, P108, DOI 10.1016/j.ajo.2011.01.012
   Diabetic Retinopathy Study Coordinating Center, 1972, DIAB RET STUD MAN OP
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TY, 2010, INVEST OPHTH VIS SCI, V51
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lamoureux EL, 2008, OPHTHALMOLOGY, V115, P1973, DOI 10.1016/j.ophtha.2008.05.005
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   *MAC PHOT STUD GRO, 1991, ARCH OPHTHALMOL-CHIC, V109, P1219
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Tsujikawa A, 2011, EYE, V25, P481, DOI 10.1038/eye.2010.232
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
NR 38
TC 36
Z9 36
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD SEP-OCT
PY 2012
VL 40
IS 7
BP 727
EP 735
DI 10.1111/j.1442-9071.2012.02765.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 017QR
UT WOS:000309606000013
PM 22299650
DA 2022-11-30
ER

PT J
AU Grishanin, R
   Vuillemenot, B
   Sharma, P
   Keravala, A
   Greengard, J
   Gelfman, C
   Blumenkrantz, M
   Lawrence, M
   Hu, WZ
   Kiss, S
   Gasmi, M
AF Grishanin, Ruslan
   Vuillemenot, Brian
   Sharma, Pallavi
   Keravala, Annahita
   Greengard, Judith
   Gelfman, Claire
   Blumenkrantz, Mark
   Lawrence, Matthew
   Hu, Wenzheng
   Kiss, Szilard
   Gasmi, Mehdi
TI Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to
   Treating Wet Age-Related Macular Degeneration
SO MOLECULAR THERAPY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL
   NEOVASCULARIZATION; INTRAOCULAR PHARMACOKINETICS; NONHUMAN PRIMATE;
   FOLLOW-UP; RETINAL NEOVASCULARIZATION; OPEN-LABEL; VEGF TRAP;
   AFLIBERCEPT
AB Inhibition of vascular endothelial growth factor, a key contributor to the choroidal neovascularization associated with wet age-related macular degeneration, is the mode of action of several approved therapies, including aflibercept, which requires frequent intravitreal injections to provide clinical benefit. Lack of compliance with the dosing schedule may result in recurrence of active wet macular degeneration, leading to irreversible vision impairment. Gene therapy providing sustained anti-vascular endothelial growth factor levels in the retina following a single injection could drastically reduce the treatment burden and improve visual outcomes. ADVM-022, an adeno-associated virus vector encoding aflibercept, is optimized for intravitreal delivery and strong protein expression. Here, we report the long-term expression and efficacy of ADVM-022-derived aflibercept in a laser-induced choroidal neovascularization model in non-human primates. Intravitreal administration of ADVM-022 was well tolerated and resulted in sustained aflibercept levels. In addition, ADVM-022 administration 13 months before lasering prevented the occurrence of clinically relevant choroidal neovascularization lesions, similar to animals that received a bolus of intravitreal aflibercept (standard of care) at the time of lesioning. These results demonstrate that a single intravitreal administration of ADVM-022 may provide a safe and effective long-term treatment option for wet macular degeneration and may ultimately improve patients' visual outcomes.
C1 [Grishanin, Ruslan; Vuillemenot, Brian; Sharma, Pallavi; Keravala, Annahita; Greengard, Judith; Gelfman, Claire; Gasmi, Mehdi] Adverum Biotechnol, 1035 OBrien Dr, Menlo Pk, CA 94025 USA.
   [Blumenkrantz, Mark] Stanford Univ, Palo Alto, CA 94304 USA.
   [Lawrence, Matthew; Hu, Wenzheng] RxGen Inc, New Haven, CT USA.
   [Kiss, Szilard] Weill Cornell Med Coll, New York, NY USA.
C3 Stanford University; Cornell University
RP Gasmi, M (通讯作者)，Adverum Biotechnol, 1035 OBrien Dr, Menlo Pk, CA 94025 USA.
EM mehdi@adverum.com
OI Kiss, Szilard/0000-0003-3433-8432
FU Adverum Biotechnologies, Inc.
FX This study was funded by Adverum Biotechnologies, Inc. The authors thank
   S. Seiler for editorial assistance; J. Nieves, A. Nguyen, and R. Rosario
   for technical support; and A. Ramirez and M. Steel for test article
   production and quality control. We also thank A. Phillips for insights
   and helpful suggestions during the development of this project.
CR Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Ashraf M, 2017, EYE, V31, P1523, DOI 10.1038/eye.2017.81
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Bruewer AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060218
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Celik N, 2015, INVEST OPHTH VIS SCI, V56, P5574, DOI 10.1167/iovs.15-16418
   Cloutier F, 2012, INVEST OPHTH VIS SCI, V53, P1195, DOI 10.1167/iovs.11-9064
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Cook GP, 2011, RETINA TODAY, P70
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Goody RJ, 2011, EXP EYE RES, V92, P464, DOI 10.1016/j.exer.2011.03.006
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hickey DG, 2017, GENE THER, V24, P787, DOI 10.1038/gt.2017.85
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Hussain R. M, 2018, REV OPHTHALMOL, V25, P20
   Hussain RM, 2017, OSLI RETINA, V48, P780, DOI 10.3928/23258160-20170928-01
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Ochakovski GA, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00174
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rota R, 2004, J GENE MED, V6, P992, DOI 10.1002/jgm.586
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sidman RL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4882
   Woodburn KW, 2016, HUM GENE THER, V27, pA40
   Xue K, 2017, EYE, V31, P1308, DOI 10.1038/eye.2017.158
   Ye GJ, 2015, HUM GENE THER CL DEV, V26, P165, DOI 10.1089/humc.2015.076
NR 48
TC 40
Z9 44
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD JAN 2
PY 2019
VL 27
IS 1
BP 118
EP 129
DI 10.1016/j.ymthe.2018.11.003
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA HG1IX
UT WOS:000454708300013
PM 30528929
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU van Wijngaarden, P
   Qureshi, SH
AF van Wijngaarden, Peter
   Qureshi, Salmaan H.
TI Inhibitors of vascular endothelial growth factor (VEGF) in the
   management of neovascular age-related macular degeneration: a review of
   current practice
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE age-related macular degeneration; neovascularisation; retina; VEGF
   inhibitors
ID INTRAVITREAL BEVACIZUMAB AVASTIN; CHOROIDAL NEOVASCULARIZATION; VISUAL
   IMPAIRMENT; CRYSTAL-STRUCTURE; FACTOR ANTIBODY; FULL-LENGTH; SAFETY;
   INJECTION; RANIBIZUMAB; MACULOPATHY
AB We review the fundamental changes that are now occurring to the management of neovascular (wet) age-related macular degeneration (AMD). An improved understanding of the role of vascular endothelial growth factor (VEGF) in the genesis of choroidal neovascular membranes has led to the creation and use of intravitreous anti-VEGF antibodies (bevacizumab and ranubizumab) and an aptamer (pegaptanib) in the treatment of these lesions. These new intravitreous injections for AMD have supplanted previous treatments in both efficacy and safety and are now the standard of care for neovascular AMD. We discuss the biochemistry of the anti-VEGF pathway. While there is substantial evidence for the use of ranubizumab and pegaptanib, the intravitreous administration of bevacizumab has not been tested in randomised controlled clinical trials. We review the evidence base for all three agents and the patho-physiological basis for adverse reactions to intravitreous VEGF blockade.
C1 [van Wijngaarden, Peter; Qureshi, Salmaan H.] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
C3 Royal Victorian Eye & Ear Hospital
RP Qureshi, SH (通讯作者)，Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
EM shq@unimelb.edu.au
OI van Wijngaarden, Peter/0000-0002-8800-7834
CR *ACC EC EYE RES AU, CLEAR INS EC IMP COS
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   [Anonymous], 1995, Arch Ophthalmol, V113, P1479
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Beer PM, 2006, RETINA-J RET VIT DIS, V26, P871, DOI 10.1097/01.iae.0000233327.68433.02
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dafer Rima M, 2007, Semin Ophthalmol, V22, P201, DOI 10.1080/08820530701543024
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   EVANS JR, 2006, COCHRANE DB SYST REV, V4
   Feiner L, 2006, RETINA-J RET VIT DIS, V26, P882, DOI 10.1097/01.iae.0000230717.85319.f5
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   *GEN, 2007, SAF UPD LUC
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gillies MC, 2006, ARCH OPHTHALMOL-CHIC, V124, P1478, DOI 10.1001/archopht.124.10.1478
   Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kvanta A, 2006, ACTA OPHTHALMOL SCAN, V84, P282, DOI 10.1111/j.1600-0420.2006.00659.x
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, p[e1, 12]
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707
   Presta LG, 1997, CANCER RES, V57, P4593
   Ratner M, 2004, NAT BIOTECHNOL, V22, P1198, DOI 10.1038/nbt1004-1198
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Scholl HPN, 2007, MOL VIS, V13, P196
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Zhou JH, 2005, MOL VIS, V11, P414
   Ziemssen F, 2006, BRIT J OPHTHALMOL, V90, P1440
   LUCENTIS FULL PRESCR
NR 76
TC 51
Z9 51
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD SEP
PY 2008
VL 91
IS 5
BP 427
EP 437
DI 10.1111/j.1444-0938.2008.00305.x
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 336HU
UT WOS:000258355700002
PM 18637105
OA Bronze
DA 2022-11-30
ER

PT J
AU Fauser, S
   Lambrou, GN
AF Fauser, Sascha
   Lambrou, George N.
TI Genetic predictive biomarkers of anti-VEGF treatment response in
   patients with neovascular age-related macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE biomarker; anti-VEGF; age-related macular degeneration; genetics; single
   nucleotide polymorphisms; ranibizumab; bevacizumab
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; INTRAVITREAL
   RANIBIZUMAB; PHOTODYNAMIC THERAPY; POLYMORPHISMS; ASSOCIATION;
   BEVACIZUMAB; RISK; PHARMACOGENETICS; HTRA1
AB Anti-vascular endothelial growth factor (anti-VEGF) therapies for neovascular age-related macular degeneration (nAMD) have proven efficacy at a study-population level, although individual patient responses vary, with most of the patients responding well to anti-VEGF therapies, while a few respond poorly. The pathogenesis of AMD is known to have a genetic component, but it is unclear if any particular genotype can predict response to anti-VEGF therapy. With the advent of less expensive genotyping technology, there have been numerous studies within this area. Here we analyze potential biomarker candidates identified that could be used in a clinical setting to predict response to anti-VEGF treatment of nAMD. We analyze single nucleotide polymorphisms (SNPs) identified from 39 publications. The SNPs that appeared to be of most importance fell into two main groups: those previously associated with AMD pathogenesis and those within the signaling pathway targeted by anti-VEGF therapies. A number of small studies found evidence supporting an association between anti-VEGF treatment response and two SNPs, CFH rs1061170 and VEGFA rs699947, but results from randomized controlled trials found no such association. It is possible that, in the future, the cumulative effect of several high-risk SNPs may prove useful in a clinical setting and that other genetic biomarkers may emerge. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Fauser, Sascha] Univ Hosp, Dept Ophthalmol, D-50924 Cologne, Germany.
   [Lambrou, George N.] Ctr Natl Ophtalmol, Inst Vis, Paris, France.
C3 University of Cologne; UDICE-French Research Universities; Sorbonne
   Universite
RP Fauser, S (通讯作者)，Univ Hosp, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM sascha.fauser@uk-koeln.de
FU Novartis Pharma AG, Basel, Switzerland
FX Editorial assistance in the development of this review was provided by
   Gillian Groeger, Fishawack Communications Ltd., Oxford, UK; this service
   was funded by Novartis Pharma AG, Basel, Switzerland.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Amoaku WM, 2011, EYE, V25, P399, DOI 10.1038/eye.2011.3
   [Anonymous], 2012, OPEN SPACE, V83, P18
   Bian ZM, 2004, INVEST OPHTH VIS SCI, V45, P1887, DOI 10.1167/iovs.03-0608
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang W, 2013, MOL VIS, V19, P702
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Graham JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074094
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hautamaki A, 2013, RETINA, V33, P1825
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Huang C, 2013, MOL VIS, V19, P1211
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kitts A, 2002, NCBI HDB
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Parmeggiani F, 2011, MOL DIAGN THER, V15, P195, DOI 10.2165/11592270-000000000-00000
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Tong Y, 2010, MOL VIS, V16, P1958
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P1
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wang JB, 2012, CURR DRUG METAB, V13, P978, DOI 10.2174/138920012802138552
   Wang VM, 2013, INT J INFLAM
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   World Health Organization, 2010, GLOB DAT VIS IMP 201
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yuan DQ, 2013, OPHTHALMOLOGICA, V230, P227, DOI 10.1159/000355068
NR 74
TC 24
Z9 25
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2015
VL 60
IS 2
BP 138
EP 152
DI 10.1016/j.survophthal.2014.11.002
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC7HX
UT WOS:000350539400005
PM 25596882
DA 2022-11-30
ER

PT J
AU He, F
   Li, XH
   Cai, SP
   Lu, L
   Zhang, T
   Yang, M
   Fan, N
   Wang, XZ
   Liu, XY
AF He, Fen
   Li, Xiaohong
   Cai, Suping
   Lu, Lan
   Zhang, Tong
   Yang, Ming
   Fan, Ning
   Wang, Xizhen
   Liu, Xuyang
TI Polymorphism rs11200638 enhanced HtrA1 responsiveness and expression are
   associated with age-related macular degeneration
SO EYE
LA English
DT Article
ID COMPLEMENT FACTOR-H; OXIDATIVE STRESS; PROMOTER POLYMORPHISM; A69S
   POLYMORPHISMS; CHROMOSOME 10Q26; VARIANTS; INFLAMMATION; SMOKING; RISK;
   AMD
AB Objectives To investigate the role of polymorphism rs11200638 of high-temperature requirement factor A-1 (HtrA1) gene in the pathogenesis of age-related macular degeneration (AMD). Methods Cultured adult retinal pigment epithelial cells (ARPE-19) expressing HtrA1 gene were treated with H2O2 or lipopolysaccharides (LPS) and analysed using western blot and quantitative polymerase chain reaction to illustrate the effects of oxidative and inflammatory stress on HtrA1 gene expression. Luciferase reporter plasmid driven by HtrA1 promoter with either normal allele G or risk allele A at SNP rs11200638 was transfected to ARPE-19 cells to investigate the effect of the G/A variation on HtrA1 promoter activity. The effects of HtrA1 overexpression on ARPE-19 cells were analysed with respect to percentage of cell proliferation inhibition and cell apoptosis. Results HtrA1 expression was significantly increased with LPS or H2O2 stimulations (p < 0.05). In ARPE-19 cells, HtrA1 promoters (-1 to -2175 bp from translation starting point) with risk allele A or normal G at rs11200638 did not show statistically significant differences in their luciferase reporter expression (p = 0.054425173), however, both promoters showed a persistent trend of higher luciferase expressions after 100 ng/ml LPS treatment. The luciferase expression level was significantly greater in the promoter with risk A when compared to that with normal G. Overexpression of HtrA1 resulted in apoptosis of ARPE-19 cells with 53.8 +/- 1.6% of proliferation inhibition (p < 0.01). Conclusions Risk haplotype A at rs11200638 significantly increased the responsiveness of HtrA1 promoter to inflammation and subsequently enhanced HtrA1 expression. HtrA1 overexpression induced ARPE-19 apoptosis and growth inhibition, relevant to pathogenesis of AMD.
C1 [He, Fen] Jinan Univ, Shenzhen Aier Eye Hosp, Shenzhen, Guangdong, Peoples R China.
   [Li, Xiaohong] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Dept Biopharmaceut, Chengdu, Peoples R China.
   [Cai, Suping; Zhang, Tong; Yang, Ming; Fan, Ning; Wang, Xizhen] Shenzhen Univ, Shenzhen Eye Hosp, Shenzhen Key Lab Ophthalmol, Shenzhen, Guangdong, Peoples R China.
   [Lu, Lan] Fujian Med Univ, Union Hosp, Dept Ophthalmol, Fuzhou, Fujian, Peoples R China.
   [Liu, Xuyang] Xiamen Univ, Xiamen Eye Ctr, Xiamen, Peoples R China.
   [Liu, Xuyang] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Ophthalmol, Shenzhen, Guangdong, Peoples R China.
C3 Jinan University; Sichuan University; Shenzhen University; Fujian
   Medical University; Xiamen University; Jinan University
RP Liu, XY (通讯作者)，Xiamen Univ, Xiamen Eye Ctr, Xiamen, Peoples R China.; Liu, XY (通讯作者)，Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Ophthalmol, Shenzhen, Guangdong, Peoples R China.
EM xliu1213@126.com
FU National Basic Research Program (973 Program) [2011CB510201]; National
   Natural Science Foundation of China (NNSF) [81770924, 82070963];
   Guangdong Basic and Applied Basic Research Foundation [2019A1515011234];
   Science and Technology Project of the Health Planning Committee of
   Sichuan [16PJ226]
FX This work was supported by grants from the National Basic Research
   Program (973 Program, 2011CB510201), the National Natural Science
   Foundation of China (NNSF 81770924 and 82070963), Guangdong Basic and
   Applied Basic Research Foundation (2019A1515011234), and the Science and
   Technology Project of the Health Planning Committee of Sichuan
   (16PJ226). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Askari M, 2015, REP BIOCHEM MOL BIOL, V4, P43
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bonyadi MHJ, 2016, CURR EYE RES, V41, P1519, DOI 10.3109/02713683.2016.1158274
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Giansanti V, 2013, J CELL MOL MED, V17, P103, DOI 10.1111/j.1582-4934.2012.01652.x
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hou YZ, 2013, ARTHRITIS RHEUM-US, V65, P2835, DOI 10.1002/art.38124
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Lee SJ, 2010, CLIN EXP OPHTHALMOL, V38, P698, DOI 10.1111/j.1442-9071.2010.02316.x
   Li XH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151644
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   Rajendran A, 2018, BRIT J OPHTHALMOL, V102, P1213, DOI 10.1136/bjophthalmol-2017-311384
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Richardson AJ, 2010, INVEST OPHTH VIS SCI, V51, P4932, DOI 10.1167/iovs.09-5114
   Ryu E, 2010, MOL VIS, V16, P2811
   Schwartz SG, 2016, CLIN OPHTHALMOL, V10, P1229, DOI 10.2147/OPTH.S109723
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Soysal Y, 2012, DNA CELL BIOL, V31, P322, DOI 10.1089/dna.2011.1214
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Wang GF, 2010, ARCH OPHTHALMOL-CHIC, V128, P1491, DOI 10.1001/archophthalmol.2010.256
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zhou YL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0487-2
   Zurawa-Janicka D, 2010, EXPERT OPIN THER TAR, V14, P665, DOI 10.1517/14728222.2010.487867
NR 43
TC 0
Z9 0
U1 0
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2022
VL 36
IS 8
BP 1631
EP 1638
DI 10.1038/s41433-021-01706-8
EA JUL 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3D1FT
UT WOS:000679368000004
PM 34326497
DA 2022-11-30
ER

PT J
AU Wang, GF
   Spencer, KL
   Scott, WK
   Whitehead, P
   Court, BL
   Ayala-Haedo, J
   Mayo, P
   Schwartz, SG
   Kovach, JL
   Gallins, P
   Polk, M
   Agarwal, A
   Postel, EA
   Haines, JL
   Pericak-Vance, MA
AF Wang, Gaofeng
   Spencer, Kylee L.
   Scott, William K.
   Whitehead, Patrice
   Court, Brenda L.
   Ayala-Haedo, Juan
   Mayo, Ping
   Schwartz, Stephen G.
   Kovach, Jaclyn L.
   Gallins, Paul
   Polk, Monica
   Agarwal, Anita
   Postel, Eric A.
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
TI Analysis of the indel at the ARMS2 3'UTR in age-related macular
   degeneration
SO HUMAN GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; GENOMEWIDE-SCAN;
   EXTENDED FAMILIES; CHROMOSOME 10Q26; SUSCEPTIBILITY; GENE; VARIANT;
   RISK; MACULOPATHY
AB Controversy remains as to which gene at the chromosome 10q26 locus confers risk for age-related macular degeneration (AMD) and statistical genetic analysis is confounded by the strong linkage disequilibrium (LD) across the region. Functional analysis of related genetic variations could solve this puzzle. Recently, Fritsche et al. reported that AMD is associated with unstable ARMS2 transcripts possibly caused by a complex insertion/deletion (indel; consisting of a 443 bp deletion and an adjacent 54 bp insertion) in its 3'UTR (untranslated region). To validate this indel, we sequenced our samples. We found that this indel is even more complex and is composed of two side-by-side indels separated by 17 bp: (1) 9 bp deletion with 10 bp insertion; (2) 417 bp deletion with 27 bp insertion. The indel is significantly associated with the risk of AMD, but is also in strong LD with the non-synonymous single nucleotide polymorphism rs10490924 (A69S). We also found that ARMS2 is expressed not only in placenta and retina but also in multiple human tissues. Using quantitative PCR, we found no correlation between the indel and ARMS2 mRNA level in human retina and blood samples. The lack of functional effects of the 3'UTR indel, the amino acid substitution of rs10490924 (A69S), and strong LD between them suggest that A69S, not the indel, is the variant that confers risk of AMD. To our knowledge, it is the first time it has been shown that ARMS2 is widely expressed in human tissues. Conclusively, the indel at 3'UTR of ARMS2 actually contains two side-by-side indels. The indels are associated with risk of AMD, but not correlated with ARMS2 mRNA level.
C1 [Wang, Gaofeng; Scott, William K.; Whitehead, Patrice; Court, Brenda L.; Ayala-Haedo, Juan; Gallins, Paul; Polk, Monica; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Dr John T Macdonald Fdn, Dept Human Genet,John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Spencer, Kylee L.; Mayo, Ping; Haines, Jonathan L.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37232 USA.
   [Schwartz, Stephen G.; Kovach, Jaclyn L.] Univ Miami, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Agarwal, Anita] Vanderbilt Univ, Dept Ophthalmol, Nashville, TN 37232 USA.
   [Postel, Eric A.] Duke Univ, Med Ctr, Duke Eye Ctr, Durham, NC 27710 USA.
C3 University of Miami; Vanderbilt University; Bascom Palmer Eye Institute;
   University of Miami; Vanderbilt University; Duke University
RP Wang, GF (通讯作者)，Univ Miami, Miller Sch Med, Dr John T Macdonald Fdn, Dept Human Genet,John P Hussman Inst Human Genom, Miami, FL 33136 USA.
EM gwang@med.miami.edu
RI Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU National Institutes of Health [EY12118]; NIH [P30-EY014801]; Genentech;
   NATIONAL EYE INSTITUTE [U10EY012118, R01EY012118, P30EY014801] Funding
   Source: NIH RePORTER
FX We thank all the patients, their families, and the controls who
   participated in the study. A subset of the participants was ascertained
   while Margaret A. Pericak-Vance was a faculty member at Duke University.
   This research was supported by National Institutes of Health grants
   (EY12118 to M. A. P.-V. and J.L.H.) and was partially supported by NIH
   center grant P30-EY014801 and by an unrestricted grant to the University
   of Miami from Research to Prevent Blindness, New York, NY. S. G. S. has
   previously received research funding from Genentech, owns equity in
   PWzer, and is co-holder of a patent pending entitled "Molecular targets
   for modulating intraocular pressure and differentiation of steroid
   responders versus non-responders."
CR Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chowers I, 2008, MOL VIS, V14, P2263
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   GOTOH N, 2009, AM J OPHTHALMOL
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 25
TC 40
Z9 41
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD MAR
PY 2010
VL 127
IS 5
BP 595
EP 602
DI 10.1007/s00439-010-0805-8
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 583HP
UT WOS:000276665000012
PM 20182747
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Cachulo, MD
   Lobo, C
   Figueira, J
   Ribeiro, L
   Lains, I
   Vieira, A
   Nunes, S
   Costa, M
   Simao, S
   Rodrigues, V
   Vilhena, N
   Cunha-Vaz, J
   Silva, R
AF Cachulo, Maria da Luz
   Lobo, Conceicao
   Figueira, Joao
   Ribeiro, Luisa
   Lains, Ines
   Vieira, Antonio
   Nunes, Sandrina
   Costa, Miguel
   Simao, Silvia
   Rodrigues, Victor
   Vilhena, Nelson
   Cunha-Vaz, Jose
   Silva, Rufino
TI Prevalence of Age-Related Macular Degeneration in Portugal: The Coimbra
   Eye Study - Report 1
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Neovascular age-related macular
   degeneration; Geographic atrophy
ID RISK-FACTORS; RACIAL-DIFFERENCES; CIGARETTE-SMOKING; POOLED FINDINGS;
   SEVERITY SCALE; MACULOPATHY; DISEASE; CLASSIFICATION; POPULATION; NUMBER
AB Purpose: To evaluate the age- and gender-specific prevalence of early and late age-related macular degeneration (AMD) in a Portuguese population-based sample. Methods: All patients aged >= 55 years of a Portuguese primary health-care unit were recruited for a cross-sectional population-based study. Responders underwent complete ophthalmological examination and digital fundus imaging. Early and late AMD was defined according to the International Age-Related Macular Epidemiological Study Group Classification, and the adopted staging for AMD was the same as that used in the Rotterdam study. The age- and gender-adjusted prevalence of early and late forms of AMD was calculated. Results: Of the 4,370 eligible subjects, 3,000 underwent study procedures (68.6% response rate) and 2,975 were included in the analysis; they had a mean age of 68.9 +/- 8.6 years. The overall prevalence of early and late AMD was 15.53% (95% Cl 14.25-16.88) and 0.67% (95% Cl 0.41-1.04), respectively. Neovascular AMD (NV-AMD) and geographic atrophy (GA) accounted for 0.44% (95% Cl 0.23-0.75) and 0.27% (95% Cl 0.12-0.53) of individuals, respectively. The highest prevalence of advanced AMD was among those aged >= 75 years (1.13% for NV-AMD; 0.63% for GA). Conclusions: To our knowledge, this is the first AMD epidemiological study in a Portuguese population. The early forms of the disease had a similar prevalence to that of other large-scale population-based cohorts, but late AMD was less frequent than previously reported. (C) 2015 S. Karger AG, Basel
C1 [Cachulo, Maria da Luz; Lobo, Conceicao; Figueira, Joao; Lains, Ines; Silva, Rufino] Ctr Hosp & Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Cachulo, Maria da Luz; Lobo, Conceicao; Figueira, Joao; Ribeiro, Luisa; Nunes, Sandrina; Costa, Miguel; Simao, Silvia; Cunha-Vaz, Jose; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Lobo, Conceicao; Silva, Rufino] Univ Coimbra, Fac Med, Dept Ophthalmol, Coimbra, Portugal.
   [Rodrigues, Victor] Univ Coimbra, Fac Med, Inst Higiene & Med Social, Coimbra, Portugal.
   [Vilhena, Nelson] Crit Hlth, Coimbra, Portugal.
   [Vieira, Antonio] Primary Hlth Care Ctr, Mira, Portugal.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Universidade de Coimbra; Universidade
   de Coimbra
RP Cachulo, MD (通讯作者)，AIBILL, Azinhaga Santa Comba, Celas, P-3000548 Coimbra, Portugal.
EM 4c@aibili.pt
RI Rodrigues, Vitor/AAU-9992-2020; Silva, Rufino M/J-2817-2012; Lobo,
   Conceição/ABB-8609-2021; Lobo, Conceicao/B-4122-2016
OI Rodrigues, Vitor/0000-0003-4174-9061; Silva, Rufino
   M/0000-0001-8676-0833; Ribeiro, Maria Luisa/0000-0002-5801-8487;
   Cachulo, Maria Luz/0000-0002-0900-4548; Cunha-Vaz,
   Jose/0000-0002-0947-9850; Figueira, Joao P/0000-0002-3511-1515; Costa,
   Miguel Angelo/0000-0002-0362-1713; Lains, Ines/0000-0002-8136-4724;
   Lobo, Conceicao/0000-0001-5831-7711; Nunes, Sandrina/0000-0001-5401-9637
FU Novartis
FX This study was financially supported by Novartis.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Marques J.P., 2013, ISRN OPHTHALMOL, V2013
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 43
TC 26
Z9 26
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 233
IS 3-4
BP 119
EP 127
DI 10.1159/000371584
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK3LO
UT WOS:000356117800001
PM 25677077
DA 2022-11-30
ER

PT J
AU Chung, SD
   Lee, CZ
   Kao, LT
   Lin, HC
   Tsai, MC
   Sheu, JJ
AF Chung, Shiu-Dong
   Lee, Cha-Ze
   Kao, Li-Ting
   Lin, Herng-Ching
   Tsai, Ming-Chieh
   Sheu, Jau-Jiuan
TI Association between Neovascular Age-Related Macular Degeneration and
   Dementia: A Population-Based Case-Control Study in Taiwan
SO PLOS ONE
LA English
DT Article
ID ALZHEIMERS-DISEASE; RISK-FACTORS; COGNITIVE FUNCTION; VASCULAR DEMENTIA;
   EYE; IMPAIRMENT; PREVALENCE; ATHEROSCLEROSIS
AB Background
   Most available studies focusing on the association between neovascular age-related macular degeneration (AMD) and dementia have conflicting results. This study aimed to investigate the association between previously diagnosed AMD and dementia using a populationbased dataset in Taiwan.
   Methods
   Data for this case-control study were retrospectively collected from the Taiwan National Health Insurance Research Database. We identified 13,402 subjects who had a diagnosis of dementia as cases, and 40,206 subjects without dementia as controls. A conditional logistic regression was used to examine the association of dementia with previously diagnosed neovascular AMD.
   Results
   We found that of the study sample of 53,608 subjects, 1.01% had previously diagnosed neovascular AMD, 1.35% and 0.90% for cases and the controls, respectively (p<0.001). The conditional logistic regression analysis suggested that the odds ratio of prior neovascular AMD for cases was 1.37 (95% confidence interval: 1.14 similar to 1.65) compared to the controls after adjusting for subjects' age, monthly income, geographic location, urbanization level, and hyperlipidemia, diabetes, hypertension, stroke, ischemic heart disease, and whether or not a subjects underwent cataract surgery prior to index date than controls.
   Conclusions
   Dementia subjects were associated with a higher proportion of prior neovascular AMD than were the controls.
C1 [Chung, Shiu-Dong] Taipei Med Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chung, Shiu-Dong; Lin, Herng-Ching] Taipei Med Univ Hosp, Sleep Res Ctr, Taipei, Taiwan.
   [Lee, Cha-Ze] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
   [Kao, Li-Ting] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.
   [Lin, Herng-Ching; Tsai, Ming-Chieh] Taipei Med Univ, Sch Hlth Care Adm, Taipei, Taiwan.
   [Tsai, Ming-Chieh] Cathay Gen Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan.
   [Sheu, Jau-Jiuan] Taipei Med Univ Hosp, Dept Neurol, Taipei, Taiwan.
   [Sheu, Jau-Jiuan] Taipei Med Univ, Coll Med, Sch Med, Dept Neurol, Taipei, Taiwan.
C3 Taipei Medical University; Taipei Medical University Hospital; Taipei
   Medical University; Taipei Medical University Hospital; National Taiwan
   University; National Taiwan University Hospital; National Defense
   Medical Center; Taipei Medical University; Cathay General Hospital;
   Taipei Medical University; Taipei Medical University Hospital; Taipei
   Medical University
RP Sheu, JJ (通讯作者)，Taipei Med Univ Hosp, Dept Neurol, Taipei, Taiwan.
EM jjs2239@tmu.edu.tw
RI Kao, Li-Ting/W-9287-2018
OI Kao, Li-Ting/0000-0003-0692-7408
CR Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7
   Chauhan Ved, 2006, Pathophysiology, V13, P195, DOI 10.1016/j.pathophys.2006.05.004
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Gorelick PB, 2004, STROKE, V35, P2620, DOI 10.1161/01.STR.0000143318.70292.47
   Ho YS, 2012, CURR PHARM DESIGN, V18, P15, DOI 10.2174/138161212798919039
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kalaria RN, 2008, LANCET NEUROL, V7, P812, DOI 10.1016/S1474-4422(08)70169-8
   Kang JH, 2010, ANN RHEUM DIS, V69, P1165, DOI 10.1136/ard.2009.116178
   Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498
   Lindekleiv H, 2013, EYE, V27, P1281, DOI 10.1038/eye.2013.181
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Ong SY, 2012, ARCH OPHTHALMOL-CHIC, V130, P895, DOI 10.1001/archophthalmol.2012.152
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Saczynski JS, 2010, NEUROLOGY, V75, P35, DOI 10.1212/WNL.0b013e3181e62138
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252
   Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Wortmann M, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt143
NR 33
TC 12
Z9 12
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 6
PY 2015
VL 10
IS 3
AR e0120003
DI 10.1371/journal.pone.0120003
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CC9KQ
UT WOS:000350689400091
PM 25748702
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Kang, S
   Roh, YJ
AF Kang, Seungbum
   Roh, Young-Jung
TI Ranibizumab Treatment Administered as Needed for Occult and Minimally
   Classic Neovascular Membranes in Age-Related Macular Degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; as-needed basis; intravitreal
   injection; ranibizumab
ID INTRAVITREAL BEVACIZUMAB AVASTIN; CHOROIDAL NEOVASCULARIZATION;
   VISUAL-ACUITY; REGIMEN
AB Purpose: To report the clinical experience of intravitreal ranibizumab administered as needed for the treatment of neovascular age-related macular degeneration (AMD).
   Methods: We retrospectively reviewed the charts of 41 patients (41 eyes) with occult and minimally classic neovascular membrane in AMD. Patients received intravitreal injections (0.5 mg) of ranibizumab and were monitored monthly for 12 months. Forty-one eyes were retreated at the discretion of the treating physician on an as-needed basis after the first injection, instead of initially giving three monthly injections. The main outcomes measured were change in mean visual acuity and central retinal thickness, and the total number of injections received by patients during the 12 months.
   Results: At 12 months, the mean logarithm of the minimum angle of resolution (logMAR) visual acuity improved by 0.078 logMAR units (P = 0.046) and the mean central retinal thickness decreased by 85.7 mu m (P < 0.001). Thirty of 41 eyes (73.2%) avoided any loss of vision, and 20 eyes (48.8 %) showed improved visual acuity. A mean of 4.07 injections were given over the 12 months.
   Conclusions: Ranibizumab administered on an as-needed basis may stabilize visual acuity in patients with neovascular AMD. Jpn J Ophthalmol 2011;55:123-127 (C) Japanese Ophthalmological Society 2011
C1 [Kang, Seungbum; Roh, Young-Jung] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, St Marys Hosp, Coll Med, Seoul 150713, South Korea.
C3 Catholic University of Korea; Catholic University Korea Hospital; Seoul
   St. Mary's Hospital
RP Roh, YJ (通讯作者)，Catholic Univ Korea, Dept Ophthalmol & Visual Sci, St Marys Hosp, Coll Med, 62 Yoido Dong, Seoul 150713, South Korea.
EM youngjungroh@hanmail.net
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hernandez-Pastor LJ, 2008, AM J HEALTH-SYST PH, V65, P1805, DOI 10.2146/ajhp070342
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SLOAN LL, 1959, AM J OPHTHALMOL, V48, P807, DOI 10.1016/0002-9394(59)90626-9
NR 16
TC 5
Z9 8
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR
PY 2011
VL 55
IS 2
BP 123
EP 127
DI 10.1007/s10384-010-0910-1
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 778XL
UT WOS:000291742600007
PM 21400056
DA 2022-11-30
ER

PT J
AU Yang, X
   Hu, J
   Zhang, J
   Guan, H
AF Yang, X.
   Hu, J.
   Zhang, J.
   Guan, H.
TI Polymorphisms in CFH, HTRA1 and CX3CR1 confer risk to exudative
   age-related macular degeneration in Han Chinese
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H GENE; VISUAL IMPAIRMENT; ASSOCIATION; SUSCEPTIBILITY; VARIANT;
   POPULATION
AB Background/Aims Single nucleotide polymorphisms (SNPs) in Complement Factor H (CFH), HTRA1 and CX3CR1 are associated with age-related macular degeneration (AMD) in Caucasian population. We aimed to determine whether, and of what magnitude, these AMD susceptibility SNPs are associated with exudative AMD in Han Chinese.
   Methods Exudative AMD cases and age-matched controls were recruited from Nantong University Hospital (109 cases, 150 controls). Six SNPs in CFH, HTRA1 and CX3CR1 were genotyped. The allele/genotype frequencies were compared between the case and the control. Interactions of SNP-SNP or SNP-smoking status were assessed.
   Results The CFH rs800292 showed significant associations with a reduced risk for exudative AMD. CX3CR1 V249I and T280M and the HTRA1 promoter SNP were significantly associated with the risk of exudative AMD. The two SNPs in CX3CR1 were in complete linkage disequilibrium. None of the AMD-susceptibility SNPs had interactions with each other or with smoking status to confer an altered AMD risk.
   Conclusions We have replicated the associations of the CFH and HTRA1 SNPs and report for the first time the association of CX3CR1 with exudative AMD in Han Chinese. There was no interaction among the SNPs from different genes, indicating that they might alter the AMD risk independently.
C1 [Yang, X.; Hu, J.; Zhang, J.; Guan, H.] Nantong Univ, Affiliated Hosp, Dept Ophthalmol, Nantong 226001, Peoples R China.
C3 Nantong University
RP Guan, H (通讯作者)，Nantong Univ, Affiliated Hosp, Dept Ophthalmol, 20 Xisi Rd, Nantong 226001, Peoples R China.
EM gtnantongeye@gmail.com
FU Nantong University
FX Nantong University.
CR Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen San-Ni, 1993, Journal of the Formosan Medical Association, V92, P823
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yang C S, 1995, Zhonghua Yi Xue Za Zhi (Taipei), V56, P411
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 23
TC 45
Z9 48
U1 1
U2 54
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2010
VL 94
IS 9
BP 1211
EP 1214
DI 10.1136/bjo.2009.165811
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 654YF
UT WOS:000282206500021
PM 20538655
DA 2022-11-30
ER

PT J
AU Cardinault, N
   Abalain, JH
   Sairafi, B
   Coudray, C
   Grolier, P
   Rambeau, M
   Carre, JL
   Mazur, A
   Rock, E
AF Cardinault, N
   Abalain, JH
   Sairafi, B
   Coudray, C
   Grolier, P
   Rambeau, M
   Carre, JL
   Mazur, A
   Rock, E
TI Lycopene but not lutein nor zeaxanthin decreases in serum and
   lipoproteins in age-related macular degeneration patients
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE ARMD; macula; carotenoids; lycopene; lipoparticles
ID RISK-FACTORS; VITAMIN-E; BETA-CAROTENE; MACULOPATHY; PIGMENT;
   SUPPLEMENTATION; DENSITY; DIET; EYE; ASSOCIATION
AB Background: Epidemiological studies have established that a low serum concentration of carotenoids was associated with risk of Age-Related Macular Degeneration (ARMD). The aim of this study was to determine carotenoid levels in serum and in different lipoprotein fractions in patients diagnosed for ARMD and in matched control group.
   Method: Thirty-four ARMD patients and 21 control subjects from Brest area (France) have been included to this study. Lipoproteins have been separated from serum by gradient density ultracentrifugation. We measured concentration of carotenoids and tocopherols in serum and in different lipoprotein fractions by HPLC.
   Results: No difference was observed between ARMD patients and control subjects in total serum carotenoids. Individual carotenoid levels showed that only lycopene was decreased significantly in serum, LDL and HDL fractions in patients (P < 0.05). Concentrations in serum and lipoparticle fractions of lutein and zeaxanthin, the major pigments present in macula were not modified between both groups.
   Conclusions: Lycopene, as liposoluble antioxidant nutrient, is the only carotenoid altered in ARMD patients. It cannot be excluded that this effect is related to different dietary habits, but we hypothesise that lower lycopene status could result also from specific antioxidant protection of lutein and zeaxanthin by lycopene. (c) 2005 Elsevier B.V. All rights reserved.
C1 INRA Clermont Ferrand Theix, Unite Malad Metab & Micronutriments, F-63122 St Genes Champanelle, France.
   Fac Med, Biochim Lab, F-29200 Brest, France.
   Univ Alep, Fac Pharm, Aleppo, Syria.
C3 INRAE; Universite de Bretagne Occidentale; Universite de Franche-Comte
RP Cardinault, N (通讯作者)，INRA Clermont Ferrand Theix, Unite Malad Metab & Micronutriments, F-63122 St Genes Champanelle, France.
EM Nicolas.Cardinault@clermont.inra.fr
RI COUDRAY, Charles/AGG-4757-2022; Mazur, Andre/AAG-9751-2020
OI Mazur, Andre/0000-0002-1067-5066; Coudray, Charles/0000-0003-2680-7796
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Agarwal S, 1998, LIPIDS, V33, P981, DOI 10.1007/s11745-998-0295-6
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Arnold JJ, 2000, BRIT MED J, V321, P741, DOI 10.1136/bmj.321.7263.741
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Brevik A, 2004, EUR J CLIN NUTR, V58, P1166, DOI 10.1038/sj.ejcn.1601945
   Cardinault N, 2003, EUR J NUTR, V42, P315, DOI 10.1007/s00394-003-0426-2
   Carroll YL, 1999, EUR J CLIN NUTR, V53, P644, DOI 10.1038/sj.ejcn.1600827
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   During A, 2000, BRIT J NUTR, V84, P117
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Frank J, 2003, J NUTR, V133, P3195, DOI 10.1093/jn/133.10.3195
   Grolier P, 2000, BRIT J NUTR, V84, P711
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 1997, AM J OPHTHALMOL, V123, P338, DOI 10.1016/S0002-9394(14)70129-1
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Stahl W, 1998, FEBS LETT, V427, P305, DOI 10.1016/S0014-5793(98)00434-7
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 34
TC 57
Z9 60
U1 1
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD JUL 1
PY 2005
VL 357
IS 1
BP 34
EP 42
DI 10.1016/j.cccn.2005.01.030
PG 9
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 946LK
UT WOS:000230573500003
PM 15963792
DA 2022-11-30
ER

PT J
AU Wang, XQ
   Zeng, LZ
   Chen, M
   Liu, LQ
AF Wang, Xiaoqin
   Zeng, Liuzhi
   Chen, Ming
   Liu, Longqian
TI Choroidal vascular changes in age-related macular degeneration A
   protocol for systematic review and meta-analysis
SO MEDICINE
LA English
DT Review
DE age-related macular degeneration; choroidal thickness; choroidal
   vascularity index; optical coherence tomography
ID HEALTHY EYES; VASCULOPATHY; BINARIZATION; THICKNESS; PATHOGENESIS;
   INDEX; AMD
AB Background: As an increasing age-related eye disease, age-related macular degeneration (AMD) is becoming a common cause of irreversible visual loss in elder population. The mechanism of AMD remains uncertain and covers a complex risk factors. Choroidal vascularity index (CVI) is a sensitive parameter obtained by enhanced depth imaging of optical coherence tomography which allows the choroid in more detail and accurate assessment in the pathogenesis of AMD. The objective of this current study is to evaluate choroidal structural alternations measured by CVI in AMD. Methods: We will review 4 English databases (PubMed, Embase, Cochrane Library, and Web of Science) from their inception until present to select eligible articles. English-language and case-control studies will be accepted. The data extraction content and quantitative analysis will be performed systematically by 2 independent authors. The primary outcome is the alternation of CVI in AMD. The secondary outcomes consist of choroidal thickness (CT), luminal area (LA), stromal area (SA), and total choroidal area (TCA). Subgroup analysis, sensitivity analysis, and publication bias will be performed to check the robustness of the pooled outcome data. Results: Changes of quantitative parameters such as CVI will be obtained in patients with AMD. Conclusion: This study will elucidate alternations of choroidal vascular and stromal component in AMD and provide robust evidence on the pathophysiology of AMD. Registration number: INPLASY.
C1 [Wang, Xiaoqin; Liu, Longqian] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Xiaoqin; Zeng, Liuzhi; Chen, Ming] Chendu First Peoples Hosp, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.
C3 Sichuan University
RP Liu, LQ (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610041, Sichuan, Peoples R China.
EM b.q15651@hotmail.com
FU Sichuan Provincial Health Commission Popularization Project [20PJ192]
FX This work is supported by the Sichuan Provincial Health Commission
   Popularization Project (no. 20PJ192).
CR Agrawal R, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2020.100829
   Agrawal R, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.4.7
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Broadhead GK, 2017, OPHTHALMIC RES, V58, P27, DOI 10.1159/000464447
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   Invernizzi A, 2018, INVEST OPHTH VIS SCI, V59, P3836, DOI 10.1167/iovs.18-23960
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kaarniranta K, 2020, PROG RETIN EYE RES, V1008, P58
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liu B, 2019, CLIN EXP OPHTHALMOL, V47, P631, DOI 10.1111/ceo.13467
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moher D, 2016, REV ESP NUTR HUM DIE, V20, P148, DOI 10.14306/renhyd.20.2.223
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ozcaliskan S, 2020, EUR J OPHTHALMOL, V30, P1512, DOI 10.1177/1120672120919341
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P371, DOI 10.4103/ijo.IJO_1173_18
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 31
TC 3
Z9 3
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV 13
PY 2020
VL 99
IS 46
AR e23200
DI 10.1097/MD.0000000000023200
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA OS0ED
UT WOS:000589836300067
PM 33181699
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gu, XY
   Yu, XB
   Dai, H
AF Gu, Xiaoya
   Yu, Xiaobing
   Dai, Hong
TI Intravitreal Injection of Ranibizumab for Treatment of Age-Related
   Macular Degeneration: Effects on Serum VEGF Concentration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; VEGF; ranibizumab
ID VERTEPORFIN PHOTODYNAMIC THERAPY; PHARMACOKINETICS; BEVACIZUMAB; EYE
AB Aims: To evaluate potential adverse ranibizumab-related systemic events through analysis of variations in serum levels of vascular endothelial growth factor (VEGF) in neovascular age-related macular degeneration (AMD) patients before and after a single intravitreal injection of ranibizumab.
   Methods: Thirty-nine patients with neovascular AMD and 39 healthy control subjects were enrolled in the study. Patients received a single intravitreal injection of ranibizumab (0.5 mg) in one eye. Venous blood was collected and placed in coagulation-promoting tubes 1 day before and on post-injection days 1, 3, 7 and 30. Serum concentrations of VEGF were measured by ELISA at each time point.
   Results: VEGF concentrations were 323.64 pg/ml in AMD patients and 392.94 pg/ml in control subjects before injection (p>0.05). VEGF significantly decreased to 304.65 pg/ml 1 day later (p<0.05) in AMD patients, then increased to 310.77 (p>0.05), 317.89 (p>0.05) and 311.79 pg/ml (p>0.05) on post-injection days 3, 7 and 30, respectively.
   Conclusion: No significant changes in serum levels of VEGF were found from 3 to 30 days following a single intravitreal ranibizumab injection. Although certain influences existed 24-h post-injection, effect(s) of a single intravitreal ranibizumab injection on the homeostasis of the cardiovascular system during such a brief period is unknown.
C1 [Gu, Xiaoya; Yu, Xiaobing; Dai, Hong] Minist Hlth, Beijing Hosp, Dept Ophthalmol, Beijing, Peoples R China.
C3 Beijing Hospital
RP Dai, H (通讯作者)，Minist Hlth, Beijing Hosp, Dept Ophthalmol, 1 Dahua Rd, Beijing, Peoples R China.
EM dai-hong@x263.net
FU central lab of Beijing Hospital of the Ministry of Health. Central
   Health Care Committee of China [BJ-2010-21]
FX This study was supported in part by the central lab of Beijing Hospital
   of the Ministry of Health. Central Health Care Committee of China
   (BJ-2010-21).
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Machalinska A, 2011, J OCUL PHARMACOL TH, V27, P471, DOI 10.1089/jop.2011.0091
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4
   Rouvas A, 2009, OPHTHALMOLOGICA, V223, P383, DOI 10.1159/000228590
   Wu ZQ, 2008, ANN ACAD MED SINGAP, V37, P591
NR 15
TC 22
Z9 25
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD MAY
PY 2014
VL 39
IS 5
BP 518
EP 521
DI 10.3109/02713683.2013.848899
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF5EL
UT WOS:000334736700010
PM 24215127
DA 2022-11-30
ER

PT J
AU Narendra, U
   Pauer, GJT
   Hagstrom, SA
AF Narendra, Umadevi
   Pauer, Gayle J. T.
   Hagstrom, Stephanie A.
TI Genetic analysis of complement factor H related 5, CFHR5, in patients
   with age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; RISK; POLYMORPHISM; PROTEIN-5;
   COMPONENT; DISEASE; VARIANT; DRUSEN
AB Purpose: To investigate the complement factor H related 5 (CFHR5) gene, encoding a member of the complement factor H family, for the presence of genetic polymorphisms or mutations associated with age-related macular degeneration (AMD).
   Methods: We screened 639 unrelated patients with AMD and 663 age-matched normal controls using direct genomic sequencing of the ten coding exons, along with the immediately flanking intronic DNA. The pathologic impact of the identified sequence variants were analyzed by computational methods using PolyPhen and PMut algorithms.
   Results: We identified five heterozygous sequence changes in CFHR5. Asp169Asp had a minor allele frequency of 0.001% in patients and 0.014% in controls (p<0.0001), while Arg356His had a minor allele frequency of 0.016% in patients and 0.007% in controls. Val379Leu, Met514Arg, and Cys568Ter were found only in normal controls. In silico analysis predicted Arg356His and Val379Leu to be neutral and benign. Met514Arg was predicted to be pathological and damaging to the function of the CFHR5 protein.
   Conclusions: No definitive pathogenic CFHR5 mutations have been found in any of 639 unrelated patients with AMD, indicating that sequence variations in CFHR5 do not play a major role in determining AMD susceptibility. However, our findings suggest a possible protective role for Asp169Asp. Further studies of different and larger populations of patient and control samples will be required to address this observation.
C1 [Narendra, Umadevi; Pauer, Gayle J. T.; Hagstrom, Stephanie A.] Cleveland Clin Fdn, Cole Eye Inst, Dept Ophthalm Res, Cleveland, OH 44195 USA.
   [Hagstrom, Stephanie A.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; Case Western Reserve University; Cleveland
   Clinic Foundation
RP Hagstrom, SA (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, Dept Ophthalm Res, Ophthalm Res I31,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM hagstrs@ccf.org
FU Karl Kirschgessner Foundation; Foundation Fighting Blindness; Research
   to Prevent Blindness Challenge Grant to the Cole Eye Institute; Research
   to Prevent Blindness Sybil B. Harrington Special Scholar Award; National
   Eye Institute [EY15638]; State of Ohio BRTT grant; NATIONAL EYE
   INSTITUTE [R24EY015638] Funding Source: NIH RePORTER
FX We thank the patients and their families for their participation and the
   ophthalmologists (Drs. H. Lewis, J. Sears, P. Kaiser, N. Waheed, R.
   Singh, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH)
   involved in recruiting patient samples. This work was supported by the
   Karl Kirschgessner Foundation, Foundation Fighting Blindness, a Research
   to Prevent Blindness Challenge Grant to the Cole Eye Institute, a
   Research to Prevent Blindness Sybil B. Harrington Special Scholar Award
   (SAH), National Eye Institute grant EY15638, and a State of Ohio BRTT
   grant.
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Chamary JV, 2006, NAT REV GENET, V7, P98, DOI 10.1038/nrg1770
   Chorley BN, 2008, MUTAT RES-REV MUTAT, V659, P147, DOI 10.1016/j.mrrev.2008.05.001
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrer-Costa C, 2005, BIOINFORMATICS, V21, P3176, DOI 10.1093/bioinformatics/bti486
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   McRae JL, 2001, J BIOL CHEM, V276, P6747, DOI 10.1074/jbc.M007495200
   Mersch B, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-369
   Monteferrante G, 2007, MOL IMMUNOL, V44, P1704, DOI 10.1016/j.molimm.2006.08.004
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Murphy B, 2002, AM J KIDNEY DIS, V39, P24, DOI 10.1053/ajkd.2002.29873
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Silva AL, 2009, FEBS LETT, V583, P499, DOI 10.1016/j.febslet.2008.12.058
   Stone EM, 2007, ANNU REV MED, V58, P477, DOI 10.1146/annurev.med.58.111405.133335
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
NR 25
TC 20
Z9 22
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 10
PY 2009
VL 15
IS 72-75
BP 731
EP 736
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 450OE
UT WOS:000266409900004
PM 19365580
DA 2022-11-30
ER

PT J
AU Jackson, GR
   McGwin, G
   Phillips, JM
   Klein, R
   Owsley, C
AF Jackson, GR
   McGwin, G
   Phillips, JM
   Klein, R
   Owsley, C
TI Impact of aging and age-related maculopathy on inactivation of the
   a-wave of the rod-mediated electroretinogram
SO VISION RESEARCH
LA English
DT Article
DE electroretinogram; rod photoreceptor; phototransduction; aging;
   age-related maculopathy
ID FACTOR-H POLYMORPHISM; DARK-ADAPTATION; MACULAR DEGENERATION;
   PHOTORESPONSE; RECOVERY; PHOTORECEPTORS; CONE; PHOTOTRANSDUCTION;
   PROGRESSION; ACTIVATION
AB This study examined the impact of aging and age-related maculopathy (ARM) on the inactivation of phototransduction in rod photoreceptors by measuring the recovery of the a-wave using a paired flash electroretinogram technique. Measurements were made on 32 older adults in normal retinal health, 25 with early ARM, 7 with late ARM, and 20 young adults for comparison purposes. ARM presence and severity were defined by the Wisconsin Age-Related Maculopathy Grading System based on grading of fundus photographs. The inactivation of rod phototransduction exhibited an aging-related slowing. Those with early ARM did not exhibit inactivation slowing over and above what would be expected based on normal retinal aging, Persons in the late stages of ARM exhibited dramatic slowing in inactivation kinetics. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol & Int Hlth, Birmingham, AL USA.
   Univ Alabama Birmingham, Sch Med, Dept Surg, Sect Trauma Burns & Crit Care, Birmingham, AL USA.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Wisconsin System; University of Wisconsin Madison
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
EM owsley@uab.edu
RI Owsley, Cynthia/B-7986-2014
FU NEI NIH HHS [R21-EY14071] Funding Source: Medline; NIA NIH HHS
   [R01-AG04212] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R21EY014071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG004212] Funding Source: NIH RePORTER
CR BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529
   BIRCH DG, 1995, INVEST OPHTH VIS SCI, V36, P1603
   Birch DG, 2002, ARCH OPHTHALMOL-CHIC, V120, P1045
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601
   Cideciyan AV, 1996, VISION RES, V36, P2609, DOI 10.1016/0042-6989(95)00327-4
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Derwent JJK, 2004, INVEST OPHTH VIS SCI, V45, P2447, DOI 10.1167/iovs.03-1178
   DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fulton AB, 1999, INVEST OPHTH VIS SCI, V40, P1878
   Fulton AB, 2003, VISION RES, V43, P3081, DOI 10.1016/j.visres.2003.09.003
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hansen RM, 2005, INVEST OPHTH VIS SCI, V46, P764, DOI 10.1167/iovs.04-0257
   HOOD DC, 1993, VISUAL NEUROSCI, V10, P857, DOI 10.1017/S0952523800006076
   Jackson GR, 2005, MACULAR DEGENERATION, P45, DOI 10.1007/3-540-26977-0_3
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LAMB TD, 1981, VISION RES, V21, P1773, DOI 10.1016/0042-6989(81)90211-X
   LAMB TD, 1980, NATURE, V287, P349, DOI 10.1038/287349a0
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   National Advisory Eye Council, 1999, VIS RES NAT PLAN 199
   NORREN DV, 1974, VISION RES, V14, P1237, DOI 10.1016/0042-6989(74)90222-3
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pepperberg DR, 1996, J OPT SOC AM A, V13, P586, DOI 10.1364/JOSAA.13.000586
   POKORNY J, 1987, APPL OPTICS, V26, P1437, DOI 10.1364/AO.26.001437
   Rushton W.A.H., 1955, Optica Acta, V1, P183
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Smith NP, 1997, VISION RES, V37, P2943, DOI 10.1016/S0042-6989(97)00094-1
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 52
TC 27
Z9 29
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD APR
PY 2006
VL 46
IS 8-9
BP 1422
EP 1431
DI 10.1016/j.visres.2005.09.003
PG 10
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 030VW
UT WOS:000236664200028
PM 16242751
OA Bronze
DA 2022-11-30
ER

PT J
AU Gerhardy, S
   Ultsch, M
   Tang, WJ
   Green, E
   Holden, JK
   Li, W
   Estevez, A
   Arthur, C
   Tom, I
   Rohou, A
   Kirchhofer, D
AF Gerhardy, Stefan
   Ultsch, Mark
   Tang, Wanjian
   Green, Evan
   Holden, Jeffrey K.
   Li, Wei
   Estevez, Alberto
   Arthur, Chris
   Tom, Irene
   Rohou, Alexis
   Kirchhofer, Daniel
TI Allosteric inhibition of HTRA1 activity by a conformational lock
   mechanism to treat age-related macular degeneration
SO NATURE COMMUNICATIONS
LA English
DT Article
ID SERINE-PROTEASE HTRA1; GEOGRAPHIC ATROPHY SECONDARY; MOLECULAR-DYNAMICS;
   STRUCTURAL INSIGHTS; BINDING FRAGMENT; ANTIBODY; INCREASES;
   POLYMORPHISM; PROGRESSION; ASSOCIATION
AB The trimeric serine protease HTRA1 is a genetic risk factor associated with geographic atrophy (GA), a currently untreatable form of age-related macular degeneration. Here, we describe the allosteric inhibition mechanism of HTRA1 by a clinical Fab fragment, currently being evaluated for GA treatment. Using cryo-EM, X-ray crystallography and biochemical assays we identify the exposed LoopA of HTRA1 as the sole Fab epitope, which is approximately 30 angstrom away from the active site. The cryo-EM structure of the HTRA1:Fab complex in combination with molecular dynamics simulations revealed that Fab binding to LoopA locks HTRA1 in a non-competent conformational state, incapable of supporting catalysis. Moreover, grafting the HTRA1-LoopA epitope onto HTRA2 and HTRA3 transferred the allosteric inhibition mechanism. This suggests a conserved conformational lock mechanism across the HTRA family and a critical role of LoopA for catalysis, which was supported by the reduced activity of HTRA1-3 upon LoopA deletion or perturbation. This study reveals the long-range inhibition mechanism of the clinical Fab and identifies an essential function of the exposed LoopA for activity of HTRA family proteases.
   The protease HTRA1 is a genetic risk factor for geographic atrophy. Here, Gerhardy et al. describe its inhibition by a clinical Fab, whose binding locks it in an inactive state. The mechanism identifies an essential function of LoopA with this protease family.
C1 [Gerhardy, Stefan; Tang, Wanjian; Holden, Jeffrey K.; Li, Wei; Kirchhofer, Daniel] Genentech Inc, Dept Early Discovery Biochem, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.
   [Ultsch, Mark; Green, Evan; Estevez, Alberto; Arthur, Chris; Rohou, Alexis] Genentech Inc, Dept Struct Biol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.
   [Tom, Irene] Genentech Inc, Dept OMNI Biomarker Dev, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech
RP Kirchhofer, D (通讯作者)，Genentech Inc, Dept Early Discovery Biochem, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.
EM dak@gene.com
OI Tang, Wanjian/0000-0001-7374-6442; Gerhardy, Stefan/0000-0003-1826-5907
FU U.S. Department of Energy, Office of Science, Office of Basic Energy
   Sciences [DE-AC02-76SF00515]; DOE Office of Biological and Environmental
   Research; National Institutes of Health, National Institute of General
   Medical Sciences [P30GM133894]
FX We would like to thank Aimin Song and Jeffrey Tom for synthesis of
   peptides, the BMR group at Genentech for help with construct design and
   expression of proteins and Saeed Izadi for support and input on the MD
   simulations. We thank Bob Lazarus and Claudio Ciferri for helpful
   discussions on the manuscript, Andrea Cochran for advice on the
   ss-hairpin motif construct and Dick Vandlen for preparing the
   scFv15H6.v4. Use of the Stanford Synchrotron Radiation Lightsource, SLAC
   National Accelerator Laboratory, is supported by the U.S. Department of
   Energy, Office of Science, Office of Basic Energy Sciences under
   Contract No. DE-AC02-76SF00515. The SSRL Structural Molecular Biology
   Program is supported by the DOE Office of Biological and Environmental
   Research, and by the National Institutes of Health, National Institute
   of General Medical Sciences (P30GM133894).
CR Acharya S, 2020, BIOCHEM J, V477, P407, DOI 10.1042/BCJ20190706
   Afonine PV, 2018, ACTA CRYSTALLOGR D, V74, P814, DOI 10.1107/S2059798318009324
   Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408
   Blouse GE, 2009, J BIOL CHEM, V284, P4647, DOI 10.1074/jbc.M804922200
   Bricogne G, 2017, BUSTER VERSION 2116
   Cabrera AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14208-z
   Chaganti LK, 2013, FASEB J, V27, P3054, DOI 10.1096/fj.13-227256
   Cheatham T.E., 2019, AMBER 2019
   Chen PH, 2019, AM J PATHOL, V189, P1423, DOI 10.1016/j.ajpath.2019.03.013
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2009, CURR CANCER DRUG TAR, V9, P451, DOI 10.2174/156800909788486704
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Ciferri C, 2015, BIOCHEM J, V472, P169, DOI 10.1042/BJ20150601
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Clausen T, 2011, NAT REV MOL CELL BIO, V12, P152, DOI 10.1038/nrm3065
   Cochran AG, 2001, P NATL ACAD SCI USA, V98, P5578, DOI 10.1073/pnas.091100898
   Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574
   Dere E, 2021, TOXICOL PATHOL, V49, P610, DOI 10.1177/0192623320976095
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Drag M, 2010, NAT REV DRUG DISCOV, V9, P690, DOI 10.1038/nrd3053
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EIGENBROT C, 1993, J MOL BIOL, V229, P969, DOI 10.1006/jmbi.1993.1099
   Eigenbrot C, 2012, STRUCTURE, V20, P1040, DOI 10.1016/j.str.2012.03.021
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Ganesan R, 2010, BIOCHEM J, V430, P179, DOI 10.1042/BJ20100634
   Ganesan R, 2009, STRUCTURE, V17, P1614, DOI 10.1016/j.str.2009.09.014
   Glaza P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131142
   Goo HG, 2017, CURR PROTEIN PEPT SC, V18, P746, DOI 10.2174/1389203717666160311115750
   Grant BJ, 2021, PROTEIN SCI, V30, P20, DOI 10.1002/pro.3923
   Grant T, 2018, ELIFE, V7, DOI 10.7554/eLife.35383
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   HARTLEY BS, 1970, PHILOS T ROY SOC B, V257, P77, DOI 10.1098/rstb.1970.0010
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hopkins CW, 2015, J CHEM THEORY COMPUT, V11, P1864, DOI 10.1021/ct5010406
   Hou YZ, 2013, ARTHRITIS RHEUM-US, V65, P2835, DOI 10.1002/art.38124
   Huang PS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024109
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jiang LG, 2021, FASEB J, V35, DOI 10.1096/fj.202002139RR
   Jiang LG, 2013, BIOCHEM J, V449, P161, DOI 10.1042/BJ20121132
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Khanani AM, 2021, AM J OPHTHALMOL, V232, P49, DOI 10.1016/j.ajo.2021.06.017
   Kirchhofer D, 2018, EXTRACELLULAR TARGETING OF CELL SIGNALING IN CANCER: STRATEGIES DIRECTED AT MET AND RON RECEPTOR TYROSINE KINASE PATHWAYS, P229
   Koschubs T, 2012, BIOCHEM J, V442, P483, DOI 10.1042/BJ20111317
   Kromann-Hansen T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03457-7
   Lehner A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060359
   Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795
   Lv QY, 2018, BIOCHEM BIOPH RES CO, V503, P2918, DOI 10.1016/j.bbrc.2018.08.070
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   Maun HR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20143-x
   Maun HR, 2019, CELL, V179, P417, DOI 10.1016/j.cell.2019.09.009
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Merdanovic M, 2020, P NATL ACAD SCI USA, V117, P1414, DOI 10.1073/pnas.1918721117
   Merski M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.487
   Meyerson JR, 2014, SCI REP-UK, V4, DOI 10.1038/srep07084
   Milner JM, 2008, ARTHRITIS RHEUM-US, V58, P3644, DOI 10.1002/art.24046
   Nozaki H, 2016, NEUROLOGY, V86, P1964, DOI 10.1212/WNL.0000000000002694
   Pettersen EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/pro.3943
   Poepsel S, 2015, NAT CHEM BIOL, V11, P862, DOI [10.1038/NCHEMBIO.1931, 10.1038/nchembio.1931]
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Schaefer M, 2019, J MOL BIOL, V431, P4817, DOI 10.1016/j.jmb.2019.09.008
   Scheres SHW, 2012, J MOL BIOL, V415, P406, DOI 10.1016/j.jmb.2011.11.010
   Skorko-Glonek J, 2013, CURR PHARM DESIGN, V19, P977, DOI 10.2174/1381612811319060003
   Tom I, 2020, P NATL ACAD SCI USA, V117, P9952, DOI 10.1073/pnas.1917608117
   Truebestein L, 2011, NAT STRUCT MOL BIOL, V18, P386, DOI 10.1038/nsmb.2013
   Tsuchiya A, 2005, BONE, V37, P323, DOI 10.1016/j.bone.2005.03.015
   Uemura M, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00693
   Wenta T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101112
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Wu J, 2007, ARTHRITIS RHEUM-US, V56, P3675, DOI 10.1002/art.22876
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhang YN, 2017, NAT STRUCT MOL BIOL, V24, P848, DOI 10.1038/nsmb.3453
   Zurawa-Janicka D, 2017, ARCH BIOCHEM BIOPHYS, V621, P6, DOI 10.1016/j.abb.2017.04.004
NR 80
TC 0
Z9 0
U1 5
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD SEP 5
PY 2022
VL 13
IS 1
AR 5222
DI 10.1038/s41467-022-32760-9
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 4I1PN
UT WOS:000850348400005
PM 36064790
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, Y
   Zhao, GQ
AF Zhang, Yu
   Zhao, Guiqiu
TI Association Between Monocyte Chemotactic Protein 1 Variants and
   Age-Related Macular Degeneration Onset Among Chinese People
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Amplified Fragment Length Polymorphism Analysis; Macular Degeneration;
   Receptors, CCR2
ID POLYMORPHISM; MCP-1; RISK; INFLAMMATION
AB Background: We assessed the potential association between monocyte chemotactic protein 1 (MCP-1) variants (rs1024611 and rs3760396) and age-related macular degeneration (AMD) susceptibility among Chinese Han people.
   Material/Methods: Our research included 129 AMD patients and 131 healthy controls. Genotyping for MCP-1 variants was per- formed in the 2 groups, and genotype and allele distributions were checked between groups by chi(2) analysis. Odds ratio (OR) and 95% confidence interval (CI) reflected the potential association between MCP-1 variants and AMD risk. The linkage disequilibrium of polymorphisms was detected using Haploview.
   Results: Significant differences in rs1024611 genotype distributions were detected between the 2 groups, and homozygous carriers with GG genotype had higher AMD incidence (P<0.05, OR=2.650, 95% CI=1.127-6.231). The rs1024611 G allele frequency was significantly higher in AMD patients, suggesting that the G allele promotes AMD onset (P<0.05, OR=1.447, 95% CI=1.013-2.068). Strong linkage disequilibrium was found between rs1024611 and rs3760396, and haplotype A(rs1024611)-C-rs3760396 was significantly associated with decreased risk of AMD (P=0.001, OR=0.502, 95% CI=0.335-0.752).
   Conclusions: MCP-1 rs1024611 variant appears to contribute to risk of AMD in the Chinese Han population, and the inter- action of MCP-1 polymorphisms may also influence individual susceptibility to AMD.
C1 [Zhang, Yu] Qingdao Municipal Hosp, Dept Opthalmol, Qingdao, Shandong, Peoples R China.
   [Zhao, Guiqiu] Qingdao Univ, Affiliated Hosp, Dept Opthalmol, Qingdao, Shandong, Peoples R China.
C3 Qingdao Municipal Hospital; Qingdao University
RP Zhao, GQ (通讯作者)，Qingdao Univ, Affiliated Hosp, Dept Opthalmol, Qingdao, Shandong, Peoples R China.
EM llmcbvvq@163.com
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   An QY, 2018, INT IMMUNOPHARMACOL, V65, P119, DOI 10.1016/j.intimp.2018.09.011
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Bonyadi M, 2017, OPHTHALMIC GENET, V38, P365, DOI 10.1080/13816810.2016.1242019
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Desmettre TJ, 2018, J FR OPHTALMOL, V41, pE407, DOI 10.1016/j.jfo.2018.09.001
   Dong L, 2014, GRAEF ARCH CLIN EXP, V252, P1921, DOI 10.1007/s00417-014-2651-1
   Duvvari MR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152047
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lee Hankil, 2017, Korean J Ophthalmol, V31, P557, DOI 10.3341/kjo.2017.0025
   Li X, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2328-8
   Liu Y, 2017, VIRUS RES, V240, P190, DOI 10.1016/j.virusres.2017.08.013
   Ma L, 2016, SCI REP-UK, V6, DOI 10.1038/srep19718
   Mao B, 2013, GENET TEST MOL BIOMA, V17, P857, DOI 10.1089/gtmb.2013.0318
   Martel-Pelletier J, 2019, OSTEOARTHR CARTILAGE, V27, P1163, DOI 10.1016/j.joca.2019.04.016
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Pham MHT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049498
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schlottmann PG, 2017, ASIA-PAC J OPHTHALMO, V6, P514, DOI 10.22608/APO.2017258
   Schwartz SG, 2017, CURR PHARM DESIGN, V23, P547, DOI 10.2174/1381612822666161208114847
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sharma NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193423
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Silva MR, 2016, SCI REP-UK, V6, DOI 10.1038/srep32288
   Su N, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011232, 10.1097/md.0000000000011232]
   Umare VD, 2017, CYTOKINE, V96, P189, DOI 10.1016/j.cyto.2017.04.016
NR 31
TC 1
Z9 1
U1 0
U2 1
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD JUN 2
PY 2020
VL 26
AR e921584
DI 10.12659/MSM.921584
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA LT8MG
UT WOS:000537321600001
PM 32485729
OA Green Published
DA 2022-11-30
ER

PT J
AU Romano, GL
   Platania, CBM
   Drago, F
   Salomone, S
   Ragusa, M
   Barbagallo, C
   Di Pietro, C
   Purrello, M
   Reibaldi, M
   Avitabile, T
   Longo, A
   Bucolo, C
AF Romano, Giovanni L.
   Platania, Chiara B. M.
   Drago, Filippo
   Salomone, Salvatore
   Ragusa, Marco
   Barbagallo, Cristina
   Di Pietro, Cinzia
   Purrello, Michele
   Reibaldi, Michele
   Avitabile, Teresio
   Longo, Antonio
   Bucolo, Claudio
TI Retinal and Circulating miRNAs in Age-Related Macular Degeneration: An
   In vivo Animal and Human Study
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE age relatedmacular degeneration; retinal diseases; Alzheimer's disease;
   amyloid beta; miRN
ID PIGMENT EPITHELIAL-CELLS; C-REACTIVE PROTEIN; A-BETA OLIGOMERS;
   AMYLOID-BETA; ALZHEIMERS-DISEASE; POTENTIAL BIOMARKERS; VITREOUS-HUMOR;
   MICRORNAS; EXPRESSION; MARKERS
AB Age related macular degeneration (AMD) is the leading cause of blindness among people aged 50 and over. Retinal deposition of amyloid-beta (A beta) aggregates in AMD patients has suggested a potential link between AMD and Alzheimer's disease (AD). We have evaluated the differential retinal expression profile of miRNAs in a rat model of AMD elicited by A b. A serum profile of miRNAs in AMD patients has been also assessed using single TaqMan assay. Analysis of retina from rats intravitreally injected with A b revealed that miR-27a, miR-146a, and miR-155 were up-regulated in comparison to control rats. Seven miRNA (miR-9, miR-23a, miR-27a, miR-34a, miR-126, miR-146a, and miR-155) have been found to be dysregulated in serum of AMD patients in comparison to control group. Analysis of pathways has revealed that dysregulated miRNAs, both in the AMD animal model and in AMD patients, can target genes regulating pathways linked to neurodegeneration and inflammation, reinforcing the hypothesis that AMD is a protein misfolding disease similar to AD. In fact, miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-155 have been found to be dysregulated both in AMD and AD. In conclusion, we suggest that miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-155 represent potential biomarkers and new pharmacological targets for AMD.
C1 [Romano, Giovanni L.; Platania, Chiara B. M.; Drago, Filippo; Salomone, Salvatore; Bucolo, Claudio] Univ Catania, Dept Biomed & Biotechnol Sci, Pharmacol Sect, Catania, Italy.
   [Ragusa, Marco; Barbagallo, Cristina; Di Pietro, Cinzia; Purrello, Michele] Univ Catania, Dept Biomed & Biotechnol Sci, Biomol Genome & Complex Syst BioMedicine Unit, Sect Biol & Genet G Sichel, Catania, Italy.
   [Reibaldi, Michele; Avitabile, Teresio; Longo, Antonio] Univ Catania, Sch Med, Dept Ophthalmol, Catania, Italy.
C3 University of Catania; University of Catania; University of Catania
RP Bucolo, C (通讯作者)，Univ Catania, Dept Biomed & Biotechnol Sci, Pharmacol Sect, Catania, Italy.
EM claudio.bucolo@unict.it
RI Reibaldi, Michele/AAL-1113-2021; Drago, Francesco/H-7563-2019;
   Avitabile, Teresio/AAC-6076-2022; Barbagallo, Cristina/AAA-8871-2022;
   Longo, Antonio/AAC-6092-2022; Ragusa, Marco/D-7691-2010; Platania,
   Chiara BM/AHE-1140-2022; Romano, Giovanni Luca/AAS-9208-2020; Drago,
   Filippo/AAC-5090-2022
OI Barbagallo, Cristina/0000-0002-6769-4516; Ragusa,
   Marco/0000-0002-4282-920X; Romano, Giovanni Luca/0000-0002-8722-7835;
   LONGO, Antonio/0000-0002-9525-1800; Platania, Chiara Bianca
   Maria/0000-0002-8630-5993; Bucolo, Claudio/0000-0002-4879-4140
CR Anderson PJB, 2008, CLIN OPHTHALMOL, V2, P801
   Arora A, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-1
   Bai YY, 2011, EXP MOL PATHOL, V91, P471, DOI 10.1016/j.yexmp.2011.04.016
   Barghorn S, 2005, J NEUROCHEM, V95, P834, DOI 10.1111/j.1471-4159.2005.03407.x
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Caraci F, 2008, NEUROBIOL DIS, V30, P234, DOI 10.1016/j.nbd.2008.01.007
   Caraci F, 2015, SCI REP-UK, V5, DOI 10.1038/srep11252
   Caraci F, 2012, EUR NEUROPSYCHOPHARM, V22, P281, DOI 10.1016/j.euroneuro.2011.08.006
   Caraci F, 2012, CELL TISSUE RES, V347, P291, DOI 10.1007/s00441-011-1230-6
   Caraci F, 2011, CNS NEUROSCI THER, V17, P237, DOI 10.1111/j.1755-5949.2009.00115.x
   Chen JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116549
   Creemers EE, 2012, CIRC RES, V110, P483, DOI 10.1161/CIRCRESAHA.111.247452
   Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Denk J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126423
   Dentchev T, 2003, MOL VIS, V9, P184
   Devlin C, 2011, IUBMB LIFE, V63, P94, DOI [10.1002/iub.427, 10.1002/iub.00427]
   Ertekin S, 2014, MOL VIS, V20, P1057
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Frigerio CS, 2013, NEUROLOGY, V81, P2103, DOI 10.1212/01.wnl.0000437306.37850.22
   Galimberti D, 2014, J ALZHEIMERS DIS, V42, P1261, DOI 10.3233/JAD-140756
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Giuffrida ML, 2012, MOL NEUROBIOL, V46, P605, DOI 10.1007/s12035-012-8313-6
   Gontier G, 2015, J NEUROSCI, V35, P11500, DOI 10.1523/JNEUROSCI.0343-15.2015
   Guedes JR, 2014, HUM MOL GENET, V23, P6286, DOI 10.1093/hmg/ddu348
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Han XJ, 2016, CELL MOL NEUROBIOL, V36, P851, DOI 10.1007/s10571-015-0268-5
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Hou Q, 2013, INVEST OPHTH VIS SCI, V54, P6481, DOI 10.1167/iovs.13-11873
   Howlett DR, 2011, EXP BRAIN RES, V214, P185, DOI 10.1007/s00221-011-2819-4
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kiko T, 2014, J ALZHEIMERS DIS, V39, P253, DOI 10.3233/JAD-130932
   Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5
   Kutty RK, 2013, MOL VIS, V19, P737
   Kutty RK, 2010, MOL VIS, V16, P1475
   Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x
   Lau P, 2013, EMBO MOL MED, V5, P1613, DOI 10.1002/emmm.201201974
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lopez-Ramirez MA, 2014, FASEB J, V28, P2551, DOI 10.1096/fj.13-248880
   Lugli G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139233
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Maes OC, 2009, CURR GENOMICS, V10, P154, DOI 10.2174/138920209788185252
   Matsui A, 2016, OPHTHALMIC RES, V55, P37, DOI 10.1159/000440885
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Muller M, 2014, NEUROBIOL AGING, V35, P152, DOI 10.1016/j.neurobiolaging.2013.07.005
   Pascolini D, 2010, BR J OPHTHALMOL, V96, P614, DOI DOI 10.1136/BJ0PHTHALM0L-2011-300539
   Ragusa M, 2015, CANCER BIOL THER, V16, P1387, DOI 10.1080/15384047.2015.1046021
   Romano GL, 2015, PROG BRAIN RES, V220, P217, DOI 10.1016/bs.pbr.2015.04.013
   Sajan M, 2016, DIABETES, V65, P1892, DOI 10.2337/db15-1428
   Saxena K, 2015, INVEST OPHTH VIS SCI, V56, P1820, DOI 10.1167/iovs.14-15449
   Schonrock N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011070
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Smit-McBride Z, 2014, MOL VIS, V20, P1569
   Sonntag KC, 2012, EXP NEUROL, V235, P427, DOI 10.1016/j.expneurol.2011.11.035
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Takach O, 2015, NEUROBIOL AGING, V36, P1378, DOI 10.1016/j.neurobiolaging.2014.11.018
   Tea M, 2013, MOL VIS, V19, P501
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405
   Weilner S, 2013, EXP GERONTOL, V48, P626, DOI 10.1016/j.exger.2012.11.017
   Yan LL, 2015, J BIOL CHEM, V290, P23264, DOI 10.1074/jbc.M115.646950
   Yorston David, 2006, Community Eye Health, V19, P4
   Zhuang Z, 2015, MOL VIS, V21, P1173
NR 74
TC 68
Z9 69
U1 2
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 30
PY 2017
VL 8
AR 168
DI 10.3389/fphar.2017.00168
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EQ0KW
UT WOS:000397761100002
PM 28424619
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Detaram, HD
   Mitchell, P
   Russell, J
   Burlutsky, G
   Liew, G
   Gopinath, B
AF Dharamdasani Detaram, Harshil
   Mitchell, Paul
   Russell, Joanna
   Burlutsky, George
   Liew, Gerald
   Gopinath, Bamini
TI Dietary zinc intake is associated with macular fluid in neovascular
   age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; epidemiology; micronutrient
ID CLINICAL-TRIAL; VISUAL-ACUITY; ORAL ZINC; SUPPLEMENTATION; RANIBIZUMAB;
   THICKNESS
AB Importance Numerous dietary factors have been shown to reduce progression from early to late age-related macular degeneration (AMD), however, little is known on their impact in patients diagnosed with late-stage disease. Background To determine whether a dietary intake high in antioxidants and zinc, fruits, vegetables and fish is associated with favourable clinical outcomes in patients with neovascular AMD (nAMD) undergoing anti-vascular endothelial growth factor therapy. Design Cross-sectional study carried out at a private ophthalmology clinic. Participants Five hundred forty-seven participants with nAMD. Methods Diet was determined using a validated food frequency questionnaire. Presence of intra-retinal and sub-retinal fluid (IRF, SRF), pigment epithelial detachment and central macular thickness (CMT) were recorded from ocular coherence tomography images. Main Outcome Measures Fluid presence, mean CMT and visual acuity. Results Participants with daily zinc intake below (n = 91) vs above (n = 333) 8.1 mg had greater odds of SRF being present, multivariable-adjusted odds ratio (OR) of 0.56 (95% CI 0.36-0.96). This association was stronger in persons with at least 6 months of treatment, OR of 0.32 (95% CI 0.14-0.75). In the entire cohort, participants in the lowest or first quartile compared to those in the upper three quartiles of zinc intake combined had significantly greater mean CMT (254.81 mu m vs 232.15 mu m, respectively, multivariable-adjusted P = .03). Conclusions and Relevance Low dietary zinc intake was associated with a greater likelihood of SRF presence, particularly in those treated for at least 6 months, and increased macular thickness in treated eyes with nAMD.
C1 [Dharamdasani Detaram, Harshil; Mitchell, Paul; Burlutsky, George; Liew, Gerald; Gopinath, Bamini] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
   [Dharamdasani Detaram, Harshil; Mitchell, Paul; Burlutsky, George; Liew, Gerald; Gopinath, Bamini] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Russell, Joanna] Univ Wollongong, Sch Hlth & Soc, Fac Social Sci, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Wollongong
RP Gopinath, B (通讯作者)，Univ Sydney, Dept Ophthalmol, Westmead Hosp, Westmead Inst Med Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.; Gopinath, B (通讯作者)，Univ Sydney, Ctr Vis Res, Westmead Hosp, Westmead Inst Med Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Liew, Gerald/AAB-6870-2022
OI Dharamdasani Detaram, Harshil/0000-0002-6095-5963
FU Macular Disease Foundation Australia
FX Macular Disease Foundation Australia
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], NUTTAB 2010 AUSTR FO
   [Anonymous], 2006, NUTR REF VAL AUSTR N
   Aoki A, 2016, SCI REP, V6, P1
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Evans Jennifer, 2014, Community Eye Health, V27, P48
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Gopinath B, 2017, BRIT J OPHTHALMOL, V101, P1027, DOI 10.1136/bjophthalmol-2016-309490
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   Joussen AM, 2009, DTSCH ARZTEBL INT, V106, P312, DOI 10.3238/arztebl.2009.0312
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Miceli MV, 1999, INVEST OPHTH VIS SCI, V40, P1238
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Ou WC, 2017, AM J OPHTHALMOL, V180, P8, DOI 10.1016/j.ajo.2017.05.014
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Stevens R, 2017, BRIT J VISUAL IMPA, V35, P185, DOI 10.1177/0264619616683989
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Ugarte M, 2014, METALLOMICS, V6, P189, DOI 10.1039/c3mt00291h
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   ULM K, 1991, STAT MED, V10, P341, DOI 10.1002/sim.4780100306
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
NR 37
TC 7
Z9 7
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2020
VL 48
IS 1
BP 61
EP 68
DI 10.1111/ceo.13644
EA OCT 2019
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LP3HG
UT WOS:000492683300001
PM 31593342
DA 2022-11-30
ER

PT J
AU Prasuhn, M
   Hillers, C
   Rommel, F
   Riemekasten, G
   Heidecke, H
   Nassar, K
   Ranjbar, M
   Grisanti, S
   Tura, A
AF Prasuhn, Michelle
   Hillers, Caroline
   Rommel, Felix
   Riemekasten, Gabriela
   Heidecke, Harald
   Nassar, Khaled
   Ranjbar, Mahdy
   Grisanti, Salvatore
   Tura, Aysegul
TI Specific Autoantibodies in Neovascular Age-Related Macular Degeneration:
   Evaluation of Morphological and Functional Progression over Five Years
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Article
DE autoantibodies; age-related macular degeneration; biomarkers;
   AT1-receptor; PAR1; VEGF-A; VEGF-B; VEGF-receptor 2
ID ENDOTHELIAL GROWTH-FACTOR; II TYPE-1 RECEPTOR; PLASMA-LEVELS;
   INTRAVITREAL INJECTION; BEVACIZUMAB; ANTIBODIES; DISEASE
AB (1) Background: Altered levels of autoantibodies (aab) and their networks have been identified as biomarkers for various diseases. Neovascular age-related macular degeneration (nAMD) is a leading cause for central vision loss worldwide with highly variable inter- and intraindividual disease courses. Certain aab networks could help in daily routine to identify patients with a high disease activity who need to be visited and treated more regularly. (2) Methods: We analyzed levels of aab against Angiotensin II receptor type 1 (AT1-receptor), Protease-activated receptors (PAR1), vascular endothelial growth factor (VEGF) -A, VEGF-B, and VEGF-receptor 2 in sera of 164 nAMD patients. In a follow-up period of five years, we evaluated changes in functional and morphological characteristics. Using correlation analyses, multiple regression models, and receiver operator characteristics, we assessed whether the five aab have a clinical significance as biomarkers that correspond to the clinical properties. (3) Results: Neither the analyzed aab individually nor taken together as a network showed statistically significant results that would allow us to draw conclusions on the clinical five-year course in nAMD patients. (4) Conclusions: The five aab that we analyzed do not correspond to the clinical five-year course of nAMD patients. However, larger, prospective studies should reevaluate different and more aab to gain deeper insights.
C1 [Prasuhn, Michelle; Hillers, Caroline; Rommel, Felix; Nassar, Khaled; Ranjbar, Mahdy; Grisanti, Salvatore; Tura, Aysegul] Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Ophthalmol, D-23562 Lubeck, Germany.
   [Prasuhn, Michelle; Hillers, Caroline; Rommel, Felix; Ranjbar, Mahdy] Lab Angiogenesis & Ocular Cell Transplantat, D-23562 Lubeck, Germany.
   [Riemekasten, Gabriela] Univ Lubeck, Univ Hosp Schleswig Holstein, Clin Rheumatol & Clin Immunol, D-23562 Lubeck, Germany.
   [Heidecke, Harald] CellTrend GmbH, D-14943 Luckenwalde, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Lubeck; University of Kiel; Schleswig Holstein University Hospital;
   University of Lubeck
RP Prasuhn, M (通讯作者)，Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Ophthalmol, D-23562 Lubeck, Germany.; Prasuhn, M (通讯作者)，Lab Angiogenesis & Ocular Cell Transplantat, D-23562 Lubeck, Germany.
EM michelle.prasuhn@uksh.de; caroline.hillers@student.uni-luebeck.de;
   felix.rommel@uksh.de; Gabriela.Riemekasten@uksh.de;
   heidecke@celltrend.de; khaled.nassar@uksh.de; eye.research101@gmail.com;
   Salvatore.Grisanti@uksh.de; Ayseguel.Tura@uksh.de
RI Rommel, Felix/AAK-7582-2020
OI Rommel, Felix/0000-0003-2584-0607; Prasuhn, Michelle/0000-0001-7304-2963
CR Adamus G, 2017, AUTOIMMUN REV, V16, P231, DOI 10.1016/j.autrev.2017.01.005
   Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Banasik M, 2014, TRANSPL P, V46, P2618, DOI 10.1016/j.transproceed.2014.09.029
   Baxter JM, 2016, EYE, V30, P698, DOI 10.1038/eye.2016.18
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Duncan MB, 2009, MOL INTERV, V9, P168, DOI 10.1124/mi.9.4.4
   Imai N, 2007, LAB INVEST, V87, P189, DOI 10.1038/labinvest.3700504
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Nagele EP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060726
   Philogene MC, 2019, HUM IMMUNOL, V80, P561, DOI 10.1016/j.humimm.2019.04.012
   Plotz PH, 2003, NAT REV IMMUNOL, V3, P73, DOI 10.1038/nri976
   Riemekasten G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.564526
   Riemekasten G, 2011, ANN RHEUM DIS, V70, P530, DOI 10.1136/ard.2010.135772
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Yin YJ, 2003, FASEB J, V17, P163, DOI 10.1096/fj.02-0316com
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 28
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD NOV
PY 2021
VL 11
IS 11
AR 1207
DI 10.3390/jpm11111207
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA XF7UV
UT WOS:000724274500001
PM 34834560
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kuppermann, BD
   Goldstein, M
   Maturi, RK
   Pollack, A
   Singer, M
   Tufail, A
   Weinberger, D
   Li, XY
   Liu, CC
   Lou, J
   Whitcup, SM
AF Kuppermann, Baruch D.
   Goldstein, Michaella
   Maturi, Raj K.
   Pollack, Ayala
   Singer, Michael
   Tufail, Adnan
   Weinberger, Dov
   Li, Xiao-Yan
   Liu, Ching-Chi
   Lou, Jean
   Whitcup, Scott M.
CA Ozurdex ERIE Study Grp
TI Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab
   in Neovascular Age-Related Macular Degeneration: A Multicenter
   Randomized Controlled Trial
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Corticosteroid; Dexamethasone; Intravitreal implant; Ranibizumab
ID DRUG-DELIVERY SYSTEM; RETINAL VEIN OCCLUSION; CHOROIDAL
   NEOVASCULARIZATION; CEREBROVASCULAR ACCIDENTS; TRIAMCINOLONE ACETONIDE;
   EPITHELIAL-CELLS; EYE DISEASES; EDEMA; BEVACIZUMAB; PHARMACOKINETICS
AB Purpose: To evaluate the efficacy and safety of dexamethasone intravitreal implant 0.7 mg (DEX) as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration (nvAMD). Procedures: This was a 6-month, single-masked, multicenter study. Patients were randomized to DEX implant (n = 123) or sham procedure (n = 120) and received 2 protocol-mandated intravitreal ranibizumab injections. The main outcome measure was injection-free interval to first as-needed ranibizumab injection. Results: DEX increased the injection-free interval versus sham (50th percentile, 34 vs. 29 days; 75th percentile, 85 vs. 56 days; p = 0.016). 8.3% of DEX versus 2.5% of sham-treated patients did not require rescue ranibizumab (p = 0.048). Visual acuity and retinal thickness outcomes were similar in DEX and sham-treated patients. Only reports of conjunctival hemorrhage (18.2 vs. 8.5%) and intraocular pressure elevation (13.2 vs. 4.2%) were significantly different in the DEX versus the sham treatment groups. Conclusion: DEX reduced the need for adjunctive ranibizumab treatment and showed acceptable tolerability in nvAMD patients. (C) 2015 S. Karger AG, Basel
C1 [Kuppermann, Baruch D.] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92697 USA.
   [Li, Xiao-Yan; Liu, Ching-Chi; Lou, Jean; Whitcup, Scott M.] Allergan Pharmaceut Inc, Irvine, CA 92715 USA.
   [Maturi, Raj K.] Midwest Eye Inst, Indianapolis, IN USA.
   [Maturi, Raj K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [Singer, Michael] Med Ctr Ophthalmol Associates, San Antonio, TX USA.
   [Goldstein, Michaella] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [Pollack, Ayala] Kaplan Med Ctr, Rehovot, Israel.
   [Pollack, Ayala] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel.
   [Weinberger, Dov] Rabin Med Ctr, Petah Tiqwa, Israel.
   [Tufail, Adnan] Moorfields Eye Hosp, London, England.
C3 University of California System; University of California Irvine;
   AbbVie; Allergan; Indiana University System; Indiana University
   Bloomington; Tel Aviv University; Sackler Faculty of Medicine; Hebrew
   University of Jerusalem; Kaplan Medical Center; Hebrew University of
   Jerusalem; Rabin Medical Center; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust
RP Kuppermann, BD (通讯作者)，Univ Calif Irvine, 850 Hlth Sci Rd, Irvine, CA 92697 USA.
EM bdkupper@uci.edu
RI Zacharias, Leandro C/G-3960-2013; Silva, Rufino M/J-2817-2012; Duarte,
   Lilianne/AAA-5318-2021; Aslam, Tariq/A-8532-2016
OI Zacharias, Leandro C/0000-0003-2965-3315; Silva, Rufino
   M/0000-0001-8676-0833; Duarte, Lilianne/0000-0003-3953-0730; Aslam,
   Tariq/0000-0002-9739-7280; Tufail, Adnan/0000-0001-6131-7640; Gaudric,
   Alain/0000-0002-2486-4722
FU Allergan Inc. (Irvine, Calif., USA)
FX This study was sponsored by Allergan Inc. (Irvine, Calif., USA). B.D.
   Kuppermann, R.K. Maturi, M. Goldstein, M. Singer, A. Tufail, and D.
   Weinberger have no proprietary interest in the study medications or
   Allergan Inc. B.D. Kuppermann is a consultant for Allergan Inc. X.-Y.
   Li, C.-C. Liu, J. Lou, and S.M. Whitcup are employees of Allergan Inc.
   and own stock in the company through matching benefits. Writing and
   editorial assistance was provided to the authors by Kate Ivins, PhD, and
   Lauren Swenarchuk, PhD, of Evidence Scientific Solutions, Philadelphia,
   Pa., USA, and funded by Allergan Inc. All authors met the ICMJE
   authorship criteria. Neither honoraria nor payments were made for
   authorship.
CR Adamis AP, 2009, RETINA-J RET VIT DIS, V29, pS42, DOI 10.1097/IAE.0b013e3181ad2500
   Ahmadieh H, 2011, RETINA-J RET VIT DIS, V31, P1819, DOI 10.1097/IAE.0b013e31820d58f2
   Andreau K, 1998, IMMUNOPHARMACOLOGY, V40, P67, DOI 10.1016/S0162-3109(98)00034-4
   [Anonymous], 2008, TRIV PACK INS
   Bollinger KE, 2009, CURR OPIN OPHTHALMOL, V20, P99, DOI 10.1097/ICU.0b013e32831d7f3a
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P4605, DOI 10.1167/iovs.10-6387
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P80, DOI 10.1167/iovs.10-5285
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   Criswell MH, 2008, ARCH OPHTHALMOL-CHIC, V126, P946, DOI 10.1001/archopht.126.7.946
   Croxtall JD, 2002, BRIT J PHARMACOL, V135, P511, DOI 10.1038/sj.bjp.0704474
   Das RA, 2011, CURR DRUG TARGETS, V12, P182
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Druilhe A, 2003, APOPTOSIS, V8, P481, DOI 10.1023/A:1025590308147
   Flammer JR, 2011, MOL ENDOCRINOL, V25, P1075, DOI 10.1210/me.2011-0068
   Forte R, 2011, OPHTHALMIC RES, V45, P129, DOI 10.1159/000318877
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Haller JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P289, DOI 10.1001/archophthalmol.2010.21
   Haller JA, 2009, RETINA-J RET VIT DIS, V29, P46, DOI 10.1097/IAE.0b013e318188c814
   Herrero-Vanrell R, 2011, CLIN OPHTHALMOL, V5, P139, DOI 10.2147/OPTH.S15783
   Iwami Hisashi, 2011, Osaka City Med J, V57, P49
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Joshi L, 2013, BRIT J OPHTHALMOL, V97, P1040, DOI 10.1136/bjophthalmol-2013-303207
   Kim YH, 2007, NEUROBIOL DIS, V26, P569, DOI 10.1016/j.nbd.2007.02.002
   Kovacs KD, 2011, RETINA-J RET VIT DIS, V31, P446, DOI 10.1097/IAE.0b013e3181f6391f
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   London NJS, 2011, ADV THER, V28, P351, DOI 10.1007/s12325-011-0019-z
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Migita K, 1997, TRANSPLANTATION, V63, P583, DOI 10.1097/00007890-199702270-00017
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Sharma A, 2011, J OCUL PHARMACOL TH, V27, P265, DOI 10.1089/jop.2010.0120
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Spaide Richard F, 2009, Retina, V29, pS5, DOI 10.1097/IAE.0b013e3181ad237a
   Spitzer MS, 2008, ACTA OPHTHALMOL, V86, P842, DOI 10.1111/j.1755-3768.2007.01149.x
   Udoetuk JD, 2012, OPHTHALMOLOGY, V119, P1569, DOI 10.1016/j.ophtha.2012.01.043
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   US Food and Drug Administration, DRUGS FDA FDA APPR D
   Williams GA, 2009, AM J OPHTHALMOL, V147, P1048, DOI 10.1016/j.ajo.2008.12.033
   Yeh WS, 2012, OPHTHALMOLOGY, V119, P1190, DOI 10.1016/j.ophtha.2011.12.028
   Yeung CK, 2004, JPN J OPHTHALMOL, V48, P236, DOI 10.1007/s10384-003-0053-8
   Yong T, 2011, OPHTHALMOLOGICA, V225, P1, DOI 10.1159/000317909
   Zambelli-Weiner A, 2012, AM J OPHTHALMOL, V154, pS23, DOI 10.1016/j.ajo.2012.03.018
NR 51
TC 26
Z9 26
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 234
IS 1
BP 40
EP 54
DI 10.1159/000381865
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ9KP
UT WOS:000360933700005
PM 26088793
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Lipecz, A
   Miller, L
   Kovacs, I
   Czako, C
   Csipo, T
   Baffi, J
   Csiszar, A
   Tarantini, S
   Ungvari, Z
   Yabluchanskiy, A
   Conley, S
AF Lipecz, Agnes
   Miller, Lauren
   Kovacs, Illes
   Czako, Cecilia
   Csipo, Tamas
   Baffi, Judit
   Csiszar, Anna
   Tarantini, Stefano
   Ungvari, Zoltan
   Yabluchanskiy, Andriy
   Conley, Shannon
TI Microvascular contributions to age-related macular degeneration (AMD):
   from mechanisms of choriocapillaris aging to novel interventions
SO GEROSCIENCE
LA English
DT Review
DE Retina; SD-OCT; OCTA; Choroidal thickness; Cardiovascular risk factors;
   Smoking; Hypertension
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL BLOOD-FLOW; RETINAL-PIGMENT
   EPITHELIUM; COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; MITOCHONDRIAL
   OXIDATIVE STRESS; VERTEPORFIN PHOTODYNAMIC THERAPY; SMOOTH-MUSCLE-CELLS;
   KAPPA-B ACTIVATION; ENDOTHELIAL-CELLS
AB Aging of the microcirculatory network plays a central role in the pathogenesis of a wide range of age-related diseases, from heart failure to Alzheimer's disease. In the eye, changes in the choroid and choroidal microcirculation (choriocapillaris) also occur with age, and these changes can play a critical role in the pathogenesis of age-related macular degeneration (AMD). In order to develop novel treatments for amelioration of choriocapillaris aging and prevention of AMD, it is essential to understand the cellular and functional changes that occur in the choroid and choriocapillaris during aging. In this review, recent advances in in vivo analysis of choroidal structure and function in AMD patients and patients at risk for AMD are discussed. The pathophysiological roles of fundamental cellular and molecular mechanisms of aging including oxidative stress, mitochondrial dysfunction, and impaired resistance to molecular stressors in the choriocapillaris are also considered in terms of their contribution to the pathogenesis of AMD. The pathogenic roles of cardiovascular risk factors that exacerbate microvascular aging processes, such as smoking, hypertension, and obesity as they relate to AMD and choroid and choriocapillaris changes in patients with these cardiovascular risk factors, are also discussed. Finally, future directions and opportunities to develop novel interventions to prevent/delay AMD by targeting fundamental cellular and molecular aging processes are presented.
C1 [Lipecz, Agnes; Csipo, Tamas; Csiszar, Anna; Tarantini, Stefano; Ungvari, Zoltan; Yabluchanskiy, Andriy] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol,Reynolds Oklahoma Ctr Agi, Translat Gerosci Lab,Ctr Gerosci & Hlth Brain Agi, Oklahoma City, OK 73190 USA.
   [Lipecz, Agnes; Miller, Lauren; Kovacs, Illes; Csipo, Tamas; Baffi, Judit; Csiszar, Anna; Tarantini, Stefano; Ungvari, Zoltan; Yabluchanskiy, Andriy; Conley, Shannon] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol,Vasc Cognit Impairment &, Ctr Gerosci & Hlth Brain Aging,Reynolds Oklahoma, Oklahoma City, OK 73190 USA.
   [Lipecz, Agnes] Josa Andras Hosp, Dept Ophthalmol, Nyiregyhaza, Hungary.
   [Lipecz, Agnes; Csipo, Tamas; Csiszar, Anna; Tarantini, Stefano; Ungvari, Zoltan] Semmelweis Univ, Dept Publ Hlth, Doctoral Sch Basic & Translat Med, Int Training Program Gerosci, Budapest, Hungary.
   [Lipecz, Agnes; Kovacs, Illes; Czako, Cecilia] Semmelweis Univ, Dept Ophthalmol, Budapest, Hungary.
   [Miller, Lauren; Conley, Shannon] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, 940 Stanton L Young Blvd,BMSB553, Oklahoma City, OK 73104 USA.
   [Kovacs, Illes] Weill Cornell Med Coll, Dept Ophthalmol, New York, NY USA.
   [Csipo, Tamas] Univ Debrecen, Fac Med, Dept Cardiol, Int Training Program Gerosci,Div Clin Physiol, Debrecen, Hungary.
   [Csiszar, Anna; Tarantini, Stefano; Ungvari, Zoltan] Univ Szeged, Theoret Med Doctoral Sch, Int Training Program Gerosci, Szeged, Hungary.
   [Ungvari, Zoltan] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Hlth Promot Sci, Oklahoma City, OK USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; Semmelweis University; Semmelweis University;
   University of Oklahoma System; University of Oklahoma Health Sciences
   Center; Cornell University; University of Debrecen; Szeged University;
   University of Oklahoma System; University of Oklahoma Health Sciences
   Center
RP Conley, S (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, 940 Stanton L Young Blvd,BMSB553, Oklahoma City, OK 73104 USA.
EM Shannon-conley@ouhsc.edu
RI Ungvari, Zoltan/GZK-8127-2022; Ungvari, Zoltan/ADU-0095-2022; Csipo,
   Tamas/GWR-0012-2022
OI Yabluchanskiy, Andriy/0000-0002-9648-7161
FU National Institutes of Health [NIGMS 1 P20 GM12552801A1]; Oklahoma
   Center for the Advancement of Science and Technology [HRP HR18-118];
   Government of Hungary [EFOP-3.6.3-VEKOP-16-2017-00009]; Presbyterian
   Health Foundation
FX This work was supported by the National Institutes of Health (NIGMS 1
   P20 GM12552801A1, SMC, AY), the Oklahoma Center for the Advancement of
   Science and Technology (HRP HR18-118, SMC), the Government of Hungary
   (EFOP-3.6.3-VEKOP-16-2017-00009 to CC), and the Presbyterian Health
   Foundation (SMC, LM).
CR Aberami S, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107718
   Addabbo F, 2009, AM J PATHOL, V174, P34, DOI 10.2353/ajpath.2009.080650
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Ivanescu AA, 2015, NUTRIENTS, V7, P5423, DOI 10.3390/nu7075229
   Ahmad M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175691
   Akahori T, 2017, INVEST OPHTH VIS SCI, V58, P5076, DOI 10.1167/iovs.17-21745
   Akay F, 2016, EUR J OPHTHALMOL, V26, P152, DOI 10.5301/ejo.5000675
   Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   ALDER VA, 1983, INVEST OPHTH VIS SCI, V24, P30
   Alvarez IV, 2012, ELECT ROBOT AUTO MEC, P255, DOI 10.1109/CERMA.2012.48
   An JY, 2018, GEROSCIENCE, V40, P1, DOI 10.1007/s11357-017-0004-9
   An JY, 2017, GEROSCIENCE, V39, P457, DOI 10.1007/s11357-017-9994-6
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson B Jr, 1968, Trans Am Ophthalmol Soc, V66, P423
   Arend N, 2015, OPHTHALMOLOGICA, V234, P73, DOI 10.1159/000381726
   Aryan Nona, 2016, Open Neurol J, V10, P83, DOI 10.2174/1874205X01610010083
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Ayhan Z, 2017, OSLI RETINA, V48, P617, DOI 10.3928/23258160-20170802-03
   Bailey-Downs LC, 2013, J GERONTOL A-BIOL, V68, P780, DOI 10.1093/gerona/gls238
   Balaiya S, 2013, MOL VIS, V19, P2385
   Balaiya S, 2012, MOL VIS, V18, P114
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bhutto IA, 2002, OPHTHALMIC RES, V34, P54, DOI 10.1159/000048329
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Bonilha VL, 2017, FREE RADICAL BIO MED, V104, P226, DOI 10.1016/j.freeradbiomed.2017.01.018
   Bonyadi MHJ, 2017, OPHTHALMIC GENET, V38, P308, DOI 10.1080/13816810.2016.1237664
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bouteleux V, 2019, GRAEF ARCH CLIN EXP, V257, P699, DOI 10.1007/s00417-018-04216-8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bulteau AL, 2002, ARCH BIOCHEM BIOPHYS, V397, P298, DOI 10.1006/abbi.2001.2663
   Bulus AD, 2017, OSLI RETINA, V48, P10, DOI 10.3928/23258160-20161219-02
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Calzetti G, 2018, BRIT J OPHTHALMOL, V102, P1679, DOI 10.1136/bjophthalmol-2017-311750
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Campos MM, 2017, ULTRASTRUCT PATHOL, V41, P312, DOI 10.1080/01913123.2017.1348418
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang LYL, 2019, CLIN EXP OPTOM, V102, P184, DOI 10.1111/cxo.12831
   Chen S, 2018, MOL CELL BIOCHEM, V448, P225, DOI 10.1007/s11010-018-3328-6
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chinta SJ, 2018, CELL REP, V22, P930, DOI 10.1016/j.celrep.2017.12.092
   Chinta SJ, 2015, EXP GERONTOL, V68, P3, DOI 10.1016/j.exger.2014.09.018
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Chua J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41917-4
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   COLEMAN DJ, 1979, AM J OPHTHALMOL, V88, P369
   Connelly JJ, 2013, HUM MOL GENET, V22, P5107, DOI 10.1093/hmg/ddt365
   Csipo T, 2018, GEROSCIENCE, V40, P337, DOI 10.1007/s11357-018-0028-9
   Csiszar A, 2003, FASEB J, V17, P1183, DOI 10.1096/fj.02-1049fje
   Csiszar A, 2008, AM J PHYSIOL-HEART C, V295, pH1882, DOI 10.1152/ajpheart.412.2008
   Csiszar A, 2008, AM J PHYSIOL-HEART C, V294, pH2721, DOI 10.1152/ajpheart.00235.2008
   Csiszar A, 2007, AGING CELL, V6, P783, DOI 10.1111/j.1474-9726.2007.00339.x
   Csiszar A, 2019, AM J PHYSIOL-HEART C, V316, pH1253, DOI 10.1152/ajpheart.00039.2019
   Csiszar A, 2014, AM J PHYSIOL-HEART C, V307, pH292, DOI 10.1152/ajpheart.00307.2014
   Csiszar A, 2012, J GERONTOL A-BIOL, V67, P811, DOI 10.1093/gerona/glr228
   Csiszar A, 2009, AM J PHYSIOL-HEART C, V297, pH13, DOI 10.1152/ajpheart.00368.2009
   Csiszar A, 2009, FRONT BIOSCI-LANDMRK, V14, P3128, DOI 10.2741/3440
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Dikalov SI, 2013, AM J PHYSIOL-HEART C, V305, pH1417, DOI 10.1152/ajpheart.00089.2013
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dogan B, 2016, EUR REV MED PHARMACO, V20, P886
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eichler W, 2008, EXP EYE RES, V87, P342, DOI 10.1016/j.exer.2008.06.017
   Ersan I, 2016, J AAPOS, V20, P58, DOI 10.1016/j.jaapos.2015.10.006
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   Fry JL, 2016, HYPERTENSION, V68, P775, DOI 10.1161/HYPERTENSIONAHA.116.07622
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   Fulop GA, 2018, GEROSCIENCE, V40, P513, DOI 10.1007/s11357-018-0047-6
   Gattoussi S, 2019, RETINA-J RET VIT DIS, V39, P34, DOI 10.1097/IAE.0000000000002237
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Gok M, 2015, INDIAN J OPHTHALMOL, V63, P239, DOI 10.4103/0301-4738.156928
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Granstam E, 1998, CURR EYE RES, V17, P189, DOI 10.1076/ceyr.17.2.189.5609
   Grebe R, 2019, EXP EYE RES, V181, P252, DOI 10.1016/j.exer.2019.02.018
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta T, 2017, J HISTOCHEM CYTOCHEM, V65, P567, DOI 10.1369/0022155417726507
   Ha JM, 2015, BIOCHEM BIOPH RES CO, V464, P57, DOI 10.1016/j.bbrc.2015.05.097
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hashitani H, 1998, J PHYSIOL-LONDON, V510, P209, DOI 10.1111/j.1469-7793.1998.209bz.x
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Ho AC, 2012, OPHTHALMOLOGY, V119, P2179, DOI 10.1016/j.ophtha.2012.07.058
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Icel E, 2018, TURK J MED SCI, V48, P1247, DOI 10.3906/sag-1803-171
   Ida H, 2004, INVEST OPHTH VIS SCI, V45, P2348, DOI 10.1167/iovs.03-1337
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Inan S, 2019, CURR EYE RES, V44, P908, DOI 10.1080/02713683.2019.1600195
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Invernizzi A, 2018, INVEST OPHTH VIS SCI, V59, P3836, DOI 10.1167/iovs.18-23960
   Ismayilov AS, 2019, CLIN EXP OPTOM, V102, P617, DOI 10.1111/cxo.12877
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jiang HY, 2017, J NEUROCHEM, V143, P375, DOI 10.1111/jnc.14214
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kanavi MR, 2014, MOLECULES, V19, P17578, DOI 10.3390/molecules191117578
   Kantarci FA, 2016, RETINA-J RET VIT DIS, V36, P986, DOI 10.1097/IAE.0000000000000815
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   KIEL JW, 1992, INVEST OPHTH VIS SCI, V33, P2399
   Kim J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau6732
   Kim JT, 2013, INVEST OPHTH VIS SCI, V54, P3378, DOI 10.1167/iovs.12-11503
   Kim M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18511-7
   Kiss T, 2019, GEROSCIENCE, V41, P619, DOI 10.1007/s11357-019-00074-2
   Kivinen N, 2016, BIOGERONTOLOGY, V17, P749, DOI 10.1007/s10522-016-9647-7
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Kolosova NG, 2012, AM J PATHOL, V181, P472, DOI 10.1016/j.ajpath.2012.04.018
   KOSS MC, 1993, EXP EYE RES, V57, P441, DOI 10.1006/exer.1993.1146
   Kozhevnikova OS, 2013, BIOGERONTOLOGY, V14, P753, DOI 10.1007/s10522-013-9439-2
   Kumase F, 2010, ACTA MED OKAYAMA, V64, P277
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kurokawa K, 2017, BIOMED OPT EXPRESS, V8, P1803, DOI 10.1364/BOE.8.001803
   Labinskyy N, 2009, AM J PHYSIOL-HEART C, V296, pH946, DOI 10.1152/ajpheart.00693.2008
   Lavinsky Fabio, 2016, Int J Retina Vitreous, V2, P25
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lee HJ, 2018, GEROSCIENCE, V40, P163, DOI 10.1007/s11357-018-0018-y
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Lee MB, 2017, GEROSCIENCE, V39, P419, DOI 10.1007/s11357-017-9988-4
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lesniewski LA, 2017, AGING CELL, V16, P17, DOI 10.1111/acel.12524
   Li JJ, 2018, CURR EYE RES, V43, P934, DOI 10.1080/02713683.2018.1454477
   Li R, 2016, CURR EYE RES, V41, P1566, DOI 10.3109/02713683.2016.1145234
   Lin AL, 2013, J CEREBR BLOOD F MET, V33, P1412, DOI 10.1038/jcbfm.2013.82
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Lutjen-Drecoll E, 2006, EXP EYE RES, V82, P357, DOI 10.1016/j.exer.2005.09.015
   Lutty G, 1999, Mol Vis, V5, P35
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marfella R, 2008, J GERONTOL A-BIOL, V63, P200, DOI 10.1093/gerona/63.2.200
   Markovets AM, 2011, AGING-US, V3, P44
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mattison JA, 2014, CELL METAB, V20, P183, DOI 10.1016/j.cmet.2014.04.018
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Minor RK, 2011, SCI REP-UK, V1, DOI 10.1038/srep00070
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   MOSCHOS MM, 2016, OXID MED CELL LONGEV, V2016, DOI DOI 10.1155/2016/2905789
   Mottet B, 2018, ACTA OPHTHALMOL, V96, pE783, DOI 10.1111/aos.13763
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Muraleva NA, 2014, CELL CYCLE, V13, P3499, DOI 10.4161/15384101.2014.958393
   Nacarelli T, 2018, GEROSCIENCE, V40, P243, DOI 10.1007/s11357-018-0030-2
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Nakamura S, 2019, INVEST OPHTH VIS SCI, V60, P1943, DOI 10.1167/iovs.18-25745
   Nanoudis S, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00209
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Nguyen A, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8627384
   Ninomiya H., 2014, Open Journal of Veterinary Medicine, V4, P91
   Nita M, 2017, CURR PHARM DESIGN, V23, P639, DOI 10.2174/1381612823666170111095723
   Valcarcel-Ares MN, 2012, J GERONTOL A-BIOL, V67, P821, DOI 10.1093/gerona/glr229
   Oner RI, 2018, ARQ BRAS OFTALMOL, V81, P461, DOI 10.5935/0004-2749.20180088
   Orosz Z, 2007, AM J PHYSIOL-HEART C, V292, pH130, DOI 10.1152/ajpheart.00599.2006
   Pandian S, 2017, IET NANOBIOTECHNOL, V11, P32, DOI 10.1049/iet-nbt.2016.0069
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Pawlowska E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9682318
   Paz AA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143474
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Pemp B, 2008, CAN J OPHTHALMOL, V43, P295, DOI 10.3129/i08-049
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Pilotto E, 2019, GRAEF ARCH CLIN EXP, V257, P1159, DOI 10.1007/s00417-019-04289-z
   Polak K, 2003, EYE, V17, P84, DOI 10.1038/sj.eye.6700246
   Polska E, 2007, INVEST OPHTH VIS SCI, V48, P3768, DOI 10.1167/iovs.07-0307
   Possek E., 1905, Z AUGENHEILKD, V13, P771, DOI [10.1159/000290375, DOI 10.1159/000290375]
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P6017, DOI 10.1167/iovs.12-9692
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0B013E31822F5678, 10.1097/IAE.0b013e31822f5678]
   Rezkallah Amina, 2019, Am J Ophthalmol Case Rep, V13, P131, DOI 10.1016/j.ajoc.2019.01.001
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P1752
   Riva CE, 2010, ACTA OPHTHALMOL, V88, P622, DOI 10.1111/j.1755-3768.2009.01621.x
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roos CM, 2016, AGING CELL, V15, P973, DOI 10.1111/acel.12458
   Rossman MJ, 2017, AM J PHYSIOL-HEART C, V313, pH890, DOI 10.1152/ajpheart.00416.2017
   Saito M, 2018, INT OPHTHALMOL, V38, P2205, DOI 10.1007/s10792-017-0705-1
   Sato T, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011572
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Schuster AK, 2020, CLIN RES CARDIOL, V109, P172, DOI 10.1007/s00392-019-01498-8
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Shen ZJ, 2017, INT J OPHTHALMOL-CHI, V10, P613, DOI 10.18240/ijo.2017.04.18
   Shiragami C, 2002, GRAEF ARCH CLIN EXP, V240, P436, DOI 10.1007/s00417-002-0451-5
   Sigler EJ, 2014, EYE, V28, P838, DOI 10.1038/eye.2014.100
   Sizmaz S, 2013, BRIT J OPHTHALMOL, V97, P601, DOI 10.1136/bjophthalmol-2012-302393
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Smit-McBride Z, 2014, MOL VIS, V20, P1569
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Sohn EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086538
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Springo Z, 2015, J GERONTOL A-BIOL, V70, P1355, DOI 10.1093/gerona/glu244
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Stalmans I, 2011, ACTA OPHTHALMOL, V89, pe609, DOI 10.1111/j.1755-3768.2011.02178.x
   Straubhaar M, 2000, ARCH OPHTHALMOL-CHIC, V118, P211
   Sugiyama T, 2010, ACTA OPHTHALMOL, V88, P723, DOI 10.1111/j.1755-3768.2009.01586.x
   Sun LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14015-6
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   Synowiec E, 2012, EXP EYE RES, V98, P58, DOI 10.1016/j.exer.2012.02.008
   Tamaki Y, 2000, EYE, V14, P67, DOI 10.1038/eye.2000.15
   Tan KA, 2016, ACTA OPHTHALMOL, V94, pE612, DOI 10.1111/aos.13044
   Tarantini S, 2017, GEROSCIENCE, V39, P465, DOI 10.1007/s11357-017-9980-z
   Tarantini S, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101192
   Tarantini S, 2018, J GERONTOL A-BIOL, V73, P853, DOI 10.1093/gerona/glx177
   Tarantini S, 2018, AGING CELL, V17, DOI 10.1111/acel.12731
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Telegina DV, 2015, CELL CYCLE, V14, P3544, DOI 10.1080/15384101.2015.1080399
   Thomas J, 2015, SOUTH MED J, V108, P502, DOI 10.14423/SMJ.0000000000000329
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Tokarz P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060898
   Tomassoni D, 2002, CLIN EXP HYPERTENS, V24, P741, DOI 10.1081/CEH-120015349
   Topcu-Yilmaz P, 2018, J PEDIATR ENDOCR MET, V31, P855, DOI 10.1515/jpem-2018-0079
   Toth P, 2015, AGING CELL, V14, P400, DOI 10.1111/acel.12315
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Tucsek Z, 2017, GEROSCIENCE, V39, P385, DOI 10.1007/s11357-017-9981-y
   Tucsek Z, 2014, J GERONTOL A-BIOL, V69, P1339, DOI 10.1093/gerona/glu080
   Tucsek Z, 2014, J GERONTOL A-BIOL, V69, P1212, DOI 10.1093/gerona/glt177
   Ulas F, 2014, CURR EYE RES, V39, P504, DOI 10.3109/02713683.2013.850099
   Ungvari Z, 2004, AM J PATHOL, V165, P219, DOI 10.1016/S0002-9440(10)63290-7
   Ungvari Z, 2008, AM J PHYSIOL-HEART C, V294, pH2121, DOI 10.1152/ajpheart.00012.2008
   Ungvari Z, 2007, AM J PHYSIOL-HEART C, V293, pH37, DOI 10.1152/ajpheart.01346.2006
   Ungvari Z, 2018, CIRC RES, V123, P849, DOI 10.1161/CIRCRESAHA.118.311378
   Ungvari Z, 2017, AM J PHYSIOL-HEART C, V312, pH1128, DOI 10.1152/ajpheart.00780.2016
   Ungvari Z, 2017, GEROSCIENCE, V39, P33, DOI 10.1007/s11357-017-9964-z
   Ungvari Z, 2011, J GERONTOL A-BIOL, V66, P866, DOI 10.1093/gerona/glr092
   Ungvari Z, 2011, AM J PHYSIOL-HEART C, V301, pH363, DOI 10.1152/ajpheart.01134.2010
   Ungvari Z, 2011, AM J PHYSIOL-HEART C, V300, pH1133, DOI 10.1152/ajpheart.00402.2010
   Ungvari Z, 2009, AM J PHYSIOL-HEART C, V297, pH1876, DOI 10.1152/ajpheart.00375.2009
   Urfer SR, 2017, GEROSCIENCE, V39, P117, DOI 10.1007/s11357-017-9972-z
   Uryga AK, 2016, J PHYSIOL-LONDON, V594, P2115, DOI 10.1113/JP270923
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Valcarcel-Ares MN, 2019, J GERONTOL A-BIOL, V74, P290, DOI 10.1093/gerona/gly127
   Van Skike CE, 2018, AM J PHYSIOL-HEART C, V314, pH693, DOI 10.1152/ajpheart.00570.2017
   VANSTOKKUM IHM, 1995, GRAEF ARCH CLIN EXP, V233, P123, DOI 10.1007/BF00166603
   Verstappen M, 2019, RETINA-J RET VIT DIS, V39, pE12, DOI 10.1097/IAE.0000000000002509
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Vujosevic S, 2019, ACTA OPHTHALMOL, V97, pE919, DOI 10.1111/aos.14088
   Vujosevic S, 2012, RETINA-J RET VIT DIS, V32, P1781, DOI 10.1097/IAE.0b013e31825db73d
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wang AL, 2008, MOL VIS, V14, P644
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wang CY, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000143
   Wang J, 2019, BIOMED OPT EXPRESS, V10, P1532, DOI 10.1364/BOE.10.001532
   Wang L, 2016, J PATHOL, V240, P495, DOI 10.1002/path.4811
   Wei X, 2019, INVEST OPHTH VIS SCI, V60, P1316, DOI 10.1167/iovs.18-25764
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yang JY, 2019, GRAEF ARCH CLIN EXP, V257, P1393, DOI 10.1007/s00417-019-04326-x
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshinaga N, 2011, LAB INVEST, V91, P1277, DOI 10.1038/labinvest.2011.101
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhang Wenbo, 2011, J Cardiovasc Dis Res, V2, P96, DOI 10.4103/0975-3583.83035
   Zhang YY, 2018, HYPERTENS RES, V41, P96, DOI 10.1038/hr.2017.96
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhdankina AA, 2008, B EXP BIOL MED+, V146, P455, DOI 10.1007/s10517-009-0298-4
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
   Zhuang Pei, 2011, Eye Sci, V26, P23, DOI 10.3969/j.issn.1000-4432.2011.01.006
NR 309
TC 32
Z9 33
U1 3
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2509-2715
EI 2509-2723
J9 GEROSCIENCE
JI GeroScience
PD DEC
PY 2019
VL 41
IS 6
SI SI
BP 813
EP 845
DI 10.1007/s11357-019-00138-3
EA DEC 2019
PG 33
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA KI9NS
UT WOS:000500795500001
PM 31797238
OA Green Published
DA 2022-11-30
ER

PT J
AU Rubin, GS
   Bressler, NM
AF Rubin, GS
   Bressler, NM
CA Treatment Age-Related Macular Degener
TI Effects of verteporfin therapy on contrast sensitivity - Results from
   the Treatment of Age-Related Macular Degeneration with Photodynamic
   Therapy (TAP) investigation - TAP Report No. 4
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL;
   VISUAL IMPAIRMENT; LASER PHOTOCOAGULATION; DISABILITY; VISION;
   PERFORMANCE; PERCEPTION; MOBILITY; LESIONS
AB Background: In the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation, verteporfin therapy reduced the risk of at least moderate vision loss (defined as a loss of at least 15 letters of visual acuity) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). This report presents detailed analyses of 24-month contrast sensitivity outcomes in these patents.
   Methods: The patients included in the TAP investigation had subfoveal CNV secondary to ARMD and received verteporfin therapy (n = 402) or placebo (n = 207) at the first visit, with retreatment at each 3-month follow-up visit if angiography revealed fluorescein leakage from CNV. Contrast sensitivity was determined at each visit using a Pelli-Robson chart.
   Results: At the month 24 examination, verteporfin-treated patients were less likely to lose at least 6 or 15 letters of contrast sensitivity than placebo-treated patients (86 [21%] versus 94 [45%], and 27 [7%] versus 24 [12%], respectively; P < 0.05 for both comparisons). The superiority of verteporfin therapy over placebo was greater in patients with predominantly classic CNV at baseline, although verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes.
   Conclusions: Consistent with visual acuity outcomes, verteporfin therapy reduced the risk of a clinically relevant loss of contrast sensitivity in the total study population, with the greatest effect in patients with predominantly classic subfoveal CNV secondary to ARMD. Verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes than patients who received placebo. Given the association between contrast sensitivity and visual disability, the beneficial effects of verteporfin therapy on contrast sensitivity outcomes are expected to have a favorable impact on patients' daily activities.
C1 UCL, Inst Ophthalmol, London EC1V 9EL, England.
   Wilmer Ophthalmol Inst, Baltimore, MD USA.
C3 University of London; University College London; Johns Hopkins
   University; Johns Hopkins Medicine
RP Rubin, GS (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM g.rubin@ucl.ac.uk
OI Mones, Jordi/0000-0003-3685-2160; Kaiser, Peter/0000-0001-5126-045X
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   EVANS DW, 1985, HUM FACTORS, V27, P637, DOI 10.1177/001872088502700602
   Haegerstrom-Portnoy G, 1999, OPTOMETRY VISION SCI, V76, P141, DOI 10.1097/00006324-199903000-00014
   Hakkinen L, 1984, Scand J Soc Med Suppl, V35, P5
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   LEAT SJ, 1993, OPHTHAL PHYSL OPT, V13, P9, DOI 10.1111/j.1475-1313.1993.tb00420.x
   LENNERSTRAND G, 1989, ACTA OPHTHALMOL, V67, P225
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   OWSLEY C, 1981, INVEST OPHTH VIS SCI, V21, P362
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rosenfeld PJ, 2001, INVEST OPHTH VIS SCI, V42, pS512
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   RUBIN GS, 2001, LOW VISION REHABILIT
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   *TAP STUD GROUP, 2002, IN PRESS ARCH OPHTHA
NR 21
TC 58
Z9 61
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2002
VL 22
IS 5
BP 536
EP 544
DI 10.1097/00006982-200210000-00002
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 604LC
UT WOS:000178621400002
PM 12441717
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Vilkeviciute, A
   Kriauciuniene, L
   Banevicius, M
   Budiene, B
   Stanislovaitiene, D
   Zemaitiene, R
   Deltuva, VP
AF Liutkeviciene, Rasa
   Vilkeviciute, Alvita
   Kriauciuniene, Loresa
   Banevicius, Mantas
   Budiene, Brigita
   Stanislovaitiene, Daiva
   Zemaitiene, Reda
   Deltuva, Vytenis P.
TI Association of genetic variants at CETP, AGER, and CYP4F2 locus with the
   risk of atrophic age-related macular degeneration
SO MOLECULAR GENETICS & GENOMIC MEDICINE
LA English
DT Article
DE age-related macular degeneration; CYP4F2; CETP; AGER; CYP4F2; gene
   polymorphism
ID RETINAL-PIGMENT EPITHELIUM; END-PRODUCTS; POLYMORPHISMS; RECEPTOR;
   DISEASE; ACCUMULATION; CHOLESTEROL; PROGRESSION; EXPRESSION; BIOMARKERS
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly individuals. The etiology of AMD includes environmental and genetic factors.
   Methods: We aimed to determine the association between CETP (rs5882; rs708272; rs3764261; rs1800775; rs2303790), AGER (rs1800624; rs1800625), and CYP4F2 (rs1558139) gene polymorphisms and development of atrophic AMD. About 52 patients with atrophic AMD and 800 healthy control subjects were evaluated. The genotyping of single-nucleotide polymorphisms in CETP, AGER, and CYP4F2 was carried out using the real-time-PCR method.
   Results: Genetic risk models in the analysis of CETP rs5882 revealed statistically significant variables with increased risk of atrophic AMD in the codominant (p < .001), dominant (p < .001), recessive (p < .001), and additive (p < .001) models with the highest 25.4-fold increased risk of atrophic AMD in the codominant model (p < .001). The AGER rs1800625 was associated with a highly increased risk of atrophic AMD in the codominant (p < .001), recessive (p < .001), and additive (p < .001) genetic models.
   Conclusion: We identified two polymorphisms with a higher risk of atrophic AMD (CETP rs5882 and AGER rs1800625).
C1 [Liutkeviciene, Rasa; Vilkeviciute, Alvita; Kriauciuniene, Loresa; Deltuva, Vytenis P.] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Kriauciuniene, Loresa; Banevicius, Mantas; Budiene, Brigita; Stanislovaitiene, Daiva; Zemaitiene, Reda] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Liutkeviciene, R (通讯作者)，Kaunas Lithuanian Univ Hlth Sci, Eiveniu 2, Kaunas, Lithuania.
EM rasa.liutkeviciene@lsmuni.lt
FU Lietuvos Mokslo Taryba [SEN-11/2015]
FX Lietuvos Mokslo Taryba, Grant/Award Number: SEN-11/2015
CR Abu-Asab MS, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/453934
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Buraczynska M, 2015, HUM IMMUNOL, V76, P843, DOI 10.1016/j.humimm.2015.09.046
   Chen JJ, 2014, DNA CELL BIOL, V33, P807, DOI 10.1089/dna.2013.2265
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Emamian M, 2015, GENE, V558, P195, DOI 10.1016/j.gene.2014.12.070
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fourgeux C, 2012, INVEST OPHTH VIS SCI, V53, P7026, DOI 10.1167/iovs.12-9652
   Geng H, 2019, GENET TEST MOL BIOMA, V23, P700, DOI 10.1089/gtmb.2018.0202.correx
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Huang YC, 2019, GENES-BASEL, V10, DOI 10.3390/genes10100782
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Iwanicka J, 2018, MOL BIOL REP, V45, P1929, DOI 10.1007/s11033-018-4342-1
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Lee SH, 2000, J BIOL CHEM, V275, P33679, DOI 10.1074/jbc.M004994200
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liutkeviciene R, 2013, MED LITH, V49, P273
   Liutkeviciene R, 2012, CURR EYE RES, V37, P94, DOI 10.3109/02713683.2011.629069
   Meng QY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143924
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   NEEPER M, 1992, J BIOL CHEM, V267, P14998
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Sakiene Ruta, 2016, Adv Med, V2016, P3917916, DOI 10.1155/2016/3917916
   Sallo FB, 2009, CURR EYE RES, V34, P238, DOI 10.1080/02713680802714058
   Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002
   Semaev S, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110739
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Stasiukonyte Neringa, 2017, Ophthalmic Genet, V38, P357, DOI 10.1080/13816810.2016.1242018
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Wang D, 2015, OPHTHALMIC GENET, V36, P303, DOI 10.3109/13816810.2014.881506
   Wang J, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-176
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu ND, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226763
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yu XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076966
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 49
TC 2
Z9 2
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2324-9269
J9 MOL GENET GENOM MED
JI Mol. Genet. Genom. Med.
PD SEP
PY 2020
VL 8
IS 9
AR e1357
DI 10.1002/mgg3.1357
EA JUL 2020
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA NS3GW
UT WOS:000548105200001
PM 32666702
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, S
   Kim, S
   Jeon, JS
AF Lee, Seokhun
   Kim, Seunggyu
   Jeon, Jessie S.
TI Microfluidic outer blood-retinal barrier model for inducing wet
   age-related macular degeneration by hypoxic stress
SO LAB ON A CHIP
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; MESENCHYMAL
   TRANSITION; VEGF
AB Wet age-related macular degeneration (AMD) is a severe ophthalmic disease that develops in the outer blood-retinal barrier (oBRB), involving two types of cells, the retinal pigment epithelium (RPE) and the choriocapillaris endothelium (CCE). Unfortunately, the pathogenesis of AMD is unclear, and the risk of the only effective therapy (Anti-VEGF injection) has been consistently argued. Also, since oBRB is hard to observe in vivo, an in vitro model for the pathological study is necessary. Here, we propose an advanced oBRB model, enhanced in two major ways: fully vascularized CCE and the in vivo analogous distance between RPE and CCE. Our model consists of an RPE (ARPE-19) monolayer with adjacent CCE (HUVEC) embedded fibrin gel in the microfluidic chip and required four days to construct an oBRB. Notably, the intercellular distance was tuned to the in vivo scale (<100 mu m) without any extraneous scaffold in between. Thus, the two cell layers can interact freely through the extracellular matrix (ECM) in vivo. This is significant as wet AMD is mainly developed through broken intercellular interaction. Thanks to this in vivo similarity, the model incubated under hypoxic conditions, similar to an oxygen-induced retinopathy animal model, showed upregulated vascularization comparable to the AMD condition. We envisage that our model can be used to assist the investigation of AMD.
C1 [Lee, Seokhun; Kim, Seunggyu; Jeon, Jessie S.] Korea Adv Inst Sci & Technol, Dept Mech Engn, Daejeon 34141, South Korea.
C3 Korea Advanced Institute of Science & Technology (KAIST)
RP Jeon, JS (通讯作者)，Korea Adv Inst Sci & Technol, Dept Mech Engn, Daejeon 34141, South Korea.
EM jsjeon@kaist.ac.kr
RI Jeon, Jessie/J-2167-2015
OI Jeon, Jessie/0000-0001-6690-5775
FU National Research Foundation of Korea [2020R1A5A8018367]; BK 21 Plus
   program
FX This study was funded by the National Research Foundation of Korea
   (2020R1A5A8018367) and the BK 21 Plus program.
CR Ahn J, 2021, HUM REPROD, V36, P2720, DOI 10.1093/humrep/deab186
   Arik YB, 2021, LAB CHIP, V21, P272, DOI 10.1039/d0lc00639d
   Berry SB, 2017, LAB CHIP, V17, P4253, DOI 10.1039/c7lc00878c
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chen LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03788-5
   Cho H, 2021, BIOCHIP J, V15, P362, DOI 10.1007/s13206-021-00035-y
   Chung M, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700028
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Dardik R, 2010, INVEST OPHTH VIS SCI, V51, P6188, DOI 10.1167/iovs.09-5095
   Farjood F, 2018, LAB CHIP, V18, P3413, DOI 10.1039/c8lc00659h
   Fernandes AR, 2022, INT J PHARMACEUT, V617, DOI 10.1016/j.ijpharm.2022.121615
   Forooghian F, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.123125
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Hachey SJ, 2021, LAB CHIP, V21, P1333, DOI 10.1039/d0lc01216e
   Hamilton RD, 2007, J ANAT, V211, P707, DOI 10.1111/j.1469-7580.2007.00812.x
   Jeon JS, 2015, P NATL ACAD SCI USA, V112, P214, DOI 10.1073/pnas.1417115112
   Kang SM, 2022, BIOCHIP J, V16, P13, DOI 10.1007/s13206-021-00043-y
   Kano F, 2000, MOL BIOL CELL, V11, P3073, DOI 10.1091/mbc.11.9.3073
   KAPUSCINSKI J, 1995, BIOTECH HISTOCHEM, V70, P220, DOI 10.3109/10520299509108199
   Kim S, 2021, ACS BIOMATER SCI ENG, V7, P1230, DOI 10.1021/acsbiomaterials.0c01542
   Kim S, 2021, BIOMATERIALS, V279, DOI 10.1016/j.biomaterials.2021.121210
   Lim J, 2021, ADV NANOBIOMED RES, V1, DOI 10.1002/anbr.202100078
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mannermaa E, 2010, EUR J PHARM SCI, V40, P289, DOI 10.1016/j.ejps.2010.04.001
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Medici D, 2012, SEMIN CANCER BIOL, V22, P379, DOI 10.1016/j.semcancer.2012.04.004
   Moysidis SN, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/815937
   Naylor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010211
   Osaki T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23512-1
   Paek J, 2019, ACS NANO, V13, P7627, DOI 10.1021/acsnano.9b00686
   Poventud-Fuentes I, 2021, SMALL, V17, DOI 10.1002/smll.202004889
   Rastoin O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134627
   Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Scott A, 2010, EYE, V24, P416, DOI 10.1038/eye.2009.306
   Selvam S, 2018, PROG RETIN EYE RES, V63, P1, DOI 10.1016/j.preteyeres.2017.11.001
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Smith L.E.H., 1994, INVEST OPHTH VIS SCI, V153, P665
   Tamiya S, 2016, EXP EYE RES, V142, P26, DOI 10.1016/j.exer.2015.02.008
   Tolentino MJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P78
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   Yoon N, 2021, BBA-GEN SUBJECTS, V1865, DOI 10.1016/j.bbagen.2020.129796
   Yu DY, 1999, INVEST OPHTH VIS SCI, V40, P2082
NR 49
TC 0
Z9 0
U1 6
U2 6
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
EI 1473-0189
J9 LAB CHIP
JI Lab Chip
PD NOV 8
PY 2022
VL 22
IS 22
BP 4359
EP 4368
DI 10.1039/d2lc00672c
EA SEP 2022
PG 10
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology; Instruments & Instrumentation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics; Instruments & Instrumentation
GA 6C6IC
UT WOS:000869031500001
PM 36254466
DA 2022-11-30
ER

PT J
AU Kim, JH
   Shin, JP
   Kim, IT
   Park, DH
AF Kim, Jong Ho
   Shin, Jae Pil
   Kim, In Taek
   Park, Dong Ho
TI ANGIOPOIETIN-LIKE 4 CORRELATES WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB
   INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; optical
   coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL VEIN OCCLUSION; AQUEOUS-HUMOR LEVELS;
   CHOROIDAL NEOVASCULARIZATION; CYTOKINES; ANGPTL4; EDEMA
AB Purpose: To investigate whether the aqueous angiopoietin-like 4 (ANGPTL4) level correlates with clinical features in neovascular age-related macular degeneration (AMD).
   Methods: The control and study groups consisted of all consecutive patients who received senile cataract surgery or intravitreal ranibizumab injection for treatment-naive neovascular AMD, respectively. The AMD group received 3 monthly ranibizumab injections followed by monthly pro re nata for at least 12 months. Aqueous ANGPTL4 and vascular endothelial growth factor (VEGF) were measured at baseline and 4 weeks after the first injection. In the AMD group, best-corrected visual acuity, lesion area by fluorescein angiography, and central subfield thickness were measured at baseline and at 12 months.
   Results: The AMD group (30 eyes) had higher baseline aqueous ANGPTL4 and VEGF levels than those of the control group (32 eyes) (both P < 0.001). Four weeks after the first injection, VEGF in the patients with AMD had dropped significantly (P < 0.001). Baseline ANGPTL4 correlated with the lesion area at baseline and at 12 months (P < 0.05, respectively), and also correlated with the frequency of anti-VEGF injections during 12 months (P = 0.008).
   Conclusion: Aqueous ANGPTL4 levels correlated with the lesion area and anti-VEGF treatment frequency. Angiopoietin-like 4 may be a potential diagnostic and/or therapeutic biomarker in the neovascular AMD.
C1 [Kim, Jong Ho; Shin, Jae Pil; Kim, In Taek; Park, Dong Ho] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, 130 Dongdeok Ro, Daegu 41944, South Korea.
C3 Kyungpook National University
RP Park, DH (通讯作者)，Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, 130 Dongdeok Ro, Daegu 41944, South Korea.
EM sarasate2222@gmail.com
FU National Research Foundation of Korea (NRF); Ministry of Education
   [NRF-2014R1A1A2055007]; Korea Health Technology R&D Project of the Korea
   Health Industry Development Institute (KHIDI); Ministry of Health &
   Welfare, Republic of Korea [HI16C1501]
FX Supported by the Basic Science Research Program of the National Research
   Foundation of Korea (NRF), which is funded by the Ministry of Education
   (NRF-2014R1A1A2055007), and by the Korea Health Technology R&D Project
   of the Korea Health Industry Development Institute (KHIDI), which is
   funded by the Ministry of Health & Welfare, Republic of Korea
   (HI16C1501). The sponsor/funding organization played no role in the
   design or conduct of this research.
CR Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Babapoor-Farrokhran S, 2015, P NATL ACAD SCI USA, V112, pE3030, DOI 10.1073/pnas.1423765112
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868
   Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Kim JH, 2016, INVEST OPHTH VIS SCI, V57, P6, DOI 10.1167/iovs.15-18304
   Kwon SH, 2015, OPHTHALMOLOGY, V122, P968, DOI 10.1016/j.ophtha.2015.01.007
   Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Ma T, 2010, P NATL ACAD SCI USA, V107, P14363, DOI 10.1073/pnas.1001065107
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Xin XB, 2013, P NATL ACAD SCI USA, V110, pE3425, DOI 10.1073/pnas.1217091110
   Zhu PC, 2012, BIOSCIENCE REP, V32, P211, DOI 10.1042/BSR20110102
NR 28
TC 11
Z9 12
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2018
VL 38
IS 3
BP 523
EP 530
DI 10.1097/IAE.0000000000001554
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2AB
UT WOS:000440619200014
PM 28151839
DA 2022-11-30
ER

PT J
AU Joussen, AM
   Heussen, FMA
   Joeres, S
   Llacer, H
   Prinz, B
   Rohrschneider, K
   Maaijwee, KJM
   van Meurs, J
   Kirchhof, B
AF Joussen, Antonia M.
   Heussen, Florian M. A.
   Joeres, Sandra
   Llacer, Helene
   Prinz, Beate
   Rohrschneider, Klaus
   Maaijwee, Kristel J. M.
   van Meurs, Jan
   Kirchhof, Bernd
TI Autologous translocation of the choroid and retinal pigment epithelium
   in age-related macular degeneration.
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL NEOVASCULAR MEMBRANES; SCANNING LASER OPHTHALMOSCOPE;
   GEOGRAPHIC ATROPHY; FUNDUS PERIMETRY; SURGICAL REMOVAL; PHOTODYNAMIC
   THERAPY; PERIPHERAL RETINECTOMY; 360-DEGREES RETINOTOMY; SUBMACULAR
   SURGERY; READING CHART
AB PURPOSE: To evaluate the autologous translocation of peripheral choroid and retinal pigment epithelium (RPE) in 45 eyes of 43 patients with age related macular degeneration (AMD).
   DESIGN: Prospective nonrandomized study.
   METHODS: All patients bad visual loss due to AMD (n 5 classic membranes, n = 14 occult, n = 2 mixed, n 16 pigment epithelial detachment (PED), n = 5 subretinal hemorrhage, n = 3 geographic atrophy). After extraction of the neovascular complex, an autologous peripheral full thickness explant of RPE, Bruch membrane, and choroid was translocated from the midperiphery to the macula.
   RESULTS: Preoperative distant visual acuity ranged from 20/800 to 20/40. Reading vision ranged from 1.4 logarithm of reading acuity determination (logRAD) to 03 logRAD (0.04 to 0.32 Snellen equivalent). Revision surgery was required in 22 eyes as a result of proliferative vitreoretinopathy (PVR), retinal detachment, macular pucker, or vitreous hemorrhage. In eight patients, the patch was renewed. At six months, distant visual acuity ranged from light perception to 20/50 (increase of 15 letters in four eyes). Reading vision ranged from 1.4 to 0.4 logRAD. Visual outcome was unrelated to the type of AMD. Vascularization of the transplant was visible on indocyanine green (ICG) angiography in 40 of 42 eyes. In most patients, autofluorescence of the pigment epithelium was coincident with revascularization of the graft. Fixation on the patch was positively related to visual acuity.
   CONCLUSIONS: Autologous translocation of a full-thickness transplant of choroid and RPE usually results in a vascularized and functioning graft. Vascularization was even achieved in patients with geographic atrophy. Fixation stability and microperimetry before the patch translocation may be helpful in selecting patients who will profit from surgery.
C1 Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50931 Cologne, Germany.
   Univ Heidelberg, Dept Ophthalmol, D-6900 Heidelberg, Germany.
   Rotterdam Eye Hosp, Rotterdam, Netherlands.
C3 University of Cologne; Ruprecht Karls University Heidelberg; Rotterdam
   Eye Hospital
RP Joussen, AM (通讯作者)，Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Joseph Stelzmannstr 9, D-50931 Cologne, Germany.
EM JoussenA@googlemail.com
RI Joussen, Antonia/AAA-6901-2022
OI Heussen, Florian Moritz/0000-0003-0536-9870; Rohrschneider,
   Klaus/0000-0003-1996-7935
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   ADELBERG DA, 1995, RETINA-J RET VIT DIS, V15, P198, DOI 10.1097/00006982-199515030-00003
   Aisenbrey S, 2002, OPHTHALMOLOGE, V99, P164, DOI 10.1007/s00347-001-0582-9
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   ASSADOULLINA A, 2003, SPECTRUM AUGENHEILK, V17, P120
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bellmann C, 2003, BRIT J OPHTHALMOL, V87, P1381, DOI 10.1136/bjo.87.11.1381
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Castellarin AA, 1998, RETINA-J RET VIT DIS, V18, P143, DOI 10.1097/00006982-199818020-00008
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   COFFEY AJH, 1986, AM J OPHTHALMOL, V102, P164, DOI 10.1016/0002-9394(86)90138-8
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   CULLINAN TR, 1987, CLIN OPHTHALMOL, P571
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt Claus, 1996, Ophthalmologe, V93, P688, DOI 10.1007/s003470050059
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   HUDSON HL, 1995, BRIT J OPHTHALMOL, V79, P417, DOI 10.1136/bjo.79.5.417
   KAHN HA, 1973, PUBLICATION NIH, V73, P427
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KOCIOK N, 2006, GRAEFES ARCH CLI APR
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   LEIBOWITZ H, 1984, SURV OPHTHALMOL S, V25, P335
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Majji AB, 2000, GRAEF ARCH CLIN EXP, V238, P779, DOI 10.1007/s004170000132
   Melberg NS, 1996, RETINA-J RET VIT DIS, V16, P190, DOI 10.1097/00006982-199616030-00002
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   ORMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Rohrschneider K, 1998, AM J OPHTHALMOL, V126, P52, DOI 10.1016/S0002-9394(98)00065-8
   Rohrschneider K, 1997, BRIT J OPHTHALMOL, V81, P568, DOI 10.1136/bjo.81.7.568
   ROHRSCHNEIDER K, 1995, GRAEF ARCH CLIN EXP, V233, P743, DOI 10.1007/BF00184084
   RYAN SJ, 1989, RETINA, V2, P107
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Stanga P. E., 2001, International Ophthalmology, V23, P309, DOI 10.1023/A:1014434110031
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Stifter E, 2004, GRAEF ARCH CLIN EXP, V242, P31, DOI 10.1007/s00417-003-0776-8
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   THOMAS JW, 1993, RETINA-J RET VIT DIS, V13, P93, DOI 10.1097/00006982-199313020-00001
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   van Meurs JC, 2004, GRAEF ARCH CLIN EXP, V242, P442, DOI 10.1007/s00417-003-0852-0
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
NR 67
TC 117
Z9 124
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2006
VL 142
IS 1
BP 17
EP 30
DI 10.1016/j.ajo.2006.01.090
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064HF
UT WOS:000239079100003
PM 16815247
DA 2022-11-30
ER

PT J
AU Veckeneer, M
   Augustinus, C
   Feron, E
   Schauwvlieghe, PP
   Ruys, J
   Cosemans, I
   Van Meurs, J
AF Veckeneer, M.
   Augustinus, C.
   Feron, E.
   Schauwvlieghe, P-P
   Ruys, J.
   Cosemans, I.
   Van Meurs, J.
TI OCT angiography documented reperfusion of translocated autologous full
   thickness RPE-choroid graft for complicated neovascular age-related
   macular degeneration
SO EYE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL
   GROWTH-FACTOR; SUBMACULAR HEMORRHAGE; THERAPY
AB Purpose The purpose of this study is to investigate the reperfusion of translocated retinal pigment epithelium (RPE)-choroid graft in the treatment of patients with neovascular age-related macular degeneration (nAMD), using OCT angiography (OCTA), a novel noninvasive, high-resolution imaging modality.
   Patients and methods Eighteen eyes of 18 consecutive patients suffering from complicated nAMD underwent RPE-choroid patch graft translocation surgery using a peripheral retinotomy and flap-over technique. We analyzed functional and anatomical outcome using visual acuity, Spectral Domain OCT and OCTA.
   Results With a mean follow-up of 11 months, out of 18 patients, 15 gained vision, 1 remained stable, and 2 lost vision. Overall, the visual acuity improved with a mean of 30 letters. Perfusion of the graft tissue was confirmed in all patients. Two patients developed signs of a recurrent neovascular membrane during follow-up. No cases of proliferative vitreoretinopathy occurred in this series.
   Conclusions OCTA images show signs of perfusion in all grafts. Encouraging functional results and low risk of severe complications suggest that RPE-choroid graft translocation is a valid option in patients with complicated nAMD.
C1 [Veckeneer, M.; Augustinus, C.; Feron, E.; Schauwvlieghe, P-P; Ruys, J.; Cosemans, I.] ZNA Middelheim, Dept Ophthalmol, Lindedreef 1, BE-2020 Antwerp, Belgium.
   [Van Meurs, J.] Rotterdam Eye Hosp, Rotterdam, Netherlands.
C3 ZNA Middelheim Hospital; Rotterdam Eye Hospital
RP Veckeneer, M (通讯作者)，ZNA Middelheim, Dept Ophthalmol, Lindedreef 1, BE-2020 Antwerp, Belgium.
EM Veckeneer.icare@gmail.com
RI Schauwvlieghe, Pieter-Paul/AAK-6018-2020
OI Schauwvlieghe, Pieter-Paul/0000-0001-8180-3187
CR Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   De Jong JH, 2016, RETINA-J RET VIT DIS, V36, P914, DOI 10.1097/IAE.0000000000000954
   Degenring RF, 2011, ACTA OPHTHALMOL, V89, P654, DOI 10.1111/j.1755-3768.2010.01867.x
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   Hirashima T, 2015, RETINA-J RET VIT DIS, V35, P1969, DOI 10.1097/IAE.0000000000000574
   Joeres S, 2008, EYE, V22, P782, DOI 10.1038/sj.eye.6702761
   Kim HS, 2015, EYE, V29, P1142, DOI 10.1038/eye.2015.131
   Ma ZZ, 2009, INVEST OPHTH VIS SCI, V50, P2975, DOI 10.1167/iovs.08-2573
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Maaijwee KJM, 2007, BRIT J OPHTHALMOL, V91, P546, DOI 10.1136/bjo.2006.103259
   Neubauer AS, 2010, INT J OPHTHALMOL-CHI, V3, P228, DOI 10.3980/j.issn.2222-3959.2010.03.11
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   van Romunde SHM, 2015, OPHTHALMOLOGY, V122, P1366, DOI 10.1016/j.ophtha.2015.03.012
   van Zeeburg EJT, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.1.2
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   van Zeeburg EJT, 2011, INVEST OPHTH VIS SCI, V52, P5881, DOI 10.1167/iovs.11-7245
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 24
TC 7
Z9 9
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2017
VL 31
IS 9
SI SI
BP 1274
EP 1283
DI 10.1038/eye.2017.137
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FG7JZ
UT WOS:000410594600004
PM 28731053
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Harris, A
   Ciulla, TA
   Pratt, LM
   Rechtman, E
   Kagemann, L
   Piper, HC
   Garzozi, HJ
AF Harris, A
   Ciulla, TA
   Pratt, LM
   Rechtman, E
   Kagemann, L
   Piper, HC
   Garzozi, HJ
TI The effects of dorzolamide on choroidal and retinal perfusion in
   non-exudative age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OCULAR BLOOD-FLOW; CIRCULATION; DISEASE
AB Aim: To comprehensively evaluate the effects of dorzolamide on the choroidal and retinal circulation in patients with age related macular degeneration (AMD).
   Methods: In this randomised, double masked, parallel study, 36 non-exudative AMD patients were randomised in a 2 to 1 fashion to placebo versus topical dorzolamide and underwent assessment of their choroidal and retinal circulation. Scanning laser ophthalmoscope indocyanine green angiograms (ICGA) were analysed by a new area dilution analysis technique. Four areas in the perifoveal region and two areas in the temporal peripapillary region were evaluated by plotting intensity of fluorescence of each area over time. The means of the choroidal filling times and the heterogeneity of the filling times were assessed. Scanning laser ophthalmoscope fluorescein angiography ( FA) was evaluated for retinal arteriovenous passage (AVP) times by plotting intensity of fluorescence of retinal vessels over time. Assessment was performed at baseline and at 4 months.
   Results: Compared to placebo, AMD patients treated with dorzolamide showed a significantly increased rapidity of choroidal filling in the superior and inferior peripapillary regions ( p= 0.007, p= 0.02, respectively). No significant difference in choroidal filling times was found in any of the perifoveal areas ( p= 0.9). Also, on FA assessment, treatment with dorzolamide showed no statistical differences in AVP times ( p= 0.19).
   Conclusions: Dorzolamide may increase peripapillary choroidal perfusion in non-exudative AMD patients. Further studies are merited.
C1 Indiana Univ, Sch Med, Dept Ophthalmol, Bloomington, IN 47405 USA.
   Midw Eye Inst, Indianapolis, IN USA.
   Bnai Zion Med Ctr, Dept Ophthalmol, Haifa, Israel.
C3 Indiana University System; Indiana University Bloomington; Bnai Zion
   Medical Center
RP Harris, A (通讯作者)，IUMC, 702 Rotary Circle, Indianapolis, IN 46260 USA.
EM alharris@indiana.edu
RI Kagemann, Larry/B-6255-2013; Ciulla, Thomas/AAA-1299-2020
OI Kagemann, Larry/0000-0001-8961-0187; Ciulla, Thomas/0000-0001-5557-6777;
   Harris, Alon/0000-0001-8770-3726
FU NEI NIH HHS [EY10801] Funding Source: Medline
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   EAGLE RC, 1984, OPHTHALMOLOGY, V91, P613
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   GRUNWALD J, 1998, INVEST OPHTH VIS SCI, P385
   Harris A, 1996, ACTA OPHTHALMOL SCAN, V74, P569
   Harris A, 1998, SURV OPHTHALMOL, V42, P509, DOI 10.1016/S0039-6257(98)00011-3
   Harris A, 2000, OPHTHALMOLOGY, V107, P430, DOI 10.1016/S0161-6420(99)00093-7
   Harris A, 1998, OPHTHALMOL CLIN N AM, V11, P331, DOI 10.1016/s0896-1549(05)70060-2
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   PIGUET B, 1992, AM J OPHTHALMOL, V113, P657, DOI 10.1016/S0002-9394(14)74790-7
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   ZHAO J, 1995, INT OPHTHALMOL, V19, P1, DOI 10.1007/BF00156412
NR 21
TC 8
Z9 10
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2003
VL 87
IS 6
BP 753
EP 757
DI 10.1136/bjo.87.6.753
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 683LH
UT WOS:000183149800022
PM 12770975
OA Green Submitted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Cousins, SW
   Espinosa-Heidmann, DG
   Csaky, KG
AF Cousins, SW
   Espinosa-Heidmann, DG
   Csaky, KG
TI Monocyte activation in patients with age-related macular degeneration -
   A biomarker of risk for choroidal neovascularization?
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; BRUCHS MEMBRANE; FACTOR-ALPHA; TNF-ALPHA;
   MACROPHAGE; EXPRESSION; CELLS; INFLAMMATION; DISEASE; ATHEROSCLEROSIS
AB Objective: To evaluate the activation state of macrophage function in patients with age-related macular degeneration (AMD) by quantifying the production of the proinflammatory and angiogenic factor tumor necrosis factor alpha (TNF-alpha) and by correlating its expression with dry and wet AMD.
   Methods: Circulating monocytes were obtained from the blood of patients with AMD or age-matched control subjects by gradient centrifugation. The monocytes were then analyzed for either TNF-alpha release from cultured macrophages in response to retinal pigment epithelium-derived blebs and cytokines or TNF-alpha. messenger RNA content by reverse transcriptase-polymerase chain reaction.
   Results: In human monocytes obtained from controls and AMD patients, TNF-alpha was expressed by freshly isolated monocytes and produced by macrophages in culture after stimulation with retinal pigment epithelium-derived blebs. However, wide variability in TNF-alpha expression was observed among different patients. Patients with monocytes that expressed the greatest amount of TNF-alpha demonstrated higher prevalence of choroidal neovascularization.
   Conclusions: Both controls and AMD patients vary in the activation state (defined as TNF-alpha expression) of circulating monocytes. Partially active monocytes, defined as high TNF-alpha expression, may be a biomarker to identify patients at risk for formation of choroidal neovascularization.
   Clinical Relevance: Early diagnostic testing may prove useful to detect those patients who will progress to the more severe complications of the disease.
C1 Miami Univ, Mcknight Vis Res Ctr, Bascom Palmer Eye Inst, Sch Med,Dept Ophthalmol, Miami, FL 33136 USA.
   NEI, NIH, Bethesda, MD 20892 USA.
C3 Bascom Palmer Eye Institute; National Institutes of Health (NIH) - USA;
   NIH National Eye Institute (NEI)
RP Cousins, SW (通讯作者)，Miami Univ, Mcknight Vis Res Ctr, Bascom Palmer Eye Inst, Sch Med,Dept Ophthalmol, 1638 NW 10th Ave, Miami, FL 33136 USA.
EM scousins@med.miami.edu
FU NATIONAL EYE INSTITUTE [R01EY013318, Z01EY000369] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY/AI 13318] Funding Source: Medline
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Caicedo A, 2003, INVEST OPHTH VIS SCI, V44, pU409
   COUSINS SW, 2002, AGE RELATED MACULAR, V27, P65
   Eikelenboom P, 1998, EXP NEUROL, V154, P89, DOI 10.1006/exnr.1998.6920
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128
   Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477
   GrazianiBowering GM, 1997, J IMMUNOL METHODS, V207, P157, DOI 10.1016/S0022-1759(97)00114-2
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Ikeda U, 2002, CLIN CARDIOL, V25, P143, DOI 10.1002/clc.4960250403
   JOHNSON RJ, 1994, KIDNEY INT, V45, P1769, DOI 10.1038/ki.1994.230
   Katschinski DM, 1999, CANCER RES, V59, P3404
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kockx MM, 2003, ARTERIOSCL THROM VAS, V23, P440, DOI 10.1161/01.ATV.0000057807.28754.7F
   Krohne TU, 2003, INVEST OPHTH VIS SCI, V44, pU78
   LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0
   Majka S, 2002, INVEST OPHTH VIS SCI, V43, P260
   Margetts PJ, 2002, AM J PATHOL, V160, P2285, DOI 10.1016/S0002-9440(10)61176-5
   Murphy CA, 2002, J IMMUNOL, V169, P7054, DOI 10.4049/jimmunol.169.12.7054
   Norrby K, 1996, MICROVASC RES, V52, P79, DOI 10.1006/mvre.1996.0045
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Pawluczyk IZA, 1997, J AM SOC NEPHROL, V8, P1525
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   SELMAJ K, 1991, ANN NEUROL, V30, P694, DOI 10.1002/ana.410300510
   SPRANGER J, 1995, MED KLIN, V90, P134
   Tracy RP, 2003, INT J CLIN PRACT, P10
   Vervoordeldonk Margriet J B M, 2002, Curr Rheumatol Rep, V4, P208, DOI 10.1007/s11926-002-0067-0
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Zhang CX, 2003, J CELL SCI, V116, P1915, DOI 10.1242/jcs.00390
NR 34
TC 124
Z9 143
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2004
VL 122
IS 7
BP 1013
EP 1018
DI 10.1001/archopht.122.7.1013
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 838HF
UT WOS:000222703400009
PM 15249366
OA Bronze
DA 2022-11-30
ER

PT J
AU Litts, KM
   Wang, XL
   Clark, ME
   Owsley, C
   Freund, KB
   Curcio, CA
   Zhang, YH
AF Litts, Katie M.
   Wang, Xiaolin
   Clark, Mark E.
   Owsley, Cynthia
   Freund, K. Bailey
   Curcio, Christine A.
   Zhang, Yuhua
TI EXPLORING PHOTORECEPTOR REFLECTIVITY THROUGH MULTIMODAL IMAGING OF OUTER
   RETINAL TUBULATION IN ADVANCED AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; cones; ellipsoid; Muller cells; outer
   retinal tubulation; spectral domain optical coherence tomography;
   photoreceptors
ID OPTICAL-COHERENCE-TOMOGRAPHY; SCANNING LASER OPHTHALMOSCOPY; HUMAN CONE
   PHOTORECEPTORS; LIVING HUMAN EYE; ADAPTIVE OPTICS; ULTRAHIGH-RESOLUTION;
   GEOGRAPHIC ATROPHY; LIGHT-SCATTERING; INNER SEGMENTS; INTACT-CELLS
AB Purpose: To investigate the microscopic structure of outer retinal tubulation (ORT) and optical properties of cone photoreceptors in vivo, we studied ORT appearance by multimodal imaging, including spectral domain optical coherence tomography (SD-OCT) and adaptive optics scanning laser ophthalmoscopy.
   Methods: Four eyes of four subjects with advanced age-related macular degeneration underwent color fundus photography, infrared reflectance imaging, SD-OCT, and adaptive optics scanning laser ophthalmoscopy with a high-resolution research instrument. Outer retinal tubulation was identified in closely spaced (11 mm) SD-OCT volume scans.
   Results: Outer retinal tubulation in cross-sectional and en face SD-OCT was a hyporeflective area representing a lumen surrounded by a hyperreflective border consisting of cone photoreceptor mitochondria and external limiting membrane, per previous histology. In contrast, ORT by adaptive optics scanning laser ophthalmoscopy was a hyporeflective structure of the same shape as in en face SD-OCT but lacking visualizable cone photoreceptors.
   Conclusion: Lack of ORT cone reflectivity by adaptive optics scanning laser ophthalmoscopy indicates that cones have lost their normal directionality and waveguiding property due to loss of outer segments and subsequent retinal remodeling. Reflective ORT cones by SD-OCT, in contrast, may depend partly on mitochondria as light scatterers within inner segments of these degenerating cells, a phenomenon enhanced by coherent imaging. Multimodal imaging of ORT provides insight into cone degeneration and reflectivity sources in optical coherence tomography.
C1 [Litts, Katie M.] Univ Alabama Birmingham, Vis Sci Grad Program, Birmingham, AL USA.
   [Litts, Katie M.; Wang, Xiaolin; Clark, Mark E.; Owsley, Cynthia; Curcio, Christine A.; Zhang, Yuhua] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Volker Hall 390C,1670 Univ Blvd, Birmingham, AL 35294 USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; Vitreous
   Retina Macula Consultants of New York; New York University
RP Zhang, YH (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Volker Hall 390C,1670 Univ Blvd, Birmingham, AL 35294 USA.
EM zhanghua@uab.edu
RI Litts, Katie M/AAK-1564-2021; Freund, K. Bailey/V-7488-2018
OI Litts, Katie M/0000-0001-6707-8273; Freund, K.
   Bailey/0000-0002-7888-9773
FU NIH [EY06019]; Research to Prevent Blindness; EyeSight Foundation of
   Alabama; NATIONAL EYE INSTITUTE [P30EY003039, R01EY024378, R01EY006109]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004212]
   Funding Source: NIH RePORTER
FX Vision Science Graduate Program (K.M.L.), NIH grant EY06019 (C.A.C.),
   NIH EY024378 (Y.Z.), Unrestricted funds to the Department of
   Ophthalmology form Research to Prevent Blindness and EyeSight Foundation
   of Alabama (C.A.C., Y.Z.); Macula Foundation, Inc (K.B.F.); National
   Institute on Aging R01AG04212 (C.O.); Alfreda J. Schueler Trust,
   Chicago, IL (C.O.); NIH P30 EY003039. K. B. Freund is a consultant for
   Genentech, Optovue, Optos, Bayer Healthcare, and Heidelberg Engineering.
   C. A. Curcio is a consultant for Genentech, Novartis, Merck, Janssen
   Cell Therapy, Ora. The remaining authors have no conflicting interests
   to disclose.
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   BORWEIN B, 1980, AM J ANAT, V159, P125, DOI 10.1002/aja.1001590202
   Bruce KS, 2015, INVEST OPHTH VIS SCI, V56, P4431, DOI 10.1167/iovs.15-16547
   BURNS SA, 1995, J OPT SOC AM A, V12, P2329, DOI 10.1364/JOSAA.12.002329
   Carroll J, 2012, INVEST OPHTH VIS SCI, V53, P8006, DOI 10.1167/iovs.12-11087
   Cense B, 2004, OPT EXPRESS, V12, P2435, DOI 10.1364/OPEX.12.002435
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Elner Susan G, 2008, Trans Am Ophthalmol Soc, V106, P215
   ENOCH JM, 1963, J OPT SOC AM, V53, P71, DOI 10.1364/JOSA.53.000071
   Fujinami K, 2013, AM J OPHTHALMOL, V156, P487, DOI 10.1016/j.ajo.2013.05.003
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Iriyama Aya, 2013, Retina, V33, P1462, DOI 10.1097/IAE.0b013e31828221ae
   Jacob J, 2015, AM J OPHTHALMOL, V159, P118, DOI 10.1016/j.ajo.2014.09.043
   Jacques SL, 2013, PHYS MED BIOL, V58, pR37, DOI 10.1088/0031-9155/58/11/R37
   Jonnal RS, 2007, OPT EXPRESS, V15, P16141, DOI 10.1364/OE.15.016141
   Jonnal RS, 2014, INVEST OPHTH VIS SCI, V55, P7904, DOI 10.1167/iovs.14-14907
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Krebs W., 1991, PRIMATE RETINA CHORO
   LATIES AM, 1971, INVEST OPHTH VISUAL, V10, P69
   Leitgeb RA, 2004, OPT EXPRESS, V12, P2156, DOI 10.1364/OPEX.12.002156
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Litts KM, 2016, INVEST OPHTH VIS SCI, V57, P2647, DOI 10.1167/iovs.16-19262
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Litts KM, OUTER RETINAL TUBULA
   Liu ZL, 2015, BIOMED OPT EXPRESS, V6, P3378, DOI 10.1364/BOE.6.003378
   Lu RW, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.6.060504
   Lujan BJ, 2015, RETINA-J RET VIT DIS, V35, P1511, DOI 10.1097/IAE.0000000000000527
   Meadway A, 2013, OPT EXPRESS, V21, P29792, DOI 10.1364/OE.21.029792
   Miller DT, 2011, EYE, V25, P321, DOI 10.1038/eye.2011.1
   Miller DT, 1996, VISION RES, V36, P1067, DOI 10.1016/0042-6989(95)00225-1
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Pallikaris A, 2003, INVEST OPHTH VIS SCI, V44, P4580, DOI 10.1167/iovs.03-0094
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Putnam NM, 2010, OPT EXPRESS, V18, P24902, DOI 10.1364/OE.18.024902
   Reidel B, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002469
   Roorda A, 2015, ANNU REV VIS SCI, V1, P19, DOI 10.1146/annurev-vision-082114-035357
   Ross DH, 2015, INVEST OPHTH VIS SCI, V56, P4166, DOI 10.1167/iovs.14-15256
   ROWE MP, 1994, J OPT SOC AM A, V11, P55, DOI 10.1364/JOSAA.11.000055
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Scoles D, 2015, RETINA, V26, P91
   Scoles D, 2014, INVEST OPHTH VIS SCI, V55, P4244, DOI 10.1167/iovs.14-14542
   Sharma R, 2016, INVEST OPHTH VIS SCI, V57, P632, DOI 10.1167/iovs.15-17961
   SNYDER AW, 1973, VISION RES, V13, P1115, DOI 10.1016/0042-6989(73)90148-X
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Syed R, 2013, INVEST OPHTH VIS SCI, V54, P950, DOI 10.1167/iovs.12-10707
   Vogel CR, 2006, OPT EXPRESS, V14, P487, DOI 10.1364/OPEX.14.000487
   Williams DR, 2011, VISION RES, V51, P1379, DOI 10.1016/j.visres.2011.05.002
   Wilson JD, 2005, OPT LETT, V30, P2442, DOI 10.1364/OL.30.002442
   Wilson JD, 2005, BIOPHYS J, V88, P2929, DOI 10.1529/biophysj.104.054528
   Wilson JD, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2437765
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Yoon MK, 2009, INVEST OPHTH VIS SCI, V50, P1838, DOI 10.1167/iovs.08-2029
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 62
TC 15
Z9 16
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2017
VL 37
IS 5
BP 978
EP 988
DI 10.1097/IAE.0000000000001265
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW0IO
UT WOS:000402173400040
PM 27584549
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gayton, JL
   Mackool, RJ
   Ernest, PH
   Seabolt, RA
   Dumont, S
AF Gayton, Johnny L.
   Mackool, Richard J.
   Ernest, Paul H.
   Seabolt, ReBecca A.
   Dumont, Susan
TI Implantation of multifocal intraocular lenses using a magnification
   strategy in cataractous eyes with age-related macular degeneration
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID VISUAL FUNCTION; SURGERY
AB PURPOSE: To examine visual function after targeting 2.0 diopter (D) spherical equivalent (SE) when implanting a multifocal intraocular lens (IOL) in eyes with cataract and age-related macular degeneration (AMD).
   SETTING: Three private practices.
   DESIGN: Case series.
   METHODS: Lenses of cataractous eyes with AMD were replaced with the Acrysof Restor SN60D3 multifocal IOL, targeting an SE of 2.0 D, which yielded +5.2 D near addition. Near and distance visual acuities were examined. Patients completed a visual function questionnaire preoperatively and 6 months postoperatively.
   RESULTS: At 6 months, 13 patients with 20 eligible eyes were examined. The uncorrected near visual acuity improved in 18 eyes (90%) and was unchanged in 2 eyes. The corrected distance visual acuity improved in 14 eyes (70%), was unchanged in 4 eyes (20%), and decreased ( 3 lines) in 2 eyes (10%). All vision-related questionnaire items improved.
   CONCLUSION: For cataractous eyes with AMD, replacing the crystalline lens with this myopia-targeted multifocal IOL improved or maintained near vision without severely compromising distance vision. Financial Disclosure: Drs. Mackool and Ernest are consultants to Alcon. Dr. Mackool is an inventor in the patent of the IOLs related to this strategy. No other author has a financial or proprietary interest in any material or method mentioned.
C1 [Gayton, Johnny L.; Seabolt, ReBecca A.; Dumont, Susan] Eyesight Associates, Warner Robins, GA 31088 USA.
   [Mackool, Richard J.] Mackool Eye Inst, Astoria, NY USA.
   [Ernest, Paul H.] TLC Eye Care Michigan, Jackson, MI USA.
RP Gayton, JL (通讯作者)，Eyesight Associates, 216 Corder Rd, Warner Robins, GA 31088 USA.
EM jlgayton@aol.com
FU Alcon Research
FX Funded by Alcon Research, which also assisted with the data analysis and
   preparation of the manuscript.
CR Alcon Surgical, 2009, ARCRYSOF IQ RESTOR M
   Alio JL, 2004, J CATARACT REFR SURG, V30, P1177, DOI 10.1016/j.jcrs.2003.10.038
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   BOUTROS GJE, 1995, OPHTHALMIC SURG LAS, V26, P153
   Casparis H, 2009, COCHRANE DB SYST REV, V1
   Davison JA, 2006, J CATARACT REFR SURG, V32, P849, DOI 10.1016/j.jcrs.2006.02.006
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Iizuka M, 2007, CAN J OPHTHALMOL, V42, P854, DOI 10.3129/i07-152
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Mackool RJ, 2009, EP patent, Patent No. [07101409.6, 1 818 023 B1, 1818023]
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Pham TQ, 2004, CLIN EXP OPHTHALMOL, V32, P383, DOI 10.1111/j.1442-9071.2004.00842.x
NR 13
TC 15
Z9 16
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD MAR
PY 2012
VL 38
IS 3
BP 415
EP 418
DI 10.1016/j.jcrs.2011.12.022
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 904OS
UT WOS:000301208400007
PM 22340604
DA 2022-11-30
ER

PT J
AU Soubrane, G
   Cruess, A
   Lotery, A
   Pauleikhoff, D
   Mones, J
   Xu, X
   Zlateva, G
   Buggage, R
   Conlon, J
   Goss, TF
AF Soubrane, Gisele
   Cruess, Alan
   Lotery, Andrew
   Pauleikhoff, Daniel
   Mones, Jordi
   Xu, Xiao
   Zlateva, Gergana
   Buggage, Ronald
   Conlon, John
   Goss, Thomas F.
TI Burden and health care resource utilization in neovascular age-related
   macular degeneration - Findings of a multicountry study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; ELDERLY-WOMEN; IMPACT; RESPONSIVENESS; PREVALENCE;
   FALLS
AB Objective: To describe the burden of bilateral neovascular age-related macular degeneration (NV-AMD) on patient-reported functioning and health resource utilization.
   Methods: A cross-sectional study of 401 patients with bilateral NV-AMD and 471 elderly control subjects without AMD was conducted in 5 countries. Subjects completed a telephone survey, including the National Eye Institute 25-Item Visual Function Questionnaire, the EuroQol instrument, the Hospital Anxiety and Depression Scale, and history of falls, fractures, and health care resource utilization.
   Results: The mean age for patients with NV-AMD was 78.1 years, and 65% were women. The patients reported 45% worse vision-related functioning, 13% worse overall wellbeing, and 30% more anxiety and 42% more depression symptoms than controls after adjusting for covariates (all, P <. 001). The effect of NV-AMD was also observed as a doubled fall rate (16% vs 8% [P <. 001]) and a quadrupled need for assistance with daily activities (29% vs 7% [P <. 001]) in the patients compared with controls.
   Conclusions: The evidence of extensive decline in quality of life and increased need of daily living assistance for patients with NV-AMD compared with a control population substantiates the need for new treatments that prevent vision loss and progression to blindness.
C1 Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal, Creteil, France.
   Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada.
   Univ Southampton, Div Clin Neurosci, Southampton, Hants, England.
   St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   Inst Microcirugia Ocular Barcelona, Barcelona, Spain.
   Covance Market Access Serv Inc, Gaithersburg, MD USA.
   Pfizer Ophthalm, New York, NY USA.
   Covance Inc, Princeton, NJ USA.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Dalhousie
   University; University of Southampton; St. Franziskus-Hospital; Covance;
   Pfizer; Covance
RP Soubrane, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal, 40 Ave Verdum, Creteil, France.
EM gisele.soubrane@chicreteil.fr
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160; Lotery, Andrew/0000-0001-5541-4305
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Eichenbaum JW, 1999, ARCH GERONTOL GERIAT, V28, P191, DOI 10.1016/S0167-4943(99)00009-6
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Harwood RH, 2005, BRIT J OPHTHALMOL, V89, P53, DOI 10.1136/bjo.2004.049478
   Harwood RH, 2001, AGE AGEING, V30, P13, DOI 10.1093/ageing/30.suppl_4.13
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Hawkins BS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1616, DOI 10.1001/archopht.122.11.1616
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KNUR KK, 2004, ANN M ASS RES VIS OP
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   *NAT I CLIN EXC, 2003, TECHN APPR GUID 68 G
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Verma Lalit, 2000, Indian Journal of Ophthalmology, V48, P263
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 28
TC 109
Z9 112
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2007
VL 125
IS 9
BP 1249
EP 1254
DI 10.1001/archopht.125.9.1249
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 208TM
UT WOS:000249342100014
PM 17846366
OA Bronze
DA 2022-11-30
ER

PT J
AU Ebeling, MC
   Geng, ZH
   Kapphahn, RJ
   Roehrich, H
   Montezuma, SR
   Dutton, JR
   Ferrington, DA
AF Ebeling, Mara C.
   Geng, Zhaohui
   Kapphahn, Rebecca J.
   Roehrich, Heidi
   Montezuma, Sandra R.
   Dutton, James R.
   Ferrington, Deborah A.
TI Impaired Mitochondrial Function in iPSC-Retinal Pigment Epithelium with
   the Complement Factor H Polymorphism for Age-Related Macular
   Degeneration
SO CELLS
LA English
DT Article
DE induced pluripotent stem cell; retinal pigment epithelium; age-related
   macular degeneration; complement factor H; mitochondrial function;
   inflammation
AB Age-related macular degeneration (AMD), the leading cause of vision loss in the elderly, is characterized by loss of the retinal pigment epithelium (RPE). While the disease mechanism remains unclear, prior studies have linked AMD with RPE mitochondrial defects and genetic polymorphisms in the complement pathway. This study used RPE generated from induced pluripotent stem cells (iPSC-RPE), which were derived from human donors with or without AMD and genotyped for the complement factor H (CFH) AMD high-risk allele (rs1061170, Y402H) to investigate whether donor disease state or genotype had a detrimental effect on mitochondrial function and inflammation. Results show that cells derived from donors with AMD display decreased mitochondrial function under conditions of stress and elevated expression of inflammatory markers compared to iPSC-RPE from individuals without AMD. A more pronounced reduction in mitochondrial function and increased inflammatory markers was observed in CFH high-risk cells, irrespective of disease state. These results provide evidence for a previously unrecognized link between CFH and mitochondrial function that could contribute to RPE loss in AMD patients harboring the CFH high-risk genotype.
C1 [Ebeling, Mara C.; Kapphahn, Rebecca J.; Montezuma, Sandra R.; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Geng, Zhaohui; Dutton, James R.; Ferrington, Deborah A.] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.
   [Geng, Zhaohui; Dutton, James R.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
   [Roehrich, Heidi] Univ Minnesota, Histol Core Vis Res, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Ferrington, DA (通讯作者)，Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.; Dutton, JR; Ferrington, DA (通讯作者)，Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.; Dutton, JR (通讯作者)，Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
EM ebeli017@umn.edu; gengx027@umn.edu; kapph001@umn.edu; rohri002@umn.edu;
   smontezu@umn.edu; dutto015@umn.edu; ferri013@umn.edu
OI Montezuma, Sandra/0000-0003-3731-8082; , Heidi/0000-0002-2232-9494;
   Ferrington, Deborah/0000-0003-2561-7464
FU NIH [R01EY026012, R01EY0285541, P30EY11374]; Regenerative Medicine
   Minnesota [2015-5337, 091718 TR 009]; Lindsay Family Foundation; Elaine
   and Robert Larson Endowed Vision Research Chair
FX This research was funded by NIH (grant number R01EY026012 to D.A.F.,
   R01EY0285541 to D.A.F. and J.R.D., P30EY11374 to H.R.), Regenerative
   Medicine Minnesota (grant number 2015-5337, 091718 TR 009), an anonymous
   benefactor for Macular Degeneration Research, and the Lindsay Family
   Foundation, and the Elaine and Robert Larson Endowed Vision Research
   Chair (D.A.F). None of the funding agencies had a role in study design,
   in the collection, analysis and interpretation of data, in writing the
   manuscript, or in the decision to submit the manuscript for publication.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arbore G, 2016, EUR J IMMUNOL, V46, P1563, DOI 10.1002/eji.201546131
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Bent R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082155
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Calaza KC, 2015, NEUROBIOL AGING, V36, P2869, DOI 10.1016/j.neurobiolaging.2015.06.010
   Cao SJ, 2016, BRIT J OPHTHALMOL, V100, P713, DOI 10.1136/bjophthalmol-2015-307213
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Chacko BK, 2014, CLIN SCI, V127, P367, DOI 10.1042/CS20140101
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   de Carvalho JER, 2013, INVEST OPHTH VIS SCI, V54, P6489, DOI 10.1167/iovs.13-12374
   Ebeling MC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101552
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geng ZH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173575
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Hess C, 2016, IMMUNITY, V45, P240, DOI 10.1016/j.immuni.2016.08.003
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Kolev M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00001
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Leffler J, 2010, J BIOL CHEM, V285, P3766, DOI 10.1074/jbc.M109.045427
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018
   Luo C, 2011, MOL VIS, V17, P1588
   Luo Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00604
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Martin M, 2016, CELL DEATH DIFFER, V23, P903, DOI 10.1038/cdd.2015.164
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Reichhardt MP, 2018, SEMIN IMMUNOL, V38, P54, DOI 10.1016/j.smim.2018.03.003
   Revelo NH, 2020, J CELL SCI, V133, DOI 10.1242/jcs.234781
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Samanta A, 2021, ASIA-PAC J OPHTHALMO, V10, P408, DOI 10.1097/APO.0000000000000355
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Sivapathasuntharam C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37673-6
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Terluk MR, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5174957
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
NR 61
TC 15
Z9 15
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD APR
PY 2021
VL 10
IS 4
AR 789
DI 10.3390/cells10040789
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA RR1RB
UT WOS:000642882800001
PM 33918210
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, Y
   Xu, HW
   Wang, L
   Li, SY
   Zhao, CJ
   Hao, J
   Li, QY
   Zhao, TT
   Wu, W
   Wang, Y
   Zhou, Q
   Qian, C
   Wang, L
   Yin, ZQ
AF Liu, Yong
   Xu, Hai Wei
   Wang, Lei
   Li, Shi Ying
   Zhao, Cong Jian
   Hao, Jie
   Li, Qi You
   Zhao, Tong Tao
   Wu, Wei
   Wang, Yi
   Zhou, Qi
   Qian, Cheng
   Wang, Liu
   Yin, Zheng Qin
TI Human embryonic stem cell-derived retinal pigment epithelium transplants
   as a potential treatment for wet age-related macular degeneration
SO CELL DISCOVERY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; OPHTHALMIC FINDINGS; SURGERY
AB Stem cell therapy may provide a safe and promising treatment for retinal diseases. Wet age-related macular degeneration (wet-AMD) is a leading cause of blindness in China. We developed a clinical-grade human embryonic stem cell (hESC) line, Q-CTS-hESC-2, under xeno-free conditions that differentiated into retinal pigment epithelial cells (Q-CTS-hESC-2-RPE). A clinical trial with three wet-AMD patients was initiated in order to study the safety and tolerance to Q-CTS-hESC-2-RPE cell transplants. The choroidal neovascularization membrane was removed and then a suspension of 1 x 106 Q-CTS-hESC-2-RPE cells were injected into a subfoveal pocket. The patients were followed for 12 months during which no adverse effects resulting from the transplant were observed. Anatomical evidence suggested the existence of new RPE-like cell layer in the previously damaged area. Visual and physiological testing indicated limited functional improvement, albeit to different degrees between patients. This study provides some promising early results concerning the use of transplanted hESC-RPE cells to alleviate wet-AMD.
C1 [Liu, Yong; Xu, Hai Wei; Li, Shi Ying; Zhao, Cong Jian; Li, Qi You; Zhao, Tong Tao; Wu, Wei; Wang, Yi; Yin, Zheng Qin] Amy Med Univ, Mil Med Univ 3, Southwest Eye Hosp, Southwest Hosp, Chongqing 400038, Peoples R China.
   [Wang, Lei; Hao, Jie; Zhou, Qi; Wang, Liu] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.
   [Wang, Lei; Zhou, Qi; Wang, Liu] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Qian, Cheng] Amy Med Univ, Mil Med Univ 3, Southwest Hosp, Inst Pathol, Chongqing 400038, Peoples R China.
   [Qian, Cheng] Amy Med Univ, Mil Med Univ 3, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China.
C3 Army Medical University; Chinese Academy of Sciences; Institute of
   Zoology, CAS; Chinese Academy of Sciences; University of Chinese Academy
   of Sciences, CAS; Army Medical University; Army Medical University
RP Yin, ZQ (通讯作者)，Amy Med Univ, Mil Med Univ 3, Southwest Eye Hosp, Southwest Hosp, Chongqing 400038, Peoples R China.; Wang, L (通讯作者)，Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.
EM wangliu@ioz.ac.cn; yzhengqin@163.com
RI Zhao, CongJian/AAW-8262-2020; Xu, Haiwei/AFN-3524-2022; Xu,
   Haiwei/AAV-6591-2021; Li, Shiying/AAL-4898-2021
OI Zhao, CongJian/0000-0002-2920-6286; Xu, Haiwei/0000-0002-8840-7918; Xu,
   Haiwei/0000-0002-8840-7918; Li, Shiying/0000-0001-9783-9520; Wu,
   Wei/0000-0002-7097-2150
FU National Basic Research Program of China [2013CB967002]; Strategic
   Priority Research Program of the CAS [XDA01030507, XDA01030506];
   National Key Research Program [2016YFC1101103]; Southwest Hospital Key
   Pgrogram [SWH2016ZDCX1001]
FX This work was supported by the National Basic Research Program of China
   (2013CB967002, to Prof. Zheng Qin Yin), the Strategic Priority Research
   Program of the CAS (XDA01030507, to Prof. Zheng Qin Yin; XDA01030506, to
   Liu Wang), Southwest Hospital Key Pgrogram (SWH2016ZDCX1001, to Prof.
   Zheng Qin Yin) and the National Key Research Program (2016YFC1101103, to
   Dr. Yong Liu). The authors thank Dr. T. FitzGibbon for comments on
   earlier drafts of the paper and Dr. Guihai Feng for the data analysis of
   whole exome sequencing.
CR Bertolotti E, 2014, PROG RETIN EYE RES, V42, P130, DOI 10.1016/j.preteyeres.2014.06.002
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GHARTEY KN, 1980, ARCH OPHTHALMOL-CHIC, V98, P1248, DOI 10.1001/archopht.1980.01020040100014
   Gu Q, 2017, STEM CELL REP, V9, P366, DOI 10.1016/j.stemcr.2017.04.017
   Han L, 2013, INVEST OPHTH VIS SCI, V54, P4956, DOI 10.1167/iovs.13-11957
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Lai TYY, 2007, SURV OPHTHALMOL, V52, P61, DOI 10.1016/j.survophthal.2006.10.005
   LEAVER PK, 1984, BRIT J OPHTHALMOL, V68, P432, DOI 10.1136/bjo.68.6.432
   Li RW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024417
   Li SY, 2009, CURR EYE RES, V34, P523, DOI 10.1080/02713680902936148
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Majji AB, 2000, GRAEF ARCH CLIN EXP, V238, P779, DOI 10.1007/s004170000132
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Odom JV, 2016, DOC OPHTHALMOL, V133, P1, DOI 10.1007/s10633-016-9553-y
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Walsh P, 2005, J NEUROL NEUROSUR PS, V76, P16, DOI 10.1136/jnnp.2005.068130
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wu W, 2016, ONCOTARGET, V7, P22819, DOI 10.18632/oncotarget.8185
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
NR 33
TC 39
Z9 44
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2056-5968
J9 CELL DISCOV
JI Cell Discov.
PD SEP 25
PY 2018
VL 4
AR 50
DI 10.1038/s41421-018-0053-y
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IH9TT
UT WOS:000474850000001
PM 30245845
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dadgostar, H
   Waheed, N
AF Dadgostar, H.
   Waheed, N.
TI The evolving role of vascular endothelial growth factor inhibitors in
   the treatment of neovascular age-related macular degeneration
SO EYE
LA English
DT Review
DE VEGF; age related macular degeneration; intravitreal injection
ID INTRAVITREAL BEVACIZUMAB AVASTIN; OCCULT CHOROIDAL NEOVASCULARIZATION;
   ARTERIAL THROMBOEMBOLIC EVENTS; RANIBIZUMAB; SAFETY; PERMEABILITY;
   VERTEPORFIN; PEGAPTANIB; ANTIBODY
AB Age-related macular degeneration (AMD) is the leading cause of blindness among the ageing population. The introduction of molecular inhibitors of vascular endothelial growth factor (VEGF), such as pegaptanib, ranibizumab, and bevacizumab, as treatments for exudative AMD has provided new hope for affected patients and has transformed the practices of retina specialists. Phase III clinical trials have demonstrated the efficacy and safety of monthly ranibizumab for the preservation as well as improvement of visual acuity in patients with exudative AMD. Ongoing trials are evaluating the effectiveness of different dosing regimens, monitoring strategies, and combination therapies to determine the optimal niche for this new class of drugs in AMD management. Based on emerging evidence, most clinicians are now adopting a variable VEGF inhibitor dosing strategy guided by serial diagnostic reevaluation by optical coherence tomography. Some are also finding benefit through the addition of photodynamic therapy and steroids to the treatment regimen. The results of current and upcoming trials systematically addressing these issues are expected to establish new guidelines for the management of AMD. Indeed, a new paradigm may emerge wherein numerous modular therapeutic modalities are administered in customized combinations based on specific clinical and diagnostic findings.
C1 [Dadgostar, H.; Waheed, N.] Cleveland Clin Fdn, Dept Ophthalmol, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Waheed, N (通讯作者)，Cleveland Clin Fdn, Dept Ophthalmol, Cole Eye Inst, Jan-32,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM waheedn@ccf.org
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Clarke MS, 2004, OPHTHALMOLOGY, V111, P2316, DOI 10.1016/j.ophtha.2004.09.009
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dafer Rima M, 2007, Semin Ophthalmol, V22, P201, DOI 10.1080/08820530701543024
   DAMICO DJ, 2003, OPHTHALMOLOGY, V110, P2384
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Freeman WR, 2006, RETINA-J RET VIT DIS, V26, P853, DOI 10.1097/01.iae.0000244722.35073.7c
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244
   PULIAFITO CA, 2007, ANN ADV VITR TECHN T
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   ROSENFELD PJ, 2006, ANN M ASS RES VIS OP
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 40
TC 33
Z9 36
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2008
VL 22
IS 6
BP 761
EP 767
DI 10.1038/eye.2008.86
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 312HL
UT WOS:000256659800004
PM 18388961
OA Bronze
DA 2022-11-30
ER

PT J
AU Hwang, S
   Kang, SW
   Han, J
   Han, K
   Kim, D
   Lee, KN
   Jeon, KH
   Yoo, JE
   Lee, DY
   Shin, DW
   Lim, DH
AF Hwang, Sungsoon
   Kang, Se Woong
   Han, Jisang
   Han, Kyungdo
   Kim, Dahye
   Lee, Kyu Na
   Jeon, Keun Hye
   Yoo, Jung Eun
   Lee, Dong-Yun
   Shin, Dong Wook
   Lim, Dong Hui
TI FEMALE REPRODUCTIVE FACTORS AND THE RISK OF EXUDATIVE AGE-RELATED
   MACULAR DEGENERATION A Nationwide Cohort Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE exudative age-related macular degeneration; female hormone; hormone
   replacement therapy; reproductive factors
ID PIGMENT EPITHELIAL-CELLS; ESTROGEN; PREVALENCE; EXPRESSION; GENDER
AB Purpose: To evaluate the association between female reproductive factors and the incidence of exudative age-related macular degeneration (AMD). Methods: A total of 1,297,388 postmenopausal women over 50 years of age who participated in both national health screening and cancer screening in 2009 were identified using the Korea National Health Insurance System database. Data on female reproductive factors were collected using a self-administered questionnaire. Patients were followed up until 2018, and the incident cases of exudative AMD were identified. The hazard ratios and 95% confidence intervals for exudative AMD were estimated using the multivariable-adjusted Cox proportional hazard model. Results: During a mean follow-up of 7.27 years, 4,086 patients were newly diagnosed with exudative AMD. The hazard ratio (95% confidence intervals) for exudative AMD was 1.14 (1.01-1.31) for a reproductive period >= 40 years compared with a reproductive period <30 years, 1.72 (1.48-2.00) for patients with >= 5 years of hormone replacement therapy, and 1.29 (1.09-1.52) for those with 2 to 5 years of hormone replacement therapy compared with those who never underwent hormone replacement therapy. Conclusion: Female reproductive factors were associated with the risk of exudative AMD. Greater lifetime exposure to endogenous and exogenous estrogen was associated with a higher incidence of exudative AMD.
C1 [Hwang, Sungsoon; Kang, Se Woong; Lim, Dong Hui] Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
   [Hwang, Sungsoon; Shin, Dong Wook; Lim, Dong Hui] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol SAIHST, Dept Clin Res Design & Evaluat, Seoul, South Korea.
   [Han, Jisang] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Ophthalmol, Sch Med, Seoul, South Korea.
   [Han, Kyungdo] Soongsil Univ, Dept Stat & Actuarial Sci, Seoul, South Korea.
   [Kim, Dahye] Catholic Univ Korea, Coll Med, Dept Med Stat, Seoul, South Korea.
   [Lee, Kyu Na] Catholic Univ Korea, Dept Biomed & Hlth Sci, Seoul, South Korea.
   [Jeon, Keun Hye; Yoo, Jung Eun; Shin, Dong Wook] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Family Med, Seoul, South Korea.
   [Lee, Dong-Yun] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Obstet & Gynecol, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Samsung;
   Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Samsung
   Medical Center; Soongsil University; Catholic University of Korea;
   Catholic University of Korea; Sungkyunkwan University (SKKU); Samsung
   Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center
RP Lim, DH (通讯作者)，Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
EM ldhlse@gmail.com
FU National Research Foundation of Korea - Korean government's Ministry of
   Education [NRF-2019R1C1C1007917]; Korea Health Technology R&D Project
   through the Korea Health Industry Development Institute (KHIDI) -
   Ministry of Health and Welfare, Republic of Korea [HI19C0481, HC19C0142]
FX Supported by a National Research Foundation of Korea grant funded by the
   Korean government's Ministry of Education (NRF-2019R1C1C1007917; Seoul,
   Korea), which was received by J. Han, and a grant from the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI) funded by the Ministry of Health and Welfare, Republic
   of Korea (grant number: HI19C0481, HC19C0142), which was received by D.
   H. Lim.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   Bhavnani BR, 2001, MENOPAUSE, V8, P408, DOI 10.1097/00042192-200111000-00005
   Cho BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102816
   Erke MG, 2013, BRIT J OPHTHALMOL, V97, P1036, DOI 10.1136/bjophthalmol-2012-302461
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P413, DOI 10.1016/j.exer.2004.10.008
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Hwang S, 2018, AM J OPHTHALMOL, V192, P56, DOI 10.1016/j.ajo.2018.04.027
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Jeon KH, 2020, BRIT J CANCER, V122, P1417, DOI 10.1038/s41416-020-0789-7
   Kaarniranta K, 2015, CURR EYE RES, V40, P226, DOI 10.3109/02713683.2014.925933
   Lee J, 2017, INT J EPIDEMIOL, V46, DOI 10.1093/ije/dyv319
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Patnaik JL, 2020, OPHTHAL EPIDEMIOL, V27, P148, DOI 10.1080/09286586.2019.1701041
   Rim TH, 2019, BRIT J OPHTHALMOL, V103, P19, DOI 10.1136/bjophthalmol-2018-312693
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Seong SC, 2017, INT J EPIDEMIOL, V46, P799, DOI 10.1093/ije/dyw253
   Tanemura M, 2004, MOL VIS, V10, P923
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   World Health Organization, 2000, REG OFF W P AS PAC P
   Yoo JE, 2020, EUR J NEUROL, V27, P1448, DOI 10.1111/ene.14315
   Yoo KY, 2008, JPN J CLIN ONCOL, V38, P327, DOI 10.1093/jjco/hyn026
   Yu XR, 2005, MECH AGEING DEV, V126, P1135, DOI 10.1016/j.mad.2005.05.005
NR 30
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2021
VL 41
IS 10
BP 2088
EP 2097
DI 10.1097/IAE.0000000000003164
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5GS
UT WOS:000711796500012
PM 33675332
DA 2022-11-30
ER

PT J
AU Vaze, A
   Fraser-Bell, S
   Gillies, M
AF Vaze, Anagha
   Fraser-Bell, Samantha
   Gillies, Mark
TI REASONS FOR DISCONTINUATION OF INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH
   FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; vascular endothelial growth factor
   inhibitors; treatment efficacy; patient acceptance; quality of life;
   patient outcomes; treatment discontinuation
ID VISION-RELATED FUNCTION; RANIBIZUMAB TREATMENT; PHOTODYNAMIC THERAPY;
   DOSING REGIMEN; CLINICAL-TRIAL; ANCHOR
AB Background: This study was aimed to identify the reasons for discontinuing intravitreal anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration.
   Methods: This study is a retrospective chart review of a single Australian private practice. Analysis included patients who discontinued treatment from March 2006 to June 2012.
   Results: Of 248 patients who commenced treatment, 105 (42.3%) had discontinued by June 2012. The reasons for discontinuation were available for 102 of the 105 (97.1%) patients. In 9 (3.6%) patients of the entire cohort, the doctor stopped the treatment as the lesion became inactive, whereas further treatment was thought to be futile in 27 (10.9%) patients. Twenty-six (10.5%) patients declined further treatment with 2 (0.8%) because of excessive treatment visits, 2 (0.8%) because of difficulty in attending, 2 (0.8%) because of the expense, 3 (1.2%) because of pain/discomfort, 6 (2.4%) thought that the treatment was not beneficial, and 11 (4.4%) had other medical conditions that were more severe. Treatment was discontinued in 40 (16.1%) patients for other reasons such as moving to another region in 27 (10.9%) and death in 11 (4.4%).
   Conclusion: These results indicate that the burden of intravitreal anti-vascular endothelial growth factor injections was a reason for treatment discontinuation in only a small minority of patients.
C1 [Vaze, Anagha; Fraser-Bell, Samantha; Gillies, Mark] Univ Sydney, Save Sight Inst, Sydney, NSW 2000, Australia.
C3 University of Sydney
RP Vaze, A (通讯作者)，Univ Sydney, Sydney Eye Hosp, Save Sight Inst, Level 1,South Block,8 Macquarie St, Sydney, NSW 2000, Australia.
EM anagha.vaze@sydney.edu.au
RI Fraser-Bell, Samantha/ABE-8574-2020
OI Fraser-Bell, Samantha/0000-0001-5646-9359
FU RANZCO Eye Foundation, Sydney; National Health and Medical Research
   Council, Canberra; NHMRC Practitioner Fellowship
FX Supported by grants from the RANZCO Eye Foundation, Sydney, and the
   National Health and Medical Research Council, Canberra. M. Gillies is a
   fellow in Sydney Medical School Foundation and is supported by an NHMRC
   Practitioner Fellowship.
CR Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Ehlers JP, 2013, BRIT J OPHTHALMOL, V97, P248, DOI 10.1136/bjophthalmol-2012-302489
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Hampton T, 2010, JAMA-J AM MED ASSOC, V304, P1541, DOI 10.1001/jama.2010.1411
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
NR 17
TC 31
Z9 31
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2014
VL 34
IS 9
BP 1774
EP 1778
DI 10.1097/IAE.0000000000000173
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO8UL
UT WOS:000341630400012
PM 24837049
DA 2022-11-30
ER

PT J
AU Liberski, S
   Wichrowska, M
   Kociecki, J
AF Liberski, Slawomir
   Wichrowska, Malgorzata
   Kociecki, Jaroslaw
TI Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related
   Macular Degeneration and Diabetic Macular Edema: A Review
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE aflibercept; faricimab; anti-VEGF; angiopoietin-2; DME; diabetic macular
   edema; nAMD; neovascular age-related macular degeneration; Ang; Tie-2
   pathway
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR TRAP-EYE; PHASE-I TRIAL; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL AFLIBERCEPT; VEGF TRAP; VITREOUS
   LEVELS; MESSENGER-RNA; DA VINCI; EXPRESSION
AB Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are common retinal vascular diseases responsible for most blindness in the working-age and older population in developed countries. Currently, anti-VEGF agents that block VEGF family ligands, including ranibizumab, bevacizumab (off-label use), brolucizumab, and aflibercept, are the first-line treatment for nAMD and DME. However, due to the complex pathophysiological background of nAMD and DME, non-response, resistance during anti-VEGF therapy, and relapses of the disease are still observed. Moreover, frequent injections are a psychological and economic burden for patients, leading to inadequate adhesion to therapy and a higher risk of complications. Therefore, therapeutic methods are strongly needed to develop and improve, allowing for more satisfactory disease management and lower treatment burden. Currently, the Ang/Tie-2 pathway is a promising therapeutic target for retinal vascular diseases. Faricimab is the first bispecific monoclonal antibody for intravitreal use that can neutralize VEGF and Ang-2. Due to the prolonged activity, faricimab allows extending the interval between successive injections up to three or four months in nAMD and DME patients, which can be a significant benefit for patients and an alternative to implanted drug delivery systems.
C1 [Liberski, Slawomir; Wichrowska, Malgorzata; Kociecki, Jaroslaw] Poznan Univ Med Sci, Dept Ophthalmol, Ul Augustyna Szamarzewskiego 84, PL-61848 Poznan, Poland.
   [Wichrowska, Malgorzata] Poznan Univ Med Sci, Doctoral Sch, Ul Bukowska 70, PL-60812 Poznan, Poland.
C3 Poznan University of Medical Sciences; Poznan University of Medical
   Sciences
RP Liberski, S (通讯作者)，Poznan Univ Med Sci, Dept Ophthalmol, Ul Augustyna Szamarzewskiego 84, PL-61848 Poznan, Poland.
EM liberski.slawomir@gmail.com
OI Wichrowska, Malgorzata/0000-0002-1523-6222; Kociecki,
   Jaroslaw/0000-0001-7321-1835
FU Poznan University of Medical Sciences
FX This work was supported by the Poznan University of Medical Sciences.
CR Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019
   Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Al Kahtani E, 2017, EYE, V31, P529, DOI 10.1038/eye.2016.246
   [Anonymous], NCT04423718
   [Anonymous], NCT04429503
   Baris ME, 2020, TURK OFTALMOL DERG, V50, P275, DOI 10.4274/tjo.galenos.2020.38488
   Beltramo E, 2013, CURR MED CHEM, V20, P3218, DOI 10.2174/09298673113209990022
   Boss JD, 2017, INVEST OPHTH VIS SCI, V58, P5594, DOI 10.1167/iovs.17-21973
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Browning DJ, 2018, INDIAN J OPHTHALMOL, V66, P1736, DOI 10.4103/ijo.IJO_1240_18
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Chang ML, 2007, J ANAT, V210, P54, DOI 10.1111/j.1469-7580.2006.00671.x
   Chauhan MZ, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11121950
   Chawla Aastha, 2016, Indian J Endocrinol Metab, V20, P546, DOI 10.4103/2230-8210.183480
   Chen JH, 2018, NUTR METAB, V15, DOI 10.1186/s12986-018-0306-7
   Chopra R, 2022, EYE, V36, P1373, DOI 10.1038/s41433-021-01646-3
   Corliss BA, 2016, MICROCIRCULATION, V23, P95, DOI 10.1111/micc.12259
   Daien V, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1208-9
   Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Do DV, 2011, OPHTHALMOLOGY, V118, P1819, DOI 10.1016/j.ophtha.2011.02.018
   Doganay S, 2002, EYE, V16, P163, DOI 10.1038/sj/eye/6700095
   Flores R, 2021, OPHTHALMOLOGICA, V244, P495, DOI 10.1159/000517520
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Foxton RH, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810204
   Gerhardinger C, 1998, AM J PATHOL, V152, P1453
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Heier JS, 2016, OPHTHALMOLOGY, V123, P2376, DOI 10.1016/j.ophtha.2016.07.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Huang H, 2015, DIABETES, V64, P200, DOI 10.2337/db14-0016
   Hussain RM, 2019, EXPERT OPIN INV DRUG, V28, P861, DOI 10.1080/13543784.2019.1667333
   Iglicki M, 2022, EYE, V36, P273, DOI 10.1038/s41433-021-01722-8
   Jakubiak P, 2021, MOL PHARMACEUT, V18, P2208, DOI 10.1021/acs.molpharmaceut.0c01218
   Joussen AM, 2021, EYE, V35, P1305, DOI 10.1038/s41433-020-01377-x
   Khan M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081869
   Khanani Arshad M, 2021, Ophthalmol Sci, V1, P100076, DOI 10.1016/j.xops.2021.100076
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Klein C, 2019, METHODS, V154, P21, DOI 10.1016/j.ymeth.2018.11.008
   Klein C, 2016, MABS-AUSTIN, V8, P1010, DOI 10.1080/19420862.2016.1197457
   Klein R, 2008, OPHTHALMOLOGY, V115, P1859, DOI 10.1016/j.ophtha.2008.08.023
   Koleva-Georgieva Desislava N, 2011, Folia Med (Plovdiv), V53, P44
   Kuroiwa DAK, 2021, OPHTHALMOLOGICA, V244, P485, DOI 10.1159/000516614
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Kozak I, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0254569
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Leppanen VM, 2017, P NATL ACAD SCI USA, V114, P4376, DOI 10.1073/pnas.1616166114
   Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852
   Mekjavic PJ, 2019, VALUE HEALTH REG ISS, V19, P1, DOI 10.1016/j.vhri.2018.11.002
   Moisseiev E, 2020, EYE, V34, P605, DOI 10.1038/s41433-019-0584-y
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Nicolo M, 2021, EXPERT OPIN INV DRUG, V30, P193, DOI 10.1080/13543784.2021.1879791
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   O'Neill HC, 2020, CURR STEM CELL RES T, V15, P89, DOI 10.2174/1574888X15666191218094020
   Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732
   Ohr M, 2012, THER ADV CHRONIC DIS, V3, P153, DOI 10.1177/2040622312446007
   Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442
   Park SW, 2014, DIABETES, V63, P3057, DOI 10.2337/db13-1942
   Patel P, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112436
   Peach CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041264
   Nguyen QD, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00250-z
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regillo C, 2022, INVEST OPHTH VIS SCI, V63
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Sharma A, 2021, OCUL IMMUNOL INFLAMM, DOI 10.1080/09273948.2021.1931350
   Sharma A, 2020, EYE, V34, P802, DOI 10.1038/s41433-019-0670-1
   Sharma A, 2020, EYE, V34, P797, DOI 10.1038/s41433-019-0607-8
   Sharma A, 2020, EYE, V34, P611, DOI 10.1038/s41433-019-0583-z
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Shirley M, 2022, DRUGS, V82, P825, DOI 10.1007/s40265-022-01713-3
   Spooner KL, 2019, DIABETES METAB SYNDR, V12, P1913, DOI 10.2147/DMSO.S214098
   Stewart MW, 2015, DIABET METAB SYND OB, V8, P473, DOI 10.2147/DMSO.S72792
   Surowka M, 2021, MABS-AUSTIN, V13, DOI 10.1080/19420862.2021.1967714
   Swidzinska Ewa, 2006, Pneumonol Alergol Pol, V74, P414
   Tadayoni R, 2021, OPHTHALMOLOGICA, V244, P93, DOI 10.1159/000513048
   Usui-Ouchi A, 2021, LIFE-BASEL, V11, DOI 10.3390/life11020083
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Watanabe D, 2005, AM J OPHTHALMOL, V139, P476, DOI 10.1016/j.ajo.2004.10.004
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2022, OPHTHALMOL THER, V11, P1705, DOI 10.1007/s40123-022-00532-9
   Wykoff CC, 2022, LANCET, V399, P741, DOI 10.1016/S0140-6736(22)00018-6
   Xu D, 2013, IMMUNOTHERAPY-UK, V5, P121, DOI [10.2217/IMT.12.158, 10.2217/imt.12.158]
   Yamada M, 2003, ARTERIOSCL THROM VAS, V23, P1996, DOI 10.1161/01.ATV.0000096208.80992.63
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   You QS, 2018, RETINA-J RET VIT DIS, V38, P1156, DOI 10.1097/IAE.0000000000001726
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Yun JH, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.347
NR 101
TC 0
Z9 0
U1 5
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2022
VL 23
IS 16
AR 9424
DI 10.3390/ijms23169424
PG 30
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 4B4YA
UT WOS:000845783700001
PM 36012690
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chrapek, O
   Jarkovsky, J
   Sin, M
   Studnicka, J
   Kolar, P
   Jirkova, B
   Dusek, L
   Pitrova, S
   Rehak, J
AF Chrapek, Oldrich
   Jarkovsky, Jiri
   Sin, Martin
   Studnicka, Jan
   Kolar, Petr
   Jirkova, Barbora
   Dusek, Ladislav
   Pitrova, Sarka
   Rehak, Jiri
TI Prognostic Factors of Early Morphological Response to Treatment with
   Ranibizumab in Patients with Wet Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EARLY CHOROIDAL NEOVASCULARIZATION; EFFICACY
AB Aim. To assess the significance of age, gender, baseline best corrected visual acuity, baseline macula thickness, and type and size of choroidal neovascularization in early morphological therapeutic response to ranibizumab treatment in patients with the wet form of age-related macular degeneration. Methods. From 09/2008 to 06/2013 we evaluated 1153 newly diagnosed, treatment-naive patients treated with ranibizumab. Based on the morphological findings in the macula following the initial 3 injections of ranibizumab, the patients were divided into two groups based on active and inactive choroidal neovascularization. Results. After the initial 3 injections of ranibizumab, we examined the sample of 841 eyes with active CNV and 312 eyes with inactive CNV. In the inactive group, we found a statistically higher proportion of occult CNV (P < 0.001) and lower incidence of CNV greater than 5DA (P < 0.001) compared with the active group. We found no statistically significant difference in age, gender, baseline best corrected visual acuity, or baseline macula thickness between the inactive and active groups. Conclusion. Occult CNV and CNV smaller than 5DA are optimistic factors for a better morphological therapeutic response at the beginning of ranibizumab treatment.
C1 [Chrapek, Oldrich; Sin, Martin; Jirkova, Barbora; Rehak, Jiri] Palacky Univ, Fac Med & Dent, Dept Ophthalmol, Olomouc 77520, Czech Republic.
   [Jarkovsky, Jiri; Dusek, Ladislav] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno 62500, Czech Republic.
   [Jarkovsky, Jiri; Dusek, Ladislav] Masaryk Univ, Fac Sci, Brno 62500, Czech Republic.
   [Studnicka, Jan] Charles Univ Prague, Fac Med Hradec Kralove, Dept Ophthalmol, Hradec Kralove 50003, Czech Republic.
   [Studnicka, Jan] Univ Hosp Hradec Kralove, Hradec Kralove 50003, Czech Republic.
   [Kolar, Petr] Univ Hosp, Dept Ophthalmol, Brno 62500, Czech Republic.
   [Pitrova, Sarka] Private Eye Clin, Prague 15800, Czech Republic.
C3 Palacky University Olomouc; Institute of Biostatistics & Analyses;
   Masaryk University Brno; Masaryk University Brno; Charles University
   Prague; University Hospital Brno
RP Kolar, P (通讯作者)，Univ Hosp, Dept Ophthalmol, Jihlavska 340-20, Brno 62500, Czech Republic.
EM pe.kolar@gmail.com
RI Studnicka, Jan/K-2875-2017; Sin, Martin/AAJ-6818-2021; Chrapek,
   Oldrich/ABD-9894-2020; Studnička, Jan/AAC-4127-2022; Dušek,
   Ladislav/G-8794-2013; Jarkovsky, Jiri/G-5494-2017
OI Studnicka, Jan/0000-0002-9911-4379; Chrapek,
   Oldrich/0000-0002-1403-4936; Kolar, Petr/0000-0003-3709-4648; Sin,
   Martin/0000-0002-5073-9482; Dusek, Ladislav/0000-0002-8589-4378
FU Novartis Pharma AG
FX A grant from Novartis Pharma AG was received for the national registry
   AMADEUS.
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
NR 6
TC 2
Z9 2
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 867479
DI 10.1155/2015/867479
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD9BN
UT WOS:000351391200001
PM 25821593
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Corazza, P
   Maddison, J
   Bonetti, P
   Guo, L
   Luong, V
   Garfinkel, A
   Younis, S
   Cordeiro, MF
AF Corazza, Paolo
   Maddison, John
   Bonetti, Paolo
   Guo, Li
   Luong, Vy
   Garfinkel, Alan
   Younis, Saad
   Cordeiro, Maria Francesca
TI Predicting wet age-related macular degeneration (AMD) using DARC
   (detecting apoptosing retinal cells) AI (artificial intelligence)
   technology
SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
LA English
DT Article
DE DARC; biomarker; AMD; CNV; angiogenesis; SRF
ID PREVALENCE
AB Objectives
   To assess a recently described CNN (convolutional neural network) DARC (Detection of Apoptosing Retinal Cells) algorithm in predicting new Subretinal Fluid (SRF) formation in Age-related-Macular-Degeneration (AMD).
   Methods
   Anonymized DARC, baseline and serial OCT images (n = 427) from 29 AMD eyes of Phase 2 clinical trial (ISRCTN10751859) were assessed with CNN algorithms, enabling the location of each DARC spot on corresponding OCT slices (n = 20,629). Assessment of DARC in a rabbit model of angiogenesis was performed in parallel.
   Results
   A CNN DARC count >5 at baseline was significantly (p = 0.0156) related to development of new SRF throughout 36 months. Prediction rate of eyes using unique DARC spots overlying new SRF had positive predictive values, sensitivities and specificities >70%, with DARC count significantly (p < 0.005) related to the magnitude of SRF accumulation at all time points. DARC identified earliest stages of angiogenesis in-vivo.
   Conclusions
   DARC was able to predict new wet-AMD activity. Using only an OCT-CNN definition of new SRF, we demonstrate that DARC can identify early endothelial neovascular activity, as confirmed by rabbit studies. Although larger validation studies are required, this shows the potential of DARC as a biomarker of wet AMD, and potentially saving vision-loss.
C1 [Corazza, Paolo; Bonetti, Paolo; Younis, Saad; Cordeiro, Maria Francesca] Imperial Coll London, ICORG, London, England.
   [Corazza, Paolo; Younis, Saad; Cordeiro, Maria Francesca] Imperial Coll Healthcare NHS Trust, Western Eye Hosp, London, England.
   [Corazza, Paolo] Polyclin Hosp San Martino IRCCS, Univ Eye Clin, DINOGMI, Genoa, Italy.
   [Maddison, John] Novai Ltd, Reading, Berks, England.
   [Guo, Li; Luong, Vy; Cordeiro, Maria Francesca] UCL Inst Ophthalmol, London, England.
   [Garfinkel, Alan] Univ Oxford, Lincoln Coll, Oxford, England.
   [Garfinkel, Alan] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
C3 Imperial College London; Imperial College London; University of London;
   University College London; University of Oxford; University of
   California System; University of California Los Angeles
RP Cordeiro, MF (通讯作者)，UCL Inst Ophthalmol, London, England.
EM M.Cordeiro@ucl.ac.uk
OI Cordeiro, Maria Francesca/0000-0001-8663-6525; Maddison,
   John/0000-0001-9675-8681; Corazza, Paolo/0000-0002-6865-7362
FU Wellcome Trust [WT099729]
FX This paper was funded by the Wellcome Trust (Grant WT099729).
CR Altman DG, 1994, BMJ-BRIT MED J, V309, P6947
   Babenko B, 2019, PREDICTING PROGRESSI
   Banerjee I, 2019, ARXIV PREPRINT ARXIV
   Bek T, 2018, GRAEF ARCH CLIN EXP, V256, P2061, DOI 10.1007/s00417-018-4100-z
   Bhuiyan A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.25
   Bogunovi H, 2019, RETOUCH RETINAL OCT
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Challen R, 2019, BMJ QUALITY SAFETY, V28
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cordeiro MF, 2017, BRAIN, V140, P1757, DOI 10.1093/brain/awx088
   Domalpally A, 2019, OPHTHALMOL RETIN, V3
   Fasler K, 2020, BR J OPHTHALMOL, V104
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hogarty DT, 2019, CLIN EXP OPHTHALMOL, V47
   Keenan TDL, 2021, OPHTHALMOLOGY, V128, P100, DOI [10.1016/j.opatha.2020.06.038, 10.1016/j.ophtha.2020.06.038]
   Li T, 2015, INVEST OPHTHALMOL VI, V56
   Liakopoulos S, 2020, BR J OPHTHALMOL
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91
   Marques Joao Pedro, 2013, ISRN Ophthalmol, V2013, P464218, DOI 10.1155/2013/464218
   Martin DF, 2011, N ENGL J MED, V364
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   McKinney SM, 2020, NATURE, V577, P89, DOI 10.1038/s41586-019-1799-6
   Normando EM, 2020, EXPERT REV MOL DIAGN, V20, P737, DOI 10.1080/14737159.2020.1758067
   Patel R, 2018, INVESTIG OPHTHALMOL, V59
   Rebitschek FG, 2020, BUNDESGESUNDHEITSBLA, V63, P665, DOI 10.1007/s00103-020-03146-3
   Rein DB, 2009, ARCH OPHTHALMOL, V127
   Ronneberger O., U NET CONVOLUTIONAL
   Russakoff DB, 2019, INVESTIG OPHTHALMOL, V60
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2018, INVESTIGATIVE OPTHAL, V59
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Told R, 2018, INVESTIGATIVE OPTHAL, V59
   Toth CA, 2015, RETINA, V35
   Trevethan R, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00307
   Wong CG, 2009, INTRAVITREAL VEGF BF
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121
NR 40
TC 3
Z9 3
U1 1
U2 2
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 1473-7159
EI 1744-8352
J9 EXPERT REV MOL DIAGN
JI Expert Rev. Mol. Diagn.
PD JAN 2
PY 2021
VL 21
IS 1
BP 109
EP 118
DI 10.1080/14737159.2020.1865806
EA DEC 2020
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA QQ1WO
UT WOS:000603779000001
PM 33355491
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Tou, JS
   Smith, BC
   Bojanowski, CM
   Meleth, AD
   Gery, I
   Csaky, KG
   Chew, EY
   Chan, CC
AF Tou, JS
   Smith, BC
   Bojanowski, CM
   Meleth, AD
   Gery, I
   Csaky, KG
   Chew, EY
   Chan, CC
TI The involvement of sequence variation and expression of CX3CR1 in the
   pathogenesis of age-related macular degeneration
SO FASEB JOURNAL
LA English
DT Article
DE chemoattractant; single nucleotide polymorphism; archived
   paraffin-embedded slide; gene expression; risk factor
ID APOLIPOPROTEIN-E; RECEPTOR CX3CR1; GENETIC RISK; FRACTALKINE; CX(3)CR1;
   DRUSEN; INFLAMMATION; POLYMORPHISM; ASSOCIATION; MACULOPATHY
AB This study examined the association between the sequence variation/expression of CX3CR1, a chemokine receptor, and age-related macular degeneration (AMD). Peripheral blood from 85 AMD patients and 105 subjects without AMD (controls), as well as ocular tissue from 40 pathological sections with AMD and two normal eye sections, were screened for V249I and T280M, two single nucleotide polymorphisms (SNPs) in CX3CR1. An increased prevalence, with the highest odds ratio of 3.57, of the I249 and M280 carriers was found among the AMD cases as compared with the controls. When comparing CX3CR1 expression in the archived eye sections, CX3CR1 transcripts were not detectable in the maculae of AMD eyes bearing T/M280; however, transcripts were detected in the maculae of normal eyes bearing T/T280 or T/M280 as well as in the AMD maculae bearing T/T280. Furthermore, lower CX3CR1 protein expression was observed in the maculae of AMD eyes bearing T/M280 compared with the controls bearing T/T280. The I249 and M280 alleles result in a lowered number of receptor binding sites and a decreased ligand affinity. Our data suggest that a decrease, caused by sequence variation and/or lower CX3CR1 expression, in CX3CR1-induced cellular activities could contribute to AMD development.
C1 NEI, Immunol Lab, Bethesda, MD 20892 USA.
   NEI, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA.
   NEI, HHMI, Bethesda, MD 20892 USA.
   NEI, Sect Gene Therapy, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Howard Hughes Medical Institute; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Chan, CC (通讯作者)，NEI, Immunol Lab, Bldg 10,10 Ctr Dr,Rm 10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
FU Intramural NIH HHS [Z99 EY999999, Z01 EY000418-04, Z01 EY000222-22]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000069,
   Z01EY000222, Z01EY000418] Funding Source: NIH RePORTER
CR Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726
   Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468
   Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   DeVries ME, 2003, J BIOL CHEM, V278, P11985, DOI 10.1074/jbc.M211422200
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413
   Foxman EF, 2002, J IMMUNOL, V168, P2483, DOI 10.4049/jimmunol.168.5.2483
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lutty G, 1999, MOL VIS, V5
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   McDermott D H, 2000, Science, V290, P2031
   McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790
   McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sunnemark D, 2003, BRAIN PATHOL, V13, P617
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
NR 40
TC 156
Z9 164
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2004
VL 18
IS 9
BP 1297
EP +
DI 10.1096/fj.04-1862fje
PG 24
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 833HJ
UT WOS:000222327500016
PM 15208270
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gao, LQ
   Wang, J
   You, QS
   Guo, YK
   Flaxel, CJ
   Hwang, TS
   Huang, D
   Jia, YL
   Bailey, ST
AF Gao, Liqin
   Wang, Jie
   You, Qisheng
   Guo, Yukun
   Flaxel, Christina J.
   Hwang, Thomas S.
   Huang, David
   Jia, Yali
   Bailey, Steven T.
TI Plexus-specific retinal capillary avascular area in exudative
   age-related macular degeneration with projection-resolved OCT
   angiography
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; OCULAR BLOOD-FLOW; VASCULAR
   ABNORMALITIES; MACULOPATHY; VELOCITY; DISEASE
AB Objective To detect the plexus-specific retinal capillary avascular area in exudative age-related macular degeneration (EAMD) with projection-resolved optical coherence tomography angiography (PR-OCTA).
   Methods and analysis In this prospective cross-sectional single centre study, eyes with treatment-naive EAMD underwent macular 3x3 mm OCTA with AngioVue system. OCTA scans were analysed and processed including three-dimensional projection artefact removal, retinal layer semi-automated segmentation and en face angiogram generation. Automated quantification of extrafoveal (excluding the central 1 mm circle) avascular area (EAA) were calculated on projection-resolved superficial vascular complex (SVC), intermediate capillary plexus (ICP) and deep capillary plexus (DCP), respectively.
   Results Nineteen eyes with EAMD and 19 age-matched healthy control eyes were included. There was no significant difference between the EAMD and control eyes in terms of age, sex, axial length and mean ocular perfusion pressure (all p>0.05). Compared with control eyes, EAMD eyes had significantly larger EAA in SVC (median 0.125 vs 0.059 mm(2), p=0.006), ICP (0.016 vs 0.000 mm(2), p=0.004) and DCP (0.033 vs 0.000 mm2, p<0.001).
   Conclusion PR-OCTA showed that EAMD is associated with focal avascular area in all the three retinal vascular plexuses.
C1 [Gao, Liqin] Beijing Tongren Eye Ctr, Ophthalmol, Beijing, Peoples R China.
   [Wang, Jie; You, Qisheng; Guo, Yukun; Flaxel, Christina J.; Hwang, Thomas S.; Huang, David; Jia, Yali; Bailey, Steven T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Ophthalmol, Portland, OR 97239 USA.
C3 Oregon Health & Science University
RP Bailey, ST (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
EM bailstev@ohsu.edu
RI You, Qisheng/AAG-7153-2020
OI You, Qisheng/0000-0003-0743-7320; Bailey, Steven/0000-0003-4949-1464
FU National Institutes of Health [R01 EY024544, R01 EY027833, P30
   EY010572]; Research to Prevent Blindness, New York
FX The study was supported by grants R01 EY024544, R01 EY027833 and P30
   EY010572 from the National Institutes of Health, an unrestricted
   departmental funding grant and William & Mary Greve Special Scholar
   Award from Research to Prevent Blindness, New York.
CR Burgansky-Eliash Z, 2014, CURR EYE RES, V39, P304, DOI 10.3109/02713683.2013.840384
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Feigl B, 2007, CLIN EXP OPTOM, V90, P263, DOI 10.1111/j.1444-0938.2007.00152.x
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N., 1999, ADV ORG BIO, P25
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   GAUDRIC A, 1982, AM J OPHTHALMOL, V94, P489, DOI 10.1016/0002-9394(82)90242-2
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hwang TS, 2018, JAMA OPHTHALMOL, V136, P929, DOI 10.1001/jamaophthalmol.2018.2257
   Ikram MK, 2005, OPHTHALMOLOGY, V112, P548, DOI 10.1016/j.ophtha.2004.10.038
   Jackson TL, 2014, RETINA-J RET VIT DIS, V34, P568, DOI 10.1097/IAE.0b013e3182a487be
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   KORNZWEIG AL, 1966, ARCH OPHTHALMOL-CHIC, V75, P326
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Patel RC, 2018, OPHTHALMOL RETINA, V2, P816, DOI 10.1016/j.oret.2017.11.010
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Wang J, 2020, BIOMED OPT EXPRESS, V11, P330, DOI 10.1364/BOE.11.000330
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   You QS, 2020, AM J OPHTHALMOL, V217, P268, DOI 10.1016/j.ajo.2020.04.024
   You QS, 2020, AM J OPHTHALMOL, V209, P206, DOI 10.1016/j.ajo.2019.09.004
   Zhang M, 2016, INVEST OPHTH VIS SCI, V57, P5101, DOI 10.1167/iovs.16-19776
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 32
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2022
VL 106
IS 5
BP 719
EP 723
DI 10.1136/bjophthalmol-2020-317562
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0V8MH
UT WOS:000788593700021
PM 33355172
DA 2022-11-30
ER

PT J
AU Ye, FX
   Kaneko, H
   Nagasaka, Y
   Ijima, R
   Nakamura, K
   Nagaya, M
   Takayama, K
   Kajiyama, H
   Senga, T
   Tanaka, H
   Mizuno, M
   Kikkawa, F
   Hori, M
   Terasaki, H
AF Ye, Fuxiang
   Kaneko, Hiroki
   Nagasaka, Yosuke
   Ijima, Ryo
   Nakamura, Kae
   Nagaya, Masatoshi
   Takayama, Kei
   Kajiyama, Hiroaki
   Senga, Takeshi
   Tanaka, Hiromasa
   Mizuno, Masaaki
   Kikkawa, Fumitaka
   Hori, Masaru
   Terasaki, Hiroko
TI Plasma-activated medium suppresses choroidal neovascularization in mice:
   a new therapeutic concept for age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DIELECTRIC BARRIER DISCHARGE; MOUSE; CELLS; ANGIOGENESIS; RANIBIZUMAB;
   MECHANISMS; TARGET
AB Choroidal neovascularization (CNV) is the main pathogenesis of age-related macular degeneration (AMD), which leads to severe vision loss in many aged patients in most advanced country. CNV compromises vision via hemorrhage and retinal detachment on account of pathological neovascularization penetrating the retina. Plasma medicine represents the medical application of ionized gas "plasma" that is typically studied in the field of physical science. Here we examined the therapeutic ability of plasma-activated medium (PAM) to suppress CNV. The effect of PAM on vascularization was assessed on the basis of human retinal endothelial cell (HREC) tube formation. In mice, laser photocoagulation was performed to induce CNV (laser-CNV), followed by intravitreal injection of PAM. N-Acetylcysteine was used to examine the role of reactive oxygen species in PAM-induced CNV suppression. Fundus imaging, retinal histology examination, and electroretinography (ERG) were also performed to evaluate PAM-induced retinal toxicity. Interestingly, HREC tube formation and laser-CNV were both reduced by treatment with PAM. N-acetylcysteine only partly neutralized the PAM-induced reduction in laser-CNV. In addition, PAM injection had no effect on regular retinal vessels, nor did it show retinal toxicity in vivo. Our findings indicate the potential of PAM as a novel therapeutic agent for suppressing CNV.
C1 [Ye, Fuxiang; Kaneko, Hiroki; Nagasaka, Yosuke; Ijima, Ryo; Nagaya, Masatoshi; Takayama, Kei; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Nakamura, Kae; Kajiyama, Hiroaki; Kikkawa, Fumitaka] Nagoya Univ, Grad Sch Med, Dept Obstet & Gynecol, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Senga, Takeshi] Nagoya Univ, Div Canc Biol, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Tanaka, Hiromasa; Hori, Masaru] Nagoya Univ, Inst Innovat Future Soc, Chikusa Ku, Nagoya, Aichi 4648603, Japan.
   [Mizuno, Masaaki] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Showa Ku, Nagoya, Aichi 4668560, Japan.
C3 Nagoya University; Nagoya University; Nagoya University; Nagoya
   University; Nagoya University
RP Terasaki, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM h-kaneko@med.nagoya-u.ac.jp; terasaki@med.nagoya-u.ac.jp
RI Tanaka, Hiromasa/AAE-3764-2019; KIKKAWA, Fumitaka/I-7341-2014; Kaneko,
   Hiroki/AHA-2461-2022; Terasaki, Hiroko/M-5054-2014; Kaneko,
   Hiroki/O-7695-2015
OI Kaneko, Hiroki/0000-0003-0731-6465; Kaneko, Hiroki/0000-0003-0731-6465;
   Takayama, Kei/0000-0002-1477-9014; Ye, Fuxiang/0000-0003-2550-2173
FU Japan Society for the Promotion of Science; Chukyo Longevity Medical and
   Promotion Foundation; Takeda Science Foundation; Takeda Medical Research
   Foundation; Yokoyama Foundation for Clinical Pharmacology [YRY1411];
   Hori Science and Arts Foundation; Grants-in-Aid for Scientific Research
   [15H00900] Funding Source: KAKEN
FX The authors would like to thank Seina Ito and Reona Kimoto for technical
   assistance. This work was supported by a Grant-in-Aid for Young
   Scientists (A) and a Grant-in-Aid for Challenging Exploratory Research
   from the Japan Society for the Promotion of Science (H.K.), the Chukyo
   Longevity Medical and Promotion Foundation (H.K.), the Takeda Science
   Foundation (H.K.), Takeda Medical Research Foundation (H.K), Yokoyama
   Foundation for Clinical Pharmacology (YRY1411, H.K.), and the Hori
   Science and Arts Foundation (F.Y.)
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arjunan KP, 2012, J R SOC INTERFACE, V9, P147, DOI 10.1098/rsif.2011.0220
   Bid HK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035513
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033245
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   FRIDMAN A, 2008, PLASMA CHEM
   Fridman G, 2008, PLASMA PROCESS POLYM, V5, P503, DOI 10.1002/ppap.200700154
   Fridman G, 2006, PLASMA CHEM PLASMA P, V26, P425, DOI 10.1007/s11090-006-9024-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hara R, 2010, CURR EYE RES, V35, P1012, DOI 10.3109/02713683.2010.500112
   Iseki S, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.3694928
   Ito T, 2013, AM J PATHOL, V182, P586, DOI 10.1016/j.ajpath.2012.10.012
   Iwasaki M, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2885084
   Jia FD, 2011, APPL PHYS EXPRESS, V4, DOI 10.1143/APEX.4.026101
   Kaneko H, 2008, INVEST OPHTH VIS SCI, V49, P4162, DOI 10.1167/iovs.08-1738
   Kaneko H, 2014, BRIT J PHARMACOL, V171, P3754, DOI 10.1111/bph.12737
   Kim CH, 2010, J BIOTECHNOL, V150, P530, DOI 10.1016/j.jbiotec.2010.10.003
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Lebrun-Julien F, 2010, P NATL ACAD SCI USA, V107, P3817, DOI 10.1073/pnas.0909276107
   Lee HW, 2009, J ENDODONT, V35, P587, DOI 10.1016/j.joen.2009.01.008
   Lei H, 2010, AM J PATHOL, V177, P132, DOI 10.2353/ajpath.2010.090604
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Michels S, 2006, BRIT J OPHTHALMOL, V90, P1333, DOI 10.1136/bjo.2006.102293
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Miyata K, 2007, INVEST OPHTH VIS SCI, V48, P820, DOI 10.1167/iovs.06-0845
   Morfill GE, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115011
   Nishiguchi KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013493
   Oh SH, 2006, TOXICOL APPL PHARM, V212, P212, DOI 10.1016/j.taap.2005.07.018
   Palomero J, 2014, BLOOD, V124, P2235, DOI 10.1182/blood-2014-04-569566
   REMTULLA S, 1985, VISION RES, V25, P21, DOI 10.1016/0042-6989(85)90076-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2011, J PHYS D APPL PHYS, V44, DOI 10.1088/0022-3727/44/37/372001
   Sharma S, 2005, VISUAL NEUROSCI, V22, P631, DOI 10.1017/S0952523805225129
   Simo R, 2008, DIABETOLOGIA, V51, P1574, DOI 10.1007/s00125-008-0989-9
   Solban N, 2006, LASER SURG MED, V38, P522, DOI 10.1002/lsm.20345
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tomida D, 2011, INVEST OPHTH VIS SCI, V52, P3193, DOI 10.1167/iovs.10-6737
   Torii K, 2015, GASTRIC CANCER, V18, P635, DOI 10.1007/s10120-014-0395-6
   Utsumi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081576
   Vandamme M, 2010, PLASMA PROCESS POLYM, V7, P264, DOI 10.1002/ppap.200900080
   Yamazaki H, 2011, DENT MATER J, V30, P384, DOI 10.4012/dmj.2010-190
   Yousfi M, 2014, FUND CLIN PHARMACOL, V28, P123, DOI 10.1111/fcp.12018
   Yu DY, 2006, INVEST OPHTH VIS SCI, V47, P1109, DOI 10.1167/iovs.05-1118
   Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001
NR 47
TC 37
Z9 38
U1 1
U2 17
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 9
PY 2015
VL 5
AR 7705
DI 10.1038/srep07705
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CH7NF
UT WOS:000354222900007
PM 25573059
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mylona, I
   Floros, G
   Dermenoudi, M
   Ziakas, N
   Tsinopoulos, I
AF Mylona, Ioanna
   Floros, Georgios
   Dermenoudi, Maria
   Ziakas, Nikolaos
   Tsinopoulos, Ioannis
TI A comparative study of depressive symptomatology among cataract and
   age-related macular degeneration patients with impaired vision
SO PSYCHOLOGY HEALTH & MEDICINE
LA English
DT Article
DE Vision impairment; liaison psychiatry; ARMD; cataract
AB Vision impairment remains an important cause of disability with the leading being age-related cataract (ARC) and age-related macular degeneration (ARMD) with depression symptoms often reported in vision impairment. This is a cross-sectional survey of two groups of fifty patients with ARC and ARMD and no prior psychiatric history on depressive symptomatology. Results indicate that ARMD patients scored higher on the BDI-II than ARC patients, in line with their poorer prognosis. Female patients with ARMD, living alone, with a higher number of other comorbid health issues, are more likely to have more depressive symptomatology. ARMD patients scored higher in the items related to pessimism for the future, feelings of past failure and feelings of self-dislike. There is a need for liaison psychiatry services to be readily available in patients with suspected ARC and ARMD coming forward with substantial vision loss. ARMD patients in particular tend to be more pessimistic and blame themselves for the progression of their disease. This should be taken into consideration with patient education on the causes of the disease and more effort should be undertaken to instill hope. The impact of vision loss on psychic status is related to disease prognosis and not only current state.
C1 [Mylona, Ioanna; Dermenoudi, Maria; Ziakas, Nikolaos; Tsinopoulos, Ioannis] Aristotle Univ Thessaloniki, Sch Med, Dept Ophthalmol, Thessaloniki, Greece.
   [Floros, Georgios] Aristotle Univ Thessaloniki, Sch Med, Dept Psychiat, Thessaloniki, Greece.
C3 Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki
RP Mylona, I (通讯作者)，Papageorgiou Gen Hosp Thessaloniki, Dept Ophthalmol, Agiou Pavlou 76, Thessaloniki 56429, Greece.
EM milona_ioanna@windowslive.com
RI Mylona, Ioanna/AAF-2264-2019; Floros, Georgios D./AAT-8106-2021
OI Mylona, Ioanna/0000-0002-1032-3730; Floros, Georgios
   D./0000-0001-8193-3571; Tsinopoulos, Ioannis/0000-0002-9189-805X;
   Ziakas, nikolaos/0000-0001-8362-6794
CR Andley U., 2000, PRINCIPLES PRACTICE, P1428
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Elshout M, 2018, ACTA OPHTHALMOL, V96, P770, DOI 10.1111/aos.13824
   Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056
   Freeman EE, 2009, CAN J OPHTHALMOL, V44, P171, DOI 10.3129/i09-001
   Segal DL, 2008, BEHAV MODIF, V32, P3, DOI 10.1177/0145445507303833
   van der Aa HPA, 2015, INVEST OPHTH VIS SCI, V56, P849, DOI 10.1167/iovs.14-15848
   Weiss M, 2018, RETINA-J RET VIT DIS, V38, P2293, DOI 10.1097/IAE.0000000000001892
   Zheng YJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46453
NR 12
TC 4
Z9 4
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1354-8506
EI 1465-3966
J9 PSYCHOL HEALTH MED
JI Psychol. Health Med.
PD OCT 20
PY 2020
VL 25
IS 9
BP 1130
EP 1136
DI 10.1080/13548506.2020.1728351
EA FEB 2020
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA OU3GG
UT WOS:000514504000001
PM 32064912
DA 2022-11-30
ER

PT J
AU da Cruz, L
   Fynes, K
   Georgiadis, O
   Kerby, J
   Luo, YH
   Ahmado, A
   Vernon, A
   Daniels, JT
   Nommiste, B
   Hasan, SM
   Gooljar, SB
   Carr, AJF
   Vugler, A
   Ramsden, CM
   Bictash, M
   Fenster, M
   Steer, J
   Harbinson, T
   Wilbrey, A
   Tufail, A
   Feng, G
   Whitlock, M
   Robson, AG
   Holder, GE
   Sagoo, MS
   Loudon, PT
   Whiting, P
   Coffey, PJ
AF da Cruz, Lyndon
   Fynes, Kate
   Georgiadis, Odysseas
   Kerby, Julie
   Luo, Yvonne H.
   Ahmado, Ahmad
   Vernon, Amanda
   Daniels, Julie T.
   Nommiste, Britta
   Hasan, Shazeen M.
   Gooljar, Sakina B.
   Carr, Amanda-Jayne F.
   Vugler, Anthony
   Ramsden, Conor M.
   Bictash, Magda
   Fenster, Mike
   Steer, Juliette
   Harbinson, Tricia
   Wilbrey, Anna
   Tufail, Adnan
   Feng, Gang
   Whitlock, Mark
   Robson, Anthony G.
   Holder, Graham E.
   Sagoo, Mandeep S.
   Loudon, Peter T.
   Whiting, Paul
   Coffey, Peter J.
TI Phase 1 clinical study of an embryonic stem cell-derived retinal pigment
   epithelium patch in age-related macular degeneration
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID RCS RATS; RPE; TRANSLOCATION; THERAPIES; RESCUE; DERIVATION;
   TRANSPLANTATION; MEMBRANE; SURGERY; SAFETY
AB Age-related macular degeneration (AMD) remains a major cause of blindness, with dysfunction and loss of retinal pigment epithelium (RPE) central to disease progression. We engineered an RPE patch comprising a fully differentiated, human embryonic stem cell (hESC)-derived RPE monolayer on a coated, synthetic basement membrane. We delivered the patch, using a purpose-designed microsurgical tool, into the subretinal space of one eye in each of two patients with severe exudative AMD. Primary endpoints were incidence and severity of adverse events and proportion of subjects with improved best-corrected visual acuity of 15 letters or more. We report successful delivery and survival of the RPE patch by biomicroscopy and optical coherence tomography, and a visual acuity gain of 29 and 21 letters in the two patients, respectively, over 12 months. Only local immunosuppression was used long-term. We also present the preclinical surgical, cell safety and tumorigenicity studies leading to trial approval. This work supports the feasibility and safety of hESC-RPE patch transplantation as a regenerative strategy for AMD.
C1 [da Cruz, Lyndon; Fynes, Kate; Georgiadis, Odysseas; Luo, Yvonne H.; Ahmado, Ahmad; Nommiste, Britta; Hasan, Shazeen M.; Carr, Amanda-Jayne F.; Vugler, Anthony; Ramsden, Conor M.; Coffey, Peter J.] UCL, Inst Ophthalmol, London Project Cure Blindness, ORBIT, London, England.
   [da Cruz, Lyndon; Georgiadis, Odysseas; Luo, Yvonne H.; Tufail, Adnan; Robson, Anthony G.; Holder, Graham E.; Sagoo, Mandeep S.; Coffey, Peter J.] UCL Inst Ophthalmol, Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Georgiadis, Odysseas; Luo, Yvonne H.; Ramsden, Conor M.; Tufail, Adnan; Robson, Anthony G.; Holder, Graham E.; Sagoo, Mandeep S.] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [da Cruz, Lyndon; Nommiste, Britta] Charles Bell House, Wellcome EPSRC Ctr Intervent & Surg Sci WEISS, London, England.
   [Kerby, Julie; Bictash, Magda; Fenster, Mike; Steer, Juliette; Harbinson, Tricia; Wilbrey, Anna; Feng, Gang; Whitlock, Mark; Loudon, Peter T.; Whiting, Paul] Plizer, Granta Pk, Cambridge, England.
   [Kerby, Julie] Cell & Gene Therapy Catapult, London, England.
   [Vernon, Amanda; Daniels, Julie T.] UCL Inst Ophthalmol, Cells Sight Transplantat & Res Program, London, England.
   [Whiting, Paul] UCL Inst Neurol, Queen Sq, London, England.
   [Coffey, Peter J.] UC Santa Barbara, NRI, Ctr Stem Cell Biol & Engn, Santa Barbara, CA USA.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; UK Research & Innovation (UKRI); Engineering &
   Physical Sciences Research Council (EPSRC); University of London;
   University College London; University of London; University College
   London; University of London; University College London; University of
   California System; University of California Santa Barbara
RP da Cruz, L (通讯作者)，UCL, Inst Ophthalmol, London Project Cure Blindness, ORBIT, London, England.
EM Lyndon.dacruz@Moorfields.nhs.uk
RI Ahmado, Ahmad/R-5537-2019; Carr, Amanda/ABG-6282-2020
OI Carr, Amanda/0000-0002-5469-0030; Tufail, Adnan/0000-0001-6131-7640;
   Daniels, Julie/0000-0003-2099-9360; Steer, Juliette/0000-0001-8086-7955;
   Whiting, Paul/0000-0002-4121-1379; Sagoo, Mandeep/0000-0003-1530-3824;
   Robson, Anthony/0000-0002-8391-6123; Coffey, Peter/0000-0002-5427-2939
FU Production Of A Cell Based Therapy For Late Stage Age-Related Macular
   Degeneration [P12761]; Macular Disease Society Studentship - Donation
FX We acknowledge H. Moore, Stem Cell Derivation Facility, Centre for Stem
   Cell Biology (CSCB), University of Sheffield for derivation of the
   original SHEF-1 hESC line and P. Keane and M. Cheetham for comments on
   the paper. We thank R. McKernan for support and input throughout the
   project. L.d.C. and P.J.C. received the following grants and donations
   and would like to acknowledge that they were used to fund the studies
   reported in this article: Anonymous Donor, USA, Establishment of The
   London Project to Cure Blindness - Donation. Lincy Foundation, USA, The
   London Project To Cure Blindness: Funding Towards The Production Of A
   Cell Based Therapy For Late Stage Age-Related Macular Degeneration -
   P12761. Macular Disease Society Studentship - Donation. MRC, Stem Cell
   Based Treatment Strategy For Age-Related Macular Degeneration (AMD) -
   G1000730. CIRM (California Institute of Regenerative Medicine)
   LA1_C2-02086. Pfizer Inc, The Development Plan For A Phase I/IIa
   Clinical Trial Implanting HESC Derived RPE for AMD - PF-05406388.
   Moorfields Biomedical Research Centre, National Institute for Health
   Research (NIHR) - BRC2_011. The Michael Uren Foundation R170010A.
CR Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Allegrucci C, 2007, HUM MOL GENET, V16, P1253, DOI 10.1093/hmg/ddm074
   Amer MH, 2015, J PHARM PHARMACOL, V67, P640, DOI 10.1111/jphp.12362
   Atala A, 2012, LANCET, V379, P689, DOI 10.1016/S0140-6736(12)60118-4
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Carr AJ, 2009, MOL VIS, V15, P283
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P1848, DOI 10.1167/iovs.08-2845
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hewitt ZA, 2007, CLIN PHARMACOL THER, V82, P448, DOI 10.1038/sj.clpt.6100321
   Holz F.G., 2007, ATLAS FUNDUS AUTOFLU, V1st ed.
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mao Yingyu, 2013, Methods Mol Biol, V935, P285, DOI 10.1007/978-1-62703-080-9_20
   Muthiah MN, 2014, OPHTHALMOLOGY, V121, P430, DOI 10.1016/j.ophtha.2013.10.008
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Ramsden CM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00142-7
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Skottman H, 2006, FEBS LETT, V580, P2875, DOI 10.1016/j.febslet.2006.03.083
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Uppal G, 2007, CLIN EXP OPHTHALMOL, V35, P448, DOI 10.1111/j.1442-9071.2007.01528.x
   van Romunde SHM, 2019, RETINA-J RET VIT DIS, V39, P288, DOI 10.1097/IAE.0000000000001945
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P416, DOI 10.1167/iovs.07-0992
NR 38
TC 309
Z9 312
U1 12
U2 113
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD APR
PY 2018
VL 36
IS 4
BP 1
EP +
DI 10.1038/nbt.4114
PG 15
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA GB8RG
UT WOS:000429342400017
PM 29553577
OA Green Submitted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Ito, A
   Matsumoto, H
   Morimoto, M
   Mimura, K
   Akiyama, H
AF Ito, Arisa
   Matsumoto, Hidetaka
   Morimoto, Masahiro
   Mimura, Kensuke
   Akiyama, Hideo
TI Two-Year Outcomes of a Treat-and-Extend Regimen Using Intravitreal
   Aflibercept Injections for Typical Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Medical treatment of age-related macular degeneration; Anti-vascular
   endothelial growth factor; Choroidal neovascularization; Macula; Macular
   degeneration; Optical coherence tomography; Retina
ID PIGMENT EPITHELIAL DETACHMENT; OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL
   NEOVASCULARIZATION; VEGF TRAP; RANIBIZUMAB; THERAPY; BEVACIZUMAB;
   VERTEPORFIN; TEARS
AB Purpose: The aim of this study was to evaluate the efficacy of a treat-and-extend (TAE) regimen using intravitreal injection of aflibercept (IVA) for typical age-related macular degeneration (tAMD). Methods: We retrospectively studied 61 treatment-naive eyes with tAMD. Best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), number of injections, and complications during 2 years were evaluated. Results: BCVA significantly improved by on average 0.13 logMAR units, and CMT and CCT significantly decreased after 2 years. The number of injections was on average 13.6. In the second year, eyes with classic choroidal neovascularization (CNV) needed significantly fewer treatments than eyes with occult CNV. Fourteen eyes, which developed subfoveal fibrosis, showed significantly poorer BCVA after 2 years. Subfoveal fibrosis was significantly common in classic CNV. Conclusion: A TAE regimen using IVA for tAMD might be effective for improving BCVA and exudative changes. The exudation may be suppressed with fewer treatments in classic CNV compared to occult CNV. (C) 2017 S. Karger AG, Basel
C1 [Ito, Arisa; Matsumoto, Hidetaka; Morimoto, Masahiro; Mimura, Kensuke; Akiyama, Hideo] Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Matsumoto, H (通讯作者)，Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
EM hide-m@gunma-u.ac.jp
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Castro-Navarro V, 2016, OPHTHALMOLOGICA, V236, P215, DOI 10.1159/000453281
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P668
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yanai H, 2015, STATCELTHE USEFUL AD
NR 26
TC 13
Z9 13
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 238
IS 4
BP 236
EP 242
DI 10.1159/000479937
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FK9LQ
UT WOS:000413833100007
PM 28898873
DA 2022-11-30
ER

PT J
AU Nikolopoulou, E
   Lorusso, M
   Ferrari, LM
   Cicinelli, MV
   Bandello, F
   Querques, G
   Ferrari, TM
AF Nikolopoulou, Eleni
   Lorusso, Massimo
   Ferrari, Luisa Micelli
   Cicinelli, Maria Vittoria
   Bandello, Francesco
   Querques, Giuseppe
   Ferrari, Tommaso Micelli
TI Optical Coherence Tomography Angiography versus Dye Angiography in
   Age-Related Macular Degeneration: Sensitivity and Specificity Analysis
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID QUIESCENT CHOROIDAL NEOVASCULARIZATION; GUIDELINES; DIAGNOSIS; DISEASES;
   THERAPY; VEGF
AB Introduction. Optical coherence tomography angiography (OCTA) could be a valid tool to detect choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD), allowing the analysis of the type, the morphology, and the extension of CNV in most of the cases. Purpose. To determine the sensitivity and specificity of OCTA in detecting CNV secondary to nAMD, compared to fluorescein angiography (FA) and indocyanine green angiography (ICGA). Methods. Prospective observational study. Patients with suspected nAMD were recruited between May and December 2016. Patients underwent FA, ICGA, spectral domain OCT, and OCTA (AngioVue, Optovue, Inc.). Sensitivity and specificity of FA, with or without ICGA, were assessed and compared with OCTA. Results. Seventy eyes of 70 consecutive patients were included: 32 eyes (45.7%) with type I CNV, 8 eyes (11.4%) with type II CNV, 4 eyes (5.7%) with type III CNV, 6 eyes (8.6%) with mixed type I and type II CNV, and 20 eyes (28.6%) with no CNV. Sensitivity of OCTA was 88% and specificity was 90%. Concordance between FA/ICGA and OCTA was very good (0,91; range 0,81-1,00). Conclusions. OCTA showed high sensitivity and specificity for detection of CNV. Concordance between OCTA and gold-standard dye-based techniques was excellent. OCTA may represent a first-line noninvasive method for the diagnosis of nAMD.
C1 [Nikolopoulou, Eleni; Lorusso, Massimo; Ferrari, Luisa Micelli; Ferrari, Tommaso Micelli] Ente Ecclesiast Osped Gen Reg F Miulli, Dept Ophthalmol, Bari, Italy.
   [Cicinelli, Maria Vittoria; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Lorusso, Massimo/AGX-5889-2022; cicinelli, maria vittoria/M-1611-2019;
   bandello, francesco/AAH-2405-2019
OI cicinelli, maria vittoria/0000-0003-2938-0409; bandello,
   francesco/0000-0003-3238-9682; lorusso, massimo/0000-0002-3624-1776;
   Querques, Giuseppe/0000-0002-3292-9581
CR Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuehlewein L., 2015, AM J OPHTHALMOL, V160
   Mathew R, 2014, OPHTHALMOLOGICA, V231, P153, DOI 10.1159/000355091
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souedan V., 2017, INT OPHTHALMOLOGY, P1
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P416
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
NR 21
TC 21
Z9 21
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2018
VL 2018
AR 6724818
DI 10.1155/2018/6724818
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA FY6VA
UT WOS:000426999800001
PM 29707575
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Patel, PJ
   Chen, FK
   Da Cruz, L
   Rubin, GS
   Tufail, A
AF Patel, Praveen J.
   Chen, Fred K.
   Da Cruz, Lyndon
   Rubin, Gary S.
   Tufail, Adnan
TI Test-Retest Variability of Reading Performance Metrics Using MNREAD in
   Patients with Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID INTERSESSION REPEATABILITY; VISION; SPEED; SCORES
AB PURPOSE. To determine the test-retest variability of reading ability using the MNREAD charts in patients with stable age-related macular degeneration (AMD).
   METHODS. In this prospective study, reading ability was measured at two visits in 124 nontreated eyes of 124 patients with AMD, who were enrolled in an ongoing clinical trial using a standardized MNREAD protocol. Only patients with stable AMD who could perform the reading test at 40 cm at both visits were included in the analysis. Different scoring rules were applied to calculate critical print size and maximum reading speed.
   RESULTS. Data from the 59 patients with a mean (SD) age of 78 (7.6) years who met the study criteria were analyzed at a mean (SD) interval of 43 (6) days between measurements. The 95% coefficient of repeatability (CR) was 0.30 logMAR for reading acuity. The CR for critical print size and maximum reading speed varied depending on the analysis method applied.
   CONCLUSIONS. This is a report of estimates of the intersession test-retest variability of reading performance metrics in patients with stable AMD. The results are helpful both in defining end points in clinical trials for AMD and in distinguishing clinical change from measurement variability in clinical practice. (Invest Ophthalmol Vis Sci. 2011; 52: 3854-3859) DOI: 10.1167/iovs.10-6601
C1 [Patel, Praveen J.] Moorfields Eye Hosp, Med Retina Serv, NIHR, Biomed Res Ctr Ophthalmol, London EC1V 2PD, England.
   [Patel, Praveen J.; Chen, Fred K.; Da Cruz, Lyndon; Rubin, Gary S.; Tufail, Adnan] UCL Inst Ophthalmol, London, England.
   [Chen, Fred K.] Univ Western Australia, Ctr Ophthalmol & Vis Sci, Perth, WA 6009, Australia.
C3 University of London; King's College London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; University of Western Australia
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp, Med Retina Serv, NIHR, Biomed Res Ctr Ophthalmol, 162 City Rd, London EC1V 2PD, England.
EM praveenjpatel@yahoo.co.uk
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Tufail, Adnan/0000-0001-6131-7640
FU Moorfields Eye Hospital; Department of Health's NIHR Biomedical Research
   Centre for Ophthalmology at Moorfields Eye Hospital; UCL Institute of
   Ophthalmology; Fight for Sight [1777/78] Funding Source: researchfish
FX Supported by The Special Trustees of Moorfields Eye Hospital. This
   research has received a proportion of its funding from the Department of
   Health's NIHR Biomedical Research Centre for Ophthalmology at Moorfields
   Eye Hospital and UCL Institute of Ophthalmology. The views expressed in
   the publication are those of the authors and not necessarily those of
   the Department of Health.
CR AHN SJ, 1995, VISION RES, V35, P1939, DOI 10.1016/0042-6989(94)00294-V
   Bland JM, 1996, BRIT MED J, V313, P744
   Cheung SH, 2008, INVEST OPHTH VIS SCI, V49, P828, DOI 10.1167/iovs.07-0555
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Finger RP, 2009, INVEST OPHTH VIS SCI, V50, P1366, DOI 10.1167/iovs.08-2032
   Gallucci M, 2011, ARCH GERONTOL GERIAT, V52, P309, DOI 10.1016/j.archger.2010.05.007
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Maajwee K, 2008, OPTOMETRY VISION SCI, V85, P353, DOI 10.1097/OPX.0b013e31816bf58b
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P2621, DOI 10.1167/iovs.08-2407
   Pesudovs K, 2002, CLIN EXP OPHTHALMOL, V30, P183, DOI 10.1046/j.1442-9071.2002.00522.x
   Radner W, 2002, GRAEF ARCH CLIN EXP, V240, P461, DOI 10.1007/s00417-002-0443-5
   Subramanian A, 2009, INVEST OPHTH VIS SCI, V50, P3643, DOI 10.1167/iovs.08-2823
   Tufail A, 2010, BMJ-BRIT MED J, V340, pc2459
   Virgili G, 2004, INVEST OPHTH VIS SCI, V45, P3418, DOI 10.1167/iovs.04-0390
NR 17
TC 37
Z9 39
U1 1
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2011
VL 52
IS 6
BP 3854
EP 3859
DI 10.1167/iovs.10-6601
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800CF
UT WOS:000293335400056
PM 21421873
DA 2022-11-30
ER

PT J
AU Segal, O
   Barayev, E
   Nemet, AY
   Mimouni, M
AF Segal, Ori
   Barayev, Edward
   Nemet, Arie Y.
   Mimouni, Michael
TI PREDICTING RESPONSE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION TO
   BEVACIZUMAB BASED ON SPECTRALIS OPTICAL COHERENCE TOMOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE spectral domain; optical coherence tomography; prognostic; factors;
   bevacizumab; response; exudative; age-related macular degeneration
ID SUBGROUP ANALYSIS; VISUAL PROGNOSIS; RANIBIZUMAB; ASSOCIATION;
   VERTEPORFIN; THERAPY; ANCHOR; IMPACT
AB Purpose:To identify baseline optical coherence tomography factors in exudative age-related macular degeneration that predict response to bevacizumab injections.Methods:Patients underwent spectral domain optical coherence tomography at diagnosis and the width, height, area, and location of the subretinal fluid, intraretinal fluid, pigment epithelial detachment, and subretinal tissue were measured. The location and size of photoreceptor and the loss of retinal pigment epithelium were recorded as well as quantitative retinal measurements. Patients received three consecutive monthly injections of bevacizumab after which their best-corrected visual acuity was recorded.Results:Overall 105 eyes of 105 patients aging 88 8.6 years were included. In univariate correlational analyses, only subretinal fluid width demonstrated a significant positive correlation with improved best-corrected visual acuity (R-2 = 0.230, P = 0.018). Eyes with intraretinal fluid (P = 0.020) and retinal pigment epithelial loss (P = 0.009) located in the subfoveal (as opposed to the juxtafoveal area) demonstrating worst visual outcomes. In stepwise backwards regression, the subretinal fluid width and intraretinal fluid location were the only parameters that remained significant explaining 9.23% of the variation in delta best-corrected visual acuity scores.Conclusion:Improvement in best-corrected visual acuity after three injections of bevacizumab can be predicted from optical coherence tomography measurements. Specifically, the authors identified subretinal fluid width and intraretinal fluid location as significant markers.
C1 [Segal, Ori; Barayev, Edward; Nemet, Arie Y.] Meir Med Ctr, Dept Ophthalmol, Kefar Sava, Israel.
   [Segal, Ori; Barayev, Edward; Nemet, Arie Y.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
   [Mimouni, Michael] Rambam Hlth Care Campus, Dept Ophthalmol, Haifa, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Sackler Faculty of Medicine; Rambam Health Care Campus
RP Segal, O (通讯作者)，Meir Med Ctr, Dept Ophthalmol, IL-44281 Kefar Sava, Israel.
EM orisegal@gmail.com
RI Mimouni, Michael/S-2916-2018
OI Mimouni, Michael/0000-0002-4661-0993; Segal, Ori/0000-0001-5701-9544
CR Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   Austin PC, 2004, STAT MED, V23, P1159, DOI 10.1002/sim.1687
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Einwallner E, 2010, OPHTHALMOLOGE, V107, P158, DOI 10.1007/s00347-009-1948-7
   Gamulescu MA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/851648
   Hawkes N., 2012, BMJ-BRIT MED J, V344, P3275
   Heimes B, 2011, OPHTHALMOLOGE, V108, P124, DOI 10.1007/s00347-010-2210-z
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Ristau T, 2012, J CLIN EXP OPHTHALMO, V4, P264
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
NR 27
TC 11
Z9 11
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2016
VL 36
IS 2
BP 259
EP 263
DI 10.1097/IAE.0000000000000690
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DC9AU
UT WOS:000369513500004
PM 26200510
DA 2022-11-30
ER

PT J
AU Tang, D
   Mitchell, P
   Liew, G
   Burlutsky, G
   Flood, V
   Gopinath, B
AF Tang, Diana
   Mitchell, Paul
   Liew, Gerald
   Burlutsky, George
   Flood, Victoria
   Gopinath, Bamini
TI Evaluation of a Novel Tool for Screening Inadequate Food Intake in
   Age-Related Macular Degeneration Patients
SO NUTRIENTS
LA English
DT Article
DE age-related macular degeneration; diet adequacy; diet screening tool;
   nutrition
ID MEDITERRANEAN DIET; FREQUENCY QUESTIONNAIRE; BETA-CAROTENE; EYE DISEASE;
   RISK; ADHERENCE; CONSUMPTION; VALIDITY; WATER; SUPPLEMENTATION
AB Diet assessment tools provide valuable nutrition information in research and clinical settings. With growing evidence supporting dietary modification to delay development and progression of age -related macular degeneration (AMD), an AMD-specific diet assessment tool could encourage eye-care practitioners to refer patients in need of further dietary behavioural support to a dietitian and/or support network. Therefore, the aim of this study was to evaluate clinical use of a novel, short dietary questionnaire (SDQ-AMD) to screen for inadequate food intake in AMD patients by comparing it against a validated food frequency questionnaire (FFQ). Recruitment sources included Sydney-based private eye clinics and research databases (N = 155; 57% female; 78 +/- 8 years). Scoring criteria based on the Australian Dietary Guidelines and dietary recommendations for AMD in literature were developed and applied to dietary data from the FFQ and SDQ-AMD. Bland Altman plot of difference suggests agreement between the FFQ and SDQ-AMD as most mean difference scores were within the 95% CI (6.91, 9.94), and no significant bias between the scores as the mean score increased ((regression equation: y = 0.11x - 2.60) (95% CI: -0.058, 0.275, p-value = 0.20)). Scores were also significantly correlated (0.57, p <= 0.0001). The SDQ-AMD shows potential as a diet screening tool for clinical use, however, additional studies are warranted to validate the SDQ-AMD.
C1 [Tang, Diana; Mitchell, Paul; Liew, Gerald; Burlutsky, George; Gopinath, Bamini] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Tang, Diana; Mitchell, Paul; Liew, Gerald; Burlutsky, George; Gopinath, Bamini] Univ Sydney, Westmead Inst Med Res, Sydney, NSW 2006, Australia.
   [Flood, Victoria] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia.
   [Flood, Victoria] Westmead Hosp, Western Sydney Local Hlth Dist, Westmead, NSW 2151, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Sydney; University of Sydney
RP Gopinath, B (通讯作者)，Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.; Gopinath, B (通讯作者)，Univ Sydney, Westmead Inst Med Res, Sydney, NSW 2006, Australia.
EM diana.tang@sydney.edu.au; paul.mitchell@sydney.edu.au;
   gerald.liew@sydney.edu.au; george.burlutsky@sydney.edu.au;
   vicki.flood@sydney.edu.au; bamini.gopinath@sydney.edu.au
RI Liew, Gerald/AAB-6870-2022; Flood, Victoria M/A-8732-2016
OI Flood, Victoria M/0000-0001-5310-7221; Gopinath,
   Bamini/0000-0003-3573-359X; Tang, Diana/0000-0003-2007-9054
FU National Health and Medical Research Council (NHMRC) [APP1150101]
FX The writing of this paper is supported by funding from National Health
   and Medical Research Council (NHMRC), grant number APP1150101.
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Ali ZC, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.1.4
   [Anonymous], 2019, REV OPHTHALMOLOGY
   [Anonymous], EAT HLTH AUSTR DIET
   Australian Bureau of Statistics, 2014, AUSTR HLTH SURV NUTR
   Australian Bureau of Statistics, 2018, NAT HLTH SURV 1 RES
   Australian Government Department of Health, 2019, MUCH ALC IS SAF DRIN
   Barclay W., 2008, PUBLIC HLTH NUTR, V11
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bringmann A, 2016, MOL VIS, V22, P1437
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Chan J, 2002, AM J EPIDEMIOL, V155, P827, DOI 10.1093/aje/155.9.827
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Ciccarone E, 2003, J THROMB HAEMOST, V1, P1744, DOI 10.1046/j.1538-7836.2003.00323.x
   Cougnard-Gregoire A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160240
   Downie LE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124533
   Drewnowski A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063277
   Eisenhauer B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020120
   Flood VM, 2008, FOOD AUST, V60, P37
   Flood VM, 2004, PUBLIC HEALTH NUTR, V7, P751, DOI 10.1079/PHN2004604
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Gopinath B., 2019, CLIN NUTR
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Goulet J, 2003, ATHEROSCLEROSIS, V170, P115, DOI 10.1016/S0021-9150(03)00243-0
   Grains and Legumes Nutrition Council, 2013, LIFT LID LEG BEN CHO
   Heart Foundation, 2019, MEAT POULTR SEAF
   Hochstetler BS, 2010, RETINA-J RET VIT DIS, V30, P1166, DOI 10.1097/IAE.0b013e3181cea5c6
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kim EK, 2018, EUR J CLIN NUTR, V72, P161, DOI 10.1038/ejcn.2017.152
   Lidder S, 2013, BRIT J CLIN PHARMACO, V75, P677, DOI 10.1111/j.1365-2125.2012.04420.x
   Lieberman HR, 2007, J AM COLL NUTR, V26, p555S, DOI 10.1080/07315724.2007.10719658
   Mangione C.M., 2001, ARCH OPHTHALMOL, V119
   Marks K., 2001, MONITORING FOOD HABI
   Martin L, 2017, CLIN OPTOM, V9, P77, DOI 10.2147/OPTO.S129942
   Ministry of Health, 2014, NUTR REF VAL WAT
   Mohn E. S., 2017, Nutrition Today, V52, P183, DOI 10.1097/NT.0000000000000226
   Morris MC, 2015, ALZHEIMERS DEMENT, V11, P1015, DOI 10.1016/j.jalz.2015.04.011
   Mukaka MM, 2012, MALAWI MED J, V24, P69
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Nicklett EJ, 2013, MATURITAS, V75, P305, DOI 10.1016/j.maturitas.2013.05.005
   Nidhi B, 2014, EUR J NUTR, V53, P117, DOI 10.1007/s00394-013-0507-9
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Panagiotakos D, 2009, INT J FOOD SCI NUTR, V60, P168, DOI 10.1080/09637480902810338
   Popkin BM, 2010, NUTR REV, V68, P439, DOI 10.1111/j.1753-4887.2010.00304.x
   Radd-Vagenas S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10121913
   Radd-Vagenas S, 2018, BRIT J NUTR, V120, P1189, DOI 10.1017/S0007114518002428
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Shim JS, 2014, EPIDEMIOL HEALTH, V36, DOI 10.4178/epih/e2014009
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Sotos-Prieto M, 2015, PUBLIC HEALTH NUTR, V18, P959, DOI 10.1017/S1368980014001360
   Tanaka M., 2003, GERIATR GERONTOL INT, V3, P69, DOI [10.1046/j.1444-1586.2003.00074.x, DOI 10.1046/j.1444-1586.2003.00074.x]
   Tang D, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024774
   U.S. Department for Agriculture and Center for Nutrition Policy and Promotion, 2007, NUTR INSIGHT, V34, P143
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Wilson MMG, 2003, EUR J CLIN NUTR, V57, pS24, DOI 10.1038/sj.ejcn.1601898
NR 61
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD DEC
PY 2019
VL 11
IS 12
AR 3031
DI 10.3390/nu11123031
PG 11
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA KC0ZV
UT WOS:000506917800193
PM 31842257
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Klein, R
   Meuer, SM
   Myers, CE
   Buitendijk, GHS
   Rochtchina, E
   Choudhury, F
   de Jong, PTVM
   McKean-Cowdin, R
   Iyengar, SK
   Gao, XY
   Lee, KE
   Vingerling, JR
   Mitchell, P
   Klaver, CCW
   Wang, JJ
   Klein, BEK
AF Klein, Ronald
   Meuer, Stacy M.
   Myers, Chelsea E.
   Buitendijk, Gabrielle H. S.
   Rochtchina, Elena
   Choudhury, Farzana
   de Jong, Paulus T. V. M.
   McKean-Cowdin, Roberta
   Iyengar, Sudha K.
   Gao, Xiaoyi
   Lee, Kristine E.
   Vingerling, Johannes R.
   Mitchell, Paul
   Klaver, Caroline C. W.
   Wang, Jie Jin
   Klein, Barbara E. K.
TI Harmonizing the Classification of Age-related Macular Degeneration in
   the Three-Continent AMD Consortium
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; classification; epidemiology; grading;
   population-based studies
ID BEAVER-DAM-EYE; ANGELES-LATINO-EYE; BLUE MOUNTAINS EYE; VISUAL-ACUITY;
   POOLED FINDINGS; 3 CONTINENTS; 10-YEAR INCIDENCE; 5-YEAR INCIDENCE;
   GRADING SYSTEM; RISK-FACTORS
AB Purpose: To describe methods to harmonize the classification of age-related macular degeneration (AMD) phenotypes across four population-based cohort studies: the Beaver Dam Eye Study (BDES), the Blue Mountains Eye Study (BMES), the Los Angeles Latino Eye Study (LALES), and the Rotterdam Study (RS).
   Methods: AMD grading protocols, definitions of categories, and grading forms from each study were compared to determine whether there were systematic differences in AMD severity definitions and lesion categorization among the three grading centers. Each center graded the same set of 60 images using their respective systems to determine presence and severity of AMD lesions. A common 5-step AMD severity scale and definitions of lesion measurement cutpoints and early and late AMD were developed from this exercise.
   Results: Applying this severity scale changed the age-sex adjusted prevalence of early AMD from 18.7% to 20.3% in BDES, from 4.7% to 14.4% in BMES, from 14.1% to 15.8% in LALES, and from 7.5% to 17.1% in RS. Age-sex adjusted prevalences of late AMD remained unchanged. Comparison of each center's grades of the 60 images converted to the consortium scale showed that exact agreement of AMD severity among centers varied from 61.0-81.4%, and one-step agreement varied from 84.7-98.3%.
   Conclusion: Harmonization of AMD classification reduced categorical differences in phenotypic definitions across the studies, resulted in a new 5-step AMD severity scale, and enhanced similarity of AMD prevalence among the four cohorts. Despite harmonization it may still be difficult to remove systematic differences in grading, if present.
C1 [Klein, Ronald; Meuer, Stacy M.; Myers, Chelsea E.; Lee, Kristine E.; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Buitendijk, Gabrielle H. S.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Rochtchina, Elena; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Rochtchina, Elena; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Choudhury, Farzana; McKean-Cowdin, Roberta] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
   [Choudhury, Farzana; McKean-Cowdin, Roberta; Gao, Xiaoyi] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   [de Jong, Paulus T. V. M.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Dept Ophthalmogenet, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Leiden Univ, Dept Ophthalmol, Med Ctr, Leiden, Netherlands.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
C3 University of Wisconsin System; University of Wisconsin Madison; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; Centre for Eye Research Australia; University of
   Melbourne; University of Southern California; University of Southern
   California; Royal Netherlands Academy of Arts & Sciences; Netherlands
   Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic
   Medical Center Amsterdam; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC; Case Western Reserve
   University
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th FloorWARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Mitchell, Paul/P-1498-2014; /S-1190-2019; wang, jie/GRS-0942-2022; Wang,
   Jie Jin/P-1499-2014; Klaver, Caroline C.W./A-2013-2016
OI /0000-0001-7488-250X; Wang, Jie Jin/0000-0001-9491-4898; Klaver,
   Caroline/0000-0002-2355-5258
FU National Institutes of Health [EY06594, EY11753, EY03040]; Research to
   Prevent Blindness, New York, NY; National Health & Medical Research
   Council, Canberra, Australia [974159, 211069, 457349, 512423]; Stichting
   Lijf en Leven, Krimpen aan de Lek; MD Fonds, Utrecht; Rotterdamse
   Vereniging Blindenbelangen, Rotterdam; Stichting Oogfonds Nederland,
   Utrecht; Blindenpenning, Amsterdam; Blindenhulp, The Hague; Algemene
   Nederlandse Vereniging ter Voorkoming van Blindheid (ANVVB), Doorn;
   Landelijke Stichting voor Blinden en Slechtzienden, Utrecht; Swart van
   Essen, Rotterdam; Stichting Winckel-Sweep, Utrecht; Henkes Stichting,
   Rotterdam; Lameris Ootech BV, Nieuwegein; Medical Workshop, de Meern;
   Topcon Europe BV, Capelle aan de IJssel, all in the Netherlands, and
   Heidelberg Engineering, Dossenheim, Germany; Pfizer, Inc; NATIONAL EYE
   INSTITUTE [P30EY003040, U10EY006594, U10EY011753] Funding Source: NIH
   RePORTER
FX The Beaver Dam Eye Study was supported by National Institutes of Health
   grant EY06594 (BEK Klein and R Klein) and, in part, by an unrestricted
   grant from Research to Prevent Blindness, New York, NY. The National Eye
   Institute provided funding for the entire study including collection and
   analyses of data; RPB provided additional support for data analyses. The
   Blue Mountains Eye Study was supported by grants 974159, 211069, 457349,
   and 512423 from the National Health & Medical Research Council,
   Canberra, Australia. The Rotterdam Study is supported by Stichting Lijf
   en Leven, Krimpen aan de Lek; MD Fonds, Utrecht; Rotterdamse Vereniging
   Blindenbelangen, Rotterdam; Stichting Oogfonds Nederland, Utrecht;
   Blindenpenning, Amsterdam; Blindenhulp, The Hague; Algemene Nederlandse
   Vereniging ter Voorkoming van Blindheid (ANVVB), Doorn; Landelijke
   Stichting voor Blinden en Slechtzienden, Utrecht; Swart van Essen,
   Rotterdam; Stichting Winckel-Sweep, Utrecht; Henkes Stichting,
   Rotterdam; Lameris Ootech BV, Nieuwegein; Medical Workshop, de Meern;
   Topcon Europe BV, Capelle aan de IJssel, all in the Netherlands, and
   Heidelberg Engineering, Dossenheim, Germany. The Los Angeles Latino Eye
   Study was supported by the National Institutes of Health grants EY11753
   and EY03040, an unrestricted grant from Research to Prevent Blindness,
   New York, NY, and Pfizer, Inc.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chew EY, 2010, OPHTHALMOLOGY, V117, P2112, DOI 10.1016/j.ophtha.2010.02.033
   Cornelis MC, 2010, GENET EPIDEMIOL, V34, P364, DOI 10.1002/gepi.20492
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Bakker PI, 2010, COLD SPRING HARB PRO, V2010
   Fan Q, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002753
   FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hofman A, 2011, EUR J EPIDEMIOL, V26, P657, DOI 10.1007/s10654-011-9610-5
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1991, PB91184267 NAT TECHN
   Klein R, 1991, PB91149823 NAT TECHN
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McKean-Cowdin R, 2010, OPHTHALMOLOGY, V117, P1900, DOI 10.1016/j.ophtha.2010.01.059
   MILTON RC, 1977, BRIT J OPHTHALMOL, V61, P192, DOI 10.1136/bjo.61.3.192
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Sim X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065804
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Verhoeven VJM, 2013, NAT GENET, V45, P314, DOI 10.1038/ng.2554
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 43
TC 61
Z9 61
U1 0
U2 12
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD FEB
PY 2014
VL 21
IS 1
BP 14
EP 23
DI 10.3109/09286586.2013.867512
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 303ZF
UT WOS:000330714100002
PM 24467558
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Fortuna, J
   Riddering, A
   Shuster, L
   Lopez-Jeng, C
AF Fortuna, Jennifer
   Riddering, Anne
   Shuster, Linda
   Lopez-Jeng, Cassie
TI Assessment of online patient education materials designed for people
   with age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Health literacy; Age-related macular degeneration; Patient education
   materials; Readability; Suitability
ID QUALITY-OF-LIFE; HEALTH LITERACY; READABILITY; PERCEPTIONS
AB Background Age-related macular degeneration (AMD) is a chronic eye condition that leads to permanent vision loss in the central visual field. AMD makes reading challenging and inefficient. People with AMD often find it difficult to access, process and understand written patient education materials (PEMs). To promote health literacy, the demands of written PEMs must match the literacy capacities of the target audience. This study aims to evaluate the readability (grade level) and suitability (appropriateness) of online PEMs designed for people with AMD. Methods Online PEMs were sourced from websites of national organizations providing patient education materials designed for people with AMD. The Flesch-Kincaid Grade Level formula and the Suitability Assessment of Materials instrument were used to assess the readability and suitability of PEMs. Descriptive statistics were used to compare online PEMs by organization based on national guidelines for readability level (<= sixth grade) and the recommended suitability score (>= 70%) for "superior" material. Results One hundred online PEMs were evaluated from websites of 16 professional organizations. The mean readability level was 9.3 (range 5.0-16.6). The mean suitability score was 53% (range 18-78%). Only six (6%) of PEMs achieved the recommended guidelines for readability level and suitability score. Conclusion The majority of online PEMs designed for people with AMD were written above the recommended readability level, and below the suggested suitability score. To promote health literacy, the demands of written health information must match the reading capacities of the target audience. Heeding to evidence-based guidelines for providing written information to patients with low health literacy and low vision is beneficial for both patients and health care providers. Future research is warranted.
C1 [Fortuna, Jennifer] Grand Valley State Univ, Occupat Sci & Therapy Dept, 500 Lafayette Ave NE, Grand Rapids, MI 49503 USA.
   [Riddering, Anne] Western Michigan Univ, Dept Occupat Therapy, 1903 W Michigan Ave, Kalamazoo, MI 49008 USA.
   [Shuster, Linda] Western Michigan Univ, Dept Speech Language & Hearing Sci, 1903 W Michigan Ave, Kalamazoo, MI 49008 USA.
   [Lopez-Jeng, Cassie] Western Michigan Univ, Sch Interdisciplinary Hlth Programs, 1903 W Michigan Ave, Kalamazoo, MI 49008 USA.
C3 Grand Valley State University; Western Michigan University; Western
   Michigan University; Western Michigan University
RP Fortuna, J (通讯作者)，Grand Valley State Univ, Occupat Sci & Therapy Dept, 500 Lafayette Ave NE, Grand Rapids, MI 49503 USA.
EM fortunje@gvsu.edu
OI Fortuna, Jennifer/0000-0002-3536-2605
CR Albright J, 1996, APPL NURS RES, V9, P139, DOI 10.1016/S0897-1897(96)80254-0
   [Anonymous], 2019, SPSS SOFTWARE
   [Anonymous], 2016, WORD SOFTW
   [Anonymous], 2019, AGE RELATED MACULAR
   [Anonymous], 2019, UND LIT NUM
   [Anonymous], 2018, CLEAR COMM CLEAR SIM
   [Anonymous], 2015, COMM EYE DIS
   [Anonymous], 2006, MED COMM BEN PRESCR
   [Anonymous], 2020, READ CALC
   Armstrong-Heimsoth A., 2019, OP J OCCUPAT THERAPY, V7, P1, DOI [10.15453/2168-6408.1595, DOI 10.15453/2168-6408.1595]
   Badarudeen S, 2010, CLIN ORTHOP RELAT R, V468, P2572, DOI 10.1007/s11999-010-1380-y
   Beverley CA, 2004, HEALTH SOC CARE COMM, V12, P1, DOI 10.1111/j.1365-2524.2004.00460.x
   Carrier Emily, 2009, Issue Brief Cent Stud Health Syst Change, P1
   Chaudry I, 2015, CAN J OPHTHALMOL, V50, P217, DOI 10.1016/j.jcjo.2015.02.004
   Chung STL, 2020, OPHTHAL PHYSL OPT, V40, P171, DOI 10.1111/opo.12664
   Cooley M E, 1995, Oncol Nurs Forum, V22, P1345
   D'Alessandro DM, 2001, ARCH PEDIAT ADOL MED, V155, P807, DOI 10.1001/archpedi.155.7.807
   DAVIS TC, 1990, J FAM PRACTICE, V31, P533
   Doak CC, 1996, ASSESSING SUITABILIT, V2nd
   Doak CC, 1996, ASSESSING SUITABILIT, V2nd
   Eames Sally, 2003, Top Stroke Rehabil, V10, P70
   Edmunds MR, 2013, JAMA OPHTHALMOL, V131, P1610, DOI 10.1001/jamaophthalmol.2013.5521
   Eltorai AEM, 2014, ARCH TRAUMA RES, V3, DOI 10.5812/atr.18161
   Fox S., 2011, SOCIAL LIFE HLTH INF
   Hansberry DR, 2014, LARYNGOSCOPE, V124, P405, DOI 10.1002/lary.24261
   Harrison TC, 2010, RES GERONTOL NURS, V3, P49, DOI 10.3928/19404921-20090731-01
   Huang G, 2015, JAMA OPHTHALMOL, V133, P449, DOI 10.1001/jamaophthalmol.2014.6104
   John Ann M, 2016, J Clin Aesthet Dermatol, V9, P23
   John AM, 2015, J AAPOS, V19, P430, DOI 10.1016/j.jaapos.2015.07.286
   John ES, 2014, INVEST OPHTH VIS SCI, V55
   Kher A, 2017, ADV PREV MED
   Kincaid J.P., 1975, DERIVATION NEW READA
   Kirrsch IS., 1993, ADULT LITERACY AM, P201
   Kitchel JE, 2011, APH GUIDELINES PRINT
   Kutner M., 2006, HLTH LITERACY AM ADU
   Legge GE, 2007, PSYCHOPHYSICS READIN
   Organisation for Economic Co-operation and Development, 2013, OECD SKILLS OUTL 201
   Owsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681, DOI 10.1001/archophthalmol.2009.55
   Parker R, 2000, HEALTH PROMOT INT, V15, P277, DOI 10.1093/heapro/15.4.277
   Ratzan S, 2004, NATL LIB MED CURRENT
   Rubin GS, 2013, VISION RES, V90, P43, DOI 10.1016/j.visres.2013.02.015
   Rudd RE, 2007, AM J HEALTH BEHAV, V31, pS8
   Stossel LM, 2012, J GEN INTERN MED, V27, P1165, DOI 10.1007/s11606-012-2046-0
   Taylor-Clarke K, 2012, J CARDIOVASC NURS, V27, P485, DOI 10.1097/JCN.0b013e318220720c
   Warren Mary, 2016, Am J Occup Ther, V70, p7003270010p1, DOI 10.5014/ajot.2016.017400
   Warren M, 2013, TOP GERIATR REHABIL, V29, P107, DOI 10.1097/TGR.0b013e31827e4840
   Weintraub D, 2004, PATIENT EDUC COUNS, V55, P275, DOI 10.1016/j.pec.2003.10.003
   Weiss, 2007, HLTH LITERACY MANUAL
   Wolf MS, 2012, J GEN INTERN MED, V27, P1300, DOI 10.1007/s11606-012-2079-4
   Zhang SD, 2015, J GLAUCOMA, V24, P508, DOI 10.1097/IJG.0000000000000056
NR 50
TC 3
Z9 3
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD OCT 2
PY 2020
VL 20
IS 1
AR 391
DI 10.1186/s12886-020-01664-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA NZ2JN
UT WOS:000576921800003
PM 33008367
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Flood, VM
   Rochtchina, E
   Wang, JJ
   Mitchell, P
AF Gopinath, Bamini
   Flood, Victoria M.
   Rochtchina, Elena
   Wang, Jie Jin
   Mitchell, Paul
TI Homocysteine, folate, vitamin B-12, and 10-y incidence of age-related
   macular degeneration
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID BLUE-MOUNTAINS-EYE; LONG-TERM INCIDENCE; FOOD-FREQUENCY QUESTIONNAIRE;
   NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; FOLIC-ACID;
   ENDOTHELIAL DYSFUNCTION; PLASMA HOMOCYSTEINE; OLDER POPULATION; GLYCEMIC
   INDEX
AB Background: Epidemiologic evidence of a relation between serum total homocysteine (tHcy), vitamin B-12, and folate and age-related macular degeneration (AMD) is inconsistent and unresolved.
   Objective: In this cohort study, we aimed to investigate associations between intakes and serum concentrations of folate and vitamin B-12 or serum tHcy and 10-y AMD incidence.
   Design: Serum folate, vitamin B-12, and tHcy were determined from blood samples drawn in 1997-1999 from cohort members aged >= 55 y. AMD was assessed in 1760 survivors from retinal photographs taken in 2002-2004 and 2007-2009. Total intakes of folate and vitamin B-12 were assessed by using a food-frequency questionnaire.
   Results: After adjustment for age, sex, current smoking, white blood cell count, and fish consumption, each 1-SD increase in serum tHcy was associated with increased risk of incident early and any AMID [ORs (95% CIs): 1.33 (1.09, 1.63) and 1.33 (1.11, 1.60), respectively]. Participants with a serum vitamin B-12 deficiency (<185 pmol/L) had higher risk of incident early and late AND [ORs (95% CIs): 1.58 (1.06, 2.36) and 2.56 (1.38, 4.73), respectively]. Folate deficiency (<11 nmol/L) was associated with 75% and 89% increased risk of incident early and any AMID, respectively, 10 y later. Participants who reported supplementary vitamin B-12 intake had 47% reduced risk of incident any AMD (OR: 0.53; 95% CI: 0.33, 0.85).
   Conclusion: Elevated serum tHcy and folate and vitamin B-12 deficiencies predicted increased risk of incident AMID, which suggests a potential role for vitamin B-12 and folate in reducing AMD risk.
C1 [Gopinath, Bamini; Rochtchina, Elena; Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Gopinath, Bamini; Rochtchina, Elena; Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Flood, Victoria M.] Univ Wollongong, Fac Hlth & Behav Sci, Sydney, NSW, Australia.
   [Wang, Jie Jin] Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Wollongong; Centre for Eye Research
   Australia; University of Melbourne
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul.mitchell@sydney.edu.au
RI Mitchell, Paul/P-1498-2014; wang, jie/GRS-0942-2022; Gopinath,
   Bamini/K-4286-2019; Flood, Victoria M/A-8732-2016; Wang, Jie
   Jin/P-1499-2014
OI Gopinath, Bamini/0000-0003-3573-359X; Flood, Victoria
   M/0000-0001-5310-7221; Wang, Jie Jin/0000-0001-9491-4898
FU Australian National Health and Medical Research Council [974159, 991407,
   211069, 262120]; Kellogg's Pty Ltd; Westmead Millennium Institute;
   Macular Degeneration Foundation; Blackmores Dr Paul Beaumont Fellowship
FX The Blue Mountains Eye Study was supported by the Australian National
   Health and Medical Research Council (grants 974159, 991407, 211069, and
   262120), Kellogg's Pty Ltd, and Westmead Millennium Institute. BG is
   supported by a Macular Degeneration Foundation and Blackmores Dr Paul
   Beaumont Fellowship.
CR Abraham B., 2001, INTERIM EVALUATION V
   ANZFA, 1999, NAT NUTR SURV NUTR D
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Austin RC, 2004, CELL DEATH DIFFER, V11, pS56, DOI 10.1038/sj.cdd.4401451
   Barclay AW, 2008, PUBLIC HEALTH NUTR, V11, P573, DOI 10.1017/S1368980007001103
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015
   Department of Community Services and Health, 1995, NUTTAB95 NUTR DAT TA
   Department of Community Services and Health, 1990, NUTTAB90 NUTR DAT TA
   Fassbender K, 1999, LANCET, V353, P1586
   Flood VM, 2006, AUST NZ J PUBL HEAL, V30, P38, DOI 10.1111/j.1467-842X.2006.tb00084.x
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Friedman AN, 2001, J AM SOC NEPHROL, V12, P2181, DOI 10.1681/ASN.V12102181
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Herbert V, 1997, AM J CLIN NUTR, V65, P572, DOI 10.1093/ajcn/65.2.572
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Holland B., 1991, MCCANCE WIDDOWSONS C, V5
   IOM, 1998, DIET REF INT THIAM R
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Klein BEK, 2009, ARCH OPHTHALMOL-CHIC, V127, P1175, DOI 10.1001/archophthalmol.2009.172
   KLEIN BEK, 1989, INVEST OPHTH VIS SCI, V30, P304
   Lawrence M. A., 1999, Australian Journal of Nutrition and Dietetics, V56, P15
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   McNulty H, 2008, BRIT J NUTR, V99, pS48, DOI 10.1017/S0007114508006855
   Mennen LI, 2002, AM J CLIN NUTR, V76, P1279, DOI 10.1093/ajcn/76.6.1279
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moat Stuart J, 2005, Semin Vasc Med, V5, P172, DOI 10.1055/s-2005-872402
   NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Selhub J, 1999, ANN INTERN MED, V131, P331, DOI 10.7326/0003-4819-131-5-199909070-00003
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Shimakawa T, 1997, ANN EPIDEMIOL, V7, P285, DOI 10.1016/S1047-2797(97)00004-5
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   STABLER SP, 1995, J AM GERIATR SOC, V43, P1290, DOI 10.1111/j.1532-5415.1995.tb07408.x
   Stuhlinger MC, 2001, CIRCULATION, V104, P2569, DOI 10.1161/hc4601.098514
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Verhaar MC, 1998, CIRCULATION, V97, P237, DOI 10.1161/01.CIR.97.3.237
   Virdis A, 2001, J AM COLL CARDIOL, V38, P1106, DOI 10.1016/S0735-1097(01)01492-9
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Woo KS, 1999, J AM COLL CARDIOL, V34, P2002, DOI 10.1016/S0735-1097(99)00469-6
NR 53
TC 55
Z9 56
U1 0
U2 12
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JUL
PY 2013
VL 98
IS 1
BP 129
EP 135
DI 10.3945/ajcn.112.057091
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 171EZ
UT WOS:000320909200017
PM 23636242
OA Bronze
DA 2022-11-30
ER

PT J
AU Barthelmes, D
   Walton, R
   Campain, AE
   Simpson, JM
   Arnold, JJ
   McAllister, IL
   Guymer, RH
   Hunyor, AP
   Essex, RW
   Morlet, N
   Gillies, MC
AF Barthelmes, Daniel
   Walton, Richard
   Campain, Anna E.
   Simpson, Judy M.
   Arnold, Jennifer J.
   McAllister, Ian L.
   Guymer, Robyn H.
   Hunyor, Alex P.
   Essex, Rohan W.
   Morlet, Nigel
   Gillies, Mark C.
CA Fight Retinal Blindness Project In
TI Outcomes of persistently active neovascular age-related macular
   degeneration treated with VEGF inhibitors: observational study data
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB; PHOTODYNAMIC THERAPY; VISUAL OUTCOMES;
   BEVACIZUMAB; PREDICTORS; APOPTOSIS
AB Aim To describe outcomes of eyes with wet age-related macular degeneration (AMD) subdivided by lesion activity in a large multicentre cohort study.
   Methods Treatment-naive eyes with subfoveal choroidal neovascularisation receiving antivascular endothelial growth factor therapy enrolled in the Fight Retinal Blindness observational study were included. Lesions were graded at each visit as active if there was intraretinal or subretinal fluid attributable to leak from choroidal neovascularisation lesion or fresh haemorrhage. Eyes were divided into four groups; based on the proportion of visits, each eye was graded as active during the first 12 months of treatment (persistent, high, moderate and low activity).
   Results 655 eyes were included. Similar mean visual acuity changes compared with baseline were observed in all four groups at 12 months (+6.8, +8.3, +6.2 and +5.5 letters for the low, moderate, high and persistent groups, respectively; p<0.001 for each group). The mean number of injections given increased only modestly in groups with more active lesions (7.6, 7.9, 8.4 and 8.3, respectively, p=0.015). Occult and minimally classic lesions were more frequent in the more active groups (p=0.024).
   Conclusions Persistent activity of neovascular lesions during 12 months after starting intravitreal therapy was not associated with worse visual outcomes in this observational study of AMD.
C1 [Barthelmes, Daniel; Walton, Richard; Campain, Anna E.; Hunyor, Alex P.; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
   [Simpson, Judy M.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, NSW, Australia.
   [McAllister, Ian L.] Lions Eye Inst, Perth, WA, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Hunyor, Alex P.] Retina Associates, Chatswood, NSW, Australia.
   [Essex, Rohan W.] Canberra Hosp, Dept Ophthalmol, Garran, ACT, Australia.
   [Gillies, Mark C.] Univ Western Australia, Dept Populat Hlth, Perth, WA 6009, Australia.
C3 University of Sydney; University of Zurich; University Zurich Hospital;
   University of Sydney; Lions Eye Institute; University of Western
   Australia; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital; University of Melbourne; Australian National University;
   Canberra Hospital; University of Western Australia
RP Gillies, MC (通讯作者)，Save Sight Inst, South Block,8 Macquarie St, Sydney, NSW 2001, Australia.
EM mark.gillies@sydney.edu.au
RI Hunyor, Alex/AAT-8205-2021
OI Hunyor, Alex/0000-0002-8182-6167; Simpson, Judy M/0000-0001-5172-3004;
   Campain, Anna/0000-0003-1057-0085; Essex, Rohan/0000-0001-5323-0334;
   Guymer, Robyn/0000-0002-9441-4356; Fraser-Bell,
   Samantha/0000-0001-5646-9359
FU Eye Foundation; National Health and Medical Research Council, Canberra,
   Australia [NHRMC 2010-1012]
FX Supported by a grant from the Eye Foundation (2007-2009) and a grant
   from the National Health and Medical Research Council, Canberra,
   Australia (NHRMC 2010-1012).
CR Agresti A., 2019, INTRO CATEGORICAL DA
   [Anonymous], 2013, R LANG ENV STAT COMP
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   CASTROCORREIA J, 1992, DOC OPHTHALMOL, V81, P379
   Cleveland W, 1992, STAT MODELS, DOI 10.1201/9780203738535
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   MALINOWSKI SM, 1993, OPHTHALMOLOGY, V100, P818
   Malinowski SM, 1993, OPHTHALMOLOGY, V100, P25
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ranty ML, 2009, GRAEF ARCH CLIN EXP, V247, P215, DOI 10.1007/s00417-008-0957-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Williams PD, 2012, CLIN OPHTHALMOL, V6, P1519, DOI 10.2147/OPTH.S31010
   Wykoff CC, 2013, OPHTHAL SURG LAS IM, V44, P121, DOI 10.3928/23258160-20130313-04
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yoshizawa C, 2013, JPN J OPHTHALMOL, V57, P68, DOI 10.1007/s10384-012-0206-8
NR 26
TC 14
Z9 14
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2015
VL 99
IS 3
BP 359
EP 364
DI 10.1136/bjophthalmol-2014-305514
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC0AU
UT WOS:000349998000015
PM 25249615
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Nita, M
   Michalska-Malecka, K
   Mazurek, U
   Kimsa, M
   Strzalka-Mrozik, B
   Grzybowski, A
   Romaniuk, D
AF Nita, Malgorzata
   Michalska-Malecka, Katarzyna
   Mazurek, Urszula
   Kimsa, Malgorzata
   Strzalka-Mrozik, Barbara
   Grzybowski, Andrzej
   Romaniuk, Dorota
TI Influence of ranibizumab treatment on the extracellular matrix in
   patients with neovascular age-related macular degeneration
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Neovascular (Exudative) Age-Related Macular Degeneration; Ranibizumab;
   Extracellular Matrix; Bruch's Membrane; Collagen; Elastin; Laminin
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL DETACHMENT; INTRAVITREAL
   RANIBIZUMAB; HOLE FORMATION; COLLAGEN-IV; METALLOPROTEINASES;
   ANGIOGENESIS; COMPONENTS; OCCULT; CELLS
AB Background: We know the influence of the intravitreal anti-vascular endothelial growth factor (VEGF) injections on the choroidal neovascularization in the course of exudative age-related macular degeneration (AMD). However, the influence of the ranibizumab therapy in question on the extracellular matrix (ECM) remains unknown. We aimed to estimate the influence of Lucentis intravitreal injections on the gene expression of structural components of the extracellular matrix in patients with neovascular AMD.
   Material/Methods: Patients with subfoveal localization of neovascularization in AMD, which was clinically active and observed using optical coherence tomography, were treated with ranibizumab (0.5 mg/0.05 mL) in accordance with the PrONTO scheme. Total RNA was extracted from peripheral blood mononuclear cells, and an oligonucleotide microarray technique enabled comparison of the expression level of genes encoding collagens, elastin, and laminins in AMD patients compared to control subjects.
   Results: After 3 intravitreal injections of ranibizumab (Lucentis), COL1A1 and COL6A1 genes showed increased expression, whereas decreased expression mainly occurred for the following genes: COL4A5, COL11A1, COL4A6, LAMB4, and LAMC2.
   Conclusions: Anti-VEGF local therapy influences the gene expression of structural components of the ECM as measured from blood samples. The loading dose of ranibizumab for the retina changes the expression of collagen and laminin genes, but does not influence the expression of the elastin gene.
C1 [Nita, Malgorzata] Domest & Specialized Med Ctr Dilmed, Katowice, Poland.
   [Michalska-Malecka, Katarzyna; Romaniuk, Dorota] Med Univ Silesia, Dept Ophthalmol, Independent Publ Clin Hosp, Katowice, Poland.
   [Mazurek, Urszula; Kimsa, Malgorzata; Strzalka-Mrozik, Barbara] Med Univ Silesia, Dept Mol Biol, Sosnowiec, Poland.
   [Grzybowski, Andrzej] Poznan City Hosp, Dept Ophthalmol, Poznan, Poland.
   [Grzybowski, Andrzej] Univ Warmia & Mazury, Fac Med, Olsztyn, Poland.
C3 Medical University Silesia; Medical University Silesia; University of
   Warmia & Mazury
RP Grzybowski, A (通讯作者)，Poznan City Hosp, Dept Ophthalmol, Poznan, Poland.
EM ae.grzybowski@gmail.com
RI Grzybowski, A/E-4486-2010
OI Grzybowski, A/0000-0002-3724-2391; MICHALSKA-MALECKA,
   KATARZYNA/0000-0002-0550-8386; STRZALKA-MROZIK,
   BARBARA/0000-0001-9854-2569; Kimsa-Furdzik,
   Malgorzata/0000-0003-1985-2038; Mazurek, Urszula/0000-0003-1181-4934
CR Agtmael TV, 2010, CELL TISSUE RES, V339, P67
   Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Bishop P, 1996, GRAEF ARCH CLIN EXP, V234, P710, DOI 10.1007/BF00292358
   BISHOP PN, 1994, BIOCHEM J, V299, P497, DOI 10.1042/bj2990497
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Cano MD, 2009, INVEST OPHTH VIS SCI, V50, P3840, DOI 10.1167/iovs.08-2607
   Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)02122-5
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Clemens CR, 2010, J OCUL PHARMACOL TH, V26, P297, DOI 10.1089/jop.2009.0140
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Des Parkin J, 2011, HUM MUTAT, V32, P127, DOI 10.1002/humu.21401
   Elliot SJ, 2010, EXP EYE RES, V90, P10, DOI 10.1016/j.exer.2009.09.001
   Erickson AC, 2000, J HISTOCHEM CYTOCHEM, V48, P1291, DOI 10.1177/002215540004801001
   FICHARD A, 1995, MATRIX BIOL, V14, P515, DOI 10.1016/S0945-053X(05)80001-0
   Figurska M, 2012, MED SCI MONITOR, V18, pCR32, DOI 10.12659/MSM.882198
   Figurska M, 2011, MED SCI MONITOR, V17, pCR485, DOI 10.12659/MSM.881934
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Griffith AJ, 1998, AM J HUM GENET, V62, P816, DOI 10.1086/301789
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P1493, DOI 10.1167/iovs.03-0765
   Huang WB, 2013, MED SCI MONIT BASIC, V19, P237, DOI 10.12659/MSMBR.889061
   Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918
   Ihanamaki T, 2004, PROG RETIN EYE RES, V23, P403, DOI 10.1016/j.preteyeres.2004.04.002
   Imai H, 2007, CURR EYE RES, V32, P903, DOI 10.1080/02713680701604749
   Kang S, 2011, JPN J OPHTHALMOL, V55, P123, DOI 10.1007/s10384-010-0910-1
   Khoshnoodi J, 2008, MICROSC RES TECHNIQ, V71, P357, DOI 10.1002/jemt.20564
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   Knupp C, 2006, J STRUCT BIOL, V154, P312, DOI 10.1016/j.jsb.2006.03.023
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li J, 2003, MICROSC RES TECHNIQ, V60, P107, DOI 10.1002/jemt.10249
   Lobo ED, 2004, J PHARM SCI-US, V93, P2645, DOI 10.1002/jps.20178
   Los LI, 2003, INVEST OPHTH VIS SCI, V44, P2828, DOI 10.1167/iovs.02-0588
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Marini JC, 2007, HUM MUTAT, V28, P209, DOI 10.1002/humu.20429
   MAYNE R, 1993, J BIOL CHEM, V268, P9381
   Mckee KK, 2007, J BIOL CHEM, V282, P21437, DOI 10.1074/jbc.M702963200
   Meyer CH, 2006, EYE, V20, P1090, DOI 10.1038/sj.eye.6702121
   Miner JH, 2008, MICROSC RES TECHNIQ, V71, P349, DOI 10.1002/jemt.20563
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mundel TM, 2007, MICROVASC RES, V74, P85, DOI 10.1016/j.mvr.2007.05.005
   Murphy G, 2002, METHOD ENZYMOL, V248, P470
   Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nguyen M, 2001, INT J BIOCHEM CELL B, V33, P960, DOI 10.1016/S1357-2725(01)00007-3
   Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037
   Reale E, 2009, CELLS TISSUES ORGANS, V190, P170, DOI 10.1159/000187632
   Richards AJ, 2000, AM J HUM GENET, V67, P1083
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schellekens H, 2002, CLIN THER, V24, P1720, DOI 10.1016/S0149-2918(02)80075-3
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Sweeney SM, 2008, J BIOL CHEM, V283, P21187, DOI 10.1074/jbc.M709319200
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Volonghi I, 2010, CURR MED CHEM, V17, P1317, DOI 10.2174/092986710790936293
   Wang J, 2003, INVEST OPHTH VIS SCI, V44, P1793, DOI 10.1167/iovs.02-0802
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200
NR 65
TC 6
Z9 6
U1 0
U2 3
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD MAY 28
PY 2014
VL 20
BP 875
EP 883
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AI9LM
UT WOS:000337254100001
PM 24866589
OA Green Published
DA 2022-11-30
ER

PT J
AU Hahn, P
   Acquah, K
   Cousins, SW
   Lee, PP
   Sloan, FA
AF Hahn, Paul
   Acquah, Kofi
   Cousins, Scott W.
   Lee, Paul P.
   Sloan, Frank A.
TI TEN-YEAR INCIDENCE OF AGE-RELATED MACULAR DEGENERATION ACCORDING TO
   DIABETIC RETINOPATHY CLASSIFICATION AMONG MEDICARE BENEFICIARIES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; AMD; incidence; diabetes; diabetic
   retinopathy; Medicare database
ID RISK-FACTORS; VISUAL IMPAIRMENT; EYE DISEASE; ASSOCIATION; MACULOPATHY;
   PREVALENCE; MELLITUS; POPULATION; VARIABLES; GLUCOSE
AB Purpose: To compare the longitudinal incidence over 10 years of dry and wet age-related macular degeneration (AMD) in a U.S. sample of Medicare beneficiaries with no diabetes mellitus, diabetes mellitus without retinopathy, nonproliferative diabetic retinopathy (NPDR), and proliferative diabetic retinopathy (PDR).
   Methods: Using Medicare claims data, the 10-year incidence of dry and wet AMD from 1995 to 2005 in beneficiaries older than 69 years with newly diagnosed diabetes mellitus (n = 6,621), NPDR (n = 1,307), and PDR (n = 327) compared with each other and matched controls without diabetes for each group.
   Results: After controlling for covariates, newly diagnosed NPDR was associated with significantly increased risk of incident diagnosis of dry AMD (hazard ratio, 1.24; 95% confidence interval: 1.08-1.43) and wet AMD (hazard ratio 1.68; 95% confidence interval: 1.23-2.31). Newly diagnosed PDR was associated with significantly increased risk of wet AMD only (hazard ratio 2.15; 95% confidence interval: 1.07-4.33). Diabetes without retinopathy did not affect risk of dry or wet AMD. There was no difference in risk of wet AMD in PDR compared with NPDR.
   Conclusion: Elderly individuals with NPDR or PDR may be at higher risk of AMD compared to those without diabetes mellitus or diabetic retinopathy. RETINA 33: 911-919, 2013
C1 [Hahn, Paul; Cousins, Scott W.] Duke Univ, Ctr Eye, Dept Ophthalmol, Durham, NC 27710 USA.
   [Acquah, Kofi] Brown Univ, Dept Econ, Providence, RI 02912 USA.
   [Lee, Paul P.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA.
   [Sloan, Frank A.] Duke Univ, Dept Econ, Durham, NC 27708 USA.
C3 Duke University; Brown University; University of Michigan System;
   University of Michigan; Duke University
RP Sloan, FA (通讯作者)，Duke Univ, Dept Econ, 213 Social Sci Bldg,Box 90097, Durham, NC 27708 USA.
EM fsloan@duke.edu
OI Hahn, Paul/0000-0002-6574-388X; Lee, Paul/0000-0002-3338-136X
FU National Institute on Aging, Bethesda, MD [2R01AG017473-09A2]; Ronald G.
   Michels Foundation; Heed Ophthalmic Foundation; Alcon; National
   Institutes of Health; Washington University; NATIONAL INSTITUTE ON AGING
   [R01AG017473] Funding Source: NIH RePORTER
FX Supported in part by Grant 2R01AG017473-09A2 from the National Institute
   on Aging, Bethesda, MD. P. Hahn received support from the Ronald G.
   Michels Foundation and the Heed Ophthalmic Foundation.; P. P. Lee has
   served as a consultant for Allergan, Pfizer, and Genentech, and he has
   received financial support from Alcon, the National Institutes of
   Health, and the Washington University Award.
CR ALGVERE P, 1985, BRIT J OPHTHALMOL, V69, P416, DOI 10.1136/bjo.69.6.416
   Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580
   Benson WE, 1988, DIABETES ITS OCULAR
   Bethel MA, 2007, ARCH INTERN MED, V167, P921, DOI 10.1001/archinte.167.9.921
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JENSEN V A, 1955, Ophthalmologica, V129, P89
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Parsons LS, PERFORMING 1 N CASE
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sloan FA, 2008, ARCH INTERN MED, V168, P192, DOI 10.1001/archinternmed.2007.35
   Stitt AW, 2010, INVEST OPHTH VIS SCI, V51, P4867, DOI 10.1167/iovs.10-5881
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   VIDAURRI JS, 1984, OPHTHALMOLOGICA, V188, P243, DOI 10.1159/000309370
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Wong J, 2008, DIABETES CARE, V31, P1985, DOI 10.2337/dc08-0580
   Zhang XZ, 2008, ARCH OPHTHALMOL-CHIC, V126, P1421, DOI 10.1001/archopht.126.10.1421
   Zylbermann R, 1997, EYE, V11, P872, DOI 10.1038/eye.1997.224
NR 34
TC 28
Z9 29
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2013
VL 33
IS 5
BP 911
EP 919
DI 10.1097/IAE.0b013e3182831248
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131QY
UT WOS:000318011100003
PM 23407352
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Finger, RP
   Fleckenstein, M
   Holz, FG
   Scholl, HPN
AF Finger, Robert P.
   Fleckenstein, Monika
   Holz, Frank G.
   Scholl, Hendrik P. N.
TI Quality of life in age-related macular degeneration: a review of
   available vision-specific psychometric tools
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE age-related macular degeneration (AMD); quality of life; psychometric
   tools; psychometric and non-psychometric properties; quality criteria
ID VISUAL FUNCTION QUESTIONNAIRE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   CATARACT-SURGERY OUTCOMES; FUNCTION INDEX VF-14; FUNCTIONING
   QUESTIONNAIRE; SELF-MANAGEMENT; IMPAIRMENT QUESTIONNAIRE; PHOTODYNAMIC
   THERAPY; REDUCED VISION; CLINICAL-TRIAL
AB Purpose Age-related macular degeneration (AMD) has a considerable impact on older adults' independence and autonomy. Recently, patient reported outcomes (PROs) such as QoL have been met with increasing interest by the scientific community, healthcare payers and planners. Against this background, the multitude of psychometric tools used to measure QoL in AMD was reviewed.
   Methods A search of the literature from 1990 onwards yielded 355 results, out of which 58 publications were included in the review. Data regarding design, validation and extent of utilization were obtained where available.
   Results The National Eye Institute-Visual Function Questionnaire (NEI VFQ-25-item) was found to be the most often used (29% of studies) and best validated psychometric tool, followed by the Visual Function Questionnaire (VF-14; 17%), and the Impact of Vision Impairment Profile (IVI; 9%). Most tools that were identified have been validated for the use in AMD patients.
   Conclusion Psychometric tools specifically designed to measure vision-related quality of life are well equipped and validated to measure QoL in AMD. More recent developments such as the Macular Disease-dependent Quality of Life (MacDQoL) questionnaire might be able to depict dimensions of vision-related QoL in greater depth. Future studies should endeavour to use a suggested standard when gathering data on vision related QoL, allowing for international comparisons.
C1 [Finger, Robert P.; Fleckenstein, Monika; Holz, Frank G.; Scholl, Hendrik P. N.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Scholl, HPN (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Hendrik.Scholl@ukb.uni-bonn.de
OI Finger, Robert P/0000-0003-4253-7597; Fleckenstein,
   Monika/0000-0001-8321-8037
CR Alonso J, 1997, OPHTHALMOLOGY, V104, P799, DOI 10.1016/S0161-6420(97)30230-9
   Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Birk T, 2004, GERONTOLOGIST, V44, P836, DOI 10.1093/geront/44.6.836
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Carta A, 1998, CURR EYE RES, V17, P506, DOI 10.1076/ceyr.17.5.506.5191
   CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005
   Chassany O, 2002, DRUG INF J, V36, P209, DOI 10.1177/009286150203600127
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   *COMM MED PROD HUM, 2005, EMEA
   Crabtree HL, 1999, BRIT J OPHTHALMOL, V83, P519, DOI 10.1136/bjo.83.5.519
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   de Boer MR, 2004, OPHTHAL PHYSL OPT, V24, P257, DOI 10.1111/j.1475-1313.2004.00187.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Denny F, 2007, INVEST OPHTH VIS SCI, V48, P1976, DOI 10.1167/iovs.06-0135
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fitzpatrick R, 1998, HEALTH TECHNOL ASSES, V2
   Fuhs A, 2005, KLIN MONATSBL AUGENH, V222, P649, DOI 10.1055/s-2005-858367
   Gupta SK, 2005, BRIT J OPHTHALMOL, V89, P621, DOI 10.1136/bjo.2004.050732
   Hart PM, 2005, BRIT J OPHTHALMOL, V89, P1127, DOI 10.1136/bjo.2004.059683
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Hassell JB, 2000, CLIN EXP OPHTHALMOL, V28, P156, DOI 10.1046/j.1442-9071.2000.00312.x
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Hewitt AW, 2006, GRAEF ARCH CLIN EXP, V244, P972, DOI 10.1007/s00417-005-0218-x
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keeffe JE, 1999, AUST NZ J OPHTHALMOL, V27, P184, DOI 10.1046/j.1440-1606.1999.00179.x
   Krummenauer F, 2005, EUR J OPHTHALMOL, V15, P74, DOI 10.1177/112067210501500112
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   Langelaan M, 2007, OPTOMETRY VISION SCI, V84, P775, DOI 10.1097/OPX.0b013e3181334b98
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   OSHAUGHNESSY JA, 1991, J CLIN ONCOL, V9, P2225, DOI 10.1200/JCO.1991.9.12.2225
   Pallant JF, 2007, BRIT J CLIN PSYCHOL, V46, P1, DOI 10.1348/014466506X96931
   Pesudovs K, 1998, BRIT J OPHTHALMOL, V82, P617, DOI 10.1136/bjo.82.6.617
   Pesudovs K, 2003, INVEST OPHTH VIS SCI, V44, P2892, DOI 10.1167/iovs.02-1075
   Pham TQ, 2007, EYE, V21, P324, DOI 10.1038/sj.eye.6702171
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   Rossi GCM, 2003, J GLAUCOMA, V12, P213, DOI 10.1097/00061198-200306000-00006
   Schmier JK, 2006, OPHTHAL EPIDEMIOL, V13, P137, DOI 10.1080/09286580600573049
   Scilley K, 2004, OPHTHAL EPIDEMIOL, V11, P131, DOI 10.1076/opep.11.2.131.28159
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Toprak AB, 2005, OPHTHAL EPIDEMIOL, V12, P259, DOI 10.1080/09286580590967763
   Trautner C, 2003, INVEST OPHTH VIS SCI, V44, P1031, DOI 10.1167/iovs.02-0304
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Velozo C A, 2000, J Outcome Meas, V4, P667
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
NR 87
TC 50
Z9 53
U1 0
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD MAY
PY 2008
VL 17
IS 4
BP 559
EP 574
DI 10.1007/s11136-008-9327-4
PG 16
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 303EZ
UT WOS:000256025100007
PM 18365767
DA 2022-11-30
ER

PT J
AU Sjoberg, AP
   Trouw, LA
   Clark, SJ
   Sjolander, J
   Heinegard, D
   Sim, RB
   Day, AJ
   Blom, AM
AF Sjoberg, Andreas P.
   Trouw, Leendert A.
   Clark, Simon J.
   Sjolander, Jonatan
   Heinegard, Dick
   Sim, Robert B.
   Day, Anthony J.
   Blom, Anna M.
TI The factor H variant associated with age-related macular degeneration
   (His-384) and the non-disease-associated form bind differentially to
   C-reactive protein, fibromodulin, DNA, and necrotic cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID COMPLEMENT ACTIVATION; ALTERNATIVE PATHWAY; C4B-BINDING PROTEIN;
   INHIBITORY-ACTIVITY; SITE; PROTEOGLYCANS; INFLAMMATION; PATHOGENESIS;
   POLYMORPHISM; HEPARIN
AB Recently, a polymorphism in the complement regulator factor H (FH) gene has been associated with age-related macular degeneration. When histidine instead of tyrosine is present at position 384 in the seventh complement control protein (CCP) domain of FH, the risk for age-related macular degeneration is increased. It was recently shown that these allotypic variants of FH, in the context of a recombinant construct corresponding to CCPs 6 - 8, recognize polyanionic structures differently, which may lead to altered regulation of the alternative pathway of complement. We show now that His-384, corresponding to the risk allele, binds C-reactive protein (CRP) poorly compared with the Tyr-384 form. We also found that C1q and phosphorylcholine do not compete with FH for binding to C-reactive protein. The interaction with extracellular matrix protein fibromodulin, which we now show to be mediated, at least in part, by CCP6 - 8 of FH, occurs via the polypeptide of fibromodulin and not through its glycosaminoglycan modifications. The Tyr-384 variant of FH bound fibromodulin better than the His-384 form. Furthermore, we find that CCP6 - 8 is able to interact with DNA and necrotic cells, but in contrast the His-384 allotype binds these ligands more strongly than the Tyr-384 variant. The variations in binding affinity of the two alleles indicate that complement activation and local inflammation in response to different targets will differ between His/His and Tyr/Tyr homozygotes.
C1 Lund Univ, Dept Lab Med, Sect Med Prot Chem, Malmo Univ Hosp, S-20502 Malmo, Sweden.
   Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England.
   Lund Univ, Dept Expt Med Sci, S-22184 Lund, Sweden.
   Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England.
C3 Lund University; Skane University Hospital; University of Oxford; Lund
   University; University of Manchester
RP Blom, AM (通讯作者)，Lund Univ, Dept Lab Med, Sect Med Prot Chem, Malmo Univ Hosp, S-20502 Malmo, Sweden.
EM anna.blom@med.lu.se
RI Blom, Anna/AFS-7369-2022; Trouw, Leendert/AGK-5202-2022; Blom,
   Anna/B-9607-2009; Day, Anthony/O-1658-2015; Sim, Bob/A-1354-2008
OI Trouw, Leendert/0000-0001-5186-2290; Blom, Anna/0000-0002-1348-1734;
   Day, Anthony/0000-0002-1415-3134; Sim, Bob/0000-0002-2855-7455; Clark,
   Simon/0000-0001-8394-8355
FU MRC [MC_U138274352] Funding Source: UKRI; NATIONAL INSTITUTE OF
   ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U01AR050926] Funding
   Source: NIH RePORTER; Medical Research Council [MC_U138274352] Funding
   Source: Medline; NIAMS NIH HHS [5U01 AR050926] Funding Source: Medline
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANTONSSON P, 1991, J BIOL CHEM, V266, P16859
   ARONOV RA, 1992, PRIRODA, V3, P87
   Bang R, 2005, J BIOL CHEM, V280, P25095, DOI 10.1074/jbc.M504782200
   BIRO A, 2007, IMMUNOLOGY      0117
   Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   BUCKWALTER JA, 1994, MICROSC RES TECHNIQ, V28, P398, DOI 10.1002/jemt.1070280506
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200
   Fishelson Z, 2001, MOL IMMUNOL, V38, P207, DOI 10.1016/S0161-5890(01)00055-4
   GARDNER WD, 1980, BIOCHEM BIOPH RES CO, V94, P61, DOI 10.1016/S0006-291X(80)80187-2
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4
   HEINEGARD D, 1986, J BIOL CHEM, V261, P3866
   Jarva H, 1999, J IMMUNOL, V163, P3957
   JIANG HX, 1992, J BIOL CHEM, V267, P25597
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lutz HU, 2006, MOL IMMUNOL, V43, P2, DOI 10.1016/j.molimm.2005.06.020
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008
   Muller M, 2001, SCHMERZ, V15, P3, DOI 10.1007/s004820170042
   OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x
   Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200
   Padilla ND, 2004, J IMMUNOL METHODS, V293, P1, DOI 10.1016/j.jim.2004.06.011
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Schonherr E, 2004, J VASC RES, V41, P499, DOI 10.1159/000081806
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200
   Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612
   STANESCU V, 1990, SEMIN ARTHRITIS RHEU, V20, P51, DOI 10.1016/0049-0172(90)90047-J
   Sztrolovics R, 1999, SPINE, V24, P1765, DOI 10.1097/00007632-199909010-00003
   Taylor KE, 2005, ARTERIOSCL THROM VAS, V25, P1225, DOI 10.1161/01.ATV.0000164623.41250.28
   TENNER AJ, 1981, J IMMUNOL, V127, P648
   Trouw LA, 2005, J EXP MED, V201, P1937, DOI 10.1084/jem.20050189
NR 45
TC 105
Z9 109
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 13
PY 2007
VL 282
IS 15
BP 10894
EP 10900
DI 10.1074/jbc.M610256200
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 160LG
UT WOS:000245941500008
PM 17293598
OA hybrid
DA 2022-11-30
ER

PT J
AU Capuano, V
   Sacconi, R
   Borrelli, E
   Miere, A
   Gelormini, F
   Farci, R
   Bandello, F
   Souied, EH
   Querques, G
AF Capuano, Vittorio
   Sacconi, Riccardo
   Borrelli, Enrico
   Miere, Alexandra
   Gelormini, Francesco
   Farci, Roberta
   Bandello, Francesco
   Souied, Eric H.
   Querques, Giuseppe
TI Dimple in vascularized serous pigment epithelial detachment secondary to
   neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Dimple; Retinal imaging; Optical
   coherence tomography; Vascularized serous pigment epithelial detachment
ID OPTICAL COHERENCE TOMOGRAPHY
AB Background To describe the "dimple," a previously unreported structural optical coherence tomography (OCT) finding in vascularized serous pigment epithelial detachment (PED) secondary to neovascular age-related macular degeneration (AMD). Methods Retrospective, longitudinal, case series study. Clinical charts and multimodal imaging including OCT (structural and angiography) and dye-based angiography (fluorescein and indocyanine green) examinations of patients with dimple-defined as a localized invagination of the vascularized serous PED-were analyzed in 2 high-volume referral centers. Results Nineteen eyes of 18 patients were included. Mean follow-up was at 64.1 +/- 35.8 months. The greater basal and height diameters of the vascularized serous PED were respectively 3425.8 +/- 1049.6 mu m and 667.1 +/- 279.9 mu m at baseline and 3076.2 +/- 1649.9 mu m (p = 0.8) and 368.3 +/- 295.1 at last follow-up (p = 0.0006). OCT analysis identified 2 phenotypes of dimple: type 1 or ("top denting") (9 eyes) and type 2 (or "side denting") (10 eyes). Both phenotypes are associated with hyper-reflective holding sub-retinal pigment epithelium (RPE) band encompassing the posterior face of the RPE and extending to the Bruch's membrane. Hyper-reflective holding band is not correlated with angiographic signs of neovascular tissue in all cases. During follow-up, no case of RPE tear was observed. Conclusions We describe the characteristics of the dimple and its association with hyper-reflective holding sub-RPE bands in the context of large vascularized serous PED in neovascular AMD. The presence of a dimple does not seem to be an additional risk factor for the development of RPE tearing in high-risk PED secondary to neovascular AMD.
C1 [Capuano, Vittorio; Miere, Alexandra; Farci, Roberta; Souied, Eric H.; Querques, Giuseppe] Creteil Univ Paris Est Creteil, Ctr Hosp Intercommunal, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
   [Sacconi, Riccardo; Borrelli, Enrico; Gelormini, Francesco; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute, Hosp San Raffaele, IRCCS, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Creteil Univ Paris Est Creteil, Ctr Hosp Intercommunal, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.; Querques, G (通讯作者)，Univ Vita Salute, Hosp San Raffaele, IRCCS, Dept Ophthalmol, Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; Borrelli,
   Enrico/0000-0003-2815-5031; bandello, francesco/0000-0003-3238-9682;
   Sacconi, Riccardo/0000-0003-2891-2012; Querques,
   Giuseppe/0000-0002-3292-9581
CR Au A, 2019, INVEST OPHTH VIS SCI, V60, P3310, DOI 10.1167/iovs.18-26478
   Clemens CR, 2012, BRIT J OPHTHALMOL, V96, P1088, DOI 10.1136/bjophthalmol-2011-301415
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gass J D, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P990
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Lam D, 2018, RETINA-J RET VIT DIS, V38, P1100, DOI 10.1097/IAE.0000000000001698
   Lin DS, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-87
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
NR 18
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2020
VL 258
IS 8
BP 1597
EP 1605
DI 10.1007/s00417-020-04732-6
EA MAY 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MN9RI
UT WOS:000532890700002
PM 32409980
DA 2022-11-30
ER

PT J
AU Deemer, AD
   Massof, RW
   Rovner, BW
   Casten, RJ
   Piersol, CV
AF Deemer, Ashley D.
   Massof, Robert W.
   Rovner, Barry W.
   Casten, Robin J.
   Piersol, Catherine V.
TI Functional Outcomes of the Low Vision Depression Prevention Trial in
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE visual function; depression; age-related macular degeneration; low
   vision rehabilitation
ID VISUAL DISABILITY VARIABLES; INTERVENTION TRIAL; OLDER-ADULTS;
   REHABILITATION; IMPAIRMENT; PHQ-9; QUESTIONNAIRE; PERFORMANCE;
   VALIDATION; DIFFICULTY
AB PURPOSE. To compare the efficacy of behavioral activation (BA) plus low vision rehabilitation with an occupational therapist (OT-LVR) with supportive therapy (ST) on visual function in patients with age-related macular degeneration (AMD).
   METHODS. Single-masked, attention-controlled, randomized clinical trial with AMD patients with subsyndromal depressive symptoms (n = 188). All subjects had two outpatient low vision rehabilitation optometry visits, then were randomized to in-home BA + OT-LVR or ST. Behavioral activation is a structured behavioral treatment aiming to increase adaptive behaviors and achieve valued goals. Supportive therapy is a nondirective, psychological treatment that provides emotional support and controls for attention. Functional vision was assessed with the activity inventory (AI) in which participants rate the difficulty level of goals and corresponding tasks. Participants were assessed at baseline and 4 months.
   RESULTS. Improvements in functional vision measures were seen in both the BA + OT-LVR and ST groups at the goal level (d = 0.71; d = 0.56 respectively). At the task level, BA + OT-LVR patients showed more improvement in reading, inside-the-home tasks and outside-the-home tasks, when compared to ST patients. The greatest effects were seen in the BA + OT-LVR group in subjects with a visual acuity >= 20/70 (d = 0.360 reading; d = 0.500 inside the home; d = 0.468 outside the home).
   CONCLUSIONS. Based on the trends of the AI data, we suggest that BA + OT-LVR services, provided by an OT in the patient's home following conventional low vision optometry services, are more effective than conventional optometric low vision services alone for those with mild visual impairment. (ClinicalTrials.gov number, NCT00769015.)
C1 [Deemer, Ashley D.; Massof, Robert W.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, B 43, Baltimore, MD 21287 USA.
   [Rovner, Barry W.] Thomas Jefferson Univ, Dept Psychiat, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
   [Rovner, Barry W.] Thomas Jefferson Univ, Dept Neurol, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
   [Rovner, Barry W.] Thomas Jefferson Univ, Dept Ophthalmol, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
   [Casten, Robin J.] Thomas Jefferson Univ, Dept Psychiat & Human Behav, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
   [Piersol, Catherine V.] Thomas Jefferson Univ, Dept Occupat Therapy, Jefferson Elder Care, Jefferson Sch Hlth Profess, Philadelphia, PA 19107 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Jefferson University;
   Jefferson University; Jefferson University; Jefferson University;
   Jefferson University
RP Deemer, AD (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, B 43, Baltimore, MD 21287 USA.
EM adeemer1@jhmi.edu
RI Deemer, Ashley/AAO-1106-2020
OI Deemer, Ashley/0000-0002-3945-8532; Piersol, Catherine
   Verrier/0000-0003-4992-8988
FU NEI [U01 EY018819]; Multiple District 22 Lions Vision Research
   Foundation Fellowship Grant; NATIONAL EYE INSTITUTE [U01EY018819]
   Funding Source: NIH RePORTER
FX Supported by NEI Grant U01 EY018819 and Multiple District 22 Lions
   Vision Research Foundation Fellowship Grant.
CR Bond TG, 1977, APPL RASCH MODEL FUN, P314
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Coco-Martin MB, 2013, OPHTHALMOLOGY, V120, P151, DOI 10.1016/j.ophtha.2012.07.035
   Fine SL, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Goldstein JE, 2015, JAMA OPHTHALMOL, V133, P762, DOI 10.1001/jamaophthalmol.2015.0693
   Goldstein JE, 2014, JAMA OPHTHALMOL, V132, P1169, DOI 10.1001/jamaophthalmol.2014.1747
   Gothwal VK, 2014, J AFFECT DISORDERS, V167, P171, DOI 10.1016/j.jad.2014.06.019
   Hamer M, 2011, AM J GERIAT PSYCHIAT, V19, P72, DOI 10.1097/JGP.0b013e3181df465e
   Haymes SA, 2001, OPTOMETRY VISION SCI, V78, P373, DOI 10.1097/00006324-200106000-00008
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lamoureux EL, 2009, OPTOMETRY VISION SCI, V86, P139, DOI 10.1097/OPX.0b013e318194eb47
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, P763, DOI 10.1097/OPX.0b013e3181339efd
   Massof RW, 2014, STAT METHODS MED RES, V23, P409, DOI 10.1177/0962280213476380
   Massof RW, 2013, OPTOMETRY VISION SCI, V90, P788, DOI 10.1097/OPX.0000000000000011
   Massof RW, 2011, OPHTHAL EPIDEMIOL, V18, P1, DOI 10.3109/09286586.2010.545501
   Massof Robert W, 2010, J Appl Meas, V11, P253
   Massof RW, 2005, ARCH PHYS MED REHAB, V86, P946, DOI 10.1016/j.apmr.2004.09.016
   Massof RW, 2005, ARCH PHYS MED REHAB, V86, P954, DOI 10.1016/j.apmr.2004.09.017
   MASSOF RW, 1995, OPTOMETRY VISION SCI, V72, P725, DOI 10.1097/00006324-199510000-00005
   Pearce E, 2011, BRIT J OPHTHALMOL, V95, P105, DOI 10.1136/bjo.2009.175703
   Reischies FM, 1997, BRIT J PSYCHIAT, V171, P449, DOI 10.1192/bjp.171.5.449
   Rovner BW, 2007, INT J GERIATR PSYCH, V22, P789, DOI 10.1002/gps.1742
   Rovner BW, 2006, OPHTHALMOLOGY, V113, P1743, DOI 10.1016/j.ophtha.2006.05.033
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Stelmack J, 2001, OPTOMETRY VISION SCI, V78, P335, DOI 10.1097/00006324-200105000-00017
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Stelmack JA, 2006, INVEST OPHTH VIS SCI, V47, P3253, DOI 10.1167/iovs.05-1319
   Stelmack JA, 2012, ARCH OPHTHALMOL-CHIC, V130, P1162, DOI 10.1001/archophthalmol.2012.1820
   West CG, 2002, J AM GERIATR SOC, V50, P136, DOI 10.1046/j.1532-5415.2002.50019.x
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
NR 35
TC 15
Z9 16
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2017
VL 58
IS 3
BP 1514
EP 1520
DI 10.1167/iovs.16-20001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ4ZA
UT WOS:000398089000020
PM 28273318
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Jabs, DA
   Van Natta, ML
   Sezgin, E
   Pak, JW
   Danis, R
AF Jabs, Douglas A.
   Van Natta, Mark L.
   Sezgin, Efe
   Pak, Jeong Won
   Danis, Ronald
CA Studies Ocular Complications Aids
TI Prevalence of Intermediate-Stage Age-Related Macular Degeneration in
   Patients With Acquired Immunodeficiency Syndrome
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; HIV-INFECTION; ANTIRETROVIRAL THERAPY; OCULAR
   COMPLICATIONS; LIFE EXPECTANCY; SEVERITY SCALE; UNITED-STATES;
   RISK-FACTORS; EYE DISEASE; ACTIVATION
AB PURPOSE: To evaluate the prevalence of intermediate-stage age-related macular degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS).
   DESIGN: Cross-sectional study of patients with AIDS enrolled in the Longitudinal Study of the Ocular Complications of AIDS.
   METHODS: Intermediate-stage AMD was determined from enrollment retinal photographs by graders at a centralized Reading Center, using the Age-Related Eye Disease Study grading system. Graders were masked as to clinical data.
   RESULTS: Of 1825 participants with AIDS and no ocular opportunistic infections, 9.9% had intermediate-stage AMD. Risk factors included age, with an odds ratio (OR) of 1.9 (95% confidence interval [CI] 1.6, 2.3, P <.001) for every decade of age; the prevalence of AMID ranged from 4.0% for participants 30-39 years old to 24.3% for participants 60 years old. Other risk factors included the human immunodeficiency virus (HIV) risk groups of injection drug use (OR = 2.4, 95% CI 1.5, 3.9, P <.001) or heterosexual contact (OR = 1.9, 95% CI 1.3, 2.8, P =.001). Compared with the HIV-uninfected population in the Beaver Dam Offspring Study, there was an approximate 4-fold increased age-adjusted prevalence of intermediate-stage AMD.
   CONCLUSIONS: Patients with AIDS have an increased age-adjusted prevalence of intermediate-stage AMD compared with that found in a non-HIV-infected cohort evaluated with similar methods. This increased prevalence is consistent with the increased prevalence of other age-related diseases in antiretroviral-treated, immune-restored, HIV-infected persons when compared to non-HIV-infected persons. (C) Published by Elsevier Inc.
C1 [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, New York, NY 10029 USA.
   [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Jabs, Douglas A.; Van Natta, Mark L.; Sezgin, Efe] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Ctr Clin Trials, Baltimore, MD USA.
   [Pak, Jeong Won; Danis, Ronald] Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; University of Wisconsin System; University of Wisconsin
   Madison
RP Jabs, DA (通讯作者)，Icahn Sch Med Mt Sinai, Dept Ophthalmol, One Gustave L Levy Pl,Box 1183, New York, NY 10029 USA.
EM douglas.jabs@mssm.edu
RI Sezgin, Efe/B-8418-2012
OI Sezgin, Efe/0000-0002-8000-7485
FU National Eye Institute, the National Institutes of Health, Bethesda,
   Maryland [U10 EY 08052]; Johns Hopkins University Bloomberg School of
   Public Health, Baltimore, Maryland [U10 EY 08057]; University of
   Wisconsin, Madison School of Medicine, Madison, Wisconsin [U10 EY
   08067]; Johns Hopkins Center for AIDS Research, Baltimore, Maryland [P30
   AI 094189]; National Institute of Allergy and Infectious Diseases;
   National Cancer Institute; National Institute of Child Health and
   Development; National Heart, Lung, and Blood Institute; National
   Institute of Drug Abuse; National Institute of Mental Health; National
   Institute of Aging; Fogarty International Center; National Institute of
   General Medical Sciences; National Institute of Diabetes and Digestive
   and Kidney Diseases; Office of AIDS Research, the National Institutes of
   Health, Bethesda, Maryland; NATIONAL EYE INSTITUTE [U10EY008067,
   U10EY008057, U10EY008052] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI094189] Funding
   Source: NIH RePORTER
FX Funding/Support: Supported by cooperative agreements from the National
   Eye Institute, the National Institutes of Health, Bethesda, Maryland, to
   the Icahn School Of Medicine at Mount Sinai, New York, New York (U10 EY
   08052); The Johns Hopkins University Bloomberg School of Public Health,
   Baltimore, Maryland (U10 EY 08057);. and the University of Wisconsin,
   Madison School of Medicine, Madison, Wisconsin (U10 EY 08067); and in
   part by the Johns Hopkins Center for AIDS Research (P30 AI 094189),
   Baltimore, Maryland, co-funded by the National Institute of Allergy and
   Infectious Diseases; the National Cancer Institute; the National
   Institute of Child Health and Development; the National Heart, Lung, and
   Blood Institute; the National Institute of Drug Abuse; the National
   Institute of Mental Health; the National Institute of Aging; the Fogarty
   International Center; the National Institute of General Medical
   Sciences; the National Institute of Diabetes and Digestive and Kidney
   Diseases; and the Office of AIDS Research, the National Institutes of
   Health, Bethesda, Maryland. All authors attest that they meet the
   current ICMJE requirements to qualify as authors.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Altman DG, 1991, PRACTICAL STAT MED R, p[213, 241]
   Braithwaite RS, 2008, ANN INTERN MED, V148, P178, DOI 10.7326/0003-4819-148-3-200802050-00004
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Edison L, 2014, MMWR-MORBID MORTAL W, V63, P55
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Holtzer CD, 1998, AIDS, V12, P1931
   Hunt PW, 2014, J INFECT DIS, V210, P1228, DOI 10.1093/infdis/jiu238
   Jabs DA, 2007, OPHTHALMOLOGY, V114, P780, DOI 10.1016/j.ophtha.2006.11.008
   Jabs DA, 2007, OPHTHALMOLOGY, V114, P787, DOI 10.1016/j.ophtha.2006.07.065
   Jabs DA, 2011, AM J OPHTHALMOL, V151, P198, DOI 10.1016/j.ajo.2010.10.018
   Kaplan RC, 2007, CLIN INFECT DIS, V45, P1074, DOI 10.1086/521935
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2012, ARCH OPHTHALMOL-CHIC, V128, P750
   Late HIV testing-34 states 1996-2005, 2009, MORBIDITY MORTALITY, V58, P661
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Lohse N, 2007, ANN INTERN MED, V146, P87, DOI 10.7326/0003-4819-146-2-200701160-00003
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Nassar K., 2014, GRAEFES ARCH CLIN EX
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pathai S, 2014, J GERONTOL A-BIOL, V69, P833, DOI 10.1093/gerona/glt168
   Salter ML, 2013, JAIDS-J ACQ IMM DEF, V64, P488, DOI 10.1097/QAI.0b013e3182a7ee2e
   Sugar EA, 2012, AM J OPHTHALMOL, V153, P1016, DOI 10.1016/j.ajo.2011.11.014
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Van Belle G, 2004, BIOSTATISTICS METHOD, P642
   Wang Z., 2000, STATA TECHNICAL B, V54, P47
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   1992, MORB MORTAL WKLY REP, V41, P1
NR 37
TC 14
Z9 14
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2015
VL 159
IS 6
BP 1115
EP 1122
DI 10.1016/j.ajo.2015.01.037
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CI9DL
UT WOS:000355070500015
PM 25769246
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Oishi, A
   Shimozono, M
   Mandai, M
   Hata, M
   Nishida, A
   Kurimoto, Y
AF Oishi, Akio
   Shimozono, Masataka
   Mandai, Michiko
   Hata, Masayuki
   Nishida, Akihiro
   Kurimoto, Yasuo
TI Recovery of photoreceptor outer segments after anti-VEGF therapy for
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Optical coherence tomography; Inner
   segment/outer segment junction; External limiting membrane
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY;
   ULTRAHIGH-RESOLUTION; VISUAL-ACUITY; RANIBIZUMAB; PREDICTORS;
   VERTEPORFIN; PARAMETERS
AB To evaluate whether the status of the external limiting membrane (ELM) or inner segment/outer segment junction (IS/OS) improves after intravitreal injection of ranibizumab for age-related macular degeneration (AMD). We also evaluated whether the pre-operative values of these parameters are associated with the visual prognosis.
   This was a hospital-based, cross-sectional study. Seventy-six eyes of 76 treatment-naive AMD patients who received three monthly intravitreal injections of ranibizumab followed for more than 6 months with additional as-needed injections were investigated. Spectral domain OCT was used to evaluate the length of ELM, IS/OS, and foveal thickness pre- and post-operatively. Changes of ELM and IS/OS length were evaluated postoperatively. Correlation coefficients between pre-operative parameters and post-operative visual acuity were also analyzed.
   Significant changes were noted in mean logMAR (0.66 to 0.53), foveal thickness (231.1 to 151.1 mu m), and IS/OS length (514.9 to 832.3 mu m) after the treatment. ELM length did not improve significantly (1,312.4 to 1,376.7 mu m). Restoration of IS/OS occured where ELM is retained. Although pre-operative ELM length, IS/OS length, and foveal thickness showed correlation with post-operative logMAR (R = -0.51, -0.39, and 0.46, respectively), the most powerful predictive factor for visual prognosis was pre-operative logMAR (R = 0.77, p < 0.001).
   IS/OS status improves in response to anti-VEGF therapy but ELM seems to have less plasticity. The status of IS/OS and ELM can be used as prognostic factors but the predictive power is inferior to that of baseline visual acuity.
C1 [Oishi, Akio; Shimozono, Masataka; Mandai, Michiko; Hata, Masayuki; Nishida, Akihiro; Kurimoto, Yasuo] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Chuo Ku, Kobe, Hyogo 6500046, Japan.
   [Oishi, Akio] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Mandai, Michiko] RIKEN, Lab Retinal Regenerat, Ctr Dev Biol, Kobe, Hyogo, Japan.
C3 Kobe City Medical Center General Hospital; Kyoto University; RIKEN
RP Oishi, A (通讯作者)，Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Chuo Ku, 4-6 Minatojima Minamimachi, Kobe, Hyogo 6500046, Japan.
EM aquio@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020
OI Oishi, Akio/0000-0002-0977-9458
FU Japanese Society for the Promotion of Science, Tokyo [22791706]
FX The study was supported in part by a Grant-In-Aid for Scientific
   Research (No. 22791706) from the Japanese Society for the Promotion of
   Science, Tokyo. Financial disclosures: none.
CR Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Coker J G, 1996, Curr Opin Ophthalmol, V7, P33, DOI 10.1097/00055735-199606000-00006
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P97
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Landa Gennady, 2009, International Ophthalmology, V29, P1, DOI 10.1007/s10792-007-9176-0
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Moroz I, 2009, OPHTHAL SURG LAS IM, V40, P570, DOI 10.3928/15428877-20091030-06
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Shimozono M, 2012, AM J OPHTHALMOL, V153, P698, DOI 10.1016/j.ajo.2011.09.011
   Shimozono M, 2011, GRAEF ARCH CLIN EXP, V249, P1469, DOI 10.1007/s00417-011-1681-1
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Sung CH, 2010, J CELL BIOL, V190, P953, DOI 10.1083/jcb.201006020
   Unver YB, 2009, EYE, V23, P453, DOI 10.1038/eye.2008.349
NR 28
TC 35
Z9 37
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2013
VL 251
IS 2
BP 435
EP 440
DI 10.1007/s00417-012-2034-4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 086KT
UT WOS:000314683200002
PM 22576370
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Sitnilska, V
   Altay, L
   Enders, P
   Hermann, M
   Muether, PS
   Fauser, S
AF Sitnilska, Vasilena
   Altay, Lebriz
   Enders, Philip
   Hermann, Manuel
   Muether, Philipp S.
   Fauser, Sascha
TI Onset of Retinal Pigment Epithelium Atrophy Subsequent to Anti-VEGF
   Therapy in Patients with Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Aqueous humor; Atrophy; Complement;
   Vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; GEOGRAPHIC ATROPHY; COMPLEMENT ACTIVATION;
   RISK; RANIBIZUMAB; PROGRESSION; EXPRESSION
AB Purpose: The aim of this study was to evaluate risk factors for the development of retinal pigment epithelium (RPE) atrophy in patients with neovascular age-related macular degeneration (nAMD). Procedures: This post hoc analysis of the prospective RESPONSE study includes 52 therapy-naive nAMD patients without baseline RPE atrophy, who were treated with >= 9 anti-vascular endothelial growth factor (VEGF) injections for >= 3 years. RPE atrophy was assessed via multimodal imaging. Baseline aqueous VEGF and serum complement levels (C3d/C3) were measured. Risk factors for atrophy development were evaluated via logistic regression analysis. Results: Atrophy onset was significantly associated with the duration of nAMD (mean 5.34 years; odds ratio = 1.83, p = 0.012). Anti-VEGF injection number, age, C3d/C3 ratio, baseline intraocular VEGF, or delay to the first treatment had no influence on RPE atrophy. Conclusions: The duration of treatment-requiring nAMD was identified as primary risk factor for the onset of concomitant RPE atrophy after commencing therapy. Targeting concomitant atrophy in nAMD patients might improve the long-term prognosis of the disease. (c) 2018 S. Karger AG, Basel
C1 [Sitnilska, Vasilena; Altay, Lebriz; Enders, Philip; Hermann, Manuel; Muether, Philipp S.; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, DE-50924 Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche & Cie AG, Basel, Switzerland.
C3 University of Cologne; Roche Holding
RP Altay, L (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, DE-50924 Cologne, Germany.
EM lebriz.altay@uk-koeln.com
OI Enders, Philip/0000-0002-9527-4957
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Binder DR, 2012, VET OPHTHALMOL, V15, P223, DOI 10.1111/j.1463-5224.2011.00973.x
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Schick T, 2015, INVEST OPHTH VIS SCI, V56, P7269, DOI 10.1167/iovs.15-16989
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
NR 28
TC 6
Z9 6
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2019
VL 241
IS 3
BP 154
EP 160
DI 10.1159/000492924
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HR0NA
UT WOS:000462824100005
PM 30304737
DA 2022-11-30
ER

PT J
AU Doyle, SL
   Campbell, M
   Ozaki, E
   Salomon, RG
   Mori, A
   Kenna, PF
   Farrar, GJ
   Kiang, AS
   Humphries, MM
   Lavelle, EC
   O'Neill, LAJ
   Hollyfield, JG
   Humphries, P
AF Doyle, Sarah L.
   Campbell, Matthew
   Ozaki, Ema
   Salomon, Robert G.
   Mori, Andres
   Kenna, Paul F.
   Farrar, Gwyneth Jane
   Kiang, Anna-Sophia
   Humphries, Marian M.
   Lavelle, Ed C.
   O'Neill, Luke A. J.
   Hollyfield, Joe G.
   Humphries, Peter
TI NLRP3 has a protective role in age-related macular degeneration through
   the induction of IL-18 by drusen components
SO NATURE MEDICINE
LA English
DT Article
ID OXIDATIVE STRESS; INTRAVITREAL INFLIXIMAB; NALP3 INFLAMMASOME; PROTEIN;
   CELLS; C1Q; ACTIVATION; CRYSTALS; BINDING; RETINA
AB Age-related macular degeneration (AMD) is the leading cause of central vision loss worldwide. Drusen accumulation is the major pathological hallmark common to both dry and wet AMD. Although activation of the immune system has been implicated in disease progression, the pathways involved are unclear. Here we show that drusen isolated from donor AMD eyes activates the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome, causing secretion of interleukin-1 beta (IL-1 beta) and IL-18. Drusen component C1Q also activates the NLRP3 inflammasome. Moreover, the oxidative-stress-related protein-modification carboxyethylpyrrole (CEP), a biomarker of AMD, primes the inflammasome. We found cleaved caspase-1 and NLRP3 in activated macrophages in the retinas of mice immunized with CEP-adducted mouse serum albumin, modeling a dry-AMD-like pathology. We show that laser-induced choroidal neovascularization (CNV), a mouse model of wet AMD, is exacerbated in Nlrp3(-/-) but not Il1r1(-/-) mice, directly implicating IL-18 in the regulation of CNV development. These findings indicate a protective role for NLRP3 and IL-18 in the progression of AMD.
C1 [Campbell, Matthew; Ozaki, Ema; Kenna, Paul F.; Farrar, Gwyneth Jane; Kiang, Anna-Sophia; Humphries, Marian M.; Humphries, Peter] Trinity Coll Dublin, Smurfit Inst Genet, Ocular Genet Unit, Dublin 2, Ireland.
   [Doyle, Sarah L.; Mori, Andres; Lavelle, Ed C.; O'Neill, Luke A. J.] Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin 2, Ireland.
   [Salomon, Robert G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Kenna, Paul F.] Royal Victoria Eye & Ear Hosp, Res Fdn, Dublin 2, Ireland.
   [Hollyfield, Joe G.] Cleveland Clin, Lerner Coll Med, Cole Eye Inst, Dept Ophthalmol, Cleveland, OH 44106 USA.
C3 Trinity College Dublin; Trinity College Dublin; Case Western Reserve
   University; Case Western Reserve University; Cleveland Clinic Foundation
RP Campbell, M (通讯作者)，Trinity Coll Dublin, Smurfit Inst Genet, Ocular Genet Unit, Lincoln Pl Gate, Dublin 2, Ireland.
EM matthew.campbell@tcd.ie
RI Doyle, Sarah/C-1453-2014; Bateson, Jane Farrar/AAO-6147-2020; Salomon,
   Robert G/C-3463-2008; Lavelle, Ed/A-1716-2008
OI Lavelle, Ed/0000-0002-3167-1080; Salomon, Robert/0000-0001-9456-3557;
   O'Neill, Luke/0000-0002-4333-2748; Doyle, Sarah/0000-0002-6294-9380
FU American Health Assistance Foundation (AHAF); Science Foundation Ireland
   (SFI) [07/SRC/B1144, 08/RFP/MBT1363]; Health Research Board of Ireland
   (HRB); Irish Research Council for Science Engineering and Technology
   (IRCSET); Enterprise Ireland (EI); Telemedicine and Advanced Technology
   Research Center (TATRC); Fighting Blindness Ireland (FB-Ireland); SFI
   Immunology Research Centre (IRC); US National Institutes of Health
   [EY014240, GM021249, EY016813]; Macular Vision Research Foundation;
   Research to Prevent Blindness; Llura and Gordon Gund Foundation;
   NATIONAL EYE INSTITUTE [R56EY014240, R01EY016813, R01EY014240] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [R01GM021249] Funding Source: NIH RePORTER
FX The Ocular Genetics Unit at Trinity College Dublin is supported by the
   American Health Assistance Foundation (AHAF), Science Foundation Ireland
   (SFI), The Health Research Board of Ireland (HRB), Irish Research
   Council for Science Engineering and Technology (IRCSET), Enterprise
   Ireland (EI), Telemedicine and Advanced Technology Research Center
   (TATRC) and Fighting Blindness Ireland (FB-Ireland). S.L.D. and L.A.J.O.
   are supported by the SFI Immunology Research Centre (IRC) and the SFI
   Strategic Research Cluster (07/SRC/B1144). Support for the laboratory of
   J.G.H. was provided by the US National Institutes of Health through
   grant EY014240, the Macular Vision Research Foundation, Research to
   Prevent Blindness and the Llura and Gordon Gund Foundation. Support for
   the laboratory of R.G.S. was provided by the US National Institutes of
   Health through grants GM021249 and EY016813. Support for the laboratory
   of E.C.L. was from SFI grant number 08/RFP/MBT1363 and SFI Strategic
   Research Cluster 07/SRC/B1144. We would like to thank C. Woods, C.
   Murray, D. Flynn and R. Robertson for animal husbandry. The authors
   would also like to thank the Research Foundation at the Royal Victoria
   Eye and Ear Hospital for assistance in the acquisition of the Iridex
   laser system. We thank E. Latz (University of Bonn) for the provision of
   BMDMs expressing YFP-labeled ASC. We would like to acknowledge the
   expertise of K. Shadrach in isolating drusen from AMD donor eyes.
CR Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Arias L, 2010, RETINA-J RET VIT DIS, V30, P1601, DOI 10.1097/IAE.0b013e3181e9f942
   Blanquet-Grossard F, 2005, BIOCHEMISTRY-US, V44, P4349, DOI 10.1021/bi047370a
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Campbell M, 2011, EMBO MOL MED, V3, P235, DOI 10.1002/emmm.201100126
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Coughlin CM, 1998, J CLIN INVEST, V101, P1441, DOI 10.1172/JCI1555
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 1999, MOL VIS, V5
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Ishii T, 1984, Appl Pathol, V2, P370
   Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106
   Jiang HR, 2001, INVEST OPHTH VIS SCI, V42, P177
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Luo XG, 2003, J NEUROIMMUNOL, V135, P62, DOI 10.1016/S0165-5728(02)00444-7
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Mallat Z, 2002, CIRC RES, V91, P441, DOI 10.1161/01.RES.0000033592.11674.D8
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935
   McDonald B, 2010, SCIENCE, V330, P362, DOI 10.1126/science.1195491
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Nauta AJ, 2002, EUR J IMMUNOL, V32, P1726, DOI 10.1002/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R
   PERCOPO CM, 1990, J IMMUNOL, V145, P4101
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Qiao H, 2004, LAB INVEST, V84, P973, DOI 10.1038/labinvest.3700115
   Qiao H, 2007, J LEUKOCYTE BIOL, V81, P1012, DOI 10.1189/jlb.0506342
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Ten VS, 2010, J NEUROSCI, V30, P2077, DOI 10.1523/JNEUROSCI.5249-09.2010
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P410
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
NR 56
TC 289
Z9 325
U1 1
U2 55
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD MAY
PY 2012
VL 18
IS 5
BP 791
EP U191
DI 10.1038/nm.2717
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 938WE
UT WOS:000303763500047
PM 22484808
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Garg, S
   Brod, R
   Kim, D
   Lane, RG
   Maguire, J
   Fischer, D
AF Garg, Sunir
   Brod, Roy
   Kim, David
   Lane, R. Gary
   Maguire, Joseph
   Fischer, David
TI Retinal pigment epithelial tears after intravitreal bevacizumab
   injection for exudative age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Avastin; bevacizumab; macular degeneration; retinal pigment epithelium;
   tear
ID PROLIFERATIVE DIABETIC-RETINOPATHY; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; IRIS NEOVASCULARIZATION;
   AVASTIN; RANIBIZUMAB; VERTEPORFIN; REGRESSION; DETACHMENT; SECONDARY
AB Purpose: To determine the incidence of and the risk factors for the development of retinal pigment epithelial (RPE) tears after intravitreal bevacizumab (Avastin) injection for the treatment of exudative age-related macular degeneration (AMD).
   Methods: A retrospective, multicentre, consecutive interventional case series of all patients with subfoveal exudative AMD treated with intravitreal bevacizumab between August 2005 and April 2007. The main outcome measures were pre- and post-RPE tear visual acuity and choroidal neovascular membrane lesion types, incidence of tears and time from first injection until development of the tear.
   Results: A total of 920 eyes with exudative AMD were treated with intravitreal bevacizumab. Fifteen eyes from 15 patients developed a RPE tear for an incidence of 1.6%. The average patient age was 79 years. Fourteen of the fifteen eyes (93%) had an occult subfoveal choroidal neovascular membrane. Forty-seven per cent (7/15) of the RPE tears occurred within the first 6 weeks of treatment, and all tears occurred within the first 18 weeks of treatment initiation. The mean pre-injection visual acuity was 20/100 with a mean post-tear visual acuity of 20/200. In all 10 eyes in which the tear involved the fovea, the final visual acuity was poor. Six of the 15 eyes continued with bevacizumab/ranibizumab (Lucentis) injections after tear development, and four of these six eyes continued to have visual improvement.
   Conclusion: RPE tears occur after intravitreal bevacizumab injections for exudative AMD in approximately 1.6% of eyes and can cause severe vision loss. Maintenance of therapy may help preserve vision after RPE tear development.
C1 [Garg, Sunir; Maguire, Joseph; Fischer, David] Thomas Jefferson Univ, Retina Serv, Wills Eye Inst, Philadelphia, PA 19107 USA.
   [Brod, Roy] Roy Brod, Lancaster, PA USA.
   [Kim, David; Lane, R. Gary] Wilford Hall USAF Med Ctr, San Antonio, TX 78236 USA.
C3 Jefferson University; United States Department of Defense; United States
   Air Force
RP Garg, S (通讯作者)，Thomas Jefferson Univ, Retina Serv, Wills Eye Inst, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM sunirgarg@yahoo.com
CR Ahmadieh Hamid, 2005, International Ophthalmology, V26, P191, DOI 10.1007/s10792-007-9036-y
   Apte Rajendra S., 2007, International Ophthalmology, V27, P59, DOI 10.1007/s10792-007-9066-5
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chen E, 2006, RETINA-J RET VIT DIS, V26, P699, DOI 10.1097/01.iae.0000225351.87205.69
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Isaacs TW, 2006, CLIN EXP OPHTHALMOL, V34, P802, DOI 10.1111/j.1442-9071.2006.01378.x
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Oshima Y, 2006, AM J OPHTHALMOL, V142, P155, DOI 10.1016/j.ajo.2006.02.015
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Pece A, 2007, RETINA-J RET VIT DIS, V27, P342, DOI 10.1097/01.iae.0000239253.78495.8c
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Tewari A, 2006, RETINA-J RET VIT DIS, V26, P1093, DOI 10.1097/01.iae.0000254896.78766.74
NR 32
TC 43
Z9 44
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD APR
PY 2008
VL 36
IS 3
BP 252
EP 256
DI 10.1111/j.1442-9071.2008.01710.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 288LY
UT WOS:000254989100010
PM 18412594
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Chung, STL
AF Chung, Susana T. L.
TI Size or spacing: Which limits letter recognition in people with
   age-related macular degeneration?
SO VISION RESEARCH
LA English
DT Article
DE Letter recognition; Crowding; Age-related macular degeneration;
   Peripheral vision
ID READING SPEED; VISUAL RESOLUTION; REORGANIZATION; PREVALENCE
AB Recent evidence suggests a double dissociation of size and spacing limit on letter recognition it is limited by size in the fovea and critical spacing in the normal periphery. Here, we evaluated whether size or spacing limits letter recognition in people with age-related macular degeneration (AMD) who must use their peripheral vision. We measured the size threshold for recognizing lowercase letters presented alone, or flanked by two letters at various center-to-center nominal letter spacings (multiples of letter size) for 11 observers with AMD. For comparison, similar measurements were obtained at 50 and 100 eccentricity in the nasal and lower visual fields in three older adults with normal vision. Single-letter size thresholds were worse for observers with AMD than at comparable retinal locations in the normal periphery. For flanked letters, size threshold improved with larger nominal spacing up to the critical spacing, beyond which size threshold was unaffected by the flankers. Seven AMD observers had a nominal critical spacing between 1.25x and 1.80x, values close to those in the normal fovea, suggesting that their letter recognition is size-limited; two had a nominal critical spacing of 3-4x, values close to those in the normal periphery, implying that their letter recognition is limited by spacing; and another two had a nominal critical spacing of similar to 2.3 x, implying that their letter recognition is limited by both size and spacing. The wide range of nominal critical spacings observed in our AMD observers may reflect the degree of completeness of their adaptation process to vision loss. (C) 2014 Elsevier Ltd. All rights reserved.
C1 Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA.
C3 University of California System; University of California Berkeley
RP Chung, STL (通讯作者)，Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA.
EM s.chung@berkeley.edu
OI Chung, Susana/0000-0003-2729-1808
FU National Eye Institute, NIH [R01-EY012810]; NATIONAL EYE INSTITUTE
   [R01EY012810] Funding Source: NIH RePORTER
FX This work was supported by research Grant R01-EY012810 from the National
   Eye Institute, NIH. The author thanks Dennis Levi for his helpful
   comments on an earlier version of the paper and Daniel Coates for the
   invaluable discussions on the topic.
CR Bailey IL, 2013, VISION RES, V90, P2, DOI 10.1016/j.visres.2013.05.004
   BAILEY IL, 1980, AM J OPTOM PHYS OPT, V57, P378
   Baker CI, 2008, VISION RES, V48, P1910, DOI 10.1016/j.visres.2008.05.020
   Blackmore-Wright S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080325
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Calabrese A, 2010, INVEST OPHTH VIS SCI, V51, P1247, DOI 10.1167/iovs.09-3682
   Chung STL, 2001, VISION RES, V41, P1833, DOI 10.1016/S0042-6989(01)00071-2
   Chung STL, 2008, OPTOMETRY VISION SCI, V85, P827, DOI 10.1097/OPX.0b013e31818527ea
   Chung STL, 2013, J NEUROSCI, V33, P18080, DOI 10.1523/JNEUROSCI.2764-13.2013
   Chung STL, 2013, OPTOMETRY VISION SCI, V90, P520, DOI 10.1097/OPX.0b013e318294c2da
   Chung STL, 2012, OPTOMETRY VISION SCI, V89, P1288, DOI 10.1097/OPX.0b013e318264c9dd
   Coates DR, 2013, OPTOMETRY VISION SCI, V90, P628, DOI 10.1097/OPX.0b013e31829908a4
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Flom M., 1991, PROBL OPTOM, V3, P237
   FLOM MC, 1963, J OPT SOC AM, V53, P1026, DOI 10.1364/JOSA.53.001026
   FLOM MERTON C., 1963, SCIENCE, V142, P979, DOI 10.1126/science.142.3594.979
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   JACOBS RJ, 1979, VISION RES, V19, P1187, DOI 10.1016/0042-6989(79)90183-4
   KLEEN SR, 1981, AM J OPTOM PHYS OPT, V58, P200
   LEAT SJ, 1990, OPHTHAL PHYSL OPT, V10, P8, DOI 10.1111/j.1475-1313.1990.tb01098.x
   Levi DM, 2007, J VISION, V7, DOI 10.1167/7.2.21
   Levi DM, 2008, VISION RES, V48, P635, DOI 10.1016/j.visres.2007.12.009
   Levi DM, 2002, J VISION, V2, P140, DOI 10.1167/2.2.2
   Mansfield J.S., 1993, OPT SOC AM TECHNOL D, V3, P232
   Mansfield JS, 1999, INVEST OPHTH VIS SCI, V40, pS35
   Pelli DG, 2008, NAT NEUROSCI, V11, P1129, DOI 10.1038/nn.2187
   Pelli DG, 2007, J VISION, V7, DOI 10.1167/7.2.20
   Pelli DG, 2008, CURR OPIN NEUROBIOL, V18, P445, DOI 10.1016/j.conb.2008.09.008
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Pelli DG, 2004, J VISION, V4, P1136, DOI 10.1167/4.12.12
   Rawlinson G.E., 1976, THESIS U NOTTINGHAM
   Song S, 2014, J VISION, V14, DOI 10.1167/14.5.3
   TOET A, 1992, VISION RES, V32, P1349, DOI 10.1016/0042-6989(92)90227-A
   WERTHEIM T, 1980, AM J OPTOM PHYS OPT, V57, P915
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   Whitney D, 2011, TRENDS COGN SCI, V15, P160, DOI 10.1016/j.tics.2011.02.005
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
NR 38
TC 12
Z9 12
U1 0
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD AUG
PY 2014
VL 101
BP 167
EP 176
DI 10.1016/j.visres.2014.06.015
PG 10
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA AN1MU
UT WOS:000340348800017
PM 25014400
OA Green Accepted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Klein, R
   Knudtson, MD
   Klein, BEK
AF Klein, Ronald
   Knudtson, Michael D.
   Klein, Barbara E. K.
TI Statin use and the five-year incidence and progression of age-related
   macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM EYE; VISUAL-ACUITY; POOLED FINDINGS; MEDICATION USE; 3
   CONTINENTS; RISK-FACTORS; MACULOPATHY; CHOLESTEROL; POPULATION; PERIOD
AB PURPOSE: To examine the association of hydroxymethyl, glutaryl-coenzyme A (HMG,CoA) reductase inhibitors (statins) with the five-year incidence of age-related macular degeneration (AMD). DESIGN: Population,based cohort study.
   METHODS: SETTINGS: Beaver Dam, Wisconsin. STUDY POPULATION: Participants included persons 53 to 96 years of age at examination in 1998 to 2000 (n = 2,962), of whom 2,204 participated in a follow,up five years later.
   OBSERVATION PROCEDURES: Standardized procedures were used for physical examinations, blood collection, and questionnaire administration. AMD was determined by grading images of the posterior pole using a standard protocol. Standard univariate and multivariate analyses were performed. MAIN OUTCOME MEASURES: Incident early and late AMD and progressed AMD.
   RESULTS: There were 1,347 and 1,638 persons not using statins and 339 and 429 using statins at the 1998 to 2000 examination at risk of early and late AMD, respectively. The unadjusted five-year incidence of early and late AMD, respectively, was 5.9% and 1.8% in those not using statins and 6.8% and 2.3% in those using statins. While controlling for age, gender, smoking sta-. tus, and multivitamin use, a history of statin use was not associated with the five-year incidence of early AMD (odds ratio [OR] 1.16, 95% confidence interval [CI] 0.71 to 1.91, P =.55), progression of AMD (OR 1.16, 95% CI 0.75 to 1.78, P =.5 1) or incidence of late AMD (OR 1.27, 95% CI 0.60 to 2.69. P =.53).
   CONCLUSION: These findings do not show an association between statin use and the incidence or progression of AMD over a five-year period.
C1 Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
FU NATIONAL EYE INSTITUTE [U10EY006594] Funding Source: NIH RePORTER; NEI
   NIH HHS [U10 EY006594, EY06594, U10 EY006594-20] Funding Source: Medline
CR *AM SOC HLTH SYST, 2000, AM HOSP FORM SERV DR
   [Anonymous], 1976, Prev Med, V5, P207
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1991, PB91149823 NTIS, P74
   KLEIN R, 1995, PB95273827 NTIS, P61
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
NR 29
TC 47
Z9 48
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2007
VL 144
IS 1
BP 1
EP 6
DI 10.1016/j.ajo.2007.02.047
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 187SD
UT WOS:000247867800001
PM 17475196
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sawa, M
   Shunto, T
   Nishiyama, I
   Yokoyama, A
   Shigeta, R
   Miura, S
   Kawasaki, R
AF Sawa, Miki
   Shunto, Takuya
   Nishiyama, Issei
   Yokoyama, Ayako
   Shigeta, Ryujiro
   Miura, Satoko
   Kawasaki, Ryo
TI Effects of Lutein Supplementation in Japanese Patients with Unilateral
   Age-Related Macular Degeneration: The Sakai Lutein Study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PIGMENT OPTICAL-DENSITY; RISK-FACTORS; EYE DISEASE; MACULOPATHY;
   ZEAXANTHIN; HYPERTENSION; CAROTENOIDS; SERUM
AB This prospective randomized double-masked study investigated the effects of 20 mg lutein supplementation with two different capsules (beeswax or glycerol fatty acid esters) for 6 months on the fellow eyes of 39 Japanese patients with unilateral age-related macular degeneration, and assessed the factors associated with baseline plasma lutein concentration via lifestyle interviews. Macular pigment optical density (MPOD), determined with the two-wavelength autofluorescence method, increased over time in the beeswax group (ANOVA, p = 0.0451), although the increase from 3 months to 6 months was only marginally significant. No significant increase was observed in the glycerol fatty acid esters group (ANOVA, p = 0.7396). Plasma lutein concentrations significantly increased at 3 and 6 months from baseline in both groups (both p < 0.01). In a multiple regression model, age was negatively associated with higher plasma lutein concentration (p = 0.0305), while consumption of green vegetables was positively associated with baseline plasma lutein concentration (p = 0.0322). In conclusion, a significant increase in MPOD was not fully confirmed with 6 months intake duration despite a significant increase in plasma lutein concentrations. Consumption of green vegetable was confirmed to be associated with plasma lutein concentration after adjusting for other potential factors including age.
C1 [Sawa, Miki; Shunto, Takuya; Nishiyama, Issei; Yokoyama, Ayako; Miura, Satoko] Sakai City Med Ctr, Eye Ctr, Osaka, Japan.
   [Shigeta, Ryujiro] Osaka Habikino Med Ctr, Dept Ophthalmol, Osaka, Japan.
   [Kawasaki, Ryo] Osaka Univ, Dept Vis Informat, Grad Sch Med, Osaka, Japan.
C3 Osaka University
RP Sawa, M (通讯作者)，Sakai City Med Ctr, Eye Ctr, Osaka, Japan.
EM sawamikimd@gmail.com
RI Kawasaki, Ryo/B-7266-2009
OI Kawasaki, Ryo/0000-0002-7492-6303
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Aoshima H, 2005, INT J PHARMACEUT, V293, P25, DOI 10.1016/j.ijpharm.2004.12.007
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Fujimura S, 2016, CLIN OPHTHALMOL, V10, P2149, DOI 10.2147/OPTH.S119251
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hozawa A, 2009, J HYPERTENS, V27, P237, DOI 10.1097/HJH.0b013e32832258c9
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy RD, 2012, CLIN EXP OPTOM, V95, P590, DOI 10.1111/j.1444-0938.2012.00789.x
   Kondo T., 1996, KOBUNSHI HIGH POLYM, V45, P398
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Obana A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139257
   Ozawa Yoko, 2016, Nippon Ganka Gakkai Zasshi, V120, P41
   Sasamoto Y, 2010, INVEST OPHTH VIS SCI, V51, P5219, DOI 10.1167/iovs.09-4881
   Sawa M, 2014, INVEST OPHTH VIS SCI, V55, P5238, DOI 10.1167/iovs.14-14470
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Tanito M, 2012, JPN J OPHTHALMOL, V56, P488, DOI 10.1007/s10384-012-0157-0
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Uchimoto T, 2011, EUR J PHARM BIOPHARM, V78, P492, DOI 10.1016/j.ejpb.2011.01.014
   Umigai N, 2018, COMPLEMENT THER MED, V41, P47, DOI 10.1016/j.ctim.2018.09.003
   Wolf-Schnurrbusch UEK, 2015, INVEST OPHTH VIS SCI, V56, P8069, DOI 10.1167/iovs.15-17586
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Yamaguchi T, 2009, J CATARACT REFR SURG, V35, P57, DOI 10.1016/j.jcrs.2008.09.012
   Zhu ZT, 2019, JAMA OPHTHALMOL, V137, P248, DOI 10.1001/jamaophthalmol.2018.6150
NR 32
TC 4
Z9 4
U1 1
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 6
PY 2020
VL 10
IS 1
AR 5958
DI 10.1038/s41598-020-62483-0
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NF7JF
UT WOS:000563470000010
PM 32249850
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Aghdam, KA
   Pielen, A
   Framme, C
   Junker, B
AF Aghdam, Kaveh Abri
   Pielen, Amelie
   Framme, Carsten
   Junker, Bernd
TI Visual and anatomic outcomes after conversion to aflibercept in
   neovascular age-related macular degeneration: 12-month results
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Choroidal
   neovascularization; Spectral-domain optical coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL AFLIBERCEPT; CHOROIDAL
   NEOVASCULARIZATION; FACTOR VEGF; RANIBIZUMAB; EYES; TACHYPHYLAXIS;
   BEVACIZUMAB; MACULOPATHY; INHIBITORS
AB Purpose: To investigate 12-month outcomes of conversion to aflibercept in patients with neovascular age-related macular degeneration resistant to ranibizumab.
   Methods: Twenty-two eyes of 19 consecutive patients received 3 monthly aflibercept injections followed by a pro re nata protocol. Spectral-domain optical coherence tomography (OCT) images were obtained before each injection. All 49 cross-sectional OCT B-scans obtained in each examination were investigated and the largest choroidal neovascularization (CNV) size was chosen. The same cross-sectional B-scan sections containing the maximum CNV size were used during the follow-up.
   Results: After 12 months, best-corrected visual acuity increased from 45.68 +/- 20.25 to 59.09 +/- 17.50 Early Treatment Diabetic Retinopathy Study letters (p< 0.001), central subfield thickness decreased from 399.91 +/- 148.85 to 304.55 +/- 97.89 mu m (p = 0.003), area of CNV declined from 0.38 +/- 0.24 to 0.28 +/- 0.19 mm(2) (p = 0.003), and macular volume improved from 9.64 +/- 1.75 to 8.45 +/- 0.98 mm(3) (p< 0.001). There was a significant resolution of intraretinal fluid (p = 0.016), but reduction of subretinal fluid was not significant (p = 0.25).
   Conclusions: Visual and anatomic improvement were obtained after conversion to aflibercept.
C1 [Aghdam, Kaveh Abri; Pielen, Amelie; Framme, Carsten; Junker, Bernd] Hannover Med Sch, Univ Eye Hosp, Dept Ophthalmol, Hannover, Germany.
   [Aghdam, Kaveh Abri] Univ Tehran Med Sci, Inst Neurosci, Brain & Spinal Cord Injury Res Ctr, Tehran, Iran.
C3 Hannover Medical School; Tehran University of Medical Sciences
RP Aghdam, KA (通讯作者)，Hannover Med Sch, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM kaveh.abri@gmail.com
RI Abri Aghdam, Kaveh/M-6352-2018
OI Abri Aghdam, Kaveh/0000-0001-7568-6455; Pielen,
   Amelie/0000-0001-9401-2501
FU German Ministry of Lower Saxony; Niedersachsen Vorab
FX The authors thank the German Ministry of Lower Saxony for its scientific
   and cultural organization to support our retinal imaging studies in the
   ophthalmology department of Hannover Medical School financed by the
   "Niedersachsen Vorab".
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Chong V, 2012, OPHTHALMOLOGICA, V227, P2, DOI 10.1159/000337152
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lazzeri S, 2015, ANGIOGENESIS, V18, P397, DOI 10.1007/s10456-015-9483-4
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zhang F, 2009, P NATL ACAD SCI USA, V106, P6152, DOI 10.1073/pnas.0813061106
NR 30
TC 11
Z9 13
U1 0
U2 1
PU WICHTIG PUBLISHING
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2016
VL 26
IS 5
BP 473
EP 478
DI 10.5301/ejo.5000757
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK1MB
UT WOS:000393688500027
PM 26868007
DA 2022-11-30
ER

PT J
AU Koss, MJ
   Lewicka-Chomont, A
   Schramm, K
   Rejdak, R
   Ohrloff, C
   Koch, FH
AF Koss, Michael J.
   Lewicka-Chomont, Aneta
   Schramm, Katharina
   Rejdak, Robert
   Ohrloff, Christian
   Koch, Frank H.
TI Quadruple Therapy Leads to a Sustained Improvement of Vision in Patients
   with Wet Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Combined intravitreal therapy; Photodynamic therapy; Age-related macular
   degeneration, wet; Choroidal neovascularization
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   COMBINATION THERAPY; OCULAR OXYGENATION; VERTEPORFIN; VITRECTOMY;
   RANIBIZUMAB; MECHANISM; SURGERY; LENS
AB Aim: To investigate the efficacy of a combined intravitreal therapy with prior photodynamic therapy (PDT) in patients with wet age-related macular degeneration. Methods: Fifty-two patients (mean age: 72.7 years) with predominantly classic choroidal neovascularization received low-fluence PDT (42 J/cm(2) for 72 s), followed 24 h later by a 0.4-ml core pars plana vitrectomy with intravitreal injection of dexamethasone (0.8 mg) and bevacizumab (1.25 mg). The best-corrected visual acuity (BCVA; 6 m Snellen), central macular thickness (optical coherence tomography), intraocular pressure and the need for retreatment were assessed. Results: BCVA changed significantly (vs. baseline) at 3 months (+0.11), 9 months (+0.19) and 14 months (+0.16). At the end of the follow-up period, BCVA had improved by > 0.1 in the majority of the patients (72.9%), and the mean central retinal thickness had decreased by -44.3% (-211 mu m). The retreatment rate was 25%. No increase in intraocular pressure or other adverse event was reported. Conclusions: The pharmacological effects of the drugs, the low-fluence PDT, and the physiological effects of the therapy may have contributed to the sustainability of the therapeutic benefits. Copyright (C) 2011 S. Karger AG, Basel
C1 [Koss, Michael J.; Schramm, Katharina; Ohrloff, Christian; Koch, Frank H.] Goethe Univ Frankfurt, Dept Ophthalmol, DE-60590 Frankfurt, Germany.
   [Lewicka-Chomont, Aneta; Rejdak, Robert] Med Univ Lublin, Dept Ophthalmol, Lublin, Poland.
   [Rejdak, Robert] Polish Acad Sci, Med Res Ctr, Warsaw, Poland.
C3 Goethe University Frankfurt; Medical University of Lublin; Polish
   Academy of Sciences
RP Koss, MJ (通讯作者)，Goethe Univ Frankfurt, Dept Ophthalmol, Theodor Stern Kai 7, DE-60590 Frankfurt, Germany.
EM Michael.Koss@me.com
FU Insight Instruments, Stuart, Fla., USA
FX F.H.K. declares a potential conflict of interest in the subject matter
   presented. He has received funding from Insight Instruments, Stuart,
   Fla., USA, for travel expenses with regard to scientific meetings and
   conferences. All remaining authors have no conflict of interest in the
   subject matter presented.
CR [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Augustin AJ, 2007, DRUG AGING, V24, P979, DOI 10.2165/00002512-200724120-00002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Barbazetto IA, 2004, EXP EYE RES, V78, P917, DOI 10.1016/j.exer.2004.01.003
   Blair N P, 2000, Trans Am Ophthalmol Soc, V98, P305
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fuseya Miki, 2007, Retin Cases Brief Rep, V1, P160, DOI 10.1097/01.ICB.0000279649.37443.70
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P302, DOI 10.1016/j.ajo.2004.09.046
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   KOROTKIN A, 2006, INVEST OPHTHALMOL VI, V47
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   MENNEL S, 2010, KLIN MONATSBL AUGENH
   Pournaras CJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1553, DOI 10.1001/archopht.1997.01100160723009
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   STEFANSSON E, 1982, RETINA-J RET VIT DIS, V2, P159, DOI 10.1097/00006982-198200230-00006
   STEFANSSON E, 1990, INVEST OPHTH VIS SCI, V31, P284
   Stefansson E, 2006, SURV OPHTHALMOL, V51, P364, DOI 10.1016/j.survophthal.2006.04.005
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   WILSON CA, 1994, ARCH OPHTHALMOL-CHIC, V112, P839, DOI 10.1001/archopht.1994.01090180139048
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   2001, AM J OPHTHALMOL, V131, P541
NR 30
TC 4
Z9 4
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 226
IS 2
BP 45
EP 50
DI 10.1159/000327702
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 771JO
UT WOS:000291153200003
PM 21546780
DA 2022-11-30
ER

PT J
AU Temel, E
   Ornek, K
   Asikgarip, N
AF Temel, Emine
   Ornek, Kemal
   Asikgarip, Nazife
TI Choroidal structural changes determined by the binarization method after
   intravitreal aflibercept treatment in neovascular age-related macular
   degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE aflibercept; choroidal vascularity index; intravitreal; neovascular
   age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB INJECTIONS; THICKNESS CHANGES;
   SUBFOVEAL; THERAPY; BEVACIZUMAB
AB AIM: To assess the choroidal structural alterations after intravitreal injection of aflibercept in neovascular age-related macular degeneration (nAMD).
   METHODS: Fifty eyes with treatment-naive nAMD were evaluated at baseline, 3rd, and 12th month. Fifty eyes of 50 healthy subjects were also included as controls. Choroidal thickness (CT) was measured in the subfoveal region. Total circumscribed choroidal area (CA), luminal area (LA), stromal area (SA), and choroidal vascularity index (CVI) was calculated using Image J.
   RESULTS: At baseline, subfoveal CT was increased in nAMD patients compared to controls (P=0.321). Eyes with nAMD had a significantly increased total circumscribed CA and SA (P=0.041, 0.005, respectively). The CVI was decreased (P=0.038). In the 3rd month, the subfoveal CT, LA, and CVI revealed a decrease (P=0.005, P=0.039, 0.043, respectively). In the 12th month, subfoveal CT, LA, and CVI were decreased in comparison to baseline measures (P<0.001, 0.006, 0.010, respectively).
   CONCLUSION: Significant structural alterations are found after intravitreal aflibercept treatment during the 12-month follow-up, in particular at the third month, in eyes with nAMD.
C1 [Temel, Emine; Asikgarip, Nazife] Kirsehir Training & Res Hosp, Ophthalmol Clin, TR-40100 Kirsehir, Turkey.
   [Ornek, Kemal] Ali Evran Univ, Med Sch, Ophthalmol Clin, TR-40100 Kirsehir, Turkey.
RP Temel, E (通讯作者)，Kirsehir Hosp, TR-40100 Kirsehir, Turkey.
EM emine912@hotmail.com
RI Örnek, Kemal/AFL-3613-2022
CR Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Birch DG, 2007, INT J NANOMED, V2, P65, DOI 10.2147/nano.2007.2.1.65
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Iovino C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020595
   Kaya F, 2017, J FR OPHTALMOL, V40, P832, DOI 10.1016/j.jfo.2017.04.014
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Kim H, 2015, RETINA-J RET VIT DIS, V35, P481, DOI 10.1097/IAE.0000000000000354
   Kim JH, 2015, AM J OPHTHALMOL, V160, P207, DOI 10.1016/j.ajo.2015.04.010
   Kim YK, 2016, RETINA-J RET VIT DIS, V36, P1516, DOI 10.1097/IAE.0000000000000952
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Lukic M, 2020, EUR J OPHTHALMOL
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Minnella AM, 2016, BIODRUGS, V30, P353, DOI 10.1007/s40259-016-0179-0
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Pellegrini M, GRAEFES ARCH CLIN EX, V259, P911
   Vupparaboina KK, 2015, COMPUT MED IMAG GRAP, V46, P315, DOI 10.1016/j.compmedimag.2015.09.008
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 24
TC 0
Z9 0
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD AUG 18
PY 2021
VL 14
IS 8
BP 1213
EP 1217
DI 10.18240/ijo.2021.08.12
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TY4LS
UT WOS:000683756800012
PM 34414086
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ahsan, B
   Aldwaikat, A
   Aboud, O
   Ramadan, A
   Abu-Asab, MS
AF Ahsan, Bisma
   Aldwaikat, Ahmad
   Aboud, Orwa
   Ramadan, Ali
   Abu-Asab, Mones S.
TI Retinal and choroidal capillaries contribution to age-related macular
   degeneration (AMD) phenotypes in murine models of the disease
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE Transgenic mice; blood vessel; capillaries; choriocapillaris;
   endothelial cell; endothelial fenestration; Bruch's membrane; retinal
   pigment epithelium (RPE); retina
ID MECHANISMS; FEATURES; PIGMENT; EYES; MICE
AB Mouse models of age-related macular degeneration (AMD) such as Ccl2(-/-) and Ccl2(-/-)/Cx3cr1(-/-) have not yet been fully characterized ultrastructurally. Although we have previously shown extranuclear DNA (enDNA) leakage into the cytoplasm and damaged mitochondria in the retinal pigment epithelium (RPE) of these AMD mouse models, little is known about the state of their vascular capillaries of the retina and choroid. Our ultrastructural survey shows that the aberrations were not restricted to the RPE cells, but also extended to the vasculature of the retina and choroid. Their endothelial aberrations included cytoplasmic degeneration, pyknotic DNA, hypertrophic nuclei, and loss of fenestration in addition to duplication of basement membrane and loss of density in Bruch's membrane. Moreover, the state of the vasculature in the mutant mice models suggests that the capillaries could also be active contributors to the pathological findings seen in AMD. The goal of this study is to gain insights into the early events of AMD that may lead to a better understanding of AMD's pathogenesis, improve our preventative measures, and formulate designed therapeutic regimens that are tailored to target the initial pathological events.
C1 [Ahsan, Bisma; Abu-Asab, Mones S.] NEI, Sect Histopathol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Aldwaikat, Ahmad] Wayne State Univ, Sch Med, Div Pulm & Crit Care & Sleep Med, Detroit, MI USA.
   [Aboud, Orwa] NCI, Neuro Oncol Branch, NIH, Bethesda, MD 20892 USA.
   [Ramadan, Ali] Howard Univ Hosp, Dept Pathol, Washington, DC USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Wayne State University; National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI); Howard University
RP Abu-Asab, MS (通讯作者)，NEI, Sect Histopathol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM mones@mail.nih.gov
OI Abu-Asab, Mones/0000-0002-4047-1232; Aboud, Orwa/0000-0002-7916-1629
FU National Eye Institute
FX The research was supported by the intramural program of the National Eye
   Institute.
CR Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Arunkumar R, 2018, EYE, V32, P992, DOI 10.1038/s41433-018-0044-0
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Campos MM, 2017, ULTRASTRUCT PATHOL, V41, P312, DOI 10.1080/01913123.2017.1348418
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chu XK, 2013, BIOENGINEERED, V4, P130, DOI 10.4161/bioe.22949
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Fernandez AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201000
   FOULDS WS, 1990, EYE, V4, pR9, DOI 10.1038/eye.1990.34
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Kang JH, 2016, AM J PUBLIC HEALTH, V106, P1684, DOI 10.2105/AJPH.2016.303317
   KORNZWEIG AL, 1966, ARCH OPHTHALMOL-CHIC, V75, P326
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Ogilvy AJ, 2014, ULTRASTRUCT PATHOL, V38, P335, DOI 10.3109/01913123.2014.927406
   Ransohoff RM, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a020560
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sharma NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193423
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Trinh M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.4.20
   You QS, 2020, AM J OPHTHALMOL, V209, P206, DOI 10.1016/j.ajo.2019.09.004
NR 28
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0191-3123
EI 1521-0758
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PD MAR 3
PY 2020
VL 44
IS 2
BP 174
EP 181
DI 10.1080/01913123.2020.1731039
EA FEB 2020
PG 8
WC Microscopy; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microscopy; Pathology
GA LG1JV
UT WOS:000515044200001
PM 32079449
DA 2022-11-30
ER

PT J
AU Foti, MC
   Amorati, R
   Baschieri, A
   Rocco, C
AF Foti, Mario C.
   Amorati, Riccardo
   Baschieri, Andrea
   Rocco, Concetta
TI Singlet oxygen quenching- and chain-breaking antioxidant-properties of a
   quercetin dimer able to prevent age-related macular degeneration
SO BIOPHYSICAL CHEMISTRY
LA English
DT Article
DE A2E; Photooxidation; Singlet oxygen; Quercetin; Quercetin dimer
ID COUPLED ELECTRON-TRANSFER; DPPH-CENTER-DOT; LIPOFUSCIN FLUOROPHORE;
   PHENOXYL RADICALS; VITAMIN-E; A2E; KINETICS; MECHANISMS; OXIDATION;
   PEROXYL
AB A dimer of quercetin prepared through a Mannich reaction protects pyridinium bisretinoid A2E from photo oxidation at 430 nm in aqueous medium at pH 7.4. In the presence of light and O-2, A2E is quickly attacked by 10(2) produced in situ (by excited A2E) to give nonaoxirane and other oxygenated compounds which can be involved in diseases of the macula. Peroxyl radicals might have only a marginal role on the photooxidation of A2E. The dimer is actually a potent quencher of O-1(2) with a rate constant k(Q) of 8.5 x 10(8) M-1 s(-1) in methanol at room temperature. On the other hand, its antioxidant abilities against ROO. radicals are quite limited since k(ROO). = 7.3 x 10(8) M-1 s(-1) (in buffer solution at pH 7.4), the value being essentially identical to that of quercetin. The quenching of O-1(2) by the dimer is therefore the main reason for the A2E protection and prevention of age-related macular degeneration.
C1 [Foti, Mario C.; Rocco, Concetta] CNR, Ist Chim Biomol, Via P Gaifami 18, I-95126 Catania, Italy.
   [Amorati, Riccardo; Baschieri, Andrea] Univ Bologna, Dept Chem G Ciamician, Via S Giacomo 11, I-40126 Bologna, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica
   Biomolecolare (ICB-CNR); University of Bologna
RP Foti, MC (通讯作者)，CNR, Ist Chim Biomol, Via P Gaifami 18, I-95126 Catania, Italy.
EM mario.foti@cnr.it
RI Amorati, Riccardo/A-3437-2012
OI Amorati, Riccardo/0000-0002-6417-9957; BASCHIERI,
   Andrea/0000-0002-2108-8190
CR Adam W, 2005, CHEM REV, V105, P3371, DOI 10.1021/cr0300035
   Amorati R, 2003, J ORG CHEM, V68, P5198, DOI 10.1021/jo0342931
   Amorati R, 2017, BIOMIMETICS-BASEL, V2, DOI 10.3390/biomimetics2030009
   Amorati R, 2017, CHEM-EUR J, V23, P5299, DOI 10.1002/chem.201605931
   Amorati R, 2017, J CHEM-NY, V2017, DOI 10.1155/2017/6369358
   Amorati R, 2016, CHEM-EUR J, V22, P7924, DOI 10.1002/chem.201504492
   Amorati R, 2015, J ORG CHEM, V80, P10651, DOI 10.1021/acs.joc.5b01772
   Baciocchi E, 2006, HELV CHIM ACTA, V89, P2273, DOI 10.1002/hlca.200690211
   Baschieri A, 2017, ORG BIOMOL CHEM, V15, P6177, DOI 10.1039/c7ob01195d
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Bisby RH, 1999, J PHYS CHEM A, V103, P7454, DOI 10.1021/jp990838c
   Bregnhoj M, 2016, PHYS CHEM CHEM PHYS, V18, P22946, DOI 10.1039/c6cp01635a
   BURTON GW, 1985, J AM CHEM SOC, V107, P7053, DOI 10.1021/ja00310a049
   FOTI M, 1994, J PHOTOCH PHOTOBIO B, V26, P159, DOI 10.1016/1011-1344(94)07038-5
   Foti M. C., 2016, REACTIVE OXYGEN SPEC
   Foti MC, 2007, J PHARM PHARMACOL, V59, P1673, DOI 10.1211/jpp.59.12.0010
   Foti MC, 2016, ORG BIOMOL CHEM, V14, P8331, DOI 10.1039/c6ob01439a
   Foti MC, 2010, J ORG CHEM, V75, P4434, DOI 10.1021/jo100491a
   Foti MC, 2008, J ORG CHEM, V73, P9270, DOI 10.1021/jo8016555
   Foti MC, 2004, J ORG CHEM, V69, P2309, DOI 10.1021/jo035758q
   Foti MC, 2002, J AM CHEM SOC, V124, P12881, DOI 10.1021/ja020757l
   Girotti AW, 2001, J PHOTOCH PHOTOBIO B, V63, P103, DOI 10.1016/S1011-1344(01)00207-X
   Ingold KU, 2014, CHEM REV, V114, P9022, DOI 10.1021/cr500226n
   INGOLD KU, 1961, CHEM REV, V61, P563, DOI 10.1021/cr60214a002
   Joshi D, 2013, J NAT PROD, V76, P450, DOI 10.1021/np300769c
   Kim SR, 2008, EXP EYE RES, V86, P975, DOI 10.1016/j.exer.2008.03.016
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Litwinienko G, 2004, J ORG CHEM, V69, P5888, DOI 10.1021/jo049254j
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Mader EA, 2007, J AM CHEM SOC, V129, P5153, DOI 10.1021/ja0686918
   MUKAI K, 1991, J ORG CHEM, V56, P4188, DOI 10.1021/jo00013a021
   Mulder P, 2005, J PHYS CHEM A, V109, P2647, DOI 10.1021/jp047148f
   Musialik M, 2009, J ORG CHEM, V74, P2699, DOI 10.1021/jo802716v
   Nagai S, 2005, J PHYS CHEM B, V109, P4234, DOI 10.1021/jp0451389
   Nagaoka S, 2017, J PHYS CHEM A, V121, P8069, DOI 10.1021/acs.jpca.7b07869
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   SAITO I, 1983, J AM CHEM SOC, V105, P3200, DOI 10.1021/ja00348a040
   Schweitzer C, 2003, CHEM REV, V103, P1685, DOI 10.1021/cr010371d
   Silva Oliveira M, 2007, PHOTOCHEM PHOTOBIOL, V83, P1379, DOI 10.1111/j.1751-1097.2007.00174.x
   Snelgrove DW, 2001, J AM CHEM SOC, V123, P469, DOI 10.1021/ja002301e
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   TRATNYEK PG, 1994, J PHOTOCH PHOTOBIO A, V84, P153, DOI 10.1016/1010-6030(94)03861-9
   TRATNYEK PG, 1991, ENVIRON SCI TECHNOL, V25, P1596, DOI 10.1021/es00021a011
   Wang XY, 2000, MOL MEMBR BIOL, V17, P143, DOI 10.1080/09687680010000311
   Warren JJ, 2010, CHEM REV, V110, P6961, DOI 10.1021/cr100085k
   Washington I, 2005, ANGEW CHEM INT EDIT, V44, P7097, DOI 10.1002/anie.200501346
   Wright JS, 2001, J AM CHEM SOC, V123, P1173, DOI 10.1021/ja002455u
   Yu Xiaoqi, 2018, MACROCYCLIC POLYAMIN
NR 48
TC 3
Z9 3
U1 1
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0301-4622
EI 1873-4200
J9 BIOPHYS CHEM
JI Biophys. Chem.
PD DEC
PY 2018
VL 243
BP 17
EP 23
DI 10.1016/j.bpc.2018.10.001
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA HA6FK
UT WOS:000450375200003
PM 30352336
DA 2022-11-30
ER

PT J
AU Fragiotta, S
   Rossi, T
   Cutini, A
   Grenga, PL
   Vingolo, EM
AF Fragiotta, Serena
   Rossi, Tommaso
   Cutini, Alessandro
   Grenga, Pier L.
   Vingolo, Enzo M.
TI PREDICTIVE FACTORS FOR DEVELOPMENT OF NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION A Spectral-Domain Optical Coherence Tomography Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; predictive factors;
   spectral-domain optical coherence tomography; hyperreflective foci;
   drusenoid pigment epithelial detachment; retinal bands; choroidal
   thickness
ID CHOROIDAL NEOVASCULARIZATION; HYPERREFLECTIVE FOCI; GEOGRAPHIC ATROPHY;
   SEVERITY SCALE; EYE DISEASE; CLASSIFICATION; PROGRESSION
AB Purpose: To investigate the risk factors predictive for the development of neovascular age-related macular degeneration (NVAMD) by means of spectral-domain optical coherence tomography.
   Methods: Retrospective study of 73 eyes graded Stage 2 and Stage 3 according to the AMD International Grading System with minimum follow-up of 24 months. Drusenoid pigment epithelial detachment, hyperreflective foci, external limiting membrane, inner ellipsoid band, and retinal pigment epithelium integrity were analyzed at baseline and last follow-up. Binary logistic regression model analyzed significant predictors of neovascular conversion.
   Results: The discontinuity of external limiting membrane, inner ellipsoid band, and retinal pigment epithelium bands were significantly more prevalent in the NVAMD group at baseline and last follow-up (P < 0.001). Hyperreflective foci represented the single most important predictor of neovascular conversion (Exp [B], 15.15; P = 0.005) as confirmed by Kaplan-Meier curve (P = 0.002). Drusenoid pigment epithelial detachment width was significantly greater in NVAMD group than control subjects at baseline and last follow-up (P < 0.001), and its delta value also resulted a significant neovascular predictor (Exp [B], 0.99; P = 0.04).
   Conclusion: Hyperreflective foci significantly increase the risk of NVAMD progression. The delta width of drusenoid pigment epithelial detachment also predicts disease progression, integrating the stratification of NVAMD progression risk.
C1 [Fragiotta, Serena; Cutini, Alessandro; Grenga, Pier L.; Vingolo, Enzo M.] Sapienza Univ Rome, UOC Ophthalmol, Dept Med Surg Sci & Biotechnol, Terracina, Italy.
   [Rossi, Tommaso] Univ San Martino IST, IRCCS Azienda Osped, Dept Ophthalmol, Genoa, Italy.
C3 Sapienza University Rome; University of Genoa; IRCCS AOU San Martino IST
RP Fragiotta, S (通讯作者)，Sapienza Univ Rome, UOC Ophthalmol, Dept Med Surg Sci & Biotechnol, Via Provenzale 9, I-04100 Latina, LT, Italy.
EM serena.fragiotta@uniroma1.it
RI Fragiotta, Serena/I-5227-2016; Rossi, Tommaso/H-2075-2012; Vingolo, Enzo
   Maria/E-6674-2010
OI Fragiotta, Serena/0000-0002-6214-6270; Rossi,
   Tommaso/0000-0003-0332-7757; Vingolo, Enzo Maria/0000-0002-8363-5866
CR Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Michalewski J, 2014, CAN J OPHTHALMOL, V49, P339, DOI 10.1016/j.jcjo.2014.04.018
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Sunness JS, 2006, BRIT J OPHTHALMOL, V90, P398, DOI 10.1136/bjo.2005.084830
NR 27
TC 15
Z9 16
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2018
VL 38
IS 2
BP 245
EP 252
DI 10.1097/IAE.0000000000001540
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB0KQ
UT WOS:000428735400010
PM 28166160
DA 2022-11-30
ER

PT J
AU Arcinue, CA
   Ma, FY
   Barteselli, G
   Sharpsten, L
   Gomez, ML
   Freeman, WR
AF Arcinue, Cheryl A.
   Ma, Feiyan
   Barteselli, Giulio
   Sharpsten, Lucie
   Gomez, Maria Laura
   Freeman, William R.
TI One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VEGF-TRAP; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL AFLIBERCEPT;
   RANIBIZUMAB; BEVACIZUMAB; TRIAL; FLUID; EYES
AB PURPOSE: To evaluate 6-month and 1-year outcomes of every-8-weeks (Q8W) aflibercept in patients with resistant neovascular age-related macular degeneration (AMD).
   DESIGN: Retrospective, interventional, consecutive case series.
   METHODS: Retrospective review of patients with resistance (multiple recurrences or persistent exudation) to every-4-weeks (Q4W) ranibizumab or bevacizumab that were switched to Q8W aflibercept.
   RESULTS: Sixty-three eyes of 58 patients had a median of 13 (interquartile range [IQR], 7-22) previous anti vascular endothelial growth factor (anti-VEGF) injections. At 6 months after changing to aflibercept, 60.3% of eyes were completely dry, which was maintained up to 1 year. The median maximum retinal thickness improved from 355 mu m to 269 mu m at 6 months (P < .0001) and 248 mu m at 1 year (P < .0001). There was no significant improvement in ETDRS visual acuity at 6 months (P = .2559) and 1 year follow-up (P = .1081) compared with baseline. The mean difference in ETDRS visual acuity compared to baseline at 6 months was -0.05 logMAR (+2.5 letters) and 0.04 logMAR at 1 year (-2 letters).
   CONCLUSION: Sixty percent of eyes with resistant AMD while on Q4W ranibizumab or bevacizumab were completely dry after changing to Q8W aflibercept at the 6-month and 1-year follow-ups, but visual acuity did not significantly improve. Only a third of eyes needed to be switched from Q8W to Q4W aflibercept owing to persistence of fluid; Q8W dosing of aflibercept without the initial 3 monthly loading doses may be a good alternative in a select group of patients who may have developed ranibizumab or bevacizumab resistance. 2015 by Elsevier Inc. All rights reserved.
C1 [Arcinue, Cheryl A.; Ma, Feiyan; Barteselli, Giulio; Gomez, Maria Laura; Freeman, William R.] Univ Calif San Diego, Shiley Eye Ctr, Jacobs Retina Ctr, La Jolla, CA 92093 USA.
   [Sharpsten, Lucie] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Freeman, WR (通讯作者)，Shiley Eye Ctr, 0946,9415 Campus Point Dr, La Jolla, CA 92093 USA.
EM wrfreeman@ucsd.edu
OI Barteselli, Giulio/0000-0003-0533-1135
FU NIH grants [R01EY007366, R01EY018589]; NEI vision core grant
   [P30EY022589]; Research to Prevent Blindness; Regeneron Pharmaceuticals,
   Inc.; NATIONAL EYE INSTITUTE [R01EY007366, P30EY022589, R01EY018589]
   Funding Source: NIH RePORTER
FX This study was supported by NIH grants R01EY007366 and R01EY018589, NEI
   vision core grant P30EY022589, Research to Prevent Blindness, and a
   grant from Regeneron Pharmaceuticals, Inc. The funding organizations had
   no role in the design or conduct of this research.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chhablani JK, 2012, GRAEF ARCH CLIN EXP, V250, P1415, DOI 10.1007/s00417-012-1968-x
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 18
TC 56
Z9 63
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2015
VL 159
IS 3
BP 426
EP 436
DI 10.1016/j.ajo.2014.11.022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC1BV
UT WOS:000350077100003
PM 25461263
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Figueroa, M
   Schocket, LS
   DuPont, J
   Metelitsina, TI
   Grunwald, JE
AF Figueroa, M
   Schocket, LS
   DuPont, J
   Metelitsina, TI
   Grunwald, JE
TI Effect of laser treatment for dry age related macular degeneration on
   foveolar choroidal haemodynamics
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GRID PHOTOCOAGULATION; DRUSEN REDUCTION; BLOOD-FLOW; PROGNOSIS;
   MACULOPATHY; RISK; EYES
AB Aim: Previous studies have suggested that laser photocoagulation therapy is associated with the resolution of drusen in some age related macular degeneration (AMD) patients. The main aim of the study was to determine whether low intensity laser treatment applied according to the Complications of AMD Prevention Trial (CAPT) protocol produces changes in the choroidal circulation that may help explain the mechanism leading to the resolution of drusen material.
   Methods: This ancillary study included 30 CAPT patients with bilateral drusen that were treated and followed at the University of Pennsylvania. Laser Doppler flowmetry was used to measure relative choroidal blood velocity (Ch(vel)), volume (Ch(vol)), and flow (Ch(flow)) in the centre of the fovea. Measurements were obtained through a dilated pupil in both eyes of each patient at the initial CAPT visit before laser treatment was applied in one eye. Measurements were repeated in both eyes of each subject three months later. Analysis of laser Doppler measurements was performed in a masked fashion.
   Results: In comparison to baseline, no significant differences in Ch(vel), Ch(vol), or Ch(flow) were observed three months following the application of low intensity laser according to the CAPT protocol in the untreated and treated eyes. In comparison to the untreated eyes, no significant differences were detected in the treated eyes. Based on the variability of flow measurements in the untreated eyes, the authors estimated an 85% power to detect a 15% change in relative blood flow.
   Conclusions: The results suggest that large alterations in choroidal blood flow do not occur at three months after low intensity laser therapy following the CAPT protocol.
C1 Univ Penn, Sch Med, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Grunwald, JE (通讯作者)，Univ Penn, Sch Med, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM juangrun@mail.med.upenn.edu
CR BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 17
TC 9
Z9 9
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2004
VL 88
IS 6
BP 792
EP 795
DI 10.1136/bjo.2003.033837
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 821QS
UT WOS:000221478000016
PM 15148214
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Krishna, Y
   Sheridan, C
   Kent, D
   Kearns, V
   Grierson, I
   Williams, R
AF Krishna, Y.
   Sheridan, C.
   Kent, D.
   Kearns, V.
   Grierson, I.
   Williams, R.
TI Expanded polytetrafluoroethylene as a substrate for retinal pigment
   epithelial cell growth and transplantation in age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OUTER SEGMENT PHAGOCYTOSIS; PROLIFERATION; MEMBRANE; ADHESION; MATRIX;
   ACID; PTFE
AB Background Retinal pigment epithelial (RPE) transplantation presents a potential treatment for age-related macular degeneration (AMD). A suitable transplant membrane that can support an intact functioning RPE monolayer is required. Expanded polytetrafluoroethylene (ePTFE) possesses the physical properties required for a transplanting device; however, cells do not attach and spread on ePTFE. This study investigated the ability of surface-modified ePTFE to optimise the growth and function of healthy RPE monolayers.
   Methods ePTFE discs were modified by ammonia gas plasma treatment. ARPE-19 cells were seeded on the membranes and maintained in media supplemented with retinoic acid and reduced serum. Cell number, morphology and proliferation were analysed. RPE monolayer function was investigated through formation of celle-cell junctions and phagocytosis of photoreceptor outer segments (POS).
   Results Ammonia gas plasma treatment resulted in enhanced cell growth and good monolayer formation with evidence of celle-cell junctional proteins. Furthermore, RPE monolayers were able to phagocytose POS in a time-dependent manner.
   Conclusions ePTFE can be surface-modified to support an intact functional monolayer of healthy RPE cells with normal morphology and the ability to perform RPE-specific functions. Following further investigation ePTFE may be considered for use in transplantation.
C1 [Sheridan, C.] Univ Liverpool, Inst Ageing & Chron Dis, Univ Clin Dept, Dept Eye & Vis Sci, Liverpool L69 3GA, Merseyside, England.
   [Kent, D.] Aut Even Hosp, Kilkenny, Ireland.
C3 University of Liverpool
RP Sheridan, C (通讯作者)，Univ Liverpool, Inst Ageing & Chron Dis, Univ Clin Dept, Dept Eye & Vis Sci, Duncan Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.
EM c.m.sheridan@liv.ac.uk
RI Kearns, Victoria/I-3271-2012; Sheridan, Carl/AAH-3607-2021
OI Kearns, Victoria/0000-0003-1426-6048; Sheridan,
   Carl/0000-0003-0100-9587; , Yamini/0000-0001-5067-3682; Williams,
   Rachel/0000-0002-1954-0256
FU Research & Development Support Fund; Royal Liverpool and Broadgreen
   University Hospitals; The Dunhill Medical Trust; Fight for Sight
FX Research & Development Support Fund, Royal Liverpool and Broadgreen
   University Hospitals; The Dunhill Medical Trust; and Fight for Sight.
CR Batniji Rami K, 2002, Arch Facial Plast Surg, V4, P111, DOI 10.1001/archfaci.4.2.111
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   CAMPOCHIARO PA, 1991, INVEST OPHTH VIS SCI, V32, P65
   CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Chu PK, 2002, MAT SCI ENG R, V36, P143, DOI 10.1016/S0927-796X(02)00004-9
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hall MO, 2005, EXP EYE RES, V81, P581, DOI 10.1016/j.exer.2005.03.017
   Hiscott P, 1999, PROG RETIN EYE RES, V18, P167, DOI 10.1016/S1350-9462(98)00024-X
   Kent D, 2003, WOUND REPAIR REGEN, V11, P285, DOI 10.1046/j.1524-475X.2003.11408.x
   Lu LC, 2001, BIOMATERIALS, V22, P291, DOI 10.1016/S0142-9612(00)00179-4
   Miceli MV, 1996, CURR EYE RES, V15, P17, DOI 10.3109/02713689609017607
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Pu FR, 2002, BIOMATERIALS, V23, P2411, DOI 10.1016/S0142-9612(01)00377-5
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Sheridan CM, 2009, EYE, V23, P1910, DOI 10.1038/eye.2008.420
   Stanzel BV, 2005, EXP EYE RES, V80, P103, DOI 10.1016/j.exer.2004.06.032
   Thumann G, 1998, GRAEF ARCH CLIN EXP, V236, P753, DOI 10.1007/s004170050154
   Tran HS, 2000, BIOMATERIALS ENGINEERING AND DEVICES: HUMAN APPLICATIONS, VOL 1, P137
   Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wilson DJ, 2001, SURF INTERFACE ANAL, V31, P397, DOI 10.1002/sia.1066
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
   Yasunari T, 1999, OPHTHALMIC RES, V31, P24, DOI 10.1159/000055509
NR 28
TC 33
Z9 34
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2011
VL 95
IS 4
BP 569
EP 573
DI 10.1136/bjo.2009.169953
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 736NZ
UT WOS:000288502700029
PM 21317216
DA 2022-11-30
ER

PT J
AU Ghoshal, R
   Sharanjeet-Kaur, S
   Fadzil, NM
   Mutalib, HA
   Ghosh, S
   Ngah, NF
   Abd Aziz, RA
AF Ghoshal, Rituparna
   Sharanjeet-Kaur, Sharanjeet
   Fadzil, Norliza Mohamad
   Mutalib, Haliza Abdul
   Ghosh, Somnath
   Ngah, Nor Fariza
   Abd Aziz, Roslin Azni
TI Correlation between Visual Functions and Retinal Morphology in Eyes with
   Early and Intermediate Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE early and intermediate ARMD; retinal layers morphology; visual functions
ID BRUCHS MEMBRANE; CONTRAST SENSITIVITY; GEOGRAPHIC ATROPHY; LAYER
   THICKNESS; REPEATABILITY; PERFORMANCE; PREVALENCE; DISEASE; MODELS;
   DRUSEN
AB In early and intermediate age related macular degeneration (ARMD), visual acuity alone has failed to explain the complete variation of vision. The aim of the present study was to determine correlation between different visual functions and retinal morphology in eyes with early and intermediate ARMD. In this single center cross sectional study, patients diagnosed as early or intermediate ARMD in at least one eye were recruited. Visual functions measured were best- corrected distance visual acuity (DVA), near vision acuity (NVA), reading speed (RS), and contrast sensitivity (CS). Parameters such as thickness (RT) and volume (RV) of the retina, outer retinal layer thickness (ORLT) and volume (ORLV), outer nuclear layer thickness (ONLT) and volume (ONLV), retinal pigment epithelium layer-Bruch's membrane complex thickness (RPET) and volume (RPEV) were assessed employing semi-auto segmentation method of Spectralis optical coherence tomography (OCT). Twenty-six eyes were evaluated. DVA, CS, and RS showed significantly good correlation with RPET, ONLT, and ONLV, whereas NVA showed good correlation with ONLV and RPET. The present study concluded that RS, CS, NVA, and DVA represent the morphological alteration in early stages and should be tested in clinical settings. ONLT, ONLV, and RPET morphological parameters can be employed as important biomarkers in diagnosis of early to intermediate ARMD.
C1 [Ghoshal, Rituparna; Sharanjeet-Kaur, Sharanjeet; Fadzil, Norliza Mohamad; Mutalib, Haliza Abdul] Univ Kebangsaan Malaysia, Fac Hlth Sci, Optometry & Vis Sci Program, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia.
   [Ghoshal, Rituparna] Supreme Inst Management & Technol, Dept Optometry, Mankundu Hooghly 712123, W Bengal, India.
   [Ghosh, Somnath] Brainware Univ, Dept Allied Hlth Sci, Kalkata 700125, W Bengal, India.
   [Ngah, Nor Fariza; Abd Aziz, Roslin Azni] Hosp Shah Alam, Dept Ophthalmol, Seksyen 7, Shah Alam 40000, Selangor, Malaysia.
C3 Universiti Kebangsaan Malaysia
RP Sharanjeet-Kaur, S (通讯作者)，Univ Kebangsaan Malaysia, Fac Hlth Sci, Optometry & Vis Sci Program, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia.
EM rituparna4ab@yahoo.co.in; sharanjeet@ukm.edu.my;
   norlizafadzil@ukm.edu.my; halizamutalib@ukm.edu.my;
   somnath4ab@yahoo.co.in; drfarizangah@gmail.com; roslinazni@gmail.com
RI SHARANJEET-KAUR, SHARANJEET/G-9539-2018
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Buari NH, 2015, BANGLADESH J MED SCI, V14, P236, DOI 10.3329/bjms.v14i3.18964
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cochran WG., 1963, SAMPLING TECHNIQUES, V2, DOI 10.1002/bimj.19650070312
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Girmens JF, 2012, INTRACTABLE RARE DIS, V1, P103, DOI 10.5582/irdr.2012.v1.3.103
   Haegerstrom-Portnoy G, 2000, OPTOMETRY VISION SCI, V77, P653, DOI 10.1097/00006324-200012000-00012
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Keane PA, 2011, SAUDI J OPHTHALMOL, V25, P145, DOI 10.1016/j.sjopt.2011.01.003
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Matsumoto H, 2009, AM J OPHTHALMOL, V148, P105, DOI 10.1016/j.ajo.2009.01.018
   McGill TJ, 2012, INVEST OPHTH VIS SCI, V53, P6232, DOI 10.1167/iovs.12-9569
   Menghini M, 2015, INVEST OPHTH VIS SCI, V56, P372, DOI 10.1167/iovs.14-15521
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Nixon DR, 2017, CLIN OPHTHALMOL, V11, P715, DOI 10.2147/OPTH.S131343
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Patel PJ, 2011, INVEST OPHTH VIS SCI, V52, P3854, DOI 10.1167/iovs.10-6601
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P2621, DOI 10.1167/iovs.08-2407
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Vujosevic S, 2017, GRAEF ARCH CLIN EXP, V255, P301, DOI 10.1007/s00417-016-3466-z
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JM, 2005, OPTOMETRY VISION SCI, V82, P698, DOI 10.1097/01.opx.0000175562.27101.51
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
NR 40
TC 3
Z9 3
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD SEP
PY 2020
VL 17
IS 17
AR 6379
DI 10.3390/ijerph17176379
PG 14
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA NO8FU
UT WOS:000569724200001
PM 32887214
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gil, P
   Gil, J
   Oliveira, N
   Lains, I
   Camilo, ENR
   Fonseca, C
   Raimundo, M
   Cachulo, MD
   Silva, R
AF Gil, Pedro
   Gil, Joao
   Oliveira, Nuno
   Lains, Ines
   Rossi Camilo, Eduardo Nery
   Fonseca, Cristina
   Raimundo, Miguel
   Cachulo, Maria da Luz
   Silva, Rufino
TI Influence of the Vitreoretinal Interface on the Treatment with Anti-VEGF
   for Exudative Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Posterior vitreous detachment;
   Ranibizumab; Vitreoretinal interface
ID OPTICAL COHERENCE TOMOGRAPHY; POSTERIOR VITREOUS DETACHMENT;
   VITREOMACULAR ADHESION; RANIBIZUMAB; OUTCOMES; ANGIOGRAPHY; THERAPY;
   RISK
AB Purpose: To investigate the influence of the vitreoretinal interface on the outcomes of different ranibizumab regimens for exudative age-related macular degeneration. Methods: We conducted a retrospective subanalysis of 2 prospective clinical trials. Patients were treated with ranibizumab for 12 months according to 3 different regimens: pro-re-nata (PRN), treat and extend (T&E), and monthly. Vitreoretinal interface was assessed for absence (group ON) or presence (group OFF) of posterior vitreous detachment (PVD). Results: We included 64 eyes from 64 patients. Visual improvement was poorer for group ON (0.3 +/- 10.7 letters) than for group OFF (9.2 +/- 13.3; p = 0.007). A significant difference in letters of improvement between groups was observed in the PRN cohort (ON: -5.0 +/- 12.9; OFF: 11.4 +/- 11.9; p = 0.003), but not in the cohorts with monthly (ON: 5.7 +/- 7.8; OFF: 7.9 +/- 15.2; p = 0.735) or T&E (ON: 4.3 +/- 4.3; OFF: 7.8 +/- 11.1; p = 0.424) treatment. Conclusion: The negative impact of absence of PVD is regimen dependent, with monthly dosing providing similar outcomes to PVD patients. In the absence of PVD (group ON), PRN should be avoided, and T&E might be an alternative. (C) 2018 S. Karger AG, Basel
C1 [Gil, Pedro; Gil, Joao; Oliveira, Nuno; Lains, Ines; Fonseca, Cristina; Raimundo, Miguel; Cachulo, Maria da Luz; Silva, Rufino] Ctr Hosp Univ Coimbra, Dept Ophthalmol, PT-300007 Coimbra, Portugal.
   [Gil, Pedro; Gil, Joao; Lains, Ines; Fonseca, Cristina; Raimundo, Miguel; Cachulo, Maria da Luz; Silva, Rufino] Univ Coimbra, Fac Med, Coimbra, Portugal.
   [Rossi Camilo, Eduardo Nery] Goias Eye Bank Fdn, Goiania, Go, Brazil.
   [Cachulo, Maria da Luz; Silva, Rufino] AIBILI Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Universidade de Coimbra
RP Gil, P (通讯作者)，Ctr Hosp Univ Coimbra, Dept Ophthalmol, PT-300007 Coimbra, Portugal.
EM pedroqgil@gmail.com
RI Silva, Rufino M/J-2817-2012; Gil, Pedro/N-9909-2016
OI Silva, Rufino M/0000-0001-8676-0833; Cachulo, Maria
   Luz/0000-0002-0900-4548; Gil, Pedro/0000-0002-6683-6818; Quadrado Gil,
   Joao/0000-0001-9032-1008
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Geck U, 2013, GRAEF ARCH CLIN EXP, V251, P1691, DOI 10.1007/s00417-013-2266-y
   Jacob J, 2016, OPHTHALMOLOGICA, V236, P81, DOI 10.1159/000446585
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Schubert H D, 1989, Prog Clin Biol Res, V312, P277
   Sebag J, 1996, OPHTHALMOLOGY, V103, P205
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Wolf S, 2010, OPHTHALMOLOGICA, V224, P333, DOI 10.1159/000313814
   Zapata MA, 2017, OPHTHALMOL RETINA, V1, P249, DOI 10.1016/j.oret.2016.11.001
NR 24
TC 2
Z9 2
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 240
IS 1
BP 29
EP 36
DI 10.1159/000488010
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GK2LT
UT WOS:000435962400005
PM 29734180
DA 2022-11-30
ER

PT J
AU McGwin, G
   Mitchell, B
   Searcey, K
   Albert, MA
   Feist, R
   Mason, JO
   Thomley, M
   Owsley, C
AF McGwin, Gerald, Jr.
   Mitchell, Bradford
   Searcey, Karen
   Albert, Michael A.
   Feist, Richard
   Mason, John O., III
   Thomley, Martin
   Owsley, Cynthia
TI Examining the association between age-related macular degeneration and
   motor vehicle collision involvement: a retrospective cohort study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Epidemiology; Macula; Degeneration
ID MEDIATED DARK-ADAPTATION; DRIVING HABITS; FOCUS GROUPS; A-WAVE;
   MACULOPATHY; VISION; QUESTIONNAIRE; IMPAIRMENT; IMPACT
AB Background
   Little is known about motor vehicle collision (MVC) risk in older drivers with age-related macular degeneration (AMD). The purpose of this study is to examine associations between MVC involvement and AMD presence and severity.
   Methods
   In a retrospective cohort study pooling the samples from four previous studies, we examined associations between MVC rate and older drivers with early, intermediate or advanced AMD as compared with those in normal eye health. MVC data were based on accident reports obtained from the state agency that compiles this information.
   Results
   MVC rate was highest among those in normal eye health and progressively declined among those with early and intermediate disease, and then increased for those with advanced AMD. However, only for drivers with intermediate AMD was the MVC rate significantly different (lower) as compared with those in normal eye health, regardless of whether the rate was defined in terms of person-years (RR 0.34, 95% CI 0.13 to 0.89) or person-miles (RR 0.35, 95% CI 0.13 to 0.91) of driving.
   Conclusions
   These results suggest that older drivers with intermediate AMD have a reduced risk of collision involvement. Further research should investigate whether self-regulatory driving practices by these drivers (avoiding challenging driving situations) underlies this reduced risk.
C1 [McGwin, Gerald, Jr.; Mitchell, Bradford; Searcey, Karen; Albert, Michael A.; Feist, Richard; Mason, John O., III; Thomley, Martin; Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Dept Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
FU National Institutes of Health [R01EY18966, R01AG04212, P30AG22838];
   EyeSight Foundation of Alabama; Research to Prevent Blindness; Alfreda J
   Schueler Trust; Able Trust; NATIONAL EYE INSTITUTE [R01EY018966] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004212,
   P30AG022838] Funding Source: NIH RePORTER
FX National Institutes of Health R01EY18966, R01AG04212, P30AG22838;
   EyeSight Foundation of Alabama; Research to Prevent Blindness, Alfreda J
   Schueler Trust, Able Trust.
CR [Anonymous], 2004, SUMMARY TRAVEL TREND
   Arthur W, 2005, HUM FACTORS, V47, P303, DOI 10.1518/0018720054679416
   Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4
   Baster N, ITS MY CHOICE SAFE M
   CAMPBELL MK, 1993, J GERONTOL, V48, pS230, DOI 10.1093/geronj/48.4.S230
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Cimarolli VR, 2012, CLIN REHABIL, V26, P748, DOI 10.1177/0269215511429162
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   EVANS L, 1988, J TRAUMA, V28, P368, DOI 10.1097/00005373-198803000-00013
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Jackson GR, 2006, VISION RES, V46, P1422, DOI 10.1016/j.visres.2005.09.003
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   MCCLOSKEY LW, 1994, AGE AGEING, V23, P267, DOI 10.1093/ageing/23.4.267
   *NAT HIGHW TRAFF S, 1993, ADDR SAF ISS REL YOU
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2008, J VISUAL IMPAIR BLIN, V102, P621, DOI 10.1177/0145482X0810201007
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2010, VISION RES, V50, P2348, DOI 10.1016/j.visres.2010.05.021
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sims RV, 2000, J GERONTOL A-BIOL, V55, pM22
   SZLYK JP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1033, DOI 10.1001/archopht.1995.01100080085033
NR 34
TC 10
Z9 10
U1 0
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2013
VL 97
IS 9
BP 1173
EP 1176
DI 10.1136/bjophthalmol-2013-303601
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 201SO
UT WOS:000323163500019
PM 23832967
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bae, K
   Kim, HJ
   Shin, YK
   Kang, SW
AF Bae, Kunho
   Kim, Hyo Jung
   Shin, Yong Kyun
   Kang, Se Woong
TI Predictors of neovascular activity during neovascular age-related
   macular degeneration treatment based on optical coherence tomography
   angiography
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; TYPE-1 NEOVASCULARIZATION; RISK-FACTORS;
   THERAPY; RANIBIZUMAB; DISEASE; STOP
AB The advent of anti-vascular endothelial growth factor (VEGF) therapies has remarkably improved the functional outcomes of neovascular age-related macular degeneration (nAMD) patients. However, there are guidelines on how to start treatment, the guidelines for discontinuing treatment are not yet clear. In this respect, the treat-extend-stop (TES) protocol have showed us the possibility of discontinuing treatment. In this study, we tried to investigate optical coherence tomography angiography (OCTA) biomarkers related to recurrence of neovascular activity in eyes with nAMD undergoing treatment using TES protocol. A total of 134 eyes with nAMD were divided into two groups (stop, non-stop) depending on whether they met criteria for stopping anti-VEGF treatment. Quantitative and qualitative OCTA parameters including the morphologic pattern of choroidal neovascularization (CNV) were compared between groups. Of these, 44 eyes (32.8%) were in the stop group and 90 eyes (67.2%) were in the non-stop group. In multivariate regression analysis, closed-circuit pattern of CNV and the presence of peripheral loop were associated with the non-stop group (all p <0.001). Our results imply that the morphologic appearance of CNV on OCTA after anti-VEGF treatment may be a useful biomarker to predict weaning from treatment.
C1 [Bae, Kunho] Dongguk Univ, Ilsan Hosp, Dept Ophthalmol, Goyang, South Korea.
   [Bae, Kunho; Kim, Hyo Jung; Shin, Yong Kyun; Kang, Se Woong] Sungkyunkwan Univ, Dept Ophthalmol, Samsung Med Ctr, Sch Med, Seoul, South Korea.
C3 Dongguk University; NHIS Ilsan Hospital; Sungkyunkwan University (SKKU);
   Samsung Medical Center
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Dept Ophthalmol, Samsung Med Ctr, Sch Med, Seoul, South Korea.
EM kangsewoong@gmail.com
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Baer K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46235-3
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Elshout M, 2012, INVEST OPHTH VIS SCI, V53, P4331, DOI 10.1167/iovs.11-9242
   Gale R, 2016, OPHTHALMOLOGICA, V236, P193, DOI 10.1159/000451065
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kramer M, 2000, AM J OPHTHALMOL, V129, P495, DOI 10.1016/S0002-9394(99)00388-8
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
NR 36
TC 11
Z9 12
U1 1
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 17
PY 2019
VL 9
AR 19240
DI 10.1038/s41598-019-55871-8
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JW7CH
UT WOS:000503205300008
PM 31848438
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sasaki, M
   Kato, Y
   Fujinami, K
   Hirakata, T
   Tsunoda, K
   Watanabe, K
   Akiyama, K
   Noda, T
AF Sasaki, Mariko
   Kato, Yu
   Fujinami, Kaoru
   Hirakata, Toshiaki
   Tsunoda, Kazushige
   Watanabe, Ken
   Akiyama, Kunihiko
   Noda, Toru
TI Advanced quantitative analysis of the sub-retinal pigment epithelial
   space in recurrent neovascular age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; THERAPY; RANIBIZUMAB
AB To quantitatively evaluate changes in the sub-retinal pigment epithelial (RPE) space and determine the association with recurrent neovascular age-related macular degeneration (AMD). Twenty-two eyes treated with intravitreal aflibercept for treatment-naive neovascular AMD were studied retrospectively. The sub-RPE area, volume, and central retinal thickness (CRT) were evaluated 1 and 2 months after the loading phase using spectral-domain optical coherence tomography. Recurrence was defined as newly detected neovascular activity during the 6 months after the loading phase. In eyes with recurrent AMD, the sub-RPE area increased significantly (P = 0.036) from 1 to 2 months after the loading phase and the sub-RPE volume increased marginally (P = 0.06). Subgroup analysis showed significant (P = 0.008 and P = 0.016, respectively) increases in the sub-RPE area and volume in typical AMD. In eyes with no recurrence, no significant changes occurred in the two parameters. No significant CRT changes occurred in eyes with or without a recurrence. A quantitative analysis demonstrated an increased likelihood of the sub-RPE space shortly after the loading phase in eyes with recurrent AMD; no changes occurred in eyes without a recurrence. These early changes in the sub-RPE space could indicate disease activity and are valuable for predicting recurrences of neovascular AMD.
C1 [Sasaki, Mariko; Kato, Yu; Fujinami, Kaoru; Hirakata, Toshiaki; Tsunoda, Kazushige; Watanabe, Ken; Akiyama, Kunihiko; Noda, Toru] Natl Tokyo Med Ctr, Natl Inst Sensory Organs, Dept Ophthalmol, Tokyo, Japan.
   [Sasaki, Mariko] Tachikawa Hosp, Dept Ophthalmol, Tokyo, Japan.
   [Sasaki, Mariko; Fujinami, Kaoru] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Kato, Yu] Metropolitan Komagome Hosp, Dept Ophthalmol, Tokyo, Japan.
   [Fujinami, Kaoru] UCL Inst Ophthalmol, Genet, London, England.
C3 Tachikawa Hospital; Keio University; University of London; University
   College London
RP Sasaki, M (通讯作者)，Natl Tokyo Med Ctr, Natl Inst Sensory Organs, Dept Ophthalmol, Tokyo, Japan.; Sasaki, M (通讯作者)，Tachikawa Hosp, Dept Ophthalmol, Tokyo, Japan.; Sasaki, M (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
EM mariko.sasaki@a2.keio.jp
RI Akiyama, Kunihiko/AAF-6894-2020
OI Akiyama, Kunihiko/0000-0003-3935-5434; Kato, YU/0000-0003-2568-0084;
   Sasaki, Mariko/0000-0001-5608-0546
FU Japan Society for the Promotion of Science, Japan (JSPS KAKENHI)
   [17K09150]; Grants-in-Aid for Scientific Research [17K09150] Funding
   Source: KAKEN
FX This study was supported in part by a Grant-in-Aid for Scientific
   Research from the Japan Society for the Promotion of Science, Japan
   (JSPS KAKENHI, 17K09150)to MS. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Parikh R, 2008, INDIAN J OPHTHALMOL, V56, P45, DOI 10.4103/0301-4738.37595
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   RAYESS N, 2015, AM J OPHTHALMOL, V159, pE1, DOI DOI 10.1016/j.ajo.2014.09.033
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yasukawa T, 2015, EXPERT REV OPHTHALMO, V10, P105, DOI 10.1586/17469899.2015.1019473
NR 19
TC 4
Z9 4
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 2
PY 2017
VL 12
IS 11
AR e0186955
DI 10.1371/journal.pone.0186955
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FL6FI
UT WOS:000414340200034
PM 29095879
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Mitra, RN
   Gao, RJ
   Zheng, M
   Wu, MJ
   Voinov, MA
   Smirnov, AI
   Smirnova, TI
   Wang, K
   Chavala, S
   Han, ZC
AF Mitra, Rajendra N.
   Gao, Ruijuan
   Zheng, Min
   Wu, Ming-Jing
   Voinov, Maxim A.
   Smirnov, Alex I.
   Smirnova, Tatyana I.
   Wang, Kai
   Chavala, Sai
   Han, Zongchao
TI Glycol Chitosan Engineered Autoregenerative Antioxidant Significantly
   Attenuates Pathological Damages in Models of Age-Related Macular
   Degeneration
SO ACS NANO
LA English
DT Article
DE age-related macular degeneration; cerium oxide nanoparticles;
   antioxidant; reactive oxygen species; laser-induced choroidal
   neovascularization
ID CERIUM OXIDE NANOPARTICLES; ENDOTHELIAL GROWTH-FACTOR; PIGMENT
   EPITHELIAL-CELLS; INDUCED CHOROIDAL NEOVASCULARIZATION; OXIDATIVE
   STRESS; INTRAVITREAL INJECTION; RETINAL DEGENERATION; MOUSE MODEL;
   IN-VITRO; OCULAR NEOVASCULARIZATION
AB Age-related macular degeneration (AMD) is the foremost cause of irreversible blindness in people over the age of 65 especially in developing countries. Therefore, an exploration of effective and alternative therapeutic interventions is an unmet medical need. It has been established that oxidative stress plays a key role in the pathogenesis of AMD, and hence, neutralizing oxidative stress is an effective therapeutic strategy for treatment of this serious disorder. Owing to autoregenerative properties, nanoceria has been widely used as a nonenzymatic antioxidant in the treatment of oxidative stress related disorders. Yet, its potential clinical implementation has been greatly hampered by its poor water solubility and lack of reliable tracking methodologies/processes and hence poor absorption, distribution, and targeted delivery. The water solubility and surface engineering of a drug with biocompatible motifs are fundamental to pharmaceutical products and precision medicine. Here, we report an engineered water-soluble, biocompatible, trackable nanoceria with enriched antioxidant activity to scavenge intracellular reactive oxygen species (ROS). Experimental studies with in vitro and in vivo models demonstrated that this antioxidant is autoregenerative and more active in inhibiting laser-induced choroidal neovascularization by decreasing ROS-induced pro-angiogenic vascular endothelial growth factor (VEGF) expression, cumulative oxidative damage, and recruitment of endothelial precursor cells without exhibiting any toxicity. This advanced formulation may offer a superior therapeutic effect to deal with oxidative stress induced pathogeneses, such as AMD.
C1 [Mitra, Rajendra N.; Gao, Ruijuan; Zheng, Min; Wu, Ming-Jing; Wang, Kai; Han, Zongchao] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA.
   [Han, Zongchao] Univ N Carolina, Carolina Inst NanoMed, Chapel Hill, NC 27599 USA.
   [Han, Zongchao] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA.
   [Gao, Ruijuan] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China.
   [Gao, Ruijuan] Peking Union Med Coll, Beijing 100050, Peoples R China.
   [Voinov, Maxim A.; Smirnov, Alex I.; Smirnova, Tatyana I.] North Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA.
   [Chavala, Sai] Univ North Texas, Hlth Sci Ctr, North Texas Eye Res Inst, Ft Worth, TX 76107 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Institute of Medicinal Biotechnology - CAMS; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College;
   University of North Carolina; North Carolina State University;
   University of North Texas System; University of North Texas Denton
RP Han, ZC (通讯作者)，Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA.; Han, ZC (通讯作者)，Univ N Carolina, Carolina Inst NanoMed, Chapel Hill, NC 27599 USA.; Han, ZC (通讯作者)，Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA.
EM zongchao@med.unc.edu
RI (CHANL), Chapel Hill Analytical and Nanofabrication
   Laboratory/AAA-9271-2022; Smirnov, Alex I/Q-9818-2016; Wang,
   Kai/GQI-1260-2022; GAO, RUIJUAN/AAE-3015-2020; Wang, Kai/AAE-4566-2021
OI Smirnov, Alex I/0000-0002-0037-2555; Wang, Kai/0000-0002-4419-9598;
   Wang, Kai/0000-0002-4419-9598; Han, Zongchao/0000-0002-2019-395X;
   Voynov, Maxim/0000-0002-5565-5843; Smirnova, Tatyana/0000-0001-7867-7116
FU U.S. National Eye Institute [R21EY024059, R01EY026564]; Carolina Center
   of Nanotechnology Excellence; NC TraCS Translational Research Grant [550
   KR151611]; UNC Junior Faculty Development Award;  [NIH-S10RR023614]; 
   [NSF CHE-0840501];  [NCBC 2009-IDG-1015]
FX This work was supported in part by the U.S. National Eye Institute
   (R21EY024059 and R01EY026564, Z.H.), the Carolina Center of
   Nanotechnology Excellence (Z.H.), the NC TraCS Translational Research
   Grant (550 KR151611, Z.H.), and the UNC Junior Faculty Development Award
   (Z.H.). This work was performed in part at the Chapel Hill Analytical
   and Nanofabrication Laboratory, a member of the North Carolina Research
   Triangle Nanotechnology Network and part of the National Nanotechnology
   Coordinated Infrastructure. The EPR instrumentation at North Carolina
   State University used in this work is supported by grants
   NIH-S10RR023614, NSF CHE-0840501, and NCBC 2009-IDG-1015. The authors
   thank Drs. Marina Sokolsky and Alexander Kabanov for their help with the
   thermogravimetric analyses and Cassandra Janowski Barnhart, M.P.H.
   (Department of Ophthalmology, University of North Carolina at Chapel
   Hill), for her critical reading of the manuscript.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Asati A, 2009, ANGEW CHEM INT EDIT, V48, P2308, DOI 10.1002/anie.200805279
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cai X, 2016, ADV EXP MED BIOL, V854, P111, DOI 10.1007/978-3-319-17121-0_16
   Cai X, 2014, BIOMATERIALS, V35, P249, DOI 10.1016/j.biomaterials.2013.10.022
   Cai X, 2012, BIOMATERIALS, V33, P8771, DOI 10.1016/j.biomaterials.2012.08.030
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Chetram M. A., 2013, FRONT BIOL BEIJING C, V8, P8
   Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4
   Das M, 2007, BIOMATERIALS, V28, P1918, DOI 10.1016/j.biomaterials.2006.11.036
   Dong AL, 2011, P NATL ACAD SCI USA, V108, P14614, DOI 10.1073/pnas.1012859108
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Dowding JM, 2014, CELL DEATH DIFFER, V21, P1622, DOI 10.1038/cdd.2014.72
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Esch F, 2005, SCIENCE, V309, P752, DOI 10.1126/science.1111568
   Fontmorin JM, 2016, WATER RES, V99, P24, DOI 10.1016/j.watres.2016.04.053
   Giri S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054578
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Heckert EG, 2008, BIOMATERIALS, V29, P2705, DOI 10.1016/j.biomaterials.2008.03.014
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hong X, 2006, CANCER LETT, V236, P39, DOI 10.1016/j.canlet.2005.05.011
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Karakoti AS, 2007, J PHYS CHEM C, V111, P17232, DOI 10.1021/jp076164k
   Kim CK, 2012, ANGEW CHEM INT EDIT, V51, P11039, DOI 10.1002/anie.201203780
   Kim JH, 2008, J CONTROL RELEASE, V127, P41, DOI 10.1016/j.jconrel.2007.12.014
   Kim K., 2008, ICMMT 2008, V2008, P29
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kong L, 2011, NEUROBIOL DIS, V42, P514, DOI 10.1016/j.nbd.2011.03.004
   Koo H, 2012, BIOMATERIALS, V33, P3485, DOI 10.1016/j.biomaterials.2012.01.030
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Kwon HJ, 2016, ACS NANO, V10, P2860, DOI 10.1021/acsnano.5b08045
   Kyosseva SV, 2013, EXP EYE RES, V116, P63, DOI 10.1016/j.exer.2013.08.003
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee E, 2010, INVEST OPHTH VIS SCI, V51, P3666, DOI 10.1167/iovs.09-3802
   Li M, 2013, CHEM SCI, V4, P2536, DOI 10.1039/c3sc50697e
   Li QH, 2008, MOL THER, V16, P1688, DOI 10.1038/mt.2008.164
   Li YY, 2015, ANGEW CHEM INT EDIT, V54, P1832, DOI 10.1002/anie.201410398
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Lord MS, 2013, BIOMATERIALS, V34, P8808, DOI 10.1016/j.biomaterials.2013.07.083
   Mitra RN, 2016, ADV EXP MED BIOL, V854, P463, DOI 10.1007/978-3-319-17121-0_62
   Mitra RN, 2014, FREE RADICAL BIO MED, V75, P140, DOI 10.1016/j.freeradbiomed.2014.07.013
   Mitra RN, 2014, CHEMMEDCHEM, V9, P189, DOI 10.1002/cmdc.201300371
   Mitra RN, 2016, J CONTROL RELEASE, V236, P31, DOI 10.1016/j.jconrel.2016.06.020
   Na JH, 2012, J CONTROL RELEASE, V163, P2, DOI 10.1016/j.jconrel.2012.07.028
   Perez JM, 2008, SMALL, V4, P552, DOI 10.1002/smll.200700824
   Pirmohamed T, 2010, CHEM COMMUN, V46, P2736, DOI 10.1039/b922024k
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Roggia MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098864
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Schimel AM, 2011, AM J PATHOL, V178, P2032, DOI 10.1016/j.ajpath.2011.01.036
   Sengupta N, 2010, INVEST OPHTH VIS SCI, V51, P2697, DOI 10.1167/iovs.09-4137
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Villamena FA, 2003, J PHYS CHEM A, V107, P4407, DOI 10.1021/jp027829f
   Voinov MA, 2011, J AM CHEM SOC, V133, P35, DOI 10.1021/ja104683w
   Wan AJ, 2013, J AGR FOOD CHEM, V61, P6921, DOI 10.1021/jf402242e
   Wang AL, 2008, MOL VIS, V14, P644
   Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yoo HS, 2005, J CONTROL RELEASE, V103, P235, DOI 10.1016/j.jconrel.2004.11.033
   Zamiri R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122989
   Zhai YW, 2013, RSC ADV, V3, P6833, DOI 10.1039/c3ra22251a
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhong L, 2014, INT J CANCER, V135, P2972, DOI 10.1002/ijc.28944
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
NR 82
TC 44
Z9 44
U1 5
U2 56
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD MAY
PY 2017
VL 11
IS 5
BP 4669
EP 4685
DI 10.1021/acsnano.7b00429
PG 17
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA EW4VG
UT WOS:000402498400032
PM 28463509
DA 2022-11-30
ER

PT J
AU Cheng, SY
   Cipi, J
   Ma, S
   Hafler, BP
   Kanadia, RN
   Brush, RS
   Agbaga, MP
   Punzo, C
AF Cheng, Shun-Yun
   Cipi, Joris
   Ma, Shan
   Hafler, Brian P.
   Kanadia, Rahul N.
   Brush, Richard S.
   Agbaga, Martin-Paul
   Punzo, Claudio
TI Altered photoreceptor metabolism in mouse causes late stage age-related
   macular degeneration-like pathologies
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE AMD; photoreceptors; geographic atrophy; wet AMD; photoreceptor;
   metabolism
ID PIGMENT EPITHELIAL-CELLS; GEOGRAPHIC ATROPHY; AEROBIC GLYCOLYSIS;
   FATTY-ACIDS; CONE DEATH; MTOR; OMEGA-3-FATTY-ACIDS; TRANSLOCATION;
   RECURRENCE; SIROLIMUS
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. While the histopathology of the different disease stages is well characterized, the cause underlying the pro-gression, from the early drusen stage to the advanced macular degeneration stage that leads to blindness, remains unknown. Here, we show that photoreceptors (PRs) of diseased individuals display increased expression of two key glycolytic genes, sugges-tive of a glucose shortage during disease. Mimicking aspects of this metabolic profile in PRs of wild-type mice by activation of the mammalian target of rapamycin complex 1 (mTORC1) caused early drusen-like pathologies, as well as advanced AMD-like pa-thologies. Mice with activated mTORC1 in PRs also displayed other early disease features, such as a delay in photoreceptor outer seg-ment (POS) clearance and accumulation of lipofuscin in the retinal-pigmented epithelium (RPE) and of lipoproteins at the Bruch's membrane (BrM), as well as changes in complement accumulation. Interestingly, formation of drusen-like deposits was dependent on activation of mTORC1 in cones. Both major types of advanced AMD pathologies, including geographic atrophy (GA) and neovas-cular pathologies, were also seen. Finally, activated mTORC1 in PRs resulted in a threefold reduction in di-docosahexaenoic acid (DHA)-containing phospholipid species. Feeding mice a DHA-enriched diet alleviated most pathologies. The data recapitulate many as-pects of the human disease, suggesting that metabolic adaptations in photoreceptors could contribute to disease progression in AMD. Identifying the changes downstream of mTORC1 that lead to ad-vanced pathologies in mouse might present new opportunities to study the role of PRs in AMD pathogenesis.
C1 [Cheng, Shun-Yun; Cipi, Joris; Ma, Shan; Punzo, Claudio] Univ Massachusetts, Med Sch, Dept Ophthalmol & Visual Sci, Worcester, MA 01655 USA.
   [Hafler, Brian P.] Yale Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06510 USA.
   [Hafler, Brian P.] Yale Sch Med, Dept Pathol, New Haven, CT 06510 USA.
   [Kanadia, Rahul N.] Univ Connecticut, Dept Physiol & Neurobiol, Storrs, CT 06269 USA.
   [Brush, Richard S.; Agbaga, Martin-Paul] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   [Brush, Richard S.; Agbaga, Martin-Paul] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
   [Brush, Richard S.; Agbaga, Martin-Paul] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Oklahoma City, OK 73104 USA.
   [Brush, Richard S.; Agbaga, Martin-Paul] Univ Oklahoma, Hlth Sci Ctr, Dean A McGee Eye Inst, Oklahoma City, OK 73104 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; Yale University; Yale University; University of Connecticut;
   University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University of Oklahoma System; University of Oklahoma
   Health Sciences Center; University of Oklahoma System; University of
   Oklahoma Health Sciences Center
RP Punzo, C (通讯作者)，Univ Massachusetts, Med Sch, Dept Ophthalmol & Visual Sci, Worcester, MA 01655 USA.; Agbaga, MP (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.; Agbaga, MP (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA.; Agbaga, MP (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Oklahoma City, OK 73104 USA.; Agbaga, MP (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dean A McGee Eye Inst, Oklahoma City, OK 73104 USA.
EM martin-paul-agbaga@ouhsc.edu; Claudio.Punzo@umassmed.edu
RI Punzo, Claudio/AAJ-8291-2021
OI Punzo, Claudio/0000-0001-5207-0041
FU BrightFocus Foundation [M2017071]; NIH [R01: EY030513]; Oklahoma Center
   for Advancement of Science and Technology
FX We thank Markus Ruegg, Michael Hall, Yun Le, and Ching-Kang Chen for
   reagents. We thank Daryl Bosco, Hemant Khanna, Alexandra Byrne, and
   Dohoon Kim for discussions. We thank Chih-Yun Cheng for drawing the
   entire schematic of SI Appendix, Fig. S8. This work was supported by
   BrightFocus Foundation Grant M2017071 and NIH Grant R01: EY023570 (to
   C.P.); by the Oklahoma Center for Advancement of Science and Technology;
   and by NIH Grant R01: EY030513 (to M.-P.A.). We also thank DSM
   (https://www.dsm.com/corporate/home.html) for providing us the DHASCO
   used in this study.
CR Agbaga MP, 2018, J LIPID RES, V59, P1586, DOI 10.1194/jlr.M082495
   Bazan NG, 2018, MOL ASPECTS MED, V64, P18, DOI 10.1016/j.mam.2018.09.003
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chinchore Y, 2017, ELIFE, V6, DOI 10.7554/eLife.25946
   Chuang JZ, 2010, MOL BIOL CELL, V21, P3017, DOI 10.1091/mbc.E09-10-0907
   Dayton TL, 2016, EMBO REP, V17, P1721, DOI 10.15252/embr.201643300
   Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fisher Cody R., 2018, INVEST OPHTH VIS SCI, V59, P41, DOI DOI 10.1167/I0VS.18-24289
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Georgiou Tassos, 2015, J Stem Cells, V10, P205
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642
   Gutierrez S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205028
   Huang JC, 2019, THERANOSTICS, V9, P1170, DOI 10.7150/thno.26281
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Keeling E., 2018, CELLS, V7, pE16, DOI [10.20944/preprints201801.0269.v1, DOI 10.20944/PREPRINTS201801.0269.V1]
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Li F, 2001, J MOL NEUROSCI, V16, P205, DOI 10.1385/JMN:16:2-3:205
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021
   Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Petit L, 2018, CELL REP, V23, P2629, DOI 10.1016/j.celrep.2018.04.111
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Polchi A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051474
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Rajala A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0712-9
   Rajala A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0296-4
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rockenfeller P, 2015, CELL DEATH DIFFER, V22, P499, DOI 10.1038/cdd.2014.219
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   SCOTT BL, 1988, J NEUROSCI RES, V20, P202, DOI 10.1002/jnr.490200209
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108
   Venkatesh A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.182
   Venkatesh A, 2015, J CLIN INVEST, V125, P1446, DOI 10.1172/JCI79766
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yu B, 2014, INVEST OPHTH VIS SCI, V55, P8638, DOI 10.1167/iovs.14-14758
   Zieger M, 2016, ONCOTARGET, V7, P9620, DOI 10.18632/oncotarget.7330
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 58
TC 36
Z9 36
U1 1
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 1091-6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 9
PY 2020
VL 117
IS 23
BP 13094
EP 13104
DI 10.1073/pnas.2000339117
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MG3PN
UT WOS:000545946100017
PM 32434914
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU McLeod, DS
   Bhutto, I
   Edwards, MM
   Silver, RE
   Seddon, JM
   Lutty, GA
AF McLeod, D. Scott
   Bhutto, Imran
   Edwards, Malia M.
   Silver, Rachel E.
   Seddon, Johanna M.
   Lutty, Gerard A.
TI Distribution and Quantification of Choroidal Macrophages in Human Eyes
   With Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; choriocapillaris; choroidal
   neovascularization; choroidal vasculature; macrophages
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; BRUCHS MEMBRANE; DRUSEN; CELLS;
   RISK; POLARIZATION; MICROGLIA; INCREASES; ETIOLOGY
AB PURPOSE. Increasing evidence suggests a role for macrophages in the pathogenesis of age-related macular degeneration (AMD). This study examined choroidal macrophages and their activation in postmortem eyes from subjects with and without AMD.
   METHODS. Choroids were incubated with anti-ionized calcium-binding adapter molecule 1 (anti-IBA1) to label macrophages, anti-human leukocyte antigen-antigen D-related (anti-HLA-DR) as a macrophage activation marker, and Ulex europaeus agglutinin lectin to label blood vessels. Whole mounts were imaged using confocal microscopy. IBA1- and HLA-DR-positive (activated) cells were counted in submacula, paramacula, and nonmacula, and cell volume and sphericity were determined using computer-assisted image analysis.
   RESULTS. In aged control eyes, the mean number of submacular IBA1(+) and HLA-DR+ macrophages was 433/mm(2) and 152/mm(2), respectively. In early AMD eyes, there was a significant increase in IBA1(+) and HLA-DR+ cells in submacula compared to those in controls (P = 0.0015 and P = 0.008, respectively). In eyes with neovascular AMD, there were significantly more HLA-DR+ cells associated with submacular choroidal neovascularization (P = 0.001). Mean cell volume was significantly lower (P <= 0.02), and sphericity was significantly higher (P <= 0.005) in all AMD groups compared to controls.
   CONCLUSIONS. The average number of IBA1(+) macrophages in submacular and paramacular choroid was significantly higher in early/intermediate AMD compared to that in aged controls. HLA-DR+ submacular macrophages were significantly increased in all stages of AMD, and they were significantly more round and smaller in size in the submacular AMD choroid, suggesting their activation. These findings support the concept that AMD is an inflammatory disease.
C1 [McLeod, D. Scott; Bhutto, Imran; Edwards, Malia M.; Lutty, Gerard A.] Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 North Broadway, Baltimore, MD 21287 USA.
   [Silver, Rachel E.; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Tufts Medical Center;
   Tufts University
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 North Broadway, Baltimore, MD 21287 USA.
EM glutty@jhmi.edu
FU National Institutes of Health [EY-01765, R01-EY016151, RO1 EY08552];
   Research to Prevent Blindness; Macular Degeneration Research Fund, Tufts
   Medical Center, Tufts University School of Medicine (Boston, MA, USA);
   Arnold and Mabel Beckman Foundation; Foundation Fighting Blindness;
   Bright Focus Foundation; Altsheler Durell Foundation; RPB Senior
   Scientific Investigator Award; NATIONAL EYE INSTITUTE [R01EY016151,
   P30EY001765] Funding Source: NIH RePORTER
FX Supported by National Institutes of Health Grants EY-01765 (Wilmer),
   R01-EY016151 (GAL), and RO1 EY08552 (JMS), unrestricted funds from
   Research to Prevent Blindness (Wilmer and Tufts Medical Center), the
   Macular Degeneration Research Fund, Tufts Medical Center, Tufts
   University School of Medicine (Boston, MA, USA) (JMS), the Arnold and
   Mabel Beckman Foundation (GAL and JMS), the Foundation Fighting
   Blindness (GAL and JMS), Bright Focus Foundation (IB), and the Altsheler
   Durell Foundation. GAL received an RPB Senior Scientific Investigator
   Award in 2008.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Condren AB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053386
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He LZ, 2014, J BIOL CHEM, V289, P8019, DOI 10.1074/jbc.M113.535765
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kumar A, 2014, INVEST OPHTH VIS SCI, V55, P1787, DOI 10.1167/iovs.13-13522
   Lahat N, 2011, TRANSPL INT, V24, P1018, DOI 10.1111/j.1432-2277.2011.01304.x
   Liddiard K, 2015, NAT MED, V21, P119, DOI 10.1038/nm.3798
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McWhorter FY, 2013, P NATL ACAD SCI USA, V110, P17253, DOI 10.1073/pnas.1308887110
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Riboldi E, 2013, INT IMMUNOL, V25, P67, DOI 10.1093/intimm/dxs110
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
NR 44
TC 58
Z9 59
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2016
VL 57
IS 14
BP 5843
EP 5855
DI 10.1167/iovs.16-20049
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI3HG
UT WOS:000392380000001
PM 27802514
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rogala, J
   Zangerl, B
   Assaad, N
   Fletcher, EL
   Kalloniatis, M
   Nivison-Smith, L
AF Rogala, James
   Zangerl, Barbara
   Assaad, Nagi
   Fletcher, Erica L.
   Kalloniatis, Michael
   Nivison-Smith, Lisa
TI In Vivo Quantification of Retinal Changes Associated With Drusen in
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE drusen; age-related macular degeneration; optical coherence tomography;
   retinal thickness
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL IMPAIRMENT; VISION LOSS;
   PREVALENCE; THICKNESS; EYES; ROD; CLASSIFICATION; VULNERABILITY;
   SEGMENTATION
AB PURPOSE. Drusen alters retinal architecture in early age-related macular degeneration (AMD). However, abnormalities also may exist in drusen-free areas of the AMD retina. This study examines retinal thickness above drusen relative to drusen-free areas in the same patient and a normal population.
   METHODS. Patients with early to intermediate AMD (n = 122) or no disease (n = 30) were examined at the Center for Eye Health. Spectral domain optical coherence tomography (SDOCT) scans through single, isolated druse (n = 125) or confluent drusen (n = 54) were obtained. The thickness of individual retinal layers was measured above the druse and in a drusen-free area, 150 lm from the drusen edge.
   RESULTS. Intraeye comparisons found total retinal thickness above drusen was 16 +/- 0.6% less than drusen-free areas. Thinning was mostly in the retinal pigment epithelium/photoreceptor layer (32 +/- 1% reduction) and the outer nuclear layer (22 +/- 1% reduction). Confluent drusen showed similar thinning of the outer retina as well as inner retina loss (5%). Thinning was strongly correlated with drusen height, but only modestly correlated with drusen width. When compared to the normal population, retinal thickness above drusen and drusen-free areas were significantly reduced.
   CONCLUSIONS. We confirm outer retina thinning above drusen in early/intermediate AMD compared to drusen-free areas in the same retina or a normal population. Interestingly, drusen-free areas in AMD patients were not the same as control patients suggesting `` normal'' areas of the AMD retina are abnormal. The strong correlation between retinal thinning and drusen height, rather than width, suggests current grading systems for AMD may need refinement.
C1 [Rogala, James] Western Univ Hlth Sci, Coll Optometry, Pomona, CA USA.
   [Rogala, James; Zangerl, Barbara; Assaad, Nagi; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New S Wales, Ctr Eye Hlth, Sydney, NSW 2052, Australia.
   [Zangerl, Barbara; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
   [Assaad, Nagi] Prince Wales Hosp, Dept Ophthalmol, Randwick, NSW 2031, Australia.
   [Fletcher, Erica L.; Kalloniatis, Michael] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia.
C3 Western University of Health Sciences; University of New South Wales
   Sydney; University of New South Wales Sydney; University of Melbourne
RP Nivison-Smith, L (通讯作者)，Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
EM l.nivison-smith@unsw.edu.au
RI Zangerl, Barbara/K-7433-2016; Nivison-Smith, Lisa/H-3297-2019; Fletcher,
   Erica/E-6364-2012
OI Zangerl, Barbara/0000-0002-7470-6298; Fletcher,
   Erica/0000-0001-9412-9523; Nivison-Smith, Lisa/0000-0001-6677-1949;
   Kalloniatis, Michael/0000-0002-5264-4639
FU National Health and Medical Research Council of Australia [1033224];
   University of New South Wales Early Career Research Grant [PS35430]
FX Supported in part by research grants from the National Health and
   Medical Research Council of Australia (#1033224) and the University of
   New South Wales Early Career Research Grant 2014 (#PS35430). The authors
   alone are responsible for the content and writing of the paper.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   Chua J, 2009, J COMP NEUROL, V514, P473, DOI 10.1002/cne.22029
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Jamous KF, 2015, CLIN EXP OPHTHALMOL, V43, P308, DOI 10.1111/ceo.12466
   Jeganathan VSE, 2009, CURR OPIN OPHTHALMOL, V20, P223, DOI 10.1097/ICU.0b013e328329b656
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lim MCC, 2005, INVEST OPHTH VIS SCI, V46, P974, DOI 10.1167/iovs.04-0828
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Obata R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091873
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Sadigh S, 2014, CURR EYE RES, P1
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Song WK, 2010, INVEST OPHTH VIS SCI, V51, P3913, DOI 10.1167/iovs.09-4189
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Sun D, 2007, J COMP NEUROL, V505, P114, DOI 10.1002/cne.21481
   Sunness JS, 1999, MOL VIS, V5
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
NR 58
TC 30
Z9 32
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2015
VL 56
IS 3
BP 1689
EP 1700
DI 10.1167/iovs.14-16221
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE9BF
UT WOS:000352137600040
PM 25670493
DA 2022-11-30
ER

PT J
AU Tam, POS
   Ng, TK
   Liu, DTL
   Chan, WM
   Chiang, SWY
   Chen, LJ
   Dewan, A
   Hoh, J
   Lam, DSC
   Pang, CP
AF Tam, Pancy O. S.
   Ng, Tsz Kin
   Liu, David T. L.
   Chan, Wai Man
   Chiang, Sylvia W. Y.
   Chen, Li Jia
   DeWan, Andrew
   Hoh, Josephine
   Lam, Dennis S. C.
   Pang, Chi Pui
TI HTRA1 variants in exudative age-related macular degeneration and
   interactions with smoking and CFH
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT-FACTOR-H; BODY-MASS INDEX; CIGARETTE-SMOKING; SUSCEPTIBILITY
   LOCI; JAPANESE POPULATION; GENOMEWIDE-SCAN; ENVIRONMENTAL ASSOCIATIONS;
   PROMOTER POLYMORPHISM; FAMILIAL AGGREGATION; GENE POLYMORPHISM
AB PURPOSE. Mapping the genes for age-related macular degeneration (AMD) had not been successful until recent genome-wide association studies revealed Tyr402His in CFH and rs11200638 in HTRA1 as AMD-related genetic variants. This study was conducted to identify other critical factors in HTRA1 that are associated with exudative AMD.
   METHODS. The promoter, splice regions, and coding exons of HTRA1 were sequenced in 163 patients with exudative AMD and 183 sex- and age-matched control subjects. Also documented were the CFH genotype and smoking status.
   RESULTS. Four significant SNPs were found in the promoter and the first exon of HTRA1: rs11200638 (-625G>A), rs2672598 (-487T>C), rs1049331 (102C>T, Ala34Ala), and rs2293870 (108G>T, Gly36Gly) with respective P = 1.7 x 10(-14), 3.0 x 10(-10), 3.7 x 10(-12), and 3.7 x 10(-12). Among them, rs11200638 is the most significant associated SNP with a high odds ratio (OR) of 7.6 (95% CI: 3.94-14.51). One risk haplotype block across the promoter and exon 1, ACCTT, significantly predisposes to AMD (P = 6.68 x 10(-14)). In both models, significant independent additive effects were identified with smoking and rs800292 (184G>A, Val62Ile) of CFH. Smoking and rs11200638 (HTRA1) combined caused a 15.7-fold increased risk, whereas combined rs800292 and rs11200638 caused a 23.3-fold increased risk. An extremely high population attributable risk (PAR) of 78% was also found.
   CONCLUSIONS. A high impact of the additive effect of CFH and HTRA1 in the development of exudative AMD was shown. The HTRA1-smoking additive effect found in this study further suggests the importance of this environmental risk factor in AMD.
C1 [Pang, Chi Pui] Chinese Univ Hong Kong, Univ Eye Ctr, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
   [DeWan, Andrew; Hoh, Josephine] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
C3 Chinese University of Hong Kong; Yale University
RP Pang, CP (通讯作者)，Chinese Univ Hong Kong, Univ Eye Ctr, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk
RI Ng, Tsz Kin/I-8061-2014; Pang, Chi P/I-5388-2014; Lam,
   Dennis/AAL-1211-2020; Chen, Li Jia/I-5078-2014
OI Ng, Tsz Kin/0000-0001-7863-7229; Chen, Li Jia/0000-0003-3500-5840;
   DeWan, Andrew/0000-0002-7679-8704
FU NATIONAL EYE INSTITUTE [R21EY018127] Funding Source: NIH RePORTER; NEI
   NIH HHS [R21 EY018127-02] Funding Source: Medline
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen LJ, 2006, MOL VIS, V12, P1536
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Mitchell P, 1999, MED J AUSTRALIA, V171, P173, DOI 10.5694/j.1326-5377.1999.tb123591.x
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   North BV, 2005, HUM HERED, V59, P79, DOI 10.1159/000085222
   O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001
   Okamoto H, 2006, MOL VIS, V12, P156
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
NR 45
TC 64
Z9 68
U1 1
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2008
VL 49
IS 6
BP 2357
EP 2365
DI 10.1167/iovs.07-1520
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 307GG
UT WOS:000256306800009
PM 18316707
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Strafella, C
   Caputo, V
   Termine, A
   Fabrizio, C
   Ruffo, P
   Potenza, S
   Cusumano, A
   Ricci, F
   Caltagirone, C
   Giardina, E
   Cascella, R
AF Strafella, Claudia
   Caputo, Valerio
   Termine, Andrea
   Fabrizio, Carlo
   Ruffo, Paola
   Potenza, Saverio
   Cusumano, Andrea
   Ricci, Federico
   Caltagirone, Carlo
   Giardina, Emiliano
   Cascella, Raffaella
TI Genetic Determinants Highlight the Existence of Shared Etiopathogenetic
   Mechanisms Characterizing Age-Related Macular Degeneration and
   Neurodegenerative Disorders
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE age-related macular degeneration; neurodegenerative disorders;
   etiopathogenesis; susceptibility; miRNAs; genetic network
ID ALZHEIMERS-DISEASE; PRECISION MEDICINE; POLYMORPHISMS; RISK;
   INFLAMMATION; MICROGLIA; ALLELES; RETINA; BRAIN; FOCUS
AB Age-related macular degeneration (AMD) showed several processes and risk factors in common with neurodegenerative disorders (NDDs). The present work explored the existence of genetic determinants associated with AMD, which may provide insightful clues concerning its relationship with NDDs and their possible application into the clinical practice. In this study, 400 AMD patients were subjected to the genotyping analysis of 120 genetic variants by OpenArray technology. As the reference group, 503 samples representative of the European general population were utilized. Statistical analysis revealed the association of 23 single-nucleotide polymorphisms (SNPs) with AMD risk. The analysis of epistatic effects revealed that ARMS2, IL6, APOE, and IL2RA could contribute to AMD and neurodegenerative processes by synergistic modulation of the expression of disease-relevant genes. In addition, the bioinformatic analysis of the associated miRNA variants highlighted miR-196a, miR-6796, miR-6499, miR-6810, miR-499, and miR-7854 as potential candidates for counteracting AMD and neurodegenerative processes. Finally, this work highlighted the existence of shared disease mechanisms (oxidative stress, immune-inflammatory response, mitochondrial dysfunction, axonal guidance pathway, and synaptogenesis) between AMD and NDDs and described the associated SNPs as candidate biomarkers for developing novel strategies for early diagnosis, monitoring, and treatment of such disorders in a progressive aging population.
C1 [Strafella, Claudia; Caputo, Valerio; Termine, Andrea; Fabrizio, Carlo; Ruffo, Paola; Giardina, Emiliano] IRCCS Santa Lucia Fdn, Genom Med Lab UILDM, Rome, Italy.
   [Strafella, Claudia; Caputo, Valerio; Giardina, Emiliano; Cascella, Raffaella] Tor Vergata Univ, Dept Biomed & Prevent, Med Genet Lab, Rome, Italy.
   [Potenza, Saverio] Tor Vergata Univ, Dept Biomed & Prevent, Rome, Italy.
   [Cusumano, Andrea] UOSD Ophthalmol PTV Fdn, Policlin Tor Vergata, Rome, Italy.
   [Ricci, Federico] PTV Fdn, Policlin Tor Vergata, Unit Retinal Dis, Rome, Italy.
   [Caltagirone, Carlo] IRCCS Fdn Santa Lucia, Dept Clin & Behav Neurol, Rome, Italy.
   [Cascella, Raffaella] Catholic Univ Our Lady Good Counsel, Dept Biomed Sci, Tirana, Albania.
C3 IRCCS Santa Lucia; University of Rome Tor Vergata; University of Rome
   Tor Vergata; University of Rome Tor Vergata; Policlin Tor Vergata;
   University of Rome Tor Vergata; Policlin Tor Vergata; IRCCS Santa Lucia
RP Strafella, C (通讯作者)，IRCCS Santa Lucia Fdn, Genom Med Lab UILDM, Rome, Italy.; Strafella, C (通讯作者)，Tor Vergata Univ, Dept Biomed & Prevent, Med Genet Lab, Rome, Italy.
EM claudia.strafella@gmail.com
RI Fabrizio, Carlo/GYA-1274-2022; Caputo, Valerio/AAB-6481-2019; Fabrizio,
   Carlo/ABF-3261-2021; Termine, Andrea/AAC-2253-2022; Giardina,
   Emiliano/J-1965-2012; Ruffo, Paola/ABB-6376-2021
OI Fabrizio, Carlo/0000-0002-7824-8423; Caputo,
   Valerio/0000-0002-3503-3318; Fabrizio, Carlo/0000-0002-7824-8423;
   Termine, Andrea/0000-0003-4374-7430; Ruffo, Paola/0000-0001-6246-5901
FU Project MUSA CNR [FOE 2019]
FX This work was supported by Project MUSA CNR (FOE 2019).
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bachiller S, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00488
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bhattacharya A, 2014, NUCLEIC ACIDS RES, V42, pD86, DOI 10.1093/nar/gkt1028
   Bossu P, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00632
   Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120
   Cascella R, 2018, EYE, V32, P446, DOI 10.1038/eye.2017.192
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Cascella R, 2017, ONCOTARGET, V8, P95401, DOI 10.18632/oncotarget.20727
   Cascella R, 2015, J AM ACAD DERMATOL, V73, P528, DOI 10.1016/j.jaad.2015.06.022
   Choi S, 2020, AM J OPHTHALMOL, V210, P41, DOI 10.1016/j.ajo.2019.11.001
   Cukier H N, 2017, J Alzheimers Dis Parkinsonism, V7, DOI 10.4172/2161-0460.1000355
   Devyatkin VA, 2020, J ALZHEIMERS DIS, V73, P1167, DOI 10.3233/JAD-190956
   Docampo E, 2011, ARTHRITIS RHEUM-US, V63, P1860, DOI 10.1002/art.30340
   Fink KL, 2017, CELL REP, V18, P2687, DOI 10.1016/j.celrep.2017.02.058
   Franceschi C, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00061
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Giardina E, 2004, ANN HUM GENET, V68, P639, DOI 10.1046/j.1529-8817.2004.00118.x
   Gorlov IP, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005371
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Gruber AR, 2008, NUCLEIC ACIDS RES, V36, pW70, DOI 10.1093/nar/gkn188
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Kehl T, 2020, NUCLEIC ACIDS RES, V48, pD142, DOI 10.1093/nar/gkz1022
   Kido T, 2018, BMC MED GENOMICS, V11, DOI 10.1186/s12920-018-0322-5
   Kuhn M, 2020, **DATA OBJECT**
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Lin KJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215312
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Lumsden AL, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102954
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Malik M, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0048-1
   Masuzzo A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00127
   Moos WH, 2017, BIORESEARCH OPEN ACC, V6, P169, DOI 10.1089/biores.2017.0036
   O'Day DH, 2019, AIMS NEUROSCI, V6, P231, DOI 10.3934/Neuroscience.2019.4.231
   Prestoz L, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00032
   Rashmi KV, 2015, JMLR WORKSH CONF PRO, V38, P489
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   SanGiovanni JP, 2017, CLIN CHEM LAB MED, V55, P763, DOI 10.1515/cclm-2016-0898
   Storey JD., 2019, QVALUE Q VALUE ESTIM
   Strafella C, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3457898
   Strafella C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071578
   Strafella C, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00701
   Sun R, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0638-9
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Team RC. R, 2013, R CORE TEAM R LANGUA, DOI DOI 10.1890/0012-9658(2002)083[3097:CFHIWS]2.0.CO;2
   Yu SS, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00119
   Zhang D, 2018, **DATA OBJECT**
NR 56
TC 8
Z9 8
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD MAY 31
PY 2021
VL 12
AR 626066
DI 10.3389/fneur.2021.626066
PG 12
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA SR5RT
UT WOS:000661100100001
PM 34135841
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ochinciuc, R
   Balta, F
   Branisteanu, DC
   Burcea, M
   Zemba, M
   Ochinciuc, U
   Barac, R
AF Ochinciuc, Radu
   Balta, Florian
   Branisteanu, Daniel Constantin
   Burcea, Marian
   Zemba, Mihail
   Ochinciuc, Uliana
   Barac, Ramona
TI Subretinal alteplase injections in massive subretinal hemorrhage due to
   age-related macular degeneration: A case report series
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE subretinal injection; subretinal hemorrhage; alteplase; age-related
   macular degeneration
ID TISSUE-PLASMINOGEN-ACTIVATOR; RETINAL TOXICITY
AB This report describes a series of cases with massive subretinal hemorrhage (SRH) due to age-related macular degeneration (AMD) treated by subretinal alteplase injections. In all cases, the surgical technique consisted in 25-gauge pars plana vitrectomy (PPV) and alteplase injection under the retina using a 38-gauge cannula. After the fluid-gas exchange, bevacizumab injection was performed in all patients. Three cases of SRH in which this technique was used, as well as their evolution at one week and one month postoperatively are described. Visual acuity was hand motion in all three cases at presentation. After surgery, a significant anatomical and functional improvement was noted in all cases. One month postoperatively, none of the patients had blood under the macula, and visual acuities significantly improved to 0.8, 0.2 and 0.16 (decimal fraction). A consistent reduction of central retinal thickness was observed on optical coherence tomography (OCT) from the first week postoperatively. No intra and postoperative complications were noted. Subretinal alteplase injection proved as a viable solution in these severe SRH with early presentation. There was no need to change the systemic anticoagulant and antiaggregant therapy. Bevacizumab intravitreal injection at the end of surgery has an important role in preventing further bleeding.
C1 [Ochinciuc, Radu] Victor Babes Univ Med & Pharm, Dept Ophthalmol, Timisoara 300041, Romania.
   [Balta, Florian; Burcea, Marian; Zemba, Mihail; Barac, Ramona] Carol Davila Univ Med & Pharm, Dept Ophthalmol, 37 Dionisie Lupu St, Bucharest 050474, Romania.
   [Branisteanu, Daniel Constantin] Grigore T Popa Univ Med & Pharm, Dept Ophthalmol, 16 Univ St, Iasi 700115, Romania.
   [Ochinciuc, Uliana] Dr Carol Davila Cent Mil Emergency Univ Hosp, Dept Ophthalmol, Bucharest 010825, Romania.
C3 Victor Babes University of Medicine & Pharmacy, Timisoara; Carol Davila
   University of Medicine & Pharmacy; Grigore T Popa University of Medicine
   & Pharmacy
RP Balta, F (通讯作者)，Carol Davila Univ Med & Pharm, Dept Ophthalmol, 37 Dionisie Lupu St, Bucharest 050474, Romania.; Branisteanu, DC (通讯作者)，Grigore T Popa Univ Med & Pharm, Dept Ophthalmol, 16 Univ St, Iasi 700115, Romania.
EM florian.balta@umfcd.ro; daniel.branisteanu@umfiasi.ro
RI Branisteanu, Daniel Constantin/AGZ-3495-2022; Burcea,
   Marian/AAZ-2644-2021
CR Chintala SK, 2016, EXP EYE RES, V143, P17, DOI 10.1016/j.exer.2015.10.003
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Harvison P.J, 2007, XPHARM COMPREHENSIVE, P1
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Lee JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186272
   Maranduca MA, 2019, ONCOL LETT, V17, P4183, DOI 10.3892/ol.2019.10071
   Michel P, 2019, ALTEPLASE RECOMBINAN
   Moraru AD, 2020, EXP THER MED, V20, P3528, DOI 10.3892/etm.2020.9094
   Munteanu M, 2019, INT OPHTHALMOL, V39, P461, DOI 10.1007/s10792-018-0822-5
   Novelli FJD, 2017, RETINA-J RET VIT DIS, V37, P1607, DOI 10.1097/IAE.0000000000001491
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Stanca HT, 2019, EXP THER MED, V18, P4993, DOI 10.3892/etm.2019.7858
   Stanca HT, 2014, VOJNOSANIT PREGL, V71, P1072, DOI 10.2298/VSP130511056S
NR 15
TC 2
Z9 2
U1 1
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD DEC
PY 2020
VL 20
IS 6
AR 208
DI 10.3892/etm.2020.9338
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA OZ9VS
UT WOS:000595267100085
PM 33123237
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Miura, M
   Makita, S
   Sugiyama, S
   Hong, YJ
   Yasuno, Y
   Elsner, AE
   Tamiya, S
   Tsukahara, R
   Iwasaki, T
   Goto, H
AF Miura, Masahiro
   Makita, Shuichi
   Sugiyama, Satoshi
   Hong, Young-Joo
   Yasuno, Yoshiaki
   Elsner, Ann E.
   Tamiya, Shigeo
   Tsukahara, Rintaro
   Iwasaki, Takuya
   Goto, Hiroshi
TI Evaluation of intraretinal migration of retinal pigment epithelial cells
   in age-related macular degeneration using polarimetric imaging
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; HYPERREFLECTIVE FOCI; IN-VIVO; GEOGRAPHIC
   ATROPHY; MESENCHYMAL TRANSITION; EPIRETINAL MEMBRANE; VEIN OCCLUSION;
   OUTER RETINA; MELANIN; AUTOFLUORESCENCE
AB The purpose of the present study was to evaluate the intraretinal migration of the retinal pigment epithelium (RPE) cells in age-related macular degeneration (AMD) using polarimetry. We evaluated 155 eyes at various AMD stages. Depolarized light images were computed using a polarization-sensitive scanning laser ophthalmoscope (PS-SLO), and the degree of polarization uniformity was calculated using polarization-sensitive optical coherence tomography (OCT). Each polarimetry image was compared with the corresponding autofluorescence (AF) images at 488 nm (SW-AF) and at 787 nm (NIR-AF). Intraretinal RPE migration was defined by the presence of depolarization at intraretinal hyperreflective foci on PS-SLO and PS-OCT images, and by the presence of hyper-AF on both NIR-AF and SW-AF images. RPE migration was detected in 52 of 155 eyes (33.5%) and was observed in drusenoid pigment epithelial detachment (PED) and serous PED with significantly higher frequencies than in other groups (P = 0.015). The volume of the migrated RPE cluster in serous PED was significantly correlated with the volume of the PED (R-2 = 0.26; P = 0.011). Overall, our results showed that intraretinal RPE migrations occurred in various AMD stages, and that they occurred more commonly in eyes with serous and drusenoid PED.
C1 [Miura, Masahiro; Tsukahara, Rintaro; Iwasaki, Takuya] Tokyo Med Univ, Dept Ophthalmol, Ibaraki Med Ctr, Ami, Ibaraki, Japan.
   [Miura, Masahiro; Tsukahara, Rintaro; Iwasaki, Takuya] Tokyo Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Makita, Shuichi; Sugiyama, Satoshi; Hong, Young-Joo; Yasuno, Yoshiaki] Univ Tsukuba, Computat Opt Grp, Tsukuba, Ibaraki, Japan.
   [Sugiyama, Satoshi] Tomey Corp, Nagoya, Aichi, Japan.
   [Elsner, Ann E.] Indiana Univ, Sch Optometry, Bloomington, IN USA.
   [Tamiya, Shigeo] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
C3 Tokyo Medical University; Tokyo Medical University; University of
   Tsukuba; Indiana University System; Indiana University Bloomington;
   University of Louisville
RP Miura, M (通讯作者)，Tokyo Med Univ, Dept Ophthalmol, Ibaraki Med Ctr, Ami, Ibaraki, Japan.; Miura, M (通讯作者)，Tokyo Med Univ, Dept Ophthalmol, Tokyo, Japan.
EM m-miura@tokyo-med.ac.jp
RI Makita, Shuichi/G-3806-2011; Yasuno, Yoshiaki/F-2586-2011
OI Makita, Shuichi/0000-0002-6614-3640; Yasuno,
   Yoshiaki/0000-0003-1645-7948; Tamiya, Shigeo/0000-0003-0234-2664
FU KAKENHI [15K10905]; Japan Science and Technology Agency through a
   program of the Development of Systems and Technology for Advanced
   Measurement and Analysis; Research to Prevent Blindness, New York, NY,
   USA; NATIONAL EYE INSTITUTE [R41EY026105] Funding Source: NIH RePORTER
FX This project was supported in part by KAKENHI (15K10905), Research to
   Prevent Blindness, New York, NY, USA, and the Japan Science and
   Technology Agency through a program of the Development of Systems and
   Technology for Advanced Measurement and Analysis.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augustin M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164419
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Baumann B, 2015, INVEST OPHTH VIS SCI, V56, P7462, DOI 10.1167/iovs.15-17742
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Boulton ME, 2014, EXP EYE RES, V126, P61, DOI 10.1016/j.exer.2014.01.016
   Burns SA, 2003, INVEST OPHTH VIS SCI, V44, P4061, DOI 10.1167/iovs.03-0124
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hogg PA, 2002, INVEST OPHTH VIS SCI, V43, P2749
   Hong YJ, 2014, INVEST OPHTH VIS SCI, V55, P5016, DOI 10.1167/iovs.14-14005
   Huang ZW, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2204007
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Ju MJ, 2013, OPT EXPRESS, V21, P19412, DOI 10.1364/OE.21.019412
   Kang JW, 2014, GRAEF ARCH CLIN EXP, V252, P1413, DOI 10.1007/s00417-014-2595-5
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Kuroda M, 2014, CLIN OPHTHALMOL, V8, P435, DOI 10.2147/OPTH.S58164
   Lammer J, 2014, INVEST OPHTH VIS SCI, V55, P1564, DOI 10.1167/iovs.13-13539
   Lim Y, 2012, OPT LETT, V37, P1958, DOI 10.1364/OL.37.001958
   Makita S, 2014, OPT LETT, V39, P6783, DOI 10.1364/OL.39.006783
   Malamos P, 2011, RETINA-J RET VIT DIS, V31, P453, DOI 10.1097/IAE.0b013e3181eef031
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Miura M, 2005, AM J OPHTHALMOL, V140, P1014, DOI 10.1016/j.ajo.2005.06.033
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Miura M, 2007, J OPT SOC AM A, V24, P1431, DOI 10.1364/JOSAA.24.001431
   Nishijima K, 2014, RETINA-J RET VIT DIS, V34, P732, DOI 10.1097/IAE.0000000000000005
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   PRAKASH YS, 1994, NEUROIMAGE, V1, P325, DOI 10.1006/nimg.1994.1017
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schmitz-Valckenberg S, 2011, BRIT J OPHTHALMOL, V95, P1134, DOI 10.1136/bjo.2010.189498
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Sugiyama S, 2015, BIOMED OPT EXPRESS, V6, P4951, DOI 10.1364/BOE.6.004951
   Tamiya S, 2016, EXP EYE RES, V142, P26, DOI 10.1016/j.exer.2015.02.008
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
NR 63
TC 36
Z9 36
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 9
PY 2017
VL 7
AR 3150
DI 10.1038/s41598-017-03529-8
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EX1CM
UT WOS:000402957400031
PM 28600515
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mori, K
   Gehlbach, PL
   Nishiyama, Y
   Yoneya, S
AF Mori, K
   Gehlbach, PL
   Nishiyama, Y
   Yoneya, S
TI Decreased arterial dye-filling and venous dilation in the macular
   choroid associated with age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; indocyanine green angiography;
   arterial dye-filling; venous dilation; choroidal perfusion
ID INDOCYANINE GREEN ANGIOGRAPHY; SYSTEMIC VASCULAR-DISEASE; BRUCHS
   MEMBRANE; NEOVASCULARIZATION
AB Purpose: To compare the angioarchitecture of choroidal arteries and veins in patients with age-related macular degeneration (AMD) to the angioarchitecture of age-matched normal subjects using indocyanine green (ICG) angiography.
   Methods: ICG angiography was performed in 35 consecutive AMD patients and 18 normal age-matched volunteers with a fundus ICG camera. ICG video images, including the arterial and venous phases, were quantitatively analyzed using image analyzing software.
   Results: In patients with AMD, the choroidal arterioles are dilated, fewer, run a straighter course, and possess fewer bifurcations. The number of choroidal arteries and the macular fluorescent intensity in the arterial phase of choroidal filling was significantly less in patients with AMD as compared to age-matched normal controls (P=0.008). The mean and maximum caliber of choroidal veins in the macula was dilated in AMD eyes than in age-matched normal control eyes (P<0.001). There was no statistically significant difference in arterial dye filling or venous caliber observed in AMD eyes, with or without choroidal neovascular membrane (CNV).
   Conclusion: Choroidal arterial perfusion in the macula was significant decreased in eyes with AMD with and without CNV, and was associated with choroidal venous dilation. These observations implicate poor choroidal perfusion of the macula in the pathogenesis of AMD.
C1 Saitama Med Sch, Dept Ophthalmol, Moroyama, Saitama 3500495, Japan.
   Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 Saitama Medical University; Johns Hopkins University; Johns Hopkins
   Medicine
RP Mori, K (通讯作者)，Saitama Med Sch, Dept Ophthalmol, 37 Morohongo, Moroyama, Saitama 3500495, Japan.
EM keisuke@saitama-med.ac.jp
CR BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Ciulla TA, 1998, AM J OPHTHALMOL, V126, P153
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   GREEN WR, 1997, INDOCYANINE GREEN AN, P151
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lutty G, 1999, MOL VIS, V5
   Mori K, 2004, OPHTHALMOLOGY, V111, P507, DOI 10.1016/j.ophtha.2003.06.009
   Mori K, 2002, RETINA-J RET VIT DIS, V22, P309, DOI 10.1097/00006982-200206000-00009
   Nishiyama Y, 2001, RETINA-J RET VIT DIS, V21, P237, DOI 10.1097/00006982-200106000-00007
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Yoneya S, 1998, INVEST OPHTH VIS SCI, V39, P1286
   Yoneya S, 1998, RETINA-J RET VIT DIS, V18, P30
NR 19
TC 13
Z9 14
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2005
VL 25
IS 4
BP 430
EP 437
DI 10.1097/00006982-200506000-00006
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 008AN
UT WOS:000235012700006
PM 15933588
DA 2022-11-30
ER

PT J
AU Khademloo, E
   Kadhodaeian, HA
   Jameie, SB
   Farhadi, M
   Saeidian, H
AF Khademloo, Elham
   Kadhodaeian, Hamid Aboutaleb
   Jameie, Seyed Behnamodin
   Farhadi, Mona
   Saeidian, Hamid
TI A detailed density functional theory investigation on physicochemical
   properties of ciclopirox derivatives: A potential candidate for
   prevention of age-related macular degeneration
SO JOURNAL OF MOLECULAR STRUCTURE
LA English
DT Article
DE Ciclopirox; DFT calculation; Aromaticity; Lipophilicity; Antioxidant;
   NBO analysis; Cation affinity
ID INDEPENDENT CHEMICAL-SHIFTS; DFT CALCULATIONS; INDEX; STABILITY;
   ENERGIES; REDOX; NICS
AB Structural, electronic and spectral data such as intramolecular hydrogen bonding interaction, HOMO, LUMO energies, reactivity indices, molecular electrostatic potential maps, aromaticity indices,(HNMR)-H- 1 and (CNMR)-C-13 of ciclopirox derivatives 1-7 as antifungal agents and efficient compounds for treatment and prevention of age-related macular degeneration were calculated using B3LYP/6-311 + G(d, p) method and in-terpreted in detail. Their antioxidant properties were also investigated by three mechanisms. The results show that the antioxidant activity of ciclopirox derivatives 1-7 is higher than phenol as the reference molecule. Finally, the interaction of ciclopirox 3 with metals cations Mn + was investigated by DFT calculations. The calculated cation affinity for 3 increases as Cu + < Fe2+< Cu2+ < Fe3 +. Cation affinity is strongly dependent on the charge-to-size ratio of the Mn +.(c) 2022 Elsevier B.V. All rights reserved.
C1 [Khademloo, Elham] Islamic Azad Univ, Dept Chem, Sci & Res Branch, Tehran, Iran.
   [Kadhodaeian, Hamid Aboutaleb] Semnan Univ Med Sci, Nervous Syst Stem Cell Res Ctr, Semnan, Iran.
   [Kadhodaeian, Hamid Aboutaleb] Semnan Univ Med Sci, Sch Med, Dept Anat Sci, Semnan, Iran.
   [Jameie, Seyed Behnamodin; Farhadi, Mona] Iran Univ Med Sci, Neurosci Res Ctr, Tehran, Iran.
   [Saeidian, Hamid] Payame Noor Univ PNU, Dept Sci, POB 19395 3697, Tehran, Iran.
C3 Islamic Azad University; Semnan University of Medical Sciences; Semnan
   University of Medical Sciences; Iran University of Medical Sciences;
   Payame Noor University
RP Kadhodaeian, HA (通讯作者)，Semnan Univ Med Sci, Nervous Syst Stem Cell Res Ctr, Semnan, Iran.; Saeidian, H (通讯作者)，Payame Noor Univ PNU, Dept Sci, POB 19395 3697, Tehran, Iran.
EM haboutaleb@semums.ac.ir; Saeidian1980@pnu.ac.ir
RI kadkhodaeian, Hamid Aboutaleb/K-7997-2017
OI kadkhodaeian, Hamid Aboutaleb/0000-0002-9736-9722
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Ahmadi MS, 2012, STRUCT CHEM, V23, P613, DOI 10.1007/s11224-011-9906-9
   Aihara J, 1999, J PHYS CHEM A, V103, P7487, DOI 10.1021/jp990092i
   Antolovich M, 2002, ANALYST, V127, P183, DOI 10.1039/b009171p
   Cai H, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.04.009
   Chen ZF, 2005, CHEM REV, V105, P3842, DOI 10.1021/cr030088+
   Cohen AJ, 2008, SCIENCE, V321, P792, DOI 10.1126/science.1158722
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Demidchik V, 2015, ENVIRON EXP BOT, V109, P212, DOI 10.1016/j.envexpbot.2014.06.021
   DiLabio GA, 1999, J PHYS CHEM A, V103, P1653, DOI 10.1021/jp984369a
   Dmitry B., 2014, PHYSIOL REV, V94, P909, DOI [10.1152/physrev.00026.2013, DOI 10.1152/PHYSREV.00026.2013]
   Domingo LR, 2016, MOLECULES, V21, DOI 10.3390/molecules21060748
   Domingo LR, 2013, J ORG CHEM, V78, P2462, DOI 10.1021/jo3027017
   Esmaeeli Z, 2022, STRUCT CHEM, V33, P147, DOI 10.1007/s11224-021-01830-x
   Fallah-Bagher-Shaidaei H, 2006, ORG LETT, V8, P863, DOI 10.1021/ol0529546
   Frenzel BA, 2014, INORG CHEM COMMUN, V50, P51, DOI 10.1016/j.inoche.2014.10.024
   Jafari E, 2019, J MOL STRUCT, V1178, P305, DOI 10.1016/j.molstruc.2018.10.024
   Jalezadeh A, 2022, STRUCT CHEM, V33, P1241, DOI 10.1007/s11224-022-01929-9
   Jaramillo P, 2008, J MOL STRUC-THEOCHEM, V865, P68, DOI 10.1016/j.theochem.2008.06.022
   Javan AJ, 2013, J AGR FOOD CHEM, V61, P1534, DOI 10.1021/jf304926m
   Kauffman C.A., 2007, INFECT MANAGEMENT GE, V2nd, P20
   Kikuchi S, 1997, J CHEM EDUC, V74, P194, DOI 10.1021/ed074p194
   KRUSZEWSKI J, 1972, TETRAHEDRON LETT, P3839
   Krygowski TM, 2001, CHEM REV, V101, P1385, DOI 10.1021/cr990326u
   Laird B.B., 1996, CHEM APPL DENSITY FU, V629
   Leem SH, 2003, MOL CELLS, V15, P55
   Leopoldini M, 2006, J AGR FOOD CHEM, V54, P6343, DOI 10.1021/jf060986h
   Lin J, 2021, ACS OMEGA, V6, P8477, DOI 10.1021/acsomega.1c00273
   Linstrom P.J., 2001, NIST CHEM WEBBOOK
   LUCARINI M, 1994, J ORG CHEM, V59, P5063, DOI 10.1021/jo00096a061
   Makkar P, 2021, RSC ADV, V11, P27897, DOI 10.1039/d1ra04876g
   Mattsson AE, 2005, MODEL SIMUL MATER SC, V13, pR1, DOI 10.1088/0965-0393/13/1/R01
   Miller Nicholas J., 2002, Journal of Nutritional and Environmental Medicine (Abingdon), V12, P39, DOI 10.1080/13590840220123352
   Mohammadpour M, 2016, COMPUT THEOR CHEM, V1078, P96, DOI 10.1016/j.comptc.2015.12.023
   Murray JS, 1996, MOL ELECTROSTATIC PO, V1
   Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x
   PARR RG, 1984, J AM CHEM SOC, V106, P4049, DOI 10.1021/ja00326a036
   Qi JJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02779-1
   Raczynska ED, 2010, SYMMETRY-BASEL, V2, P1485, DOI 10.3390/sym2031485
   Saeidian H, 2020, NEW J CHEM, V44, P12967, DOI 10.1039/d0nj02207a
   Santos-SuYnchez N.F., 2019, ANTIOXIDANT COMPOUND, DOI 10.5772/intechopen.85270
   Schlegel H.B., 2016, GAUSSIAN 16 REV C 01
   Schleyer PV, 1996, J AM CHEM SOC, V118, P6317, DOI 10.1021/ja960582d
   Shahi A, 2016, J CHEM SCI, V128, P1571, DOI 10.1007/s12039-016-1156-3
   Shams B, 2018, COMPUT THEOR CHEM, V1135, P48, DOI 10.1016/j.comptc.2018.05.011
   Shen T, 2016, CURR PHARM DESIGN, V22, P4443, DOI 10.2174/1381612822666160530151209
   Sholl D. S., 2011, DENSITY FUNCTIONAL T
   Swart M, 2008, J CHEM THEORY COMPUT, V4, P2057, DOI 10.1021/ct800277a
   Szelag M, 2015, OPEN CHEM, V13, P17, DOI 10.1515/chem-2015-0001
   Takano Y, 2005, J CHEM THEORY COMPUT, V1, P70, DOI 10.1021/ct049977a
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Valko M, 2016, ARCH TOXICOL, V90, P1, DOI 10.1007/s00204-015-1579-5
   Weinhold F, 2016, INT REV PHYS CHEM, V35, P399, DOI 10.1080/0144235X.2016.1192262
   Wen LR, 2017, FREE RADICAL BIO MED, V110, P92, DOI 10.1016/j.freeradbiomed.2017.05.027
   Zborowski KK, 2013, MOL PHYS, V111, P958, DOI 10.1080/00268976.2012.760052
   Zeb A, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13394
NR 56
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2860
EI 1872-8014
J9 J MOL STRUCT
JI J. Mol. Struct.
PD NOV 15
PY 2022
VL 1268
AR 133678
DI 10.1016/j.molstruc.2022.133678
PG 11
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 3H0AR
UT WOS:000831707400006
DA 2022-11-30
ER

PT J
AU Voisin, A
   Gaillard, A
   Balbous, A
   Leveziel, N
AF Voisin, Audrey
   Gaillard, Afsaneh
   Balbous, Anais
   Leveziel, Nicolas
TI Proteins Associated with Phagocytosis Alteration in Retinal Pigment
   Epithelial Cells Derived from Age-Related Macular Degeneration Patients
SO ANTIOXIDANTS
LA English
DT Article
DE age-related macular degeneration; atrophic AMD; exudative AMD; iPSC-RPE
   phagocytosis; RNA-seq
ID OUTER SEGMENT PHAGOCYTOSIS; FOCAL ADHESION KINASE; OXIDATIVE STRESS;
   ARPE-19 CELLS; ALPHA-V-BETA-5 INTEGRIN; PATHWAYS; SURVIVAL
AB Age-related macular degeneration (AMD) is partially characterized by retinal pigment epithelial (RPE) cell dysfunction. This study focused on phagocytosis activity and its involvement in AMD. Phagocytic activity was analyzed by flow cytometry using porcine photoreceptor outer segment (POS) and fluorescent beads in basal and under oxidative stress condition induced by Fe-NTA in fifteen hiPSC-RPE cell lines (six controls, six atrophic AMD and three exudative AMD). Oxidative stress exposure inhibited phagocytosis in the same manner for control, atrophic AMD (AMDa) and exudative AMD (AMDe) cell lines. However, altered phagocytosis in basal condition in hiPSC-RPE AMDa/e was observed compared to control cell lines. Gene expression after 3 or 24 h of POS incubation was analyzed by RNA-Seq based transcriptomic profiling. Differential gene expression was observed by RNA seq after 3 and 24 h POS exposure. We have focused on the genes involved in mTOR/PI3K-AKT/MEK-ERK pathway. We investigated differences in gene expression by analyzing the expression levels and activity of the corresponding proteins by Western blot. We showed the involvement of three proteins essential for phagocytosis activity: fak, tuberin and rictor. These findings demonstrate that hiPSC-RPE AMDa/e cells have a typical disease phenotype characterized by alteration of the main function of RPE cells, phagocytosis activity.
C1 [Voisin, Audrey; Gaillard, Afsaneh; Balbous, Anais; Leveziel, Nicolas] Univ Poitiers, INSERM, Lab Neurosci Expt & Clin, Equipe Therapie Cellulaire Pathol Cerebrales, F-86073 Poitiers, France.
   [Voisin, Audrey; Balbous, Anais; Leveziel, Nicolas] CHU Poitiers, F-86021 Poitiers, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Poitiers; CHU Poitiers; Universite de Poitiers
RP Voisin, A (通讯作者)，Univ Poitiers, INSERM, Lab Neurosci Expt & Clin, Equipe Therapie Cellulaire Pathol Cerebrales, F-86073 Poitiers, France.; Voisin, A (通讯作者)，CHU Poitiers, F-86021 Poitiers, France.
EM audrey.voisin@univ-poitiers.fr; afsaneh.gaillard@univ-poitiers.fr;
   anais.balbous.gautier@univ-poitiers.fr; nicolas.leveziel@chu-poitiers.fr
OI Voisin, Audrey/0000-0002-9766-5759; Gaillard,
   Afsaneh/0000-0002-9375-6506
FU Novartis; Fond Alienor
FX This research was funded by the Novartis and the Fond Alienor.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Alberio T, 2012, FEBS J, V279, P1146, DOI 10.1111/j.1742-4658.2012.08516.x
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Bulloj A, 2013, EXP EYE RES, V113, P9, DOI 10.1016/j.exer.2013.05.002
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Chiang CK, 2017, J BIOL CHEM, V292, P19826, DOI 10.1074/jbc.M117.812677
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Dalvi S, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0171-9
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Goncharova EA, 2011, MOL CELL BIOL, V31, P2484, DOI 10.1128/MCB.01061-10
   Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442
   He F., 2020, MULTIPLE PHOSPHATIDY, DOI [10.1101/2020.01.09.899815, DOI 10.1101/2020.01.09.899815]
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Joly MM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0868-8
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Leng N, 2015, BIOINFORMATICS, V31, P2614, DOI 10.1093/bioinformatics/btv193
   Malpass Katy, 2011, Nat Rev Neurol, V7, P536, DOI 10.1038/nrneurol.2011.144
   Mao YY, 2012, MOL BIOL CELL, V23, P1104, DOI 10.1091/mbc.E11-10-0840
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Mullins RF, 2017, HUM MOL GENET, V26, pR51, DOI 10.1093/hmg/ddx181
   Mustafi D, 2009, PROG RETIN EYE RES, V28, P289, DOI 10.1016/j.preteyeres.2009.05.003
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Oh WJ, 2011, CELL CYCLE, V10, P2305, DOI 10.4161/cc.10.14.16586
   Olchawa M, 2010, PHOTOCHEM PHOTOBIOL, V86, P772, DOI 10.1111/j.1751-1097.2010.00727.x
   Olchawa MM, 2016, FREE RADICAL RES, V50, P887, DOI 10.1080/10715762.2016.1194519
   Parinot C, 2014, JOVE-J VIS EXP, DOI 10.3791/52100
   Rakoczy EP, 2017, LANCET, V390, P6, DOI 10.1016/S0140-6736(17)31262-X
   Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Samuel W, 2017, MOL VIS, V23, P60
   Sethna S, 2016, J BIOL CHEM, V291, P6494, DOI 10.1074/jbc.M115.687004
   Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Voisin A, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5637075
   Voisin A, 2018, EXP EYE RES, V177, P76, DOI 10.1016/j.exer.2018.07.017
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YUODELIS C, 1986, VISION RES, V26, P847, DOI 10.1016/0042-6989(86)90143-4
NR 43
TC 0
Z9 0
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD APR
PY 2022
VL 11
IS 4
AR 713
DI 10.3390/antiox11040713
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 0T6BY
UT WOS:000787053200001
PM 35453399
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ethen, CM
   Reilly, C
   Feng, X
   Olsen, TW
   Ferrington, DA
AF Ethen, Cheryl M.
   Reilly, Cavan
   Feng, Xiao
   Olsen, Timothy W.
   Ferrington, Deborah A.
TI The proteome of central and peripheral retina with progression of
   age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; PIGMENT EPITHELIUM; EXPRESSION; PROTEINS;
   TRANSLOCATION; CRYSTALLIN; EYES; VULNERABILITY; PATHOGENESIS;
   MACULOPATHY
AB PURPOSE. A growing understanding of the molecular events in age-related macular degeneration (AMD) has lead to targeted therapies for a select group of patients with advanced AMD. Development of therapies for the earlier stages requires further elucidation of disease mechanisms. In this study, a proteomics approach was used to identify proteins that had altered content in human donor eyes with progression of AMD.
   METHODS. The early molecular events associated with AMD were identified by comparing the proteome of the macular and peripheral neurosensory retina during four progressive stages of AMD. Proteins were resolved and quantified by two-dimensional gel electrophoresis. Twenty-six proteins exhibited changes in content and were identified by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. Two-dimensional (2-D) and semiquantitative one-dimensional (1-D) Western blot analyses were used to determine whether changes identified by proteomic analysis were specific for a protein subpopulation or representative of the entire protein population.
   RESULTS. Twenty-six proteins were identified that exhibited changes at disease onset or with progression (indicating potential causal mechanisms) and at end-stage disease (indicating potential secondary consequences). These proteins are involved in key functional pathways, such as microtubule regulation and protection from stress-induced protein unfolding. Approximately 60% of the proteins exhibited changes specific to either the macula or periphery, with the remaining 40% changing in both regions. These results imply that both the macula and periphery are affected by AMD.
   CONCLUSIONS. This study provides the first direct evidence of AMD stage- and region-specific changes in retinal protein levels and highlights potential novel, disease-related proteins and biochemical pathways for future studies of AMD.
C1 Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Mol Biol & Biophys, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.
   Univ Minnesota, Div Biostat, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Ferrington, DA (通讯作者)，380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU NATIONAL EYE INSTITUTE [T32EY007133, R03EY014176] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025392] Funding Source: NIH
   RePORTER; NEI NIH HHS [T32-EY07133, EY014176] Funding Source: Medline;
   NIA NIH HHS [R01 AG025392, AG025392] Funding Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Cowan NJ, 2002, ADV PROTEIN CHEM, V59, P73
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Eckmiller MS, 2004, PROG RETIN EYE RES, V23, P495, DOI 10.1016/j.preteyeres.2004.04.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   Ferrington DA, 1998, J BIOL CHEM, V273, P5885, DOI 10.1074/jbc.273.10.5885
   Fitzgibbon J, 1996, FEBS LETT, V385, P185, DOI 10.1016/0014-5793(96)00365-1
   Golenhofen N, 2002, HISTOCHEM CELL BIOL, V117, P203, DOI 10.1007/s00418-001-0378-7
   GORIN MB, 1995, OPHTHALMOLOGY, V102, P246
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Kapphahn RJ, 2003, BIOCHEMISTRY-US, V42, P15310, DOI 10.1021/bi034774e
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   LEWIS H, 1985, OPHTHALMOLOGY, V92, P1485
   Lopez-Fanarraga M, 2001, J STRUCT BIOL, V135, P219, DOI 10.1006/jsbi.2001.4386
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   MEANS GE, 1993, BIOCHEMISTRY-US, P215
   MERRIL CR, 1998, GEL ELECTROPHORESIS, P57
   Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353
   Nakazawa T, 2000, BRAIN RES, V861, P399, DOI 10.1016/S0006-8993(00)02056-4
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Odunuga OO, 2004, BIOESSAYS, V26, P1058, DOI 10.1002/bies.20107
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Simon P, 2002, J FR OPHTALMOL, V25, P694
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Traboulsi EI, 2005, AM J OPHTHALMOL, V139, P908, DOI 10.1016/j.ajo.2005.01.045
   Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4
   Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 50
TC 84
Z9 90
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2006
VL 47
IS 6
BP 2280
EP 2290
DI 10.1167/iovs.05-1395
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 048LQ
UT WOS:000237949000005
PM 16723435
DA 2022-11-30
ER

PT J
AU Warwick, A
   Gibson, J
   Sood, R
   Lotery, A
AF Warwick, A.
   Gibson, J.
   Sood, R.
   Lotery, A.
TI A rare penetrant TIMP3 mutation confers relatively late onset choroidal
   neovascularisation which can mimic age-related macular degeneration
SO EYE
LA English
DT Article
ID SORSBY FUNDUS DYSTROPHY; GENE
AB Purpose To perform a genotype-phenotype correlation for three patients heterozygous for a missense mutation in the tissue inhibitor of metalloproteinase 3 (TIMP3) gene.
   Methods Retrospective, observational case series. The medical records and photographs were reviewed for three patients diagnosed at the time with neovascular age-related macular degeneration (AMD). All were later found to carry a predicted C113G mutation in the TIMP3 gene, other known mutations in which are associated with Sorsby's fundus dystrophy.
   Results All three patients developed drusen and bilateral choroidal neovascularisation with subsequent disciform scarring and atrophy. Visual acuity rapidly deteriorated to <6/60 in both eyes. The age of onset varied from 56 to 64 years and the interval to contralateral eye involvement varied from 4 to 6 years. Two of the three patients had a family history of AMD. All three patients were heterozygous for the C113G nucleotide change, resulting in a Ser38Cys change at the N terminus of the TIMP3 protein.
   Conclusion This case series suggests the C113G TIMP3 variant may represent a novel highly penetrant mutation causing choroidal neovascularisation of relatively late onset for Sorsby's fundus dystrophy, mimicking early onset AMD.
C1 [Warwick, A.; Lotery, A.] Univ Southampton, Fac Med, Clin & Expt Sci, Clin Neurosci Res Grp, Southampton SO16 6YD, Hants, England.
   [Warwick, A.; Lotery, A.] Univ Southampton NHS Trust, Eye Unit, Southampton, Hants, England.
   [Gibson, J.; Sood, R.] Univ Southampton, Fac Nat & Environm Sci, Ctr Biol Sci, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton
RP Lotery, A (通讯作者)，Univ Southampton, Fac Med, Univ Southampton UK, Div Neurosci, South Lab & Path Block,Mailpoint 806,Level D, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
RI Gibson, Jane/I-1630-2012
OI Gibson, Jane/0000-0002-0973-8285; Sood, Roshan K/0000-0002-1318-7025;
   Lotery, Andrew/0000-0001-5541-4305; Warwick,
   Alasdair/0000-0002-0800-2890
FU Sight Appeal; Rosetree Trust; National Institute for Health Research
   [NF-SI-0515-10020] Funding Source: researchfish; Rosetrees Trust
   [M124-F1] Funding Source: researchfish
FX The International AMD Genomics Consortium who assisted with genotyping.
   The Wellcome Trust Clinical Research Facility Southampton who assisted
   with DNA collection. Ms Helen Griffiths and Ms Angela Cree for DNA
   extraction. Funding from the Gift of Sight Appeal and the Rosetree
   Trust.
CR Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2014, ROLE RARE TIMP3 MUTA
   Gemenetzi Maria K, 2011, Retin Cases Brief Rep, V5, P132, DOI 10.1097/ICB.0b013e3181cc216b
   Jacobson SG, 2002, ARCH OPHTHALMOL-CHIC, V120, P376
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Schoenberger SD, 2013, RETINA-J RET VIT DIS, V33, P429, DOI 10.1097/IAE.0b013e318263d3b4
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
NR 10
TC 14
Z9 14
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2016
VL 30
IS 3
BP 488
EP 491
DI 10.1038/eye.2015.204
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI4SV
UT WOS:000373490500023
PM 26493035
OA Bronze, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Rochtchina, E
   Wang, JJ
   Flood, VM
   Mitchell, P
AF Rochtchina, Elena
   Wang, Jie Jin
   Flood, Victoria M.
   Mitchell, Paul
TI Elevated serum homocysteine, low serum vitamin B12, folate, and
   age-related macular degeneration: The Blue Mountains Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POPULATION
AB PURPOSE: To assess associations between increased serum homocysteine, low vitamin B12, low folate, and age, related macular degeneration (AMD). DESIGN: Population-based, cross-sectional analysis.
   METHODS: Serum homocysteine, vitamin B12, and folate were measured in 2,335 participants of the Blue Mountains Eye Study second survey. AMD detected from retinal photographs included atrophic or neovascular lesions.
   RESULTS: After adjusting for age, gender, and smoking in logistic regression models, homocysteine > 15 mu mol/l was associated with an increased likelihood of AMD in participants aged < 75 years (odds ratio [OR] 3.21, 95% confidence interval [95% CI] 1.09 to 9.43). A similar association was found for vitamin B 12 < 125 pmol/l (OR 2.30, 95% CI 1.08 to 4.89) among all participants. In participants with homocysteine <= 15 mu mol/l, low serum B12 was associated with nearly four,fold higher odds of AMD (OR 3.74, 95% CI 1.06 to 13.24). Folate was not statistically significantly associated with AMD.
   CONCLUSIONS: Increased homocysteine and low vitamin B12 were independently associated with an increased risk of AMD in this study population.
C1 Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res,Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   Univ Sydney, Dept Mol & Microbial Biosci, Human Nutr Unit, New S Wales Ctr Publ Hlth Nutr, Westmead, NSW 2145, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res,Westmead Millennium Inst, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; Flood, Victoria
   M/A-8732-2016; wang, jie/GRS-0942-2022; Flood, Victoria/H-2279-2011
OI Wang, Jie Jin/0000-0001-9491-4898; Flood, Victoria
   M/0000-0001-5310-7221; 
CR Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Flood VM, 2006, AUST NZ J PUBL HEAL, V30, P38, DOI 10.1111/j.1467-842X.2006.tb00084.x
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202
   Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507
NR 7
TC 59
Z9 62
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2007
VL 143
IS 2
BP 344
EP 346
DI 10.1016/j.ajo.2006.08.032
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 137CV
UT WOS:000244271400025
PM 17258528
DA 2022-11-30
ER

PT J
AU Castellino, N
   Longo, A
   Avitabile, T
   Russo, A
   Fallico, M
   Bonfiglio, V
   Toro, MD
   Rejdak, R
   Murabito, P
   Furino, C
   Reibaldi, M
AF Castellino, Niccolo
   Longo, Antonio
   Avitabile, Teresio
   Russo, Andrea
   Fallico, Matteo
   Bonfiglio, Vincenza
   Toro, Mario Damiano
   Rejdak, Robert
   Murabito, Paolo
   Furino, Claudio
   Reibaldi, Michele
TI Circulating insulin-like growth factor-1: a new clue in the pathogenesis
   of age-related macular degeneration
SO AGING-US
LA English
DT Article
DE age-related macular degeneration; neovascular AMD; IGF-1; anti-VEGF;
   senescence; somatomedin C.
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; AQUEOUS-HUMOR
AB In order to investigate Insulin-like growth factor-1 (IGF-1) blood levels in male and female age-matched patients affected by early, intermediate, neovascular age related macular degeneration (AMD) and healthy subjects (no AMD) were enrolled in a prospective, observational study. All patients enrolled were classified according to 4 stages classification of AMD from Age-related eye disease study (AREDS). Each subject underwent a complete ophthalmic examination including best corrected visual acuity (BCVA), applanation tonometry, slit-lamp biomicroscopic examination, color fundus photography, optical coherence tomography (OCT) and, if needed, fluorescein angiography. Overall, 224 anti-VEGF naive subjects including 56 patients in early AMD group, 56 patients in intermediate AMD group, 56 patients in neovascular AMD group and 56 patients in no AMD group were recruited. For each group 28 male patients and 28 female patients were enrolled. IGF-1 hematic levels were significantly higher (p<0.005) in the neovascular AMD group and in the intermediate AMD group in comparison to no AMD group; no significant difference between early AMD group and no AMD group was found. Our analysis has shown an increment of IGF-1 levels in both neovascular and intermediate stage of AMD supporting the hypothesis that IGF-1 may play a role in the pathogenesis of AMD.
C1 [Castellino, Niccolo; Longo, Antonio; Avitabile, Teresio; Russo, Andrea; Fallico, Matteo; Bonfiglio, Vincenza; Toro, Mario Damiano; Murabito, Paolo; Reibaldi, Michele] Univ Catania, Policlin Gaspare Rodolico, Catania, Italy.
   [Furino, Claudio] Univ Bari, Eye Clin, Bari, Italy.
   [Toro, Mario Damiano; Rejdak, Robert] Med Univ Lublin, Dept Gen Ophthalmol, Lublin, Poland.
C3 University of Catania; Universita degli Studi di Bari Aldo Moro; Medical
   University of Lublin
RP Longo, A (通讯作者)，Univ Catania, Policlin Gaspare Rodolico, Catania, Italy.
EM antlongo@unict.it
RI Reibaldi, Michele/AAL-1113-2021; Castellino, Niccolò/AAC-4717-2022;
   Russo, Andrea/AAC-5349-2022; Avitabile, Teresio/AAC-6076-2022; Longo,
   Antonio/AAC-6092-2022; Toro, Mario/AAA-1371-2021; TORO, Mario
   Damiano/R-9042-2019; Fallico, Matteo/AAC-5284-2022; Toro, Mario
   D/N-8051-2018
OI Russo, Andrea/0000-0002-7725-5971; TORO, Mario
   Damiano/0000-0001-7152-2613; Rejdak, Robert/0000-0003-3321-2723;
   FALLICO, MATTEO/0000-0003-2639-1321; Murabito,
   Paolo/0000-0002-2662-1898; Castellino, Niccolo/0000-0003-1818-6686;
   Nowomiejska, Katarzyna/0000-0002-5805-8761; LONGO,
   Antonio/0000-0002-9525-1800
CR Austad SN, 2016, GERONTOLOGY, V62, P40, DOI 10.1159/000381472
   Balasubramanian P, 2016, GROWTH HORM IGF RES, V28, P66, DOI 10.1016/j.ghir.2016.01.001
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Economou MA, 2008, ACTA OPHTHALMOL, V86, P930, DOI [10.1111/j.1755-3768.2008.01188.x, 10.1111/j.1755-3768.2008.01182.x, 10.1111/j.1755-3768.2008.01185.x, 10.1111/j.1755-3768.2008.01184.x]
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   GRANT MB, 1993, DIABETOLOGIA, V36, P282, DOI 10.1007/BF00400229
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Longo A, 2017, AGING-US, V9, P147, DOI 10.18632/aging.101137
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Ong SS, 2019, J NEUROL, V266, P1566, DOI 10.1007/s00415-018-9028-z
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Reibaldi M, 2018, RETINA-J RET VIT DIS, V38, P1, DOI 10.1097/IAE.0000000000001583
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001
   Westwood AJ, 2014, NEUROLOGY, V82, P1613, DOI 10.1212/WNL.0000000000000382
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 28
TC 6
Z9 7
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD DEC
PY 2018
VL 10
IS 12
BP 4241
EP 4247
DI 10.18632/aging.101727
PG 7
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA HG0KM
UT WOS:000454633200052
PM 30594908
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Makarev, E
   Cantor, C
   Zhavoronkov, A
   Buzdin, A
   Aliper, A
   Csoka, AB
AF Makarev, Evgeny
   Cantor, Charles
   Zhavoronkov, Alex
   Buzdin, Anton
   Aliper, Alexander
   Csoka, Antonei Benjamin
TI Pathway activation profiling reveals new insights into Age-related
   Macular Degeneration and provides avenues for therapeutic interventions
SO AGING-US
LA English
DT Article
DE AMD; Age-related Macular Degeneration; gene expression; Transcriptome
   profiling; signaling pathway activation strength
ID PIGMENT EPITHELIAL-CELLS; ALTERED GENE-EXPRESSION; SIGNALING PATHWAYS;
   BRUCHS MEMBRANE; COMPLEMENT; PROLIFERATION; INDUCTION; DISEASE; CANCER;
   DRUSEN
AB Age-related macular degeneration (AMD) is a major cause of blindness in older people and is caused by loss of the central region of the retinal pigment epithelium (RPE). Conventional methods of gene expression analysis have yielded important insights into AMD pathogenesis, but the precise molecular pathway alterations are still poorly understood. Therefore we developed a new software program, "AMD Medicine", and discovered differential pathway activation profiles in samples of human RPE/choroid from AMD patients and controls. We identified 29 pathways in RPE-choroid AMD phenotypes: 27 pathways were activated in AMD compared to controls, and 2 pathways were activated in controls compared to AMD. In AMD, we identified a graded activation of pathways related to wound response, complement cascade, and cell survival. Also, there was downregulation of two pathways responsible for apoptosis. Furthermore, significant activation of pro-mitotic pathways is consistent with dedifferentiation and cell proliferation events, which occur early in the pathogenesis of AMD. Significantly, we discovered new global pathway activation signatures of AMD involved in the cell-based inflammatory response: IL-2, STAT3, and ERK. The ultimate aim of our research is to achieve a better understanding of signaling pathways involved in AMD pathology, which will eventually lead to better treatments.
C1 [Makarev, Evgeny; Zhavoronkov, Alex; Buzdin, Anton; Aliper, Alexander] Johns Hopkins Univ, Insilico Med Inc, ETC, Baltimore, MD 21218 USA.
   [Cantor, Charles] Boston Univ, Boston, MA 02215 USA.
   [Cantor, Charles] Retrotope Inc, Los Altos Hills, CA 94022 USA.
   [Zhavoronkov, Alex] Biogerontol Res Fdn, London, England.
   [Buzdin, Anton] Pathway Pharmaceut Ltd, Hong Kong, Hong Kong, Peoples R China.
   [Csoka, Antonei Benjamin] Vis Genom LLC, Washington, DC 20010 USA.
   [Csoka, Antonei Benjamin] Howard Univ, Dept Anat, Epigenet Lab, Washington, DC 20059 USA.
C3 Johns Hopkins University; Boston University; Howard University
RP Csoka, AB (通讯作者)，Vis Genom LLC, Washington, DC 20010 USA.
EM antonei.csoka@howard.edu
RI Zhavoronkov, Alex/HCI-9762-2022; Zhavoronkov, Alex/X-6241-2019; Buzdin,
   Anton/R-2611-2016
OI Zhavoronkov, Alex/0000-0001-7067-8966; 
CR Aliper AM, 2014, ONCOTARGET, V5, P11345, DOI 10.18632/oncotarget.2489
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bandyopadhyay M, 2012, INVEST OPHTH VIS SCI, V53, P1953, DOI 10.1167/iovs.11-8638
   Blagosklonny MV, 2008, CANCER BIOL THER, V7, P1520, DOI 10.4161/cbt.7.10.6663
   Blagosklonny MV, 2012, AGING-US, V4, P861, DOI 10.18632/aging.100525
   Blagosklonny MV, 2012, AM J PATHOL, V181, P1142, DOI 10.1016/j.ajpath.2012.06.024
   Blagosklonny MV, 2012, AGING-US, V4, P547, DOI 10.18632/aging.100479
   Blagosklonny MV, 2009, AGING-US, V1, P281, DOI 10.18632/aging.100034
   Blagosklonny MV, 2009, CELL CYCLE, V8, P1883, DOI 10.4161/cc.8.12.8815
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Borisov NM, 2014, ONCOTARGET, V5, P10198, DOI 10.18632/oncotarget.2548
   Borisov NM, 2014, FRONTIERS MOL BIOSCI, V1
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chao W, 2008, CYTOKINE GROWTH F R, V19, P111, DOI 10.1016/j.cytogfr.2008.01.005
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Drier Y, 2013, P NATL ACAD SCI USA, V110, P6388, DOI 10.1073/pnas.1219651110
   Erridge C, 2007, ATHEROSCLEROSIS, V193, P77, DOI 10.1016/j.atherosclerosis.2006.08.032
   Hamamura K, 2008, CELL BIOL INT, V32, P1238, DOI 10.1016/j.cellbi.2008.07.007
   Huang Y, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-40
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kolosova NG, 2012, AM J PATHOL, V181, P472, DOI 10.1016/j.ajpath.2012.04.018
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Lezhnina K, 2014, ONCOTARGET, V5, P9022, DOI 10.18632/oncotarget.2493
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Maftouh M, 2014, ONCOTARGET, V5, P5335, DOI 10.18632/oncotarget.2104
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Morozevich GE, 2012, AGING-US, V4, P368, DOI 10.18632/aging.100457
   Moskalev AA, 2014, CELL CYCLE, V13, P1063, DOI 10.4161/cc.28433
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Spirin PV, 2014, LEUKEMIA, V28, P2222, DOI 10.1038/leu.2014.130
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Viola A, 2008, ANNU REV PHARMACOL, V48, P171, DOI 10.1146/annurev.pharmtox.48.121806.154841
   Wang ZY, 2009, FREE RADICAL BIO MED, V46, P1032, DOI 10.1016/j.freeradbiomed.2008.11.027
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yonekawa Y, 2014, COLD SPRING HARBOR P
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zamkova M, 2013, CELL CYCLE, V12, P826, DOI 10.4161/cc.23723
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhao C, 2011, AGING-US, V3, P346, DOI 10.18632/aging.100303
   Zhavoronkov A, 2013, INT J ENV RES PUB HE, V10, P5936, DOI 10.3390/ijerph10115936
   Zhavoronkov A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022597
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
NR 56
TC 38
Z9 39
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD DEC
PY 2014
VL 6
IS 12
BP 1064
EP 1075
DI 10.18632/aging.100711
PG 12
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA AZ2HR
UT WOS:000348055500006
PM 25543336
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Karagiannis, D
   Chatziralli, I
   Kaprinis, K
   Georgalas, I
   Parikakis, E
   Mitropoulos, P
AF Karagiannis, Dimitrios
   Chatziralli, Irini
   Kaprinis, Konstantinos
   Georgalas, Ilias
   Parikakis, Efstratios
   Mitropoulos, Panagiotis
TI Location of submacular hemorrhage as a predictor of visual outcome after
   intravitreal ranibizumab for age-related macular degeneration
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE age-related macular degeneration; ranibizumab; submacular hemorrhage;
   treatment
ID TISSUE-PLASMINOGEN ACTIVATOR; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; PNEUMATIC DISPLACEMENT; INJECTION; GAS; MANAGEMENT;
   SECONDARY
AB Purpose: To evaluate the anatomical and functional outcomes in patients with submacular hemorrhage (SMH) due to age-related macular degeneration (AMD) treated with ranibizumab, and to evaluate the potential role of the SMH location in the final outcome after treatment.
   Methods: Participants in this study were 12 treatment-naive patients with SMH due to neovascular AMD who were treated with intravitreal ranibizumab and had at least 12 months' follow-up. All patients underwent best-corrected visual acuity measurement and optical coherence tomography at baseline and at every visit posttreatment, while fluorescein angiography was done at baseline and at the discretion of the physician thereafter.
   Results: Of the patients, 83.4% showed improvement or stabilization in best-corrected visual acuity after treatment at the 12-month follow-up, with a mean number of 7.3 +/- 2.9 injections. Patients with SMH surrounding the foveal area in 360 degrees presented worse anatomical and functional outcomes compared to those with SMH adjacent to the fovea.
   Conclusion: Intravitreal ranibizumab seems to be safe and effective, either improving or stabilizing visual acuity, in patients with SMH due to wet AMD. The location of the SMH may predict the final outcome after treatment.
C1 [Karagiannis, Dimitrios; Chatziralli, Irini; Kaprinis, Konstantinos; Parikakis, Efstratios; Mitropoulos, Panagiotis] Ophthalmiatr Athinon, Dept Ophthalmol 2, 4 Sina St, Athens 10678, Greece.
   [Georgalas, Ilias] Univ Athens, Dept Ophthalmol 1, Athens, Greece.
C3 National & Kapodistrian University of Athens
RP Karagiannis, D (通讯作者)，Ophthalmiatr Athinon, Dept Ophthalmol 2, 4 Sina St, Athens 10678, Greece.
EM dimitrioskaragiannis@doctors.org.uk
RI Chatziralli, Irini/AAG-4779-2020; Georgalas, Ilias/AAD-5946-2019
OI Chatziralli, Irini/0000-0001-8523-1024; Georgalas,
   Ilias/0000-0002-6171-5865
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Bakri SJ, 2006, OPHTHAL SURG LAS IM, V37, P278, DOI 10.3928/15428877-20060701-03
   Gonzalez-Lopez JJ, 2016, EYE, V30, P929, DOI 10.1038/eye.2016.65
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hong T, 2013, OPHTHALMOLOGY, V120, P2091, DOI 10.1016/j.ophtha.2013.03.032
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   Kim HS, 2015, EYE, V29, P1142, DOI 10.1038/eye.2015.131
   Kitagawa Y, 2016, OPHTHALMOLOGY, V123, P1278, DOI 10.1016/j.ophtha.2016.01.035
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shin JY, 2016, OPTOMETRY VISION SCI, V93, P173, DOI 10.1097/OPX.0000000000000777
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Shin Kyung-Hoon, 2016, Korean J Ophthalmol, V30, P369
   Sobolewska B, 2014, J OCUL PHARMACOL TH, V30, P567, DOI 10.1089/jop.2013.0135
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
NR 16
TC 4
Z9 4
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2017
VL 12
BP 1829
EP 1833
DI 10.2147/CIA.S145893
PG 5
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA FL7SH
UT WOS:000414449800001
PM 29138543
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Gerding, H
AF Gerding, H.
TI Ranibizumab Treatment in Age-Related Macular Degeneration: A
   Meta-Analysis of One-Year Results
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Review
DE age-related macular degeneration; AMD; wAMD; nAMD; anti-VEGF;
   ranibizumab; retina; macula; meta-analysis; review
ID VERTEPORFIN PLUS RANIBIZUMAB; INTRAVITREAL RANIBIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; CLINICAL-PRACTICE; VISUAL-ACUITY; DOSING REGIMEN;
   EXUDATIVE AMD; SAFETY; BEVACIZUMAB; EFFICACY
AB Background: Although ranibizumab is widely used in age-related macular degeneration there is no systematic data available on the relation between treatment frequency and functional efficacy within the first 12 months of follow-up. Material and
   Methods: A meta-analysis was performed on available MEDLINE literature. 47 relevant clinical studies (54 case series) could be identified covering 11706 treated eyes. Non-linear and linear regressions were calculated for the relation between treatment frequency and functional outcome (average gain in visual acuity, % of eyes losing less than 15 letters of visual acuity, % of eyes gaining >= 15 letters) within the first year of care.
   Results: Mean improvement of average visual gain was + 4.9 +/- 3.6 (mean +/- 1 standard deviation) letters (case-weighted: 3.3 letters). The average number of ranibizumab injections until month 12 was 6.3 +/- 2.0 (case-weighted: 5.9). 92.4 +/- 3.9% of eyes (case-weighted: 91.9%) lost less than three lines of visual acuity and 24.5 +/- 8.2% (case-weighted: 23.3) gained more than 3 lines within the first year. Analysis of the relation between the number of injections and functional improvement indicated best fit for non-linear equations. A nearly stepwise improvement of functional gain occurred between 6.8 and 7.2 injections/year. A saturation effect of treatment occurred at higher injection frequency.
   Conclusions: The results of this meta-analysis clearly indicate a non-linear relation between the number of injections and functional gain of ranibizumab within the first 12 months of treatment. Treatment saturation seems to occur at a treatment frequency > 7.2 injections within the first 12 months.
C1 [Gerding, H.] Klin Pallas, Dept Retinol, CH-4600 Olten, Switzerland.
   [Gerding, H.] Univ Munster, Dept Ophthalmol, Munster, Germany.
C3 University of Munster
RP Gerding, H (通讯作者)，Klin Pallas, Dept Retinol, Louis Giroud Str 20, CH-4600 Olten, Switzerland.
EM hgerding@klinik-pallas.ch
RI Gerding, Heinrich/M-2363-2019
OI Gerding, Heinrich/0000-0003-3968-5601
CR Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Cohen SP, 2013, SHOOTING FOR A CENTURY: THE INDIA-PAKISTAN CONUNDRUM, P33
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Kwon OW, 2012, GRAEF ARCH CLIN EXP, V250, P1467, DOI 10.1007/s00417-012-1970-3
   Lala C, 2013, ACTA OPHTHALMOL, V91, P526, DOI 10.1111/j.1755-3768.2012.02457.x
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Marques IR, 2013, OPHTHALMOLOGICA, V229, P158, DOI 10.1159/000343709
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muniraju R, 2013, OPHTHALMOLOGICA, V230, P27, DOI 10.1159/000350238
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Tan SZ, 2013, INT OPHTHALMOL, V33, P467, DOI 10.1007/s10792-013-9717-7
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Toalster N, 2013, RETINA, V33, P13518
NR 50
TC 9
Z9 9
U1 0
U2 4
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2014
VL 231
IS 4
BP 427
EP 431
DI 10.1055/s-0034-1368241
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI4PX
UT WOS:000336848400043
PM 24771184
DA 2022-11-30
ER

PT J
AU Bai, ZL
   Ren, BC
   Yang, JG
   He, YA
   Chen, L
   Sun, NX
AF Bai, Zhi-Lan
   Ren, Bai-Chao
   Yang, Jian-Gang
   He, Yuan
   Chen, Li
   Sun, Nai-Xue
TI Epidemiological investigation on age related macular degeneration in
   rural area of Shaanxi Province, China
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age related macular degeneration; epidemiology; prevalence; risk
   factors; old people
AB AIM: To assess the prevalence and risk factors for age related macular degeneration (AMD) in a rural population in Shaanxi Province of China.
   METHODS: A total of 2 835 (81.00%) people aged 40 years old or more, from Fuping county, Jingbian county and Yang county of Shaanxi Province, China, underwent a comprehensive interview and a relative eye examination. The present of AMD was classified into neovascular AMD (NV) and pure geographic atrophy (GA) by using direct ophthalmoscopy for fundus examination according to International Classification System.
   RESULTS: The prevalence (95% CI) of AMD was 3.00% (2.42, 3.71) in this population, of which NV accounted for 1.45% (1.05, 1.98) and 1.55% (1.14, 2.10) for GA. The prevalence of AMD increased significantly with increasing age ( P<0.01). AMD was present in 0.47% of participants aged 40 to 49 years, rising to 11.90% of participants older than 80 years, of which the corresponding data increased from 0.28% to 4.76% for NV and from 0.19% to 7.14% for GA. No significant difference was found in the prevalence of NA and GA between genders in this population. With multiple logistic analysis, apart from advancing age, only smoking was found to have a strong association with any type of AMD.
   CONCLUSION: The prevalence of AMD in the rural population of Shaanxi Province of China is lower than that reported from other population-based studies in different provinces of China, less than that reported in whites, more than that reported in blacks. Besides increasing age, smoking is also a significant well-known risk factor for AMD.
C1 [Bai, Zhi-Lan] Xi An Jiao Tong Univ, Dept Image, Hosp 2, Xian 710004, Shaanxi Prov, Peoples R China.
   [Bai, Zhi-Lan; Ren, Bai-Chao; Yang, Jian-Gang; He, Yuan; Chen, Li; Sun, Nai-Xue] Xi An Jiao Tong Univ, Grp Ophthalmol Epidemiol Study, Hosp 2, Xian 710004, Shaanxi Prov, Peoples R China.
   [He, Yuan] Sun Yat Sen Univ, Zhongshan Eye Ctr, Guangzhou 510060, Guangdong, Peoples R China.
   [Chen, Li] 4 Hosp, Dept Ophthalmol, Xian 710004, Shaanxi Prov, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Sun Yat Sen
   University
RP Bai, ZL (通讯作者)，Xi An Jiao Tong Univ, Dept Image, Hosp 2, Xian 710004, Shaanxi Prov, Peoples R China.
EM rbc369@yahoo.com.cn
FU Department of Health Shaanxi Province of China [00125]
FX Supported by the Department of Health Shaanxi Province of China(No.
   00125)
CR Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   HE MG, 1998, CHIN J OCUL FUNDUS D, V114, P122
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1997, ARCH OPHTHALMOL-CHIC, V115, P945, DOI 10.1001/archopht.1997.01100160115033
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MITH W, 1996, AM J OPHTHALMOL, V122, P743
   Moeller Suzen M., 2003, International Ophthalmology Clinics, V43, P47
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Newland H S, 1996, Ophthalmic Epidemiol, V3, P97, DOI 10.3109/09286589609080114
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VARMUS H, 1997, AGE RELATED MACULAR
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   WEILH LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   XUAN MZ, 1994, J ZHEJIANG MED U, V23, P78
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 40
TC 1
Z9 1
U1 0
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2008
VL 1
IS 1
BP 77
EP 84
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V13KV
UT WOS:000207666600020
DA 2022-11-30
ER

PT J
AU Belgio, B
   Boschetti, F
   Mantero, S
AF Belgio, Beatrice
   Boschetti, Federica
   Mantero, Sara
TI Towards an In Vitro Retinal Model to Study and Develop New Therapies for
   Age-Related Macular Degeneration
SO BIOENGINEERING-BASEL
LA English
DT Article
DE retina; 3R; in vitro model; ophthalmology; age-related macular
   degeneration; biomechanics; electrospinning
AB Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly worldwide. So far, the etiology and the progression of AMD are not well known. Animal models have been developed to study the mechanisms involved in AMD; however, according to the "Three Rs" principle, alternative methods have been investigated. Here we present a strategy to develop a "Three Rs" compliant retinal three-dimensional (3D) in vitro model, including a Bruch's membrane model and retina pigment epithelium (RPE) layer. First, tensile testing was performed on porcine retina to set a reference for the in vitro model. The results of tensile testing showed a short linear region followed by a plastic region with peaks. Then, Bruch's membrane (BrM) was fabricated via electrospinning by using Bombyx mori silk fibroin (BMSF) and polycaprolactone (PCL). The BrM properties and ARPE-19 cell responses to BrM substrates were investigated. The BrM model displayed a thickness of 44 mu m, with a high porosity and an average fiber diameter of 1217 +/- 101 nm. ARPE-19 cells adhered and spread on the BMSF/PCL electrospun membranes. In conclusion, we are developing a novel 3D in vitro retinal model towards the replacement of animal models in AMD studies.
C1 [Belgio, Beatrice; Boschetti, Federica; Mantero, Sara] Politecn Milan, Dept Chem Mat & Chem Engn Giulio Natta, I-20133 Milan, Italy.
C3 Polytechnic University of Milan
RP Belgio, B (通讯作者)，Politecn Milan, Dept Chem Mat & Chem Engn Giulio Natta, I-20133 Milan, Italy.
EM beatrice.belgio@polimi.it; federica.boschetti@polimi.it;
   sara.mantero@polimi.it
RI BOSCHETTI, FEDERICA/I-8623-2018
OI BOSCHETTI, FEDERICA/0000-0002-1932-7535; MANTERO,
   SARA/0000-0002-1264-0465; Belgio, Beatrice/0000-0002-7964-9122
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Apte RS, 2016, EBIOMEDICINE, V5, P26, DOI 10.1016/j.ebiom.2016.02.003
   Asnaghi MA, 2011, J APPL BIOMATER BIOM, V9, P73, DOI 10.5301/JABB.2011.8562
   BEAUCHEMIN ML, 1974, A GRAEF ARCH KLIN EX, V190, P27, DOI 10.1007/BF00414333
   Chan W.H., 2007, INVEST OPHTHALMOL VI, V48, P2187
   Chandler Matthew J., 1999, Veterinary Ophthalmology, V2, P179
   Chen K, 2010, J BIOMECH, V43, P1417, DOI 10.1016/j.jbiomech.2009.09.056
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Fenwick N, 2009, CAN VET J, V50, P523
   Fridrikh SV, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.144502
   Guymer R., 2014, CURR ISSUES AGE RELA, P3, DOI [10.2217/FMEB2013.13.304, DOI 10.2217/FMEB2013.13.304]
   Hunt NC, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800226
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Popelka S, 2015, BIOMED MATER, V10, DOI 10.1088/1748-6041/10/4/045022
   Santos E, 2012, TRENDS BIOTECHNOL, V30, P331, DOI 10.1016/j.tibtech.2012.03.005
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Srivastava GK, 2011, J BIOMED MATER RES A, V97A, P243, DOI 10.1002/jbm.a.33050
   Tan YSE, 2018, BRIT J OPHTHALMOL, V102, P1182, DOI 10.1136/bjophthalmol-2017-311390
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Wollensak G, 2004, RETINA-J RET VIT DIS, V24, P967, DOI 10.1097/00006982-200412000-00021
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Zhang DD, 2015, SCI REP-UK, V5, DOI 10.1038/srep14326
NR 26
TC 3
Z9 3
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2306-5354
J9 BIOENGINEERING-BASEL
JI Bioengineering-Basel
PD FEB
PY 2021
VL 8
IS 2
AR 18
DI 10.3390/bioengineering8020018
PG 12
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA QM9YH
UT WOS:000622128300001
PM 33499168
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Richert, E
   Klettner, A
   von der Burchard, C
   Roider, J
   Tode, J
AF Richert, Elisabeth
   Klettner, Alexa
   von der Burchard, Claus
   Roider, Johann
   Tode, Jan
TI CRB1(rd8) mutation influences the age-related macular degeneration
   phenotype of NRF2 knockout mice and favors choroidal neovascularization
SO ADVANCES IN MEDICAL SCIENCES
LA English
DT Article
DE Crumbs homolog 1 (CRB1); Retinal degeneration 8 (rd8); Age related
   macular degeneration (AMD); Nuclear factor erythroid 2-related factor 2
   (NRF2); Choroidal neovascularization (CNV)
ID RETINITIS-PIGMENTOSA; DROSOPHILA-CRUMBS; RD8 MUTATION; CRB1; HOMOLOG
AB Purpose: We examined the influence of retinal degeneration 8 (rd8) mutation of crumbs homolog 1 (CRB1) gene on age-related macular degeneration (AMD) phenotype in nuclear factor E2-related factor 2 knock out (NRF2(-/-)) mouse model.
   Methods: CRB1(rd8) mutation genotype was determined by polymerase chain reaction from tail clips in 73 NRF2(-/-) mice originating from C57BL/6J background on mixed C57BL/6J and C57BL/6N ancestry. The clinical grade of AMD-like fundus alterations was determined by funduscopy, optical coherence tomography (OCT) and fluorescein angiography (FLA) at the age of 9 or 12 months.
   Results: Twelve NRF2(-/-) mice were wildtype CRB1(+/+), 61 NRF2(-/-) were homozygous CRB1(rd8/rd8). NRF2(-/-) CRB1(rd8/rd8) mice had a significantly higher probability to show an advanced grade (grade 4 and 5) of AMD-like fundus alterations known to appear in NRF2(-/-) mice. Choroidal neovascularization (CNV) was only detected in NRF2(-/-) CRB1(rd8/rd8) homozygous mice.
   Conclusions: Homozygous CRB1(rd8/rd8) mutation is common in commercial vendor mice strains of C57BL/6J origin if partly on C57BL/6N ancestry. The mutation has an influence on the extent of AMD-like retinal alterations in NRF2(-/-) mice and favors CNV formation.
C1 [Richert, Elisabeth; Klettner, Alexa; von der Burchard, Claus; Roider, Johann; Tode, Jan] Christian Albrechts Univ Kiel, Univ Med Ctr, Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Tode, J (通讯作者)，Christian Albrechts Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller Str 3, D-24105 Kiel, Germany.
EM Jan.tode.eye@gmail.com
RI von der Burchard, Claus/GZG-4104-2022
OI Klettner, Alexa/0000-0002-2709-1059
FU German Ministry of Education and Research (BMBF) [13GW0043D]
FX This paper was supported by the German Ministry of Education and
   Research (BMBF): grant 13GW0043D.
CR Aredo B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0221-4
   den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848
   den Hollander AI, 2001, HUM MOL GENET, V10, P2767, DOI 10.1093/hmg/10.24.2767
   den Hollander AI, 2002, MECH DEVELOP, V110, P203, DOI 10.1016/S0925-4773(01)00568-8
   den Hollander AI, 2001, AM J HUM GENET, V69, P198
   Gosens I, 2008, EXP EYE RES, V86, P713, DOI 10.1016/j.exer.2008.02.005
   Lajko M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180384
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Pellikka M, 2002, NATURE, V416, P143, DOI 10.1038/nature721
   Sahu B, 2015, MOL VIS, V21, P273
   Stojic A, 2017, INVEST OPHTH VIS SCI, V58, P318, DOI 10.1167/iovs.16-20419
   Tode J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.2
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 15
TC 4
Z9 4
U1 2
U2 2
PU MEDICAL UNIV BIALYSTOK
PI BIALYSTOK
PA UL KILINSKIEGO 1, BIALYSTOK, 15-089, POLAND
SN 1896-1126
EI 1898-4002
J9 ADV MED SCI-POLAND
JI Adv. Med. Sci.
PD MAR
PY 2020
VL 65
IS 1
BP 71
EP 77
DI 10.1016/j.advms.2019.11.003
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA MJ4LO
UT WOS:000548063400008
PM 31918066
DA 2022-11-30
ER

PT J
AU Altaweel, MM
   Daniel, E
   Martin, DF
   Mittra, RA
   Grunwald, JE
   Lai, MM
   Melamud, A
   Morse, LS
   Huang, JY
   Ferris, FL
   Fine, SL
   Maguire, MG
AF Altaweel, Michael M.
   Daniel, Ebenezer
   Martin, Daniel F.
   Mittra, Robert A.
   Grunwald, Juan E.
   Lai, Michael M.
   Melamud, Alexander
   Morse, Lawrence S.
   Huang, Jiayan
   Ferris, Frederick L., III
   Fine, Stuart L.
   Maguire, Maureen G.
CA Comparison Age-related Macular
TI Outcomes of Eyes with Lesions Composed of > 50% Blood in the Comparison
   of Age-Related Macular Degeneration Treatments Trials (CATT)
SO OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL TEARS; TISSUE-PLASMINOGEN ACTIVATOR; ENDOTHELIAL
   GROWTH-FACTOR; CHOROIDAL NEOVASCULAR LESIONS; LARGE SUBMACULAR
   HEMORRHAGE; SUBRETINAL HEMORRHAGE; INTRAVITREAL RANIBIZUMAB; PNEUMATIC
   DISPLACEMENT; NATURAL-HISTORY; BEVACIZUMAB
AB Objective: To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of the lesion composed of blood (B50 group) versus all other eyes (Other group) enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
   Design: Prospective cohort study within a multicenter randomized clinical trial.
   Participants: CATT patients with neovascular age-related macular degeneration (AMD).
   Methods: Treatment for the study eye was assigned randomly to either ranibizumab or bevacizumab and to 3 different dosing regimens over a 2-year period. Reading center graders evaluated baseline and follow-up morphology in color fundus photographs, fluorescein angiography (FA), and optical coherence tomography (OCT). Masked examiners tested VA.
   Main Outcome Measures: Morphologic features and VA at 1 and 2 years.
   Results: The B50 group consisted of 84 of 1185 (7.1%) patients enrolled in CATT. Baseline lesion characteristics differed between groups. In the B50 group, choroidal neovascularization size was smaller (0.73 vs 1.83 disc areas [DA]; P < 0.001), total lesion size was greater (4.55 vs 2.31 DA; P < 0.001), total retinal thickness was greater (524 vs 455 mm; P = 0.02), and mean VA was worse (56.0 vs 60.9 letters; P = 0.002). Increases in mean VA were similar in the B50 and Other groups at 1 year (+9.3 vs +7.2 letters; P = 0.22) and at 2 years (9.0 vs 6.1 letters; P = 0.17). Eyes treated PRN received a similar number of injections in the 2 groups (12.2 vs 13.4; P = 0.27). Mean lesion size in the B50 group decreased by 1.2 DA at both 1 and 2 years (primarily owing to resolution of hemorrhage) and increased in the Other group by 0.33 DA at 1 year and 0.91 DA at 2 years (P < 0.001). Leakage on FA and fluid on OCT were similar between groups at 1 and 2 years.
   Conclusions: In CATT, the B50 group had a visual prognosis similar to the Other group. Lesion size decreased markedly through 2 years. Eyes like those enrolled in CATT with neovascular AMD lesions composed of >50% blood can be managed similarly to those with less or no blood. (C) 2015 by the American Academy of Ophthalmology.
C1 [Altaweel, Michael M.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53705 USA.
   [Daniel, Ebenezer; Grunwald, Juan E.; Huang, Jiayan; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Mittra, Robert A.] VitreoRetinal Surg, Edina, MN USA.
   [Lai, Michael M.; Melamud, Alexander] Retina Grp Washington, Chevy Chase, MD USA.
   [Morse, Lawrence S.] Univ Calif Davis, Med Ctr, Dept Ophthalmol, Sacramento, CA 95817 USA.
   [Ferris, Frederick L., III] NEI, Bethesda, MD 20892 USA.
   [Fine, Stuart L.] Univ Colorado Denver, Dept Ophthalmol, Aurora, CO USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Pennsylvania; Cleveland Clinic Foundation; University of
   California System; University of California Davis; National Institutes
   of Health (NIH) - USA; NIH National Eye Institute (NEI); Children's
   Hospital Colorado; University of Colorado System; University of Colorado
   Anschutz Medical Campus
RP Altaweel, MM (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 2870 Univ Ave, Madison, WI 53705 USA.
EM mmaltaweel@wisc.edu
RI Ciulla, Thomas/AAA-1299-2020; Mittra, Robert/AAC-8249-2021
OI Ciulla, Thomas/0000-0001-5557-6777; Folk, James/0000-0002-6271-2906;
   Ferris, Frederick/0000-0002-4933-0639; Losordo,
   Douglas/0000-0002-6857-7506; Vavvas, Demetrios/0000-0002-8622-6478;
   Morse, Lawrence/0000-0002-1758-2348
FU Genentech; National Eye Institute, National Institutes of Health,
   Department of Health and Human Services [U10 EY017823, U10 EY017825, U10
   EY017826, U10 EY017828]; NATIONAL EYE INSTITUTE [U10EY017823,
   U10EY017826, U10EY017828] Funding Source: NIH RePORTER
FX L.M.: Consultant - Genentech; Lecture fees Genentech.; Supported by
   cooperative agreements U10 EY017823, U10 EY017825, U10 EY017826, and U10
   EY017828 from the National Eye Institute, National Institutes of Health,
   Department of Health and Human Services. ClinicalTrials.gov number:
   NCT00593450.
CR Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Skaf AR, 2011, SEMIN OPHTHALMOL, V26, P181, DOI 10.3109/08820538.2011.577133
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   Todorich B, 2011, RETINA-J RET VIT DIS, V31, P1749, DOI 10.1097/IAE.0b013e31821504df
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Varshney N, 2013, CAN J OPHTHALMOL, V48, P210, DOI 10.1016/j.jcjo.2013.01.023
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 39
TC 32
Z9 34
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2015
VL 122
IS 2
BP 391
EP +
DI 10.1016/j.ophtha.2014.08.020
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ5WT
UT WOS:000348290000032
PM 25307130
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ristau, T
   Keane, PA
   Walsh, AC
   Engin, A
   Mokwa, N
   Kirchhof, B
   Sadda, SR
   Liakopoulos, S
AF Ristau, Tina
   Keane, Pearse A.
   Walsh, Alexander C.
   Engin, Alicia
   Mokwa, Nils
   Kirchhof, Bernd
   Sadda, SriniVas R.
   Liakopoulos, Sandra
TI Relationship between Visual Acuity and Spectral Domain Optical Coherence
   Tomography Retinal Parameters in Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Optical coherence tomography; Visual acuity; Age-related macular
   degeneration; Fluorescein angiography
ID QUANTITATIVE SUBANALYSIS; RANIBIZUMAB; VERTEPORFIN; MORPHOLOGY; IMPACT
AB Purpose: Relationship between spectral domain optical coherence tomography (SD-OCT) and visual acuity (VA) in neovascular age-related macular degeneration (NVAMD). Procedures: VA and SD-OCTs of 64 treatment-naive eyes with NVAMD were retrospectively collected at baseline and 1 year (n = 30). Retinal and subretinal spaces were manually analyzed. Volume and thickness measurements were correlated with VA. Results: At baseline, lower VA correlated with increased volume of subretinal hyperreflective material (R = 0.4, p < 0.001) and with decreased volume of the photoreceptor layer (PRL, R = -0.4, p < 0.01). At 1 year, lower VA correlated with decreased volume of the retina (R = -0.7, p < 0.001), outer nuclear layer (R = -0.6, p < 0.05) and PRL (R = -0.7, p < 0.001). Decrease in VA after 1 year correlated with a decrease in PRL (R = 0.4, p < 0.05). Conclusions: Quantitative analysis of SD-OCT revealed correlations between VA and retinal and subretinal morphological changes in NVAMD. Message: Atrophy of the outer retina is an important correlate for lower VA in NVAMD. (C) 2013 S. Karger AG, Basel
C1 [Ristau, Tina; Engin, Alicia; Mokwa, Nils; Kirchhof, Bernd; Liakopoulos, Sandra] Univ Hosp Cologne, Cologne Image Reading Ctr, Dept Ophthalmol, DE-50924 Cologne, Germany.
   [Keane, Pearse A.] Moorfields Eye Hosp, NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Keane, Pearse A.] UCL Inst Ophthalmol, London, England.
   [Sadda, SriniVas R.] Univ So Calif, Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA USA.
   [Walsh, Alexander C.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
C3 University of Cologne; Oxford University Hospitals NHS Foundation Trust;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Liakopoulos, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 92, DE-50924 Cologne, Germany.
EM sandra.liakopoulos@uk-koeln.de
RI Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X
FU Department of Health's NIHR Biomedical Research Centre for Ophthalmology
   at Moorfields Eye Hospital; UCL Institute of Ophthalmology; Academy of
   Medical Sciences (AMS) [AMS-SGCL6-Keane] Funding Source: researchfish;
   National Institute for Health Research [CL-2010-18-004] Funding Source:
   researchfish
FX Dr. Keane has received a proportion of his funding from the Department
   of Health's NIHR Biomedical Research Centre for Ophthalmology at
   Moorfields Eye Hospital and UCL Institute of Ophthalmology. The views
   expressed in the publication are those of the author and not necessarily
   those of the Department of Health.
CR Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Einwallner E, 2010, OPHTHALMOLOGE, V107, P158, DOI 10.1007/s00347-009-1948-7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   YAYLALI S, 2012, INT OPHTHALMOL, V32, P25, DOI DOI 10.1007/S10792-012-9519-3
NR 25
TC 34
Z9 35
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 231
IS 1
BP 37
EP 44
DI 10.1159/000354551
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 278UJ
UT WOS:000328915100006
PM 24107542
DA 2022-11-30
ER

PT J
AU Shen, XL
   Jia, LH
   Zhao, P
   Fan, R
   Pan, XY
   Yang, HM
   Liu, L
AF Shen, X. L.
   Jia, L. H.
   Zhao, P.
   Fan, R.
   Pan, X. Y.
   Yang, H. M.
   Liu, L.
TI Changes in blood oxidative and antioxidant parameters in a group of
   Chinese patients with age-related macular degeneration
SO JOURNAL OF NUTRITION HEALTH & AGING
LA English
DT Article
DE Antioxidant capacity; malondialdehyde; chinese; age-related macular
   degeneration
ID LIPID-PEROXIDATION; ENZYME-ACTIVITIES
AB To measure the oxidative and antioxidant biochemical parameters in the serum of Chinese patients with age-related macular degeneration (AMD) and in a similar age control group from the same area.
   A case-control study.
   56 AMD patients (21 early dry, 13 geographic atrophy and 22 wet form) and 34 normal subjects, similar for age and sex were studied.
   Both groups completed a questionnaire about demographic characters and dieatry habit, and the levels of serum lipid peroxidation (malondialdehyde, MDA) and antioxidants parameters (vitamin C and E, the activities of superoxide dismutase-SOD, total antioxidant capacity - TAC) were determined.
   There was a significantly higher frequency of daily intake of fruit and legumes in controls than in AMD patients. There was a significantly increased serum MDA levels and SOD activities, and significantly decreased serum vitamin C and total antioxidant capacity in AMD patients as compared to controls. The intensity of lipid peroxidation was higher with the progression of AMD. There was not difference in serum vitamin E levels between AMD patients and controls.
   Oxido-reduction disturbance may be involved in the pathogenesis of AMD. There is a significantly decreased antioxidant capacity in AMD patients.
C1 [Shen, X. L.] China Med Univ, Dept Neurol, Affiliated Hosp 1, Shenyang 110001, Peoples R China.
   [Jia, L. H.; Pan, X. Y.; Yang, H. M.; Liu, L.] China Med Univ, Dept Nutr & Food Hyg, Sch Publ Hlth, Shenyang 110001, Peoples R China.
   [Zhao, P.; Fan, R.] Shenyang AIER Ophthalmol Hosp, Shenyang, Peoples R China.
C3 China Medical University; China Medical University
RP Shen, XL (通讯作者)，China Med Univ, Dept Neurol, Affiliated Hosp 1, Shenyang 110001, Peoples R China.
EM sxl630101@126.com
FU Nutritional Science Foundation of Chinese Nutrition Society, China
   [07016]
FX This study was supported by the Nutritional Science Foundation of
   Chinese Nutrition Society (No. 07016), China.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JAIN SK, 1988, BIOCHIM BIOPHYS ACTA, V937, P205, DOI 10.1016/0005-2736(88)90242-8
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Likidlilid Atip, 2010, Journal of the Medical Association of Thailand, V93, P682
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   Noel SE, 2009, J NUTR, V139, P1360, DOI 10.3945/jn.109.105874
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   The Chinese Nutrition Society, 1999, NUTR TODAY, V34, P106
   Tobias M, 2006, AUST NZ J PUBL HEAL, V30, P26, DOI 10.1111/j.1467-842X.2006.tb00082.x
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Uno K, 2010, BIOMARK MED, V4, P361, DOI [10.2217/bmm.10.57, 10.2217/BMM.10.57]
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wiktorowska-Owczarek A, 2010, POSTEP HIG MED DOSW, V64, P333
   Willett Walter, 1998, NUTR EPIDEMIOLIGY
   Yildirim O, 2004, OPHTHALMOLOGICA, V218, P202, DOI 10.1159/000076845
NR 26
TC 22
Z9 22
U1 0
U2 2
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 1279-7707
EI 1760-4788
J9 J NUTR HEALTH AGING
JI J. Nutr. Health Aging
PD MAR
PY 2012
VL 16
IS 3
BP 201
EP 204
DI 10.1007/s12603-011-0350-8
PG 4
WC Geriatrics & Gerontology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Nutrition & Dietetics
GA 929HD
UT WOS:000303051000002
PM 22456773
DA 2022-11-30
ER

PT J
AU Montero, JA
   Ruiz-Moreno, JM
   Tavolato, M
AF Montero, JA
   Ruiz-Moreno, JM
   Tavolato, M
TI Follow-up of age-related macular degeneration patients treated by
   photodynamic therapy with optical coherence tomography 3
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   photodynamic therapy; optical coherence tomography 3
ID VERTEPORFIN
AB Background. Photodynamic therapy (PDT) has been described to effectively reduce or delay severe vision loss in eyes with predominantly classic form of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Optical coherence tomography 3 (OCT3) is a non-invasive diagnostic procedure which provides information about retinal thickness and volume at the posterior pole, as well as about the presence of certain structures under the retina. Methods. Prospective interventional study. Eleven eyes (9 patients) with AMD and CNV were treated with Verteporfin PDT. A complete ophthalmologic examination was performed. Fluorescein angiography (FA) and OCT3 scans were performed before treatment and 1, 2, 4, and 12 weeks after it. Results. Two different patterns of changes were observed. One group (7 eyes) showed changes in the amount of subretinal fluid (decrease, increase, and finally stable decrease), with a reduction in the CNV and the appearance of a subretinal band of hyperreflective tissue. The second group (4 eyes) showed little or no changes in retinal thickness, fluid, or reflectivity. Conclusion. Changes observed in OCT3 scans represent variations in retinal thickness, fluid, and CNV after PDT. OCT3 provides a useful tool in the follow-up and measurement of changes appeared in eyes with CNV associated to AMD after treatment with PDT.
C1 Univ Miguel Hernandez, Div Oftalmol, Alicante 03550, Spain.
   Inst Oftalmol Alicante, Vitreo Retinal Unit, Alicante 03015, Spain.
C3 Universidad Miguel Hernandez de Elche
RP Ruiz-Moreno, JM (通讯作者)，Univ Miguel Hernandez, Div Oftalmol, Campus San Juan, Alicante 03550, Spain.
EM jm.ruiz@umh.es
RI Ruiz-Moreno, José M/E-4644-2016
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chauhan DS, 1999, INVEST OPHTH VIS SCI, V40, P2332
   Hamada S, 2000, OPHTHALMIC SURG LAS, V31, P253
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Konno S, 2001, RETINA-J RET VIT DIS, V21, P57, DOI 10.1097/00006982-200102000-00010
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Tan WC, 2003, RETINA-J RET VIT DIS, V23, P166, DOI 10.1097/00006982-200304000-00005
NR 15
TC 25
Z9 26
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2003
VL 241
IS 10
BP 797
EP 802
DI 10.1007/s00417-003-0752-3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 742WZ
UT WOS:000186542200003
PM 14605900
DA 2022-11-30
ER

PT J
AU Vounotrypidis, E
   Hillenmayer, A
   Wertheimer, CM
   Athanasiou, A
   Siedlecki, J
   Orth, M
   Ohlmann, A
   Priglinger, SG
   Wolf, A
AF Vounotrypidis, Efstathios
   Hillenmayer, Anna
   Wertheimer, Christian M.
   Athanasiou, Alexis
   Siedlecki, Jakob
   Orth, Michael
   Ohlmann, Andreas
   Priglinger, Siegfried G.
   Wolf, Armin
TI In vitro evaluation of simulated stereotactic radiotherapy for wet
   age-related macular degeneration on three different cell lines
SO SCIENTIFIC REPORTS
LA English
DT Article
ID X-RAY-IRRADIATION; EXTERNAL-BEAM RADIOTHERAPY; RANIBIZUMAB THERAPY;
   RADIATION RESPONSE; CLINICAL-RESPONSE; RADIOSURGERY; RETINOPATHY;
   APOPTOSIS; THICKNESS
AB Low energy stereotactic radiotherapy has been proposed for the treatment of neovascular age related macular degeneration. We investigated the in vitro effect of the radiotherapy on pericytes, retinal pigment epithelium and endothelial cells. Primary human retinal pigment epithelium cells, human umbilical vein endothelial cells and human pericytes from Placenta were cultivated. In a pairwise protocol, one plate was irradiated at a dose of 16 Gy, while the second plate served as a non-irradiated control. Thereafter, cells were cultivated either in serum-free (non-permissive) or serum-stimulated (permissive) conditions. A life/dead assay, an XTT and a BrdU assay were performed up to 7 days after irradiation. No cell death occurred at any timepoint in any cell line after treatment nor in the control. Compared to the unirradiated controls, cell viability and metabolic activity were significantly reduced in irradiated cells in the XTT assay, except for non-permissive RPE cells. In the BrdU assay, proliferation was inhibited. While no cell death was detected in vitro, viability and proliferative capacity of all cell lines were significantly reduced. Therefore, it seems that low energy stereotactic radiotherapy inhibits angiogenesis without a direct induction of apoptosis but influencing microvascular function and stability.
C1 [Vounotrypidis, Efstathios; Hillenmayer, Anna; Wertheimer, Christian M.; Wolf, Armin] Univ Hosp Ulm, Dept Ophthalmol, Prittwitzstr 43, D-89075 Ulm, Germany.
   [Vounotrypidis, Efstathios; Hillenmayer, Anna; Wertheimer, Christian M.; Athanasiou, Alexis; Siedlecki, Jakob; Ohlmann, Andreas; Priglinger, Siegfried G.; Wolf, Armin] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Munich, Germany.
   [Orth, Michael] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Univ Hosp, Munich, Germany.
C3 Ulm University; University of Munich; University of Munich
RP Vounotrypidis, E (通讯作者)，Univ Hosp Ulm, Dept Ophthalmol, Prittwitzstr 43, D-89075 Ulm, Germany.; Vounotrypidis, E (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Munich, Germany.
EM efstathios.vounotrypidis@uniklinik-ulm.de
RI Orth, Michael/AAQ-7299-2021
OI Orth, Michael/0000-0002-4608-7151; Vounotrypidis,
   Efstathios/0000-0002-9833-2200
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Aisenbrey S, 2003, GRAEF ARCH CLIN EXP, V241, P269, DOI 10.1007/s00417-003-0634-8
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Archer D B, 1994, Curr Opin Ophthalmol, V5, P59, DOI 10.1097/00055735-199406000-00011
   Borges HL, 2004, CELL DEATH DIFFER, V11, P494, DOI 10.1038/sj.cdd.4401366
   Brand C, 2018, EYE, V32, P1345, DOI 10.1038/s41433-018-0080-9
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Ehlken C, 2018, GRAEF ARCH CLIN EXP, V256, P105, DOI 10.1007/s00417-017-3849-9
   Finger PT, 2016, EUR J OPHTHALMOL, V26, P60, DOI 10.5301/ejo.5000670
   Freiberg FJ, 2019, BRIT J OPHTHALMOL, V103, P469, DOI 10.1136/bjophthalmol-2018-311865
   Gaddini L, 2018, EXP EYE RES, V166, P21, DOI 10.1016/j.exer.2017.09.009
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Guan JZ, 2014, MOL CELL BIOCHEM, V396, P129, DOI 10.1007/s11010-014-2149-5
   Guymer R, 2020, CLIN EXP OPHTHALMOL, V48, P983, DOI 10.1111/ceo.13837
   Hanlon J, 2011, INVEST OPHTH VIS SCI, V52, P2334, DOI 10.1167/iovs.10-6421
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Hatz K, 2022, BRIT J OPHTHALMOL, V106, P415, DOI 10.1136/bjophthalmol-2020-317563
   Hatz K, 2018, OSLI RETINA, V49, P86, DOI 10.3928/23258160-20180129-02
   HUTCHINSON F, 1966, CANCER RES, V26, P2045
   Jackson TL, 2012, EYE, V26, P557, DOI 10.1038/eye.2011.351
   Jackson TL, 2015, RETINA-J RET VIT DIS, V35, P194, DOI 10.1097/IAE.0000000000000283
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Kirwan JF, 2003, EYE, V17, P207, DOI 10.1038/sj.eye.6700306
   Kurz M, 2019, KLIN MONATSBL AUGENH, V236, P892, DOI 10.1055/s-0043-115903
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   Lee ST, 2018, MOL NEUROBIOL, V55, P4918, DOI 10.1007/s12035-017-0695-z
   MATSUMOTO M, 1993, INVEST OPHTH VIS SCI, V34, P2068
   Miyamoto H, 1999, INVEST OPHTH VIS SCI, V40, P1496
   Mohammadkarim A, 2019, CELL BIOCHEM BIOPHYS, V77, P179, DOI 10.1007/s12013-018-0864-3
   Mohammadkarim A, 2018, J MECH BEHAV BIOMED, V85, P188, DOI 10.1016/j.jmbbm.2018.06.009
   Morales-Canton V, 2013, AM J OPHTHALMOL, V155, P1000, DOI 10.1016/j.ajo.2013.01.015
   Moshfeghi AA, 2012, BRIT J OPHTHALMOL, V96, P1320, DOI 10.1136/bjophthalmol-2011-301222
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Neffendorf JE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1676-7
   Neffendorf JE, 2015, CLIN OPHTHALMOL, V9, P1829, DOI 10.2147/OPTH.S75638
   Ohlmann A, 2010, J NEUROSCI, V30, P183, DOI 10.1523/JNEUROSCI.3210-09.2010
   OHUCHI T, 1991, GRAEF ARCH CLIN EXP, V229, P75, DOI 10.1007/BF00172266
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P765, DOI 10.1016/0360-3016(94)90347-6
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Ranjbar M, 2018, OSLI RETINA, V49, P320, DOI 10.3928/23258160-20180501-05
   Ranjbar M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005729
   Ranjbar M, 2019, J CURR OPHTHALMOL, V31, P92, DOI 10.1016/j.joco.2018.12.004
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt JF, 1997, CURR EYE RES, V16, P1142, DOI 10.1076/ceyr.16.11.1142.5110
   Taddei PJ, 2010, PHYS MED BIOL, V55, P7037, DOI 10.1088/0031-9155/55/23/S06
   Hoang T, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-37
   Venkatesulu BP, 2018, JACC-BASIC TRANSL SC, V3, P563, DOI 10.1016/j.jacbts.2018.01.014
   Wertheimer C, 2017, INVEST OPHTH VIS SCI, V58, P6408, DOI 10.1167/iovs.17-22555
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
NR 52
TC 1
Z9 1
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 13
PY 2021
VL 11
IS 1
AR 8068
DI 10.1038/s41598-021-87466-7
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA RN8OX
UT WOS:000640612400019
PM 33850228
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Prea, SM
   Chan, EC
   Dusting, GJ
   Vingrys, AJ
   Bui, BV
   Liu, GS
AF Prea, Selwyn M.
   Chan, Elsa C.
   Dusting, Gregory J.
   Vingrys, Algis J.
   Bui, Bang V.
   Liu, Guei-Sheung
TI Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular
   Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; RETINAL-PIGMENT
   EPITHELIUM; LONG-TERM TRANSDUCTION; CHOROIDAL NEOVASCULARIZATION; TISSUE
   INHIBITOR; PLASMINOGEN KRINGLE-5; MEDIATED DELIVERY; BRUCHS MEMBRANE;
   OCULAR NEOVASCULARIZATION
AB Age-related macular degeneration (AMD) is the leading cause of substantial and irreversible vision loss amongst elderly populations in industrialized countries. The advanced neovascular (or "wet") form of the disease is responsible for severe and aggressive loss of central vision. Current treatments aim to seal off leaky blood vessels via laser therapy or to suppress vessel leakage and neovascular growth through intraocular injections of antibodies that target vascular endothelial growth factor (VEGF). However, the long-term success of anti-VEGF therapy can be hampered by limitations such as low or variable efficacy, high frequency of administration (usually monthly), potentially serious side effects, and, most importantly, loss of efficacy with prolonged treatment. Gene transfer of endogenous antiangiogenic proteins is an alternative approach that has the potential to provide long-term suppression of neovascularization and/or excessive vascular leakage in the eye. Preclinical studies of gene transfer in a large animal model have provided impressive preliminary results with a number of transgenes. In addition, a clinical trial in patients suffering from advanced neovascular AMD has provided proof-of-concept for successful gene transfer. In this mini review, we summarize current theories pertaining to the application of gene therapy for neovascular AMD and the potential benefits when used in conjunction with endogenous antiangiogenic proteins.
C1 [Prea, Selwyn M.; Vingrys, Algis J.; Bui, Bang V.] Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.
   [Prea, Selwyn M.; Chan, Elsa C.; Dusting, Gregory J.; Liu, Guei-Sheung] Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
   [Chan, Elsa C.; Dusting, Gregory J.; Liu, Guei-Sheung] Univ Melbourne, Dept Ophthalmol, East Melbourne, Vic 3002, Australia.
C3 University of Melbourne; Centre for Eye Research Australia; University
   of Melbourne
RP Bui, BV (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, 4th Floor,Alice Hoy Bldg,162 Monash Rd, Parkville, Vic 3010, Australia.
EM bvb@unimelb.edu.au; guei-sheung.liu@unimelb.edu.au
RI Liu, Guei-Sheung/Q-6472-2018; Bui, Bang/AAD-2679-2021
OI Liu, Guei-Sheung/0000-0003-3379-724X; Bui, Bang/0000-0001-7298-1352;
   Vingrys, Algis/0000-0001-5920-4604
FU National Health and Medical Research Council of Australia (NHMRC)
   [1061912]; Ophthalmic Research Institute of Australia; NHMRC
FX This work was supported by project grants from the National Health and
   Medical Research Council of Australia (NHMRC #1061912) and the
   Ophthalmic Research Institute of Australia. Gregory J. Dusting receives
   a Principal Research Fellowship from NHMRC. The Centre for Eye Research
   Australia receives Operational Infrastructure Support from the Victorian
   Government.
CR Allocca M, 2007, J VIROL, V81, P11372, DOI 10.1128/JVI.01327-07
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Bai YJ, 2013, J OCUL PHARMACOL TH, V29, P619, DOI 10.1089/jop.2012.0225
   Bainbridge JWB, 2006, GENE THER, V13, P1191, DOI 10.1038/sj.gt.3302812
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bainbridge JWB, 2001, GENE THER, V8, P1665, DOI 10.1038/sj.gt.3301574
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   Ban Y, 2000, DEV BRAIN RES, V121, P89
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   BOK D, 1993, J CELL SCI, P189
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2012, GENE THER, V19, P121, DOI 10.1038/gt.2011.164
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2011, HUM GENE THER, V22, P523, DOI 10.1089/hum.2011.050
   Carneiro A, 2009, EXP EYE RES, V88, P522, DOI 10.1016/j.exer.2008.11.011
   Chalberg TW, 2005, INVEST OPHTH VIS SCI, V46, P2140, DOI 10.1167/iovs.04-1252
   Challa P, 2005, MOL VIS, V11, P425
   Chavakis T, 2005, BLOOD, V105, P1036, DOI 10.1182/blood-2004-01-0166
   Cheng HC, 2007, MOL VIS, V13, P2344
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Contreras-Ruiz L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075937
   Cordeiro S, 2010, INVEST OPHTH VIS SCI, V51, P6001, DOI 10.1167/iovs.09-4720
   Costa R, 2009, J CELL BIOCHEM, V108, P1410, DOI 10.1002/jcb.22378
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Distler JHW, 2003, Q J NUCL MED, V47, P149
   Drixler TA, 2001, INVEST OPHTH VIS SCI, V42, P3325
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Farjo R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000038
   Felcht M, 2012, J CLIN INVEST, V122, P1991, DOI 10.1172/JCI58832
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263
   Folkman J, 2006, EXP CELL RES, V312, P594, DOI 10.1016/j.yexcr.2005.11.015
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRAYMORE CN, 1970, BRIT MED BULL, V26, P130, DOI 10.1093/oxfordjournals.bmb.a070763
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hari Danielle, 2000, Molecular Cell Biology Research Communications, V3, P277, DOI 10.1006/mcbr.2000.0222
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Huegel R, 2007, J INVEST DERMATOL, V127, P65, DOI 10.1038/sj.jid.5700484
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   Jin J, 2011, INVEST OPHTH VIS SCI, V52, P6230, DOI 10.1167/iovs.10-6229
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kim YM, 2002, J BIOL CHEM, V277, P27872, DOI 10.1074/jbc.M202771200
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Lipinski DM, 2013, PROG RETIN EYE RES, V32, P22, DOI 10.1016/j.preteyeres.2012.09.001
   Loewen N, 2004, MOL VIS, V10, P272
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Mancuso K, 2009, NATURE, V461, P784, DOI 10.1038/nature08401
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McConnell MJ, 2004, HUM GENE THER, V15, P1022, DOI 10.1089/hum.2004.15.1022
   MILLER SS, 1977, EXP EYE RES, V25, P235, DOI 10.1016/0014-4835(77)90090-2
   Molina RP, 2004, HUM GENE THER, V15, P865, DOI 10.1089/hum.2004.15.865
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nguyen TMB, 2007, BLOOD, V109, P4793, DOI 10.1182/blood-2006-11-059352
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Qin D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061831
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Rolling F, 2004, GENE THER, V11, pS26, DOI 10.1038/sj.gt.3302366
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   Sheu SJ, 2009, MOL VIS, V15, P1897
   Sheu SJ, 2005, EXP EYE RES, V81, P673, DOI 10.1016/j.exer.2005.04.005
   Smith RH, 2008, GENE THER, V15, P817, DOI 10.1038/gt.2008.55
   Sorenson CM, 2013, J DIABETES METAB, V4, DOI 10.4172/2155-6156.S12-005
   Spranger J, 2000, DIABETOLOGIA, V43, P1404, DOI 10.1007/s001250051546
   STEINBERG RH, 1983, VISION RES, V23, P1315, DOI 10.1016/0042-6989(83)90107-4
   Stieger K, 2011, METHODS MOL BIOL, V807, P179, DOI 10.1007/978-1-61779-370-7_8
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   Viita H, 2009, HUM GENE THER, V20, P1679, DOI 10.1089/hum.2009.069
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Wang SJ, 2003, DEV DYNAM, V228, P630, DOI 10.1002/dvdy.10412
   Wang YJ, 2013, ASN NEURO, V5, DOI 10.1042/AN20130028
   Weber M, 2003, MOL THER, V7, P774, DOI 10.1016/S1525-0016(03)00098-4
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zhang D, 2001, DIABETOLOGIA, V44, P757, DOI 10.1007/s001250051685
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   Zhang SX, 2005, CURR EYE RES, V30, P681, DOI 10.1080/02713680590934102
   Zhang ZH, 2005, INVEST OPHTH VIS SCI, V46, P4062, DOI 10.1167/iovs.04-1330
   Zhou R., 2010, F1000 BIOL REPORTS
NR 114
TC 15
Z9 15
U1 0
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 201726
DI 10.1155/2015/201726
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD9AJ
UT WOS:000351387700001
PM 25821585
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Wang, ZY
   Huang, XY
   Lv, X
   Chen, C
   Qu, S
   Ma, XY
   Zhang, L
   Bi, YL
AF Wang, Zhiyue
   Huang, Xinyu
   Lv, Xiao
   Chen, Chao
   Qu, Shen
   Ma, Xiaoyu
   Zhang, Li
   Bi, Yanlong
TI Bioinformatic analysis identifies potential key genes in the
   pathogenesis of age-related macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; bioinformatic analysis; potential
   genes; Gene Expression Omnibus database; functional enrichment;
   protein-protein interaction network analysis
ID SUSCEPTIBILITY LOCUS; VARIANTS; DAPL1
AB Purpose: Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in older individuals. More studies focused on screening the genes, which may be correlated with the development of AMD. With advances in various technologies like multiple microarray datasets, researchers could identify differentially expressed genes (DEGs) more accurately. Exploring abnormal gene expression in disease status can help to understand pathophysiological changes in complex diseases. This study aims to identify the key genes and upstream regulators in AMD and reveal factors, especially genetic association, and the prognosis of the development of this disease. Methods: Data from expression profile GSE125564 and profile GSE29801 were obtained from the Gene Expression Omnibus (GEO) database. We analyzed DEGs using R software (version 3.6.3). Functional enrichment and PPI network analysis were performed using the R package and online database STRING (version 11.0). Results: We compared AMD with normal and found 68 up-regulated genes (URGs) and 25 down-regulated genes (DRGs). We also compared wet AMD with dry AMD and found 41 DRGs in dry AMD. Further work including PPI network analysis, GO classification, and KEGG analysis was done to find connections with AMD. The URGs were mainly enriched in the biological process such as DNA replication, nucleoplasm, extracellular exosome, and cadherin binding. Besides, DRGs were mainly enriched in these functions such as an integral component of membrane and formation of the blood-aqueous barrier (BAB). Conclusion: This study implied that core genes might involve in the process of AMD. Our findings may contribute to revealing the pathogenesis, developing new biomarkers, and raising strategies of treatment for AMD.
C1 [Wang, Zhiyue; Huang, Xinyu; Lv, Xiao; Chen, Chao; Qu, Shen; Ma, Xiaoyu; Zhang, Li; Bi, Yanlong] Tongji Univ, Tongji Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Tongji University
RP Bi, YL (通讯作者)，Tongji Univ, Tongji Hosp, Sch Med, Dept Ophthalmol, Shanghai 200065, Peoples R China.
EM biyanlong@tongji.edu.cn
FU National Natural Science Foundation of China [82070920]; Laboratory
   animal research of "Science and technology innovation action plan" of
   Shanghai [201409006500]; Major Interdisciplinary Projects in Key Fields
   of Tongji University [15022150004]
FX Supported by National Natural Science Foundation of China (82070920);
   Laboratory animal research of "Science and technology innovation action
   plan" of Shanghai (201409006500); Major Interdisciplinary Projects in
   Key Fields of Tongji University in 2019 (15022150004).
CR AlTalbishi A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46811-7
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Christakis PG, 2020, OPHTHALMOLOGY, V127, P784, DOI 10.1016/j.ophtha.2019.11.016
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Grassmann F, 2015, NEUROMOL MED, V17, P111, DOI 10.1007/s12017-015-8342-1
   HENKIND P, 1971, ANNU REV MED, V22, P95, DOI 10.1146/annurev.me.22.020171.000523
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183
   Khan KN, 2018, EUR J HUM GENET, V26, P687, DOI 10.1038/s41431-017-0082-2
   Ma XY, 2017, HUM MOL GENET, V26, P1612, DOI 10.1093/hmg/ddx063
   Manes G, 2013, AM J HUM GENET, V93, P571, DOI 10.1016/j.ajhg.2013.07.018
   Miljkovic-Licina M, 2012, MOL CANCER THER, V11, P2588, DOI 10.1158/1535-7163.MCT-12-0245
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Olivier G, 2021, J MED GENET, V58, P570, DOI 10.1136/jmedgenet-2020-107150
   Persad PJ, 2017, INVEST OPHTH VIS SCI, V58, P4027, DOI 10.1167/iovs.17-21734
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Renata K, 2017, ADV OPHTHALMOL VIS S, V7, P259
   Roshandel D, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.2.38
   Sakai Y, 2015, BIOCHEM BIOPH RES CO, V461, P35, DOI 10.1016/j.bbrc.2015.03.163
   Schneider K, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108287
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Theurl M, 2016, FASEB J, V30, P813, DOI 10.1096/fj.15-276758
   von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034
   Wang Z, 2005, CURR EYE RES, V30, P691, DOI 10.1080/02713680590968259
   Wei TT, 2022, FEBS J, V289, P1968, DOI 10.1111/febs.16272
   Zhang GH, 2020, MOL MED REP, V22, P3635, DOI 10.3892/mmr.2020.11478
NR 30
TC 0
Z9 0
U1 1
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD SEP
PY 2022
VL 70
IS 9
BP 3347
EP 3355
DI 10.4103/ijo.IJO_3211_21
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6G2XP
UT WOS:000884620600040
PM 36018119
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Olea, JL
   Tunon, J
AF Olea, Jose Luis
   Tunon, Jose
TI Patients with neovascular age-related macular degeneration in Spain
   display a high cardiovascular risk
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Cardiovascular; Risk factors
ID CORONARY-HEART-DISEASE; ENDOTHELIAL GROWTH-FACTOR; VISUAL IMPAIRMENT;
   MACULOPATHY; POPULATION; PREVALENCE; MORTALITY; RANIBIZUMAB; PREDICTION;
   VARIANT
AB PURPOSE. Cardiovascular disease and its risk factors may have a significant role in the development of neovascular age-related macular degeneration (NV-AMD). This study aims to assess the impact of these factors in this population and define their level of cardiovascular risk according to the Framing: ham model.
   METHODS. This was a cross-sectional, observational, multicenter study that included patients aged 50 years or older who attended ophthalmic centers for the diagnosis or follow-up of NV-AMD. Information collected included demographic and AMD data, a complete history of cardiovascular disease and its risk factors, lipid profile, blood pressure, and treatment history.
   RESULTS. The study population consisted of 901 patients, predominantly Caucasian, with a mean age of 75.7 years, receiving anti-vascular endothelial growth factor therapy for their NV-AMD in 77.7% of the cases. Blood pressure measurement during the study visit and lipid analyses revealed poor control in 67.7% and 93.3% of the patients, respectively. Hypertension was the most prevalent cardiovascular risk factor (77.7%), followed by a history of cardiac disease or other forms of atherosclerotic disease (53.8%). Diabetes was present in 28% of the subjects. The study population was considered a high-risk population according to the National Cholesterol Education Program Expert Panel Clinical Guidelines (NCEP ATP III), with a probability of a cardiovascular event in 10 years of 19.3% according to the Framingham model.
   CONCLUSIONS. This NV-AMD population is associated with a significant cardiovascular risk, and the Framingham model can help us identify those subjects with higher risk levels in order to improve their overall management.
C1 [Olea, Jose Luis] Hosp Son Dureta, Dept Ophthalmol, Palma de Mallorca, Spain.
   [Tunon, Jose] Fdn Jimenez Diaz, Dept Cariol, E-28040 Madrid, Spain.
   [Tunon, Jose] Fdn Jimenez Diaz, Vasc Res Lab, E-28040 Madrid, Spain.
C3 Hospital Universitari Son Espases; Hospital Universitari Son Dureta
RP Olea, JL (通讯作者)，Hosp Son Dureta, Dept Oftalmol, C-Andrea Doria 55, Baleares 07014, Spain.
EM oleajl@eresmas.net
RI Tunon, Jose/ABA-8847-2020; Tuñón, José L/R-3037-2016
OI Tuñón, José L/0000-0003-2220-180X; OLEA, JOSE LUIS/0000-0002-3645-8262;
   Tunon, Jose/0000-0002-1373-0999
FU Pfizer Spain
FX Dr. Tunon has participated in advisory boards for Schering-Plough and
   Pfizer. The study was funded by Pfizer Spain. The authors have full
   control of the data. The study was performed with informed consent and
   following all the guidelines for experimental investigations required by
   the Institutional Review Board/Ethics Committee of which all authors are
   affiliated.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Brindle P, 2006, HEART, V92, P1752, DOI 10.1136/hrt.2006.087932
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Chou E, 2002, CIRCULATION, V105, P373, DOI 10.1161/hc0302.102143
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525
   Donnan PT, 2006, DIABETES CARE, V29, P1231, DOI 10.2337/dc05-1911
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   Gabriel R, 2008, REV ESP CARDIOL, V61, P1030, DOI 10.1016/S1885-5857(09)60006-2
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E
   Guzder RN, 2005, DIABETIC MED, V22, P554, DOI 10.1111/j.1464-5491.2005.01494.x
   Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lee ET, 2006, CIRCULATION, V113, P2897, DOI 10.1161/CIRCULATIONAHA.105.593178
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Liew G, 2007, NEW ENGL J MED, V356, P747
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Turner ST, 2007, HYPERTENSION, V50, P1, DOI 10.1161/HYPERTENSIONAHA.107.087049
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 34
TC 13
Z9 13
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2012
VL 22
IS 3
BP 404
EP 411
DI 10.5301/ejo.5000023
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 969ZZ
UT WOS:000306099200018
PM 21786274
DA 2022-11-30
ER

PT J
AU Wang, X
   Zhang, Y
   Zhang, MN
AF Wang, Xin
   Zhang, Ying
   Zhang, Mao-Nian
TI Complement factor B polymorphism (rs641153) and susceptibility to
   age-related macular degeneration: evidence from published studies
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE complement factor B; rs641153; age-related; macular degeneration;
   meta-analysis
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; COMPONENT 2 C2; FACTOR-H; CHINESE
   POPULATION; GENE POLYMORPHISMS; RISK; ASSOCIATION; METAANALYSIS;
   VARIANTS; C3
AB AIM: To determine whether single nucleotide polymorphism (SNP) rs641153 is associated with the risk of age-related macular degeneration (AMD), we performed a systematic meta-analysis of 15 eligible studies. SNP in the complement factor B (CFB) gene is considered to have significant association with AMD susceptibility, but there is great discrepancy in these results.
   METHODS: The eligible studies were identified by searching the databases of PubMed, EMBASE, and Web of Science. Odds ratios (ORs) with 95% confidence intervals (Cis) were used to assess the association. All data were analyzed using Stata software.
   RESULTS: The association between rs641153 and AMD risk was statistically significant under the homozygous model (AA vs GG:OR=0.26, 95%CI=0.15-0.45, P-h=0.973, 1(2)=0.0%, fixed effects), dominant model (AA+GA vsGG: OR=0.49, 95%CI=0.40-0.59, P-h=0.004, 1(2)=56.4%, random effects) and recessive model (AA vs GA+GG:OR=0.30, 95%CI=0.17-0.51, P-h=0.983, 1(2)=0.0%, fixed effects). The same results were also observed in the stratified analyses by ethnicity, source of control and sample size.
   CONCLUSION: Our meta-analysis suggests that rs641153 in the CFB gene may play a protective role in AMD susceptibility, the late AMD in particular, both in Caucasians and in Asians.
C1 [Wang, Xin; Zhang, Ying; Zhang, Mao-Nian] Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Zhang, MN (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing 100853, Peoples R China.
EM Zhangmaonian_2000@163.com
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Cipriani V, 2012, IMMUNOBIOLOGY, V217, P158, DOI 10.1016/j.imbio.2011.09.002
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hughes AE, 2013, AM J EPIDEMIOL
   Hughes AE, 2011, MOL VIS, V17, P983
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mantel I, 2013, OPHTHALMIC GENET
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
NR 43
TC 9
Z9 10
U1 0
U2 5
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD DEC 18
PY 2013
VL 6
IS 6
BP 861
EP 867
DI 10.3980/j.issn.2222-3959.2013.06.21
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 276CS
UT WOS:000328726300021
PM 24392338
DA 2022-11-30
ER

PT J
AU Kauppinen, A
   Niskanen, H
   Suuronen, T
   Kinnunen, K
   Salminen, A
   Kaarniranta, K
AF Kauppinen, Anu
   Niskanen, Henri
   Suuronen, Tiina
   Kinnunen, Kati
   Salminen, Antero
   Kaarniranta, Kai
TI Oxidative stress activates NLRP3 inflammasomes in ARPE-19
   cells-Implications for age-related macular degeneration (AMD)
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE Age-related macular degeneration (AMD); Aging; Inflammasome;
   Inflammation; NLRP3; Retinal pigment epithelium (RPE)
ID PIGMENT EPITHELIAL-CELLS; NF-KAPPA-B; GENE-EXPRESSION; INNATE IMMUNITY;
   RECEPTORS; INTERLEUKIN-1-BETA; ACCUMULATION; PATHOGENESIS; SECRETION;
   DISEASE
AB Oxidative stress and inflammation are known to be associated with age-related macular degeneration (AMD). Retinal pigment epithelial (RPE) cells play the principal role in the immune defense of macula, and their dysfunction is a crucial event leading to clinically relevant changes seen in AMD. In the present study, we have examined the ability of oxidative stress to activate inflammasome signaling in the human ARPE-19 cells by adding the lipid peroxidation end product 4-hydroxynonenal (HNE) to cell cultures pre-treated or not treated with the endotoxin, LPS. Our results indicate that LPS and HNE significantly increased the production of IL-6 and IL-18, respectively. LPS treatment preceding HNE induced an even greater increase in the production of IL-18 than HNE alone. In addition to IL-18, HNE significantly increased the production of IL-1 beta. The productions of IL-1 beta and IL-18 were reduced in the cell cultures pre-treated with the Caspase-1 inhibitor. PCR analysis revealed that HNE induced an over 5-fold increase in the amount of NLRP3 mRNA compared to control cells; LPS had no effect. In conclusion, our present data suggest that oxidative stress can activate NLRP3 inflammasomes in RPE cells which occupy center stage in the pathogenesis of AMD. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Kauppinen, Anu; Kinnunen, Kati; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
   [Niskanen, Henri] Univ Eastern Finland, Dept Biotechnol & Mol Med, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland.
   [Suuronen, Tiina; Salminen, Antero] Univ Eastern Finland, Dept Neurol, Inst Clin Med, FIN-70211 Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland.
   [Kinnunen, Kati; Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Eastern Finland; Kuopio University Hospital; Kuopio University
   Hospital
RP Kauppinen, A (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FIN-70211 Kuopio, Finland.
EM anu.kauppinen@uef.fi
OI Niskanen, Henri/0000-0002-8361-5531; Kaarniranta,
   Kai/0000-0003-2600-8679
FU Academy of Finland; Paivikki and Sakari Sohlberg Foundation;
   Orion-Farmos Research Foundation; Evald and Hilda Nissi Foundation
FX We thank Dr. Ewen MacDonald for revising the language of this article.
   This study was financially supported by the Academy of Finland, The
   Paivikki and Sakari Sohlberg Foundation, the Orion-Farmos Research
   Foundation, and the Evald and Hilda Nissi Foundation.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x
   Busillo JM, 2011, J BIOL CHEM, V286, P38703, DOI 10.1074/jbc.M111.275370
   Cannizzo ES, 2011, J PROTEOMICS, V74, P2313, DOI 10.1016/j.jprot.2011.06.005
   Cassel SL, 2009, SEMIN IMMUNOL, V21, P194, DOI 10.1016/j.smim.2009.05.002
   Chen G, 2009, ANNU REV PATHOL-MECH, V4, P365, DOI 10.1146/annurev.pathol.4.110807.092239
   Dinarello CA, 2005, CRIT CARE MED, V33, pS460, DOI 10.1097/01.CCM.0000185500.11080.91
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   HOGQUIST KA, 1991, J IMMUNOL, V147, P2181
   Jin CC, 2010, J CLIN IMMUNOL, V30, P628, DOI 10.1007/s10875-010-9440-3
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Martinon F, 2004, CURR BIOL, V14, P1929, DOI 10.1016/j.cub.2004.10.027
   Martinon F, 2010, EUR J IMMUNOL, V40, P616, DOI 10.1002/eji.200940168
   Mattson MP, 2009, EXP GERONTOL, V44, P625, DOI 10.1016/j.exger.2009.07.003
   Melloul D, 2008, BIOCHEM SOC T, V36, P334, DOI 10.1042/BST0360334
   Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946
   Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Connor W, 2003, J IMMUNOL, V171, P6329, DOI 10.4049/jimmunol.171.12.6329
   Paimela T, 2007, IMMUNOL LETT, V110, P139, DOI 10.1016/j.imlet.2007.04.008
   Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002
   Puren AJ, 1999, P NATL ACAD SCI USA, V96, P2256, DOI 10.1073/pnas.96.5.2256
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Sola-Villa D, 2006, KIDNEY INT, V70, P1935, DOI 10.1038/sj.ki.5001948
   Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
NR 37
TC 159
Z9 169
U1 4
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
J9 IMMUNOL LETT
JI Immunol. Lett.
PD SEP-OCT
PY 2012
VL 147
IS 1-2
BP 29
EP 33
DI 10.1016/j.imlet.2012.05.005
PG 5
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 013MX
UT WOS:000309310600004
PM 22698681
DA 2022-11-30
ER

PT J
AU Hu, JY
   Yuan, Y
   Shen, L
   Zhang, JF
   Hu, N
   Guan, HJ
AF Hu, Jianyan
   Yuan, Yuan
   Shen, Lei
   Zhang, Junfang
   Hu, Nan
   Guan, Huaijin
TI Age-Related Macular Degeneration-Susceptibility Single Nucleotide
   Polymorphisms in a Han Chinese Control Population
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Single nucleotide polymorphisms; Age-related macular degeneration;
   Frequency; Han Chinese; Population-based study
ID COMPLEMENT-FACTOR-H; VISUAL IMPAIRMENT; GEOGRAPHIC ATROPHY; HTRA1;
   ASSOCIATION; GENE; VARIANTS; LOC387715; CFH; BLINDNESS
AB Purpose: Our study aimed to detect the frequency of age-related macular degeneration (AMD)-susceptibility single nucleotide polymorphisms (SNPs) in control subjects of Han Chinese in a population-based study.
   Methods: A total of 419 subjects of Han Chinese without AMD were recruited from our population-based Nantong Eye Study. Nine AMD-susceptibility SNPs were genotyped. The allele/genotype frequencies were compared with the data from the literature and NCBI Reference Assembly.
   Results: The call rates of genotyping were > 98%. All tested SNPs except for HTRA1 rs11200638 were in Hardy-Weinberg Equilibrium (HWE). The allele distributions of some AMD-susceptibility SNPs were different from the records for the Chinese population in the National Center for Biotechnology Information (NCBI) Reference Assembly. Compared to those in a Caucasian population, the frequency of minor alleles of CFH rs800292 (48% vs. 19.2%) and HTRA1 rs11200638 were much higher (47% vs. 25%), while the frequency of minor alleles of CFH rs1061170 (9% vs. 35%), CX3CR1 rs3732379 (3% vs. 21%), CX3CR1 rs3732378 (3% vs. 11%) and SERPING1 rs2511989 (11% vs. 48%) were much lower in the Han Chinese population. Minor differences were observed in the frequency of minor alleles of CFB rs4151667, C2 rs547154 and TLR3 rs3775291. The allele/genotype frequencies of CFH rs1061170 and HTRA1 rs11200638, two well-confirmed AMD-susceptible SNPs, were close to each other in the Han Chinese and Japanese population.
   Conclusion: The distribution of AMD-susceptibility SNPs shows ethnicity specificity. Substantial differences of the SNPs' distribution were noted from study to study, even within the same ethnic group. The genotype data will be used for longitudinal observation of AMD onset in the follow-up of the cohort.
C1 [Hu, Jianyan; Yuan, Yuan; Shen, Lei; Zhang, Junfang; Hu, Nan; Guan, Huaijin] Nantong Univ, Dept Ophthalmol, Affiliated Hosp, Nantong 226001, Jiangsu Prov, Peoples R China.
C3 Nantong University
RP Guan, HJ (通讯作者)，Nantong Univ, Dept Ophthalmol, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu Prov, Peoples R China.
EM gtnantongeye@gmail.com
FU Key Medical Laboratory Program of Jiangsu Province [XK200724]
FX This research was supported by the Key Medical Laboratory Program of
   Jiangsu Province (No. XK200724).
CR Abdulla MA, 2009, SCIENCE, V326, P1541, DOI 10.1126/science.1177074
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chen JM, 2009, AM J HUM GENET, V85, P775, DOI 10.1016/j.ajhg.2009.10.016
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chowers I, 2008, MOL VIS, V14, P1829
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cotter SA, 2006, OPHTHALMOLOGY, V113, P1574, DOI 10.1016/j.ophtha.2006.05.002
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Guan HJ, 2009, EXPERT REV OPHTHALMO, V4, P377, DOI 10.1586/EOP.09.29
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Li L, 2008, EYE, V22, P1069, DOI 10.1038/eye.2008.53
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Pulido JS, 2007, OPHTHALMIC GENET, V28, P203, DOI 10.1080/13816810701649617
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SIMONELLI F, 2006, BR J OPHTHALMOL, V90, P1080
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Xu SH, 2009, AM J HUM GENET, V85, P762, DOI 10.1016/j.ajhg.2009.10.015
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhou J, 2010, INVEST OPHTH VIS SCI, V51, P3924, DOI 10.1167/iovs.10-5240
NR 35
TC 13
Z9 13
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD JUN
PY 2011
VL 18
IS 3
BP 137
EP 142
DI 10.3109/09286586.2011.574335
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 768RL
UT WOS:000290954700006
PM 21609242
DA 2022-11-30
ER

PT J
AU Quellec, G
   Russell, SR
   Scheetz, TE
   Stone, EM
   Abramoff, MD
AF Quellec, Gwenole
   Russell, Stephen R.
   Scheetz, Todd E.
   Stone, Edwin M.
   Abramoff, Michael D.
TI Computational Quantification of Complex Fundus Phenotypes in Age-Related
   Macular Degeneration and Stargardt Disease
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; AUTOMATED DETECTION; RISK; SUSCEPTIBILITY;
   VARIANT; GENE; PHOTOGRAPHS; DRUSEN; SEGMENTATION; INCREASES
AB PURPOSE. To describe an automated method of quantification of specific fundus phenotypes and evaluate its performance in differentiating drusen, the hallmark lesions of age-related macular degeneration (AMD), from similar-looking bright lesions, the pisciform deposits or flecks typical of Stargardt disease (SD).
   METHODS. Fundus macular images of 30 eyes of 30 subjects were studied. Fifteen subjects had a clinical diagnosis of AMD with at least 10 intermediate and/or 1 large drusen, and the other 15 had SD. As a test of bright-lesion separation, AMD and SD subjects were chosen from the heterogeneous phenotypes of each disorder, to be as visually similar as possible. Drusen and fleck properties were quantified from the color images by using an automated method, and a shape classifier was used to divide the images as characteristic of either AMD or SD. Image identification performance was quantified by using the area under the receiver operating characteristic curve (AUC).
   RESULTS. All SD subjects demonstrated at least one disease-associated variant of the ABCA4 gene. The method achieved an AUC of 0.936 for differentiating AMD from SD.
   CONCLUSIONS. Automated quantification of fundus phenotypes was achieved, and the results show that the method can differentiate AMD from SD, two distinctly different genetically associated disorders, by quantifying the properties of the bright lesions (drusen and flecks) in their fundus images, even when the images were visually selected to be similar. Quantification of fundus phenotypes may allow recognition of new phenotypes, correlation with new genotypes and may measure disease-specific biomarkers to improve management of patients with AMD or SD. (Invest Ophthalmol Vis Sci. 2011;52:2976-2981) DOI:10.1167/iovs.10-6232
C1 [Quellec, Gwenole; Russell, Stephen R.; Scheetz, Todd E.; Stone, Edwin M.; Abramoff, Michael D.] Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Russell, Stephen R.; Scheetz, Todd E.; Stone, Edwin M.; Abramoff, Michael D.] Univ Iowa, Inst Vis Res, Iowa City, IA USA.
   [Quellec, Gwenole; Scheetz, Todd E.; Abramoff, Michael D.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
   [Stone, Edwin M.] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] Iowa City VA Med Ctr, Dept Vet Affairs, Iowa City, IA USA.
C3 University of Iowa; University of Iowa; University of Iowa; University
   of Iowa; Howard Hughes Medical Institute; University of Iowa; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Iowa City VA Health Care System
RP Abramoff, MD (通讯作者)，Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM michael-abramoff@uiowa.edu
RI Abramoff, Michael D/A-5836-2009; Quellec, Gwenole/L-9946-2015
OI Abramoff, Michael D/0000-0002-3490-0037; Quellec,
   Gwenole/0000-0003-1669-7140; Scheetz, Todd/0000-0002-1965-5811; Russell,
   Stephen/0000-0003-3776-1367; Stone, Edwin M./0000-0003-3343-4414
FU National Eye Institute [R01 EY017066, R01 EY11309, R01 EY16822];
   Research to Prevent Blindness, NY; Department of Veterans Affairs;
   NATIONAL EYE INSTITUTE [R01EY016822, R01EY011309, R01EY017066] Funding
   Source: NIH RePORTER
FX Supported by National Eye Institute Grants R01 EY017066, R01 EY11309,
   and R01 EY16822; Research to Prevent Blindness, NY; and the Department
   of Veterans Affairs.
CR Abramoff MD, 2007, INVEST OPHTH VIS SCI, V48, P1665, DOI 10.1167/iovs.06-1081
   Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Abramoff MD, 2010, OPHTHALMOLOGY, V117, P1147, DOI 10.1016/j.ophtha.2010.03.046
   Arya S, 1998, J ACM, V45, P891, DOI 10.1145/293347.293348
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Barthes A, 2001, MED PHYS, V28, P2410, DOI 10.1118/1.1420735
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   EBDON D, 1985, STAT GEOGRAPHY, P232
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fleming AD, 2007, PHYS MED BIOL, V52, P7385, DOI 10.1088/0031-9155/52/24/012
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koenekoop Robert K, 2003, Ophthalmic Genet, V24, P75, DOI 10.1076/opge.24.2.75.13996
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Quellec G, 2008, IEEE T MED IMAGING, V27, P1230, DOI 10.1109/TMI.2008.920619
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schindler EI, 2010, HUM MOL GENET, V19, P3693, DOI 10.1093/hmg/ddq284
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   STONE EM, 2004, NEW ENGL J MED, V351, P20
   Walia S, 2009, OPHTHALMIC GENET, V30, P63, DOI 10.1080/13816810802695550
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 34
TC 13
Z9 13
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2011
VL 52
IS 6
BP 2976
EP 2981
DI 10.1167/iovs.10-6232
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 770PN
UT WOS:000291100800015
PM 21310908
OA Green Published
DA 2022-11-30
ER

PT J
AU Pariente, A
   Pelaez, R
   Perez-Sala, A
   Larrayoz, IM
AF Pariente, Ana
   Pelaez, Rafael
   Perez-Sala, Alvaro
   Larrayoz, Ignacio M.
TI Inflammatory and cell death mechanisms induced by 7-ketocholesterol in
   the retina. Implications for age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE Retina; 7-Ketocholesterol; Cell death; Inflammation; Signaling;
   Age-related macular degeneration; Sterculid acid; Antioxidants; ROS
ID LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; ARYL-HYDROCARBON RECEPTOR;
   DOCOSAHEXAENOIC ACID DHA; GENOME-WIDE ASSOCIATION; LIVER X RECEPTOR;
   NF-KAPPA-B; CHOLESTEROL OXIDATION; PIGMENT EPITHELIUM; ALPHA-TOCOPHEROL
AB This review will focus on the inflammatory and toxic mechanism of action of 7-ketocholesterol (7KCh) and the potential implications of its accumulation, especially in the retina. 7KCh is a pro-inflammatory oxysterol usually associated with oxidized lipoprotein deposits present in aged retinas. High amounts of 7KCh can be generated in situ in these lipoprotein deposits possibly through a free radical-mediated mechanism catalyzed by iron. 7KCh seems to activate several kinase signaling pathways that work via multiple transcription factors to induce cytokines and intracellular effectors causing cell death. There seems to be a controversy in the literature in relation to the mechanisms of death induced by 7KCh. Some of the discrepancies arise from the way the oxysterol is delivered because different signaling pathways are activated in different experimental setups. The elucidation of the inflammatory and toxic mechanisms is crucial for the discovery and design of new therapies. Importantly, there is little evidence of 7KCh detoxifying mechanisms in the retina, although some potential enzymes have been described. Thus, continuous formation throughout life and potential toxicity of 7KCh points it out as an "age-related" risk factor in pathologies such as age-related macular degeneration.
C1 [Pariente, Ana; Pelaez, Rafael; Perez-Sala, Alvaro; Larrayoz, Ignacio M.] Ctr Biomed Res La Rioja CIBIR, Neurodegenerat Area, Biomarkers & Mol Signaling Grp, Piqueras 98, Logrono 26006, Spain.
RP Larrayoz, IM (通讯作者)，Ctr Biomed Res La Rioja CIBIR, Neurodegenerat Area, Biomarkers & Mol Signaling Grp, Piqueras 98, Logrono 26006, Spain.
EM ilarrayoz@riojasalud.es
RI Larrayoz, Ignacio M/I-5613-2012
OI Larrayoz, Ignacio M/0000-0003-1629-152X; Pariente Delgado,
   Ana/0000-0001-9046-6629; Perez Sala, Alvaro/0000-0002-7310-6792
FU Miguel Servet contract from the nstituto de Salud Carlos III- FEDER
   (Fondo Europeo de Desarrollo Regional, a way to build Europe)
   [CP15/00198]; Fundacion Rioja Salud
FX I.M.L. is supported by a Miguel Servet contract (CP15/00198) from the
   Instituto de Salud Carlos III- FEDER (Fondo Europeo de Desarrollo
   Regional, a way to build Europe) and by Fundacion Rioja Salud.
CR Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002
   Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Amaral J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056099
   Ananth S, 2014, BBA-MOL BASIS DIS, V1842, P603, DOI 10.1016/j.bbadis.2014.01.010
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Badreddine A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102220
   Baranowski M, 2008, J PHYSIOL PHARMACOL, V59, P31
   BERGER JW, 1999, AGE RELATED MACULAR
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592
   Bjorkhem I, 2009, MOL ASPECTS MED, V30, P171, DOI 10.1016/j.mam.2009.02.001
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   Brown AJ, 1996, J LIPID RES, V37, P320
   Brown AJ, 2009, MOL ASPECTS MED, V30, P111, DOI 10.1016/j.mam.2009.02.005
   Buttari B, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/257543
   Butterfield DA, 2012, INT J NEUROPSYCHOPH, V15, P981, DOI 10.1017/S1461145711001118
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chang MC, 2016, ONCOTARGET, V7, P74473, DOI 10.18632/oncotarget.12578
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cho HR, 2018, BIOCHEM BIOPH RES CO, V497, P521, DOI 10.1016/j.bbrc.2018.02.064
   Choudhary M, 2015, J PATHOL, V235, P101, DOI 10.1002/path.4433
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dasari B, 2013, CURR EYE RES, V38, P1159, DOI 10.3109/02713683.2013.811257
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Debbabi M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121973
   Deiana M, 2017, FREE RADICAL BIO MED, V113, P539, DOI 10.1016/j.freeradbiomed.2017.10.390
   Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Dulakk J, 2001, ATHEROSCLEROSIS, V159, P325, DOI 10.1016/S0021-9150(01)00520-2
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Dzeletovic S, 1995, CHEM PHYS LIPIDS, V78, P119, DOI 10.1016/0009-3084(95)02489-6
   Erridge C, 2007, ATHEROSCLEROSIS, V193, P77, DOI 10.1016/j.atherosclerosis.2006.08.032
   Escajadillo T, 2016, MOL CELL ENDOCRINOL, V427, P73, DOI 10.1016/j.mce.2016.03.006
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Filomenko R, 2015, STEROIDS, V99, P259, DOI 10.1016/j.steroids.2015.02.004
   FLIESLER SJ, 1993, FEBS LETT, V335, P234, DOI 10.1016/0014-5793(93)80736-E
   Flores-Bellver M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.288
   Freeman NE, 2005, J LIPID RES, V46, P1933, DOI 10.1194/jlr.M500101-JLR200
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fuda H, 2007, J LIPID RES, V48, P1343, DOI 10.1194/jlr.M700018-JLR200
   Gehlbach P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub3
   Girao H, 2003, EXP CELL RES, V291, P502, DOI 10.1016/j.yexcr.2003.08.002
   Goldin E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029861
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   GORDON WC, 1997, CELLULAR ORG BIOCH R
   Gramajo AL, 2010, INVEST OPHTH VIS SCI, V51, P1164, DOI 10.1167/iovs.09-3443
   Hakamata H, 1998, J Atheroscler Thromb, V5, P66
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   Hazim RA, 2019, EXP EYE RES, V179, P18, DOI 10.1016/j.exer.2018.10.009
   He CY, 2013, AM J PATHOL, V183, P626, DOI 10.1016/j.ajpath.2013.04.028
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Heo GY, 2011, J LIPID RES, V52, P1117, DOI 10.1194/jlr.M014217
   Hozoji M, 2008, J BIOL CHEM, V283, P30057, DOI 10.1074/jbc.M804599200
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Huang JD, 2012, BBA-MOL CELL BIOL L, V1821, P637, DOI 10.1016/j.bbalip.2012.01.013
   Huang JN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109996
   Hynynen R, 2009, J LIPID RES, V50, P1305, DOI 10.1194/jlr.M800661-JLR200
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Ingueneau C, 2009, J CELL MOL MED, V13, P1620, DOI 10.1111/j.1582-4934.2008.00593.x
   Ito MK, 2006, PHARMACOTHERAPY, V26, p85S, DOI 10.1592/phco.26.7part2.85S
   Ito MK, 2006, PHARMACOTHERAPY, V26, p98S, DOI 10.1592/phco.26.7part2.98S
   Ito MK, 2006, PHARMACOTHERAPY, V26, p106S
   Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266
   Jessup W, 2005, REJUV RES, V8, P9, DOI 10.1089/rej.2005.8.9
   Jessup W, 2002, VASC PHARMACOL, V38, P239, DOI 10.1016/S1537-1891(02)00174-X
   Joffre C, 2007, CURR EYE RES, V32, P271, DOI 10.1080/02713680601187951
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kawajiri K, 2017, EXP ANIM TOKYO, V66, P75, DOI 10.1538/expanim.16-0092
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim A, 2017, BRAIN RES BULL, V134, P63, DOI 10.1016/j.brainresbull.2017.07.008
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Lee JW, 2006, EXP EYE RES, V83, P465, DOI 10.1016/j.exer.2005.11.018
   Lee JW, 2015, BBA-MOL CELL BIOL L, V1851, P605, DOI 10.1016/j.bbalip.2015.01.007
   Lemaire S, 1998, FEBS LETT, V440, P434, DOI 10.1016/S0014-5793(98)01496-3
   Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2
   Leoni V, 2017, J STEROID BIOCHEM, V169, P96, DOI 10.1016/j.jsbmb.2016.03.029
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Li-Hawkins J, 2000, J BIOL CHEM, V275, P16543, DOI 10.1074/jbc.M001810200
   Liao WL, 2011, J PROTEOME RES, V10, P241, DOI 10.1021/pr1008898
   Lin JB, 2016, J LIPID RES, V57, P258, DOI 10.1194/jlr.M064469
   Lordan S, 2009, J NUTR BIOCHEM, V20, P321, DOI 10.1016/j.jnutbio.2009.01.001
   Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316
   Luthra S, 2008, MICROVASC RES, V75, P343, DOI 10.1016/j.mvr.2007.10.003
   Luu WN, 2016, ANNU REV PHARMACOL, V56, P447, DOI 10.1146/annurev-pharmtox-010715-103233
   Lyons MA, 1999, INT J BIOCHEM CELL B, V31, P369, DOI 10.1016/S1357-2725(98)00123-X
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Martinet W, 2008, BRIT J PHARMACOL, V154, P1236, DOI 10.1038/bjp.2008.181
   Mast N, 2018, DRUG METAB DISPOS, V46, P1528, DOI 10.1124/dmd.118.083345
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Mitic T, 2013, BIOCHIMIE, V95, P548, DOI 10.1016/j.biochi.2012.08.007
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Miyashita Yoh, 2002, J Atheroscler Thromb, V9, P65
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Mutemberezi V, 2016, PROG LIPID RES, V64, P152, DOI 10.1016/j.plipres.2016.09.002
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Norlin M, 2007, CURR MOL MED, V7, P199, DOI 10.2174/156652407780059168
   Nury T, 2015, STEROIDS, V99, P194, DOI 10.1016/j.steroids.2015.02.003
   Nury T, 2014, BIOCHEM BIOPH RES CO, V446, P714, DOI 10.1016/j.bbrc.2013.11.081
   Olivier E, 2016, BIOCHIMIE, V127, P70, DOI 10.1016/j.biochi.2016.04.014
   Olkkonen VM, 2009, MOL ASPECTS MED, V30, P123, DOI 10.1016/j.mam.2009.02.004
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pfeffer BA, 2016, EXP EYE RES, V145, P297, DOI 10.1016/j.exer.2016.01.016
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Poli G, 2009, MOL ASPECTS MED, V30, P180, DOI 10.1016/j.mam.2009.02.003
   Raccosta L, 2013, J EXP MED, V210, P1711, DOI 10.1084/jem.20130440
   Ragot K, 2013, BIOCHEM PHARMACOL, V86, P67, DOI 10.1016/j.bcp.2013.02.028
   Ragot K, 2011, CHEM PHYS LIPIDS, V164, P469, DOI 10.1016/j.chemphyslip.2011.04.014
   Ramirez DMO, 2008, J COMP NEUROL, V507, P1676, DOI 10.1002/cne.21605
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rodriguez IR, 2009, PHOTOCHEM PHOTOBIOL, V85, P1116, DOI 10.1111/j.1751-1097.2009.00568.x
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Rosa-Fernandes L., 2017, CHEM PHYS LIPIDS
   Rosales C, 2015, ATHEROSCLEROSIS, V239, P224, DOI 10.1016/j.atherosclerosis.2015.01.004
   Royer MC, 2009, J BIOL CHEM, V284, P15826, DOI 10.1074/jbc.M808641200
   Ruiz JLM, 2013, BIOCHEM PHARMACOL, V86, P80, DOI 10.1016/j.bcp.2013.02.033
   Saadane A, 2019, AM J PATHOL, V189, P405, DOI 10.1016/j.ajpath.2018.10.013
   Saadane A, 2018, J LIPID RES, V59, P2368, DOI 10.1194/jlr.M090043
   Saadane A, 2016, J BIOL CHEM, V291, P20427, DOI 10.1074/jbc.M116.744656
   Samuel W, 2017, MOL VIS, V23, P60
   Sato Y, 2017, MOL GENET METAB REP, V10, P56, DOI 10.1016/j.ymgmr.2017.01.006
   Savouret JF, 2001, J BIOL CHEM, V276, P3054, DOI 10.1074/jbc.M005988200
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Seimon T, 2009, J LIPID RES, V50, pS382, DOI 10.1194/jlr.R800032-JLR200
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shi GP, 2015, INVEST OPHTH VIS SCI, V56, P1658, DOI 10.1167/iovs.14-14557
   Shimozawa M, 2004, REDOX REP, V9, P370, DOI 10.1179/135100004225006902
   Shinkyo R, 2011, J BIOL CHEM, V286, P33021, DOI 10.1074/jbc.M111.282434
   Smith L., 1990, MECH FORMATION OXYST, P115
   Song D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00024
   Sung SC, 2009, J VASC RES, V46, P36, DOI 10.1159/000135663
   Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675
   Tall AR, 2008, J INTERN MED, V263, P256, DOI 10.1111/j.1365-2796.2007.01898.x
   Tall AR, 2008, CELL METAB, V7, P365, DOI 10.1016/j.cmet.2008.03.001
   Taylor A, 2012, MOL ASPECTS MED, V33, P291, DOI 10.1016/j.mam.2012.04.002
   Terasaka N, 2007, P NATL ACAD SCI USA, V104, P15093, DOI 10.1073/pnas.0704602104
   Tesoriere L, 2013, BRIT J NUTR, V110, P230, DOI 10.1017/S000711451200493X
   Tian B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02407-7
   Tian L, 2011, J AGR FOOD CHEM, V59, P6453, DOI 10.1021/jf200544r
   Torocsik D, 2009, MOL ASPECTS MED, V30, P134, DOI 10.1016/j.mam.2009.02.002
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   van Reyk DM, 2006, REDOX REP, V11, P255, DOI 10.1179/135100006X155003
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Vejux A, 2009, MOL ASPECTS MED, V30, P153, DOI 10.1016/j.mam.2009.02.006
   Wang HB, 2016, INVEST OPHTH VIS SCI, V57, P5525, DOI 10.1167/iovs.16-19691
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang YJ, 2010, J BIOL CHEM, V285, P5013, DOI 10.1074/jbc.M109.080614
   Wu TH, 2010, J NEUROCHEM, V114, P1734, DOI 10.1111/j.1471-4159.2010.06884.x
   Wu ZL, 1999, J LIPID RES, V40, P2195
   Wysokinski D, 2013, EXP EYE RES, V106, P14, DOI 10.1016/j.exer.2012.10.003
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yamagata K, 2013, MICROVASC RES, V88, P25, DOI 10.1016/j.mvr.2013.03.006
   Yang P, 2017, INVEST OPHTH VIS SCI, V58, P3073, DOI 10.1167/iovs.16-20083
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zarrouk A, 2015, STEROIDS, V99, P238, DOI 10.1016/j.steroids.2015.01.018
   Zhang CX, 2003, J CELL SCI, V116, P1915, DOI 10.1242/jcs.00390
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
NR 181
TC 12
Z9 13
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2019
VL 187
AR 107746
DI 10.1016/j.exer.2019.107746
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JB9FO
UT WOS:000488887100001
PM 31394101
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Libondi, T
   Ihloff, AK
   Harder, B
   Kreissig, I
   Schlichtenbrede, F
   Sauder, G
   Spandau, UHM
AF Jonas, Jost B.
   Libondi, Teodosio
   Ihloff, Anna K.
   Harder, Bjorn
   Kreissig, Ingrid
   Schlichtenbrede, Frank
   Sauder, Gangolf
   Spandau, Ulrich H. M.
TI Visual acuity change after intravitreal bevacizumab for exudative
   age-related macular degeneration in relation to subfoveal membrane type
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE intravitreal bevacizumab; Avastin; exudative age-related macular
   degeneration; intraocular antiangiogenesis
ID CHOROIDAL NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE; AVASTIN;
   VERTEPORFIN; INJECTION; THERAPY
AB Purpose: To examine an association between the subfoveal neovascular membrane type and visual acuity change after intravitreal bevacizumab injection for exudative age-related macular degeneration (AMD).
   Methods: We carried out a clinical, retrospective, interventional case-series study including 66 consecutive patients (67 eyes) with exudative AMD who received an intravitreal injection of 1.5 mg bevacizumab. Study subgroups included the occult type without or with minimally classic subfoveal neovascularization (n = 28 eyes, 42%), predominantly or purely classic subfoveal neovascularization (n = 22 eyes, 33%), and eyes with retinal pigment epithelium detachment (n = 17 eyes, 25%). Follow-up was >= 2 months.
   Results: The maximal visual acuity (VA) gain (mean +/- standard deviation - 0.07 +/- 0.30 logMAR, 0.5 +/- 2.9 Snellen lines; p = 0.87), and VA gain at 1 month (p = 0.10), 2 months (p = 0.77) and 3 months (p = 0.35) after the injection did not vary significantly between the three study subgroups. Correspondingly, a multivariate analysis did not reveal a statistically significant (p = 0.57) influence of subfoveal lesion type on gain in VA.
   Conclusions: Visual improvement after intravitreal bevacizumab does not differ markedly between various types of subfoveal neovascularization in AMD.
C1 Heidelberg Univ, Fac Clin Med Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
   Univ Naples Federico II, Fac Med, Dept Ophthalmol, Naples, Italy.
C3 Ruprecht Karls University Heidelberg; University of Naples Federico II
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uniheidelberg.de
CR Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
NR 18
TC 39
Z9 42
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD AUG
PY 2007
VL 85
IS 5
BP 563
EP 565
DI 10.1111/j.1600-0420.2007.00891.x
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 193OF
UT WOS:000248282700014
PM 17324219
DA 2022-11-30
ER

PT J
AU Hoffman, JD
   Bailey, JNC
   D'Aoust, L
   Cade, W
   Ayala-Haedo, J
   Fuzzell, D
   Laux, R
   Adams, LD
   Reinhart-Mercer, L
   Caywood, L
   Whitehead-Gay, P
   Agarwal, A
   Wang, GF
   Scott, WK
   Pericak-Vance, MA
   Haines, JL
AF Hoffman, Joshua D.
   Bailey, Jessica N. Cooke
   D'Aoust, Laura
   Cade, William
   Ayala-Haedo, Juan
   Fuzzell, Denise
   Laux, Renee
   Adams, Larry D.
   Reinhart-Mercer, Lori
   Caywood, Laura
   Whitehead-Gay, Patrice
   Agarwal, Anita
   Wang, Gaofeng
   Scott, William K.
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI Rare Complement Factor H Variant Associated With Age-Related Macular
   Degeneration in the Amish
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; linkage analysis; rare variant; exome
   sequencing; risk score analysis
ID AMERICAN ANABAPTIST GENEALOGY; LINKAGE ANALYSIS; CHROMOSOME 10Q26;
   HIGH-RISK; GENE; MACULOPATHY; PREVALENCE; IDENTIFICATION; POPULATION;
   LOC387715
AB PURPOSE. Age-related macular degeneration is the leading cause of blindness among the adult population in the developed world. To further the understanding of this disease, we have studied the genetically isolated Amish population of Ohio and Indiana.
   METHODS. Cumulative genetic risk scores were calculated using the 19 known allelic associations. Exome sequencing was performed in three members of a small Amish family with AMD who lacked the common risk alleles in complement factor H (CFH) and ARMS2/HTRA1. Follow-up genotyping and association analysis was performed in a cohort of 973 Amish individuals, including 95 with self-reported AMD.
   RESULTS. The cumulative genetic risk score analysis generated a mean genetic risk score of 1.12 (95% confidence interval [CI]: 1.10, 1.13) in the Amish controls and 1.18 (95% CI: 1.13, 1.22) in the Amish cases. This mean difference in genetic risk scores is statistically significant (P = 0.0042). Exome sequencing identified a rare variant (P503A) in CFH. Association analysis in the remainder of the Amish sample revealed that the P503A variant is significantly associated with AMD (P = 9.27 X 10(-13)). Variant P503A was absent when evaluated in a cohort of 791 elderly non-Amish controls, and 1456 non-Amish cases.
   CONCLUSIONS. Data from the cumulative genetic risk score analysis suggests that the variants reported by the AMDGene consortium account for a smaller genetic burden of disease in the Amish compared with the non-Amish Caucasian population. Using exome sequencing data, we identified a novel missense mutation that is shared among a densely affected nuclear Amish family and located in a gene that has been previously implicated in AMD risk.
C1 [Hoffman, Joshua D.; D'Aoust, Laura; Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
   [Bailey, Jessica N. Cooke; Fuzzell, Denise; Laux, Renee; Haines, Jonathan L.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Cade, William; Ayala-Haedo, Juan; Adams, Larry D.; Reinhart-Mercer, Lori; Caywood, Laura; Whitehead-Gay, Patrice; Wang, Gaofeng; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Agarwal, Anita] Vanderbilt Univ, Dept Ophthalmol & Visual Sci, Nashville, TN 37235 USA.
C3 Vanderbilt University; Case Western Reserve University; University of
   Miami; Vanderbilt University
RP Haines, JL (通讯作者)，Case Western Reserve Univ, Inst Computat Biol, Dept Epidemiol & Biostat, 2-529 Wolstein Res Bldg,2103 Cornell Rd, Cleveland, OH 44106 USA.
EM jlh213@case.edu
RI Haines, Jonathan/C-3374-2012; Bailey, Jessica Cooke/Q-5062-2019; Cooke
   Bailey, Jessica Nicole/AFQ-5925-2022
OI Haines, Jonathan/0000-0002-4351-4728; Bailey, Jessica
   Cooke/0000-0002-4001-8702; Cooke Bailey, Jessica
   Nicole/0000-0002-4001-8702; Scott, William/0000-0001-9336-6404
FU National Institutes of Health [AG019085, AG019726, EY21453-2, AG044089];
   NATIONAL EYE INSTITUTE [T32EY021453, R01EY012118] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347,
   T32GM080178] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG019085, R01AG019726, F31AG044089] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health Grants AG019085 (JLH,
   MAP-V), AG019726 (WKS), EY21453-2 (JNCB), and AG044089 (JDH).
CR Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Agarwala R, 1999, AM J MED GENET, V86, P156, DOI 10.1002/(SICI)1096-8628(19990910)86:2<156::AID-AJMG13>3.0.CO;2-5
   Agarwala R, 2003, AM J MED GENET C, V121C, P32, DOI 10.1002/ajmg.c.20004
   Agarwala R, 2001, HUM BIOL, V73, P533, DOI 10.1353/hub.2001.0045
   Cummings AC, 2012, ANN HUM GENET, V76, P342, DOI 10.1111/j.1469-1809.2012.00721.x
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Exome Variant Server, NHLBI GO EX SEQ PROJ
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hahs DW, 2006, AM J MED GENET B, V141B, P160, DOI 10.1002/ajmg.b.30257
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haung D., 2006, RETINAL IMAGING, P145
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hostetler J. A., 1993, AMISH SOC, DOI 10.2307/539066
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lee WJ, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-68
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liu F, 2008, EUR J HUM GENET, V16, P854, DOI 10.1038/ejhg.2008.24
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   McCauley JL, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-19
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thornton T, 2007, AM J HUM GENET, V81, P321, DOI 10.1086/519497
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 38
TC 37
Z9 43
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2014
VL 55
IS 7
BP 4455
EP 4460
DI 10.1167/iovs.13-13684
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL9UI
UT WOS:000339487000055
PM 24906858
OA Green Published
DA 2022-11-30
ER

PT J
AU Yadav, G
   Narayanan, R
   Hathibelagal, AR
AF Yadav, Gayatri
   Narayanan, Raja
   Hathibelagal, Amithavikram R.
TI Chromatic and flicker threshold changes in age-related macular
   degeneration following anti-VEGF treatment
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE Neovascular AMD; flicker; colour assessment; rod; cone; anti-VEGF
AB Background: High-contrast visual acuity (VA) is not a sensitive clinical marker in the management of age-related macular degeneration (AMD). Therefore, flicker and chromatic sensitivity changes were assessed following anti-VEGF treatment in subjects with neovascular AMD. Methods: Subjects diagnosed with neovascular AMD were recruited. VA was measured using a COMPlog chart. Flicker (in central 5 degrees) and chromatic thresholds (red-green and yellow-blue) were measured using Flicker-plus test and Colour Assessment and Diagnosis (CAD) tests, respectively. Baseline thresholds and foveal thickness were measured on the same day, just before anti-VEGF injection delivery and 5 weeks +/- 5 days later. Results: Thirteen subjects (8 males, 5 females) with a mean age of 67.5 +/- 8.2 years completed the study. Median VA was not significantly different post-treatment (0.57 logMAR [similar to 6/22: Snellen equivalent], IQR: 0.33) compared to baseline (0.56 logMAR, IQR: 0.33), Wilcoxon matched-pair test, p = 0.55). Median Red-Green thresholds improved significantly post-treatment (22.15 CAD units, IQR: 26.06, n = 9), compared to baseline (24.24 CAD units, IQR: 26.21, p = 0.02). Median photopic and mesopic FMT did not show significant change post treatment compared to baseline (p > 0.01, statistical significance of p-value corrected for multiple comparisons was set to 0.01). Similarly, the foveal thickness was not significantly different at post-treatment visit than baseline (p = 0.53). Conclusion: Red/green sensitivity recovered better than yellow/blue sensitivity, thus, providing insight into recovery mechanisms in AMD and usefulness of these tests as clinical markers in the management of AMD.
C1 [Yadav, Gayatri; Hathibelagal, Amithavikram R.] LV Prasad Eye Inst, Brien Holden Inst Optometry & Vis Sci, Hyderabad, India.
   [Narayanan, Raja] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute
RP Hathibelagal, AR (通讯作者)，LV Prasad Eye Inst, Brien Holden Inst Optometry & Vis Sci, Hyderabad, India.
EM amithavikram@lvpei.org
RI Hathibelagal, Amithavikram rugvedi/H-8737-2019; Narayanan,
   Raja/AAT-3098-2021
OI Hathibelagal, Amithavikram rugvedi/0000-0002-6087-2690; Narayanan,
   Raja/0000-0001-9688-5859
FU Hyderabad Eye Research Foundation
FX We would like to thank the Hyderabad Eye Research Foundation for the
   support during this study.
CR Abdel-Hay A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199693
   Amoaku W, 2018, CLIN OPHTHALMOL, V12, P1731, DOI 10.2147/OPTH.S174560
   Barbur JL, 2012, WOODHEAD PUBL SER TE, P24
   Barbur JL, 2015, HANDBOOK OF COLOR PSYCHOLOGY, P180
   Bi W, 2016, INVEST OPHTH VIS SCI, V57, P387, DOI 10.1167/iovs.15-16481
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bokinni Y, 2015, EYE, V29, P1085, DOI 10.1038/eye.2015.94
   BOYCOTT BB, 1991, EUR J NEUROSCI, V3, P1069, DOI 10.1111/j.1460-9568.1991.tb00043.x
   Braganza, 2013, J CLIN OPHTHALMOL RE, V1, P11
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Dimopoulos IS, 2013, INVEST OPHTH VIS SCI, V54, P5186, DOI 10.1167/iovs.13-12194
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Feigl B, 2007, CLIN EXP OPTOM, V90, P263, DOI 10.1111/j.1444-0938.2007.00152.x
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferraz D, 2010, EUR J OPHTHALMOL, V20, P740, DOI 10.1177/112067211002000415
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01554-2
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Harlow, 2006, CIE EXP S CIE P 75 Y
   Hathibelagal AR, 2021, OPHTHAL PHYSL OPT, V41, P874, DOI 10.1111/opo.12799
   Hathibelagal AR, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81530-y
   Hathibelagal AR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232784
   HIRVELA H, 1995, ACTA OPHTHALMOL SCAN, V73, P111
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Inoue M, 2014, CLIN OPHTHALMOL, V8, P1711, DOI 10.2147/OPTH.S68293
   Iwata E, 2012, INVEST OPHTH VIS SCI, V53, P4185, DOI 10.1167/iovs.11-9335
   Jackson GR, 2005, MACULAR DEGENERATION, P45, DOI 10.1007/3-540-26977-0_3
   Laidlaw DAH, 2008, BRIT J OPHTHALMOL, V92, P241, DOI 10.1136/bjo.2007.121715
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Nixon DR, 2017, CLIN OPHTHALMOL, V11, P715, DOI 10.2147/OPTH.S131343
   Paulus YM, 2017, QUAL LIFE RES, V26, P2139, DOI 10.1007/s11136-017-1547-z
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Robinson DG, 2019, INVEST OPHTH VIS SCI, V60, P580, DOI 10.1167/iovs.18-25092
   Seshadri J, 2005, OPTOMETRY VISION SCI, V82, P882, DOI 10.1097/01.opx.0000182211.48498.4e
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Vemala R, 2017, INVEST OPHTH VIS SCI, V58, P247, DOI 10.1167/iovs.17-21771
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Ziemssen Focke, 2008, International Ophthalmology, V28, P101, DOI 10.1007/s10792-007-9122-1
   Zuo CG, 2010, GRAEF ARCH CLIN EXP, V248, P191, DOI 10.1007/s00417-009-1210-7
NR 46
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD APR 3
PY 2022
VL 105
IS 3
BP 313
EP 319
DI 10.1080/08164622.2021.1916384
EA MAY 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0D2VZ
UT WOS:000646878400001
PM 33941047
DA 2022-11-30
ER

PT J
AU Chakravarthy, U
   Wong, TY
   Fletcher, A
   Piault, E
   Evans, C
   Zlateva, G
   Buggage, R
   Pleil, A
   Mitchell, P
AF Chakravarthy, Usha
   Wong, Tien Y.
   Fletcher, Astrid
   Piault, Elisabeth
   Evans, Christopher
   Zlateva, Gergana
   Buggage, Ronald
   Pleil, Andreas
   Mitchell, Paul
TI Clinical risk factors for age-related macular degeneration: a systematic
   review and meta-analysis
SO BMC OPHTHALMOLOGY
LA English
DT Review
ID COMPLEMENT FACTOR-H; LONG-TERM INCIDENCE; BODY-MASS INDEX; BEAVER DAM;
   CATARACT-SURGERY; CARDIOVASCULAR-DISEASE; 10-YEAR INCIDENCE; POOLED
   FINDINGS; PRIMARY PREVENTION; CIGARETTE-SMOKING
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness in Western countries. Numerous risk factors have been reported but the evidence and strength of association is variable. We aimed to identify those risk factors with strong levels of evidence which could be easily assessed by physicians or ophthalmologists to implement preventive interventions or address current behaviours.
   Methods: A systematic review identified 18 prospective and cross-sectional studies and 6 case control studies involving 113,780 persons with 17,236 cases of late AMD that included an estimate of the association between late AMD and at least one of 16 pre-selected risk factors. Fixed-effects meta-analyses were conducted for each factor to combine odds ratio (OR) and/or relative risk (RR) outcomes across studies by study design. Overall raw point estimates of each risk factor and associated 95% confidence intervals (CI) were calculated.
   Results: Increasing age, current cigarette smoking, previous cataract surgery, and a family history of AMD showed strong and consistent associations with late AMD. Risk factors with moderate and consistent associations were higher body mass index, history of cardiovascular disease, hypertension, and higher plasma fibrinogen. Risk factors with weaker and inconsistent associations were gender, ethnicity, diabetes, iris colour, history of cerebrovascular disease, and serum total and HDL cholesterol and triglyceride levels.
   Conclusions: Smoking, previous cataract surgery and a family history of AMD are consistent risk factors for AMD. Cardiovascular risk factors are also associated with AMD. Knowledge of these risk factors that may be easily assessed by physicians and general ophthalmologists may assist in identification and appropriate referral of persons at risk of AMD.
C1 [Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis Sci, Belfast, Antrim, North Ireland.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Fletcher, Astrid] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England.
   [Piault, Elisabeth; Evans, Christopher] Mapi Values, Boston, MA USA.
   [Zlateva, Gergana; Pleil, Andreas] Pfizer Inc, New York, NY USA.
   [Buggage, Ronald] Novartis, E Hanover, NJ USA.
   [Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Ctr Vis Res, Sydney, NSW 2006, Australia.
C3 Queens University Belfast; National University of Singapore; Singapore
   National Eye Center; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne; University of London;
   London School of Hygiene & Tropical Medicine; Pfizer; Novartis;
   University of Sydney; Westmead Institute for Medical Research
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Ctr Vis Sci, Belfast, Antrim, North Ireland.
EM U.Chakravarthy@qub.ac.uk
RI Mitchell, Paul/P-1498-2014; Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Chakravarthy,
   Usha/0000-0002-2606-3734
FU Pfizer Inc, New York, New York; Pfizer Inc.; Pfizer; Novartis; Alcon;
   Bausch and Lomb; Allergan; Solvay; Lilly; Bayer
FX The research was supported by Pfizer Inc, New York, New York.; This
   study was sponsored by Pfizer Inc. Assistance with the literature
   screening, database development, data retrieval, analysis, and
   manuscript development was provided by L. Chen, an employee of Pfizer
   Inc, and Daria Pelech and Steve Hwang both employees of MAPI Values and
   funded by Pfizer Inc. Christopher Evans and Elisabeth Piault in their
   capacity of employees of Mapi Values were paid consultants in connection
   with the development of this manuscript.; Drs. Chakravarthy, Wong,
   Fletcher, and Mitchell were paid consultants to Pfizer Inc and Ms Piault
   and Dr. Evans were employees of Mapi Values, Boston, Massachusetts at
   the time the research was conducted and the manuscript was developed.
   Mapi Values is a consultancy whose activities on the project were funded
   by Pfizer. Drs. Zlateva and Pleil are employees of Pfizer Inc. Dr.
   Buggage was an employee of Pfizer during part of the study and now is an
   employee of Novartis, East Hanover, NJ. Usha Chakravarthy has served on
   advisory boards to Pfizer, Oraya Therapeutics, Allergan and Novartis and
   has received honoraria and travel support. She has been and continues to
   be an investigator on controlled clinical trials and observational
   studies sponsored by Pfizer, Novartis, Alcon and Bausch and Lomb and her
   department has received funds for the conduct of these studies.; Tien
   Wong has been on advisory boards for Pfizer, Allergan and Novartis, and
   has received honoraria and travel and accommodation payments from them.
   He has also received research support from Pfizer. He has also been an
   investigator on clinical trials sponsored by them and has received
   payments to support the conduct of these trials.; Paul Mitchell has been
   on advisory boards for Novartis, Pfizer, Allergan and Solvay, and has
   received honoraria and travel and accommodation payments from them. He
   has also been an investigator on clinical trials sponsored by these
   companies, as well as Lilly and Bayer, and has received payments to
   support the conduct of these trials.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2007, BRIT MED J, V334, P269, DOI 10.1136/bmj.39100.460671.BE
   Chakravarthy U, 2006, BMJ-BRIT MED J, V333, P869, DOI 10.1136/bmj.39009.366736.80
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Haines JL, 2007, JAMA-J AM MED ASSOC, V297, P401, DOI 10.1001/jama.297.4.401
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Varma R, 2004, OPHTHALMOLOGY, V111, P1439, DOI 10.1016/j.ophtha.2004.01.025
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2008, AM J OPHTHALMOL, V146, P656, DOI 10.1016/j.ajo.2008.07.048
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 78
TC 466
Z9 481
U1 0
U2 72
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 13
PY 2010
VL 10
AR 31
DI 10.1186/1471-2415-10-31
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 700MP
UT WOS:000285747300001
PM 21144031
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Martinez-Velasco, A
   Martinez-Villasenor, L
   Miralles-Pechuan, L
   Perez-Ortiz, AC
   Zenteno, JC
   Estrada-Mena, FJ
AF Martinez-Velasco, Antonieta
   Martinez-Villasenor, Lourdes
   Miralles-Pechuan, Luis
   Perez-Ortiz, Andric C.
   Zenteno, Juan C.
   Estrada-Mena, Francisco Javier
TI The Relevance of Cataract as a Risk Factor for Age-Related Macular
   Degeneration: A Machine Learning Approach
SO APPLIED SCIENCES-BASEL
LA English
DT Article
DE age-related macular degeneration; cataract; unsupervised machine
   learning; risk factors; interpretability
ID BEAVER DAM; UNITED-STATES; MACULOPATHY; PREVALENCE; POLYMORPHISMS;
   ASSOCIATION; SURGERY; CFH
AB Age-related macular degeneration (AMD) is the leading cause of visual dysfunction and irreversible blindness in developed countries and a rising cause in underdeveloped countries. There is a current debate on whether or not cataracts are significant risk factors for AMD development. In particular, research regarding this association is so far inconclusive. For this reason, we aimed to employ here a machine-learning approach to analyze the relevance and importance of cataracts as a risk factor for AMD in a large cohort of Hispanics from Mexico. We conducted a nested case control study of 119 cataract cases and 137 healthy unmatched controls focusing on clinical data from electronic medical records. Additionally, we studied two single nucleotide polymorphisms in the CFH gene previously associated with the disease in various populations as positive control for our method. We next determined the most relevant variables and found the bivariate association between cataracts and AMD. Later, we used supervised machine-learning methods to replicate these findings without bias. To improve the interpretability, we detected the five most relevant features and displayed them using a bar graph and a rule-based tree. Our findings suggest that bilateral cataracts are not a significant risk factor for AMD development among Hispanics from Mexico.
C1 [Martinez-Velasco, Antonieta; Martinez-Villasenor, Lourdes] Univ Panamer, Fac Ingn, Augusto Rodin 498, Mexico City 03920, DF, Mexico.
   [Miralles-Pechuan, Luis] Univ Coll Dublin, Ctr Appl Data Analyt Res CeADAR, Nexus UCD, Belfield Off Pk,Beech Hill Rd, Dublin D04 V2N9, Ireland.
   [Perez-Ortiz, Andric C.] Massachusetts Gen Hosp, Transplant Ctr, 55 Fruit St, Boston, MA 02114 USA.
   [Perez-Ortiz, Andric C.; Estrada-Mena, Francisco Javier] Univ Panamer, Fac Ciencias Salud, Mexico City 03920, DF, Mexico.
   [Zenteno, Juan C.] Inst Oftalmol Conde Valenciana, Dept Genet, Res Unit, Chimalpopoca 14, Mexico City 06800, DF, Mexico.
   [Zenteno, Juan C.] Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Circuito Escolar SN,CU, Mexico City 04510, DF, Mexico.
C3 Universidad Panamericana - Ciudad de Mexico; University College Dublin;
   Harvard University; Massachusetts General Hospital; Universidad
   Panamericana - Ciudad de Mexico; Universidad Nacional Autonoma de Mexico
RP Martinez-Velasco, A (通讯作者)，Univ Panamer, Fac Ingn, Augusto Rodin 498, Mexico City 03920, DF, Mexico.
EM amartinezv@up.edu.mx; lmartine@up.edu.mx; miralles.luis@gmail.com;
   andric@aya.yale.edu; jczenteno@institutodeoftalmologia.org;
   festrada@up.edu.mx
RI Perez-Ortiz, Andric C/AAA-3292-2019; Miralles, Luis/O-2472-2016;
   Martinez-Villasenor, Lourdes/N-7607-2018
OI Perez-Ortiz, Andric C/0000-0003-0731-2464; Miralles,
   Luis/0000-0002-7565-6894; Zenteno, Juan Carlos/0000-0002-9716-8146;
   MARTINEZ-VELASCO, ANTONIETA/0000-0001-6535-1440; Martinez-Villasenor,
   Lourdes/0000-0002-9038-7821
CR Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Franco R., 2018, J CLIN EXP, V9, P754
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   HALL P, 2017, IDEAS INTERPRETING M
   Khalid S., 2014, P SCI INF C LOND UK
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kursa MB, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i11
   Lipton ZC, 2018, COMMUN ACM, V61, P36, DOI 10.1145/3233231
   Louppe G, 2019, J HIGH ENERGY PHYS, DOI 10.1007/JHEP01(2019)057
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Ribeiro M.T., 2016, P 2016 CHI C HUM FAC, P5686
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Ruping S., 2006, THESIS
   Sokolova M, 2009, INFORM PROCESS MANAG, V45, P427, DOI 10.1016/j.ipm.2009.03.002
   Soysal Y, 2012, DNA CELL BIOL, V31, P322, DOI 10.1089/dna.2011.1214
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wang YX, 2016, LECT NOTES COMPUT SC, V9910, P616, DOI 10.1007/978-3-319-46466-4_37
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, BLINDN VIS IMP
NR 30
TC 0
Z9 0
U1 2
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD DEC
PY 2019
VL 9
IS 24
AR 5550
DI 10.3390/app9245550
PG 14
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA KS1AC
UT WOS:000518042000285
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Martinez-de-la-Casa, JM
   Ruiz-Calvo, A
   Saenz-Frances, F
   Reche-Frutos, J
   Calvo-Gonzalez, C
   Donate-Lopez, J
   Garcia-Feijoo, J
AF Martinez-de-la-Casa, Jose M.
   Ruiz-Calvo, Aurora
   Saenz-Frances, Federico
   Reche-Frutos, Juan
   Calvo-Gonzalez, Cristina
   Donate-Lopez, Juan
   Garcia-Feijoo, Julian
TI Retinal Nerve Fiber Layer Thickness Changes in Patients with Age-Related
   Macular Degeneration Treated with Intravitreal Ranibizumab
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID INTRAOCULAR-PRESSURE CHANGES; RANDOMIZED CLINICAL-TRIAL; VISION-RELATED
   FUNCTION; OPEN-ANGLE GLAUCOMA; BEVACIZUMAB; INJECTIONS; PREVALENCE;
   MEDICATION; THERAPY; SAFETY
AB PURPOSE. To assess the effects of intravitreal ranibizumab therapy on intraocular pressure (IOP) and retinal nerve fiber (RNFL) thickness.
   METHODS. Forty-nine eyes of 49 patients with neovascular age-related macular degeneration (AMD) treated with intravitreal ranibizumab injections and 27 fellow eyes not requiring treatment were followed for 1 year. RNFL thickness, as measured by Fourier domain optical coherence tomography, and IOP were determined pre- and postinjection.
   RESULTS. After 12 months, the mean number of injections received was 4.8 +/- 1.6. The incidence of IOP elevations (>5 mm Hg over baseline) observed at the time of injection was 0.4%. Baseline RNFL thickness was 105.7 +/- 12.2 mu m in the treatment group compared with 101.8 +/- 11.6 mu m in the control group (P=0.176). At the end of follow-up, significant RNFL thinning was noted in the treatment group (100.2 +/- 11.0 mu m, P < 0.001), whereas no differences were found in the control group (100.5 +/- 10.8 mu m, P=0.477).
   CONCLUSIONS. Intravitreal ranibizumab injections used to treat AMD caused a significant change in RNFL thickness after 12 months of follow-up. (Invest Ophthalmol Vis Sci. 2012;53:6214-6218) DOI: 10.1167/iovs.12-9875
C1 Hosp Clin San Carlos IdISSC, Inst Invest Sanitaria, Madrid, Spain.
   Univ Complutense Madrid, Fac Med, Dept Oftalmol, Madrid, Spain.
   [Martinez-de-la-Casa, Jose M.] Hosp Clin San Carlos, Serv Oftalmol, Madrid 28040, Spain.
C3 Hospital Clinico San Carlos; Complutense University of Madrid; Hospital
   Clinico San Carlos
RP Martinez-de-la-Casa, JM (通讯作者)，Hosp Clin San Carlos, Serv Oftalmol, Madrid 28040, Spain.
EM martinezcasa@ya.com
RI Donate-Lopez, Juan/AAB-5144-2019; GARCIA FEIJOO, JULIAN/G-9762-2017;
   Saenz-Frances, Federico/A-3350-2012
OI Donate-Lopez, Juan/0000-0002-9944-6736; Martinez-de-la-Casa, Jose
   Maria/0000-0001-9441-0542; GARCIA FEIJOO, JULIAN/0000-0002-7772-5718;
   Saenz-Frances, Federico/0000-0002-3196-1491
FU Instituto de Salud Carlos III, "Red tematica de Investigacion
   Cooperativa, Proyecto: Patologia ocular del envejecimiento, calidad
   visual y calidad de vida'' [RD07/0062]; Grupo de Investigacion de la
   Universidad Complutense de Madrid [920415-GR58/08]
FX Supported in part by Instituto de Salud Carlos III, "Red tematica de
   Investigacion Cooperativa, Proyecto RD07/0062: Patologia ocular del
   envejecimiento, calidad visual y calidad de vida'' and Grupo de
   Investigacion de la Universidad Complutense de Madrid 920415-GR58/08.
CR Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Frenkel MPC, 2010, ARCH OPHTHALMOL-CHIC, V128, P1523, DOI 10.1001/archophthalmol.2010.297
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Lanzl IM, 2007, AM J OPHTHALMOL, V143, P1034
   Rudnicka AR, 2006, INVEST OPHTH VIS SCI, V47, P4254, DOI 10.1167/iovs.06-0299
   Serbecic N, 2011, BRIT J OPHTHALMOL, V95, P804, DOI 10.1136/bjo.2010.186221
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Zayit-Soudry S, 2010, RETINA-J RET VIT DIS, V30, P671, DOI 10.1097/IAE.0b013e3181c0858c
NR 18
TC 74
Z9 76
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2012
VL 53
IS 10
BP 6214
EP 6218
DI 10.1167/iovs.12-9875
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 016NQ
UT WOS:000309526200031
PM 22915037
DA 2022-11-30
ER

PT J
AU Ruiz-Moreno, JM
   Arias, L
   Abraldes, MJ
   Montero, J
   Udaondo, P
AF Ruiz-Moreno, Jose M.
   Arias, Luis
   Abraldes, Maximino J.
   Montero, Javier
   Udaondo, Patricia
CA RAMDEBURS study grp
TI Economic burden of age-related macular degeneration in routine clinical
   practice: the RAMDEBURS study
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Health economics; Economic burden;
   Vascular endothelial growth factor inhibitors; VEGF
ID VISUAL IMPAIRMENT; RANIBIZUMAB; PREVALENCE; ENDOPHTHALMITIS;
   MACULOPATHY; MANAGEMENT; IMPACT; COST; EYE
AB Purpose To describe and evaluate the main direct health costs, in routine clinical practice, of age-related macular degeneration (AMD) patients, from hospital perspective, in Spain. Methods Retrospective, multicenter, and observational study conducted on five third-level Spanish hospitals, between December 2018 and December 2019. The study included patients who were diagnosed of AMD before December 2018. Direct healthcare costs were obtained from a Spanish database. Study variables included demographic and clinical variables, and resources, such as treatment, diagnostic tests, medical examination, and surgery. Among the 1414 screened AMD patients, 1164 patients were included. In the overall study patients, the total cost was euro5,386,511.0, with a mean cost per patient of euro4627.6 +/- 2383.9. The largest cost items were diagnostic examinations (euro2.832.902,0) and vascular endothelial growth factor inhibitors (anti-VEGF) treatment (euro2.038.257,2). Bevacizumab was administered to 325 (27.9%) patients, ranibizumab to 328 (28.2%), and aflibercept to 626 (53.8%); 115 (10.7%) patients received two anti-VEGF treatments, while 90 (7.7%) did not receive any. Over the course of the study, a total of 6,057 anti-VEGF injections were administered, with a mean (95% confidence interval) of 4.8 (4.4-5.2) injections per patient. Regarding safety, 29 patients experience injection-related adverse events, among them 12 patients had cataract and 11 ones elevated intraocular pressure (IOP). The incidence of endophthalmitis was 0.5% (6/1164). Conclusions AMD was associated with considerable healthcare costs for regional healthcare systems. Diagnostic examinations, particularly OCT examinations, and anti-VEGF treatment represented the largest cost items.
C1 [Ruiz-Moreno, Jose M.] Puerta de Hierro Majadahonda Univ Hosp, Joaquin Rodrigo 2, Madrid 28222, Spain.
   [Ruiz-Moreno, Jose M.] Castilla La Mancha Univ, Dept Ophthalmol, Albacete, Spain.
   [Ruiz-Moreno, Jose M.] Inst Salud Carlos III, Red Temat Invest Cooperat Salud Prevenc Detect Pr, Spanish Minist Hlth, Madrid, Spain.
   [Arias, Luis] Bellvitge Univ Hosp, Barcelona, Spain.
   [Abraldes, Maximino J.] Santiago de Compostela Univ Hosp Complex, La Coruna, Spain.
   [Montero, Javier] Rio Ortega Univ Hosp, Valladolid, Spain.
   [Udaondo, Patricia] Univ & Polytech Hosp La Fe, Valencia, Spain.
C3 Hospital Puerta de Hierro-Majadahonda; Universidad de Castilla-La
   Mancha; Instituto de Salud Carlos III; Institut d'Investigacio Biomedica
   de Bellvitge (IDIBELL); Bellvitge University Hospital; University of
   Barcelona
RP Ruiz-Moreno, JM (通讯作者)，Puerta de Hierro Majadahonda Univ Hosp, Joaquin Rodrigo 2, Madrid 28222, Spain.
EM josemaria.ruiz@uclm.es
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788; Udaondo,
   Patricia/0000-0002-5241-0066
FU Ciencia y Deporte S.L.; Allergan - Allergan, an AbbVie company
FX Medical writing and Editorial assistant services have been provided by
   Ciencia y Deporte S.L. and covered by a Grant from Allergan. Support for
   this assistance was funded by Allergan, an AbbVie company.
CR [Anonymous], LUSO FARMACI ITALIA
   [Anonymous], SPANISH DATABASE HEA
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Autores no listados. Instituto nacional de Estadistica, DATA SPANISH POPULAT
   Avastin (bevacizumab), SUMMARY PRODUCT CHAR
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Cidad-Betegon MD, 2020, J DRUG ASSESS, V9, P66, DOI 10.1080/21556660.2020.1742723
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Dossarps D, 2015, AM J OPHTHALMOL, V160, P17, DOI 10.1016/j.ajo.2015.04.013
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freiberg FJ, 2017, RETINA-J RET VIT DIS, V37, P2341, DOI 10.1097/IAE.0000000000001488
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kernick DP, 2003, POSTGRAD MED J, V79, P147, DOI 10.1136/pmj.79.929.147
   Klein R, 2020, OPHTHALMOLOGY, V127, pS122, DOI 10.1016/j.ophtha.2020.01.033
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   OECD/European Observatory on Health Systems and Policies, 2017, SPAIN COUNTRY HLTH P, DOI [10.1787/9789264283565-en, DOI 10.1787/9789264283565-EN]
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pezzullo L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2836-0
   Rajesh B, 2020, BRIT J OPHTHALMOL, V104, P39, DOI 10.1136/bjophthalmol-2019-313991
   Rodriguez-Blas, ESTADISTICA GASTO SA
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Stem MS, 2017, JAMA OPHTHALMOL, V135, P379, DOI 10.1001/jamaophthalmol.2016.5883
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   VanderBeek BL, 2015, OPHTHALMOLOGY, V122, P2311, DOI 10.1016/j.ophtha.2015.07.005
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zapata MA, 2017, TELEMED E-HEALTH, V23, P31, DOI 10.1089/tmj.2016.0020
NR 38
TC 3
Z9 3
U1 1
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD OCT
PY 2021
VL 41
IS 10
BP 3427
EP 3436
DI 10.1007/s10792-021-01906-x
EA JUN 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA US1GW
UT WOS:000659857700003
PM 34110547
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Pilotto, E
   Guidolin, F
   Convento, E
   Spedicato, L
   Vujosevic, S
   Cavarzeran, F
   Midena, E
AF Pilotto, Elisabetta
   Guidolin, Francesca
   Convento, Enrica
   Spedicato, Luigi
   Vujosevic, Stela
   Cavarzeran, Fabiano
   Midena, Edoardo
TI Fundus autofluorescence and microperimetry in progressing geographic
   atrophy secondary to age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Purpose To prospectively analyse microperimetry, standard short-wavelength fundus autofluorescent (SW-FAF) and near infrared-wavelength FAF (NIR-FAF) changes in eyes with geographic atrophy (GA) secondary to age-related macular degeneration.
   Methods Twenty consecutive eyes (14 patients) affected by GA were enrolled. Repeated microperimetric examinations and FAF images were obtained over a mean follow-up period of 12.3 +/- 4.5 months.
   Results GA area was always wider on NIR-FAF versus SW-FAF images (5.05 +/- 2.40 mm(2) vs 4.45 +/- 2.41 mm(2), p=0.005 baseline; 5.78 +/- 2.87 mm(2) vs 5.21 +/- 2.77 mm(2), p<0.0001 follow-up). Mean retinal sensitivity significantly decreased during follow-up from 7.68 +/- 3.92 dB to 6.71 +/- 4.37 dB (p=0.0013). 47.3% of the relative dense scotomas (<= 5 dB) progressed to dense scotoma (0 dB). Retinal areas showing relative dense scotoma and characterised by hypo-SW-FAF or hyper-NIR-FAF at baseline had a higher risk of evolving to dense scotoma compared with normo-FAF and hyper-FAF on SW-FAF (OR=2.62 and 2.77, respectively), or normo-FAF at NIR-FAF (OR=2.96).
   Conclusions SW-FAF, compared with NIR-FAF, underestimates GA area at baseline and at follow-up. The enlargement rate of progression based on NIR-FAF is not greater than on SW-FAF. Different SW-FAF and NIR-FAF patterns show different relative risk of progression from relative to dense scotoma. Microperimetry, SW-FAF and NIR-FAF should be combined to obtain adequate morphological and functional prospective information.
C1 [Pilotto, Elisabetta; Guidolin, Francesca; Convento, Enrica; Spedicato, Luigi; Cavarzeran, Fabiano; Midena, Edoardo] Univ Padua, Dept Ophthalmol, I-35128 Padua, Italy.
   [Vujosevic, Stela; Midena, Edoardo] IRCCS, GB Bietti Fdn, Rome, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Midena, E (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
EM edoardo.midena@unipd.it
RI Vujosevic, Stela/AAI-4874-2020; Midena, Edoardo/AAB-6010-2020
OI Vujosevic, Stela/0000-0001-6773-9967; Guidolin,
   Francesca/0000-0002-5956-7007
CR Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Ishiko S, 2010, CURR EYE RES, V35, P651, DOI 10.3109/02713681003707235
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   McBain VA, 2012, AM J OPHTHALMOL, V154, P146, DOI 10.1016/j.ajo.2012.01.019
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Mogk LG, 2012, OPHTHALMOLOGY, V119, P885, DOI 10.1016/j.ophtha.2011.09.052
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Sparrow JR, 2010, INVEST OPHTH VIS SCI, V51, P4351, DOI 10.1167/iovs.10-5852
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141
NR 25
TC 46
Z9 46
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2013
VL 97
IS 5
BP 622
EP 626
DI 10.1136/bjophthalmol-2012-302633
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 126AG
UT WOS:000317582900018
PM 23410728
DA 2022-11-30
ER

PT J
AU Tokarz, P
   Kaarniranta, K
   Blasiak, J
AF Tokarz, Paulina
   Kaarniranta, Kai
   Blasiak, Janusz
TI Role of antioxidant enzymes and small molecular weight antioxidants in
   the pathogenesis of age-related macular degeneration (AMD)
SO BIOGERONTOLOGY
LA English
DT Review
DE AMD; Oxidative stress; Antioxidant enzymes; Small molecular weight
   antioxidants; ROS; Retinal pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; MANGANESE-SUPEROXIDE-DISMUTASE;
   LIGHT-INDUCED DAMAGE; ENDOPLASMIC-RETICULUM STRESS; POLYUNSATURATED
   FATTY-ACIDS; TRANSCRIPTION FACTOR NRF2; MITOCHONDRIAL-DNA DAMAGE;
   GLUTATHIONE-PEROXIDASE 4; OXIDATIVE STRESS; LIPID-PEROXIDATION
AB Cells in aerobic condition are constantly exposed to reactive oxygen species (ROS), which may induce damage to biomolecules, including proteins, nucleic acids and lipids. In normal circumstances, the amount of ROS is counterbalanced by cellular antioxidant defence, with its main components-antioxidant enzymes, DNA repair and small molecular weight antioxidants. An imbalance between the production and neutralization of ROS by antioxidant defence is associated with oxidative stress, which plays an important role in the pathogenesis of many age-related and degenerative diseases, including age-related macular degeneration (AMD), affecting the macula-the central part of the retina. The retina is especially prone to oxidative stress due to high oxygen pressure and exposure to UV and blue light promoting ROS generation. Because oxidative stress has an established role in AMD pathogenesis, proper functioning of antioxidant defence may be crucial for the occurrence and progression of this disease. Antioxidant enzymes play a major role in ROS scavenging and changes of their expression or/and activity are reported to be associated with AMD. Therefore, the enzymes in the retina along with their genes may constitute a perspective target in AMD prevention and therapy.
C1 [Tokarz, Paulina; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, Fac Biol & Environm Protect, PL-90236 Lodz, Poland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 University of Lodz; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland
RP Tokarz, P (通讯作者)，Univ Lodz, Dept Mol Genet, Fac Biol & Environm Protect, Pomorska 141-143, PL-90236 Lodz, Poland.
EM ptokarz@biol.uni.lodz.pl
RI Tokarz, Paulina/L-9983-2013
OI Tokarz, Paulina/0000-0001-9016-3089; Kaarniranta,
   Kai/0000-0003-2600-8679; Blasiak, Janusz/0000-0001-9539-9584
FU Kuopio University Hospital; Finnish Cultural Foundation; North Savo
   Fund; Finnish Eye Foundation; Finnish Funding Agency for Technology and
   Innovation; Health Research Council of the Academy of Finland; Paivikki
   and Sakari Sohlberg Foundation
FX This work was supported by the EVO grants of Kuopio University Hospital,
   the Finnish Cultural Foundation and its North Savo Fund, the Finnish Eye
   Foundation, the Finnish Funding Agency for Technology and Innovation,
   Health Research Council of the Academy of Finland, and the Paivikki and
   Sakari Sohlberg Foundation.
CR Agency for Toxic Substances and Disease Registry (ATSDR), 2005, CERCLA PRIOR LIST HA
   AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANDERSON RE, 1974, EXP EYE RES, V18, P205, DOI 10.1016/0014-4835(74)90149-3
   ANDERSON SM, 1973, PHOTOCHEM PHOTOBIOL, V18, P403, DOI 10.1111/j.1751-1097.1973.tb06440.x
   ARSTILA AU, 1972, SCIENCE, V175, P530, DOI 10.1126/science.175.4021.530
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Bannon DI, 2003, AM J PHYSIOL-CELL PH, V284, pC44, DOI 10.1152/ajpcell.00184.2002
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Behndig A, 2008, MOL VIS, V14, P2025
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bernstein PS, 2012, INVEST OPHTH VIS SCI, V53, P6178, DOI 10.1167/iovs.12-10275
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   BLOCH CA, 1986, J BACTERIOL, V168, P795, DOI 10.1128/jb.168.2.795-798.1986
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BOULTON M, 1998, RETINAL PIGMENT EPIT, P68
   BUSH RA, 1991, EXP EYE RES, V53, P741, DOI 10.1016/0014-4835(91)90109-R
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chen PC, 2009, P NATL ACAD SCI USA, V106, P2933, DOI 10.1073/pnas.0813361106
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiba Y, 2009, NEUROCHEM RES, V34, P679, DOI 10.1007/s11064-008-9812-8
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chorny M, 2010, J CONTROL RELEASE, V146, P144, DOI 10.1016/j.jconrel.2010.05.003
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Chu Y, 2003, CIRC RES, V92, P461, DOI 10.1161/01.RES.0000057755.02845.F9
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   DeLaPaz MA, 1996, CURR EYE RES, V15, P273, DOI 10.3109/02713689609007621
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Deleon E, 2009, INVEST OPHTH VIS SCI, V50, P1360, DOI 10.1167/iovs.08-1856
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Desler Claus, 2011, J Aging Res, V2011, P407536, DOI 10.4061/2011/407536
   Dong X, 2011, MOL VIS, V17, P2040
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edge R, 1997, J PHOTOCH PHOTOBIO B, V41, P189, DOI 10.1016/S1011-1344(97)00092-4
   ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   FARNSWORTH CC, 1979, BIOCHIM BIOPHYS ACTA, V552, P281, DOI 10.1016/0005-2736(79)90283-9
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FOOTE CS, 1968, J AM CHEM SOC, V90, P6233, DOI 10.1021/ja01024a061
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   Girijashanker K, 2008, MOL PHARMACOL, V73, P1413, DOI 10.1124/mol.107.043588
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gotoh N, 2008, AM J OPHTHALMOL, V146, P146, DOI 10.1016/j.ajo.2008.03.017
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   HAYES KC, 1974, INVEST OPHTH VISUAL, V13, P499
   He L, 2006, MOL PHARMACOL, V70, P171, DOI 10.1124/mol.106.021521
   He Yuan, 2010, J Ocul Biol Dis Infor, V3, P92, DOI 10.1007/s12177-011-9061-y
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Jia LH, 2011, AGING CLIN EXP RES, V23, P264, DOI 10.1007/BF03324965
   Jiang C, 2000, MOL CARCINOGEN, V29, P236, DOI 10.1002/1098-2744(200012)29:4<236::AID-MC1006>3.0.CO;2-E
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   JORGENSEN K, 1993, Z LEBENSM UNTERS FOR, V196, P423, DOI 10.1007/BF01190806
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Julien S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029245
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khavinson VK, 2003, NEUROENDOCRINOL LETT, V24, P329
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kim JH, 2008, FREE RADICAL BIO MED, V45, P885, DOI 10.1016/j.freeradbiomed.2008.06.019
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   KLEIN LR, 1990, J COMP NEUROL, V293, P331, DOI 10.1002/cne.902930302
   Kliment CR, 2009, J MOL CELL CARDIOL, V47, P730, DOI 10.1016/j.yjmcc.2009.08.010
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kondo N, 2009, MOL VIS, V15, P1819
   Kowalski M, 2010, MED SCI MONITOR, V16, pCR190
   Kowluru RA, 2011, INVEST OPHTH VIS SCI, V52, P8665, DOI 10.1167/iovs.10-6768
   KRETZSCHMAR M, 1993, SPORTS MED, V15, P196, DOI 10.2165/00007256-199315030-00005
   KRINSKY NI, 1982, J NATL CANCER I, V69, P205
   Kritchevsky SB, 2000, AM J EPIDEMIOL, V152, P1065, DOI 10.1093/aje/152.11.1065
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Kutty RK, 2010, MOL VIS, V16, P1475
   Kuusisto E, 2002, NEUROPATH APPL NEURO, V28, P228, DOI 10.1046/j.1365-2990.2002.00394.x
   Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009
   LAM S, 1990, ARCH OPHTHALMOL-CHIC, V108, P1751, DOI 10.1001/archopht.1990.01070140105039
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LANG CA, 1992, J LAB CLIN MED, V120, P720
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200
   Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200
   Lee TB, 2012, CELL BIOL TOXICOL, V28, P11, DOI 10.1007/s10565-011-9201-y
   Lee YS, 2013, J INVEST DERMATOL, V133, P732, DOI 10.1038/jid.2012.406
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Liu ZB, 2007, J NEUROCHEM, V103, P2690, DOI 10.1111/j.1471-4159.2007.04954.x
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Maksimenko Alexander V, 2012, Heart Int, V7, pe3, DOI 10.4081/hi.2012.e3
   Maksimenko AV, 2004, J PHARM PHARMACOL, V56, P1463, DOI 10.1211/0022357044544
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Martin P, 2006, BIOCHEM BIOPH RES CO, V351, P294, DOI 10.1016/j.bbrc.2006.10.035
   MCCORD JM, 1969, J BIOL CHEM, V244, P6049
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Min JY, 2010, FEBS LETT, V584, P2427, DOI 10.1016/j.febslet.2010.04.048
   Miyamura N, 2004, INVEST OPHTH VIS SCI, V45, P1562, DOI 10.1167/iovs.02-0761
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nagaoka U, 2004, J NEUROCHEM, V91, P57, DOI 10.1111/j.1471-4159.2004.02692.x
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Ohira A, 2003, INVEST OPHTH VIS SCI, V44, P1230, DOI 10.1167/iovs.02-0191
   ORGANISCIAK DT, 1990, INVEST OPHTH VIS SCI, V31, P1195
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   Organisciak DT, 1996, INVEST OPHTH VIS SCI, V37, P2243
   ORGANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1, DOI 10.1016/1350-9462(94)90003-5
   Organisciak DT, 1998, INVEST OPHTH VIS SCI, V39, P1107
   ORGANISCIAK DT, 1991, EXP EYE RES, V53, P773, DOI 10.1016/0014-4835(91)90113-S
   ORGANISCIAK DT, 1992, CURR EYE RES, V11, P231, DOI 10.3109/02713689209001774
   PACKER L, 1993, ANN NY ACAD SCI, V691, P48, DOI 10.1111/j.1749-6632.1993.tb26156.x
   PEASE PL, 1987, VISION RES, V27, P705, DOI 10.1016/0042-6989(87)90067-8
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Quan X, 2011, FEBS LETT, V585, P3436, DOI 10.1016/j.febslet.2011.09.035
   Ragsdale SW, 2009, J BIOL CHEM, V284, P18571, DOI 10.1074/jbc.R900020200
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Ranchon I, 1999, INVEST OPHTH VIS SCI, V40, P1191
   RAPP LM, 1980, VISION RES, V20, P1127, DOI 10.1016/0042-6989(80)90050-4
   RAPP LM, 1979, PHOTOCHEM PHOTOBIOL, V29, P731, DOI 10.1111/j.1751-1097.1979.tb07758.x
   RECASENS JF, 1992, AGE, V15, P114, DOI 10.1007/BF02434901
   Rex TS, 2004, HUM GENE THER, V15, P960, DOI 10.1089/hum.2004.15.960
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Ryoo HD, 2007, EMBO J, V26, P242, DOI 10.1038/sj.emboj.7601477
   Ryu E, 2010, MOL VIS, V16, P2811
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Satarug S, 2008, EXP EYE RES, V87, P587, DOI 10.1016/j.exer.2008.09.014
   SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T
   SCOTT MD, 1987, J BIOL CHEM, V262, P3640
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shaban H, 2001, ARCH BIOCHEM BIOPHYS, V394, P111, DOI 10.1006/abbi.2001.2535
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003
   SIES H, 1992, ANN NY ACAD SCI, V669, P7
   SINGH SV, 1984, CURR EYE RES, V3, P1273, DOI 10.3109/02713688409007413
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Synowiec E, 2013, FRONT BIOSCI-LANDMRK, V18, P80, DOI 10.2741/4088
   Synowiec E, 2012, MOL BIOL REP, V39, P7077, DOI 10.1007/s11033-012-1539-6
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1864, DOI 10.1167/iovs.06-1065
   Tantin D, 2005, CANCER RES, V65, P10750, DOI 10.1158/0008-5472.CAN-05-2399
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tate DJ, 1997, CURR EYE RES, V16, P1017
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Ueta T, 2012, J BIOL CHEM, V287, P7675, DOI 10.1074/jbc.M111.335174
   van Herpen-Broekmans WMR, 2004, EUR J EPIDEMIOL, V19, P915, DOI 10.1007/s10654-004-5760-z
   Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008
   Viiri J, 2010, MOL VIS, V16, P1399
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   WITTING LA, 1965, J AM OIL CHEM SOC, V42, P908, DOI 10.1007/BF02632443
   Wysokinski D, 2013, EXP EYE RES, V106, P14, DOI 10.1016/j.exer.2012.10.003
   Yang LP, 2008, J NEUROSCI RES, V86, P910, DOI 10.1002/jnr.21535
   Yang LP, 2007, INVEST OPHTH VIS SCI, V48, P5191, DOI 10.1167/iovs.07-0512
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
   YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zadlo A, 2007, PIGM CELL RES, V20, P52, DOI 10.1111/j.1600-0749.2006.00350.x
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
   Zhang J, 2013, SYNAPSE, V67, P515, DOI 10.1002/syn.21674
   Zhong YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038616
   Zhuo P, 2009, CANCER RES, V69, P8183, DOI 10.1158/0008-5472.CAN-09-1791
NR 213
TC 107
Z9 110
U1 0
U2 38
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-5729
EI 1573-6768
J9 BIOGERONTOLOGY
JI Biogerontology
PD OCT
PY 2013
VL 14
IS 5
BP 461
EP 482
DI 10.1007/s10522-013-9463-2
PG 22
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 234CM
UT WOS:000325617400001
PM 24057278
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Zhao, S
   Huang, Z
   Jiang, H
   Xiu, JF
   Zhang, LY
   Long, QR
   Yang, YH
   Yu, L
   Lu, L
   Gu, H
AF Zhao, Su
   Huang, Zhi
   Jiang, Hao
   Xiu, Jiangfan
   Zhang, Liying
   Long, Qiurong
   Yang, Yuhan
   Yu, Lu
   Lu, Lu
   Gu, Hao
TI Sirtuin 1 Induces Choroidal Neovascularization and Triggers Age-Related
   Macular Degeneration by Promoting LCN2 through SOX9 Deacetylation
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID NF-KAPPA-B; INFLAMMATION; EXPRESSION
AB Increasing studies have identified the function of sirtuin-1 (SIRT1) in ocular diseases. Hence, this study is aimed at exploring the potential role of SIRT1 in choroidal neovascularization- (CNV-) induced age-related macular degeneration (AMD) development and the associated mechanism. Expression of SIRT1/SOX9/LCN2 in the hypoxic cells was determined, and their interactions were predicted by bioinformatics websites and followed by the verification by luciferase assay and chromatin immunoprecipitation (ChIP). Their in vitro effects on hypoxic cells concerning cell viability, apoptosis, migration, and angiogenesis were detected through gain- and loss-of-function assays. Besides, their in vivo effect was explored using the established CNV mouse models. Highly expressed LCN2, SOX9, and SIRT1 were observed in hypoxic cells. LCN2 was increased by SOX9 and SIRT1 deacetylated SOX9 to promote its nuclear translocation, which further inhibited the viability of human retinal pigment epithelial cells and promoted cell apoptosis and angiogenesis as well as CNV-induced AMD formation. The relieving role of LCN2 inhibition on CNV-induced AMD without toxicity for mice was also demonstrated by in vivo experiments. Overall, SIRT1 promoted the formation of CNV-induced AMD through SOX9 deacetylation-caused LCN2 upregulation, representing a promising target for CNV-induced AMD management.
C1 [Zhao, Su; Jiang, Hao; Zhang, Liying; Long, Qiurong; Yang, Yuhan; Yu, Lu; Gu, Hao] Guizhou Med Univ, Dept Ophthalmol, Affiliated Hosp, Guiyang 550002, Peoples R China.
   [Zhao, Su] Guizhou Med Univ, Sch Clin Med, Guiyang 550002, Peoples R China.
   [Huang, Zhi; Xiu, Jiangfan] Guizhou Med Univ, Sch Basic Med Sci, Guiyang 550002, Peoples R China.
   [Lu, Lu] Shenzhen Eye Hosp, Shenzhen Key Lab Ophthalmol, Shenzhen, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University; Guizhou Medical
   University
RP Gu, H (通讯作者)，Guizhou Med Univ, Dept Ophthalmol, Affiliated Hosp, Guiyang 550002, Peoples R China.; Lu, L (通讯作者)，Shenzhen Eye Hosp, Shenzhen Key Lab Ophthalmol, Shenzhen, Peoples R China.
EM zhaosu@gmc.edu.cn; hilltake@qq.com; kidd5jh@sina.com; 156735385@qq.com;
   zhangliying725@126.com; 420244652@qq.com; yuhanyang0424@163.com;
   w18690720576@163.com; 19188508@qq.com; guhao@gmc.edu.cn
FU Cultivation Project of National Natural Science Foundation of China in
   2020 in Affiliated Hospital of Guizhou Medical University [gyfynsfc
   [2020]-39]; Science and Technology Fund of Guizhou Provincial Department
   of Science and Technology [Qian Ke He Ji Chu-ZK (2021) general 425];
   fund for the Science and Technology Projects of Guizhou Province [2022,
   184, 4Y145]; Regional Common Diseases and Adult Stem Cell Transformation
   Research Innovation Platform, Science and Technology Department of
   Guizhou Province [(2019) 4008]; Graduate Education Innovation Project of
   Guizhou Provincial Department of Education [Qian Jiao He YJSCXJH, 152]
FX This study was supported by Cultivation Project of National Natural
   Science Foundation of China in 2020 in Affiliated Hospital of Guizhou
   Medical University (gyfynsfc [2020]-39), Science and Technology Fund of
   Guizhou Provincial Department of Science and Technology (No. Qian Ke He
   Ji Chu-ZK (2021) general 425), the fund for the Science and Technology
   Projects of Guizhou Province (Qian Ke He Support Plan [2022] normal No.
   184 and Qian Ke He Support Plan [2020] 4Y145), Regional Common Diseases
   and Adult Stem Cell Transformation Research Innovation Platform, Science
   and Technology Department of Guizhou Province [Guizhou specific grant
   (2019) 4008], and Graduate Education Innovation Project of Guizhou
   Provincial Department of Education (Qian Jiao He YJSCXJH (2020) No.
   152). We acknowledge and appreciate our colleagues for their valuable
   efforts and comments on this paper.
CR Afacan B, 2020, J PERIODONTOL, V91, P1495, DOI 10.1002/JPER.19-0521
   Agaoglu NB, 2019, TURK J MED SCI, V49, P1068, DOI 10.3906/sag-1810-182
   Agbo J, 2021, J INTEGR NEUROSCI, V20, P265, DOI 10.31083/j.jin2002026
   Arjamaa O, 2017, GRAEF ARCH CLIN EXP, V255, P1757, DOI 10.1007/s00417-017-3711-0
   Bar Oz M, 2016, AGING CELL, V15, P499, DOI 10.1111/acel.12456
   Cao L, 2013, BRAZ J MED BIOL RES, V46, P659, DOI 10.1590/1414-431X20132903
   Chadha S, 2019, J LEUKOCYTE BIOL, V106, P337, DOI 10.1002/JLB.2RU1118-422R
   Chen M, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00205-w
   Feng DX, 2020, J BIOL CHEM, V295, P13640, DOI 10.1074/jbc.RA119.011164
   Fry JL, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002384
   George J, 2019, MOL CARCINOGEN, V58, P1876, DOI 10.1002/mc.23080
   Ghosh S, 2020, CELL MOL LIFE SCI, V77, P835, DOI 10.1007/s00018-019-03423-8
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Goto S, 2018, ELIFE, V7, DOI 10.7554/eLife.32358
   Hagbi-Levi S, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/8535273
   Hwang JW, 2013, FREE RADICAL BIO MED, V61, P95, DOI 10.1016/j.freeradbiomed.2013.03.015
   Jabbehdari S, 2021, SURV OPHTHALMOL, V66, P423, DOI 10.1016/j.survophthal.2020.09.002
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kauppinen A, 2013, CELL SIGNAL, V25, P1939, DOI 10.1016/j.cellsig.2013.06.007
   Kiel C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082689
   Koo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04175-y
   Li J, 2020, EXP CELL RES, V388, DOI 10.1016/j.yexcr.2019.111811
   Liu H, 2015, INT J CLIN EXP PATHO, V8, P7644
   Maloney SC, 2013, RETINA-J RET VIT DIS, V33, P862, DOI 10.1097/IAE.0b013e31826af556
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Meng XF, 2017, CELL MOL NEUROBIOL, V37, P17, DOI 10.1007/s10571-016-0355-2
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nakagawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136994
   Parmar T, 2018, J IMMUNOL, V200, P3128, DOI 10.4049/jimmunol.1701573
   Qu P, 2016, STEM CELLS, V34, P1934, DOI 10.1002/stem.2365
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Shen MQ, 2016, BBA-PROTEINS PROTEOM, V1864, P787, DOI 10.1016/j.bbapap.2016.04.001
   Tang BL, 2016, MOL CELLS, V39, P87, DOI 10.14348/molcells.2016.2318
   Tang WY, 2018, CELL PHYSIOL BIOCHEM, V46, P375, DOI 10.1159/000488472
   Wan HF, 2021, GENE, V774, DOI 10.1016/j.gene.2021.145423
   Wang X, 2019, MOL VIS, V25, P703
   Wu WT, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018-021-02305-9
   Xu Fengli, 2019, Redox Rep, V24, P70, DOI 10.1080/13510002.2019.1658377
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197279
   Zhang HM, 2015, CYTOKINE, V76, P549, DOI 10.1016/j.cyto.2015.06.019
   Zhang WY, 2020, CELL DEATH DIFFER, V27, P482, DOI 10.1038/s41418-019-0369-7
   Zhao MW, 2019, ENVIRON TOXICOL, V34, P699, DOI 10.1002/tox.22736
   Zhou MW, 2018, INT J MOL MED, V42, P13, DOI 10.3892/ijmm.2018.3623
NR 43
TC 0
Z9 0
U1 2
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD JUN 9
PY 2022
VL 2022
AR 1671438
DI 10.1155/2022/1671438
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 2G9MJ
UT WOS:000813924900003
PM 35720180
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Javadzadeh, A
   Ghorbanihaghjo, A
   Heidari, E
   Baharivand, N
   Sadeghi, K
   Sorkhabi, R
   Ahoor, MH
AF Javadzadeh, Alireza
   Ghorbanihaghjo, Amir
   Heidari, Ebadolah
   Baharivand, Nader
   Sadeghi, Karim
   Sorkhabi, Rana
   Ahoor, Mohammad Hossein
TI Matrix gamma-carboxyglutamate protein and Fetuin-A, in wet type
   age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE high sensitivity C-reactive protein; Fetuin-A; matrix
   gamma-carboxyglutamate protein; age-related macular degeneration;
   choroidal neovascularization
ID INSULIN-RESISTANCE; OXIDATIVE STRESS; TYROSINE KINASE; INFLAMMATION;
   SERUM; PATHOGENESIS; MORTALITY; DIALYSIS; ATHEROSCLEROSIS; ASSOCIATIONS
AB AIM: To evaluate the high sensitivity C-reactive protein (hsCRP), Fetuin -A and matrix gamma -carboxyglutamate protein (MGP) as the main factors for vascular calcification and inflammation in serum of patients with advanced age related macular degeneration (ARMD) in comparison to healthy controls.
   METHODS: The subjects were 40 patients with choroidal neovascularization (CNV) having a mean age of 70.9 +/- 9.1y and a matched group of 49 apparently healthy control subjects. The ARMD was diagnosed using a slit-lamp with superfield lens, fundus photography and fluorescein angiography. Measurement of hsCRP was done by nephelometry method. Levels of Fetuin-A and MGP were measured by enzyme-linked immunosorbent assay (ELISA) technique.
   RESULTS: hsCRP [0.45(0.07-2.63) mg/L vs 0.25(0.03-1.2) mg/L, P=0.02)] and Fetuin-A levels (50.27 +/- 5.04 vs 44.99 +/- 10.28 ng/mL, P=0.009) were higher in the patients than in the control groups. We could not find significant difference in MGP level between two groups (P=0.08). There was not a significant correlation between MGP with Fetuin A and hsCRP among the patients (P=0.7, P=0.9 respectively). A significant negative correlation of hsCRP with Fetuin A was observed in both case and control groups (P=0.004, r=-0.33 and P=0.001, r =-0.54, respectively).
   CONCLUSION: Although our study shows that serum hsCRP and Fetuin A is increased in CNV patients as well as negatively correlated with both study groups, their direct role on pathogenesis of ARMD required future studies.
C1 [Javadzadeh, Alireza; Ghorbanihaghjo, Amir; Heidari, Ebadolah; Baharivand, Nader; Sadeghi, Karim; Sorkhabi, Rana; Ahoor, Mohammad Hossein] Tabriz Univ Med Sci, Tabriz 51664, Iran.
C3 Tabriz University of Medical Science
RP Ahoor, MH (通讯作者)，Tabriz Univ Med Sci, Tabriz 51664, Iran.
EM mh.ahoor@gmail.com
RI sorkhabi, rana/F-4721-2017; ahoor, mohammad hosein/M-1850-2017;
   Javadzadeh, Aliehsadat/J-9830-2017; Javadzadeh, Alireza/L-6424-2017
OI ahoor, mohammad hosein/0000-0002-0359-7012; Javadzadeh,
   Alireza/0000-0002-5151-6125; ghorbanihaghjo, amir/0000-0001-6742-0526;
   sorkhabi, rana/0000-0003-4996-898X
FU Tabriz University of Medical Sciences, Tabriz, Iran
FX Foundation: Supported by the vice-chancellor for research of Tabriz
   University of Medical Sciences, Tabriz, Iran.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Denecke B, 2003, BIOCHEM J, V376, P135, DOI 10.1042/BJ20030676
   Hennige AM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001765
   Hermans MMH, 2007, KIDNEY INT, V72, P202, DOI 10.1038/sj.ki.5002178
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Ix JH, 2012, CIRCULATION, V125, P2316, DOI 10.1161/CIRCULATIONAHA.111.072751
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jung CH, 2013, DIABETES VASC DIS RE, V10, P459, DOI 10.1177/1479164113490766
   Ketteler M, 2003, LANCET, V361, P827, DOI 10.1016/S0140-6736(03)12710-9
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Li X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047600
   Lorant DP, 2011, DIABETES CARE, V34, P156, DOI 10.2337/dc10-0788
   Mathews ST, 2002, DIABETES, V51, P2450, DOI 10.2337/diabetes.51.8.2450
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Promsote W, 2014, MOL VIS, V20, P73
   RAUTH G, 1992, EUR J BIOCHEM, V204, P523, DOI 10.1111/j.1432-1033.1992.tb16663.x
   Rector RS, 2008, WORLD J GASTROENTERO, V14, P185, DOI 10.3748/wjg.14.185
   Reinhard H, 2010, DIABETES CARE, V33, P2561, DOI 10.2337/dc10-0858
   SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stefan N, 2006, DIABETES CARE, V29, P853, DOI 10.2337/diacare.29.04.06.dc05-1938
   Stenvinkel P, 2005, KIDNEY INT, V67, P2383, DOI 10.1111/j.1523-1755.2005.00345.x
   Sun Q, 2013, DIABETES, V62, P49, DOI 10.2337/db12-0372
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Wang AYM, 2005, NEPHROL DIAL TRANSPL, V20, P1676, DOI 10.1093/ndt/gfh891
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
NR 31
TC 2
Z9 2
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUN 18
PY 2015
VL 8
IS 3
BP 556
EP 559
DI 10.3980/j.issn.2222-3959.2015.03.21
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ8VH
UT WOS:000355781100021
PM 26086007
DA 2022-11-30
ER

PT J
AU Stewart, MW
AF Stewart, Michael W.
TI Individualized Treatment of Neovascular Age-Related Macular
   Degeneration: What are Patients Gaining? Or Losing?
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration; as-needed therapy; bevacizumab;
   choroidal neovascularization; monthly therapy; ranibizumab; treat and
   extend
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL VEIN OCCLUSION; INTRAVITREAL
   AFLIBERCEPT INJECTION; VERTEPORFIN PHOTODYNAMIC THERAPY;
   VASCULAR-PERMEABILITY FACTOR; RANIBIZUMAB TREATMENT; CHOROIDAL
   NEOVASCULARIZATION; DOSING REGIMEN; VISUAL IMPAIRMENT; ECONOMIC-IMPACT
AB The widespread use of drugs that bind diffusible vascular endothelial growth factor (VEGF) has revolutionized the treatment of neovascular age-related macular degeneration (AMD). The pivotal ranibizumab and aflibercept registration trials featured monthly intravitreal injections for 12 months, during which visual acuities and macular edema rapidly improved for the first 3 months and modest gains or stabilization continued until the primary endpoint. In many subsequent trials, patients were evaluated monthly and treated as-needed (PRN) according to the results of visual acuity (VA) testing, fundus examinations and optical coherence tomography scans. Compared to monthly-treated control groups, PRN treated patients require fewer injections during the first year but they also experience smaller VA gains (1-3 letters). A small number of prospective trials that directly compared monthly with PRN therapy showed that VA gains with discontinuous therapy lag slightly behind those achieved with monthly injections. Physicians recognize that monthly office visits with frequent intraocular injections challenge patients' compliance, accrue high drug and professional service costs, and clog office schedules with frequently returning patients. To decrease the numbers of both office visits and anti-VEGF injections without sacrificing VA gains, physicians have embraced the treat-and-extend strategy. Treat-and-extend has not been studied as rigorously as PRN but it has become popular among both vitreoretinal specialists and patients. Despite the possible risks associated with discontinuous therapy (decreased VA and increased macular fluid), most physicians individualize treatment (PRN or treat-and-extend) for the majority of their patients. This review chapter explores the many advantages of individualized therapy, while balancing these against suboptimal responses due to the decreased frequency of anti-VEGF injections.
C1 Mayo Clin Florida, Dept Ophthalmol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
C3 Mayo Clinic
RP Stewart, MW (通讯作者)，Mayo Clin Florida, Dept Ophthalmol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM stewart.michael@mayo.edu
FU Regeneron
FX Allergan: advisory board; Boehringer-Ingelheim: consultant; Regeneron:
   advisory board, research support.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Barbazetto I, 2010, RETINA-J RET VIT DIS, V30, P1376, DOI 10.1097/IAE.0b013e3181dcfb0b
   Bashshur ZF, 2011, RETINA-J RET VIT DIS, V31, P636, DOI 10.1097/IAE.0b013e3181fe54ab
   Bellerive C, 2012, CAN J OPHTHALMOL, V47, P165, DOI 10.1016/j.jcjo.2012.01.011
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, AM J OPHTHALMOL, V155, P429, DOI 10.1016/j.ajo.2012.09.026
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P538, DOI 10.1016/j.ophtha.2014.08.031
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Chong V., 2007, P 7 EURETINA C MONT
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Geirsdottir A, 2012, BRIT J OPHTHALMOL, V96, P444, DOI 10.1136/bjophthalmol-2011-300304
   Goff SL, 2008, J GEN INTERN MED, V23, P236, DOI 10.1007/s11606-007-0470-3
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hasler PW, 2015, ACTA OPHTHALMOL, V93, P122, DOI 10.1111/aos.12589
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P278, DOI 10.1136/bjophthalmol-2012-301504
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Johanson R, 2000, J PUBLIC HEALTH MED, V22, P439, DOI 10.1093/pubmed/22.3.439
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lanzetta P, 2011, EC BURDEN DIABETIC M
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michelotti MM, 2014, CLIN OPHTHALMOL, V8, P755, DOI 10.2147/OPTH.S59982
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sonmez K, 2011, RETINA-J RET VIT DIS, V31, P645, DOI 10.1097/IAE.0b013e3182012d18
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Tarn DM, 2009, J AM GERIATR SOC, V57, P462, DOI 10.1111/j.1532-5415.2008.02133.x
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   Tuulonen A, 2009, ACTA OPHTHALMOL, V87, P820, DOI 10.1111/j.1755-3768.2009.01532.x
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Ziemssen F, 2011, DRUG AGING, V28, P853, DOI 10.2165/11594720-000000000-00000
NR 82
TC 28
Z9 28
U1 0
U2 3
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2015
VL 4
IS 5
BP 1079
EP 1101
DI 10.3390/jcm4051079
PG 23
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT9MV
UT WOS:000363142200020
PM 26239466
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Jones, MM
   Manwaring, N
   Wang, JJ
   Rochtchina, E
   Mitchell, P
   Sue, CM
AF Jones, Michael M.
   Manwaring, Neil
   Wang, Jie Jin
   Rochtchina, Elena
   Mitchell, Paul
   Sue, Carolyn M.
TI Mitochondrial DNA haplogroups and age-related Maculopathy
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; RISK-FACTORS; MACULAR
   DEGENERATION; VISUAL IMPAIRMENT; PREVALENCE; DISEASE; MTDNA; BLINDNESS;
   PEDIGREE
AB Objective: To investigate whether mitochondrial haplogroups are associated with age-related maculopathy (ARM).
   Methods: We assessed the association between mitochondrial haplogroups and ARM in a population-based sample of 3509 persons aged 49 years or older residing west of Sydney. Retinal photographs of both eyes were taken (1999-2001) and subsequently graded for ARM following the Wisconsin grading system. Genetic analysis for mitochondrial DNA haplogroups was performed. Associations between these genetic markers and risk factors for ARM were assessed.
   Results: After adjusting for age, sex, and smoking, haplogroup H was associated with a reduced prevalence of any (early and late) ARM (odds ratio [OR], 0.75; 95% confidence interval [CI], 0.58-0.97), early ARM(OR, 0.75; 95% CI, 0.57-0.98), and large distinct and indistinct soft drusen (OR, 0.70;95% CI, 0.56-0.89). Haplogroup J was associated with a higher prevalence of large, soft distinct drusen (OR, 1.80; 95% CI, 1.18-2.73). Haplogroup U was associated with an increased prevalence of retinal pigment abnormalities (OR, 1.45; 95% CI, 1.11-1.91).
   Conclusions: Our findings of associations between different haplogroup types and prevalent ARM or ARM lesions suggest that these haplogroups may be genetic markers indicative of an individual's susceptibility to ARM.
C1 Univ Sydney, Kolling Inst, Dept Neurogenet, Sydney, NSW 2006, Australia.
   Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
C3 University of Sydney; Kolling Institute of Medical Research; University
   of Sydney; Westmead Institute for Medical Research
RP Sue, CM (通讯作者)，Royal N Shore Hosp, Dept Neurogenet, Clin 4,Reserve Rd, St Leonards, NSW 2065, Australia.
EM csue@med.usyd.edu.au
RI Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   Baudouin SV, 2005, LANCET, V366, P2118, DOI 10.1016/S0140-6736(05)67890-7
   Biousse V, 2001, SEMIN NEUROL, V21, P275, DOI 10.1055/s-2001-17945
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   GATES GA, 1990, EAR HEARING, V11, P247, DOI 10.1097/00003446-199008000-00001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Howell N, 2003, AM J MED GENET A, V119A, P147, DOI 10.1002/ajmg.a.20135
   Kalman B, 1999, ACTA NEUROL SCAND, V99, P16
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Majamaa K, 1998, LANCET, V352, P455, DOI 10.1016/S0140-6736(05)79190-X
   Manwaring N, 2006, INTERN MED J, V36, P530, DOI 10.1111/j.1445-5994.2006.01118.x
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040
   Sadun AA, 2003, AM J OPHTHALMOL, V136, P231, DOI 10.1016/S0002-9394(03)00099-0
   Sadun F, 2004, AM J OPHTHALMOL, V137, P271, DOI 10.1016/j.ajo.2003.08.010
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Souied EH, 2005, MOL VIS, V11, P1135
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Sue CM, 1997, NEUROLOGY, V49, P1013, DOI 10.1212/WNL.49.4.1013
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Torroni A, 1996, GENETICS, V144, P1835
   TORRONI A, 1994, AM J HUM GENET, V55, P760
   Tsao K, 1999, BRIT J OPHTHALMOL, V83, P577, DOI 10.1136/bjo.83.5.577
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
NR 47
TC 72
Z9 76
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2007
VL 125
IS 9
BP 1235
EP 1240
DI 10.1001/archopht.125.9.1235
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 208TM
UT WOS:000249342100012
PM 17846364
OA Bronze
DA 2022-11-30
ER

PT J
AU Chen, ZJ
   Lu, SY
   Rong, SS
   Ho, M
   Ng, DSC
   Chen, HY
   Gong, B
   Yam, JC
   Young, AL
   Brelen, M
   Tham, CC
   Pang, CP
   Chen, L
AF Chen, Zhen Ji
   Lu, Shi Yao
   Rong, Shi Song
   Ho, Mary
   Ng, Danny Siu-Chun
   Chen, Haoyu
   Gong, Bo
   Yam, Jason C.
   Young, Alvin L.
   Brelen, Marten
   Tham, Clement C.
   Pang, Chi Pui
   Chen, Li Jia
TI Genetic associations of central serous chorioretinopathy: a systematic
   review and meta-analysis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; COMPLEMENT FACTOR-H; MACULAR
   DEGENERATION; MINERALOCORTICOID RECEPTOR; PHOTODYNAMIC THERAPY;
   VARIANTS; SUSCEPTIBILITY; CFH; POLYMORPHISMS; INFLAMMATION
AB Aims To identify single-nucleotide polymorphisms (SNPs) associated with central serous chorioretinopathy (CSCR) by a systematic review and meta-analysis, and to compare the association profiles between CSCR, neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV).
   Methods We searched the EMBASE, PubMed and Web of Science for genetic studies of CSCR from the starting dates of the databases to 12 September 2020. We then performed meta-analyses on all SNPs reported by more than two studies and calculated the pooled OR and 95% CIs. We also conducted sensitivity analysis and adopted the funnel plot to assess potential publication bias.
   Results Totally 415 publications were reviewed, among them 10 were eligible for meta-analysis. We found 10 SNPs that have been reported at least twice. Meta-analysis and sensitivity analysis confirmed significant associations between CSCR and six SNPs in three genes, namely age-related maculopathy susceptibility 2 (ARMS2) (rs10490924, OR=1.37; p=0.00064), complement factor H (CFH) (rs800292, OR=1.44; p=7.80x10(-5); rs1061170, OR=1.34; p=0.0028; rs1329428, OR=1.40; p=0.012; and rs2284664, OR=1.36; p=0.0089) and tumour necrosis factor receptor superfamily, member 10a (TNFRSF10A) (rs13278062, OR=1.34; p=1.44x10(-15)). Among them, only TNFRSF10A rs13278062 showed the same trend of effect on CSCR, nAMD and PCV, while the SNPs in ARMS2 and CFH showed opposite trends in the SNP associations.
   Conclusions This study confirmed the associations of ARMS2, CFH and TNFRSF10A with CSCR, and revealed that ARMS2, CFH and TNFRSF10A may affect different phenotypic expressions of CSCR, nAMD and PCV.
C1 [Chen, Zhen Ji; Lu, Shi Yao; Ho, Mary; Ng, Danny Siu-Chun; Yam, Jason C.; Young, Alvin L.; Brelen, Marten; Tham, Clement C.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Rong, Shi Song] Harvard Med Sch, Dept Ophthalmol, Boston, MA USA.
   [Ho, Mary; Young, Alvin L.; Brelen, Marten; Chen, Li Jia] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Chen, Haoyu; Pang, Chi Pui] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Gong, Bo] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Sichuan Key Lab Dis Gene Study, Chengdu, Peoples R China.
C3 Chinese University of Hong Kong; Harvard University; Harvard Medical
   School; Chinese University of Hong Kong; Prince of Wales Hospital;
   Shantou University; Sichuan Provincial People's Hospital
RP Chen, L (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
RI Chen, Haoyu/A-7432-2013; Tham, Chee Yung Clement/AAD-6528-2020; Yam,
   Jason C./AAI-2522-2020
OI Chen, Haoyu/0000-0003-0676-4610; Tham, Chee Yung
   Clement/0000-0003-4407-6907; Yam, Jason C./0000-0002-2156-1486; Ho,
   Mary/0000-0001-8864-2988; Rong, Shi Song/0000-0001-8352-6363; Lu, Shi
   Yao/0000-0001-6828-233X
FU Department of Science and Technology of Sichuan Province [2020ZYD035];
   Chinese University of Hong Kong [4054560]; Endowment Fund for Lim
   Por-Yen Eye Genetics Research Centre, Hong Kong
FX This work was supported in part by a research grant from the Department
   of Science and Technology of Sichuan Province (2020ZYD035; BG); a Direct
   Grant from The Chinese University of Hong Kong (4054560; LJC), and the
   Endowment Fund for Lim Por-Yen Eye Genetics Research Centre, Hong Kong.
CR Akyol M, 2015, INT J OPHTHALMOL-CHI, V8, P23, DOI 10.3980/j.issn.2222-3959.2015.01.04
   Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117
   Berka JLW, 2009, CIRC RES, V104, P124, DOI 10.1161/CIRCRESAHA.108.176008
   Bossi F, 2008, INT IMMUNOPHARMACOL, V8, P143, DOI 10.1016/j.intimp.2007.08.006
   Breukink MB, 2015, INVEST OPHTH VIS SCI, V56, P5608, DOI 10.1167/iovs.15-17343
   Cho SC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57747-8
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Eser, 2016, INT EYE SCI, V16, P1203
   Finnberg N, 2008, J CLIN INVEST, V118, P111, DOI 10.1172/JCI29900
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hayashida M, 2020, MOL VIS, V26, P505
   Hosoda Y, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0712-z
   Hosoda Y, 2019, OPHTHALMOL RETINA, V3, P985, DOI 10.1016/j.oret.2019.05.025
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Hueber A, 2002, GRAEF ARCH CLIN EXP, V240, P551, DOI 10.1007/s00417-002-0487-6
   Ijuin N, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01443-8
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaye R, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100865
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lee K, 2020, GRAEF ARCH CLIN EXP, V258, P1157, DOI 10.1007/s00417-020-04620-z
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Liegl R, 2014, OPHTHALMOLOGICA, V232, P65, DOI 10.1159/000360014
   Liew G, 2013, CLIN EXP OPHTHALMOL, V41, P201, DOI 10.1111/j.1442-9071.2012.02848.x
   Linghu DD, 2020, INT OPHTHALMOL, V40, P951, DOI 10.1007/s10792-019-01261-y
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Malle EM, 2018, OPHTHALMIC GENET, V39, P714, DOI 10.1080/13816810.2018.1536219
   Maugeri A, 2019, ACTA OPHTHALMOL, V97, pE8, DOI 10.1111/aos.13849
   Miki A, 2018, INVEST OPHTH VIS SCI, V59, P5542, DOI 10.1167/iovs.18-25497
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   Mohabati D, 2020, RETINA-J RET VIT DIS, V40, P1734, DOI 10.1097/IAE.0000000000002682
   Moschos MM, 2016, RETINA-J RET VIT DIS, V36, P402, DOI 10.1097/IAE.0000000000000693
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111
   Pryds A, 2010, INVEST OPHTH VIS SCI, V51, P5853, DOI 10.1167/iovs.09-4830
   Sari ES, 2014, CUTAN OCUL TOXICOL, V33, P270, DOI 10.3109/15569527.2013.854372
   Sauteur L, 2014, CELL REP, V9, P504, DOI 10.1016/j.celrep.2014.09.024
   Schellevis RL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43152-3
   Schellevis RL, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.576
   Schellevis RL, 2018, JAMA OPHTHALMOL, V136, P1128, DOI 10.1001/jamaophthalmol.2018.3190
   Schubert C, 2014, HUM MUTAT, V35, P859, DOI 10.1002/humu.22551
   Semeraro F, 2019, CLIN OPHTHALMOL, V13, P2341, DOI 10.2147/OPTH.S220845
   Told R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060424
   van Dijk EHC, 2017, JAMA OPHTHALMOL, V135, P446, DOI 10.1001/jamaophthalmol.2017.0245
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Yamashiro K, 2020, JPN J OPHTHALMOL, V64, P555, DOI 10.1007/s10384-020-00773-w
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
   Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427
NR 58
TC 3
Z9 3
U1 3
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2022
VL 106
IS 11
BP 1542
EP 1548
DI 10.1136/bjophthalmol-2021-318953
EA MAY 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5U6TH
UT WOS:000727035500001
PM 34039561
DA 2022-11-30
ER

PT J
AU Michels, S
   Rosenfeld, PJ
   Puliafito, CA
   Marcus, EN
   Venkatraman, AS
AF Michels, S
   Rosenfeld, PJ
   Puliafito, CA
   Marcus, EN
   Venkatraman, AS
TI Systemic bevacizumab (Avastin) therapy for neovascular age-related
   macular degeneration - Twelve-week results of an uncontrolled open-label
   clinical study
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; FACTOR
   ANTIBODY; INTRAVITREAL TRIAMCINOLONE; PHOTODYNAMIC THERAPY;
   RANDOMIZED-TRIAL; FLUOROURACIL; LEUCOVORIN; PREVENTION; ANGIOGENESIS
AB Purpose: To evaluate the short-term safety of systemic bevacizumab (Avastin, Genentech, Inc., South San Francisco, CA) and its effects on visual acuity (VA) and subfoveal choroidal neovascularization (CNV) in patients with neovascular age-related macular degeneration (AMD).
   Design: Open-label, single-center, uncontrolled clinical study.
   Participants: Age-related macular degeneration patients with subfoveal CNV (N = 9) and best-corrected VA letter scores of 70 to 20 (approximate Snellen equivalent, 20/40-20/400).
   Methods: Patients were treated at baseline with an infusion of bevacizumab (5 mg/kg), followed by 1 or 2 additional doses given at 2-week intervals. Safety assessments were performed at all visits. Ophthalmologic evaluations included protocol VA measurements and ocular examinations, along with optical coherence tomography (OCT) imaging, fluorescein angiography, and indocyanine green angiography.
   Main Outcome Measurements: Safety assessments were performed, along with assessments of changes from baseline in VA scores, OCT measurements, and angiographic lesion characteristics.
   Results: There were no serious ocular or systemic adverse events identified. By 6 weeks, the only adverse event identified was a mild elevation of systolic blood pressure (BP) (+ 12 mmHg; P = 0.035), and this elevation was controlled by either changing or initiating anti hypertensive medication. By 12 weeks, the elevation of systolic BP was no longer significant (P = 0.51). In the study eyes, significant increases in VA were evident within 1 week of treatment, and by 12 weeks, the median and mean VA letter scores increased by 8 letters (P = 0.011) and 12 letters (P = 0.008), respectively. The median and mean central retinal thickness measurements decreased by 157 mu m (P = 0.008) and 177 mu m (P = 0.001), respectively. In the fellow eyes at 12 weeks, the median and mean VA letter scores increased by 27 letters (P = 0.018) and 16 letters (P = 0.012), and the median and mean central retinal thickness measurements decreased by 59 mu m (P = 0.028) and 92 mu m (P = 0.06). In all study eyes, angiography revealed a marked reduction or an absence of leakage from CNV.
   Conclusion: Overall, bevacizumab therapy was well tolerated, with an improvement in VA, OCT, and angiographic outcomes. Although these preliminary results are promising, a randomized controlled clinical trial is necessary before concluding that systemic bevacizumab therapy is safe and effective for patients with neovascular AMD.
C1 Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   Univ Miami, Sch Med, Div Gen Med, Dept Internal Med, Miami, FL USA.
C3 Bascom Palmer Eye Institute; University of Miami; University of Miami
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
FU NATIONAL EYE INSTITUTE [P30EY014801] Funding Source: NIH RePORTER
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BARRON H, IMPORTANT DRUG WARNI
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Choti MA, 2004, CANCER TREAT REV, V30, P715, DOI 10.1016/j.ctrv.2004.09.003
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   *JOINT NAT COMM PR, 7 JOINT NAT COMM PRE
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Konerding MA, 2004, EXPERT OPIN THER TAR, V8, P255, DOI 10.1517/14728222.8.3.255
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   MICHELS S, 2004, RETIN PHYS, V1, P16
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Pickering Thomas G., 2005, Hypertension (Baltimore), V45, P142
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   SINGERMAN LJ, 2004, RETIN PHYS, V1, P34
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Tolentino MJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P78
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   Wulff C, 2002, ENDOCRINOLOGY, V143, P2797, DOI 10.1210/en.143.7.2797
   Yang JC, 2004, CLIN CANCER RES, V10, p6367S, DOI 10.1158/1078-0432.CCR-050006
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   2003, CLIN COLORECTAL CANC, V8, P85
NR 44
TC 498
Z9 555
U1 1
U2 42
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2005
VL 112
IS 6
BP 1035
EP 1047
DI 10.1016/j.ophtha.2005.02.007
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 932CI
UT WOS:000229531400015
PM 15936441
DA 2022-11-30
ER

PT J
AU Kalra, G
   Kar, SS
   Sevgi, DD
   Madabhushi, A
   Srivastava, SK
   Ehlers, JP
AF Kalra, Gagan
   Kar, Sudeshna Sil
   Sevgi, Duriye Damla
   Madabhushi, Anant
   Srivastava, Sunil K.
   Ehlers, Justis P.
TI Quantitative Imaging Biomarkers in Age-Related Macular Degeneration and
   Diabetic Eye Disease: A Step Closer to Precision Medicine
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Review
DE retinal imaging; quantitative biomarkers; diabetic retinopathy; diabetic
   macular edema; age-related macular degeneration; precision medicine;
   anti-VEGF therapy
ID OPTICAL COHERENCE TOMOGRAPHY; WIDEFIELD FLUORESCEIN ANGIOGRAPHY; FOVEAL
   AVASCULAR ZONE; RETINAL INNER LAYERS; SUBFOVEAL GEOGRAPHIC ATROPHY;
   HYPERREFLECTIVE FOCI; VISUAL-ACUITY; GLOBAL PREVALENCE; OCT BIOMARKERS;
   NON-PERFUSION
AB The management of retinal diseases relies heavily on digital imaging data, including optical coherence tomography (OCT) and fluorescein angiography (FA). Targeted feature extraction and the objective quantification of features provide important opportunities in biomarker discovery, disease burden assessment, and predicting treatment response. Additional important advantages include increased objectivity in interpretation, longitudinal tracking, and ability to incorporate computational models to create automated diagnostic and clinical decision support systems. Advances in computational technology, including deep learning and radiomics, open new doors for developing an imaging phenotype that may provide in-depth personalized disease characterization and enhance opportunities in precision medicine. In this review, we summarize current quantitative and radiomic imaging biomarkers described in the literature for age-related macular degeneration and diabetic eye disease using imaging modalities such as OCT, FA, and OCT angiography (OCTA). Various approaches used to identify and extract these biomarkers that utilize artificial intelligence and deep learning are also summarized in this review. These quantifiable biomarkers and automated approaches have unleashed new frontiers of personalized medicine where treatments are tailored, based on patient-specific longitudinally trackable biomarkers, and response monitoring can be achieved with a high degree of accuracy.
C1 [Kalra, Gagan; Sevgi, Duriye Damla; Srivastava, Sunil K.; Ehlers, Justis P.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Kalra, Gagan; Kar, Sudeshna Sil; Sevgi, Duriye Damla; Srivastava, Sunil K.; Ehlers, Justis P.] Cleveland Clin, Tony & Leona Campane Ctr Excellence Image Guided, Cleveland, OH 44195 USA.
   [Kar, Sudeshna Sil; Madabhushi, Anant] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
   [Madabhushi, Anant] Louis Stokes Cleveland Vet Adm Med Ctr, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western
   Reserve University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Case Western Reserve University; Louis Stokes
   Cleveland Veterans Affairs Medical Center
RP Ehlers, JP (通讯作者)，Cleveland Clin, Cole Eye Inst, Cleveland, OH 44195 USA.; Ehlers, JP (通讯作者)，Cleveland Clin, Tony & Leona Campane Ctr Excellence Image Guided, Cleveland, OH 44195 USA.
EM kalrag2@ccf.org; SXS2440@case.edu; ddamlasevgi@gmail.com;
   axm788@case.edu; srivass2@ccf.org; ehlersj@ccf.org
RI Kalra, Gagan/AAV-3465-2020
OI Kalra, Gagan/0000-0002-3367-3047; Sevgi, Duriye
   Damla/0000-0002-0395-8711; Madabhushi, Anant/0000-0002-5741-0399
FU Regeneron; Allergan; Gilead; Astrazeneca; Bristol Myers-Squibb; Philips;
   Roche; Aerpio; NIH/NEI [K23-EY022947-01A1]
FX NIH/NEI K23-EY022947-01A1. S.K.S. has research support from Regeneron,
   Allergan, and Gilead; is a consultant for Bausch and Lomb, Novartis, and
   Regeneron. A.M. has research funding from Astrazeneca, Bristol
   Myers-Squibb, and Philips. They have equity in Inspirata Inc., Elucid
   Bioimaging. They are also a consultant for Aiforia, Caris, Roche, and
   Cernostics. J.P.E. has research support from the following: Aerpio,
   Alcon, Thrombogenics/Oxurion, Regeneron, Genentech, Novartis, Allergan;
   is a consultant for the following: Aerpio, Adverum, Alcon, Allegro,
   Allergan, Genentech/Roche, Stealth, Novartis, Thrombogenics/Oxurion,
   Leica, Zeiss, Regeneron, and Santen; holds a patent with Leica. All
   other authors do not have any financial disclosures.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Abraham JR, 2022, BRIT J OPHTHALMOL, V106, P1444, DOI 10.1136/bjophthalmol-2020-318726
   Abraham JR, 2021, AM J OPHTHALMOL, V222, P328, DOI 10.1016/j.ajo.2020.08.047
   Akkus Z, 2017, J DIGIT IMAGING, V30, P449, DOI 10.1007/s10278-017-9983-4
   Babiuch AS, 2020, RETINA-J RET VIT DIS, V40, P2175, DOI 10.1097/IAE.0000000000002727
   Balaratnasingam C, 2016, OPHTHALMOLOGY, V123, P2352, DOI 10.1016/j.ophtha.2016.07.008
   Banerjee I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72359-y
   Barraso M, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.34
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Byon I, 2021, RETINA-J RET VIT DIS, V41, P393, DOI 10.1097/IAE.0000000000002906
   Camino A, 2019, NEUROPHOTONICS, V6, DOI 10.1117/1.NPh.6.4.041108
   Chatziralli I, 2018, OPHTHALMOL THER, V7, P101, DOI 10.1007/s40123-018-0119-9
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Chu ZD, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.066008
   Cicinelli MV, 2018, SURV OPHTHALMOL, V63, P236, DOI 10.1016/j.survophthal.2017.06.005
   Couturier A, 2019, OPHTHALMOLOGY, V126, P1685, DOI 10.1016/j.ophtha.2019.06.022
   De Benedetto U, 2015, RETINA-J RET VIT DIS, V35, P449, DOI 10.1097/IAE.0000000000000336
   de Carlo TE, 2016, OSLI RETINA, V47, P115, DOI 10.3928/23258160-20160126-03
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   De Pretto LR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43958-1
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Deak GG, 2018, JAMA OPHTHALMOL, V136, P1215, DOI 10.1001/jamaophthalmol.2018.3848
   Dong V, 2021, INVEST OPHTH VIS SCI, V62
   Dupas B, 2018, JAMA OPHTHALMOL, V136, P721, DOI 10.1001/jamaophthalmol.2018.1319
   Ehlers JP, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.3.29
   Ehlers JP, 2021, AM J OPHTHALMOL, V224, P217, DOI 10.1016/j.ajo.2020.11.010
   Ehlers JP, 2021, OPHTHALMOL RETINA, V5, P1204, DOI 10.1016/j.oret.2021.02.012
   Ehlers JP, 2019, OPHTHALMOL RETINA, V3, P1056, DOI 10.1016/j.oret.2019.06.010
   Ehlers JP, 2019, OPHTHALMOLOGY, V126, P1527, DOI 10.1016/j.ophtha.2019.05.034
   Ehlers JP, 2018, OPHTHALMOL RETINA, V2, P263, DOI 10.1016/j.oret.2017.05.006
   Ehlers JP, 2017, BRIT J OPHTHALMOL, V101, P696, DOI 10.1136/bjophthalmol-2016-310047
   Eliwa TF, 2018, RETINA-J RET VIT DIS, V38, P805, DOI 10.1097/IAE.0000000000001599
   Falavarjani KG, 2016, J CURR OPHTHALMOL, V28, P57, DOI 10.1016/j.joco.2016.04.001
   Fan WY, 2020, AM J OPHTHALMOL, V209, P99, DOI 10.1016/j.ajo.2019.08.015
   Fan WY, 2020, RETINA-J RET VIT DIS, V40, P1029, DOI 10.1097/IAE.0000000000002579
   Fan W, 2019, AM J OPHTHALMOL, V206, P154, DOI 10.1016/j.ajo.2019.04.023
   Fang MY, 2019, AM J OPHTHALMOL, V206, P74, DOI 10.1016/j.ajo.2019.03.030
   Figueiredo N, 2020, OPHTHALMOL RETINA, V4, P154, DOI 10.1016/j.oret.2019.09.001
   Freiberg FJ, 2016, GRAEF ARCH CLIN EXP, V254, P1051, DOI 10.1007/s00417-015-3148-2
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Hanumanthu A, 2021, INVEST OPHTH VIS SCI, V62
   Hormel TT, 2021, PROG RETIN EYE RES, V80, DOI 10.1016/j.preteyeres.2020.100878
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jiang AC, 2020, OPHTHALMOL RETINA, V4, P49, DOI 10.1016/j.oret.2019.08.008
   Joltikov KA, 2018, INVEST OPHTH VIS SCI, V59, P5481, DOI 10.1167/iovs.18-24955
   Kaines A, 2009, SEMIN OPHTHALMOL, V24, P19, DOI 10.1080/08820530802520095
   Kar SS, 2021, IEEE J TRANSL ENG HE, V9, P1, DOI 10.1109/JTEHM.2021.3096378
   Kurmann T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49740-7
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Le D, 2019, BIOMED OPT EXPRESS, V10, P2493, DOI 10.1364/BOE.10.002493
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee H, 2018, RETINA-J RET VIT DIS, V38, P976, DOI 10.1097/IAE.0000000000001618
   Lee H, 2018, INVEST OPHTH VIS SCI, V59, P715, DOI 10.1167/iovs.17-23042
   Lunasco L., 2021, OSLI RETIN
   Lunasco L, 2021, INVEST OPHTH VIS SCI, V62
   Lundervold AS, 2019, Z MED PHYS, V29, P102, DOI 10.1016/j.zemedi.2018.11.002
   MAINSTER MA, 1990, EYE, V4, P235, DOI 10.1038/eye.1990.33
   Maloca PM, 2020, GRAEF ARCH CLIN EXP, V258, P711, DOI 10.1007/s00417-019-04582-x
   Manivannan A, 2005, AM J OPHTHALMOL, V140, P525, DOI 10.1016/j.ajo.2005.02.055
   Moosavi A, 2021, IEEE T BIO-MED ENG, V68, P1777, DOI 10.1109/TBME.2020.3018464
   Moraes G, 2021, OPHTHALMOLOGY, V128, P693, DOI 10.1016/j.ophtha.2020.09.025
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nguyen TT, 2008, DIABETES CARE, V31, P544, DOI 10.2337/dc07-1528
   Nicholson L, 2015, CLIN EXP OPHTHALMOL, V43, P735, DOI 10.1111/ceo.12557
   O'Connell M, 2020, INVEST OPHTH VIS SCI, V61
   Okuwobi IP, 2020, IEEE J BIOMED HEALTH, V24, P1125, DOI 10.1109/JBHI.2019.2929842
   Parekh VS, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0045-3
   Penzias G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200730
   Prahs P, 2018, GRAEF ARCH CLIN EXP, V256, P91, DOI 10.1007/s00417-017-3839-y
   Prasanna P, 2021, BRIT J OPHTHALMOL, V105, P1155, DOI 10.1136/bjophthalmol-2020-317182
   Querques L, 2017, ACTA DIABETOL, V54, P769, DOI 10.1007/s00592-017-1010-1
   Rabbani H, 2015, INVEST OPHTH VIS SCI, V56, P1482, DOI 10.1167/iovs.14-15457
   Rasti R, 2020, BIOMED OPT EXPRESS, V11, P1139, DOI 10.1364/BOE.379150
   Reznicek L, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/305084
   Rizzo Stefania, 2018, Eur Radiol Exp, V2, P36, DOI 10.1186/s41747-018-0068-z
   Roberts PK, 2020, JAMA OPHTHALMOL, V138, P945, DOI 10.1001/jamaophthalmol.2020.2457
   Rubsam Anne, 2021, J Diabetes Res, V2021, P8820216, DOI 10.1155/2021/8820216
   Salz DA, 2016, JAMA OPHTHALMOL, V134, P644, DOI 10.1001/jamaophthalmol.2016.0600
   Samara WA, 2017, OPHTHALMOLOGY, V124, P235, DOI 10.1016/j.ophtha.2016.10.008
   Sawada O, 2018, GRAEF ARCH CLIN EXP, V256, P1275, DOI 10.1007/s00417-018-3992-y
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Sevgi Duriye Damla, 2021, Ophthalmol Sci, V1, DOI 10.1016/j.xops.2021.100049
   Sevgi DD, 2022, BRIT J OPHTHALMOL, V106, P251, DOI 10.1136/bjophthalmol-2020-317241
   Sevgi DD, 2020, INVEST OPHTH VIS SCI, V61
   Shahlaee A, 2016, AM J OPHTHALMOL, V161, P50, DOI 10.1016/j.ajo.2015.09.026
   Shi R, 2018, CURR EYE RES, V43, P244, DOI 10.1080/02713683.2017.1387669
   Sil K.S., 2021, INVESTIG OPHTHALMOL, V62, P3
   Silva PS, 2015, OPHTHALMOLOGY, V122, P2465, DOI 10.1016/j.ophtha.2015.07.034
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Sumathipala Y, 2018, J MED IMAGING, V5, DOI 10.1117/1.JMI.5.4.044507
   Sun JK, 2014, JAMA OPHTHALMOL, V132, P1309, DOI 10.1001/jamaophthalmol.2014.2350
   Tang FY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02767-0
   Toth CA, 2018, OPHTHALMOL RETINA, V2, P481, DOI 10.1016/j.oret.2017.09.016
   Tsai ASH, 2011, DIABETES RES CLIN PR, V94, P291, DOI 10.1016/j.diabres.2011.07.032
   Uchida A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218889
   Verma A, 2020, GRAEF ARCH CLIN EXP, V258, P725, DOI 10.1007/s00417-020-04607-w
   Vujosevic S, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/491835
   Vujosevic S, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/905058
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu GQ, 2018, IEEE T MED IMAGING, V37, P893, DOI 10.1109/TMI.2017.2776967
   Wykoff CC, 2019, OPHTHALMOL RETINA, V3, P1076, DOI 10.1016/j.oret.2019.07.011
   Yu HJ, 2021, AM J OPHTHALMOL, V226, P126, DOI 10.1016/j.ajo.2021.01.024
   Zarranz-Ventura J, 2019, BMC MED IMAGING, V19, DOI 10.1186/s12880-019-0391-8
NR 107
TC 3
Z9 3
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD NOV
PY 2021
VL 11
IS 11
AR 1161
DI 10.3390/jpm11111161
PG 15
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA XH3QU
UT WOS:000725354000001
PM 34834513
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schwartz, SD
   Regillo, CD
   Lam, BL
   Eliott, D
   Rosenfeld, PJ
   Gregori, NZ
   Hubschman, JP
   Davis, JL
   Heilwell, G
   Spirn, M
   Maguire, J
   Gay, R
   Bateman, J
   Ostrick, RM
   Morris, D
   Vincent, M
   Anglade, E
   Del Priore, LV
   Lanza, R
AF Schwartz, Steven D.
   Regillo, Carl D.
   Lam, Byron L.
   Eliott, Dean
   Rosenfeld, Philip J.
   Gregori, Ninel Z.
   Hubschman, Jean-Pierre
   Davis, Janet L.
   Heilwell, Gad
   Spirn, Marc
   Maguire, Joseph
   Gay, Roger
   Bateman, Jane
   Ostrick, Rosaleen M.
   Morris, Debra
   Vincent, Matthew
   Anglade, Eddy
   Del Priore, Lucian V.
   Lanza, Robert
TI Human embryonic stem cell-derived retinal pigment epithelium in patients
   with age-related macular degeneration and Stargardt's macular dystrophy:
   follow-up of two open-label phase 1/2 studies
SO LANCET
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; RCS RATS; TRANSPLANTATION; TRANSLOCATION;
   VITRECTOMY; SURGERY; NEOVASCULARIZATION; RESCUE; SAFETY
AB Background Since they were first derived more than three decades ago, embryonic stem cells have been proposed as a source of replacement cells in regenerative medicine, but their plasticity and unlimited capacity for self-renewal raises concerns about their safety, including tumour formation ability, potential immune rejection, and the risk of differentiating into unwanted cell types. We report the medium-term to long-term safety of cells derived from human embryonic stem cells (hESC) transplanted into patients.
   Methods In the USA, two prospective phase 1/2 studies were done to assess the primary endpoints safety and tolerability of subretinal transplantation of hESC-derived retinal pigment epithelium in nine patients with Stargardt's macular dystrophy (age > 18 years) and nine with atrophic age-related macular degeneration (age > 55 years). Three dose cohorts (50 000, 100 000, and 150 000 cells) were treated for each eye disorder. Transplanted patients were followed up for a median of 22 months by use of serial systemic, ophthalmic, and imaging examinations. The studies are registered with ClinicalTrials.gov, numbers NCT01345006 (Stargardt's macular dystrophy) and NCT01344993 (age-related macular degeneration).
   Findings There was no evidence of adverse proliferation, rejection, or serious ocular or systemic safety issues related to the transplanted tissue. Adverse events were associated with vitreoretinal surgery and immunosuppression. 13 (72%) of 18 patients had patches of increasing subretinal pigmentation consistent with transplanted retinal pigment epithelium. Best-corrected visual acuity, monitored as part of the safety protocol, improved in ten eyes, improved or remained the same in seven eyes, and decreased by more than ten letters in one eye, whereas the untreated fellow eyes did not show similar improvements in visual acuity. Vision-related quality-of-life measures increased for general and peripheral vision, and near and distance activities, improving by 16-25 points 3-12 months after transplantation in patients with atrophic age-related macular degeneration and 8-20 points in patients with Stargardt's macular dystrophy.
   Interpretation The results of this study provide the first evidence of the medium-term to long-term safety, graft survival, and possible biological activity of pluripotent stem cell progeny in individuals with any disease. Our results suggest that hESC-derived cells could provide a potentially safe new source of cells for the treatment of various unmet medical disorders requiring tissue repair or replacement.
C1 [Schwartz, Steven D.; Hubschman, Jean-Pierre; Heilwell, Gad; Ostrick, Rosaleen M.] Univ Calif Los Angeles, Jules Stein Eye Inst, Retina Div, Los Angeles, CA 90024 USA.
   [Schwartz, Steven D.; Hubschman, Jean-Pierre; Heilwell, Gad; Ostrick, Rosaleen M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Regillo, Carl D.; Spirn, Marc; Maguire, Joseph] Thomas Jefferson Univ, Wills Eye Hosp, Philadelphia, PA 19107 USA.
   [Lam, Byron L.; Gregori, Ninel Z.; Davis, Janet L.] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA.
   [Eliott, Dean] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Eliott, Dean] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Gay, Roger; Bateman, Jane; Morris, Debra; Vincent, Matthew; Anglade, Eddy; Lanza, Robert] Adv Cell Technol, Marlborough, MA 01752 USA.
   [Del Priore, Lucian V.] Med Univ S Carolina, Storm Eye Inst, Charleston, SC 29425 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Jefferson University; Bascom Palmer Eye Institute;
   University of Miami; Harvard University; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Medical
   University of South Carolina
RP Lanza, R (通讯作者)，Adv Cell Technol, Marlborough, MA 01752 USA.
EM schwartz@jsei.ucla.edu; rlanza@advancedcell.com
RI Davis, Janet L/GPC-8037-2022
OI Davis, Janet L/0000-0001-6395-5881; Hubschman,
   Jean-Pierre/0000-0002-8631-3467; Lanza, Robert/0000-0002-3047-3074
FU Advanced Cell Technology
FX Advanced Cell Technology funded the study. We thank Maureen McMahon and
   Jennifer Grossman for patient evaluation and follow-up; Donald Kohn,
   Aisha Khan, Omaima Hanif, and Darlene Miller for good manufacturing
   practice therapeutic material preparation; Tong Li, Deborah Peak, and
   Judson Ratliff for their help in preparation and technical transfer of
   the retinal pigment epithelium cells; and Robert Almanzor, Jennifer
   Verriotto, Cristy Lage-Rodriguez, Nina Zelcer, and Logan Hitchcock for
   clinical coordination and data monitoring.
CR Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Berger AS, 2003, OPHTHALMOLOGY, V110, P383, DOI 10.1016/S0161-6420(02)01738-4
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Bull ND, 2011, STEM CELLS, V29, P1170, DOI 10.1002/stem.676
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Del Priore LV, 2005, ARCH OPHTHALMOL-CHIC, V123, P1156, DOI 10.1001/archopht.123.8.1156-a
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Grisanti S, 2002, JPN J OPHTHALMOL, V46, P36, DOI 10.1016/S0021-5155(01)00464-6
   Hentze H, 2009, STEM CELL RES, V2, P198, DOI 10.1016/j.scr.2009.02.002
   Kaplan H J, 1999, Chem Immunol, V73, P207
   Klimanskaya I, 2006, NATURE, V444, P481, DOI 10.1038/nature05142
   Lanza R, 2009, ESSENTIALS OF STEM CELL BIOLOGY, 2ND EDITION, pXV, DOI 10.1016/B978-0-12-374729-7.00073-1
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire JI, 2008, EYE, V22, P1290, DOI 10.1038/eye.2008.51
   Mahmoud TH, 2003, GRAEF ARCH CLIN EXP, V241, P298, DOI 10.1007/s00417-003-0637-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Pan CK, 2013, EXPERT OPIN BIOL TH, V13, P1125, DOI 10.1517/14712598.2013.793304
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SILVERMAN MS, 1990, CURR EYE RES, V9, P183, DOI 10.3109/02713689008995205
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stein JD, 2009, ARCH OPHTHALMOL-CHIC, V127, P1656, DOI 10.1001/archophthalmol.2009.300
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tezel TH, 1998, EXP EYE RES, V66, P807, DOI 10.1006/exer.1998.0492
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
NR 34
TC 777
Z9 826
U1 11
U2 69
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD FEB 7
PY 2015
VL 385
IS 9967
BP 509
EP 516
DI 10.1016/S0140-6736(14)61376-3
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CA9AV
UT WOS:000349213600029
PM 25458728
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Caporossi, T
   Bacherini, D
   Governatori, L
   Oliverio, L
   Di Leo, L
   Tartaro, R
   Rizzo, S
AF Caporossi, Tomaso
   Bacherini, Daniela
   Governatori, Lorenzo
   Oliverio, Leandro
   Di Leo, Laura
   Tartaro, Ruggero
   Rizzo, Stanislao
TI Management of submacular massive haemorrhage in age-related macular
   degeneration: comparison between subretinal transplant of human amniotic
   membrane and subretinal injection of tissue plasminogen activator
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; human
   amniotic membrane; OCT-Angiography; submacular massive haemorrhage;
   tissue plasminogen activator; vitrectomy
ID STEM-CELLS; INTRAVITREAL; VITRECTOMY; DISPLACEMENT; SECONDARY;
   RANIBIZUMAB; APOPTOSIS; GAS
AB Purpose: Macular neovascularization (MNV) can complicate age-related macular degeneration (AMD) and lead to severe visual acuity reduction. Massive submacular haemorrhage (SMH) is a sight-threatening complication of MNV and a challenge in the management of complications related to MNV in AMD since the effects of anti-vascular endothelial growth factor treatment alone are insufficient. Here, we evaluate the different postoperative outcomes of patients affected by MNV complicated by SMH that underwent subretinal implant of human amniotic membrane (hAM) or subretinal injection of tissue plasminogen activator (tPA).
   Methods: This is a retrospective, consecutive, comparative, non-randomized interventional study. We included 44 eyes of 44 patients affected by AMD complicated by MNV and SMH. Twenty-two eyes underwent a pars plana vitrectomy (PPV), SMH and neovascular membrane removal, with a subretinal implant of hAM and silicone oil, and 22 eyes underwent PPV, subretinal injection of tPA, and 20% sulphur hexafluoride. The primary study outcome was visual acuity improvement. Secondary outcomes were postoperative complications, and MNV recurrence and optical coherence tomography (OCT)-Angiography parameters correlated with best-corrected visual acuity (BCVA).
   Results: Mean preoperative BCVA was 1.9 logarithm of the minimal angle of resolution (logMAR) in the amniotic membrane-group and 2 logMAR in the tPA-group. The mean final BCVA values were 1.25 and 1.4 logMAR, respectively, with a statistically significant difference. Optical coherence tomography (OCT)-Angiography scan was be used to evaluate the retinal vascularization in the treated eye.
   Conclusion: Both techniques report similar VA improvements and postoperative complications. However, transplantation of hAM seems to have a significant benefit in inhibiting MNV recurrence.
C1 [Caporossi, Tomaso; Rizzo, Stanislao] Univ Cattolica Sacro Cuore, Dept Ophthalmol, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy.
   [Bacherini, Daniela; Governatori, Lorenzo; Oliverio, Leandro; Di Leo, Laura; Tartaro, Ruggero] Univ Florence, Dept NEUROFARBA, Ophthalmol, Largo Brambilla 3, I-50134 Florence, Careggi, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   University of Florence; Azienda Ospedaliero Universitaria Careggi
RP Governatori, L (通讯作者)，Univ Florence, Dept NEUROFARBA, Ophthalmol, Largo Brambilla 3, I-50134 Florence, Careggi, Italy.
EM lorenzo.gov@gmail.com
OI caporossi, tomaso/0000-0002-6902-2983
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Cheng AMS, 2016, CORNEA, V35, P736, DOI 10.1097/ICO.0000000000000784
   Ching JCJ., 2019, AUSTIN J CLIN OPHTHA, V6, P1099
   De Jong JH, 2016, RETINA-J RET VIT DIS, V36, P914, DOI 10.1097/IAE.0000000000000954
   Deihim T, 2016, CORNEA, V35, P997, DOI 10.1097/ICO.0000000000000867
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Fassbender JM, 2016, RETINA-J RET VIT DIS, V36, P1860, DOI 10.1097/IAE.0000000000001030
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gonzalez-Lopez JJ, 2016, EYE, V30, P929, DOI 10.1038/eye.2016.65
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   Juncal VR, 2018, CAN J OPHTHALMOL, V53, P408, DOI 10.1016/j.jcjo.2017.10.010
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Kishikova L, 2021, EUR J OPHTHALMOL, V31, P2621, DOI 10.1177/1120672120959551
   Lu AQ, 2020, EXPERT REV OPHTHALMO, V15, P43, DOI 10.1080/17469899.2020.1725474
   Marcus AJ, 2008, J CELL MOL MED, V12, P1256, DOI 10.1111/j.1582-4934.2008.00180.x
   Marcus AJ, 2008, J CELL MOL MED, V12, P730, DOI 10.1111/j.1582-4934.2008.00221.x
   Marcus AJ, 2008, DIFFERENTIATION, V76, P130, DOI 10.1111/j.1432-0436.2007.00194.x
   Niknejad H, 2016, CELL TISSUE RES, V363, P599, DOI 10.1007/s00441-016-2364-3
   Niknejad H, 2015, MED HYPOTHESES, V85, P197, DOI 10.1016/j.mehy.2015.04.030
   Ochinciuc R, 2020, EXP THER MED, V20, DOI 10.3892/etm.2020.9338
   Ozkaya A, 2018, SAUDI J OPHTHALMOL, V32, P269, DOI 10.1016/j.sjopt.2018.08.002
   Parolini B, 2020, RETINA-J RET VIT DIS, V40, P507, DOI 10.1097/IAE.0000000000002429
   Rizzo S, 2020, OPHTHALMOL RETINA, V4, P996, DOI 10.1016/j.oret.2020.04.017
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Sharma S, 2018, OPHTHALMOL RETINA, V2, P180, DOI 10.1016/j.oret.2017.07.012
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Souied EH, 2016, DEV OPHTHALMOL, V56, P86, DOI 10.1159/000442783
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Tehrani FA, 2013, CRYOBIOLOGY, V67, P293, DOI 10.1016/j.cryobiol.2013.08.010
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tseng SCG, 2001, BIOSCIENCE REP, V21, P481, DOI 10.1023/A:1017995810755
   Tseng Scheffer C G, 2004, Ocul Surf, V2, P177
   van Romunde SHM, 2019, RETINA-J RET VIT DIS, V39, P288, DOI 10.1097/IAE.0000000000001945
   van Zeeburg Elsbeth J T, 2018, Am J Ophthalmol Case Rep, V10, P62, DOI 10.1016/j.ajoc.2018.01.042
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Waked Naji, 2005, J Med Liban, V53, P39
NR 39
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2022
VL 100
IS 5
BP E1143
EP E1152
DI 10.1111/aos.15045
EA OCT 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2R9UK
UT WOS:000703559200001
PM 34609787
DA 2022-11-30
ER

PT J
AU Ahmad, I
   Balasubramanian, S
   Del Debbio, CB
   Parameswaran, S
   Katz, AR
   Toris, C
   Fariss, RN
AF Ahmad, Iqbal
   Balasubramanian, Sudha
   Del Debbio, Carolina B.
   Parameswaran, Sowmya
   Katz, Allen R.
   Toris, Carol
   Fariss, Robert N.
TI Regulation of Ocular Angiogenesis by Notch Signaling: Implications in
   Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; BLOOD-VESSEL FORMATION; CHOROIDAL
   NEOVASCULARIZATION; VASCULAR DEVELOPMENT; EMBRYONIC LETHALITY; TUMOR
   ANGIOGENESIS; STEM-CELLS; VEGF; RECEPTOR; MICE
AB PURPOSE. Wet age-related macular degeneration (AMD), which accounts for most AMD-related vision loss, is characterized by choroidal neovascularization (CNV). The underlying mechanism of CNV is poorly understood, but evidence indicates pathologic recruitment of normal angiogenic signaling pathways such as the VEGF pathway. Recent evidence suggests that the VEGF pathway regulates angiogenesis in concert with Notch signaling. Here, the authors examined the role of Notch signaling in CNV in the backdrop of Notch signaling-mediated regulation of retinal angiogenesis.
   METHODS. Choroid sclera complexes, after laser-induced CNV, were examined for changes in CNV lesion volume and in proangiogenic and antiangiogenic gene expression after perturbation in Notch signaling. Retinal vessels and angiogenic gene expression in retinal endothelial cells were analyzed in postnatal rats after perturbations in Notch signaling. Notch signaling was activated and inhibited by intravitreal or systemic injection of Jagged1 peptide and gamma secretase inhibitor DAPT, respectively.
   RESULTS. The authors demonstrated that activation of the canonical Notch pathway reduced the volume of CNV lesions as it attenuated the development of postnatal retinal vasculature. In contrast, inhibition of the Notch pathway exacerbated CNV lesions as it led to the development of hyperdense retinal vasculature. The authors also identified genes associated with proangiogenesis (Vegfr2, Ccr3, and Pdgfb) and antiangiogenesis (Vegfr1 and Unc5b) as targets of Notch signaling-mediated vascular homeostasis, the disruption of which might underlie CNV.
   CONCLUSIONS. This study suggests that Notch signaling is a key regulator of CNV and thus a molecular target for therapeutic intervention in wet AMD. (Invest Ophthalmol Vis Sci. 2011;52: 2868-2878) DOI:10.1167/iovs.10-6608
C1 [Ahmad, Iqbal; Balasubramanian, Sudha; Del Debbio, Carolina B.; Parameswaran, Sowmya; Katz, Allen R.; Toris, Carol] Univ Nebraska Med Ctr, Dept Ophthalmol & Visual Sci, Omaha, NE 68198 USA.
   [Fariss, Robert N.] NEI, Biol Imaging Core Unit, Bethesda, MD 20892 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Ahmad, I (通讯作者)，Univ Nebraska Med Ctr, Dept Ophthalmol & Visual Sci, Omaha, NE 68198 USA.
EM iahmad@unmc.edu
RI Sowmya, Parameswaran/GZK-8635-2022; Fariss, Robert/ABI-1771-2020
OI Fariss, Robert/0000-0003-3227-7170
FU Lincy Foundation; Pearson Foundation; Nebraska Department of Health and
   Human Services; Research to Prevent Blindness; NATIONAL EYE INSTITUTE
   [ZICEY000459] Funding Source: NIH RePORTER
FX Supported by the Lincy Foundation, the Pearson Foundation, the Nebraska
   Department of Health and Human Services, and Research to Prevent
   Blindness.
CR Ahmad I, 2004, SEMIN CELL DEV BIOL, V15, P53, DOI 10.1016/j.semcdb.2003.09.003
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arboleda-Velasquez JF, 2008, P NATL ACAD SCI USA, V105, P4856, DOI 10.1073/pnas.0709867105
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Balasubramanian S, 2009, STEM CELLS, V27, P3053, DOI 10.1002/stem.242
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Bikfalvi A, 2002, TRENDS PHARMACOL SCI, V23, P576, DOI 10.1016/S0165-6147(02)02109-0
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Cabrerizo M, 2006, BIOMED SCI INSTRUM, V42, P243
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2007, J CELL PHYSIOL, V210, P575, DOI 10.1002/jcp.20893
   Das AV, 2008, DEV NEUROSCI-BASEL, V30, P389, DOI 10.1159/000178017
   Duarte A, 2004, GENE DEV, V18, P2474, DOI 10.1101/gad.1239004
   Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Gridley T, 2007, DEVELOPMENT, V134, P2709, DOI 10.1242/dev.004184
   Harrington LS, 2008, MICROVASC RES, V75, P144, DOI 10.1016/j.mvr.2007.06.006
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Hellstrom M, 2007, CELL ADHES MIGR, V1, P133, DOI 10.4161/cam.1.3.4978
   Holderfield MT, 2008, CIRC RES, V102, P637, DOI 10.1161/CIRCRESAHA.107.167171
   Holderfield MT, 2006, BIOCHEM BIOPH RES CO, V346, P637, DOI 10.1016/j.bbrc.2006.05.177
   Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111
   Kearney JB, 2002, BLOOD, V99, P2397, DOI 10.1182/blood.V99.7.2397
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Kinose F, 2005, MOL VIS, V11, P366
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kokubo H, 2005, DEV BIOL, V278, P301, DOI 10.1016/j.ydbio.2004.10.025
   Krebs LT, 2000, GENE DEV, V14, P1343
   Krebs LT, 2004, GENE DEV, V18, P2469, DOI 10.1101/gad.1239204
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Larrivee B, 2007, GENE DEV, V21, P2433, DOI 10.1101/gad.437807
   Lejmi E, 2008, P NATL ACAD SCI USA, V105, P12491, DOI 10.1073/pnas.0804008105
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu XW, 2004, NATURE, V432, P179, DOI 10.1038/nature03080
   Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Phng LK, 2009, DEV CELL, V16, P196, DOI 10.1016/j.devcel.2009.01.015
   Rehman AO, 2006, TRENDS CELL BIOL, V16, P293, DOI 10.1016/j.tcb.2006.04.003
   Roberts DM, 2004, AM J PATHOL, V164, P1531, DOI 10.1016/S0002-9440(10)63711-X
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Stone EM, 2007, ANNU REV MED, V58, P477, DOI 10.1146/annurev.med.58.111405.133335
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Su XJ, 2003, MOL VIS, V9, P171
   Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tanemura M, 2004, MOL VIS, V10, P923
   Weijzen S, 2002, J IMMUNOL, V169, P4273, DOI 10.4049/jimmunol.169.8.4273
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723
NR 57
TC 32
Z9 39
U1 1
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2011
VL 52
IS 6
BP 2868
EP 2878
DI 10.1167/iovs.10-6608
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 770PN
UT WOS:000291100800002
PM 21228388
OA Green Published
DA 2022-11-30
ER

PT J
AU Karnon, J
   Czoski-Murray, C
   Smith, K
   Brand, C
   Chakravarthy, U
   Davis, S
   Bansback, N
   Beverley, C
   Bird, A
   Harding, S
   Chisholm, I
   Yang, YC
AF Karnon, J.
   Czoski-Murray, C.
   Smith, K.
   Brand, C.
   Chakravarthy, U.
   Davis, S.
   Bansback, N.
   Beverley, C.
   Bird, A.
   Harding, S.
   Chisholm, I.
   Yang, Y. C.
TI A preliminary model-based assessment of the cost-utility of a screening
   programme for early age-related macular degeneration
SO HEALTH TECHNOLOGY ASSESSMENT
LA English
DT Review
ID GEOGRAPHIC ATROPHY FORM; VISUAL-ACUITY LOSS; 5-YEAR FOLLOW-UP;
   QUALITY-OF-LIFE; CHOROIDAL NEOVASCULARIZATION; RISK-FACTORS; EYE
   DISEASE; FELLOW EYES; INTRAVITREAL TRIAMCINOLONE; CARDIOVASCULAR-DISEASE
AB Objectives: To estimate the cost-effectiveness of screening for age-related macular degeneration (AMD) by developing a decision analytic model that incorporated and assessed all of the National Screening Committee criteria. A further objective was to identify the major areas of uncertainty in the model, and so inform future research priorities in this disease area.
   Data sources: Major databases were searched in March 2004 and updated in January 2005.
   Review methods: Systematic literature reviews covered the epidemiology and natural history of AMD, the screening and treatment effectiveness and health-related quality of life relating to AMD. A hybrid cohort-individual sampling model was implemented to describe the range of pathways between the incidence of age-related maculopathy (ARM) and death via clinical presentation and treatment at different stages of the disease. As significant shortfalls in the data available from the literature were apparent, so a range of primary data sources were also used to populate the model. To obtain estimates for the value of parameters deemed to be within an expert's remit, data describing some parameters were elicited from relevant experts. The data identified informed probability distributions describing the uncertainty around the model parameters. To incorporate joint parameter uncertainty (i.e. correlations between parameters), the AMD natural history model was calibrated probabilistically. Randomly sampled sets of input parameters were assigned weights representing the accuracy of their predictions of a set of observed model outputs. The analysis of the AMD screening model estimated the costs, numbers of quality-adjusted life-years (QALYs) and cases of blindness in a general population sample of 50-year-olds over the remainder of their lifetime, for 16 alternative screening options (including no screening). The reference case analysis incorporated current treatment options of laser photocoagulation and photodynamic therapy. Sensitivity analyses describing six alternative sets of intervention strategies, based on horizon scanning of potential future treatments for AMD, were also undertaken.
   Results: There remains significant uncertainty about whether any form of screening for AMD is cost-effective. However, annual screening from age 60 years seems to provide the highest mean net benefits, but this is based on a cost-effectiveness estimate that has very poor precision (high levels of uncertainty). The probabilistic sensitivity analysis shows that the 95% credible interval for annual screening from age 60 years ranges from this option dominating the previous option to an incremental cost per QALY of over 0.5 pound million. Plotting a cost-effectiveness acceptability frontier shows that although annual screening from age 60 years has the highest net benefits at a value of QALY of 30,000 pound, the associated probability of this option being the most cost-effective option is only around 20%. The sensitivity analyses around potential future treatment options indicate that screening may become more cost-effective with the new treatments.
   Conclusions: The conclusions focus on the interpretation of the results from the perspective of defining the major areas of uncertainty, which were defined as disease progression, rates of clinical presentation, screening test and optician effectiveness, treatment effectiveness, and costs of blindness. Future research may be best targeted at assessing how routine data may be used to describe clinical presentation rates of ARM. Other potential studies include a pilot study of the effectiveness of screening and opticians' referral patterns for AMD and a costing study of blindness as a continuum of association with deterioration in vision.
C1 [Karnon, J.; Czoski-Murray, C.; Smith, K.; Davis, S.; Bansback, N.; Beverley, C.] Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England.
   [Brand, C.] Univ Sheffield, Teaching Hosp, Sheffield, S Yorkshire, England.
   [Chakravarthy, U.] Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland.
   [Bird, A.] Moorfields Eye Hosp, London, England.
   [Harding, S.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.
   [Chisholm, I.] Southampton Univ Hosp NHS Trust, Southampton, Hants, England.
   [Yang, Y. C.] Wolverhampton Eye Infirm, Wolverhampton, England.
C3 University of Sheffield; University of Sheffield; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Southampton; University Hospital Southampton NHS Foundation Trust
RP Karnon, J (通讯作者)，Univ Adelaide, Sch Populat Hlth & Clin Practice, Adelaide, SA 5005, Australia.
RI Davis, Sarah/A-2801-2010
OI Chakravarthy, Usha/0000-0002-2606-3734; Karnon,
   Jonathan/0000-0003-3220-2099; Bansback, Nick/0000-0002-1510-3462;
   Harding, Simon/0000-0003-4676-1158; Davis, Sarah/0000-0002-6609-4287
CR Ali F, 2004, ARCH OPHTHALMOL-CHIC, V122, P710, DOI 10.1001/archopht.122.5.710
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1998, Ophthalmology, V105, P11
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Barthes A, 2001, MED PHYS, V28, P2410, DOI 10.1118/1.1420735
   Bartlett H, 2003, OPHTHAL PHYSL OPT, V23, P383, DOI 10.1046/j.1475-1313.2003.00130.x
   BAUN O, 1993, ACTA OPHTHALMOL, V71, P398
   BHAVSAR A, 2004, COMBINED VERTEPORFIN
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3
   *CLINICALTRIALS GO, OP LAB POST JUXT INJ
   COOKE R, 2005, AARP B
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   DAS BN, 1994, J ROY SOC MED, V87, P219
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Devlin N, 2002, COST EFFECTIVENESS T
   Dickinson AJ, 1997, EYE, V11, P301, DOI 10.1038/eye.1997.66
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   EVANS JR, 2004, COCHRANE LIB
   *EYE FACTS, 2007, ANTIVEGF TREATM AG R
   Farber MD, 2003, OPHTHAL EPIDEMIOL, V10, P267, DOI 10.1076/opep.10.4.267.15910
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Foran S, 2002, ARCH OPHTHALMOL-CHIC, V120, P613, DOI 10.1001/archopht.120.5.613
   Frennesson CI, 2004, ACTA OPHTHALMOL SCAN, V82, P651, DOI 10.1111/j.1600-0420.2004.00382.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   *GEN, GEN GRANT 6 MONTH PR
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   GOVERDHAN SV, 2004, OPTOMETRY TODAY 1217, P39
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Henstock E., 2002, EVALUATION HPV LBC C
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Huang GH, 2003, AM J EPIDEMIOL, V157, P721, DOI 10.1093/aje/kwg011
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Karlsson G, 1996, PHARMACOECONOMICS, V9, P113, DOI 10.2165/00019053-199609020-00003
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P158, DOI 10.1007/PL00007885
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Maguire MG, 1997, OPHTHALMOLOGY, V104, P5, DOI 10.1016/S0161-6420(97)30369-8
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Meads C, 2004, BRIT J OPHTHALMOL, V88, P212, DOI 10.1136/bjo.2003.019471
   Meads C., 2001, HLTH TECHNOL ASSESS, V7
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MITCHELL P, 2002, OPHTHALMOLOGY, V109, P1588
   MITCHELL RA, 1993, J EPIDEMIOL COMMUN H, V47, P42, DOI 10.1136/jech.47.1.42
   Munier A, 1998, BRIT J OPHTHALMOL, V82, P630, DOI 10.1136/bjo.82.6.630
   National Screening Committee, NSC CRIT APPR VIAB E
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   POLLACK A, 2005, NY TIMES        0927
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   ROBERTS D, 2007, AVASTIN WET AMD
   RODERICK P, 2003, HLTH TECHNOL ASSESS, V7
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitt NJ, 2003, AM J OPHTHALMOL, V136, P314, DOI 10.1016/S0002-9394(03)00208-3
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Stevenson MD, 2004, MED DECIS MAKING, V24, P89, DOI 10.1177/0272989X03261561
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   THOMAS MA, 1993, AM J OPHTHALMOL, V116, P279, DOI 10.1016/S0002-9394(14)71344-3
   Tomany SC, 2001, AM J OPHTHALMOL, V132, P271, DOI 10.1016/S0002-9394(01)00895-9
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Weinstein MC, 2003, VALUE HEALTH, V6, P9, DOI 10.1046/j.1524-4733.2003.00234.x
   Wilkinson CP, 1996, ARCH OPHTHALMOL-CHIC, V114, P677
   Wilson J., 1968, 34 WHO
   Woods RL, 1998, OPHTHALMOLOGY, V105, P2318, DOI 10.1016/S0161-6420(98)91235-0
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
   2005, RETINAL PHYS
NR 114
TC 5
Z9 5
U1 0
U2 5
PU NIHR JOURNALS LIBRARY
PI SOUTHAMPTON
PA UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE,
   ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND
SN 1366-5278
EI 2046-4924
J9 HEALTH TECHNOL ASSES
JI Health Technol. Assess.
PD JUN
PY 2008
VL 12
IS 27
BP 2
EP +
PG 133
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA 309HR
UT WOS:000256451800001
DA 2022-11-30
ER

PT J
AU Reiter, GS
   Hacker, V
   Told, R
   Schranz, M
   Krotka, P
   Schlanitz, FG
   Sacu, S
   Pollreisz, A
   Schmidt-Erfurth, U
AF Reiter, Gregor S.
   Hacker, Valentin
   Told, Reinhard
   Schranz, Markus
   Krotka, Pavla
   Schlanitz, Ferdinand G.
   Sacu, Stefan
   Pollreisz, Andreas
   Schmidt-Erfurth, Ursula
TI LONGITUDINAL CHANGES IN QUANTITATIVE AUTOFLUORESCENCE DURING PROGRESSION
   FROM INTERMEDIATE TO LATE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; complete RPE and outer retinal
   atrophy; drusen; geographic atrophy; macular neovascularization; retinal
   pigment epithelium; quantitative autofluorescence
ID RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE;
   SPATIAL-DISTRIBUTION; LIPOFUSCIN; CLASSIFICATION; FLUORESCENCE;
   PREDICTION; DENSITY; EYES
AB Purpose: To prospectively investigate the development of quantitative autofluorescence (qAF) during progression from intermediate to late age-related macular degeneration (AMD). Methods: Quantitative autofluorescence images from patients with intermediate AMD were acquired every three months with a Spectralis HRA + OCT (Heidelberg Engineering, Heidelberg, Germany) using a built-in autofluorescence reference. The association between changes in longitudinal qAF and progression toward late AMD was assessed using Cox regression models with time-dependent covariates. Results: One hundred and twenty-one eyes of 71 patients were included, and 653 qAF images were acquired. Twenty-one eyes of 17 patients converted to late AMD (median follow-up: 21 months; 12 eyes: atrophic AMD; nine eyes: neovascular AMD). The converting patients' mean age was 74.6 +/- 4.4 years. Eleven eyes in the converting group (52.4%) were pseudophakic. The presence of an intraocular lens did not affect the qAF regression slopes (P > 0.05). The median change for atrophic AMD was -2.34 qAF units/3 months and 0.78 qAF units/3 months for neovascular AMD. A stronger decline in qAF was significantly associated with an increased risk of developing atrophic AMD (hazard ratio = 1.022, P < 0.001). This association, however, was not present in the group progressing toward neovascular AMD (hazard ratio = 1.001, P = 0.875). Conclusion: The qAF signal declines with progression to atrophy, contrary to developing neovascularization. Quantitative autofluorescence may allow identification of patients at risk of progressing to late AMD and benefits individualized patient care in intermediate AMD.
C1 [Reiter, Gregor S.; Schmidt-Erfurth, Ursula] Med Univ Vienna, Vienna Reading Ctr, Dept Ophthalmol & Optometry, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
   [Reiter, Gregor S.; Hacker, Valentin; Told, Reinhard; Schranz, Markus; Schlanitz, Ferdinand G.; Sacu, Stefan; Pollreisz, Andreas; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna Clin Trial Ctr VTC, Vienna, Austria.
   [Krotka, Pavla] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Reiter, Gregor/0000-0001-7661-4015; Told, Reinhard/0000-0003-2046-7081;
   Krotka, Pavla/0000-0001-5727-4270
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Armenti ST, 2016, JOVE-J VIS EXP, DOI 10.3791/53577
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kim HJ, 2018, J LIPID RES, V59, P1620, DOI 10.1194/jlr.M084459
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Orellana-Rios J, 2018, OSLI RETINA, V49, pS34, DOI 10.3928/23258160-20180814-06
   Pollreisz A, 2018, EXP EYE RES, V166, P131, DOI 10.1016/j.exer.2017.10.018
   Reiter GS, 2020, RETINA-J RET VIT DIS, V40, P1657, DOI 10.1097/IAE.0000000000002653
   Reiter GS, 2019, INVEST OPHTH VIS SCI, V60, P1937, DOI 10.1167/iovs.19-26566
   Reiter GS, 2019, ACTA OPHTHALMOL, V97, pE526, DOI 10.1111/aos.13987
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schlanitz F, 2019, BRIT J OPHTHALMOL, V103, P227, DOI 10.1136/bjophthalmol-2017-311782
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2017, RETINA-J RET VIT DIS, V5, P1
   van de Kraats J, 2007, J OPT SOC AM A, V24, P1842, DOI 10.1364/JOSAA.24.001842
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
NR 30
TC 4
Z9 4
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2021
VL 41
IS 6
BP 1236
EP 1241
DI 10.1097/IAE.0000000000002995
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO2SL
UT WOS:000658826900013
PM 33084296
DA 2022-11-30
ER

PT J
AU Stravalaci, M
   Davi, F
   Parente, R
   Gobbi, M
   Bottazzi, B
   Mantovani, A
   Day, AJ
   Clark, SJ
   Romano, MR
   Inforzato, A
AF Stravalaci, Matteo
   Davi, Francesca
   Parente, Raffaella
   Gobbi, Marco
   Bottazzi, Barbara
   Mantovani, Alberto
   Day, Anthony J.
   Clark, Simon J.
   Romano, Mario R.
   Inforzato, Antonio
TI Control of Complement Activation by the Long Pentraxin PTX3:
   Implications in Age-Related Macular Degeneration
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE age-related macular degeneration; retinal pigmented epithelium; vitreous
   humor; complement system; alternative pathway; pentraxins; pentraxin 3
ID PIGMENT EPITHELIAL-CELLS; C-REACTIVE PROTEIN; FACTOR-H; BRUCHS MEMBRANE;
   BINDING; INFLAMMATION; VARIANT; RECOGNITION; EXPRESSION; ETIOLOGY
AB Dysregulation of the complement system is central to age-related macular degeneration (AMD), the leading cause of blindness in the developed world. Most of the genetic variation associated with AMD resides in complement genes, with the greatest risk associated with polymorphisms in the complement factor H (CFH) gene; factor H (FH) is the major inhibitor of the alternative pathway (AP) of complement that specifically targets C3b and the AP C3 convertase. Long pentraxin 3 (PTX3) is a soluble pattern recognition molecule that has been proposed to inhibit AP activation via recruitment of FH. Although present in the human retina, if and how PTX3 plays a role in AMD is still unclear. In this work we demonstrated the presence of PTX3 in the human vitreous and studied the PTX3-FH-C3b crosstalk and its effects on complement activation in a model of retinal pigment epithelium (RPE). RPE cells cultured in inflammatory AMD-like conditions overexpressed the PTX3 protein, and up-regulated AP activating genes. PTX3 bound RPE cells in a physiological setting, however this interaction was reduced in inflammatory conditions, whereby PTX3 had no complement-inhibiting activity on inflamed RPE. However, on non-cellular surfaces, PTX3 formed a stable ternary complex with FH and C3b that acted as a "hot spot" for complement inhibition. Our findings suggest a protective role for PTX3 in response to complement dysregulation in AMD and point to a novel mechanism of complement regulation by this pentraxin with potential implications in pathology and pharmacology of AMD.
C1 [Stravalaci, Matteo; Mantovani, Alberto; Romano, Mario R.; Inforzato, Antonio] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
   [Stravalaci, Matteo; Davi, Francesca; Parente, Raffaella; Bottazzi, Barbara; Mantovani, Alberto; Inforzato, Antonio] Humanitas Clin & Res Ctr IRCCS, Milan, Italy.
   [Gobbi, Marco] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy.
   [Mantovani, Alberto] Queen Mary Univ London, William Harvey Res Inst, London, England.
   [Day, Anthony J.] Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester Acad Hlth Sci Ctr,Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Day, Anthony J.] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Sch Biol Sci,Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth,Div Cell Matrix Biol & Regen, Manchester, Lancs, England.
   [Clark, Simon J.] Univ Augenklin Tubingen, Eberhard Karls Univ Tubingen, Tubingen, Germany.
   [Clark, Simon J.] Univ Manchester, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England.
   [Romano, Mario R.] Humanitas Gavazzeni Castelli, Eye Ctr, Bergamo, Italy.
C3 Humanitas University; Istituto di Ricerche Farmacologiche Mario Negri
   IRCCS; University of London; Queen Mary University London; University of
   Manchester; University of Manchester; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; University of Manchester
RP Inforzato, A (通讯作者)，Humanitas Univ, Dept Biomed Sci, Milan, Italy.; Inforzato, A (通讯作者)，Humanitas Clin & Res Ctr IRCCS, Milan, Italy.
EM antonio.inforzato@humanitasresearch.it
RI Inforzato, Antonio/ABG-4513-2020; Parente, Raffaella/HDM-3960-2022;
   Stravalaci, Matteo/AAB-8963-2019; Gobbi, Marco/J-2638-2016; Mantovani,
   Alberto/HCI-7449-2022
OI Inforzato, Antonio/0000-0001-8110-0027; Parente,
   Raffaella/0000-0003-3607-1380; Stravalaci, Matteo/0000-0002-5636-4204;
   Gobbi, Marco/0000-0003-1014-6225; Mantovani,
   Alberto/0000-0001-5578-236X; Davi, Francesca/0000-0002-4593-7089
FU Italian Society of Ophtalmology (SOI); Fondazione Beppe and Nuccy
   Angiolini
FX MRR is recipient of a Research Prize from the Italian Society of
   Ophtalmology (SOI) that funded FD. The financial support of Fondazione
   Beppe and Nuccy Angiolini to RP is greatly acknowledged.
CR Altay L, 2019, EYE, V33, P1859, DOI 10.1038/s41433-019-0501-4
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bally I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00461
   Baranova NS, 2014, J BIOL CHEM, V289, P30481, DOI 10.1074/jbc.M114.568154
   Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   Bonavita E, 2015, CELL, V160, P700, DOI 10.1016/j.cell.2015.01.004
   Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817
   Bottazzi B, 2010, ANNU REV IMMUNOL, V28, P157, DOI 10.1146/annurev-immunol-030409-101305
   Braunschweig A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023991
   Canovi M, 2014, SENSORS-BASEL, V14, P10864, DOI 10.3390/s140610864
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433
   Doni A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00712
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559
   Hourcade DE, 2006, J BIOL CHEM, V281, P2128, DOI 10.1074/jbc.M508928200
   Hwang N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236028
   Inforzato A, 2008, J BIOL CHEM, V283, P10147, DOI 10.1074/jbc.M708535200
   Inforzato A, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00407
   Inforzato A, 2010, J BIOL CHEM, V285, P17681, DOI 10.1074/jbc.M109.085639
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Juel HB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132800
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Langford-Smith A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00025
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Madeira MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20733-2
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Parente R, 2020, FEBS LETT, V594, P2480, DOI 10.1002/1873-3468.13744
   Parente R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02628
   Parente R, 2017, CELL MOL LIFE SCI, V74, P1605, DOI 10.1007/s00018-016-2418-4
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Rutar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093343
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Shibuya M, 2015, ENDOCR METAB IMMUNE, V15, P135, DOI 10.2174/1871530315666150316121956
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Swinkels M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18395-7
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Touhami S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1106-8
   Wang L, 2016, J PATHOL, V240, P495, DOI 10.1002/path.4811
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo JM, 2013, MOL VIS, V19, P303
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
NR 59
TC 6
Z9 6
U1 1
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 26
PY 2020
VL 11
AR 591908
DI 10.3389/fphar.2020.591908
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA PC2IA
UT WOS:000596829700001
PM 33324220
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wang, D
   Zhou, J
   Hou, XM
   Nguyen, DH
   Cao, GQ
   Li, G
   Qiu, GX
   Zhang, K
   Zhang, M
   Su, ZG
AF Wang, Dan
   Zhou, Jie
   Hou, Xiaoming
   Nguyen, Duy H.
   Cao, Guiqun
   Li, Gen
   Qiu, Guoxian
   Zhang, Kang
   Zhang, Ming
   Su, Zhiguang
TI CETP Gene may be Associated with Advanced Age-Related Macular
   Degeneration in the Chinese Population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; CETP; genetic polymorphism; HDL
ID COMPLEMENT-FACTOR-H; CORONARY-HEART-DISEASE; HEPATIC LIPASE; RISK;
   SUSCEPTIBILITY; VARIANT; DRUSEN; POLYMORPHISM; MECHANISMS; INCREASES
AB Objectives: This study aims to investigate whether variations in LIPC, CETP, ABCA1 and LPL, which are involved in high/density lipoprotein (HDL) metabolism, are associated with advanced age-related macular degeneration (AMD) in the Chinese population.
   Design and Methods: A total of 119 Chinese patients with advanced AMD and 99 control individuals were recruited. Genomic DNA was extracted from peripheral blood leukocytes. Genotypes of seven single nucleotide polymorphisms (SNPs) including rs1061170 and rs1410996 in CFH, rs10490924 in HTRA1, rs10468017 in LIPC, rs3764261 in CETP, rs1883025 in ABCA1 and rs12678919 near LPL were determined by polymerase chain reaction (PCR) followed by allele-specific restriction enzyme digestion or SNaPshot. Unconditional logistic regression analyses were performed to generate a risk predictive model.
   Results: We observed the frequency of allele A of rs3764261 in CETP to be significantly lower in advanced AMD after Bonferroni correction (15.5% in patients with AMD and 20.7% in controls; OR=0.49, 95% CI: 0.29-0.85; p = 0.011). Furthermore, we found that it was also associated with reduced risk of both unilateral AMD (OR = 0.52, 95% CI: 0.28-0.98; p = 0.043) and bilateral AMD (OR = 0.45, 95% CI: 0.22-0.91; p = 0.026). Rs10468017 in LIPC, rs12678919 near LPL and rs1883025 in ABCA1 were not found to be associated with advanced AMD (all p>0.05).
   Conclusion: Our data suggested that the allele A in rs3764261 in CETP gene may be associated with a decreased risk of advanced AMD in Chinese population.
C1 [Wang, Dan; Zhou, Jie; Hou, Xiaoming; Cao, Guiqun; Li, Gen; Zhang, Kang; Su, Zhiguang] Sichuan Univ, West China Hosp, Mol Med Res Ctr, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   [Wang, Dan; Zhou, Jie; Qiu, Guoxian; Zhang, Ming] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
   [Nguyen, Duy H.; Zhang, Kang] Univ Calif San Diego, Dept Ophthalmol, San Diego, CA 92103 USA.
C3 Sichuan University; Sichuan University; University of California System;
   University of California San Diego
RP Su, ZG (通讯作者)，Sichuan Univ, West China Hosp, Mol Med Res Ctr, 1 Ke Yuan 4th Rd,Gao Peng St, Chengdu 610041, Peoples R China.
EM zhiguang_su@hotmail.com
RI Zhang, Kang/Y-2740-2019; Nguyen, Duy/HDO-8098-2022; Su,
   Zhiguang/AFS-0022-2022
OI Zhang, Kang/0000-0002-4549-1697; 
FU National Basic Research Program of China [2011CB510200]; National
   Natural Science Foundation of China [31071108, 81271019]; Program for
   New Century Excellent Talents in University [NCET-10-0600]; National
   High Technology Research and Development Program of China (863 Program)
   [SS2014AA021604]
FX This study was supported by the National Basic Research Program of China
   [Grant no. 2011CB510200], the National Natural Science Foundation of
   China [Grant nos. 31071108, 81271019], the Program for New Century
   Excellent Talents in University [Grant no: NCET-10-0600], and the
   National High Technology Research and Development Program of China (863
   Program) [Grant no. SS2014AA021604].
CR Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz F.G., 2012, AGE RELATED MACULAR
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Papp AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031930
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Su ZG, 2002, EUR J PHARMACOL, V454, P9, DOI 10.1016/S0014-2999(02)02427-5
   Su ZG, 2002, J LIPID RES, V43, P1595, DOI 10.1194/jlr.M200046-JLR200
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Xu L, 2008, OPHTHALMOLOGICA, V222, P378, DOI 10.1159/000151468
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Yuan YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050848
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751
   Zhou J, 2013, CLIN BIOCHEM, V46, P1689, DOI 10.1016/j.clinbiochem.2013.07.002
NR 36
TC 12
Z9 13
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2015
VL 36
IS 4
BP 303
EP 308
DI 10.3109/13816810.2014.881506
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA DD3YG
UT WOS:000369858800003
PM 24498989
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Fleckenstein, M
   Issa, PC
   Helb, HM
   Schmitz-Valckenberg, S
   Finger, RP
   Scholl, HPN
   Loeffler, KU
   Holz, FG
AF Fleckenstein, Monika
   Issa, Peter Charbel
   Helb, Hans-Martin
   Schmitz-Valckenberg, Steffen
   Finger, Robert P.
   Scholl, Hendrik P. N.
   Loeffler, Karin U.
   Holz, Frank G.
TI High-resolution spectral domain-OCT imaging in geographic atrophy
   associated with age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; FUNDUS
   AUTOFLUORESCENCE PATTERNS; ULTRAHIGH-RESOLUTION; IN-VIVO; JUNCTIONAL
   ZONE; NATURAL-HISTORY; CLINICAL-TRIALS; VISUAL-ACUITY; HIGH-RISK
AB PURPOSE. To describe morphologic variations in outer retinal layers in eyes with atrophic age-related macular degeneration (AMD) using high-resolution, spectral-domain optical coherence tomography (SD-OCT).
   METHODS. SD-OCT scans were obtained with a combined confocal scanning laser ophthalmoscope (cSLO) and SD-OCT for simultaneous tomographic and topographic in vivo imaging. A total of 81 eyes of 56 patients (mean age, 77.8 +/- 7.4 years) with geographic atrophy (GA) were examined. Morphologic alterations were analyzed and classified in the perilesional zone, at the junction between GA and nonatrophic retina, and in the atrophic area itself.
   RESULTS. In the perilesional zone, distinct morphologic alterations included elevations of the outer retinal layers, thickening, and spikes of the outer hyperreflective band as well as clumps at different neurosensory retinal levels. At the junction, highly variable transitions of the outer retinal layers were present with different degrees of loss of the normal hyperreflective bands. Within the actual GA, hyperreflective clumps at different retinal levels, segmented plaques of the outer band and elevations with variable reflectivity were visualized.
   CONCLUSIONS. SD-OCT imaging in eyes with GA revealed a wide spectrum of morphologic alterations, both in the surrounding retinal tissue and in the atrophic area. These alterations may reflect different disease stages or, alternatively, heterogeneity on a cellular and molecular level. Longitudinal studies using in vivo SD-OCT imaging may allow evaluation of the relevance of these phenotypic changes as potential predictive markers for the progression of disease (i.e., enlargement rates of GA over time) and may be used for monitoring of future therapeutic interventions.
C1 [Fleckenstein, Monika; Issa, Peter Charbel; Helb, Hans-Martin; Schmitz-Valckenberg, Steffen; Finger, Robert P.; Scholl, Hendrik P. N.; Loeffler, Karin U.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM frank.holz@ukb.uni-bonn.de
RI Issa, Peter Charbel/E-8935-2018; Issa, Peter Charbel/O-2580-2019; Issa,
   Peter Charbel/F-9603-2011
OI Issa, Peter Charbel/0000-0002-0351-6673; Issa, Peter
   Charbel/0000-0002-0351-6673; Finger, Robert P/0000-0003-4253-7597;
   Fleckenstein, Monika/0000-0001-8321-8037
FU DFG (German Research Council); Research Priority Program Age-Related
   Macular Degeneration [SPP 1088, Ho 1926/1-3]; European Union FP6;
   Integrated Project Grant EVI-GENORET [(LSHG-CT-2005-512036)]; DOG
   (German Society of Ophthalmology)
FX Supported by the DFG (German Research Council), Research Priority
   Program Age-Related Macular Degeneration SPP 1088, Ho 1926/1-3; European
   Union FP6, Integrated Project Grant EVI-GENORET (LSHG-CT-2005-512036);
   and a DOG (German Society of Ophthalmology) research grant.
CR Ahlers C, 2005, EUR J OPHTHALMOL, V15, P774, DOI 10.1177/112067210501500619
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Cense B, 2006, Bull Soc Belge Ophtalmol, P123
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Drexler W, 1999, OPT LETT, V24, P1221, DOI 10.1364/OL.24.001221
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Drexler W, 2004, J BIOMED OPT, V9, P47, DOI 10.1117/1.1629679
   Drexler Wolfgang, 2007, Invest Ophthalmol Vis Sci, V48, P5339
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Loeffler KU, 1998, BRIT J OPHTHALMOL, V82, P1104, DOI 10.1136/bjo.82.10.1104
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MESSMER EP, 1997, PATHOLOGIE AUGES, P1089
   Michels S, 2008, BRIT J OPHTHALMOL, V92, P204, DOI 10.1136/bjo.2007.130047
   Nassif N, 2004, OPT LETT, V29, P480, DOI 10.1364/OL.29.000480
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS S, 1994, RETINA, P1071
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Sunness JS, 2007, RETINA-J RET VIT DIS, V27, P204, DOI 10.1097/01.iae.0000248148.56560.b1
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wojtkowski M, 2003, OPT LETT, V28, P1745, DOI 10.1364/OL.28.001745
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
NR 45
TC 220
Z9 226
U1 0
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2008
VL 49
IS 9
BP 4137
EP 4144
DI 10.1167/iovs.08-1967
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 344AB
UT WOS:000258896500053
PM 18487363
DA 2022-11-30
ER

PT J
AU Waters, SB
   Zhou, C
   Nguyen, T
   Zelkha, R
   Lee, H
   Kazlauskas, A
   Rosenblatt, MI
   Malik, AB
   Yamada, KH
AF Waters, Stephen B.
   Zhou, Christopher
   Nguyen, Tara
   Zelkha, Ruth
   Lee, Hyun
   Kazlauskas, Andrius
   Rosenblatt, Mark I.
   Malik, Asrar B.
   Yamada, Kaori H.
TI VEGFR2 Trafficking by KIF13B Is a Novel Therapeutic Target for Wet
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE wet AMD; angiogenesis; eyedrop; therapy; VEGFR2
ID SINGLE INTRAVITREAL INJECTION; ENDOTHELIAL GROWTH-FACTOR; INTRAOCULAR
   PHARMACOKINETICS; TUMOR-SUPPRESSOR; MOTOR PROTEINS; RANIBIZUMAB;
   BEVACIZUMAB; ANGIOGENESIS; ENDOCYTOSIS; SWITCH
AB PURPOSE. Vascular endothelial growth factor (VEGF) and its receptor VEGFR2 are promising therapeutic targets for wet age-related macular degeneration (AMD). As a topically applicable option, we developed the peptide KAI to selectively interfere with VEGFR2 trafficking to the cell surface where it receives VEGF. This study sought to determine the efficacy of KAI in the mouse model of choroidal neovascularization (CNV).
   METHODS. The specificity of KAI was tested by surface plasmon resonance. The drug delivery was analyzed by cryosection and the ELISA after treatment of KAI eyedrop to the mouse eyes. For the laser-induced CNV model, mice with laser-induced ruptures in Bruch's membrane received daily treatment of KAI eyedrop or control peptide. The other groups of mice received intravitreal injection of anti-VEGF or IgG control. After two weeks, CNV was quantified and compared.
   RESULTS. First, we showed the specificity and high affinity of KAI to VEGFR2. Next, biodistribution revealed successful delivery of KAI eyedrop to the back of the mouse eyes. KM significantly reduced the disease progression in laser-induced CNV. The comparison with current therapy suggests that KAI eyedrop is as effective as current therapy to prevent CNV in wet AMD. Moreover, the genetic deletion of a kinesin KIF13B, which mediates VEGFR2 trafficking to the cell surface, confirmed the pivotal role of KIF13B in disease progression of wet AMD and neovascularization from choroidal vessels.
   CONCLUSIONS. Taken together, pharmacologic inhibition and genetic deletion complementarily suggest the therapeutic possibility of targeting VEGFR2 trafficking to inhibit pathological angiogenesis in wet AMD.
C1 [Waters, Stephen B.; Zhou, Christopher; Malik, Asrar B.; Yamada, Kaori H.] Univ Illinois, Coll Med, Dept Pharmacol & Regenerat Med, Chicago, IL 60612 USA.
   [Nguyen, Tara; Zelkha, Ruth; Kazlauskas, Andrius; Rosenblatt, Mark I.; Yamada, Kaori H.] Univ Illinois, Coll Med, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
   [Lee, Hyun] Univ Illinois, Coll Med, Biophys Core, Chicago, IL USA.
   [Lee, Hyun] Univ Illinois, Coll Med, Dept Pharmaceut Sci, Chicago, IL USA.
   [Kazlauskas, Andrius] Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Yamada, KH (通讯作者)，Univ Illinois, Coll Med, Dept Pharmacol & Regenerat Med, Chicago, IL 60612 USA.
EM horiguch@uic.edu
OI Lee, Hyun/0000-0003-2570-8120; Malik, Asrar/0000-0002-8205-7128; Yamada,
   Kaori/0000-0003-4075-9866
FU NIH [R01 EY029339, R56 HL128342]; RPB Stein Innovation Award; UIC
   Chancellor's Innovation Fund
FX Supported by NIH grants R01 EY029339 (K.H.Y), NIH R56 HL128342 (K.H.Y.),
   RPB Stein Innovation Award (A.B.M.), and UIC Chancellor's Innovation
   Fund (K.H.Y.).
CR Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bruns AF, 2010, TRAFFIC, V11, P161, DOI 10.1111/j.1600-0854.2009.01001.x
   CHANG YS, 1994, J BIOCHEM BIOPH METH, V29, P321
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Crawford Y, 2009, TRENDS PHARMACOL SCI, V30, P624, DOI 10.1016/j.tips.2009.09.004
   Crawford Y, 2009, CELL TISSUE RES, V335, P261, DOI 10.1007/s00441-008-0675-8
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Ewan LC, 2006, TRAFFIC, V7, P1270, DOI 10.1111/j.1600-0854.2006.00462.x
   Fantin A, 2017, J EXP MED, V214, P1049, DOI 10.1084/jem.20160311
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Gampel A, 2006, BLOOD, V108, P2624, DOI 10.1182/blood-2005-12-007484
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200
   Hayashi M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2683
   Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774
   Horiguchi K, 2006, J CELL BIOL, V174, P425, DOI 10.1083/jcb.200604031
   Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103
   Jenkins B, 2012, J CELL BIOL, V198, P749, DOI 10.1083/jcb.201205070
   Jopling HM, 2009, ARTERIOSCL THROM VAS, V29, P1119, DOI 10.1161/ATVBAHA.109.186239
   Kanai Y, 2014, J CELL BIOL, V204, P395, DOI 10.1083/jcb.201309066
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lampugnani MG, 2006, J CELL BIOL, V174, P593, DOI 10.1083/jcb.200602080
   Lanahan AA, 2010, DEV CELL, V18, P713, DOI 10.1016/j.devcel.2010.02.016
   Liao EH, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007184
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Manickam V, 2011, BLOOD, V117, P1425, DOI 10.1182/blood-2010-06-291690
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Nakayama M, 2013, NAT CELL BIOL, V15, P249, DOI 10.1038/ncb2679
   Noseda R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002440
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Schou KB, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14177
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87
   Simons M, 2012, PHYSIOLOGY, V27, P213, DOI 10.1152/physiol.00016.2012
   Yamada KH, 2007, BIOCHEMISTRY-US, V46, P10039, DOI 10.1021/bi701169w
   Yamada KH, 2017, AM J PATHOL, V187, P214, DOI 10.1016/j.ajpath.2016.09.010
   Yamada KH, 2014, J CELL SCI, V127, P4518, DOI 10.1242/jcs.156109
   Yamaoka-Tojo M, 2004, CIRC RES, V95, P276, DOI 10.1161/01.RES.0000136522.58649.60
NR 46
TC 3
Z9 3
U1 1
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2021
VL 62
IS 2
AR 5
DI 10.1167/iovs.62.2.5
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QQ5MM
UT WOS:000624567800005
PM 33533881
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hara, C
   Wakabayashi, T
   Toyama, H
   Fukushima, Y
   Sayanagi, K
   Sato, S
   Sakaguchi, H
   Nishida, K
AF Hara, Chikako
   Wakabayashi, Taku
   Toyama, Hiroshi
   Fukushima, Yoko
   Sayanagi, Kaori
   Sato, Shigeru
   Sakaguchi, Hirokazu
   Nishida, Kohji
TI Characteristics of patients with neovascular age-related macular
   degeneration who are nonresponders to intravitreal aflibercept
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ENDOTHELIAL GROWTH-FACTOR; VASCULAR
   HYPERPERMEABILITY; VEGF-TRAP; RANIBIZUMAB; BEVACIZUMAB; THERAPY;
   THICKNESS
AB Purpose To investigate the frequency and patient characteristics that influence anatomic response of intravitreal aflibercept in treatment-naive neovascular age-related macular degeneration (AMD). Design Retrospective, interventional, consecutive case series. Methods Three hundred and sixty-five eyes of 365 patients with AMD who underwent 3 monthly intravitreal aflibercept treatments with follow-up for at least 12 months were investigated. Treatment response was evaluated as follows. Responders were defined as those with complete resolution of exudation, including intraretinal oedema, subretinal fluid and pigment epithelial detachment, or more than a 100 mu m decrease of central retinal thickness at 3 months compared with baseline. Non-responders were defined as patients exhibiting an increase in exudation or a decreased central retinal thickness of less than 100 mu m. Results Nineteen (5.2%) of 365 eyes were identified as non-responders. The remaining were responders to intravitreal aflibercept. The non-responders group was significantly associated with choroidal vascular hyperpermeability on indocyanine green angiography and lower frequency of subretinal hyper-reflective materials on optical coherence tomography. The central choroidal thickness at baseline and after 3 monthly injections tended to be thicker in the non-responder group than the responder group, although the differences did not meet statistical significance (p= 0.066 and p= 0.051, respectively). Additional treatments with either intravitreal ranibizumab or PDT in combination with aflibercept were effective in 15 (79%) of 19 nonresponders. Conclusion Intravitreal aflibercept is effective for treating eye pathology in most naive AMD cases. However, non-responsiveness may occur in small subgroup of patients with choroidal vascular hyperpermeability.
C1 [Hara, Chikako; Wakabayashi, Taku; Toyama, Hiroshi; Fukushima, Yoko; Sayanagi, Kaori; Sato, Shigeru; Sakaguchi, Hirokazu; Nishida, Kohji] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Hara, C (通讯作者)，Osaka Univ, Dept Ophthalmol, Grad Sch Med, Suita, Osaka 5650871, Japan.
EM chikako.ueno@ophthal.med.osaka-u.ac.jp
OI Hara, Chikako/0000-0001-9320-5408
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Inoue R, 2010, AM J OPHTHALMOL, V149, P441, DOI 10.1016/j.ajo.2009.10.011
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Murinello S, 2014, INVEST OPHTH VIS SCI, V55, P247, DOI 10.1167/iovs.13-11821
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Teper SJ, 2010, MOL VIS, V16, P2598
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 25
TC 14
Z9 15
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2019
VL 103
IS 5
BP 623
EP 629
DI 10.1136/bjophthalmol-2018-312275
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ID7PB
UT WOS:000471873700009
PM 29907628
DA 2022-11-30
ER

PT J
AU Ebrahimi, KB
   Fijalkowski, N
   Cano, M
   Handa, JT
AF Ebrahimi, Katayoon B.
   Fijalkowski, Natalia
   Cano, Marisol
   Handa, James T.
TI Decreased membrane complement regulators in the retinal pigmented
   epithelium contributes to age-related macular degeneration
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE ageing; age-related macular degeneration; apoptosis; complement;
   exosome; oxidative stress
ID LOW-DENSITY LIPOPROTEINS; FACTOR-H POLYMORPHISM; MEDIATED CELL-DEATH;
   BRUCHS MEMBRANE; OXIDIZED LDL; POLY(ADP-RIBOSE) POLYMERASE; GEOGRAPHIC
   ATROPHY; HEPARAN-SULFATE; BASAL DEPOSITS; HUMAN EYES
AB Dysregulated complement is thought to play a central role in age-related macular degeneration (AMD) pathogenesis, but the specific mechanisms have yet to be determined. In maculae of AMD specimens, we found that the complement regulatory protein, CD59, was increased in regions of uninvolved retinal pigmented epithelium (RPE) of early AMD, but decreased in the RPE overlying drusen and in geographic atrophy, an advanced form of AMD. While CD46 immunostaining was basolaterally distributed in the RPE of unaffected controls, it was decreased in diseased areas of early AMD samples. Since oxidized low-density lipoproteins (oxLDL) collect in drusen of AMD and are a known complement trigger, we treated ARPE-19 cells with oxLDL and found that cellular CD46 and CD59 proteins were decreased by 2.9- and nine-fold (p < 0.01), respectively. OxLDLs increased complement factor B mRNA and Bb protein, but not factor D, I or H. OxLDLs increased C3b, but not C3a, C5 or C5b-9. C5b-9 was increased by 27% (p < 0.01) when the medium was supplemented with human serum, which was sufficient to induce poly(ADP-ribose) polymerase cleavage, a marker of apoptosis. The decreased levels of CD46 and CD59 were in part explained by their release in exosomal and apoptotic membranous particles. In addition, CD59 was partially degraded through activation of IRE1. Collectively, these results suggest that a combination of impaired complement regulators results in inadequately controlled complement by the RPE in AMD that induces RPE damage. Copyright (c) 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Ebrahimi, Katayoon B.; Fijalkowski, Natalia; Cano, Marisol; Handa, James T.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Handa, JT (通讯作者)，400 North Broadway,Smith Bldg,Room 3015, Baltimore, MD 21287 USA.
EM jthanda@jhmi.edu
OI Callaway, Natalia/0000-0002-9788-9605
FU National Institutes of Health (NIH) [EY14005, EY019904]; Thome
   Foundation; American Health Assistance Foundation (AHAF); Research to
   Prevent Blindness; NIH [P30EY001765]; Robert Bond Welch Professorship;
   NATIONAL EYE INSTITUTE [P30EY001765, R01EY014005, R01EY019904] Funding
   Source: NIH RePORTER
FX We thank Christian Gutierrez, David O'Brien, Laura Asnaghi, Lei Wang and
   Sony Dike for technical support, Cathy Bowes Rickman for valuable
   advice, and Russell Read MD and Christine Curcio PhD, University of
   Alabama, Birmingham, for providing the geographic atrophy samples. The
   study was funded by the National Institutes of Health (NIH; Grant Nos
   EY14005 and EY019904, to JTH), the Thome Foundation (to JTH), American
   Health Assistance Foundation (AHAF; to JTH), a Research to Prevent
   Blindness Senior Scientist Award (to JTH), an unrestricted grant from
   Research to Prevent Blindness to the Wilmer Eye Institute, an NIH core
   grant (No. P30EY001765), the Robert Bond Welch Professorship and a gift
   from the Merlau family and Aleda Wright.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Atkinson JP, 2007, J EXP MED, V204, P1245, DOI 10.1084/jem.20070664
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   CALL TW, 1990, EXP EYE RES, V51, P451, DOI 10.1016/0014-4835(90)90158-Q
   Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353
   Cole DS, 2006, MOL IMMUNOL, V43, P1953, DOI 10.1016/j.molimm.2005.11.015
   COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A
   Cragg MS, 2000, CELL DEATH DIFFER, V7, P48, DOI 10.1038/sj.cdd.4400627
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakulinen J, 2004, EUR J IMMUNOL, V34, P2620, DOI 10.1002/eji.200424969
   Hirose K, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-1
   Hollien J, 2009, J CELL BIOL, V186, P323, DOI 10.1083/jcb.200903014
   Holvoet P, 2001, ARTERIOSCL THROM VAS, V21, P844, DOI 10.1161/01.ATV.21.5.844
   Huang Y, 2006, J BIOL CHEM, V281, P27398, DOI 10.1074/jbc.M603690200
   Hussain AA, EXP EYE RES, V90, P703
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lehto MT, 2002, BIOCHEMISTRY-US, V41, P1398, DOI 10.1021/bi011579w
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Nadanaka S, 2008, J BIOCHEM, V144, P7, DOI 10.1093/jb/mvn040
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   Nishi K, 2002, ARTERIOSCL THROM VAS, V22, P1649, DOI 10.1161/01.ATV.0000033829.14012.18
   Oikawa D, 2010, NUCLEIC ACIDS RES, V38, P6265, DOI 10.1093/nar/gkq452
   Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533
   PAPADIMITRIOU JC, 1991, J IMMUNOL, V147, P212
   PAPADIMITRIOU JC, 1994, VIRCHOWS ARCH, V424, P677, DOI 10.1007/BF01069750
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Satirapoj B, 2012, AM J NEPHROL, V35, P520, DOI 10.1159/000338484
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seibold S, 2004, J AM SOC NEPHROL, V15, P3026, DOI 10.1097/01.ASN.0000146425.58046.6A
   Seimon TA, CELL METAB, V12, P467
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Tegla CA, 2011, IMMUNOL RES, V51, P45, DOI 10.1007/s12026-011-8239-5
   TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   van den Berg CW, 2002, IMMUNOLOGY, V107, P102, DOI 10.1046/j.1365-2567.2002.01468.x
   van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jb/mvj128
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
NR 52
TC 92
Z9 96
U1 1
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
J9 J PATHOL
JI J. Pathol.
PD APR
PY 2013
VL 229
IS 5
BP 729
EP 742
DI 10.1002/path.4128
PG 14
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 108WE
UT WOS:000316326100009
PM 23097248
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hung, SH
   Xirasagar, S
   Kuang, TMT
   Chang, WW
   Cheng, YF
   Kuo, NW
   Lin, HC
AF Hung, Shih-Han
   Xirasagar, Sudha
   Kuang, Tung-Mei Tammy
   Chang, Wei-Wen
   Cheng, Yen-Fu
   Kuo, Nai-Wen
   Lin, Herng-Ching
TI Association of Age-Related Macular Degeneration with Prior
   Hyperthyroidism and Hypothyroidism: A Case-Control Study
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Article
DE age-related macular degeneration; hypothyroidism; hyperthyroidism;
   epidemiology
ID COMPLEMENT FACTOR-H; THYROID-DYSFUNCTION; POOLED FINDINGS; RISK-FACTORS;
   VITAMIN-E; PREVALENCE; MACULOPATHY; DISEASE
AB Prior studies suggest a possible association between thyroid disease and the subsequent development of age-related macular degeneration (AMD), although it remains inconclusive. This study aimed to evaluate the association of AMD with prior hyper-/hypothyroidism based on nationwide population-based data. We retrieved records of the study patients from the National Health Insurance Research Database, 7522 patients with a first-time diagnosis of AMD and 7522 propensity score-matched controls. Multiple logistic regression analyses were performed to explore the association of neovascular AMD with previously diagnosed hyperthyroidism or hypothyroidism. The Chi-square test shows that there was a statistically significant difference in the prevalence of prior hyperthyroidism between cases and controls (1.18 vs. 0.13%, p < 0.001). Furthermore, there was a statistically significant difference the prevalence of prior hypothyroidism between cases and controls (0.44 vs. 0.69%, p < 0.001). Multiple logistic regression analysis reveals that AMD was statistically and significantly associated with prior hyperthyroidism after adjusting for age, sex, monthly income, geographical location, urbanization level, hypertension, hyperlipidemia, diabetes, and coronary heart disease (odds ratio (OR) = 9.074, 95% CI = 4.713-17.471). The adjusted OR of prior hypothyroidism in patients with AMD was 3.794 (95% CI: 2.099 similar to 6.858) when compared to the controls. We conclude that patients with thyroid dysfunction are at higher risk of developing AMD Results suggest that these patients could benefit from proactive regular eye checkups to detect evolving eye pathology, even while vision remains normal during the initial phases.
C1 [Hung, Shih-Han] Taipei Med Univ, Coll Med, Sch Med, Dept Otolaryngol, Taipei 110, Taiwan.
   [Hung, Shih-Han] Taipei Med Univ, Wan Fang Hosp, Dept Otolaryngol, Taipei 110, Taiwan.
   [Hung, Shih-Han] Taipei Med Univ, Coll Med, Int Master PhD Program Med, Taipei 110, Taiwan.
   [Xirasagar, Sudha] Univ South Carolina, Arnold Sch Publ Hlth, Dept Hlth Serv Policy & Management, Columbia, SC 29208 USA.
   [Kuang, Tung-Mei Tammy] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 112, Taiwan.
   [Kuang, Tung-Mei Tammy] Natl Yang Ming Chiao Tung Univ, Sch Med, Dept Ophthalmol, Taipei 112, Taiwan.
   [Chang, Wei-Wen] Taipei Med Univ, Wan Fang Hosp, Dept Surg, Div Gen Surg, Taipei 110, Taiwan.
   [Cheng, Yen-Fu] Taipei Vet Gen Hosp, Dept Med Res, Taipei 112, Taiwan.
   [Cheng, Yen-Fu] Taipei Vet Gen Hosp, Dept Otolaryngol Head & Neck Surg, Taipei 112, Taiwan.
   [Cheng, Yen-Fu] Natl Chiao Tung Univ, Fac Med, Taipei 112, Taiwan.
   [Kuo, Nai-Wen; Lin, Herng-Ching] Taipei Med Univ, Coll Management, Sch Hlth Care Adm, Taipei 110, Taiwan.
   [Lin, Herng-Ching] Taipei Med Univ Hosp, Sleep Res Ctr, Taipei 110, Taiwan.
C3 Taipei Medical University; Taipei Medical University; Taipei Municipal
   WanFang Hospital; Taipei Medical University; University of South
   Carolina System; University of South Carolina Columbia; Taipei Veterans
   General Hospital; National Yang Ming Chiao Tung University; Taipei
   Medical University; Taipei Municipal WanFang Hospital; Taipei Veterans
   General Hospital; Taipei Veterans General Hospital; National Yang Ming
   Chiao Tung University; Taipei Medical University; Taipei Medical
   University; Taipei Medical University Hospital
RP Lin, HC (通讯作者)，Taipei Med Univ, Coll Management, Sch Hlth Care Adm, Taipei 110, Taiwan.; Lin, HC (通讯作者)，Taipei Med Univ Hosp, Sleep Res Ctr, Taipei 110, Taiwan.
EM seedturtle@gmail.com; sxirasagar@sc.edu; kuangtammy@gmail.com;
   weiwenabow@gmail.com; yfcheng2@vghtpe.gov.tw; nwkuo@tmu.edu.tw;
   henry11111@tmu.edu.tw
OI Cheng, Yen-Fu/0000-0003-1995-5854; Hung, Shih-Han/0000-0001-9591-5489;
   KUO, NAI-WEN/0000-0001-9199-2882; Lin, Herng-Ching/0000-0003-4661-959X
FU Ministry of Science and Technology [MOST-110-2622-8-075-001]; Taipei
   Veterans General Hospital [V111C-162]; Veterans General Hospitals and
   University System of Taiwan Joint Research Program [VGHUST111C-140]
FX We thank the Ministry of Science and Technology
   (MOST-110-2622-8-075-001), Taipei Veterans General Hospital (V111C-162)
   and Veterans General Hospitals and University System of Taiwan Joint
   Research Program (VGHUST111C-140) for grant support.
CR Alfadda AA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010088
   Bromfield S, 2012, CURR EYE RES, V37, P549, DOI 10.3109/02713683.2011.647223
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   de Jong EK, 2020, GENETICS AND GENOMICS OF EYE DISEASE: ADVANCING TO PRECISION MEDICINE, P155, DOI 10.1016/B978-0-12-816222-4.00010-1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin SY, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050902
   Ma HW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2216-7
   Ma HW, 2014, P NATL ACAD SCI USA, V111, P3602, DOI 10.1073/pnas.1317041111
   MARCOCCI C, 1989, ACTA ENDOCRINOL-COP, V120, P473, DOI 10.1530/acta.0.1200473
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Stefanowicz-Rutkowska MM, 2020, ENDOKRYNOL POL, V71, P176, DOI 10.5603/EP.a2020.0013
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu ZM, 2021, OPHTHALMIC RES, V64, P696, DOI 10.1159/000515273
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 31
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD APR
PY 2022
VL 12
IS 4
AR 602
DI 10.3390/jpm12040602
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA 0Q7OH
UT WOS:000785102700001
PM 35455718
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Parodi, MB
   Di Bartolo, E
   Brue, C
   Cappello, E
   Furino, C
   Giuffrida, S
   Imparato, M
   Reibaldi, M
AF Parodi, Maurizio Battaglia
   Di Bartolo, Emanuele
   Brue, Claudia
   Cappello, Ezio
   Furino, Claudio
   Giuffrida, Sebastiano
   Imparato, Manuela
   Reibaldi, Michele
TI Pegaptanib: choroidal neovascularization in patients with age-related
   macular degeneration and previous arterial thromboembolic events
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Pegaptanib; Thromboembolism
ID CEREBROVASCULAR ACCIDENTS; RANIBIZUMAB; BEVACIZUMAB; INHIBITION; SODIUM
AB Purpose: To evaluate the efficacy and the rate of side effects of the pegylated aptamer pegaptanib in the treatment of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and a history of previous arterial thromboembolic events (ATEs).
   Methods: Twenty-three eyes of 23 patients with subfoveal CNV due to AMD and cerebrovascular accidents (n = 12) and myocardial infarction (n = 11) in the previous 6 months received intravitreal pegaptanib 0.3 mg according to a pro re nata regimen and were followed for 12 months. The paired Student t test was used to evaluate mean changes in best-corrected visual acuity (BCVA; primary outcome measure) and central foveal thickness (CFT).
   Results: The mean patient age was 71.5 +/- 4.6 years; there were 14 women and 9 men. The CNV was type 1, 2, and 3 in 18, 3, and 2 eyes, respectively. The mean BCVA improved from 0.67 +/- 0.23 logMAR at baseline to 0.52 +/- 0.31 logMAR at the end of 12-month follow-up (p = 0.044). Thirty-five percent of patients achieved >= 3 Early Treatment Diabetic Retinopathy Study lines improvement at 12 months. Mean CFT at baseline (381 +/- 111 mu m) decreased to 304 +/- 82 mu m at 12 months (p = 0.008). Patients received a mean of 4.3 +/- 1.3 (range 3-7) injections. No systemic or ocular side effects occurred; no patient experienced further ATEs.
   Conclusions: Intravitreal pegaptanib can be considered a viable treatment option for patients with AMD-related CNV who are at high risk of ATEs.
C1 [Parodi, Maurizio Battaglia] Osped San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Di Bartolo, Emanuele] Azienda Osped Univ Pisana, Dept Ophthalmol, Pisa, Italy.
   [Brue, Claudia] Polytech Univ Marche, Dept Ophthalmol, Ancona, Italy.
   [Cappello, Ezio] Osped San Bassiano, Dept Ophthalmol, Bassano Del Grappa, Italy.
   [Furino, Claudio] Univ Bari, Dept Ophthalmol, Bari, Italy.
   [Giuffrida, Sebastiano] Bausch & Lomb Iom SpA, Milan, Italy.
   [Imparato, Manuela] Fdn IRCCS Policlin San Matteo, Dept Ophthalmol, Pavia, Italy.
   [Reibaldi, Michele] Univ Catania, Dept Ophthalmol, Catania, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   University of Pisa; Azienda Ospedaliero Universitaria Pisana; Marche
   Polytechnic University; ULSS 7 Pedemontana; Ospedale San Bassiano;
   Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle
   Ricerche (CNR); Istituto Officina dei Materiali (IOM-CNR); IRCCS
   Fondazione San Matteo; University of Catania
RP Parodi, MB (通讯作者)，Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM battagliaparodi.maurizio@hsr.it
RI Parodi, Maurizio Battaglia/K-7876-2016; Reibaldi, Michele/AAL-1113-2021
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961
CR Biagi C, 2014, EUR J CLIN PHARMACOL, V70, P1505, DOI 10.1007/s00228-014-1755-1
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Duffy A.M., 2000, MADAME CURIE BIOSCIE
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gorenoi V, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011741.pub2
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Moncada S, 2006, BRIT J PHARMACOL, V147, pS193, DOI 10.1038/sj.bjp.0706458
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P851, DOI 10.1097/IAE.0b013e31806458f0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shiragami C, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000116
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Sivaprasad S, 2010, EYE, V24, P793, DOI 10.1038/eye.2009.232
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
NR 22
TC 4
Z9 4
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2018
VL 28
IS 1
BP 58
EP 62
DI 10.5301/ejo.5001060
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC5BJ
UT WOS:000429800100011
PM 29077191
DA 2022-11-30
ER

PT J
AU Azuma, M
   Chung, K
   Fujii, A
   Shearer, TR
AF Azuma, Mitsuyoshi
   Chung, Kelly
   Fujii, Atsuko
   Shearer, Thomas R.
TI Patient Selection Criteria for Pilot Studies on Amelioration of
   Non-Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID CALPAIN
AB Purposes: Non-neovascular age-related macular degeneration (AMD) is characterized by accumulation of macular drusen, changes in pigmentation of the retinal pigment epithelium, and geographic atrophy. The purposes of this study were to (1) measure the rate of progression of non-neovascular AMD and (2) from the rate data, to propose patient selection criteria for testing drugs to prevent progression of non-neovascular AMD.
   Methods: Medical charts were searched for all AMD billing codes, consecutively reviewed, and 51 patients with a median age of 76 years were mined for severity of AMD using a standardized worsening scale from 0 to 6, visual acuity (VA, Snellen), medications or procedures to treat eye diseases, date of eye examinations, age, and sex. Individual eyes, excluding those with cataract, were grouped and compared.
   Results: Using all grades, VA (logMAR) was positively correlated with AMD scores (P < 0.0001, n=66). The median length of time to progress from AMD grade 3 or 4 to the next grade was 1.0 (n=14) and 1.7 years (n=7), respectively. Statistical analyses predicted that drug-treated and nontreated groups, each containing 409 grade 3 and 4 AMD eyes, could detect 50% drug inhibition (P=0.05) in a 2-year trial.
   Conclusions: VA measurements and structural AMD grades would be useful markers in clinical trials on non-neovascular AMD. Recruiting only grade 3 and 4 patients may be ideal for time- and cost-efficient pilot drug efficacy studies on moderately progressing non-neovascular AMD.
C1 [Azuma, Mitsuyoshi; Shearer, Thomas R.] Oregon Hlth & Sci Univ, Dept Integrat Biosci, Portland, OR 97239 USA.
   [Chung, Kelly] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97239 USA.
   [Azuma, Mitsuyoshi; Fujii, Atsuko] Senju Pharmaceut Corp Ltd, Lab Ocular Sci, Beaverton, OR USA.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Senju Pharmaceutical Co. Ltd.
RP Shearer, TR (通讯作者)，Oregon Hlth & Sci Univ, Dept Integrat Biosci, 611 SW Campus Dr, Portland, OR 97239 USA.
EM shearert@ohsu.edu
FU Senju Pharmaceutical Co. Ltd.
FX Drs. Shearer and Chung have significant financial interests (research
   contract and/or consulting fee) in Senju Pharmaceutical Co. Ltd., and
   Dr. Azuma and Ms. Fujii are employees of Senju Pharmaceutical Co., Ltd.,
   a company that may have commercial interest in the results of this
   research and technology. These potential conflicts of interest have been
   reviewed and managed by the OHSU Conflict of Interest in Research
   Committee.
CR Azuma MS, 2008, SURV OPHTHALMOL, V53, P308, DOI 10.1016/j.survophthal.2008.05.001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Kanan Y, 2007, INVEST OPHTH VIS SCI, V48, P40, DOI 10.1167/iovs.06-0592
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Ma H, 2009, J OCUL PHARMACOL TH, V25, P409, DOI 10.1089/jop.2009.0030
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   STOKKERMANS TJ, 2008, REV OPTOMETRY S  NOV
   Tamada Y, 2007, CURR EYE RES, V32, P565, DOI 10.1080/02713680701359633
NR 11
TC 3
Z9 3
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD AUG
PY 2010
VL 26
IS 4
BP 367
EP 371
DI 10.1089/jop.2010.0042
PG 5
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 637FY
UT WOS:000280802900011
PM 20653480
OA Green Published
DA 2022-11-30
ER

PT J
AU Young, M
   Forooghian, F
AF Young, Mei
   Forooghian, Farzin
TI Serous Index of Pigment Epithelial Detachments in Neovascular
   Age-Related Macular Degeneration Predicts Response to Anti-Vascular
   Endothelial Growth Factor Treatment
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL RANIBIZUMAB; SUBRETINAL
   FLUID; VISUAL-ACUITY; EYES; RETREATMENT; BEVACIZUMAB; AFLIBERCEPT
AB BACKGROUND AND OBJECTIVE: To determine whether optical density measurements of pigment epithelial detachments (PEDs) in neovascular age-related macular degeneration (AMD) can predict the response to treatment with anti-VEGF therapy.
   PATIENTS AND METHODS: Retrospective review of SD-OCT scans of 21 eyes of 21 patients with neovascular AMD and PED. Response to treatment was determined using SD-OCT volumetric analysis. The authors used optical density measurements of PED lesions on SD-OCT images to calculate the serous index, which is a measure of the serous component of PEDs.
   RESULTS: The serous index was found to correlate with the response to anti-VEGF treatment (r = .69, P = .0005), and to be predictive of the response to treatment (P = .007).
   CONCLUSION: The serous index of PEDs can help predict the response to anti-VEGF treatment. This measure may be useful in decisions regarding switching anti-VEGF agents in the clinical care of patients with neovascular AMD and PED.
C1 [Young, Mei; Forooghian, Farzin] Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada.
C3 University of British Columbia
RP Forooghian, F (通讯作者)，St Pauls Hosp, Dept Ophthalmol, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM farzin.forooghian@gmail.com
FU Retina Foundation of Canada
FX Supported by a grant from the Retina Foundation of Canada.
CR Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Baek J, 2015, AM J OPHTHALMOL, V159, P386, DOI 10.1016/j.ajo.2014.11.011
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Kashani AH, 2015, RETINA-J RET VIT DIS, V35, P149, DOI 10.1097/IAE.0000000000000267
   Ozkaya A, 2014, J FR OPHTALMOL, V37, P280, DOI 10.1016/j.jfo.2013.08.006
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
NR 15
TC 1
Z9 1
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUL
PY 2015
VL 46
IS 7
BP 724
EP 727
DI 10.3928/23258160-20150730-06
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9TW
UT WOS:000378841300007
PM 26247453
DA 2022-11-30
ER

PT J
AU Nakanishi, H
   Yamashiro, K
   Yamada, R
   Gotoh, N
   Hayashi, H
   Nakata, I
   Saito, M
   Iida, T
   Oishi, A
   Kurimoto, Y
   Matsuo, K
   Tajima, K
   Matsuda, F
   Yoshimura, N
AF Nakanishi, Hideo
   Yamashiro, Kenji
   Yamada, Ryo
   Gotoh, Norimoto
   Hayashi, Hisako
   Nakata, Isao
   Saito, Masaaki
   Iida, Tomohiro
   Oishi, Akio
   Kurimoto, Yasuo
   Matsuo, Keitaro
   Tajima, Kazuo
   Matsuda, Fumihiko
   Yoshimura, Nagahisa
TI Joint Effect of Cigarette Smoking and CFH and LOC387715/HTRA1
   Polymorphisms on Polypoidal Choroidal Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; AGE-RELATED
   MACULOPATHY; MACULAR DEGENERATION; RISK; GENE; SUSCEPTIBILITY;
   ASSOCIATION; VARIANT; JAPANESE
AB PURPOSE. To investigate whether the major genetic and environmental risk factors of age-related macular degeneration (AMD)-CFH Y402H and LOC387715 A69S and cigarette smoking-are also associated with polypoidal choroidal vasculopathy (PCV) and whether the associations of CFH Y402H and LOC387715 A69S with PCV are modified by smoking.
   METHODS. Three hundred seventy-five Japanese patients with PCV and 847 Japanese who served as population-based control subjects, all >= 55 years of age, were studied. CFH Y402H (rs1061170) and LOC387715 A69S (rs10490924) were genotyped with a single-nucleotide polymorphism (SNP) assay. An unconditional logistic regression model was used to analyze the association between age, sex, smoking status, CFH Y402H, LOC387715 A69S, and PCV. The synergy index (SI) was measured to assess gene-smoking and gene-gene interaction as a departure from additivity.
   RESULTS. CFH Y402H, LOC3387715 A69S, and cigarette smoking status were all significantly associated with PCV; for CFH Y402H, the adjusted odds ratio (OR) for the number of copies of the allele was 1.63 (95% confidence interval [CI], 1.12-2.36; P < 0.05); for LOC387715 A69S, the adjusted OR was 2.26 (95% CI, 1.83-2.78; P < 0.0001); and for smoking status (ever versus never smoked), the adjusted OR was 1.45 (95% CI, 1.00-2.10; P < 0.05). The joint effect of CFH Y402H and smoking was significantly greater than the additive scale, with an SI of 2.41 (95% CI, 1.14-5.10).
   CONCLUSIONS. CFH Y402H and LOC387715 A69S are both significantly associated with PCV. Cigarette smoking is an environmental risk factor for PCV. The findings suggest interactions between CFH 402H and cigarette smoking in PCV. (Invest Ophthalmol Vis Sci. 2010;51:6183-6187) DOI:10.1167/iovs.09-4948
C1 [Nakanishi, Hideo; Yamashiro, Kenji; Gotoh, Norimoto; Hayashi, Hisako; Nakata, Isao; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
   [Nakanishi, Hideo; Yamada, Ryo; Gotoh, Norimoto; Hayashi, Hisako; Nakata, Isao; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto 6068507, Japan.
   [Saito, Masaaki; Iida, Tomohiro] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Oishi, Akio; Kurimoto, Yasuo] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan.
   [Matsuo, Keitaro; Tajima, Kazuo] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 464, Japan.
C3 Kyoto University; Kyoto University; Fukushima Medical University; Kobe
   City Medical Center General Hospital; Aichi Cancer Center
RP Nakanishi, H (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Shogoin Kawahara Cho 54, Kyoto 6068507, Japan.
EM hideon@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; Matsuo, Keitaro/H-6758-2019; Saito,
   Masaaki/ABI-2783-2020; Matsuda, Fumihiko/B-9893-2009
OI Oishi, Akio/0000-0002-0977-9458; Matsuo, Keitaro/0000-0003-1761-6314;
   Saito, Masaaki/0000-0003-1494-6350; Yamashiro,
   Kenji/0000-0001-9354-8558; Yamada, Ryo/0000-0002-1587-630X
FU Japan Society for the Promotion of Science, Tokyo, Japan [19390442,
   27091294]; Japanese National Society for the Prevention of Blindness
FX Supported in part by Grants-in-Aid for Scientific Research 19390442 and
   27091294 from the Japan Society for the Promotion of Science, Tokyo,
   Japan, and by the Japanese National Society for the Prevention of
   Blindness.
CR Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   BETTMAN JW, 1958, ARCH OPHTHALMOL-CHIC, V59, P481
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Francis PJ, 2008, MOL VIS, V14, P1395
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kalilani Linda, 2006, Epidemiol Perspect Innov, V3, P5, DOI 10.1186/1742-5573-3-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Maresh JG, 2005, PHYSIOL GENOMICS, V21, P308, DOI 10.1152/physiolgenomics.00310.2004
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   ROTHMAN KJ, 1976, AM J EPIDEMIOL, V103, P506, DOI 10.1093/oxfordjournals.aje.a112252
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Singerman Lawrence J, 2005, Retina, V25, pS1
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida T, 2007, MOL VIS, V13, P545
NR 51
TC 31
Z9 35
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2010
VL 51
IS 12
BP 6183
EP 6187
DI 10.1167/iovs.09-4948
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 688GJ
UT WOS:000284837500014
PM 20688737
DA 2022-11-30
ER

PT J
AU Lee, JH
   Lee, WK
AF Lee, Jae Hyung
   Lee, Won Ki
TI Anti-vascular endothelial growth factor monotherapy for polypoidal
   choroidal vasculopathy with polyps resembling grape clusters
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor; Photodynamic therapy;
   Polypoidal choroidal vasculopathy
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB;
   FOLLOW-UP; JAPANESE PATIENTS; VASCULAR NETWORK; VERTEPORFIN;
   BEVACIZUMAB; INJECTIONS; EFFICACY
AB The objective of this study was to investigate the 2-year outcomes of treatment with anti-vascular endothelial growth factor (VEGF) in patients with polypoidal choroidal vasculopathy (PCV) with polyps resembling grape clusters.
   Twenty eyes in 20 patients were included. All patients initially received three consecutive anti-VEGF injections, followed by an as-needed re-injection schedule. Patients were followed regularly at 1- to 3-month intervals. The primary outcome was change in best-corrected visual acuity (BCVA).
   The mean number of injections administered over the course of 24 months was 12.50 +/- 2.77 (range, 9-18). The logarithm of the minimum angle of resolution (logMAR) BCVA improved from 0.61 +/- 0.28 to 0.42 +/- 0.27 at 12 months (P = 0.015), and 0.44 +/- 0.31 at 24 months (P = 0.056). At 24 months, BCVA had improved in 6 (30.0 %) eyes by 0.3 logMAR or more, was stable in 11 (55.0 %) eyes, and had decreased in 3 (15.0 %) eyes. Complete absorption of fluid was achieved with anti-VEGF treatment in 18 (90 %) eyes at least once during the 2-year follow-up period, and 10 (50 %) eyes revealed a dry macula at 24 months. Two eyes (10.0 %) received rescue photodynamic therapy because subfoveal fluid persisted despite six and seven consecutive anti-VEGF injections. Of 18 eyes treated only with anti-VEGF agents, 3 (16.7 %) revealed partial resolution of the polypoidal lesions at 24 months.
   A treatment regimen with anti-VEGF effectively improved or maintained visual acuity over a 24-month period in patients with PCV with clusters of grape-like polyps, and required frequent injections, comparable to typical choroidal neovascularization in age-related macular degeneration.
C1 [Lee, Jae Hyung; Lee, Won Ki] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Ophthalmol, 222 Banpo Daero, Seoul 137701, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Ophthalmol, 222 Banpo Daero, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2015, INITIAL VERSUS DELAY
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hikichi T, 2013, RETINA-J RET VIT DIS, V33, P1949, DOI 10.1097/IAE.0b013e31828bcafa
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wolf A, 2013, RETINA-J RET VIT DIS, V33, P1843, DOI 10.1097/IAE.0b013e318287d9be
NR 32
TC 9
Z9 10
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2016
VL 254
IS 4
BP 645
EP 651
DI 10.1007/s00417-015-3092-1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH2IJ
UT WOS:000372608100005
PM 26138657
DA 2022-11-30
ER

PT J
AU Joachim, SC
   Bruns, K
   Lackner, KJ
   Pfeiffer, N
   Grus, FH
AF Joachim, Stephanie C.
   Bruns, Kai
   Lackner, Karl J.
   Pfeiffer, Norbert
   Grus, Franz H.
TI Analysis of IgG antibody patterns against retinal antigens and
   antibodies to alpha-crystallin, GFAP, and alpha-enolase in sera of
   patients with "wet" age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; antibody patterns; alpha-crystallin;
   alpha-enolase; GFAP; retina
ID CANCER-ASSOCIATED RETINOPATHY; FIBRILLARY ACIDIC PROTEIN; SMALL-CELL
   CARCINOMA; AUTOANTIBODY-REPERTOIRES; RETINITIS-PIGMENTOSA; NATURAL
   AUTOANTIBODIES; AUTOIMMUNE RETINOPATHY; DISCRIMINANT-ANALYSIS;
   MULTIPLE-SCLEROSIS; B-CRYSTALLIN
AB Background The aim of this study was to compare the IgG antibody patterns against retinal antigens in sera of patients with age-related macular degeneration (AMD) and healthy subjects to learn more about possible immunological aspects of this disease and to identify some of the most important antigens. Methods Sera of 140 patients were analyzed: healthy volunteers (CO, n=101) and patients with "wet" age-related macular degeneration (AMD, n=39). The sera were tested against western blots of bovine retinal antigens. The IgG antibody patterns were analyzed by multivariate statistical techniques and some antigens were identified via LC-MS/MS. Results All patients showed complex patterns of IgG antibodies against retinal antigens. The discriminant analysis revealed a statistical significant difference between the antibody profiles of the AMD and the CO group (P=0.000023). Not only up-regulations of antigen-antibody-reactivities in the AMD group at some molecular weight ranges, e.g. at 46 and 52 kDa, could be seen, but also down-regulations, e.g. at 18 and 36 kDa. The 18 kDa antigen band was identified as alpha B-crystallin, the band at 46 kDa as alpha-enolase, and one at 52 kDa as glial fibrillary acidic protein. Conclusions We could demonstrate that both groups (wet AMD and CO) show complex IgG antibody patterns against retinal antigens, which are highly specific for each group. This provides further hints for the immunological basis of the disease. These changes in the antibody profiles in "wet" AMD could represent a secondary response to retinal damage or can play a causative role in the disease.
C1 Johannes Gutenberg Univ Mainz, Dept Ophthalmol, D-55101 Mainz, Germany.
   Johannes Gutenberg Univ Mainz, Dept Clin Chem & Lab Med, D-55101 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz
RP Grus, FH (通讯作者)，Johannes Gutenberg Univ Mainz, Dept Ophthalmol, Langenbeckstr 1, D-55101 Mainz, Germany.
EM grus@EYE-RESEARCH.ORG
RI Pfeiffer, Norbert/AAO-7586-2020
CR Adam JA, 2004, DISCRETE CONT DYN-B, V4, P1
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154
   Bazhin AV, 2006, CANCER IMMUNOL IMMUN, P1
   BRINKMAN CJJ, 1980, INVEST OPHTH VIS SCI, V19, P743
   CAVALLERANO AA, 1997, MACULAR DISORDERS
   Chen A, 2002, GLIA, V38, P115, DOI 10.1002/glia.10061
   Chen H, 1993, Yan Ke Xue Bao, V9, P113
   Dot C, 2005, AM J OPHTHALMOL, V139, P746, DOI 10.1016/j.ajo.2004.10.044
   DUMONDE DC, 1982, LANCET, V2, P787
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   GALBRAITH GMP, 1986, J CLIN INVEST, V78, P865, DOI 10.1172/JCI112672
   Garcia-Castineiras S, 1993, P R Health Sci J, V12, P123
   Grus FH, 2006, INVEST OPHTH VIS SCI, V47, P968, DOI 10.1167/iovs.05-0685
   Grus FH, 2004, MOL VIS, V10, P132
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Heckenlively JR, 2000, ARCH OPHTHALMOL-CHIC, V118, P1525
   HYMAN L, 1992, AGE RELATED MACULAR
   IIDA H, 1985, NATURE, V315, P688, DOI 10.1038/315688a0
   Jankowska R, 2004, PATHOBIOLOGY, V71, P323, DOI 10.1159/000081728
   Joachim SC, 2005, GRAEF ARCH CLIN EXP, V243, P817, DOI 10.1007/s00417-004-1094-5
   Joachim SC, 2003, EUR J OPHTHALMOL, V13, P752, DOI 10.1177/1120672103013009-1003
   KINCAID M, 1992, AGE RELATED MACULAR
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652
   KUMAR M, 1983, ANN OPHTHALMOL, V15, P838
   Lacroix-Desmazes S, 1998, J IMMUNOL METHODS, V216, P117, DOI 10.1016/S0022-1759(98)00074-X
   Lam TT, 2003, INVEST OPHTH VIS SCI, V44, P638, DOI 10.1167/iovs.02-0255
   Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1
   Luiz JE, 1998, J NEURO-OPHTHALMOL, V18, P178
   MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014
   Norgren N, 2004, NEUROLOGY, V63, P1586, DOI 10.1212/01.WNL.0000142988.49341.D1
   OMALLEY P, 1989, GEN OPHTHALMOLOGY
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Pratesi F, 2000, J RHEUMATOL, V27, P109
   Ren GY, 2004, J AUTOIMMUN, V23, P161, DOI 10.1016/j.jaut.2004.06.003
   SANDBERG HO, 1979, SCAND J IMMUNOL, V10, P549, DOI 10.1111/j.1365-3083.1979.tb01389.x
   Sanna G, 2000, LUPUS, V9, P573, DOI 10.1191/096120300678828695
   Savchenko MS, 2003, LUNG CANCER-J IASLC, V41, P363, DOI 10.1016/S0169-5002(03)00239-3
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Singer HS, 2003, J NEUROIMMUNOL, V136, P154, DOI 10.1016/S0165-5728(03)00034-1
   Singer HS, 2004, MOVEMENT DISORD, V19, P406, DOI 10.1002/mds.20052
   Singh VK, 1997, PEDIATR NEUROL, V17, P88, DOI 10.1016/S0887-8994(97)00045-3
   Stoevring B, 2005, CLIN CHIM ACTA, V356, P95, DOI 10.1016/j.cccn.2005.01.034
   THIRKILL CE, 1992, INVEST OPHTH VIS SCI, V33, P2768
   Thirkill CE, 1997, OCUL IMMUNOL INFLAMM, V5, P55, DOI 10.3109/09273949709085051
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wakui H, 1999, CLIN EXP IMMUNOL, V118, P445
   Weleber RG, 2005, AM J OPHTHALMOL, V139, P780, DOI 10.1016/j.ajo.2004.12.104
   Wendlandt JT, 2001, J NEUROIMMUNOL, V119, P106, DOI 10.1016/S0165-5728(01)00370-8
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   ZIMMERMANN CW, 1995, ELECTROPHORESIS, V16, P941, DOI 10.1002/elps.11501601158
NR 56
TC 44
Z9 46
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2007
VL 245
IS 5
BP 619
EP 626
DI 10.1007/s00417-006-0429-9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 163SK
UT WOS:000246183300001
PM 17058093
DA 2022-11-30
ER

PT J
AU Rabina, G
   Ayalon, A
   Mimouni, M
   Stanescu, N
   Moisseiev, E
   Nemet, AY
   Geffen, N
   Segal, O
AF Rabina, Gilad
   Ayalon, Anfisa
   Mimouni, Michael
   Stanescu, Nir
   Moisseiev, Elad
   Nemet, Arie Y.
   Geffen, Noa
   Segal, Ori
TI Optical Coherence Tomography Prognostic Factors in Age-Related Macular
   Degeneration Patients with Peripapillary Choroidal Neovascularization
SO OPHTHALMOLOGICA
LA English
DT Article
DE Choroidal neovascularization; Peripapillary; Age-related macular
   degeneration; Optical coherence tomography; Prognostic signs
ID RANIBIZUMAB THERAPY; VISUAL-ACUITY; PARAMETERS; MEMBRANES
AB Purpose: The aim of the study was to investigate the correlation between optical coherence tomography (OCT) findings and visual acuity outcomes after treatment with intravitreal bevacizumab (IVB) injections for age-related macular degeneration (AMD) patients with peripapillary choroidal neovascularization (PPCNV). Methods: The study involved a retrospective case series of consecutive patients diagnosed with PPCNV secondary to AMD. All patients were treated with IVB injections with a follow-up time of 1 year. Data collected included best-corrected visual acuity (BCVA) and automated and manually measured OCT parameters. Results: A total of 68 eyes were diagnosed with PPMV. Of them, 30 eyes of 30 patients aged 84.3 +/- 6.9 years of which 63.3% female gender were included. Baseline BCVA was 0.46 +/- 0.62 logMAR (Snellen 20/57), average choroidal thickness was 193.2 +/- 22 mu m, and mean number of IVB injections was 7.2 +/- 1.9. After 1 year, BCVA was 0.56 +/- 0.78 logMAR (Snellen 20/72) (p = 0.28). Eyes with greater central retinal thickness (r = -0.36, p = 0.05), greater subretinal hyper-reflective material (SHRM) area (r = -0.37, p = 0.05), and greater sub-retinal fluid (SRF) area (r = -0.73, p < 0.001) had a significantly smaller improvement in BCVA. Eyes with pigment epithelium detachment (PED) (0.68 +/- 0.90 vs. 0.21 +/- 0.12, p = 0.03) had a significantly worse BCVA. Conclusions: Our data suggest that AMD-related PPCNV with greater foveal thickness, PED size, SHRM, and SRF areas have worse final BCVA prognosis.
C1 [Rabina, Gilad] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
   [Ayalon, Anfisa; Stanescu, Nir; Moisseiev, Elad; Nemet, Arie Y.; Segal, Ori] Tel Aviv Univ, Sackler Fac Med, Meir Med Ctr, Dept Ophthalmol, Kefar Sava, Israel.
   [Mimouni, Michael] Rambam Hlth Care Campus, Dept Ophthalmol, H_efa, Israel.
   [Geffen, Noa] Rabin Med Ctr, Dept Ophthalmol, Petah Tiqwa, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Rambam
   Health Care Campus; Rabin Medical Center
RP Rabina, G (通讯作者)，Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
EM giladrabina@hotmail.com
RI ; Mimouni, Michael/S-2916-2018
OI Stanescu, Nir/0000-0002-1193-2933; Mimouni, Michael/0000-0002-4661-0993
CR Adrean SD, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4802690
   Almony A, 2008, OPHTHALMOLOGY, V115, P540, DOI 10.1016/j.ophtha.2007.08.045
   Bernstein PS, 2008, RETINA-J RET VIT DIS, V28, P81, DOI 10.1097/IAE.0b013e31815e9351
   Black AA, 2011, OPHTHAL PHYSL OPT, V31, P283, DOI 10.1111/j.1475-1313.2010.00811.x
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Figueroa MS, 2008, BRIT J OPHTHALMOL, V92, P1244, DOI 10.1136/bjo.2008.144196
   Hamoudi H, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/602729
   Hosseini H, 2021, GRAEF ARCH CLIN EXP, V259, P1153, DOI 10.1007/s00417-020-05024-9
   Jutley G, 2011, EYE, V25, P675, DOI 10.1038/eye.2011.24
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lin TZ, 2019, RETINA-J RET VIT DIS, V39, P1936, DOI 10.1097/IAE.0000000000002272
   LOPEZ PF, 1992, RETINA-J RET VIT DIS, V12, P147, DOI 10.1097/00006982-199212020-00012
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   RUBEN S, 1994, ACTA OPHTHALMOL, V72, P118
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Singh SR, 2020, BRIT J OPHTHALMOL, V104, P678, DOI 10.1136/bjophthalmol-2019-314542
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   TURCOTTE P, 1991, RETINA-J RET VIT DIS, V11, P295, DOI 10.1097/00006982-199111030-00004
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Wilde C, 2019, EYE, V33, P451, DOI 10.1038/s41433-018-0232-y
   Yun C, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0203-7
NR 31
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD AUG
PY 2022
VL 245
IS 4
BP 342
EP 349
DI 10.1159/000520930
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3N5ZL
UT WOS:000836226400005
PM 34808637
OA hybrid
DA 2022-11-30
ER

PT J
AU Moreau-Gaudry, VV
   Geiser, M
   Romanet, JP
   Hera, R
   Millet, JY
   Chiquet, C
AF Moreau-Gaudry, V. Vinh
   Geiser, M.
   Romanet, J. P.
   Hera, R.
   Millet, J. Y.
   Chiquet, C.
TI Effects of photodynamic therapy on subfoveal blood flow in neovascular
   age-related macular degeneration patients
SO EYE
LA English
DT Article
DE neovascular age-related macular degeneration; blood flow; laser Doppler
   flowmetry; photodynamic therapy
ID LASER-DOPPLER FLOWMETRY; CHOROIDAL NEOVASCULARIZATION; OPTIC-NERVE;
   VERTEPORFIN; CIRCULATION; VEGF; EYES
AB Aim To assess the short-term changes in choroidal blood flow (ChBF) after photodynamic therapy (PDT) in patients with neovascular age-related macular degeneration (AMD).
   Methods Fourteen patients with exudative AMD were included after a complete ophthalmological examination, fluorescein and indocyanine green angiography and optical coherence tomography. Subfoveal ChBF was assessed using laser Doppler flowmetry (LDF) in both treated (n = 14) and nontreated contralateral (n = 8) eyes, 1 h and 1 week after PDT. Ocular perfusion pressure was calculated.
   Results The detection sensitivity of the LDF measurements at 2-min intervals before PDT in treated eyes was 7.4% for volume, 6.3% for velocity, and 10.4% for ChBF. The initial mean visual acuity was 0.68 +/- 0.3 logMar. Macular thickness at baseline as measured by OCT3 was at median (interquartile range), 326.5 mu m (188-367). At 1 h and 7 days after PDT, a significant increase in velocity (15.8 and 24.4%, respectively) and a significant decrease in volume (11 and 17.9%, respectively) were noted in treated eyes. Choroidal blood flow and ocular perfusion pressure (OPP) remained similar during follow-up. No significant change in flow parameters was reported in untreated eyes.
   Conclusion The LDF technique provides feasible and reliable measurements of blood flow parameters before and after PDT in a selective population of patients with exudative AMD. The prognostic value of these early blood flow parameter changes also needs to be assessed. Eye (2010) 24, 706-712; doi: 10.1038/eye.2009.130; published online 19 June 2009
C1 [Chiquet, C.] Univ Grenoble 1, Univ Hosp, Dept Ophthalmol, CHU Grenoble, F-38043 Grenoble 09, France.
   [Geiser, M.] HES SO Valais, Sion, Switzerland.
   [Chiquet, C.] Univ Grenoble 1, INSERM, EA 3745, Lab HP2,ERI 0017, F-38043 Grenoble 09, France.
C3 CHU Grenoble Alpes; UDICE-French Research Universities; Communaute
   Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University
   of Applied Sciences & Arts Western Switzerland; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Communaute Universite Grenoble Alpes; Universite Grenoble
   Alpes (UGA)
RP Chiquet, C (通讯作者)，Univ Grenoble 1, Univ Hosp, Dept Ophthalmol, CHU Grenoble, F-38043 Grenoble 09, France.
EM cchiquet@chu-grenoble.fr
RI Chiquet, Christophe/M-7426-2014
OI Chiquet, Christophe/0000-0002-7601-4885; Geiser, Martial
   Henri/0000-0002-1017-2872
FU University Hospital of Grenoble, France
FX This study was supported by a grant from University Hospital of
   Grenoble, France (CHU de Grenoble, Innovations Hospitalieres 2005).
CR AVELINE B, 1994, PHOTOCHEM PHOTOBIOL, V59, P328, DOI 10.1111/j.1751-1097.1994.tb05042.x
   BILL A, 1985, J CARDIOVASC PHAR S3, V7, P96
   BONNER RF, 1990, DEV CARDIOVASC MED, P73
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Figueroa M, 2006, AM J OPHTHALMOL, V141, P863, DOI 10.1016/j.ajo.2005.11.049
   Geiser MH, 1999, J BIOMED OPT, V4, P459, DOI 10.1117/1.429960
   Gelisken F, 2004, BRIT J OPHTHALMOL, V88, P207, DOI 10.1136/bjo.2003.018754
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 1999, BRIT J OPHTHALMOL, V83, P162, DOI 10.1136/bjo.83.2.162
   Gugleta K, 2002, INVEST OPHTH VIS SCI, V43, P723
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Kubicka-Trzaska Agnieszka, 2007, Klin Oczna, V109, P138
   Longo A, 2004, INVEST OPHTH VIS SCI, V45, P546, DOI 10.1167/iovs.03-0757
   Lovasik JV, 2003, INVEST OPHTH VIS SCI, V44, P2126, DOI 10.1167/iovs.02-0825
   Luksch A, 2000, INVEST OPHTH VIS SCI, V41, P3080
   Metelitsina TI, 2005, EXP EYE RES, V81, P159, DOI 10.1016/j.exer.2005.01.017
   Metelitsina TI, 2004, BRIT J OPHTHALMOL, V88, P1568, DOI 10.1136/bjo.2004.046607
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Ozdemir H, 2006, AM J OPHTHALMOL, V141, P574, DOI 10.1016/j.ajo.2005.09.031
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   RIVA CE, 1992, EXP EYE RES, V55, P499, DOI 10.1016/0014-4835(92)90123-A
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Smith BT, 2007, CURR OPIN OPHTHALMOL, V18, P240, DOI 10.1097/ICU.0b013e32810c8e05
   Uhlmann S, 2001, MICROVASC RES, V62, P179, DOI 10.1006/mvre.2001.2334
NR 28
TC 4
Z9 4
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD APR
PY 2010
VL 24
IS 4
BP 706
EP 712
DI 10.1038/eye.2009.130
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 583SY
UT WOS:000276701300031
PM 19543242
OA Bronze
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
   Hegel, MT
   Massof, RW
   Leiby, BE
   Ho, AC
   Tasman, WS
AF Rovner, Barry W.
   Casten, Robin J.
   Hegel, Mark T.
   Massof, Robert W.
   Leiby, Benjamin E.
   Ho, Allen C.
   Tasman, William S.
TI Improving Function in Age-related Macular Degeneration A Randomized
   Clinical Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; QUALITY-OF-LIFE; LOW-VISION; DEPRESSION;
   RANIBIZUMAB; REHABILITATION; MANAGEMENT; OUTCOMES; IMPACT
AB Purpose: To compare the efficacy of problem-solving therapy (PST) with supportive therapy (ST) to improve targeted vision function (TVF) in age-related macular degeneration (AMD).
   Design: Single-masked, attention-controlled, randomized clinical trial with outcome assessments at 3 months (main trial endpoint) and 6 months (maintenance effects).
   Participants: Patients with AMD (n = 241) attending retina practices.
   Interventions: Whereas PST uses a structured problem-solving approach to reduce vision-related task difficulty, ST is a standardized attention-control treatment.
   Main Outcome Measures: We assessed TVF, the 25-item National Eye Institute Vision Function Questionnaire plus Supplement (NEI VFQ), the Activities Inventory (AI), and vision-related quality of life (QoL).
   Results: There were no between-group differences in TVF scores at 3 (P = 0.47) or 6 (P = 0.62) months. For PST subjects, mean +/- standard deviation TVF scores improved from 2.71 +/- 0.52 at baseline to 2.18 +/- 0.88 at 3 months (P = 0.001) and were 2.18 +/- 0.95 at 6 months (change from 3 to 6 months, P = 0.74). For ST subjects, TVF scores improved from 2.73 +/- 0.52 at baseline to 2.14 +/- 0.96 at 3 months (P 0.001) and were 2.15 +/- 0.96 at 6 months (change from 3 to 6 months, P = 0.85). Similar proportions of PST and ST subjects had less difficulty performing a TVF goal at 3 months (77.4% vs 78.6%, respectively; P = 0.83) and 6 months (76.2% vs 79.1%, respectively; P = 0.61). There were no changes in the NEI VFQ or AI. Vision-related QoL improved for PST relative to ST subjects at 3 months (F(4, 192) = 2.46; P = 0.05) and at 6 months (F(4, 178) = 2.55; P = 0.05). The PST subjects also developed more adaptive coping strategies than ST subjects.
   Conclusions: We found that PST was not superior to ST at improving vision function in patients with AMD, but that PST improved their vision-related QoL. Despite the benefits of anti-vascular endothelial growth factor treatments, AMD remains associated with disability, depression, and diminished QoL. This clinical reality necessitates new rehabilitative interventions to improve the vision function and QoL of older persons with AMD. (C) 2013 by the American Academy of Ophthalmology.
C1 [Rovner, Barry W.] Jefferson Hosp Neurosci, Jefferson Med Coll, Dept Psychiat & Neurol, Philadelphia, PA USA.
   [Casten, Robin J.] Jefferson Hosp Neurosci, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA USA.
   [Hegel, Mark T.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Lebanon, NH 03766 USA.
   [Hegel, Mark T.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Lebanon, NH 03766 USA.
   [Massof, Robert W.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, Baltimore, MD 21205 USA.
   [Leiby, Benjamin E.] Jefferson Med Coll, Dept Pharmacol & Expt Therapeut, Div Biostat, Philadelphia, PA USA.
   [Ho, Allen C.; Tasman, William S.] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Dept Ophthalmol, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University; Dartmouth College; Dartmouth
   College; Johns Hopkins University; Johns Hopkins Medicine; Jefferson
   University; Jefferson University
RP Rovner, BW (通讯作者)，Jefferson Hosp Neurosci, 900 Walnut St,2nd Floor, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu
OI Ho, Allen/0000-0003-3921-608X
FU NEI [U01 EY 015839]; NATIONAL EYE INSTITUTE [U01EY015839] Funding
   Source: NIH RePORTER
FX Supported by NEI grant U01 EY 015839.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cuijpers P, 2007, EUR PSYCHIAT, V22, P9, DOI 10.1016/j.eurpsy.2006.11.001
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Heckhausen J, 2010, PSYCHOL REV, V117, P32, DOI 10.1037/a0017668
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Leinhaas MM, 2001, ISSUES LOW VISION RE, P39
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, P763, DOI 10.1097/OPX.0b013e3181339efd
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, P689
   MASSOF RW, 1995, OPTOMETRY VISION SCI, V72, P725, DOI 10.1097/00006324-199510000-00005
   Noavalis PN, 1993, CLIN MANUAL SUPPORTI
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Szabo SM, 2008, J AM GERIATR SOC, V56, P800, DOI 10.1111/j.1532-5415.2008.01666.x
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   Wahl HW, 2007, J GERONTOL B-PSYCHOL, V62, pP90, DOI 10.1093/geronb/62.2.P90
   Watson GR, 2001, J AM GERIATR SOC, V49, P317, DOI 10.1046/j.1532-5415.2001.4930317.x
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wysong A, 2009, ARCH OPHTHALMOL-CHIC, V127, P320, DOI 10.1001/archophthalmol.2008.613
NR 27
TC 29
Z9 30
U1 0
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2013
VL 120
IS 8
BP 1649
EP 1655
DI 10.1016/j.ophtha.2013.01.022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 196LW
UT WOS:000322778000027
PM 23642378
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Giansanti, F
   Eandi, CM
   Virgili, G
AF Giansanti, Fabrizio
   Eandi, Chiara M.
   Virgili, Gianni
TI Submacular surgery for choroidal neovascularisation secondary to
   age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID OPHTHALMIC FINDINGS; CONTROLLED-TRIALS; DISPLACEMENT; PREVALENCE;
   HEMORRHAGE; MEMBRANES; EXCISION
AB Background
   Vitreoretinal surgeons proposed submacular surgery to remove the fibrovascular tissue causing damage to the centre of the retina, in the attempt to limit central visual loss in people affected by neovascular age-related macular degeneration (AMD).
   Objectives
   This review aims at assessing the effectiveness of submacular surgery for preserving or improving vision in patients with AMD.
   Search strategy
   We searched CENTRAL, MEDLINE, EMBASE and LILACS. There were no language or date restrictions in the search for trials. The electronic databases were last searched on 11 February 2009.
   Selection criteria
   We included randomised or quasi-randomised controlled trials comparing submacular surgery with any other treatment or observation.
   Date collection and analysis
   Two authors independently extracted the data. The risk ratio (RR) of visual loss and visual gain was estimated at one year.
   Main results
   Two multicentre studies with a similar design were conducted between 1997 and 2003 and compared submacular surgery with observation in people affected by subfoveal neovascular AMD with (n=336) or without (n=454) extensive blood in the macula. At one year there was high quality evidence of no benefit for preventing visual loss ( RR: 0.96; 95% confidence interval (CI): 0.84 to 1.09). No difference could be demonstrated regarding the chance of visual gain ( RR: 1.06; 95% CI: 0.75 to 1.51), although this evidence was of low quality because of imprecision. The risk difference was -2% ( 95% CI: -10% to 5%) and 1% ( 95% CI: -4% to 6%) for visual loss and visual gain, respectively, thus excluding a large benefit with surgery in terms of absolute risk in this sample. There was high quality evidence that cataract needing surgery ( RR: 8.69; 95% CI: 4.06 to 18.61) and retinal detachment ( RR: 6.13; 95% CI: 2.81 to 13.38) were more common among operated patients, and detachment occurred in 5% of patients with no extensive blood and in 18% of those with extensive blood beneath the macula. A pilot study compared submacular surgery with laser photocoagulation in 70 patients. No difference between the two treatments could be demonstrated for any outcome measure, but estimates were very imprecise because of small sample size.
   Authors' conclusions
   There is no benefit with submacular surgery in most people with subfoveal choroidal neovascularisation due to AMD in terms of prevention of visual loss. Furthermore, the risk of developing cataract and retinal detachment increases after surgery.
C1 [Giansanti, Fabrizio; Virgili, Gianni] Univ Florence, Eye Clin, Dept Neurootoophthalmol Surg Sci, I-50134 Florence, Italy.
   [Eandi, Chiara M.] Univ Turin, Dept Clin Physiopathol, Eye Clin, Turin, Italy.
C3 University of Florence; University of Turin
RP Giansanti, F (通讯作者)，Univ Florence, Eye Clin, Dept Neurootoophthalmol Surg Sci, Via Morgagni 85, I-50134 Florence, Italy.
EM fabrizio.giansanti@unifi.it
RI Giansanti, Fabrizio/I-2193-2012; Virgili, Gianni/P-6607-2014
OI Giansanti, Fabrizio/0000-0002-4107-2807; Virgili,
   Gianni/0000-0002-9960-2989; Eandi, Chiara Maria/0000-0003-3656-1689
CR Bender R, 2008, J CLIN EPIDEMIOL, V61, P857, DOI 10.1016/j.jclinepi.2008.03.004
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   BLINDER KJ, 1991, INT OPHTHALMOL, V15, P215
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Deeks JJ., 2020, COCHRANE HDB SYSTEMA, V1
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Evans JR, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007650, DOI 10.1002/14651858.CD007650]
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HERRIOT WJ, 1997, P 1997 UPD MAC SURG, P82
   Higgins JPT., 2022, COCHRANE HDB SYSTEMA
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Krzystolik MG, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   THOMAS MA, 2000, AM J OPHTHALMOL, V130, P387
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   2000, AM J OPHTHALMOLOGY 2, V130, P408
NR 34
TC 14
Z9 14
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2009
IS 2
AR CD006931
DI 10.1002/14651858.CD006931.pub2
PG 39
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 469DK
UT WOS:000267875600005
PM 19370663
DA 2022-11-30
ER

PT J
AU Wong, T
   Chakravarthy, U
   Klein, R
   Mitchell, P
   Zlateva, G
   Buggage, R
   Fahrbach, K
   Probst, C
   Sledge, I
AF Wong, Tien
   Chakravarthy, Usha
   Klein, Ronald
   Mitchell, Paul
   Zlateva, Gergana
   Buggage, Ronald
   Fahrbach, Kyle
   Probst, Corey
   Sledge, Isabella
TI The natural history and prognosis of neovascular age-related macular
   degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE
   ACETONIDE; INDOCYANINE GREEN ANGIOGRAPHY; PHOTODYNAMIC THERAPY;
   VISUAL-LOSS; 2ND EYE; SUBRETINAL HEMORRHAGE; VERTEPORFIN THERAPY;
   RADIATION-THERAPY; LASER TREATMENT
AB Purpose: To describe the natural history and progression of visual loss in eyes with untreated neovascular age-related macular degeneration (AMD).
   Design: Systematic review and meta-analysis.
   Participants: Four thousand three hundred sixty-two untreated neovascular AMD patients from published interventional studies.
   Methods: A systematic review of the literature from 1980 to August 2005 was performed. Studies reporting disease progression outcomes for untreated patients with neovascular AMD were included. Outcome measures were summarized using simple counts and means. Random effects meta-analyses were conducted and tests of heterogeneity were performed where appropriate.
   Main Outcome Measures: Changes in visual acuity (VA) loss, development of comorbidities, and fellow eye involvement.
   Results: Fifty-three primary studies were included. Nearly half of the studies (28) were randomized clinical trials. The quality of the studies was high, with over 80% providing level I or II evidence. Mean baseline VA among study patients was 0.64 logarithm of the minimum angle of resolution (logMAR) (similar to 20/87 Snellen). The mean VA change in logMAR progressed from 0.1 (1 line lost) at 3 months to 0.3 (2.7 lines lost) after 12 months and 0.4 (4 lines lost) after 24 months. The proportion of patients who developed severe vision loss (>6 lines) from baseline increased from 21.3% at 6 months to 41.9% by 3 years. The proportion of patients with VA worse than logMAR 1.0 (20/200 Snellen) increased from 19.7% at baseline to 75.7% by 3 years. Neovascular AMD developed in the fellow eye in 12.2% of patients by 12 months and in 26.8% by 4 years. Meta-analyses of vision outcome by subtype of neovascular AMD were not possible.
   Conclusions: A doubling of the visual angle of presenting VA may be expected to occur in the year after initial presentation in eyes with untreated neovascular AMD. No conclusions can be drawn as to the differences in rates of disease progression by neovascular AMD subtype. The diversity of reporting formats, paucity of long-term natural history data, and heterogeneity among the reported clinical studies impose limits to the clear understanding of long-term prognosis for visual function in neovascular AMD. Ophthalmology 2008;115:116-126 (c) 2008 by the American Academy of Ophthalmology.
C1 [Fahrbach, Kyle; Probst, Corey; Sledge, Isabella] United BioSource Corp, Medford, MA 02155 USA.
   [Wong, Tien] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Chakravarthy, Usha] Queens Univ Belfast, Inst Clin Sci, Ctr Visual Sci, Belfast, Antrim, North Ireland.
   [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
   [Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Ctr Visual Res, Sydney, NSW 2006, Australia.
   [Zlateva, Gergana; Buggage, Ronald] Pfizer Inc, New York, NY USA.
C3 United Biosource Corporation; Centre for Eye Research Australia;
   University of Melbourne; Queens University Belfast; University of
   Wisconsin System; University of Wisconsin Madison; University of Sydney;
   Westmead Institute for Medical Research; Pfizer
RP Sledge, I (通讯作者)，United BioSource Corp, 101 Stn Landing, Medford, MA 02155 USA.
RI Wong, Tien Yin/AAC-9724-2020; Mitchell, Paul/P-1498-2014
OI Wong, Tien Yin/0000-0002-8448-1264; Klein, Ronald/0000-0002-4428-6237;
   Chakravarthy, Usha/0000-0002-2606-3734
CR AHN SJ, 1995, VISION RES, V35, P1939, DOI 10.1016/0042-6989(94)00294-V
   [Anonymous], 1982, Br J Ophthalmol, V66, P745
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], 1998, Ophthalmology, V105, P11
   Arnold J, 1997, GRAEF ARCH CLIN EXP, V235, P208, DOI 10.1007/BF00941761
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   ATMACA LS, 1993, ANN OPHTHALMOL, V25, P412
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Baumal CR, 1997, OPHTHALMOLOGY, V104, P761, DOI 10.1016/S0161-6420(97)30236-X
   BAUN O, 1993, ACTA OPHTHALMOL, V71, P398
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1996, ARCH OPHTHALMOL-CHIC, V114, P1456, DOI 10.1001/archopht.1996.01100140654002
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   BRESSLER SB, 1983, RETINA-J RET VIT DIS, V3, P7, DOI 10.1097/00006982-198300310-00002
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   ENGLER C, 1994, BRIT J OPHTHALMOL, V78, P749, DOI 10.1136/bjo.78.10.749
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gudnadottir GS, 2005, ACTA OPHTHALMOL SCAN, V83, P333, DOI 10.1111/j.1600-0420.2005.00451.x
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Lim JI, 2006, RETINA-J RET VIT DIS, V26, pS17, DOI 10.1097/00006982-200607001-00005
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Papadaki T, 2003, RETINA-J RET VIT DIS, V23, P800, DOI 10.1097/00006982-200312000-00010
   Parodi MB, 2004, CLIN REHABIL, V18, P828, DOI 10.1191/0269215504cr801oa
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Pece A, 2000, ARCH OPHTHALMOL-CHIC, V118, P630
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Saric B, 2001, COLLEGIUM ANTROPOL, V25, P89
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Schneider U, 2005, ACTA OPHTHALMOL SCAN, V83, P141, DOI 10.1111/j.1600-0420.2005.00443.x
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Sharma S, 2004, ARCH OPHTHALMOL-CHIC, V122, P853, DOI 10.1001/archopht.122.6.853
   SINGERMAN LJ, 1989, GRAEF ARCH CLIN EXP, V227, P501, DOI 10.1007/BF02169440
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   UYAMA M, 1991, Nippon Ganka Gakkai Zasshi, V95, P1145
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   *VERT PHOT THER ST, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   YASSUR Y, 1982, RETINA-J RET VIT DIS, V2, P127, DOI 10.1097/00006982-198200230-00001
NR 91
TC 414
Z9 430
U1 1
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2008
VL 115
IS 1
BP 116
EP 126
DI 10.1016/j.ophtha.2007.03.008
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 248FK
UT WOS:000252137300018
PM 17675159
DA 2022-11-30
ER

PT J
AU Poor, SH
   Weissgerber, G
   Adams, CM
   Bhatt, H
   Browning, DJ
   Chastain, J
   Ciulla, TA
   Ferriere, M
   Gedif, K
   Glazer, LC
   Joondeph, BC
   Normand, G
   Sheth, V
   Watters, C
   Grosskreutz, CL
AF Poor, Stephen H.
   Weissgerber, Georges
   Adams, Christopher M.
   Bhatt, Harit
   Browning, David J.
   Chastain, James
   Ciulla, Thomas A.
   Ferriere, Michael
   Gedif, Kinfemichael
   Glazer, Louis C.
   Joondeph, Brian C.
   Normand, Guillaume
   Sheth, Veeral
   Watters, Christie
   Grosskreutz, Cynthia L.
TI A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib
   (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in
   Treatment-Experienced Subjects With Neovascular Age-Related Macular
   Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID THERAPY; RANIBIZUMAB; PAZOPANIB; OUTCOMES
AB PURPOOSE: To evaluate whether topical acrizanib (LHA510), a small-molecule vascular endothelial growth factor receptor inhibitor, could suppress the need for anti-vascular endothelial growth factor therapy over a 12-week period in patients with neovascular age-related macular degeneration. DESIGN : A phase 2 multicenter randomized double-masked, vehicle-controlled proof-of-concept study. METHODS: Trial includes n = 90 patients with active choroidal neovascularization due to neovascular age-related macular degeneration and under anti-vascular endothelial growth factor treatment. All patients received an intravitreal injection of ranibizumab at baseline and were retreated when there was evidence of disease recurrence (rescue). Patients were randomized 1:1 to receive topical LHA510 or vehicle for 12 weeks. Drops were administered twice a day for 8 weeks and then 3 times a day for the last 4 weeks. MAIN OUTCOME MEASURE: The primary outcome was the number of patients requiring rescue over 84 days of topical dosing. Key secondary outcome measures were time to first rescue, total number of ranibizumab injections, changes in central subfield thickness, and changes of visual acuity from baseline to day 84. RESULTS: The extended per protocol set included 70 patients of whom 25 of 33 patients in the LHA510 group (75.8%) and 25 of 37 patients in the placebo group (67.6%) required rescue by day 84 (P = .8466). Secondary and subgroup analysis did not support evidence of efficacy. Twenty-one of 46 patients administered LHA510 developed a reversible corneal haze that resolved with cessation of treatment and did not recur in patients restarted at once daily frequency. CONCLUSIONS: In spite of extensive optimization for topical efficacy, LHA510 failed to demonstrate clinical efficacy. Copyright (C) 2022 The Authors. Published by Elsevier Inc. All rights reserved.
C1 [Poor, Stephen H.; Grosskreutz, Cynthia L.] Novartis Inst Biomed Res, Translat Med Res, Cambridge, MA USA.
   [Adams, Christopher M.] Novartis Inst Biomed Res, Global Discovery Chem, Cambridge, MA USA.
   [Chastain, James] Novartis Inst Biomed Res, PK Sci, Cambridge, MA USA.
   [Ferriere, Michael] Novartis Inst Biomed Res, Clin Data Operat, Cambridge, MA USA.
   [Watters, Christie; Grosskreutz, Cynthia L.] Novartis Inst Biomed Res, Cambridge, MA 02139 USA.
   [Weissgerber, Georges; Normand, Guillaume] Clin Dev, Basel, Switzerland.
   [Gedif, Kinfemichael] Novartis Pharma Inc, Basel, Switzerland.
   [Bhatt, Harit] Retina & Macula Associates, Oak Forest, IL USA.
   [Bhatt, Harit] Univ Illinois, Chicago, IL USA.
   Charlotte Eye Ear Nose & Throat Associates, Charlotte, NC USA.
   Clearside Biomed Inc, Alpharetta, GA USA.
   Vitreo Retinal Associates, Grand Rapids, MI USA.
   Colorado Retina Associates, Denver, CO USA.
C3 Novartis; Novartis; Novartis; Novartis; Novartis; Novartis; University
   of Illinois System; University of Illinois Chicago; University of
   Illinois Chicago Hospital
RP Poor, SH (通讯作者)，Novartis Inst Biomed Res, Cambridge, MA 02139 USA.
EM stephen.poor@novartis.com
OI Adams, Christopher/0000-0002-5246-884X; Poor,
   Stephen/0000-0003-4374-1178; , Michael/0000-0003-3112-9328; Ciulla,
   Thomas/0000-0001-5557-6777
FU Novartis Pharmaceuticals, head-quarters Basel, Switzerland
FX Financial Disclosures: This study was conducted and funded under
   Novartis Pharmaceuticals, head-quarters Basel, Switzerland. S.H.P.,
   G.W., C.M.A., J.C., M.F., K.G., G.N., C.W., and C.L.G. are employees of
   Novartis Pharmaceuticals (Cambridge, MA; East Hanover, NJ; Fort Worth,
   TX; and Basel, Switzerland) . The other authors have no conflict of
   interest to disclose. All authors attest that they meet the current
   ICMJE criteria for authorship.
CR Adams CM, 2018, J MED CHEM, V61, P1622, DOI 10.1021/acs.jmedchem.7b01731
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Connolly Brian, 2006, Ophthalmol Clin North Am, V19, P381
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Danis R, 2014, BRIT J OPHTHALMOL, V98, P172, DOI 10.1136/bjophthalmol-2013-303117
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gadek T., 2011, TOPICAL DRUG DELIVER
   Joussen AM, 2019, BRIT J CLIN PHARMACO, V85, P347, DOI 10.1111/bcp.13794
   McLaughlin MM, 2013, JAMA OPHTHALMOL, V131, P1595, DOI 10.1001/jamaophthalmol.2013.5002
   Modern Retina, 2016, TOP TREATM NEOV AMD
   Ohr Pharmaceutical Inc, 2017, EFF SAF STUD SQUAL O
   Palanki MSS, 2008, J MED CHEM, V51, P1546, DOI 10.1021/jm7011276
   PanOptica, STUD PAN 90806 EYE D
   Rush JS, 2016, INVEST OPHTH VIS SCI, V57, P5864, DOI 10.1167/iovs.16-19952
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 21
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2022
VL 239
BP 180
EP 189
DI 10.1016/j.ajo.2022.02.019
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1V7CL
UT WOS:000806243000019
PM 35247334
OA hybrid
DA 2022-11-30
ER

PT J
AU Ogura, Y
   Jaffe, GJ
   Cheung, CMG
   Kokame, GT
   Iida, T
   Takahashi, K
   Lee, WK
   Chang, AA
   Mones, J
   D'Souza, D
   Weissgerber, G
   Gedif, K
   Koh, A
AF Ogura, Yuichiro
   Jaffe, Glenn J.
   Cheung, Chui Ming Gemmy
   Kokame, Gregg T.
   Iida, Tomohiro
   Takahashi, Kanji
   Lee, Won Ki
   Chang, Andrew A.
   Mones, Jordi
   D'Souza, Divya
   Weissgerber, Georges
   Gedif, Kinfemichael
   Koh, Adrian
TI Efficacy and safety of brolucizumab versus aflibercept in eyes with
   polypoidal choroidal vasculopathy in Japanese participants of HAWK
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE clinical trial; retina
ID MACULAR DEGENERATION; MANAGEMENT; DIAGNOSIS
AB Purpose To compare the efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK study. Design HAWK was a global, 2-year, randomised, double-masked, multicentre phase III trial in participants with neovascular age-related macular degeneration. Methods Of the Japanese participants with PCV, 39 received brolucizumab 6 mg and 30 received aflibercept 2 mg. After 3 monthly loading doses, brolucizumab-treated eyes received an injection every 12 weeks (q12w) but were adjusted to q8w if disease activity was detected. Aflibercept-treated eyes received fixed q8w dosing. Mean change in best-corrected visual acuity (BCVA), the proportion of participants on q12w, retinal thickness, retinal fluid changes and safety were assessed to Week 96. Results Mean change in BCVA (early treatment diabetic retinopathy study (ETDRS) letters) from baseline to week 48/week 96 was+10.4/+11.4 for brolucizumab and +11.6/+11.1 for aflibercept. For brolucizumab-treated eyes, the probability of only q12w dosing after loading through week 48 was 76%, and 68% through week 96. Fluid resolution was greater with brolucizumab than aflibercept: respective proportions of eyes with intraretinal fluid and/or subretinal fluid were 7.7% and 30% at week 48% and 12.8% and 16.7% at week 96. Brolucizumab exhibited an overall well-tolerated safety profile despite a higher rate of intraocular inflammation compared with aflibercept. Conclusion In Japanese eyes with PCV, brolucizumab q12w/q8w monotherapy resulted in robust and consistent BCVA gains that were comparable to q8w aflibercept dosing. Anatomical outcomes favoured brolucizumab over aflibercept, with 76% of brolucizumab participants maintained on q12w dosing after loading to week 48.
C1 [Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Cheung, Chui Ming Gemmy] SingHlth Duke NUS Acad Med Ctr, Singapore, Singapore.
   [Kokame, Gregg T.] Univ Hawaii, Sch Med, Honolulu, HI 96822 USA.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Takahashi, Kanji] Kansai Med Univ, Dept Ophthalmol, Moriguchi, Osaka, Japan.
   [Lee, Won Ki] Nune Eye Hosp, Seoul, South Korea.
   [Chang, Andrew A.] Univ Sydney, Sydney Eye Hosp, Sydney Retina Clin, Sydney, NSW, Australia.
   [Mones, Jordi] Inst Macula, Barcelona, Spain.
   [Mones, Jordi] Barcelona Macula Fdn, Barcelona, Spain.
   [D'Souza, Divya; Weissgerber, Georges; Gedif, Kinfemichael] Novartis Pharma AG, Basel, Switzerland.
   [Koh, Adrian] Camden Med Ctr, Singapore, Singapore.
C3 Nagoya City University; Duke University; University of Hawaii System;
   Tokyo Women's Medical University; Kansai Medical University; University
   of Sydney; Novartis
RP Ogura, Y (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi 4678601, Japan.
EM ogura@med.nagoya-cu.ac.jp
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160; Kokame, Gregg/0000-0001-7487-2205;
   Chang, Andrew/0000-0001-7555-1585; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU Novartis Pharma AG (Basel, Switzerland); Novartis
FX This study was funded by Novartis Pharma AG (Basel, Switzerland;
   award/grant number not applicable). Medical writing support was provided
   by Susan Simpson, PhD (Novartis Ireland Ltd.) and Apra Manral (Novartis
   Healthcare Pvt. Ltd., Hyderabad, India), in accordance with Good
   Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).The
   funding for this writing support was provided by Novartis.
CR Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Goldhardt R, 2019, CURR OPHTHALMOL REP, V7, P66, DOI 10.1007/s40135-019-00201-4
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Nicholas, 2016, INVEST OPHTHALMOL VI, V57
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
NR 19
TC 12
Z9 12
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2022
VL 106
IS 7
BP 994
EP 999
DI 10.1136/bjophthalmol-2021-319090
EA JUL 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2L7SE
UT WOS:000727738500001
PM 34301613
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Mrowicka, M
   Mrowicki, J
   Kucharska, E
   Smigielska, B
   Szaflik, JP
   Szaflik, J
   Majsterek, I
AF Mrowicka, Malgorzata
   Mrowicki, Jerzy
   Kucharska, Ewa
   Smigielska, Barbara
   Szaflik, Jacek Pawel
   Szaflik, Jerzy
   Majsterek, Ireneusz
TI The Role of Oxidative Stress and the Importance of miRNAs as Potential
   Biomarkers in the Development of Age-Related Macular Degeneration
SO PROCESSES
LA English
DT Review
DE age-related macular degeneration; oxidative stress; DNA repair genes;
   antioxidant capacity; microRNAs; biomarkers
ID BASE EXCISION-REPAIR; SINGLE-NUCLEOTIDE POLYMORPHISMS; MITOCHONDRIAL-DNA
   DAMAGE; CIRCULATING MIRNAS; GENETIC-VARIANTS; RISK-FACTOR; ASSOCIATION;
   MICRORNAS; OGG1; EXPRESSION
AB Age-related macular degeneration (AMD) is the primary cause of blindness in developed countries. With the progressive aging of the population, AMD is a significant ophthalmological problem in the population over 50 years of age. The etiology of AMD is known to be based on various biochemical, immunological and molecular pathways and to be influenced by a range of genetic and environmental elements. This review provides an overview of the pathophysiological role of oxidative stress and free radicals in the retina with a special focus on the DNA repair efficiency and enzymatic antioxidant defense. It also presents a correlation between miRNA profile and AMD, and indicates their involvement in inflammation, angiogenesis, increased oxidation of cellular components, enzymatic antioxidant capacity and DNA repair efficiency, which play particularly important roles in AMD pathogenesis. Gene silencing by miRNAs can induce changes in antioxidant enzymes, leading to a complex interplay between redox imbalance by free radicals and miRNAs in modulating cellular redox homeostasis.
C1 [Mrowicka, Malgorzata; Mrowicki, Jerzy; Majsterek, Ireneusz] Med Univ Lodz, Dept Clin Chem & Biochem, PL-90136 Lodz, Poland.
   [Kucharska, Ewa] Jesuit Univ Ignatianum, Dept Gerontol, Geriatr & Social Work, PL-31501 Krakow, Poland.
   [Smigielska, Barbara; Szaflik, Jacek Pawel] Med Univ Warsaw, SPKSO Ophthalm Hosp, Dept Ophthalmol, PL-00576 Warsaw, Poland.
   [Szaflik, Jerzy] Laser Eye Microsurg Ctr, Clin Jerzy Szaflik, PL-00215 Warsaw, Poland.
C3 Medical University Lodz; Medical University of Warsaw
RP Mrowicka, M; Majsterek, I (通讯作者)，Med Univ Lodz, Dept Clin Chem & Biochem, PL-90136 Lodz, Poland.
EM malgorzata.mrowicka@umed.lodz.pl; jerzy.mrowicki@umed.lodz.pl;
   ewa.kucharska@ignatianum.edu.pl; klinika@spkso.waw.pl;
   jacek.szaflik@wum.edu.pl; kontakt@okolaser.com.pl;
   ireneusz.majsterek@umed.lodz.pl
RI Kucharska, Ewa/H-5802-2018; Kucharska, Ewa/AAY-6470-2020
OI Kucharska, Ewa/0000-0001-8757-6958; Kucharska, Ewa/0000-0001-8757-6958;
   Majsterek, Ireneusz/0000-0001-6231-3334
FU Medical University of Lodz [503/5-108-05/503-51-001-19-00]
FX This work was supported by Medical University of Lodz
   (503/5-108-05/503-51-001-19-00).
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Axmann M, 2018, GENES-BASEL, V9, DOI 10.3390/genes9110533
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Baek JH, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0941-9
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Berger F, 2013, MUTAT RES-GEN TOX EN, V755, P115, DOI 10.1016/j.mrgentox.2013.04.020
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Boal AK, 2009, P NATL ACAD SCI USA, V106, P15237, DOI 10.1073/pnas.0908059106
   Catalanotto C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101712
   Chang YY, 2017, BIOMED RES-INDIA, V28, P7503
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cooke John P, 2015, Methodist Debakey Cardiovasc J, V11, P156, DOI 10.14797/mdcj-11-3-156
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Elbay A, 2019, SCAND J CLIN LAB INV, V79, P388, DOI 10.1080/00365513.2019.1637931
   Ertekin S, 2014, MOL VIS, V20, P1057
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hansen RD, 2009, MUTAT RES-FUND MOL M, V664, P13, DOI 10.1016/j.mrfmmm.2009.01.009
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hou LQ, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009234
   Hu J, 2010, BREAST CANCER RES TR, V124, P425, DOI 10.1007/s10549-010-0841-z
   Huang HL, 2017, CELL PHYSIOL BIOCHEM, V42, P889, DOI 10.1159/000478644
   Jadeja RN, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101336
   Jiang SQ, 2013, AGE, V35, P2435, DOI 10.1007/s11357-013-9512-4
   Johnston H, 2019, P NATL ACAD SCI USA, V116, P19753, DOI 10.1073/pnas.1909455116
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Konovalova J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236055
   Kowalski M, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-37
   Krzywinska O, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4525410
   Kucukgergin C, 2011, MINERVA UROL NEFROL, V63, P183
   Lee H, 2016, PROTEIN CELL, V7, P100, DOI 10.1007/s13238-015-0212-y
   Lenska-Mieciek M, 2020, NEUROL NEUROCHIR POL, V54, P323, DOI 10.5603/PJNNS.a2020.0042
   Li XH, 2020, AGING DIS, V11, P1219, DOI 10.14336/AD.2019.1126
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120157
   Lin ST, 2009, DIS MODEL MECH, V2, P178, DOI 10.1242/dmm.001065
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P12163, DOI 10.1073/pnas.1508426112
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Madelaine R, 2017, CELL REP, V20, P1533, DOI 10.1016/j.celrep.2017.07.051
   Mattes J, 2007, AM J RESP CELL MOL, V36, P8, DOI 10.1165/rcmb.2006-0227TR
   Mehdizadeh F., 2016, JAMSAT, V2, P257, DOI [10.18869/nrip.jamsat.2.3.257, DOI 10.18869/NRIP.JAMSAT.2.3.257]
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mrowicka M, 2017, ACTA OPHTHALMOL, V95, P530, DOI 10.1111/aos.13289
   Pan C, 2017, ONCOTARGET, V8, P68317, DOI 10.18632/oncotarget.19344
   Panshin DD, 2020, MOL BIOL+, V54, P213, DOI 10.1134/S0026893320010112
   Paradowska D., 2020, WORLD SCI NEWS, V139, P221
   Peng Y, 2014, INT J CANCER, V135, P2687, DOI 10.1002/ijc.28892
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pogue AI, 2018, CELL MOL NEUROBIOL, V38, P1021, DOI 10.1007/s10571-017-0572-3
   Pugazhendhi A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031170
   Ragusa M, 2013, MOL VIS, V19, P430
   Ren CD, 2017, CELL PHYSIOL BIOCHEM, V41, P1413, DOI 10.1159/000467941
   Renganathan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076325
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Rusca Nicole, 2011, Mol Biol Int, V2011, P437301, DOI 10.4061/2011/437301
   Saghar Y., 2014, MOL BIOCH DIAGN J, V1, P77
   Sangokoya C, 2010, BLOOD, V116, P4338, DOI 10.1182/blood-2009-04-214817
   Santos JC, 2014, INT J MOL SCI, V15, P17333, DOI 10.3390/ijms151017333
   Sato F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005540
   Sharma S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27527-6
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shin JY, 2017, BIOTECHNOL BIOPROC E, V22, P52, DOI 10.1007/s12257-016-0504-y
   Simonelli V, 2013, FREE RADICAL BIO MED, V63, P401, DOI 10.1016/j.freeradbiomed.2013.05.031
   Song R, 2010, METHODS MOL BIOL, V629, P285, DOI 10.1007/978-1-60761-657-3_18
   Sun CX, 2010, FREE RADICAL BIO MED, V48, P430, DOI 10.1016/j.freeradbiomed.2009.11.015
   Synowiec E, 2014, RETINA-J RET VIT DIS, V34, P38, DOI 10.1097/IAE.0b013e31829477d8
   Synowiec E, 2012, EXP EYE RES, V98, P58, DOI 10.1016/j.exer.2012.02.008
   Szaflik JP, 2013, MUTAT RES-GEN TOX EN, V753, P12, DOI 10.1016/j.mrgentox.2012.12.019
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Szemraj M, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.902366
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Tinaburri L, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9147326
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254
   Ulanczyk Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225750
   Upadhyay M, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101623
   Usui H, 2019, J CELL SCI, V132, DOI 10.1242/jcs.215798
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Wang AL, 2008, MOL VIS, V14, P644
   Wang AL, 2010, NEUROBIOL AGING, V31, P2002, DOI 10.1016/j.neurobiolaging.2008.10.019
   Wang C, 2015, INT J CLIN EXP PATHO, V8, P16036
   Wang Q, 2014, INVEST OPHTH VIS SCI, V55, P3986, DOI 10.1167/iovs.13-13076
   Wang Q, 2014, J BIOL CHEM, V289, P5654, DOI 10.1074/jbc.M113.526152
   Wang RX, 2018, CELL MOL LIFE SCI, V75, P3741, DOI 10.1007/s00018-018-2887-8
   Wang YM, 2013, CELL CYCLE, V12, P32, DOI 10.4161/cc.23051
   Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Wozniak K, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/827562
   Xu XY, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8445-y
   Xu Z, 2015, CELL CYCLE, V14, P269, DOI 10.4161/15384101.2014.980641
   Yan LL, 2015, J BIOL CHEM, V290, P23264, DOI 10.1074/jbc.M115.646950
   Yang SF, 2019, EXP THER MED, V17, P3530, DOI 10.3892/etm.2019.7359
   Ye JW, 2019, J PHARM ANAL, V9, P217, DOI 10.1016/j.jpha.2019.05.004
   Yu QQ, 2015, GENE, V561, P249, DOI 10.1016/j.gene.2015.02.039
   Zetterberg M, 2016, MATURITAS, V83, P19, DOI 10.1016/j.maturitas.2015.10.005
   Zhang D, 2019, THORAX, V74, P865, DOI 10.1136/thoraxjnl-2018-212994
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhang XM, 2012, CANCER RES, V72, P4707, DOI 10.1158/0008-5472.CAN-12-0639
   Zhang Y, 2010, MOL VIS, V16, P1754
NR 112
TC 1
Z9 1
U1 4
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9717
J9 PROCESSES
JI Processes
PD AUG
PY 2021
VL 9
IS 8
AR 1328
DI 10.3390/pr9081328
PG 16
WC Engineering, Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA UH5HK
UT WOS:000689961600001
OA gold
DA 2022-11-30
ER

PT J
AU Nidhi, B
   Mamatha, BS
   Padmaprabhu, CA
   Pallavi, P
   Vallikannan, B
AF Nidhi, Bhatiwada
   Mamatha, Bangera Sheshappa
   Padmaprabhu, Chamrajnagar Anantharajiah
   Pallavi, Prabhu
   Vallikannan, Baskaran
TI Dietary and lifestyle risk factors associated with age-related macular
   degeneration: A hospital based study
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; carotenoids; cross-sectional studies;
   lutein
ID BEAVER DAM; CATARACT-SURGERY; MACULOPATHY; PREVALENCE; POPULATION;
   CAROTENOIDS; CLASSIFICATION; EPIDEMIOLOGY; VEGETABLES; SMOKING
AB Aim : To establish the frequency, associations and risk factors for age-related macular degeneration (AMD) in hospital population of South India. Materials and Methods : In this cross-sectional hospital based study, 3549 subjects (2090 men and 1459 women) above 45 years of age were screened randomly for AMD. Participants underwent ocular evaluation and were interviewed for lifestyle variables and dietary intake of carotenoids by structured food frequency questionnaire. AMD was defined according to the international classifications and grading system. Results : Either form of AMD was detected in 77 (2.2%) participants. Of which, early and late AMD was present in 63 (1.8%) and 14 (0.4%) subjects, respectively. Binary logistic analysis showed that the incidence of AMD was significantly higher with increasing age (Odds ratio [OR] 1.17; 95% CI 1.13-1.22) and diabetes (OR 3.97; 95% CI 2.11-7.46). However, AMD was significant among heavy cigarette smokers (OR 5.58; 95% CI 0.88-7.51) and alcoholics (OR 4.85; 95% CI 2.45-12.22). Dietary lutein/zeaxanthin (L/Z) and -carotene intake were associated (P < 0.001) with the reduction in risk for AMD, with an OR of 0.38 and 0.65, respectively. Conclusions : Higher dietary intake of carotenoids, especially L/Z, was associated with lower risk for AMD. Risk of AMD is higher with increasing age and was prevalent among subjects with diabetes. Cessation of smoking and alcohol may reduce the risk of AMD in this population.
C1 [Nidhi, Bhatiwada; Mamatha, Bangera Sheshappa; Vallikannan, Baskaran] CSIR, Dept Mol Nutr, Cent Food Technol Res Inst, Mysore 570020, Karnataka, India.
   [Padmaprabhu, Chamrajnagar Anantharajiah; Pallavi, Prabhu] Sushrutha Eye Hosp, Dept Ophthalmol, Mysore, Karnataka, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   Central Food Technological Research Institute (CFTRI)
RP Vallikannan, B (通讯作者)，CSIR, Dept Mol Nutr, Cent Food Technol Res Inst, Mysore 570020, Karnataka, India.
EM baskaranv@cftri.res.in
RI Bangera, Mamatha/AAL-9883-2021
OI Bangera, Mamatha/0000-0002-4957-9098
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1986, OPHTHALMOLOGY, V93, P1183
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lakshminarayana R, 2005, J AGR FOOD CHEM, V53, P2838, DOI 10.1021/jf0481711
   Mamatha BS, 2011, INT J FOOD SCI TECH, V46, P315, DOI 10.1111/j.1365-2621.2010.02481.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Raju M, 2007, FOOD CHEM, V101, P1598, DOI 10.1016/j.foodchem.2006.04.015
   Rock CL, 2002, J NUTR, V132, p525S, DOI 10.1093/jn/132.3.525S
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 26
TC 15
Z9 16
U1 0
U2 18
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD DEC
PY 2013
VL 61
IS 12
BP 722
EP 727
DI 10.4103/0301-4738.120218
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA1NG
UT WOS:000330862400007
PM 24178404
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Tsai, TH
   Yang, CM
   Yang, CH
   Ho, TC
   Huang, JS
   Chen, MS
AF Tsai, T-H
   Yang, C-M
   Yang, C-H
   Ho, T-C
   Huang, J-S
   Chen, M-S
TI Transpupillary thermotherapy for the treatment of choroidal
   neovascularization in age-related macular degeneration in Taiwan
SO EYE
LA English
DT Article
DE transpupillary thermotherapy; age-related macular degeneration;
   choroidal neovascularization
ID PHOTODYNAMIC THERAPY; LASER PHOTOCOAGULATION; VERTEPORFIN THERAPY;
   CLINICAL-TRIALS; OCCULT; LESIONS; SIZE
AB Purpose To evaluate the therapeutic outcome and the recurrence of choroidal neovascularization ( CNV) secondary to age-related macular degeneration ( AMD) after transpupillary thermotherapy ( TTT) in light-brown retinas.
   Methods A retrospective, non-randomized study of 58 eyes in 55 patients with subfoveal CNV treated with TTT was conducted. Power settings were set about half the value for Caucasian eyes. The outcome was assessed with best-corrected visual acuity, fluorescein angiography, indocyanine green angiography, and fundoscopic examination.
   Results Forty-four membranes were occult, six classic, and eight mixed. Mean follow-up was 16.6 +/- 10.7 months ( range: 6-48 months). Membranes closed in 46 eyes. Iatrogenic complications included three subretinal haemorrhage, two retinal pigment epithelium tears, and two macular area cystic changes. In eyes with occult CNV, visual acuity improved in six ( 13.6%), 14 ( 31.8%) remained unchanged, and 24 ( 54.6%) deteriorated. For various CNV, average logMAR changes from baseline at last follow-up were 0.30 in occult, -0.08 in classic, and 0.59 in mixed ( P < 0.01). Thirty eyes experienced recurrence within 9.2 +/- 6.2 months ( range: 2-22 months). Cumulative recurrence rate was 45% at 12 months and 71% at 22 months, with no significant difference between occult and non-occult type CNV.
   Conclusions Transpupillary thermotherapy does not cure CNV secondary to AMD. High recurrence was found independent of CNV type. Most improved vision was found mostly in classic CNV. Complications associated with high energy level should be considered in light-brown retinas.
C1 Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei 100, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital
RP Yang, CM (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Chung Shan S Rd, Taipei 100, Taiwan.
EM chungmay@ha.mc.ntu.edu.tw
RI Yang, Chang-Hao/AAR-3759-2021; Yang, Chung-May/AAV-3737-2020
OI YANG, CHANG-HAO/0000-0002-4328-8716; TSAI, TZU-HSUN/0000-0001-8565-5150;
   YANG, CHUNG-MAY/0000-0003-4082-420X
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Atarashi T, 2004, EYE, V18, P615, DOI 10.1038/sj.eye.6700733
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rougier MB, 2005, RETINA-J RET VIT DIS, V25, P784, DOI 10.1097/00006982-200509000-00016
   Thach AB, 2003, ARCH OPHTHALMOL-CHIC, V121, P817, DOI 10.1001/archopht.121.6.817
NR 15
TC 2
Z9 2
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2007
VL 21
IS 6
BP 721
EP 726
DI 10.1038/sj.eye.6702312
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 176WR
UT WOS:000247116100006
PM 16543926
OA Bronze
DA 2022-11-30
ER

PT J
AU Studnicka, J
   Rihova, B
   Rencova, E
   Rozsival, P
   Dubska, Z
   Chrapek, O
   Kolar, P
   Kandrnal, V
   Demlova, R
   Pitrova, S
   Rehak, J
AF Studnicka, Jan
   Rihova, Barbora
   Rencova, Eva
   Rozsival, Pavel
   Dubska, Zora
   Chrapek, Oldrich
   Kolar, Petr
   Kandrnal, Vit
   Demlova, Regina
   Pitrova, Sarka
   Rehak, Jiri
TI Cost and Effectiveness of Therapy for Wet Age-Related Macular
   Degeneration in Routine Clinical Practice
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascular membrane;
   Ranibizumab; Pegaptanib; Photodynamic therapy with verteporfin;
   Cost-effectiveness
ID DOSING REGIMEN; RANIBIZUMAB; PEGAPTANIB; VERTEPORFIN
AB Purpose: Evaluation of the cost and effectiveness of therapy for patients with the wet form of age-related macular degeneration (AMD) in routine clinical practice. Methods: A retrospective multicentre evaluation of changes in the best-corrected visual acuity in applied kinds of therapy and a comparison with the cost of individual therapeutic procedures. Results: An overall total of 788 eyes of 763 patients with an average age of 73.2 +/- 8.6 years was evaluated for a 1-year minimum period. In the ranibizumab and pegaptanib therapy groups, a reduction of 1.3 letters (p = 0.303) and 1.4 letters (p = 0.197) was found, respectively. In the group of photodynannic therapy (PDT) with verteporfin, a reduction of 5.2 letters was achieved (p < 0.001). Under the conditions of routine practice in the Czech Republic, the annual cost is highest (EUR 5,467.63/patient) in patients with pegaptanib therapy. The annual cost in patients with ranibizumab therapy is lower by EUR 1,220.16. The cost is nearly half (EUR 2,783.65) in the group treated with PDT with verteporfin. Conclusion: An initiation of AMD therapy by ranibizumab is cost-effective as compared to pegaptanib. Both ranibizumab and pegaptanib are significantly more efficient as compared to PDT with verteporfin. Therapy with ranibizunnab and pegaptanib, as compared to PDT with verteporfin, prevents the loss of 1 line of vision on the ETDRS chart for EUR 1,225.98 and 2,286.18, respectively. Copyright (C) 2013 S. Karger AG, Basel
C1 [Studnicka, Jan; Rencova, Eva; Rozsival, Pavel] Charles Univ Prague, Fac Med Hradec Kralove, Dept Ophthalmol, Hradec Kralove, Czech Republic.
   [Studnicka, Jan; Rencova, Eva; Rozsival, Pavel] Univ Hosp, Hradec Kralove, Czech Republic.
   [Rihova, Barbora; Demlova, Regina] Masaryk Univ, Fac Med, Dept Pharmacol, Brno, Czech Republic.
   [Kandrnal, Vit] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic.
   [Kandrnal, Vit] Masaryk Univ, Fac Sci, CS-61137 Brno, Czech Republic.
   [Kolar, Petr] Univ Hosp, Dept Ophthalmol, CZ-62500 Brno, Czech Republic.
   [Dubska, Zora] Charles Univ Prague, Fac Med 1, Dept Ophthalmol, Olomouc, Czech Republic.
   [Dubska, Zora] Gen Univ Hosp, Olomouc, Czech Republic.
   [Pitrova, Sarka] Private Eye Clin, Prague, Czech Republic.
   [Chrapek, Oldrich; Rehak, Jiri] Univ Hosp, Dept Ophthalmol, Olomouc, Czech Republic.
C3 Charles University Prague; Masaryk University Brno; Institute of
   Biostatistics & Analyses; Masaryk University Brno; Masaryk University
   Brno; University Hospital Brno; Charles University Prague; General
   University Hospital Prague; University Hospital Olomouc; University
   Hospital Olomouc
RP Kolar, P (通讯作者)，Univ Hosp, Dept Ophthalmol, Jihlavska 340-20, CZ-62500 Brno, Czech Republic.
EM pe-kolar@seznam.cz
RI Demlova, Regina/AAI-2232-2020; Rihova, Barbora/AAU-9696-2020; Studnicka,
   Jan/K-2875-2017; Rihova, Barbora/ABD-9904-2021; Studnička,
   Jan/AAC-4127-2022; Rozsival, Pavel/N-9978-2017
OI Studnicka, Jan/0000-0002-9911-4379; Rihova, Barbora/0000-0003-3835-9062;
   Rozsival, Pavel/0000-0001-6628-7954; Kolar, Petr/0000-0003-3709-4648
FU Novartis Pharma AG
FX A grant from Novartis Pharma AG was received for the national registry
   AMADEUS.
CR Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Meads C, 2003, Health Technol Assess, V7, pv
   Meads C, 2001, 24 WMHTAC U BIRM DEP
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 21
TC 6
Z9 7
U1 0
U2 13
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 230
IS 1
BP 34
EP 42
DI 10.1159/000350802
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 178RW
UT WOS:000321466100005
PM 23751929
DA 2022-11-30
ER

PT J
AU Atmaca, LS
   Batioglu, F
AF Atmaca, Leyla S.
   Batioglu, Figen
TI Long-term efficacy of transpupillary thermotherapy for subfoveal
   choroidal neovascularization in age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE transpupillary thermotherapy; CNV; subfoveal CNV; age-related macular
   degeneration
AB AIM: To determine the long-term efficacy of transpupillary thermotherapy (TTT) in the treatment of subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
   METHODS: Fourteen eyes of 14 patients with subfoveal CNV secondary to AMD were treated with diode laser (810nm) TTT. The mean age was 67.1 years. Complete ophthalmic examination was done, color fundus photographs and macular optical coherence tomography scans were taken, fluorescein and indocyanine green angiography were performed during initial and at subsequent follow-up examinations. Treatment was given in one minute using 2-3mm spot sizes, and laser power settings were between 650-800mW. The follow-up period was between 5 and 64 months and the mean was 28.6 months.
   RESULTS: There was subfoveal classic CNV in 10, predominantly classic CNV in 2, minimally classic CNV in 1, and type 1 occult CNV in one of the fourteen eyes. Four patients were noted to have post-treatment hemorrhage which was absorbed in a short time. Macular non-perfusion occurred in one patient immediately after treatment. Most of the eyes demonstrated a decrease in exudation during the follow-up. With a mean follow-up of 28.6 months, visual acuity improved in 5, remained the same in 8 and decreased in 1 of the 14 eyes.
   CONCLUSION: Transpupillary thermotherapy is shown to close subfoveal CNV with rapid resolution of subretinal fluid while maintaining visual function in patients with AMD. It may be performed as an alternative laser treatment in classic and predominantly classic subfoveal choroidal neovascularization due to AMD.
C1 [Atmaca, Leyla S.; Batioglu, Figen] Ankara Univ, Fac Med, Dept Ophthalmol, TR-06100 Ankara, Turkey.
C3 Ankara University
RP Atmaca, LS (通讯作者)，Gazi Mustafa Kemal Bulvari 23-1, TR-06440 Ankara, Turkey.
EM leylaatmaca@ttmail.com
RI Batıoğlu, Figen/AAQ-3727-2020
OI Batıoğlu, Figen/0000-0002-5834-7512
CR Agarwal Manisha, 2004, Indian Journal of Ophthalmology, V52, P45
   Ahuja R M, 2001, Semin Ophthalmol, V16, P81, DOI 10.1076/soph.16.2.81.4215
   Algvere P V, 2001, Semin Ophthalmol, V16, P90, DOI 10.1076/soph.16.2.90.4210
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Auer C, 2001, INVEST OPHTH VIS SCI, V42, pS442
   FU T, 2007, INT J OPHTHALMOL, V7, P1636
   Fuisting BH, 2001, INVEST OPHTH VIS SCI, V42, pS443
   Kim J E, 2001, Semin Ophthalmol, V16, P86, DOI 10.1076/soph.16.2.86.4212
   LI WS, 2002, INT J OPHTHALMOL, V2, P24
   Miller-Rivero NE, 2000, INVEST OPHTH VIS SCI, V41, pS179
   Newsom RSB, 2005, OPHTHAL SURG LAS IM, V36, P94, DOI 10.3928/1542-8877-20050301-03
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Petrone S, 2000, INVEST OPHTH VIS SCI, V41, pS320
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Zhang X, 2007, INT J OPHTHALMOL, V7, P1674
NR 17
TC 0
Z9 0
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2009
VL 2
IS 1
BP 53
EP 56
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664BK
UT WOS:000282933700013
DA 2022-11-30
ER

PT J
AU Goverdhan, SV
   Lochhead, J
AF Goverdhan, S. V.
   Lochhead, J.
TI Submacular haemorrhages after intravitreal bevacizumab for large occult
   choroidal neovascularisation in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; AVASTIN; RANIBIZUMAB; INJECTION
AB Objective: To report the occurrence of submacular haemorrhages following intravitreal bevacizumab for occult choroidal neovascularisation (CNV) in age-related macular degeneration (AMD).
   Methods: Retrospective chart review of 53 patients with occult CNV who had received intravitreal bevacizumab 1.25 mg. Analysis was done in three groups based on mean CNV lesion size: < 10 mm(2) (n=17), >= 10 to < 15 mm(2) (n=17) and >= 15 mm(2) (n=18). ETDRS derived acuity, incidence of fresh macular haemorrhages and haemorrhage size (pre-existing or fresh) were documented and analysed.
   Results: The median injection number was 1.0 ( range: 1 to 3) with a minimum follow-up of 6 months ( range: 4 to 12 months). The mean presenting size of occult lesions was 13.4 mm(2) (range: 3.0 to 30.3 mm(2)). Submacular fresh haemorrhages were seen in the absence of preexisting haemorrhage in four out of 10 patients in the >= 15 mm(2) CNV size group (40%) but none in the remaining groups with CNV sizes,15 mm(2) (OR=20.1, p=0.01, 95% Cl=0.99 to 409.3). These haemorrhages developed at a median of 14 days.
   Conclusions: Submacular haemorrhages seem to be a significant adverse event following intravitreal bevacizumab in large occult choroidal neovascularisation and may affect visual outcomes. Prospective studies are required to establish the optimal dose of bevacizumab for larger lesion sizes or to identify the most appropriate anti-VEGF agent in large occult CNV with fibrovascular and serous PED lesions.
C1 [Goverdhan, S. V.; Lochhead, J.] St Marys Hosp, Dept Ophthalmol, Newport PO30 5TG, Isle Wight, England.
RP Lochhead, J (通讯作者)，St Marys Hosp, Dept Ophthalmol, Newport PO30 5TG, Isle Wight, England.
EM lochhead@iow.nhs.uk
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Handler Joel, 2006, J Clin Hypertens (Greenwich), V8, P526, DOI 10.1111/j.1524-6175.2006.05147.x
   Iguchi Y, 2006, BRIT J OPHTHALMOL, V90, P1256, DOI 10.1136/bjo.2006.099259
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   Kim J E, 2001, Semin Ophthalmol, V16, P86, DOI 10.1076/soph.16.2.86.4212
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Recchia FM, 2006, RETINA-J RET VIT DIS, V26, P1042, DOI 10.1097/01.iae.0000254894.94013.d8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 14
TC 23
Z9 24
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2008
VL 92
IS 2
BP 210
EP 212
DI 10.1136/bjo.2007.127902
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 256GH
UT WOS:000252715200012
PM 17965104
DA 2022-11-30
ER

PT J
AU Desideri, LF
   Barra, F
   Ferrero, S
   Traverso, CE
   Nicolo, M
AF Desideri, Lorenzo Ferro
   Barra, Fabio
   Ferrero, Simone
   Traverso, Carlo Enrico
   Nicolo, Massimo
TI Clinical efficacy and safety of ranibizumab in the treatment of wet
   age-related macular degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Ranibizumab; macular degeneration; retina; OCT; angiogenesis; targeted
   therapy
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PLUS RANIBIZUMAB; 2.0 MG
   RANIBIZUMAB; VEGF TRAP-EYE; INTRAVITREAL INJECTION; CHOROIDAL
   NEOVASCULARIZATION; INTRAOCULAR PHARMACOKINETICS; PHOTODYNAMIC THERAPY;
   ANTIBODY FRAGMENT; PEGAPTANIB SODIUM
AB Introduction: Although several approaches have been studied for treating wet age-related macular degeneration (w-AMD), currently, the most effective strategy in the management of this visual disorder is represented by anti-VEGF drugs. Among them, ranibizumab (RBZ) is widely adopted in clinical practice for treating w-AMD. Areas covered: VEGF (vascular endothelial growth factor) is a hypoxia-induced growth factor promoting neoangiogenesis, which has been correlated to the pathogenesis of w-AMD. RBZ is a humanized, recombinant, monoclonal antibody fragment (Fab), which binds all the isoform of VEGF-A and, therefore, exerts an inhibitory activity on the growth of new pathological vessels leading to the reabsorption of VEGF-related macular edema. The pivotal trials ANCHOR and MARINA revealed its clinical efficacy and good safety profile for treating w-AMD, leading ultimately to its FDA approval. Further trials have analyzed the best dosage and regimen modality, reporting RBZ at 0.5 mg with a 'pro re nata' regimen (PRN) to be non-inferior to the 0.5 mg formulation administered monthly. The treat-to-extend (TAE) regimen has also been investigated, demonstrating encouraging results in terms of clinical efficacy and nonetheless, it was proven to be a well-tolerated option with the possibility of reducing the treatment burden for the patients. Conclusions: RBZ has been proven to be an effective anti-VEGF agent for treating w-AMD; however, more optimal therapeutic regimens and drug delivery systems are being investigated in order to improve patients' compliance and treatment burden.
C1 [Desideri, Lorenzo Ferro; Traverso, Carlo Enrico; Nicolo, Massimo] IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Genoa, Italy.
   [Desideri, Lorenzo Ferro; Barra, Fabio; Ferrero, Simone; Traverso, Carlo Enrico; Nicolo, Massimo] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
   [Barra, Fabio; Ferrero, Simone] IRCCS Osped Policlin San Martino, Acad Unit Obstet & Gynecol, Genoa, Italy.
   [Nicolo, Massimo] Macula Onlus Fdn, Genoa, Italy.
C3 University of Genoa
RP Ferrero, S (通讯作者)，IRCCS AOU San Martino IST, Acad Unit Obstet & Gynecol, Largo R Benzi 10, I-16132 Genoa, Italy.
EM simoneferrero@me.com
RI Barra, Fabio/E-2539-2017; Desideri, Lorenzo Ferro/AAM-5368-2020
OI Barra, Fabio/0000-0003-4117-6603; Ferrero, Simone/0000-0003-2225-5568
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Apte RS, 2008, EXPERT OPIN PHARMACO, V9, P499, DOI [10.1517/14656566.9.3.499, 10.1517/14656566.9.3.499 ]
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Ayata A, 2008, CLIN EXP OPHTHALMOL, V36, P390, DOI 10.1111/j.1442-9071.2008.001742.x
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen YFN, 2016, RETINA-J RET VIT DIS, V36, P272, DOI 10.1097/IAE.0000000000000691
   Christoforidis JB, 2017, INVEST OPHTH VIS SCI, V58, P5636, DOI 10.1167/iovs.17-22431
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Doggrell SA, 2005, EXPERT OPIN PHARMACO, V6, P1421, DOI 10.1517/14656566.6.8.1421
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kawczyk-Krupka A, 2015, PHOTODIAGN PHOTODYN, V12, P161, DOI 10.1016/j.pdpdt.2015.03.007
   Keating GM, 2014, DRUGS, V74, P1891, DOI 10.1007/s40265-014-0302-9
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Korf BR, 2013, HAND CLINIC, V111, P333, DOI 10.1016/B978-0-444-52891-9.00039-7
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lai TYY, 2015, ASIA-PAC J OPHTHALMO, V4, P321, DOI 10.1097/APO.0000000000000146
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lobo ED, 2004, J PHARM SCI-US, V93, P2645, DOI 10.1002/jps.20178
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Motohashi R, 2017, OPHTHALMIC RES, V58, P209, DOI 10.1159/000478705
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Parodi MB, 2016, DEV OPHTHALMOL, V55, P330, DOI 10.1159/000434704
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.OPHTHA.2006.01.027
   Ruiz Ramos J, 2015, Arch Soc Esp Oftalmol, V90, P566, DOI 10.1016/j.oftal.2015.07.018
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schwartz SG, 2014, EXPERT OPIN DRUG DEL, V11, P61, DOI 10.1517/17425247.2013.859135
   Shahar J., 2006, RETINA, V26, P262, DOI DOI 10.1097/00006982-200603000-00002
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Stewart MW, 2013, EXPERT REV CLIN PHAR, V6, P103, DOI [10.1586/ECP.12.81, 10.1586/ecp.12.81]
   Vottonen P, 2016, ACTA OPHTHALMOL, V94, P652, DOI 10.1111/aos.13185
   Wei CX, 2016, ADV EXP MED BIOL, V854, P103, DOI 10.1007/978-3-319-17121-0_15
   Wei Y, 2018, MEDICINE, V97, DOI DOI 10.1097/MD.0000000000010422
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
   Yasunari T, 2000, LANCET, V356, P988, DOI 10.1016/S0140-6736(00)02716-1
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Yu LL, 2008, INVEST OPHTH VIS SCI, V49, P522, DOI 10.1167/iovs.07-1175
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zhang Y, 2014, OPHTHALMOLOGY, V121, P2237, DOI 10.1016/j.ophtha.2014.05.012
NR 97
TC 18
Z9 18
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD AUG 3
PY 2019
VL 19
IS 8
BP 735
EP 751
DI 10.1080/14712598.2019.1627322
EA JUN 2019
PG 17
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA IO0LE
UT WOS:000472285900001
PM 31180279
DA 2022-11-30
ER

PT J
AU Razavi, H
   Baglin, E
   Sharangan, P
   Caruso, E
   Tindill, N
   Griffin, S
   Guymer, R
AF Razavi, Hessom
   Baglin, Elizabeth
   Sharangan, Pyrawy
   Caruso, Emily
   Tindill, Nicole
   Griffin, Susan
   Guymer, Robyn
TI Gaming to improve vision: 21st century self-monitoring for patients with
   age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; medical device; self-monitoring
ID RANIBIZUMAB; DEVICES; SYSTEM; IMPACT
AB ImportanceImproved vision self-monitoring tools are required for people at risk of neovascular complications from age related macular degeneration (AMD).
   Backgroundto report the self-monitoring habits of participants with intermediate AMD using the Amsler grid chart, and the use of personal electronic devices and gameplay in this over 50year old cohort.
   Designsingle-centre descriptive study carried out at the Centre for Eye Research (CERA), Melbourne, Australia.
   Participants140 participants over 50years of age, with a diagnosis of intermediate AMD and best-corrected visual acuity (BCVA) of 6/12 in each eye.
   Methodsstructured questionnaire survey of participants who were enrolled in natural history of AMD studies at CERA.
   Main outcome measuresfrequency of vision self-monitoring using the Amsler grid chart, and frequency of general use of personal electronic devices and gameplay.
   ResultsOf 140 participants with mean age of 70.5years, 83.6% used an Amsler grid chart, but only 39.3% used it once per week. Most participants (91.4%) used one or more personal electronic devices. Of these, over half (54.7%) played games on them, among whom 39% played games once a day. Of participants aged 50-69years, 92% (95%CI 85.1-98.9) were willing to play a game to monitor their vision, compared to 78% (95%CI 69.0-87.0) of those aged 70years and older (P<0.05).
   Conclusions and Relevancea large proportion of AMD patients already use personal electronic devices. Gamification techniques are likely to increase compliance with self-monitoring, leading to earlier detection in the next generation of patients with neovascular AMD.
C1 [Razavi, Hessom; Baglin, Elizabeth; Sharangan, Pyrawy; Caruso, Emily; Tindill, Nicole; Griffin, Susan; Guymer, Robyn] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Razavi, Hessom; Baglin, Elizabeth; Sharangan, Pyrawy; Caruso, Emily; Tindill, Nicole; Guymer, Robyn] Univ Melbourne, Dept Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Razavi, H (通讯作者)，Lions Eye Inst, 2 Verdun St, Nedlands, WA 6009, Australia.
EM hessomrazavi@lei.org.au
OI Razavi, Hessom/0000-0002-2232-8731; Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council of Australia [GNT1103013]
FX This study is supported by National Health and Medical Research Council
   of Australia grant fellowship GNT1103013 (RGH). CERA receives
   operational infrastructure support from the Victorain Government.
CR AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Razavi H, 2017, AUST J RURAL HEALTH, V25, P45, DOI 10.1111/ajr.12277
   Schmier JK, 2012, AM J OPHTHALMOL, V154, P675, DOI 10.1016/j.ajo.2012.04.017
   Trevino Richard, 2008, Optometry, V79, P397, DOI 10.1016/j.optm.2007.09.017
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wu ZC, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.13
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 15
TC 6
Z9 6
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2018
VL 46
IS 5
BP 480
EP 484
DI 10.1111/ceo.13097
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM8QJ
UT WOS:000438497300005
PM 29131493
OA Green Published
DA 2022-11-30
ER

PT J
AU Shinomiya, K
   Mukai, A
   Ito, E
   Yoneda, K
   Ueno, M
   Sotozono, C
   Kinoshita, S
   Hamuro, J
AF Shinomiya, Katsuhiko
   Mukai, Atsushi
   Ito, Eiko
   Yoneda, Kazuhito
   Ueno, Morio
   Sotozono, Chie
   Kinoshita, Shigeru
   Hamuro, Junji
TI Potential participation of CTRP6, a complement regulator, in the
   pathology of age related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE C1q and tumor necrosis factor related protein (CTRP) 6; Age-related
   macular degeneration; Drusen; Alternative pathway of complement
   activation
ID FACTOR-H POLYMORPHISM; PROTEIN; FAMILY; GENE; ASSOCIATIONS; MACROPHAGES;
   ACTIVATION; EXPRESSION; MUTATION; DISEASE
AB Purpose To investigate the localized expression of C1q/tumor necrosis factor related protein (CTRP) 6 in human age-related macular degeneration (AMD) retinal tissues. Experimental study design 4 AMD and 3 non-AMD whole eyes of Caucasian donors were used. Eyecups were excised at Eye Bank CorneaGen, Inc. Methods To elucidate the effects of CTRP6, C3b was measured by an enzyme-linked immunosorbent-like assay. CFB versus CTRP6 competitive binding assay was applied to clarify the inhibition by CTRP6 of C3bBb complex formation. The cornea, iris, lens, and vitreous were removed and the eyes were cut into a posterior eye-cup including the retina, choroid, and sclera. Six-mu m-thick serial sections of frozen samples underwent hematoxylin-eosin (HE) staining and indirect immunohistochemical staining using primary antibodies, anti-CTRP6, -CTRP5, -CTRP10, -Complement factor H (CFH) and -Clusterin (CLU). Results The two in vitro studies confirmed that CTRP6 has an inhibitory effect on alternative pathways of complement (APC) function and that the molecular target of CTRP6 is the inhibition of the formation of C3bBb. Localized expression for CTRP6 and CFH was found in the drusen of the AMD eyes, both associated with APC inhibition, CLU associated with membrane-attack complex (MAC) inhibition, and CTRP5 associated with retinal degeneration. Conclusion The localized expression of CTRP6 in the drusen of AMD eyes may open a new insight into the possible involvement of APC regulatory factors in the pathogenesis of AMD, together with the known CFH so far analyzed solely as an APC inhibitor.
C1 [Shinomiya, Katsuhiko; Mukai, Atsushi; Ito, Eiko; Yoneda, Kazuhito; Ueno, Morio; Sotozono, Chie; Hamuro, Junji] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.
   [Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Frontier Med Sci & Technol Ophthalmol, Kyoto, Japan.
   [Shinomiya, Katsuhiko] Santen Pharmaceut Co Ltd, Prod Dev Div, Pharmacol Pharmaceut & Pharmacol Dept, Nara, Japan.
C3 Kyoto Prefectural University of Medicine; Kyoto Prefectural University
   of Medicine; Santen Pharmaceutical Co Ltd
RP Hamuro, J (通讯作者)，Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.
EM jshimo@koto.kpu-m.ac.jp
FU Program for the Promotion of Science from Ministry of Education,
   Culture, Sports, Science and Technology (MEXT) Japan [KAKENHI
   JP15K15638]
FX The authors greatly thank Masanori Murayama and Yoichiro Iwakura for
   their valuable instructions to analyze the biochemical functions of
   CTRP6. The authors also wish to thank John Bush for reviewing the
   manuscript and Tomoko Fujita for her excellent assistance. Hamuro J
   received a research grant from The Program for the Promotion of Science
   from Ministry of Education, Culture, Sports, Science and Technology
   (MEXT) Japan (KAKENHI JP15K15638) and all the authors greatly appreciate
   the funding support. The funder played no role in the conduct of the
   study or in the writing of the manuscript.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Armento A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168727
   Atkinson JP, 2007, J EXP MED, V204, P1245, DOI 10.1084/jem.20070664
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Chavali VRM, 2011, HUM MOL GENET, V20, P2000, DOI 10.1093/hmg/ddr080
   Choudhary M, 2019, ADV EXP MED BIOL, V1185, P9, DOI 10.1007/978-3-030-27378-1_2
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   Dinculescu A, 2015, INVEST OPHTH VIS SCI, V56, P6971, DOI 10.1167/iovs.15-17166
   Dolgin E, 2021, NAT BIOTECHNOL, V39, P123, DOI 10.1038/s41587-021-00828-4
   Dong XZ, 2018, BIOMED PHARMACOTHER, V103, P844, DOI 10.1016/j.biopha.2018.04.112
   Ebeling MC, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040789
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Falgarone G, 2009, ADV CANCER RES, V104, P139, DOI 10.1016/S0065-230X(09)04008-1
   Fan RH, 2016, BIOCHEM BIOPH RES CO, V475, P356, DOI 10.1016/j.bbrc.2016.05.013
   FINK B, 1979, J HISTOCHEM CYTOCHEM, V27, P1299, DOI 10.1177/27.9.383832
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Ghai R, 2007, IMMUNOBIOLOGY, V212, P253, DOI 10.1016/j.imbio.2006.11.001
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Iwata Y, 2021, J CANCER, V12, P1161, DOI 10.7150/jca.46765
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kim MJ, 2012, J KOREAN MED SCI, V27, P465, DOI 10.3346/jkms.2012.27.5.465
   Kimura Y, 2008, BLOOD, V111, P732, DOI 10.1182/blood-2007-05-089821
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   La Cunza N, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.142254
   Lee W, 2010, FEBS LETT, V584, P968, DOI 10.1016/j.febslet.2010.01.040
   Lei H, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0492-7
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   Murayama MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9483
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Otsuki Y, 2021, EXP EYE RES, V205, DOI 10.1016/j.exer.2021.108496
   Schaffler A, 2012, TRENDS ENDOCRIN MET, V23, P194, DOI 10.1016/j.tem.2011.12.003
   Seldin MM, 2014, REV ENDOCR METAB DIS, V15, P111, DOI 10.1007/s11154-013-9255-7
   Sfyroera G, 2005, J IMMUNOL, V174, P2143, DOI 10.4049/jimmunol.174.4.2143
   Shinomiya K, 2013, BRIT J OPHTHALMOL, V97, P362, DOI 10.1136/bjophthalmol-2012-302631
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Wong GW, 2008, BIOCHEM J, V416, P161, DOI 10.1042/BJ20081240
   Wong GW, 2004, P NATL ACAD SCI USA, V101, P10302, DOI 10.1073/pnas.0403760101
   Xie YH, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173755
   Xu ED, 2020, CLIN EXP PHARMACOL P, V47, P1203, DOI 10.1111/1440-1681.13289
   Yamawaki T, 2016, INVEST OPHTH VIS SCI, V57, P5945, DOI 10.1167/iovs.16-20604
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhuo XZ, 2019, BIOSCI BIOTECH BIOCH, V83, P2000, DOI 10.1080/09168451.2019.1634997
NR 52
TC 0
Z9 0
U1 2
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2022
VL 66
IS 3
BP 326
EP 334
DI 10.1007/s10384-022-00913-4
EA APR 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0V8UO
UT WOS:000781207700001
PM 35397057
DA 2022-11-30
ER

PT J
AU Thomas, A
   Harikrishnan, PM
   Krishna, AK
   Palanisamy, P
   Gopi, VP
AF Thomas, Anju
   Harikrishnan, P. M.
   Krishna, Adithya K.
   Palanisamy, P.
   Gopi, Varun P.
TI A novel multiscale convolutional neural network based age-related
   macular degeneration detection using OCT images
SO BIOMEDICAL SIGNAL PROCESSING AND CONTROL
LA English
DT Article
DE Age-related macular degeneration; Multiscale CNN; Sigmoid activation
   function
ID COHERENCE TOMOGRAPHY IMAGES; CLASSIFICATION; EDEMA; DISEASE; PREVALENCE;
   BURDEN
AB Age-related macular degeneration (AMD) is an ocular disorder that affects the elderly. The prevalence of AMD is growing due to the aging population in society; hence early diagnosis is necessary to prevent vision loss in the elderly. Arranging a detailed eye screening system for detecting AMD is a very challenging process. This paper proposes a novel multiscale convolutional neural network (CNN) architecture for accurate diagnosis of AMD. The architecture proposed is a multiscale CNN with seven convolutional layers for classifying AMD or normal images. The multiscale convolution layer enables a large number of local structures to be generated with various filter sizes. In this proposed network, the sigmoid function is used as the classifier. The proposed CNN network is trained on the Mendeley dataset and tested on four datasets, namely Mendeley, OCTID, Duke, SD-OCT Noor dataset and achieved an accuracy of 99.73%, 98.08%, 96.66%, and 97.95% respectively. Comparison with alternative methods yielded results that exhibit the efficiency of the proposed algorithm in AMD detection. Even if the proposed model is trained only on the Mendeley dataset, it achieved good detection accuracy when tested with other datasets. This indicates the proposed model?s ability to classify AMD/Normal images from other datasets. Comparison with other approaches produced results that exhibit the efficiency of the proposed algorithm in detecting AMD. The proposed architecture can be applied in rapid screening of the eye for the early detection of AMD. Due to less complexity and fewer learnable parameters, the proposed CNN can be implemented in real-time.
C1 [Thomas, Anju; Harikrishnan, P. M.; Krishna, Adithya K.; Palanisamy, P.; Gopi, Varun P.] Natl Inst Technol Tiruchirappalli, Dept Elect & Commun Engn, Tiruchirappalli 620015, Tamil Nadu, India.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Tiruchirappalli
RP Palanisamy, P (通讯作者)，Natl Inst Technol Tiruchirappalli, Dept Elect & Commun Engn, Tiruchirappalli 620015, Tamil Nadu, India.
EM 408119001@nitt.edu; 408119002@nitt.edu; 108118004@nitt.edu;
   palan@nitt.edu; varun@nitt.edu
RI H M, Prof.Omprakash/AAC-4394-2022; PONNUSAMY, PALANISAMY/AAM-5285-2020;
   M, Harikrishnan P/AAR-3451-2021; Gopi, Varun P/S-3943-2019; Thomas,
   Anju/ABF-6145-2021
OI PONNUSAMY, PALANISAMY/0000-0003-3687-5944; M, Harikrishnan
   P/0000-0003-1844-9503; Gopi, Varun P/0000-0001-5593-3949; Thomas,
   Anju/0000-0002-2178-0531; K KRISHNA, ADITHYA/0000-0002-2284-703X
FU Science and Engineering Research Board (SERB), Government of India
   [SERB/F/11639/20182019]
FX This research work is funded by Science and Engineering Research Board
   (SERB), Government of India, Grant No. SERB/F/11639/20182019 dated 26
   February 2019.
CR Alqudah AM, 2020, MED BIOL ENG COMPUT, V58, P41, DOI 10.1007/s11517-019-02066-y
   Arabi PM, 2018, IOP CONF SER-MAT SCI, V310, DOI 10.1088/1757-899X/310/1/012096
   Bhatia KK, 2020, RETINA-J RET VIT DIS, V40, P1549, DOI 10.1097/IAE.0000000000002640
   Bouvrie J., 2006, NEURAL NETS
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   Das V, 2019, BIOMED SIGNAL PROCES, V54, DOI 10.1016/j.bspc.2019.101605
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DeBuc DC, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070996
   Dumar A.T.H., 2019, CHOROIDAL NEOVASCULA
   Fang LY, 2019, J VIS COMMUN IMAGE R, V59, P327, DOI 10.1016/j.jvcir.2019.01.022
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Garcia-Layana A, 2017, OPTICAL COHERENCE TO
   Gayathri S, 2020, BIOMED SIGNAL PROCES, V62, DOI 10.1016/j.bspc.2020.102115
   Gayathri S, 2020, PHYS ENG SCI MED, V43, P927, DOI 10.1007/s13246-020-00890-3
   Gayathri S, 2020, IEEE ACCESS, V8, P57497, DOI 10.1109/ACCESS.2020.2979753
   Gholami P., 2018, **DATA OBJECT**, DOI [10.5683/SP/YEM3RA, DOI 10.5683/SP/YEM3RA]
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   *GLOB BURD DIS STU, 2015, LANCET, V386, P743, DOI [DOI 10.1016/S0140-6736(15)60692-4, 10.1016/S0140-6736(15)60692-4]
   Huang LF, 2019, IEEE SIGNAL PROC LET, V26, P1026, DOI 10.1109/LSP.2019.2917779
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Jemshi KM, 2018, INT J COMPUT ASS RAD, V13, P1369, DOI 10.1007/s11548-018-1795-6
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kaymak S, 2018, INT C INTELL COMP CO, P265, DOI 10.1109/ICCP.2018.8516635
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Khalid S., 2017, INTERVIEW BASED ITER
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Kuwayama S, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/6319581
   LeCun Y, 1998, LECT NOTES COMPUT SC, V1524, P9, DOI 10.1007/3-540-49430-8_2
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Meng TQ, 2018, CHIN CONTR CONF, P9362, DOI 10.23919/ChiCC.2018.8483036
   Milgram J., 2006, 10 INT WORKSH FRONT, V1
   Naz S., 2016, 2016 6 INT C IMAGE P, P1
   Nunes A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218826
   Oakley J., 2014, EYE WINDOW CENTRAL N
   Raju M, 2020, PHYS ENG SCI MED, V43, P1219, DOI 10.1007/s13246-020-00924-w
   Rasti R, 2018, IEEE T MED IMAGING, V37, P1024, DOI 10.1109/TMI.2017.2780115
   Rong YB, 2019, IEEE J BIOMED HEALTH, V23, P253, DOI 10.1109/JBHI.2018.2795545
   Selvaraju RR, 2020, INT J COMPUT VISION, V128, P336, DOI 10.1007/s11263-019-01228-7
   Serener A, 2019, 2019 SCIENTIFIC MEETING ON ELECTRICAL-ELECTRONICS & BIOMEDICAL ENGINEERING AND COMPUTER SCIENCE (EBBT)
   Smith R.T., 2018, PLOS ONE, V13
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Srivastava N, 2014, J MACH LEARN RES, V15, P1929
   Sugmk J, 2014, 7 2014 BIOM ENG INT, P1, DOI DOI 10.1109/BMEICON.2014.7017441
   Sun YK, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.1.016012
   Tan JH, 2018, FUTURE GENER COMP SY, V87, P127, DOI 10.1016/j.future.2018.05.001
   Thomas A, 2021, COMPUT METH PROG BIO, V200, DOI 10.1016/j.cmpb.2020.105822
   Trichonas G, 2014, BRIT J OPHTHALMOL, V98, P24, DOI 10.1136/bjophthalmol-2014-305305
   Visa S., 2011, MAICS, V710, P120
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu Z., BRIT J OPHTHALMOL
   Yaqoob Z, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2360525
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
NR 54
TC 12
Z9 12
U1 1
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1746-8094
EI 1746-8108
J9 BIOMED SIGNAL PROCES
JI Biomed. Signal Process. Control
PD MAY
PY 2021
VL 67
AR 102538
DI 10.1016/j.bspc.2021.102538
EA MAR 2021
PG 10
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA RO2UN
UT WOS:000640903100001
DA 2022-11-30
ER

PT J
AU Hata, M
   Yamashiro, K
   Ooto, S
   Oishi, A
   Tamura, H
   Miyata, M
   Ueda-Arakawa, N
   Takahashi, A
   Tsujikawa, A
   Yoshimura, N
AF Hata, Masayuki
   Yamashiro, Kenji
   Ooto, Sotaro
   Oishi, Akio
   Tamura, Hiroshi
   Miyata, Manabu
   Ueda-Arakawa, Naoko
   Takahashi, Ayako
   Tsujikawa, Akitaka
   Yoshimura, Nagahisa
TI Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid
   Neovasculopathy and Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE pachychoroid neovasculopathy; neovascular age-related macular
   degeneration; vascular endothelial growth factor
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   AQUEOUS-HUMOR; RANIBIZUMAB; AFLIBERCEPT
AB PURPOSE. To investigate the difference in intraocular vascular endothelial growth factor (VEGF) concentration between pachychoroid neovasculopathy and neovascular age-related macular degeneration (nAMD) and its associations with responses to three monthly anti-VEGF injections as an initial treatment for the two conditions.
   METHODS. This study included nine eyes with treatment-naive pachychoroid neovasculopathy and 21 eyes with treatment-naive nAMD. Before the initial intravitreal anti-VEGF injection, aqueous humor samples were collected and the concentration of VEGF was measured using enzyme-linked immunosorbent assay. The concentration was compared between the two conditions, and its associations with responses to anti-VEGF therapy were investigated.
   RESULTS. The mean VEGF concentration in pachychoroid neovasculopathy was significantly lower than that in nAMD (63.4+/-17.8 pg/ml and 89.8+/-45.0 pg/ml, respectively; P = 0.035). The VEGF concentration was associated with the presence or absence of drusen (b = 0.503, P = 0.004). After anti-VEGF therapy, 6 (66.7%) of 9 eyes with pachychoroid neovasculopathy and 17 (81.0%) of 21 eyes with nAMD achieved dry macula (P = 0.640). Dry macula at 3 months and 12 months was significantly associated with a low VEGF concentration in pachychoroid neovasculopathy (P = 0.013 and P = 0.042, respectively), but not in nAMD (P = 0.108 and P = 0.219).
   CONCLUSIONS. The mean VEGF concentration in pachychoroid neovasculopathy was lower than that in nAMD, suggesting that the way in which VEGF is involved in angiogenesis may differ between pachychoroid neovasculopathy and nAMD.
C1 [Hata, Masayuki; Yamashiro, Kenji; Ooto, Sotaro; Oishi, Akio; Tamura, Hiroshi; Miyata, Manabu; Ueda-Arakawa, Naoko; Takahashi, Ayako; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Tsujikawa, Akitaka] Kyoto Univ, Fac Med, Dept Ophthalmol, Miki, Kagawa, Japan.
C3 Kyoto University; Kyoto University
RP Hata, M (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM trj74h6@kuhp.kyoto-u.ac.jp
RI Miyata, Manabu/U-9008-2018; Oishi, Akio/AAE-9996-2020; TAMURA,
   Hiroshi/H-1855-2011
OI Oishi, Akio/0000-0002-0977-9458; TAMURA, Hiroshi/0000-0002-7740-2732;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Miyata, Manabu/0000-0002-7574-1749
FU Japan Society for the Promotion of Science, Tokyo, Japan [24791847];
   Innovative Techno-Hub for Integrated Medical Bio-Imaging of the Project
   for Developing Innovation Systems from the Ministry of Education,
   Culture, Sports, Science, and Technology, Tokyo, Japan; Grants-in-Aid
   for Scientific Research [26861451] Funding Source: KAKEN
FX Supported in part by a grant-in-aid for scientific research (no.
   24791847) from the Japan Society for the Promotion of Science, Tokyo,
   Japan, and the Innovative Techno-Hub for Integrated Medical Bio-Imaging
   of the Project for Developing Innovation Systems from the Ministry of
   Education, Culture, Sports, Science, and Technology, Tokyo, Japan. None
   of these organizations had any role in the design or conduct of this
   research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Jung SH, 2014, CLIN EXP OPTOM, V97, P264, DOI 10.1111/cxo.12125
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lafaut BA, 1998, GRAEF ARCH CLIN EXP, V236, P513, DOI 10.1007/s004170050114
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Nomura Y, 2016, GRAEF ARCH CLIN EXP, V254, P53, DOI 10.1007/s00417-015-3006-2
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Shin MC, 2011, RETINA-J RET VIT DIS, V31, P1937, DOI 10.1097/IAE.0b013e31820a6a17
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 30
TC 64
Z9 68
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2017
VL 58
IS 1
BP 292
EP 298
DI 10.1167/iovs.16-20967
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ1EW
UT WOS:000392954300035
PM 28114590
OA gold
DA 2022-11-30
ER

PT J
AU Zareparsi, S
   Buraczynska, M
   Branham, KEH
   Shah, S
   Eng, D
   Li, MY
   Pawar, H
   Yashar, BM
   Moroi, SE
   Lichter, PR
   Petty, HR
   Richards, JE
   Abecasis, GR
   Elner, VM
   Swaroop, A
AF Zareparsi, S
   Buraczynska, M
   Branham, KEH
   Shah, S
   Eng, D
   Li, MY
   Pawar, H
   Yashar, BM
   Moroi, SE
   Lichter, PR
   Petty, HR
   Richards, JE
   Abecasis, GR
   Elner, VM
   Swaroop, A
TI Toll-like receptor 4 variant D299G is associated with susceptibility to
   age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID TOLL-LIKE RECEPTOR-4; APOLIPOPROTEIN-E ALLELES; C-REACTIVE PROTEIN;
   GENOMEWIDE-SCAN; MALATTIA LEVENTINESE; STARGARDT-DISEASE; EXTENDED
   FAMILIES; DRUSEN FORMATION; BRUCHS MEMBRANE; RISK-FACTORS
AB Age-related macular degeneration (AMD) is a genetically heterogeneous disease that leads to progressive and irreversible vision loss among the elderly. Inflammation, oxidative damage, cholesterol metabolism and/or impaired function of retinal pigment epithelium (RPE) have been implicated in AMD pathogenesis. We examined toll-like receptor 4 (TLR4) as a candidate gene for AMD susceptibility because: (i) the TLR4 gene is located on chromosome 9q32-33, a region exhibiting evidence of linkage to AMD in three independent reports; (ii) the TLR4-D299G variant is associated with reduced risk of atherosclerosis, a chronic inflammatory disease with subendothelial accumulation; (iii) the TLR4 is not only a key mediator of proinflammatory signaling pathways but also linked to regulation of cholesterol efflux and (iv) the TLR4 participates in phagocytosis of photoreceptor outer segments by the RPE. We examined D299G and T399I variants of TLR4 in a sample of 667 unrelated AMD patients and 439 unrelated controls, all of Caucasian ancestry. Multiple logistic regression demonstrated an increased risk of AMD in carriers of the G allele at TLR4 residue 299 (odds ratio=2.65, P=0.025), but lack of an independent effect by T399I variant. TLR4-D299G showed an additive effect on AMD risk (odds ratio=4.13, P=0.002) with allelic variants of apolipoprotein E (APOE) and ATP-binding cassette transporter-1 (ABCA1), two genes involved in cholesterol efflux. Interestingly, the effect of TLR4, APOE and ABCA1 variants on AMD susceptibility was opposite to that of association with atherosclerosis risk. Our data provide evidence of a link between multiple diverse mechanisms underlying AMD pathogenesis.
C1 Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Biostat, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Human Genet, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Pathol, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan
RP Swaroop, A (通讯作者)，Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
EM swaroop@umich.edu
RI Branham, Kari/AAA-8336-2022; Abecasis, Goncalo R/B-7840-2010
OI Lichter, Paul/0000-0001-8394-4813; Yashar, Beverly
   M./0000-0003-0807-3258; Elner, Victor/0000-0001-7708-1898; Moroi, Sayoko
   E/0000-0002-0418-0657; Swaroop, Anand/0000-0002-1975-1141; Branham,
   Kari/0000-0002-2492-254X; Abecasis, Goncalo/0000-0003-1509-1825
FU NATIONAL EYE INSTITUTE [F32EY014085] Funding Source: NIH RePORTER; NEI
   NIH HHS [F32-EY014085] Funding Source: Medline
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048
   Armant MA, 2002, GENOME BIOL, V3
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158
   Boekholdt SM, 2003, CIRCULATION, V107, P2416, DOI 10.1161/01.CIR.0000068311.40161.28
   Bok D, 2002, P NATL ACAD SCI USA, V99, P14619, DOI 10.1073/pnas.242607899
   Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8
   Clee SM, 2001, CIRCULATION, V103, P1198
   Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gordon S, 2003, DEV CELL, V5, P666, DOI 10.1016/S1534-5807(03)00329-0
   Gorin MB, 1999, MOL VIS, V5, pU31
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   HIXSON JE, 1990, J LIPID RES, V31, P545
   Hoh J, 2004, CURR OPIN GENET DEV, V14, P229, DOI 10.1016/j.gde.2004.04.006
   Humphries SE, 2004, LANCET NEUROL, V3, P227, DOI 10.1016/S1474-4422(04)00708-2
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Janeway C, 2000, P NATL ACAD SCI USA, V97, P10682, DOI 10.1073/pnas.97.20.10682
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Joseph SB, 2003, CURR OPIN PHARMACOL, V3, P192, DOI 10.1016/S1471-4892(03)00009-2
   Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Libby P, 2004, AM J MED, V116, P9, DOI 10.1016/j.amjmed.2004.02.006
   Lorenz E, 2001, BIOTECHNIQUES, V31, P22, DOI 10.2144/01311bm01
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Michel O, 2003, J ALLERGY CLIN IMMUN, V112, P923, DOI 10.1016/j.jaci.2003.05.001
   Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101
   Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rccm.200207-634OC
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   SEARLE SR, 1987, LINEAR MODELS UNBALA, P887
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Walczak R, 2004, J BIOL CHEM, V279, P9905, DOI 10.1074/jbc.M310587200
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 66
TC 143
Z9 156
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUN 1
PY 2005
VL 14
IS 11
BP 1449
EP 1455
DI 10.1093/hmg/ddi154
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 928QF
UT WOS:000229286100005
PM 15829498
OA Bronze
DA 2022-11-30
ER

PT J
AU McHugh, KJ
   Li, DA
   Wang, JC
   Kwark, L
   Loo, J
   Macha, V
   Farsiu, S
   Kim, LA
   Saint-Geniez, M
AF McHugh, Kevin J.
   Li, Dian
   Wang, Jay C.
   Kwark, Leon
   Loo, Jessica
   Macha, Venkata
   Farsiu, Sina
   Kim, Leo A.
   Saint-Geniez, Magali
TI Computational modeling of retinal hypoxia and photoreceptor degeneration
   in patients with age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; OXYGEN DISTRIBUTION; ENERGY-METABOLISM;
   HYPERBARIC-OXYGEN; CONSUMPTION; PROGRESSION; TENSION
AB Although drusen have long been acknowledged as a primary hallmark of dry age-related macular degeneration (AMD) their role in the disease remains unclear. We hypothesize that drusen accumulation increases the barrier to metabolite transport ultimately resulting in photoreceptor cell death. To investigate this hypothesis, a computational model was developed to evaluate steady-state oxygen distribution in the retina. Optical coherence tomography images from fifteen AMD patients and six control subjects were segmented and translated into 3D in silico representations of retinal morphology. A finite element model was then used to determine the steady-state oxygen distribution throughout the retina for both generic and patient-specific retinal morphology. Oxygen levels were compared to the change in retinal thickness at a later time point to observe possible correlations. The generic finite element model of oxygen concentration in the retina agreed closely with both experimental measurements from literature and clinical observations, including the minimal pathological drusen size identified by AREDS (64 mu m). Modeling oxygen distribution in the outer retina of AMD patients showed a substantially stronger correlation between hypoxia and future retinal thinning (Pearson correlation coefficient, r = 0.2162) than between drusen height and retinal thinning (r = 0.0303) indicating the potential value of this physiology-based approach. This study presents proof-of-concept for the potential utility of finite element modeling in evaluating retinal health and also suggests a potential link between transport and AMD pathogenesis. This strategy may prove useful as a prognostic tool for predicting the clinical risk of AMD progression.
C1 [McHugh, Kevin J.; Li, Dian; Kim, Leo A.; Saint-Geniez, Magali] Massachusetts Eye & Ear, Schepens Eye Res Inst, Boston, MA 02114 USA.
   [McHugh, Kevin J.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
   [Wang, Jay C.; Kim, Leo A.; Saint-Geniez, Magali] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
   [Kwark, Leon; Loo, Jessica; Farsiu, Sina] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Kwark, Leon; Loo, Jessica; Farsiu, Sina] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
   [Macha, Venkata] Harvard Univ, Dept Comp Sci, Cambridge, MA USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Schepens Eye
   Research Institute; Boston University; Harvard University; Harvard
   Medical School; Duke University; Duke University; Harvard University
RP Kim, LA; Saint-Geniez, M (通讯作者)，Massachusetts Eye & Ear, Schepens Eye Res Inst, Boston, MA 02114 USA.; Kim, LA; Saint-Geniez, M (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
EM leo_kim@meei.harvard.edu; magali_saintgeniez@meei.harvard.edu
RI Li, Dian/AAQ-3482-2020; Kim, Leo/Y-3323-2018; SAINT-GENIEZ,
   MAGALI/Q-1875-2018
OI Li, Dian/0000-0002-5374-7314; Kim, Leo/0000-0001-9106-6416;
   SAINT-GENIEZ, MAGALI/0000-0001-9897-138X; McHugh,
   Kevin/0000-0001-6801-4431; Loo, Jessica/0000-0002-5484-9339
FU NIH National Eye Institute [5P30EY005722-32]; NIH Director's New
   Innovator Award Program [1-DP2-OD006649]; Research to Prevent Blindness
   Dolly Green Special Scholar Award; VitreoRetinal Surgery Foundation
   Research Award; NEI/NIH [K12EY16335]; Massachusetts Lions Eye Research
   Fund; NIH National Eye Institute core grant [5P30EY005722-32]; 2018
   Unrestricted Grant from Research to Prevent Blindness (Duke University);
   Grimshaw-Gudewicz Charitable Foundation; NATIONAL EYE INSTITUTE
   [P30EY003790, P30EY005722, K12EY016335] Funding Source: NIH RePORTER
FX This work was supported by the NIH National Eye Institute
   [https://nei.nih.gov/] core grant P30EY003790 (Schepens Eye Research
   Institute), the NIH [https://www.nih.gov/] Director's New Innovator
   Award Program 1-DP2-OD006649 (M.S.G.), the Research to Prevent Blindness
   [https://www.rpbusa.org/rpb/?] Dolly Green Special Scholar Award (M. S.
   G.), the Grimshaw-Gudewicz Charitable Foundation
   [http://grimshaworigin.org/miscellaneous-grimshaw-individuals/grimshaw-g
   udewicz-foundation/] (K.J.M, M.S.G, L.A.K.), and the VitreoRetinal
   Surgery Foundation Research Award (J.C.W., L.A.K). L.A.K. was supported
   by the NEI/NIH grants K12EY16335, and by the Massachusetts Lions Eye
   Research Fund. S.F., L.K., and J.L. were supported in part by the NIH
   National Eye Institute core grant 5P30EY005722-32 (Duke University) and
   the 2018 Unrestricted Grant from Research to Prevent Blindness (Duke
   University). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   ALM A, 1972, ACTA PHYSIOL SCAND, V84, P261, DOI 10.1111/j.1748-1716.1972.tb05177.x
   Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2
   ANDERSON B, 1964, ARCH OPHTHALMOL-CHIC, V72, P792
   Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Avtar R, 2008, EUR J PHARM SCI, V35, P175, DOI 10.1016/j.ejps.2008.06.004
   Birol G, 2007, AM J PHYSIOL-HEART C, V293, pH1696, DOI 10.1152/ajpheart.00221.2007
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   GRAGOUDAS ES, 1976, ARCH OPHTHALMOL-CHIC, V94, P755, DOI 10.1001/archopht.1976.03910030365003
   HAUGH LM, 1990, ANN BIOMED ENG, V18, P19, DOI 10.1007/BF02368415
   Kashani AH, 2014, RETINA-J RET VIT DIS, V34, P1854, DOI 10.1097/IAE.0000000000000146
   Kuo AN, 2013, AM J OPHTHALMOL, V156, P304, DOI 10.1016/j.ajo.2013.03.012
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521
   LINSENMEIER RA, 1990, GRAEF ARCH CLIN EXP, V228, P143, DOI 10.1007/BF02764309
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nguyen QD, 2004, INVEST OPHTH VIS SCI, V45, P617, DOI 10.1167/iovs.03-0557
   Okawa H, 2008, CURR BIOL, V18, P1917, DOI 10.1016/j.cub.2008.10.029
   Padnick-Silver L, 2003, INVEST OPHTH VIS SCI, V44, P745, DOI 10.1167/iovs.02-0432
   Panfoli I, 2012, MED HYPOTHESES, V78, P423, DOI 10.1016/j.mehy.2011.12.012
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pfau M, 2019, RETINA-J RET VIT DIS, V39, P1527, DOI 10.1097/IAE.0000000000002206
   PFOFF DS, 1987, J CATARACT REFR SURG, V13, P136, DOI 10.1016/S0886-3350(87)80127-X
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Randolph SA, 2014, WORKPLACE HEALTH SAF, V62, P352, DOI 10.3928/21650799-20140708-06
   Roberts PA, 2016, PROG RETIN EYE RES, V53, P48, DOI 10.1016/j.preteyeres.2016.04.001
   Roberts PA, 2016, J MATH BIOL, V73, P1, DOI 10.1007/s00285-015-0931-y
   ROH HD, 1990, ADV EXP MED BIOL, V277, P127
   Roos MW, 2004, PHYSIOL MEAS, V25, P1523, DOI 10.1088/0967-3334/25/6/016
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Weiss JN, 2010, UNDERSEA HYPERBAR M, V37, P101
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Yi J, 2015, LIGHT-SCI APPL, V4, DOI 10.1038/lsa.2015.107
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
NR 50
TC 16
Z9 16
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 11
PY 2019
VL 14
IS 6
AR e0216215
DI 10.1371/journal.pone.0216215
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IC4XB
UT WOS:000470970000003
PM 31185022
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Bakbak, B
   Ozturk, BT
   Zamani, AG
   Gonul, S
   Iyit, N
   Gedik, S
   Yildirim, MS
AF Bakbak, Berker
   Ozturk, Banu Turgut
   Zamani, Ayse Gul
   Gonul, Saban
   Iyit, Neslihan
   Gedik, Sansal
   Yildirim, M. Selman
TI Association of Apolipoprotein E Polymorphism with Intravitreal
   Ranibizumab Treatment Outcomes in Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; ApoE; Apolipoprotein E; ranibizumab
ID GENETIC ASSOCIATION; EPSILON-4 ALLELE; RISK; AMD; GENOTYPE; CFH
AB Purpose: Genetic factors are known to influence the response to anti-vascular endothelial growth factor (VEGF) treatment in exudative age-related macular degeneration (AMD). The current study was conducted to investigate the association of Apolipoprotein E (ApoE) polymorphism with the treatment response to ranibizumab for exudative AMD.Methods: One hundred nine eyes (109 patients, 59.6% male, mean age 63.847.22 years) treated with intravitreal ranibizumab injections were included in the analysis. Smoking status and lesion type were recorded. Patients were categorized into three groups according to visual acuity (VA) change at 6 months after the first injection: VA loss >5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Group 1); VA change between five ETDRS letters gain and loss (Group 2); VA improvement >5 ETDRS letters (Group 3). The association of ApoE gene polymorphisms with the three groups was evaluated.Results: Both smoking status and lesion type showed no significant association with VA change (p=0.12 and p=0.64, respectively). A lower frequency of 2 and a higher frequency of 4 were observed in Group 3 (2.9 and 25.7%, respectively). VA improvement with more than five ETDRS letters was significantly associated with the presence of the 4 genotype (p=0.01).Conclusions: This study demonstrated that carriers of the ApoE 4 polymorphism genotype show demonstrable improvement in VA after treatment with ranibizumab in exudative AMD. ApoE polymorphism identification may be used as a genetic screening to tailor individualized therapeutic approach for optimal treatment in neovascular AMD.
C1 [Bakbak, Berker; Ozturk, Banu Turgut; Gonul, Saban; Gedik, Sansal] Selcuk Univ, Fac Med, Dept Ophthalmol, Konya, Turkey.
   [Zamani, Ayse Gul; Yildirim, M. Selman] Meram Necmettin Erbakan Univ, Fac Med, Dept Med Genet, Konya, Turkey.
   [Iyit, Neslihan] Selcuk Univ, Fac Sci Fac, Dept Stat, Konya, Turkey.
C3 Selcuk University; Necmettin Erbakan University; Selcuk University;
   Selcuk University
RP Bakbak, B (通讯作者)，Selcuk Univ, Dept Ophthalmol, Fac Med, Ophthalmol, TR-42075 Konya, Turkey.
EM drberkerbakbak@yahoo.com
RI YILDIRIM, Mahmut Selman/AAR-7483-2021; ZAMANI, Ayse Gul/A-6567-2016
OI ZAMANI, Ayse Gul/0000-0003-0329-9047; YILDIRIM, MAHMUT
   SELMAN/0000-0002-3986-5517; Gonul, Saban/0000-0003-0803-1197
FU Scientific Research Coordination Center of Selcuk University
   [BAP-13401104]
FX The authors have no conflict of interest to declare. This study is
   supported by The Scientific Research Coordination Center of Selcuk
   University (BAP-13401104).
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Brown DM, 2009, OPHTHALMOLOGY, V116
   Gorin MB, 1999, MOL VIS, V5, pU31
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Huang WY, 2004, ARCH NEUROL-CHICAGO, V61, P1930, DOI 10.1001/archneur.61.12.1930
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 30
TC 7
Z9 8
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2016
VL 41
IS 6
BP 862
EP 866
DI 10.3109/02713683.2015.1067325
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO6ZJ
UT WOS:000377931700016
PM 26398858
DA 2022-11-30
ER

PT J
AU Henein, C
   Steel, DHW
AF Henein, Christin
   Steel, David H. W.
TI Photobiomodulation for non-exudative age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID NIGHTTIME LIGHT THERAPY; 670 NM LIGHT; LASER; VISION; TRIALS
AB Background
   Age-related macular degeneration (AMD) is one of the leading causes of blindness in high-income countries. The majority of cases of AMD are of the non-exudative type. Experts have proposed photobiomodulation (PBM) therapy as a non-invasive procedure to restore mitochondrial function, upregulate cytoprotective factors and prevent apoptotic cell death in retinal tissue aJected by AMD.
   Objectives
   To assess the eJectiveness and safety of PBM compared to standard care, no treatment or sham treatment for people with non-exudative AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (Issue 5, 2020), Ovid MEDLINE, Embase, ISRCTN, ClinicalTrials.gov and the WHO ICTRP to 11 May 2020 with no language restrictions.
   Selection criteria
   The review included randomised controlled trials (RCTs) on participants receiving any type of PBM therapy for non-exudative AMD compared to standard care, sham treatment or no treatment.
   Data collection and analysis
   We used standard methodological procedures expected by Cochrane. We considered the following outcome measures at 12 months: bestcorrected visual acuity (BCVA); contrast sensitivity; near vision; low luminance density score; reading speed; vision-related quality of life score; and adverse events such as progression of AMD and conversion to exudative AMD. We graded the certainty of the evidence using GRADE.
   Main results
   We included two published RCTs from single centres in the UK and Canada, which recruited 60 participants (60 eyes) and 30 participants (46 eyes) respectively. Participants in these trials were people with non-exudative AMD with Age-Related Eye Disease Study (AREDS) categories 2 to 4. One study compared single wavelength PBM with no treatment. This study was at risk of performance bias because the study was not masked, and there was attrition bias. One study compared multi-wavelength PBM with sham treatment and conflicts of interest were reported by study investigators. We also identified three eligible ongoing RCTs from searching the clinical trials database.
   When comparing PBM with sham treatment or no treatment for non-exudative AMD, there was no evidence of any meaningful clinical diJerence in BCVA at 12 months (mean diJerence (MD) 0.02 logMAR, 95% confidence interval (CI) -0.02 to 0.05; 2 RCTs, 90 eyes; low-certainty evidence). One study comparing multi-wavelength PBM with sham treatment showed an improvement in contrast sensitivity at Level E (18 cycles/degree) at 12 months (MD 0.29 LogCS, 95% CI 0.23 to 0.35; 1 RCT, 46 eyes; low-certainty evidence). Visual function and healthrelated quality of life scores were comparable between single wavelength PBM and no treatment groups at 12 months (VFQ-48 score MD 0.43, 95% CI -0.17 to 1.03; P = 0.16; 1 RCT, 47 eyes; low-certainty evidence).
   When comparing PBM with sham treatment or no treatment for non-exudative AMD, there was no evidence of any meaningful clinical diJerence in conversion to exudative AMD (risk ratio (RR) 0.97, 95% CI 0.17 to 5.44; 2 RCTs, 96 eyes; very low-certainty evidence) at 12 months. There was inconclusive evidence that single wavelength PBM prevents the progression of AMD (RR 0.79, 95% CI 0.41 to 1.53; P = 0.48; 1 RCT, 50 eyes; low-certainty evidence). Disease progression was defined as the development of advanced AMD or significant increase in drusen volume.
   No included study reported near vision, low luminance vision or reading speed outcomes.
   Authors' conclusions
   Currently there remains uncertainty whether PBM treatment is beneficial in slowing progression of non-exudative macular degeneration. There is a need for further well-designed controlled trials assessing dosimetry, powered for both eJectiveness and safety outcomes. Consideration should be given to the adoption of agreed clinical outcome measures and patient-based outcome measures for AMD.
C1 [Henein, Christin; Steel, David H. W.] Newcastle Univ, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Henein, Christin] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Henein, Christin] UCL Inst Ophthalmol, London, England.
   [Steel, David H. W.] Sunderland Eye Infirm, Sunderland, England.
C3 Newcastle University - UK; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London
RP Henein, C (通讯作者)，Newcastle Univ, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England.; Henein, C (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.; Henein, C (通讯作者)，UCL Inst Ophthalmol, London, England.
EM christin.henein@gmail.com
FU National Institute for Health Research (NIHR), UK; Department of Health
   through National Institute for Health Research; NIHR, via Cochrane
   Infrastructure funding
FX External sources; National Institute for Health Research (NIHR), UK;
   Richard Wormald, Co-ordinating Editor for Cochrane Eyes and Vision (CEV)
   acknowledged financial support for his CEV research sessions from the
   Department of Health through the award made by the National Institute
   for Health Research to Moorfields Eye Hospital NHS Foundation Trust and
   UCL Institute of Ophthalmology for a Specialist Biomedical Research
   Centre for Ophthalmology.; This review was supported by the NIHR, via
   Cochrane Infrastructure funding to the CEV UK editorial base.
CR Abramov MV, 1996, VESTNIK OFTALMOLOGII, V112
   Altman DG, 1996, BRIT MED J, V313, P1200, DOI 10.1136/bmj.313.7066.1200
   [Anonymous], STUDY PHOTOBIOMODULA
   [Anonymous], PHOTOBIOMODULATION K
   Arden GB, 2010, EYE, V24, P1149, DOI 10.1038/eye.2009.328
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Fitzgerald M, 2013, REV NEUROSCIENCE, V24, P205, DOI 10.1515/revneuro-2012-0086
   Fuma S, 2015, MOL VIS, V21, P883
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Guymer RH, 2019, OPHTHALMOLOGY, V126
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Henein C, 2018, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD013029, DOI 10.1002/14651858.CD013029]
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   James Lind Alliance Sight Loss and Vision Priority Setting Partnership, 2018, SETT PRIOR EYE RES
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Koev K, 2018, J PHYS CONF SER, V992, DOI 10.1088/1742-6596/992/1/012061
   Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014
   Krezel AK, 2020, BRIT J OPHTHALMOL, V104, P1196, DOI 10.1136/bjophthalmol-2019-314949
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Macular Society, YOUR GUID AG REL MAC
   Markowitz SN, 2020, RETINA-J RET VIT DIS, V40, P1471, DOI 10.1097/IAE.0000000000002632
   McKeague C, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-246
   McMaster University, DEV EV PRIM GRADEPRO
   Merry G, TREATMENT DRY AGE RE
   Merry GF, 2016, ACTA OPHTHALMOL, V95
   Minassian D, FUTURE SIGHT LOSS DE
   National Institute for Health and Care Excellence, LOW LEVEL LASER THER
   Nordic Cochrane Centre, 2014, REV MAN REVMAN COMP
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Robinson DG, 2018, INVEST OPHTH VIS SCI, V59, P4531, DOI 10.1167/iovs.18-24284
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257
   Sanderson TH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21869-x
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sivapathasuntharam C, 2017, NEUROBIOL AGING, V52, P66, DOI 10.1016/j.neurobiolaging.2017.01.001
   Veritas Health Innovation Covidence, 2020, MELB AUSTR VER HLTH
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   World Association of Laser Therapy, CONS AGR DES COND CL
   Yu AK, 2013, INVEST OPHTH VIS SCI, V54, P2216, DOI 10.1167/iovs.12-11382
NR 45
TC 0
Z9 0
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2021
IS 5
AR CD013029
DI 10.1002/14651858.CD013029.pub2
PG 35
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SR3VO
UT WOS:000660970700014
PM 34097768
OA Green Published
DA 2022-11-30
ER

PT J
AU Park, YS
   Moon, H
   Woo, JM
   Min, JK
AF Park, Yong Seok
   Moon, Haein
   Woo, Je Moon
   Min, Jung Kee
TI Changes in the Foveal Avascular Zone Area and Retinal Vessel Density
   after Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE aflibercept; foveal avascular zone; neovascular age-related macular
   degeneration; ranibizumab; retinal vessel density
AB Purpose
   To investigate changes in the foveal avascular zone (FAZ) area and retinal vessel density (VD) in the macula of patients receiving multiple anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (N-AMD).
   Methods
   This study included 54 eyes of 54 treatment-naive N-AMD patients. Thirty-three eyes were treated with intravitreal aflibercept injections, and 21 eyes were treated with intravitreal ranibizumab injections. Unaffected fellow eyes (54 eyes) were used as controls. All image scans were acquired after the macular architecture had recovered with drying up of the subretinal fluid/hemorrhage after treatment.
   Results
   Both the superficial and deep FAZ areas were significantly larger in the aflibercept group than in the control group. The VD was also significantly reduced in the aflibercept group.
   Conclusions
   Prolonged and repeated anti-VEGF therapy may cause an increase in the FAZ area and a decrease in the VD in patients with N-AMD, indicating ischemic damage.
C1 [Park, Yong Seok; Moon, Haein; Woo, Je Moon; Min, Jung Kee] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Ophthalmol, 877 Bangeojinsunhwando Ro, Ulsan, South Korea.
C3 University of Ulsan; Ulsan University Hospital
RP Min, JK (通讯作者)，Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Ophthalmol, 877 Bangeojinsunhwando Ro, Ulsan, South Korea.
EM jkmin@uuh.ulsan.kr
OI Min, Jung Kee/0000-0002-8006-8560
CR AGEMY S, 2015, RETINA-J RET VIT DIS, V35
   [Anonymous], Avastin (bevacizumab) injection, for intravenous use [Prescribing Information]
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Balaratnasingam C, 2016, OPHTHALMOLOGY, V123, P2352, DOI 10.1016/j.ophtha.2016.07.008
   BONNIN S, 2015, RETINA-J RET VIT DIS, V35
   Carpineto P, 2016, BRIT J OPHTHALMOL, V100, P671, DOI 10.1136/bjophthalmol-2015-307330
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Fenner BJ, 2018, BRIT J OPHTHALMOL, V102, P509, DOI 10.1136/bjophthalmol-2017-310700
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lu YS, 2018, INVEST OPHTH VIS SCI, V59, P2212, DOI 10.1167/iovs.17-23498
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mastropasqua R, 2017, INT J OPHTHALMOL-CHI, V10, P1545, DOI 10.18240/ijo.2017.10.11
   Mastropasqua R, 2017, EUR J OPHTHALMOL, V27, P336, DOI 10.5301/ejo.5000858
   Rothen Michelle, 2005, Ophthalmol Clin North Am, V18, P561
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P66, DOI 10.1001/jamaophthalmol.2014.3950
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Woo JM, 2018, CURR EYE RES, V43, P674, DOI 10.1080/02713683.2018.1437922
NR 18
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD APR 3
PY 2021
VL 36
IS 3
BP 110
EP 114
DI 10.1080/08820538.2021.1889612
EA FEB 2021
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RN5SV
UT WOS:000620520100001
PM 33617401
DA 2022-11-30
ER

PT J
AU Wiryasaputra, S
   Nguyen, V
   Arnold, JJ
   Ferrier, R
   Hinchcliffe, P
   Barthelmes, D
   Gillies, MC
AF Wiryasaputra, Shaan
   Nguyen, Vuong
   Arnold, Jennifer J.
   Ferrier, Ross
   Hinchcliffe, Peter
   Barthelmes, Daniel
   Gillies, Mark C.
TI Four-week outcomes of vascular endothelial growth factor inhibitors for
   neovascular age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularisation;
   intravitreal VEGF inhibitors
ID CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY; RANIBIZUMAB; VERTEPORFIN;
   SIZE
AB Importance To assess early outcomes of intravitreal vascular endothelial growth factor (VEGF) inhibitor treatment in neovascular age-related macular degeneration (nAMD) before patients have a chance to miss or discontinue treatment. Background Intravitreal VEGF inhibitors used to treat nAMD have been compared in various ways. The present study compared the 4-week responses to the first injection of either aflibercept, bevacizumab, or ranibizumab. Design Observational study. Participants Treatment-naive nAMD patients with visual acuity (VA) taken 22 to 48 days after the first treatment with an intravitreal VEGF inhibitor. Methods An observational study from a prospectively designed database. Main outcome measures VA change from baseline and proportion of eyes judged active 22 to 48 days after the first treatment. Results The overall mean (95% confidence interval [CI]) VA change at 4 weeks was +3.7 (3.3, 4.0) letters. No pairwise comparisons in crude VA change or VA change after multivariate adjustment between the three agents were significant. However, after multivariate adjustment, more eyes treated with bevacizumab (90%) had active disease 4 weeks after the first injection than ranibizumab (84%;P= .013) and aflibercept (82%;P= .004). Older age, higher baseline vision and larger lesions were associated with lower VA change. Conclusion There was no significant difference in VA gains amongst all three drugs but ranibizumab and aflibercept seemed to be more efficacious in quelling disease activity 4 weeks after the first treatment. VA change after the first injection was driven largely by baseline characteristics such as age, baseline VA and lesion size.
C1 [Wiryasaputra, Shaan; Nguyen, Vuong; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Save Sight Inst, Sydney Med Sch, Sydney, NSW, Australia.
   [Wiryasaputra, Shaan] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, NSW, Australia.
   [Ferrier, Ross] Gosford Eye Surg, Gosford, NSW, Australia.
   [Hinchcliffe, Peter] Tamworth Eye Ctr, Tamworth, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Zurich, Switzerland.
C3 University of Sydney; Singapore National Eye Center; University of
   Zurich; University Zurich Hospital
RP Wiryasaputra, S (通讯作者)，Singapore Natl Eye Ctr, Med Retina & Ocular Inflammat & Immunol Serv, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM wiryasaputra.shaan@singhealth.com.sg
OI Nguyen, Vuong/0000-0001-9070-9803
FU National Health and Medical Research Council, Australia [NHMRC
   2010-2012]; Royal Australian New Zealand College of Ophthalmologists'
   Eye Foundation [2007-2009]; Macular Dieseases Foundation, Australia;
   Glaukos; Bayer; Novartis
FX National Health and Medical Research Council, Australia, Grant/Award
   Number: NHMRC 2010-2012; Royal Australian New Zealand College of
   Ophthalmologists' Eye Foundation, Grant/Award Number: 2007-2009; Macular
   Dieseases Foundation, Australia; Funding was also provided by Novartis,
   Glaukos and Bayer; The supporting organisations had no role in the
   design or conduct of the research
CR [Anonymous], 2021, R LANGUAGE ENV STAT
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nguyen V, 2020, RETINA-J RET VIT DIS, V40, P866, DOI 10.1097/IAE.0000000000002485
   RHB Christensen, 2018, ORDINAL REGRESSION M, P8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rough K, 2018, OPHTHALMOLOGY, V125, P1136, DOI 10.1016/j.ophtha.2018.04.034
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Nguyen V, 2019, OPHTHALMOLOGY, V126, P64, DOI 10.1016/j.ophtha.2018.08.023
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 19
TC 1
Z9 1
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD SEP
PY 2020
VL 48
IS 7
BP 946
EP 955
DI 10.1111/ceo.13798
EA JUN 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NY9LU
UT WOS:000540373400001
PM 32463528
DA 2022-11-30
ER

PT J
AU Metelitsina, TI
   Grunwald, JE
   DuPont, JC
   Ying, GS
AF Metelitsina, Tatyana I.
   Grunwald, Juan E.
   DuPont, Joan C.
   Ying, Gui-Shuang
TI Effect of isometric exercise on choroidal blood flow in patients with
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Aim We compared the regulatory responses induced by isometric exercise in control subjects and patients with age-related macular degeneration (AMD) to investigate choroidal vascular regulation in AMD.
   Methods Seventeen eyes of 17 patients with dry AMD in the study eye and 19 eyes of 19 controls were included in this study. Both groups were well matched for age, race and sex. Brachial artery blood pressure determinations and laser Doppler flowmetry (Oculix) measurements of relative foveolar choroidal blood velocity, volume and flow were obtained in the study eye of each subject during 30 s of baseline, and then during 3 min of isometric exercise consisting of squeezing a handgrip in each hand. Similar measurements were then also obtained during the 2 min following the cessation of exercise. Using non-paired, two-tailed t test, changes in circulatory parameters during exercise and following the end of exercise were compared between AMD patients and control subjects. The slope for the relationship between circulatory changes and perfusion pressure changes was calculated and compared between patients with AMD and controls using linear regression analysis. Analysis of data was performed in a masked fashion.
   Results There were no statistically significant differences between the changes in choriodal blood velocity, volume and flow observed in control subjects and patients with AMD during the isometric exercise phase and after exercise.
   Conclusions Our results suggest that the response of the choroidal circulation to this type of isometric exercise resulting in a moderate increase in blood pressure does not seem to be affected by AMD.
C1 [Metelitsina, Tatyana I.; Grunwald, Juan E.; DuPont, Joan C.; Ying, Gui-Shuang] Univ Penn, Sch Med, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Grunwald, JE (通讯作者)，Univ Penn, Sch Med, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM juangrun@mail.med.upenn.edu
FU National Institutes of Health [NEI EY12769, 5 P30 EY 01583]; Vivian
   Simkins Lasko Research Fund; Nina C. Mackall Trust; Research to Prevent
   Blindness; NATIONAL EYE INSTITUTE [P30EY001583, R01EY012769] Funding
   Source: NIH RePORTER
FX This investigation was supported by the National Institutes of Health
   grant NEI EY12769 and 5 P30 EY 01583, the Vivian Simkins Lasko Research
   Fund, the Nina C. Mackall Trust, and an unrestricted grant from Research
   to Prevent Blindness.
CR Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kiss B, 2001, MICROVASC RES, V61, P1, DOI 10.1006/mvre.2000.2269
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Movaffaghy A, 2002, KLIN MONATSBL AUGENH, V219, P299, DOI 10.1055/s-2002-30665
   Petrig BL, 1996, OCULAR BLOOD FLOW, P120
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P2338
   RIVA CE, 1992, EXP EYE RES, V55, P499, DOI 10.1016/0014-4835(92)90123-A
   Riva CE, 1996, OCULAR BLOOD FLOW, P128
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Riva Charles E., 2001, International Ophthalmology, V23, P183, DOI 10.1023/A:1014433913240
   Tittl M, 2005, INVEST OPHTH VIS SCI, V46, P4717, DOI 10.1167/iovs.05-0268
NR 14
TC 10
Z9 10
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2010
VL 94
IS 12
BP 1629
EP 1631
DI 10.1136/bjo.2009.176859
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 683IJ
UT WOS:000284469000016
PM 20837789
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Castillo, MM
   Mowatt, G
   Lois, N
   Elders, A
   Fraser, C
   Amoaku, W
   Burr, JM
   Lotery, AJ
   Ramsay, CR
   Azuara-Blanco, A
AF Castillo, M. M.
   Mowatt, G.
   Lois, N.
   Elders, A.
   Fraser, C.
   Amoaku, W.
   Burr, J. M.
   Lotery, A. J.
   Ramsay, C. R.
   Azuara-Blanco, A.
TI Optical coherence tomography for the diagnosis of neovascular
   age-related macular degeneration: a systematic review
SO EYE
LA English
DT Review
ID INDOCYANINE GREEN ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN
   ANGIOGRAPHY; PHOTODYNAMIC THERAPY; LASER PHOTOCOAGULATION; TEST
   ACCURACY; FELLOW EYE; RANIBIZUMAB; VERTEPORFIN; MEMBRANES
AB The purpose is to study the diagnostic performance of optical coherence tomography (OCT) and alternative diagnostic tests for neovascular age-related macular degeneration (nAMD). Methods employed are as follows:systematic review and meta-analysis; Index test: OCT including time-domain (TD-OCT) and the most recently developed spectral domain (SD-OCT); comparator tests: visual acuity, clinical evaluation (slit lamp), Amsler chart, colour fundus photographs, infra-red reflectance, red-free images/blue reflectance, fundus autofluorescence imaging (FAF), indocyanine green angiography (ICGA), preferential hyperacuity perimetry (PHP), and microperimetry; reference standard: fundus fluorescein angiography. Databases searched included MEDLINE, MEDLINE In Process, EMBASE, Biosis, SCI, the Cochrane Library, DARE, MEDION, and HTA database. Last literature searches: March 2013. Risk of bias assessed using QUADAS-2. Meta-analysis models were fitted using hierarchical summary receiver operating characteristic (HSROC) curves. Twenty-two studies (2 abstracts and 20 articles) enrolling 2124 participants were identified, reporting TD-OCT (12 studies), SD-OCT (1 study), ICGA (8 studies), PHP (3 studies), Amsler grid, colour fundus photography and FAF (1 study each). Most studies were considered to have a high risk of bias in the patient selection (55%, 11/20), and flow and timing (40%, 8/20) domains. In a meta-analysis of TD-OCT studies, sensitivity and specificity (95% CI) were 88% (46-98%) and 78% (64-88%), respectively. There was insufficient information to undertake meta-analysis for other tests. TD-OCT is a sensitive test for detecting nAMD, although specificity was only moderate. Data on SD-OCT are sparse. Diagnosis of nAMD should not rely solely on OCT.
C1 [Castillo, M. M.; Mowatt, G.; Fraser, C.; Ramsay, C. R.] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB9 1FX, Scotland.
   [Lois, N.; Azuara-Blanco, A.] Queens Univ Belfast, Ctr Vision & Vasc Sci, Belfast BT12 6BA, Antrim, North Ireland.
   [Lois, N.; Azuara-Blanco, A.] Glasgow Caledonian Univ, Glasgow G4 0BA, Lanark, Scotland.
   [Amoaku, W.] Univ Nottingham, Nottingham NG7 2RD, England.
   [Burr, J. M.] Univ St Andrews, St Andrews KY16 9AJ, Fife, Scotland.
   [Lotery, A. J.] Univ Southampton, Southampton, Hants, England.
C3 University of Aberdeen; Queens University Belfast; Glasgow Caledonian
   University; University of Nottingham; University of St Andrews;
   University of Southampton
RP Azuara-Blanco, A (通讯作者)，Queens Univ Belfast, Dept Ophthalmol, Belfast BT12 6BA, Antrim, North Ireland.
EM a.azuara-blanco@qub.ac.uk
RI Ramsay, Craig/AAD-8249-2021; Elders, Andrew/N-4195-2015
OI Ramsay, Craig/0000-0003-4043-7349; Elders, Andrew/0000-0003-4172-4702;
   Azuara-Blanco, Augusto/0000-0002-4805-9322; Lotery,
   Andrew/0000-0001-5541-4305; Burr, Jennifer/0000-0002-9478-738X; Amoaku,
   Winfried/0000-0001-5028-7984
FU National Institute for Health Research Health Technology Assessment
   (NIHR HTA) Programme [10/57/22]; Chief Scientist Office (CSO) of the
   Scottish Government Health and Social Care Directorates; National
   Institute for Health Research [10/57/22] Funding Source: researchfish;
   Chief Scientist Office [NMAHP2] Funding Source: researchfish
FX This paper was based on a wider piece of research that was funded by the
   National Institute for Health Research Health Technology Assessment
   (NIHR HTA) Programme (project number 10/57/22) that will be published in
   full in Health Technology Assessment. The Health Services Research Unit
   is core-funded by the Chief Scientist Office (CSO) of the Scottish
   Government Health and Social Care Directorates. The views and opinions
   expressed therein are those of the authors and do not necessarily
   reflect those of the HTA programme, NIHR, NHS, Department of Health or
   the CSO.
CR Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Amercian Academy of Ophthalmology, 2011, AM AC OPHTH RET PAN
   [Anonymous], 2009, ONT HLTH TECHN ASS S
   [Anonymous], 2009, OPT COH TOM MSAC APP
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen S, 2003, CHIN OPHTHALMIC RES, V21, P428
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Fujii C, 1996, FOLIA OPHTHALMOL JPN, V47, P300
   Glasziou P, 2008, ANN INTERN MED, V149, P816, DOI 10.7326/0003-4819-149-11-200812020-00009
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Khondkaryan A, 2009, INVEST OPHTHALMOL VI, V50
   Kim SG, 2003, YONSEI MED J, V44, P821, DOI 10.3349/ymj.2003.44.5.821
   Kozak I, 2008, RETINA-J RET VIT DIS, V28, P538, DOI 10.1097/IAE.0b013e318167270b
   Krebs I, 2007, SPEKTRUM AUGENHEILKD, V21, P33, DOI 10.1007/s00717-006-0169-6
   Leeflang MMG, 2008, ANN INTERN MED, V149, P889, DOI 10.7326/0003-4819-149-12-200812160-00008
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Parravano M, 2012, ACTA OPHTHALMOL COPE, V90
   Reichel E, 1995, OPHTHALMOLOGY, V102, P1871, DOI 10.1016/S0161-6420(95)30781-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royal College of Ophthalmologists, 2009, AG REL MAC DEG GUID
   Rutter CM, 2001, STAT MED, V20, P2865, DOI 10.1002/sim.942
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Sturzlinger H, 2007, EVALUATION OPTICAL C
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Torron FB, 2002, ARCH SOC ESP OFTALMO, V77, P353
   Torron FB, 2001, ARCH SOC ESP OFTALMO, V76, P221
   Van den Bruel A, 2008, GUIDANCE USE 5 OPHTH
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
NR 41
TC 17
Z9 17
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2014
VL 28
IS 12
BP 1399
EP 1406
DI 10.1038/eye.2014.214
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW6FQ
UT WOS:000346365600001
PM 25233820
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Fauser, S
   Schwabecker, V
   Muether, PS
AF Fauser, Sascha
   Schwabecker, Viktoria
   Muether, Philipp S.
TI Suppression of Intraocular Vascular Endothelial Growth Factor During
   Aflibercept Treatment of Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AQUEOUS-HUMOR LEVELS; VEGF TRAP; VITREOUS LEVELS; RANIBIZUMAB;
   BEVACIZUMAB; CYTOKINES
AB PURPOSE: To determine the duration of suppression of aqueous humor concentrations of vascular endothelial growth factor (VEGF) in eyes with neovascular age-related macular degeneration (AMD) treated with aflibercept.
   DESIGN: Nonrandomized prospective clinical study.
   METHODS: Twenty-seven eyes of 27 neovascular AMD patients receiving intravitreal aflibercept injections on a pro re nata regimen driven by spectral-domain optical coherence tomography (SD OCT) were included in this study. A total of 132 aqueous humor specimens were collected before intravitreal aflibercept injections and their VEGF-A concentrations assayed by multiplex bead analysis.
   RESULTS: Mean aqueous humor VEGF concentrations before treatment initiation were 90.6 +/- 37.1 pg/mL (range 23.4-190.3 pg/mL). Intravitreal injection of aflibercept suppressed the aqueous VEGF concentrations to below the lower limit of quantification (< 4 pg/mL) in all patients. The mean duration of VEGF suppression below the lower limit of quantification was >71 +/- 18 days. The earliest time after injection at which the VEGF concentration recovered to above the lower limit of quantification was 55 days in 1 patient and >56 days, the recommended aflibercept treatment interval, in 20 patients. The aqueous VEGF recovery status of 6 patients was uncertain after 56 days.
   CONCLUSIONS: On average, VEGF concentrations in the aqueous humor were suppressed below the lower limit of quantification after intravitreal aflibercept injections for about 10 weeks. This aqueous suppression time suggests durable VEGF inhibition for most patients dosed with aflibercept every 8 weeks. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Fauser, Sascha; Schwabecker, Viktoria; Muether, Philipp S.] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
C3 University of Cologne
RP Muether, PS (通讯作者)，Univ Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM philmuether@mac.com
FU Gilen and Nolting Foundations, Germany; Novartis; Bayer; Heidelberg
   Engineering
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. Sascha Fauser received grants from
   the Gilen and Nolting Foundations, Germany; and from Novartis. He is a
   consultant to Novartis and received payment for lectures from Bayer and
   Novartis. Philipp Muether reveived payment for lectures from Novartis,
   Heidelberg Engineering, and Bayer. Viktoria Schwabecker has no financial
   disclosures. This study did not receive any funding or financial
   support. Contributions of authors: involved in conception and design
   (S.F., V.S., P.S.M.); data analysis and interpretation (S.F., P.S.M);
   writing the article (S.F., P.S.M.); critical review of the article
   (S.F., V.S., P.S.M.); final approval of the article (S.F., V.S.,
   P.S.M.); data collection (S.F., V.S., P.S.M.); and statistical expertise
   (S.F., P.S.M.).
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2014, BRIT J OPHTHALMOL, V98, P179, DOI 10.1136/bjophthalmol-2013-303954
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
NR 11
TC 54
Z9 61
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2014
VL 158
IS 3
BP 532
EP 536
DI 10.1016/j.ajo.2014.05.025
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2CZ
UT WOS:000341124400016
PM 24879948
DA 2022-11-30
ER

PT J
AU Holz, FG
   Oleksy, P
   Ricci, F
   Kaiser, PK
   Kiefer, J
   Schmitz-Valckenberg, S
AF Holz, Frank G.
   Oleksy, Piotr
   Ricci, Federico
   Kaiser, Peter K.
   Kiefer, Joachim
   Schmitz-Valckenberg, Steffen
CA COLUMBUS-AMD Study Grp
TI Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in
   Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
DE Biosimilar; FYB201; Lucentis; Neovascular age-related macular
   degeneration; Ranibizumab
ID BEVACIZUMAB; OUTCOMES; THERAPY; BURDEN; IMPACT; TRIAL
AB Purpose: This trial was conducted to investigate the clinical equivalence of the proposed biosimilar FYB201 and reference ranibizumab in patients with treatment-naive, subfoveal choroidal neovascularization caused by neovascular age-related macular degeneration (nAMD).
   Design: This was a prospective, multicenter, evaluation-masked, parallel-group, 48-week, phase III randomized study.
   Participants: A total of 477 patients were randomly assigned to receive FYB201 (n = 238) or reference ranibizumab (n = 239).
   Methods: Patients received FYB201 or reference ranibizumab 0.5 mg by intravitreal (IVT) injection in the study eye every 4 weeks.
   Main Outcome Measures: The primary end point was change from baseline in best-corrected visual acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letters at 8 weeks before the third monthly IVT injection. Biosimilarity of FYB201 to its originator was assessed via a 2-sided equivalence test, with an equivalence margin in BCVA of 3 ETDRS letters.
   Results: The BCVA improved in both groups, with a mean improvement of +5.1 (FYB201) and +5.6 (reference ranibizumab) ETDRS letters at week 8. The analysis of covariance (ANCOVA) least squares mean difference for the change from baseline between FYB201 and reference ranibizumab was -0.4 ETDRS letters with a 90% confidence interval (CI) of -1.6 to 0.9. Primary end point was met as the 90% CI was within the predefined equivalence margin. Adverse events were comparable between treatment groups.
   Conclusions: FYB201 is biosimilar to reference ranibizumab in terms of clinical efficacy and ocular and systemic safety in the treatment of patients with nAMD. (C) 2021 by the American Academy of Ophthalmology.
C1 [Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Oleksy, Piotr] Ctr Med UNO MED, Dept Ophthalmol, Tarnow, Poland.
   [Ricci, Federico] Univ Tor Vergata, UNIT Retina Dis, Policlin Tor Vergata, Rome, Italy.
   [Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Kiefer, Joachim] Bioeq GmbH, Holzkirchen, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
C3 University of Bonn; University of Rome Tor Vergata; Policlin Tor
   Vergata; Cleveland Clinic Foundation; Utah System of Higher Education;
   University of Utah
RP Holz, FG (通讯作者)，Univ Bonn, Ernst Abbe Str, D-53127 Bonn, Germany.
EM Frank.Holz@ukbonn.de
OI Kiefer, Joachim/0000-0002-3990-0917
FU bioeq GmbH
FX The COLUMBUS-AMD trial was sponsored by bioeq GmbH.
CR Aladul MI, 2017, BIODRUGS, V31, P533, DOI 10.1007/s40259-017-0252-3
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Eandi CM, 2016, EUR J PHARMACOL, V787, P78, DOI 10.1016/j.ejphar.2016.03.002
   Erie JC, 2016, OPHTHALMOLOGY, V123, P1257, DOI 10.1016/j.ophtha.2016.02.015
   European Medicines Agency, 2019, BIOSIMILARS EU INFOR
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Giuliani J, 2019, ANTICANCER RES, V39, P3971, DOI 10.21873/anticanres.13552
   Jaffe DH, 2018, J COMP EFFECT RES, V7, P1125, DOI 10.2217/cer-2018-0058
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mavija M, 2014, MED ARCH, V68, P204, DOI DOI 10.5455/MEDARH.2014.68.204-208
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   QuintilesIMS, 2017, IMP BIOS COMP EUR, P2020
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharma A, 2020, BRIT J OPHTHALMOL, V104, P2, DOI 10.1136/bjophthalmol-2019-314443
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smolen JS, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-000900
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 26
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2022
VL 129
IS 1
BP 54
EP 64
DI 10.1016/j.ophtha.2021.04.031
EA DEC 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XR9VN
UT WOS:000732568200011
PM 33957183
OA hybrid
DA 2022-11-30
ER

PT J
AU Capuano, V
   Miere, A
   Querques, L
   Sacconi, R
   Carnevali, A
   Amoroso, F
   Bandello, F
   Souied, EH
   Querques, G
AF Capuano, Vittorio
   Miere, Alexandra
   Querques, Lea
   Sacconi, Riccardo
   Carnevali, Adriano
   Amoroso, Francesca
   Bandello, Francesco
   Souied, Eric H.
   Querques, Giuseppe
TI Treatment-Naive Quiescent Choroidal Neovascularization in Geographic
   Atrophy Secondary to Nonexudative Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE; ANGIOGRAPHY;
   PROGRESSION; THICKNESS; EYES
AB PURPOSE: To describe the characteristics and natural history of quiescent choroidal neovascularization (CNV) in geographic atrophy (GA) secondary to nonexudative age-related macular degeneration (AMD) through multimodal imaging.
   DESIGN: Retrospective observational case series.
   METHODS: Patients diagnosed with quiescent CNV were analyzed in 2 high-volume referral centers. Imaging features obtained using fluorescein angiography (FA), indocyanine green angiography (ICGA), structural optical coherence tomography (OCT), and OCT angiography (OCT-A) were noted at first presentation and during the study period.
   RESULTS: Nineteen eyes of 19 patients were included. Mean (+SD) follow-up was 45.7 +/- 14.7 months. Quiescent CNV appeared as an ill-defined hyperfluorescent lesion without leakage or pooling of dye in the late phase of FA. On ICGA, quiescent CNV appeared as a distinct area of hyperfluorescence (vascular network) in early to intermediate frames and as a hyperfluorescent plaque in the late frame (late plaque). OCT-A revealed a flow signal beneath the small irregular elevation of the retinal pigment epithelium at the site of the quiescent CNV visualized by structural OCT. During the study period, 5 of the 19 CNV patients developed exudation. The remainder showed specific alterations in both structural OCT and OCT-A imaging. At last follow-up, 92% of the quiescent CNV seemed to cover the area spared from atrophy.
   CONCLUSIONS: The characteristics of the quiescent CNVs were very similar to those already described for intermediate AMD, although they had several specific features in the context of GA. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Capuano, Vittorio; Miere, Alexandra; Amoroso, Francesca; Souied, Eric H.; Querques, Giuseppe] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, Creteil, France.
   [Querques, Lea; Sacconi, Riccardo; Carnevali, Adriano; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, Dept Ophthalmol, IRCCS Osped San Raffaele, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
RI Miere, Alexandra/AIC-4074-2022; bandello, francesco/AAH-2405-2019
OI Miere, Alexandra/0000-0003-4123-8210; bandello,
   francesco/0000-0003-3238-9682; Sacconi, Riccardo/0000-0003-2891-2012;
   Querques, Giuseppe/0000-0002-3292-9581
CR Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Camevali A, 2016, AM J OPHTHALMOL, V169, P189
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Nehemy MB, 2015, OSLI RETINA, V46, P1056, DOI 10.3928/23258160-20151027-13
   Panthier C, 2014, RETINA-J RET VIT DIS, V34, P576, DOI 10.1097/01.iae.0000433986.32991.1e
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
NR 26
TC 47
Z9 48
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2017
VL 182
BP 45
EP 55
DI 10.1016/j.ajo.2017.07.009
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI4DW
UT WOS:000411920900007
PM 28734811
DA 2022-11-30
ER

PT J
AU Bonilha, VL
   Shadrach, KG
   Rayborn, ME
   Li, Y
   Pauer, GJT
   Hagstrom, SA
   Bhattacharya, SK
   Hollyfield, JG
AF Bonilha, Vera L.
   Shadrach, Karen G.
   Rayborn, Mary E.
   Li, Yong
   Pauer, Gayle J. T.
   Hagstrom, Stephanie A.
   Bhattacharya, Sanjoy K.
   Hollyfield, Joe G.
TI Retinal deimination and PAD2 levels in retinas from donors with
   age-related macular degeneration (AMD)
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE posttranslational modifications; protein deimination;
   immunohistochemistry; AMD; retina; retinal pigment epithelium
ID CITRULLINATED PROTEINS; PEPTIDYLARGININE DEIMINASE; BRUCHS MEMBRANE;
   POSTTRANSLATIONAL MODIFICATION; CHOROIDAL NEOVASCULARIZATION;
   RISK-FACTORS; PATHOGENESIS; EXPRESSION; PROGRESSION; DISEASE
AB Deimination is a form of protein posttranslational modification carried out by the peptidyl arginine deiminases (PADS) enzymes. PAD2 is the principal deiminase expressed in the retina. Elevated levels of PAD2 and protein deimination are present in a number of human neurological diseases, with or without ocular manifestation. To define the association of deimination with the pathogenesis of age-related macular degeneration (AMD), we studied protein deimination and PAD2 levels in retinas of AMD donor eyes compared to age-matched non-AMD retinas. Eyes from non-AMD and AMD donors were fixed in 4% paraformaldehyde and 0.5% glutaraldehyde in phosphate buffer. Retina and retinal pigment epithelium (RPE) from donor eyes were processed for immunohistochemical detection and western blotting using antibodies to PAD2 and citrulline residues. The ganglion cell, inner plexiform, inner nuclear and outer nuclear layers were labeled by both PAD2 and citrulline antibodies. Changes in the localization of deiminated residues and PAD2 were evident as the retinal layers were remodeled coincident with photoreceptor degeneration in AMD retinas. Immunodetection of either PAD2 or citrulline residues could not be evaluated in the RPE layer due to the high autofluorescence levels in this layer. Interestingly, higher deimination immunoreactivity was detected in AMD retinal lysates. However, no significant changes in PAD2 were detected in the AMD and non-AMD retinas and RPE lysates. Our observations show increased levels of protein deimination but not PAD2 in AMD retinas and RPE, suggesting a reduced rate of turnover of deiminated proteins in these AMD retinas. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Bonilha, Vera L.; Shadrach, Karen G.; Rayborn, Mary E.; Li, Yong; Pauer, Gayle J. T.; Hagstrom, Stephanie A.; Hollyfield, Joe G.] Cleveland Clin, Lerner Coll Med, Cole Eye Inst i31, Dept Ophthalmol, Cleveland, OH 44195 USA.
   [Bhattacharya, Sanjoy K.] Univ Miami, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation; Bascom
   Palmer Eye Institute; University of Miami
RP Bonilha, VL (通讯作者)，Cleveland Clin, Lerner Coll Med, Cole Eye Inst i31, Dept Ophthalmol, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM bonilhav@ccf.org
RI Bonilha, Vera/AAS-8566-2020
OI Bonilha, Vera/0000-0002-6166-5124
FU NIH [EY014240]; Research Center Grant from the Foundation Fighting
   Blindness; Challenge Grant from Research to Prevent Blindness; Research
   to Prevent Blindness career award; NATIONAL EYE INSTITUTE [R56EY014240,
   R01EY016112, R01EY014240] Funding Source: NIH RePORTER
FX Supported by NIH grants EY014240 (JGH), a Research Center Grant from the
   Foundation Fighting Blindness (JGH), a Challenge Grant from Research to
   Prevent Blindness (JGH) and Research to Prevent Blindness career award
   (SKB).
CR Acharya NK, 2012, J AUTOIMMUN, V38, P369, DOI 10.1016/j.jaut.2012.03.004
   Asaga H, 2002, NEUROSCI LETT, V326, P129, DOI 10.1016/S0304-3940(02)00334-8
   Asaga H, 2001, NEUROSCI LETT, V299, P5, DOI 10.1016/S0304-3940(00)01735-3
   Bando H, 2007, EXP EYE RES, V84, P135, DOI 10.1016/j.exer.2006.09.008
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhattacharya SK, 2008, AGING CELL, V7, P441, DOI 10.1111/j.1474-9726.2008.00376.x
   Bhattacharya SK, 2009, IUBMB LIFE, V61, P504, DOI 10.1002/iub.184
   Bhattacharya SK, 2006, INVEST OPHTH VIS SCI, V47, P2508, DOI 10.1167/iovs.05-1499
   Bhattacharya SK, 2006, CURR EYE RES, V31, P1063, DOI 10.1080/02713680600991437
   Biarnes M, 2011, OPTOMETRY VISION SCI, V88, P881, DOI 10.1097/OPX.0b013e31821988c1
   Bonilha VL, 2008, EXP EYE RES, V86, P150, DOI 10.1016/j.exer.2007.10.006
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Cafaro TA, 2010, MOL VIS, V16, P1654
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chou SM, 1996, J NEUROL SCI, V139, P16, DOI 10.1016/0022-510X(96)00090-1
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Enriquez-Algeciras M, 2013, J CLIN INVEST, V123, P646, DOI 10.1172/JCI64811
   Ethen CM, 2007, FEBS LETT, V581, P885, DOI 10.1016/j.febslet.2007.01.061
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Giles JT, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3752
   Gyorgy B, 2006, INT J BIOCHEM CELL B, V38, P1662, DOI 10.1016/j.biocel.2006.03.008
   Harris ML, 2008, ARTHRITIS RHEUM-US, V58, P1958, DOI 10.1002/art.23596
   Ishigami A, 2005, J NEUROSCI RES, V80, P120, DOI 10.1002/jnr.20431
   Klareskog L, 2006, ARTHRITIS RHEUM-US, V54, P38, DOI 10.1002/art.21575
   Klareskog L, 2006, NAT CLIN PRACT RHEUM, V2, P425, DOI 10.1038/ncprheum0249
   Kochi Y, 2011, ANN RHEUM DIS, V70, P512, DOI 10.1136/ard.2010.130526
   Kochi Yuta, 2010, Nihon Rinsho Meneki Gakkai Kaishi, V33, P48
   KOIKE H, 1994, BIOSCI BIOTECH BIOCH, V58, P2286, DOI 10.1271/bbb.58.2286
   Li GY, 2010, BIOMED ENVIRON SCI, V23, P371, DOI 10.1016/S0895-3988(10)60078-5
   Louw C, 2007, J ENZYM INHIB MED CH, V22, P121, DOI 10.1080/14756360600990829
   Mahdi H, 2009, NAT GENET, V41, P1319, DOI 10.1038/ng.480
   Mechin MC, 2011, M S-MED SCI, V27, P49, DOI 10.1051/medsci/201127149
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Mohlake P, 2010, MOL NEUROBIOL, V41, P149, DOI 10.1007/s12035-010-8112-x
   MOSCARELLO MA, 1994, J CLIN INVEST, V94, P146, DOI 10.1172/JCI117300
   Moscarello MA, 2007, NEUROCHEM RES, V32, P251, DOI 10.1007/s11064-006-9144-5
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Nicholas AP, 2011, NEUROSCI LETT, V495, P26, DOI 10.1016/j.neulet.2011.03.028
   Nicholas AP, 2005, J COMP NEUROL, V486, P254, DOI 10.1002/cne.20527
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357
   Yamada R, 2005, FRONT BIOSCI, V10, P54, DOI 10.2741/1506
NR 50
TC 18
Z9 18
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2013
VL 111
BP 71
EP 78
DI 10.1016/j.exer.2013.03.017
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 155ZF
UT WOS:000319788700009
PM 23562679
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Brown, MM
   Brown, GC
   Sharma, S
   Landy, J
   Bakal, J
AF Brown, MM
   Brown, GC
   Sharma, S
   Landy, J
   Bakal, J
TI Quality of life with visual acuity loss from diabetic retinopathy and
   age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID UTILITY VALUES
AB Objective: To compare the quality of life in patients with visual acuity loss occurring secondary to diabetic retinopathy with visual acuity loss occurring secondary to age-related macular degeneration (ARMD).
   Methods: Consecutive patients with diabetic retinopathy and ARMD were evaluated using the time trade-off method of utility value analysis. Both groups were stratified according to the degree of visual acuity loss in the better-seeing eye (group 1: 20/20-20/25, group 2: 20/30-20/40, group 3: 20/50-20/100, group 4 less than or equal to20/200). Utility values obtained from the patients, once stratified for visual acuity group, were compared with use of the t test and the Mann-Whitney U test. In addition, a 2-way analysis of variance was performed to control for potential confounding variables.
   Results: No difference was found between the utility value means of the diabetic retinopathy (n = 333) and ARMD (n = 246) subgroups stratified according to visual acuity levels: group 1, P = .54; group 2, P = .96; group 3, P = .09; and group 4, P = 32. A 2-way analysis of variance demonstrated that, among the variables of ocular disease, sex, age, and visual acuity in the better-seeing eye, only visual acuity was significantly associated with utility values (P = .003).
   Conclusions: At similar levels of visual acuity loss, that associated with diabetic retinopathy causes a similar reduction in quality of life to that associated with ARMD. This information has important implications for use in cost-utility analyses of ophthalmic interventions.
C1 Ctr Evidence Based Hlth Care Econ, Flourtown, PA 19031 USA.
   Wills Eye Hosp & Res Inst, Jefferson Med Coll, Cataract & Primary Eye Care Serv, Philadelphia, PA USA.
   Wills Eye Hosp & Res Inst, Jefferson Med Coll, Retina Vasc Unit, Philadelphia, PA USA.
   Queens Univ, Cost Effect Ocular Hlth Policy Unit, Kingston, ON, Canada.
C3 Jefferson University; Jefferson University; Queens University - Canada
RP Brown, MM (通讯作者)，Ctr Evidence Based Hlth Care Econ, Suite 210,1107 Bethlehem Pike, Flourtown, PA 19031 USA.
EM lissa1011@aol.com
RI Bakal, Jeff/ABE-4051-2021
OI Bakal, Jeffrey/0000-0002-3658-2554
CR American Medical Association, 2001, CURR PROC TERM CPT 2
   ANDERSON RN, 1999, US LIFE TABLES 1997, P1
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown G C, 2000, Qual Manag Health Care, V9, P23
   Brown G C, 2001, Trans Am Ophthalmol Soc, V99, P199
   Brown G C, 1999, J Health Care Finance, V26, P14
   Brown GC, 2000, J DIABETES COMPLICAT, V14, P18, DOI 10.1016/S1056-8727(00)00061-1
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 1998, INT OPHTHALMOL, V22, P307, DOI 10.1023/A:1006311910304
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P27
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Brown MM, 2001, HARVARD BUS REV, V79, P151
   DAMIANO AM, 1995, MED CARE, V33, pAS120
   *DIAB RET STUD RES, 1996, ARCH OPHTHALMOL-CHIC, V113, P1144
   DRUMMOND ME, 1999, METHODS EC EVALUATIO, P143
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Hollands H, 2001, CAN J OPHTHALMOL, V36, P202, DOI 10.1016/S0008-4182(01)80041-7
   Mills R P, 1998, Trans Am Ophthalmol Soc, V96, P753
   *NAT EY I, 2001, VIS FUNCT QUEST 25
   Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016
   PARRISH RK, 1886, T AM OPHTHAL SOC, V94, P919
   REDELMEIER DA, 1995, PRIMARY CARE, V22, P271
   Sharma S, 2000, Curr Opin Ophthalmol, V11, P175, DOI 10.1097/00055735-200006000-00004
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   *WHO, 2000, WHO REP
NR 29
TC 140
Z9 142
U1 1
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2002
VL 120
IS 4
BP 481
EP 484
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 538JU
UT WOS:000174813300007
PM 11934322
DA 2022-11-30
ER

PT J
AU Zucchiatti, I
   Cicinelli, MV
   Parodi, MB
   Pierro, L
   Gagliardi, M
   Accardo, A
   Bandello, F
AF Zucchiatti, Ilaria
   Cicinelli, Maria V.
   Parodi, Maurizio Battaglia
   Pierro, Luisa
   Gagliardi, Marco
   Accardo, Agostino
   Bandello, Francesco
TI EFFECT OF INTRAVITREAL RANIBIZUMAB ON GANGLION CELL COMPLEX AND
   PERIPAPILLARY RETINAL NERVE FIBER LAYER IN NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal thickness; ganglion cell complex; optical coherence
   tomography; neovascular agerelated macular degeneration; retinal nerve
   fiber layer; retinal thickness
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL THICKNESS; INJECTIONS; THERAPY
AB Purpose: To analyze the changes in ganglion cell complex and peripapillary retinal nerve fiber layer thickness, in central macular thickness and choroidal thickness on spectral domain optical coherence tomography in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab injections.
   Methods: All consecutive patients with untreated neovascular age-related macular degeneration received loading phase of three monthly intravitreal ranibizumab, followed by retreatments on a pro re nata protocol for 12 months. Primary outcome: changes in ganglion cell complex and retinal nerve fiber layer at the end of follow-up. Secondary outcome: changes in best-corrected visual acuity, central macular thickness, and choroidal thickness at the end of follow-up. Choroidal thickness was measured at 500 mm, 1000 mm, and 1,500 mm intervals nasally, temporally, superiorly, and inferiorly to the fovea, respectively, on horizontal and vertical line scans centered on the fovea.
   Results: Twenty-four eyes were included. Ganglion cell complex and peripapillary retinal nerve fiber layer thickness did not show statistically significant changes through 12 months (55.6 +/- 18.5 and 81.9 +/- 9.9 mm at baseline, 52.7 +/- 19.3 and 84.6 +/- 15.5 mm at month 12, P > 0.05). Central macular thickness showed progressive decrease from baseline to month 12, with maximum reduction at month 3 (P < 0.001). Statistically significant reduction in choroidal thickness was registered in the nasal 500, 1000, and 1,500 mm from the fovea, corresponding to the papillomacular region (from 169.6 +/- 45.3 to 153.9 +/- 46.9, P < 0.001).
   Conclusion: Intravitreal ranibizumab injections did not affect retinal nerve fiber layer and ganglion cell complex thickness in 1-year follow-up. Choroidal thickness in papillomacular area and central macular thickness was significantly reduced at the end of treatment. Further studies, with larger sample, longer follow-up, and greater number of injections, are warranted.
C1 [Zucchiatti, Ilaria; Cicinelli, Maria V.; Parodi, Maurizio Battaglia; Pierro, Luisa; Gagliardi, Marco; Bandello, Francesco] Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
   [Accardo, Agostino] Univ Trieste, Dept Engn & Architecture, Trieste, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   University of Trieste
RP Zucchiatti, I (通讯作者)，Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM ilaria.zucchiatti@gmail.com
RI Gagliardi, Marco/AAN-4364-2020; cicinelli, maria vittoria/M-1611-2019;
   Parodi, Maurizio Battaglia/K-7876-2016; Pierro, Luisa/AAN-3900-2020;
   bandello, francesco/AAH-2405-2019; Zucchiatti, Ilaria/ABA-7083-2020
OI Gagliardi, Marco/0000-0001-8779-607X; cicinelli, maria
   vittoria/0000-0003-2938-0409; bandello, francesco/0000-0003-3238-9682;
   Battaglia Parodi, Maurizio/0000-0002-0385-7961; pierro,
   luisa/0000-0003-2168-5224
CR Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   El-Ashry MF, 2015, CLIN OPHTHALMOL, V9, P1269, DOI 10.2147/OPTH.S80704
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Entezari Morteza, 2014, J Ophthalmic Vis Res, V9, P449, DOI 10.4103/2008-322X.150815
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Kent D, 2015, EYE, V29, P1416, DOI 10.1038/eye.2015.140
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Perdicchi A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/268796
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 23
TC 9
Z9 10
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2017
VL 37
IS 7
BP 1314
EP 1319
DI 10.1097/IAE.0000000000001360
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EY6ZG
UT WOS:000404133400016
PM 28574419
DA 2022-11-30
ER

PT J
AU Ou, WC
   Denlar, RA
   Csaky, KG
AF Ou, William C.
   Denlar, Renee A.
   Csaky, Karl G.
TI The Relationship Between Central Drusen Volume and Low-Luminance Deficit
   in Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE retina; age-related macular degeneration; image analysis
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL-ACUITY; COMPLEMENT INHIBITION;
   GEOGRAPHIC ATROPHY; MICROPERIMETRY; PROGRESSION; VISION; MACULOPATHY;
   PREDICTOR; LAYER
AB Purpose: To determine the relationship between central drusen volume and low-luminance deficit (LLD) in visual acuity (VA) in patients with intermediate age-related macular degeneration (AMD).
   Methods: In this cross-sectional study, 42 patients with intermediate AMD underwent testing for VA and low-luminance VA (LLVA), as well as spectral-domain optical coherence tomography. LLD was calculated as the difference between VA and LLVA. Central drusen volume was measured in the central 3 mm of the macula, defined as the volume between the inner border of the retinal pigment epithelium and Bruch's membrane.
   Results: Mean +/- standard deviation (SD) LLD was 0.32 +/- 0.12 logMAR and mean +/- SD drusen volume was 0.18 +/- 0.09 mm(3). No linear relationship was identified between central 3 mm drusen volume and LLD (P = 0.215). R-2 for the bivariate linear model was 0.038 (95% confidence interval 0-0.222). Limitation of the analysis to drusen volumes measured in the central 1mm of the macula did not impact results (R-2 = 0.075), nor did incorporation of lens status into the model (R-2 = 0.067) or censoring of patients with nonfoveal subretinal drusenoid deposits (R-2 = 0.071).
   Conclusions: The amount of drusen within the central 3 mm of the macula does not appear to be related to LLD in intermediate AMD. These measures may be manifestations of different underlying pathophysiological mechanisms.
   Translational Relevance: Understanding relationships between markers for AMD progression may help guide development of improved clinical grading scales for AMD.
C1 [Ou, William C.; Denlar, Renee A.; Csaky, Karl G.] Retina Fdn Southwest, 9600 North Cent Expressway,Suite 200, Dallas, TX 75231 USA.
C3 Retina Foundation of the Southwest
RP Csaky, KG (通讯作者)，Retina Fdn Southwest, 9600 North Cent Expressway,Suite 200, Dallas, TX 75231 USA.
EM kcsaky@me.com
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P8241, DOI 10.1167/iovs.11-7858
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hicks D, 1999, INVEST OPHTH VIS SCI, V40, P3071
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Stockman A, 2006, OPHTHAL PHYSL OPT, V26, P225, DOI 10.1111/j.1475-1313.2006.00325.x
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
NR 40
TC 3
Z9 3
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAR
PY 2020
VL 9
IS 4
AR 10
DI 10.1167/tvst.9.4.10
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LB9VX
UT WOS:000524980600010
PM 32821472
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Duvvari, MR
   van de Ven, JPH
   Geerlings, MJ
   Saksens, NTM
   Bakker, B
   Henkes, A
   Neveling, K
   del Rosario, M
   Westra, D
   van den Heuvel, LPWJ
   Schick, T
   Fauser, S
   Boon, CJF
   Hoyng, CB
   de Jong, EK
   den Hollander, AI
AF Duvvari, Maheswara R.
   van de Ven, Johannes P. H.
   Geerlings, Maartje J.
   Saksens, Nicole T. M.
   Bakker, Bjorn
   Henkes, Arjen
   Neveling, Kornelia
   del Rosario, Marisol
   Westra, Dineke
   van den Heuvel, Lambertus P. W. J.
   Schick, Tina
   Fauser, Sascha
   Boon, Camiel J. F.
   Hoyng, Carel B.
   de Jong, Eiko K.
   den Hollander, Anneke I.
TI Whole Exome Sequencing in Patients with the Cuticular Drusen Subtype of
   Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID BASAL LAMINAR DRUSEN; EXTRACELLULAR-MATRIX; BRUCHS MEMBRANE; GRADING
   SYSTEM; HIGH-RISK; CFH GENE; DISEASE; MUTATION; RARE; CLASSIFICATION
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in elderly people worldwide. Cuticular drusen (CD) is a clinical subtype of AMD, which typically displays an earlier age at onset, and has a strong genetic component. Genetic studies support a role for rare sequence variants in CD susceptibility, and rare sequence variants in the CFH gene have been identified in 8.8% of CD cases. To further explore the role of rare variants in CD, we performed whole exome sequencing (WES) in 14 affected members of six families and 12 sporadic cases with CD. We detected rare sequence variants in CFH and FBLN5, which previously were shown to harbor rare variants in patients with CD. In addition, we detected heterozygous rare sequence variants in several genes encoding components of the extracellular matrix (ECM), including FBLN1, FBLN3/EFEMP1, FBLN5, FBLN6/HMCN1, FBN2, and COL15A1. Two rare pathogenic variants were identified in the COL15A1 gene: one in a sporadic case and another was found to segregate in a family with six affected individuals with CD. In addition, two rare pathogenic variants were identified in the FGL1 gene in three unrelated CD cases. These findings suggest that alterations in the ECM and in the coagulation pathway may play a role in the pathogenesis of CD. The identified candidate genes require further analyses in larger cohorts to confirm their role in the CD subtype of AMD. No evidence was found of rare sequence variants in a single gene that segregate with CD in the six families, suggesting that the disease is genetically heterogeneous.
C1 [Duvvari, Maheswara R.; van de Ven, Johannes P. H.; Geerlings, Maartje J.; Saksens, Nicole T. M.; Bakker, Bjorn; Henkes, Arjen; Boon, Camiel J. F.; Hoyng, Carel B.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Henkes, Arjen; Neveling, Kornelia; del Rosario, Marisol; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
   [Westra, Dineke; van den Heuvel, Lambertus P. W. J.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat Nephrol, NL-6525 ED Nijmegen, Netherlands.
   [Schick, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Boon, Camiel J. F.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; University of Cologne; Leiden University; Leiden
   University Medical Center (LUMC); Leiden University - Excl LUMC
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.; den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
EM Anneke.denHollander@radboudumc.nl
RI van den Heuvel, L.P.W.J./H-8044-2014; van den Heuvel,
   Lambertus/AAM-1772-2021; Bakker, Bjorn/E-2842-2016; Geerlings,
   Maartje/P-8309-2015; de Jong, Eiko/P-3407-2015; Hollander, Anneke
   den/N-4911-2014; Geerlings, Maartje/P-3338-2019; Boon, CJF/P-7534-2014
OI van den Heuvel, L.P.W.J./0000-0003-3917-6727; van den Heuvel,
   Lambertus/0000-0003-3917-6727; Geerlings, Maartje/0000-0003-1164-3573;
   de Jong, Eiko/0000-0001-6520-0407; Geerlings,
   Maartje/0000-0003-1164-3573; Boon, CJF/0000-0002-6737-7932
FU Netherlands Organization for Scientific Research (Vidi Innovational
   Research Award) [016.096.309]; Foundation Fighting Blindness USA
   [C-GE-0811-0548-RAD04]; European Research Council under the European
   Union's Seventh Framework Programme (FP) / ERC [310644]
FX This study was supported by the Netherlands Organization for Scientific
   Research (Vidi Innovational Research Award 016.096.309) and the
   Foundation Fighting Blindness USA (grant C-GE-0811-0548-RAD04). The
   research leading to these results has received funding from the European
   Research Council under the European Union's Seventh Framework Programme
   (FP/2007-2013) / ERC grant agreement n. 310644 (MACULA).
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Booij JC, 2010, THESIS
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Duvvari MR, 2015, MOL VIS, V21, P285
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Li DQ, 2000, J BIOL CHEM, V275, P22339, DOI 10.1074/jbc.M000519200
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Malek G, 2006, BRIT J OPHTHALMOL, V90, P1080, DOI 10.1136/bjo.2006.098715
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Ratnapriya R, 2014, HUM MOL GENET
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rijken DC, 2006, BIOCHEM BIOPH RES CO, V350, P191, DOI 10.1016/j.bbrc.2006.09.018
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Saksens NTM, 2014, INVEST OPHTH VIS SCI, V55, P7085, DOI 10.1167/iovs.14-14659
   Saksens NT, 2016, JAMA OPHTHALMOL, P1
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   van de Ven JPH, 2012, AM J OPHTHALMOL, V154, P560, DOI 10.1016/j.ajo.2012.03.012
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P681, DOI 10.1006/bbrc.1993.1678
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 39
TC 24
Z9 25
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 23
PY 2016
VL 11
IS 3
AR e0152047
DI 10.1371/journal.pone.0152047
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DH3QJ
UT WOS:000372701200091
PM 27007659
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nordgaard, CL
   Karunadharma, PP
   Feng, X
   Olsen, TW
   Ferrington, DA
AF Nordgaard, Curtis L.
   Karunadharma, Pabalu P.
   Feng, Xiao
   Olsen, Timothy W.
   Ferrington, Deborah A.
TI Mitochondrial proteomics of the retinal pigment epithelium at
   progressive stages of age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ATP SYNTHASE; DNA DAMAGE; VISUAL IMPAIRMENT; F1F0-ATP SYNTHASE; RPE
   CELLS; PROTEIN; TRANSLATION; MUTATIONS; EYE; DYSFUNCTION
AB PURPOSE. Age-related macular degeneration (AMD) is the leading cause of vision loss in individuals over the age of 65. Histopathological changes become evident in the retinal pigment epithelium (RPE), a monolayer that provides metabolic support for the overlying photoreceptors, even at the earliest stages of AMD that precede vision loss. In a previous global RPE proteome analysis, changes were identified in the content of several mitochondrial proteins associated with AMD. In this study, the subproteome of mitochondria isolated from human donor RPE graded with the Minnesota Grading System (MGS) was analyzed.
   METHODS. Human donor eye bank eyes were categorized into one of four progressive stages (MGS 1-4) based on the clinical features of AMD. After dissection of the RPE, mitochondrial proteins were isolated and separated by two-dimensional gel electrophoresis based on their charge and mass. Protein spot densities were compared between the four MGS stages. Peptides from spots that changed significantly with MGS stage were extracted and analyzed by using mass spectrometry to identify the protein.
   RESULTS. Western blot analyses verified that mitochondria were consistently enriched between MGS stages. The densities of eight spots increased or decreased significantly as a function of MGS stage. These spots were identified as the alpha-, beta-, and delta-ATP synthase subunits, subunit VIb of the cytochrome c oxidase complex, mitofilin, mtHsp70, and the mitochondrial translation factor Tu.
   CONCLUSIONS. The results are consistent with the hypothesis that mitochondrial dysfunction is associated with AMD and further suggest specific pathophysiological mechanisms involving altered mitochondrial translation, import of nuclear-encoded proteins, and ATP synthase activity.
C1 [Nordgaard, Curtis L.; Karunadharma, Pabalu P.; Feng, Xiao; Olsen, Timothy W.; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.
   [Karunadharma, Pabalu P.; Ferrington, Deborah A.] Univ Minnesota, Grad Program, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Ferrington, DA (通讯作者)，380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU NATIONAL EYE INSTITUTE [R03EY014176] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [R01AG025392] Funding Source: NIH RePORTER;
   NEI NIH HHS [R03 EY014176, EY014176] Funding Source: Medline; NIA NIH
   HHS [R01 AG025392, AG025392] Funding Source: Medline
CR Arselin G, 2004, J BIOL CHEM, V279, P40392, DOI 10.1074/jbc.M404316200
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Bornhovd C, 2006, J BIOL CHEM, V281, P13990, DOI 10.1074/jbc.M512334200
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feuermann M, 2003, EMBO REP, V4, P53, DOI 10.1038/sj.embor.embor713
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Garcia JJ, 2006, BIOCHEMISTRY-US, V45, P12695, DOI 10.1021/bi060339j
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Hojlund K, 2003, J BIOL CHEM, V278, P10436, DOI 10.1074/jbc.M212881200
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Kapphahn RJ, 2003, BIOCHEMISTRY-US, V42, P15310, DOI 10.1021/bi034774e
   Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Latvala T, 2002, GRAEF ARCH CLIN EXP, V240, P795, DOI 10.1007/s00417-002-0555-y
   Lenaz G, 2004, BBA-BIOENERGETICS, V1658, P89, DOI 10.1016/j.bbabio.2004.03.013
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lill R, 2006, ANNU REV CELL DEV BI, V22, P457, DOI 10.1146/annurev.cellbio.22.010305.104538
   Martinez LO, 2003, NATURE, V421, P75, DOI 10.1038/nature01250
   Minauro-Sanmiguel F, 2005, P NATL ACAD SCI USA, V102, P12356, DOI 10.1073/pnas.0503893102
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Rodnina MV, 2005, FEBS LETT, V579, P938, DOI 10.1016/j.febslet.2004.11.048
   Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Smith PR, 1999, OPHTHALMOLOGY, V106, P1101, DOI 10.1016/S0161-6420(99)90244-0
   Stojanovski D, 2006, BBA-MOL CELL RES, V1763, P414, DOI 10.1016/j.bbamcr.2006.02.008
   Szabadkai G, 2006, J CELL BIOL, V175, P901, DOI 10.1083/jcb.200608073
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Wadhwa R, 2002, EXP CELL RES, V274, P246, DOI 10.1006/excr.2002.5468
   Yamamoto K, 2007, AM J PHYSIOL-HEART C, V293, pH1646, DOI 10.1152/ajpheart.01385.2006
NR 46
TC 126
Z9 132
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2008
VL 49
IS 7
BP 2848
EP 2855
DI 10.1167/iovs.07-1352
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318WR
UT WOS:000257124000010
PM 18344451
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Parmeggiani, F
   Costagliola, C
   Gemmati, D
   D'Angelo, S
   Perri, P
   Campa, C
   Catozzi, L
   Federici, F
   Sebastiani, A
   Incorvaia, C
AF Parmeggiani, Francesco
   Costagliola, Ciro
   Gemmati, Donato
   D'Angelo, Sergio
   Perri, Paolo
   Campa, Claudio
   Catozzi, Linda
   Federici, Federica
   Sebastiani, Adolfo
   Incorvaia, Carlo
TI Coagulation gene predictors of photodynamic therapy for occult choroidal
   neovascularization in age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-XIII FXIII; ENDOTHELIAL DYSFUNCTION; VERTEPORFIN THERAPY; OXIDANT
   STRESS; LESION SIZE; POLYMORPHISMS; ACTIVATION; SECONDARY; RISK;
   HYPERHOMOCYSTEINEMIA
AB PURPOSE. To determine whether different coagulation-balance genetic polymorphisms explain the variable clinical outcomes of photodynamic therapy with verteporfin (PDT-V) in Caucasian patients with occult subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
   METHODS. The clinical records of consecutive patients with AMD-related occult CNV, treated with PDT-V for evidence of disease progression, were retrospectively examined. Eighty-four eligible subjects were subdivided into responders and nonresponders based on CNV responsiveness to the first PDT-V over a 3- month period. Six gene polymorphisms (i.e., factor V G1691A, prothrombin G20210A, factor XIII-A G185T, methylenetetrahydrofolate reductase C677T, methionine synthase A2756G, and methionine synthase reductase A66G) were genotyped in each patient. Logistic regression analyses were performed to explore the predictive role of phenotypic and genotypic variables for PDT-V effectiveness.
   RESULTS. Regression models documented that PDT-V nonresponders were more frequently patients with the hyperfibrinolytic G185T mutation of factor XIII-A (odds ratio [OR], 0.28; 95% confidence interval [CI], 0.11-0.73; P < 0.01). Univariate logistic regression was indicative of an overrepresentation of PDT-V responders among the combined carriers of thrombophilic factor V 1691A and prothrombin 20210A alleles (OR = 3.8; 95% CI: 0.94-15.6; P = 0.07). All the other predictors considered did not significantly influence the short-term CNV responsiveness to PDT-V.
   CONCLUSIONS. These data provide evidence of the presence of a pharmacogenetic relationship between peculiar coagulation-balance genetic backgrounds and different levels of PDT-V effectiveness in patients with AMD with occult CNV.
C1 [Parmeggiani, Francesco; D'Angelo, Sergio; Perri, Paolo; Campa, Claudio; Sebastiani, Adolfo; Incorvaia, Carlo] Univ Ferrara, Dept Discipline Med Chirurg Comun Comportamento, Dept Ophthalmol, Sect Clin Oculist, I-44100 Ferrara, Italy.
   [Gemmati, Donato; Catozzi, Linda; Federici, Federica] Univ Ferrara, Study Ctr Hemostasis & Thrombosis, Dept Hematol, I-44100 Ferrara, Italy.
   [Costagliola, Ciro] Univ Molise, Dept Hlth Sci, Campobasso, Italy.
C3 University of Ferrara; University of Ferrara; University of Molise
RP Parmeggiani, F (通讯作者)，Univ Ferrara, Dept Discipline Med Chirurg Comun Comportamento, Dept Ophthalmol, Sect Clin Oculist, Corso Giovecca 203, I-44100 Ferrara, Italy.
EM francesco.parmeggiani@unife.it
RI Gemmati, Donato/E-5107-2010; Costagliola, Ciro/G-5707-2012; Perri,
   Paolo/L-3047-2015
OI Costagliola, Ciro/0000-0001-8477-6188; Perri, Paolo/0000-0003-4652-9842;
   D'Angelo, Sergio/0000-0003-1118-3845; Gemmati,
   Donato/0000-0001-6213-6120; Federici, Federica/0000-0002-6628-3803
CR Ariens RAS, 2002, BLOOD, V100, P743, DOI 10.1182/blood.V100.3.743
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Austin RC, 2004, CELL DEATH DIFFER, V11, pS56, DOI 10.1038/sj.cdd.4401451
   Bernardi F, 2002, PATHOPHYSIOL HAEMO T, V32, P335, DOI 10.1159/000076692
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Castoldi E, 2004, CURR OPIN HEMATOL, V11, P176, DOI 10.1097/01.moh.0000130315.41033.32
   Castro R, 2006, J INHERIT METAB DIS, V29, P3, DOI 10.1007/s10545-006-0106-5
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Coppola A, 2000, SEMIN THROMB HEMOST, V26, P243, DOI 10.1055/s-2000-8469
   Danckwardt S, 2006, ACTA HAEMATOL-BASEL, V115, P192, DOI 10.1159/000090934
   Dardik R, 2006, J THROMB HAEMOST, V4, P19, DOI 10.1111/j.1538-7836.2005.01473.x
   Dardik R, 2003, ARTERIOSCL THROM VAS, V23, P1472, DOI 10.1161/01.ATV.0000081636.25235.C6
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gemmati D, 2004, CANCER EPIDEM BIOMAR, V13, P787
   Gemmati D, 2001, HAEMOSTASIS, V31, P99
   Gemmati D, 2001, AM J HEMATOL, V67, P183, DOI 10.1002/ajh.1104
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holven KB, 2007, J THROMB HAEMOST, V5, P193, DOI 10.1111/j.1538-7836.2006.02275.x
   Holven KB, 2003, J NUTR, V133, P3588, DOI 10.1093/jn/133.11.3588
   Inbal A, 2006, PATHOPHYSIOL HAEMO T, V35, P162, DOI 10.1159/000093562
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kanani PM, 1999, CIRCULATION, V100, P1161, DOI 10.1161/01.CIR.100.11.1161
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Manku KK, 2007, CLIN EXP OPHTHALMOL, V35, P330, DOI 10.1111/j.1442-9071.2007.01482.x
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Parmeggiani F, 2006, OPHTHALMOLOGY, V113, P157
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Postea O, 2006, ARTERIOSCL THROM VAS, V26, P508, DOI 10.1161/01.ATV.0000201039.21705.dc
   Rongioletti M, 2005, PLATELETS, V16, P185, DOI 10.1080/09537100400020187
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai K, 2003, J PHARMACOL SCI, V91, P182
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schwahn B, 2001, Am J Pharmacogenomics, V1, P189, DOI 10.2165/00129785-200101030-00004
   Shemirani AH, 2006, BBA-PROTEINS PROTEOM, V1764, P1420, DOI 10.1016/j.bbapap.2006.06.007
   Sivaprasad S, 2006, EYE, V20, P43, DOI 10.1038/sj.eye.6701787
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2
   Weiss N, 2005, CURR DRUG METAB, V6, P27, DOI 10.2174/1389200052997357
   Wickens J, 2006, DRUG SAFETY, V29, P189, DOI 10.2165/00002018-200629030-00003
   WORMALD R, 2007, COCHRANE DB SYST REV, V18
   Yang N, 2006, EYE, V20, P523, DOI 10.1038/sj.eye.6701991
   Ye Z, 2006, LANCET, V367, P651, DOI 10.1016/S0140-6736(06)68263-9
   Zuluaga MF, 2007, INVEST OPHTH VIS SCI, V48, P1767, DOI 10.1167/iovs.06-1224
NR 61
TC 31
Z9 33
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2008
VL 49
IS 7
BP 3100
EP 3106
DI 10.1167/iovs.07-1654
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318WR
UT WOS:000257124000041
PM 18378576
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Simsek, M
   Citirik, M
   Ozates, S
   Simsek, T
AF Simsek, Mert
   Citirik, Mehmet
   Ozates, Serdar
   Simsek, Tulay
TI Quantitative analysis of the optic nerve head parameters in patients
   with age-related macular degeneration
SO TURKISH JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Age-related macular degeneration; confocal scanning laser
   ophthalmoscopy; cup shape; Heidelberg retinal tomography; optic nerve
   head parameters
ID HEIDELBERG RETINA TOMOGRAPHY; RISK-FACTORS; GLAUCOMA; DISC; LAYER
AB Background/aim: To evaluate the topographic parameters of the optic disc of patients with age-related macular degeneration (AMD) by performing confocal scanning laser ophthalmoscopy.
   Materials and methods: This prospective study included 41 eyes of 41 patients with neovascular AMD, 56 eyes of 56 patients with nonneovascular AMD, and 48 eyes of 48 healthy control subjects. Images of the optic nerve head of all of the participants were obtained using Heidelberg retinal tomography III software 3.1. The following stereometric parameters were measured for each participant: disc area, cup area, rim area, cup volume, rim volume, cup-to-disc ratio, mean cup depth, maximum cup depth, cup shape, and mean retinal nerve fiber layer thickness.
   Results: The cup shape values of the patients with neovascular and nonneovascular AMD were significantly different from those of the control subjects (P = 0.002 and P < 0.001, respectively). The cup-to-disc ratio was significantly higher in the patients with nonneovascular AMD when compared with the control subjects (P = 0.013), but no difference was found between the patients with neovascular AMD and the control subjects (P > 0.05). No significant differences were observed among the 3 groups with respect to the other optic disc parameters (P > 0.05).
   Conclusion: These data showed that the deterioration of the cup shape was an important finding in patients with AMD. Because AMD manifests with progressive ocular damage, including the optic nerve head, examination of the cup shape may be important during the follow-up of these patients.
C1 [Simsek, Mert; Citirik, Mehmet] Univ Hlth Sci, Ulucanlar Eye Educ & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
   [Ozates, Serdar] Kars Harakani State Hosp, Dept Ophthalmol, Kars, Turkey.
   [Simsek, Tulay] Osmangazi Univ, Fac Med, Dept Ophthalmol, Eskisehir, Turkey.
C3 Ankara Ulucanlar Eye Training & Research Hospital; University of Health
   Sciences Turkey; Kars State Hospital; Eskisehir Osmangazi University
RP Simsek, M (通讯作者)，Univ Hlth Sci, Ulucanlar Eye Educ & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
RI Simsek, Tulay/ABI-7278-2020; Simsek, Mert/AAJ-3145-2021; CITIRIK,
   Mehmet/A-1694-2018
OI CITIRIK, Mehmet/0000-0002-0558-5576; Simsek, Tulay/0000-0001-5132-9066
CR BECK RW, 1987, OPHTHALMOLOGY, V94, P1503
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Budde WM, 1999, AM J OPHTHALMOL, V127, P220, DOI 10.1016/S0002-9394(98)00348-1
   Citirik M, 2012, RETINA-J RET VIT DIS, V32, P985, DOI 10.1097/IAE.0b013e318229b0dc
   Cohen SY, 2016, RETINA-J RET VIT DIS, V36, P458, DOI 10.1097/IAE.0000000000000741
   Durukan AH, 2004, CLIN EXP OPHTHALMOL, V32, P259, DOI 10.1111/j.1442-9071.2004.00790.x
   Faschinger C, 2007, WIEN MED WOCHENSCHR, V157, P173, DOI 10.1007/s10354-007-0380-3
   GUSEK GC, 1990, KLIN MONATSBL AUGENH, V197, P14, DOI 10.1055/s-2008-1046236
   Hall ER, 2006, AM J OPHTHALMOL, V141, P494, DOI 10.1016/j.ajo.2005.10.049
   Hayreh SS, 2012, RETINA-J RET VIT DIS, V32, P2108, DOI 10.1097/IAE.0b013e31825620f2
   Jurisic D, 2017, ACTA CLIN CROAT, V56, P227, DOI 10.20471/acc.2017.56.02.05
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Law SK, 2004, AM J OPHTHALMOL, V138, P38, DOI 10.1016/j.ajo.2004.02.021
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Mamikonyan V R, 2015, Vestn Oftalmol, V131, P15, DOI 10.17116/oftalma2015131415-20
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Risovic D, 2014, VOJNOSANIT PREGL, V71, P341, DOI 10.2298/VSP1404341R
   Saarela V, 2008, ACTA OPHTHALMOL, V86, P603, DOI 10.1111/j.1600-0420.2007.01119.x
   Shin HY, 2013, JPN J OPHTHALMOL, V57, P41, DOI 10.1007/s10384-012-0205-9
   Sigler EJ, 2013, OPTOMETRY VISION SCI, V90, P84, DOI 10.1097/OPX.0b013e318278fc15
   Trick GL, 2006, J NEURO-OPHTHALMOL, V26, P284, DOI 10.1097/01.wno.0000249327.65227.67
   Uchida H, 1996, INVEST OPHTH VIS SCI, V37, P2393
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
NR 25
TC 0
Z9 0
U1 0
U2 0
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0144
EI 1303-6165
J9 TURK J MED SCI
JI Turk. J. Med. Sci.
PY 2019
VL 49
IS 5
BP 1518
EP 1523
DI 10.3906/sag-1904-210
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA JX9MI
UT WOS:000504050500037
PM 31651123
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Galbinur, T
   Averbukh, E
   Banin, E
   Hemo, I
   Chowers, I
AF Galbinur, T.
   Averbukh, E.
   Banin, E.
   Hemo, I.
   Chowers, I.
TI Intravitreal bevacizumab therapy for neovascular age-related macular
   degeneration associated with poor initial visual acuity
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB
AB Aim: The aim of the study was to assess the efficacy of intravitreal bevacizumab injections for eyes with neovascular age-related macular degeneration (NVAMD) and poor initial visual acuity (VA).
   Methods: A retrospective study of 44 consecutive treatment-naive eyes with NVAMD who had initial VA of 0.1 decimal or worse, and that were treated with intravitreal bevacizumab injections, was undertaken. Charts, optical coherence tomography (OCT) and fluorescein angiograms (FAs) were reviewed for the purpose of the study.
   Results: Mean lesion size was 3375 (SD 2116) mu m, all lesions showed sub- or intra-retinal fluid in OCT, and active neovascularisation comprised 41.6 (SD 17.7)% (range 10-90%) of the lesion area according to FA. The mean follow-up time was 3.9 (SD 5.8) (range 1-21) months. Patients received a mean of 2.6 (SD 2.4) bevacizumab injections (range 1-14), and mean VA improved from 1.85 (SD 0.64) to 1.52 (SD 0.77) LogMAR (p = 0.002). At final examination, nine eyes (20%) had reduced VA, ten eyes (23%) had stable VA and 25 eyes (57%) had improved VA compared with baseline. Following treatment, mean macular thickness was reduced from 332 (SD 98) to 248 (SD 79) mu m (p < 0.0001).
   Conclusions: Poor initial VA should not prevent use of bevacizumab in eyes with NVAMD. Selection of patients with signs of active neovascularisation based on ophthalmoscopy, OCT and FA may increase the likelihood of a favourable response to treatment.
C1 Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   Hadassah Hebrew Univ, Sch Med, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Hadassah University Medical Center
RP Chowers, I (通讯作者)，Hadassah Univ Hosp, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cervantes-Castaneda RA, 2008, EYE, V22, P777, DOI 10.1038/sj.eye.6702691
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 6
TC 6
Z9 6
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2009
VL 93
IS 10
BP 1351
EP 1352
DI 10.1136/bjo.2009.158931
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 498JN
UT WOS:000270135700017
PM 19520693
DA 2022-11-30
ER

PT J
AU Mackay, AM
   Brown, MC
   Hagan, RP
   Fisher, AC
   Grierson, I
   Harding, SP
AF Mackay, Alison M.
   Brown, Malcolm C.
   Hagan, Richard P.
   Fisher, Anthony C.
   Grierson, Ian
   Harding, Simon P.
TI Deficits in the electroretinogram in neovascular age-related macular
   degeneration and changes during photodynamic therapy
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE electroretinogram; age-related macular degeneration; photodynamic
   therapy
ID MULTIFOCAL ELECTRORETINOGRAPHY; RETINAL FUNCTION; VERTEPORFIN THERAPY
AB Purpose To describe the deficits in four electroretinography (ERG) modalities in patients with neovascular age-related macular degeneration (AMD). To describe the changes in these parameters during a course of verteporfin photodynamic therapy (PDT).
   Methods Pattern (PERG), multifocal (mfERG) (19 segment simplified test protocol), flash ERG and flicker ERG were performed in patients with active neovascular AMD before PDT and compared to fellow eye controls using paired t-tests. Changes in ERG parameters during the 12 month treatment course were visualised using 95% confidence intervals of the median difference. The statistical significance of any changes was quantified using Wilcoxon signed ranks tests.
   Results Fifty patients were recruited and followed. At presentation all ERG amplitudes were reduced with greater reductions in focal as opposed to global test protocols (P < 0.05). Over the 12 month course of PDT, PERG P50 amplitude showed a general downward trend and latency remained unchanged. mfERG p1 amplitude density showed an upward trend at six months before returning to baseline by 12 months. mfERG ring 2 amplitude density was significantly increased at 12 months compared to baseline (P = 0.010). Flicker ERG latency was significantly increased at six months compared to baseline (P = 0.015).
   Discussion The simplified mfERG protocol was tolerated by this patient group, however, they found the full test protocol demanding. Large deficits in the retinal ERG function occur in neovascular AMD and involve retinal locations adjacent to as well as overlying choroidal neovascularisation (CNV). After PDT there is an improvement in electro-retinal function in retinal locations overlying the CNV.
C1 Royal Liverpool Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England.
   Royal Liverpool Hosp, Dept Clin Engn, Liverpool L7 8XP, Merseyside, England.
   Univ Liverpool, Dept Med, Unit Ophthalmol, Liverpool L69 3BX, Merseyside, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; Royal Liverpool & Broadgreen University
   Hospitals NHS Trust; Royal Liverpool University Hospital; University of
   Liverpool; University of Liverpool
RP Harding, SP (通讯作者)，Royal Liverpool Hosp, St Pauls Eye Unit, Prescot St, Liverpool L7 8XP, Merseyside, England.
EM simonpharding@aol.com
OI Harding, Simon/0000-0003-4676-1158; Mackay, Alison/0000-0002-6652-1154
CR Anand R, 2003, ARCH OPHTHALMOL-CHIC, V121, P415
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CELESIA GG, 1986, ELECTROEN CLIN NEURO, V64, P29
   Elsner H, 2002, OPHTHALMOLOGE, V99, P620, DOI 10.1007/s00347-001-0593-6
   Hagan RP, 2006, DOC OPHTHALMOL, V113, P21, DOI 10.1007/s10633-006-9009-x
   Heinemann-Vernaleken B, 2001, GRAEF ARCH CLIN EXP, V239, P556, DOI 10.1007/s004170100308
   HEINEMANNVERNAL.B, 1999, INVEST OPHTH VIS SCI, V40, P3773
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   HUANG S, 2001, DOC OPHTHALMOL, V101, P115
   Jackson GR, 2002, J OPT SOC AM A, V19, P185, DOI 10.1364/JOSAA.19.000185
   Jackson GR, 2001, INVEST OPHTH VIS SCI, V42, pS69
   Jiang LB, 2003, DOC OPHTHALMOL, V107, P165, DOI 10.1023/A:1026215221569
   JURKIES B, 2000, INVEST OPHTH VIS SCI, V41, P4749
   JURKIES B, 1999, INVEST OPHTH VIS SCI, V40, P1668
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   JURKLIES B, 2001, GRAEF ARCH CLIN EXP, V240, P867
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   Mennel S, 2005, AM J OPHTHALMOL, V139, P748, DOI 10.1016/j.ajo.2004.08.072
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Moschos MM, 2004, J FR OPHTALMOL, V27, P1001, DOI 10.1016/S0181-5512(04)96255-9
   Neveu MM, 2006, DOC OPHTHALMOL, V113, P71, DOI 10.1007/s10633-006-9016-y
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   PARKS S, 2000, INVEST OPHTH VIS SCI, V41, P847
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Rudolph G, 2002, GRAEF ARCH CLIN EXP, V240, P874, DOI 10.1007/s00417-002-0549-9
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Seiple W, 2003, INVEST OPHTH VIS SCI, V44, P1783, DOI 10.1167/iovs.02-0518
   WRIGHT CE, 1985, DOC OPHTHALMOL, V59, P365, DOI 10.1007/BF00159171
NR 34
TC 12
Z9 14
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD SEP
PY 2007
VL 115
IS 2
BP 69
EP 76
DI 10.1007/s10633-007-9056-y
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 209QQ
UT WOS:000249403500002
PM 17671804
DA 2022-11-30
ER

PT J
AU Takayama, K
   Kaneko, H
   Sugita, T
   Maruko, R
   Hattori, K
   Ra, E
   Kawano, K
   Kataoka, K
   Ito, Y
   Terasaki, H
AF Takayama, Kei
   Kaneko, Hiroki
   Sugita, Tadasu
   Maruko, Ruka
   Hattori, Kyoko
   Ra, Eimei
   Kawano, Kenichi
   Kataoka, Keiko
   Ito, Yasuki
   Terasaki, Hiroko
TI One-Year Outcomes of 1+pro re nata versus 3+pro re nata Intravitreal
   Aflibercept Injection for Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Treatment; Vascular endothelial growth
   factor; Retinal disease
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; BEVACIZUMAB; EFFICACY
AB Purpose: We compared 1-year outcomes of 1 + pro re nata (PRN) versus 3 + PRN of intravitreal aflibercept injection (IAI) for age-related macular degeneration (AMD). Methods: Forty-two eyes with naive AMD received 3 + PRN IAI treatment and 47 eyes with naive AMD received 1 + PRN IAI treatment. Visual acuity (VA), central retinal thickness (CRT), and central choroidal thickness (CCT) and number of administered IAIs during 12 months were compared. Results: VAs improved, and CRTs reduced significantly at any given month from baseline in both groups (p < 0.01, respectively). CCT reduced significantly at 3 months in the 3 + PRN group (p = 0.024) but not in the 1 + PRN group. The 1 + PRN group received fewer injections than the 3 + PRN group (p < 0.01). Conclusions: Aflibercept leads to equivalent VA and morphologic retinal improvement without administering 3 injections. (C) 2017 S. Karger AG, Basel
C1 [Takayama, Kei; Kaneko, Hiroki; Sugita, Tadasu; Maruko, Ruka; Hattori, Kyoko; Ra, Eimei; Kawano, Kenichi; Kataoka, Keiko; Ito, Yasuki; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
C3 Nagoya University
RP Takayama, K (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM keitaka1234@med.nagoya-u.ac.jp
RI Maruko, Ruka/M-4929-2014; Kaneko, Hiroki/AHA-2461-2022; Kaneko,
   Hiroki/O-7695-2015; Ito, Yasuki/M-4876-2014; Kataoka, Keiko/B-2806-2016
OI Maruko, Ruka/0000-0003-0208-1011; Kaneko, Hiroki/0000-0003-0731-6465;
   Kaneko, Hiroki/0000-0003-0731-6465; Ito, Yasuki/0000-0001-9219-9261;
   Kataoka, Keiko/0000-0002-8795-6536; Takayama, Kei/0000-0002-1477-9014
FU Novartis Co.; Santen Co.; Wakamoto Co.; Pfizer Co.; Chukyo Longevity
   Medical and Promotion Foundation; Takeda Medical Research Foundation; 
   [15H04994];  [16K20313]
FX H. Terasaki received research funding from Novartis Co., Santen Co.,
   Wakamoto Co., and Pfizer Co. This work was partially supported by
   Grants-in-Aid for Scientific Research B (H. Terasaki; 15H04994), a
   Grant-in-Aid for Young Scientists B (K. Kataoka; 16K20313), the Chukyo
   Longevity Medical and Promotion Foundation (H. Kaneko), and the Takeda
   Medical Research Foundation (H. Kaneko).
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Klettner A, 2014, GRAEF ARCH CLIN EXP, V252, P1593, DOI 10.1007/s00417-014-2719-y
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Pitcher JD, 2015, BRIT J OPHTHALMOL, V99, P848, DOI 10.1136/bjophthalmol-2014-306018
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stewart MW, 2013, EXPERT REV CLIN PHAR, V6, P103, DOI [10.1586/ECP.12.81, 10.1586/ecp.12.81]
   Ventrice P, 2013, J PHARMACOL PHARMACO, V4, pS38, DOI 10.4103/0976-500X.120947
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
NR 22
TC 10
Z9 11
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 237
IS 2
BP 105
EP 110
DI 10.1159/000461785
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ7EV
UT WOS:000398247400006
PM 28231566
DA 2022-11-30
ER

PT J
AU Lehrer, S
   Rheinstein, PH
AF Lehrer, S.
   Rheinstein, P. H.
TI Cannabis smoking and age-related macular degeneration in the UK Biobank
   cohort
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Cannabis; Tar; Retina; Toxicity
AB Background. - A major cause of blindness in older persons is age-related macular degeneration (AMD). Cigarette smoking is one of the major risk factors for AMD. In the present study, we analyzed UK Biobank data to determine whether smoking cannabis, like cigarettes, might be related to AMD.Methods. - Our UK Biobank application was approved as UKB project 57245 (S.L., P.H.R.). Our analysis included all subjects with AMD and cannabis smoking information. The diagnosis of AMD was ascertained based on the 10th Revision of the International Classification of Diseases (ICD10), H35.3. Age at time of diagnosis of AMD was obtained from data field 5923. Cannabis information was recorded in UKB category 143, data field 20453, ever taken cannabis. A touch screen posed the question, "Have you taken CANNABIS (cannabis, grass, hash, ganja, blow, draw, skunk, weed, spliff, dope), even if it was a long time ago?" Possible answers were no, yes, 1-2 times, yes 3-10 times, yes, 11-100 times, yes, more than 100 times.Results. - Subjects who had used marijuana more than 100 times had a significantly reduced risk of AMD, compared to subjects who had never used marijuana, and use of marijuana every day was associated with less AMD than use of marijuana less than once a month. But subjects who used cannabis 100 times or more were significantly younger (8 years) when they developed AMD than subjects who never used cannabis.Conclusion. - Drusen, deposits of lipids, proteins, and cellular debris, accumulate in Bruch's membrane, limiting transport between the retinal pigment epithelium and the vasculature, triggering an inflammatory reaction. Marijuana can retard the inflammatory process because it is a powerful anti-inflammatory agent. Therefore, marijuana could reduce the risk of AMD. At the same time, blood vessels in the choriocapillaris below Bruch's membrane become more sparse with age. This phenomenon is believed to be a starting point for AMD. Marijuana can accelerate the loss of blood vessels due to its anti-angiogenic properties. Therefore, marijuana use might cause AMD to develop sooner in younger people.(c) 2022 Elsevier Masson SAS. All rights reserved.
C1 [Lehrer, S.] Icahn Sch Med Mt Sinai, Dept Radiat Oncol, New York, NY USA.
   [Rheinstein, P. H.] Severn Hlth Solut, Severna Pk, MD USA.
   [Lehrer, S.] Mt Sinai Med Ctr, Box 1236 Radiat Oncol,1 Gustave L Levy Pl, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai
RP Lehrer, S (通讯作者)，Mt Sinai Med Ctr, Box 1236 Radiat Oncol,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM steven.lehrer@mssm.edu
OI lehrer, steven/0000-0002-4850-094X
FU Office ofResearch Infrastructure of the National Institutes of Health
   [S10OD018522, S10OD026880]
FX This work was supported in part through the computational resources and
   staff expertise provided by Scientific Computing at the Icahn School of
   Medicine at Mount Sinai. Researchreported in this paper was also
   supported by the Office ofResearch Infrastructure of the National
   Institutes of Healthunder award numbers S10OD018522 and S10OD026880. The
   content is solely the responsibility of the authors and doesnot
   necessarily represent the official views of the NationalInstitutes of
   Health.
CR Arthur RS, 2020, JNCI-J NATL CANCER I, V112, P893, DOI 10.1093/jnci/djz241
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Eisenstein M, 2021, NATURE, V600, pS1, DOI 10.1038/d41586-021-03574-4
   Gates P, 2014, RESPIROLOGY, V19, P655, DOI 10.1111/resp.12298
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Mahmood SS, 2014, LANCET, V383, P999, DOI 10.1016/S0140-6736(13)61752-3
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Ramer R, 2015, INT REV CEL MOL BIO, V314, P43, DOI 10.1016/bs.ircmb.2014.10.005
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Wang MTM, 2021, SURV OPHTHALMOL, V66, P327, DOI 10.1016/j.survophthal.2020.07.002
   Zhu A., 2019, UK BIOBANK DATA PARS, DOI 10.1007/s11682-021-00548-y
   Zurier RB, 2003, J CELL BIOCHEM, V88, P462, DOI 10.1002/jcb.10291
NR 12
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD SEP
PY 2022
VL 45
IS 7
BP 756
EP 761
DI 10.1016/j.jfo.2022.01.004
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4X7NA
UT WOS:000861023200009
PM 35753852
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, I
   Ryu, G
   Sagong, M
AF Kim, Inhye
   Ryu, Gahyung
   Sagong, Min
TI Morphological features and prognostic significance of multilayered
   pigment epithelium detachment in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE diagnostic tests; Investigation; degeneration; imaging; macula; retina
ID GROWTH-FACTOR; CELLS; TEAR
AB Aims To investigate the structure of multilayered pigment epithelial detachment (m-PED) in neovascular age-related macular degeneration, and its association with visual prognosis and the progression of fibrotic scars at 12 months. Methods We retrospectively analysed 68 eyes of 63 patients with m-PED that included a prechoroidal cleft. The compartments within m-PED were divided into neovascular tissue (layer 1), a hyper-reflective band (layer 2), and a prechoroidal cleft (layer 3). Clinical variables were compared between patients manifesting layer 2 and those who did not. Multiple regression analyses were used to find the factors related to visual outcome and fibrotic scar formation. Results Layer 2 was detected in 38 (55.9 %) of 68 eyes. With continuous treatment, the group with layer 2 showed gradual visual deterioration (p<0.001 at month 12), while the group without layer 2 showed visual improvement (p<0.001 at month 12). In the group with layer 2, the thickness of layer 2 significantly increased, and in the group without layer 2, if it formed, it increased gradually (p=0.004 at month 12). In both groups, other layers significantly decreased by month 12. The presence of layer 2 at baseline was significantly associated with a poor visual outcome (p=0.009) and fibrotic scar formation (p=0.023). Conclusions The m-PED with layer 2 had a higher risk of fibrotic scar formation and was associated with a poor visual prognosis. Layer 2 may be an early stage precursor of a fibrotic scar.
C1 [Kim, Inhye; Ryu, Gahyung; Sagong, Min] Yeungnam Univ, Coll Med, Dept Ophthalmol, Daegu 42415, South Korea.
   [Kim, Inhye; Ryu, Gahyung; Sagong, Min] Yeungnam Univ Hosp, Yeungnam Eye Ctr, Daegu, South Korea.
C3 Yeungnam University; Yeungnam University; Yeungnam University Hospital
RP Sagong, M (通讯作者)，Yeungnam Univ, Sch Med, Dept Ophthalmol, Daegu 42415, South Korea.; Sagong, M (通讯作者)，Yeungnam Univ, Coll Med, Daegu 42415, South Korea.
EM msagong@ynu.ac.kr
FU 2020 Yeungnam University research grant
FX MS was supported by the 2020 Yeungnam University research grant.
CR Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Kim JH, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/2578349
   Kim JM, 2017, RETINA-J RET VIT DIS, V37, P2047, DOI 10.1097/IAE.0000000000001435
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Mukai R, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-159
   Mukai R, 2014, ACTA OPHTHALMOL, V92, pE407, DOI 10.1111/aos.12350
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Ohayon A, 2020, BRIT J OPHTHALMOL, V104, P1085, DOI 10.1136/bjophthalmol-2019-314923
   Pedrosa AC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4263017
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Singh SR, 2020, SURV OPHTHALMOL, V65, P451, DOI 10.1016/j.survophthal.2020.01.001
   Souied EH, 2020, AM J OPHTHALMOL, V214, P151, DOI 10.1016/j.ajo.2020.02.016
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 24
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2022
VL 106
IS 8
BP 1073
EP 1078
DI 10.1136/bjophthalmol-2020-318616
EA MAR 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3N6ON
UT WOS:000727740000001
PM 33658232
DA 2022-11-30
ER

PT J
AU Augustin, AJ
   Diehm, C
   Grieger, F
   Bentz, J
AF Augustin, Albert J.
   Diehm, Curt
   Grieger, Frank
   Bentz, Juergen
TI Alprostadil infusion in patients with dry age related macular
   degeneration: a randomized controlled clinical trial
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Article
DE age related macular degeneration; alprostadil; prostaglandin E1;
   therapy; visual acuity
ID CHOROIDAL BLOOD-FLOW; RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   PROSTAGLANDIN E-1; VISUAL-ACUITY; HYPERTENSION; PREVALENCE; THERAPY;
   PGE(1)
AB Background: Age-related macular degeneration is the leading cause of blindness among elderly individuals in industrialized countries. New drugs and advanced concepts for the treatment of dry AMD (dAMD) are needed. A new approach is the application of intravenous infusions of prostaglandin E1.
   Objective: The aim of this study was to assess efficacy and safety of intravenous alprostadil infusion in patients with dAMD.
   Methods: This was a prospective, randomized, multi-center study. Patients were treated with intravenous infusion of either 60 mu g alprostadil or placebo over 3 weeks. Main efficacy outcomes were mean differences in best corrected visual acuity (BCVA) from baseline assessed in early treatment diabetic retinopathy study (ETDRS) lines immediately, 3 months and 6 months after treatment.
   Results: In the full analysis set (FAS) a mean difference of 0.89 - 0.537 ETDRS lines according to analysis of variance-covariance (ANCOVA) resulted in the alprostadil group (n = 16) and a mean difference of -0.05 - 0.578 in the placebo group (n = 17) 3 months after end of treatment. Thus, effectiveness of alprostadil infusion was numerically superior to placebo treatment by a mean of 0.94 lines after 3 months (1.51 lines after 6 months). These findings were more pronounced in the per protocol set (PPS). Safety results were in line with the good safety profile of alprostadil.
   Conclusion: A numerical treatment effect in favor of alprostadil was visible, which lasted until the end of follow up. These results provide further evidence that alprostadil probably has a therapeutic effect in the treatment of dAMD and justify further clinical studies.
C1 [Augustin, Albert J.] Klinikum Karlsruhe, Augenklin, D-76133 Karlsruhe, Germany.
   [Diehm, Curt] Heidelberg Univ, Akad Lehrkrankenhaus, SRH Klinikum Karlsbad Langensteinbach GmbH, D-76307 Karlsbad, Germany.
   [Grieger, Frank; Bentz, Juergen] UCB Pharma SA, CH-1630 Bulle, Switzerland.
C3 Municipal Hospital Karlsruhe; University of Hamburg; University Medical
   Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; UCB
   Pharma SA
RP Augustin, AJ (通讯作者)，Klinikum Karlsruhe, Augenklin, Moltkestr 90, D-76133 Karlsruhe, Germany.
EM albertjaugustin@googlemail.com
RI Bentz, Juergen WG/GSM-9291-2022
OI Bentz, Juergen WG/0000-0002-6947-1666; Bentz,
   Jurgen/0000-0002-2162-2410; Augustin, Prof. Dr. Albert
   J./0000-0003-1591-0536
FU UCB Pharma SA
FX E Stetzer, QuintesScience, provided editorial support which was funded
   by UCB Pharma SA. AJ Augustin and C Diehm indicate no proprietary
   interest. F Grieger and J Bentz are employees of UCB Pharma SA. No
   further funding of this work was received from any organization.
CR Amendt K, 2005, ANGIOLOGY, V56, P409, DOI 10.1177/000331970505600408
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Augustin A., 2012, EUR OPHTHALMIC REV, V6, P72
   Augustin AJ, 2002, OPHTHALMOLOGE, V99, P299, DOI 10.1007/s00347-002-0629-6
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Creutzig A, 2004, VASA-J VASCULAR DIS, V33, P137, DOI 10.1024/0301-1526.33.3.137
   Creutzig A, 1997, VASA-J VASCULAR DIS, V26, P122
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Ferris FL, 1996, OPHTHALMOLOGY, V103, P181, DOI 10.1016/S0161-6420(96)30742-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   HEIDRICH H, 1989, KLIN MONATSBL AUGENH, V194, P282, DOI 10.1055/s-2008-1046371
   Heidrich H, 1994, INT J ANGIOLOGY, V3, P160
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Karagianni N, 2010, ADV EXP MED BIOL, V703, P1, DOI 10.1007/978-1-4419-5635-4_1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Ladewig MS, 2005, PROSTAG LEUKOTR ESS, V72, P251, DOI 10.1016/j.plefa.2004.11.006
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schror K, 2004, VASA-J VASCULAR DIS, V33, P119, DOI 10.1024/0301-1526.33.3.119
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yehoshua Zohar, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS6, DOI 10.3928/15428877-20101031-19
NR 35
TC 15
Z9 17
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD JUL
PY 2013
VL 22
IS 7
BP 803
EP 812
DI 10.1517/13543784.2013.794782
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 180UE
UT WOS:000321623300001
PM 23627650
DA 2022-11-30
ER

PT J
AU Hosoda, Y
   Miyake, M
   Yamashiro, K
   Ooto, S
   Takahashi, A
   Oishi, A
   Miyata, M
   Uji, A
   Muraoka, Y
   Tsujikawa, A
AF Hosoda, Yoshikatsu
   Miyake, Masahiro
   Yamashiro, Kenji
   Ooto, Sotaro
   Takahashi, Ayako
   Oishi, Akio
   Miyata, Manabu
   Uji, Akihito
   Muraoka, Yuki
   Tsujikawa, Akitaka
TI Deep phenotype unsupervised machine learning revealed the significance
   of pachychoroid features in etiology and visual prognosis of age-related
   macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL ANGIOMATOUS PROLIFERATION;
   AXIAL LENGTH; CLINICAL CHARACTERISTICS; PHOTODYNAMIC THERAPY; 10-YEAR
   INCIDENCE; RISK-FACTORS; EYE DISEASE; NEOVASCULARIZATION; THICKNESS
AB Unsupervised machine learning has received increased attention in clinical research because it allows researchers to identify novel and objective viewpoints for diseases with complex clinical characteristics. In this study, we applied a deep phenotyping method to classify Japanese patients with age-related macular degeneration (AMD), the leading cause of blindness in developed countries, showing high phenotypic heterogeneity. By applying unsupervised deep phenotype clustering, patients with AMD were classified into two groups. One of the groups had typical AMD features, whereas the other one showed the pachychoroid-related features that were recently identified as a potentially important factor in AMD pathogenesis. Based on these results, a scoring system for classification was established; a higher score was significantly associated with a rapid improvement in visual acuity after specific treatment. This needs to be validated in other datasets in the future. In conclusion, the current study demonstrates the usefulness of unsupervised classification and provides important knowledge for future AMD studies.
C1 [Hosoda, Yoshikatsu; Miyake, Masahiro; Yamashiro, Kenji; Ooto, Sotaro; Takahashi, Ayako; Oishi, Akio; Miyata, Manabu; Uji, Akihito; Muraoka, Yuki; Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin, Kyoto 6068507, Japan.
   [Yamashiro, Kenji] Otsu Red Cross Hosp, Dept Ophthalmol, Otsu, Shiga, Japan.
C3 Kyoto University
RP Miyake, M (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin, Kyoto 6068507, Japan.
EM miyakem@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; Miyata, Manabu/U-9008-2018
OI Oishi, Akio/0000-0002-0977-9458; 
CR Aiello LP, 2010, OPHTHALMOLOGY, V117, P946, DOI 10.1016/j.ophtha.2009.10.002
   Awan SE, 2018, CURR OPIN CARDIOL, V33, P190, DOI 10.1097/HCO.0000000000000491
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chiang MMT, 2010, J CLASSIF, V27, P3, DOI 10.1007/s00357-010-9049-5
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cikes M, 2019, EUR J HEART FAIL, V21, P74, DOI 10.1002/ejhf.1333
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Flores-Moreno I, 2013, AM J OPHTHALMOL, V155, P314, DOI 10.1016/j.ajo.2012.07.015
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Ho CYD, 2018, CLIN EXP OPHTHALMOL, V46, P485, DOI 10.1111/ceo.13131
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Jain AK, 2010, PATTERN RECOGN LETT, V31, P651, DOI 10.1016/j.patrec.2009.09.011
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rasmussen A, 2017, ACTA OPHTHALMOL, V95, P128, DOI 10.1111/aos.13233
   Ruan JH, 2004, ITSC 2004: 7TH INTERNATIONAL IEEE CONFERENCE ON INTELLIGENT TRANSPORTATION SYSTEMS, PROCEEDINGS, P29, DOI 10.1109/ITSC.2004.1398867
   Scholl S, 2009, EXPERT REV OPHTHALMO, V4, P617, DOI 10.1586/EOP.09.51
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Suhler EB, 2018, OPHTHALMOLOGY, V125, P1075, DOI 10.1016/j.ophtha.2017.12.039
   Tibshirani R, 2001, J ROY STAT SOC B, V63, P411, DOI 10.1111/1467-9868.00293
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Wagstaff K., 2001, ICML, P577
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Zha HY, 2002, ADV NEUR IN, V14, P1057
NR 66
TC 13
Z9 13
U1 2
U2 7
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 28
PY 2020
VL 10
IS 1
AR 18423
DI 10.1038/s41598-020-75451-5
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA OO8UW
UT WOS:000587650700009
PM 33116208
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Majeed, M
   Majeed, S
   Nagabhushanam, K
AF Majeed, Muhammed
   Majeed, Shaheen
   Nagabhushanam, Kalyanam
TI An Open-Label Pilot Study on Macumax Supplementation for Dry-Type
   Age-Related Macular Degeneration
SO JOURNAL OF MEDICINAL FOOD
LA English
DT Article
DE bilberry; lutein; zeaxanthin; piperine; saffron; zinc monomethionine
ID LUTEIN; ZEAXANTHIN; CAROTENOIDS; PREVALENCE
AB Age-related macular degeneration (AMD) is one of the most widespread degenerative disorders in elderly people. A 90-day, open-label clinical study was conducted in 40 patients, aged 50 years or older, with early-stage dry-type AMD to evaluate the safety and efficacy of Macumax(R), a novel mixture of a phyto-mineral nutritional supplement containing ZeaLutein(R) (consisting of lutein, zeaxanthin, and piperine), extracts of bilberry, saffron, and zinc monomethionine. Subjects received one capsule of the supplement twice daily for 90 days. The treatment measures included physical examination, vital signs, and assessment of subjective and objective symptoms at baseline and after treatment. For efficacy assessment, baseline values were compared with the values after treatment at 30-day intervals, on days 30, 60, and 90. The safety of the treatment was assessed during all the visits. Overall, the patients showed improvement in the subjective symptoms, such as vision scores after treatment compared with baseline. The changes in diminished and distorted vision scores were found to be significant from day 60 (P < .05). In the case of objective symptoms, only 40% of the subjects (P < .05) had abnormal Amsler's grid aberration scores on day 90 compared with 77.5% of subjects at the beginning of the study. No adverse events were observed during the study. This pilot study provides evidence that Macumax(R) supplementation is safe and maintained eye health without further progression of the disease in patients with early-stage dry-type AMD. Clinical Trial Registration number: CTRI/2016/02/006676
C1 [Majeed, Muhammed] Sami Labs Ltd, Bangalore, Karnataka, India.
   [Majeed, Muhammed; Majeed, Shaheen] Sabinsa Corp, Payson, AZ USA.
   [Majeed, Muhammed; Nagabhushanam, Kalyanam] Sabinsa Corp, 20 Lake Dr, East Windsor, NJ 08520 USA.
RP Nagabhushanam, K (通讯作者)，Sabinsa Corp, 20 Lake Dr, East Windsor, NJ 08520 USA.
EM kalyanam@sabinsa.com
CR Arnold C, 2013, NUTRITION, V29, P1412, DOI 10.1016/j.nut.2013.05.012
   Bartlett H, 2004, OPHTHAL PHYSL OPT, V24, P339, DOI 10.1111/j.1475-1313.2004.00218.x
   Bernstein PS, 2009, ACTA HORTIC, V841, P103
   Bhowmik D, 2010, INT J PHARM SCI RES, V1, P1, DOI 10.13040/IJPSR.0975-8232.1(8).1-12
   Biswal MR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203816
   CDC, DEF AD OV OB
   Chew EY, 2017, OPHTHALMOLOGICA, V238, P1, DOI 10.1159/000473865
   CTRI, 2016, CLIN TRIALS REG IND
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Fields MA, 2013, STEM CELL BIOL REGEN, P1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Majeed M., 1996, U.S. Patent, Patent No. [5,536,506, 5536506]
   Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228
   Miyake S, 2012, LAB INVEST, V92, P102, DOI 10.1038/labinvest.2011.132
   Neelam K, 2017, BR J OPHTHALMOL, V101, P1
   Ogawa K, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-120
   Osada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178627
   Ozawa Y, 2015, J NUTR HEALTH AGING, V19, P548, DOI 10.1007/s12603-014-0573-6
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Srinivasan K, 2007, CRIT REV FOOD SCI, V47, P735, DOI 10.1080/10408390601062054
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Tian Y, 2015, ACTA OPHTHALMOL, V93, P141, DOI 10.1111/aos.12535
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo TTY, 2013, GRAEF ARCH CLIN EXP, V251, P41, DOI 10.1007/s00417-012-2128-z
   Zadok D, 1999, EYE, V13, P734, DOI 10.1038/eye.1999.218
NR 37
TC 3
Z9 3
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-620X
EI 1557-7600
J9 J MED FOOD
JI J. Med. Food
PD MAY 1
PY 2021
VL 24
IS 5
BP 551
EP 557
DI 10.1089/jmf.2020.0097
EA AUG 2020
PG 7
WC Chemistry, Medicinal; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology; Nutrition &
   Dietetics
GA SE2OA
UT WOS:000592090900001
PM 33180005
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Lesauskaite, V
   Sinkunaite-Marsalkiene, G
   Simonyte, S
   Zemaitiene, R
   Kriauciuniene, L
   Zaliuniene, D
AF Liutkeviciene, Rasa
   Lesauskaite, Vaiva
   Sinkunaite-Marsalkiene, Giedre
   Simonyte, Sandrita
   Zemaitiene, Reda
   Kriauciuniene, Loresa
   Zaliuniene, Dalia
TI MMP-2 Rs24386 (C-->T) gene polymorphism and the phenotype of age-related
   macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; phenotype; matrix metalloproteinases;
   gene polymorphism
ID MATRIX METALLOPROTEINASES; EYE DISEASE; VARIANTS
AB AIM: To examine the MMP-2 (-1306 C/T) gene polymorphism and the phenotype characterized by soft and hard drusen of early age-related macular degeneration (AMD) and geographic atrophy of late AMD form.
   METHODS: The study enrolled 850 investigations (290 AMD patients with soft and hard drusen, 34 with geographic atrophy and a random sample of the population n=526). Early AMD was classified according to the International Classification and Grading System. For geographic atrophy diagnosis the Age-Related Eye Disease Study classification was used. The potential association with single nucleotide polymorphisms on MMP-2 Rs243865 was evaluated for all patients, adjusted for age and sex. The genotyping test of MMP-2 Rs243865 (C-->T) was conducted using the real-time polymerase chain reaction method.
   RESULTS: MMP-2 (-1306 C/T) C/C genotype was more frequently detected in AMD patients with hard drusen than the soft drusen or control group (66.43% vs 53.74%, vs 54.94%, P=0.047). Logistic regression analysis showed that the MMP-2 (-1306) C/C genotype increased the likelihood to develop hard drusen in AMD patients (OR=1.7, 95% CI: 1.06-2.74; P=0.028). No association between MMP-2 (-1306 C/T) gene polymorphism in patients with atrophic AMD and control group was found (54.94%, 37.64%, 7.41% vs 50%, 38.24%, 11.76%; P=0.6).
   CONCLUSION: The MMP-2 Rs24386 (C-->T) polymorphism is found to be associated with the development of hard drusen in patients with AMD.
C1 [Liutkeviciene, Rasa; Zemaitiene, Reda; Kriauciuniene, Loresa; Zaliuniene, Dalia] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, LT-50161 Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Kriauciuniene, Loresa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, LT-50161 Kaunas, Lithuania.
   [Lesauskaite, Vaiva; Sinkunaite-Marsalkiene, Giedre; Simonyte, Sandrita] Lithuanian Univ Hlth Sci, Med Acad, 3Intitute Cardiol, Sukileliu 17, LT-50161 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Simonyte, S (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, 3Intitute Cardiol, Sukileliu 17, LT-50161 Kaunas, Lithuania.
EM sandrita.simonyte@lsmuni.lt
OI Lesauskaite, Vaiva/0000-0003-2736-3111
FU Lithuanian Science Council [MIP-10330]
FX Supported by Lithuanian Science Council (No. MIP-10330).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   FRAMPTON GK, 2016, HLTH TECHNOL ASSESS, V20, P1
   Grabauskas Vilius, 2003, Medicina (Kaunas), V39, P1215
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lesauskaite V, 2006, GERONTOLOGY, V52, P40, DOI 10.1159/000089824
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Moitinho F, 2007, VIP IM THEM C COMP V
   Ortak H, 2013, OPHTHALMIC GENET, V34, P217, DOI 10.3109/13816810.2013.781192
   Peasey A, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-255
   Price SJ, 2001, J BIOL CHEM, V276, P7549, DOI 10.1074/jbc.M010242200
   S Seregard S, 2003, INVEST OPHTH VIS SCI, V44, P403
   Seitzman RL, 2008, AM J EPIDEMIOL, V167, P1217, DOI 10.1093/aje/kwn024
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P32, DOI 10.1055/s-2008-1034940
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zeng RP, 2013, MOL VIS, V19, P729
NR 21
TC 4
Z9 4
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD SEP 18
PY 2017
VL 10
IS 9
BP 1349
EP 1353
DI 10.18240/ijo.2017.09.03
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FG1LQ
UT WOS:000409558000003
PM 28944191
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Chen, YX
   Han, F
AF Chen, Youxin
   Han, Fei
TI Profile of ranibizumab: efficacy and safety for the treatment of wet
   age-related macular degeneration
SO THERAPEUTICS AND CLINICAL RISK MANAGEMENT
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   ranibizumab; efficacy; safety
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY; CHOROIDAL
   NEOVASCULARIZATION; PIGMENT EPITHELIUM; INJECTION; VISION; DELAY; TRIAL
AB Wet age-related macular degeneration (AMD) causes severe vision loss due to the development of choroidal neovascularization (CNV). The critical role of vascular endothelial growth factor in the pathogenesis of CNV is well understood. Ranibizumab plays an inhibitory role with CNV and reduces vascular permeability by binding to vascular endothelial growth factor. Intravitreal ranibizumab reduces the risk of visual acuity (VA) loss and increases the chance of VA gain compared with no treatment or photodynamic therapy for CNV in AMD. Some high-quality research has shown that the optimal timing for ranibizumab treating wet AMD is the first 3 months. It is recommended that ranibizumab is intravitreally injected monthly in the initiation for at least 3 months. Subsequent managing of regimens should be made dependent on the VA change, fundus examination, and image of optical coherence topography. An individualized strategy or combined method with photodynamic therapy is beneficial to the active lesion in the consecutive treatment of ranibizumab for CNV, and may be a good choice in order to decrease injection times. Regarding the safety profile, ranibizumab has been well tolerated in clinical trials. The principal ocular adverse event detected in clinical trials is a low frequency of ocular inflammation. Key serious ocular adverse events occurred in <5% of ranibizumab-treated patients in large-scale clinical trials. It appears unlikely that treatment with ranibizumab increases the risk of vascular events significantly. Less frequent injections on an as-needed schedule, based on monthly monitoring may have the most optimal risk: benefit ratio.
C1 [Chen, Youxin] Peking Union Med Coll Hosp, Dept Ophthalmol, Peking Union Med Coll, Beijing 100730, Peoples R China.
   Chinese Acad Med Sci, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Chinese Academy of Medical Sciences - Peking Union Medical College
RP Chen, YX (通讯作者)，Peking Union Med Coll Hosp, Dept Ophthalmol, Peking Union Med Coll, 1 Shuai Fu Yuan,Wang Fu Jing St, Beijing 100730, Peoples R China.
EM chenyouxin@medmail.com.cn
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Amoaku W, 2009, EYE, V23, P2140, DOI 10.1038/eye.2008.241
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   BOYER DS, 2008, AM AC OPHTH AAO 2008
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   CATT Research Group, 2012, OPHTHALMOLOGY   0501
   Center for Drug Evaluation and Research, BLA APPL 125156 CLIN
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Chua PYS, 2009, ARCH OPHTHALMOL-CHIC, V127, P939, DOI 10.1001/archophthalmol.2009.139
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   European Medicines Agency, ASS REP LUC RAN PROC
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   *GEN INC, 2010, LUC RAN INJ FULL PRE
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Koh A, 2011, SINGAP MED J, V52, P232
   LEY AM, AAO 2009
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Matthe E, 2011, OPHTHALMOLOGE, V108, P237, DOI 10.1007/s00347-010-2282-9
   Mones J, 2011, OPHTHALMOLOGICA, V225, P112, DOI 10.1159/000319906
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Singer MA, 2012, OPHTHALMOLOGY   0204
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837
NR 47
TC 8
Z9 8
U1 0
U2 11
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-203X
J9 THER CLIN RISK MANAG
JI Therap. Clin. Risk Manag.
PY 2012
VL 8
BP 343
EP 351
DI 10.2147/TCRM.S32801
PG 9
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA 971VR
UT WOS:000306233100001
PM 22911433
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ly, A
   Zangerl, B
   Kalloniatis, M
AF Ly, Angelica
   Zangerl, Barbara
   Kalloniatis, Michael
TI Introduction of structured record keeping in age-related macular
   degeneration: a before and after study
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE Clinical decision support; electronic health records structured record
   keeping; evidence-based practice
ID PREVALENCE; STANDARDS; AUSTRALIA; AUDIT
AB Background Structured record keeping has been associated with a range of advantages including improved history taking and communication, reduced number of unnecessary referrals, and enhanced diagnostic accuracy. The aim of this study was to examine the impact of a structured record keeping, quality improvement tool on recording, reporting and management congruency. Methods A before and after retrospective record review study was performed in a single academic, intermediate-tier care institute in New South Wales, Australia. The structured record keeping tool intervention captured 31 items in addition to the prior pre-existing medical record: six items relating to historical risk factors, two items relating to patient activation, 13 items signifying core clinical signs, five items for change analysis and five items regarding the ongoing patient management plan. Results Two hundred medical records from 151 patients with age-related macular degeneration were analysed. There was a statistically significant improvement in the number of reports that explicitly specified the number of clinical structural risk factors (from 24 to 75%; Fisher's exact p < 0.001) and risk of progression to advanced disease (from 71 to 84%; p = 0.041); however, this documentation had no statistically significant effect on the report-recommended management plan and/or the final report-recommended review period. Conclusion Disease-specific, structured record keeping improves the outgoing documentation of key clinical signs and is effective in prompting the transposition of these signs into a quantified risk progression score. It has limited value in improving management consistency among a group of highly trained eye care staff.
C1 [Ly, Angelica; Zangerl, Barbara; Kalloniatis, Michael] Unsw Sydney, Ctr Eye Hlth, Sydney, NSW, Australia.
   [Ly, Angelica; Zangerl, Barbara; Kalloniatis, Michael] Unsw Sydney, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Ly, A (通讯作者)，Unsw Sydney, Ctr Eye Hlth, Sydney, NSW, Australia.
EM a.ly@unsw.edu.au
OI Kalloniatis, Michael/0000-0002-5264-4639; Ly,
   Angelica/0000-0001-7881-1522
FU Guide Dogs NSW/ACT
FX This work was supported by Guide Dogs NSW/ACT.
CR American Academy of Ophthalmology Retina/Vitreous Panel, 2019, PREF PRACT PATT GUID
   Fernando B, 2012, BMJ QUAL SAF, V21, P337, DOI 10.1136/bmjqs-2011-000450
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gocuk SA, 2021, OPHTHAL PHYSL OPT, V41, P53, DOI 10.1111/opo.12754
   Goenka A, 2014, TROP DOCT, V44, P96, DOI 10.1177/0049475513515477
   Hart KM, 2020, CLIN EXP OPTOM, V103, P254, DOI 10.1111/cxo.12964
   Haworth S, 2016, EMERG MED J, V33, P268, DOI 10.1136/emermed-2015-205141
   Jalbert I, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228858
   Keel S, 2017, JAMA OPHTHALMOL, V135, P1242, DOI 10.1001/jamaophthalmol.2017.4182
   Kern C, 2020, BRIT J OPHTHALMOL, V104, P312, DOI 10.1136/bjophthalmol-2019-314161
   Kiely PM, 2015, CLIN EXP OPTOM, V98, P65, DOI 10.1111/cxo.12216
   Ly A, 2018, CLIN EXP OPTOM, V101, P243, DOI 10.1111/cxo.12607
   Ly A, 2017, CLIN EXP OPTOM, V100, P718, DOI 10.1111/cxo.12528
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P632, DOI 10.1111/opo.12322
   Mahomed Ozayr H., 2015, Curationis, V38, P1, DOI [10.4102/curationis.v38i1.1497, 10.4102/CURATIONIS.V38I1.1497]
   Michele Harrop, 2005, Nurs Stand, V19, P33
   Muen Wisam J, 2011, JRSM Short Rep, V2, P64, DOI 10.1258/shorts.2011.011042
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Ogrinc G, 2015, AM J CRIT CARE, V24, P466, DOI 10.4037/ajcc2015455
   RANZCO, 2018, RANZCO REF PATHW AMD
   Schmidt M, 2005, INT J STD AIDS, V16, P822, DOI 10.1258/095646205774988073
   Sutton RT, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0221-y
   The Royal College of Ophthalmologists, 2013, AGE RELATED MACULAR
NR 25
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD OCT 3
PY 2022
VL 105
IS 7
BP 754
EP 760
DI 10.1080/08164622.2021.1971490
EA SEP 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4E7WK
UT WOS:000697419200001
PM 34538228
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Wills, NK
   Kalariya, N
   Ramanujam, VMS
   Lewis, JR
   Abdollahi, SH
   Husain, A
   van Kuijk, FJGM
AF Wills, N. K.
   Kalariya, N.
   Ramanujam, V. M. Sadagopa
   Lewis, J. R.
   Abdollahi, S. Haji
   Husain, A.
   van Kuijk, F. J. G. M.
TI Human retinal cadmium accumulation as a factor in the etiology of
   age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE cadmium; zinc; copper; age-related macular degeneration; retina; RPE;
   choroid; human; gender; aging
ID COMPLEMENT FACTOR-H; PIGMENT EPITHELIUM; ZINC TRANSPORTERS; VITAMIN-E;
   SUSCEPTIBILITY; MACULOPATHY; GENES; LOCALIZATION; ASSOCIATION;
   EXPRESSION
AB Cadmium is a naturally occurring, highly toxic, metallic element. It pollutes the environment as a result of industrial activity and accumulates in human tissues with a long biological half-life. Cadmium content has been demonstrated to increase in human retinal tissues as a function of age and tobacco smokers have approximately twice as much cadmium in retinal tissues than non-smokers. Smoking is also a key environmental risk factor for the retinal disease age-related macular degeneration (AMD). Recent studies have shown that urinary cadmium levels (a measure of Cd body burden) are higher in smokers who have AMD. We now report the Cd measurements in human retinal tissues from eyes afflicted with AMD compared to non-diseased eyes (controls) from age-matched donors. Human donor eyes frozen under argon gas were assessed for AMD severity using color stereoscopic fundus photographs and the Minnesota Grading System. Cadmium, zinc and, copper levels were measured in retinal tissues (neural retina, retinal pigment epithelium and choroid) using inductively coupled plasma mass spectrometry and graphite furnace spectrophotometry and values were normalized to tissue protein levels. Higher Cd levels were found in the neural retina and RPE for eyes afflicted with AMD compared to controls in males, differences were not statistically significant in females. The results indicate that higher retinal cadmium burdens are associated with the presence of AMD at least in males and suggest possible gender differences in the metabolism of metals in the human retina. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Wills, N. K.; Lewis, J. R.; Abdollahi, S. Haji] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.
   [Wills, N. K.; Kalariya, N.; Husain, A.; van Kuijk, F. J. G. M.] Univ Texas Med Branch, AMD Ctr, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
   [Ramanujam, V. M. Sadagopa] Univ Texas Med Branch, Div Human Nutr, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA.
C3 University of Texas System; University of Texas Medical Branch
   Galveston; University of Texas System; University of Texas Medical
   Branch Galveston; University of Texas System; University of Texas
   Medical Branch Galveston
RP Wills, NK (通讯作者)，Univ Texas Med Branch, Dept Neurosci, Galveston, TX 77554 USA.
EM nkwills@utmb.edu
FU Philip Morris USA, Inc.; Philip Morris Internationals AMD Fund;
   University of Texas
FX We wish to thank Dr. Daniel Freeman for his expert assistance with
   statistical power analysis. The research described in this article was
   supported by Philip Morris USA, Inc. and Philip Morris Internationals
   AMD Fund, and the University of Texas Medical Branch Human Nutrition
   Trace Metals Research Facility.
CR Agency for Toxic Substances and Disease Registry (ATSDR), 2005, CERCLA PRIOR LIST HA
   Bhattacharyya M., 2000, MOL BIOL TOXICOLOGY
   CHAN HM, 1993, P SOC EXP BIOL MED, V202, P420
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   ECKHERT CD, 1983, EXP EYE RES, V37, P639, DOI 10.1016/0014-4835(83)90138-0
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erie JC, 2007, AM J OPHTHALMOL, V144, P414, DOI 10.1016/j.ajo.2007.05.020
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   GALIN MA, 1962, INVEST OPHTH VISUAL, V1, P142
   Girijashanker K, 2008, MOL PHARMACOL, V73, P1413, DOI 10.1124/mol.107.043588
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He L, 2006, MOL PHARMACOL, V70, P171, DOI 10.1124/mol.106.021521
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jarup L, 2003, BRIT MED BULL, V68, P167, DOI 10.1093/bmb/ldg032
   KARCIOGLU ZA, 1982, SURV OPHTHALMOL, V27, P114, DOI 10.1016/0039-6257(82)90195-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Leung KW, 2008, INVEST OPHTH VIS SCI, V49, P1221, DOI 10.1167/iovs.07-0781
   Liu Z, 2008, BIOCHEM BIOPH RES CO, V365, P814, DOI 10.1016/j.bbrc.2007.11.067
   Lu HS, 2002, EXP EYE RES, V74, P83, DOI 10.1006/exer.2001.1101
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Martelli A, 2006, BIOCHIMIE, V88, P1807, DOI 10.1016/j.biochi.2006.05.013
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   MULLIN JM, 2004, SCI STKE, pPE2, DOI DOI 10.1126/STKE.2162004PE2
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   Nishijo M, 2004, MOL CELL BIOCHEM, V255, P87, DOI 10.1023/B:MCBI.0000007264.37170.39
   Nordberg GF, 2007, HANDBOOK ON THE TOXICOLOGY OF METALS, 3RD EDITION, P445, DOI 10.1016/B978-012369413-3/50078-1
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Organisation for Economic Co-operation and Development (OECD), 1994, RISK RED MON, V5
   Prozialeck WC, 2003, TOXICOL APPL PHARM, V189, P180, DOI 10.1016/S0041-008X(03)00130-3
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Satarug S, 2004, TOXICOL LETT, V148, P177, DOI 10.1016/j.toxlet.2003.09.015
   Satarug S, 2008, EXP EYE RES, V87, P587, DOI 10.1016/j.exer.2008.09.014
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Tate DJ, 2002, CURR EYE RES, V24, P12, DOI 10.1076/ceyr.24.1.12.5426
   Taylor KM, 2007, MOL MED, V13, P396, DOI 10.2119/2007-00040.Taylor
   THEVENOD F, 2003, NEPHRON PHYSIOL, V93, P87, DOI DOI 10.1159/000070241
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Ugarte M, 1999, EXP EYE RES, V69, P459, DOI 10.1006/exer.1999.0727
   Ugarte M, 1998, GEN PHARMACOL-VASC S, V30, P297, DOI 10.1016/S0306-3623(97)00358-3
   VANASSCHE FJ, 1998, P 8 INT NICK CADM BA
   VANKUIJK FJGM, 1991, INVEST OPHTH VIS SCI, V32, P1962
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   *WHO, 1992, IPCS INT PROGR CHEM, V134
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 60
TC 31
Z9 33
U1 1
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2009
VL 89
IS 1
BP 79
EP 87
DI 10.1016/j.exer.2009.02.014
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 456SS
UT WOS:000266869200010
PM 19254715
DA 2022-11-30
ER

PT J
AU Garrigan, H
   Hamati, J
   Lalakia, P
   Frasso, R
   Salzman, B
   Hyman, L
AF Garrigan, Hannah
   Hamati, Jacquelyn
   Lalakia, Parth
   Frasso, Rosemary
   Salzman, Brooke
   Hyman, Leslie
TI Does Age-Related Macular Degeneration (AMD) Treatment Influence Patient
   Falls and Mobility? A Systematic Review
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Review
DE Age-related macular degeneration; anti-VEGF; photocoagulation; falls;
   mobility
ID QUALITY-OF-LIFE; OLDER-PEOPLE; VISUAL IMPAIRMENT; GAIT DISORDERS;
   VISION; RISK; ADULTS; PERFORMANCE; PREVALENCE; PREVENTION
AB Purpose: Age-related macular degeneration (AMD), a leading cause of irreversible blindness, increases fall risk through impaired central vision. Falls place an enormous economic burden on healthcare systems. We hypothesized that AMD treatments may reduce patients' falls risk. This systematic review (ID #: 172623) synthesized the current understanding of wet and dry AMD treatments' impact on patient falls and mobility, connecting these two public health issues. Methods: On April 17, 2020, PubMed, Scopus, CINAHL, and the Cochrane Central Register of Controlled Trials were queried. Clinical trials and observational studies were included, while non-English and non-primary studies were excluded. Two authors screened, extracted data, and assessed bias using RoB-2 and ROBINS-I. A third author served as a tie breaker. Results: This database search resulted in 3,525 studies, with an additional 112 identified through bibliography review. Ten articles met eligibility criteria. Most studies featured the outcome of interest as a secondary outcome (n = 4) and patient-reported adverse events (n = 5), rather than a primary focus (n = 2). Ten out of the 11 outcomes had a moderate to serious risk of bias. No two studies used the same instrument to measure falls or mobility. Conclusion: Despite the potential positive impact of AMD treatments on patient falls and mobility, quality data on this relationship are lacking. This work underscores the need to broaden ophthalmologic research outcomes beyond visual parameters to include patient-centred, functional measures. Incorporating standardized methods to track falls and screen for difficulty with walking and balance would enable evaluation of AMD treatments on functional outcomes, potentially helping guide management.
C1 [Garrigan, Hannah; Hamati, Jacquelyn; Salzman, Brooke; Hyman, Leslie] Thomas Jefferson Univ, Sidney Kimmel Med Coll, 901 Walnut St, Philadelphia, PA 19107 USA.
   [Garrigan, Hannah; Hamati, Jacquelyn; Lalakia, Parth; Frasso, Rosemary] Thomas Jefferson Univ, Coll Populat Hlth, Philadelphia, PA 19107 USA.
   [Lalakia, Parth] Thomas Jefferson Univ, Off Global Affairs, Philadelphia, PA 19107 USA.
   [Lalakia, Parth] Rowan Univ, Sch Osteopath Med, Stratford, NJ USA.
   [Salzman, Brooke] Thomas Jefferson Univ, Dept Family Med, Div Geriatr Med & Palliat Care, Philadelphia, PA 19107 USA.
   [Hyman, Leslie] Wills Eye Hosp & Res Inst, Vickie & Jack Farber Vis Res Ctr, Philadelphia, PA USA.
C3 Jefferson University; Jefferson University; Jefferson University; Rowan
   University; Rowan University School of Osteopathic Medicine; Jefferson
   University; Jefferson University
RP Garrigan, H (通讯作者)，Thomas Jefferson Univ, Sidney Kimmel Med Coll, 901 Walnut St, Philadelphia, PA 19107 USA.
EM hannah.garrigan@students.jefferson.edu
OI Lalakia, Parth/0000-0001-9818-9953
CR [Anonymous], 2010, PREVENTION FALLS OLD
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arroyo JG, 2020, UPTODATE
   Aspden P, 2004, ADVERSE EVENT ANAL P
   Burns E, 2018, MMWR-MORBID MORTAL W, V67, P509, DOI 10.15585/mmwr.mm6718a1
   CDC, 2017, TAK STAND FALLS
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chang JT, 2004, BRIT MED J, V328, P680, DOI 10.1136/bmj.328.7441.680
   CULLEN DJ, 1995, JOINT COMM J QUAL IM, V21, P541, DOI 10.1016/S1070-3241(16)30180-8
   Cumming RG, 2007, J AM GERIATR SOC, V55, P175, DOI 10.1111/j.1532-5415.2007.01046.x
   Dhital A, 2010, EYE, V24, P1437, DOI 10.1038/eye.2010.60
   E JY, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009233.pub3
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Friedman DS, 2012, AM GERIATRIC SOC GER
   Ganz DA, 2005, J AM GERIATR SOC, V53, P2190, DOI 10.1111/j.1532-5415.2005.00509.x
   Haran Mark J, 2010, BMJ, V340, pc2265, DOI 10.1136/bmj.c2265
   Hazell L, 2006, DRUG SAFETY, V29, P385, DOI 10.2165/00002018-200629050-00003
   Hendrie Delia, 2004, Aust Health Rev, V28, P363
   Kenny RAM, 2011, J AM GERIATR SOC, V59, P148, DOI 10.1111/j.1532-5415.2010.03234.x
   Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.1136/bmj.l4898, 10.4084/MJHID.2010.005]
   Kiser AK, 2008, CLIN EXP OPHTHALMOL, V36, P514, DOI 10.1111/j.1442-9071.2008.01824.x
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krummenauer F, 2004, EUR J OPHTHALMOL, V15, P1
   Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Mackenzie L, 2006, CLIN REHABIL, V20, P331, DOI 10.1191/0269215506cr947oa
   MATHIAS S, 1986, ARCH PHYS MED REHAB, V67, P387
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Mohanty S, 2015, OPTIMAL PERIOPERATIV, P620
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   MORSE JM, 1989, CAN J AGING, V8, P366, DOI 10.1017/S0714980800008576
   National Eye Institute, 2019, REL MAC DEG DAT STAT
   Neacsu G., 2019, COGNITIVE CRCS, P482, DOI [10.15405/epsbs.2019.02.60, DOI 10.15405/EPSBS.2019.02.60]
   Nguyen NX, 2007, ACTA OPHTHALMOL SCAN, V85, P877, DOI 10.1111/j.1600-0420.2007.00963.x
   Nurmi I, 2002, SCAND J PRIM HEALTH, V20, P118, DOI 10.1080/713796400
   Patino CM, 2010, OPHTHALMOLOGY, V117, P199, DOI 10.1016/j.ophtha.2009.06.063
   Peel N, 2000, ACCIDENT ANAL PREV, V32, P371, DOI 10.1016/S0001-4575(99)00066-4
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pirker W, 2017, WIEN KLIN WOCHENSCHR, V129, P81, DOI 10.1007/s00508-016-1096-4
   PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x
   Reed-Jones RJ, 2013, MATURITAS, V75, P22, DOI 10.1016/j.maturitas.2013.01.019
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Rubenstein LZ, 2006, AGE AGEING, V35, P37, DOI 10.1093/ageing/afl084
   Salzman B, 2010, AM FAM PHYSICIAN, V82, P61
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Stevens M, 2001, J AM GERIATR SOC, V49, P1448, DOI 10.1046/j.1532-5415.2001.4911236.x
   Sudarsky L, 2001, ADV NEUROL, V87, P111
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   United Nations, 2017, WORLD POP AG 2017 HI
   WHO, 2008, WHO GLOB REP FALLS P, V1st
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   World Health Organization, FALLS
   Zhang XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep10559
NR 55
TC 2
Z9 2
U1 2
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD MAR 4
PY 2022
VL 29
IS 2
BP 128
EP 138
DI 10.1080/09286586.2021.1921227
EA MAY 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 0U4EZ
UT WOS:000651307000001
PM 33993827
DA 2022-11-30
ER

PT J
AU Kovacs, KD
   Quirk, MT
   Kinoshita, T
   Gautam, S
   Ceron, OM
   Murtha, TJ
   Arroyo, JG
AF Kovacs, Kyle D.
   Quirk, Matthew T.
   Kinoshita, Taiga
   Gautam, Shiva
   Ceron, Olga M.
   Murtha, Timothy J.
   Arroyo, Jorge G.
TI A RETROSPECTIVE ANALYSIS OF TRIPLE COMBINATION THERAPY WITH INTRAVITREAL
   BEVACIZUMAB, POSTERIOR SUB-TENON'S TRIAMCINOLONE ACETONIDE, AND
   LOW-FLUENCE VERTEPORFIN PHOTODYNAMIC THERAPY IN PATIENTS WITH
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; combination therapy;
   triamcinolone acetonide; verteporfin; low-fluence
ID CHOROIDAL NEOVASCULARIZATION; PHARMACOKINETICS; RANIBIZUMAB; PREVALENCE;
   EYES
AB Purpose: To assess the efficacy of triple combination therapy (TCT) including bevacizumab (BEV), low-fluence photodynamic therapy, and posterior sub-Tenon's triamcinolone acetonide in patients with wet age-related macular degeneration.
   Methods: This institutional review board-approved retrospective consecutive case series included 31 eyes treated for wet age-related macular degeneration with TCT at the Beth Israel Deaconess Medical Center between June 2004 and November 2008. Outcome measures included visual acuity, retinal thickness as measured by optical coherence tomography, time to retreatment, and complications.
   Results: Triple combination therapy eyes showed significant 3-month and 6-month improvement in visual acuity of 0.140 +/- 0.273 logarithm of the minimum angle of resolution and 0.182 +/- 0.383 logarithm of the minimum angle of resolution after treatment, respectively (P = 0.0219 and 0.0470, respectively). Central retinal thickness significantly improved at 3 months (-123.8 +/- 102.7 mu m), 6 months (-87.7 +/- 99.8 mu m), and 12 months (-101.6 +/- 103.3 mu m) on optical coherence tomography. Half of eyes that underwent TCT required retreatment by the conclusion of their follow-up, and eyes that underwent TCT had a 1-year Kaplan-Meier survival rate of 62.1 +/- 10.8%.
   Conclusion: Triple combination therapy (TCT) appears to effectively improve visual acuity and decrease retinal thickness often without need for subsequent retreatment within the first year of follow-up. Further investigation of TCT in prospective trials is warranted. RETINA 31: 446-452, 2011
C1 [Arroyo, Jorge G.] Beth Israel Deaconess Med Ctr, Div Ophthalmol, Retina Serv, Boston, MA 02215 USA.
   [Murtha, Timothy J.] Joslin Diabet Ctr, Beetham Eye Inst, Retina Serv, Boston, MA 02215 USA.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   University; Joslin Diabetes Center, Inc.
RP Arroyo, JG (通讯作者)，Beth Israel Deaconess Med Ctr, Div Ophthalmol, Retina Serv, 330 Brookline Ave, Boston, MA 02215 USA.
EM jarroyo@bidmc.harvard.edu
OI Murtha, Timothy/0000-0002-2194-1059; Arroyo, Jorge/0000-0001-9812-296X
FU Beth Israel Deaconess Medical Center Retina Service; Grimshaw-Gudewicz
   Charitable Foundation; Novartis Pharmaceuticals
FX Supported in part by funds from the Beth Israel Deaconess Medical Center
   Retina Service and the Grimshaw-Gudewicz Charitable Foundation and a
   research grant from the Novartis Pharmaceuticals.
CR Ahmadieh Hamid, 2007, BMC Ophthalmol, V7, P10, DOI 10.1186/1471-2415-7-10
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, pe55
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gilson MM, 2007, OPHTHALMOLOGY, V114, P1713, DOI 10.1016/j.ophtha.2007.03.071
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Inoue M, 2004, AM J OPHTHALMOL, V138, P1046, DOI 10.1016/j.ajo.2004.05.028
   Jermak CM, 2007, SURV OPHTHALMOL, V52, P503, DOI 10.1016/j.survophthal.2007.06.004
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe22, DOI 10.1111/j.1755-3768.2008.01453.x
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kim Aya, 2006, Nippon Ganka Gakkai Zasshi, V110, P19
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KOVACS KD, 2010, 2010 ARVO ANN M FORT
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Navea A, 2009, RETINA-J RET VIT DIS, V29, P13, DOI 10.1097/IAE.0b013e31818a1fd3
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   NOZIK R A, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P695
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Shah AR, 2009, BRIT J OPHTHALMOL, V93, P1027, DOI 10.1136/bjo.2008.149674
   Thomas ER, 2006, AM J OPHTHALMOL, V142, P860, DOI 10.1016/j.ajo.2006.05.023
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
NR 37
TC 11
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2011
VL 31
IS 3
BP 446
EP 452
DI 10.1097/IAE.0b013e3181f6391f
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 722YW
UT WOS:000287472400004
PM 21336068
DA 2022-11-30
ER

PT J
AU Wang, YL
   Yang, JY
   Li, B
   Yuan, MZ
   Chen, YX
AF Wang, Yuelin
   Yang, Jingyuan
   Li, Bing
   Yuan, Mingzhen
   Chen, Youxin
TI Detection Rate and Diagnostic Value of Optical Coherence Tomography
   Angiography in the Diagnosis of Polypoidal Choroidal Vasculopathy: A
   Systematic Review and Meta-Analysis
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
AB Purpose. This study aimed to evaluate the detection rate of polyps and branching vascular networks (BVNs) in polypoidal choroidal vasculopathy (PCV) by optical coherence tomography angiography (OCTA) and assess the sensitivity and specificity of OCTA in differentiating PCV from wet age-related macular degeneration (wAMD). Materials and Methods. We searched PubMed, EMBASE, Cochrane Library, and other sources. The detection rates of polyps and BVNs in observational studies and the sensitivity and specificity of PCV diagnosis from wAMD in diagnostic studies were extracted. Results. Twenty studies (573 eyes) were eligible. The combined detection rate of OCTA in PCV polyp lesion diagnosis was 0.67 (95% CI: 0.55-0.79), while that of BVNs was 0.86 (95% CI: 0.81-0.91). The detection rate of polyps was compared with that of BVNs in the same study, and the combined relative risk was 0.82 (95% CI: 0.72-0.92). The combined sensitivity of PCV diagnosis in wAMD patients using OCTA was 0.77 (95% CI: 0.55-0.90), combined specificity 0.84 (95% CI: 0.60-0.95), and area under the SROC curve 0.87 (95% CI: 0.84-0.90). Conclusion. OCTA has a high PCV polyp and BVN detection rate, and the detection rate of BVNs is higher than that of the polyp. OCTA has acceptable sensitivity and specificity for diagnosing PCV from wAMD. Thus, OCTA may be helpful for clinical diagnosis of PCV.
C1 [Wang, Yuelin; Yang, Jingyuan; Li, Bing; Yuan, Mingzhen; Chen, Youxin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
EM violin95@qq.com; 1547868133@qq.com; byyxbyyx@tom.com;
   yuanmingzhenpumc@sohu.com; chenyx@pumch.cn
OI Chen, Youxin/0000-0002-7231-5058
CR Chan SY, 2018, RETINA-J RET VIT DIS, V38, P1187, DOI 10.1097/IAE.0000000000001702
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Chu HT, 2006, J CLIN EPIDEMIOL, V59, P1331, DOI 10.1016/j.jclinepi.2006.06.011
   de Carlo T. E., 2018, RETINA, V39, P1343
   de Carlo TE, 2018, OPHTHALMOLOGICA, V239, P103, DOI 10.1159/000481540
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Huang YM, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/3479695
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lin G. Q., 2018, CHINESE J MODERN DRU, V12, P76, DOI [10.1038/s41598-018-37384-y, DOI 10.1038/S41598-018-37384-Y]
   [马楠 Ma Nan], 2015, [中华眼底病杂志, Chinese Journal of Ocular Fundus Diseases], V31, P421
   Mao J. B., 2018, CHINESE J OCULAR FUN, V34, P65
   Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]
   Peiretti E, 2019, RETINA-J RET VIT DIS, V39, P1693, DOI 10.1097/IAE.0000000000002234
   Rebhun CB, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.6.4
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Xu H. Y., 2017, GUOJI YANKE ZAZHI, V7, P1362
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 3
Z9 3
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD DEC 14
PY 2019
VL 2019
AR 6837601
DI 10.1155/2019/6837601
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JY2NJ
UT WOS:000504257200002
PM 31915542
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Anastassiou, G
   Schneegans, AL
   Selbach, M
   Kremmer, S
AF Anastassiou, Gerasimos
   Schneegans, Anna-Lena
   Selbach, Michael
   Kremmer, Stephan
TI Transpalpebral electrotherapy for dry age-related macular degeneration
   (AMD): An exploratory trial
SO RESTORATIVE NEUROLOGY AND NEUROSCIENCE
LA English
DT Article
DE AMD; electrical stimulation; therapy; choroid; electrostimulation;
   transpalpebral
ID ALTERNATING-CURRENT STIMULATION; TRANSCORNEAL ELECTRICAL-STIMULATION;
   VISUAL-SYSTEM; VISION; RESTORATION; RETINA; DAMAGE
AB Purpose: To evaluate the effect of transpalpebral electrotherapy on patients with dry age-related macular degeneration (AMD).
   Methods: 22 patients were randomized in two groups to either receive therapy (n = 12) or placebo (n = 10). There was no statistically significant difference for age and initial visual acuity (VA) between the two groups (p = 0.6; ANOVA). Treatment was performed on 5 consecutive days. On each day two sessions were applied. Every session included 8 spots (40 sec/spot) around the eye globe. The current applied (changing frequency 5-80 Hz) varied individually between 150 and 220 mu A. Patients were examined before treatment, at the end of the 5-day treatment period, after 4 weeks and at 6 months. Examinations included a standardized VA testing, using ETDRS letters, contrast sensitivity, macular sensitivity and fixation stability using microperimetry and measurements with SD-OCT.
   Results: At the end of week 1, mean VA improved markedly (p = 0.001; T test), with 7 out of 12 patients showing an improvement of more than 5 letters. After 4 weeks, there was an improvement of more than 10 letters in 3 patients (mean + 5.7 letters; p = 0.001; T test) whereas at 6 months a loss of 1.6 letters was observed. Only 4 (33%) of our patients did not show any improvement at all. Contrast sensitivity displayed a similar pattern. Within one week after treatment, there was a rapid improvement (+ 4.4 optotypes; p = 0.006; T test). After 6 months, contrast sensitivity declined again (+1.5 optotypes; p = 0.2; T test). Compared to the placebo group changes on VA failed statistical significance (p = 0.1 at 4 week; T test) whereas changes on contrast sensitivity were statistically significant (p = 0.01 at week 4; T test). No adverse events were seen or reported during the study period.
   Conclusions: To the best of our knowledge, this is the first report of a transpalpebral electrostimulation in patients with dry AMD that demonstrates a temporary increase in visual function in some of these patients; results that seem to justify further research on this potential treatment option for dry AMD.
C1 [Anastassiou, Gerasimos; Selbach, Michael; Kremmer, Stephan] Hosp Eye, Gelsenkirchen, Germany.
   [Anastassiou, Gerasimos; Schneegans, Anna-Lena; Selbach, Michael; Kremmer, Stephan] Univ Duisburg Essen, Essen, Germany.
C3 University of Duisburg Essen
RP Anastassiou, G (通讯作者)，Evangel Kliniken Gelsenkirchen GmbH, Hosp Eye, Munckelstr 27, D-45879 Gelsenkirchen, Germany.
EM gerasimos.anastassion@uni-essen.de
CR Al-Majed AA, 2000, J NEUROSCI, V20, P2602
   Brushart TM, 2005, EXP NEUROL, V194, P221, DOI 10.1016/j.expneurol.2005.02.007
   Dispenza J., 2007, EVOLVE YOUR BRAIN SC
   Dor H, 1873, GRAEFES ARCH CLIN EX, V19, P352
   Fedorov A, 2011, BRAIN STIMUL, V4, P189, DOI 10.1016/j.brs.2011.07.007
   Fedorov Anton, 2010, Restor Neurol Neurosci, V28, P825, DOI 10.3233/RNN-2010-0580
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujikado T, 2006, JPN J OPHTHALMOL, V50, P266, DOI 10.1007/s10384-005-0304-y
   Gall C, 2011, BRAIN STIMUL, V4, P175, DOI 10.1016/j.brs.2011.07.003
   Gall C, 2010, NEUROREHABILITATION, V27, P335, DOI 10.3233/NRE-2010-0617
   Henrich-Noack P., 2013, BRAIN RES B
   Henrich-Noack P, 2013, NEUROSCI LETT, V543, P1, DOI 10.1016/j.neulet.2013.03.013
   Inomata K, 2007, GRAEF ARCH CLIN EXP, V245, P1773, DOI 10.1007/s00417-007-0610-9
   Jarding J. B., 2001, United States Patent, Patent No. [US 6,275,735 B1, 6275735]
   Kurimoto T, 2010, CLIN OPHTHALMOL, V4, P1441, DOI 10.2147/OPTH.S14573
   NAKANOME Y, 1995, EXP EYE RES, V60, P37, DOI 10.1016/S0014-4835(05)80081-8
   Ni YQ, 2009, EXP NEUROL, V219, P439, DOI 10.1016/j.expneurol.2009.06.016
   Sabel BA, 1997, ADV NEUROL, V73, P251
   Sabel BA, 2011, RESTOR NEUROL NEUROS, V29, P493, DOI 10.3233/RNN-2011-0624
   Sabel BA, 2011, PROG BRAIN RES, V192, P199, DOI 10.1016/B978-0-444-53355-5.00013-0
   Schatz A, 2011, INVEST OPHTH VIS SCI, V52, P4485, DOI 10.1167/iovs.10-6932
   Sergeeva EG, 2012, J NEUROPHYSIOL, V108, P2494, DOI 10.1152/jn.00341.2012
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Wang X, 2011, EXP EYE RES, V93, P753, DOI 10.1016/j.exer.2011.09.022
NR 25
TC 26
Z9 28
U1 0
U2 9
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6028
EI 1878-3627
J9 RESTOR NEUROL NEUROS
JI Restor. Neurol. Neurosci.
PY 2013
VL 31
IS 5
BP 571
EP 578
DI 10.3233/RNN-130322
PG 8
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 216DQ
UT WOS:000324262100005
PM 23760223
DA 2022-11-30
ER

PT J
AU Han, GG
   Wei, PH
   He, MQ
   Teng, H
AF Han, Guoge
   Wei, Pinghui
   He, Meiqin
   Teng, He
TI Glucose Metabolic Characterization of Human Aqueous Humor in Relation to
   Wet Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE aqueous humor; glucose metabolism; age-related macular degeneration
ID GLUTAMINE; INFLAMMATION; MECHANISMS; CELLS; LENS
AB PURPOSE. Energy compromise underpins wet age-related macular degeneration (wAMD) pathogenesis, but the relationship between glucose metabolism and the disease remains unclear. Here, we characterized aqueous humor (AH) to elucidate glucose-related metabolic signatures in patients with wAMD.
   METHODS. In total, 25 eyes of 25 patients with wAMD were divided into phakic (15 eyes), pseudophakic (10 eyes), and intravitreal injections of ranibizumab (13 eyes) wAMD groups. Twenty patients with cataract (21 eyes) served as controls. Ultrahigh-performance liquid chromatography tandem mass spectrometry was used to quantitatively characterize AH.
   RESULTS. Twenty-one metabolites related to glucose metabolism were identified in AH from 45 patients. Tricarboxylic acid (TCA)-related metabolic substrates, including citrate, were detected in AH and were significantly increased in AMD (P < 0.01) and AMD pseudophakic groups (P < 0.05). In contrast, alpha-ketoglutarate levels were decreased in the AMD group (P < 0.05). The alpha-ketoglutarate/citrate ratio was significantly decreased, corresponding to 71.71% and 93.6% decreases in the AMD (phakic and pseudophakic) groups as compared with controls (P < 0.001), revealing a significant positive correlation with glutamine. A lower mean glutamine and higher glutamate level were detected in AMD cases compared with controls. No significant differences were observed for lactic acid or other Krebs cycle metabolites. Intravitreal injection significantly alleviated mean central foveal thickness but did not significantly alter metabolites.
   CONCLUSIONS. Compromised glucose TCA cycle and altered glutamine metabolism are implicated in the AH metabolism in wAMD. These findings highlight potential treatments for alleviating wAMD from a metabolic perspective.
C1 [Han, Guoge; Wei, Pinghui; He, Meiqin] Tianjin Eye Hosp, Tianjin Key Lab Ophthalmol & Visual Sci, 4 Gansu Rd, Tianjin 300020, Peoples R China.
   [Teng, He] Tianjin Med Univ, Eye Hosp, Eye Inst, Tianjin, Peoples R China.
   [Teng, He] Tianjin Med Univ, Eye Hosp, Sch Optometry & Ophthalmol, Tianjin, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University
RP Han, GG (通讯作者)，Tianjin Eye Hosp, Tianjin Key Lab Ophthalmol & Visual Sci, 4 Gansu Rd, Tianjin 300020, Peoples R China.
EM dovehanguoge@hotmail.com
FU National Natural Science Foundation of China [81700849]; Natural Science
   Foundation of Tianjin City [18JCQNJC10600]
FX Supported by a grant from the National Natural Science Foundation of
   China (81700849) and Natural Science Foundation of Tianjin City
   (18JCQNJC10600).
CR Agathocleous M, 2012, NAT CELL BIOL, V14, P859, DOI 10.1038/ncb2531
   Altman BJ, 2016, NAT REV CANCER, V16, P773, DOI 10.1038/nrc.2016.131
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   BRUBAKER RF, 1991, INVEST OPHTH VIS SCI, V32, P3145
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Casson RJ, 2014, OPHTHALMOLOGY, V121, P1203, DOI 10.1016/j.ophtha.2013.12.011
   Casson RJ, 2013, CLIN EXP OPHTHALMOL, V41, P517, DOI 10.1111/ceo.12050
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Du JH, 2016, J BIOL CHEM, V291, P4698, DOI 10.1074/jbc.M115.698985
   Fendt SM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3236
   Fiske BP, 2012, NAT CELL BIOL, V14, P790, DOI 10.1038/ncb2554
   Han GG, 2013, INVEST OPHTH VIS SCI, V54, P7567, DOI 10.1167/iovs.13-12200
   Hejtmancik JF, 2015, PROG MOL BIOL TRANSL, V134, P169, DOI 10.1016/bs.pmbts.2015.04.007
   Hu RG, 2012, CURR EYE RES, V37, P633, DOI 10.3109/02713683.2012.669509
   Icard P, 2012, BBA-REV CANCER, V1825, P111, DOI 10.1016/j.bbcan.2011.10.007
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Joyal JS, 2018, PROG RETIN EYE RES, V64, P131, DOI 10.1016/j.preteyeres.2017.11.002
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kersten E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218457
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602
   Mimura T, 2019, OPHTHALMOLOGICA, V241, P81, DOI 10.1159/000490153
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642
   Ng SK, 2015, CLIN EXP OPHTHALMOL, V43, P367, DOI 10.1111/ceo.12462
   Nicholson JK, 2012, NATURE, V491, P384, DOI 10.1038/nature11708
   Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Pouyssegur J, 2006, BIOL CHEM, V387, P1337, DOI 10.1515/BC.2006.167
   RILEY MV, 1972, INVEST OPHTH VISUAL, V11, P600
   TRAYHURN P, 1973, EXP EYE RES, V17, P149, DOI 10.1016/0014-4835(73)90204-2
   Tretter L, 2005, PHILOS T R SOC B, V360, P2335, DOI 10.1098/rstb.2005.1764
   Vallee A, 2017, J MOL NEUROSCI, V62, P368, DOI 10.1007/s12031-017-0947-4
   Williams NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00141
   WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667
   Winkler BS, 2004, NEUROCHEM INT, V45, P311, DOI 10.1016/j.neuint.2003.08.017
   Winkler BS, 2000, INVEST OPHTH VIS SCI, V41, P3183
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 45
TC 7
Z9 7
U1 1
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2020
VL 61
IS 3
AR 49
DI 10.1167/iovs.61.3.49
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA8BU
UT WOS:000524168000049
PM 32232346
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lott, LA
   Schneck, ME
   Haegerstrom-Portnoy, G
   Hewlett, S
   Stepien-Bernabe, N
   Gauer, BM
   Zaidi, A
   Fu, AD
   Brabyn, JA
AF Lott, Lori A.
   Schneck, Marilyn E.
   Haegerstrom-Portnoy, Gunilla
   Hewlett, Susan
   Stepien-Bernabe, Natalie
   Gauer, Bonnie M.
   Zaidi, Ali
   Fu, Arthur D.
   Brabyn, John A.
TI Simple Vision Function Tests that Distinguish Eyes with Early to
   Intermediate Age-related Macular Degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
ID VISUAL FUNCTION; CONTRAST SENSITIVITY; SHAPE-DISCRIMINATION; FLICKER
   SENSITIVITY; SEVERITY SCALE; GLARE RECOVERY; MACULOPATHY; PREVALENCE;
   RISK; RANIBIZUMAB
AB Purpose To present and compare baseline vision findings in eyes with early age-related macular degeneration (E-AMD), intermediate AMD (I-AMD), and age-similar participants with normal aging changes to the retina (No-AMD). Methods Two hundred and thirty-seven eyes of 125 individuals (66.4% female, mean age 75.3 years) were tested monocularly using several simple, rapid psychophysical tests: high contrast visual acuity, low contrast visual acuity at reduced luminance, contrast sensitivity, shape discrimination hyperacuity, colour vision, reading rate, and glare recovery. Retinal status was determined using colour fundus photographs that were graded according to the Beckman Initiative for Macular Research Classification Committee scale. Logistic regression analyses with generalized estimating equations were used to assess the association between each vision variable and AMD category, while taking into account the correlation between the two eyes. Results Three vision measures (contrast sensitivity [CS], shape discrimination hyperacuity [SDH], and colour discrimination [DesatCCS]) were significantly and independently associated with intermediate AMD. Relative Risk Ratios (RRR), 95% Confidence Intervals (in parentheses), beta coefficients, and significance (p) for the I-AMD vs. No-AMD model are: CS: RRR = 6.5 (1.91-22.0), beta = 1.87,p< .01; SDH: RRR = 2.34 (1.24-4.44), beta = 0.85,p< .001; DesatCCS: RRR = 1.43 (1.22-1.68), beta = 0.36,pConclusions Simple screening tests distinguish eyes with intermediate AMD from eyes with less severe AMD or normal aging changes. This suggests that these vision measures may be significant predictors of which participants will go on to develop advanced AMD.
C1 [Lott, Lori A.; Schneck, Marilyn E.; Haegerstrom-Portnoy, Gunilla; Hewlett, Susan; Stepien-Bernabe, Natalie; Brabyn, John A.] Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA.
   [Haegerstrom-Portnoy, Gunilla; Hewlett, Susan] Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA.
   [Gauer, Bonnie M.] OD MS LLC, Roseburg, OR USA.
   [Zaidi, Ali] Pacific Eye Associates, San Francisco, CA USA.
   [Fu, Arthur D.] West Coast Retina Med Grp, San Francisco, CA USA.
C3 The Smith-Kettlewell Eye Research Institute; University of California
   System; University of California Berkeley
RP Lott, LA (通讯作者)，Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA.
EM lott@ski.org
FU National Eye Institute of the National Institutes of Health, USA
   [EY023320]
FX Supported by The National Eye Institute of the National Institutes of
   Health, USA. Grant #EY023320.
CR Adams AJ., 1987, DIAGNOSIS MANAGEMENT, P671
   Adams AJ, 1982, DOC OPHTHALMOL P SER
   Allison P., 2012, STAT HORIZONS
   APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Arditi A, 2005, INVEST OPHTH VIS SCI, V46, P2225, DOI 10.1167/iovs.04-1198
   Bedell HE, 2009, OPTOMETRY VISION SCI, V86, P485, DOI 10.1097/OPX.0b013e31819fa6e2
   BOWMAN KJ, 1982, ACTA OPHTHALMOL, V60, P907
   BROWN B, 1984, AM J OPTOM PHYS OPT, V61, P265
   Brown B, 1987, CLIN EXP OPTOM, V70, P145
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cheong Allen C Y, 2002, Clin Exp Optom, V85, P229
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   COLLINS M, 1989, CLIN VISION SCI, V4, P145
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   Collins MJ, 1986, CLIN EXP OPTOM, V69, P223, DOI DOI 10.1111/J.1444-0938.1986.TB04596.X
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Fan Q, 2011, INVEST OPHTH VIS SCI, V52, P6059, DOI 10.1167/iovs.10-7108
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Haegerstrom-Portnoy G, 1999, OPTOMETRY VISION SCI, V76, P141, DOI 10.1097/00006324-199903000-00014
   HaegerstromPortnoy G, 1997, INVEST OPHTH VIS SCI, V38, P207
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Hardin JW, 2013, GEN ESTIMATING EQUAT
   Hess RF, 1999, VISION RES, V39, P4354, DOI 10.1016/S0042-6989(99)00153-4
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jeffrey BG, 2002, VISION RES, V42, P2773, DOI 10.1016/S0042-6989(02)00332-2
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Ku JY, 2016, PEERJ, V4, DOI 10.7717/peerj.2650
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Loffler G, 2003, VISION RES, V43, P519, DOI 10.1016/S0042-6989(02)00686-7
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Maynard ML, 2016, ACTA OPHTHALMOL, V94, pE772, DOI 10.1111/aos.13112
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Murdoch IE, 1998, BRIT J OPHTHALMOL, V82, P971, DOI 10.1136/bjo.82.8.971
   National Eye Institute (NEI), AG REL MAC DEG AMD T
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Schneck ME, 2014, OPTOMETRY VISION SCI, V91, P284, DOI 10.1097/OPX.0000000000000152
   Schneck ME, OPTOM VIS SCI
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Shin KU, 2017, OPHTHALMIC RES, V57, P32, DOI 10.1159/000449168
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Touloumis A, 2013, BIOMETRICS, V69, P633, DOI 10.1111/biom.12054
   Trauzettel-Klosinski S, 2012, INVEST OPHTH VIS SCI, V53, P5452, DOI 10.1167/iovs.11-8284
   U.S. Census Bureau, 2014, AG NAT OLD POP US PO
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VINGRYS AJ, 1988, INVEST OPHTH VIS SCI, V29, P50
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   Wilkinson F, 1998, VISION RES, V38, P3555, DOI 10.1016/S0042-6989(98)00039-X
NR 68
TC 2
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD MAR 4
PY 2021
VL 28
IS 2
BP 93
EP 104
DI 10.1080/09286586.2020.1793371
EA AUG 2020
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RC2XS
UT WOS:000559153800001
PM 32781860
OA hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Park, SW
   Im, S
   Jun, HO
   Lee, K
   Park, YJ
   Kim, JH
   Park, WJ
   Lee, YH
   Kim, JH
AF Park, Sung Wook
   Im, Sora
   Jun, Hyoung Oh
   Lee, Kihwang
   Park, Young-Jun
   Kim, Jin Hyoung
   Park, Woo Jin
   Lee, Young-Hoon
   Kim, Jeong Hun
TI Dry age-related macular degeneration like pathology in aged 5XFAD mice:
   Ultrastructure and microarray analysis
SO ONCOTARGET
LA English
DT Article
DE amyloid beta; age-related macular degeneration; transmission electron
   microscopy; retinal pigment epithelium; microarray; Gerotarget
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; AMYLOID-BETA;
   ALZHEIMERS-DISEASE; TRANSGENIC MICE; TIGHT JUNCTION; MODEL; DRUSEN;
   PHAGOCYTOSIS; POLYMORPHISM
AB Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly. The two types of AMD are: dry and wet AMD. While laser-induced choroidal neovascularization has been used extensively in the studies of wet AMD, there is no established mouse model that fully recapitulates the cardinal features of dry AMD. A lack of appropriate mouse model for dry AMD has hampered the translational research on the pathogenesis of the disease and the development of therapeutic agents. We hypothesized that 5XFAD mice, an animal model for the study of Alzheimer's disease, can be used as a mouse model for dry AMD with regard to the amyloid beta (A beta) related pathology. In this study, the ultrastructure of the retinal pigment epithelium (RPE) of 5XFAD mice was analyzed using transmission electron microscopy. Of importance, the aged 5XFAD mice show ultrastructural changes in the RPE and Bruch's membrane (BM) that are compatible with the cardinal features of human dry AMD, including a loss of apical microvilli and basal infolding of the RPE, increased BM thickness, basal laminar and linear deposits, and accumulation of lipofuscin granules and undigested photoreceptor outer segment-laden phagosomes. In microarray-based analysis, the RPE complex of the aged 5XFAD mice shows differential gene expression profiles consistent with dry AMD in the inflammation response, immune reaction pathway, and decreased retinol metabolism. Taken together, we suggest that aged 5XFAD mice can be used as a mouse model of dry AMD to study A beta related pathology and develop a new therapeutic approaches.
C1 [Park, Sung Wook; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.
   [Park, Sung Wook; Jun, Hyoung Oh; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ Hosp, Fight Angiogenesis Related Blindness Lab, Biomed Res Inst, Seoul, South Korea.
   [Im, Sora; Park, Woo Jin] Gwangju Inst Sci & Technol Cheomdan Gwagiro, Dept Life Sci, Life Sci Concentrat, Gwangju, South Korea.
   [Lee, Kihwang] Ajou Univ, Dept Ophthalmol, Suwon, Gyeonggi Do, South Korea.
   [Park, Young-Jun] Korea Res Inst Biosci & Biotechnol, Immunotherapy Res Ctr, Daejeon, South Korea.
   [Lee, Young-Hoon] Chonbuk Natl Univ, Sch Dent, Dept Oral Anat, Jeonju Si, Jeollabuk Do, South Korea.
   [Kim, Jeong Hun] Chonbuk Natl Univ, Inst Oral Biosci, Jeonju Si, Jeollabuk Do, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Gwangju Institute of Science & Technology
   (GIST); Ajou University; Korea Research Institute of Bioscience &
   Biotechnology (KRIBB); Jeonbuk National University; Jeonbuk National
   University
RP Kim, JH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ Hosp, Fight Angiogenesis Related Blindness Lab, Biomed Res Inst, Seoul, South Korea.; Kim, JH (通讯作者)，Chonbuk Natl Univ, Inst Oral Biosci, Jeonju Si, Jeollabuk Do, South Korea.
EM steph25@snu.ac.kr
RI Park, Sung Wook/D-5541-2012
OI Park, Sung Wook/0000-0001-8151-6663; Kim, Jeong Hun/0000-0003-2957-1766
FU Pioneer Research Program of NRF/MEST [2012-0009544]; Bio & Medical
   Technology Development Program of the National Research Foundation; MSIP
   [NRF-2015M3A9E6028949]; Development of Platform Technology for
   Innovative Medical Measurements Program from Korea research Institute of
   Standards and Science [KRISS-2016-16011064]; MD-PhD program of Korea
   Research Institute of Bioscience and Biotechnology
FX This study was supported by the Pioneer Research Program of NRF/MEST
   (2012-0009544 to Je.H.K.), the Bio & Medical Technology Development
   Program of the National Research Foundation, and MSIP
   (NRF-2015M3A9E6028949 to Je.H.K.), the Development of Platform
   Technology for Innovative Medical Measurements Program from Korea
   research Institute of Standards and Science (KRISS-2016-16011064), the
   MD-PhD program of Korea Research Institute of Bioscience and
   Biotechnology (Y.-J.P., Je.H.K.).
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Chowers I, 2004, INVEST OPHTH VIS SCI, V45, P2098, DOI 10.1167/iovs.03-0863
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EDWARDS RL, 1979, BLOOD, V54, P359
   Emery M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021586
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Gimenez E, 2001, LAB ANIM-UK, V35, P153, DOI 10.1258/0023677011911525
   HSU SL, 1992, BIOCHEM J, V283, P611, DOI 10.1042/bj2830611
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lang D, 1998, J IMMUNOL, V161, P6871
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   MAYERSON PL, 1986, J CELL BIOL, V103, P299, DOI 10.1083/jcb.103.1.299
   More SS, 2015, ACS CHEM NEUROSCI, V6, P306, DOI 10.1021/cn500242z
   Nikopoulos K, 2015, SCI REP-UK, V5, DOI 10.1038/srep13902
   Nishiyama K, 2002, ANAT REC, V267, P196, DOI 10.1002/ar.10102
   Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Park SW, 2015, ONCOTARGET, V6, P35263, DOI 10.18632/oncotarget.5894
   Park SW, 2014, NEUROBIOL AGING, V35, P2013, DOI 10.1016/j.neurobiolaging.2014.03.008
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Sun H, 1997, P NATL ACAD SCI USA, V94, P9893, DOI 10.1073/pnas.94.18.9893
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Yang WJ, 2015, EMBO MOL MED, V7, P1267, DOI 10.15252/emmm.201404922
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 35
TC 15
Z9 16
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 20
PY 2017
VL 8
IS 25
BP 40006
EP 40018
DI 10.18632/oncotarget.16967
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EY8YG
UT WOS:000404283700009
PM 28467791
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Le Tien, V
   Streho, M
   D'Athis, P
   Taillandier-Heriche, E
   Paillaud, E
   Mahiddine, H
   Coscas, G
   Lejonc, JL
   Soubrane, G
   Souied, EH
AF Le Tien, Valerie
   Streho, Mate
   D'Athis, Philippe
   Taillandier-Heriche, Elodie
   Paillaud, Elena
   Mahiddine, Hassina
   Coscas, Gabriel
   Lejonc, Jean-Louis
   Soubrane, Gisele
   Souied, Eric H.
TI Interobserver and intraobserver reliability of detecting age-related
   macular degeneration using a nonmydriatic digital camera
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC-RETINOPATHY; FUNDUS PHOTOGRAPHY; EYE DISEASE; MACULOPATHY;
   PREVALENCE; PROGRAM; RISK
AB PURPOSE: To evaluate the interobserver and intraobserver reliability of detecting early and late age-related macular degeneration (AMD) using a nonmydriatic digital camera in two distinct groups of older people.
   DESIGN: Prospective study.
   METHODS: The two groups consisted of a series of patients older than 70 years hospitalized in a geriatric unit and a younger series of people older than 55 years. In both groups, nonmydriatic color fundus photographs were obtained and graded independently by two ophthalmologists (V.L. and M.S.). No ophthalmic examination was performed. Main outcome measures were frequencies of early and late AMD and interobserver and intraobserver agreement.
   RESULTS: Among 233 patients in group 1 (mean age, 84.6 years), only 119 patients (51%) could undergo photography because of associated multiple morbidities. Mean age of group 2 was 63.8 years. In group 1, 35 (14.5%) of 238 pictures were ungradable. In series 2, 65 (9.1%) of 716 pictures were ungradable. Frequencies of early and late AMD were 30.3% and 5.9% vs 12.6% and 2.6% in series 1 and 2, respectively. Interobserver and intraobserver agreement was good or excellent (kappa > 0.6) in both groups.
   CONCLUSIONS: In the entire geriatric cohort, 43% of the patients had gradable pictures allowing a diagnosis. These patients would otherwise have had no access to any form of funduscopy. In the younger population, nonmydriatic pictures permitted a diagnosis in 90% of the individuals. Detection of AMD with a nonmydriatic digital camera may lead to large-scale screening and specific management.
C1 [Le Tien, Valerie; Streho, Mate; Mahiddine, Hassina; Coscas, Gabriel; Soubrane, Gisele; Souied, Eric H.] Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal, F-94010 Creteil, France.
   [D'Athis, Philippe] Ctr Hosp Univ, Dept Biostat, Dijon, France.
   [Taillandier-Heriche, Elodie; Paillaud, Elena; Lejonc, Jean-Louis] Univ Paris 12, Dept Gerontol, Ctr Hosp Univ Henri Mondor Albert Chenevier, AP HP, F-94010 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; CHU Dijon
   Bourgogne; Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP
RP Souied, EH (通讯作者)，Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal, 40 Ave Verdun, F-94010 Creteil, France.
EM eric.souied@chicreteil.fr
RI Paillaud, Elena/K-5616-2017
OI Paillaud, Elena/0000-0002-5579-9927
CR [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baker CF, 2004, CAN J OPHTHALMOL, V39, P746, DOI 10.1016/S0008-4182(04)80068-1
   Baltes PB, 2003, GERONTOLOGY, V49, P123, DOI 10.1159/000067946
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chow SP, 2006, OPHTHALMOLOGY, V113, P833, DOI 10.1016/j.ophtha.2005.12.025
   Deb-Joardar N, 2005, AM J OPHTHALMOL, V140, P814, DOI 10.1016/j.ajo.2005.05.051
   Ferraro JG, 2006, OPHTHAL EPIDEMIOL, V13, P127, DOI 10.1080/09286580500545717
   GEXFABRY M, 1994, HANDB EXP PHARMACOL, V110, P507
   Jain S, 2006, EYE, V20, P471, DOI 10.1038/sj.eye.6701916
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Le Tien V, 2006, J FR OPHTALMOL, V29, P796, DOI 10.1016/S0181-5512(06)73849-9
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Maberley D, 2004, OPHTHAL EPIDEMIOL, V11, P191, DOI 10.1080/09286580490514496
   Maberley DAL, 2005, EYE, V19, P611, DOI 10.1038/sj.eye.6701584
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Massin P, 2005, DIABETES METAB, V31, P153, DOI 10.1016/S1262-3636(07)70181-7
   Massin P, 2003, DIABETIC MED, V20, P635, DOI 10.1046/j.1464-5491.2003.01002.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pasquale Louis R, 2007, Optometry, V78, P657, DOI 10.1016/j.optm.2007.04.101
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Somani R, 2005, CAN J OPHTHALMOL, V40, P293, DOI 10.1016/S0008-4182(05)80072-9
   Tikellis G, 2000, CLIN EXP OPHTHALMOL, V28, P367, DOI 10.1046/j.1442-9071.2000.00336.x
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   WHITMORE WG, 1989, OPHTHALMOLOGY, V96, P393, DOI 10.1016/S0161-6420(89)32880-6
NR 37
TC 21
Z9 21
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2008
VL 146
IS 4
BP 520
EP 526
DI 10.1016/j.ajo.2008.05.031
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 355XH
UT WOS:000259742200008
PM 18619569
DA 2022-11-30
ER

PT J
AU Fraser-Bell, S
   Donofrio, J
   Wu, J
   Klein, R
   Azen, SP
   Varma, R
AF Fraser-Bell, S
   Donofrio, J
   Wu, J
   Klein, R
   Azen, SP
   Varma, R
CA Los Angeles Latino Eye Study Grp
TI Sociodemographic factors and age-related macular degeneration in
   latinos: The Los Angeles Latino Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; NATIONAL-HEALTH; RACIAL-DIFFERENCES; CIGARETTE-SMOKING;
   GEOGRAPHIC REGION; MACULOPATHY; PREVALENCE; POPULATION; AUSTRALIA;
   WISCONSIN
AB PURPOSE: To assess the association of various sociode-mographic factors and early and advanced (geographic atrophy, exudative) age-related macular degeneration (AMD) in Latinos.
   DESIGN: Population-based, cross,sectional study
   METHODS: The study population included Latinos (primarily Mexican-American) aged 40 years and older living in La Puente, California. Sociodemographic factors, obtained from an interviewer,administered questionnaire, included age, sex, Native American ancestry, acculturation, country of birth, employment, income, marital status, health insurance, and education level. All participants underwent complete ophthalmic examination. AMD was diagnosed from stereoscopic macular photo, graphs. Univariate and multivariable logistic regression was used to assess associations between sociodemographic factors and AMD.
   RESULTS: Gradable retinal photographs from 5875 participants were included. Mean participant age was 54.9 years, 42% were male, and 5% had Native American ancestry. Stepwise logistic regression analyses indicated that age, sex, and being born in the United States were associated with early AMD (odds ratio [OR] = 1.8, 1.8, and 0.80, respectively). Native American ancestry was the associated with any advanced AMD and geographic atrophy (OR = 3.8 and 16.4, respectively). Family history of AMD was also associated with geographic atrophy (OR = 28.1). Acculturation was not associated with AMD.
   CONCLUSION: Independent risk indicators for the various types of AMD include older age, male sex, being born outside of the United States, Native American ancestry, and a family history of AMD. These risk factors were independent of other possible behavioral factors such as smoking and alcohol consumption. (C) 2005 by Elsevier Inc. All rights reserved.
C1 Univ So Calif, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA.
   Univ So Calif, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   Univ So Calif, Sch Pharm, Dept Econ & Policy, Los Angeles, CA 90033 USA.
   Univ Wisconsin, Dept Ophthalmol, Madison, WI 53706 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; University of Southern California; University of
   Southern California; University of Southern California; University of
   Wisconsin System; University of Wisconsin Madison
RP Varma, R (通讯作者)，Univ So Calif, Doheny Eye Inst, 1450 San Pablo St,DEI4900, Los Angeles, CA 90033 USA.
EM rvarma@usc.edu
RI Fraser-Bell, Samantha/ABE-8574-2020
OI Fraser-Bell, Samantha/0000-0001-5646-9359; Wu,
   Joanne/0000-0003-0932-4979
FU NEI NIH HHS [EY 11753, EY 03040, U10 EY011753, P30 EY003040] Funding
   Source: Medline; NATIONAL EYE INSTITUTE [P30EY003040] Funding Source:
   NIH RePORTER
CR Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Cuellar IHL., 1980, HISPANIC J BEHAV SCI, V2, P199, DOI DOI 10.1177/07399863950173001
   EVANS J, 1995, 57 LOND MAJ STAT OFF
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   PLEIS JR, 2003, VITAL HLTH STAT, V10, P85
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   SOLIS JM, 1990, AM J PUBLIC HEALTH, V80, P11, DOI 10.2105/AJPH.80.Suppl.11
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   United States Census Bureau, 1996, CURR POP REP POP PRO
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   2003, POPULATION PROJECTIO
NR 44
TC 23
Z9 23
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2005
VL 139
IS 1
BP 30
EP 38
DI 10.1016/j.ajo.2004.08.029
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 885XW
UT WOS:000226191700004
PM 15652825
DA 2022-11-30
ER

PT J
AU Starr, MR
   Mahr, MA
   Barkmeier, AJ
   Iezzi, R
   Smith, WM
   Bakri, SJ
AF Starr, Matthew R.
   Mahr, Michael A.
   Barkmeier, Andrew J.
   Iezzi, Raymond
   Smith, Wendy M.
   Bakri, Sophie J.
TI Outcomes of Cataract Surgery in Patients With Exudative Age-related
   Macular Degeneration and Macular Fluid
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; VERTEPORFIN; PROGRESSION; RISK
AB PURPOSE: To investigate whether having macular fluid on optical coherence tomography (OCT) prior to cataract surgery adversely affected vision or anatomic outcomes after cataract surgery in patients with exudative age related macular degeneration (AMD).
   DESIGN: Retrospective cohort study.
   METHODS: We examined all patients who underwent cataract surgery and were receiving intravitreal anti vascular endothelial growth factor (anti-VEGF) injections from January 1, 2012 through December 31, 2016. There were 81 eyes that underwent cataract surgery and had received at least 1 intravitreal anti-VEGF injection for a diagnosis of exudative AMD within 6 months prior to surgery. Data collected included the development of subretinal or intraretinal macular fluid, or subretinal hemorrhage, in the 6 months following surgery; number of injections; best-corrected visual acuity (BCVA); and central subfield thickness (CST).
   RESULTS: There was a significant improvement between preopertive and postoperative BCVA when comparing all patients (P values <.0001) and no significant difference in CST before and after surgery (P>.05). There were 23 eyes with fluid on the preoperative OCT. There were no differences in final BCVA or CST and no difference in the development of fluid postoperatively when compared to patients without fluid preoperatively (all P values >.05). These patients also saw a significant improvement in BCVA (P=.006).
   CONCLUSION: In a real-world setting, patients with both cataracts and wet AMD may safely undergo cataract surgery. Patients with stable preoperative fluid on OCT should be considered for cataract surgery, as these patients did well postoperatively, with no worsening of their neovascular process. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Starr, Matthew R.; Mahr, Michael A.; Barkmeier, Andrew J.; Iezzi, Raymond; Smith, Wendy M.; Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, 200 First St Southwest, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 First St Southwest, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
RI Barkmeier, Andrew/AAV-1021-2020
OI Starr, Matthew/0000-0002-3021-5630
FU RESEARCH TO PREVENT BLINDNESS, NEW YORK, NEW YORK, USA
FX THIS WORK WAS SUPPORTED BY RESEARCH TO PREVENT BLINDNESS, NEW YORK, NEW
   YORK, USA. THE funding source did not have any involvement in study
   design; collection, analysis, or interpretation of the data; writing the
   report; or the decision to submit for publication.
CR Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Casparis H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub3
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Engman SJ, 2011, SEMIN OPHTHALMOL, V26, P380, DOI 10.3109/08820538.2011.622337
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rappoport Daniel, 2017, Harefuah, V156, P79
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   Virgili G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub3
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
NR 25
TC 7
Z9 7
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2018
VL 192
BP 91
EP 97
DI 10.1016/j.ajo.2018.05.014
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP9HA
UT WOS:000441226900015
PM 29802819
DA 2022-11-30
ER

PT J
AU Vassilev, ZP
   Ruigomez, A
   Soriano-Gabarro, M
   Rodriguez, LAG
AF Vassilev, Zdravko P.
   Ruigomez, Ana
   Soriano-Gabarro, Montse
   Garcia Rodriguez, Luis A.
TI Diabetes, Cardiovascular Morbidity, and Risk of Age-Related Macular
   Degeneration in a Primary Care Population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; diabetes; cardiovascular; healthcare
   use
ID CIGARETTE-SMOKING; 5-YEAR INCIDENCE; POOLED FINDINGS; ASPIRIN USE;
   STATIN USE; MACULOPATHY; HEALTH; ASSOCIATION; DISEASES; PEOPLE
AB PURPOSE. Age-related macular degeneration (AMD) is the most common cause of legal blindness in Western patients over 65 years of age. We aimed to establish the incidence of AMD, and the association of diabetes, and cardiovascular and eye diseases with the risk of AMD, in a large cohort of primary care patients in the United Kingdom.
   METHODS. Using data from The Health Improvement Network database in the United Kingdom, all individuals with a first recorded diagnosis of AMD from 2004 to 2010 were identified (N = 10,516) and frequency-matched to 19,389 AMD-free individuals by age, sex, and calendar year of AMD occurrence. Logistic regression was used to examine comorbidities and risk factors for AMD.
   RESULTS. The incidence of AMD was 18.08 (95% confidence interval [CI], 17.74-18.43) per 10,000 person-years. A positive association with AMD was observed for smoking, a high frequency of primary care visits, and referrals. Diabetes and use of antidiabetic drugs were associated with an increased risk of AMD. Prevalence of cardiovascular diseases among AMD patients was slightly higher than in controls, with a small increased risk of AMD among patients with myocardial infarction, heart failure, or hyperlipidemia. Positive associations were observed between prior eye diseases and risk of AMD, in particular for chorioretinal disorders.
   CONCLUSIONS. The incidence of AMD in the United Kingdom is in line with previously reported incidence rates from population-based studies. The study suggests an association between diabetes, prior eye diseases, cardiovascular comorbidities and AMD risk, and a link between AMD and higher healthcare utilization.
C1 [Vassilev, Zdravko P.] Bayer Healthcare Pharmaceut, Whippany, NJ 07981 USA.
   [Ruigomez, Ana; Garcia Rodriguez, Luis A.] Spanish Ctr Pharmacoepidemiol Res CEIFE, Madrid, Spain.
   [Soriano-Gabarro, Montse] Bayer Pharma AG, Berlin, Germany.
C3 Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare
   Pharmaceuticals
RP Vassilev, ZP (通讯作者)，Bayer Healthcare Pharmaceut, 100 Bayer Blvd, Whippany, NJ 07981 USA.
EM zdravko.vassilev@bayer.com
RI Ruigomez, Ana/HDN-8290-2022; rodriguez, luis a garcia/B-1980-2010
FU Bayer Pharma AG, Berlin, Germany; Bayer Pharma AG
FX Supported by Bayer Pharma AG, Berlin, Germany. Medical writing
   assistance was provided by Susan Bromley (EpiMed Communications Ltd,
   Oxford, UK), and funded by Bayer Pharma AG.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung N, 2013, BRIT J OPHTHALMOL, V97, P785, DOI 10.1136/bjophthalmol-2012-302253
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P4430, DOI 10.1167/iovs.14-14379
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Evans JR, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-16
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Flammer J, 2013, EUR HEART J, V34, P1270, DOI 10.1093/eurheartj/eht023
   Goldacre MJ, 2012, BRIT J OPHTHALMOL, V96, P872, DOI 10.1136/bjophthalmol-2012-301519
   Goodman Denise M, 2012, JAMA, V308, P1702, DOI 10.1001/jama.2012.4091
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stuart-Buttle C D, 1996, Proc AMIA Annu Fall Symp, P75
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Vassilev ZP, 2014, 30 ANN INT C PHARM T
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang SB, 2015, BRIT J OPHTHALMOL, V99, P365, DOI 10.1136/bjophthalmol-2014-305793
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
NR 49
TC 27
Z9 29
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2015
VL 56
IS 3
BP 1585
EP 1592
DI 10.1167/iovs.14-16271
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE9BF
UT WOS:000352137600022
PM 25670489
DA 2022-11-30
ER

PT J
AU van Grinsven, MJJP
   Lechanteur, YTE
   van de Ven, JPH
   van Ginneken, B
   Hoyng, CB
   Theelen, T
   Sanchez, CI
AF van Grinsven, Mark J. J. P.
   Lechanteur, Yara T. E.
   van de Ven, Johannes P. H.
   van Ginneken, Bram
   Hoyng, Carel B.
   Theelen, Thomas
   Sanchez, Clara I.
TI Automatic Drusen Quantification and Risk Assessment of Age-Related
   Macular Degeneration on Color Fundus Images
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; drusen detection; risk assessment
ID DIABETIC-RETINOPATHY; NATURAL-HISTORY; RETINAL IMAGES; SD-OCT;
   MACULOPATHY; PROGRESSION; PHOTOGRAPHS; PROGNOSIS; ABNORMALITIES;
   SEGMENTATION
AB PURPOSE. To evaluate a machine learning algorithm that allows for computer-aided diagnosis (CAD) of nonadvanced age-related macular degeneration (AMD) by providing an accurate detection and quantification of drusen location, area, and size.
   METHODS. Color fundus photographs of 407 eyes without AMD or with early to moderate AMD were randomly selected from a large European multicenter database. A machine learning system was developed to automatically detect and quantify drusen on each image. Based on detected drusen, the CAD software provided a risk assessment to develop advanced AMD. Evaluation of the CAD system was performed using annotations made by two blinded human graders.
   RESULTS. Free-response receiver operating characteristics (FROC) analysis showed that the proposed system approaches the performance of human observers in detecting drusen. The estimated drusen area showed excellent agreement with both observers, with mean intraclass correlation coefficients (ICC) larger than 0.85. Maximum druse diameter agreement was lower, with a maximum ICC of 0.69, but comparable to the interobserver agreement (ICC = 0.79). For automatic AMD risk assessment, the system achieved areas under the receiver operating characteristic (ROC) curve of 0.948 and 0.954, reaching similar performance as human observers.
   CONCLUSIONS. A machine learning system capable of separating high-risk from low-risk patients with nonadvanced AMD by providing accurate detection and quantification of drusen, was developed. The proposed method allows for quick and reliable diagnosis of AMD, opening the way for large dataset analysis within population studies and genotype-phenotype correlation analysis.
C1 [van Grinsven, Mark J. J. P.; van Ginneken, Bram; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Diagnost Image Anal Grp, NL-6525 EX Nijmegen, Netherlands.
   [Lechanteur, Yara T. E.; van de Ven, Johannes P. H.; Hoyng, Carel B.; Theelen, Thomas] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 EX Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP Theelen, T (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol 409, Philips Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM t.theelen@ohk.umcn.nl
RI Lechanteur, Yara/ABB-6875-2020; Gutiérrez, Clara Isabel
   Sánchez/B-3800-2014; Lehtimäki, Terho/AAD-1094-2022; van Ginneken,
   Bram/A-3728-2012; Theelen, Thomas/A-3192-2012; Gutierrez, Clara Isabel
   Sanchez/N-3580-2014; Hoyng, C.B./H-8050-2014
OI Lechanteur, Yara/0000-0003-0951-4625; Gutiérrez, Clara Isabel
   Sánchez/0000-0001-9787-8319; Lehtimäki, Terho/0000-0002-2555-4427; van
   Ginneken, Bram/0000-0003-2028-8972; Theelen, Thomas/0000-0001-9067-1171;
   
FU MD-fonds, Oogfonds, Algemene Nederlandse Vereniging ter Voorkoming van
   Blindheid
FX Supported by MD-fonds, Oogfonds, Algemene Nederlandse Vereniging ter
   Voorkoming van Blindheid.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   [Anonymous], 1991, Ophthalmology, V98, P786
   Arlot S, 2010, STAT SURV, V4, P40, DOI 10.1214/09-SS054
   BELLMAN R, 1952, P NATL ACAD SCI USA, V38, P716, DOI 10.1073/pnas.38.8.716
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brandon L, 2003, LECT NOTES COMPUT SC, V2878, P618
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   GOLDBAUM MH, 1990, INVEST OPHTH VIS SCI, V31, P617
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   He Xin, 2009, J Am Coll Radiol, V6, P652, DOI 10.1016/j.jacr.2009.06.001
   Ho TK, 1998, IEEE T PATTERN ANAL, V20, P832, DOI 10.1109/34.709601
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Karnon J, 2008, Health Technol Assess, V12, piii
   Karnon J, 2009, MED DECIS MAKING, V29, P304, DOI 10.1177/0272989X08327491
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KIRKPATRICK JNP, 1995, EYE, V9, P48, DOI 10.1038/eye.1995.7
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koch, 1982, ENCY STAT SCI, V4, P213, DOI DOI 10.1002/0471667196.ESS1275.PUB2
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Liang ZY, 2010, IEEE ENG MED BIO, P4100, DOI 10.1109/IEMBS.2010.5627289
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Metz Charles E, 2006, J Am Coll Radiol, V3, P413, DOI 10.1016/j.jacr.2006.02.021
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   MORGAN WH, 1994, AUST NZ J OPHTHALMOL, V22, P7, DOI 10.1111/j.1442-9071.1994.tb01688.x
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Ong BB, 2013, EYE, V27, P554, DOI 10.1038/eye.2012.292
   PELI E, 1986, OPHTHALMOLOGY, V93, P1575
   Quellec G, 2011, INVEST OPHTH VIS SCI, V52, P9195, DOI 10.1167/iovs.10-6793
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Sanchez CI, 2012, MED IMAGE ANAL, V16, P50, DOI 10.1016/j.media.2011.05.004
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   SEBAG M, 1991, ACTA OPHTHALMOL, V69, P603
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Shin DS, 1999, OPHTHALMOLOGY, V106, P1119, DOI 10.1016/S0161-6420(99)90257-9
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P40, DOI 10.1001/archophthalmol.2010.328
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   van de Ven JPH, 2012, AM J OPHTHALMOL, V154, P560, DOI 10.1016/j.ajo.2012.03.012
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
NR 54
TC 28
Z9 28
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2013
VL 54
IS 4
BP 3019
EP 3027
DI 10.1167/iovs.12-11449
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 156KV
UT WOS:000319821700075
PM 23572106
OA Green Published
DA 2022-11-30
ER

PT J
AU Kubista, KE
   Tosakulwong, N
   Wu, YH
   Ryu, E
   Roeder, JL
   Hecker, LA
   Baratz, KH
   Brown, WL
   Edwards, AO
AF Kubista, Katharina E.
   Tosakulwong, Nirubol
   Wu, Yanhong
   Ryu, Euijung
   Roeder, Jaime L.
   Hecker, Laura A.
   Baratz, Keith H.
   Brown, William L.
   Edwards, Albert O.
TI Copy number variation in the complement factor H-related genes and
   age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID DEPENDENT PROBE AMPLIFICATION; HEMOLYTIC-UREMIC SYNDROME; HUMAN GENOME;
   FACTOR-B; RISK; POLYMORPHISM; CFH; ASSOCIATION; HAPLOTYPES; VARIANT
AB Purpose: To determine the contribution of copy number variation (CNV) in the regulation of complement activation (RCA) locus to the development of age-related macular degeneration (AMD).
   Methods: A multiplex ligation-dependent probe amplification assay was developed to quantify the number of copies of CFH, CFHR3, CFHR1, CFHR4, CFHR2, and CFHR5 in humans. Subjects with (451) and without (362) AMD were genotyped using the assay, and the impact on AMD risk was evaluated.
   Results: Eight unique combinations of copy number variation were observed in the 813 subjects. Combined deletion of CFHR3 and CFHR1 was protective (OR=0.47, 95% confidence interval 0.36-0.62) against AMD and was observed in 88 (82 [18.6%] with one deletion, 6 [1.4%] with two deletions) subjects with AMD and 127 (108 [30.7%] with one deletion, 19 [5.4%] with two deletions) subjects without AMD. Other deletions were much less common: CFH intron 1 (n=2), CFH exon 18 (n=2), combined CFH exon 18 and CFHR3 (n=1), CFHR3 (n=2), CFHR1 (n=1), combined CFHR1 and CFHR4 (n=15), and CFHR2 deletion (n=7, 0.9%). The combined CFHR3 and CFHR1 deletion was observed on a common protective haplotype, while the others appeared to have arisen on multiple different haplotypes.
   Conclusions: We found copy number variations of CFHR3, CFHR1, CFHR4, and CFHR2. Combined deletion of CFHR3 and CFHR1 was associated with a decreased risk of developing AMD. Other deletions were not sufficiently common to have a statistically detectable impact on the risk of AMD, and duplications were not observed.
C1 [Kubista, Katharina E.] Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Roeder, Jaime L.; Hecker, Laura A.; Baratz, Keith H.; Brown, William L.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
   [Edwards, Albert O.] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
C3 Ludwig Boltzmann Institute; Mayo Clinic; University of Oregon
RP Kubista, KE (通讯作者)，Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM kubista@proeyes.at
RI Brown, William/GXN-2777-2022
FU Max Kade Foundation, New York, NY; National Eye Institute, Bethesda, MD
   [EY014467]; Foundation Fighting Blindness, Owing Mills, MD; American
   Health Assistance Foundation, Clarksburg, MD; Research to Prevent
   Blindness, New York, NY; Mayo Foundation, Rochester, MN; NATIONAL EYE
   INSTITUTE [R01EY014467] Funding Source: NIH RePORTER
FX We thank Daniel Kluge and the Mayo Advanced Genomics Technology Center
   for assistance with the capillary electrophoresis. The research was
   supported by the Max Kade Foundation, New York, NY, National Eye
   Institute (EY014467), Bethesda, MD, the Foundation Fighting Blindness,
   Owing Mills, MD, the American Health Assistance Foundation, Clarksburg,
   MD, unrestricted departmental grants from Research to Prevent Blindness,
   New York, NY, and the Mayo Foundation, Rochester, MN. The authors have
   no commercial interests. The data was presented as a poster at the ARVO
   Meeting 2011 in Fort Lauderdale.
CR Aitman TJ, 2006, NATURE, V439, P851, DOI 10.1038/nature04489
   Boon CJF, 2009, PROG RETIN EYE RES, V28, P187, DOI 10.1016/j.preteyeres.2009.04.002
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fellermann K, 2006, AM J HUM GENET, V79, P439, DOI 10.1086/505915
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gale DP, 2010, LANCET, V376, P794, DOI 10.1016/S0140-6736(10)60670-8
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gonzalez JR, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-261
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hebecker M, 2010, MOL IMMUNOL, V47, P1347, DOI 10.1016/j.molimm.2009.12.005
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ionita-Laza I, 2009, GENOMICS, V93, P22, DOI 10.1016/j.ygeno.2008.08.012
   Jankowski Stephane, 2008, J Biomol Tech, V19, P238
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McKinney C, 2008, ANN RHEUM DIS, V67, P409, DOI 10.1136/ard.2007.075028
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Moore I, 2010, BLOOD, V115, P379, DOI 10.1182/blood-2009-05-221549
   Narendra U, 2009, MOL VIS, V15, P731
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Park KH, 2009, MOL VIS, V15, P200
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Shen YP, 2009, J GENET GENOMICS, V36, P257, DOI 10.1016/S1673-8527(08)60113-7
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562
   Yang Y, 2007, AM J HUM GENET, V80, P1037, DOI 10.1086/518257
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
NR 47
TC 25
Z9 27
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD AUG 6
PY 2011
VL 17
IS 227
BP 2080
EP 2092
PG 13
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 807GF
UT WOS:000293883600001
PM 21850184
DA 2022-11-30
ER

PT J
AU Xu, XQ
   Ritz, B
   Coleman, A
   Liew, Z
   Deapen, D
   Lee, EJ
   Bernstein, L
   Pinder, R
   Marshall, S
   Heck, JE
AF Xu, Xiaoqing
   Ritz, Beate
   Coleman, Anne
   Liew, Zeyan
   Deapen, Dennis
   Lee, Eunjung
   Bernstein, Leslie
   Pinder, Rich
   Marshall, Sarah
   Heck, Julia E.
TI Hypertension, antihypertensive medications use and risk of age-related
   macular degeneration in California Teachers Cohort
SO JOURNAL OF HUMAN HYPERTENSION
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; CARDIOVASCULAR-DISEASE; NATIONAL-HEALTH;
   BLOOD-PRESSURE; TERM INCIDENCE; ASPIRIN USE; MACULOPATHY; PATHOGENESIS;
   ASSOCIATION; PREVALENCE
AB Sustained and inadequately controlled hypertension can promote the development of age-related macular degeneration (AMD) through multiple biologic pathways. Epidemiologic studies of high blood pressure, antihypertensive therapies, and the risk of AMD thus far have been inconclusive. However, few studies evaluated risks according to the use of different classes of antihypertensive drugs or took combinations of use into account. We performed a prospective cohort study by linking the California Teachers Study (CTS) cohort (N = 88 481) to statewide hospital discharge records up to December 31, 2012. History of high blood pressure, regular use of antihypertensive medications, and comprehensive risk factor information was collected via self-administered questionnaires at baseline in 1995-1996, and information on specific classes of antihypertensive drugs was provided by a subsample of CTS participants who completed a follow-up questionnaire in 2000. We identified 1762 female teachers with AMD during 14.8 years of follow-up on average. Applying Cox proportional hazard regression, we estimated increased risks of AMD among women treated for hypertension at baseline (HR = 1.15, 95% CI: 1.03, 1.30); the magnitude of the association increased with longer duration of antihypertensive treatment. In the subsample with more specific information on type of medication use, we estimated a 45% increased risk of AMD among women receiving diuretics as monotherapy compared to women with medications more potent than diuretics (HR = 1.45, 95% CI 1.10, 1.90). In women treated with a combination of antihypertensive drugs, we observed no increased risk of AMD for any individual class of drugs.
C1 [Xu, Xiaoqing; Ritz, Beate; Coleman, Anne; Liew, Zeyan; Heck, Julia E.] Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.
   [Coleman, Anne] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Deapen, Dennis; Lee, Eunjung; Pinder, Rich; Marshall, Sarah] Univ Southern Calif USC, Dept Preventat Med, Keck Sch Med, Los Angeles, CA USA.
   [Bernstein, Leslie] City Hope Natl Med Ctr, Div Canc Etiol, Dept Populat Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA.
   [Bernstein, Leslie] Comprehens Canc Ctr, Duarte, CA USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; City of Hope
RP Heck, JE (通讯作者)，Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.
EM jeheck@ucla.edu
RI Heck, Julia/B-5230-2009
OI Heck, Julia/0000-0001-8713-8413; Lee, Eunjung/0000-0002-8287-6131;
   Bernstein, Leslie/0000-0002-7692-6518
FU NCI NIH HHS [K05 CA136967, UM1 CA164917, R01 CA074847, P30 CA023100, R01
   CA077398, U01 CA199277, P30 CA033572, R03 CA096400, R01 CA108634, P01
   CA017054] Funding Source: Medline
CR Amar J, 2003, J HYPERTENS, V21, P1199, DOI 10.1097/00004872-200306000-00021
   AMES RP, 1976, AM J MED, V61, P748, DOI 10.1016/0002-9343(76)90156-X
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barro-Soria R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049624
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernstein L, 2002, CANCER CAUSE CONTROL, V13, P625, DOI 10.1023/A:1019552126105
   Blumenfeld JD, 1998, AM J HYPERTENS, V11, P894, DOI 10.1016/S0895-7061(98)00080-6
   BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305
   Canchola AJ, 2012, CANCER CAUSE CONTROL, V23, P473, DOI 10.1007/s10552-012-9897-x
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Duan L, 2012, FERTIL STERIL, V97, P111, DOI 10.1016/j.fertnstert.2011.10.004
   Ernst ME, 2009, NEW ENGL J MED, V361, P2153, DOI 10.1056/NEJMra0907219
   Halpern MT, 2006, HEALTH CARE FINANC R, V27, P37
   Hikichi T, 2001, AM J OPHTHALMOL, V132, P587, DOI 10.1016/S0002-9394(01)01139-4
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197
   Kahawita SK, 2014, CAN J OPHTHALMOL, V49, P35, DOI 10.1016/j.jcjo.2013.07.016
   Katsi VK, 2015, J HYPERTENS, V33, P2382, DOI 10.1097/HJH.0000000000000766
   Khedun S. M., 1995, Central African Journal of Medicine, V41, P312
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Liew G, 2006, J HYPERTENS, V24, P1329, DOI 10.1097/01.hjh.0000234113.33025.33
   Mancia G, 2013, J HYPERTENS, V31, P1281, DOI 10.1097/01.hjh.0000431740.32696.cc
   Marshall SF, 2005, JNCI-J NATL CANCER I, V97, P805, DOI 10.1093/jnci/dji140
   Marshall SF, 2003, AM J EPIDEMIOL, V158, P1012, DOI 10.1093/aje/kwg256
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Sarafidis PA, 2010, EXPERT OPIN DRUG SAF, V9, P243, DOI 10.1517/14740330903499240
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wang TD, 2014, HYPERTENSION, V63, P958, DOI 10.1161/HYPERTENSIONAHA.113.02455
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
NR 37
TC 5
Z9 5
U1 0
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-9240
EI 1476-5527
J9 J HUM HYPERTENS
JI J. Hum. Hypertens.
PD SEP
PY 2020
VL 34
IS 8
BP 568
EP 576
DI 10.1038/s41371-019-0269-9
PG 9
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA NA8LZ
UT WOS:000560070600004
PM 31595025
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Bogunovic, H
   Montuoro, A
   Baratsits, M
   Karantonis, MG
   Waldstein, SM
   Schlanitz, F
   Schmidt-Erfurth, U
AF Bogunovic, Hrvoje
   Montuoro, Alessio
   Baratsits, Magdalena
   Karantonis, Maria G.
   Waldstein, Sebastian M.
   Schlanitz, Ferdinand
   Schmidt-Erfurth, Ursula
TI Machine Learning of the Progression of Intermediate Age-Related Macular
   Degeneration Based on OCT Imaging
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; drusen; optical coherence tomography;
   image analysis; machine learning
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; NATURAL-HISTORY;
   DRUSEN VOLUME; SEGMENTATION; DISEASE; TRIAL
AB PURPOSE. To develop a data-driven interpretable predictive model of incoming drusen regression as a sign of disease activity and identify optical coherence tomography (OCT) biomarkers associated with its risk in intermediate age-related macular degeneration (AMD).
   METHODS. Patients with AMD were observed every 3 months, using Spectralis OCT imaging, for a minimum duration of 12 months and up to a period of 60 months. Segmentation of drusen and the overlying layers was obtained using a graph-theoretic method, and the hyperreflective foci were segmented using a voxel classification method. Automated image analysis steps were then applied to identify and characterize individual drusen at baseline, and their development was monitored at every follow-up visit. Finally, a machine learning method based on a sparse Cox proportional hazard regression was developed to estimate a risk score and predict the incoming regression of individual drusen.
   RESULTS. The predictive model was trained and evaluated on a longitudinal dataset of 61 eyes from 38 patients using cross-validation. The mean follow-up time was 37.8 +/- 13.8 months. A total of 944 drusen were identified at baseline, out of which 249 (26%) regressed during follow-up. The prediction performance was evaluated as area under the curve (AUC) for different time periods. Prediction within the first 2 years achieved an AUC of 0.75.
   CONCLUSIONS. The predictive model proposed in this study represents a promising step toward image-guided prediction of AMD progression. Machine learning is expected to accelerate and contribute to the development of new therapeutics that delay the progression of AMD.
C1 [Bogunovic, Hrvoje; Montuoro, Alessio; Baratsits, Magdalena; Karantonis, Maria G.; Waldstein, Sebastian M.; Schlanitz, Ferdinand; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Spitalgasse 23, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI Bogunovic, Hrvoje/J-3445-2014
OI Bogunovic, Hrvoje/0000-0002-9168-0894; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
FU Austrian Federal Ministry of Science, Research and Economy; National
   Foundation for Research, Technology and Development
FX Supported in part by the Austrian Federal Ministry of Science, Research
   and Economy and the National Foundation for Research, Technology and
   Development.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Bay H, 2008, COMPUT VIS IMAGE UND, V110, P346, DOI 10.1016/j.cviu.2007.09.014
   Bogunovic H, 2016, MICCAI WORKSH OPHTH, P41
   Bogunovic H., 2014, MICCAI WORKSH OPHTH, P129, DOI DOI 10.17077/OMIA.1018
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Hastie T, 2015, STAT LEARNING SPARSI
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee K, 2010, IEEE T MED IMAGING, V29, P159, DOI 10.1109/TMI.2009.2031324
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Montuoro A, 2015, SPIE MED IMAGING
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Phadikar Prateep, 2017, Int J Retina Vitreous, V3, P1, DOI 10.1186/s40942-016-0054-7
   Qian J, 2013, GLMNET FOR MATLAB
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Szeliski R, 2011, TEXTS COMPUT SCI, P1, DOI 10.1007/978-1-84882-935-0
   Tu ZW, 2010, IEEE T PATTERN ANAL, V32, P1744, DOI 10.1109/TPAMI.2009.186
   van Engelen A, 2014, STROKE, V45, P2695, DOI 10.1161/STROKEAHA.114.005752
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Vermeer KA, 2014, BIOMED OPT EXPRESS, V5, P322, DOI 10.1364/BOE.5.000322
   Vogl Wolf-Dieter, 2015, Inf Process Med Imaging, V24, P152, DOI 10.1007/978-3-319-19992-4_12
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 42
TC 53
Z9 59
U1 1
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2017
VL 58
IS 6
SI SI
BP BIO141
EP BIO150
DI 10.1167/iovs.17-21789
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EZ3EI
UT WOS:000404593000018
PM 28658477
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Nakata, I
   Yamashiro, K
   Nakanishi, H
   Akagi-Kurashige, Y
   Miyake, M
   Tsujikawa, A
   Matsuda, F
   Yoshimura, N
AF Nakata, Isao
   Yamashiro, Kenji
   Nakanishi, Hideo
   Akagi-Kurashige, Yumiko
   Miyake, Masahiro
   Tsujikawa, Akitaka
   Matsuda, Fumihiko
   Yoshimura, Nagahisa
CA Nagahama Cohort Res Grp
TI Prevalence and Characteristics of Age-Related Macular Degeneration in
   the Japanese Population: The Nagahama Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; BEAVER DAM EYE; ANGELES LATINO EYE;
   RISK-FACTORS; CLINICAL CHARACTERISTICS; RETICULAR PSEUDODRUSEN;
   MACULOPATHY; SMOKING; ASSOCIATION; PROGRESSION
AB PURPOSE: To estimate the age- and sex-specific prevalence of early age-related macular degeneration (AMD; drusen and retinal pigment abnormalities) and late AMD (exudative AMD and geographic atrophy) in the Japanese population.
   DESIGN: Community-based, cross-sectional study.
   METHODS: The study was held in Nagahama, Japan, and included 6065 Japanese individuals (aged >= 50 years) recruited in 2008-2010. We graded fundus photographs of both eyes for the AMD phenotype based on drusen size, the presence of retinal pigment abnormalities, and late AMD. The associations between smoking and AMD phenotypes were also evaluated.
   RESULTS: We assessed 5595 subjects (women, 65%) with a gradable macular condition. Early and late AMD prevalence increased from 16.1% and 0.27% at 50-59 years to 31.2% and 0.98%, respectively, at 70-74 years and was predominant in male subjects in each age group. Smoking was associated with both early and late AMD stages and retinal pigment abnormalities (P < .0001), but not with drusen (P = .305). The prevalence of retinal pigment abnormalities was significantly higher in men (P < .0001), which was associated with high rates of cigarette smoking. We found no sex difference for the prevalence of large drusen (P = .264).
   CONCLUSIONS: The prevalence of early AMD among adult Japanese persons was similar to the rates in white populations. The prevalence of late AMD in Japanese people aged <70 years was similar to that observed in white populations, whereas that in Japanese people aged >= 70 years was relatively lower. (C) 2013 by Elsevier Inc. All rights reserved.
C1 [Nakata, Isao; Yamashiro, Kenji; Nakanishi, Hideo; Akagi-Kurashige, Yumiko; Miyake, Masahiro; Tsujikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol, Grad Sch Med, Kyoto 6068507, Japan.
   [Nakata, Isao; Nakanishi, Hideo; Akagi-Kurashige, Yumiko; Miyake, Masahiro; Matsuda, Fumihiko] Kyoto Univ, INSERM, U852, Ctr Genom Med,Grad Sch Med, Kyoto 6068507, Japan.
C3 Kyoto University; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Kyoto University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Miyake, Masahiro/V-1261-2019
OI Miyake, Masahiro/0000-0001-7410-3764; Yamashiro,
   Kenji/0000-0001-9354-8558; Tsujikawa, Akitaka/0000-0003-0779-7799
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Japan Society for the Promotion of Science [19390442, 22791706,
   22791653]; Japanese National Society for the Prevention of Blindness;
   Takeda Science Foundation
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and none were reported. This study
   was partly supported by grants-in-aid from the following organizations:
   the Ministry of Education, Culture, Sports, Science and Technology of
   Japan (2006-2012); the Japan Society for the Promotion of Science (Nos.
   19390442, 22791706, and 22791653); the Japanese National Society for the
   Prevention of Blindness; and the Takeda Science Foundation (2008-2012).
   The funding agency had no role in the design or conduct of the research
   presented in this paper. Contributions of authors: conception and design
   of the study (I.N., K.Y., N.Y.); analysis and interpretation (I.N.,
   K.Y., N.Y.); writing of the article (IN.); critical revision of the
   article (IN., K.Y., AT., F.M., N.Y.); final approval of the article
   (IN., K.Y., H.N., Y.K., M.M., A.T., F.M., N.Y.); and data collection
   (I.N., K.Y., H.N., Y.K., M.M., A.T., N.Y.).
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BRINKMAN GL, 1963, AM REV RESPIR DIS, V87, P684
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Ministry of Health Labour and Welfare of Japan, 2009, DIET REF INT JAP
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 41
TC 47
Z9 48
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2013
VL 156
IS 5
BP 1002
EP 1009
DI 10.1016/j.ajo.2013.06.007
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 250NJ
UT WOS:000326859200020
PM 23938127
DA 2022-11-30
ER

PT J
AU Cho, YE
   Wang, JJ
   Chew, EY
   Ferris, FL
   Mitchell, P
   Chan, CC
   Tuo, JS
AF Cho, Youngeun
   Wang, Jie Jin
   Chew, Emily Y.
   Ferris, Frederick L., III
   Mitchell, Paul
   Chan, Chi-Chao
   Tuo, Jingsheng
TI Toll-like Receptor Polymorphisms and Age-Related Macular Degeneration:
   Replication in Three Case-Control Samples
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID GEOGRAPHIC ATROPHY; VISUAL-LOSS; FACTOR-H; PREVALENCE; AUSTRALIA;
   VARIANT; TLR4
AB PURPOSE. Innate immunity appears to play a key role in age-related macular degeneration (AMD). Although two previous studies reported that gene variations in Toll-like receptor (TLR)-3 and -4 are associated with AMD, other studies have not confirmed these associations. In this study, three independent samples (two U. S. clinic-based case-control study samples and one Australian population-based study sample) were used to further assess the association of the polymorphisms rs3775291 in TLR3 and rs4986790 in TLR4 with AMD.
   METHODS. AMD cases and unrelated controls were collected from the National Eye Institute Clinical Center (NEI, n = 320), the Age-Related Eye Disease Study (AREDS, n = 483), and the Blue Mountains Eye Study (BMES, n = 852). DNA extracted from subjects was genotyped for rs3775291 and rs4986790, and the associations with AMD were investigated.
   RESULTS. Neither of the two polymorphisms rs3775291 and rs4986790 had a statistically significant association with AMD in any of the three sample sets or in combinations of the sets. Analysis of the combined geographic atrophy or neovascular AMD cases in the NEI, AREDS, and BMES sample sets also failed to demonstrate statistically significant associations of those two single nucleotide polymorphisms with advanced AMD.
   CONCLUSIONS. Even with previously verified samples sets and adequate study powers, the results did not confirm the reported associations of TLR3 rs3775291 and TLR4 rs4986790 with AMD in the three independent samples, individually or combined. (Invest Ophthalmol Vis Sci. 2009; 50: 5614-5618) DOI: 10.1167/iovs.09-3688
C1 [Cho, Youngeun; Chan, Chi-Chao; Tuo, Jingsheng] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Chew, Emily Y.; Ferris, Frederick L., III] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); University of Sydney; University of Sydney; Westmead
   Institute for Medical Research
RP Tuo, JS (通讯作者)，NEI, Immunol Lab, NIH, 10-10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM tuoj@nei.nih.gov
RI Mitchell, Paul/P-1498-2014; wang, jie/GRS-0942-2022; Wang, Jie
   Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898; Tuo, Jingsheng/0000-0002-1372-7810;
   Ferris, Frederick/0000-0002-4933-0639
FU Intramural Research Program of National Eye Institute, National
   Institutes of Health (NIH); Australian National Health and Medical
   Research Council; NATIONAL EYE INSTITUTE [ZIAEY000222, ZIEEY000487,
   ZICEY000461, ZIAEY000418] Funding Source: NIH RePORTER
FX Supported by the Intramural Research Program of National Eye Institute,
   National Institutes of Health (NIH), the Contracts from NIH for AREDS,
   and the Australian National Health and Medical Research Council.
CR Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arancibia SA, 2007, BIOL RES, V40, P97, DOI 10.4067/S0716-97602007000200001
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2009, NEW ENGL J MED, V360, P2254
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Liu L, 2008, SCIENCE, V320, P379, DOI 10.1126/science.1155406
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Park DW, 2007, BIOCHEM BIOPH RES CO, V362, P1090, DOI 10.1016/j.bbrc.2007.08.119
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 28
TC 45
Z9 48
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2009
VL 50
IS 12
BP 5614
EP 5618
DI 10.1167/iovs.09-3688
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 527GS
UT WOS:000272355900015
PM 19628747
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Dubuc, S
   Wittich, W
   Gomolin, JE
   Kapusta, M
   Overbury, O
AF Dubuc, Sara
   Wittich, Walter
   Gomolin, Julius E.
   Kapusta, Michael
   Overbury, Olga
TI Beyond visual acuity: functional outcome and patient satisfaction
   following treatment for age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE macular degeneration; patient satisfaction; photodynamic therapy
ID QUALITY-OF-LIFE; OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; CONTRAST SENSITIVITY;
   VERTEPORFIN THERAPY; LOW-VISION; IMPAIRMENT; LESIONS; IMPACT
AB Objective: The success of current medical treatments for choroidal neovascular membranes secondary to age-related macular degeneration (AMD) has often been determined anatomically by change in lesion size and cessation of leakage. Measuring the functional success of treatments has most often revolved around visual acuity and has seldom encompassed patients' satisfaction with treatment. Using additional objective and subjective measures to assess the outcome of treatments may provide greater insight into the visual functions that are lost, maintained, or improved during the course of treatment.
   Study Design: Cross-sectional study.
   Participants: Forty-six patients diagnosed with exudative AMD. Participants had received at least 1 photodynamic therapy (PDT) treatment at the time of testing (mean 3.0, SD 1.9)
   Methods: Objective tests of visual function (Snellen, Early Treatment Diabetic Retinopathy Study, Minnesota Low-Vision Reading Test, Contrast Sensitivity, Face Acuity) and a subjective questionnaire, the Visual Function-14 (VF-14) were administered to all patients. Treating ophthalmologists completed a 3-item questionnaire.
   Results: No objective measures of visual function correlated with patient satisfaction or with the ophthalmologists' evaluation of treatment success. The VF-14 was not related to the ophthalmologists' evaluation of treatment outcome. Similarly, patient satisfaction was unrelated to the ophthalmologists' assessment of treatment success. A correlation was found between the VF-14 and patient satisfaction, r = 0.50, p < 0.05.
   Conclusions: Objective measures of visual function do not necessarily reflect the viewpoint of patients regarding PDT treatment outcome. Patients and doctors differ in their interpretation of treatment success and patients' overall satisfaction might best be reflected through a visual function questionnaire.
C1 [Dubuc, Sara; Gomolin, Julius E.; Kapusta, Michael; Overbury, Olga] Sir Mortimer B Davis Jewish Hosp, Dept Ophthalmol, Montreal, PQ H3T 1E2, Canada.
   [Dubuc, Sara; Overbury, Olga] Univ Montreal, Sch Optometry, Montreal, PQ, Canada.
   [Dubuc, Sara; Wittich, Walter] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
   [Wittich, Walter] McGill Univ, Dept Neurol & Neurosurg Neurosci, Montreal, PQ, Canada.
C3 McGill University; Universite de Montreal; Lady Davis Institute; McGill
   University; McGill University
RP Dubuc, S (通讯作者)，Sir Mortimer B Davis Jewish Hosp, Dept Ophthalmol, Pavil E-008,3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.
EM sara.dubuc@sympatico.ca
RI Wittich, Walter/AAH-2145-2020
OI Wittich, Walter/0000-0003-2184-6139
FU Reseau de recherche en sante de la vision
FX This study was supported in part by a grant from the Reseau de recherche
   en sante de la vision.
CR Arditi A, 2005, INVEST OPHTH VIS SCI, V46, P2225, DOI 10.1167/iovs.04-1198
   Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   Broman AT, 2002, INVEST OPHTH VIS SCI, V43, P3393
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Foran S, 2000, CLIN EXP OPHTHALMOL, V28, P143, DOI 10.1046/j.1442-9071.2000.00292.x
   FOSSE P, 2004, J VISUAL IMPAIR BLIN, V98, P398
   Ghanchi FD, 2008, EYE, V22, P671, DOI 10.1038/sj.eye.6702713
   Hewitt AW, 2006, GRAEF ARCH CLIN EXP, V244, P972, DOI 10.1007/s00417-005-0218-x
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kumar Atul, 2007, Indian Journal of Ophthalmology, V55, P207
   Laouar K, 2007, J FR OPHTALMOL, V30, P233, DOI 10.1016/S0181-5512(07)89583-0
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mansfield JS, 1996, INVEST OPHTH VIS SCI, V37, P1492
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Potter MJ, 2008, EYE, V22, P194, DOI 10.1038/sj.eye.6702547
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Sharp DM, 2007, CLIN EXP OPHTHALMOL, V35, P24, DOI 10.1111/j.1442-9071.2007.01394.x
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
NR 27
TC 4
Z9 5
U1 0
U2 6
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD DEC
PY 2009
VL 44
IS 6
BP 680
EP 685
DI 10.3129/i09-163
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 534TW
UT WOS:000272921200010
PM 20029487
DA 2022-11-30
ER

PT J
AU Francis, PJ
   George, S
   Schultz, DW
   Rosner, B
   Hamon, S
   Ott, J
   Weleber, RG
   Klein, ML
   Seddon, JM
AF Francis, Peter J.
   George, Sarah
   Schultz, Dennis W.
   Rosner, Bernard
   Hamon, Sara
   Ott, Jurg
   Weleber, Richard G.
   Klein, Michael L.
   Seddon, Johanna M.
TI The LOC387715 gene, smoking, body mass index, environmental associations
   with advanced age-related macular degeneration
SO HUMAN HEREDITY
LA English
DT Article
DE AMD; environmental risk factor; epidemiologic approaches; gene
   environment interaction; genotype; macular degeneration
ID COMPLEMENT FACTOR-H; SUSCEPTIBILITY LOCI; CIGARETTE-SMOKING; GENOMEWIDE
   SCAN; RISK-FACTORS; VITAMIN-C; MACULOPATHY; VARIANT; POLYMORPHISM;
   CAROTENOIDS
AB Background and Aims: Age-related macular degeneration (AMD) is the leading cause of blindness in the Western World. It is now evident that both genetic and environmental factors contribute to disease susceptibility. We tested the hypotheses that (a) a common coding SNP in the LOC387715 gene is associated with advanced AMD (geographic atrophy or choroidal neovascularization), and (b) that modifiable environmental exposures alter AMD susceptibility associated with this SNP. Methods: A case-control association analysis was performed on participants (530 advanced AMD cases and 280 controls) ascertained as part of the multi-center Age-Related Eye Disease Study. AMD status was determined by the reading center from fundus photographs using the AREDS AMD grading categorization. Environmental risk factor exposure data was collected from participants whose DNA was also genotyped for the LOC387715 gene SNP rs10490924. Multivariate logistic regression analyses were performed. Results and Conclusions: The number of risk alleles at the LOC387715 SNP was associated with advanced AMD, with odds ratios (OR) = 3.0 (95% confidence interval (CI) 2.1-4.3) for the GT heterozygous genotype and OR = 12.1 (5.6-26.5) for the homozygous TT risk genotype, after controlling for demographic and behavioral risk factors. The LOC387715 SNP was associated with both forms of advanced AMD. Current cigarette smoking and body mass index were independently related to AMD, controlling for genotype. However, there was no statistical interaction between LOC387715 genotype and smoking with regard to advanced AMD development. Copyright (c) 2007 S. Karger AG, Basel.
C1 Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97239 USA.
   Harvard Grad Sch Educ, Boston, MA USA.
   Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   Tufts Univ New England Med Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
C3 Oregon Health & Science University; Harvard University; Harvard
   University; Harvard T.H. Chan School of Public Health; Rockefeller
   University; Tufts Medical Center
RP Klein, ML (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM kleinm@ohsu.edu
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein Michael L, 2003, Ophthalmol Clin North Am, V16, P567, DOI 10.1016/S0896-1549(03)00063-4
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEDDON JM, 2005, RETINA, V2
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 29
TC 68
Z9 70
U1 1
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5652
J9 HUM HERED
JI Hum. Hered.
PY 2007
VL 63
IS 3-4
BP 212
EP 218
DI 10.1159/000100046
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 146RP
UT WOS:000244952500008
PM 17347568
DA 2022-11-30
ER

PT J
AU Yan, X
   Kang, ZF
   Li, L
   Guan, RJ
AF Yan Xin
   Kang Zefeng
   Li Ling
   Guan Ruijuan
TI Association between NF-kB polymorphism and age-related macular
   degeneration in a high-altitude population
SO PLOS ONE
LA English
DT Article
ID KAPPA-B; INFLAMMATION; THERAPY; PATHWAY; IMPACT
AB Objective To investigate the association between the nuclear factor kappa B (NF-kB) gene polymorphism and age-related macular degeneration (AMD) in a high-altitude population.
   Methods Fifty-five patients with AMD and 57 control subjects were recruited from the Qinghai Provincial People's Hospital, China. Genomic DNA was extracted from the blood sample of each participant. Four NF-kB polymorphisms (rs3774959, rs3774932, rs3774937, and rs230526) were genotyped using a MassARRAY system. The genotype and allele frequencies were compared between the case and control groups using the chi-squared test or Fisher's exact test.
   Results There was no significant difference in sex, age, hypertension, diabetes, blood lipid level or smoking and drinking status between the AMD and control groups (P > 0.05). The genotype distributions of four NF-kB polymorphisms were in accordance with Hardy-Weinberg equilibrium in the control group (P > 0.05). The frequencies of genotype AA of rs3774932 and genotype CC of rs3774937 were nominally significantly higher in the AMD group than in the control group (P = 0.046 and 0.023, respectively), although these associations did not survive the Bonferroni correction (corrected P > 0.05). Genotype distributions of rs3774959 and rs230526 were not significantly different between the two groups (P = 0.08 and 0.16, respectively). No significant difference in the allele frequencies of the four polymorphisms was found between the AMD and control groups (P > 0.05).
   Conclusions Genotype AA of rs3774932 and genotype CC of rs3774937 in NF-kB might be risk factors for AMD.
C1 [Yan Xin] Qinghai Univ, Coll Med, Xining, Qinghai, Peoples R China.
   [Kang Zefeng] Chinese Acad Tradit Chinese Med, Ophthalm Hosp, Beijing, Peoples R China.
   [Li Ling; Guan Ruijuan] Qinghai Prov Peoples Hosp, Dept Ophthalmol, Xining, Qinghai, Peoples R China.
C3 Qinghai University; China Academy of Chinese Medical Sciences
RP Kang, ZF (通讯作者)，Chinese Acad Tradit Chinese Med, Ophthalm Hosp, Beijing, Peoples R China.; Guan, RJ (通讯作者)，Qinghai Prov Peoples Hosp, Dept Ophthalmol, Xining, Qinghai, Peoples R China.
EM zefeng2531@163.com; grjchuer@163.com
FU Department of Science and Technology of Qinghai Province; 
   [13279497309];  [13552597717];  [13309712948];  [18997150572]
FX Ruijuan Guan; Xin Yan:13279497309 Zefeng Kang: 13552597717; Ling Li:
   13309712948, Ruijuan Guan: 18997150572; Department of Science and
   Technology of Qinghai Province.
CR AAO, 2021, AM ACAD OPHTHALMOL
   Chang CC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9015765
   Chen C, 2017, CANCER LETT, V388, P21, DOI 10.1016/j.canlet.2016.11.027
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   De Simone V, 2015, ONCOGENE, V34, P3493, DOI 10.1038/onc.2014.286
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grussel T, 1997, TIERAERZTL PRAX, V25, P28
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111
   Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7
   Khongthong P, 2019, ENDOCR-RELAT CANCER, V26, pR369, DOI 10.1530/ERC-19-0087
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Mitchell JP, 2018, INT REV CEL MOL BIO, V335, P41, DOI 10.1016/bs.ircmb.2017.07.007
   Nashine S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051102
   Peng X, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1483-7
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Roubeix C, 2020, M S-MED SCI, V36, P886, DOI 10.1051/medsci/2020159
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Tang XJ, 2018, CURR PROTEIN PEPT SC, V19, P172, DOI 10.2174/1389203718666171009111835
   Vequaud E, 2015, ONCOTARGET, V6, P13476, DOI 10.18632/oncotarget.3638
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Wei Q, 2020, LIFE SCI, V241, DOI 10.1016/j.lfs.2019.117142
   Yi WW, 2019, AGING-US, V11, P7294, DOI 10.18632/aging.102266
NR 30
TC 1
Z9 1
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 8
PY 2021
VL 16
IS 6
AR e0251931
DI 10.1371/journal.pone.0251931
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SW6RP
UT WOS:000664641500006
PM 34101738
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bak, M
   Sorensen, TL
   Flachs, EM
   Zwisler, AD
   Juel, K
   Frederiksen, H
   Hasselbalch, HC
AF Bak, Marie
   Sorensen, Torben Lykke
   Flachs, Esben Meulengracht
   Zwisler, Ann-Dorthe
   Juel, Knud
   Frederiksen, Henrik
   Hasselbalch, Hans Carl
TI Age-Related Macular Degeneration in Patients With Chronic
   Myeloproliferative Neoplasms
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID LONG-TERM INCIDENCE; C-REACTIVE PROTEIN; ESSENTIAL THROMBOCYTHEMIA;
   OXIDATIVE STRESS; POLYCYTHEMIA-VERA; RISK-FACTORS; DATA QUALITY;
   INFLAMMATION; CLASSIFICATION; ASSOCIATION
AB IMPORTANCE It has been suggested that systemic inflammation increases the risk of age-related macular degeneration (AMD). Given that chronic immune modulation is present in patients with myeloproliferative neoplasms (MPNs), the risk of AMD in these patients may be increased.
   OBJECTIVE To compare the risk of AMD in patients with MPNs with the risk of AMD in matched controls from the general population.
   DESIGN, SETTING, AND PARTICIPANTS A nationwide population-based cohort study using Danish registers was conducted of all patients in Denmark who received a diagnosis between January 1, 1994, and December 31, 2013, of essential thrombocythemia, polycythemia vera, myelofibrosis, or unclassifiable MPNs. For each patient, 10 age-and sex-matched controls were included. All patients without prior AMD were followed up from the date of diagnosis (or corresponding entry date for the controls) until the first AMD diagnosis, death or emigration, or December 31, 2013, whichever occurred first. Data analysis was performed from April 1, 2015, to October 31, 2016.
   MAIN OUTCOMES AND MEASURES Incidence of AMD recorded in specialized hospital-based care. The rates and absolute risk of AMD were calculated. Using Cox proportional hazards regression models, smoking and risk-time adjusted hazard ratios (HRs) between patients and controls were calculated. In addition, HRs of neovascular AMD after 2006 were calculated since antivascular endothelial growth factor treatment was introduced nationwide at hospitals thereafter.
   RESULTS A total of 7958 patients with MPNs (4279 women [53.8%] and 3679men [46.2%]; mean [SD] age at diagnosis, 66.4 [14.3] years) were included in the study. The rate of AMD per 1000 person-years at risk was 5.2 (95% CI, 4.6-5.9) for patients with MPNs (2628 with essential thrombocythemia, 3063 with polycythemia vera, 547 withmyelofibrosis, and 1720 with unclassifiable MPNs) and 4.3 (95% CI, 4.1-4.4) for the 77 445 controls, while the 10-year risk of AMD was 2.4%(95% CI, 2.1%-2.8%) for patients with MPNs and 2.3%(95% CI, 2.2%-2.4%) for the controls. The risk of AMD was increased overall for patients with MPNs (adjusted HR, 1.3; 95% CI, 1.1-1.5), with adjusted HRs for the subtypes of 1.2 (95% CI, 1.0-1.6) for essential thrombocythemia, 1.4 (95% CI, 1.2-1.7) for polycythemia vera, 1.7 (95% CI, 0.8-4.0) formyelofibrosis, and 1.5 (95% CI, 1.1-2.1) for unclassifiable MPNs. In addition, patients with MPNs had a higher risk of neovascular AMD (adjusted HR, 1.4; 95% CI, 1.2-1.6).
   CONCLUSIONS AND RELEVANCE Our results suggest that patients with MPNs are at increased risk of AMD, supporting the possibility that systemic inflammation is involved in the pathogenesis of AMD.
C1 [Bak, Marie; Hasselbalch, Hans Carl] Univ Copenhagen, Zealand Univ Hosp, Dept Haematol, Sygehusvej 10, DK-4000 Roskilde, Denmark.
   [Sorensen, Torben Lykke] Univ Copenhagen, Zealand Univ Hosp, Dept Ophthalmol, Roskilde, Denmark.
   [Flachs, Esben Meulengracht] Univ Copenhagen, Bispebjerg Hosp, Dept Occupat & Environm Med, Copenhagen, Denmark.
   [Zwisler, Ann-Dorthe] Univ Southern Denmark, Danish Knowledge Ctr Rehabil & Palliat Care, Odense, Denmark.
   [Zwisler, Ann-Dorthe] Odense Univ Hosp, Odense, Denmark.
   [Juel, Knud] Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen, Denmark.
   [Frederiksen, Henrik] Odense Univ Hosp, Dept Haematol, Odense, Denmark.
   [Frederiksen, Henrik] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark.
C3 University of Copenhagen; University of Copenhagen; Aarhus University;
   University of Copenhagen; Bispebjerg Hospital; University of Southern
   Denmark; University of Southern Denmark; Odense University Hospital;
   University of Southern Denmark; University of Southern Denmark; Odense
   University Hospital; Aarhus University
RP Bak, M (通讯作者)，Univ Copenhagen, Zealand Univ Hosp, Dept Haematol, Sygehusvej 10, DK-4000 Roskilde, Denmark.
EM doctormariebak@gmail.com
RI Juel, Knud/C-8916-2013; Frederiksen, Henrik/AAN-5450-2021
OI Frederiksen, Henrik/0000-0001-8905-0220; Bak, Marie/0000-0002-1511-6749;
   Hasselbalch, Hans/0000-0003-3936-8032; Juel, Knud/0000-0002-4134-1173
FU Faculty of Health and Medical Sciences, University of Copenhagen,
   Copenhagen, Denmark; Region Zealand Health Scientific Research
   Foundation; Anders Hasselbalch Anti-Leukemia Foundation; A. P. Moller
   Foundation
FX This study was supported by grants from the Faculty of Health and
   Medical Sciences, University of Copenhagen, Copenhagen, Denmark; the
   Region Zealand Health Scientific Research Foundation; the Anders
   Hasselbalch Anti-Leukemia Foundation; and the A. P. Moller Foundation
   for the Advancement of Medical Science.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544
   Aroldi A, 2016, EUR J HAEMATOL, V96, P593, DOI 10.1111/ejh.12638
   Bak M, 2015, 20 C EUR HEM ASS JUN
   Barbui T, 2013, BLOOD, V122, P2176, DOI 10.1182/blood-2013-03-460154
   Barbui T, 2011, HAEMATOL-HEMATOL J, V96, P315, DOI 10.3324/haematol.2010.031070
   Barcellini W, 2013, LEUKEMIA RES, V37, P1509, DOI 10.1016/j.leukres.2013.09.001
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cella G, 2010, THROMB HAEMOSTASIS, V104, P151, DOI 10.1160/TH09-09-0663
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen XX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085716, 10.1371/journal.pone.0091809, 10.1371/journal.pone.0103330, 10.1371/journal.pone.0115462, 10.1371/journal.pone.0087752, 10.1371/journal.pone.0091830]
   Christen W. G., 2013, US OPHTHALMIC REV, V6, P144
   Christensen AS, 2014, LEUKEMIA RES, V38, P490, DOI 10.1016/j.leukres.2014.01.014
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Farmer S, 2013, BRIT J HAEMATOL, V163, P603, DOI 10.1111/bjh.12581
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frederiksen H, 2011, BLOOD, V118, P6515, DOI 10.1182/blood-2011-04-348755
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geyer HL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/284706
   Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001
   Hasselbalch HC, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/102476
   Hasselbalch HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112786
   Hultcrantz M, 2012, J CLIN ONCOL, V30, P2995, DOI 10.1200/JCO.2012.42.1925
   Jabs DA, 2015, AM J OPHTHALMOL, V159, P1115, DOI 10.1016/j.ajo.2015.01.037
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kao LT, 2015, J AM ACAD DERMATOL, V72, P1090, DOI 10.1016/j.jaad.2015.03.002
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Koudstaal PJ, 1997, SEMIN THROMB HEMOST, V23, P365, DOI 10.1055/s-2007-996110
   Kristinsson SY, 2010, HAEMATOL-HEMATOL J, V95, P1216, DOI 10.3324/haematol.2009.020412
   Landolfi R, 2008, LEUKEMIA, V22, P2020, DOI 10.1038/leu.2008.253
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Madelung AB, 2013, AM J HEMATOL, V88, P1012, DOI 10.1002/ajh.23554
   Michiels JJ, 2015, ACTA HAEMATOL-BASEL, V133, P56, DOI 10.1159/000360388
   MICHIELS JJ, 1993, NEUROLOGY, V43, P1107, DOI 10.1212/WNL.43.6.1107
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Norgaard M, 2005, EUR J CANCER PREV, V14, P201, DOI 10.1097/00008469-200506000-00002
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Paulsrud C, 2016, J BLOOD RES HEMATOL, V1, DOI [10.4172/jbrhd.1000102, DOI 10.4172/JBRHD.1000102]
   Rampal R, 2014, BLOOD, V123, pE123, DOI 10.1182/blood-2014-02-554634
   Reikvam H, 2012, LEUKEMIA, V26, P563, DOI 10.1038/leu.2011.314
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125
   Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Sorensen AL, 2016, EUR J HAEMATOL, V97, P63, DOI 10.1111/ejh.12684
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tefferi A, 2014, BLOOD, V124, P2507, DOI 10.1182/blood-2014-05-579136
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tsai JJ, 2013, NAT CELL BIOL, V15, P309, DOI 10.1038/ncb2699
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Wu Yan, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P59
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 58
TC 21
Z9 21
U1 1
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2017
VL 135
IS 8
BP 835
EP 843
DI 10.1001/jamaophthalmol.2017.2011
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FD3MS
UT WOS:000407437700006
PM 28655032
OA Green Published
DA 2022-11-30
ER

PT J
AU Lee, H
   Kang, KE
   Chung, H
   Kim, HC
AF Lee, Hyungwoo
   Kang, Kyung Eun
   Chung, Hyewon
   Kim, Hyung Chan
TI Automated Segmentation of Lesions Including Subretinal Hyperreflective
   Material in Neovascular Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EPITHELIUM DETACHMENT SEGMENTATION; VISUAL-ACUITY; FLUID; FRAMEWORK;
   IMAGES
AB PURPOSE: To evaluate an automated segmentation algorithm with a convolutional neural network (CNN) to quantify and detect intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), and subretinal hyperreflective material (SHRM) through analyses of spectral-domain optical coherence tomography (SD-OCT) images from patients with neovascular age-related macular degeneration (nAMD).
   DESIGN: Reliability and validity analysis of a diagnostic tool.
   METHODS: We constructed a dataset including 930 B-scans from 93 eyes of 93 patients with nAMD. A CNN-based deep neural network was trained using 11 550 augmented images derived from 550 B-scans. The performance of the trained network was evaluated using a validation set including 140 B-scans and a test set of 240 B-scans. The Dice coefficient, positive predictive value (PPV), sensitivity, relative area difference (RAD), and intraclass correlation coefficient (ICC) were used to evaluate segmentation and detection performance.
   RESULTS: Good agreement was observed for both segmentation and detection of lesions between the trained network and clinicians. The Dice coefficients for segmentation of IRF, SRF, SHRM, and PED were 0.78, 0.82, 0.75, and 0.80, respectively; the PPVs were 0.79, 0.80, 0.75, and 0.80, respectively; and the sensitivities were 0.77, 0.84, 0.73, and 0.81, respectively. The RADs were -4.32%, -10.29%, 4.13%, and 0.34%, respectively, and the ICCs were 0.98, 0.98, 0.97, and 0.98, respectively. All lesions were detected with high PPVs (range 0.94-0.99) and sensitivities (range 0.97-0.99).
   CONCLUSIONS: A CNN-based network provides clinicians with quantitative data regarding nAMD through automatic segmentation and detection of pathologic lesions, including IRF, SRF, PED, and SHRM. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Lee, Hyungwoo; Kang, Kyung Eun; Chung, Hyewon; Kim, Hyung Chan] Konkuk Univ, Med Ctr, Sch Med, Dept Ophthalmol, 120-1 Neungdong Ro, Seoul 05030, South Korea.
C3 Konkuk University; Konkuk University Medical Center
RP Kim, HC (通讯作者)，Konkuk Univ, Med Ctr, Sch Med, Dept Ophthalmol, 120-1 Neungdong Ro, Seoul 05030, South Korea.
EM eyekim@kuh.ac.kr
CR Abadi M., ARXIV160304467
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Ciresan DC, 2012, ADV NEURAL INFORM PR
   DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kayaiibay B, 2017, ARXIV170103056
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lee H, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20637
   Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965
   Pereira S, 2016, IEEE T MED IMAGING, V35, P1240, DOI 10.1109/TMI.2016.2538465
   Pilch M, 2013, INVEST OPHTH VIS SCI, V54, P4385, DOI 10.1167/iovs.12-11396
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sun ZL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21739
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Xu YP, 2017, BIOMED OPT EXPRESS, V8, P4061, DOI 10.1364/BOE.8.004061
   Zheng YL, 2013, AM J OPHTHALMOL, V155, P277, DOI 10.1016/j.ajo.2012.07.030
   ZIJDENBOS AP, 1994, IEEE T MED IMAGING, V13, P716, DOI 10.1109/42.363096
NR 27
TC 26
Z9 26
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2018
VL 191
BP 64
EP 75
DI 10.1016/j.ajo.2018.04.007
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GL7MX
UT WOS:000437387100014
PM 29655643
DA 2022-11-30
ER

PT J
AU Canan, H
   Sizmaz, S
   Altan-Yaycioglu, R
   Sariturk, C
   Yilmaz, G
AF Canan, Handan
   Sizmaz, Selcuk
   Altan-Yaycioglu, Rana
   Sariturk, Cagla
   Yilmaz, Gursel
TI Visual outcome of intravitreal ranibizumab for exudative age-related
   macular degeneration: timing and prognosis
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE age-related macular degeneration (AMD); optical coherence tomography
   (OCT); ranibizumab; visual acuity
ID DELAY
AB Purpose: To describe 1-year clinical results of intravitreal ranibizumab treatment in patients with choroidal neovascularization secondary to exudative age-related macular degeneration (AMD) and to evaluate whether early treatment is a predictive value for prognosis of the disease.
   Materials and methods: Clinical records were retrospectively reviewed of 104 eyes that underwent intravitreal ranibizumab therapy for exudative AMD. Patients were divided into two groups according to their symptom duration: group 1,,1 month; and group 2, 1-3 months. After three monthly injections, patients were examined monthly, and subsequent injections were performed as needed.
   Results: There were 43 female (48.9%) and 45 males (51.1%). The follow-up time was 13.7 +/- 1.9 (12-19) months. The mean logarithm of minimum angle of resolution best-corrected visual acuity (BCVA) improved significantly, from 0.45 +/- 0.639 at baseline to 0.08 +/- 0.267 at 12 months in group 1, and from 1.06 +/- 0.687 at baseline to 0.75 +/- 0.563 at 12 months in group 2. The increase in BCVA was statistically significant in group 1 (P=0.009). The mean central retinal thickness (CRT) decreased significantly, from 355.13 +/- 119.93 mu m at baseline to 250.85 +/- 45.48 mu m at 12 months in group 1, and from 371.88 +/- 91.047 mu m at baseline to 268.61 +/- 53.51 mu m at 12 months in group 2. The decrease in CRT was statistically significant in group 1 (P=0.001).
   Conclusion: Intravitreal ranibizumab therapy was effective in significantly increasing mean BVCA and reducing CRT. Shorter duration of AMD, as measured by the subjective duration of visual symptoms, is associated with better visual outcome after treatment.
C1 [Canan, Handan; Altan-Yaycioglu, Rana] Baskent Univ, Sch Med, Adana Teaching & Med Res Ctr, Dept Ophthalmol, TR-01250 Ankara, Turkey.
   [Sizmaz, Selcuk] Cukurova Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
   [Sariturk, Cagla] Baskent Univ, Sch Med, Adana Teaching & Med Res Ctr, Dept Biostat, TR-06490 Ankara, Turkey.
   [Yilmaz, Gursel] Baskent Univ, Sch Med, Dept Ophthalmol, TR-06490 Ankara, Turkey.
C3 Adana Numune Training & Research Hospital; Baskent University; Cukurova
   University; Adana Numune Training & Research Hospital; Baskent
   University; Baskent University
RP Canan, H (通讯作者)，Baskent Univ, Sch Med, Adana Teaching & Med Res Ctr, Dept Ophthalmol, Dadaloglu Mah,Serinevler 2591 Sok, TR-01250 Adana, Turkey.
EM handanakkaya@yahoo.com
RI Altan-Yaycioglu, Rana/AAL-4440-2020; sarıtürk, çağla/AAS-7129-2021;
   Canan, Handan/AAB-6394-2021; Yılmaz, Gürsel/AAK-6987-2021;
   Altan-Yaycioglu, Rana/AAG-3306-2019
OI Canan, Handan/0000-0002-5877-6536; Yılmaz, Gürsel/0000-0002-2589-7294;
   Altan-Yaycioglu, Rana/0000-0002-9139-8848
CR Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fong AHC, 2013, CLIN INTERV AGING, V8, P467, DOI 10.2147/CIA.S36811
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
NR 19
TC 13
Z9 13
U1 0
U2 5
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2014
VL 9
BP 141
EP 145
DI 10.2147/CIA.S56863
PG 5
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 286UZ
UT WOS:000329495600001
PM 24453484
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Yoshimine, S
   Ogawa, S
   Horiguchi, H
   Terao, M
   Miyazaki, A
   Matsumoto, K
   Tsuneoka, H
   Nakano, T
   Masuda, Y
   Pestilli, F
AF Yoshimine, Shoyo
   Ogawa, Shumpei
   Horiguchi, Hiroshi
   Terao, Masahiko
   Miyazaki, Atsushi
   Matsumoto, Kenji
   Tsuneoka, Hiroshi
   Nakano, Tadashi
   Masuda, Yoichiro
   Pestilli, Franco
TI Age-related macular degeneration affects the optic radiation white
   matter projecting to locations of retinal damage
SO BRAIN STRUCTURE & FUNCTION
LA English
DT Article
DE White matter; Diffusion; MRI; Age-related macular degeneration;
   Tractography
ID DIFFUSION-TENSOR MRI; OPEN-ANGLE GLAUCOMA; VISUAL PATHWAYS; IN-VIVO;
   CORTEX; TRACTS; ABNORMALITIES; ORGANIZATION; AMBLYOPIA; CONNECTIVITY
AB We investigated the impact of age-related macular degeneration (AMD) on visual acuity and the visual white matter. We combined an adaptive cortical atlas and diffusion-weighted magnetic resonance imaging (dMRI) and tractography to separate optic radiation (OR) projections to different retinal eccentricities in human primary visual cortex. We exploited the known anatomical organization of the OR and clinically relevant data to segment the OR into three primary components projecting to fovea, mid- and far-periphery. We measured white matter tissue propertiesfractional anisotropy, linearity, planarity, sphericityalong the aforementioned three components of the optic radiation to compare AMD patients and controls. We found differences in white matter properties specific to OR white matter fascicles projecting to primary visual cortex locations corresponding to the location of retinal damage (fovea). Additionally, we show that the magnitude of white matter properties in AMD patients' correlates with visual acuity. In sum, we demonstrate a specific relation between visual loss, anatomical location of retinal damage and white matter damage in AMD patients. Importantly, we demonstrate that these changes are so profound that can be detected using magnetic resonance imaging data with clinical resolution. The conserved mapping between retinal and white matter damage suggests that retinal neurodegeneration might be a primary cause of white matter degeneration in AMD patients. The results highlight the impact of eye disease on brain tissue, a process that may become an important target to monitor during the course of treatment.
C1 [Yoshimine, Shoyo; Ogawa, Shumpei; Horiguchi, Hiroshi; Tsuneoka, Hiroshi; Nakano, Tadashi; Masuda, Yoichiro] Jikei Univ, Sch Med, Dept Ophthalmol, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.
   [Ogawa, Shumpei] Atsugi City Hosp, Dept Ophthalmol, Atsugi, Kanagawa, Japan.
   [Terao, Masahiko] Yamaguchi Univ, Res Inst Time Studies, Yamaguchi, Japan.
   [Miyazaki, Atsushi] Tamagawa Univ, Res Inst, Machida, Tokyo, Japan.
   [Matsumoto, Kenji] Tamagawa Univ, Brain Sci Inst, Machida, Tokyo, Japan.
   [Pestilli, Franco] Indiana Univ, Indiana Network Sci Inst, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA.
   [Pestilli, Franco] Indiana Univ, Dept Comp Sci, Bloomington, IN 47405 USA.
   [Pestilli, Franco] Indiana Univ, Dept Intelligent Syst Engn, Bloomington, IN 47405 USA.
   [Pestilli, Franco] Indiana Univ, Program Neurosci, Bloomington, IN 47405 USA.
   [Pestilli, Franco] Indiana Univ, Program Cognit Sci, Bloomington, IN 47405 USA.
   [Pestilli, Franco] Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
C3 Jikei University; Yamaguchi University; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington; Indiana University System; Indiana University
   Bloomington; Indiana University System; Indiana University Bloomington;
   Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington
RP Yoshimine, S (通讯作者)，Jikei Univ, Sch Med, Dept Ophthalmol, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.; Pestilli, F (通讯作者)，Indiana Univ, Indiana Network Sci Inst, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA.; Pestilli, F (通讯作者)，Indiana Univ, Dept Comp Sci, Bloomington, IN 47405 USA.; Pestilli, F (通讯作者)，Indiana Univ, Dept Intelligent Syst Engn, Bloomington, IN 47405 USA.; Pestilli, F (通讯作者)，Indiana Univ, Program Neurosci, Bloomington, IN 47405 USA.; Pestilli, F (通讯作者)，Indiana Univ, Program Cognit Sci, Bloomington, IN 47405 USA.; Pestilli, F (通讯作者)，Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
EM s.yoshimine@jikei.ac.jp; franpest@indiana.edu
RI Ogawa, Shumpei/G-6963-2019
OI Ogawa, Shumpei/0000-0003-3841-6004; Horiguchi,
   Hiroshi/0000-0002-9536-5875; Matsumoto, Kenji/0000-0003-0883-4280;
   Pestilli, Franco/0000-0002-2469-0494
FU JSPS [18K16939, 17K18131, 80570332]; Charitable Trust Fund for
   Ophthalmic Research in Commemoration of Santen Pharmaceutical's Founder;
   Jikei University Research found; NSF [IIS-1636893, BCS-1734853]; NIH
   NIMH [ULTTR001108]; Microsoft Research Award; Indiana University Areas
   of Emergent Research initiative "Learning: Brains, Machines, Children";
   Pervasive Technology Institute
FX We thank Brian A. Wandell, Sophia Vinci-Booher, Brent McPherson and
   Bradley Caron for comments on an early version of the manuscript.
   Takaaki Hayashi for clinical evaluation of the patients. Ikuya Murakami
   for institutional support. Y.S. is supported by JSPS Grant-in-Aid for
   Young Scientists (B) 80570332. S.O. is supported by JSPS Grant-in-Aid
   for Young Scientists (B) 17K18131. H.H. is supported by JSPS
   Grant-in-Aid for Young Scientists 18K16939 and Charitable Trust Fund for
   Ophthalmic Research in Commemoration of Santen Pharmaceutical's Founder.
   Y.M. is supported by The Jikei University Research found and Charitable
   Trust Fund for Ophthalmic Research in Commemoration of Santen
   Pharmaceutical's Founder. F.P. is supported by NSF IIS-1636893, NSF
   BCS-1734853, NIH NIMH ULTTR001108, a Microsoft Research Award and the
   Indiana University Areas of Emergent Research initiative "Learning:
   Brains, Machines, Children." and Pervasive Technology Institute.
CR Ajina S, 2015, ELIFE, V4, DOI 10.7554/eLife.08935
   Allen B, 2018, INVEST OPHTH VIS SCI, V59, P921, DOI 10.1167/iovs.17-22930
   Allen B, 2015, VISION RES, V114, P48, DOI 10.1016/j.visres.2014.12.021
   Ashburner J, 2012, NEUROIMAGE, V62, P791, DOI 10.1016/j.neuroimage.2011.10.025
   Ashburner J, 2009, MAGN RESON IMAGING, V27, P1163, DOI 10.1016/j.mri.2009.01.006
   Barcella V, 2010, HUM BRAIN MAPP, V31, P1900, DOI 10.1002/hbm.20985
   Baseler H, 2010, J VIS, V9, P733, DOI [10.1167/9.8.733, DOI 10.1167/9.8.733]
   Baseler HA, 2011, NAT NEUROSCI, V14, P649, DOI 10.1038/nn.2793
   Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610
   Basser PJ, 2002, NMR BIOMED, DOI [10. 1002/nbm. 783/full, DOI 10.1002/NBM.783/FULL]
   Benson NC, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003538
   Benson NC, 2012, CURR BIOL, V22, P2081, DOI 10.1016/j.cub.2012.09.014
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown HDH, 2016, OPHTHAL PHYSL OPT, V36, P240, DOI 10.1111/opo.12293
   Caiafa CF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09250-w
   Ciccarelli O, 2005, HUM BRAIN MAPP, V25, P308, DOI 10.1002/hbm.20101
   Dai H, 2013, NEURORADIOLOGY, V55, P233, DOI 10.1007/s00234-012-1122-9
   Devlin JT, 2007, NEUROIMAGE, V37, P1033, DOI 10.1016/j.neuroimage.2006.09.055
   Dougherty RF, 2005, P NATL ACAD SCI USA, V102, P7350, DOI 10.1073/pnas.0500003102
   Dougherty RF, 2007, P NATL ACAD SCI USA, V104, P8556, DOI 10.1073/pnas.0608961104
   Duan YR, 2015, INVEST OPHTH VIS SCI, V56, P5152, DOI 10.1167/iovs.15-17097
   Dubois J, 2016, TRENDS COGN SCI, V20, P425, DOI 10.1016/j.tics.2016.03.014
   Efron B., 1994, INTRO BOOTSTRAP
   Engelhorn T, 2012, ACAD RADIOL, V19, P485, DOI 10.1016/j.acra.2011.12.005
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fischl B, 2008, CEREB CORTEX, V18, P1973, DOI 10.1093/cercor/bhm225
   Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021
   Garaci FG, 2009, RADIOLOGY, V252, P496, DOI 10.1148/radiol.2522081240
   Gomez J, 2015, NEURON, V85, P216, DOI 10.1016/j.neuron.2014.12.027
   Gonzalez C, 2011, ACTA OPHTHALMOL, V89
   Green DM, 1988, SIGNAL DETECTION THE
   Haak KV, 2016, OPHTHAL PHYSL OPT, V36, P335, DOI 10.1111/opo.12279
   Hastie T., 2013, ELEMENTS STAT LEARNI
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hernowo AT, 2014, CORTEX, V56, P99, DOI 10.1016/j.cortex.2013.01.003
   Hernowo AT, 2011, INVEST OPHTH VIS SCI, V52, P2758, DOI 10.1167/iovs.10-5682
   Hinds OP, 2008, NEUROIMAGE, V39, P1585, DOI 10.1016/j.neuroimage.2007.10.033
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jbabdi S, 2015, NAT NEUROSCI, V18, P1546, DOI 10.1038/nn.4134
   Lee JY, 2014, INVEST OPHTH VIS SCI, V55, P3468, DOI 10.1167/iovs.14-13902
   Leong JK, 2016, NEURON, V89, P63, DOI 10.1016/j.neuron.2015.12.015
   Levin N, 2010, NEURON, V65, P21, DOI 10.1016/j.neuron.2009.12.006
   Li M, 2009, NEUROIMAGE, V47, pS127, DOI [10.1016/S1053-8119(09)71226-1, DOI 10.1016/S1053-8119(09)71226-1]
   Libero LE, 2016, BRAIN CONNECT, V6, P691, DOI 10.1089/brain.2016.0442
   Ling S, 2015, BRAIN STRUCT FUNCT, V220, P1237, DOI 10.1007/s00429-014-0818-5
   Malania M, 2017, INVEST OPHTH VIS SCI, V58, P2939, DOI 10.1167/iovs.16-21191
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mayda A, 2010, IMAGING AGING BRAIN
   Milesi J, 2012, J NEUROL, V259, P1801, DOI 10.1007/s00415-011-6406-1
   Millington RS, 2014, CURR OPIN NEUROL, V27, P92, DOI 10.1097/WCO.0000000000000050
   Ogawa S, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14737
   Ohno N, 2015, BRIT J OPHTHALMOL, V99, P1051, DOI 10.1136/bjophthalmol-2014-305809
   Pan WJ, 2007, NEUROIMAGE, V37, P212, DOI 10.1016/j.neuroimage.2007.05.014
   PARRAVANO JG, 1993, J COMPUT ASSIST TOMO, V17, P688, DOI 10.1097/00004728-199309000-00003
   Pestilli F, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005758
   Pestilli F, 2015, SCI DATA, V2, DOI 10.1038/sdata.2014.57
   Pestilli F, 2014, NAT METHODS, V11, P1058, DOI 10.1038/nmeth.3098
   Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765
   Prins D, 2016, ACTA OPHTHALMOL, V94, P113, DOI 10.1111/aos.12825
   Prins D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146684
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rizzo G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050230
   Rokem A, 2017, J VISION, V17, DOI 10.1167/17.2.4
   Rokem A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123272
   Rotshenker S., 2007, ENCY PAIN, P2659
   Rykhlevskaia EI, 2009, NEUROIMAGE, V47, pS128
   Sergott RC, 2011, YB OPHTHALMOL, V2011, P196, DOI [10.1016/j.yoph.2011.06.053, DOI 10.1016/J.YOPH.2011.06.053]
   Shao YB, 2013, EUR J NEUROSCI, V38, P3456, DOI 10.1111/ejn.12349
   Sherbondy AJ, 2008, J VISION, V8, DOI 10.1167/8.9.15
   Thomas C, 2008, J COGNITIVE NEUROSCI, V20, P268, DOI 10.1162/jocn.2008.20025
   Thomas C, 2014, P NATL ACAD SCI USA, V111, P16574, DOI 10.1073/pnas.1405672111
   Thomason ME, 2011, ANNU REV CLIN PSYCHO, V7, P63, DOI 10.1146/annurev-clinpsy-032210-104507
   Wandell BA, 2007, NEURON, V56, P366, DOI 10.1016/j.neuron.2007.10.012
   Wandell BA, 2017, NEURON, V96, P298, DOI 10.1016/j.neuron.2017.08.007
   Wandell BA, 2016, ANNU REV NEUROSCI, V39, P103, DOI 10.1146/annurev-neuro-070815-013815
   Wandell BA, 2011, VISION RES, V51, P718, DOI 10.1016/j.visres.2010.08.004
   Wandell BA, 2009, NAT REV NEUROSCI, V10, P873, DOI 10.1038/nrn2741
   Wang Y, 2010, ALZHEIMERS DEMENT, V6, pS37, DOI [10.1016/j.jalz.2010.05.105, DOI 10.1016/J.JALZ.2010.05.105]
   Wang Y, 2012, BBA-MOL BASIS DIS, V1822, P423, DOI 10.1016/j.bbadis.2011.08.002
   Wendell BA, 2015, TRENDS COGN SCI, V19, P349, DOI 10.1016/j.tics.2015.03.009
   Westin C, 1997, P 5 ANN M ISMRM, P1742
   Westin CF, 2002, MED IMAGE ANAL, V6, P93, DOI 10.1016/S1361-8415(02)00053-1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yeatman JD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5932
   Yeatman JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049790
NR 86
TC 18
Z9 20
U1 0
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2653
EI 1863-2661
J9 BRAIN STRUCT FUNCT
JI Brain Struct. Funct.
PD NOV
PY 2018
VL 223
IS 8
BP 3889
EP 3900
DI 10.1007/s00429-018-1702-5
PG 12
WC Anatomy & Morphology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anatomy & Morphology; Neurosciences & Neurology
GA GX7SU
UT WOS:000447977600024
PM 29951918
OA Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Loprinzi, PD
   Swenor, BK
   Ramulu, PY
AF Loprinzi, Paul D.
   Swenor, Bonnielin K.
   Ramulu, Pradeep Y.
TI Age-Related Macular Degeneration Is Associated with Less Physical
   Activity among US Adults: Cross-Sectional Study
SO PLOS ONE
LA English
DT Article
ID UNCORRECTED REFRACTIVE ERROR; VISUAL IMPAIRMENT; CARDIOVASCULAR-DISEASE;
   SEDENTARY BEHAVIOR; UNITED-STATES; RISK-FACTORS; PREVALENCE; POPULATION;
   VISION; MACULOPATHY
AB Background
   We have a limited understanding of the effects of age-related macular degeneration (AMD) on physical activity (PA), and we have no prevalence estimates of the daily movement patterns among Americans with AMD. Therefore, we examined the association between AMD and PA and provided estimates of the daily movement patterns of Americans with AMD.
   Methods
   Data from the 2005-2006 National Health and Nutrition Examination Survey were used, including 1,656 adults (40-85 yrs). Retinal imaging was performed to classify individuals as no AMD, early AMD, or late AMD. Participants wore an ActiGraph 7164 accelerometer for 7 days to measure PA behavior.
   Results
   93.2% of participants with late AMD were in the least desirable group (not sufficiently active and having a negative light intensity-sedentary behavior balance). After adjustments (including age), participants with late AMD, as compared to those with no AMD, engaged in 50% less moderate-to-vigorous physical activity (MVPA) (RR = 0.50; 95% CI: 0.28-0.90). When visual acuity was entered into the model along with the other covariates, the association between late AMD and MVPA was no longer significant (RR = 0.54; 95% CI: 0.29-1.01), suggesting that visual acuity may partially mediate this relationship.
   Conclusions
   Individuals with late AMD engage in very little moderate-to-vigorous physical activity. Visually acuity, in part, explains the relationship between late AMD and PA.
C1 [Loprinzi, Paul D.] Univ Mississippi, Ctr Hlth Behav Res, Dept Hlth Exercise Sci & Recreat Management, University, MS 38677 USA.
   [Swenor, Bonnielin K.; Ramulu, Pradeep Y.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
C3 University of Mississippi; Johns Hopkins University; Johns Hopkins
   Medicine
RP Loprinzi, PD (通讯作者)，Univ Mississippi, Ctr Hlth Behav Res, Dept Hlth Exercise Sci & Recreat Management, University, MS 38677 USA.
EM pdloprin@olemiss.edu
RI Swenor, Bonnie/ABH-1542-2021
OI Swenor, Bonnie/0000-0002-6044-0951
FU Research to Prevent Blindness; National Institutes of Health [EY015025,
   EY022976]; NATIONAL EYE INSTITUTE [K12EY015025, R01EY022976] Funding
   Source: NIH RePORTER
FX This work was supported by Research to Prevent Blindness
   (http://www.rpbusa.org/rpb/) and National Institutes of Health grants
   EY015025 and EY022976 (PYR; http://www.nih.gov/). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aquilante K, 2001, OPTOMETRY VISION SCI, V78, P290, DOI 10.1097/00006324-200105000-00012
   Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1564, DOI 10.1136/bjo.2008.143875
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chomistek AK, 2013, J AM COLL CARDIOL, V61, P2346, DOI 10.1016/j.jacc.2013.03.031
   Ford ES, 2012, INT J EPIDEMIOL, V41, P1338, DOI 10.1093/ije/dys078
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Healy GN, 2008, DIABETES CARE, V31, P661, DOI 10.2337/dc07-2046
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Ko F, 2012, JAMA-J AM MED ASSOC, V308, P2361, DOI 10.1001/jama.2012.85685
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   Loprinzi PD, 2013, MAYO CLIN PROC, V88, P942, DOI 10.1016/j.mayocp.2013.05.015
   Loprinzi PD, 2013, OBESITY FACTS, V6, P380, DOI 10.1159/000354752
   Loprinzi PD, 2013, J PHYS ACT HEALTH
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Matthews CE, 2008, AM J EPIDEMIOL, V167, P875, DOI 10.1093/aje/kwm390
   MCPHILLIPS JB, 1989, AM J PREV MED, V5, P65, DOI 10.1016/S0749-3797(18)31107-3
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Rani PK, 2012, MIDDLE EAST AFR J OP, V19, P129, DOI 10.4103/0974-9233.92129
   Richman J, 2010, ARCH OPHTHALMOL-CHIC, V128, P1576, DOI 10.1001/archophthalmol.2010.275
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   Rovner BW, 2009, ALZHEIMERS DEMENT, V5, P12, DOI 10.1016/j.jalz.2008.06.001
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Shephard RJ, 2003, BRIT J SPORT MED, V37, P197, DOI 10.1136/bjsm.37.3.197
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3
   van Poppel MNM, 2010, SPORTS MED, V40, P565, DOI 10.2165/11531930-000000000-00000
   Warburton DER, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-39
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   Westerterp KR, 2009, EUR J APPL PHYSIOL, V105, P823, DOI 10.1007/s00421-009-1000-2
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Willis JR, 2013, JAMA OPHTHALMOL, V131, P1049, DOI 10.1001/jamaophthalmol.2013.316
   Willis JR, 2012, ARCH OPHTHALMOL-CHIC, V130, P329, DOI 10.1001/archopthalmol.2011.1773
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 39
TC 24
Z9 24
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2015
VL 10
IS 5
AR e0125394
DI 10.1371/journal.pone.0125394
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CH2XA
UT WOS:000353887100105
PM 25933421
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Gok, M
   Karabas, VL
   Aslan, MS
   Kara, O
   Karaman, S
   Yenihayat, F
AF Gok, Mustafa
   Karabas, V. Levent
   Aslan, Mehmet S.
   Kara, Ozgur
   Karaman, Suleyman
   Yenihayat, Fatih
TI Tissue plasminogen activator-assisted vitrectomy for submacular
   hemorrhage due to age-related macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Expansile gas; recombinant tissue plasminogen activator; subretinal
   hemorrhage; vitrectomy
ID ENDOTHELIAL GROWTH-FACTOR; PNEUMATIC DISPLACEMENT; SUBRETINAL
   HEMORRHAGE; CHOROIDAL NEOVASCULARIZATION; INTRAVITREOUS INJECTION;
   NATURAL-HISTORY; GAS; SECONDARY; MANAGEMENT; OUTCOMES
AB Purpose: The purpose of this study was to evaluate the treatment efficacy of vitrectomy combined with subretinal recombinant tissue plasminogen activator (r-tPA) and factors affecting visual improvement in patients with submacular hemorrhage (SMH) due to neovascular age-related macular degeneration (nAMD). Materials and Methods: Medical records of 17 consecutive patients diagnosed with SMH secondary to nAMD were retrospectively reviewed. The initial surgical procedure involved a 23-gauge transconjunctival vitrectomy, subretinal r-tPA application through a self-sealing inferior retinotomy, and sulfur hexafluoride gas for tamponade in all patients. The duration, size, and thickness of the hemorrhage and the pre-and post-operative visual acuity (VA) using a Snellen chart were recorded. VA was converted to logMAR for statistical analysis. Results: The average duration and size of the SMH were 12.8 +/- 18.2 days and 8.6 +/- 5.3 disc areas, respectively. The mean follow-up time was 16.9 +/- 4.7 months. A statistically significant visual improvement was found when comparing initial VA with postoperative best-corrected VA (BCVA) and final BCVA (Wilcoxon rank test, P = 0.01). There was no significant correlation between the size of the hemorrhage and postoperative BCVA and final BCVA (Spearman's rho test). There was no statistically significant correlation between the initial VA and postoperative BCVA and final BCVA (Spearman's rho test). There was no significant correlation between the duration of hemorrhage and postoperative BCVA and final BCVA (Spearman's rho test). The preoperative thickness of hemorrhage (747.5 +/- 30 mu m) was not correlated with postoperative BCVA or final BCVA (Pearson's test). Conclusions: Vitrectomy combined with subretinal r-tPA injection and gas tamponade is an effective surgical intervention to preserve VA in selected patients with apparent SMH.
C1 [Gok, Mustafa] Ordu Univ Res & Training Hosp, Minist Hlth, Dept Ophthalmol, Ordu, Turkey.
   [Kara, Ozgur] Fatsa Govt Hosp, Dept Ophthalmol, Ordu, Turkey.
   [Karabas, V. Levent; Yenihayat, Fatih] Kocaeli Univ, Med Sch, Dept Ophthalmol, Kocaeli, Turkey.
   [Aslan, Mehmet S.] Arnavutkoy Govt Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Karaman, Suleyman] Agri State Hosp, Dept Ophthalmol, Agri, Turkey.
C3 Ministry of Health - Turkey; Fatsa State Hospital; Kocaeli University;
   Agri State Hospital
RP Gok, M (通讯作者)，Ordu Univ Training & Res Hosp, Minist Hlth, Dept Ophthalmol, TR-52200 Ordu, Turkey.
EM drmgok81@gmail.com
RI Yenihayat, Fatih/A-9776-2019
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Dewilde E, 2014, ACTA OPHTHALMOL, V92, pE497, DOI 10.1111/aos.12458
   Fujikawa M, 2013, RETINA-J RET VIT DIS, V33, P1908, DOI 10.1097/IAE.0b013e318287d99d
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Green-Simms AE, 2011, SEMIN OPHTHALMOL, V26, P137, DOI 10.3109/08820538.2011.559512
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 2000, RETINA-J RET VIT DIS, V20, P500, DOI 10.1097/00006982-200009000-00011
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Hirashima T, 2015, RETINA-J RET VIT DIS, V35, P1969, DOI 10.1097/IAE.0000000000000574
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kauffmann Y, 2014, J FR OPHTALMOL, V37, P195, DOI 10.1016/j.jfo.2013.08.005
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Lee SS, 2010, INVEST OPHTH VIS SCI, V51, P2135, DOI 10.1167/iovs.09-3582
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Moisseiev E, 2014, EUR J OPHTHALMOL, V24, P925, DOI 10.5301/ejo.5000500
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Ratra D, 2012, ARCH OPHTHALMOL-CHIC, V130, P795, DOI 10.1001/archophthalmol.2011.1856
   Rishi E, 2012, INDIAN J OPHTHALMOL, V60, P521, DOI 10.4103/0301-4738.103779
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shultz RW, 2011, SEMIN OPHTHALMOL, V26, P361, DOI 10.3109/08820538.2011.585368
   Sobolewska B, 2014, J OCUL PHARMACOL TH, V30, P567, DOI 10.1089/jop.2013.0135
   Williamson TH, 2009, GRAEF ARCH CLIN EXP, V247, P1019, DOI 10.1007/s00417-009-1072-z
   Yiu G, 2014, DEV OPHTHALMOL, V54, P213, DOI 10.1159/000360469
NR 37
TC 6
Z9 6
U1 0
U2 2
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUN
PY 2017
VL 65
IS 6
BP 482
EP 487
DI 10.4103/ijo.IJO_129_16
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EZ5FW
UT WOS:000404739900011
PM 28643713
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pedula, KL
   Coleman, AL
   Yu, F
   Cauley, JA
   Ensrud, KE
   Hochberg, MC
   Fink, HA
   Hillier, TA
AF Pedula, Kathryn L.
   Coleman, Anne L.
   Yu, Fei
   Cauley, Jane A.
   Ensrud, Kristine E.
   Hochberg, Marc C.
   Fink, Howard A.
   Hillier, Teresa A.
CA Study Osteoporotic Fractures Res
TI Age-Related Macular Degeneration and Mortality in Older Women: The Study
   of Osteoporotic Fractures
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE age-related macular degeneration; mortality; older women
ID BEAVER DAM EYE; CORONARY-HEART-DISEASE; COPENHAGEN CITY EYE; BLUE
   MOUNTAINS EYE; VISUAL IMPAIRMENT; RISK-FACTORS; UNITED-STATES; HIP
   FRACTURE; FOLLOW-UP; DEPRESSION
AB ObjectivesTo examine the association between age-related macular degeneration (AMD) and all-cause and cause-specific mortality in a population of older women.
   DesignProspective cohort study.
   SettingFour U.S. clinical centers.
   ParticipantsA random sample of 1,202 women with graded fundus photographs at the Year 10 visit of the Study of Osteoporotic Fractures (mean age 79.5).
   MeasurementsForty-five-degree stereoscopic fundus photographs were graded for presence and severity (early vs late) of AMD. Vital status was adjudicated from death certificates. Cox proportional hazards models, adjusted for appropriate confounders, were used to estimate mortality hazards ratios.
   ResultsPrevalence of any AMD was 40.5% at baseline, with 441 (36.7%) having early AMD and 46 (3.8%) having late AMD. Cumulative mortality was 51.6% over 15years of follow-up. Overall, there was no significant association between AMD presence or severity and all-cause or cause-specific mortality. Because there was a significant interaction between AMD and age in predicting mortality (P<.05 for each mortality type), analyses were stratified according to age group. In women younger than 80, after adjusting for covariates, late AMD was associated with cardiovascular disease (CVD) mortality (hazard ratio (HR)=2.61, 95% confidence interval (CI)=1.05-6.46). In women aged 80 and older, early AMD was associated with all-cause (HR=1.39, 95% CI=1.11-1.75) and non-CVD, noncancer (HR=1.45, 95% CI=1.05-2.00) mortality. Any AMD was associated with all-cause (HR=1.42, 95% CI=1.13-1.78) and CVD (HR=1.45, 95% CI=1.01-2.09) mortality in women aged 80 and older.
   ConclusionAMD is a predictor of poorer survival in women, especially those aged 80 and older. Determination of shared risk factors may identify novel pathways for intervention that may reduce the risk of both conditions.
C1 [Pedula, Kathryn L.; Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res, Northwest Hawaii, Portland, OR USA.
   [Coleman, Anne L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Coleman, Anne L.; Yu, Fei] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA.
   [Yu, Fei] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
   [Cauley, Jane A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
   [Ensrud, Kristine E.; Fink, Howard A.] Vet Affairs Med Ctr, Minneapolis, MN USA.
   [Ensrud, Kristine E.; Fink, Howard A.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
   [Ensrud, Kristine E.; Fink, Howard A.] Univ Minnesota, Dept Epidemiol, Minneapolis, MN USA.
   [Hochberg, Marc C.] Univ Maryland, Div Rheumatol, Baltimore, MD 21201 USA.
   [Fink, Howard A.] Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Minneapolis, MN USA.
C3 Kaiser Permanente; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California System; University of California Los Angeles; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Minneapolis VA Health Care System; University of
   Minnesota System; University of Minnesota Twin Cities; University of
   Minnesota System; University of Minnesota Twin Cities; University System
   of Maryland; University of Maryland Baltimore; Geriatric Research
   Education & Clinical Center; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Minneapolis VA Health Care System
RP Pedula, KL (通讯作者)，Ctr Hlth Res, 3800 N,Interstate Ave, Portland, OR 97227 USA.
EM kathy.pedula@kpchr.org
RI Cauley, Jane A/N-4836-2015
OI Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036
FU National Institutes of Health [EY013626-03]; Research to Prevent
   Blindness; Public Health Service from the National Institutes of Health
   [AG05407, AR35582, AG05394, AR35584, AR35583, R01 AG005407, R01
   AG027576-22, 2 R01 AG005394-22A1, 2 R01 AG027574-22A1]; NATIONAL EYE
   INSTITUTE [U10EY013626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582,
   R01AR035584, R01AR035583] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [R01AG005394, R01AG027574, R01AG027576, R01AG005407]
   Funding Source: NIH RePORTER
FX Supported by National Institutes of Health Grant EY013626-03 and
   Research to Prevent Blindness. SOF is supported by Public Health Service
   research Grants AG05407, AR35582, AG05394, AR35584, AR35583, R01
   AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, 2 R01 AG027574-22A1 from
   the National Institutes of Health.
CR Ahto M, 2007, INT J GERIATR PSYCH, V22, P757, DOI 10.1002/gps.1735
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fitti J E, 1987, Vital Health Stat 1, P1
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Kulmala J, 2008, AGING CLIN EXP RES, V20, P25
   Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663
   Osby U, 2001, ARCH GEN PSYCHIAT, V58, P844, DOI 10.1001/archpsyc.58.9.844
   Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881
   Pedula KL, 2006, J AM GERIATR SOC, V54, P1871, DOI 10.1111/j.1532-5415.2006.00983.x
   Penninx BWJH, 2001, ARCH GEN PSYCHIAT, V58, P221, DOI 10.1001/archpsyc.58.3.221
   PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107
   Pulska T, 1999, BRIT MED J, V318, P432, DOI 10.1136/bmj.318.7181.432
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Xu L, 2009, OPHTHALMOLOGY, V116, P732, DOI 10.1016/j.ophtha.2008.11.003
NR 42
TC 17
Z9 17
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2015
VL 63
IS 5
BP 910
EP 917
DI 10.1111/jgs.13405
PG 8
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA CI4NH
UT WOS:000354726400009
PM 25941039
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Limoli, PG
   Vingolo, EM
   Limoli, C
   Scalinci, SZ
   Nebbioso, M
AF Limoli, Paolo Giuseppe
   Vingolo, Enzo Maria
   Limoli, Celeste
   Scalinci, Sergio Zaccaria
   Nebbioso, Marcella
TI Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related
   Macular Degeneration: Preliminary In Vivo Report
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 132; Age-related macular degeneration; Best corrected
   visual acuity (BCVA); Autologous cell graft; Electroretinogram; Growth
   factor (GF); Limoli Retinal Restoration Technique (LRRT);
   Microperimetry; Regenerative therapy; Suprachoroidal autograft
ID ENDOTHELIAL GROWTH-FACTOR; ADIPOSE-TISSUE; RETINA
AB This study is aimed at examining whether a suprachoroidal graft of autologous cells can improve best corrected visual acuity (BCVA) and responses to microperimetry (MY) in eyes affected by dry Age-related Macular Degeneration (AMD) over time through the production and secretion of growth factors (GFs) on surrounding tissue. Patients were randomly assigned to each study group. All patients were diagnosed with dry AMD and with BCVA equal to or greater than 1 logarithm of the minimum angle of resolution (logMAR). A suprachoroidal autologous graft by Limoli Retinal Restoration Technique (LRRT) was carried out on group A, which included 11 eyes from 11 patients. The technique was performed by implanting adipocytes, adipose-derived stem cells obtained from the stromal vascular fraction, and platelets from platelet-rich plasma in the suprachoroidal space. Conversely, group B, including 14 eyes of 14 patients, was used as a control group. For each patient, diagnosis was verified by confocal scanning laser ophthalmoscope and spectral domain-optical coherence tomography (SD-OCT). In group A, BCVA improved by 0.581 to 0.504 at 90 days and to 0.376 logMAR at 180 days (+32.20%) postoperatively. Furthermore, MY test increased by 11.44 dB to 12.59 dB at 180 days. The different cell types grafted behind the choroid were able to ensure constant GF secretion in the choroidal flow. Consequently, the results indicate that visual acuity (VA) in the grafted group can increase more than in the control group after six months.
C1 [Limoli, Paolo Giuseppe; Limoli, Celeste] Low Vis Res Ctr Milan, Milan, Italy.
   [Vingolo, Enzo Maria] Sapienza Univ Rome, A Fiorini Hosp, Rome, Italy.
   [Scalinci, Sergio Zaccaria] Univ Bologna, Dept Gen Surg & Organ Transplants, Glaucoma & Low Vis Study Ctr, Bologna, Italy.
   [Nebbioso, Marcella] Sapienza Univ Rome, Fac Med & Odontol, Dept Sense Organs, Rome, Italy.
C3 Sapienza University Rome; University of Bologna; Sapienza University
   Rome
RP Nebbioso, M (通讯作者)，Sapienza Univ Rome, Fac Med & Odontol, Dept Sense Organs, Rome, Italy.
EM marcella.nebbioso@uniroma1.it
RI Vingolo, Enzo Maria/E-6674-2010; Nebbioso, Marcella/K-6878-2018; Limoli,
   Paolo/AAB-9828-2021
OI Vingolo, Enzo Maria/0000-0002-8363-5866; Nebbioso,
   Marcella/0000-0002-5512-0849; 
CR Bagchi M, 2013, FASEB J, V27, P3257, DOI 10.1096/fj.12-221812
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Carron JA, 2000, INT J BIOCHEM CELL B, V32, P1137, DOI 10.1016/S1357-2725(00)00065-0
   Chen GF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073673
   Coleman WP, 2001, J AM ACAD DERMATOL, V45, P438, DOI 10.1067/mjd.2001.117045
   Daftarian Narsis, 2010, J Ophthalmic Vis Res, V5, P250
   Dang YL, 2015, CLIN INTERV AGING, V10, P255, DOI 10.2147/CIA.S73705
   FILATOV V P, 1951, Med Gen Fr, V11, P3
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kevy S. V., 2001, T SOC BIOM 27 ANN M
   Kim SY, 2003, EXP EYE RES, V77, P433, DOI 10.1016/S0014-4835(03)00174-X
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Lawrence Naomi, 2002, J Am Acad Dermatol, V47, P105, DOI 10.1067/mjd.2002.122189
   Limoli P, 2014, RETINAL CELL NEURORE, V40, P159
   Limoli PG, 2016, ONCOTARGET, V7, P46913, DOI 10.18632/oncotarget.10442
   Limoli PG, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000355
   Lin KJ, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt223
   McHarg S, 2015, JOVE-J VIS EXP, DOI 10.3791/53382
   Meduri R., 2007, ARVO 2007 ANN M FORT
   Nebbioso M, 2011, CLIN EXP OPTOM, V94, P276, DOI 10.1111/j.1444-0938.2010.00476.x
   Pelaez O., 1997, CUBAN EXPERIENCE
   Schaffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006-0589
   Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559
   Thanos C, 2005, EXPERT OPIN BIOL TH, V5, P1443, DOI 10.1517/14712598.5.11.1443
   Tischler Michael, 2002, N Y State Dent J, V68, P22
   Ueki Y, 2013, GLIA, V61, P778, DOI 10.1002/glia.22472
   Wang P, 2008, J CELL PHYSIOL, V216, P3, DOI 10.1002/jcp.21386
   Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105
NR 30
TC 15
Z9 15
U1 0
U2 10
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD FEB
PY 2018
IS 132
AR e56469
DI 10.3791/56469
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FX9UK
UT WOS:000426453400021
PM 29553543
OA Green Published
DA 2022-11-30
ER

PT J
AU Yuan, DQ
   Yang, Q
   Liu, XY
   Yuan, DL
   Yuan, ST
   Xie, P
   Liu, QH
AF Yuan, Dongqing
   Yang, Qin
   Liu, Xiaoyi
   Yuan, Donglan
   Yuan, Songtao
   Xie, Ping
   Liu, Qinghuai
TI Complement factor H Val62Ile variant and risk of age-related macular
   degeneration: A meta-analysis
SO MOLECULAR VISION
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; GENOME-WIDE ASSOCIATION; JAPANESE
   POPULATION; GENE POLYMORPHISMS; HAN CHINESE; CFH; C3; SUSCEPTIBILITY;
   HTRA1; ARMS2
AB Purpose: To evaluate the precise association of complement factor H (CFH) Val62Ile polymorphism with age-related macular degeneration (AMD) susceptibility.
   Methods: We performed a meta-analysis using databases including PubMed, EMBASE, and Web of Science to find relevant studies. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using fixed-effect and random-effects models. The inconsistency index (I-2) was used to assess heterogeneity. Funnel plots and Egger's test were used to evaluate publication bias. Sensitivity analysis was also performed.
   Results: Fourteen studies including 4,438 patients with AMD and 6,099 controls based on the search criteria were involved in the meta-analysis. In overall populations, the pooled OR1 for genotype GA+GG versus homozygous genotype AA was 2.28 (95% confidence interval (CI): 1.48-3.52), the OR2 of heterozygous genotype GA versus AA was 1.58 (95% CI: 1.13-2.19), the OR3 of homozygous genotype GG versus AA was 2.90 (95% CI: 1.95-4.30), and the OR4 of allele G versus A was 1.77 (95% CI: 1.43-2.21). In Asian populations, our results provided substantial evidence that the Val62Ile variant was significantly associated with AMD (OR4 = 1.85, 95% CI: 1.63-2.09). However, in Caucasian populations, no significant association of Val62Ile with AMD was established in all circumstances.
   Conclusions: Our analysis provides substantial evidence that the Val62Ile variant is significantly associated with AMD in Asian populations. However, our results have demonstrated no link between the Val62Ile polymorphism and AMD in Caucasian populations.
C1 [Yuan, Dongqing; Yang, Qin; Liu, Xiaoyi; Yuan, Songtao; Xie, Ping; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
   [Yuan, Donglan] Nanjing Med Univ, Affiliated Hosp 1, Dept Nucl Med, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
EM liuqh@njmu.edu.cn
OI Liu, Qinghuai/0000-0003-1605-1964; Xie, Ping/0000-0003-4257-8970
FU National Basic Research Program of China (973 Program) [2011CB510200];
   General Project of the National Natural Science Funds [81170855,
   81070743]; Research and Innovation Project for College Graduates of
   Jiangsu Province [CXZZ12_0586]
FX Dongqing Yuan (DQY) and Qin Yang (QY) are co-first authors, who have
   contributed equally to conceiving and designing the study; Dongqing
   Yuan, Qin Yang, Xiaoyi Liu (XYL) and Donglan Yuan (DLY) performed the
   experiment and analysis; Songtao Yuan (STY), Ping Xie (PX) and Qinghuai
   Liu (QHL) critically revised the manusicript and participated in paper
   modification; Dongqing Yuan, Qin Yang and Xiaoyi Liu were responsible
   for composing the manuscript. This research project was supported by
   National Basic Research Program of China (973 Program, No.2011CB510200),
   General Project of the National Natural Science Funds (No.81170855 and
   No.81070743) and Research and Innovation Project for College Graduates
   of Jiangsu Province (No.CXZZ12_0586). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Chen LJ, 2006, MOL VIS, V12, P1536
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Wells GA., 2000, NEWCASTLEOTTAWA SCAL
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
NR 38
TC 12
Z9 13
U1 0
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD FEB 13
PY 2013
VL 19
BP 374
EP 383
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 089LN
UT WOS:000314912100003
PM 23441108
DA 2022-11-30
ER

PT J
AU Reiter, GS
   Told, R
   Schlanitz, FG
   Bogunovic, H
   Baumann, L
   Sacu, S
   Schmidt-Erfurth, U
   Pollreisz, A
AF Reiter, Gregor Sebastian
   Told, Reinhard
   Schlanitz, Ferdinand Georg
   Bogunovic, Hrvoje
   Baumann, Lukas
   Sacu, Stefan
   Schmidt-Erfurth, Ursula
   Pollreisz, Andreas
TI Impact of Drusen Volume on Quantitative Fundus Autofluorescence in Early
   and Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; drusen; lipofuscin; fundus
   autofluorescence; retinal pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; REFRACTILE
   DRUSEN; OCT IMAGES; LIPOFUSCIN; SEGMENTATION; EYES; QUANTIFICATION;
   CLASSIFICATION; FLUORESCENCE
AB PURPOSE. Drusen volume (DV) and quantitative autofluorescence (qAF) are potential indicators of progression in age-related macular degeneration (AMD). This prospective and observational study examined the association between DV and qAF of the retinal pigment epithelium.
   METHODS. Eighty-eight eyes of 52 patients with early and intermediate AMD were included. The mean follow-up was 9.2 +/- 5.6 months, resulting in 312 examinations. DV was extracted from 6 x 6-mm spectral-domain optical coherence tomography scans. qAF was measured using a rotated Delori pattern. The associations between qAF and DV, age, sex, and lens status were investigated using linear mixed models.
   RESULTS. Patients' mean age was 75.6 +/- 5.0 years (range, 61.0-83.4 years). Sixty-eight eyes (77.3%) were from females. No significant association between DV and qAF was found, neither within the total outer Early Treatment Diabetic Retinopathy Study (ETDRS) grid nor for ETDRS segments six to nine (all P > 0.05). Sex and lens status were not associated with qAF (P = 0.429 and P = 0.213, respectively). A significant association between age and qAF (P = 0.025) was found, indicating a decrease of qAF with age.
   CONCLUSIONS. Quantification of DV and fundus autofluorescence did not reveal any correlation in early and intermediate AMD. qAF decreased with age, whereas DV increased in about half of the patients. This finding is a quantitative corroboration that fundus autofluorescence and the buildup of drusen are not correlated processes in AMD.
C1 [Reiter, Gregor Sebastian; Told, Reinhard; Schlanitz, Ferdinand Georg; Sacu, Stefan; Schmidt-Erfurth, Ursula; Pollreisz, Andreas] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna Clin Trial Ctr VTC, Vienna, Austria.
   [Bogunovic, Hrvoje; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna Reading Ctr, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
   [Baumann, Lukas] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna
RP Pollreisz, A (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM andreas.pollreisz@meduniwien.ac.at
RI Pollreisz, Andreas/AAJ-1538-2021; Bogunovic, Hrvoje/J-3445-2014
OI Told, Reinhard/0000-0003-2046-7081; Baumann, Lukas/0000-0001-7931-7470;
   Bogunovic, Hrvoje/0000-0002-9168-0894; Reiter,
   Gregor/0000-0001-7661-4015
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Armenti ST, 2016, JOVE-J VIS EXP, V109, P53577
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Curcio C, 2017, INVEST OPHTH VIS SCI, V58
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Sisternes L., 2017, ARVO TRANSL VIS SCI, V6, P1
   de Sisternes L, 2017, BIOMED OPT EXPRESS, V8, P1926, DOI 10.1364/BOE.8.001926
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DELORI FC, INVEST OPHTHALMOL VI, V41, P496
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Gliem M, 2017, INVEST OPHTH VIS SCI, V58, P6159, DOI 10.1167/iovs.17-22007
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   IWASAKI M, 1988, INVEST OPHTH VIS SCI, V29, P671
   KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9
   KITAGAWA K, 1989, OPHTHALMOLOGICA, V199, P116, DOI 10.1159/000310027
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Ong BB, 2013, EYE, V27, P554, DOI 10.1038/eye.2012.292
   Orellana-Rios J, 2018, OSLI RETINA, V49, pS34, DOI 10.3928/23258160-20180814-06
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Pollreisz A, 2018, EXP EYE RES, V166, P131, DOI 10.1016/j.exer.2017.10.018
   Reiter GS, 2019, ACTA OPHTHALMOL, V97, pE526, DOI 10.1111/aos.13987
   Rossberger S, 2013, BRIT J OPHTHALMOL, V97, P518, DOI 10.1136/bjophthalmol-2012-302350
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schlanitz F, 2019, BRIT J OPHTHALMOL, V103, P227, DOI 10.1136/bjophthalmol-2017-311782
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   van de Kraats J, 2007, J OPT SOC AM A, V24, P1842, DOI 10.1364/JOSAA.24.001842
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 49
TC 13
Z9 13
U1 1
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2019
VL 60
IS 6
BP 1937
EP 1942
DI 10.1167/iovs.19-26566
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HZ6RS
UT WOS:000468980600015
PM 31050721
OA gold
DA 2022-11-30
ER

PT J
AU Le, JT
   Agron, E
   Keenan, TDL
   Clemons, TE
   Brenowitz, WD
   Yaffe, K
   Chew, EY
AF Le, Jimmy T.
   Agron, Elvira
   Keenan, Tiarnan D. L.
   Clemons, Traci E.
   Brenowitz, Willa D.
   Yaffe, Kristine
   Chew, Emily Y.
CA AREDS2 Res Grp
TI Assessing bidirectional associations between cognitive impairment and
   late age-related macular degeneration in the Age-Related Eye Disease
   Study 2
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE age-related macular degeneration; Alzheimer's disease; cognitive
   impairment; eyes; older adults; ophthalmology
ID ALZHEIMERS-DISEASE; MEDITERRANEAN DIET; GLOBAL PREVALENCE; AREDS;
   DEMENTIA; OMEGA-3-FATTY-ACIDS; SUPPLEMENTATION; ANCILLARY; RISK
AB Introduction We aimed to investigate bidirectional associations between cognitive impairment and late age-related macular degeneration (AMD). Methods Participants in the Age-Related Eye Disease Study 2 (AREDS2) received annual eye examinations and cognitive function testing (e.g., Modified Telephone Interview for Cognitive Status [TICS-M]). We examined bidirectional associations between cognitive impairment (e.g., a TICS-M score < 30) and late AMD at 5 and 10 years. Results Five thousand one hundred eighty-nine eyes (3157 participants; mean age 72.7 years) were analyzed and followed for a median of 10.4 years. Eyes of participants with cognitive impairment at baseline were more likely to progress to late AMD at 5 years (hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.08-1.43) and 10 years (HR, 1.20; 95% CI, 1.05-1.37) than eyes of participants without cognitive impairment. Worse baseline AMD severity was not associated with developing cognitive impairment. Discussion Cognitive impairment is associated with late AMD progression in AREDS2. Our finding highlights the importance of eyecare for people with cognitive impairment.
C1 [Le, Jimmy T.] Natl Inst Hlth, Natl Eye Inst, Div Extramural Res, Div Epidemiol & Clin Applicat, 6700B RockledgeDrive,Suite 3400, Bethesda, MD 20817 USA.
   [Agron, Elvira; Keenan, Tiarnan D. L.; Chew, Emily Y.] Natl Inst Hlth, Natl Eye Inst, Div Epidemiol & Clin Applicat, Bethesda, MD USA.
   [Clemons, Traci E.] Emmes Co, LLC, Rockville, MD USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA USA.
   [Brenowitz, Willa D.] Univ Calif San Francisco, Dept Neurol & Epidemiol & Biostatist, San Francisco, CA USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); University of California System; University of
   California San Francisco; University of California System; University of
   California San Francisco; University of California System; University of
   California San Francisco
RP Le, JT (通讯作者)，Natl Inst Hlth, Natl Eye Inst, Div Extramural Res, Div Epidemiol & Clin Applicat, 6700B RockledgeDrive,Suite 3400, Bethesda, MD 20817 USA.
EM jimmy.le@nih.gov
FU National Eye Institute; National Institutes of Health; National
   Institute onAging; National Heart, Lung, and Blood Institute; National
   Institute ofNeurological Disorders and Stroke; National Center for
   Complementary; NIHOffice of Dietary Supplements
FX National Eye Institute; National Institutes of Health; National
   Institute onAging; National Heart, Lung, and Blood Institute; National
   Institute ofNeurological Disorders and Stroke; National Center for
   Complementary; AlternativeMedicine andNIHOffice of Dietary Supplements
CR Abondio P, 2019, GENES-BASEL, V10, DOI 10.3390/genes10030222
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Chew EY, 2017, OPHTHALMOLOGICA, V238, P1, DOI 10.1159/000473865
   Chew Emily Y, 2016, JAMA, V315, P516, DOI 10.1001/jama.2015.16467
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hammond BR, 2016, ADV NUTR, V7, P433, DOI 10.3945/an.115.011866
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2020, ALZHEIMERS DEMENT, V16, P831, DOI 10.1002/alz.12077
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Le JT, 2019, JAMA OPHTHALMOL, V137, P1399, DOI 10.1001/jamaophthalmol.2019.4016
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Markelov, 2020, ALZHEIMERS DEMENT, V16
   Paulus YM, 2017, QUAL LIFE RES, V26, P2139, DOI 10.1007/s11136-017-1547-z
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007
   Rankin MW, 2005, OPHTHAL EPIDEMIOL, V12, P271, DOI 10.1080/09286580591003815
   Rezazadeh M, 2019, J CELL PHYSIOL, V234, P16873, DOI 10.1002/jcp.28372
   Rong SS, 2019, BRIT J OPHTHALMOL, V103, P1777, DOI 10.1136/bjophthalmol-2018-313277
   Rovner BW, 2009, ALZHEIMERS DEMENT, V5, P12, DOI 10.1016/j.jalz.2008.06.001
   Samieri C, 2013, EPIDEMIOLOGY, V24, P490, DOI 10.1097/EDE.0b013e318294a065
   Samra SK, 2007, STROKE, V38, P1864, DOI 10.1161/STROKEAHA.106.477448
   Vu TA, 2021, OPHTHALMOLOGY, V128, P981, DOI 10.1016/j.ophtha.2020.12.010
   Thielke, 2020, ALZHEIMERS DEMENT, V16
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   van Asten F, 2019, OPHTHALMOLOGY, V126, P1541, DOI 10.1016/j.ophtha.2019.06.004
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   Vitale S, 2020, JAMA OPHTHALMOL, V138, P610, DOI 10.1001/jamaophthalmol.2020.0824
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yang SP, 2004, NEUROBIOL AGING, V25, P283, DOI 10.1016/S0197-4580(03)00111-8
   Zhou LX, 2016, CLIN INTERV AGING, V11, P215, DOI 10.2147/CIA.S102213
NR 47
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JUL
PY 2022
VL 18
IS 7
BP 1296
EP 1305
DI 10.1002/alz.12473
EA NOV 2021
PG 10
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 3D8ZM
UT WOS:000716488700001
PM 34758100
DA 2022-11-30
ER

PT J
AU Krebs, I
   Glittenberg, C
   Ansari-Shahrezaei, S
   Hagen, S
   Steiner, I
   Binder, S
AF Krebs, Ilse
   Glittenberg, Carl
   Ansari-Shahrezaei, Siamak
   Hagen, Stefan
   Steiner, Irene
   Binder, Susanne
TI Non-responders to treatment with antagonists of vascular endothelial
   growth factor in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; VITREOMACULAR TRACTION; RANIBIZUMAB; THERAPY;
   TRIAMCINOLONE; TACHYPHYLAXIS
AB Purpose Most of the publications on modern therapy of neovascular age-related macular degeneration focus on the effect of the treatment. The purpose of this study is to determine the frequency of non-responders to anti-vascular endothelial growth factor (anti-VEGF) treatment and find possible reasons for their failure to respond.
   Methods The records of patients treated until the end of 2008 the first time with either bevacizumab or ranibizumab were reviewed. Based on the availability of measurable results and according to prior publications showing the effect of the therapy, loss of three lines of distance acuity, increase of retinal thickness or lesion size were identified as indicators of non-responders. Two of these three signs had to be present.
   Results 334 eyes of 283 patients were included; 74.55% received bevacizumab and 25.45% received ranibizumab. Overall 14.37% of the eyes were identified as non-responders (14.06% in the bevacizumab group and 15.29% in the ranibizumab group). Baseline distance acuity and vitreo-retinal adhesions were significantly correlated with non-responders. Correlations with age, gender, lesion type, other morphologic features, and the kind of anti-VEGF agent failed to be significant. 10.4% of the non-responders showed a delayed but good response to anti-VEGF treatment.
   Conclusions About 15% did not sufficiently respond to anti-VEGF treatment. Vitreo-retinal adherences were the only ophthalmologic factor which could be identified to be significantly correlated with insufficient response.
C1 [Krebs, Ilse; Glittenberg, Carl; Ansari-Shahrezaei, Siamak; Hagen, Stefan; Binder, Susanne] Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
   [Krebs, Ilse; Glittenberg, Carl; Ansari-Shahrezaei, Siamak; Hagen, Stefan; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Steiner, Irene] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Sect Med Stat, Vienna, Austria.
C3 Ludwig Boltzmann Institute; Medical University of Vienna
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM Ilse.Krebs@wienkav.at
FU L. Boltzmann Institute
FX Supported by an unrestricted research grant from the L. Boltzmann
   Institute to SB.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Ahmadieh H, 2011, RETINA-J RET VIT DIS, V31, P1819, DOI 10.1097/IAE.0b013e31820d58f2
   Benz MS, 2010, OPHTHALMOLOGY, V117, P791, DOI 10.1016/j.ophtha.2009.11.005
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1552, DOI 10.1136/bjo.2010.194670
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Liu YL, 2011, ACTA OPHTHALMOL, V89, pE291, DOI 10.1111/j.1755-3768.2009.01814.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Sebag J, 2009, RETINA-J RET VIT DIS, V29, P871, DOI 10.1097/IAE.0b013e3181ac7b3c
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P207, DOI 10.1089/jop.2009.0131
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
NR 25
TC 68
Z9 70
U1 0
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2013
VL 97
IS 11
BP 1443
EP 1446
DI 10.1136/bjophthalmol-2013-303513
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 239WN
UT WOS:000326056700018
PM 23966368
OA Bronze
DA 2022-11-30
ER

PT J
AU Kunzel, SH
   Moller, PT
   Lindner, M
   Goerdt, L
   Nadal, J
   Schmid, M
   Schmitz-Valckenberg, S
   Holz, FG
   Fleckenstein, M
   Pfau, M
AF Kuenzel, Sandrine H.
   Moeller, Philipp T.
   Lindner, Moritz
   Goerdt, Lukas
   Nadal, Jennifer
   Schmid, Matthias
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   Fleckenstein, Monika
   Pfau, Maximilian
TI Determinants of Quality of Life in Geographic Atrophy Secondary to
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE geographic atrophy; quality of life; vision-related quality of life;
   patient reported outcomes; age-related macular degeneration
ID VISUAL-ACUITY
AB PURPOSE. To longitudinally evaluate vision-related quality of life (VRQoL) in geographic atrophy (GA) secondary to age-related macular degeneration (AMD) and define its relation to visual function and structural biomarkers.
   METHODS. Patients with GA secondary to AMD were recruited in the context of the prospective, non-interventional, natural-history Directional Spread in Geographic-Atrophy study (NCT02051998). Fundus autofluorescence and infrared reflectance images were semi-automatically annotated for GA. Linear mixed-effects models were applied to investigate the association of putative determinants with the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) VRQoL.
   RESULTS. A total of 87 patients with a mean age +/- SD of 77.07 +/- 7.49 years were included in the analysis. At baseline, median (IQR) best-corrected visual acuity (BCVA) was 0.3 (0.51) for the better eye and 0.89 (0.76) for the worse eye; 46% of the patients showed binocular and 25.3% monocular non-central GA. The VRQoL composite score was impaired: 69.96 (24.03). Sixty-six patients with a median of 2 (2) follow-up visits after 1.08 (0.78) years were examined longitudinally.
   In the multivariable cross-sectional analysis, predictors of the VRQoL composite score were BCVA, GA size, and low-luminance visual acuity (LLVA) for the better eye and BCVA, foveal sparing status, and LLVA for the worse eye (cross-validated R-2 = 0.32).
   In the longitudinal analysis, a similar prediction accuracy for VRQoL was determined (cross-validated R-2 = 0.28). Prediction accuracy for VRQoL did not improve when followup time was added as an independent variable.
   CONCLUSIONS. Vision-related quality of life is significantly impaired in patients with GA secondary to AMD. The cross-sectional and longitudinal association of VRQoL with visual functional and structural biomarkers supports the validity of the NEI VFQ-25 VRQoL.
C1 [Kuenzel, Sandrine H.; Moeller, Philipp T.; Goerdt, Lukas; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika; Pfau, Maximilian] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, Bonn, Germany.
   [Moeller, Philipp T.; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika; Pfau, Maximilian] GRADE Reading Ctr, Bonn, Germany.
   [Lindner, Moritz] Univ Oxford, Sleep & Circadian Neurosci Inst, Nuffield Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England.
   [Nadal, Jennifer; Schmid, Matthias] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Pfau, Maximilian] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.
C3 University of Bonn; University of Oxford; University of Bonn; Utah
   System of Higher Education; University of Utah; Stanford University
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, Bonn, Germany.
EM mfleckenstein@web.de
RI Künzel, Sandrine/ABB-4093-2020; Lindner, Moritz/AAC-8639-2021
OI Künzel, Sandrine/0000-0002-1686-4642; Lindner,
   Moritz/0000-0002-4416-3421; Schmid, Matthias/0000-0002-0788-0317; Pfau,
   Maximilian/0000-0001-9761-9640
FU German Ophthalmological Society; German Research Foundation [PF 950/1-1,
   658/4-1, 658/4-2, 2846/1-1]; BONFOR GEROK Program of the Faculty of
   Medicine, University of Bonn [O-137.0022, O-137.0025]; Research to
   Prevent Blindness
FX Supported by a dissertation grant from the German Ophthalmological
   Society (SHK), by grants from the German Research Foundation (PF 950/1-1
   to MP, 658/4-1 and 658/4-2 to MF, and 2846/1-1 to ML), and by grants
   from the BONFOR GEROK Program of the Faculty of Medicine, University of
   Bonn (O-137.0022 and O-137.0025 to MP). CenterVue SpA (Padova, Italy)
   provided research equipment (Scotopic Macular Integrity Assessment
   device) for this study. CenterVue had no role in the design or conduct
   of the experiments. MF was supported in part by an unrestricted grant
   from Research to Prevent Blindness to the Department of Ophthalmology &
   Visual Sciences, University of Utah.
CR Cheng QE, 2018, OPHTHALMOL RETINA, V2, P518, DOI 10.1016/j.oret.2017.08.018
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Csaky K, 2018, INVEST OPHTH VIS SCI, V58, P3456
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   European Medicines Agency, EU REG WORKSH OPTH S
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Groll A, 2014, STAT COMPUT, V24, P137, DOI 10.1007/s11222-012-9359-z
   Hastie T., 2011, ELEMENTS STAT LEARNI
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Kimel M, 2016, INVEST OPHTH VIS SCI, V57, P6298, DOI 10.1167/iovs.16-20361
   Lindner M, 2019, OPHTHALMOL RETINA, V3, P201, DOI 10.1016/j.oret.2018.11.005
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, pBIO61, DOI 10.1167/iovs.16-21210
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Owsley C, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0274-5
   Pelli DG, 2013, VISION RES, V90, P10, DOI 10.1016/j.visres.2013.04.015
   Pfau M, 2019, RETINA-J RET VIT DIS, V39, P1527, DOI 10.1097/IAE.0000000000002206
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Radner W, 2017, GRAEF ARCH CLIN EXP, V255, P1465, DOI 10.1007/s00417-017-3659-0
   Rasmussen A, 2014, CURR OPIN OPHTHALMOL, V25, P158, DOI 10.1097/ICU.0000000000000050
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Sivaprasad S, 2018, AM J OPHTHALMOL, V190, P1, DOI 10.1016/j.ajo.2018.03.006
   Stockman A, 2006, OPHTHAL PHYSL OPT, V26, P225, DOI 10.1111/j.1475-1313.2006.00325.x
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness Janet S, 2008, Retin Cases Brief Rep, V2, P83, DOI 10.1097/IAE.0b013e31802fa25d
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   U.S. Food and Drug Administration, PAT REP OUTC MEAS US
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
NR 38
TC 14
Z9 14
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2020
VL 61
IS 5
AR 63
DI 10.1167/iovs.61.5.63
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LZ0ET
UT WOS:000540905500046
PM 32462198
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Phasukkijwatana, N
   Tan, ACS
   Chen, XJ
   Freund, KB
   Sarraf, D
AF Phasukkijwatana, Nopasak
   Tan, Anna C. S.
   Chen, Xuejing
   Freund, K. Bailey
   Sarraf, David
TI Optical coherence tomography angiography of type 3 neovascularisation in
   age-related macular degeneration after antiangiogenic therapy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; MOTION CORRECTION; SPECTRUM
AB Background/aims To assess the microvascular response of type 3 neovascularisation secondary to age-related macular degeneration (AMD) after antivascular endothelial growth factor (anti-VEGF) therapy using optical coherence tomography angiography (OCTA).
   Methods Consecutive patients diagnosed with AMD and type 3 neovascularisation based on clinical examination, structural optical coherence tomography and fluorescein angiography when available were retrospectively evaluated. En face OCTA imaging (3x3 mm scans) with quantitative microvascular analysis was performed at baseline and after a single anti-VEGF intravitreal injection.
   Results 17 eyes of 14 patients underwent OCTA before and after anti-VEGF treatment. OCTA demonstrated significant regression of small calibre type 3 neovascular tufts in all eyes. Median lesion area was 0.061 mm(2) (range 0.003-0.198 mm(2)) at baseline and 0.009 mm(2) (range 0-0.085 mm(2), p=0.0003) at follow-up. Cystoid macular oedema and/or subretinal fluid resolved in all cases after treatment. The type 3 lesions became undetectable with OCTA post-treatment in 5 of the 17 eyes. However, in 11 eyes, large feeder vessels were identified and remained unchanged after treatment.
   Conclusions The microvascular morphology of type 3 neovascularisation secondary to AMD was assessed at baseline and follow- up and showed significant regression in response to anti-VEGF therapy by OCTA. Quantitative OCTA analysis was also performed and confirmed remarkable regression in response to a single intravitreal anti-VEGF injection.
C1 [Phasukkijwatana, Nopasak; Chen, Xuejing; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Phasukkijwatana, Nopasak] Mahidol Univ, Fac Med, Dept Ophthalmol, Siriraj Hosp, Bangkok, Thailand.
   [Tan, Anna C. S.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Tan, Anna C. S.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Tan, Anna C. S.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Mahidol University; Vitreous Retina Macula
   Consultants of New York; Manhattan Eye Ear & Throat Hospital; National
   University of Singapore; Singapore National Eye Center; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los
   Angeles Healthcare System
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Retinal Disorders & Ophthalm Genet Div, Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
RI Phasukkijwatana, Nopasak/T-8630-2019; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; chen, xuejing/0000-0001-6827-0152
FU Macula Foundation, Inc, New York, NY
FX The study was supported by the Macula Foundation, Inc, New York, NY.
CR Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P603, DOI 10.1097/IAE.0000000000000487
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 16
TC 45
Z9 49
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2017
VL 101
IS 5
BP 597
EP 602
DI 10.1136/bjophthalmol-2016-308815
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW2MQ
UT WOS:000402331100011
PM 27503396
DA 2022-11-30
ER

PT J
AU Schlanitz, FG
   Baumann, B
   Kundi, M
   Sacu, S
   Baratsits, M
   Scheschy, U
   Shahlaee, A
   Mittermuller, TJ
   Montuoro, A
   Roberts, P
   Pircher, M
   Hitzenberger, CK
   Schmidt-Erfurth, U
AF Schlanitz, Ferdinand G.
   Baumann, Bernhard
   Kundi, Michael
   Sacu, Stefan
   Baratsits, Magdalena
   Scheschy, Ulrike
   Shahlaee, Abtin
   Mittermueller, Tamara J.
   Montuoro, Alessio
   Roberts, Philipp
   Pircher, Michael
   Hitzenberger, Christoph K.
   Schmidt-Erfurth, Ursula
TI Drusen volume development over time and its relevance to the course of
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; SEGMENTATION;
   PATHOGENESIS; ETIOLOGY
AB Aims To quantify the change in drusen volume over time and identify its prognostic value for individual risk assessment.
   Methods A prospective observational study over a minimum of 3 years and maximum of 5 years and follow-up examination every 3 months was conducted at the ophthalmology department of the Medical University of Vienna. 109 patients presenting early and intermediate age-related macular degeneration (AMD) were included, of which 30 patients concluded a regular follow-up for at least 3 years. 50 eyes of 30 patients were imaged every 3 months using spectral-domain and polarisation-sensitive optical coherence tomography (OCT). Drusen volume was measured using an automated algorithm. Data of a 6-month follow-up were segmented manually by expert graders.
   Results Gradings from 24 000 individual B-scans showed solid correlation between manual and automated segmentation with an initial mean drusen volume of 0.17 mm(3). The increase in drusen volume was shown to be comparable among all eyes, and a model for long-term drusen volume development could be fitted as a cubic polynomial function and an R-2=0.955. Spontaneous drusen regression was observed in 22 of 50 eyes. In this group, four eyes developed choroidal neovascularisation and three geographic atrophy.
   Conclusions Drusen volume increase over time can be described by a cubic function. Spontaneous regression appears to precede conversion to advanced AMD. OCT might be a promising tool for predicting the individual risk of progression of AMD.
C1 [Schlanitz, Ferdinand G.; Sacu, Stefan; Baratsits, Magdalena; Scheschy, Ulrike; Shahlaee, Abtin; Mittermueller, Tamara J.; Montuoro, Alessio; Roberts, Philipp; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
   [Baumann, Bernhard; Pircher, Michael; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
   [Kundi, Michael] Med Univ Vienna, Inst Environm Hlth, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Baumann, Bernhard/0000-0001-6419-1932; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Michael, Pircher/0000-0001-9285-7527;
   Hitzenberger, Christoph/0000-0002-6608-8821
FU independent scientific grant (FWF grant, Austrian Science Fund, Vienna,
   Austria) [P19624-B02]; European Union (FP7 HEALTH programme, FUN-OCT,
   Brussels, Belgium) [201880]; independent scientific grant
   (Herzfeldersche Familienstiftung) [AP0044120FF]
FX CKH has received support by an independent scientific grant (FWF grant
   P19624-B02, Austrian Science Fund, Vienna, Austria), the European Union
   (FP7 HEALTH programme grant 201880, FUN-OCT, Brussels, Belgium). US-E
   has received support by an independent scientific grant (Herzfeldersche
   Familienstiftung, grant AP0044120FF).
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Baumann B, 2009, J BIOPHOTONICS, V2, P426, DOI 10.1002/jbio.200910031
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 25
TC 74
Z9 75
U1 0
U2 19
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2017
VL 101
IS 2
BP 198
EP 203
DI 10.1136/bjophthalmol-2016-308422
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ6CO
UT WOS:000393306300021
PM 27044341
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Ashraf, M
   Souka, AAR
AF Ashraf, M.
   Souka, A. A. R.
TI Aflibercept in age-related macular degeneration: evaluating its role as
   a primary therapeutic option
SO EYE
LA English
DT Review
ID PIGMENT EPITHELIAL DETACHMENT; TREAT-AND-EXTEND; INTRAVITREAL
   AFLIBERCEPT; GROWTH-FACTOR; SUBGROUP ANALYSIS; ZIV-AFLIBERCEPT;
   VISUAL-ACUITY; VEGF TRAP; RANIBIZUMAB; VIEW
AB The recent VIEW studies have demonstrated the non-inferiority of monthly and bi-monthly aflibercept in the management of wet age related macular degeneration (AMD) compared with ranibizumab. However, the current data are limited mainly to fixed dosing regimens with few studies looking at flexible dosing regimens of aflibercept in wet AMD. In addition, recent data from the VIEW 96 week extension has shown that patients being shifted from fixed dosing regimens to PRN have shown a drop in visual acuity and increase in central macular thickness. This is an indication that fixed dosing, a nonsustainable option, is only effective as long as it is continued. Regimens such as treat and extend (TAE) and pro-re nata (PRN) have been studied extensively in ranibizumab and bevacizumab and have shown to be effective options. With the presence of effective, established and less costly drugs such as ranibizumab and bevacizumab, the role of aflibercept as a primary treatment modality has yet to be clearly defined. The current review provides an analysis of the VIEW studies, as well as the extension phases. It also looks at post hoc analysis of predictors of response and outcomes. We have also conducted a search on studies comparing between PRN regimens using aflibercept and other anti-VEGF agents. This review also explores cheaper off label aflibercept; ziv-aflibercept in the treatment of wet AMD. The main purpose of the review is to delineate the role of aflibercept as a primary therapeutic option and if there are any significant advantages that would advocate its use over alternative anti-VEGF drugs. Finally, we propose a treatment algorithm for patients being started on aflibercept during the first year and thereafter.
C1 [Ashraf, M.] Alexandria Univ, Fac Med, Dept Ophthalmol, Front 27 Maarouf Rasafi St, Alexandria, Egypt.
   [Souka, A. A. R.] Alexandria Univ, Fac Med, Dept Ophthalmol, Alexandria, Egypt.
C3 Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge
   Bank (EKB); Alexandria University
RP Ashraf, M (通讯作者)，Alexandria Univ, Fac Med, Dept Ophthalmol, Front 27 Maarouf Rasafi St, Alexandria, Egypt.
EM Moah384@gmail.com
RI Elmasry, Mohamed Ashraf/Q-8843-2019; Souka, Ahmed/AAD-8225-2022
OI Elmasry, Mohamed Ashraf/0000-0003-4231-2566; Souka,
   Ahmed/0000-0002-1664-704X
CR Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P1126, DOI 10.1097/IAE.0000000000000913
   Chhablani J, 2015, INDIAN J OPHTHALMOL, V63, P469, DOI 10.4103/0301-4738.159909
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Christoforidis JB, 2011, INVEST OPHTH VIS SCI, V52, P5899, DOI 10.1167/iovs.10-6862
   Dias JRD, 2014, INVEST OPHTH VIS SCI, V55
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Huo XC, 2015, CELL PHYSIOL BIOCHEM, V35, P1787, DOI 10.1159/000373990
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Khanani AM, 2015, CLIN OPHTHALMOL, V9, P1315, DOI 10.2147/OPTH.S88624
   Kikushima W, 2016, J OCUL PHARMACOL TH, V32, P376, DOI 10.1089/jop.2015.0125
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Mansour AM, 2016, BRIT J OPHTHALMOL, V100, P1629, DOI 10.1136/bjophthalmol-2015-308319
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P1016
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   McKibbin M, 2015, EYE, V29, pS1, DOI 10.1038/eye.2015.77
   Moshfeghi DM, 2016, OSLI RETINA, V47, P238, DOI 10.3928/23258160-20160229-06
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Rosenfeld PJ, 2006, N ENGL J MED, V355
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Szabo SM, 2015, CURR MED RES OPIN, V31, P2031, DOI 10.1185/03007995.2015.1084909
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Udaondo P, 2016, OPHTHALMOLOGICA, V236, P29, DOI 10.1159/000445724
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yancopoulos GD, 2010, CELL, V143, P13, DOI 10.1016/j.cell.2010.09.028
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
   Zinkernagel MS, 2016, OPHTHALMOLOGICA, V235, P42, DOI 10.1159/000441428
NR 46
TC 17
Z9 18
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2017
VL 31
IS 11
BP 1523
EP 1536
DI 10.1038/eye.2017.81
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM1QK
UT WOS:000414754600004
PM 28548650
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Jabs, DA
   Van Natta, ML
   Pak, JW
   Danis, RP
   Hunt, PW
AF Jabs, Douglas A.
   Van Natta, Mark L.
   Pak, Jeong Won
   Danis, Ronald P.
   Hunt, Peter W.
TI Incidence of Intermediate-stage Age-related Macular Degeneration in
   Patients With Acquired Immunodeficiency Syndrome
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OCULAR COMPLICATIONS; LIFE EXPECTANCY; SEVERITY SCALE; HIV-INFECTION;
   EYE DISEASE; PREVALENCE; RISK; ACTIVATION; MORTALITY; AIDS
AB PURPOSE: To evaluate the incidence of intermediate stage age-related macular degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS).
   DESIGN: Cohort study.
   METHODS: Patients enrolled in the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) underwent 5-and 10-year follow-up retinal photographs. Intermediate-stage AMD (AREDS stage 3) was determined from these photographs by graders at a centralized Reading Center, using the Age-Related Eye Disease Study-2 grading system. The incidence of AMD in LSOCA was compared with that in the Multi-Ethnic Study of Atherosclerosis (MESA), a Human Immunodeficiency Virus (HIV)-uninfected cohort, which used a similar photographic methodology.
   RESULTS: The incidence of AMD in LSOCA was 0.65/100 person-years (PY). In a multivariate analysis the only significant risk factor for AMD in LSOCA was smoking; the relative risk vs never-smokers was 3.4 for former smokers (95% confidence interval [CI] 1.3, 9.5; P =.02) and 3.3 for current smokers (95% CI 1.1, 9.7; P =.03). Compared with the MESA cohort, the race/ethnicity-and sex-adjusted risk of AMD in LSOCA was 1.75 (95% CI 1.16, 2.64; P =.008), despite the fact that the mean age of the MESA cohort was 17 years greater than the LSOCA cohort (61 9 years vs 44 8 years).
   CONCLUSIONS: Patients with AIDS have a 1.75-fold increased race-and sex-adjusted incidence of intermediate-stage AMD compared with that found in an HIV -uninfected cohort. This increased incidence is consistent with the increased incidence of other age-related diseases in antiretroviral-treated, immune-restored, HIV-infected persons when compared with HIV-uninfected persons. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, One Gustave L Levy Pl,Box 1183, New York, NY 10029 USA.
   [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Jabs, Douglas A.; Van Natta, Mark L.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Pak, Jeong Won; Danis, Ronald P.] Univ Wisconsin, Dept Ophthalmol, Sch Med & Publ Hlth, Madison, WI USA.
   [Hunt, Peter W.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; University of Wisconsin System; University of Wisconsin
   Madison; University of California System; University of California San
   Francisco
RP Jabs, DA (通讯作者)，Icahn Sch Med Mt Sinai, Dept Ophthalmol, One Gustave L Levy Pl,Box 1183, New York, NY 10029 USA.
EM douglas.jabs@mssm.edu
RI Hunt, Peter W./P-2976-2017
OI Hunt, Peter W./0000-0002-4571-4870
FU THE NATIONAL EYE INSTITUTE, THE NATIONAL INSTITUTES OF Health, Bethesda,
   Maryland [R01 EY025093]; NATIONAL EYE INSTITUTE [R01EY025093] Funding
   Source: NIH RePORTER
FX SUPPORTED BY GRANT R01 EY025093 FROM THE NATIONAL EYE INSTITUTE, THE
   NATIONAL INSTITUTES OF Health, Bethesda, Maryland, to the Icahn School
   of Medicine at Mount Sinai, New York, New York.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Altman DG., 1991, PRACTICAL STAT MED R, P241
   [Anonymous], 1992, MMWR Recomm Rep, V41, P1
   Braithwaite RS, 2008, ANN INTERN MED, V148, P178, DOI 10.7326/0003-4819-148-3-200802050-00004
   Centers for Disease Control and Prevention, 2016, HIV SURV REP 2015, V27, P4
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Edison L, 2014, MMWR-MORBID MORTAL W, V63
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Holtzer CD, 1998, AIDS, V12, P1931
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Hunt PW, 2014, J INFECT DIS, V210, P1228, DOI 10.1093/infdis/jiu238
   Jabs DA, 2007, OPHTHALMOLOGY, V114, P780, DOI 10.1016/j.ophtha.2006.11.008
   Jabs DA, 2007, OPHTHALMOLOGY, V114, P787, DOI 10.1016/j.ophtha.2006.07.065
   Jabs DA, 2015, AM J OPHTHALMOL, V159, P1115, DOI 10.1016/j.ajo.2015.01.037
   Jabs DA, 2011, AM J OPHTHALMOL, V151, P198, DOI 10.1016/j.ajo.2010.10.018
   Kaplan RC, 2007, CLIN INFECT DIS, V45, P1074, DOI 10.1086/521935
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Lohse N, 2007, ANN INTERN MED, V146, P87, DOI 10.7326/0003-4819-146-2-200701160-00003
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pathai S, 2014, J GERONTOL A-BIOL, V69, P833, DOI 10.1093/gerona/glt168
   Shouse R. L., 2009, Morbidity and Mortality Weekly Report, V58, P661
   Sugar EA, 2012, AM J OPHTHALMOL, V153, P1016, DOI 10.1016/j.ajo.2011.11.014
   Van Belle G, 2004, BIOSTATISTICS METHOD, P642
   Wang WL, 2014, LANCET, V2, pe106
NR 36
TC 9
Z9 10
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2017
VL 179
BP 151
EP 158
DI 10.1016/j.ajo.2017.05.004
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA0YY
UT WOS:000405163900018
PM 28499708
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Curtis, LH
   Hammill, BG
   Qualls, LG
   Dimartino, LD
   Wang, F
   Schulman, KA
   Cousins, SW
AF Curtis, Lesley H.
   Hammill, Bradley G.
   Qualls, Laura G.
   Dimartino, Lisa D.
   Wang, Fang
   Schulman, Kevin A.
   Cousins, Scott W.
TI Treatment Patterns for Neovascular Age-Related Macular Degeneration:
   Analysis of 284 380 Medicare Beneficiaries
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; RANIBIZUMAB
AB circle PURPOSE: To examine trends in the treatment of newly diagnosed neovascular age-related macular degeneration (AMD).
   circle DESIGN: Retrospective cohort study.
   circle METHODS: Among 284 380 Medicare beneficiaries with a new diagnosis between 2006 and 2008, we used the cumulative incidence function to estimate procedure rates and the mean frequency function to estimate the cumulative mean number of intravitreous injections. We used Cox log-binomial regression to estimate predictors of the use of vascular endothelial growth factor (VEGF) antagonists within 1 year after diagnosis. Discontinuation of anti-VEGF therapy was defined by absence of treatment for 12 months. Discontinuation rates were calculated using the Kaplan-Meier method.
   circle RESULTS: The proportion of patients receiving anti-VEGF therapy increased from 60.3% to 72.7%, photodynamic therapy decreased from 12.8% to 5.3%, and thermal laser treatment decreased from 5.5% to 3.2%. Black patients (hazard ratio, 0.77; 95% confidence interval, 0.75-0.79) and patients of other/unknown race (0.83; 0.81-0.84) were less likely than white patients to receive anti-VEGF therapy. Patients with dementia were less likely to receive anti-VEGF therapy (0.88; 0.88-0.89). Among patients who received anti-VEGF therapy, the mean number of injections within 1 year of the first injection was 4.3 per treated eye. Anti-VEGF therapy was discontinued in 53.6% of eyes within 1 year, and in 61.7% of eyes within 18 months.
   circle CONCLUSIONS: Treatment of new neovascular AMD changed significantly between 2006 and 2008, most notably in the increasing use of anti-VEGF therapies. However, few patients treated with anti-VEGF medications received monthly injections, and discontinuation rates were high. (Am J Ophthalmol 2012;153:1116-1124. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Curtis, Lesley H.; Hammill, Bradley G.; Qualls, Laura G.; Dimartino, Lisa D.; Schulman, Kevin A.] Duke Clin Res Inst, Durham, NC 27715 USA.
   [Curtis, Lesley H.; Schulman, Kevin A.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
   [Cousins, Scott W.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27706 USA.
   [Wang, Fang] GlaxoSmithKline Inc, Global Hlth Outcomes, King Of Prussia, PA USA.
C3 Duke University; Duke University; Duke University; GlaxoSmithKline
RP Curtis, LH (通讯作者)，Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.
EM lesley.curtis@duke.edu
RI DiMartino, Lisa/AAL-2835-2021
OI DiMartino, Lisa/0000-0003-1616-7406
FU GlaxoSmithKline; Duke University; Allergan; Johnson Johnson; Merck . Co;
   OSI Eyetech; Alnylam Pharmaceuticals; Amylin Pharmaceuticals; Arthritis
   Foundation; The Duke Endowment; Inspire Pharmaceuticals; Medtronic;
   Merck Co; NovaCardia; Novartis; Scios; Theravance
FX Publication of this article was supported by a research agreement
   between GlaxoSmithKline and the Duke University. The sponsor had no role
   in the design or conduct of this research. Dr Curtis reported receiving
   research support from Allergan, GlaxoSmithKline, Johnson & Johnson,
   Merck &. Co, and OSI Eyetech. Dr Wang is an employee of GlaxoSmithKline.
   Dr Schulman reported receiving research support from Alnylam
   Pharmaceuticals, Amylin Pharmaceuticals, Arthritis Foundation, The Duke
   Endowment, Inspire Pharmaceuticals, Medtronic, Merck & Co, NovaCardia,
   Novartis, OSI Eyetech, Scios, and Theravance; receiving personal income
   for consulting (<$10 000 per year) from Blue Cross and Blue Shield of
   North Carolina, The Commonwealth Fund, EnablEd, Forest Laboratories,
   GlaxoSmithKline, Merck & Co, Novartis, Novo Nordisk, Orexigen
   Therapeutics, Shire, and WebMD; having equity in Alnylam
   Pharmaceuticals, General Electric, The Manufacturers Life Insurance
   Company, PepsiCo, and Procter & Gamble; having equity in and serving on
   the hoard of directors of Cancer Consultants, Inc; having equity in and
   serving on the executive board of Faculty Connection, LLC; having equity
   in and serving as a managing member of the Physician Education
   Leadership Institute; and having equity in and serving as a managing
   member of Tellus, LLC. Drs Curtis and Schulman have made available
   online detailed listings of financial disclosures
   (http://www.dcri.dukesedu/about-us/conflict-of-interest/). No other
   disclosures were reported. Involved in study concept and design (B.G.H.,
   F.W., K.A.S., S.W.C.); analysis and interpretation of data (L.H.C.,
   B.G.H., L.D.D., F.W., S.W.C.); drafting of the manuscript (L.H.C.,
   L.G.Q., L.D.D., F.W.); critical revision of the manuscript for important
   intellectual content (B.G.H., L.D.D., L.G.Q., L.M.D., F.W., K.A.S.,
   S.W.C.); final approval of the manuscript (L.H.C., B.G.H., L.G.Q.,
   L.D.D., L.M.D., F.W., K.A.S., S.W.C.; acquisition of data (L.H.C.);
   statistical analysis (B.G.H.); obtaining funding (L.H.C., F.W.);
   literature search (L.H.C., L.D.D.); administrative, technical, or
   material support (L.G.Q., L.D.D.); and study supervision (L.H.C.,
   K.A.S.). The institutional review board of the Duke University Health
   System approved this study. Damon M. Seils, Duke University, provided
   editorial assistance and prepared the manuscript. Mr Seils did not
   receive compensation for his assistance apart from his employment at the
   institution where the study was conducted.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Centers for Medicare & Medicaid Services, MED PART B DRUG AV S
   Chang MA, 2007, RETINA-J RET VIT DIS, V27, P789, DOI 10.1097/IAE.0b013e31802c0a34
   Chronic Condition Data Warehouse, 2010, DFD
   ClinicalTrials.gov, FRENCH EV GROUP AV V
   ClinicalTrials. gov, BEV VERS RAN AG REL
   ClinicalTrials.gov, EV DOS INT HIGH DOS
   ClinicalTrials.gov, CLIN ASS AG REL MAC
   ClinicalTrials.gov, LUC ADV MAC DEG
   ClinicalTrials. gov, 2011, STUD RAN ADM MONTHL
   ClinicalTrials.gov, COMP AG REL MAC DEG
   ClinicalTrials.gov, LUCAS LUC COMP AV ST
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Ghosh D, 2000, BIOMETRICS, V56, P554, DOI 10.1111/j.0006-341X.2000.00554.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Kalbfleisch D., 1980, STAT ANAL FAILURE TI, DOI DOI 10.1016/0197-2456(81)90009-X
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mittra RA, 2008, ASRS PREFERENCES TRE
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 35
TC 48
Z9 49
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2012
VL 153
IS 6
BP 1116
EP 1124
DI 10.1016/j.ajo.2011.11.032
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 953US
UT WOS:000304899300016
PM 22321802
DA 2022-11-30
ER

PT J
AU Yildirim, Z
   Ucgun, NI
   Yildirim, F
   Sepici-Dincel, A
AF Yildirim, Zuhal
   Ucgun, Nil Irem
   Yildirim, Filiz
   Sepici-Dincel, Aylin
TI Choroidal Neovascular Membrane in Age-Related Macular Degeneration is
   Associated with Increased Interleukin-6
SO INTERNATIONAL JOURNAL OF GERONTOLOGY
LA English
DT Article
DE AMD; IL-6; IL-1 beta; inflammation; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; C-REACTIVE PROTEIN;
   COMPLEMENT ACTIVATION; EPITHELIAL-CELLS; DRUSEN; MACULOPATHY;
   EXPRESSION; ATHEROSCLEROSIS; PERMEABILITY
AB Background: Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment and blindness among persons aged 60 years and older. Although inflammation has been postulated to have a role in the pathogenesis of AMD, epidemiologic studies have not shown a relationship between systemic inflammation or presence of inflammatory markers at AMD. The aim of our study was to evaluate the differences in various types of cytokines and intracelluler signaling molecules for the onset and progression of AMD.
   Materials and methods: There were two groups in our study; Group 1, which acted as the control group (n = 30, mean age 67.60 +/- 8.32 years), and Group 2, consisting of AMD patients (n = 22, mean age 70.10 +/- 10.33 years). From serum samples, vascular endothelial growth factor (VEGF) (pg/mL), interleukin-6 (IL-6) and interleukin-1 beta (IL-1 beta) (pg/mL), nitrotyrosine (nmol/L) levels were determined by enzyme linked-immuno-sorbent assay method. Nitrite/Nitrate levels were measured by photometric method (mu mol/L).
   Results: There were no significant differences between the groups with regard to age, VEGF, IL-1 beta, nitrite/nitrate, and nitrotyrosine. The significant result was the mean IL-6 levels that were higher in the AMD group (55.03 +/- 60.03 pg/mL) than in the control group (16.08 +/- 8.24 pg/mL, p < 0.001).
   Conclusion: IL-6 induces an ocular inflammatory response often accompanied by the breakdown of the blood ocular barrier. The increased levels of IL-6 can support the hypothesis that AMD may be partially mediated through inflammatory mechanisms. Copyright (c) 2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
C1 [Yildirim, Zuhal] Etimesgut Publ Hlth Lab, TR-06770 Ankara, Turkey.
   [Ucgun, Nil Irem] Ankara Numune Training & Res Hosp, TR-06100 Ankara, Turkey.
   [Yildirim, Filiz] Duatepe Govt Hosp, Clin Internal Med, TR-06900 Ankara, Turkey.
   [Sepici-Dincel, Aylin] Gazi Univ, Dept Med Biochem, Fac Med, TR-06500 Ankara, Turkey.
C3 Ankara Numune Training & Research Hospital; Gazi University
RP Yildirim, Z (通讯作者)，Etimesgut Publ Hlth Lab, TR-06770 Ankara, Turkey.
EM zyildirim2004@yahoo.com
CR Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BORIES PN, 1995, CLIN CHEM, V41, P904
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   CUBITT CL, 1995, INVEST OPHTH VIS SCI, V36, P330
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Goldstein IM, 1996, VISION RES, V36, P2979, DOI 10.1016/0042-6989(96)00017-X
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   HOEKZEMA R, 1992, INVEST OPHTH VIS SCI, V33, P532
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   KANNEL WB, 1992, JAMA-J AM MED ASSOC, V267, P1253, DOI 10.1001/jama.267.9.1253
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011
   MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710
   Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Papapetropoulos A, 2001, J CLIN INVEST, V107, P945
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619
   RayChaudhury A, 1996, J CELL BIOCHEM, V63, P125, DOI 10.1002/(SICI)1097-4644(19961101)63:2<125::AID-JCB1>3.0.CO;2-#
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451
NR 43
TC 6
Z9 6
U1 0
U2 5
PU TAIWAN SOC GERIATRIC EMERGENCY & CRITICAL CARE MEDICINE-TSGECM
PI TAIPEI
PA 12F-14, NO 42, SEC 1, MINSHENG E RD, ZHONGSHAN DIST, TAIPEI, 104, TAIWAN
SN 1873-9598
EI 1873-958X
J9 INT J GERONTOL
JI Int. J. Gerontol.
PD JUN
PY 2012
VL 6
IS 2
BP 101
EP 104
DI 10.1016/j.ijge.2012.01.018
PG 4
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 985JU
UT WOS:000307261300008
OA Bronze
DA 2022-11-30
ER

PT J
AU Chen, FK
   Patel, PJ
   Uppal, GS
   Tufail, A
   Coffey, PJ
   Da Cruz, L
AF Chen, Fred K.
   Patel, Praveen J.
   Uppal, Gurmit S.
   Tufail, Adnan
   Coffey, Peter J.
   Da Cruz, Lyndon
TI Long-term outcomes following full macular translocation surgery in
   neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; 360-DEGREE PERIPHERAL
   RETINECTOMY; PHOTODYNAMIC THERAPY; OPHTHALMIC FINDINGS; RETINOTOMY;
   VERTEPORFIN; LESIONS; RANIBIZUMAB; BEVACIZUMAB
AB Background/aims Long-term data of macular translocation for choroidal neovascularisation (CNV) secondary to age-related macular degeneration is lacking. Therefore, we describe the 3-year acuity outcomes.
   Methods This is a retrospective, interventional case series consisting of 40 consecutive patients who underwent translocation between 2003 and 2008. Best-corrected visual acuity (BCVA) at the most recent follow-up visit was compared to that of the 1 year and pre-operative visits. Delayed post-operative complications were recorded, as diagnosed by clinical examination, spectral-domain optical coherence tomography, fundus autofluorescence imaging and angiography.
   Results The mean (range) follow-up duration was 37.6 months (range 12.4-67.4 months). Median BCVA values were 0.80, 0.70 and 0.78 log(MAR) at the baseline, 1 year and most recent visits (p=0.13). A three-line gain in BCVA was seen in 12 (30%) patients at 1 year and 10 (25%) patients at the last observation. Twenty-seven (68%) patients achieved a BCVA of 6/60 or better and six (15%) patients, 6/12 or better at the final visit. In the subset of the cohort followed for two or more years, 24 of 32 patients (75%) achieved a BCVA of 6/60 at 1 year but six of these (25%) lost two lines of BCVA thereafter due to recurrent CNV, idiopathic macular oedema, macular hole or macular pucker. Recurrent CNV developed in nine patients (23%) within the first 2 years and their final mean VA was 6/30.
   Conclusions With close post-operative monitoring and early treatment of delayed complications, 25% of this cohort maintained a three-line gain in acuity at 3 years after macular translocation.
C1 [Chen, Fred K.; Patel, Praveen J.; Uppal, Gurmit S.; Tufail, Adnan; Da Cruz, Lyndon] Moorfields Eye Hosp, Dept Vitreoretinal Surg, London EC1V 2PD, England.
   [Chen, Fred K.; Patel, Praveen J.; Coffey, Peter J.; Da Cruz, Lyndon] UCL, Inst Ophthalmol, London, England.
   [Chen, Fred K.; Patel, Praveen J.; Tufail, Adnan; Coffey, Peter J.; Da Cruz, Lyndon] NIHR Biomed Res Ctr Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London
RP Chen, FK (通讯作者)，Moorfields Eye Hosp, Dept Vitreoretinal Surg, 162 City Rd, London EC1V 2PD, England.
EM fkchen02@yahoo.com
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Tufail, Adnan/0000-0001-6131-7640; Coffey,
   Peter/0000-0002-5427-2939
FU London Project to Cure Blindness; NIHR Biomedical Research Centre for
   Ophthalmology; MRC [G1000730] Funding Source: UKRI; Medical Research
   Council [G1000730] Funding Source: researchfish
FX This study is funded by the London Project to Cure Blindness and the
   NIHR Biomedical Research Centre for Ophthalmology.
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Aisenbrey S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1367, DOI 10.1001/archopht.125.10.1367
   Baer CA, 2008, RETINA-J RET VIT DIS, V28, P1221, DOI 10.1097/IAE.0b013e31817d5bce
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Sawa M, 2008, GRAEF ARCH CLIN EXP, V246, P1087, DOI 10.1007/s00417-008-0835-2
   Semkova I, 2006, FASEB J, V20, P1689, DOI 10.1096/fj.05-5653fje
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Terasaki H, 2003, OPHTHALMOLOGY, V110, P2403, DOI 10.1016/S0161-6420(03)00829-7
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Uppal G, 2007, CLIN EXP OPHTHALMOL, V35, P448, DOI 10.1111/j.1442-9071.2007.01528.x
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
NR 25
TC 21
Z9 23
U1 1
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2010
VL 94
IS 10
BP 1337
EP 1343
DI 10.1136/bjo.2009.172593
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 666FB
UT WOS:000283097700016
PM 20494910
DA 2022-11-30
ER

PT J
AU Berdeaux, GH
   Nordmann, JP
   Colin, E
   Arnould, B
AF Berdeaux, GH
   Nordmann, JP
   Colin, E
   Arnould, B
TI Vision-related quality of life in patients suffering from age-related
   macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; EYE CATARACT-SURGERY; ANGELES LATINO EYE;
   BLUE MOUNTAINS EYE; BEAVER DAM EYE; 5-YEAR INCIDENCE; MACULOPATHY;
   ACUITY; PERCEPTIONS; IMPAIRMENT
AB PURPOSE: To evaluate the relative impact of best and worst eye on vision-related quality of life in patients suffering from age-related macular degeneration (AMD).
   DESIGN: Quality of life and visual acuity data were collected at baseline during a randomized clinical trial.
   METHODS: SETTING: Multicenter (11 centers), international study. PATIENTS: One hundred fourteen patients with a diagnosis of exudative AMD and primary or recurrent subfoveal neovascular membrane (greatest linear dimension of lesion less than or equal to5400 mum; greater than or equal to50% of the total lesion was choroidal neovascularization (CNV); classic component of the total CNV greater than or equal to 1.0 mm(2)). All patients were over age 50 years, of any race, either sex. INTERVENTION OR OBSERVATION PROCEDURE: NEI-VFQ-39 questionnaire administered to patients at home by trained telephone interviewers. MAIN OUTCOME MEASURES: ETDRS visual acuity (VA) was measured in both eyes separately. Vision-related quality of life (QoL) was assessed using the NEI-VFQ-39. An analysis of variance was performed on the NEI-VFQ scores, including best eye VA (VA > 20/40 vs VA less than or equal to 20/40), worst eye VA (VA > 20/200 vs VA less than or equal to 20/200), and the interaction between the two as independent variables.
   RESULTS: Best eye VA was 0.34 on average, with VA > 20/40 in 43.0% of patients. Worst eye VA was 0.85 on average, with VA > 20/200 in 32.5% of patients. VA was not linked to general health and ocular pain scores. General Vision, Near Activities, Distance Vision, Driving, Mental Health, Role Difficulties, Dependency, Peripheral Vision, and the Global NEI-VFQ scores were affected by both best eye VA and worst eye VA.
   CONCLUSION: In the study sample, worst eye VA less than or equal to20/200) and best eye VA (less than or equal to20/40) contributed independently to vision,related QoL. These results suggest that preserving a minimal visual acuity in the worst eye may contribute to vision-related quality of life.
C1 Alcon Res Ltd, F-92563 Rueil Malmaison, France.
   Ctr Hosp 15 20, Paris, France.
   Mapi Values, Macclesfield, Cheshire, England.
   Mapi Values, Lyon, France.
C3 Novartis; Alcon; UDICE-French Research Universities; Sorbonne Universite
RP Berdeaux, GH (通讯作者)，Alcon Res Ltd, 4 Rue Henri St Claire Deville, F-92563 Rueil Malmaison, France.
EM Gilles.Berdeaux@AlconLabs.com
CR [Anonymous], 1991, OPHTHALMOL, V98, P741
   Azen SP, 2002, INVEST OPHTH VIS SCI, V43, P1742
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 1998, INT OPHTHALMOL, V22, P307, DOI 10.1023/A:1006311910304
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Chassany O, 2002, DRUG INF J, V36, P209, DOI 10.1177/009286150203600127
   Chia EM, 2003, BRIT J OPHTHALMOL, V87, P392, DOI 10.1136/bjo.87.4.392
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Deramo VA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1297, DOI 10.1001/archopht.121.9.1297
   Elliott DB, 2000, OPTOMETRY VISION SCI, V77, P13, DOI 10.1097/00006324-200001000-00009
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gardiner AM, 2002, BRIT J OPHTHALMOL, V86, P993, DOI 10.1136/bjo.86.9.993
   Globe DR, 2004, OPHTHALMOLOGY, V111, P1141, DOI 10.1016/j.ophtha.2004.02.003
   Hart PM, 1998, EYE, V12, P124, DOI 10.1038/eye.1998.20
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P686, DOI 10.1001/archopht.1993.01090050120041
   JAVITT JC, 1995, OPHTHALMOLOGY, V102, P1583
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Laidlaw DAH, 1998, LANCET, V352, P925, DOI 10.1016/S0140-6736(97)12536-3
   Leibowitz HM, 1980, SURV OPHTHALMOL S, V24
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MANGIONE CM, 1997, IN PRESS NATL EYE I
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Nelson-Quigg JM, 2000, INVEST OPHTH VIS SCI, V41, P2212
   Nichols KK, 2002, CORNEA, V21, P578, DOI 10.1097/00003226-200208000-00009
   Nordmann JP, 2004, PHARMACOECONOMICS, V22, P197, DOI 10.2165/00019053-200422030-00005
   Nunnally J., 1978, PSYCHOMETRIC THEORY
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WEINBERGER M, 1994, J AM GERIATR SOC, V42, P1295, DOI 10.1111/j.1532-5415.1994.tb06515.x
NR 43
TC 70
Z9 74
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2005
VL 139
IS 2
BP 271
EP 279
DI 10.1016/j.ajo.2004.09.028
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 903VR
UT WOS:000227454200009
PM 15733988
DA 2022-11-30
ER

PT J
AU Gupta, B
   Adewoyin, T
   Patel, SK
   Sivaprasad, S
AF Gupta, Bhaskar
   Adewoyin, Temilade
   Patel, Sheryl-Kay
   Sivaprasad, Sobha
TI Comparison of two intravitreal ranibizumab treatment schedules for
   neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Introduction Ranibizumab (Lucentis), a humanised antibody fragment that inhibits vascular endothelial growth factor (VEGF)-A, is widely used for the treatment of neovascular age-related macular degeneration (NV-AMD). The objective of this study was to compare the outcomes of two different treatment protocols: loading dose (LD) and pro re nata (PRN (as needed)) dosing schedule from baseline.
   Methods This retrospective chart review was conducted at King's College Hospital, London, UK. Consecutive patients were identified using the 'Ranibizumab in NV-AMD' database. These patients had treatment-naive choroidal neovascularisation (CNV) secondary to AMD, received ranibizumab therapy and had completed 12 months of follow-up. Baseline examination included visual acuity (Early Treatment Diabetic Retinopathy Study (ETDRS) letters), slit-lamp biomicroscopy, fluorescein angiography, and qualitative and quantitative assessment of central macular characteristics on optical coherent tomography (OCT). Intravitreal ranibizumab (0.5 mg/0.05 ml) was given to all patients at baseline. Patients on LD regimen received two further consecutive monthly intravitreal ranibizumab injections independent of clinical findings. Further injections were determined by the same re-treatment criteria as patients on PRN schedule from baseline. The main outcome variables in the two treatment groups were visual acuity and central macular thickness at different time points.
   Results The LD group contained 47 patients and the PRN group contained 31 patients. There were no significant differences between groups in the mean changes in visual acuity or central macular thickness. Visual acuity was similar in both groups at 6 months. However, twice as many patients improved visual acuity by 15 or more letters in the LD group (29.8% in the LD group compared with 12.9% in the PRN group (p=0.01)).
   Conclusion This study showed that standard protocols used for OCT-guided retreatment achieved smaller mean gains in vision than those obtained with monthly ranibizumab administration. Further, loading doses of ranibizumab resulted in more visual gains than the PRN protocol.
C1 [Gupta, Bhaskar; Adewoyin, Temilade; Patel, Sheryl-Kay; Sivaprasad, Sobha] Kings Coll Hosp London, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Denmark Hill, London SE5 9RS, England.
EM Sobha.sivaprasad@nhs.net
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Gupta, Bhaskar/0000-0002-2122-3559
FU Novartis; Pfizer; Allergan
FX SS has received research and travel grants from Novartis, Pfizer and
   Allergan.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   KIRCHHOF B, 2009, INVEST OPHTHALMOL VI, V50
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   NEUNERJEHLE M, 2009, INVEST OPHTHALMOL VI, V50
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Squirrell DM, 2010, RETINA-J RET VIT DIS, V30, P436, DOI 10.1097/IAE.0b013e3181bd2f29
NR 12
TC 38
Z9 41
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2011
VL 95
IS 3
BP 386
EP 390
DI 10.1136/bjo.2010.179499
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 722NY
UT WOS:000287440400017
PM 20693484
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Pham, TQ
   Kifley, A
   Mitchell, P
   Wang, JJ
AF Pham, Thuan Quoc
   Kifley, Annette
   Mitchell, Paul
   Wang, Jie Jin
TI Relation of age-related macular degeneration and cognitive impairment in
   an older population
SO GERONTOLOGY
LA English
DT Article
DE age-related macular degeneration; Blue Mountains Eye Study; cognitive
   impairment; mini-mental state examination
ID MENTAL-STATE-EXAMINATION; NURSING-HOME RESIDENTS; VISUAL IMPAIRMENT;
   ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; MACULOPATHY; DEMENTIA; RISK;
   AUSTRALIA; SMOKING
AB Background: The aetiology of age-related macular degeneration (AMD) and cognitive impairment is poorly understood. A link between cognitive impairment and AMD has been proposed although only a weak association was found in population-based studies. Purpose: To assess cross-sectional associations between AMD and cognitive impairment in an older Australian population. Methods: The Blue Mountains Eye Study examined 3,509 persons aged 49+ years during 1997-2000. AMD lesions were assessed from retinal photographs using the Wisconsin System. Mini-mental state examination (MMSE), demographics, lifestyle factors and medical history were collected at interview. MMSE score was categorised as high-normal (28-30), low-normal (24-27) and impaired (< 24). A modified MMSE excluded five vision related items and was dichotomised as normal (18-22) and impaired (0-17). Logistic regression was used to assess associations after adjusting for age, sex, visual impairment, stroke, current smoking status, hypertension, alcohol consumption and post-high-school qualification. Results: Prevalence rates for late and early AMD were 1.5% (n = 50) and 8.3% (n = 273), respectively. Cognitive impairment was present in 18.0% in persons with late AMD and 8.4% with early AMD, compared to 2.6% in persons without AMD. After multivariate adjustment, late AMD was associated with low normal MMSE (odds ratio (OR): 2.2, 95% confidence interval (CI): 1.1-5.0) and cognitive impairment (OR: 3.7, CI: 1.3-10.6). Using the modified MMSE, the multivariate association between late AMD and cognitive impairment remained (OR: 2.2, CI: 1.0-5.0). No significant association was found between cognitive impairment and early AMD. Conclusions: We found a significant, cross-sectional association between late AMD and cognitive impairment in a sample of older Australians that appeared to be independent of visual impairment. The association was weaker but remained significant after excluding vision-related items from the MMSE. Copyright (c) 2006 S. Karger AG, Basel.
C1 Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res,Westmead Millennium Inst, Westmead, NSW 2145, Australia.
C3 University of Sydney; Westmead Institute for Medical Research
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res,Westmead Millennium Inst, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR Anstey KJ, 2001, J GERONTOL B-PSYCHOL, V56, pP3, DOI 10.1093/geronb/56.1.P3
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Baltes PB, 1997, PSYCHOL AGING, V12, P12, DOI 10.1037/0882-7974.12.1.12
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   Dentchev T, 2003, MOL VIS, V9, P184
   Evans DA, 1997, JAMA-J AM MED ASSOC, V277, P822, DOI 10.1001/jama.277.10.822
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Giannakopoulos P, 1997, BRAIN RES REV, V25, P217, DOI 10.1016/S0165-0173(97)00023-4
   Greiner PA, 1996, AM J PUBLIC HEALTH, V86, P62, DOI 10.2105/AJPH.86.1.62
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LINDENBERGER U, 1994, PSYCHOL AGING, V9, P339, DOI 10.1037/0882-7974.9.3.339
   Mitchell P, 1997, MED J AUSTRALIA, V166, P73, DOI 10.5694/j.1326-5377.1997.tb138724.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mrak RE, 1997, J NEUROPATH EXP NEUR, V56, P1269, DOI 10.1097/00005072-199712000-00001
   Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7
   Reischies FM, 1997, BRIT J PSYCHIAT, V171, P449, DOI 10.1192/bjp.171.5.449
   Salthouse TA, 1996, J GERONTOL B-PSYCHOL, V51, pP317, DOI 10.1093/geronb/51B.6.P317
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SEVERSON MA, 1994, J AM GERIATR SOC, V42, P181
   Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P3, DOI 10.1076/opep.10.1.3.13773
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   West SK, 2003, OPHTHALMIC EPIDEMIOL, V10, P193, DOI 10.1076/opep.10.3.193.15081
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
NR 30
TC 71
Z9 73
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0304-324X
EI 1423-0003
J9 GERONTOLOGY
JI Gerontology
PY 2006
VL 52
IS 6
BP 353
EP 358
DI 10.1159/000094984
PG 6
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 102MS
UT WOS:000241816800004
PM 16902306
DA 2022-11-30
ER

PT J
AU Sharma, S
   Khan, M
   Chaturvedi, A
   Anandkumar, MB
   Jain, S
   Murthy, H
   Murlidhar, NS
   Hirawat, RS
   Sudhalkar, A
   Deka, A
   Banker, A
   Parikh, V
   Agarwal, M
   Mithal, C
   Singh, RP
   Kulkarni, D
   Desai, A
   Naigaonkar, R
   Borse, N
   Saikia, SP
   Sahu, AK
   Mange, S
   Chakraborty, A
   Roy, S
   Surong, V
AF Sharma, Shashikant
   Khan, Mujtaba
   Chaturvedi, Alok
   Anandkumar, Manjunath Bhaskar
   Jain, Sangita
   Murthy, Hemanth
   Murlidhar, Naveenam Srinivasa
   Hirawat, Raj Shri
   Sudhalkar, Aditya
   Deka, Amarendra
   Banker, Alay
   Parikh, Vatsal
   Agarwal, Manisha
   Mithal, Charu
   Singh, Rajender Pal
   Kulkarni, Deepti
   Desai, Abhishek
   Naigaonkar, Rushikesh
   Borse, Nishikant
   Saikia, Simanta Pradeep
   Sahu, Atul Kumar
   Mange, Shobhna
   Chakraborty, Arup
   Roy, Suprakash
   Surong, Valensha
CA RE-ENACT 2 Study Investigators Grp
TI A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab
   (TM) (World's First Biosimilar Ranibizumab) in Wet Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF; Biosimilar ranibizumab; Wet
   AMD
ID INTRAOCULAR-PRESSURE; VISUAL-ACUITY; PREVALENCE; AFLIBERCEPT; MORPHOLOGY
AB Introduction The REal life assessmENt of safety And effeCTiveness of Razumab (RE-ENACT) and long-term RE-ENACT 2 retrospective studies have evaluated the use of Razumab (TM) (world's first biosimilar ranibizumab) in retinal disorders in Indian patients. This report presents the subgroup analysis from the RE-ENACT 2 study in patients with wet age-related macular degeneration (wet AMD). Methods Medical charts of patients administered biosimilar ranibizumab injections as PRN treatment regimen between September 2015 and June 2018, at 17 centers across India, were reviewed. Changes from baseline in best-corrected visual acuity (BCVA, based on Snellen's or logMAR chart), central subfield thickness (CSFT), intraocular pressure (IOP), and proportions of patients having intraretinal fluid (IRF) and subretinal fluid (SRF) at weeks 4, 8, 12, 16, 20, 24, 30, 36, and 48 were evaluated. Results Of 103 patients with wet AMD, 62.1% were men and the majority (74.8%) were treatment naive. The majority (57.9%) of the patients had received 3 (range 1-5) injections. Significant improvements were observed from baseline to all timepoints for BCVA (baseline, 0.92 +/- 0.6 [n = 94]; week 48, 0.51 +/- 0.4 [n = 14]; P = 0.0014) and CSFT (baseline, 430.83 +/- 14.4 [n = 85]; week 48, 301.26 +/- 11.6 [n = 15]; P < 0.0001). Changes in IOP from baseline to 48 weeks were minimal and not significant (14.92 +/- 3.2 [n = 94] vs. 14.50 +/- 2.1 [n = 18]; P = 0.9068). A decrease in proportions of patients having IRF (baseline, 63.6% [n = 99] vs. week 48, 15% [n = 20]) and SRF (baseline, 82.3% [n = 96] vs. week 48, 5% [n = 20]) were also observed. Similar results were observed for occult and classic subgroups. There were no new safety concerns. Conclusion Razumab (biosimilar ranibizumab) demonstrated improvements in visual acuity and disease outcomes in patients with wet age-related macular degeneration without new safety issues.
C1 [Sharma, Shashikant; Khan, Mujtaba; Chaturvedi, Alok] Intas Pharmaceut Ltd, Med Serv, Ahmadabad, Gujarat, India.
   [Anandkumar, Manjunath Bhaskar] Ganesh Netralaya, Sirsi 581401, Karnataka, India.
   [Jain, Sangita] Dev Bhumi Superspecial Hosp, Dehra Dun 248001, Uttarakhand, India.
   [Murthy, Hemanth; Murlidhar, Naveenam Srinivasa] Retina Inst Karnataka, Bangalore 560018, Karnataka, India.
   [Hirawat, Raj Shri] Gomabai Netralaya, Neemuch 458441, Madhya Pradesh, India.
   [Sudhalkar, Aditya] Sudhalkar Eye Hosp, Baroda, Gujarat, India.
   [Deka, Amarendra; Saikia, Simanta Pradeep; Surong, Valensha] Mission Netralaya, Shillong 793014, Meghalaya, India.
   [Banker, Alay] Banker Retina Clin & Laser Ctr, Ahmadabad 380009, Gujarat, India.
   [Parikh, Vatsal] Drushti Eye & Retina Ctr, Mumbai 400004, Maharashtra, India.
   [Agarwal, Manisha] Shroff Char Eye Hosp, New Delhi 110002, India.
   [Mithal, Charu; Singh, Rajender Pal] Visitech Jasola Eye Ctr, New Delhi 110025, India.
   [Kulkarni, Deepti] Ameya Laser & Res Pvt Ltd, Miraj 416410, Maharashtra, India.
   [Desai, Abhishek; Naigaonkar, Rushikesh] Shri Ganpati Netralaya, Jalna 431203, Maharashtra, India.
   [Borse, Nishikant] Insight Eye Clin, Mumbai 400014, Maharashtra, India.
   [Sahu, Atul Kumar] RKN Eye Care, Varanasi 221010, Uttar Pradesh, India.
   [Mange, Shobhna] Shivam Retina Clin, Surat 395001, Gujarat, India.
   [Chakraborty, Arup] Amulya Jyoti Eye Fdn, Kolkata 700029, W Bengal, India.
   [Roy, Suprakash] Nivedita Eye Care & Microsurg Ctr, Bankura 722141, W Bengal, India.
RP Sharma, S (通讯作者)，Intas Pharmaceut Ltd, Med Serv, Ahmadabad, Gujarat, India.
EM shashikant_sharma@intaspharma.com; manj009@gmail.com;
   san-gitavrs@yahoo.co.uk; hemanth-murthy@yahoo.com; retina.nsm@gmail.com;
   drrajshreehi-rawat@gmail.com; adityasudhalkar@yahoo.com;
   dradeka@icloud.com; alay.banker@gmail.com; vatsal@-drushti.com;
   agarwalmannii@yahoo.co.in; drcharu_mithal@yahoo.co.in;
   jasola.vis-itech@gmail.com; deepti.ameya@gmail.com; drabhisid@gmail.com;
   rushikesh.naigaonkar@netralaya.org; nishikantborse@yahoo.com;
   jeet-saikia@yahoo.com; atulkrsahu@gmail.com; shobha_72@ya-hoo.com;
   drarupchak@gmail.com; dr.suprakashroy@gmail.-com;
   valenshasurong@yahoo.com
RI Agarwal, Manisha/GXH-6695-2022
OI Agarwal, Manisha/0000-0002-9621-0875; SHARMA, DR
   SHASHIKANT/0000-0002-7220-653X
FU Intas Pharmaceuticals Ltd
FX RE-ENACT 2 Study Investigator Group received an honorarium from Intas
   Pharmaceuticals Ltd. for their patient data contribution. Intas
   Pharmaceuticals Ltd supported the journal's rapid service fee. All
   authors had full access to all of the data in this study and take
   complete responsibility for the integrity of the data and accuracy of
   the data analysis.
CR Alexandru Malciolu Radu, 2016, Rom J Ophthalmol, V60, P9
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Desideri LF, 2019, EXPERT OPIN BIOL TH, V19, P735, DOI 10.1080/14712598.2019.1627322
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Figurska M, 2011, MED SCI MONITOR, V17, pCR485, DOI 10.12659/MSM.881934
   Freund KB, 2015, OPHTHALMOLOGY, V122, P1802, DOI 10.1016/j.ophtha.2015.04.018
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Lai TYY, 2018, RETINA-J RET VIT DIS, V38, P1464, DOI 10.1097/IAE.0000000000001744
   Mekjavic PJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00125
   Qi HJ, 2017, INT J OPHTHALMOL-CHI, V10, P91, DOI 10.18240/ijo.2017.01.15
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2014, RETINA TODAY, P63
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sameera VV., 2016, KERALA J OPHTHALMOL, V28, P180, DOI [DOI 10.4103/KJO.KJO_18_17, 10.4103/kjo.kjo_18_17]
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Sharma S., 2018, INT J OPHTHALMOL EYE, V6, P368
   Sharma S., 2018, INT J OPHTHALMOL EYE, V6, P377
   Sharma S, 2019, OPHTHALMOLOGICA, V241, P24, DOI 10.1159/000488602
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Sivaprasad S, 2013, BRIT MED BULL, V105, P201, DOI 10.1093/bmb/ldt004
   Thapa R, 2017, CLIN OPHTHALMOL, V11, P963, DOI 10.2147/OPTH.S132338
   Topal T, 2017, TURK OFTALMOL DERG, V47, P133, DOI 10.4274/tjo.34735
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
NR 34
TC 18
Z9 18
U1 0
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD MAR
PY 2020
VL 9
IS 1
BP 103
EP 114
DI 10.1007/s40123-019-00228-7
EA DEC 2019
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KT2AP
UT WOS:000504587200001
PM 31883056
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mullins, RF
   Skeie, JM
   Folk, JC
   Solivan-Timpe, FM
   Oetting, TA
   Huang, J
   Wang, K
   Stone, EM
   Fingert, JH
AF Mullins, Robert F.
   Skeie, Jessica M.
   Folk, James C.
   Solivan-Timpe, Frances M.
   Oetting, Thomas A.
   Huang, Jian
   Wang, Kai
   Stone, Edwin M.
   Fingert, John H.
TI Evaluation of variants in the selectin genes in age-related macular
   degeneration
SO BMC MEDICAL GENETICS
LA English
DT Article
ID CHOROIDAL NEOVASCULAR MEMBRANES; HUMAN ENDOTHELIAL-CELLS; P-SELECTIN;
   EXPRESSION; MACROPHAGE; DRUSEN; LEUKOCYTES; INJURY; ICAM-1; EYES
AB Background: Age-related macular degeneration (AMD) is a common disease of the elderly that leads to loss of the central visual field due to atrophic or neovascular events. Evidence from human eyes and animal models suggests an important role for macrophages and endothelial cell activation in the pathogenesis of AMD. We sought to determine whether common ancestral variants in genes encoding the selectin family of proteins are associated with AMD.
   Methods: Expression of E-selectin, L-selectin and P-selectin was examined in choroid and retina by quantitative PCR and immunofluorescence. Samples from patients with AMD (n = 341) and controls (n = 400) were genotyped at a total of 34 SNPs in the SELE, SELL and SELP genes. Allele and genotype frequencies at these SNPs were compared between AMD patients and controls as well as between subtypes of AMD (dry, geographic atrophy, and wet) and controls.
   Results: High expression of all three selectin genes was observed in the choroid as compared to the retina. Some selectin labeling of retinal microglia, drusen cores and the choroidal vasculature was observed. In the genetic screen of AMD versus controls, no positive associations were observed for SELE or SELL. One SNP in SELP (rs3917751) produced p-values < 0.05 (uncorrected for multiple measures). In the subtype analyses, 6 SNPs (one in SELE, two in SELL, and three in SELP) produced p-values < 0.05. However, when adjusted for multiple measures with a Bonferroni correction, only one SNP in SELP (rs3917751) produced a statistically significant p-value (p = 0.0029).
   Conclusions: This genetic screen did not detect any SNPs that were highly associated with AMD affection status overall. However, subtype analysis showed that a single SNP located within an intron of SELP (rs3917751) is statistically associated with dry AMD in our cohort. Future studies with additional cohorts and functional assays will clarify the biological significance of this discovery. Based on our findings, it is unlikely that common ancestral variants in the other selectin genes (SELE and SELL) are risk factors for AMD. Finally, it remains possible that sporadic or rare mutations in SELE, SELL, or SELP have a role in the pathogenesis of AMD.
C1 [Mullins, Robert F.; Skeie, Jessica M.; Folk, James C.; Solivan-Timpe, Frances M.; Oetting, Thomas A.; Stone, Edwin M.; Fingert, John H.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Huang, Jian] Univ Iowa, Dept Stat & Actuarial Sci, Iowa City, IA 52242 USA.
   [Wang, Kai] Univ Iowa, Dept Biostat, Iowa City, IA 52242 USA.
   [Stone, Edwin M.] Howard Hughes Med Inst, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; University of Iowa; Howard
   Hughes Medical Institute
RP Fingert, JH (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM john-fingert@uiowa.edu
RI Fingert, John/F-8787-2012; Fingert, John/AAX-4750-2021; Mullins, Robert
   F/I-6717-2013
OI Fingert, John/0000-0002-0377-0479; Fingert, John/0000-0002-0377-0479;
   Folk, James/0000-0002-6271-2906; Stone, Edwin M./0000-0003-3343-4414;
   Mullins, Robert/0000-0002-5006-0891; Oetting, Thomas/0000-0003-1764-610X
FU Macula Vision Research Foundation; Hansjoerg EJW Kolder MD;  [R01
   EY017451];  [EY016822];  [EY018825]; NATIONAL EYE INSTITUTE
   [R01EY016822, F32EY022280, R01EY017451, R01EY018825] Funding Source: NIH
   RePORTER
FX Supported in part by R01 EY017451 (RFM), EY016822 (EMS), EY018825 (JHF),
   Research to Prevent Blindness (JHF), the Macula Vision Research
   Foundation (RFM), and the Hansjoerg EJW Kolder MD, PhD Professorship in
   Best Disease Research (RFM).
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bless NM, 1998, AM J PATHOL, V153, P1113, DOI 10.1016/S0002-9440(10)65655-6
   Bojanowski Christine M, 2005, Trans Am Ophthalmol Soc, V103, P37
   BOJANOWSKI CM, 2005, T AM OPHTHAL SOC, V103, P44
   Carden D, 1998, AM J PHYSIOL-HEART C, V275, pH385, DOI 10.1152/ajpheart.1998.275.2.H385
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DONNELLY SC, 1994, LANCET, V344, P215, DOI 10.1016/S0140-6736(94)92995-5
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RF, 2005, MOL VIS, V11, P509
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2007, INVEST OPHTH VIS SCI, V48, P3372, DOI 10.1167/iovs.06-0868
   PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Rahman A, 1998, AM J PHYSIOL-LUNG C, V275, pL533, DOI 10.1152/ajplung.1998.275.3.L533
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sarks S., 1985, RETINAL DIS, P87
   SKEIE J, 2008, EYE
   Sperandio M, 2009, IMMUNOL REV, V230, P97, DOI 10.1111/j.1600-065X.2009.00795.x
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Zhou JH, 2005, MOL VIS, V11, P414
NR 36
TC 10
Z9 10
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD APR 26
PY 2011
VL 12
AR 58
DI 10.1186/1471-2350-12-58
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 766RX
UT WOS:000290805300001
PM 21521525
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Smiddy, WE
AF Smiddy, William E.
TI Relative cost of a line of vision in age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; CHOROIDAL NEOVASCULARIZATION SECONDARY; PHOTODYNAMIC
   THERAPY; DIABETIC-RETINOPATHY; TRIAMCINOLONE ACETONIDE; INTRAVITREAL
   INJECTION; UTILITY VALUES; HOLE SURGERY; VERTEPORFIN; VITRECTOMY
AB Purpose: To quantitate the relative cost of new therapies for age-related macular degeneration (AMD) versus saved vision.
   Design: Systematic review.
   Methods: Landmark AMD treatment studies were reviewed to quantitate the visual benefit. For comparison, representative treatment studies for common retinal conditions including retinal detachment, macular hole (MH), epiretinal membrane (ERM), and diabetic retinopathy were also reviewed.
   Main Outcome Measures: Several parameters to estimate Snellen lines of vision saved were defined and tabulated for each condition. A regimen of office visits, ancillary testing, and treatments was outlined. Costs for this were tabulated using Medicare-allowable costs, and costs of visual benefit (per line of vision) for each condition were calculated. Life expectancy was factored in to calculate the cost of a line of vision for each year (line-year). The proportions of costs allocated to professional, technical, and pharmaceutical expenses were tabulated for each therapy.
   Results: The cost per line of vision saved for AMD therapies ranged from $997 for laser for extrafoveal choroidal neovascularization, to $5509 for photodynamic therapy for occult lesions, to $12 482 for pegaptanib injections. This compares to $651 for retinal detachment repair, $1658 for MH repair, $2411 for ERM peeling, $5458 for diabetic macular edema laser, $594 for panretinal photocoagulation, and $2984 to $4178 for diabetic vitrectomy. The costs per line-years ranged from $77 to $1248 for AMD, and $21 to $194 for the comparison conditions. The proportion of costs for pegaptanib treatment was 17% for professional fees and 70% for pharmaceutical fees. Assumptions incorporated in estimating costs for pegaptanib could easily have doubled because second-year costs might approximate first-year costs and the maintenance of treatment effect has not been well established.
   Conclusions: Although correctly heralded as a breakthrough in macular degeneration treatment, new pharmacologic therapies for AMD are extremely expensive and some yield marginal visual dividends. As in all fields of medicine that provide care to elderly patients, these costs should be considered as they relate to health care costs for the individual patient and payors, and must be considered in a larger perspective of health care benefit apportionment.
C1 Univ Miami, Dept Ophthalmol, Bascom Palmer Eye Inst, Miller Sch Med, Miami, FL 33152 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Smiddy, WE (通讯作者)，900 NW 17th St,255, Miami, FL 33136 USA.
EM wsmiddy@med.miami.edu
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1988, OPHTHALMOLOGY, V95, P1307
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brooks HL, 2000, OPHTHALMOLOGY, V107, P1939, DOI 10.1016/S0161-6420(00)00331-6
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Burton T C, 1982, Trans Am Ophthalmol Soc, V80, P475
   BURTON TC, 1977, T AM ACAD OPHTHALMOL, V83, P499
   *EARL TREATM DIAB, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI DOI 10.1001/ARCHOPHT.1985.01050120030015
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   JAVITT JC, 1990, OPHTHALMOLOGY, V97, P483, DOI 10.1016/S0161-6420(90)32573-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Mester V, 2000, AM J OPHTHALMOL, V129, P769, DOI 10.1016/S0002-9394(00)00358-5
   MICHELS RG, 1984, OPHTHALMOLOGY, V91, P1384
   Michels S, 2005, KLIN MONATSBL AUGENH, V222, P480, DOI 10.1055/s-2005-858315
   NATALONI R, 2006, RETINAL PHYS     JAN, P53
   Polk TD, 1996, OPHTHALMOLOGY, V103, P422
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Sharma S, 2003, BRIT J OPHTHALMOL, V87, P259, DOI 10.1136/bjo.87.3.259
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   SMIDDY WE, 1995, OPHTHALMOLOGY, V102, P1688
   Smiddy WE, 1997, OPHTHALMIC SURG LAS, V28, P713
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   The Diabetic Retinopathy Study Research Group, 1979, ARCH OPHTHALMOL-CHIC, V97, P654
   The Diabetic Retinopathy Vitrectomy Study Research Group, 1985, ARCH OPHTHALMOL-CHIC, V103, P1644
   WENDEL RT, 1993, OPHTHALMOLOGY, V100, P1671
   WILLIAM GA, 2004, VITREORETINAL SURG T, V13, P1
NR 41
TC 27
Z9 27
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2007
VL 114
IS 5
BP 847
EP 854
DI 10.1016/j.ophtha.2006.10.038
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 163KM
UT WOS:000246158500004
PM 17306878
DA 2022-11-30
ER

PT J
AU Kijlstra, A
   La Heij, EC
   Hendrikse, F
AF Kijlstra, A
   La Heij, EC
   Hendrikse, F
TI Immunological factors in the pathogenesis and treatment of age-related
   macular degeneration
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Review
DE age-related macular degeneration; retinal transplantation;
   anti-inflammatory drugs; Chlamydia pneumoniae; complement system
ID PIGMENT EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL
   TRIAMCINOLONE ACETONIDE; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   CHLAMYDIA-PNEUMONIAE INFECTION; NEURAL RETINAL TRANSPLANTATION; TERM
   FOLLOW-UP; BRUCHS MEMBRANE; AUTOLOGOUS TRANSPLANTATION; COMPLEMENT
   ACTIVATION
AB Recent findings indicate that Immunological factors are involved not only in the pathogenesis of age-related macular degeneration (AMD), but also in its treatment. Earlier data showing the presence of inflammatory cells in affected areas of AMD retinas support this statement. Although a possible role for autoimmunity was initially suggested, it has never reached general acceptance. Microorganisms have also been implied in the pathogenesis of AMD. Both serum antibacterial antibody levels and positive DNA tests from neovascular membranes have pointed to a possible role for Chlamydia pneumoniae in the pathogenesis of AMD. New data is providing evidence for the hypothesis that deposits between Bruch's membrane and the retinal pigment epithelium (RPE) cell layer may act as a stimulus for the local activation of the complement system. This may lead to a further growth of the deposits due to the strong chemotactic activity of certain complement activation products (such as C5a) with an influx of inflammatory cells. The buildup of cells and extracellular deposits may lead to local ischemia resulting in the activation of RPE cells. These activated RPE cells are thought to release angiogenic stimuli leading to choroidal neovascularization, which is the most serious complication of AMD. The fact that immunosuppressive drugs such as triamcinolone acetonide and anecortave acetate are capable of inhibiting choroidal neovascularization is consistent with an inflammatory component in the pathogenesis of AMD. Specific immunotherapy directed at certain cytokines or growth factors is now being investigated at both the animal and patient levels. Various clinical trials involving engineered antibodies are now being applied to block angiogenic factors such as the vascular endothelial growth factor (VEGF). An approach using gene therapy to influence angiogenesis by inducing the production of the pigment epithelium-derived factor (PEDF) was able to block neovascularization in an experimental murine model. Besides trying to block ongoing processes in AMD, retinal transplantation is now also being investigated as a treatment option. The fact that the retina is possibly an immunoprivileged tissue in combination with experimental data showing that the subretinal space is an immunoprivileged site is an indication that transplantation would not suffer from the rejection process. A larger obstacle is the question whether transplanted retinal tissue will regain its functional properties.
C1 Univ Maastricht, Dept Ophthalmol, Eye Res Inst Maastricht, Maastricht, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC)
RP Kijlstra, A (通讯作者)，Univ Hosp Maastricht, Dept Ophthalmol, Eye Res Inst Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM aize.kijlstra@wur.nl
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Berger AS, 2003, OPHTHALMOLOGY, V110, P383, DOI 10.1016/S0161-6420(02)01738-4
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Chen L, 2003, CURR EYE RES, V26, P291, DOI 10.1076/ceyr.26.4.291.15432
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   de Smet MD, 2001, PROG RETIN EYE RES, V20, P761, DOI 10.1016/S1350-9462(01)00011-8
   del Cerro M, 2000, INVEST OPHTH VIS SCI, V41, P3142
   Dentchev T, 2003, MOL VIS, V9, P184
   DOEKES G, 1987, CURR EYE RES, V6, P909, DOI 10.3109/02713688709034859
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   FORRESTER JV, 1994, INVEST OPHTH VIS SCI, V35, P64
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gouras P, 2003, GRAEF ARCH CLIN EXP, V241, P403, DOI 10.1007/s00417-003-0648-2
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Holtkamp GM, 1999, CLIN EXP IMMUNOL, V118, P35
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Holz FG, 2003, BIOMED TECH, V48, P82
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   KALAYOGLU MV, 2003, INVEST OPHTHALMOL VI, V45
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kohen L, 1997, OPHTHALMIC RES, V29, P298, DOI 10.1159/000268028
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   Ma NL, 1998, INVEST OPHTH VIS SCI, V39, P2384
   Martin JL, 2001, EUR HEART J, V22, P14
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   MILLER DM, INVEST OPHTHALMOL VI, V45
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nauta AJ, 2003, TRENDS IMMUNOL, V24, P148, DOI 10.1016/S1471-4906(03)00030-9
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Ng TF, 2002, J IMMUNOL, V169, P5601, DOI 10.4049/jimmunol.169.10.5601
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   ROSENFELD PJ, 2003, INVEST OPHTHALMOL VI, V45
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   Van Beek J, 2003, ANN NY ACAD SCI, V992, P56
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Wenkel H, 1998, INVEST OPHTH VIS SCI, V39, P1823
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
NR 75
TC 88
Z9 98
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD FEB
PY 2005
VL 13
IS 1
BP 3
EP 11
DI 10.1080/09273940590909185
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 914ZR
UT WOS:000228267900001
PM 15804763
DA 2022-11-30
ER

PT J
AU Fang, V
   Gomez-Caraballo, M
   Lad, EM
AF Fang, Vivienne
   Gomez-Caraballo, Maria
   Lad, Eleonora M.
TI Biomarkers for Nonexudative Age-Related Macular Degeneration and
   Relevance for Clinical Trials: A Systematic Review
SO MOLECULAR DIAGNOSIS & THERAPY
LA English
DT Review
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; GEOGRAPHIC
   ATROPHY PROGRESSION; DARK-ADAPTATION; VISUAL-ACUITY; LOW LUMINANCE;
   RETICULAR PSEUDODRUSEN; POTENTIAL BIOMARKERS; NATURAL-HISTORY; OLDER
   EYES
AB Topic The purpose of the review was to identify structural, functional, blood-based, and other types of biomarkers for early, intermediate, and late nonexudative stages of age-related macular degeneration (AMD) and summarize the relevant data for proof-of-concept clinical trials.
   Methods A literature search of PubMed, ScienceDirect, EMBASE, and Web of Science from January 1, 1996 to November 30, 2020 and a patent search were conducted. Search terms included "early AMD," "dry AMD," "intermediate AMD," "biomarkers for nonexudative AMD," "fundus autofluorescence patterns," "color fundus photography," "dark adaptation," and "microperimetry." Articles were assessed for bias and quality with the Mixed-Methods Appraisal Tool. A total of 94 articles were included (61,842 individuals).
   Results Spectral-domain optical coherence tomography was superior at highlighting detailed structural changes in earlier stages of AMD. Fundus autofluorescence patterns were found to be most important in estimating progression of geographic atrophy. Delayed rod intercept time on dark adaptation was the most widely recommended surrogate functional endpoint for early AMD, while retinal sensitivity on microperimetry was most relevant for intermediate AMD. Combinational studies accounting for various patient characteristics and machine/deep-learning approaches were best suited for assessing individualized risk of AMD onset and progression.
   Conclusion This systematic review supports the use of structural and functional biomarkers in early AMD and intermediate AMD, which are more reproducible and less invasive than the other classes of biomarkers described. The use of deep learning and combinational algorithms will gain increasing importance in future clinical trials of nonexudative AMD.
C1 [Fang, Vivienne] Northwestern Univ, Feinberg Sch Med, 420 E Super St, Chicago, IL 60611 USA.
   [Gomez-Caraballo, Maria; Lad, Eleonora M.] Duke Univ, Med Ctr, Dept Ophthalmol, 2351 Erwin Rd,DUMC 3802, Durham, NC 27705 USA.
C3 Northwestern University; Feinberg School of Medicine; Duke University
RP Lad, EM (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, 2351 Erwin Rd,DUMC 3802, Durham, NC 27705 USA.
OI Fang, Vivienne/0000-0003-1248-4738
FU Apellis; LumiThera; Novartis; Roche (Duke University)
FX EML: Apellis, LumiThera, Novartis, and Roche (through Duke University).
CR Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alkeus Pharmaceuticals I, 2019, PHAS 2 3 MULT RAND D
   Allingham MJ, 2016, INVEST OPHTH VIS SCI, V57, P2283, DOI 10.1167/iovs.15-19008
   [Anonymous], 2019, HEALIO OPHTHALMOL
   Baek JH, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0941-9
   Bagheri Saghar, 2019, J Vitreoretin Dis, V3, P278, DOI 10.1177/2474126419859454
   BioSpace, 2020, GEM THER ENR 1 PAT P
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Bonfiglio V, 2020, ACTA OPHTHALMOL, V98, pE563, DOI 10.1111/aos.14315
   Borrelli E, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.5
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Carnevali A, 2021, RHEUMATOLOGY, V60, P5827, DOI 10.1093/rheumatology/keab258
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chisari CG, 2019, J CLIN MED, V8, DOI 10.3390/jcm8112022
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Cousins P., 2019, RETINAL PHYS
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V191, P23, DOI 10.1016/j.ajo.2018.03.038
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Gaffney AJ, 2013, DOC OPHTHALMOL, V127, P191, DOI 10.1007/s10633-013-9400-3
   Gin TJ, 2017, INVEST OPHTH VIS SCI, V58, P2079, DOI 10.1167/iovs.16-20105
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hageman GS, 1995, AGE RELATED MACULAR
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hong QNPP, 2018, MIXED METHODS APPRAI
   Howells K, 2017, PROG BRAIN RES, V234, P117, DOI 10.1016/bs.pbr.2017.06.002
   Hsu ST, 2019, OPHTHALMOL RETINA, V3, P637, DOI 10.1016/j.oret.2019.03.010
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kim JB, 2021, DRUG AGING, V38, P17, DOI 10.1007/s40266-020-00822-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Koman-Wierdak E, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247399
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lains I, 2018, AM J OPHTHALMOL, V190, P113, DOI 10.1016/j.ajo.2018.03.035
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Lashkari K, 2018, Methods to identify and treat age-related macular degeneration, Patent No. [WO2010/129351A1, 2010129351]
   Lashkari K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236283
   Lek JJ, 2018, OPHTHALMOL RETINA, V2, P792, DOI 10.1016/j.oret.2018.01.005
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lynch AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.12
   Lynch AM, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.14
   Markowitz SN, 2020, RETINA-J RET VIT DIS, V40, P1471, DOI 10.1097/IAE.0000000000002632
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   McGuinness MB, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.6.30
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Nattagh Khashayar, 2020, Transl Vis Sci Technol, V9, P6, DOI 10.1167/tvst.9.7.6
   Neely D, 2015, INVEST OPHTH VIS SCI, V56
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nguyen CT, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23084
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Nittala MG, 2019, RETINA-J RET VIT DIS, V39, P1540, DOI 10.1097/IAE.0000000000002210
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Ophthalmics LA, 2020, BAUSCH HLTH ACQ OPT
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2017, Method and apparatus for the detection of impaired dark adaptation, Patent No. [US 9572485 B2, 9572485]
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Qu SC, 2019, INT J OPHTHALMOL-CHI, V12, P1758, DOI 10.18240/ijo.2019.11.15
   Rabin J, 2011, INVEST OPHTH VIS SCI, V52, P816, DOI 10.1167/iovs.10-6283
   Ragusa M, 2015, CANCER BIOL THER, V16, P1387, DOI 10.1080/15384047.2015.1046021
   Ragusa M, 2013, MOL VIS, V19, P430
   Reibaldi Michele, 2012, Ophthalmic Surg Lasers Imaging, V43, pS83, DOI 10.3928/15428877-20121001-04
   Ren CD, 2017, CELL PHYSIOL BIOCHEM, V41, P1413, DOI 10.1159/000467941
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Robinson DG, 2019, INVEST OPHTH VIS SCI, V60, P580, DOI 10.1167/iovs.18-25092
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Russo A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174297
   Saha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47390-3
   Sassmannshausen M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.19
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schori C, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-24122
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Seddon JM, 2005, Biomarkers for age-related macular degeneration (AMD), Patent No. [US 2005/0250745 A1, 20050250745]
   Seddon JM, 2019, INVEST OPHTH VIS SCI, V60, P4469, DOI 10.1167/iovs.19-27475
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Stark A, 2018, CASE MED RES, DOI [10.31525/fda2-ucm604357.htm, DOI 10.31525/FDA2-UCM604357.HTM]
   Stein J, 2003, INVEST OPHTH VIS SCI, V44, pU695
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Thiele S, 2020, OPHTHALMOL RETINA, V4, P31, DOI 10.1016/j.oret.2019.08.003
   Thompson AC, 2018, INVEST OPHTH VIS SCI, V59, P289, DOI 10.1167/iovs.17-22528
   Toro MD, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.6.23
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Venkatesh P, 2016, INT J OPHTHALMOL-CHI, V9, P1779, DOI 10.18240/ijo.2016.12.13
   Vujosevic S, 2017, GRAEF ARCH CLIN EXP, V255, P301, DOI 10.1007/s00417-016-3466-z
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Wiest MRJ, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051093
   Winiarczyk M, 2018, GRAEF ARCH CLIN EXP, V256, P1127, DOI 10.1007/s00417-018-3984-y
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wrzesinska D, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/2650873
   Wrzesinska D, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/4975973
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Yan YN, 2015, OPHTHALMOLOGY, V122, P1873, DOI 10.1016/j.ophtha.2015.05.031
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
NR 142
TC 1
Z9 1
U1 2
U2 7
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1177-1062
EI 1179-2000
J9 MOL DIAGN THER
JI Mol. Diagn. Ther.
PD NOV
PY 2021
VL 25
IS 6
BP 691
EP 713
DI 10.1007/s40291-021-00551-5
EA AUG 2021
PG 23
WC Genetics & Heredity; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Pharmacology & Pharmacy
GA XD9CX
UT WOS:000688385500001
PM 34432254
DA 2022-11-30
ER

PT J
AU Pilotto, E
   Sportiello, P
   Alemany-Rubio, E
   Vujosevic, S
   Segalina, S
   Fregona, I
   Midena, E
AF Pilotto, Elisabetta
   Sportiello, Patrik
   Alemany-Rubio, Ernesto
   Vujosevic, Stela
   Segalina, Sara
   Fregona, Iva
   Midena, Edoardo
TI Confocal scanning laser ophthalmoscope in the retromode imaging modality
   in exudative age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Retromode retinal imaging; Confocal scanning laser ophthalmoscope;
   Optical coherence tomography; Fundus autofluorescence; Exudative
   age-related macular degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN
   ANGIOGRAPHY; IN-VIVO; EYE; PREVALENCE; EDEMA; MACULOPATHY; AGREEMENT
AB To evaluate the ability of confocal scanning laser ophthalmoscope (cSLO) in the retromode imaging modality in detecting retinal changes secondary to exudative age-related macular degeneration (AMD).
   Seventeen eyes of 13 consecutive patients affected by CNV secondary to AMD were evaluated with optical coherence tomography (OCT) to detect neuroretinal detachment (NRD), pigment epithelial detachment (PED), cystoid macular edema (CME), and epiretinal membranes (ERM). All eyes were examined with a cSLO equipped with infrared retromode (RM) imaging modality. Infrared and fundus autofluorescence images were also obtained (IR and FAF). The intermethod agreement between OCT and cSLO was evaluated considering single cSLO imaging modality separately (IR, FAF, and RM), and all imaging modalities together.
   Eight eyes (47 %) had NRD at OCT; intermethod agreement was poor for any single cSLO imaging modality considered separately (k: 0.14, 0.01, and 0.29 for cSLO IR, FAF, and RM, respectively). Four eyes had PED at OCT (24 %); intermethod agreement was mild for cSLO RM, poor for IR and FAF (k: 0.51, 0.16, and 0.00, respectively). CME was present in eight eyes (47 %); intermethod agreement was excellent for cSLO RM, poor for IR and FAF (k: 0.88, 0.38, and 0.26, respectively). ERM was present in three eyes (18 %); intermethod agreement was mild for cSLO IR, poor for FAF, and excellent for RM (k: 0.59, 0.00, and 0.76, respectively).
   cSLO RM imaging is a useful and reproducible technique in detecting retinal features associated with CNV, particularly CME.
C1 [Pilotto, Elisabetta; Sportiello, Patrik; Alemany-Rubio, Ernesto; Segalina, Sara; Fregona, Iva; Midena, Edoardo] Univ Padua, Dept Ophthalmol, I-35128 Padua, Italy.
   [Alemany-Rubio, Ernesto] Cuban Eye Inst Ramon Pando Ferrer, The Havana, Cuba.
   [Vujosevic, Stela; Midena, Edoardo] IRCCS, Fdn GB Bietti Oftalmol, Rome, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Pilotto, E (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
EM elisabetta.pilotto@unipd.it
RI Midena, Edoardo/AAB-6010-2020; Vujosevic, Stela/AAI-4874-2020
OI Vujosevic, Stela/0000-0001-6773-9967
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Ikeda T, 1998, AM J OPHTHALMOL, V125, P710, DOI 10.1016/S0002-9394(98)00008-7
   Ishiko S, 2002, OPHTHALMOLOGY, V109, P2165, DOI 10.1016/S0161-6420(02)01227-7
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P811, DOI 10.1007/s00417-007-0755-6
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Remky A, 1999, GRAEF ARCH CLIN EXP, V237, P897, DOI 10.1007/s004170050383
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Tanaka Y, 2010, AM J OPHTHALMOL, V149, P635, DOI 10.1016/j.ajo.2009.10.024
   Theelen T, 2009, GRAEF ARCH CLIN EXP, V247, P1625, DOI 10.1007/s00417-009-1148-9
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Vujosevic S, 2007, GRAEF ARCH CLIN EXP, V245, P1453, DOI 10.1007/s00417-007-0574-9
   Yamamoto M, 2010, CLIN EXP OPHTHALMOL, V38, P27, DOI 10.1111/j.1442-9071.2010.02193.x
   Yamamoto Motoshi, 2009, International Ophthalmology, V29, P503, DOI 10.1007/s10792-008-9274-7
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 29
TC 13
Z9 14
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2013
VL 251
IS 1
BP 27
EP 34
DI 10.1007/s00417-012-2031-7
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064KP
UT WOS:000313074100005
PM 22580948
DA 2022-11-30
ER

PT J
AU Brody, BL
   Roch-Levecq, AC
   Gamst, AC
   Maclean, K
   Kaplan, RM
   Brown, SI
AF Brody, BL
   Roch-Levecq, AC
   Gamst, AC
   Maclean, K
   Kaplan, RM
   Brown, SI
TI Self-management of age-related macular degeneration and quality of life
   - A randomized controlled trial
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; SUPPORT; EDUCATION; OPTIMISM; EYE
AB Objective: To assess the effectiveness of an age-related macular degeneration (AMD) self-management program, consisting of health education and enhancement of problem-solving skills, to improve quality of life as shown by measures of mood and function.
   Methods: Two hundred thirty-one community-dwelling cognitively intact volunteers (mean age, 80.6 years) with advanced macular degeneration were randomly assigned to a 12-hour self-management program (n = 86), a series of 12 hours of tape-recorded health lectures (n = 74), or to a waiting list (n = 72).
   Main Outcome Measures: The primary outcome measure was emotional distress (Profile of Mood States). Secondary outcome measures included function (National Eye Institute Visual Function Questionnaire), social support (Duke Social Support Index), outlook on life (Life Optimism Test-Revised), and self-confidence to handle AMD-specific challenges in daily life (AMD Self-Efficacy Questionnaire). Clinical depression was deter-mined in accord with the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Axis 1, Fourth Edition, Research Version.
   Results: The self-management group showed significant improvement in measures of mood and function compared,with controls. These changes were significantly greater for the depressed than for the nondepressed subjects. Decreased emotional distress was associated with increased self-efficacy, while improvements in function were associated with increases in self-efficacy and perceived social support.
   Conclusions: These findings suggest that the AMD self-management program was an effective intervention to enhance well-being in older persons with poor eyesight due to AMD, particularly in those who were initially depressed.
C1 Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Family & Prevent Med, Div Biostat, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Family & Prevent Med, Div Hlth Care Sci, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Brown, SI (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, 9415 Campus Point Dr, La Jolla, CA 92093 USA.
EM sbrown@eyecenter.ucsd.edu
RI KAPLAN, Robert/AAK-7342-2021; Gamst, Anthony/AAH-9440-2019
FU NATIONAL EYE INSTITUTE [R01EY011924] Funding Source: NIH RePORTER
CR BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   BANDURA A, 1991, NEUROBIOLOGY LEARNIN, P229
   Bandura Albert., 1992, SELF EFFICACY THOUGH, P3
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   CLARK NM, 1992, GERONTOLOGIST, V32, P438, DOI 10.1093/geront/32.4.438
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DSouza W, 1996, J ALLERGY CLIN IMMUN, V97, P1085, DOI 10.1016/S0091-6749(96)70262-2
   Fawzy Fawzy I., 1994, General Hospital Psychiatry, V16, P149, DOI 10.1016/0163-8343(94)90098-1
   FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P720
   FIRST MB, 1995, USERS GUIDE STRUCTUR, P1
   FOBAIR P, 1998, ADV MENTAL HLTH RES, P365
   Fries JF, 1998, HEALTH AFFAIR, V17, P70, DOI 10.1377/hlthaff.17.2.70
   GILDEN JL, 1992, J AM GERIATR SOC, V40, P147, DOI 10.1111/j.1532-5415.1992.tb01935.x
   Goodwin PJ, 2001, NEW ENGL J MED, V345, P1719, DOI 10.1056/NEJMoa011871
   Hollingshead, 1957, 2 FACTOR INDEX SOCIA, P1
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KAPLAN RM, 1984, HEALTH PSYCHOL, V3, P223, DOI 10.1037/0278-6133.3.3.223
   KATZMAN R, 1983, AM J PSYCHIAT, V140, P734
   KAYE J M, 1988, Clinical Gerontologist, V7, P35, DOI 10.1300/J018v07n03_05
   KOENIG HG, 1993, PSYCHOSOMATICS, V34, P61, DOI 10.1016/S0033-3182(93)71928-3
   LORIG K, 1984, GERONTOLOGIST, V24, P455
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   McNair D.M., 1992, POMS MANUAL PROFILE
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   MORIN CM, 1993, J CONSULT CLIN PSYCH, V61, P137, DOI 10.1037/0022-006X.61.1.137
   *NAT ADV EYE COUNC, 1998, NIH PUBL
   RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003
   SCHEIER MF, 1989, J PERS SOC PSYCHOL, V57, P1024, DOI 10.1037/0022-3514.57.6.1024
   SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063
   Scott IU, 2001, AM J OPHTHALMOL, V131, P584, DOI 10.1016/S0002-9394(01)00832-7
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653
   *SPSS INC, 1999, STAT PROGR SOC SCI V
   *STAFS, 1999, STAT VERS 5 5
NR 36
TC 99
Z9 101
U1 0
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2002
VL 120
IS 11
BP 1477
EP 1483
DI 10.1001/archopht.120.11.1477
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 614RE
UT WOS:000179203400006
PM 12427060
OA Bronze
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Kiel, C
   Zimmermann, ME
   Gorski, M
   Grassmann, V
   Stark, K
   Heid, IM
   Weber, BHF
AF Grassmann, Felix
   Kiel, Christina
   Zimmermann, Martina E.
   Gorski, Mathias
   Grassmann, Veronika
   Stark, Klaus
   Heid, Iris M.
   Weber, Bernhard H. F.
CA IAMDGC
TI Genetic pleiotropy between age-related macular degeneration and 16
   complex diseases and traits
SO GENOME MEDICINE
LA English
DT Article
DE Age-related macular degeneration; AMD; Genetic risk scores; GRS; Genetic
   association studies; Complex traits; Shared genetics
ID GENOME-WIDE ASSOCIATION; CANCER SUSCEPTIBILITY LOCI;
   RHEUMATOID-ARTHRITIS; MULTIPLE LOCI; RISK LOCI; CARDIOVASCULAR-DISEASE;
   IDENTIFIES 6; METAANALYSIS; VARIANTS; INDIVIDUALS
AB Background: Age-related macular degeneration (AMD) is a common condition of vision loss with disease development strongly influenced by environmental and genetic factors. Recently, 34 loci were associated with AMD at genome-wide significance. So far, little is known about a genetic overlap between AMD and other complex diseases or disease-relevant traits.
   Methods: For each of 60 complex diseases/traits with publicly available genome-wide significant association data, the lead genetic variant per independent locus was extracted and a genetic score was calculated for each disease/trait as the weighted sum of risk alleles. The association with AMD was estimated based on 16,144 AMD cases and 17,832 controls using logistic regression.
   Results: Of the respective disease/trait variance, the 60 genetic scores explained on average 4.8% (0.27-20.69%) and 16 of them were found to be significantly associated with AMD (Q-values < 0.01, p values from < 1.0 x 10(-16) to 1.9 x 10(-3)). Notably, an increased risk for AMD was associated with reduced risk for cardiovascular diseases, increased risk for autoimmune diseases, higher HDL and lower LDL levels in serum, lower bone-mineral density as well as an increased risk for skin cancer. By restricting the analysis to 1824 variants initially used to compute the 60 genetic scores, we identified 28 novel AMD risk variants (Q-values < 0.01, p values from 1.1 x 10(-7) to 3.0 x 10(-4)),known to be involved in cardiovascular disorders, lipid metabolism, autoimmune diseases, anthropomorphic traits, ocular disorders, and neurological diseases. The latter variants represent 20 novel AMD-associated, pleiotropic loci. Genes in the novel loci reinforce previous findings strongly implicating the complement system in AMD pathogenesis.
   Conclusions: We demonstrate a substantial overlap of the genetics of several complex diseases/traits with AMD and provide statistically significant evidence for an additional 20 loci associated with AMD. This highlights the possibility that so far unrelated pathologies may have disease pathways in common.
C1 [Grassmann, Felix; Kiel, Christina; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
   [Zimmermann, Martina E.; Gorski, Mathias; Stark, Klaus; Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
   [Grassmann, Veronika] Univ Regensburg, Inst Med Microbiol & Hyg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.; Weber, BHF (通讯作者)，Univ Regensburg, Dept Genet Epidemiol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Hollander, Anneke den/N-4911-2014; Cooke Bailey, Jessica
   Nicole/AFQ-5925-2022; Souzeau, Emmanuelle/AAB-5608-2022; Stark,
   Klaus/L-7367-2013; lake, stewart/AAH-6265-2021; Sahel,
   Jose-Alain/F-3172-2017; /S-1190-2019; Cipriani, Valentina/A-8549-2012;
   Grunin, Michelle/O-6044-2019; Weeks, Daniel E/B-2995-2012; Mackey, David
   A/H-5340-2014; Zhang, Kang/Y-2740-2019; Bailey, Jessica
   Cooke/Q-5062-2019; Peachey, Neal/G-5533-2010; Zimmermann,
   Martina/AAL-2990-2021
OI Cooke Bailey, Jessica Nicole/0000-0002-4001-8702; Souzeau,
   Emmanuelle/0000-0002-2015-6577; Stark, Klaus/0000-0002-7832-1942; lake,
   stewart/0000-0003-0078-3319; Sahel, Jose-Alain/0000-0002-4831-1153;
   /0000-0001-7488-250X; Cipriani, Valentina/0000-0002-0839-9955; Grunin,
   Michelle/0000-0002-3155-2858; Weeks, Daniel E/0000-0001-9410-7228;
   Mackey, David A/0000-0001-7914-4709; Zhang, Kang/0000-0002-4549-1697;
   Bailey, Jessica Cooke/0000-0002-4001-8702; Peachey,
   Neal/0000-0002-4419-7226; Zimmermann, Martina/0000-0002-6916-4404;
   Weber, Bernhard H.F./0000-0002-8808-7723; Van Duijn,
   Cornelia/0000-0002-2374-9204; Branham, Kari/0000-0002-2492-254X; Su,
   Zhiguang/0000-0001-8635-9310; constable, ian/0000-0002-2140-6478; Baird,
   Paul/0000-0002-1305-3502; Craig, Jamie/0000-0001-9955-9696; Kiel,
   Christina/0000-0003-3154-4847; Scott, William/0000-0001-9336-6404; Ahn,
   Jeeyun/0000-0001-9017-1652; Michaelides, Michel/0000-0002-1552-7046;
   Grassmann, Felix/0000-0003-1390-7528; Guymer, Robyn/0000-0002-9441-4356;
   Cree, Angela/0000-0002-1987-8900; Tan, Ava Grace/0000-0003-3344-0339;
   Audo, Isabelle/0000-0003-0698-5309; Hagbi-Levi,
   Shira/0000-0002-2891-0079; Blangero, John/0000-0001-6250-5723; Klaver,
   Caroline/0000-0002-2355-5258; Brandl, Caroline/0000-0001-8223-6137;
   Ratnapriya, Rinki/0000-0002-0469-4631
FU Deutsche Forschungsgemeinschaft [WE 1259/19-1, WE 1259/19-2]; Alcon
   Research Institute; German Federal Ministry of Education and Research
   [BMBF 01ER1206, 01ER1507]; CIDR [HHSN268201200008I];  [EY022310]; 
   [1X01HG006934-01]; NATIONAL EYE INSTITUTE [P30EY001583, R01EY022310,
   U10EY006594] Funding Source: NIH RePORTER
FX This study was supported in parts by the Deutsche Forschungsgemeinschaft
   (WE 1259/19-1 and WE 1259/19-2 to BHFW), the Alcon Research Institute
   (to BHFW), and by grants from the German Federal Ministry of Education
   and Research (BMBF 01ER1206 and 01ER1507 to IMH). Genotyping was
   conducted as part of the IAMDGC exome-chip project supported by CIDR
   (contract number HHSN268201200008I) and funded by EY022310 (to Jonathan
   L. Haines, Case Western Reserve University, Cleveland) and
   1X01HG006934-01 (to Goncalo R. Abecasis, University of Michigan,
   Department of Biostatistics). The funding bodies had no role in the
   design of the study and collection, analysis, and interpretation of data
   and in writing the manuscript.
CR Al Olama AA, 2014, NAT GENET, V46, P1103, DOI 10.1038/ng.3094
   Al Olama AA, 2013, HUM MOL GENET, V22, P408, DOI 10.1093/hmg/dds425
   Al Olama AA, 2009, NAT GENET, V41, P1058, DOI 10.1038/ng.452
   Al-Tassan NA, 2015, SCI REP-UK, V5, DOI 10.1038/srep10442
   Anttila V, 2013, NAT GENET, V45, P912, DOI 10.1038/ng.2676
   Bailey JNC, 2016, NAT GENET, V48, P189, DOI 10.1038/ng.3482
   Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381
   Barrett JH, 2011, NAT GENET, V43, P1108, DOI 10.1038/ng.959
   Benjamini Y, 2001, ANN STAT, V29, P1165
   Bentham J, 2015, NAT GENET, V47, P1457, DOI 10.1038/ng.3434
   Berndt SI, 2013, NAT GENET, V45, P868, DOI 10.1038/ng.2652
   Bradfield JP, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002293
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406
   Camelo S., 2014, AUTOIMMUNE DIS, V2014, P1
   Chambers JC, 2011, NAT GENET, V43, P1131, DOI 10.1038/ng.970
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cooper JD, 2008, NAT GENET, V40, P1399, DOI 10.1038/ng.249
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cuellar-Partida G, 2016, SCI REP-UK, V6, DOI 10.1038/srep26885
   Dehghan A, 2011, CIRCULATION, V123, P731, DOI 10.1161/CIRCULATIONAHA.110.948570
   Deloukas P, 2013, NAT GENET, V45, P25, DOI 10.1038/ng.2480
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90
   Eeles RA, 2013, NAT GENET, V45, P385, DOI 10.1038/ng.2560
   Eeles RA, 2009, NAT GENET, V41, P1116, DOI 10.1038/ng.450
   Ehret GB, 2011, NATURE, V478, P103, DOI 10.1038/nature10405
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Eyre S, 2012, NAT GENET, V44, P1336, DOI 10.1038/ng.2462
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Flicek P, 2014, NUCLEIC ACIDS RES, V42, pD749, DOI 10.1093/nar/gkt1196
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2015, ANNU REV VIS SCI, V1, P73, DOI 10.1146/annurev-vision-082114-035609
   Grassmann F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0548-0
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Gudmundsson J, 2008, NAT GENET, V40, P281, DOI 10.1038/ng.89
   Gudmundsson J, 2007, NAT GENET, V39, P977, DOI 10.1038/ng2062
   Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999
   Gudmundsson J, 2009, NAT GENET, V41, P1122, DOI 10.1038/ng.448
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hakonarson H, 2007, NATURE, V448, P591, DOI 10.1038/nature06010
   Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500
   Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Iannaccone A, 2012, ADV EXP MED BIOL, V723, P11, DOI 10.1007/978-1-4614-0631-0_2
   Iles MM, 2013, NAT GENET, V45, P428, DOI 10.1038/ng.2571
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582
   Kao LT, 2015, J AM ACAD DERMATOL, V72, P1090, DOI 10.1016/j.jaad.2015.03.002
   Keenan TDL, 2015, RETINA-J RET VIT DIS, V35, P2613, DOI 10.1097/IAE.0000000000000651
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   Kiefer AK, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003299
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kottgen A, 2013, NAT GENET, V45, P145, DOI 10.1038/ng.2500
   Kottgen A, 2010, NAT GENET, V42, P376, DOI 10.1038/ng.568
   Kottgen A, 2009, NAT GENET, V41, P712, DOI 10.1038/ng.377
   Kote-Jarai Z, 2011, NAT GENET, V43, P785, DOI 10.1038/ng.882
   Langholz B, 2000, CANCER CAUSE CONTROL, V11, P741, DOI 10.1023/A:1008952219416
   Law MH, 2015, NAT GENET, V47, P987, DOI 10.1038/ng.3373
   Lee PH, 2012, BIOINFORMATICS, V28, P1797, DOI 10.1093/bioinformatics/bts191
   Li YG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111707
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Lin SC, 2016, ASIA-PAC J OPHTHALMO, V5, P115, DOI 10.1097/APO.0000000000000169
   Locke AE, 2015, NATURE, V518, P197, DOI 10.1038/nature14177
   Loth DW, 2014, NAT GENET, V46, P669, DOI 10.1038/ng.3011
   Lu Y, 2013, NAT GENET, V45, P155, DOI 10.1038/ng.2506
   MacGregor S, 2011, NAT GENET, V43, P1114, DOI 10.1038/ng.958
   Mahajan A, 2014, NAT GENET, V46, P234, DOI 10.1038/ng.2897
   McGrowder Donovan, 2011, CHOLESTEROL, V2011, P1, DOI DOI 10.1155/2011/496925
   Michailidou K, 2015, NAT GENET, V47, P373, DOI 10.1038/ng.3242
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Morris AP, 2012, NAT GENET, V44, P981, DOI 10.1038/ng.2383
   Nalls MA, 2014, NAT GENET, V46, P989, DOI 10.1038/ng.3043
   Neuwirth E., **DATA OBJECT**
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   O'Seaghdha CM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003796
   Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873
   Okada Y, 2012, NAT GENET, V44, P511, DOI 10.1038/ng.2231
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Parra S, 2012, ATHEROSCLEROSIS, V225, P224, DOI 10.1016/j.atherosclerosis.2012.08.029
   Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Peters U, 2013, GASTROENTEROLOGY, V144, P799, DOI 10.1053/j.gastro.2012.12.020
   Reitz C, 2010, ARCH NEUROL-CHICAGO, V67, P1491, DOI 10.1001/archneurol.2010.297
   Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501
   Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Roederer M, 2015, CELL, V161, P387, DOI 10.1016/j.cell.2015.02.046
   Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251
   Schumacher FR, 2011, HUM MOL GENET, V20, P3867, DOI 10.1093/hmg/ddr295
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shungin D, 2015, NATURE, V518, P187, DOI 10.1038/nature14132
   So HC, 2011, GENET EPIDEMIOL, V35, P310, DOI 10.1002/gepi.20579
   Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941
   Speedy HE, 2014, NAT GENET, V46, P56, DOI 10.1038/ng.2843
   Springelkamp H, 2015, GENET EPIDEMIOL, V39, P207, DOI 10.1002/gepi.21886
   Springelkamp H, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5883
   Sun J, 2008, NAT GENET, V40, P1153, DOI 10.1038/ng.214
   Suzuki A, 2008, NAT GENET, V40, P1224, DOI 10.1038/ng.205
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140-6736(07)61342-7
   Terao C, 2011, HUM MOL GENET, V20, P2680, DOI 10.1093/hmg/ddr161
   Titus-Ernstoff L, 2005, INT J CANCER, V116, P144, DOI 10.1002/ijc.21001
   Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068
   Tomlinson IPM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002105
   Tosato M, 2007, CLIN INTERV AGING, V2, P401
   Wallace C, 2010, NAT GENET, V42, P68, DOI 10.1038/ng.493
   Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0
   Warnes GR., 2019, GPLOTS VARIOUS R PRO
   Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797
   Williams GC, 2001, SCI AGING KNOWLEDGE, V2001, pcp13
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang BC, 2016, J BASIC MICROB, V56, P670, DOI 10.1002/jobm.201500751
NR 121
TC 43
Z9 43
U1 2
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD MAR 27
PY 2017
VL 9
AR 29
DI 10.1186/s13073-017-0418-0
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EP9YE
UT WOS:000397728100001
PM 28347358
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hughes, AE
   Orr, N
   Patterson, C
   Esfandiary, H
   Hogg, R
   McConnell, V
   Silvestri, G
   Chakravarthy, U
AF Hughes, Anne E.
   Orr, Nick
   Patterson, Chris
   Esfandiary, Hossein
   Hogg, Ruth
   McConnell, Vivienne
   Silvestri, Giuliana
   Chakravarthy, Usha
TI Neovascular age-related macular degeneration risk based on CFH,
   LOC387715/HTRA1, and smoking
SO PLOS MEDICINE
LA English
DT Article
ID COMPLEMENT FACTOR-H; BEAVER DAM EYE; GENOME SCAN; SUSCEPTIBILITY LOCI;
   EXTENDED FAMILIES; CHROMOSOME 10Q26; MACULOPATHY; POLYMORPHISM; GENE;
   HAPLOTYPE
AB Background
   Age-related macular degeneration (AMD) is the major cause of blindness in the elderly. Those with the neovascular end-stage of disease have irreversible loss of central vision. AMD is a complex disorder in which genetic and environmental factors play a role. Polymorphisms in the complement factor H (CFH) gene, LOC387715, and the HTRA1 promoter are strongly associated with AMD. Smoking also contributes to the etiology. We aimed to provide a model of disease risk based on these factors.
   Methods and Findings
   We genotyped polymorphisms in CFH and LOC387715/HTRA1 in a case-control study of 401 patients with neovascular AMD and 266 controls without signs of disease, and used the data to produce genetic risk scores for the European-descent population based on haplotypes at these loci and smoking history. CFH and LOC387715/HTRA1 haplotypes and smoking status exerted large effects on AMD susceptibility, enabling risk scores to be generated with appropriate weighting of these three factors. Five common haplotypes of CFH conferred a range of odds ratios (ORs) per copy from 1 to 4.17. Most of the effect of LOC387715/HTRA1 was mediated through one detrimental haplotype (carriage of one copy: OR 2.83; 95% confidence interval [CI] 1.91-4.20), with homozygotes being at particularly high risk (OR 32.83; 95% CI 12.53-86.07). Patients with neovascular macular degeneration had considerably higher scores than those without disease, and risk of blinding AMD rose to 15.5% in the tenth of the population with highest predicted risk.
   Conclusions
   An individual's risk of developing AMD in old age can be predicted by combining haplotype data with smoking status. Until there is effective treatment for AMD, encouragement to avoid smoking in those at high genetic risk may be the best option. We estimate that total absence of smoking would have reduced the prevalence of severe AMD by 33%. Unless smoking habits change or preventative treatment becomes available, the prevalence of AMD will rise as a consequence of the increasing longevity of the population.
C1 [Hughes, Anne E.; Orr, Nick; Esfandiary, Hossein; McConnell, Vivienne] Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland.
   [Patterson, Chris] Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast, Antrim, North Ireland.
   [Hogg, Ruth; Silvestri, Giuliana; Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis Sci & Vasc Biol, Belfast, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast; Queens University
   Belfast
RP Hughes, AE (通讯作者)，Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland.
EM A.Hughes@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020; Hughes, Anne/A-1307-2012
OI Hogg, Ruth E./0000-0001-9413-2669; Chakravarthy,
   Usha/0000-0002-2606-3734
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Carlson CS, 2005, AM J HUM GENET, V77, P64, DOI 10.1086/431366
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   *INT HAPMAP CONS, 2005, DAT SOURC
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1997, ARCH OPHTHALMOL-CHIC, V115, P945, DOI 10.1001/archopht.1997.01100160115033
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MOLD C, 1984, J IMMUNOL, V133, P882
   Office for National Statistics, 2007, GEN HOUS SURV
   REID DD, 1976, LANCET, V2, P979
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 40
TC 82
Z9 83
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD DEC
PY 2007
VL 4
IS 12
BP 1993
EP 2000
AR e355
DI 10.1371/journal.pmed.0040355
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 244OG
UT WOS:000251874600021
PM 18162041
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Corveleyn, X
   Lenoble, Q
   Szaffarczyk, S
   Tran, THC
   Boucart, M
AF Corveleyn, Xavier
   Lenoble, Quentin
   Szaffarczyk, Sebastien
   Thi Ha Chau Tran
   Boucart, Muriel
TI What Is the Nature of the Reach and Grasp Deficit in Wet Age-related
   Macular Degeneration?
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
ID VISUAL FEEDBACK; TO-GRASP; PREHENSION MOVEMENTS; VISION; ONLINE; HAND;
   COORDINATION; PARTICIPANTS; PERFORMANCE; TRANSPORT
AB SIGNIFICANCE Vision is paramount for motor actions directed toward objects. Vision allows not only the identification of objects and their shape and spatial location, but also the adaptation of our movement when it arrives on the object. These findings show that vision deficits, as in age-related macular degeneration (AMD), can lead to reaching and grasping deficits.
   PURPOSE Few studies have investigated reaching and grasping in patients with AMD. They showed a deficit in the execution of motor actions in people with AMD, even though these people do not mention difficulties in their daily lives. The purpose of this study was to understand the nature of impairments in motor actions in patients.
   METHODS We compared performance in two reach-and-grasp tasks determined by whether the participants (16 people with wet AMD and 17 age-matched control subjects) had time to look at the object before reaching and grasping it.
   RESULTS The results show that the kinematic parameters of reach-and-grasp movements do not differ between groups when participants are provided time to look at the object before the movement. In contrast, performance in terms of movement duration, acceleration time, time to reach the maximum grip aperture, and the maximum velocity differ between patients and control subjects when the object is displayed immediately before the movement.
   CONCLUSIONS The motor perturbations observed in people with AMD in previous studies seem to result from difficulties in target identification rather than from visuomotor deficits.
C1 [Corveleyn, Xavier] Univ Cote Azur, Lab Anthropol & Psychol Cognit & Sociales LAPCOS, EA 7278, Nice, France.
   [Lenoble, Quentin; Szaffarczyk, Sebastien; Thi Ha Chau Tran; Boucart, Muriel] Univ Lille, CNRS, SCALab, Lille, France.
   [Thi Ha Chau Tran] Lille Catholic Univ, Lille Catholic Hosp, Dept Ophthalmol, Lille, France.
C3 UDICE-French Research Universities; Universite Cote d'Azur; Centre
   National de la Recherche Scientifique (CNRS); Universite de Lille -
   ISITE; Universite de Lille
RP Corveleyn, X (通讯作者)，Univ Cote Azur, Lab Anthropol & Psychol Cognit & Sociales LAPCOS, EA 7278, Nice, France.
EM xavier.corveleyn@unice.fr
CR Boucart M, 2015, INVEST OPHTH VIS SCI, V56, P6832, DOI 10.1167/iovs.15-16758
   CHIEFFI S, 1993, EXP BRAIN RES, V94, P471
   Connolly JD, 1999, EXP BRAIN RES, V125, P281, DOI 10.1007/s002210050684
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Grant S, 2007, INVEST OPHTH VIS SCI, V48, P1139, DOI 10.1167/iovs.06-0976
   Hommel B, 2009, PSYCHOL RES-PSYCH FO, V73, P512, DOI 10.1007/s00426-009-0234-2
   Jeannerod M., 1981, ATTENTION PERFORM, VIX, P153
   Khan MA, 2006, NEUROSCI BIOBEHAV R, V30, P1106, DOI 10.1016/j.neubiorev.2006.05.002
   Kotecha A, 2009, INVEST OPHTH VIS SCI, V50, P203, DOI 10.1167/iovs.08-2496
   La Marc J, 2011, FABRIQUE DES IDEES
   Lee YL, 2008, PERCEPT PSYCHOPHYS, V70, P1032, DOI 10.3758/PP.70.6.1032
   Lenoble Q, 2015, OPTOMETRY VISION SCI, V92, P986, DOI 10.1097/OPX.0000000000000694
   Ma-Wyatt A, 2007, EXP BRAIN RES, V179, P55, DOI 10.1007/s00221-006-0767-1
   Pardhan S, 2017, INVEST OPHTH VIS SCI, V58, P1560, DOI 10.1167/iovs.16-20273
   Pardhan S, 2012, INVEST OPHTH VIS SCI, V53, P6687, DOI 10.1167/iovs.12-9821
   Pardhan S, 2011, OPHTHAL PHYSL OPT, V31, P233, DOI 10.1111/j.1475-1313.2010.00819.x
   Penta M, 1998, ARCH PHYS MED REHAB, V79, P1038, DOI 10.1016/S0003-9993(98)90167-8
   Rand MK, 2007, EXP BRAIN RES, V181, P447, DOI 10.1007/s00221-007-0945-9
   Rubin GS, 2001, EYE, V15, P430, DOI 10.1038/eye.2001.148
   Sabes PN, 2000, CURR OPIN NEUROBIOL, V10, P740, DOI 10.1016/S0959-4388(00)00149-5
   Saunders JA, 2003, EXP BRAIN RES, V152, P341, DOI 10.1007/s00221-003-1525-2
   SERVOS P, 1994, EXP BRAIN RES, V98, P119
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Timberlake GT, 2011, INVEST OPHTH VIS SCI, V52, P2540, DOI 10.1167/iovs.10-6062
   Watt SJ, 2000, NEUROPSYCHOLOGIA, V38, P1473, DOI 10.1016/S0028-3932(00)00065-8
   Wolpert DM, 1998, NEURAL NETWORKS, V11, P1317, DOI 10.1016/S0893-6080(98)00066-5
NR 27
TC 3
Z9 3
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAR
PY 2018
VL 95
IS 3
BP 171
EP 182
DI 10.1097/OPX.0000000000001189
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA FY1EH
UT WOS:000426554100003
PM 29424830
DA 2022-11-30
ER

PT J
AU Nathoo, NA
   Or, C
   Young, M
   Chui, L
   Fallah, N
   Kirker, AW
   Albiani, DA
   Merkur, AB
   Forooghian, F
AF Nathoo, Nawaaz A.
   Or, Chris
   Young, Mei
   Chui, Lica
   Fallah, Nader
   Kirker, Andrew W.
   Albiani, David A.
   Merkur, Andrew B.
   Forooghian, Farzin
TI Optical Coherence Tomography-Based Measurement of Drusen Load Predicts
   Development of Advanced Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; CHOROIDAL NEOVASCULARIZATION; NATURAL-HISTORY;
   FOLLOW-UP; SD-OCT; RISK; PROGRESSION; RANIBIZUMAB; DISEASE; Y402H
AB PURPOSE: To determine whether baseline drusen load, as measured using spectral-domain optical coherence tomography (SD OCT), is a useful predictor of development of advanced age-related macular degeneration (AMD).
   DESIGN: Retrospective cohort study.
   METHODS: SETTING: Academic clinical practice. STUDY POPULATION: All patients with non-neovascular AMD and no retinal pigment epithelial (RPE) atrophy at baseline who were seen between 2007 and 2012 in a single academic retina practice. A minimum of 1 year of follow-up was required. OBSERVATION: Drusen load (area and volume) was assessed using automated SD OCT software algorithms. MAIN OUTCOME MEASURE: RPE atrophy area, assessed using an automated SD OCT software algorithm, and the development of neovascular AMD.
   RESULTS: Eighty-three patients met the inclusion criteria with a mean age of 80 years and a mean follow-up time of 2.8 years. Repeated-measures analysis of variance showed an association between drusen area (P = .005) and drusen volume (P = .001) and the development of RPE atrophy. We also found an association between drusen area (P = .001) and drusen volume (P = .001) and the development of neovascular AMD.
   CONCLUSIONS: Drusen load, as measured using SD OCT, is associated with the development of RPE atrophy and neovascular AMD. SD OCT assessments of drusen load are simple and practical measurements that may be useful in stratifying the risk of developing advanced AMD. These measurements have potential applications in both routine clinical care and clinical trials. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Nathoo, Nawaaz A.; Or, Chris; Young, Mei; Chui, Lica; Kirker, Andrew W.; Albiani, David A.; Merkur, Andrew B.; Forooghian, Farzin] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V6Z 1Y6, Canada.
   [Fallah, Nader] Rick Hansen Inst, Vancouver, BC, Canada.
C3 University of British Columbia
RP Forooghian, F (通讯作者)，Univ British Columbia, St Pauls Hosp, Dept Ophthalmol & Visual Sci, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM farzin.forooghian@gmail.com
RI Fallah, Nader/D-4145-2012
OI Fallah, Nader/0000-0002-7746-4773; Nathoo, Nawaaz/0000-0002-1566-290X
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Brader HS, 2013, OPHTHALMOLOGY, V120, P1871, DOI 10.1016/j.ophtha.2013.01.049
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Friberg TR, 2012, INVEST OPHTH VIS SCI, V53, P1742, DOI 10.1167/iovs.11-9338
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Williams MA, 2009, AGE AGEING, V38, P648, DOI 10.1093/ageing/afp136
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 31
TC 35
Z9 35
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2014
VL 158
IS 4
BP 757
EP 761
DI 10.1016/j.ajo.2014.06.021
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ1PI
UT WOS:000342552900015
PM 24983793
DA 2022-11-30
ER

PT J
AU Fraser-Bell, S
   Wu, J
   Klein, R
   Azen, SP
   Hooper, C
   Foong, AWP
   Varma, R
AF Fraser-Bell, Samantha
   Wu, Joanne
   Klein, Ronald
   Azen, Stanley P.
   Hooper, Claire
   Foong, Athena W. P.
   Varma, Rohit
CA Los Angeles Latino Eye Study Grp
TI Cardiovascular risk factors and age-related macular degeneration: The
   Los Angeles Latino Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE-MOUNTAINS-EYE; BEAVER-DAM EYE; NUTRITION EXAMINATION SURVEY;
   C-REACTIVE PROTEIN; NATIONAL-HEALTH; UNITED-STATES; MACULOPATHY;
   DISEASE; PREVALENCE; ATHEROSCLEROSIS
AB PURPOSE. To assess the association of cardiovascular risk factors and ocular perfusion pressure with early and advanced age-related macular degeneration (AMD) in Latinos.
   DESIGN: Population-based, cross-sectional study.
   METHODS: Data were collected from a population-based sample of self,identified adult Latinos using standardized protocols for assessing. blood pressure and intraocular pressure (IOP) measurement and stereoscopic macular photography. Hypertension was defined as either a history of hypertension or systolic blood pressure (SBP) > 140 mm Hg +/- diastolic blood pressure (DBP) >= 85 mm Hg. Ocular perfusion pressure (OPP) was defined as the difference between mean arterial blood pressure and IOP. AMD was diagnosed from photographic grading by masked trained graders. Logistic regression was used to assess associations.
   RESULTS: Gradable retinal photographs were available in 5,875 participants. After adjusting for age, gender, and cigarette smoking, higher DBP and uncontrolled diastolic hypertension were associated with exudative AMD (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.1 to 2.8; and OR, 3.3; CI, 1.2 to 9.3, respectively). Higher OPP was associated with a decreased risk of geographic atrophy (GA) (OR, 0.4 per 10 mm Hg; CI, 0.3 to 0.5). Low pulse pressure was associated with a lower risk of exudative AMD (OR, 0.2; CI, 0.1 to 0.6). Obesity was associated with increased retinal pigment (OR, 1.6; CI, 1.0 to 2.3).
   CONCLUSIONS: These data suggest that in Latinos cardiovascular risk factors may play a role in advanced AMD. Given that Latinos have a high prevalence of cardiovascular risk factors, an intervention aimed at reducing these risk factors may also have a beneficial impact on the risk of having early and advanced AMD.
C1 [Azen, Stanley P.; Foong, Athena W. P.; Varma, Rohit] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Azen, Stanley P.; Foong, Athena W. P.; Varma, Rohit] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Fraser-Bell, Samantha; Azen, Stanley P.; Varma, Rohit] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
   [Wu, Joanne] Univ So Calif, Keck Sch Med, Dept Pharm, Los Angeles, CA 90033 USA.
   [Fraser-Bell, Samantha; Hooper, Claire] Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; University of Southern California; University of
   Southern California; University of Sydney; University of Wisconsin
   System; University of Wisconsin Madison
RP Varma, R (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Eye Inst, Suite 4900,1450 San Pablo St, Los Angeles, CA 90033 USA.
EM rvarma@usc.edu
RI Fraser-Bell, Samantha/ABE-8574-2020
OI Fraser-Bell, Samantha/0000-0001-5646-9359; Klein,
   Ronald/0000-0002-4428-6237; Wu, Joanne/0000-0003-0932-4979
FU NEI NIH HHS [U10 EY011753-04S1, U10 EY011753-09, U10 EY011753-06, U10
   EY011753-02, U10 EY011753-07, U10 EY011753-03S4, U10 EY011753, U10
   EY011753-03S2, U10 EY011753-10, U10 EY011753-03S1, U10 EY011753-03, U10
   EY011753-04, U10 EY011753-08S1, U10 EY011753-08, U10 EY011753-03S5, U10
   EY011753-05, U10 EY011753-03S3, P30 EY003040, U10 EY011753-07S1] Funding
   Source: Medline; NATIONAL EYE INSTITUTE [U10EY011753] Funding Source:
   NIH RePORTER
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   *US CENS BUR, PROJ RES POP RAC HIS
   *US DEP JUST, 1993, VNTR POP DAT WORLDW, P1
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 40
TC 50
Z9 53
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2008
VL 145
IS 2
BP 308
EP 316
DI 10.1016/j.ajo.2007.10.007
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 263GG
UT WOS:000253205000020
PM 18222193
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lee, CY
   Chen, HC
   Wu, PH
   Chi, JCY
   Sun, CC
   Huang, JY
   Lin, HY
   Yang, SF
AF Lee, Chia-Yi
   Chen, Hung-Chi
   Wu, Pei-Hsuan
   Chi, Jessie Chao-Yun
   Sun, Chi-Chin
   Huang, Jing-Yang
   Lin, Hung-Yu
   Yang, Shun-Fa
TI Increased incidence of age-related macular degeneration in sensorineural
   hearing loss: A population-based cohort study
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE STRESS; INFLAMMATION
AB Background
   To evaluate the incidence of age-related macular degeneration (AMD) in patients diagnosed with sensorineural hearing loss (SNHL) via the application of the National Health Insurance Research Database in Taiwan.
   Methodology/Principal findings
   A retrospective cohort study was conducted. Patients with a diagnosis of SNHL was enrolled in the study group after exclusion and a propensity score matched group without SNHL was served as the control group with a 1:2 ratio. The main outcome was regarded as the emergence of AMD diagnostic codes. Cox proportional hazard regression was applied to analyze the incidence and adjusted hazard ratio (aHR) of AMD in the multivariate model. A total of 15,686 patients with SNHL were included in the study group while another 31,372 non-SNHL patients served as the control group. After a follow-up interval up to 16 years, there were 484 AMD events occurred in the study group and 660 AMD cases in those non-SNHL patients with a significantly higher aHR compared to the control group after adjusting for multiple potential risk factors (aHR: 1.399, 95% CI: 1.244-1.574). Other prominent risk factors for AMD included older age, ischemic heart disease, hyperlipidemia, Alzheimer's disease, liver disease and kidney disease. Besides, a higher cumulative probability of AMD was observed in the study group (log-rank P < 0.0001).
   Conclusion
   The patients with SNHL demonstrated a higher incidence of developing AMD.
C1 [Lee, Chia-Yi; Lin, Hung-Yu] Show Chwan Mem Hosp, Dept Ophthalmol, Changhua, Taiwan.
   [Lee, Chia-Yi] Chung Hwa Univ Med Technol, Coll Med & Life Sci, Dept Optometry, Tainan, Taiwan.
   [Chen, Hung-Chi] Chang Gung Mem Hosp, Dept Ophthalmol, Linkou, Taiwan.
   [Chen, Hung-Chi] Chang Gung Univ, Dept Med, Coll Med, Taoyuan, Taiwan.
   [Chen, Hung-Chi] Chang Gung Mem Hosp, Ctr Tissue Engn, Linkou, Taiwan.
   [Wu, Pei-Hsuan] Triserv Gen Hosp, Dept Otolaryngol Head & Neck Surg, Taipei, Taiwan.
   [Chi, Jessie Chao-Yun; Lin, Hung-Yu; Yang, Shun-Fa] Chung Shan Med Univ, Inst Med, Taichung, Taiwan.
   [Chi, Jessie Chao-Yun] Taichung Hosp, Dept Otorhinolaryngol Head & Neck Surg, Minist Hlth & Welf, Taichung, Taiwan.
   [Sun, Chi-Chin] Chang Gung Mem Hosp, Dept Ophthalmol, Keelung, Taiwan.
   [Sun, Chi-Chin] Chang Gung Univ, Dept Chinese Med, Taoyuan, Taiwan.
   [Huang, Jing-Yang; Yang, Shun-Fa] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
   [Lin, Hung-Yu] Chung Shan Med Univ, Dept Optometry, Taichung, Taiwan.
   [Lin, Hung-Yu] Chung Chou Univ Sci & Technol, Dept Exercise & Hlth Promot, Changhua, Taiwan.
C3 Show Chwan Memorial Hospital; Chung Hua University; Chang Gung Memorial
   Hospital; Chang Gung University; Chang Gung Memorial Hospital;
   Tri-Service General Hospital; Chung Shan Medical University; Chang Gung
   Memorial Hospital; Chang Gung University; Chung Shan Medical University;
   Chung Shan Medical University Hospital; Chung Shan Medical University
RP Lin, HY (通讯作者)，Show Chwan Mem Hosp, Dept Ophthalmol, Changhua, Taiwan.; Lin, HY; Yang, SF (通讯作者)，Chung Shan Med Univ, Inst Med, Taichung, Taiwan.; Yang, SF (通讯作者)，Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan.; Lin, HY (通讯作者)，Chung Shan Med Univ, Dept Optometry, Taichung, Taiwan.; Lin, HY (通讯作者)，Chung Chou Univ Sci & Technol, Dept Exercise & Hlth Promot, Changhua, Taiwan.
EM anthonyhungyulin@hotmail.com; ysf@csmu.edu.tw
RI Yang, Shun-Fa/AAN-1519-2020
OI Yang, Shun-Fa/0000-0002-0365-7927; Chen, Hung-Chi/0000-0002-1117-7878
CR Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Biscetti Leonardo, 2017, Front Biosci (Elite Ed), V9, P174
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Bozkurt MK, 2011, J LARYNGOL OTOL, V125, P231, DOI 10.1017/S0022215110002604
   Chau JK, 2012, OTOLARYNG CLIN N AM, V45, P941, DOI 10.1016/j.otc.2012.06.002
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Di Stadio A, 2018, EUR REV MED PHARMACO, V22, P4611, DOI 10.26355/eurrev_201807_15520
   Frisina RD, 2016, AGING-US, V8, P2081, DOI 10.18632/aging.101045
   Frost S, 2016, CURR ALZHEIMER RES, V13, P1259, DOI 10.2174/1567205013666160603003800
   Golub JS, 2017, CURR OPIN OTOLARYNGO, V25, P347, DOI 10.1097/MOO.0000000000000387
   Gul F, 2017, EUR ARCH OTO-RHINO-L, V274, P1301, DOI 10.1007/s00405-016-4301-1
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kuhn M, 2011, TRENDS AMPLIF, V15, P91, DOI 10.1177/1084713811408349
   Kujawa SG, 2015, HEARING RES, V330, P191, DOI 10.1016/j.heares.2015.02.009
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Liberman MC, 2017, HEARING RES, V349, P138, DOI 10.1016/j.heares.2017.01.003
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martini A, 2014, AUDIOL NEURO-OTOL, V19, P2, DOI 10.1159/000371593
   McHugh KJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216215
   Moon SK, 2019, ANN OTO RHINOL LARYN, V128, p8S, DOI 10.1177/0003489419837689
   Paul A, 2017, AUDIOL NEURO-OTOL, V22, P83, DOI 10.1159/000474928
   Quaranta N, 2014, AUDIOL NEURO-OTOL, V19, P10, DOI 10.1159/000371597
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Scheltens P, 2016, LANCET, V388, P505, DOI 10.1016/S0140-6736(15)01124-1
   Schreiber BE, 2010, LANCET, V375, P1203, DOI 10.1016/S0140-6736(09)62071-7
   Shin IH, 2018, RETINA-J RET VIT DIS, V38, P253, DOI 10.1097/IAE.0000000000001535
   Smith SL, 2008, J REHABIL RES DEV, V45, P597, DOI 10.1682/JRRD.2007.02.0023
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stachler RJ, 2012, OTOLARYNG HEAD NECK, V146, pS1, DOI 10.1177/0194599812436449
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Wongrakpanich S, 2016, AGING DIS, V7, P763, DOI 10.14336/AD.2016.0515
   Wu CM, 2019, ACTA OPHTHALMOL, V97, pE713, DOI 10.1111/aos.14032
NR 33
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 23
PY 2019
VL 14
IS 10
AR e0222919
DI 10.1371/journal.pone.0222919
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LM9XB
UT WOS:000532599700015
PM 31644539
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cougnard-Gregoire, A
   Delyfer, MN
   Korobelnik, JF
   Rougier, MB
   Le Goff, M
   Dartigues, JF
   Barberger-Gateau, P
   Delcourt, C
AF Cougnard-Gregoire, Audrey
   Delyfer, Marie-Noelle
   Korobelnik, Jean-Francois
   Rougier, Marie-Benedicte
   Le Goff, Melanie
   Dartigues, Jean-Francois
   Barberger-Gateau, Pascale
   Delcourt, Cecile
TI Elevated High-Density Lipoprotein Cholesterol and Age-Related Macular
   Degeneration: The Alienor Study
SO PLOS ONE
LA English
DT Article
ID CARDIOVASCULAR RISK-FACTORS; 5-YEAR INCIDENCE; APOLIPOPROTEIN-E; STATIN
   USE; LOWERING MEDICATIONS; VISUAL IMPAIRMENT; LIPID-METABOLISM;
   MACULOPATHY; PREVALENCE; ASSOCIATION
AB Background: Lipid metabolism and particularly high-density lipoprotein (HDL) may be involved in the pathogenic mechanism of age-related macular degeneration (AMD). However, conflicting results have been reported in the associations of AMD with plasma HDL and other lipids, which may be confounded by the recently reported associations of AMD with HDL-related genes. We explored the association of AMD with plasma lipid levels and lipid-lowering medication use, taking into account most of HDL-related genes associated with AMD.
   Methods: The Alienor study is a population-based study on age-related eye diseases performed in 963 elderly residents of Bordeaux (France). AMD was graded from non mydriatic color retinal photographs in three exclusive stages: no AMD (n = 430 subjects, 938 eyes); large soft distinct drusen and/or large soft indistinct drusen and/or reticular drusen and/or pigmentary abnormalities (early AMD, n = 176, 247); late AMD (n = 40, 61). Associations of AMD with plasma lipids (HDL, total cholesterol (TC), Low-density lipoprotein (LDL), and triglycerides (TG)) were estimated using Generalized Estimating Equation logistic regressions. Statistical analyses included 646 subjects with complete data.
   Results: After multivariate adjustment for age, sex, educational level, smoking, BMI, lipid-lowering medication use, cardiovascular disease and diabetes, and for all relevant genetic polymorphisms (ApoE2, ApoE4, CFH Y402H, ARMS2 A69S, LIPC rs10468017, LIPC rs493258, LPL rs12678919, ABCA1 rs1883025 and CETP rs3764261), higher HDL was significantly associated with an increased risk of early (OR = 2.45, 95% CI: 1.54-3.90; P = 0.0002) and any AMD (OR = 2.29, 95% CI: 1.46-3.59; P = 0.0003). Association with late AMD was far from statistical significance (OR = 1.58, 95% CI: 0.48-5.17; p = 0.45). No associations were found for any stage of AMD with TC, LDL and TG levels, statin or fibrate drug use.
   Conclusions: This study suggests that elderly patients with high HDL concentration may be at increased risk for AMD and, further, that HDL dysfunction might be implicated in AMD pathogenesis.
C1 [Cougnard-Gregoire, Audrey; Delyfer, Marie-Noelle; Korobelnik, Jean-Francois; Le Goff, Melanie; Dartigues, Jean-Francois; Barberger-Gateau, Pascale; Delcourt, Cecile] Univ Bordeaux, Bordeaux, France.
   [Cougnard-Gregoire, Audrey; Delyfer, Marie-Noelle; Korobelnik, Jean-Francois; Le Goff, Melanie; Dartigues, Jean-Francois; Barberger-Gateau, Pascale; Delcourt, Cecile] INSERM, ISPED, Ctr INSERM Epidemiol Biostat U897, Bordeaux, France.
   [Delyfer, Marie-Noelle; Korobelnik, Jean-Francois; Rougier, Marie-Benedicte] Ctr Hosp Univ CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
C3 UDICE-French Research Universities; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); CHU Bordeaux
RP Cougnard-Gregoire, A (通讯作者)，Univ Bordeaux, Bordeaux, France.
EM Audrey.Cougnard-Gregoire@isped.u-bordeaux2.fr
RI LE GOFF, Mélanie/A-3541-2016; Delyfer, Marie-Noelle/T-3304-2019;
   DARTIGUES, Jean François/T-4513-2019; Delcourt, Cecile/I-2627-2013;
   COUGNARD-GREGOIRE, Audrey/T-4443-2019; KOROBELNIK,
   Jean-Francois/A-5448-2016
OI Delcourt, Cecile/0000-0002-2099-0481; COUGNARD-GREGOIRE,
   Audrey/0000-0002-1494-5764; LE GOFF, Melanie/0000-0003-2848-6287
FU Laboratoires Thea (Clermont-Ferrand, France), Fondation Voir et Entendre
   (Paris, France),
FX Laboratoires Thea (Clermont-Ferrand, France), Fondation Voir et Entendre
   (Paris, France), Laboratoires Thea participated in the design of the
   study, but no sponsor participated in the collection, management,
   statistical analysis and interpretation of the data, nor in the
   preparation, review or approval of the present manuscript.
CR Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Bindu GH, 2011, CHOLESTEROL, DOI 10.1155/2011/274629
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Davari MH, 2013, J RES HEALTH SCI, V13, P98
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2011, INVEST OPHTH VIS SCI, DOI [10.11673443.10-6235, DOI 10.1167/IOVS910-6235]
   Drobek-Slowik Monika, 2008, Klin Oczna, V110, P50
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Eren Esin, 2012, Open Biochem J, V6, P78, DOI 10.2174/1874091X01206010078
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   Fisher EA, 2012, ARTERIOSCL THROM VAS, V32, P2813, DOI 10.1161/ATVBAHA.112.300133
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2005, IOVS, V46, P199
   Gehlbach P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub3
   Hall Nigel F, 2002, Expert Opin Pharmacother, V3, P803
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Merle BM, PLOS ONE IN PRESS
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Peponis V, 2010, CLIN OPHTHALMOL, V4, P865
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   TSANG NCK, 1992, DOC OPHTHALMOL, V81, P387
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 84
TC 72
Z9 75
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 7
PY 2014
VL 9
IS 3
AR e90973
DI 10.1371/journal.pone.0090973
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AC4IY
UT WOS:000332485800071
PM 24608419
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Menke, MN
   Feke, GT
AF Menke, MN
   Feke, GT
TI Assessment of the effects of morphological changes related to
   age-related macular degeneration on optical coherence tomography retinal
   thickness measurements
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID DIABETIC-PATIENTS; OCT; REPRODUCIBILITY; REPEATABILITY
AB BACKGROUND AND OBJECTIVE: Age-related macular degeneration (AMD) leads to morphological changes that can interfere with optical coherence tomography retinal thickness measurements. The effects of AMD on two available retinal thickness scan modes were tested.
   PATIENTS AND METHODS: Ninety-four scans, equally divided into Radial Line Scans (RLS) and Fast Macula Scans (FMS), of 42 patients with AMD were reviewed. Patients were graded into 4 categories regarding AMD severity. Each scan mode was evaluated for each AMD category.
   RESULTS: In dry moderate AMD, 2% of the RLS and 5% of the FMS thickness measurements failed. In dry progressed AMD, the RLS mode performed better (26% failure rate) than the FMS mode (42% failure rate). However, in exudative AMD the FMS mode performed better (6% failure rate) than the RLS mode (28% failure rate). The difference between the RLS and FMS performance in dry progressed AMD compared with exudative AMD was significant (P <.0001).
   CONCLUSION: The optical coherence tomography retinal thickness scan modes perform differently, depending on AMD severity. Retinal thickness algorithms with better performance are needed to facilitate measurements in patients with AMD.
C1 Schepens Retina Associates Fdn, Boston, MA 02215 USA.
   Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   University; Harvard Medical School
RP Menke, MN (通讯作者)，Schepens Retina Associates Fdn, 1 Autumn St,6th Floor, Boston, MA 02215 USA.
OI Menke, Marcel/0000-0002-6561-6178
CR Baumann M, 1998, OPHTHALMIC SURG LAS, V29, P280
   Goebel W, 2002, RETINA-J RET VIT DIS, V22, P759, DOI 10.1097/00006982-200212000-00012
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Koozekanani D, 2000, INVEST OPHTH VIS SCI, V41, P1486
   Lattanzio R, 2002, EUR J OPHTHALMOL, V12, P482, DOI 10.1177/112067210201200606
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Massin P, 2002, EUR J OPHTHALMOL, V12, P102, DOI 10.1177/112067210201200205
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Muscat S, 2002, INVEST OPHTH VIS SCI, V43, P490
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
   Yang CS, 2001, ACTA OPHTHALMOL SCAN, V79, P266, DOI 10.1034/j.1600-0420.2001.790311.x
NR 13
TC 7
Z9 7
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1082-3069
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JUL-AUG
PY 2005
VL 36
IS 4
BP 310
EP 314
DI 10.3928/1542-8877-20050701-10
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 968DA
UT WOS:000232140900008
PM 16156148
DA 2022-11-30
ER

PT J
AU Li, YL
   Li, X
   Li, XY
   Zeng, ZH
   Strang, N
   Shu, XH
   Tan, ZJ
AF Li, Yuli
   Li, Xing
   Li, Xiaoya
   Zeng, Zhihong
   Strang, Niall
   Shu, Xinhua
   Tan, Zhoujin
TI Non-neglectable therapeutic options for age-related macular
   degeneration: A promising perspective from traditional Chinese medicine
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Age-related macular degeneration; Pathogenesis; Therapy; Traditional
   Chinese medicine
ID LYCIUM-BARBARUM; OXIDATIVE STRESS; DAMAGE; INFLAMMATION; MECHANISMS;
   CELLS; APOPTOSIS; PROTECTS; PATHWAY; BURDEN
AB Ethnopharmacological relevance: Age-related macular degeneration (AMD) is a chronic neurodegenerative disease which causes irreversible central vision loss among the elderly population. Traditional Chinese Medicine (TCM), including formulas, acupuncture and herbs, has been used in the treatment of AMD for thousands of years and is currently used by many AMD patients around the world. Aim of the review: A comprehensive, in-depth literature review examining the use of TCM in the treatment of AMD has yet to be compiled. This review will improve current knowledge relating to the use of TCM and will open new avenues of exploration in developing new drugs for the treatment of AMD. Methods: A literature search of the PubMed database, Web of Science, Google Scholar and China National Knowledge Infrastructure (CNKI) was performed using relevant terms and keywords related to TCM in the treatment of AMD. Related books, PhD and master's theses were also researched. Results: The TCM-based interpretation of AMD has been used to establish a theoretical foundation for understanding the effect of TCM formulas and acupuncture on AMD. The possible mechanism of action of common Chinese herbs has also been discussed in detail. Conclusion: TCM is a promising treatment option of AMD patients. However, lack of rigorous scientific evidence has limited the impact and uptake of TCM therapy. Future research should focus on improving understanding of the mechanism of action and bioactive components of TCM therapies.
C1 [Li, Yuli; Li, Xiaoya; Tan, Zhoujin] Hunan Univ Chinese Med, Coll Chinese Med, Changsha 410208, Hunan, Peoples R China.
   [Li, Xing; Shu, Xinhua] Shaoyang Univ, Sch Basic Med Sci, Shaoyang 422000, Hunan, Peoples R China.
   [Zeng, Zhihong] Changsha Univ, Coll Biol & Environm Engn, Changsha 410022, Hunan, Peoples R China.
   [Strang, Niall; Shu, Xinhua] Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Shu, Xinhua] Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.
C3 Hunan University of Chinese Medicine; Shaoyang University; Changsha
   University; Glasgow Caledonian University; Glasgow Caledonian University
RP Tan, ZJ (通讯作者)，Hunan Univ Chinese Med, Coll Chinese Med, Changsha 410208, Hunan, Peoples R China.; Shu, XH (通讯作者)，Shaoyang Univ, Sch Basic Med Sci, Shaoyang 422000, Hunan, Peoples R China.
EM Xinhua.Shu@gcu.ac.uk; tanzhjin@sohu.com
RI Tan, Zhoujin/V-9258-2019; Zeng, Zhihong/HEV-8703-2022
OI Tan, Zhoujin/0000-0003-3193-073X; 
FU Rosetrees Trust [M160, M160-F1, M160-F2]; National Eye Research Centre
   [SAC037]; Lotus Scholarship Program of Hunan Province (2019)
FX This work was supported by the Rosetrees Trust (M160, M160-F1, M160-F2)
   , National Eye Research Centre (SAC037) and the Lotus Scholarship
   Program of Hunan Province (2019) .
CR Al Sabaani N, 2020, J OCUL PHARMACOL TH, V36, P563, DOI 10.1089/jop.2019.0151
   Alhasani RH, 2018, FOOD CHEM TOXICOL, V112, P76, DOI 10.1016/j.fct.2017.12.037
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson G, 2018, STEM CELLS, V36, P626, DOI 10.1002/stem.2792
   Arnett JJ, 2020, RETINA-J RET VIT DIS, V40, P1719, DOI 10.1097/IAE.0000000000002666
   Arumugam B, 2019, MOL VIS, V25, P47
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Biswas L, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2020.107931
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cao J, 2016, THESIS HEILONGJJANG
   Chan HHL, 2020, CURR ALLERGY ASTHM R, V20, DOI 10.1007/s11882-020-00959-9
   Chang RCC, 2008, CELL MOL NEUROBIOL, V28, P643, DOI 10.1007/s10571-007-9181-x
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Committee Editorial., 2016, NAM LOC AUR AC POINT
   Du MZ, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3140290
   Due WW, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1610751
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fan KS, 2017, MOL MED REP, V16, P9023, DOI 10.3892/mmr.2017.7743
   Fu J., 2019, GUIZHOU MED J, V43, P1050, DOI [10.3969/j.issn.1000- 744X.2019.07.012, DOI 10.3969/J.ISSN.1000-744X.2019.07.012]
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gao N., 2014, CHIN HIGH ALT MED BI, V35, P232, DOI [10.13452/j.cnki.jqmc.2014.04.004, DOI 10.13452/J.CNKI.JQMC.2014.04.004]
   Gopinath B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04697-3
   Guo Y.F., 2018, CHINA BREWING, V37, P160, DOI DOI 10.11882/J.ISSN.0254-5071.2018.12.031
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   Han DM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33552-2
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   He Yuan, 2010, J Ocul Biol Dis Infor, V3, P92, DOI 10.1007/s12177-011-9061-y
   He YX, 2014, INT J MOL SCI, V15, P14456, DOI 10.3390/ijms150814456
   Hesp K, 2015, EXP GERONTOL, V72, P1, DOI 10.1016/j.exger.2015.09.006
   Hou L., 2017, THESIS CHIN ACAD CHI
   [胡平会 Hu Pinghui], 2019, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V34, P2923
   Hu Y., 2013, INT EYE SCI, V13, P546, DOI [10.3980/j.issn.1672- 5123.2013.03.36, DOI 10.3980/J.ISSN.1672-5123.2013.03.36]
   Huang BingLin, 2013, Chinese Journal of Integrated Traditional and Western Medicine, V33, P531
   Huang L-x, 2010, WHO STANDARD ACUPUNC
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Hytti M, 2017, J NUTR BIOCHEM, V42, P37, DOI 10.1016/j.jnutbio.2016.12.014
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jeong JW, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-101
   Jiang B, 2004, TOXICON, V43, P53, DOI 10.1016/j.toxicon.2003.10.017
   [蒋鹏飞 Jiang Pengfei], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P136
   Jiao Nai-jun, 2011, Zhongguo Zhen Jiu, V31, P43
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Krenn H, 2008, DTSCH Z AKUPUNKT, V51, P25, DOI 10.1016/j.dza.2008.08.001
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Lee SR, 2017, BIOORG CHEM, V70, P94, DOI 10.1016/j.bioorg.2016.11.012
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Li Guimin, 2017, Zhongguo Zhen Jiu, V37, P1294, DOI 10.13703/j.0255-2930.2017.12.011
   Li HF, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4856761
   Li L, 2020, J CELL PHYSIOL, V235, P1259, DOI 10.1002/jcp.29041
   Li SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016380
   Li X., 2019, J SICHUAN TRADIT CHI, V37, P160
   Liao J., 2013, CHIN J CHIN OPHTHALM, V23, P250
   Liu L, 2020, NEURAL REGEN RES, V15, P1526, DOI 10.4103/1673-5374.274349
   Liu LB, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22052
   Liu W, 2009, THESIS GUANGZHOU U C
   Liu XF, 2019, INT J BIOL MACROMOL, V127, P39, DOI 10.1016/j.ijbiomac.2019.01.029
   Liu Y., 2018, JIANGSU J TRADIT CHI, V50, P31, DOI [10.3969/j.issn.1672- 397X.2018.08.012, DOI 10.3969/J.ISSN.1672-397X.2018.08.012]
   Lu P., 2012, SHANGHAI J TRADIT CH, V46, P71
   Luo Y. F., 2008, FUNDAMENTALS ACUPUNC
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Meng H., 2020, BEIJING J TRADIT CHI, V39, P891
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Oh YC, 2019, MOLECULES, V24, DOI 10.3390/molecules24203755
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   [欧晨 Ou Chen], 2020, [中国中医药信息杂志, Chinese Journal of Information on Traditional Chinese Medicine], V27, P141
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Petrukhin Konstantin, 2013, Drug Discov Today Ther Strateg, V10, pe11
   [齐若 Qi Ruo], 2018, [吉林大学学报. 医学版, Journal of Jilin Univeristy. Medicine edition], V44, P111
   Qin C, 2017, THESIS NANJING U TRA
   Qin Chengyao, J TIANJIN U TRADIT C, V40, P42, DOI [10.11656/j.issn.1673- 9043.2021.01.09, DOI 10.11656/J.ISSN.1673-9043.2021.01.09]
   Qiu Manling, 2020, CHIN J CHIN OPHTHALM, V30, P793, DOI [10.13444/j.cnki.zgzyykzz.2020.11.008, DOI 10.13444/J.CNKI.ZGZYYKZZ.2020.11.008]
   Quan L., 2020, J CLIN INTERN MED, V37, P371, DOI [10.3969/j.issn.1001-9057.2020.05.016, DOI 10.3969/J.ISSN.1001-9057.2020.05.016]
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P5228, DOI 10.1167/iovs.14-14299
   Ruszkowska-Ciastek B, 2014, J ZHEJIANG UNIV-SC B, V15, P575, DOI 10.1631/jzus.B1400024
   Salimiaghdam N, 2019, OPEN OPHTHALMOL J, V13, P90, DOI 10.2174/1874364101913010090
   Shen Z., 2013, OPHTHALMOL CHIN, V22, P405
   Si J., 2015, THESIS SHANDONG U TR
   Su J., 2017, CHIN J CHIN OPHTHALM, V27, P223, DOI [10.13444/j.cnki.zgzyykzz.2017.04.003, DOI 10.13444/J.CNKI.ZGZYYKZZ.2017.04.003]
   Sun R, 2020, EXPERT OPIN DRUG DEL, V17, P1305, DOI 10.1080/17425247.2020.1783236
   Tao F., 2020, CHIN J CHIN OPHTHALM, V30, P537, DOI [10.13444/j.cnki.zgzyykzz.2020.08.002, DOI 10.13444/J.CNKI.ZGZYYKZZ.2020.08.002]
   Thomas CJ, 2021, MED CLIN N AM, V105, P473, DOI 10.1016/j.mcna.2021.01.003
   Tian N., 2013, INT EYE SCI, V13, P1525, DOI [10.3980/j. issn.1672-5123.2013.08.03, DOI 10.3980/J.ISSN.1672-5123.2013.08.03]
   Tuekprakhon A, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-020-02122-7
   Wang J, 2010, ACTA PHARMACOL SIN, V31, P791, DOI 10.1038/aps.2010.71
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Wang M, 2020, J ETHNOPHARMACOL, V249, DOI 10.1016/j.jep.2019.112385
   Wang Y., 2019, WORLD CHIN MED, V14, DOI [10.3969/j.issn.1673-7202.2019.10.031, DOI 10.3969/J.ISSN.1673-7202.2019.10.031]
   [汪怿 Wang Yi], 2015, [中国临床药理学杂志, The Chinese Journal of Clinical Pharmacology], V31, P1393
   [王芝艳 Wang Zhiyan], 2016, [中国临床药理学杂志, The Chinese Journal of Clinical Pharmacology], V32, P2059
   Weiss Jeffrey N, 2018, Stem Cell Investig, V5, P18, DOI 10.21037/sci.2018.04.02
   Weng SS, 2017, MOL MED REP, V16, P3461, DOI 10.3892/mmr.2017.6964
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu X., 2018, SHANGHAI J TRADIT CH, V52, P65, DOI [10.16305/j.1007-1334.2018.01.020, DOI 10.16305/J.1007-1334.2018.01.020]
   Xia Y., 2013, J ACUPUNCTURE TUINA, V11, P358, DOI [10.1007/s11726-013-0732-z, DOI 10.1007/S11726-013-0732-Z]
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu K., 2018, THESIS CHINA ACAD CH
   Yan TQ, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0154-3
   Yang B, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.925087
   Yang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033596
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134658
   Yang Y., 2020, J NEW CHIN MED, V52, P126, DOI [10.13457/j.cnki.jncm.2020.01.036, DOI 10.13457/J.CNKI.JNCM.2020.01.036]
   Yuan X, 2020, BIOORG CHEM, V101, DOI 10.1016/j.bioorg.2020.104016
   Yuan YY, 2019, MOLECULES, V24, DOI 10.3390/molecules24244592
   Zhang HuiXi, 2016, Journal of Hainan Medical University, V22, P2365
   Zhang J., 2004, CHIN ARCH TRADIT CHI, V23, P1198, DOI [10.3969/j.issn.1673-7717.2004.07.023, DOI 10.3969/J.ISSN.1673-7717.2004.07.023]
   Zhang J., 2019, CHIN ARCH TRADIT CHI, V37, P978, DOI [10.13193/j.issn.1673- 7717.2019.04.049, DOI 10.13193/J.ISSN.1673-7717.2019.04.049]
   Zhang Q., 2017, THESIS HUBEI U TRADI
   Zhang X., 2017, J TIANJIN U TRADIT C, V36, P187, DOI [10.11656/j.issn.1673-9043.2017.03.08, DOI 10.11656/J.ISSN.1673-9043.2017.03.08]
   Zhang XJ, 2019, EXP MOL PATHOL, V110, DOI 10.1016/j.yexmp.2019.104281
   Zhang ZC, 2020, J ETHNOPHARMACOL, V255, DOI 10.1016/j.jep.2020.112715
   Zhao H., 2013, CHIN J EXP TRADIT ME, V19, P330, DOI [10.11653/syfj2013180330, DOI 10.11653/SYFJ2013180330]
   Zhao JM, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106173
   Zheng J., 2015, SHANGHAI J ACUPUNCT, V34, P335, DOI [10.13460/j.issn.1005- 0957.2015.04.0335, DOI 10.13460/J.ISSN.1005-0957.2015.04.0335]
   Zhong Q., 2015, THESIS GUANGZHOU U C
   Zhou Yun-feng, 2017, Chinese Pharmacological Bulletin, V33, P915, DOI 10.3969/j.issn.1001-1978.2017.07.007
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
   Zhu H., 2015, CHIN J CHIN OPHTHALM, V25, P265, DOI [10.13444/j.cnki.zgzyykzz.2015.04.010, DOI 10.13444/J.CNKI.ZGZYYKZZ.2015.04.010]
   Zhu HF, 2016, CHIN MED-UK, V11, DOI 10.1186/s13020-016-0096-7
   Zhu YF, 2016, J ETHNOPHARMACOL, V191, P125, DOI 10.1016/j.jep.2016.05.037
   Zhuo Y., 2013, CHIN J CHIN OPHTHALM, V23, P36
NR 124
TC 6
Z9 6
U1 25
U2 34
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
EI 1872-7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JAN 10
PY 2022
VL 282
AR 114531
DI 10.1016/j.jep.2021.114531
EA SEP 2021
PG 16
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA WD4NK
UT WOS:000704919300010
PM 34474141
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kubicka-Trzaska, A
   Wilanska, J
   Romanowska-Dixon, B
   Sanak, M
AF Kubicka-Trzaska, Agnieszka
   Wilanska, Joanna
   Romanowska-Dixon, Bozena
   Sanak, Marek
TI Serum anti-endothelial cell antibodies in patients with age-related
   macular degeneration treated with intravitreal bevacizumab
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE anti-endothelial cells autoantibodies; antiretinal antibodies;
   age-related macular degeneration; bevacizumab
ID CIRCULATING ENDOTHELIAL-CELLS; ANTI-RETINAL ANTIBODIES;
   BLUE-MOUNTAINS-EYE; PROGENITOR CELLS; BEHCETS-DISEASE; CANCER-PATIENTS;
   RANIBIZUMAB; VASCULITIS; MARKERS
AB PurposeTo analyse the prevalence and changes in circulating anti-endothelial cell antibodies (AECA) during anti-vascular endothelial growth factor (anti-VEGF) therapy.
   MethodsNinety-eight patients with exudative age-related macular degeneration (AMD) were treated with intravitreal bevacizumab. Fifty sex- and age-matched healthy subjects were used as controls. Serum AECA were detected using indirect immunofluorescence on primate skeletal muscle and cultivated human umbilical vein endothelial cells (HUVEC). These investigations were repeated at 4-week intervals within 8months of follow-up.
   ResultsAt baseline examination, 30 of the 98 patients (30.6%) were positive for AECA. The titres of AECA ranged from 1:10 to 1:320. In the control group, AECA were present in only nine sera (18%) with titres ranging between 1:20 and 1:80 (p=0.0000). The greatest rates of reduction of AECA titres were observed during the loading' phase of therapy. During the maintenance' phase, the rates of changes in serum AECA levels were less significant and remained constant. In follow-up period in 13 patients (13.3%), serum AECA were detected de novo in titres of 1:10 to 1:80. Statistical analysis did not show any significant correlation between the presence of AECA and activity of the disease.
   ConclusionsThere is growing evidence that AMD is an immune-mediated disease, and thus it cannot be excluded that AECA may be involved in its pathogenesis and progression. We also speculate that AECA develop in response to retinal damage and anti-VEGF therapy.
C1 [Kubicka-Trzaska, Agnieszka; Romanowska-Dixon, Bozena] Jagiellonian Univ, Dept Ophthalmol & Ocular Oncol, Coll Med, Krakow, Malopolska, Poland.
   [Wilanska, Joanna; Sanak, Marek] Jagiellonian Univ, Div Mol Biol & Clin Genet, Coll Med, Krakow, Malopolska, Poland.
C3 Jagiellonian University; Collegium Medicum Jagiellonian University;
   Jagiellonian University; Collegium Medicum Jagiellonian University
RP Kubicka-Trzaska, A (通讯作者)，Kopernika Str 38, PL-31501 Krakow, Poland.
EM akubicka@onet.pl
RI Sanak, Marek/AAV-1628-2021
OI Sanak, Marek/0000-0001-7635-8103
FU Polish Ministry of Science and Tertiary Education [K/PBH/000052]
FX The work was supported by a grant (K/PBH/000052) from the Polish
   Ministry of Science and Tertiary Education.
CR Bakri SJ, 2007, OPHTHALMOLOGY, V90, P1316
   Belizna C, 2006, ANN RHEUM DIS, V65, P1545, DOI 10.1136/ard.2005.035295
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Costa R, 2009, J CELL BIOCHEM, V108, P1410, DOI 10.1002/jcb.22378
   Edelsten C, 1997, CLIN REV ALLERG IMMU, V15, P41, DOI 10.1007/BF02828276
   EDELSTEN C, 1992, CURR EYE RES, V11, P203, DOI 10.3109/02713689208999534
   Emmi L, 1995, CLIN EXP RHEUMATOL, V13, P687
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Guilpain P, 2008, CLIN REV ALLERG IMMU, V35, P59, DOI 10.1007/s12016-007-8069-3
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Haefliger IO, 2001, PROG RETIN EYE RES, V20, P209, DOI 10.1016/S1350-9462(00)00020-3
   Haznedaroglu IC, 1996, THROMB HAEMOSTASIS, V75, P974
   Jarius S, 2009, J NEUROL SCI, V285, P259, DOI 10.1016/j.jns.2009.07.002
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Karlstetter M, 2012, KLIN MONATSBL AUGENH, V229, P221, DOI 10.1055/s-0031-1282050
   Kubicka-Trzaska A, 2014, ACTA OPHTHALMOL, V92, pe610, DOI 10.1111/aos.12435
   Kubicka-Trzaska A, 2012, ACTA OPHTHALMOL, V90, pE21, DOI 10.1111/j.1755-3768.2011.02237.x
   Kubicka-Trzaska Agnieszka, 2009, Przegl Lek, V66, P944
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Machaliska A, 2010, INVEST OPHTH VIS SCI, V52, P93
   Nolle B, 1994, Z Arztl Fortbild (Jena), V88, P597
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Perez-Rico C, 2010, BRIT J OPHTHALMOL, V94, P267, DOI 10.1136/bjo.2008.153353
   Ronzoni M, 2010, ANN ONCOL, V21, P2382, DOI 10.1093/annonc/mdq261
   Roodhart JM, 2010, NEOPLASIA, V12, P87, DOI 10.1593/neo.91460
   Scotti F, 2014, RETINA-J RET VIT DIS, V34, P1802, DOI 10.1097/IAE.0000000000000147
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Thanigaimani S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e13585
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Yu M, 2012, INVEST OPHTH VIS SCI, V19, P7684
NR 31
TC 7
Z9 7
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2016
VL 94
IS 7
BP E617
EP E623
DI 10.1111/aos.13033
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EA5BI
UT WOS:000386631400014
PM 27329255
DA 2022-11-30
ER

PT J
AU Limoli, PG
   Limoli, C
   Vingolo, EM
   Scalinci, SZ
   Nebbioso, M
AF Limoli, Paolo Giuseppe
   Limoli, Celeste
   Vingolo, Enzo Maria
   Scalinci, Sergio Zaccaria
   Nebbioso, Marcella
TI Cell surgery and growth factors in dry age-related macular degeneration:
   visual prognosis and morphological study
SO ONCOTARGET
LA English
DT Article
DE age-related macular degeneration (AMD); cell autologous graft; growth
   factors (GFs); limoli retinal restoration technique (LRRT);
   suprachoroidal graft; Gerotarget
ID RICH; ANGIOGENESIS; EXPRESSION; PLATELETS
AB Background: The aim of this research was to study the overall restoration effect on residual retinal cells through surgically grafted autologous cells onto the surrounding tissue, choroid and retina in order to produce a constant secretion of growth factors (GFs) in dry age-related macular degeneration (AMD) patients.
   Results: 6 months after surgery, several values were statistically significant in the group with higher RTA. Also patient compliance analysis (PCA) in relation to functional change perception appeared to be very good.
   Methods: Thirty-six eyes of 25 patients (range 64-84 years of age) affected by dry AMD were included in study, and divided in two groups by spectral domain-optical coherence tomography (SD-OCT): group A with retinal thickness average (RTA) less than 250 microns (mu m) and group B with RTA equal to or more than 250 mu m. Adipocytes, adipose-derived stem cells from the stromal-vascular fraction, and platelets from platelet-rich plasma were implanted in the suprachoroidal space. Particularly, the following parameters were evaluated: best corrected visual acuity (BCVA) for far and near distance, retinal thickness maps, scotopic and photopic electroretinogram (ERG), and microperimetry (MY). All statistical analyses were performed with STATA 14.0 (Collage Station, Texas, USA).
   Conclusions: The available set of GFs allowed biological retinal neuroenhancement. After 6 months it improved visual performance (VP), but the increase was better if RTA recorded by OCT was higher, probably in relation to the presence of areas with greater cellularity.
C1 [Limoli, Paolo Giuseppe; Limoli, Celeste] Low Vis Res Ctr Milan, Milan, Italy.
   [Vingolo, Enzo Maria] Univ Roma La Sapienza, Polo Pontino, Terracina, Dept Ophthalmol,A Fiorini Hosp, Rome, Italy.
   [Scalinci, Sergio Zaccaria] Univ Bologna, S Orsola Malpighi Hosp, Dept Ophthalmol, Glaucoma & Low Vis Study Ctr, Bologna, Italy.
   [Nebbioso, Marcella] Univ Roma La Sapienza, Fac Med & Odontol, Dept Sense Organs, Rome, Italy.
C3 Sapienza University Rome; IRCCS Azienda Ospedaliero-Universitaria di
   Bologna; University of Bologna; Sapienza University Rome
RP Nebbioso, M (通讯作者)，Univ Roma La Sapienza, Fac Med & Odontol, Dept Sense Organs, Rome, Italy.
EM marcella.nebbioso@uniroma1.it
RI Limoli, Paolo/AAB-9828-2021; Vingolo, Enzo Maria/E-6674-2010; Nebbioso,
   Marcella/K-6878-2018
OI Vingolo, Enzo Maria/0000-0002-8363-5866; Nebbioso,
   Marcella/0000-0002-5512-0849
CR Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   Anitua E, 2004, THROMB HAEMOSTASIS, V91, P4, DOI 10.1160/TH03-07-0440
   Anitua E, 2015, J CONTROL RELEASE, V202, P31, DOI 10.1016/j.jconrel.2015.01.029
   Bagchi M, 2013, FASEB J, V27, P3257, DOI 10.1096/fj.12-221812
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chen GF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073673
   Daftarian Narsis, 2010, J Ophthalmic Vis Res, V5, P250
   FILATOV V P, 1951, Med Gen Fr, V11, P3
   Grover S, 2009, AM J OPHTHALMOL, V148, P266, DOI 10.1016/j.ajo.2009.03.006
   Jin X., 2015, CURR MOL PHARM
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SY, 2003, EXP EYE RES, V77, P433, DOI 10.1016/S0014-4835(03)00174-X
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Lawrence Naomi, 2002, J Am Acad Dermatol, V47, P105, DOI 10.1067/mjd.2002.122189
   Li Q, 2014, CELL BIOCHEM BIOPHYS, V69, P189, DOI 10.1007/s12013-013-9769-3
   Limoli PG, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000355
   Limoli PG, 2011, INVEST OPHTH VIS SCI, V52, P437
   Limoli PG, 2015, ARVO M DENV US 3 7 M
   Lindroos B, 2011, STEM CELL REV REP, V7, P269, DOI 10.1007/s12015-010-9193-7
   Luo S, 2013, TOHOKU J EXP MED, V231, P101, DOI 10.1620/tjem.231.101
   Mammoto T, 2013, MICROVASC RES, V89, P15, DOI 10.1016/j.mvr.2013.04.008
   Meduri R, 2007, ANN M FORT LAUD ARVO
   Modarressi A, 2013, WORLD J PLAST SURG, V2, P6
   Pelaez O, 1997, RETINITIS PIGMENTOSA
   Qureshi AH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007627
   Rabin DM, 2013, AGING-US, V5, P51
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Schaffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006-0589
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Ueki Y, 2013, GLIA, V61, P778, DOI 10.1002/glia.22472
   Wang P, 2008, J CELL PHYSIOL, V216, P3, DOI 10.1002/jcp.21386
   Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 36
TC 28
Z9 30
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 26
PY 2016
VL 7
IS 30
BP 46913
EP 46923
DI 10.18632/oncotarget.10442
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY8WP
UT WOS:000385413000009
PM 27391437
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Sanjay, S
   Neo, HY
   Sangtam, T
   Ku, JY
   Chau, SYM
   Rostihar, AK
   Eong, KGA
AF Sanjay, Srinivasan
   Neo, Hui Yee
   Sangtam, Tiakumzuk
   Ku, Jae Yee
   Chau, Shirley Y. M.
   Rostihar, Abdul Karim
   Eong, Kah-Guan Au
TI Survey on the knowledge of age-related macular degeneration and its risk
   factors among Singapore residents
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; awareness; population survey;
   Singapore; smoking
ID EYE DISEASES; MACULOPATHY; PREVALENCE; AUSTRALIA
AB P>Purpose:
   To assess the awareness of age-related macular degeneration (AMD) and its risk factors among Singapore residents.
   Methods:
   A cross-sectional questionnaire-based telephone survey was conducted to ascertain the awareness of AMD with regards to knowledge of the disease entity and possible risk factors among Singapore residents. A Singapore residential telephone directory was used to identify potential households by choosing the first and last entries on randomly selected pages. Respondents included individuals from households with landline telephone connection who were willing to participate in the study after a brief introduction about the study. Verbal consent was sought before proceeding with the interview. Interpreters were used for respondents whose ability to converse in English was limited. Prior to commencement of the study, the protocol was reviewed and approved by Ethics committee of the Domain Specific Review Board.
   Results:
   The interviewers contacted 796 subjects from different households, of which 520 participated (response rate, 65.3%). The age of the respondents ranged from 18 to 85 (median 41) years. Only 38 (7.3%) of them were aware of AMD, the majority of whom had completed secondary or higher education. Two hundred (38.5%) and 191 (36.7%) of the respondents considered age and smoking, respectively, to be risk factors for AMD.
   Conclusions:
   The awareness of AMD among Singapore residents is low. AMD awareness needs to be improved by educational programmes designed for this specific purpose.
C1 [Sanjay, Srinivasan; Neo, Hui Yee; Sangtam, Tiakumzuk; Ku, Jae Yee; Chau, Shirley Y. M.; Rostihar, Abdul Karim; Eong, Kah-Guan Au] Alexandra Hosp, Dept Ophthalmol & Visual Sci, Singapore 159964, Singapore.
   [Sanjay, Srinivasan; Sangtam, Tiakumzuk; Chau, Shirley Y. M.; Eong, Kah-Guan Au] Natl Univ Singapore, Jurong Med Ctr, Yong Loo Lin Sch Med, Singapore 117548, Singapore.
   [Eong, Kah-Guan Au] Natl Univ Singapore, Dept Ophthalmol, Yong Loo Lin Sch Med, Singapore 117548, Singapore.
   [Eong, Kah-Guan Au] Mt Elizabeth Med Ctr, Singapore Int Eye Cataract Retina Ctr, Singapore, Singapore.
C3 National University of Singapore; National University of Singapore;
   Mount Elizabeth Medical Centre
RP Sanjay, S (通讯作者)，Alexandra Hosp, Dept Ophthalmol & Visual Sci, 378 Alexandra Rd, Singapore 159964, Singapore.
EM sanjay_s@alexhosp.com.sg
RI Neo, Harvey/AAH-8483-2019
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Attebo K, 1997, AUST NZ J OPHTHALMOL, V25, P283, DOI 10.1111/j.1442-9071.1997.tb01516.x
   Bidwell G, 2005, EYE, V19, P945, DOI 10.1038/sj.eye.6701955
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lau JTF, 2002, BRIT J OPHTHALMOL, V86, P1080, DOI 10.1136/bjo.86.10.1080
   Livingston PM, 1998, BRIT J OPHTHALMOL, V82, P780, DOI 10.1136/bjo.82.7.780
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Noertjojo K, 2006, CAN J OPHTHALMOL, V41, P617, DOI 10.1016/S0008-4182(06)80035-9
   Rosenthal Bruce, 2003, Optometry, V74, P16
   The Royal College of Ophthalmologists, 2017, NAT EL AG REL MAC DA
NR 10
TC 10
Z9 10
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD NOV
PY 2009
VL 37
IS 8
BP 795
EP 800
DI 10.1111/j.1442-9071.2009.02153.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 513GX
UT WOS:000271311800008
PM 19878225
DA 2022-11-30
ER

PT J
AU Polito, A
   Isola, M
   Lanzetta, P
   Gregori, D
   Bandello, F
AF Polito, Antonio
   Isola, Miriam
   Lanzetta, Paolo
   Gregori, Dario
   Bandello, Francesco
TI The natural history of occult choroidal neovascularisation associated
   with age-related macular degeneration. A systematic review
SO ANNALS ACADEMY OF MEDICINE SINGAPORE
LA English
DT Review
DE age-related maculopathy; fluorescein angiography; meta-analysis
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; TRIAL INCLUDING LESIONS; THERAPY
   REPORT 2; PHOTODYNAMIC THERAPY; VERTEPORFIN THERAPY; CLINICAL-TRIALS;
   DETACHMENTS; PHOTOCOAGULATION; CLASSIFICATION; ANASTOMOSES
AB Introduction: The purpose of this review is to combine the results of existing literature on the natural history of occult choroidal neovascularisation (CNV) associated with age-related macular degeneration (AMD). Materials and Methods: Published reports evaluating eyes with occult CNV in AMD patients were selected for meta-analysis based on a computerised MEDLINE search. Pooled estimates of the proportions of eyes with a vision loss greater than 2 to 3 (moderate vision loss) or 6 lines (severe vision loss) at 1 year and 2 to 3 years, respectively, or developing a classic component on fluorescein angiography at I year were measured. Results: There is no significant heterogeneity among published rates of visual loss and development of classic CNV. The overall pooled estimates (95% confidence limits) of the proportions of eyes with at least moderate or severe vision loss, respectively, were 59% (53% to 64.5%)) and 34% (25% to 43%) at 1 year and 70% (64%, to 76%) and 47% (40% to 54%) at 2 to 3 years; the overall pooled estimate of the percentage of eyes developing classic CNV at 1 year was 46%, (39% to 54%). Conclusion: A substantial number of patients with occult CNV from AMD will develop at least moderate visual loss at 1 year and severe visual loss within 3 years. However, visual acuity may remain stable in up to 30% of patients. These results may help us to understand the exact role of new therapies and in planning future trials.
C1 Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   Univ Udine, Dept Med & Morophol Res, I-33100 Udine, Italy.
   Univ Turin, Dept Publ Hlth & Microbiol, Turin, Italy.
C3 University of Udine; University of Udine; University of Turin
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Ophthalmol, Piazzale S Maria Misericordia, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
RI ISOLA, Miriam/AAM-1191-2021; Gregori, Dario/F-9974-2012; bandello,
   francesco/AAH-2405-2019
OI ISOLA, Miriam/0000-0002-6391-1720; Gregori, Dario/0000-0001-7906-0580;
   bandello, francesco/0000-0003-3238-9682
CR Arnold J, 1997, GRAEF ARCH CLIN EXP, V235, P208, DOI 10.1007/BF00941761
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1996, ARCH OPHTHALMOL-CHIC, V114, P1456, DOI 10.1001/archopht.1996.01100140654002
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   *MAC PHOT STUD GRO, 1996, ARCH OPHTHALMOL-CHIC, V114, P1023
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 26
TC 15
Z9 16
U1 0
U2 0
PU ACAD MEDICINE SINGAPORE
PI REPUBLIC SINGAPORE
PA 142 NEIL RD, REPUBLIC SINGAPORE 088871, SINGAPORE
SN 0304-4602
J9 ANN ACAD MED SINGAP
JI Ann. Acad. Med. Singap.
PD MAR
PY 2006
VL 35
IS 3
BP 145
EP 150
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 047SP
UT WOS:000237899300003
PM 16625262
DA 2022-11-30
ER

PT J
AU Marquis, LM
   Mantel, I
AF Marquis, Liza-Marie
   Mantel, Irmela
TI Beneficial switch from aflibercept to ranibizumab for the treatment of
   refractory neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Ranibizumab; Switch; Refractory; Neovascular age-related
   degeneration; Anti-VEGF
ID ANTI-VEGF THERAPY; INTRAVITREAL AFLIBERCEPT; CLINICAL BURDEN; PLAN
   REGIMEN; OUTCOMES; RESISTANT; TRAP; EYES
AB Purpose The aim of this study was to evaluate the effects of switching to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) refractory to aflibercept treatment and to identify predictive factors for switch response. Methods A retrospective chart review was conducted including 32 eyes from 26 patients with refractory nAMD, who switched from monthly intravitreal aflibercept treatment (>= 6 months) to ranibizumab. Outcome measures included changes in visual acuity (VA), intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), and central retinal thickness (CRT), evaluated at 6 months before switch (T1), at the time of switch (T2), and 3 months post-switch (T3). Results There was an increase in CRT from T1 to T2, which decreased after switch from T2 to T3. Regression analysis of the changes per month observed between time points showed significant differences in PED height (p = 0.02), SRF (p = 0.01), and neuroretinal thickness as a measure for IRF (p = 0.03). No significant change was found for VA. Predictive factors for better switch response included an exacerbation between T1 and T2, thicker measurements at T2, male sex, shorter treatment duration before switch, and fewer preceding injections. No association with preceding switch was found. Conclusion Patients with nAMD refractory to aflibercept benefit from switching to ranibizumab, particularly those whose condition worsened prior to the switch. This may be explained by drug tolerance to aflibercept. Our findings may facilitate making appropriate treatment decisions, potentially improving patient outcomes.
C1 [Marquis, Liza-Marie; Mantel, Irmela] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile des Aveugles, Dept Ophthalmol, 15 Ave France,CP 5143, CH-1000 Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile des Aveugles, Dept Ophthalmol, 15 Ave France,CP 5143, CH-1000 Lausanne, Switzerland.
EM irmela.mantel@fa2.ch
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Despreaux R, 2016, GRAEF ARCH CLIN EXP, V254, P639, DOI 10.1007/s00417-015-3084-1
   Dirani A, 2018, CLIN OPHTHALMOL, V12, P593, DOI 10.2147/OPTH.S160367
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Gale RP, 2020, BRIT J OPHTHALMOL, V104, P493, DOI 10.1136/bjophthalmol-2019-314251
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Griffin DR, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/497178
   Hara C, 2019, GRAEF ARCH CLIN EXP, V257, P2559, DOI 10.1007/s00417-019-04456-2
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Slean Geraldine R, 2016, Int J Retina Vitreous, V2, P2, DOI 10.1186/s40942-016-0028-9
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 26
TC 6
Z9 7
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2020
VL 258
IS 8
BP 1591
EP 1596
DI 10.1007/s00417-020-04730-8
EA MAY 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MN9RI
UT WOS:000532120400001
PM 32399582
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Tan, JSL
   Mitchell, P
   Kifley, A
   Flood, V
   Smith, W
   Wang, JJ
AF Tan, Jennifer S. L.
   Mitchell, Paul
   Kifley, Annette
   Flood, Victoria
   Smith, Wayne
   Wang, Jie Jin
TI Smoking and the long-term incidence of age-related macular degeneration
   - The blue mountains eye study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; POLYUNSATURATED FATTY-ACIDS; CORONARY-HEART-DISEASE;
   CIGARETTE-SMOKING; RISK-FACTORS; CHOROIDAL NEOVASCULARIZATION;
   ALCOHOL-CONSUMPTION; 10-YEAR INCIDENCE; POOLED FINDINGS; GRADING SYSTEM
AB Objective: To assess the association between smoking and long-term incident age-related macular degeneration (AMD).
   Methods: Of 3654 Australians 49 years and older examined at baseline (January 14, 1992, through December 18, 1993), 2454 were examined 5 years later (January 11, 1997, through February 23, 2000), 10 years later (July 10, 2002, through November 4, 2005), or both. Retinal photographs were taken to assess AMD. Smoking status was recorded at each interview.
   Results: After controlling for age, sex, and other factors, current smokers had a 4-fold higher risk of late AMD than never smokers (relative risk, 3.9; 95% confidence interval, 1.7-8.8). Past smokers had a 3-fold higher risk of geographic atrophy (relative risk, 3.4; 95% confidence interval, 1.2-9.7). Joint exposure to current smoking and (1) the lowest level of high-density lipoprotein (HDL) cholesterol, (2) the highest total to HDL cholesterol ratio, or (3) low fish consumption was associated with a higher risk of late AMD than the effect of any risk factor alone. However, interactions between smoking and HDL cholesterol level, ratio of total to HDL cholesterol, and fish consumption were not statistically significant.
   Conclusion: Smoking strongly increased the long-term risk of incident late, but not early, AMD, with a possibly greater effect in persons with a low HDL cholesterol level, a high ratio of total to HDL cholesterol, and low fish consumption.
C1 Univ Sydney, Westmead Hosp, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   Univ Sydney, Westmead Millennium Inst, Ctr Vis Res, Sydney, NSW 2006, Australia.
   Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Newcastle
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Flood, Victoria/H-2279-2011; Flood, Victoria M/A-8732-2016; Wang, Jie
   Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; wang, jie/GRS-0942-2022
OI Flood, Victoria M/0000-0001-5310-7221; Wang, Jie
   Jin/0000-0001-9491-4898; 
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Calder PC, 2001, LIPIDS, V36, P1007, DOI 10.1007/s11745-001-0812-7
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Cullen P, 1998, EUR HEART J, V19, P1632, DOI 10.1053/euhj.1998.1086
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Duncan JL, 2005, BRIT J OPHTHALMOL, V89, P1549, DOI 10.1136/bjo.2005.077370
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Fazio Sergio, 2003, Mol Interv, V3, P436, DOI 10.1124/mi.3.8.436
   FOX PL, 1988, SCIENCE, V241, P453, DOI 10.1126/science.3393911
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Harper CR, 2001, ARCH INTERN MED, V161, P2185, DOI 10.1001/archinte.161.18.2185
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KINOSIAN B, 1994, ANN INTERN MED, V121, P641, DOI 10.7326/0003-4819-121-9-199411010-00002
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   LINN S, 1993, AM J PUBLIC HEALTH, V83, P811, DOI 10.2105/AJPH.83.6.811
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Murayama K, 2002, EXP EYE RES, V74, P671, DOI 10.1006/exer.2002.1151
   Nestel PJ, 2000, AM J CLIN NUTR, V71, p228S, DOI 10.1093/ajcn/71.1.228S
   ROBBINS RA, 1991, AM J PHYSIOL, V260, pL254, DOI 10.1152/ajplung.1991.260.4.L254
   ROTHMAN KJ, 1976, AM J EPIDEMIOL, V103, P506, DOI 10.1093/oxfordjournals.aje.a112252
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schmidt S, 2005, MOL VIS, V11, P941
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
NR 53
TC 81
Z9 85
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2007
VL 125
IS 8
BP 1089
EP 1095
DI 10.1001/archopht.125.8.1089
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 197XO
UT WOS:000248590600012
PM 17698756
OA Bronze
DA 2022-11-30
ER

PT J
AU Luu, CD
   Dimitrov, PN
   Robman, L
   Varsamidis, M
   Makeyeva, G
   Aung, KZ
   Vingrys, AJ
   Guymer, RH
AF Luu, Chi D.
   Dimitrov, Peter N.
   Robman, Luba
   Varsamidis, Mary
   Makeyeva, Galina
   Aung, Khin-Zaw
   Vingrys, Algis J.
   Guymer, Robyn H.
TI Role of Flicker Perimetry in Predicting Onset of Late-Stage Age-Related
   Macular Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY; SENSITIVITY; DRUSEN; EYES; ROD; ADAPTATION; PREVALENCE;
   LOSSES; RISK
AB Objective: To investigate the longitudinal changes in flicker perimetry in patients with age-related macular degeneration (AMD) as the condition progresses from early AMD to geographic atrophy (GA) or choroidal neovascularization (CNV).
   Methods: Patients with AMD and control subjects were recruited from a longitudinal study of retinal function in early AMD consisting of 187 participants. Only those who completed at least 4 consecutive, 6-monthly flicker perimetry tests were selected for this study. Study groups consisted of everyone who went on to develop GA (n=16) or CNV (n=5), controls (n=24), and the high-risk, early-AMD participants whose eyes did not progress to GA or CNV (drusen > 125 mu m; n=18). The flicker sensitivity was determined, and its rate of change during the 18 months before the clinical detection of late AMD was calculated.
   Results: Eyes that went on to develop GA or CNV had a significantly reduced mean (SD) flicker sensitivity in the months before clinical detection of GA (15.8[5.6] dB) or CNV (19.1 [3.8] dB) compared with control eyes (22.9[3.0]dB) (P < .001) and with eyes that did not progress to GA or CNV (21.4[3.4] dB) (P < .001). The rate of change in flicker sensitivity was significantly increased in GA eyes (-0.07 dB/mo) (P < .001) but not in CNV eyes (0.006 dB/mo) (P=.56) compared with the control eyes (-0.003 dB/mo).
   Conclusions: Flicker sensitivity is reduced in eyes that go on to develop late AMD. The rate of change in flicker sensitivities over time was particularly useful in predicting eyes and areas within the eye that subsequently develop GA.
C1 [Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Macular Res Unit, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
   [Vingrys, Algis J.] Univ Melbourne, Carlton, Vic 3053, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne
RP Guymer, RH (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Macular Res Unit, Royal Victorian Eye & Ear Hosp, Level 1,32 Gisborne St, Melbourne, Vic 3002, Australia.
EM rgh@unimelb.edu.au
RI Luu, Chi/A-3307-2013
OI Luu, Chi/0000-0002-7604-7097; Vingrys, Algis/0000-0001-5920-4604;
   Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council [350224 RHG/AJV, 529905];
   Australian Research Council [ARC-LP0211474]; Royal Victorian Eye and Ear
   Hospital; Royal Victorian Eye and Ear Hospital Research Committee;
   Macular Vision Loss Support Society of Australia; National Health and
   Medical Research Council Centre for Clinical Research [529923]
FX This research was supported by grant 350224 RHG/AJV from the National
   Health and Medical Research Council, grant ARC-LP0211474 from the
   Australian Research Council Linkage Project, practitioner fellowship
   529905 from the National Health and Medical Research Council (Dr
   Guymer), a Royal Victorian Eye and Ear Hospital Wagstaff Fellowship (Dr
   Robman), the Royal Victorian Eye and Ear Hospital Research Committee,
   and the Macular Vision Loss Support Society of Australia. The Centre for
   Eye Research Australia receives operational infrastructure support from
   the Victorian government and is supported by Excellence Award 529923
   from the National Health and Medical Research Council Centre for
   Clinical Research.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Landers J, 2003, BRIT J OPHTHALMOL, V87, P690, DOI 10.1136/bjo.87.6.690
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   McKendrick AM, 2000, INVEST OPHTH VIS SCI, V41, P1239
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   TAYLOR HR, 1989, AUST NZ J OPHTHALMOL, V17, P81, DOI 10.1111/j.1442-9071.1989.tb00492.x
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGRYS AJ, 1995, PERIMETRY UPDATE 1994/1995, P159
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Zele AJ, 2008, OPTOMETRY VISION SCI, V85, P309, DOI 10.1097/OPX.0b013e31816be9e3
NR 26
TC 31
Z9 32
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2012
VL 130
IS 6
BP 690
EP 699
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 957FS
UT WOS:000305145600003
PM 22801825
OA Bronze
DA 2022-11-30
ER

PT J
AU Seitzman, RL
   Mahajan, VB
   Mangione, C
   Cauley, JA
   Ensrud, K
   Stone, KL
   Cummings, SR
   Hochberg, MC
   Hillier, T
   Sinsheimer, JS
   Yu, F
   Coleman, AL
AF Seitzman, Robin L.
   Mahajan, Vinit B.
   Mangione, Carol
   Cauley, Jane A.
   Ensrud, KristineE.
   Stone, Katie L.
   Cummings, Steven R.
   Hochberg, Marc C.
   Hillier, TeresaA.
   Sinsheimer, Janet S.
   Yu, Fei
   Coleman, Anne L.
CA Study Osteoporotic Fractures Res G
TI Estrogen receptor alpha and matrix metalloproteinase 2 polymorphisms and
   age-related maculopathy in older women
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE estrogen receptor alpha; macular degeneration; matrix metalloproteinase
   2; polymorphism; single nucleotide
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; GENE; SUSCEPTIBILITY;
   INCREASES; DISEASE; GENDER; ASSOCIATION; POPULATION; EXPRESSION
AB In this study, the authors sought to determine whether single nucleotide polymorphisms in the estrogen receptor alpha (ESR1) and matrix metalloproteinase 2 (MMP2) genes are associated with age-related maculopathy (ARM) in older women. Subjects comprised a random sample of Caucasian women aged >= 74 years participating in the Study of Osteoporotic Fractures year 10 follow-up (n = 906) in 1997-1998. Fundus photographs were graded for ARM using a modification of the Wisconsin Age-Related Maculopathy Grading System. The prevalences of early ARM and late ARM were 46% and 4%, respectively. The MMP2 rs2287074 single nucleotide polymorphism (G -> A) was associated with ARM. The A allele was present in 47%, 43%, and 30% of subjects with no, early, and late ARM, respectively (p = 0.01), and was associated with lower odds of any ARM (for AG vs. GG, odds ratio = 0.80, 95% confidence interval: 0.65, 0.99; for AA vs. GG, odds ratio = 0.64, 95% confidence interval: 0.42, 0.98). An interaction with use of postmenopausal hormone therapy was significant (p = 0.02). The MMP2 rs2287074 A allele may be associated with a lower likelihood of ARM in older Caucasian women, particularly those who have never used hormone therapy. The role of MMP2 rs2287074 in ARM should be further elucidated.
C1 [Seitzman, Robin L.] Biogen Idec Inc, Drug Safety & Risk Management, San Diego, CA 92122 USA.
   [Seitzman, Robin L.; Yu, Fei; Coleman, Anne L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Mahajan, Vinit B.] Univ Iowa, Dept Ophthalmol & Visual Sci, Omics Lab, Carver Coll Med, Iowa City, IA USA.
   [Mangione, Carol] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   [Cauley, Jane A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
   [Ensrud, KristineE.] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
   [Ensrud, KristineE.] Univ Minnesota, Sch Med & Publ Hlth, Dept Med, Minneapolis, MN USA.
   [Ensrud, KristineE.] Univ Minnesota, Sch Med & Publ Hlth, Dept Epidemiol, Minneapolis, MN USA.
   [Ensrud, KristineE.] Univ Minnesota, Sch Med & Publ Hlth, Dept Commun, Minneapolis, MN USA.
   [Stone, Katie L.; Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
   [Cummings, Steven R.] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Hochberg, Marc C.] Univ Maryland, Sch Med, Div Rheumatol, Baltimore, MD 21201 USA.
   [Hillier, TeresaA.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
   [Sinsheimer, Janet S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.
   [Sinsheimer, Janet S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA.
   [Sinsheimer, Janet S.; Yu, Fei] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
   [Coleman, Anne L.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA.
C3 Biogen; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; University of Iowa; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Minneapolis VA Health Care System;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   California Pacific Medical Center; California Pacific Medical Center
   Research Institute; University of California System; University of
   California San Francisco; University System of Maryland; University of
   Maryland Baltimore; Kaiser Permanente; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles
RP Seitzman, RL (通讯作者)，Biogen Idec Inc, Drug Safety & Risk Management, 5200 Res Pl, San Diego, CA 92122 USA.
EM seitzman@ucla.edu
RI Cauley, Jane A/N-4836-2015
OI Cauley, Jane A/0000-0003-0752-4408; Ensrud,
   Kristine/0000-0002-9069-3036; Mahajan, Vinit/0000-0003-1886-1741
FU NEI NIH HHS [EY07026] Funding Source: Medline; NIAMS NIH HHS [AR35584,
   AR35582, AR35583] Funding Source: Medline; NIA NIH HHS [AG05407,
   AG05394, AG-02-004, AG08415] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [T32EY007026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035584,
   R01AR035583, R01AR035582] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [R01AG005394, R01AG008415] Funding Source: NIH
   RePORTER
CR Abramov Y, 2004, MENOPAUSE, V11, P62, DOI 10.1097/01.GME.0000074701.19603.11
   Amin S, 2004, INVEST OPHTH VIS SCI, V45, P1281, DOI 10.1167/iovs.03-0671
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   Cheng S, 1999, GENOME RES, V9, P936, DOI 10.1101/gr.9.10.936
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P413, DOI 10.1016/j.exer.2004.10.008
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Lange K, 2005, GENET EPIDEMIOL, V29, P36, DOI 10.1002/gepi.20073
   Lange K, 2001, AM J HUM GENET, V69, P504
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5
   NEELY KA, 1993, OPHTHALMOL CLIN N AM, V2, P291
   Nirmalan PK, 2004, INVEST OPHTH VIS SCI, V45, P4273, DOI 10.1167/iovs.04-0285
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Price SJ, 2001, J BIOL CHEM, V276, P7549, DOI 10.1074/jbc.M010242200
   PUISTOLA U, 1995, FERTIL STERIL, V64, P81, DOI 10.1016/S0015-0282(16)57659-6
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rubin D.B., 1987, MULTIPLE IMPUTATION, P1
   Schafer J.L., 1997, ANAL INCOMPLETE MULT
   Seitzman RL, 2007, J AM GERIATR SOC, V55, P740, DOI 10.1111/j.1532-5415.2007.01138.x
   Sethi CS, 2000, BRIT J OPHTHALMOL, V84, P654, DOI 10.1136/bjo.84.6.654
   Shen LX, 1999, P NATL ACAD SCI USA, V96, P7871, DOI 10.1073/pnas.96.14.7871
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Turpeenniemi-Hujanen T, 2005, BIOCHIMIE, V87, P287, DOI 10.1016/j.biochi.2005.01.014
   *US BUR CENS, 2006, INT PROJ POP AGE 18
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 47
TC 22
Z9 23
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAY 15
PY 2008
VL 167
IS 10
BP 1217
EP 1225
DI 10.1093/aje/kwn024
PG 9
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 299LC
UT WOS:000255756100010
PM 18359774
OA Bronze
DA 2022-11-30
ER

PT J
AU Ly, A
   Nivison-Smith, L
   Zangerl, B
   Assaad, N
   Kalloniatis, M
AF Ly, Angelica
   Nivison-Smith, Lisa
   Zangerl, Barbara
   Assaad, Nagi
   Kalloniatis, Michael
TI Advanced imaging for the diagnosis of age-related macular degeneration:
   a case vignettes study
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related macular degeneration; case vignettes; diagnosis; imaging;
   optometrist
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL-NEOVASCULARIZATION; FUNDUS
   AUTOFLUORESCENCE; FLUORESCEIN ANGIOGRAPHY; RETICULAR PSEUDODRUSEN;
   GEOGRAPHIC ATROPHY; PHYSICIAN PRACTICE; DRUSEN VOLUME; FELLOW EYE;
   IMPACT
AB Background: The aim of this study is to evaluate the diagnosis, staging, imaging and management preferences, and the effect of advanced imaging among practising optometrists in age-related macular degeneration (AMD).
   Methods: Up to 20 case vignettes (computer-based case simulations) were completed online in a computer laboratory in random order by 81 practising optometrists of Australia. Each case presented findings from a randomly selected patient seen previously at the Centre for Eye Health for a macular assessment in the following order: case history, preliminary tests and colour fundus photography. Participants were prompted to provide their diagnosis, management and imaging preference. One additional imaging result (either modified fundus photographs and infrared images, fundus autofluorescence, or optical coherence tomography [OCT]) was then provided and the questions repeated. Finally, all imaging results were provided and the questions repeated a third time.
   Results: A total of 1,436 responses were analysed. The presence of macular pathology in AMD was accurately detected in 94 per cent of instances. The overall diagnostic accuracy of AMD was 61 per cent using colour fundus photography. This improved by one per cent using one additional imaging modality and a further four per cent using all imaging. Across all responses, a greater improvement in the diagnostic accuracy of AMD occurred following the presentation of OCT findings (versus other modalities). OCT was the most preferred imaging modality for AMD, while multimodal imaging was of greatest benefit in cases more often misdiagnosed using colour fundus photography alone. Overall, the cohort also displayed a tendency to underestimate disease severity.
   Conclusion: Despite reports that imaging technologies improve the stratification of AMD, our findings suggest that this effect may be small when applied among practising optometrists without additional or specific training.
C1 [Ly, Angelica; Nivison-Smith, Lisa; Zangerl, Barbara; Assaad, Nagi; Kalloniatis, Michael] Ctr Eye Hlth, Sydney, NSW, Australia.
   [Ly, Angelica; Nivison-Smith, Lisa; Zangerl, Barbara; Kalloniatis, Michael] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Assaad, Nagi] Prince Wales Hosp, Dept Ophthalmol, Sydney, NSW, Australia.
C3 University of New South Wales Sydney
RP Kalloniatis, M (通讯作者)，Ctr Eye Hlth, Sydney, NSW, Australia.; Kalloniatis, M (通讯作者)，Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
EM m.kalloniatis@unsw.edu.au
RI Ly, Angelica/J-2070-2019
OI Ly, Angelica/0000-0001-7881-1522; Kalloniatis,
   Michael/0000-0002-5264-4639; Nivison-Smith, Lisa/0000-0001-6677-1949
FU University of New South Wales [P535430]; National Health and Medical
   Research Council (NHMRC) [1033224]; NHMRC
FX The authors extend their thanks to the staff at the Centre for Eye
   Health for piloting the study. This work was supported, in part, by
   grants and awards from the University of New South Wales (Early Career
   Research Grant 2016 #P535430, an Australian Postgraduate Award) and a
   National Health and Medical Research Council (NHMRC) grant (#1033224).
   Guide Dogs NSW/ACT is a partner in the NHMRC grant and also provided a
   supplementary PhD scholarship for Angelica Ly and support for Lisa
   Nivison-Smith.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   American Academy of Ophthalmology Retina/Vitreous Panel Preferred Practice Pattern<(R)>Guidelines, 2015, PREF PRACT PATT GUID
   American Optometric Association Consensus Panel on Care of the Patient with Age Related Macular Degeneration, 2004, OPT CLIN PRACT GUID
   Baranano AE, 2012, ACTA OPHTHALMOL, V90, pE274, DOI 10.1111/j.1755-3768.2012.02398.x
   Barteselli G, 2013, RETINA-J RET VIT DIS, V33, P1574, DOI 10.1097/IAE.0b013e318285cd84
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Cameron JR, 2009, EYE, V23, P1134, DOI 10.1038/eye.2008.196
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Converse L, 2015, J GEN INTERN MED, V30, P586, DOI 10.1007/s11606-015-3365-8
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   De Niro JE, 2014, RETINA-J RET VIT DIS, V34, P1163, DOI 10.1097/IAE.0000000000000077
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Dhand N., 2014, SAMPLE SIZE CALC EST
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P821, DOI 10.1097/OPX.0000000000000285
   Dresselhaus TR, 2004, J GEN INTERN MED, V19, P1013, DOI 10.1007/s11606-004-0003-2
   Drexel C, 2011, INT J CHRONIC OBSTR, V6, P297, DOI 10.2147/COPD.S18257
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P632, DOI 10.1111/opo.12322
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P303, DOI 10.1111/opo.12283
   Ly A, 2015, OPTOMETRY VISION SCI, V92, P844, DOI 10.1097/OPX.0000000000000640
   Menon G, 2009, EYE, V23, pS1, DOI 10.1038/eye.2009.13
   MILLER GE, 1990, ACAD MED, V65, pS63, DOI 10.1097/00001888-199009000-00045
   Muen Wisam J, 2011, JRSM Short Rep, V2, P64, DOI 10.1258/shorts.2011.011042
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Optometry Board of Australia, OPT CONT PROF DEV RE
   Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715
   Peabody JW, 2004, ANN INTERN MED, V141, P771, DOI 10.7326/0003-4819-141-10-200411160-00008
   Pilotto E, 2013, GRAEF ARCH CLIN EXP, V251, P27, DOI 10.1007/s00417-012-2031-7
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   RANZCO, 2016, RANZCO REF PATHW AMD
   Shah R, 2007, OPHTHAL PHYSL OPT, V27, P113, DOI 10.1111/j.1475-1313.2006.00481.x
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Steele C., 2013, OPTOM TODAY, P49
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   The Angiogenesis Foundation, 2012, ADV IMPR TREATM OUTC
   The Royal College of Ophthalmologists, 2013, AG REL MAC DEG GUID
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Veloski J, 2005, AM J MED QUAL, V20, P151, DOI 10.1177/1062860605274520
   Walland MJ, 2015, CLIN EXP OPHTHALMOL, V43, P784, DOI 10.1111/ceo.12675
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
NR 54
TC 12
Z9 12
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD MAR
PY 2018
VL 101
IS 2
BP 243
EP 254
DI 10.1111/cxo.12607
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY0JF
UT WOS:000426496400014
PM 28994139
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Pondorfer, SG
   Wintergerst, MWM
   Zadeh, SG
   Schultz, T
   Heinemann, M
   Holz, FG
   Finger, RP
AF Pondorfer, Susanne G.
   Wintergerst, Maximilian W. M.
   Zadeh, Shekoufeh Gorgi
   Schultz, Thomas
   Heinemann, Manuel
   Holz, Frank G.
   Finger, Robert P.
TI Association of Visual Function Measures with Drusen Volume in Early
   Stages of Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE Automatic segmentation of drusen; drusen volume; age-related macular
   degeneration; contrast sensitivity
ID ROBSON CONTRAST SENSITIVITY; LOW-LUMINANCE; RETICULAR PSEUDODRUSEN;
   ACUITY LOSS; MICROPERIMETRY; MACULOPATHY; EYES; SEGMENTATION;
   PROGRESSION; PREVALENCE
AB PURPOSE. To assess which visual function measures are most strongly associated with overall retinal drusen volume in age-related macular degeneration (AMD).
   METHODS. A total of 100 eyes (16 eyes with early AMD, 62 eyes with intermediate AMD, and 22 eyes from healthy controls) were recruited in this cross-sectional study. All subjects underwent several functional assessments: best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), visual acuity (VA) measured with the Moorfields Acuity Chart (MAC-VA), contrast sensitivity with the Pelli-Robson test, reading speed using the International Reading Speed texts, and mesopic and dark-adapted microperimetry. Drusen volume was automatically determined based on optical coherence tomography using an approach based on convolutional neural networks. The relationship between drusen volume and visual function was assessed with linear regressions controlling for confounders.
   RESULTS. Mean drusen volume and MAC-VA differed significantly among all AMD stages and controls (P < 0.001). In univariate linear regression, LLVA, MAC-VA, contrast sensitivity, and mesopic and dark-adapted microperimetry were significantly negatively associated with the overall drusen volume (all P < 0.006). After controlling for AMD stage, age, and the presence of subretinal drusenoid deposits, MAC-VA and mesopic and dark-adapted microperimetry were still significantly associated with drusen volume (P = 0.008, P = 0.023, and P = 0.022, respectively).
   CONCLUSIONS. Our results suggest that MAC-VA, as well as mesopic and dark-adapted microperimetry, might indicate structural changes related to drusen volume in early stages of AMD.
C1 [Pondorfer, Susanne G.; Wintergerst, Maximilian W. M.; Heinemann, Manuel; Holz, Frank G.; Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Zadeh, Shekoufeh Gorgi; Schultz, Thomas] Univ Bonn, Dept Comp Sci, Bonn, Germany.
   [Zadeh, Shekoufeh Gorgi] Univ Bonn, Dept Med Biometry Informat & Epidemiol, Bonn, Germany.
   [Schultz, Thomas] Univ Bonn, Bonn Aachen Int Ctr Informat Technol, Bonn, Germany.
C3 University of Bonn; University of Bonn; University of Bonn; University
   of Bonn
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM robert.finger@ukbonn.de
RI Wintergerst, Maximilian/AAW-2972-2021; Wintergerst,
   Maximilian/E-5523-2019
OI Wintergerst, Maximilian/0000-0002-2766-7038
FU German Scholars Organization/Else Krohner Fresenius Stiftung [GSO/EKFS
   16]; BONFOR GEROK Program, Faculty of Medicine, University of Bonn
   [O-137.0028]
FX This research was supported by the German Scholars Organization/Else
   Krohner Fresenius Stiftung (GSO/EKFS 16) and BONFOR GEROK Program,
   Faculty of Medicine, University of Bonn (grant no. O-137.0028, MW). We
   are grateful for the technical support of Carlo Pellizzari from
   CenterVue SpA (Padua, Italy), which provided research material (S-MAIA)
   necessary to conduct this study. CenterVue had no role in the design or
   conduct of the experiments.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Cormen T. H., 2009, INTRO ALGORITHMS, VThird, P658
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   IBM Corp, 2017, IBM SPSS STAT WINDOW
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mantyjarvi M, 2001, J CATARACT REFR SURG, V27, P261, DOI 10.1016/S0886-3350(00)00562-9
   Maynard ML, 2016, ACTA OPHTHALMOL, V94, pE772, DOI 10.1111/aos.13112
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pfau M, 2020, RETINA-J RET VIT DIS, V40, P169, DOI 10.1097/IAE.0000000000002337
   Pfau M, 2017, OPHTHALMOLOGICA, V237, P42, DOI 10.1159/000453079
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Sassmannshausen M, 2018, INVEST OPHTH VIS SCI, V59, P1599, DOI 10.1167/iovs.17-22712
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Shah N, 2016, BRIT J OPHTHALMOL, V100, P1346, DOI 10.1136/bjophthalmol-2015-307375
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Trauzettel-Klosinski S, 2012, INVEST OPHTH VIS SCI, V53, P5452, DOI 10.1167/iovs.11-8284
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Welker Susanne G, 2018, Invest Ophthalmol Vis Sci, V59, pAMD152, DOI 10.1167/iovs.18-23878
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zadeh SG, 2017, LECT NOTES COMPUT SC, V10553, P65, DOI 10.1007/978-3-319-67558-9_8
NR 47
TC 6
Z9 6
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2020
VL 61
IS 3
AR 55
DI 10.1167/iovs.61.3.55
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA8BU
UT WOS:000524168000055
PM 32232348
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Holopainen, JM
   Karvonen, MK
   Koulu, M
   Kallio, J
   Pesonen, U
   Terasvirta, M
   Uusitalo, H
   Immonen, I
AF Kaarniranta, Kai
   Holopainen, Juha M.
   Karvonen, Matti K.
   Koulu, Markku
   Kallio, Jaana
   Pesonen, Ullamari
   Terasvirta, Markku
   Uusitalo, Hannu
   Immonen, Ilkka
TI Leucine 7-proline 7 polymorphism in the signal peptide of neuropeptide Y
   is not a risk factor for exudative age-related macular degeneration
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE age-related macular degeneration; neuropeptide Y; polymorphism
ID FACTOR-H POLYMORPHISM; BLUE MOUNTAINS EYE; CAROTID ATHEROSCLEROSIS;
   PREPRONEUROPEPTIDE-Y; STARGARDT-DISEASE; APOLIPOPROTEIN-E; GENE;
   ASSOCIATION; MACULOPATHY; SUSCEPTIBILITY
AB Purpose: Because of the regulatory role of neuropeptide Y (NPY) in angiogenesis, we set out to determine the presence of the leucine 7-proline 7 (Leu7Pro) polymorphism in exudative age-related macular degeneration (AMD) patients and to analyse its implications.
   Methods: Genotype analysis of the Leu7Pro polymorphism in the signal peptide region of the human prepro-NPY was performed in blood samples from exudative AMD patients (n = 240) and control subjects (n = 79).
   Results: In all, 11% of exudative AMD patients and 14% of control subjects exhibited the NPY signal peptide Leu7Pro polymorphism. There were no statistically significant differences in Leu7Pro polymorphism frequency between the exudative AMD and control cases, as analysed by Fisher's exact two-sided test.
   Conclusions: Leu7Pro polymorphism in the signal peptide region of the human prepro-NPY is not a risk factor for exudative AMD.
C1 Univ Kuopio, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
   Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
   Univ Helsinki, Dept Ophthalmol, Helsinki, Finland.
   Turku Univ, Cent Hosp, Dept Neurol, Turku, Finland.
   Turku Univ, Dept Pharmacol & Clin Pharmacol, Turku, Finland.
   Turku Univ, Dept Ophthalmol, Turku, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Helsinki; University of Turku; University
   of Turku; University of Turku
RP Kaarniranta, K (通讯作者)，Univ Kuopio, Dept Ophthalmol, POB 1627, FIN-70211 Kuopio, Finland.
EM kaarnira@messi.uku.fi
OI Kaarniranta, Kai/0000-0003-2600-8679; Pesonen,
   Ullamari/0000-0002-9962-212X
CR Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Ding B, 2005, REGUL PEPTIDES, V127, P45, DOI 10.1016/j.regpep.2004.10.011
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz F.G., 2004, AGE RELATED MACULAR, P24
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Karvonen MK, 1998, NAT MED, V4, P1434, DOI 10.1038/4027
   Karvonen MK, 2001, ATHEROSCLEROSIS, V159, P145, DOI 10.1016/S0021-9150(01)00468-3
   Karvonen MK, 2000, J CLIN ENDOCR METAB, V85, P1455, DOI 10.1210/jc.85.4.1455
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Koulu M, 2004, ANN MED, V36, P232, DOI 10.1080/07853890410031236
   Niskanen L, 2000, J CLIN ENDOCR METAB, V85, P2266, DOI 10.1210/jc.85.6.2266
   Niskanen L, 2000, EXP CLIN ENDOCR DIAB, V108, P235, DOI 10.1055/s-2000-7748
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VANLEEUWEN R, 2005, INVEST OPHTH VIS SCI, V44, P3771
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187
   ZukowskaGrojec Z, 1995, ANN NY ACAD SCI, V771, P219, DOI 10.1111/j.1749-6632.1995.tb44683.x
NR 33
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD MAR
PY 2007
VL 85
IS 2
BP 188
EP 191
DI 10.1111/j.1600-0420.2006.00787.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 136MA
UT WOS:000244226200011
PM 17305733
DA 2022-11-30
ER

PT J
AU Fraser-Bell, S
   Choudhury, F
   Klein, R
   Azen, S
   Varma, R
AF Fraser-Bell, Samantha
   Choudhury, Farzana
   Klein, Ronald
   Azen, Stanley
   Varma, Rohit
CA Los Angeles Latino Eye Study Grp
TI Ocular Risk Factors for Age-Related Macular Degeneration: The Los
   Angeles Latino Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; BEAVER DAM EYE; CATARACT-SURGERY;
   CLASSIFICATION-SYSTEM; IRIS PIGMENTATION; 5-YEAR INCIDENCE; OLDER
   AMERICANS; VISUAL-ACUITY; MACULOPATHY; POPULATION
AB PURPOSE: To assess the association between ocular factors and age-related macular degeneration (AMD) in Latinos.
   DESIGN: Population-based, cross-sectional study of 6357 self-identified Latinos aged 40 years and older.
   METHODS: Ophthalmic examination included subjective refraction, measurement of axial length, evaluation of iris color, Lens Opacities Classification System II (LOCS II) grading of cataracts, and stereoscopic macular photographs for AMD lesions. Generalized estimating equation analysis incorporated data from both eyes to estimate odds ratios (OR) adjusted for covariates.
   RESULTS: After controlling for confounders (age, gender, and smoking), prior cataract surgery was associated with advanced AMD (OR, 2.8; 95% CI, 1.01, 7.8), increased retinal pigment (OR, 1.6; 95% CI, 1.02, 1.5), and retinal pigment epithelial depigmentation (OR, 2.2; 95% CI, 1.1, 4.4). The presence of any lens opacity was associated with soft drusen (OR, 1.2; 95% CI, 1.002, 1.5). Longer axial length (per mm) was associated with decreased odds of soft drusen, increased retinal pigment, and geographic atrophy (GA) (ORs, 0.8 [95% CI, 0.7, 0.9], 0.8 [95% CI, 0.7, 0.9], 0.7 [95% CI, 0.5, 0.9], respectively). Myopia was inversely associated with soft drusen (OR, 0.8; 95% CI, 0.7, 0.99). Lighter-colored irises were associated with GA (OR, 5.0; 95% CI, 1.0, 25.3).
   CONCLUSIONS: Cross-sectional associations of ocular factors such as cataract, cataract surgery, and refractive errors with early AMD lesions found in Latinos are consistent with those in non-Hispanic Whites. Additionally, prior cataract surgery was associated with advanced AMD. (Am J Ophthalmol 2010;149:735-740. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Azen, Stanley; Varma, Rohit] Univ So Calif, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Fraser-Bell, Samantha; Choudhury, Farzana; Azen, Stanley; Varma, Rohit] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA.
   [Azen, Stanley; Varma, Rohit; Los Angeles Latino Eye Study Grp] Univ So Calif, Dept Ophthalmol, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Fraser-Bell, Samantha] Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; University of Southern California; University of
   Sydney; University of Wisconsin System; University of Wisconsin Madison
RP Varma, R (通讯作者)，Univ So Calif, Doheny Eye Inst, Suite 4900,1450 San Pablo St, Los Angeles, CA 90033 USA.
EM rvarma@usc.edu
RI Fraser-Bell, Samantha/ABE-8574-2020
OI Fraser-Bell, Samantha/0000-0001-5646-9359; Klein,
   Ronald/0000-0002-4428-6237
FU NATIONAL INSTITUTES OF HEALTH, BETHESDA, MARYLAND [NEI U10-EY-11753,
   EY-03040]; Research to Prevent Blindness, New York, New York; NATIONAL
   EYE INSTITUTE [U10EY011753, P30EY003040] Funding Source: NIH RePORTER
FX THIS STUDY WAS SUPPORTED BY GRANTS FROM THE NATIONAL INSTITUTES OF
   HEALTH, BETHESDA, MARYLAND (NEI U10-EY-11753 and EY-03040), and an
   unrestricted grant from the Research to Prevent Blindness, New York, New
   York. Rohit Varma is a Research to Prevent Blindness Sybil B. Harrington
   Scholar. The authors have no proprietary or commercial interests to
   report. Involved in design and conduct of the study (R.V.); collection,
   management, analysis, and interpretation of the data (S.F.B., R.K.,
   F.C., SPA., R.V.); and preparation, review, or approval of the
   manuscript (S.F.B., R.K., F.C., SPA., R.V.). The study protocol was
   approved by the Institutional Review Board (IRB)/Ethics Committee at the
   University of Southern California and all study procedures adhered to
   the recommendations of the Declaration of Helsinki. Written consent was
   obtained from all participants.
CR BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CHYLACK LT, 1988, ARCH OPHTHALMOL-CHIC, V106, P330
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Ferris FL, 1996, OPHTHALMOLOGY, V103, P181, DOI 10.1016/S0161-6420(96)30742-2
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   *NAT ADV EY COUNC, 1993, VIS RES NAT PLAN 199, P305
   Pham TQ, 2007, EYE, V21, P512, DOI 10.1038/sj.eye.6702254
   SANDBERG MA, 1994, INVEST OPHTH VIS SCI, V35, P2734
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P53
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 38
TC 26
Z9 27
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2010
VL 149
IS 5
BP 735
EP 740
DI 10.1016/j.ajo.2009.11.013
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 593WT
UT WOS:000277493800008
PM 20138605
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Enders, P
   Sitnilska, V
   Altay, L
   Fauser, S
AF Enders, Philip
   Sitnilska, Vasilena
   Altay, Lebriz
   Fauser, Sascha
TI Early Changes of Retinal Morphology in Therapy of Neovascular
   Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF
   Agents
SO OPHTHALMOLOGICA
LA English
DT Article
DE Early morphological changes; Anti-VEGF treatment; Neovascular
   age-related macular degeneration; Retinal compartments; Spectral-domain
   optical coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; VERTEPORFIN; SUPPRESSION
AB Purpose: To compare changes of retinal morphology in the first weeks following injection of anti-VEGF agents for neovascular age-related macular degeneration (nAMD). Procedures: In a prospective study 50 patients with active choroidal neovascularization secondary to nAMD were monitored weekly by spectral-domain optical coherence tomography for 3 weeks after treatment. Twenty-two patients received bevacizumab, 15 ranibizumab, and 13 aflibercept. Morphological parameters of retinal compartments were compared. Results: Mean central retinal thickness (391.22 +/- 123.41 mu m) was reduced by -26.15 mu m (p < 0.001) after 1 week, by -12.54 mu m (p < 0.001) after 2 weeks, and by -3.52 mu m (p = 0.09) after 3 weeks. Mean intraretinal layer thickness changed only significantly between baseline and week 1 (p < 0.001). Mean subretinal thickness also decreased between weeks 1 and 2 (p = 0.01). Conclusions: Early morphological changes occur primarily in the first 14 days after treatment. This information could be clinically helpful to evaluate early non-response. (C) 2017 S. Karger AG, Basel
C1 [Enders, Philip; Sitnilska, Vasilena; Altay, Lebriz; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, DE-50924 Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche & Cie AG, Basel, Switzerland.
C3 University of Cologne; Roche Holding
RP Enders, P (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, DE-50924 Cologne, Germany.
EM Philip-enders@web.de
OI Enders, Philip/0000-0002-9527-4957
CR Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Enders P, 2016, EYE, V30, P1072, DOI 10.1038/eye.2016.97
   Enders P, 2015, RETINA-J RET VIT DIS, V35, P454, DOI 10.1097/IAE.0000000000000320
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
NR 31
TC 0
Z9 0
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 239
IS 1
BP 45
EP 51
DI 10.1159/000480356
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FQ8VP
UT WOS:000418641600006
PM 28950272
DA 2022-11-30
ER

PT J
AU Ozturk, T
   Oner, H
   Saatci, AO
   Kaynak, S
AF Ozturk, Taylan
   Oner, Hakan
   Saatci, Ali Osman
   Kaynak, Suleyman
TI Low-fluence photodynamic therapy combinations in the treatment of
   exudative age -related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; photodynamic therapy; low-fluence
   photodynamic therapy; anti-VEGF
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; INTRAVITREAL BEVACIZUMAB;
   VERTEPORFIN; RANIBIZUMAB; TRIAMCINOLONE; PEGAPTANIB
AB AIM: To compare the efficacy of low-fluence photodynamic therapy (PDT) combinations in the treatment of age-related macular degeneration (AMD).
   METHODS: Forty-five previously untreated eyes of 45 patients with exudative AMD whose best-corrected visual acuity (BCVA) was >= 0.3 (Snellen) were enrolled. 15 patients in Group I underwent low-fluence PDT (25J/cm(2)-300mW/cm(2) -83sec) and intravitreal pegaptanib combination, 15 patients in Group II underwent PDT (50J/cm(2)-600mW/cm(2)-83sec) and intravitreal pegaptanib combination while, 15 patients in Group III underwent intavitreal pegaptanib monotherapy. Complete ophthalmologic examinations were performed in pre and post treatment visits, and the results were statistically analised. A clinical activity score (CAS) was calculated by using changes in lesion size, amount of hemorrhage, staining pattern in FA and OCT measurement of intra/subretinal fluid. <= 3 logMAR lines of decrease in BCVA and decrease in CAS were considered as successful treatment.
   RESULTS: The mean age of 19 female (42.2%) and 26 male (57.8%) patients was (72.82 +/- 8.02) years. Mean follow-up was (13.93 +/- 5.87) months. Lesion type was occult in 28 eyes (62.2%). Treatment success rates according to BCVA assessments were 86.7%, 80%, 60% and mean BCVA decrease were 0.3, 1.0, 2.2 logMAR lines in Group I, II and III, respectively (P >0.05). According to the changes in central macular thickness and CAS, no difference was found among the study groups(P=0.850 and P=0.811, respectively). Patients treated with combination regimens had lower intravitreal injection frequencies (P=0.015).
   CONCLUSION: Combination regimen with intraviteal pegaptanib and low-fluence PDT seems to be safe and effective in stabilizing the clinical activity and BCVA in exudative AMD.
C1 [Ozturk, Taylan] Dr Behcet Uz Childrens Hosp, Dept Ophthalmol, Izmir, Turkey.
   [Oner, Hakan; Saatci, Ali Osman; Kaynak, Suleyman] Dokuz Eylul Univ, Sch Med, Dept Ophthalmol, Izmir, Turkey.
C3 Izmir Dr Behcet Uz Children's Disease & Surgery Training & Research
   Hospital; Dokuz Eylul University
RP Ozturk, T (通讯作者)，Dr Behcet Uz Childrens Hosp, Dept Ophthalmol, Izmir, Turkey.
EM ataylan6@yahoo.com
RI Ozturk, Taylan/AAC-6680-2019
OI Ozturk, Taylan/0000-0001-6633-0553
CR [Anonymous], 1986, Arch Ophthalmol, V104, P694
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Forte R, 2010, ACTA OPHTHALMOL, V88, pe305, DOI 10.1111/j.1755-3768.2010.02021.x
   Framme C, 2006, GRAEF ARCH CLIN EXP, V244, P773, DOI 10.1007/s00417-005-0221-2
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hazin R, 2009, J NATL MED ASSOC, V101, P134, DOI 10.1016/S0027-9684(15)30825-7
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Koss MJ, 2011, OPHTHALMOLOGICA, V226, P45, DOI 10.1159/000327702
   Kovacs KD, 2011, RETINA-J RET VIT DIS, V31, P446, DOI 10.1097/IAE.0b013e3181f6391f
   MARTIDIS A, 2004, OPHTHALMOLOGY, P925
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Pehlivanli Aktac Z, 2006, RET VIT, V14, P95
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rishi P, 2011, CLIN OPHTHALMOL, V5, P167, DOI 10.2147/OPTH.S16947
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   Sivaprasad S, 2011, OPHTHALMOLOGICA, V225, P200, DOI 10.1159/000322363
   Spaide RF, 2007, MED RETINA, P89
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 37
TC 1
Z9 1
U1 0
U2 5
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUN 18
PY 2012
VL 5
IS 3
BP 377
EP 383
DI 10.3980/j.issn.2222-3959.2012.03.25
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 961XN
UT WOS:000305502900025
PM 22773992
DA 2022-11-30
ER

PT J
AU Colak, E
   Kosanovic-Jakovic, N
   Zoric, L
   Radosavljevic, A
   Stankovic, S
   Majkic-Singh, N
AF Colak, Emina
   Kosanovic-Jakovic, Natalija
   Zoric, Lepsa
   Radosavljevic, Aleksandra
   Stankovic, Sanja
   Majkic-Singh, Nada
TI The Association of Lipoprotein Parameters and C-Reactive Protein in
   Patients with Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Lipoproteins; C-reactive protein
ID FACTOR-H POLYMORPHISM; MEDIATED DILATION; RISK; INFLAMMATION;
   CHOLESTEROL; ARTERIOLES; BIOMARKERS; MARKERS; DISEASE
AB Background: Age-related macular degeneration (AMD) is the most common cause of visual impairment in individuals over 50 years of age, with the prevalence of 0.05% before the age of 50 rising to 30% after 74 years of age. An elevated concentration of plasma lipoproteins is considered to be one of the risk factors of AMD development. The aim of our study was to analyze the concentration of serum lipoproteins-total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), non-LDL cholesterol and triglycerides - as well as apolipoproteins - apoA1, apoB and Lp(a) - along with C-reactive protein (CRP) in patients with AMD in order to explore the possible association of lipid and inflammatory parameters with the pathogenesis of AMD. Material and Methods: In the cross-sectional study in the University clinical setting, 79 patients with AMD, aged 71.47 +/- 7.02 years, and 84 aged-matched control subjects were included. The patients underwent complete ophthalmological examination including visual acuity assessment, color fundus photography and fluorescein angiography. Results: Statistical processing data revealed significantly higher total (p = 0.0002), LDL (p = 0.023), non-HDL cholesterol (p = 0.0014) and CRP (p = 0.049) values in AMD patients compared to control subjects. Conclusions: Based on the obtained results, it may be concluded that lipid status disorder and inflammation could play an important role in the development of AMD in elderly people. Copyright (C) 2011 S. Karger AG, Basel
C1 [Colak, Emina; Stankovic, Sanja; Majkic-Singh, Nada] Univ Belgrade, Inst Med Biochem, Clin Ctr Serbia, RS-11000 Belgrade, Serbia.
   [Colak, Emina; Stankovic, Sanja; Majkic-Singh, Nada] Univ Belgrade, Pharmaceut Fac, RS-11000 Belgrade, Serbia.
   [Kosanovic-Jakovic, Natalija; Zoric, Lepsa; Radosavljevic, Aleksandra] Univ Belgrade, Inst Ophthalmol, Med Retina Dept, Clin Ctr Serbia, RS-11000 Belgrade, Serbia.
   [Kosanovic-Jakovic, Natalija; Zoric, Lepsa; Radosavljevic, Aleksandra] Univ Belgrade, Fac Med, RS-11000 Belgrade, Serbia.
C3 Clinical Centre of Serbia; University of Belgrade; University of
   Belgrade; Clinical Centre of Serbia; University of Belgrade; University
   of Belgrade
RP Colak, E (通讯作者)，Univ Belgrade, Inst Med Biochem, Clin Ctr Serbia, Visegradska 26, RS-11000 Belgrade, Serbia.
EM eminacolak@sbb.rs
RI Radosavljevic, Aleksandra/AAK-2407-2020; Radosavljevic,
   Aleksandra/K-3730-2014; Čolak, Emina/AAQ-1969-2021; Stankovic,
   Sanja/AAQ-3433-2021
OI Radosavljevic, Aleksandra/0000-0002-8859-5103; Radosavljevic,
   Aleksandra/0000-0002-8859-5103; Čolak, Emina/0000-0003-1901-3146;
   Stankovic, Sanja/0000-0003-0890-535X
FU Ministry of Science of Serbia [175036, 145112]
FX This work was supported by the Ministry of Science of Serbia through
   contracts No. 175036 and No. 145112.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
   Chase HP, 2004, DIABETES, V53, P2569, DOI 10.2337/diabetes.53.10.2569
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   DEJONG PT, 2005, INVEST OPHTH VIS S S, V46, pNI461
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Finger RP, 2009, RETINA-J RET VIT DIS, V29, P569, DOI 10.1097/IAE.0b013e3181a2f3fa
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Matsumoto K, 2002, DIABETIC MED, V19, P822, DOI 10.1046/j.1464-5491.2002.00799.x
   Nagaoka T, 2008, INVEST OPHTH VIS SCI, V49, P2053, DOI 10.1167/iovs.07-1387
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327
   Qamirani E, 2005, ARTERIOSCL THROM VAS, V25, P995, DOI 10.1161/01.ATV.0000159890.10526.1e
   Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sesso HD, 2003, JAMA-J AM MED ASSOC, V290, P2945, DOI 10.1001/jama.290.22.2945
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Yeh ETH, 2003, CIRCULATION, V107, P370, DOI 10.1161/01.CIR.0000053731.05365.5A
NR 28
TC 23
Z9 23
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2011
VL 46
IS 3
BP 125
EP 132
DI 10.1159/000323815
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 824PW
UT WOS:000295215400003
PM 21336002
DA 2022-11-30
ER

PT J
AU Treumer, F
   Bunse, A
   Klatt, C
   Roider, J
AF Treumer, Felix
   Bunse, Arnd
   Klatt, Carsten
   Roider, Johann
TI Autologous retinal pigment epithelium-choroid sheet transplantation in
   age related macular degeneration: morphological and functional results
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL NEOVASCULAR MEMBRANES; ARGON-LASER PHOTOCOAGULATION;
   RANDOMIZED CLINICAL-TRIALS; PHOTODYNAMIC THERAPY; VASCULAR PATTERN;
   TRANSLOCATION; VERTEPORFIN; MACULOPATHY; DETACHMENT; SURGERY
AB Objective: To evaluate the outcome of autologous retinal pigment epithelium (RPE)-choroid sheet transplantation after removal of a subfoveal choroidal neovascularisation (CNV) in patients with age related macular degeneration (AMD).
   Methods: RPE-choroid sheet transplantation was performed in 10 consecutive patients with exudative AMD (n=9) or geographic atrophy (n=1). After CNV extraction, an autologous RPE-choroid patch was translocated from the midperiphery under the macula. Follow-up was between 6 and 12 months. Visual acuity testing and microperimetry (Nidek-MP1) as well as autofluorescence, fluorescein and indocyanine green (ICG) angiography were performed and the data were analysed retrospectively.
   Results: Visual acuity (logarithm of minimum angel of resolution) before operation ranged from 0.7 to 1.8 (mean 1.37) and after operation from 0.4 to 1.6 (mean 1.24). Visual acuity after operation improved in seven patients (by a mean of 0.26), remained stable in one patient and decreased in two patients. Microperimetry showed light sensitivity and fixation on the sheet in five cases. ICG angiography demonstrated perfusion through the RPE-choroid graft in nine patients. Postoperative complications included retinal detachment (n=1) and epiretinal membrane formation (n=2). The patient with geographic atrophy developed a CNV after surgery.
   Conclusions: Autologous RPE -choroid sheet transplantation is feasible and a comparatively safe procedure. Microperimetry showed fixation and light perception over the graft with a moderate increase in mean visual acuity.
C1 Univ Schleswig Holstein, Dept Ophthalmol, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Treumer, F (通讯作者)，Univ Schleswig Holstein, Dept Ophthalmol, Campus Kiel,Hegewischstr 2, D-24105 Kiel, Germany.
EM f.treumer@ophthalmol.uni-kiel.de
RI Roider, Johann/E-4513-2010
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt Claus, 1996, Ophthalmologe, V93, P688, DOI 10.1007/s003470050059
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HAYREH SS, 1974, EXP EYE RES, V19, P101, DOI 10.1016/0014-4835(74)90078-5
   HAYREH SS, 1974, A GRAEF ARCH KLIN EX, V192, P181
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Hisatomi T, 2002, CURR EYE RES, V24, P161, DOI 10.1076/ceyr.24.3.161.8305
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   Yang L, 2004, INVEST OPHTH VIS SCI, V45, P648, DOI 10.1167/iovs.03-0827
NR 24
TC 47
Z9 50
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2007
VL 91
IS 3
BP 349
EP 353
DI 10.1136/bjo.2006.102152
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 139IQ
UT WOS:000244425900024
PM 17035275
OA Green Published
DA 2022-11-30
ER

PT J
AU Chong, EWT
   Kreis, AJ
   Wong, TY
   Simpson, JA
   Guymer, RH
AF Chong, Elaine W. -T.
   Kreis, Andreas J.
   Wong, Tien Y.
   Simpson, Julie A.
   Guymer, Robyn H.
TI Alcohol consumption and the risk of age-related macular degeneration: A
   systematic review and meta-analysis
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; BLUE-MOUNTAINS-EYE; BEAVER
   DAM EYE; PLASMA-CONCENTRATION; LIPID-PEROXIDATION; CIGARETTE-SMOKING;
   GRADING SYSTEM; MACULOPATHY; ASSOCIATION
AB PURPOSE: To review systematically the evidence currently available on alcohol consumption and the risk of age,related macular degeneration (AMD).
   DESIGN: Systematic review and meta,analysis of observational studies.
   METHODS: Seven databases were searched systematically with no limits on the year or language of publication for prospective cohort studies. References identified from pertinent reviews and articles also were retrieved. Two reviewers independently searched the above databases and selected the studies using prespecified standardized criteria. These criteria included appropriate adjustment for age and smoking in the analysis. Of the 441 studies identified initially, five cohort studies met the selection criteria. Data extraction and study quality evaluation were performed independently by two reviewers and results were pooled quantitatively using meta-analytic methods.
   RESULTS: The five cohort studies included 136,946 people, among whom AMD developed in 1923 (1,513 early and 410 late). Pooled results showed that heavy alcohol consumption was associated with an increased risk of early AMD (pooled odds ratio, 1.47; 95% confidence interval, 1.10 to 1.95), whereas the association between heavy alcohol consumption and risk of late AMD was inconclusive. There were insufficient data to evaluate a dose-response association between alcohol consumption and AMD or the association between moderate alcohol consumption and AMD.
   CONCLUSIONS: Heavy alcohol consumption (more than three standard drinks per day) is associated with an increased risk of early AMD. Although this association seems to be independent of smoking, residual confounding effects from smoking cannot be excluded completely.
C1 [Chong, Elaine W. -T.; Kreis, Andreas J.; Wong, Tien Y.; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117548, Singapore.
   [Simpson, Julie A.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3052, Australia.
   [Simpson, Julie A.] Canc Council Victoria, Canc Epidemiol Ctr, Parkville, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; National
   University of Singapore; Singapore National Eye Center; University of
   Melbourne; Cancer Council Victoria
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne st, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Simpson, Julie A/P-7299-2014
OI Wong, Tien Yin/0000-0002-8448-1264; Guymer, Robyn/0000-0002-9441-4356;
   Simpson, Julie/0000-0002-2660-2013
CR Agar E, 2003, INT J NEUROSCI, V113, P1643, DOI 10.1080/00207450390245207
   Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Albert MA, 2003, CIRCULATION, V107, P443, DOI 10.1161/01.CIR.0000045669.16499.EC
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Arroyo JG, 2006, JAMA-J AM MED ASSOC, V295, P2394, DOI 10.1001/jama.295.20.2394
   Bagnardi V, 2004, AM J EPIDEMIOL, V159, P1077, DOI 10.1093/aje/kwh142
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bora PS, 2006, FEBS J, V273, P1403, DOI 10.1111/j.1742-4658.2006.05163.x
   Brady WE, 1996, J NUTR, V126, P129, DOI 10.1093/jn/126.1.129
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   CASTELLI WP, 1977, LANCET, V2, P153
   CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Deeks J J, 2003, Health Technol Assess, V7, piii
   Dickersin K, 2002, INT J EPIDEMIOL, V31, P6, DOI 10.1093/ije/31.1.6
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Dufour MC, 1999, ALCOHOL RES HEALTH, V23, P5
   Egger M, 1998, BRIT MED J, V316, P140
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Goldberg IJ, 2001, CIRCULATION, V103, P472
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAKUBOWSKI JA, 1988, ARTERIOSCLEROSIS, V8, P436, DOI 10.1161/01.ATV.8.4.436
   KATZ ML, 1982, EXP EYE RES, V34, P339, DOI 10.1016/0014-4835(82)90082-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   Levitan EB, 2005, AM J CARDIOL, V96, P83, DOI 10.1016/j.amjcard.2005.03.031
   McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mukamal KJ, 2003, NEW ENGL J MED, V348, P109, DOI 10.1056/NEJMoa022095
   National Health and Medical Research Council (NHMRC),, 2001, AUSTR ALC GUID HLTH
   National Institutes of Health (NIH) United States National Library of Medicine, CLIN TRIALS DAT
   *NHMRC, 2000, EV REG LEV ALC CONS
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929
   Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731
   Rimm EB, 1999, BMJ-BRIT MED J, V319, P1523, DOI 10.1136/bmj.319.7224.1523
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Stewart SH, 2002, NUTR METAB CARDIOVAS, V12, P148
   The Cochrane Collaboration, REV MAN
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   2001, ARCH OPHTHALMOT, V119, P1417
NR 61
TC 77
Z9 79
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2008
VL 145
IS 4
BP 707
EP 715
DI 10.1016/j.ajo.2007.12.005
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282EN
UT WOS:000254550500020
PM 18242575
DA 2022-11-30
ER

PT J
AU Sulzbacher, F
   Kiss, C
   Kaider, A
   Eisenkoelbl, S
   Munk, M
   Roberts, P
   Sacu, S
   Schmidt-Erfurth, U
AF Sulzbacher, Florian
   Kiss, Christopher
   Kaider, Alexandra
   Eisenkoelbl, Stefan
   Munk, Marion
   Roberts, Philipp
   Sacu, Stefan
   Schmidt-Erfurth, Ursula
TI Correlation of SD-OCT Features and Retinal Sensitivity in Neovascular
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL-ACUITY; RANIBIZUMAB
AB PURPOSE. To correlate retinal sensitivity in patients with neovascular age-related macular degeneration (AMD) with specific characteristics of retinal morphology.
   METHODS. Thirty eyes of 30 patients presenting with active choroidal neovascularization were examined by spectral domain optical coherence tomography (SD-OCT) and microperimetry (MP-1). Image-processing software was used to match a fundus photographic (FP) MP-1 image with an infrared+OCT SD-OCT image. Each MP test point for retinal sensitivity was positioned at the corresponding SD-OCT location, and the microperimetric results were evaluated.
   RESULTS. An intact retinal configuration was associated with a median retinal sensitivity of 15.5 dB (quartiles: 12 dB, 18 dB). The median retinal sensitivities were 0 dB (quartiles: 0 dB, 1 dB) for the neovascular complex, 4 dB (0 dB, 9 dB) for the subretinal fluid, 1 dB (0 dB, 6 dB) for the intraretinal fluid, and 0 dB (0 dB, 3 dB) for intraretinal cysts. Pigment epithelium detachment was associated with a median retinal sensitivity of 3 dB (0 dB, 8 dB), and subretinal drusen had a median value of 8 dB (5 dB, 12 dB). Deep retinal layer analyses gave low median retinal sensitivities of 0 dB (0 dB, 3 dB) for an absent retinal pigment epithelium layer and 1 dB (0 dB, 5 dB) for an absent photoreceptor layer.
   CONCLUSIONS. Superimposition of morphological SD-OCT features and microperimetric retinal sensitivity allowed exact determination of the differential impact of retinal alteration on the corresponding sensitivity. Individual OCT-related indicators of neurosensory integrity were distinctly correlated with visual function. "Morphofunctional" findings could be relevant as prognostic factors and for (re)treatment decisions. (https://www.clinicaltrialsregister.eu/number, 2006-005684-26.) (Invest Ophthalmol Vis Sci. 2012;53:6448-6455) DOI:10.1167/iovs.11-9162
C1 [Sulzbacher, Florian; Kiss, Christopher; Eisenkoelbl, Stefan; Munk, Marion; Roberts, Philipp; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Kaider, Alexandra] Med Univ Vienna, Sect Clin Biometr, Ctr Med Stat Informat & Intelligent Syst, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Kiss, C (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM christopher.kiss@meduniwien.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR Ahlers C., 2008, OPHTHALMOLOGY, V115, P39, DOI [10.1016/j.ophtha.2008.05.0172-s2.0-48149084442, DOI 10.1016/J.OPHTHA.2008.05.0172-S2.0-48149084442]
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   Deak G, 2010, INVEST OPHTH VIS SCI, V9, P50
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Issa PC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012864
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Springer C, 2006, OPHTHALMOLOGE, V103, P214, DOI 10.1007/s00347-005-1261-z
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
NR 24
TC 33
Z9 35
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2012
VL 53
IS 10
BP 6448
EP 6455
DI 10.1167/iovs.11-9162
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 016NQ
UT WOS:000309526200060
PM 22918631
DA 2022-11-30
ER

PT J
AU Shiragami, C
   Miyake, M
   Fujiwara, A
   Morizane, Y
   Tsujikawa, A
   Yamashita, A
   Shiraga, F
AF Shiragami, Chieko
   Miyake, Masahiro
   Fujiwara, Atsushi
   Morizane, Yuki
   Tsujikawa, Akitaka
   Yamashita, Ayana
   Shiraga, Fumio
TI Effect of topical isopropyl unoprostone on macular atrophy progression
   in eyes with exudative age-related macular degeneration
SO MEDICINE
LA English
DT Article
DE a big potassium channel; age-related macular degeneration; endothelin 1;
   fundus autofluorescence; isopropyl unoprostone; macular atrophy
ID CHOROIDAL BLOOD-FLOW; GEOGRAPHIC ATROPHY; PHOTODYNAMIC THERAPY;
   RETINITIS-PIGMENTOSA; NEOVASCULARIZATION; CHORIOCAPILLARIS; RANIBIZUMAB;
   CIRCULATION; ENLARGEMENT; GLAUCOMA
AB Background: To evaluate the efficacy and safety of topical isopropyl unoprostone ( IU) in treating macular atrophy in age-related macular degeneration (AMD) patients.
   Methods: Fifty-two AMD patients with macular atrophy were included and randomly assigned (1: 1) to the treatment (topical 0.15% IU) or placebo group. Subjects used study eye drops 3 times a day for 54 weeks. The macular atrophy was documented on fundus autofluorescence photographs and measured using RegionFinder. The enlargement rate of macular atrophy and the changes in visual acuity were examined statistically between baseline and 54 weeks.
   Results: Forty-eight subjects were included in the analyses because 4 subjects withdrew fromthe study. The differences between the IU and placebo groups in mean and median area of macular atrophy were not statistically significant at baseline. The baseline median lesion size ofmacular atrophy was 2.33mm(2) in the IU group and 1.63mm(2) in the placebo group (P= 0.51). The intergroup difference in the enlargement ratio of macular atrophy (21 +/- 15% in the IU group and 111 +/- 96% in the placebo group) was statistically significant (P< 0.001). Additionally, visual acuity tended to improve over baseline in the IU group. No serious adverse events were observed.
   Conclusions: Topical IU therapy is safe and effective for treating macular atrophy in AMD patients.
C1 [Shiragami, Chieko; Tsujikawa, Akitaka; Yamashita, Ayana] Kagawa Univ, Dept Ophthalmol, Fac Med, 1750-1 Ikenobe Miki Cho, Miki, Kagawa 7610793, Japan.
   [Miyake, Masahiro] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Fujiwara, Atsushi; Morizane, Yuki; Shiraga, Fumio] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Ophthalmol, Okayama, Japan.
C3 Kagawa University; Kyoto University; Okayama University
RP Shiragami, C (通讯作者)，Kagawa Univ, Dept Ophthalmol, Fac Med, 1750-1 Ikenobe Miki Cho, Miki, Kagawa 7610793, Japan.
EM chappi@kms.ac.jp
RI Miyake, Masahiro/V-1261-2019
OI Miyake, Masahiro/0000-0001-7410-3764; Tsujikawa,
   Akitaka/0000-0003-0779-7799
FU Bayer (Osaka, Japan); Novartis (Tokyo, Japan); Pfizer (Tokyo, Japan);
   Santen (Osaka, Japan); Senju (Osaka, Japan); Alcon (Tokyo, Japan);
   Topcon (Tokyo, Japan); Chuo Sangyo (Nishinomiya, Japan); Hoya (Tokyo,
   Japan)
FX The authors disclose the following: The R-tech Ueno Corporation (Tokyo,
   Japan) provided 0.15% IU and placebo eye drops. Dr Shiragami received
   financial support from Bayer (Osaka, Japan), and Novartis (Tokyo,
   Japan). Dr Tsujikawa received financial support from Pfizer (Tokyo,
   Japan), Bayer (Osaka, Japan), Novartis (Tokyo, Japan), Santen (Osaka,
   Japan), Senju (Osaka, Japan), and Alcon (Tokyo, Japan). Dr Shiraga is a
   board member of Santen (Osaka, Japan) and a consultant of Bayer (Osaka,
   Japan), Novartis (Tokyo, Japan), Alcon (Tokyo, Japan), and Santen
   (Osaka, Japan). Dr Shiraga received financial support from Santen
   (Osaka, Japan), Novartis (Tokyo, Japan), Senju (Osaka, Japan), Alcon
   (Tokyo, Japan), Topcon (Tokyo, Japan), Chuo Sangyo (Nishinomiya, Japan),
   and Hoya (Tokyo, Japan).
CR Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Cuppoletti J, 2007, BBA-BIOMEMBRANES, V1768, P1083, DOI 10.1016/j.bbamem.2006.12.015
   Falsini B, 2011, INVEST OPHTH VIS SCI, V52, P1064, DOI 10.1167/iovs.10-5964
   FRIEDMAN E, 1965, BIBL ANAT, P129
   GRUNWALD JE, 1993, INVEST OPHTH VIS SCI, V34, P3609
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Gunawardena KA, 2003, OPHTHALMOLOGICA, V217, P129, DOI 10.1159/000068558
   Haria M, 1996, DRUG AGING, V9, P213, DOI 10.2165/00002512-199609030-00007
   Kimura I, 2005, JPN J OPHTHALMOL, V49, P287, DOI 10.1007/s10384-004-0208-2
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kojima Shota, 1997, Nippon Ganka Gakkai Zasshi, V101, P605
   Krebs I, 2005, AM J OPHTHALMOL, V140, P416, DOI 10.1016/j.ajo.2005.03.050
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Melamed S, 2002, DRUG EXP CLIN RES, V28, P63
   Mizuno K, 2009, INVEST OPHTH VIS SCI, V50, P2839, DOI 10.1167/iovs.08-2922
   Mukuno H, 2004, CURR EYE RES, V29, P457, DOI 10.1080/02713680490889465
   Munemasa Y, 2008, VISUAL NEUROSCI, V25, P197, DOI 10.1017/S095252380808053X
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Polska E, 2002, ARCH OPHTHALMOL-CHIC, V120, P348
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Querques G, 2012, BRIT J OPHTHALMOL, V96, P1479, DOI 10.1136/bjophthalmol-2012-302191
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tawada A, 2013, INDIAN J OPHTHALMOL, V61, P95, DOI 10.4103/0301-4738.109377
   Tsuruma K, 2011, MOL VIS, V17, P3556
   Vingolo EM, 2010, REGUL PEPTIDES, V160, P64, DOI 10.1016/j.regpep.2009.12.006
   Yamamoto S, 2012, OPHTHALMOL THER, V1, DOI 10.1007/s40123-012-0005-9
   Yamamoto T, 1997, SURV OPHTHALMOL, V41, pS99, DOI 10.1016/S0039-6257(97)80015-X
   Yu DY, 2001, INVEST OPHTH VIS SCI, V42, P1499
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 41
TC 7
Z9 7
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAR
PY 2017
VL 96
IS 12
AR e6422
DI 10.1097/MD.0000000000006422
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP8IT
UT WOS:000397619800050
PM 28328847
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, S
   Park, SJ
   Byun, SJ
   Park, KH
   Suh, HS
AF Kim, Siin
   Park, Sang Jun
   Byun, Seong Jun
   Park, Kyu Hyung
   Suh, Hae Sun
TI Incremental economic burden associated with exudative age-related
   macular degeneration: a population-based study
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Cost of illness; Exudative AMD;
   Incremental cost; Macular degeneration; Models; econometric;
   Ranibizumab; Propensity score
ID HEALTH; PREVALENCE; COSTS
AB Background The exudative age-related macular degeneration (AMD) causes considerable healthcare costs for patients and healthcare system, which are expected to grow as the population ages. The objective of this study was to assess the incremental economic burden of exudative AMD by comparing total healthcare costs between the exudative AMD group and non-AMD group to understand economic burden related to exudative AMD. Methods This retrospective cohort study used the National Health Insurance Service database including the entire Korean population. Exudative AMD group included individuals with at least one claim for ranibizumab and one claim using the registration code for exudative AMD (V201). Non-AMD group was defined as individuals without any claims regarding the diagnostic code of H35.3 or ranibizumab. The exudative AMD group and non-AMD group were matched using a propensity-score model. Incremental healthcare resource utilization and healthcare costs were measured during a one-year follow-up by employing econometric models: ordinary least squares (OLS) with log transformation and heteroscedastic retransformation; and generalized linear model (GLM) with a log link function and gamma distribution. Results A total of 7119 exudative AMD patients were matched to 7119 non-AMD patients. The number of outpatient visits was higher in the exudative AMD group (P-value < 0.0001), while the length of hospitalization was shorter in exudative AMD group (P-value < 0.0001). Exudative AMD patients had total costs 2.13 times (95%CI, 2.08-2.17) greater than non-AMD group using OLS, and total costs 4.06 times (95%CI, 3.82-4.31) greater than non-AMD group using GLM. Annual incremental total costs were estimated as $5519 (OLS) and $3699 (GLM). Conclusions Exudative AMD was associated with significantly increased healthcare costs compared to the non-AMD group. Attention is needed to manage the socioeconomic burden of exudative AMD.
C1 [Kim, Siin; Suh, Hae Sun] Pusan Natl Univ, Coll Pharm, 2,Busandaehak Ro 63beon Gil, Busan, South Korea.
   [Park, Sang Jun; Byun, Seong Jun; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, 82,Gumi Ro 173beon Gil, Seongnam Si, Gyeonggi Do, South Korea.
   [Byun, Seong Jun] Sungkyunkwan Univ, Sch Pharm, 2066 Seobu Ro, Suwon, Gyeonggi Do, South Korea.
C3 Pusan National University; Seoul National University (SNU); Sungkyunkwan
   University (SKKU)
RP Suh, HS (通讯作者)，Pusan Natl Univ, Coll Pharm, 2,Busandaehak Ro 63beon Gil, Busan, South Korea.; Park, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, 82,Gumi Ro 173beon Gil, Seongnam Si, Gyeonggi Do, South Korea.
EM sangjunpark@snu.ac.kr; haesun.suh@pusan.ac.kr
RI Kim, Siin/AAH-8085-2020
OI Kim, Siin/0000-0002-4368-7389
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT & Future Planning
   [NRF-2016R1C1B1009198]; Korea Health Technology R&D Project through the
   Korea Health Industry Development Institute (KHIDI) - Ministry of Health
   & Welfare, Republic of Korea [HI19C0373]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science, ICT & Future Planning (grant number:
   NRF-2016R1C1B1009198); and the Korea Health Technology R&D Project
   through the Korea Health Industry Development Institute (KHIDI), funded
   by the Ministry of Health & Welfare, Republic of Korea (grant number:
   HI19C0373). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Baser O, 2007, MODELING TRANSFORMED
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Jung EJ, 2015, RES REPORT
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Korean Statistical Information Service, 2011, POP STAT BOARD RES R
   Kume A, 2016, OPHTHALMOLOGY, V123, P1263, DOI 10.1016/j.ophtha.2016.01.042
   Lee J, 2017, INT J EPIDEMIOL, V46, DOI 10.1093/ije/dyv319
   Lee YJ, 2017, CLIN THER, V39, P527, DOI 10.1016/j.clinthera.2017.01.025
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8
   Mullahy J, 1998, J HEALTH ECON, V17, P247, DOI 10.1016/S0167-6296(98)00030-7
   Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Schachat A. P., 2017, RYANS RETINA E BOOK
   Song SO, 2014, DIABETES METAB J, V38, P395, DOI 10.4093/dmj.2014.38.5.395
NR 23
TC 13
Z9 13
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD NOV 12
PY 2019
VL 19
IS 1
AR 828
DI 10.1186/s12913-019-4666-0
PG 9
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA JO2HP
UT WOS:000497404400003
PM 31718629
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lamin, A
   Dubis, AM
   Sivaprasad, S
AF Lamin, Ali
   Dubis, Adam M.
   Sivaprasad, Sobha
TI Changes in macular drusen parameters preceding the development of
   neovascular age-related macular degeneration
SO EYE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; 10-YEAR INCIDENCE; PROGRESSION; VOLUME;
   PERFORMANCE; MACULOPATHY; SEVERITY; AREA
AB Purpose To assess the rate of change in macular drusen load in fellow eyes of patients with unilateral neovascular age-related macular degeneration (AMD) to evaluate whether the change in drusen load determines the onset and type of choroidal neovascularisation (CNV).
   Methods Subjects with unilateral neovascular AMD with a minimum of 2 years follow-up were identified retrospectively from the hospital electronic database. Drusen count, area and volume measurements at the macula of the contralateral eye were recorded using the commercial software on the Topcon 3D OCT-2000 devices over the previous 2 years. The mean rate of change of these parameters over time was compared between fellow eyes that converted to various CNV subtypes and those that did not.
   Results Two hundred forty-eight patients met the inclusion criteria. Of these patients, 179 patients did not progress to neovascular AMD (Group 1) while 69 patients converted (Group 2) at the end of 2 years follow up. Mean drusen volumes and drusen areas increased significantly in Group 2 in the 2nd year by 0.031 mm(3) (p < 0.001) and 0.572 mm(2) (p = 0.002), respectively. However, there was no difference in the rate of change between the two groups at year 1. Furthermore, for each 0.1 mm increase in the cubed root of baseline mean drusen volume increases the odds of progressing to CNV by 40% (95% CI 1.2-1.6; p < 0.001). The increase in drusen volume was higher in the occult CNV group compared to classic CNV (p = 0.048).
   Conclusion A significant increase in mean drusen volume occurs in eyes in the preceding 12 months prior to conversion to neovascular AMD and this change is more significant in eyes with occult CNV.
C1 [Lamin, Ali; Dubis, Adam M.; Sivaprasad, Sobha] Moorfields Eye Hosp NHS Fdn Trust, NIHR Moorfields Biomed Res Ctr, London, England.
   [Lamin, Ali; Dubis, Adam M.; Sivaprasad, Sobha] UCL Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Sivaprasad, S (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Moorfields Biomed Res Ctr, London, England.; Sivaprasad, S (通讯作者)，UCL Inst Ophthalmol, London, England.
EM sobha.sivaprasad@moorfields.nhs.uk
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Moorfields Eye Hospital NHS Foundation Trust; UCL Institute of
   Ophthalmology
FX The research was supported by the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology. The views expressed
   are those of the author(s) and not necessarily those of the NHS, the
   NIHR or the Department of Health.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Abugreen S, 2003, BRIT J OPHTHALMOL, V87, P307, DOI 10.1136/bjo.87.3.307
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Diniz B, 2014, RETINA-J RET VIT DIS, V34, P55, DOI 10.1097/IAE.0b013e31829d0015
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Gregori G, 2014, INVEST OPHTH VIS SCI, V55, P7662, DOI 10.1167/iovs.14-15273
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Iwama D, 2012, INVEST OPHTH VIS SCI, V53, P1576, DOI 10.1167/iovs.11-8103
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Sivaprasad S, 2006, EYE, V20, P923, DOI 10.1038/sj.eye.6702056
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 26
TC 7
Z9 7
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2019
VL 33
IS 6
BP 910
EP 916
DI 10.1038/s41433-019-0338-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IB4LC
UT WOS:000470242200011
PM 30679872
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Bandello, F
   Lafuma, A
   Berdeaux, G
AF Bandello, Francesco
   Lafuma, Antoine
   Berdeaux, Gilles
TI Public health impact of neovascular age-related macular degeneration
   treatments extrapolated from visual acuity
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   VERTEPORFIN THERAPY; HIP FRACTURE; RISK-FACTORS; IMPAIRMENT; DEPRESSION;
   MORTALITY; TAP; VISION
AB PURPOSE. To estimate the potential public health impact of treatment with new medications intended to preserve vision in patients with neovascular age-related macular degeneration (AMD).
   METHODS. A Markov model was used to simulate the natural history of AMD over the lifetime of patients with diagnosed neovascular AMD from clinical trials and epidemiologic surveys. It applied to a cohort of patients aged 75 years, with newly diagnosed neovascular AMD in one eye, whose visual acuity was 0.7 logMAR. Probabilities were calculated for the risk of AMD in the remaining eye and for premature mortality. Results of the model were expressed as the duration of low vision (worse eye VA > 1.0 and better eye VA > 0.7 logMAR) and blindness (bilateral VA > 1.0 logMAR). Health consequences of blindness and low vision were estimated for depression, hip fractures, institutionalization, and life expectancy.
   RESULTS. For AMD patients with a 50% probability of VA > 1.0 logMAR at 1 year, in one eye, the probability of lifetime bilateral blindness was > 47%. The patients would live approximately 7 years with monocular vision > 1.0 logMAR and an additional 4 years with bilateral blindness and a > 15% probability of depression due to AMD. Life expectancy was decreased by approximately 2 years, > 90/1000 patients would sustain a new hip fracture, and 1.5% of the patients would require institutional care for visual impairment due to AMD. To achieve a defined public health outcome (visual impairment and consequent comorbidity), it was necessary for the VA effectiveness of new treatments to increase in parallel with disease severity.
   CONCLUSIONS. Comorbidity related to visual impairment contributes significantly to the public health impact of AMD. Aggressive lesions need highly effective treatments. Models may be used to compare the public health impact of placebo-controlled clinical trial results.
C1 Alcon France, F-92563 Rueil Malmaison, France.
   Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   Cemka Eval, Bourge La Reine, France.
   Conservatoire Natl Arts & Metiers, Paris, France.
C3 Novartis; Alcon; University of Udine; heSam Universite; Conservatoire
   National Arts & Metiers (CNAM)
RP Berdeaux, G (通讯作者)，Alcon France, 4 Rue Henri St Claire Deville, F-92563 Rueil Malmaison, France.
EM gilles.berdeaux@alconlabs.com
RI bandello, francesco/AAH-2405-2019
OI bandello, francesco/0000-0003-3238-9682
CR Arnold JJ, 2000, BRIT MED J, V321, P741, DOI 10.1136/bmj.321.7263.741
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BERDEAUX G, IN PRESS OPHTHALMIC
   Billotte C, 2004, J CATARACT REFR SURG, V30, P2064, DOI 10.1016/j.jcrs.2004.05.003
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bouyer J, 1993, EPIDEMIOLOGIE PRINCI
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Brezin AP, 2004, BRIT J OPHTHALMOL, V88, P1330, DOI 10.1136/bjo.2003.039180
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cacciatore F, 2004, AGING CLIN EXP RES, V16, P382
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Dargent-Molina P, 2002, OSTEOPOROSIS INT, V13, P593, DOI 10.1007/s001980200078
   ELFFORS I, 1994, OSTEOPOROSIS INT, V4, P253, DOI 10.1007/BF01623349
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Galaria II, 2000, INT PSYCHOGERIATR, V12, P435, DOI 10.1017/S1041610200006554
   *GES ARB, 2001, PHOT THER VERT ALT F
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   *INSEE, INSEE B MENS STAT
   Jongenelis K, 2004, J AFFECT DISORDERS, V83, P135, DOI 10.1016/j.jad.2004.06.001
   Lafuma AJ, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-34
   Lee DJ, 2003, AM J OPHTHALMOL, V136, P1152, DOI 10.1016/S0002-9394(03)00573-7
   Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544
   Legood R, 2002, INJ PREV, V8, P155, DOI 10.1136/ip.8.2.155
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lupsakko T, 2002, INT J GERIATR PSYCH, V17, P808, DOI 10.1002/gps.689
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   *OECD, 1999, OECD HLTH DAT COMPR
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   *ROYAL NAT I BLIND, OFF NAT STAT MID 199
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409
   *SWED COUNC TECHN, 2001, PHOT TREATM MAC DEG
   Taylor H R, 2000, Trans Am Ophthalmol Soc, V98, P91
   THOMPSON JR, 1989, AGE AGEING, V18, P83, DOI 10.1093/ageing/18.2.83
   Tsai SY, 2003, J FORMOS MED ASSOC, V102, P86
   2001, J OFFICIEL REPU 0222, P2898
NR 42
TC 30
Z9 30
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2007
VL 48
IS 1
BP 96
EP 103
DI 10.1167/iovs.06-0283
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 124GC
UT WOS:000243355100015
PM 17197522
DA 2022-11-30
ER

PT J
AU Del Priore, LV
   Tezel, TH
   Kaplan, HJ
AF Del Priore, Lucian V.
   Tezel, Tongalp H.
   Kaplan, Henry J.
TI Maculoplasty for age-related macular degeneration: Reengineering Bruch's
   membrane and the human macula
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RETINAL-PIGMENT EPITHELIUM;
   INTRAVITREAL TRIAMCINOLONE ACETONIDE; COHERENCE TOMOGRAPHY FINDINGS;
   COMBINED PHOTODYNAMIC THERAPY; GENE-EXPRESSION PROFILE; BEAM
   RADIATION-THERAPY; CELL TRANSPLANTATION; EXTRACELLULAR-MATRIX; SURGICAL
   REMOVAL
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the western world. Over the last decade, there have been significant advances in the management of exudative AMD with the introduction of anti-VEGF drugs; however, many patients with exudative AMD continue to lose vision and there are no effective treatments for advanced exudative AMD or geographic atrophy. Initial attempts at macular reconstruction using cellular transplantation have not been effective in reversing vision loss. Herein we discuss the current status of surgical attempts to reconstruct damaged subretinal anatomy in advanced AMD. We reinforce the concept of maculoplasty for advanced AMD, which is defined as reconstruction of macular anatomy in patients with advanced vision loss. Successful maculoplasty is a three-step process that includes replacing or repairing damaged cells (using transplantation, translocation or stimulation of autologous cell proliferation); immune suppression (if allografts are used to replace damaged cells); and reconstruction or replacement of Bruch's membrane (to restore the integrity of the substrate for proper cell attachment).
   In the current article we will review the rationale for maculoplasty in advanced AMD, and discuss the results of initial clinical attempts at macular reconstruction. We will then discuss the role of Bruch's membrane damage in limiting transplant survival and visual recovery, and discuss the effects of age-related changes within human Bruch's membrane on the initial attachment and subsequent proliferation of transplanted cells. We will discuss attempts to repair Bruch's membrane by coating with extracellular matrix ligands, anatomic reconstitution of the inner collagen layer, and the effects of Bruch's membrane reconstruction of ultrastuctural anatomy and subsequent cell behavior. Lastly, we will emphasize the importance of continued efforts required for successful maculoplasty. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Columbia Univ, Edward S Harkness Eye Inst, Dept Ophthalmol, New York, NY USA.
   Univ Louisville, Sch Med, Dept Ophthalmol & Visual Sci, Kentucky Lions Eye Ctr, Louisville, KY 40292 USA.
C3 Columbia University; University of Louisville
RP Del Priore, LV (通讯作者)，Columbia Univ, Edward S Harkness Eye Inst, Dept Ophthalmol, New York, NY USA.
EM lvdelpriore@gmail.com
CR Abe T, 2000, TOHOKU J EXP MED, V191, P7, DOI 10.1620/tjem.191.7
   Abe T, 2000, CURR EYE RES, V20, P268
   Abe T, 1999, CELL TRANSPLANT, V8, P501, DOI 10.1177/096368979900800505
   Abe T, 1999, TOHOKU J EXP MED, V189, P295, DOI 10.1620/tjem.189.295
   Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   Aisenbrey S, 2003, AM J OPHTHALMOL, V135, P748, DOI 10.1016/S0002-9394(03)00145-4
   Akduman L, 1997, AM J OPHTHALMOL, V123, P90, DOI 10.1016/S0002-9394(14)70997-3
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Aronson D, 2003, J HYPERTENS, V21, P3, DOI 10.1097/00004872-200301000-00002
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery NC, 2005, SCAND J MED SCI SPOR, V15, P231, DOI 10.1111/j.1600-0838.2005.00464.x
   AVERY RL, 1986, ARCH OPHTHALMOL-CHIC, V104, P1220
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   BENTLEY JP, 1979, J INVEST DERMATOL, V73, P80, DOI 10.1111/1523-1747.ep12532769
   Berger AS, 2003, OPHTHALMOLOGY, V110, P383, DOI 10.1016/S0161-6420(02)01738-4
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   BOTTONI F, 2006, GRAEFES ARCH CLIN EX
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cai H, 2006, CURR EYE RES, V31, P181, DOI 10.1080/02713680500514628
   Cai H, 2006, MOL VIS, V12, P1
   Chang AA, 2003, CLIN EXP OPHTHALMOL, V31, P103, DOI 10.1046/j.1442-9071.2003.00614.x
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   CHU PG, 1991, INVEST OPHTH VIS SCI, V32, P1757
   CHU PG, 1991, INVEST OPHTH VIS SCI, V32, P1763
   Conti SM, 2006, CURR OPIN OPHTHALMOL, V17, P235, DOI 10.1097/01.icu.0000193107.00089.ee
   COSCAS G, 1993, J FR OPHTALMOL, V16, P633
   Crafoord S, 2002, ACTA OPHTHALMOL SCAN, V80, P387, DOI 10.1034/j.1600-0420.2002.800408.x
   Crafoord S, 2001, ACTA OPHTHALMOL SCAN, V79, P509, DOI 10.1034/j.1600-0420.2001.790517.x
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   D'Amico DJ, 2001, AM J OPHTHALMOL, V132, P289, DOI 10.1016/S0002-9394(01)01022-4
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   Deberg M, 2005, OSTEOARTHR CARTILAGE, V13, P258, DOI 10.1016/j.joca.2004.12.002
   Degenring RF, 2005, ACTA OPHTHALMOL SCAN, V83, P621, DOI 10.1111/j.1600-0420.2005.00506.x
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2005, ARCH OPHTHALMOL-CHIC, V123, P1156, DOI 10.1001/archopht.123.8.1156-a
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   DELPRIORE LV, 1995, ARCH OPHTHALMOL-CHIC, V113, P939, DOI 10.1001/archopht.1995.01100070113034
   DELPRIORE LV, 1998, 1 INT C NEW DEV TREA
   DELPRIORE LV, 1998, 47 ANN S NEW ORL AC
   DELPRIORE LV, 1999, RETINAL PIGMENT EPIT, P125
   DELPRIORE LV, 1997, SEMIN OPHTHALMOL, V12, P45
   DELPRIORE LV, 1993, EUR J IMPLANT REF SU, V5, P128, DOI DOI 10.1016/S0955-3681(13)80263-8
   DESAI VN, 1995, ARCH OPHTHALMOL-CHIC, V113, P409, DOI 10.1001/archopht.1995.01100040023014
   DONAHUE SP, 1994, OPHTHALMOLOGY, V101, P624
   ENGLER CB, 1993, ACTA OPHTHALMOL, V71, P27
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Finger PT, 1998, ARCH OPHTHALMOL-CHIC, V116, P1507, DOI 10.1001/archopht.116.11.1507
   Fraunfelder FW, 2005, DRUG TODAY, V41, P703, DOI 10.1358/dot.2005.41.11.917340
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Fujii GY, 2001, AM J OPHTHALMOL, V131, P90, DOI 10.1016/S0002-9394(00)00769-8
   Fujii GY, 2003, AM J OPHTHALMOL, V135, P109, DOI 10.1016/S0002-9394(02)01854-8
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   FUJII K, 1976, GERONTOLOGY, V22, P363, DOI 10.1159/000212148
   FUNG WE, 1991, AM J OPHTHALMOL, V112, P349, DOI 10.1016/S0002-9394(14)76743-1
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   GENG L, 2001, INVEST OPHTHALMO MAY
   Glacet-Bernard A, 2001, AM J OPHTHALMOL, V131, P78, DOI 10.1016/S0002-9394(00)00733-9
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gouras P, 1996, VISION RES, V36, P4121, DOI 10.1016/S0042-6989(96)00180-0
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Halfter W, 2000, DEV BIOL, V220, P111, DOI 10.1006/dbio.2000.9649
   Hamelin N, 2002, AM J OPHTHALMOL, V133, P530, DOI 10.1016/S0002-9394(02)01335-1
   Hawkins BS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1616, DOI 10.1001/archopht.122.11.1616
   HENKIND P, 1983, T OPHTHAL SOC UK, V103, P444
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Hojo M, 2004, INVEST OPHTH VIS SCI, V45, P3721, DOI 10.1167/iovs.04-0059
   HSU JK, 1995, RETINA-J RET VIT DIS, V15, P43, DOI 10.1097/00006982-199515010-00009
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Jacobson SG, 2002, ARCH OPHTHALMOL-CHIC, V120, P376
   JIANG LQ, 1994, EXP EYE RES, V58, P719, DOI 10.1006/exer.1994.1069
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Kaplan H J, 1999, Chem Immunol, V73, P207
   Kaplan HJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1168, DOI 10.1001/archopht.1997.01100160338012
   Kaplan HJ, 1998, RETINA-J RET VIT DIS, V18, P99
   KAPLAN HJ, 1998, RETINAL PIGMENT EPIT
   Kertes PJ, 2005, CAN J OPHTHALMOL, V40, P573, DOI 10.1016/S0008-4182(05)80049-3
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   KREBS I, 2005, GRAEFES ARCH CLIN EX, P1
   KUWABARA T, 1981, OPHTHALMOLOGY, V88, P331
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lee CJ, 2006, BIOMATERIALS, V27, P1670, DOI 10.1016/j.biomaterials.2005.09.008
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   LIN WL, 1989, CURR EYE RES, V8, P1171, DOI 10.3109/02713688909000042
   Liu J, 2003, AM J PHYSIOL-HEART C, V285, pH2587, DOI 10.1152/ajpheart.00516.2003
   Lois N, 2002, AM J OPHTHALMOL, V134, P468, DOI 10.1016/S0002-9394(02)01621-5
   LUKE M, 2006, BR J OPTHALMOL
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2005, KLIN MONATSBL AUGENH, V222, P480, DOI 10.1055/s-2005-858315
   MILLER FS, 1982, OPHTHALMOLOGY, V89, P1478
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Moshfeghi AA, 2005, EXPERT OPIN INV DRUG, V14, P671, DOI 10.1517/13543784.14.5.671
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Ng EWM, 2004, OPHTHALMOLOGY, V111, P1889, DOI 10.1016/j.ophtha.2004.03.037
   Nicolo M, 2006, RETINA-J RET VIT DIS, V26, P58, DOI 10.1097/00006982-200601000-00010
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Paik DC, 2001, CONNECT TISSUE RES, V42, P111, DOI 10.3109/03008200109014253
   Park CH, 2003, AM J OPHTHALMOL, V136, P830, DOI 10.1016/S0002-9394(03)00723-2
   Pauleikhoff D, 2000, OPHTHALMOLOGE, V97, P243, DOI 10.1007/s003470050520
   Pawlak D, 2004, AM J OPHTHALMOL, V137, P880, DOI 10.1016/j.ajo.2003.12.041
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Pollack JS, 1996, BRIT J OPHTHALMOL, V80, P314, DOI 10.1136/bjo.80.4.314
   Potter MJ, 2006, GRAEF ARCH CLIN EXP, V244, P639, DOI 10.1007/s00417-005-0115-3
   Rakic JM, 2005, NEW ENGL J MED, V352, P1720
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P558, DOI 10.1007/BF00947084
   Rosa RH, 1996, ARCH OPHTHALMOL-CHIC, V114, P480, DOI 10.1001/archopht.1996.01100130476025
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Roth DB, 2001, AM J OPHTHALMOL, V131, P390, DOI 10.1016/S0002-9394(00)00809-6
   Schraermeyer U, 2000, GRAEF ARCH CLIN EXP, V238, P979, DOI 10.1007/s004170000194
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shang Qing-Li, 2004, Zhonghua Yan Ke Za Zhi, V40, P266
   Sheridan C, 2004, GRAEF ARCH CLIN EXP, V242, P68, DOI 10.1007/s00417-003-0800-z
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stanga Paulo E., 2001, International Ophthalmology, V23, P297, DOI 10.1023/A:1014482025960
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Stur M, 2002, AM J OPHTHALMOL, V134, P469, DOI 10.1016/S0002-9394(02)01603-3
   Sullivan Frank, 2005, ACP J Club, V143, P18
   Susic Dinko, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P97, DOI 10.2174/1568006043481347
   SVOJTKOVA E, 1983, PHYSIOL BOHEMOSLOV, V32, P449
   Takahashi M, 1998, ARTHROSCOPY, V14, P366, DOI 10.1016/S0749-8063(98)70003-9
   TAKEUCHI M, 1993, ACTA SOC OPHTHALMOL, V97, P17
   TERAN H, 2001, MINN INTELL PROP REV, V2, P1
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Tezel TH, 1997, CURR EYE RES, V16, P802, DOI 10.1076/ceyr.16.8.802.8981
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thumann G, 1999, TRANSPLANTATION, V68, P195, DOI 10.1097/00007890-199907270-00006
   Tobin Kathleen A, 2006, Insight, V31, P11
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   VALENTINO TL, 1995, ARCH OPHTHALMOL-CHIC, V113, P932, DOI 10.1001/archopht.1995.01100070106033
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   West SK, 2000, EPIDEMIOL REV, V22, P64, DOI 10.1093/oxfordjournals.epirev.a018025
   Williams KA, 1999, TRANSPLANTATION, V68, P171, DOI 10.1097/00007890-199907270-00001
   YAMAUCHI M, 1988, BIOCHEM BIOPH RES CO, V152, P898, DOI 10.1016/S0006-291X(88)80124-4
   YE JJ, 1993, CURR EYE RES, V12, P629, DOI 10.3109/02713689309001842
NR 183
TC 39
Z9 39
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2006
VL 25
IS 6
BP 539
EP 562
DI 10.1016/j.preteyeres.2006.08.001
PG 24
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 111NO
UT WOS:000242459600002
PM 17071125
DA 2022-11-30
ER

PT J
AU Zhang, M
   Baird, PN
AF Zhang, Michael
   Baird, Paul N.
TI A decade of age-related macular degeneration risk models: What have we
   learned from them and where are we going?
SO OPHTHALMIC GENETICS
LA English
DT Review
DE AMD; genomics; logistic regression; precision medicine; prediction
ID FACTOR-H POLYMORPHISM; GENETIC RISK; VISUAL IMPAIRMENT; US TWIN;
   ASSOCIATIONS; PREDICTION; DISEASE; SUSCEPTIBILITY; PREVALENCE;
   VALIDATION
AB The genomic revolution has revealed the complexity of multifactorial diseases, making the development of effective diagnostics extremely challenging. In turn, the prospect of precision medicine as applied through targeted therapeutic treatments continues to remain largely elusive. Age-related macular degeneration (AMD) as a complex disease falls under this category, despite it being one of the most well characterized multifactorial diseases. This reflects both the extent of identified genetic components and known environmental risk factors. Additional considerations in dissecting out the roles played by genetic and non-genetic risk factors arise through the rapid increase in prevalence of AMD with age and the varying time periods over which disease progression can occur, complicating efforts to discriminate between "progressors" and non-"progressors." As a consequence, extensive research into the aetiology of AMD is yet to realize a clinically acceptable predictive test. This review covers the current climate of risk models in late AMD but will focus mainly on genetic risk factors as well as the types of models that have currently been employed in the AMD modelling literature.
C1 [Zhang, Michael; Baird, Paul N.] Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
RP Baird, PN (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM pnb@unimelb.edu.au
OI Baird, Paul/0000-0002-1305-3502
FU National Health and Medical Research Council of Australia (NHMRC)
   [1028444]
FX We acknowledge funding from the National Health and Medical Research
   Council of Australia (NHMRC) Senior Research Fellowship 1028444 (PNB).
   The Centre for Eye Research Australia (CERA) receives Operational
   Infrastructure Support from the Victorian Government.
CR Abraham G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004137
   Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Buitendijk GH, 2014, OPHTHALMOLOGY, V121, P976
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Furey TS, 2000, BIOINFORMATICS, V16, P906, DOI 10.1093/bioinformatics/16.10.906
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Goddard ME, 2009, STAT SCI, V24, P517, DOI 10.1214/09-STS306
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2014, ADV EXP MED BIOL, V801, P291, DOI 10.1007/978-1-4614-3209-8_37
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kuo JZ, 2013, EXPERT REV OPHTHALMO, V8, P127, DOI 10.1586/EOP.13.3
   MacLeod IM, 2014, GENETICS, V198, P1671, DOI 10.1534/genetics.114.168344
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Wray NR, 2007, GENOME RES, V17, P1520, DOI 10.1101/gr.6665407
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 46
TC 2
Z9 2
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD AUG
PY 2017
VL 38
IS 4
BP 301
EP 307
DI 10.1080/13816810.2016.1227451
PG 7
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA FE1OM
UT WOS:000407987500001
PM 27901647
DA 2022-11-30
ER

PT J
AU Donoso, LA
   Vrabec, T
   Kuivaniemi, H
AF Donoso, Larry A.
   Vrabec, Tamara
   Kuivaniemi, Helena
TI The Role of Complement Factor H in Age-related Macular Degeneration: A
   Review
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE abdominal aortic aneurysm (AAA); adaptive optics; age-related macular
   degeneration; alternative and classic pathway; alternative splicing;
   Alzheimer disease; ARMS2; atherosclerosis; complement control proteins
   (CCP); dense deposit disease (DDD); drusen; Factor H; hemolytic uremic
   syndrome (HUS); HIV; HTRA1; inflammation; innate and acquired immune
   system; liver; LOC387715/ARMS2; mass spectrometry; membanoproliferative
   glomerulonephritis (MPGHII); molecular mimicry; multifocal choroiditis;
   neutrophils; polyanions; relapsing polychondtitis; retinal pigment
   epithelium (RPE); risk factors; S-antigen; short consensus repeats
   (SCR); Streptococcus M protein; transplantation; trilateral
   retinoblastoma; vascular disease; Y402H polymorphism
ID HEMOLYTIC-UREMIC SYNDROME; FACTOR HY402H POLYMORPHISM; DENSE DEPOSIT
   DISEASE; HUMAN-GENOME-PROJECT; C-REACTIVE PROTEIN; RETINAL S-ANTIGEN;
   STRONG ASSOCIATION; MOLECULAR MIMICRY; COMPONENT 2; FACTOR-B
AB Factor H is a 155 kDa sialic acid containing glycoprotein that plays an integral role in the regulation of the complement-mediated immune system that is involved in microbial defense, immune complex processing, and programmed cell death. These events take place primarily in fluid phase and on the cell surface and are particularly important in the context of distinguishing self from non-self. Activation of the complement system occurs within seconds and results in a proteolytic cascade eventually forming the membrane attack complex leading to cell lysis. Factor H protects host cells from injury resulting from unrestrained complement activation. Mutations and SNPs (single nucleotide polymorphisms) in Factor H have been implicated in a variety of human conditions including age-related macular degeneration (AMD), atypical hemolytic uremic syndrome, and membranoproliferative glomuleronephritis type II or dense deposit disease. It should not be surprising that these seemingly unrelated diseases involving mutations in Factor H may share common features. Because the immune process involves, in part, an inflammatory response and common or similar surface antigens, it is also not unexpected to observe features of inflammation, including deposition of bioactive complement fragments such as C3a and C5a, a cellular influx of immune related cells such as lymphocytes, and the potential for multiple organ involvement. We review recent developments in molecular genetics; SNPs, including Y402H; the three-dimensional structure; and mass spectroscopy of Factor H as it relates to the pathogenesis of eye disease. In addition, we discuss the concepts of molecular mimicry, sequestered or hidden antigens, and antigenic cross reactivity, and propose that AMD should not simply be considered to be an eye disease, but rather a systemic vascular disease where the eye has the ability to self regulate a local immune response. Identification of the initial event or inciting antigen has yet to be determined and will significantly advance the understanding of the pathogenesis of AMD. (Surv Ophthalmol 55:227-246,2010. (C) 2010 Elsevier Inc. All rights reserved.)
C1 [Donoso, Larry A.] Eye Res Inst, Philadelphia Retina Endowment Fund, Philadelphia, PA USA.
   [Donoso, Larry A.] Wills Eye Inst, Philadelphia, PA USA.
   [Vrabec, Tamara; Kuivaniemi, Helena] Geisinger Med Ctr, Danville, PA 17822 USA.
C3 Jefferson University; Geisinger Medical Center
RP Donoso, LA (通讯作者)，POB 53429, Philadelphia, PA 19105 USA.
EM ldonoso@vision-research.org
RI Kuivaniemi, Helena/Q-8178-2019
OI Kuivaniemi, Helena/0000-0001-5753-8766
FU Elizabeth C. King Trust
FX Supported in part by the Elizabeth C. King Trust, in collaboration with
   the Wills Eye Institute, Philadelphia, PA. Gregory Hageman, PhD, Helga
   Magargal, MD, Larry Magargal, MD, David Pao, MD, and Drs Carol and Jerry
   Shields provided helpful discussions. Drs Carol and Jerry Shields
   provided clinical photographs. The Foundation also acknowledges the
   support of the residents of Pennswood Village and Twining Village who
   help to support eye research. Christine Skerka and Paul Barlow provided
   assistance with some aspects of the text and figures related to Factor
   H. None of the authors have a commercial interest in any of the
   pharmaceuticals mentioned in the text or figures.
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Adeyemo A, 2010, PUBLIC HEALTH GENOMI, V13, P72, DOI 10.1159/000218711
   Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409
   An FQ, 2009, INVEST OPHTH VIS SCI, V50, P3778, DOI 10.1167/iovs.08-3264
   Anderson DR, 2007, CARDIOVASC RES, V73, P597, DOI 10.1016/j.cardiores.2006.11.029
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   APPEL GB, 1993, NEW ENGL J MED, V328, P466
   ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99
   Badger SA, 2009, J VASC SURG, V49, P178, DOI 10.1016/j.jvs.2008.07.081
   Barlow PN, 2008, ADV EXP MED BIOL, V632, P117, DOI 10.1007/978-0-387-78952-1_10
   Barreto C, 2007, MICROSC MICROANAL, V13, P52, DOI 10.1017/S1431927607079469
   Beutel J, 2009, EXPERT OPIN EMERG DR, V14, P341, DOI [10.1517/14728210902824141, 10.1517/14728210902824141 ]
   Boddy AM, 2008, DRUG NEWS PERSPECT, V21, P142, DOI 10.1358/dnp.2008.21.3.1203410
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Capella JF, 1996, J SURG RES, V65, P31, DOI 10.1006/jsre.1996.0339
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Corbett BA, 2007, MOL PSYCHIATR, V12, P292, DOI 10.1038/sj.mp.4001943
   D'souza YB, 2009, KIDNEY INT, V75, P824, DOI 10.1038/ki.2008.658
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dizikes GJ, 1995, CLIN LAB MED, V15, P973, DOI 10.1016/S0272-2712(18)30311-1
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   DONOSO LA, 1983, ARCH OPHTHALMOL-CHIC, V101, P787, DOI 10.1001/archopht.1983.01040010787019
   DONOSO LA, 1987, AM J OPHTHALMOL, V103, P57, DOI 10.1016/S0002-9394(14)74170-4
   DONOSO LA, 1985, INVEST OPHTH VIS SCI, V26, P561
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ENGEL LW, 1993, ARCH PATHOL LAB MED, V117, P459
   Ferrara DC, 2008, ARCH OPHTHALMOL-CHIC, V126, P1562, DOI 10.1001/archopht.126.11.1562
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Grewal PK, 2008, NAT MED, V14, P648, DOI 10.1038/nm1760
   GUYER MS, 1993, AM J DIS CHILD, V147, P1145, DOI 10.1001/archpedi.1993.02160350019003
   Haapasalo K, 2008, MOL MICROBIOL, V70, P583, DOI 10.1111/j.1365-2958.2008.06347.x
   Haas P, 2009, EYE, V23, P2228, DOI 10.1038/eye.2008.422
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAGEMAN GS, Patent No. 20090124542
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Hamilton G, 2007, NEUROMOL MED, V9, P331, DOI 10.1007/s12017-007-8013-y
   Hansson AS, 2004, AM J PATHOL, V164, P959, DOI 10.1016/S0002-9440(10)63183-5
   Heinen S, 2007, J AM SOC NEPHROL, V18, P506, DOI 10.1681/ASN.2006091069
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   HERMAN JH, 1973, J CLIN INVEST, V52, P549, DOI 10.1172/JCI107215
   Herzberger P, 2009, INT J MED MICROBIOL, V299, P141, DOI 10.1016/j.ijmm.2008.06.005
   Herzberger P, 2007, INFECT IMMUN, V75, P4817, DOI 10.1128/IAI.00532-07
   Hocking HG, 2008, J BIOL CHEM, V283, P9475, DOI 10.1074/jbc.M709587200
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Hovis KM, 2004, J BACTERIOL, V186, P2612, DOI 10.1128/JB.186.9.2612-2618.2004
   Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   INWARD C, 2008, PAEDIAT CHILD HLTH, V18, P364
   Jalanko H, 2008, AM J TRANSPLANT, V8, P216, DOI 10.1111/j.1600-6143.2007.02029.x
   Janeway CA, 2005, IMMUNOBIOLOGY
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Jylhava J, 2009, CLIN EXP IMMUNOL, V155, P53, DOI 10.1111/j.1365-2249.2008.03752.x
   Jylhava J, 2009, EXP GERONTOL, V44, P297, DOI 10.1016/j.exger.2008.10.006
   Kelly U, 2009, INVEST OPHTH VIS SCI, V50, P1540, DOI 10.1167/iovs.08-2782
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Koziolek MJ, 2008, KIDNEY INT, V74, P384, DOI 10.1038/ki.2008.133
   Kraiczy P, 2003, EUR J IMMUNOL, V33, P697, DOI 10.1002/eji.200323571
   Kuivaniemi H, 2008, CIRCULATION, V117, P242, DOI 10.1161/CIRCULATIONAHA.107.690982
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lee AY, 2008, PHARMACOGENOMICS, V9, P1547, DOI 10.2217/14622416.9.10.1547
   Lee SS, 2009, OPHTHALMIC RES, V41, P124, DOI 10.1159/000209665
   Lenk GM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-237
   Lerner MP, 1995, AUTOIMMUNITY, V22, P95, DOI 10.3109/08916939508995305
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Magargal L E, 1981, Retina, V1, P96
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   MORELL AG, 1968, J BIOL CHEM, V243, P155
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murphy B, 2002, AM J KIDNEY DIS, V39, P24, DOI 10.1053/ajkd.2002.29873
   Narkio-Makela M, 2001, CLIN IMMUNOL, V100, P118, DOI 10.1006/clim.2001.5043
   Noris M, 1999, J AM SOC NEPHROL, V10, P281
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Pagano MB, 2009, CIRCULATION, V119, P1805, DOI 10.1161/CIRCULATIONAHA.108.832972
   Prosser BE, 2007, ACTA CRYSTALLOGR F, V63, P480, DOI 10.1107/S1744309107020052
   Qin S, 2008, J INFLAMM RES, V1, P49
   Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671
   Read RW, 2006, EXP EYE RES, V82, P389, DOI 10.1016/j.exer.2005.07.011
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schneider MC, 2006, J IMMUNOL, V176, P7566, DOI 10.4049/jimmunol.176.12.7566
   Schneider MC, 2009, NATURE, V458, P890, DOI 10.1038/nature07769
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1029, DOI 10.1007/s00347-005-1270-y
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Seko Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003709
   SETHI G, 2009, KIDNEY INT, V75, P876
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   SINGH VK, 1989, CELL IMMUNOL, V122, P262, DOI 10.1016/0008-8749(89)90166-4
   SINGH VK, 1992, JPN J OPHTHALMOL, V36, P108
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Skerka C, 2009, THROMB HAEMOSTASIS, V101, P227, DOI 10.1160/TH08-05-0322
   Smith RJH, 2007, J AM SOC NEPHROL, V18, P2447, DOI 10.1681/ASN.2007030356
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   Stella A, 1991, Eur J Vasc Surg, V5, P65, DOI 10.1016/S0950-821X(05)80929-6
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wildner G, 2003, EUR J IMMUNOL, V33, P2577, DOI 10.1002/eji.200324058
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zarbin M, 2007, OPTOMETRY VISION SCI, V84, pE559, DOI 10.1097/OPX.0b013e3180de4dd7
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2006, CURR OPIN RHEUMATOL, V18, P548, DOI 10.1097/01.bor.0000240370.47336.ae
   Zipfel PF, 2006, SEMIN THROMB HEMOST, V32, P146, DOI 10.1055/s-2006-939770
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   Zipfel PF, 2001, INT IMMUNOPHARMACOL, V1, P461, DOI 10.1016/S1567-5769(00)00047-3
NR 151
TC 61
Z9 64
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2010
VL 55
IS 3
BP 227
EP 246
DI 10.1016/j.survophthal.2009.11.001
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 592HR
UT WOS:000277369700003
PM 20385334
DA 2022-11-30
ER

PT J
AU Govetto, A
   Sarraf, D
   Figueroa, MS
   Pierro, L
   Ippolito, M
   Risser, G
   Bandello, F
   Hubschman, JP
AF Govetto, Andrea
   Sarraf, David
   Figueroa, Marta S.
   Pierro, Luisa
   Ippolito, Mario
   Risser, Gregoire
   Bandello, Francesco
   Hubschman, Jean Pierre
TI Choroidal thickness in non-neovascular versus neovascular age-related
   macular degeneration: a fellow eye comparative study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; AXIAL LENGTH; HEALTHY-SUBJECTS; HIGH
   MYOPIA; BLOOD-FLOW; VASCULOPATHY; CIRCULATION; PERFUSION; SEVERITY;
   NORMALS
AB Purpose To investigate the possible differences in choroidal thickness (CT) between non-neovascular (NNV) and neovascular (NV) age-related macular degeneration (AMD).
   Methods A retrospective, observational chart review of consecutive patients diagnosed with NNV AMD in one eye and with NV AMD in the fellow eye was carried out. NNV AMD was classified into four subgroups according to the Beckman Initiative for Macular Research AMD Classification Committee Meeting. CT was manually assessed using enhanced depth imaging optical coherence tomography from 1500 mm nasal to 1500 mm temporal to the fovea. Parametric and nonparametric tests were used to compare quantitative variables, a.2 test was used to compare categorical variables and logistic regression was used to evaluate associations of CT with other variables of interest.
   Results In this study, 322 eyes from 161 patients were included and 102 (63.35%) were female and 59 (36.65%) were male, with a mean age of 80.80 +/- 8.45 years (range 58-99 years). Mean follow-up was 11.2 +/- 10.8 months (range 1-38 months). In NNV AMD eyes, the choroid was significantly thicker in the subfoveal and temporal regions of the macula, if compared with NV AMD fellow eyes. Differences in CT between NNV AMD and NV AMD fellow eyes were higher at earlier stages of NNV AMD.
   Conclusions Subfoveal and temporal choroid was significantly thicker in NNV AMD compared with NV AMD fellow eyes. There was a significant choroidal thinning at advanced stages of NNV AMD.
C1 [Govetto, Andrea; Risser, Gregoire; Hubschman, Jean Pierre] Univ Calif Los Angeles, Stein Eye Inst, Retina Div, 100 Stein Plaza, Los Angeles, CA 90095 USA.
   [Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA USA.
   [Sarraf, David] Greater Angeles VA Healthcare Ctr, Los Angeles, CA USA.
   [Figueroa, Marta S.; Ippolito, Mario] Ramon y Cajal Univ Hosp, Ophthalmol Dept, Madrid, Spain.
   [Pierro, Luisa; Bandello, Francesco] San Raffaele Univ Hosp, Ophthalmol Dept, Milan, Italy.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   Hospital Universitario Ramon y Cajal; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele
RP Govetto, A (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, Retina Div, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM a.govetto@gmail.com
RI GOVETTO, ANDREA/AGR-6529-2022; Govetto, Andrea/AAH-2188-2019; bandello,
   francesco/AAH-2405-2019; Pierro, Luisa/AAN-3900-2020
OI GOVETTO, ANDREA/0000-0003-2192-810X; bandello,
   francesco/0000-0003-3238-9682; Hubschman,
   Jean-Pierre/0000-0002-8631-3467; pierro, luisa/0000-0003-2168-5224
FU Research to Prevent Blindness (RPB), New York, USA
FX This work was supported by Research to Prevent Blindness (RPB), New
   York, USA, with an unrestricted institutional grant for publications.
CR Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P7775, DOI 10.1167/iovs.14-14915
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Banitt M, 2013, CURR OPIN OPHTHALMOL, V24, P125, DOI 10.1097/ICU.0b013e32835d9245
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Brown JS, 2009, INVEST OPHTH VIS SCI, V50, P5, DOI 10.1167/iovs.08-1779
   Chen FK, 2012, INVEST OPHTH VIS SCI, V53, P975, DOI 10.1167/iovs.11-8771
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flores-Moreno I, 2013, AM J OPHTHALMOL, V155, P314, DOI 10.1016/j.ajo.2012.07.015
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   He M, 2016, SLEEP BREATH, V20, P369, DOI 10.1007/s11325-015-1306-8
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kang HM, 2015, OPHTHALMOLOGY, V122, P2363, DOI 10.1016/j.ophtha.2015.05.015
   Kim DY, 2013, ACTA OPHTHALMOL, V91, P183, DOI 10.1111/j.1755-3768.2011.02305.x
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Lee K, 2015, ACTA OPHTHALMOL, V93, pE469, DOI 10.1111/aos.12701
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Lu LN, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002967
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   McDonnell EC, 2014, EUR J OPHTHALMOL, V24, P897, DOI 10.5301/ejo.5000509
   Melancia D, 2016, GRAEF ARCH CLIN EXP, V254, P1453, DOI 10.1007/s00417-016-3360-8
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P407, DOI 10.1097/IAE.0000000000000368
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Rhodes LA, 2015, INVEST OPHTH VIS SCI, V56, P1872, DOI 10.1167/iovs.14-16179
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Ruiz-Medrano J, 2015, RETINA-J RET VIT DIS, V35, P2067, DOI 10.1097/IAE.0000000000000590
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sizmaz S, 2013, BRIT J OPHTHALMOL, V97, P601, DOI 10.1136/bjophthalmol-2012-302393
   Tan KA, 2016, SURV OPHTHALMOL, V61, P566, DOI 10.1016/j.survophthal.2016.02.007
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yan H, 2015, OCUL IMMUNOL INFLAMM, DOI [10.1186/1471-2415-14-103, DOI 10.1186/1471-2415-14-103]
   Yilmaz I, 2015, RETINA-J RET VIT DIS, V35, P2085, DOI 10.1097/IAE.0000000000000582
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
NR 47
TC 16
Z9 17
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2017
VL 101
IS 6
BP 764
EP 769
DI 10.1136/bjophthalmol-2016-309281
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW2ZG
UT WOS:000402363900015
PM 27587716
DA 2022-11-30
ER

PT J
AU Almeida, LN
   Melilo-Carolino, R
   Veloso, CE
   Pereira, PA
   Bastos-Rodrigues, L
   Sarubi, H
   Miranda, DM
   Soubrane, G
   De Marco, L
   Nehemy, MB
AF Almeida, Luciana N.
   Melilo-Carolino, Rachel
   Veloso, Carlos E.
   Pereira, Patricia A.
   Bastos-Rodrigues, Luciana
   Sarubi, Helena
   Miranda, Debora M.
   Soubrane, Gisele
   De Marco, Luiz
   Nehemy, Marcio B.
TI Association Analysis of CFH and ARMS2 Gene Polymorphisms in a Brazilian
   Cohort with Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE AMD; CFH; ARMS2; Polymorphism; CNV; Brazilian population
ID COMPLEMENT FACTOR-H; CIGARETTE-SMOKING; GENOMIC ANCESTRY; FACTOR-B;
   SUSCEPTIBILITY; LOC387715; RISK; VARIANTS; INFLAMMATION; MACULOPATHY
AB Purpose: To investigate the association between the CFH and ARMS2 gene polymorphisms and age-related macular degeneration (AMD) in a Brazilian cohort. Methods: We examined 163 individuals with AMD and 154 controls recruited at the Department of Ophthalmology of the Universidade Federal de Minas Gerais, at the Institut da Visao, and at the Centro Especializado em Olhos, in Brazil, between 2007 and 2012. Genotyping for CFH rs1061170 and ARMS2 rs10490924 single-nucleotide polymorphisms was performed. The odds ratios (OR) for all of the studied genotypes (heterozygous and homozygous) of both genes were calculated compared to homozygous ancestral alleles. Results: Homozygosity for the CFH and ARMS2 at-risk allele was 33.3 and 23.6%, respectively, for AMD individuals and 10.3 and 7.1%, respectively, for controls (p<0.0001). The OR was 7.2 (95% CI 3.6-14.5; p < 0.001) for the CFH at-risk genotype (CC) and 5.5 (95% CI 2.6-11.8; p < 0.0001) for ARMS2 (TT). Subjects homozygous for both polymorphisms had a much higher risk of developing AMD (n = 14 patients, OR 33.3, 95% CI 12.8-86.4). The proportion of ancestry in each group indicated that AMD patients had a higher European (Caucasian) component than controls. Conclusion: CFH and ARMS2 polymorphisms were strongly associated with AMD in this Brazilian cohort. Copyright (C) 2013 S. Karger AG, Basel
C1 [Almeida, Luciana N.; Veloso, Carlos E.; Nehemy, Marcio B.] Univ Fed Minas Gerais, Fac Med, Dept Ophthalmol, Belo Horizonte, MG, Brazil.
   [Melilo-Carolino, Rachel; Pereira, Patricia A.; Bastos-Rodrigues, Luciana; Sarubi, Helena; De Marco, Luiz] Univ Fed Minas Gerais, Dept Surg, Fac Med, Belo Horizonte, MG, Brazil.
   [Miranda, Debora M.] Univ Fed Minas Gerais, Dept Pediat, Fac Med, Belo Horizonte, MG, Brazil.
   [Soubrane, Gisele] Univ Paris, Dept Ophthalmol, F-75252 Paris, France.
C3 Universidade Federal de Minas Gerais; Universidade Federal de Minas
   Gerais; Universidade Federal de Minas Gerais; UDICE-French Research
   Universities; Universite Paris Cite
RP Almeida, LN (通讯作者)，Fac Med, Dept Ophthalmol, Av Alfredo Balena 190, BR-30130100 Belo Horizonte, MG, Brazil.
EM luciananfalmeida@gmail.com
RI Nehemy, Marcio/ABD-5089-2021; Miranda, Debora/AAQ-1952-2020; Veloso,
   Carlos Eduardo dos Reis/E-1815-2016; RODRIGUES, LUCIANA
   BASTOS/H-7068-2014; DE MARCO, LUIZ/H-6275-2012
OI Miranda, Debora/0000-0002-7081-8401; Veloso, Carlos Eduardo dos
   Reis/0000-0002-8817-7200; RODRIGUES, LUCIANA BASTOS/0000-0002-9053-7201;
   DE MARCO, LUIZ/0000-0003-2535-7439; Nehemy, Marcio/0000-0002-4104-0346
FU FAPEMIG; INCT/CNPq, Brazil
FX This work was partially funded by FAPEMIG and INCT/CNPq, Brazil.
CR Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Bastos-Rodrigues L, 2006, ANN HUM GENET, V70, P658, DOI 10.1111/j.1469-1809.2006.00287.x
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, AM J OPHTHALMOL, V152, P153, DOI 10.1016/j.ajo.2011.02.016
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2006, RETINA, P1017
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Suarez-Kurtz G, 2007, PHARMACOGENET GENOM, V17, P765, DOI 10.1097/FPC.0b013e3281c10e52
   Teixeira AG, 2010, ACTA OPHTHALMOL, V88, pE165, DOI 10.1111/j.1755-3768.2010.01932.x
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 38
TC 11
Z9 12
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2013
VL 50
IS 2
BP 117
EP 122
DI 10.1159/000350549
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 207IU
UT WOS:000323592900006
PM 23867343
DA 2022-11-30
ER

PT J
AU Chia, KJW
   Gunasekeran, DV
   Laude, A
AF Chia, Karen Jhi Wen
   Gunasekeran, Dinesh Visva
   Laude, Augustinus
TI The Impact of Switching Anti-Vascular Endothelial Growth Factor Therapy
   in the Management of Exudative Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; VEGF TRAP; RANIBIZUMAB; AFLIBERCEPT;
   OUTCOMES; TACHYPHYLAXIS; EYES; RESPONDERS; CONVERSION; RESISTANT
AB Switching of anti-vascular endothelial growth factor (VEGF) therapy in the management of poorly responsive exudative age-related macular degeneration (AMD) has had suggested benefits in individual reports that have yet to be consolidated. In this retrospective review, 24 studies published between 2009 and 2014 were identified. Reasons for switching included tachyphylaxis, health insurance coverage, cost issues, and nonresponse or inadequate response. Nine studies had data that could be used for comparison between studies. Median follow-up was 10.6 months (range: 4.2 months to 21.8 months). Mean baseline visual acuity (VA) ranged from 0.42 logMar to 0.94 logMar (standard deviation [SD] range: 0.05 logMar to 0.50 logMar) and mean VA on final follow-up ranged from 0.38 logMar to 0.78 logMar (SD range: 0.08 logMar to 0.50 logMar). Five of nine studies reported no statistically significant change in vision, and five of nine studies reported a statistically significant improvement in central retinal thickness. This review found that switching anti-VEGF did not confer significant improvement of VA, although it provided some anatomical improvement. Pertinent considerations for evaluating response following anti-VEGF therapy are also presented in this review.
C1 [Chia, Karen Jhi Wen; Gunasekeran, Dinesh Visva; Laude, Augustinus] Tan Tock Seng Hosp, Inst Eye, Natl Healthcare Grp, Singapore, Singapore.
   [Gunasekeran, Dinesh Visva] Singapore Gen Hosp, Anesthesiol & Intens Care, Singapore, Singapore.
C3 Tan Tock Seng Hospital; Singapore General Hospital
RP Chia, KJW (通讯作者)，FRCSED, Tan Tock Seng Hosp 11, Singapore 308433, Singapore.
EM Karen_chia@ttsh.com.sg
RI Gunasekeran, Dinesh/AAP-5268-2020
OI Gunasekeran, Dinesh/0000-0002-8502-2334
CR Almony A, 2011, CAN J OPHTHALMOL, V46, P182, DOI 10.3129/i10-095
   Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   Aslankurt M, 2013, EUR J OPHTHALMOL, V23, P553, DOI 10.5301/ejo.5000268
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Chong V, 2012, OPHTHALMOLOGICA, V227, P2, DOI 10.1159/000337152
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Ehlers JP, 2010, OPHTHAL SURG LAS IM, V41, P182, DOI 10.3928/15428877-20100303-05
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Hall LB, 2014, J OCUL PHARMACOL TH, V30, P346, DOI 10.1089/jop.2013.0188
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kaiser RS, 2012, OPHTHAL SURG LAS IM, V43, P13, DOI 10.3928/15428877-20111006-01
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P457
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kent JS, 2012, CAN J OPHTHALMOL, V47, P159, DOI 10.1016/j.jcjo.2012.01.003
   Kucukerdonmez C, 2015, EUR J OPHTHALMOL, V25, P51, DOI 10.5301/ejo.5000480
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P1, DOI 10.1136/bjophthalmol-2014-305502
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yamada K, 2011, ISRN OPHTHALMOL, V2011
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 54
TC 1
Z9 1
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD OCT
PY 2017
VL 48
IS 10
BP 859
EP 869
DI 10.3928/23258160-20170928-14
PG 11
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA FN5UF
UT WOS:000416073000014
PM 29020433
DA 2022-11-30
ER

PT J
AU Ng, DS
   Yip, YW
   Bakthavatsalam, M
   Chen, LJ
   Ng, TK
   Lai, TY
   Pang, CP
   Brelen, ME
AF Ng, Danny S.
   Yip, Yolanda W.
   Bakthavatsalam, Malini
   Chen, Li J.
   Ng, Tse K.
   Lai, Timothy Y.
   Pang, Calvin P.
   Brelen, Marten E.
TI Elevated angiopoietin 2 in aqueous of patients with neovascular age
   related macular degeneration correlates with disease severity at
   presentation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   BEVACIZUMAB; HUMOR LEVELS; RANIBIZUMAB; VEGF; NONRESPONDERS;
   AFLIBERCEPT; TIE2; ANGIOGENESIS
AB Angiopoietin 2 (ANG2) is a proangiogenic cytokine which may have an implication in neovascular age related macular degeneration (nAMD). In 24 eyes of 24 subjects presenting with treatment naive nAMD and 26 eyes of 26 control patients, aqueous humor samples were collected at the time of intervention (intravitreal injection of anti-vascular endothelial growth factor or cataract extraction). Best corrected visual acuity (BCVA) with and central macular thickness (CMT) using optical coherence tomography (OCT) were measured before each injection in the nAMD group. Aqueous cytokine levels were determined by immunoassay using a multiplex array (Quansys Biosciences, Logan, UT). Levels of ANG2 in the aqueous were significantly higher in nAMD patients than those of the control group (p < 0.0001), so were hepatocyte growth factor (HGF), interleukin-8 (IL-8) and tissue inhibitor of metalloproteinase 1 (TIMP 1), all with p < 0.001. ANG2 correlated with worse BCVA (r = 0.44, p-value = 0.027) and greater CMT (r = 0.66, p-value < 0.0001) on optical coherence tomography (OCT). ANG2 is upregulated in patients with nAMD and correlates with severity of disease at presentation.
C1 [Ng, Danny S.; Yip, Yolanda W.; Bakthavatsalam, Malini; Chen, Li J.; Ng, Tse K.; Lai, Timothy Y.; Pang, Calvin P.; Brelen, Marten E.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Brelen, ME (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Hong Kong, Hong Kong, Peoples R China.
EM marten.brelen@cuhk.edu.hk
RI Ng, Tsz Kin/I-8061-2014; Chen, Li Jia/I-5078-2014; Brelen, Marten
   E./D-1133-2016; Lai, Timothy Y Y/AAC-2120-2020; Ng, Danny Siu
   Chun/AAG-3081-2020
OI Ng, Tsz Kin/0000-0001-7863-7229; Chen, Li Jia/0000-0003-3500-5840; Lai,
   Timothy Y Y/0000-0002-7832-6428; Ng, Danny Siu Chun/0000-0001-6566-1019
FU CUHK [4054287]
FX We express our gratitude to all participants in this study. The work in
   this paper was supported by the research grants 4054287 from CUHK Direct
   Grant.
CR Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P545, DOI 10.1016/j.ophtha.2014.09.023
   Campochiaro PA, 2009, OPHTHALMOLOGY, V116, P2158, DOI 10.1016/j.ophtha.2009.04.038
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Daly C, 2013, CANCER RES, V73, P108, DOI 10.1158/0008-5472.CAN-12-2064
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Fiedler U, 2006, TRENDS IMMUNOL, V27, P552, DOI 10.1016/j.it.2006.10.004
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gerald D, 2013, CANCER RES, V73, P1649, DOI 10.1158/0008-5472.CAN-12-4697
   Gupta B, 2009, CLIN EXP OPHTHALMOL, V37, P801, DOI 10.1111/j.1442-9071.2009.02157.x
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hsu MY, 2016, SCI REP-UK, V6, DOI 10.1038/srep34631
   Huber M, 2012, OPHTHALMOLOGICA, V228, P188, DOI 10.1159/000339952
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Loewenstein A. K. B. D., 2010, INVEST OPHTHALMOL VI, V51
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuo T, 1998, JPN J OPHTHALMOL, V42, P377, DOI 10.1016/S0021-5155(98)00038-0
   Michalewski J, 2014, CAN J OPHTHALMOL, V49, P431, DOI 10.1016/j.jcjo.2014.07.012
   Monk BJ, 2014, LANCET ONCOL, V15, P799, DOI 10.1016/S1470-2045(14)70244-X
   Nambu H, 2005, J CELL PHYSIOL, V204, P227, DOI 10.1002/jcp.20292
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Otani A, 2003, RETINA-J RET VIT DIS, V23, P402, DOI 10.1097/00006982-200306000-00019
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Papadopoulos KP, 2016, CLIN CANCER RES, V22, P1348, DOI 10.1158/1078-0432.CCR-15-1221
   Peters S, 2007, CYTOKINE, V40, P144, DOI 10.1016/j.cyto.2007.09.001
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   Sung HJ, 2012, MOL VIS, V18, P234
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
NR 40
TC 22
Z9 23
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 27
PY 2017
VL 7
AR 45081
DI 10.1038/srep45081
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EQ0KV
UT WOS:000397761000001
PM 28345626
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ferrington, DA
   Kapphahn, RJ
   Leary, MM
   Atilano, SR
   Terluk, MR
   Karunadharma, P
   Chen, GKJ
   Ratnapriya, R
   Swaroop, A
   Montezuma, SR
   Kenney, MC
AF Ferrington, Deborah A.
   Kapphahn, Rebecca J.
   Leary, Michaela M.
   Atilano, Shari R.
   Terluk, Marcia R.
   Karunadharma, Pabalu
   Chen, George Kuei-Jie
   Ratnapriya, Rinki
   Swaroop, Anand
   Montezuma, Sandra R.
   Kenney, M. Cristina
TI Increased retinal mtDNA damage in the CFH variant associated with
   age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Complement factor H; Eyebank tissue;
   Mitochondria; mtDNA; Haplogroups; Inflammation
ID COMPLEMENT FACTOR-H; MITOCHONDRIAL-DNA HAPLOGROUPS; PIGMENT
   EPITHELIAL-CELLS; DISEASE-ASSOCIATED FORM; C-REACTIVE PROTEIN;
   PROGRESSIVE STAGES; OXIDATIVE STRESS; BRUCHS MEMBRANE; ACTIVATION;
   BINDING
AB Age-related macular degeneration (AMD) is a major cause of blindness among the elderly in the developed world. Genetic analysis of AMD has identified 34 high-risk loci associated with AMD. The genes at these high risk loci belong to diverse biological pathways, suggesting different mechanisms leading to AMD pathogenesis. Thus, therapies targeting a single pathway for all AMD patients will likely not be universally effective. Recent evidence suggests defects in mitochondria (mt) of the retinal pigment epithelium (RPE) may constitute a key pathogenic event in some AMD patients. The purpose of this study is to determine if individuals with a specific genetic background have a greater propensity for mtDNA damage. We used human eyebank tissues from 76 donors with AMD and 42 age-matched controls to determine the extent of mtDNA damage in the RPE that was harvested from the macula using a long extension polymerase chain reaction assay. Genotype analyses were performed for ten common AMD-associated nuclear risk alleles (ARMS2, TNFRSF10A, CFH, C2, C3, APOE, CETP, LIPC, VEGF and COL10A1) and mtDNA haplogroups. Sufficient samples were available for genotype association with mtDNA damage for TNFRSF10A, CFH, CETP, VEGFA, and COL10A1. Our results show that AMD donors carrying the high risk allele for CFH (C) had significantly more mtDNA damage compared with donors having the wild-type genetic profile. The data from an additional 39 donors (12 controls and 27 AMD) genotyped for CFH alleles further supported these findings. Taken together, these studies provide the rationale for a more personalized approach for treating AMD by uncovering a significant correlation between the CFH high risk allele and accelerated mtDNA damage. Patients harboring this genetic risk factor may benefit from therapies that stabilize and protect the mt in the RPE. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Ferrington, Deborah A.; Kapphahn, Rebecca J.; Leary, Michaela M.; Terluk, Marcia R.; Karunadharma, Pabalu; Montezuma, Sandra R.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Atilano, Shari R.; Chen, George Kuei-Jie; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92697 USA.
   [Ratnapriya, Rinki; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, Bethesda, MD 20892 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of California System; University of California Irvine;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Ferrington, DA (通讯作者)，380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu
OI Ratnapriya, Rinki/0000-0002-0469-4631; Swaroop,
   Anand/0000-0002-1975-1141; Atilano, Shari/0000-0002-7729-7864;
   Ferrington, Deborah/0000-0003-2561-7464
FU Elaine and Robert Larson Endowed Vision Research Chair; Beckman
   Initiative for Macular Research [1004, 1303]; Foundation Fighting
   Blindness [TA-NMT-0613-0620-UMN]; National Institutes of Health
   [T32-AG29796]; Discovery Eye Foundation; Polly and Michael Smith
   Foundation; National Eye Institute Intramural Research Program; Research
   to Prevent Blindness; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCES [UL1TR001414] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [ZIAEY000546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   ON AGING [T32AG029796] Funding Source: NIH RePORTER
FX This work was supported by the Elaine and Robert Larson Endowed Vision
   Research Chair (to DAF); Beckman Initiative for Macular Research (#1004,
   #1303 to DAF); Foundation Fighting Blindness (TA-NMT-0613-0620-UMN to
   DAF); An Anonymous Donor for Macular Degeneration Research and an
   unrestricted grant from Research to Prevent Blindness to the Department
   of Ophthalmology and Visual Neurosciences; National Institutes of Health
   (T32-AG29796 to MRT); Discovery Eye Foundation (to MCK); Polly and
   Michael Smith Foundation (to MCK) and the National Eye Institute
   Intramural Research Program (to AS).
CR Atilano SR, 2015, HUM MOL GENET, V24, P4491, DOI 10.1093/hmg/ddv173
   Black J.R.M., 2015, GENET MED
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG., 2015, NAT GENET
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Kennedy SR, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003794
   Kenney MC, 2014, HUM MOL GENET, V23, P3537, DOI 10.1093/hmg/ddu065
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Kenney MC, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-4
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Mansoor S, 2014, INDIAN J OPHTHALMOL, V62, P16, DOI 10.4103/0301-4738.126168
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 47
TC 45
Z9 45
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2016
VL 145
BP 269
EP 277
DI 10.1016/j.exer.2016.01.018
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL1DL
UT WOS:000375372300030
PM 26854823
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Merle, BMJ
   Cougnard-Gregoire, A
   Korobelnik, JF
   Schalch, W
   Etheve, S
   Rougier, MB
   Feart, C
   Samieri, C
   Delyfer, MN
   Delcourt, C
AF Merle, Benedicte M. J.
   Cougnard-Gregoire, Audrey
   Korobelnik, Jean-Francois
   Schalch, Wolfgang
   Etheve, Stephane
   Rougier, Marie-Benedicte
   Feart, Catherine
   Samieri, Cecilia
   Delyfer, Marie-Noelle
   Delcourt, Cecile
TI Plasma Lutein, a Nutritional Biomarker for Development of Advanced
   Age-Related Macular Degeneration: The Alienor Study
SO NUTRIENTS
LA English
DT Article
DE age-related macular degeneration; lutein; biomarker; epidemiology;
   nutrition; cohort; risk; population
ID GENOME-WIDE ASSOCIATION; VITAMIN-C; SERUM CONCENTRATIONS; MEDITERRANEAN
   DIET; PIGMENT DENSITY; ZEAXANTHIN; CAROTENOIDS; RISK; ANTIOXIDANTS;
   SUPPLEMENTATION
AB Lutein and zeaxanthin may lower the risk of age-related macular degeneration (AMD). We evaluated the associations of plasma lutein and zeaxanthin with the incidence of advanced AMD in the Alienor study (Antioxydants Lipides Essentiels Nutrition et Maladies Oculaires). Alienor study is a prospective population-based cohort of 963 residents of Bordeaux, France, who were 73 years or older at baseline (2006-2008). The present study included 609 participants with complete ophthalmologic and plasma carotenoids data. Examinations were performed every two years over an eight-year period (2006 to 2017). Plasma lutein and zeaxanthin were determined at baseline from fasting blood samples using high-performance liquid chromatography. Cox proportional hazard models were used to assess associations between plasma lutein, zeaxanthin, and their (total cholesterol (TC) + triglycerides (TG)) ratios with AMD. Among the 609 included participants, 54 developed advanced incident AMD during a median follow-up time of 7.6 years (range 0.7 to 10.4). Participants with higher plasma lutein had a reduced risk for incident advanced AMD in the fully adjusted model (HR = 0.63 per 1-SD increase (95% CI, 0.41-0.97), p = 0.03). A similar association was observed using the lutein/(TC + TG) ratio (HR = 0.59 (95% CI, 0.39-0.90), p = 0.01). No associations were evidenced for other carotenoids. Higher plasma lutein was associated with a 37% reduced risk of incident advanced AMD.
C1 [Merle, Benedicte M. J.; Cougnard-Gregoire, Audrey; Korobelnik, Jean-Francois; Feart, Catherine; Samieri, Cecilia; Delyfer, Marie-Noelle; Delcourt, Cecile] Univ Bordeaux, Bordeaux Populat Hlth, Inst Natl Sante & Rech Med INSERM, F-33000 Bordeaux, France.
   [Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Delyfer, Marie-Noelle] Ctr Hosp Univ Bordeaux, Serv Ophtalmol, F-33000 Bordeaux, France.
   [Schalch, Wolfgang; Etheve, Stephane] DSM Nutr Prod, CH-4303 Kaiserraugst, Switzerland.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; CHU
   Bordeaux; DSM NV
RP Merle, BMJ (通讯作者)，Univ Bordeaux, Bordeaux Populat Hlth, Inst Natl Sante & Rech Med INSERM, F-33000 Bordeaux, France.
EM benedicte.merle@u-bordeaux.fr; audrey.cougnard-gregoire@u-bordeaux.fr;
   jean-francois.korobelnik@chu-bordeaux.fr; wolfgang.schalch@dsm.com;
   stephane.etheve@dsm.com; marie-benedicte.rougier@chu-bordeaux.fr;
   catherineleart-couret@u-bordeaux.fr; cecilia.samieri@u-bordeaux.fr;
   marie-noelle.delyfer@chu-bordeaux.fr; cecile.delcourt@u-bordeaux.fr
RI Delcourt, Cecile/I-2627-2013; Merle, Benedicte MJ/F-1247-2015; Samieri,
   Cecilia/T-3267-2019
OI Delcourt, Cecile/0000-0002-2099-0481; Merle, Benedicte
   MJ/0000-0003-1332-0954; Samieri, Cecilia/0000-0001-9809-7506;
   Korobelnik, Jean-Francois/0000-0002-4438-9535; FEART,
   Catherine/0000-0002-7959-1610
FU Thea Pharma; Fondation Voir et Entendre; Retina France; Agence Nationale
   de la Recherch [ANR 2010-PRSP-011 VISA]; CFSR Recherche (Club
   Francophone des Specialistes de la Retine); CNSA (Caisse Nationale pour
   la Solidarite et l'Autonomie); French Ministry of Health (PHRC)
   [PHRC12_157]; European Union's Horizon 2020 research and innovation
   programme [634479]
FX The Alienor study was supported by Thea Pharma, Fondation Voir et
   Entendre, Retina France, Agence Nationale de la Recherche (ANR
   2010-PRSP-011 VISA), CFSR Recherche (Club Francophone des Specialistes
   de la Retine) and CNSA (Caisse Nationale pour la Solidarite et
   l'Autonomie). This study was supported by a grant from the French
   Ministry of Health (PHRC, 2012, PHRC12_157 pour l'etude ECLAIR).
   EYE-RISK project has received funding from the European Union's Horizon
   2020 research and innovation programme under grant agreement no. 634479.
   Thea Pharma participated in the design of the Alienor study, but none of
   the sponsors participated in the collection, management, statistical
   analysis, and interpretation of the data, or in the preparation, review,
   or approval of the present manuscript.
CR Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Craft N E, 2004, J Nutr Health Aging, V8, P156
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dai J, 2008, AM J CLIN NUTR, V88, P1364, DOI 10.3945/ajcn.2008.26528
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2014, INVEST OPHTH VIS SCI, V55, P7619, DOI 10.1167/iovs.14-14471
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   den Heijer T, 2001, J AM GERIATR SOC, V49, P642, DOI 10.1046/j.1532-5415.2001.49126.x
   Evans M, 2013, EUR J NUTR, V52, P1381, DOI 10.1007/s00394-012-0447-9
   Feart C, 2016, J GERONTOL A-BIOL, V71, P683, DOI 10.1093/gerona/glv135
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fung TT, 2005, AM J CLIN NUTR, V82, P163
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GRUBBS FE, 1950, ANN MATH STAT, V21, P27, DOI 10.1214/aoms/1177729885
   Hammond BR, 2005, OPHTHAL PHYSL OPT, V25, P315, DOI 10.1111/j.1475-1313.2005.00271.x
   Hartmann D, 2004, AM J CLIN NUTR, V79, P410
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Korobelnik JF, 2017, JAMA OPHTHALMOL, V135, P1259, DOI 10.1001/jamaophthalmol.2017.3398
   Lamarca R, 1998, J GERONTOL A-BIOL, V53, pM337, DOI 10.1093/gerona/53A.5.M337
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Mohn ES, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186767
   Ravaglia G, 2008, AM J CLIN NUTR, V87, P1306, DOI 10.1093/ajcn/87.5.1306
   Renzi LM, 2010, OPHTHAL PHYSL OPT, V30, P351, DOI 10.1111/j.1475-1313.2010.00720.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Stahl W, 2002, MOL ASPECTS MED, V23, P39, DOI 10.1016/S0098-2997(02)00016-X
   Stuerenburg HJ, 2005, NEUROENDOCRINOL LETT, V26, P696
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tanito M, 2012, JPN J OPHTHALMOL, V56, P488, DOI 10.1007/s10384-012-0157-0
   van Kappel AL, 2001, PUBLIC HEALTH NUTR, V4, P829, DOI 10.1079/PHN2000115
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
NR 62
TC 6
Z9 6
U1 2
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUN
PY 2021
VL 13
IS 6
AR 2047
DI 10.3390/nu13062047
PG 14
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA SZ0VD
UT WOS:000666293300001
PM 34203817
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Marback, RF
   Maia, OD
   Morais, FB
   Takahashi, WY
AF Marback, Roberta Ferrari
   Maia Junior, Otacilio de Oliveira
   Morais, Fabio Barreto
   Takahashi, Walter Yukihiko
TI Quality of life in patients with age-related macular degeneration with
   monocular and binocular legal blindness
SO CLINICS
LA English
DT Article
DE retina/abnormalities; macular degeneration/complications;
   blindness/psychology; vision; llow/etiology; quality of life/psychology;
   sickness impact profile
ID VISUAL FUNCTION QUESTIONNAIRE; FOCUS GROUPS; EYE; MACULOPATHY
AB OBJECTIVE: To evaluate the quality of life for persons affected by age-related macular degeneration that results in monocular or binocular legal blindness.
   METHODS: An analytic transversal study using the National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) was performed. Inclusion criteria were persons of both genders, aged more than 50 years old, absence of cataracts, diagnosis of age-related monocular degeneration in at least one eye and the absence of other macular diseases. The control group was paired by sex, age and no ocular disease.
   RESULTS: Group 1 (monocular legal blindness) was composed of 54 patients (72.22% females and 27.78% males, aged 51 to 87 years old, medium age 74.61 +/- 7.27 years); group 2 (binocular legal blindness) was composed of 54 patients (46.30% females and 53.70% males aged 54 to 87 years old, medium age 75.61 +/- 6.34 years). The control group was composed of 40 patients (40% females and 60% males, aged 50 to 81 years old, medium age 65.65 +/- 7.56 years). The majority of the scores were statistically significantly higher in group 1 and the control group in relation to group 2 and higher in the control group when compared to group 1.
   CONCLUSIONS: It was evident that the quality of life of persons with binocular blindness was more limited in relation to persons with monocular blindness. Both groups showed significant impairment in quality of life when compared to normal persons.
C1 [Marback, Roberta Ferrari; Maia Junior, Otacilio de Oliveira; Morais, Fabio Barreto; Takahashi, Walter Yukihiko] Univ Sao Paulo, Sch Med, Gen Hosp, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo
RP Marback, RF (通讯作者)，Univ Sao Paulo, Sch Med, Gen Hosp, Sao Paulo, Brazil.
EM robertamarback@uol.com.br
CR ALEXANDER LJ, 1993, J AM OPTOM ASSOC, V64, P838
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   International Council of Ophthalmology, 2002, VIS STAND ASP RANG V
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   *NAT ADV EY COUNC, 1998, NIH PUB
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442
   Sant'Anna Neusa Vidal, 2006, Arq. Bras. Oftalmol., V69, P349, DOI 10.1590/S0004-27492006000300013
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   TAKAHASHI WY, 2007, DEGENERACAO MACULAR
   Varma R, 2006, OPHTHALMOLOGY, V113, P1846, DOI 10.1016/j.ophtha.2006.04.028
NR 18
TC 15
Z9 17
U1 2
U2 12
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PD OCT
PY 2007
VL 62
IS 5
BP 573
EP 578
DI 10.1590/S1807-59322007000500007
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 278XS
UT WOS:000254320200007
PM 17952317
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Mookiah, MRK
   Acharya, UR
   Koh, JEW
   Chandran, V
   Chua, CK
   Tan, JH
   Lim, CM
   Ng, EYK
   Noronha, K
   Tong, L
   Laude, A
AF Mookiah, Muthu Rama Krishnan
   Acharya, U. Rajendra
   Koh, Joel E. W.
   Chandran, Vinod
   Chua, Chua Kuang
   Tan, Jen Hong
   Lim, Choo Min
   Ng, E. Y. K.
   Noronha, Kevin
   Tong, Louis
   Laude, Augustinus
TI Automated diagnosis of Age-related Macular Degeneration using greyscale
   features from digital fundus images
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Age-related Macular Degeneration; Entropy; Texture; Higher order
   spectra; Gabor wavelet; Computer aided diagnosis
ID DIABETIC-RETINOPATHY; FRACTAL DIMENSION; TEXTURE FEATURES; DRUSEN;
   SEGMENTATION; CLASSIFICATION; SELECTION; DISEASE; MACULOPATHY; SPECTRA
AB Age-related Macular Degeneration (AMD) is one of the major causes of vision loss and blindness in ageing population. Currently, there is no cure for AMD, however early detection and subsequent treatment may prevent the severe vision loss or slow the progression of the disease. AMD can be classified into two types: dry and wet AMDs. The people with macular degeneration are mostly affected by dry AMD. Early symptoms of AMD are formation of drusen and yellow pigmentation. These lesions are identified by manual inspection of fundus images by the ophthalmologists. It is a time consuming, tiresome process, and hence an automated diagnosis of AMD screening tool can aid clinicians in their diagnosis significantly. This study proposes an automated dry AMD detection system using various entropies (Shannon, Kapur, Renyi and Yager), Higher Order Spectra (HOS) bispectra features, Fractional Dimension (FD), and Gabor wavelet features extracted from greyscale fundus images. The features are ranked using t-test, Kullback-Lieber Divergence (KLD), Chernoff Bound and Bhattacharyya Distance (CBBD), Receiver Operating Characteristics (ROC) curve-based and Wilcoxon ranking methods in order to select optimum features and classified into normal and AMD classes using Naive Bayes (NB), k-Nearest Neighbour (k-NN), Probabilistic Neural Network (PNN), Decision Tree (DT) and Support Vector Machine (SVM) classifiers. The performance of the proposed system is evaluated using private (Kasturba Medical Hospital, Manipal, India), Automated Retinal Image Analysis (ARIA) and STructured Analysis of the Retina (STARE) datasets. The proposed system yielded the highest average classification accuracies of 90.19%, 95.07% and 95% with 42, 54 and 38 optimal ranked features using SVM classifier for private, ARIA and STARE datasets respectively. This automated AMD detection system can be used for mass fundus image screening and aid clinicians by making better use of their expertise on selected images that require further examination. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Mookiah, Muthu Rama Krishnan; Acharya, U. Rajendra; Koh, Joel E. W.; Chua, Chua Kuang; Tan, Jen Hong; Lim, Choo Min] Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
   [Acharya, U. Rajendra] Univ Malaya, Fac Engn, Dept Biomed Engn, Kuala Lumpur 50603, Malaysia.
   [Chandran, Vinod] Queensland Univ Technol, Sch Elect Engn & Comp Sci, Brisbane, Qld 4000, Australia.
   [Ng, E. Y. K.] Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore 639798, Singapore.
   [Noronha, Kevin] St Francis Inst Technol, Dept E&C, Bombay 400103, Maharashtra, India.
   [Tong, Louis] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Tong, Louis] Siganpore Eye Res Inst, Ocular Surface Res Grp, Singapore 168751, Singapore.
   [Tong, Louis] Duke NUS Grad Med Sch, Singapore 169857, Singapore.
   [Tong, Louis] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117597, Singapore.
   [Laude, Augustinus] Tan Tack Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.
C3 Universiti Malaya; Queensland University of Technology (QUT); Nanyang
   Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; Singapore National Eye
   Center; National University of Singapore; National University of
   Singapore; Tan Tock Seng Hospital
RP Mookiah, MRK (通讯作者)，Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
EM mkm2@np.edu.sg
RI Tan, Jen Hong/ABE-6525-2020; Mookiah, Muthu Rama Krishnan/G-4033-2011;
   Acharya, Rajendra U/E-3791-2010; Chandran, Vinod/N-3053-2019; Tan,
   Jenhong/AAD-3664-2020; Ng, E Y K/A-1375-2011; NORONHA,
   KEVIN/AAV-1433-2020
OI Mookiah, Muthu Rama Krishnan/0000-0001-6437-1482; Acharya, Rajendra
   U/0000-0003-2689-8552; Chandran, Vinod/0000-0003-3185-0852; Ng, E Y
   K/0000-0002-5701-1080; NORONHA, KEVIN/0000-0002-8753-5918; Tong,
   Louis/0000-0002-3986-6552
FU Social Innovation Research Fund (SIRF/Project), Singapore [T1202]
FX The authors thank Social Innovation Research Fund (SIRF/Project code:
   T1202), Singapore for providing grant for this research. Also authors
   would like to thank National medical research council
   (NMRC/CSA/045/2012).
CR Acharya UR, 2011, IEEE T INF TECHNOL B, V15, P449, DOI 10.1109/TITB.2011.2119322
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Barriga E, 2009, IEEE INT S COMP BAS, P1
   Ben Sbeh Z, 2001, IEEE T MED IMAGING, V20, P1321, DOI 10.1109/42.974927
   Biswas MK, 1998, PATTERN RECOGN LETT, V19, P309, DOI 10.1016/S0167-8655(98)00002-6
   Bressan M, 2003, IEEE T PATTERN ANAL, V25, P1312, DOI 10.1109/TPAMI.2003.1233904
   Burlina P, 2011, IEEE ENG MED BIO, P3962, DOI 10.1109/IEMBS.2011.6090984
   Chaplot S, 2006, BIOMED SIGNAL PROCES, V1, P86, DOI 10.1016/j.bspc.2006.05.002
   Cheng J, 2012, IEEE IMAGE PROC, P2805, DOI 10.1109/ICIP.2012.6467482
   Cho BH, 2008, ARTIF INTELL MED, V42, P37, DOI 10.1016/j.artmed.2007.09.005
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Chowriappa P, 2013, COMPUT BIOL MED, V43, P2156, DOI 10.1016/j.compbiomed.2013.10.003
   Chua KC, 2010, MED ENG PHYS, V32, P679, DOI 10.1016/j.medengphy.2010.04.009
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Duda R.O., 2000, PATTERN CLASSIFICATI, DOI https://doi.org/10.1007/978-3-319-57027-3_4
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Freund DE, 2009, I S BIOMED IMAGING, P61, DOI 10.1109/ISBI.2009.5192983
   Goon A.M., 1973, OUTLINE STAT THEORY
   Group M.P.S., 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Hijazi M, 2010, P INT JOINT C NEUR N, P1
   Hijazi MHA, 2012, KNOWL-BASED SYST, V29, P83, DOI 10.1016/j.knosys.2011.07.002
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hu QH, 2004, INT J UNCERTAIN FUZZ, V12, P575, DOI 10.1142/S0218488504003089
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Karmeshu Entropy Measures, 2003, MAXIMUM ENTROPY PRIN, V119
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Laude A., 2012, AM AC OPHTH AS PAC A, P184
   Liang ZY, 2010, IEEE ENG MED BIO, P4100, DOI 10.1109/IEMBS.2010.5627289
   Lim TH, 2007, ANN ACAD MED SINGAP, V36, pS15
   Ma WY, 1996, PROC CVPR IEEE, P425, DOI 10.1109/CVPR.1996.517107
   Mandelbrot B.B., 1983, FRACTAL GEOMETRY NAT
   Manjunath BS, 1996, IEEE T PATTERN ANAL, V18, P837, DOI 10.1109/34.531803
   MENDEL JM, 1991, P IEEE, V79, P278, DOI 10.1109/5.75086
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mookiah MRK, 2013, KNOWL-BASED SYST, V39, P9, DOI 10.1016/j.knosys.2012.09.008
   Mookiah M.R.K., 2013, J MECH MED BIOL, V13
   Mookiah MRK, 2013, COMPUT BIOL MED, V43, P2136, DOI 10.1016/j.compbiomed.2013.10.007
   Mookiah MRK, 2012, KNOWL-BASED SYST, V33, P73, DOI 10.1016/j.knosys.2012.02.010
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   National Statistics Office, NAT POP PROJ
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Nikias CL, 1993, IEEE SIGNAL PROC MAG, V10, P10, DOI 10.1109/79.221324
   Nirmala SR, 2010, BIOMED SIGNAL PROCES, V5, P282, DOI 10.1016/j.bspc.2010.06.005
   Pharwaha APS, 2009, P WORLD C ENG COMP S, V3, P1
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   PIZER SM, 1987, COMPUT VISION GRAPH, V39, P355, DOI 10.1016/S0734-189X(87)80186-X
   Quellec G, 2011, IEEE T MED IMAGING, V30, P523, DOI 10.1109/TMI.2010.2089383
   RADON J, 1986, IEEE T MED IMAGING, V5, P170, DOI 10.1109/TMI.1986.4307775
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Santos-Villalobos H, 2011, IEEE ENG MED BIO, P6236, DOI 10.1109/IEMBS.2011.6091540
   SARKAR N, 1994, IEEE T SYST MAN CYB, V24, P115, DOI 10.1109/21.259692
   Singh, 2010, LECT NOTES ELECT ENG, P341
   Singh K., 2008, BOOTSTRAP STAT METHO
   Singh V. P., 2013, ENTROPY THEORY ITS A, DOI 10.1002/9781118428306
   SOLIZ P, 2008, IEEE SA S SSIAI 2008, P65
   SPECHT DF, 1990, NEURAL NETWORKS, V3, P109, DOI 10.1016/0893-6080(90)90049-Q
   U RA, 2008, J MED SYST, V32, P481, DOI 10.1007/s10916-008-9154-8
   Vapnik V., 1998, STAT LEARNING THEORY
   Zhang QP, 2007, IEEE T IMAGE PROCESS, V16, P310, DOI 10.1109/TIP.2006.887731
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
   Zuo WL, 2013, BIOMED SIGNAL PROCES, V8, P364, DOI 10.1016/j.bspc.2013.02.006
NR 64
TC 34
Z9 34
U1 1
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD OCT 1
PY 2014
VL 53
BP 55
EP 64
DI 10.1016/j.compbiomed.2014.07.015
PG 10
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA AR5HY
UT WOS:000343617000007
PM 25127409
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Sousa, JA
   Paiva, A
   Silva, A
   Almeida, JD
   Braz, G
   Diniz, JO
   Figueredo, WK
   Gattass, M
AF Sousa, Jefferson Alves
   Paiva, Anselmo
   Silva, Aristofanes
   Almeida, Joao Dallyson
   Braz, Geraldo Junior
   Diniz, Joao Otavio
   Figueredo, Weslley Kelson
   Gattass, Marcelo
TI Automatic segmentation of retinal layers in OCT images with intermediate
   age-related macular degeneration using U-Net and DexiNed
SO PLOS ONE
LA English
DT Article
ID BOUNDARIES
AB Age-related macular degeneration (AMD) is an eye disease that can cause visual impairment and affects the elderly over 50 years of age. AMD is characterized by the presence of drusen, which causes changes in the physiological structure of the retinal pigment epithelium (RPE) and the boundaries of the Bruch's membrane layer (BM). Optical coherence tomography is one of the main exams for the detection and monitoring of AMD, which seeks changes through the evaluation of successive sectional cuts in the search for morphological changes caused by drusen. The use of CAD (Computer-Aided Detection) systems has contributed to increasing the chances of correct detection, assisting specialists in diagnosing and monitoring disease. Thus, the objective of this work is to present a method for the segmentation of the inner limiting membrane (ILM), retinal pigment epithelium, and Bruch's membrane in OCT images of healthy and Intermediate AMD patients. The method uses two deep neural networks, U-Net and DexiNed to perform the segmentation. The results were promising, reaching an average absolute error of 0.49 pixel for ILM, 0.57 for RPE, and 0.66 for BM.
C1 [Sousa, Jefferson Alves; Paiva, Anselmo; Silva, Aristofanes; Almeida, Joao Dallyson; Braz, Geraldo Junior; Diniz, Joao Otavio; Figueredo, Weslley Kelson] Univ Fed Maranhao, Sao Luis, Maranhao, Brazil.
   [Gattass, Marcelo] Pontifical Catholic Univ Rio de Janeiro, Rio De Janeiro, RJ, Brazil.
C3 Universidade Federal do Maranhao; Pontificia Universidade Catolica do
   Rio de Janeiro
RP Sousa, JA (通讯作者)，Univ Fed Maranhao, Sao Luis, Maranhao, Brazil.
EM jefferson.alves@nca.ufma.br
RI Diniz, João Otávio Bandeira/E-6498-2019; Paiva, Anselmo/L-2358-2013;
   Braz, Geraldo/AAW-1827-2021
OI Diniz, João Otávio Bandeira/0000-0003-3303-3346; Paiva,
   Anselmo/0000-0003-4921-0626; Braz, Geraldo/0000-0003-3731-6431; Sousa,
   Jefferson/0000-0002-5928-9959
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES) [001]; Fundacao de Amparo a Pesquisa e ao Desenvolvimento
   Cientifico e Tecnologico do Maranhao (FAPEMA)
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001 and
   Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e
   Tecnologico do Maranhao (FAPEMA) The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. There was no additional external funding
   received for this study.
CR Bradski G, 2000, DR DOBBS J, V25, P120
   Chakravarty A, 2017, COMM COM INF SC, V723, P3, DOI 10.1007/978-3-319-60964-5_1
   Chen Z., 2019, IET IMAGE PROCESS, V13, P1401
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Chollet F, 2018, KERAS PYTHON DEEP LE
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Farsiu S., 2008, P PHOT W OPHTH TECHN, P1
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Gopinath K, 2017, PROCEEDINGS 2017 4TH IAPR ASIAN CONFERENCE ON PATTERN RECOGNITION (ACPR), P888, DOI 10.1109/ACPR.2017.121
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kugelman J, 2018, BIOMED OPT EXPRESS, V9, P5759, DOI 10.1364/BOE.9.005759
   Lou SL, 2020, IEEE ACCESS, V8, P53678, DOI 10.1109/ACCESS.2020.2981206
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Rim PHH., 2012, AGE RELATED MACULAR
   Ronneberger O., 2015, INT C MED IM COMP CO, P234, DOI [DOI 10.1007/978-3-319-24574-4_28, 10.1007/978-3-319-24574-4_28]
   Santos AM., 2019, DIAGNOSIS AGE RELATE
   Soria X, 2020, IEEE WINT CONF APPL, P1912, DOI 10.1109/WACV45572.2020.9093290
   Tian J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133908
   Tomasi C, 1998, SIXTH INTERNATIONAL CONFERENCE ON COMPUTER VISION, P839, DOI 10.1109/ICCV.1998.710815
   WHO WHO, 2019, BLINDN VIS IMP
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie SN, 2015, IEEE I CONF COMP VIS, P1395, DOI 10.1109/ICCV.2015.164
NR 25
TC 7
Z9 7
U1 3
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2021
VL 16
IS 5
AR e0251591
DI 10.1371/journal.pone.0251591
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ST0XR
UT WOS:000662175000050
PM 33989316
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Srinivasan, S
   Swaminathan, G
   Kulothungan, V
   Raman, R
   Sharma, T
AF Srinivasan, S.
   Swaminathan, G.
   Kulothungan, V.
   Raman, R.
   Sharma, T.
TI Prevalence and the risk factors for visual impairment in age-related
   macular degeneration
SO EYE
LA English
DT Article
ID FIELD LOSS INCREASES; BEAVER DAM EYE; OLDER POPULATION; UNITED-KINGDOM;
   MACULOPATHY; PROJECT; FALLS; INDIA; AUSTRALIA; BLINDNESS
AB Purpose To characterize the type, and the causes of visual impairment (VI) in various stages of early and late age-related macular degeneration (AMD) and the factors associated with visual impairment in subjects with AMD
   Methods 6617 subjects >= 60 years were enumerated; 5495 (83.04%) participated in eye examination. Of which, 4791 subjects had gradable fundus images. AMD was graded per International ARM Epidemiological Study Group. Subjects underwent detailed ophthalmic exam. VI was defined per the WHO classification. Mild VI was defined as VA less than 6/12 to 6/18, moderate VI-VA less than 6/18 but up to 6/60, severe VI-VA less than 6/60 but up to 3/60 and legal blindness-VA worse than 3/60. Factors associated with VI in AMD was analyzed with univariate and logistic regression analysis.
   Results Nine hundred and eighty-eight subjects were identified as having AMD (893 with early AMD and 95 with late AMD); 85% of the subjects (95% CI: 82.7-87.1) had no VI, 13.1% had mild VI (95% CI: 11.1-15.3), 0.8% had severe VI (95% CI: 0.4-1.6), 1.1% had legal blindness (95% CI: 0.6-1.9). Prevalence of any VI was 13.7% in early AMD and 27.4% in late AMD, P= 0.0004; age group 65-70 years (OR= 1.89, 95% CI: 1.16-3.08, P= 0.011), and those >= 75 years (OR= 3.67, 95% CI: 1.956.91, P= 0.0001) had greater odds of VI compared with age group 60-64 years. Male gender was a protective factor for VI (OR= 0.57, CI: 0.36-0.90, P= 0.016). Cataract (31.8%) and refractive error (28.4%) accounted for a majority of the VI.
   Conclusions Cataract and refractive error account for a significant proportion of VI in the south Indian population with AMD. Early AMD is the third leading cause of VI. Greater age and female gender are associated with VI in subjects with AMD.
C1 [Srinivasan, S.; Swaminathan, G.; Kulothungan, V.; Raman, R.; Sharma, T.] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Madras, Tamil Nadu, India.
RP Raman, R (通讯作者)，Sankara Nethralaya, Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM rajivpgraman@gmail.com
RI Raman, Rajiv/A-7234-2009
OI Raman, Rajiv/0000-0001-5842-0233
FU Jamshetji Tata trust, Mumbai, India
FX This work was funded by Jamshetji Tata trust, Mumbai, India.
CR Agarwal S, 2005, OPHTHAL EPIDEMIOL, V12, P143, DOI 10.1080/09286580590932734
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Coleman AL, 2007, J AM GERIATR SOC, V55, P357, DOI 10.1111/j.1532-5415.2007.01094.x
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dandona R, 1999, INVEST OPHTH VIS SCI, V40, P2810
   Dandona R, 2002, BRIT J OPHTHALMOL, V86, P373, DOI 10.1136/bjo.86.4.373
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Freeman EE, 2007, INVEST OPHTH VIS SCI, V48, P4445, DOI 10.1167/iovs.07-0326
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hashemi H, 2012, EYE, V26, P1071, DOI 10.1038/eye.2012.94
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Khandekar R, 2002, BRIT J OPHTHALMOL, V86, P957, DOI 10.1136/bjo.86.9.957
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Kulkarni SR, 2013, INDIAN J OPHTHALMOL, V61, P196, DOI 10.4103/0301-4738.99870
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Raman R, 2016, EYE, V30, P688, DOI 10.1038/eye.2016.14
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
   VINDING T, 1995, ACTA OPHTHALMOL SCAN, V217, P1
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226
   Zetterberg M, 2016, MATURITAS, V83, P19, DOI 10.1016/j.maturitas.2015.10.005
NR 41
TC 9
Z9 10
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2017
VL 31
IS 6
BP 846
EP 855
DI 10.1038/eye.2017.72
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX2ON
UT WOS:000403066000004
PM 28548646
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Zhou, LX
   Sun, CL
   Wei, LJ
   Gu, ZM
   Lv, L
   Dang, YL
AF Zhou, Li-Xiao
   Sun, Cheng-Lin
   Wei, Li-Juan
   Gu, Zhi-Min
   Lv, Liang
   Dang, Yalong
TI Lower cognitive function in patients with age-related macular
   degeneration: a meta-analysis
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE age-related macular degeneration; cognitive impairment; meta-analysis;
   mini mental state examination
ID MENTAL-STATE-EXAMINATION; AMYLOID-BETA; PRIMARY-CARE; IMPAIRMENT;
   DISEASE; DEMENTIA; DRUSEN
AB Objective: To investigate the cognitive impairment in patients with age-related macular degeneration (AMD).
   Methods: Relevant articles were identified through a search of the following electronic databases through October 2015, without language restriction: 1) PubMed; 2) the Cochrane Library; 3) EMBASE; 4) ScienceDirect. Meta-analysis was conducted using STATA 12.0 software. Standardized mean differences with corresponding 95% confidence intervals were calculated. All of the included studies met the following four criteria: 1) the study design was a case-control or randomized controlled trial (RCT) study; 2) the study investigated cognitive function in the patient with AMD; 3) the diagnoses of AMD must be provided; 4) there were sufficient scores data to extract for evaluating cognitive function between cases and controls. The Newcastle-Ottawa Scale criteria were used to assess the methodological quality of the studies.
   Results: Of the initial 278 literatures, only six case-control and one RCT studies met all of the inclusion criteria. A total of 794 AMD patients and 1,227 controls were included in this study. Five studies were performed with mini-mental state examination (MMSE), two studies with animal fluency, two studies with trail making test (TMT)-A and -B, one study with Mini-Cog. Results of the meta-analysis revealed lower cognitive function test scores in patients with AMD, especially with MMSE and Mini-Cog test (P <= 0.001 for all). The results also showed that differences in the TMT-A (except AMD [total] vs controls) and TMT-B test had no statistical significance (P>0.01). The Newcastle-Ottawa Scale score was >= 5 for all of the included studies. Based on the sensitivity analysis, no single study influenced the overall pooled estimates.
   Conclusion: This meta-analysis suggests lower cognitive function test scores in patients with AMD, especially with MMSE and Mini-Cog test. The other cognitive impairment screening tests, such as animal fluency test and TMT, need more studies to assess.
C1 [Zhou, Li-Xiao; Sun, Cheng-Lin; Wei, Li-Juan; Gu, Zhi-Min; Lv, Liang] Zhengzhou Univ, Affiliated Hosp 5, Dept Ophthalmol, Kangfuqianjie St, Zhengzhou 450001, Peoples R China.
   [Dang, Yalong] Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, Kangfuqianjie St, Zhengzhou 450001, Peoples R China.
C3 Zhengzhou University; Zhengzhou University
RP Zhou, LX (通讯作者)，Zhengzhou Univ, Affiliated Hosp 5, Dept Ophthalmol, Kangfuqianjie St, Zhengzhou 450001, Peoples R China.
EM zhoulixiao@126.com
RI Dang, Yalong/Q-4156-2017
OI Dang, Yalong/0000-0003-2194-6375
CR Al-Salem Khalil M, 2014, Retina, V34, P868, DOI 10.1097/IAE.0000000000000006
   Bertone A, 2005, INT C SER, P26
   Borson S, 2006, INT J GERIATR PSYCH, V21, P349, DOI 10.1002/gps.1470
   Borson S, 2005, J AM GERIATR SOC, V53, P871, DOI 10.1111/j.1532-5415.2005.53269.x
   Chen CY, 2011, ARCH GERONTOL GERIAT, V53, P100, DOI 10.1016/j.archger.2010.06.008
   Dag E, 2014, EUR REV MED PHARMACO, V18, P3025
   Demirci S, 2015, TURK J MED SCI, V45, P1115, DOI 10.3906/sag-1406-135
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Harrabi H, 2015, INVEST OPHTH VIS SCI, V56, P1217, DOI 10.1167/iovs.14-15370
   Henry JD, 2004, NEUROPSYCHOLOGIA, V42, P1212, DOI 10.1016/j.neuropsychologia.2004.02.001
   Jefferis JM, 2012, AGE AGEING, V41, P565, DOI 10.1093/ageing/afs042
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kelly D, 2015, J ALZHEIMERS DIS, V48, P261, DOI 10.3233/JAD-150199
   Libon DJ, 2009, NEUROLOGY, V73, P535, DOI 10.1212/WNL.0b013e3181b2a4f5
   Lindekleiv H, 2013, EYE, V27, P1281, DOI 10.1038/eye.2013.181
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Mandas A, 2014, FRONT AGING NEUROSCI, P6
   Peiretti E, 2014, EXP EYE RES, V124, P11, DOI 10.1016/j.exer.2014.04.017
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8
   Wells GA., NEWCASTLE OTTAWA SCA
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
NR 24
TC 11
Z9 11
U1 1
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2016
VL 11
BP 215
EP 223
DI 10.2147/CIA.S102213
PG 9
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA DE9RU
UT WOS:000370976800001
PM 26966358
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Budnik, A
   Sabasinska-Grzes, M
   Michnowska-Kobylinska, M
   Lisowski, L
   Szpakowicz, M
   Lapinska, M
   Szpakowicz, A
   Kondraciuk, M
   Kaminski, KA
   Konopinska, J
AF Budnik, Agnieszka
   Sabasinska-Grzes, Marta
   Michnowska-Kobylinska, Magdalena
   Lisowski, Lukasz
   Szpakowicz, Malgorzata
   Lapinska, Magdalena
   Szpakowicz, Anna
   Kondraciuk, Marcin
   Kaminski, Karol Adam
   Konopinska, Joanna
TI Elevated Plasma Levels of C1qTNF1 Protein in Patients with Age-Related
   Macular Degeneration and Glucose Disturbances
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE AMD; age-related macular degeneration; C1qTNF; glucose disturbances
ID ENDOTHELIAL GROWTH-FACTOR; OXIDATIVE STRESS; PATHOGENESIS; INFLAMMATION;
   ASSOCIATION; MACULOPATHY; DRUSEN; IMPACT
AB In recent years, research has provided increasing evidence for the importance of inflammatory etiology in age-related macular degeneration (AMD) pathogenesis. This study assessed the profile of inflammatory cytokines in the serum of patients with AMD and coexisting glucose disturbances (GD). This prospective population-based cohort study addressed the determinants and occurrence of cardiovascular, neurological, ophthalmic, psychiatric, and endocrine diseases in residents of Bialystok, Poland. To make the group homogenous in terms of inflammatory markers, we analyzed only subjects with glucose disturbances (GD: diabetes or prediabetes). Four hundred fifty-six patients aged 50-80 were included. In the group of patients without macular degenerative changes, those with GD accounted for 71.7%, while among those with AMD, GD accounted for 89.45%. Increased serum levels of proinflammatory cytokines were observed in both AMD and GD groups. C1qTNF1 concentration was statistically significantly higher in the group of patients with AMD, with comparable levels of concentrations of other proinflammatory cytokines. C1qTNF1 may act as a key mediator in the integration of lipid metabolism and inflammatory responses in macrophages. Moreover, C1qTNF1 levels are increased after exposure to oxidized low-density lipoprotein (oxLDL), which plays a key role in atherosclerotic plaque formation and is also a major component of the drusen observed in AMD. C1qTNF1 may, therefore, prove to be a link between the accumulation of oxLDL and the induction of local inflammation in the development of AMD with concomitant GD.
C1 [Budnik, Agnieszka; Sabasinska-Grzes, Marta; Michnowska-Kobylinska, Magdalena; Lisowski, Lukasz; Konopinska, Joanna] Med Univ Bialystok, Dept Ophthalmol, PL-15089 Bialystok, Poland.
   [Szpakowicz, Malgorzata; Lapinska, Magdalena; Kondraciuk, Marcin; Kaminski, Karol Adam] Med Univ Bialystok, Dept Populat Med & Lifestyle Dis Prevent, PL-15259 Bialystok, Poland.
   [Szpakowicz, Anna; Kaminski, Karol Adam] Med Univ Bialystok, Dept Cardiol, PL-15089 Bialystok, Poland.
C3 Medical University of Bialystok; Medical University of Bialystok;
   Medical University of Bialystok
RP Konopinska, J (通讯作者)，Med Univ Bialystok, Dept Ophthalmol, PL-15089 Bialystok, Poland.
EM agnieszka-bartczak@o2.pl; m.sabasinska@vp.pl;
   magdalena.michnowska.evita@gmail.com; lisowski@vp.pl;
   malgorzata.szpakowicz@umb.edu.pl; magdalena.lapinska@umb.edu.pl;
   anna.szpakowicz@umb.edu.pl; marcin.kondraciuk@umb.edu.pl;
   karol.kaminski@umb.edu.pl; joannakonopinska@o2.pl
OI Kondraciuk, Marcin/0000-0002-4516-7467; Konopinska,
   Joanna/0000-0002-9088-6938
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Betzler BK, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10040645
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen LY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2582416
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Chlabicz M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081584
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Deng YF, 2010, ANN NY ACAD SCI, V1212, pE1, DOI 10.1111/j.1749-6632.2010.05875.x
   Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925
   Forrester JV, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583687
   Greenberg AS, 2002, EUR J CLIN INVEST, V32, P24, DOI 10.1046/j.1365-2362.32.s3.4.x
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hageman GS, 1999, MOL VIS, V5
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kang QZ, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101799
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koirala D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228818
   Li H, 2019, HEPATOL INT, V13, P277, DOI 10.1007/s12072-019-09944-5
   Lima-Fontes Mario, 2020, Porto Biomed J, V5, pe104, DOI 10.1097/j.pbj.0000000000000104
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Lu L, 2016, EUR HEART J, V37, P1762, DOI 10.1093/eurheartj/ehv649
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Schaffler A, 2012, TRENDS ENDOCRIN MET, V23, P194, DOI 10.1016/j.tem.2011.12.003
   Smith RO, 2020, ELIFE, V9, DOI 10.7554/eLife.54056
   Terao R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010112
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Wong GW, 2008, BIOCHEM J, V416, P161, DOI 10.1042/BJ20081240
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu BH, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.631413
   Yang XJ, 1996, J NEUROSCI, V16, P6089
   Zhang Wenbo, 2011, J Cardiovasc Dis Res, V2, P96, DOI 10.4103/0975-3583.83035
   Zhu NQ, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01352-2
NR 44
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2022
VL 11
IS 15
AR 4391
DI 10.3390/jcm11154391
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 3R8WF
UT WOS:000839186000001
PM 35956011
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wang, W
   Zhang, XL
AF Wang, Wei
   Zhang, Xiulan
TI Systemic Adverse Events after Intravitreal Bevacizumab versus
   Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR INHIBITORS; RANDOMIZED CLINICAL-TRIAL; SAFETY; OUTCOMES;
   PREVALENCE; THERAPIES; INJECTION; MORTALITY; LUCENTIS; EFFICACY
AB Objective: To assess whether the incidence of systemic adverse events differs between those who used bevacizumab and those who used ranibizumab in the treatment of age-related macular degeneration (AMD).
   Methods: A systematic literature search was conducted to identify randomised controlled trials (RCTs) comparing the use of intravitreal bevacizumab with the use of ranibizumab in AMD patients. Results were expressed as risk ratios (RRs) with accompanying 95% confidence intervals (CIs). The data were pooled using the fixed-effect or random-effect model according to the heterogeneity present.
   Results: Four RCTs were included in the final meta-analysis. Overall, the quality of the evidence was high. There were 2,613 treated patients: 1,291 treated with bevacizumab and 1,322 treated with ranibicizumab. No significant differences between bevacizumab use and ranizumab use were found in terms of the incidence of death from all causes, arteriothrombotic events, stroke, nonfatal myocardial infarction, vascular death, venous thrombotic events, and hypertension, with the pooled RRs being 1.11 (0.77, 1.61), 1.03 (0.69,1.55), 0.84 (0.39,1.80), 0.97 (0.48, 1.96), 1.24 (0.63, 2.44), 2.38 (0.94, 6.04), and 1.02 (0.29, 3.62), respectively.
   Conclusions: The meta-analysis shows that both treatments are comparably safe. However, the findings from our study must be confirmed in future research via well-designed cohort or intervention studies because of the limited number of studies.
C1 [Wang, Wei; Zhang, Xiulan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Zhang, XL (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
EM zhangxl2@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81371008]
FX This research was supported by the National Natural Science Foundation
   of China (81371008). No additional external funding was received. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abouammoh MA, 2013, CAN J OPHTHALMOL, V48, P317, DOI 10.1016/j.jcjo.2013.03.004
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Aujla JS, 2012, CLIN EXP OPTOM, V95, P538, DOI 10.1111/j.1444-0938.2012.00735.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Campbell RJ, 2013, CURR OPIN OPHTHALMOL, V24, P197, DOI 10.1097/ICU.0b013e32835f8bbe
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Donahue SP, 2010, AM J OPHTHALMOL, V150, P287, DOI 10.1016/j.ajo.2010.04.006
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   French DD, 2011, RETINA-J RET VIT DIS, V31, P1036, DOI 10.1097/IAE.0b013e31821dc66f
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kodjikian L, 2013, OPHTHALMOLOGY
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Torjesen I, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4678
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 41
TC 18
Z9 19
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2014
VL 9
IS 10
AR e109744
DI 10.1371/journal.pone.0109744
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AQ9XC
UT WOS:000343210800037
PM 25330364
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Gu, BJ
   Huang, X
   Avula, PK
   Caruso, E
   Drysdale, C
   Vessey, KA
   Ou, A
   Fowler, C
   Liu, TH
   Lin, Y
   Horton, A
   Masters, CL
   Wiley, JS
   Guymer, RH
   Fletcher, EL
AF Gu, Ben J.
   Huang, Xin
   Avula, Pavan K.
   Caruso, Emily
   Drysdale, Candace
   Vessey, Kirstan A.
   Ou, Amber
   Fowler, Christopher
   Liu, Tian-Hua
   Lin, Yong
   Horton, Adam
   Masters, Colin L.
   Wiley, James S.
   Guymer, Robyn H.
   Fletcher, Erica L.
TI Deficits in Monocyte Function in Age Related Macular Degeneration: A
   Novel Systemic Change Associated With the Disease
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE monocytes; phagocytosis; drusen; reticular pseudodrusen; glatiramer
   acetate
AB Age-related macular degeneration (AMD) is characterized by the accumulation of debris in the posterior eye. In this study we evaluated peripheral blood monocyte phagocytic function at various stages of AMD and in aged matched control participants. Real-time tri-color flow cytometry was used to quantify phagocytic function of peripheral blood monocyte subsets (non-classic, intermediate and classic) isolated from subjects with intermediate or late AMD and compared with age matched healthy controls. Assessment of phagocytic function of monocytes isolated from those with and without reticular pseudodrusen was also made, and the effect of glatiramer acetate on phagocytic function assessed. Phagocytic function was reduced in all subjects with AMD, irrespective of stage of disease. However, there was no correlation between phagocytic function and drusen load, nor any difference between the level of phagocytosis in those with or without reticular pseudodrusen. Treatment with glatiramer acetate increased phagocytosis of classical and non-classical monocytes, normalizing the reduction in phagocytosis observed in those with AMD. These findings suggest that defective systemic phagocytosis is associated with both intermediate and late stages of AMD, highlighting a potential role in the accumulation of debris that occurs early in the disease process. Assessing peripheral monocyte phagocytic function provides further insights into the etiology of this disease and offer a novel therapeutic target.
C1 [Gu, Ben J.; Huang, Xin; Avula, Pavan K.; Drysdale, Candace; Ou, Amber; Fowler, Christopher; Liu, Tian-Hua; Horton, Adam; Masters, Colin L.; Wiley, James S.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia.
   [Gu, Ben J.; Lin, Yong] Fudan Univ, Huashan Hosp, Natl Clin Res Ctr Aging & Med, Shanghai, Peoples R China.
   [Caruso, Emily; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Dept Surg Ophthalmol, East Melbourne, Vic, Australia.
   [Vessey, Kirstan A.; Fletcher, Erica L.] Univ Melbourne, Dept Anat & Neurosci, Melbourne, Vic, Australia.
C3 Florey Institute of Neuroscience & Mental Health; University of
   Melbourne; Fudan University; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; University of
   Melbourne
RP Fletcher, EL (通讯作者)，Univ Melbourne, Dept Anat & Neurosci, Melbourne, Vic, Australia.
EM elf@unimelb.edu.au
OI Huang, Xin/0000-0002-7278-3070; Fowler, Christopher/0000-0003-1397-0359
FU ARC Future Fellowship [FT120100581]; NHMRC [1048082, 1061419, 1120095,
   110178, 1103013]; Macular Disease Foundation Australia Project Grant;
   Macular Society Grant USA (2015); BrightFocus Foundation Project Grant
   [M2016061]; Victorian Government
FX This work was supported by ARC Future Fellowship (BG, FT120100581) and
   NHMRC Project Grant (1048082, 1061419, 1120095, and 110178 to RG, EF,
   and BG), Principal Research Fellowship (RG, 1103013), Macular Disease
   Foundation Australia Project Grant (EF, BG, RG, and KV), Macular Society
   Grant USA (2015), BrightFocus Foundation Project Grant (M2016061), and
   the Victorian Government's Operational Infrastructure Support Grant to
   the Florey Institute and Center for Eye research Australia.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bliederhaeuser C, 2016, ACTA NEUROPATHOL, V131, P379, DOI 10.1007/s00401-015-1504-2
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Claude J, 2013, J NEUROSCI, V33, P18270, DOI 10.1523/JNEUROSCI.2211-13.2013
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erdei A, 2019, SEMIN CELL DEV BIOL, V85, P110, DOI 10.1016/j.semcdb.2017.11.025
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Grozdanov V, 2014, ACTA NEUROPATHOL, V128, P651, DOI 10.1007/s00401-014-1345-4
   Grunin M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29046
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Gu BJ, 2016, ACTA NEUROPATHOL, V132, P377, DOI 10.1007/s00401-016-1596-3
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Gu BJ, 2012, J BIOL CHEM, V287, P17318, DOI 10.1074/jbc.M112.340885
   Gu BJ, 2011, J IMMUNOL, V187, P2365, DOI 10.4049/jimmunol.1101178
   Gu BJ, 2010, BLOOD, V115, P1621, DOI 10.1182/blood-2009-11-251744
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hagbi-Levi S, 2017, NEUROBIOL AGING, V51, P71, DOI 10.1016/j.neurobiolaging.2016.11.018
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Healy LM, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000402
   Hearps AC, 2012, AGING CELL, V11, P867, DOI 10.1111/j.1474-9726.2012.00851.x
   Hector SM, 2017, CLIN OPHTHALMOL, V11, P179, DOI 10.2147/OPTH.S121332
   Jaumouille V, 2019, NAT CELL BIOL, V21, P1357, DOI 10.1038/s41556-019-0414-2
   Jursik C, 2007, J IMMUNOL METHODS, V325, P67, DOI 10.1016/j.jim.2007.06.002
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Landa G, 2011, J OCUL PHARMACOL TH, V27, P77, DOI 10.1089/jop.2010.0109
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lukacsi S, 2017, IMMUNOL LETT, V189, P64, DOI 10.1016/j.imlet.2017.05.014
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Pul R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051867
   Pul R, 2011, J NEUROIMMUNE PHARM, V6, P381, DOI 10.1007/s11481-010-9248-1
   Silverman SM, 2019, J EXP MED, V216, P1925, DOI 10.1084/jem.20190009
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Subhi Y, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0160-0
   Subhi Y, 2019, JAMA OPHTHALMOL, V137, P515, DOI 10.1001/jamaophthalmol.2019.0010
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Vessey KA, 2017, AM J PATHOL, V187, P1670, DOI 10.1016/j.ajpath.2017.04.016
   Wijeyekoon RS, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00870
   Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558
NR 54
TC 5
Z9 5
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD MAR 17
PY 2021
VL 8
AR 634177
DI 10.3389/fmed.2021.634177
PG 15
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA RF6MO
UT WOS:000634956600001
PM 33816525
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhang, ZH
   Pan, MX
   Cai, JT
   Weiland, JD
   Chen, KO
AF Zhang, Zhen Huan
   Pan, Meng Xin
   Cai, Jia Tong
   Weiland, James D.
   Chen, Kinon
TI Viscoelastic properties of the posterior eye of normal subjects,
   patients with age-related macular degeneration, and pigs
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE viscoelastic properties; posterior eye (retina; choroid; and sclera);
   age-related macular degeneration; atherosclerotic vascular disease;
   humans and pigs
ID MECHANICAL-PROPERTIES; VISUAL IMPAIRMENT; PERIPAPILLARY SCLERA;
   STRESS-RELAXATION; VASCULAR-LESIONS; ATHEROSCLEROSIS; ARTERIOSCLEROSIS;
   PATHOGENESIS; DEFINITION; PREVALENCE
AB The purpose of this study is to measure, characterize, and compare the viscoelastic properties of the posterior eye of advanced dry age-related macular degeneration (AMD) patients, age-matched normal subjects, and pigs (3 groups). Ten horizontal and ten vertical strips of the macula retina and the underneath choroid and sclera were obtained for each group, respectively. They were examined by incremental stress-relaxation cycles in body-temperature saline. Mechanical response was characterized by the quasi-linear viscoelastic model. All the tissues were shown to be nonlinear viscoelastic. Stiffening and isotropization, increased relaxation, and softening and isotropization were found in AMD retina, choroid, and sclera, respectively, which are the mechanical features of the atherosclerotic process. The patients' medical records were in accordance with epidemiological studies indicating a relationship between the advanced AMD and atherosclerotic vascular disease (ASVD). Moreover, many differences were found between the viscoelastic properties of porcine and normal human retina, choroid, and sclera. The results suggest that AMD is associated with ASVD through a mechanism involving abnormal retinal, choroidal, and scleral mechanics similar to those seen in the atherosclerotic process. Moreover, researchers should be aware of mechanical differences when using porcine posterior eyes as a substitute for human posterior eyes. (c) 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 2151-2157, 2018.
C1 [Zhang, Zhen Huan; Pan, Meng Xin; Cai, Jia Tong; Chen, Kinon] Beihang Univ, Sch Biol Sci & Med Engn, Yifu Sci Hall,37 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Zhang, Zhen Huan; Pan, Meng Xin; Cai, Jia Tong; Chen, Kinon] Beihang Univ, Beijing Adv Innovat Ctr Biomed Engn, Beijing 100191, Peoples R China.
   [Weiland, James D.; Chen, Kinon] Univ Southern Calif, Dept Ophthalmol, 1450 San Pablo St, Los Angeles, CA 90033 USA.
   [Weiland, James D.; Chen, Kinon] Univ Southern Calif, Dept Biomed Engn, Denney Res Ctr, 1042 Downey Way, Los Angeles, CA 90089 USA.
C3 Beihang University; Beihang University; University of Southern
   California; University of Southern California
RP Chen, KO (通讯作者)，Beihang Univ, Sch Biol Sci & Med Engn, Yifu Sci Hall,37 Xueyuan Rd, Beijing 100191, Peoples R China.; Chen, KO (通讯作者)，Beihang Univ, Beijing Adv Innovat Ctr Biomed Engn, Beijing 100191, Peoples R China.; Weiland, JD; Chen, KO (通讯作者)，Univ Southern Calif, Dept Ophthalmol, 1450 San Pablo St, Los Angeles, CA 90033 USA.; Weiland, JD; Chen, KO (通讯作者)，Univ Southern Calif, Dept Biomed Engn, Denney Res Ctr, 1042 Downey Way, Los Angeles, CA 90089 USA.
EM jweiland@med.usc.edu; chen0606@umn.edu
OI Weiland, James/0000-0003-3453-9074
FU Beijing Natural Science Foundation [7154215]; US Department of Energy
   Office of Science [DE-FC02-04ER63735]; W.M. Keck Foundation; Clarence
   and Estelle Albaugh Trust
FX Contract grant sponsor: Beijing Natural Science Foundation; contract
   grant number: 7154215; Contract grant sponsor: US Department of Energy
   Office of Science; contract grant number: DE-FC02-04ER63735; Contract
   grant sponsor: W.M. Keck Foundation; Contract grant sponsor: Clarence
   and Estelle Albaugh Trust
CR Abramowitch SD, 2004, J BIOMECH ENG-T ASME, V126, P92, DOI 10.1115/1.1645528
   [Anonymous], 2012, EYE CONDITIONS MACUL
   ARCINIEGAS A, 1986, OPHTHALMOLOGICA, V193, P45, DOI 10.1159/000309678
   Basinger BC, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/5/055006
   BROEKHUYSE RM, 1975, OPHTHALMOLOGICA, V171, P82, DOI 10.1159/000307448
   Chen KN, 2014, J BIOMED MATER RES A, V102, P2001, DOI 10.1002/jbm.a.34858
   Chen K, 2014, ANN BIOMED ENG, V42, P678, DOI 10.1007/s10439-013-0936-x
   Chen KN, 2013, J MECH BEHAV BIOMED, V26, P54, DOI 10.1016/j.jmbbm.2013.05.015
   Chen K, 2012, RETINA-J RET VIT DIS, V32, P844, DOI 10.1097/IAE.0b013e318225d0c9
   Chen KN, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004289
   Chen K, 2010, J BIOMECH, V43, P1417, DOI 10.1016/j.jbiomech.2009.09.056
   Chen K, 2010, J BIOMED MATER RES A, V93A, P634, DOI 10.1002/jbm.a.32571
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curtin B J, 1969, Trans Am Ophthalmol Soc, V67, P417
   DEGUILLEBON H, 1972, ARCH OPHTHALMOL-CHIC, V87, P545, DOI 10.1001/archopht.1972.01000020547012
   DITZEL J, 1975, Acta Medica Scandinavica Supplement, V578, P59
   Downs JC, 2008, OPTOMETRY VISION SCI, V85, P425, DOI 10.1097/OPX.0b013e31817841cb
   Downs JC, 2003, J BIOMECH ENG-T ASME, V125, P124, DOI 10.1115/1.1536930
   Downs JC, 2005, INVEST OPHTH VIS SCI, V46, P540, DOI 10.1167/iovs.04-0114
   Elsheikh A, 2010, EXP EYE RES, V90, P624, DOI 10.1016/j.exer.2010.02.010
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Forgacs G, 1998, BIOPHYS J, V74, P2227, DOI 10.1016/S0006-3495(98)77932-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fung YC, 1981, BIOMECHANICS MECH PR
   GLOSTER J, 1957, Br J Ophthalmol, V41, P103, DOI 10.1136/bjo.41.2.103
   Holzapfel GA, 2003, CISM COURSES LECT, P109
   Holzapfel GA, 2004, J BIOMECH ENG-T ASME, V126, P657, DOI 10.1115/1.1800557
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Mannava S, 2011, ANN BIOMED ENG, V39, P1914, DOI 10.1007/s10439-011-0301-x
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nayar VT, 2012, TISSUE ENG PART C-ME, V18, P968, DOI [10.1089/ten.tec.2012.0034, 10.1089/ten.TEC.2012.0034]
   Negrel A D, 1998, Ophthalmic Epidemiol, V5, P143, DOI 10.1076/opep.5.3.143.8364
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Palko JR, 2011, EXP EYE RES, V93, P825, DOI 10.1016/j.exer.2011.09.018
   PARVING HH, 1983, METABOLISM, V32, P943, DOI 10.1016/0026-0495(83)90210-X
   Rastogi N, 2015, SURV OPHTHALMOL
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Salunke NV, 2001, J BIOMED MATER RES, V55, P236, DOI 10.1002/1097-4636(200105)55:2<236::AID-JBM1010>3.0.CO;2-F
   SCHLEGEL WA, 1972, INVEST OPHTH VISUAL, V11, P593
   [石杜芳 SHI Du-Fang], 2010, [中国生物医学工程学报, Chinese Journal of Biomedical Engineering], V29, P314
   Sivaprasad S., 2005, INVESTIGATIONS POSSI
   STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462
   STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355
   STHELEN R, 1961, AM J OPHTHALMOL, V52, P539
   Sugar HS., 1941, AM J OPHTHALMOL, V24, P851
   TAYLOR E, 1970, British Journal of Ophthalmology, V54, P11, DOI 10.1136/bjo.54.1.11
   van Popele NM, 2001, STROKE, V32, P454, DOI 10.1161/01.STR.32.2.454
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vlok ME., 1992, MANUAL OF NURSING, V2
   Wang SB, 2015, BRIT J OPHTHALMOL, V99, P365, DOI 10.1136/bjophthalmol-2014-305793
   WOO SLY, 1982, BIORHEOLOGY, V19, P385
   WU W, 1987, J BIOMECH ENG-T ASME, V109, P65, DOI 10.1115/1.3138644
NR 57
TC 4
Z9 4
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
EI 1552-4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD AUG
PY 2018
VL 106
IS 8
BP 2151
EP 2157
DI 10.1002/jbm.a.36417
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA GL4KL
UT WOS:000437119800006
PM 29582545
DA 2022-11-30
ER

PT J
AU Zou, MJ
   Zhang, YC
   Chen, AM
   Young, CA
   Li, Y
   Zheng, DY
   Jin, GM
AF Zou, Minjie
   Zhang, Yichi
   Chen, Aiming
   Young, Charlotte Aimee
   Li, Yi
   Zheng, Danying
   Jin, Guangming
TI Variations and trends in global disease burden of age-related macular
   degeneration: 1990-2017
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE disease burden; age-related macular degeneration; disability-adjusted
   life years; risk factors
ID VISUAL IMPAIRMENT; CATARACT; HEALTH; ASSOCIATION; EMPOWERMENT; GLAUCOMA
AB Purpose To evaluate the disease burden of age-related macular degeneration (AMD) and to evaluate the risk factors of disability-adjusted life years (DALY) caused by AMD. Methods Country-specific DALY number, rate and age-standardized rate of AMD were acquired from the Global Burden of Disease Study 2017 database. The Socio-demographic Index (SDI), Human Development Index (HDI), Inequality-adjusted Human Development Index (IA-HDI) and other related data were obtained from published data or shared databases. Regression analysis was conducted to evaluate the correlations between the potential risk factors and the age-standardized DALY rate of AMD. Results The DALY number doubled from 1990 to 2017, and DALY rate increased from 4.73 (95% CI: 3.19-6.54) to 6.95 (95% CI: 4.76-9.54). However, change was small after standardizing. Females tended to have severer burden. Disability-adjusted life years (DALY) rates were correlated to annual PM2.5 concentration, gross domestic product (GDP) per capita, population with at least some secondary education (secondary education), glaucoma prevalence and gross national income (GNI) per capita. In SDI model, glaucoma, GDP, healthcare access and quality index (HAQ) and secondary education were associated with disease burden (p < 0.001). In IA-HDI model, cataract, glaucoma, PM2.5, GDP and secondary education were correlated to DALY rates (p < 0.001). In model included four components of HDI, glaucoma, PM2.5, GDP, secondary education, expected years of schooling and life expectancy at birth were associated (p < 0.001). Conclusion Being female, older age, poor socioeconomic status and less educated are associated with a heavier disease burden of AMD. These findings would provide a basic understanding for policy making on AMD prevention and treatment.
C1 [Zou, Minjie; Zheng, Danying; Jin, Guangming] Sun Yat Sen Univ, Zhongshan Ophthalmol Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Peoples R China.
   [Zou, Minjie] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Peoples R China.
   [Zhang, Yichi] Sun Yat Sen Univ, Dept Ophthalmol, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China.
   [Chen, Aiming] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China.
   [Young, Charlotte Aimee] Nanchang Univ, Affiliated Hosp 3, Dept Ophthalmol, Nanchang, Jiangxi, Peoples R China.
   [Li, Yi] Jilin Univ, Sch Pharm & Food Sci, Zhuhai Coll, Zhuhai, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University; Nanchang University; Jilin University
RP Zheng, DY; Jin, GM (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalmol Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Peoples R China.
EM zhengdyy@163.com; jingm@mail2.sysu.edu.cn
RI ; Young, Charlotte/F-4405-2018
OI Jin, Guangming/0000-0001-9994-6338; Zhang, Yichi/0000-0001-8948-466X;
   Zou, Minjie/0000-0001-7706-6663; Young, Charlotte/0000-0002-9402-7663
FU National Natural Science Foundation of China [81873673, 81900841];
   Fundamental Research Funds of the State Key Laboratory of Ophthalmology;
   Young Teachers Training Program of Sun Yat-sen University
FX This work was supported by National Natural Science Foundation of China
   (81873673, 81900841) and the Fundamental Research Funds of the State Key
   Laboratory of Ophthalmology. Dr Jin receives support from the Young
   Teachers Training Program of Sun Yat-sen University.
CR Arnold Jennifer J, 2016, BMJ Clin Evid, V2016
   Barber RM, 2017, LANCET, V390, P231, DOI [10.1016/S0140-6736(17)30818-8, 10.1016/s0140-6736(17)30818-8]
   Bonaccio M, 2016, INT J PUBLIC HEALTH, V61, P765, DOI 10.1007/s00038-016-0822-z
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Educational UN, 2017, SCI CULT ORG UNESCO
   He M, 2017, INVEST OPHTH VIS SCI, V58, P4299, DOI 10.1167/iovs.17-21459
   Hu CC, 2017, EYE, V31, P872, DOI 10.1038/eye.2016.325
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
   Jin GM, 2019, CLIN EXP OPHTHALMOL, V47, P1019, DOI 10.1111/ceo.13580
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kawaguchi L, 2014, NAGOYA J MED SCI, V76, P161
   Khairallah M, 2015, INVEST OPHTH VIS SCI, V56, P6762, DOI 10.1167/iovs.15-17201
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Kyu HH, 2018, LANCET, V392, P1859, DOI [10.1016/S0140-6736(18)32335-3, 10.1016/s0140-6736(18)32335-3]
   Lailulo YA, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0273-3
   Lane M, 2018, SURV OPHTHALMOL, V63, P406, DOI 10.1016/j.survophthal.2017.10.009
   Lee YH, 2018, INT J HEALTH CARE Q, V31, P41, DOI 10.1108/IJHCQA-01-2017-0001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Panova I E, 2016, Vestn Oftalmol, V132, P48, DOI 10.17116/oftalma2016132448-53
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Qian CX, 2014, SEMIN OPHTHALMOL, V29, P301, DOI 10.3109/08820538.2014.962166
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   United Nations Department of Economic and Social Affairs, WORLD POP PROSP 2015
   Wang DC, 2019, CURR EYE RES, V44, P657, DOI 10.1080/02713683.2019.1576907
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
   Zhang YC, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020436
NR 28
TC 5
Z9 5
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2021
VL 99
IS 3
BP E330
EP E335
DI 10.1111/aos.14589
EA AUG 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RW8PX
UT WOS:000561938600001
PM 32833305
DA 2022-11-30
ER

PT J
AU Pedersen, KB
   Sjolie, AK
   Moller, F
AF Pedersen, Karen Bjerg
   Sjolie, Anne Katrin
   Moller, Flemming
TI Intravitreal bevacizumab (Avastin (R)) for neovascular age-related
   macular degeneration in treatment-naive patients
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; intravitreal bevacizumab;
   neovascularization; optical coherence tomography; pigment epithelial
   detachment
ID CHOROIDAL NEOVASCULARIZATION; MACULOPATHY; SECONDARY; RANIBIZUMAB;
   CANCER; VEGF
AB Purpose:
   To report the effects of intravitreal bevacizumab (Avastin (R)) in treatment-naive patients with exudative age-related macular degeneration (ARMD) assessed by visual acuity (VA), optical coherence tomography (OCT) and contrast sensitivity.
   Methods:
   A prospective, uncontrolled, pilot study of 26 eyes of 26 patients, all previously treatment-naive to photodynamic therapy, argon laser or anti-vascular endothelial growth factor (VEGF), were treated with one or more intravitreal injections of 1.25 mg bevacizumab. Of the 26 patients, 15 (57.7%) had occult choroidal neovascularization (CNV), 6 (23.1%) had predominantly classic CNV and 5 (19.2%) had minimally classic CNV. Ophthalmic outcome measures included changes in standardized Early Treatment Diabetic Research Study (ETDRS) VA, contrast sensitivity and OCT. The patients were examined at baseline and 1 week, 6 weeks, 3 months and 6 months after the first injection. Re-treatment was given on an 'as needed' basis.
   Results:
   Twenty-four eyes of 24 patients completed 6 months of follow-up. Two patients chose to discontinue the study. Mean ETDRS VA score improved from 55 letters at baseline to 60 letters at 1 week (P < 0.01) and to 61 letters at 6 weeks (P < 0.01). No significant improvement in VA from baseline was found after 3 and 6 months. Patients with pigment epithelial detachment (PED) had a significantly worse outcome in VA at 6 months. Contrast sensitivity improved from baseline to 3 or 6 months, but this improvement was not statistically significant. Mean macular thickness decreased significantly from baseline to all follow-up examinations (P < 0.01).
   Conclusion:
   Mean ETDRS VA improved significantly after 1 and 6 weeks; thereafter, it remained stable throughout the study period. Macular thickness improved significantly at all time points. The results indicate that 1.25 mg intravitreal bevacizumab is associated with functional as well as morphological improvement among treatment-naive ARMD patients.
C1 [Pedersen, Karen Bjerg; Sjolie, Anne Katrin; Moller, Flemming] Odense Univ Hosp, Dept Ophthalmol, DK-5000 Odense C, Denmark.
C3 University of Southern Denmark; Odense University Hospital
RP Pedersen, KB (通讯作者)，Odense Univ Hosp, Dept Ophthalmol, Sdr Blvd 29, DK-5000 Odense C, Denmark.
EM karenbjerg@yahoo.dk
FU The Danish Eye Health Society; The Danish Eye Research Foundation; The
   Synoptik Foundation; The AP Moller Foundation for the Advancement of
   Medical Science; The Velux Foundation
FX This study was supported by The Danish Eye Health Society, The Danish
   Eye Research Foundation, The Synoptik Foundation, The AP Moller
   Foundation for the Advancement of Medical Science and The Velux
   Foundation.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOM AF, 2006, ACTA OPHTHALMOL SCAN, V84, P713
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Cohen MH, 2007, ONCOLOGIST, V12, P713, DOI 10.1634/theoncologist.12-6-713
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 24
TC 16
Z9 16
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2009
VL 87
IS 7
BP 714
EP 719
DI 10.1111/j.1755-3768.2008.01346.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 509FF
UT WOS:000270999300004
PM 19094171
DA 2022-11-30
ER

PT J
AU Salti, HI
   Antonios, RS
   Haddad, SS
   Hamam, RN
   Bashshur, ZF
   Ghazi, NG
AF Salti, Haytham I.
   Antonios, Rafic S.
   Haddad, Sandra S.
   Hamam, Rola N.
   Bashshur, Ziad F.
   Ghazi, Nicola G.
TI Combined Nonmydriatic Spectral-Domain Optical Coherence Tomography and
   Nonmydriatic Fundus Photography for the Detection of Age-Related Macular
   Degeneration Changes
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID DIABETIC-RETINOPATHY; FOLLOW-UP; EDEMA; SENSITIVITY
AB BACKGROUND AND OBJECTIVE: Nonmydriatic fundus photography (FP) has been a suboptimal tool for detecting age-related macular degeneration (AMD) changes. This study sought to enhance the detection of AMD changes by combining nonmydriatic FP with nonmydriatic spectral-domain optical coherence tomography (SD-OCT).
   PATIENTS AND METHODS: The study population included 249 patients aged 65 years and older who were assessed for AMD changes using standard mydriatic biomicroscopic fundus examination. Each eye then underwent nonmydriatic FP in one session followed 1 week later with nonmydriatic FP coupled with nonmydriatic SD-OCT. Images were interpreted for detection of AMD changes, and findings were compared to the original mydriatic biomicroscopic examination.
   RESULTS: Nonmydriatic FP had 64% sensitivity, 97% specificity, and a kappa value of 0.67 in detecting AMD changes compared with the traditional mydriatic biomicroscopic examination. Combined nonmydriatic FP and nonmydriatic SD-OCT increased sensitivity to 91.5%, specificity to 98.6%, and kappa to 0.91.
   CONCLUSION: The addition of nonmydriatic SD-OCT to nonmydriatic FP enhances the detection of AMD changes.
C1 [Salti, Haytham I.; Antonios, Rafic S.; Hamam, Rola N.; Bashshur, Ziad F.] Amer Univ Beirut, Med Ctr, Dept Ophthalmol, Beirut 11072020, Lebanon.
   [Haddad, Sandra S.] Beirut Cent Mil Hosp, Beirut, Lebanon.
   [Ghazi, Nicola G.] King Khalid Eye Specialist Hosp, Riyadh 11462, Saudi Arabia.
C3 American University of Beirut; King Khaled Eye Specialist Hospital
RP Salti, HI (通讯作者)，Amer Univ Beirut, Med Ctr, Dept Ophthalmol, POB 110236, Beirut 11072020, Lebanon.
EM hs06@aub.edu.lb
RI Ghazi, Nicola/AAH-4169-2020; Hamam, Rola/K-7454-2019
OI Ghazi, Nicola/0000-0001-9255-8025; Hamam, Rola/0000-0001-8044-4215
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bursell SE, 2001, OPHTHALMOLOGY, V108, P572, DOI 10.1016/S0161-6420(00)00604-7
   Coker J G, 1996, Curr Opin Ophthalmol, V7, P33, DOI 10.1097/00055735-199606000-00006
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   De Bats F, 2013, OPHTHALMOLOGICA
   El-Mollayess GM, 2013, RETINA-J RET VIT DIS, V33, P1828, DOI 10.1097/IAE.0b013e3182877a0d
   Forooghian F, 2008, INVEST OPHTH VIS SCI, V49, P4290, DOI 10.1167/iovs.08-2113
   Hancox J, 2002, EYE, V16, P562, DOI 10.1038/sj.eye.6700146
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Imasawa M, 2001, AM J OPHTHALMOL, V131, P55, DOI 10.1016/S0002-9394(00)00722-4
   Ip Michael, 2003, Semin Ophthalmol, V18, P67, DOI 10.1080/08820530390897873
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Medina FJL, 2012, AM J OPHTHALMOL, V153, P536, DOI 10.1016/j.ajo.2011.08.008
   Le Tien V, 2008, AM J OPHTHALMOL, V146, P520, DOI 10.1016/j.ajo.2008.05.031
   Li HK, 1999, TELEMED J, V5, P283, DOI 10.1089/107830299312032
   Lim JI, 2002, RETINA-J RET VIT DIS, V22, P59, DOI 10.1097/00006982-200202000-00011
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Montero JA, 2003, GRAEF ARCH CLIN EXP, V241, P797, DOI 10.1007/s00417-003-0752-3
   Ouyang YL, 2013, INVEST OPHTH VIS SCI, V54, P1144, DOI 10.1167/iovs.12-9903
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Salti HI, 2009, OPHTHAL SURG LAS IM, V40, P373, DOI 10.3928/15428877-20096030-04
   Silva PS, 2012, TELEMED E-HEALTH, V18, P492, DOI 10.1089/tmj.2011.0232
   Zimmer-Galler IE, 2005, OPHTHAL SURG LAS IM, V36, P228, DOI 10.3928/1542-8877-20050501-09
NR 25
TC 5
Z9 5
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAY
PY 2015
VL 46
IS 5
BP 531
EP 537
DI 10.3928/23258160-20150521-04
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CO6UQ
UT WOS:000359292500004
PM 26057756
DA 2022-11-30
ER

PT J
AU Xing, C
   Sivakumaran, TA
   Wang, JJ
   Rochtchina, E
   Joshi, T
   Smith, W
   Mitchell, P
   Iyengar, SK
AF Xing, C.
   Sivakumaran, T. A.
   Wang, J. J.
   Rochtchina, E.
   Joshi, T.
   Smith, W.
   Mitchell, P.
   Iyengar, S. K.
TI Complement factor H polymorphisms, renal phenotypes and age-related
   macular degeneration: the Blue Mountains Eye Study
SO GENES AND IMMUNITY
LA English
DT Article
DE CFH; AMD; GFR; creatinine clearance
ID HEMOLYTIC-UREMIC SYNDROME; GLOMERULAR-FILTRATION-RATE;
   GLOMERULONEPHRITIS TYPE-II; DENSE DEPOSIT DISEASE; C-TERMINAL DOMAINS;
   MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; SERUM CREATININE; REACTIVE
   PROTEIN; KIDNEY-DISEASE; GRADING SYSTEM
AB Complement factor H (CFH) is a key regulator of the alternative pathway of complement and its mutations have been associated with membranoproliferative glomerulonephritis type II, atypical hemolytic uremic syndrome and age-related macular degeneration (AMD), suggesting that alternative pathway dysregulation is a common pathogenetic feature of these ocular and renal conditions. In this study we tested the hypothesis that common CFH variants have a global role in renal function in the Australian population-based Blue Mountains Eye Study (BMES). We replicated the association of 162V with estimated glomerular filtration rate (GFR; P=0.017) and creatinine clearance (CRCL; P=0.015). The minor allele of 162V ( G) was deleterious: adding one copy of the G allele decreased GFR/CRCL by similar to 0.98 ml min(-1) per 1.73 m(2) (95% confidence interval (CI): 0.97, 0.99). We also replicated the association of Y402H with AMD and provided an unbiased estimate of population attributable risk ( PAR). The minor allele of Y402H ( C) was deleterious: the odds ratio estimate of CC genotype compared to TT was 1.87 ( 95% CI: 1.44, 2.45). The PAR of the C allele was estimated as 0.22 (95% CI: 0.15, 0.28). In summary, in the BMES population we confirmed the association between 162V and renal function, as measured by the estimated GFR, plus the association of Y402H with both early- and late-stage AMD.
C1 [Xing, C.; Sivakumaran, T. A.; Joshi, T.; Iyengar, S. K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Xing, C.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA.
   [Xing, C.] Univ Texas SW Med Ctr Dallas, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA.
   [Wang, J. J.; Rochtchina, E.; Mitchell, P.] Univ Sydney, Ctr Vis Res, Westmead Millennium Inst, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Smith, W.] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia.
   [Iyengar, S. K.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Iyengar, S. K.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; University of Texas System; University
   of Texas Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Sydney; Westmead Institute for Medical Research; University of
   Newcastle; Case Western Reserve University; Case Western Reserve
   University
RP Iyengar, SK (通讯作者)，Case Western Reserve Univ, Dept Epidemiol & Biostat, Wolstein Res Bldg 1315,10900 Euclid Ave, Cleveland, OH 44106 USA.
EM ski@case.edu
RI Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; wang,
   jie/GRS-0942-2022; /S-1190-2019
OI Wang, Jie Jin/0000-0001-9491-4898; /0000-0001-7488-250X; Xing,
   Chao/0000-0002-1838-0502
FU NATIONAL EYE INSTITUTE [R01EY015810] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028356,
   R01GM028356] Funding Source: NIH RePORTER; NEI NIH HHS [EY015810]
   Funding Source: Medline; NIGMS NIH HHS [GM28356] Funding Source: Medline
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Alexander JJ, 2007, J AM SOC NEPHROL, V18, P1157, DOI 10.1681/ASN.2006101125
   Alexander JJ, 2007, MOL IMMUNOL, V44, P123, DOI 10.1016/j.molimm.2006.07.287
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Browning SR, 2005, GENET EPIDEMIOL, V28, P110, DOI 10.1002/gepi.20051
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Chamberlain M, 2006, SURV OPHTHALMOL, V51, P576, DOI 10.1016/j.survophthal.2006.08.003
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   Fisher R., 1948, AM STAT, V2, P30
   Fox CS, 2004, J AM SOC NEPHROL, V15, P2457, DOI 10.1097/01.ASN.0000135972.13396.6F
   FUCHSHUBER A, 1995, HUM MOL GENET, V4, P2155, DOI 10.1093/hmg/4.11.2155
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hunt SC, 2004, AM J HYPERTENS, V17, P511, DOI 10.1016/j.amjhyper.2004.02.019
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   LIEW G, 2008, J AM SOC NEPHROL, V23
   Lin J, 2003, J AM SOC NEPHROL, V14, P2573, DOI 10.1097/01.ASN.0000088721.98173.4B
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McPeek MS, 2004, BIOMETRICS, V60, P359
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neary JJ, 2002, J AM SOC NEPHROL, V13, P2052, DOI 10.1097/01.ASN.0000022006.49966.F8
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Perkins SJ, 2002, J MOL BIOL, V316, P217, DOI 10.1006/jmbi.2001.5337
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Poggio ED, 2005, J AM SOC NEPHROL, V16, P459, DOI 10.1681/ASN.2004060447
   *SAS I, 2006, SAS GUID PERS COMP V
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Tsukaguchi H, 2000, J AM SOC NEPHROL, V11, P1674, DOI 10.1681/ASN.V1191674
   Vollmer M, 1998, AM J HUM GENET, V63, P1724, DOI 10.1086/302162
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 61
TC 38
Z9 38
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
EI 1476-5470
J9 GENES IMMUN
JI Genes Immun.
PD APR
PY 2008
VL 9
IS 3
BP 231
EP 239
DI 10.1038/gene.2008.10
PG 9
WC Genetics & Heredity; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Immunology
GA 292LP
UT WOS:000255267800006
PM 18340363
DA 2022-11-30
ER

PT J
AU Detaram, HD
   Liew, G
   Lewis, JR
   Bondonno, NP
   Bondonno, CP
   Van Vu, K
   Burlutsky, G
   Hodgson, JM
   Mitchell, P
   Gopinath, B
AF Detaram, Harshil Dharamdasani
   Liew, Gerald
   Lewis, Joshua R.
   Bondonno, Nicola P.
   Bondonno, Catherine P.
   Van Vu, Kim
   Burlutsky, George
   Hodgson, Jonathan M.
   Mitchell, Paul
   Gopinath, Bamini
TI Dietary flavonoids are associated with longitudinal treatment outcomes
   in neovascular age-related macular degeneration
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE Age-related macular degeneration; Flavonoids; Retina; Tea; Catechin;
   Vision
ID EXPRESSION; QUERCETIN; ZINC
AB Purpose To assess whether dietary intake of flavonoids are associated with longitudinal treatment outcomes of patients with neovascular age-related macular degeneration (nAMD). Methods 547 participants with nAMD were recruited at baseline, 494 were followed-up after receiving 12 months of anti-vascular endothelial growth factor (anti-VEGF) therapy. Baseline dietary intake of flavonoids was determined using a validated food frequency questionnaire. At follow-up, presence of intra-retinal and sub-retinal fluid (IRF and SRF), retinal pigment epithelium detachment and measurements of central macular thickness (CMT) were recorded from optical coherence tomography scans. Visual acuity (VA) was documented using LogMAR charts. Results Participants in the first tertile of intake of the flavonol quercetin, and the flavan-3-ols epigallocatechin-3-gallate and epigallocatechin had significantly worse vision than participants in the third tertile-multivariable-adjusted least square (LS) mean VA: 14.68 vs. 19.53 (p = 0.04); 14.06 vs. 18.89 (p = 0.04); 13.86 vs. 18.86 (p = 0.03), respectively. Participants in the first compared to the third tertile of flavan-3-ol, epigallocatechin-3-gallate and epigallocatechin intake all had a twofold higher risk of IRF, multivariable-adjusted p trend of: 0.03, 0.01 and 0.02, respectively. The first vs. the third tertile of tea intake had significantly worse vision (LS mean VA: 13.49 vs. 19.04, p = 0.02), increased risk of IRF (OR 2.13, 95% CI 1.18-3.85) and greater mean CMT (279.59 mu m vs. 256.52 mu m, p = 0.04). Conclusions Higher intakes of dietary flavonoids, specifically flavonols and flavan-3-ols, could be associated with better long-term treatment outcomes in nAMD patients receiving anti-VEGF therapy. Confirmation of these associations in interventional studies could result in promising new therapeutic approaches to the treatment of nAMD.
C1 [Detaram, Harshil Dharamdasani; Liew, Gerald; Van Vu, Kim; Burlutsky, George; Mitchell, Paul; Gopinath, Bamini] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
   [Detaram, Harshil Dharamdasani; Liew, Gerald; Van Vu, Kim; Burlutsky, George; Mitchell, Paul; Gopinath, Bamini] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Lewis, Joshua R.] Univ Sydney, Sch Publ Hlth, Ctr Kidney Res, Sydney, NSW, Australia.
   [Lewis, Joshua R.] Univ Sydney, Sch Publ Hlth, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Lewis, Joshua R.; Bondonno, Nicola P.; Bondonno, Catherine P.; Hodgson, Jonathan M.] Edith Cowan Univ, Sch Med & Hlth Sci, Perth, WA, Australia.
   [Lewis, Joshua R.; Bondonno, Catherine P.; Hodgson, Jonathan M.] Univ Western Australia, Sch Med, 35 Stirling Highway, Perth, WA, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Sydney; University of Sydney; Westmead
   Institute for Medical Research; Edith Cowan University; University of
   Western Australia
RP Gopinath, B (通讯作者)，Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.; Gopinath, B (通讯作者)，Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
EM bamini.gopinath@sydney.edu.au
RI Liew, Gerald/AAB-6870-2022; lewis, josh/GZG-7164-2022
FU Macular Disease Foundation Australia (MDFA)
FX Macular Disease Foundation Australia (MDFA).
CR Bhagwat S., 2018, USDA AGR RES SERV RE, V3, P3
   Bondonno CP, 2015, NUTR REV, V73, P216, DOI 10.1093/nutrit/nuu014
   Bondonno NP, 2020, CLIN NUTR, V39, P141, DOI 10.1016/j.clnu.2019.01.004
   Chen Y, 2008, GRAEF ARCH CLIN EXP, V246, P373, DOI 10.1007/s00417-007-0728-9
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   Detaram HD, 2020, CLIN EXP OPHTHALMOL, V48, P61, DOI 10.1111/ceo.13644
   DHARAMDASANIDET.H, 2020, ACTA OPHTHALMOL
   EVANS J, 2017, COCHRANE DB SYST REV, V14
   Fukumoto LR, 2000, J AGR FOOD CHEM, V48, P3597, DOI 10.1021/jf000220w
   Gopinath B, 2018, AM J CLIN NUTR, V108, P381, DOI 10.1093/ajcn/nqy114
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Heim KE, 2002, J NUTR BIOCHEM, V13, P572, DOI 10.1016/S0955-2863(02)00208-5
   Isemura M, 2019, MOLECULES, V24, DOI 10.3390/molecules24030528
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khoo HE, 2017, FOOD NUTR RES, V61, P1, DOI 10.1080/16546628.2017.1361779
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Majumdar S, 2010, J PHARM PHARMACOL, V62, P951, DOI 10.1211/jpp.62.08.0001
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Panche AN, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2016.41
   Rhone M, 2008, NUTR REV, V66, P465, DOI 10.1111/j.1753-4887.2008.00078.x
   Russell JC, 2017, ASIA PAC J CLIN NUTR, V26, P212, DOI 10.6133/apjcn.122015.08
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Tan WF, 2003, EUR J PHARMACOL, V459, P255, DOI 10.1016/S0014-2999(02)02848-0
   Tunon MJ, 2009, CURR DRUG METAB, V10, P256, DOI 10.2174/138920009787846369
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   WANG L, 2010, PLOS ONE, V5
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang QZ, 2006, MOL CANCER THER, V5, P1227, DOI 10.1158/1535-7163.MCT-05-0490
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P425, DOI 10.1089/jop.2006.22.425
NR 37
TC 2
Z9 2
U1 1
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD DEC
PY 2021
VL 60
IS 8
BP 4243
EP 4250
DI 10.1007/s00394-021-02582-4
EA MAY 2021
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA WS2TS
UT WOS:000652075900001
PM 34009430
DA 2022-11-30
ER

PT J
AU McGuinness, MB
   Finger, RP
   Karahalios, A
   Guymer, RH
   English, DR
   Chong, EW
   Hodge, AM
   Robman, LD
   Giles, GG
   Simpson, JA
AF McGuinness, M. B.
   Finger, R. P.
   Karahalios, A.
   Guymer, R. H.
   English, D. R.
   Chong, E. W.
   Hodge, A. M.
   Robman, L. D.
   Giles, G. G.
   Simpson, J. A.
TI Continuing Medical Education: Age-related macular degeneration and
   mortality: the Melbourne Collaborative Cohort Study
SO EYE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; VISUAL IMPAIRMENT; ATHEROSCLEROSIS RISK; EYE
   DISEASES; ANTI-VEGF; INFLAMMATION; SURVIVAL; DRUSEN; SMOKING; CANCER
AB Aims To assess associations between features of age-related macular degeneration (AMD) and mortality.
   Methods A total of 21 129 participants from the Melbourne Collaborative Cohort Study aged 47-85 years (60% female) were assessed for AMD (2003-2007). Mortality data to December 31, 2012 were obtained through linkage with the National Death Index. Associations were assessed using Cox regression, adjusting for age, sex, smoking, region of birth, education, physical activity, diet and alcohol.
   Results Late AMD was identified in 122 (0.6%) participants, including those with choroidal neovascularisation (n=55, 0.3%), geographic atrophy (n=87, 0.4%) and reticular pseudodrusen (n=87, 0.4%). After a median follow-up period of 8.1 years, 1669 (8%) participants had died, including those from cardiovascular diseases (386), tobaccorelated cancers (179), and neurodegenerative disease (157). There was evidence of an increased rate of all-cause mortality for those with choroidal neovascularisation (Hazard Ratio (HR) 1.71 95% CI 1.06-2.76) and geographic atrophy (HR 1.46 95% CI 0.992.16). Choroidal neovascularisation was also associated with an increased rate of cardiovascular mortality (HR 3.16 95% CI 1.62-6.15) and geographic atrophy was associated with an increased rate of death from tobacco-related cancer (HR 2.86 95% CI 1.15-7.09). Weak evidence was also present for an association between choroidal neovascularisation and death from neurodegenerative disease (HR 2.49 95% CI 0.79-7.85). Neither reticular pseudodrusen nor the earlier stages of AMD were associated with mortality.
   Conclusions Late AMD is associated with an increased rate of all-cause mortality. Choroidal neovascularisation and geographic atrophy were associated with death from cardiovascular disease and tobacco-related cancer, respectively.
C1 [McGuinness, M. B.; Finger, R. P.; Guymer, R. H.; Chong, E. W.; Robman, L. D.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [McGuinness, M. B.; Karahalios, A.; English, D. R.; Giles, G. G.; Simpson, J. A.] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [McGuinness, M. B.; Finger, R. P.; Guymer, R. H.; Chong, E. W.; Robman, L. D.] Univ Melbourne, Dept Surg, East Melbourne, Australia.
   [Finger, R. P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [English, D. R.; Hodge, A. M.; Giles, G. G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; University of Bonn;
   Cancer Council Victoria
RP McGuinness, MB (通讯作者)，Ctr Eye Res Australia, Level 7,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM myra.mcguinness@unimelb.edu.au
RI McGuinness, Myra/G-4900-2017; English, Dallas/AAH-5005-2019
OI McGuinness, Myra/0000-0002-5422-040X; English,
   Dallas/0000-0001-7828-8188; Hodge, Allison/0000-0001-5464-2197; Guymer,
   Robyn/0000-0002-9441-4356
FU VicHealth; Cancer Council Victoria; National Health & Medical Research
   Council of Australia (NHMRC) [209057, 251533, 396414]; Ophthalmic
   Research Institute of Australia; American Health Assistance Foundation
   [M2008-082]; Jack Brockhoff Foundation; John Reid Charitable Trust;
   NHMRC Centre of Clinical Research Excellence grant [529923]; Australian
   Postgraduate Award; Victorian Centre for Biostatistics (NHMRC: Centre of
   Research Excellence grant) [1035261]; Australian National Health and
   Medical Research Council (NHMRC) [1104975]; NHMRC [1103013]
FX Khin Z Aung, MBBS, and Galina A Makeyeva, MBBS, PhD, (Centre for Eye
   Research Australia) assisted in data collection for the ophthalmic
   portion of this study and performed grading of retinal photographs.
   Vital status was ascertained through the Victorian Cancer Registry and
   the Australian Institute of Health and Welfare, including the National
   Death Index. Cohort recruitment was funded by VicHealth and Cancer
   Council Victoria. Further Melbourne Collaborative Cohort Study funding:
   the National Health & Medical Research Council of Australia (NHMRC)
   Program Grant 209057, Capacity Building Grant 251533 and Enabling Grant
   396414. The ophthalmic component was funded by the Ophthalmic Research
   Institute of Australia; American Health Assistance Foundation
   (M2008-082), Jack Brockhoff Foundation, John Reid Charitable Trust,
   Perpetual Trustees. The Centre for Eye Research Australia is a recipient
   of the NHMRC Centre of Clinical Research Excellence grant (529923) and
   Operational Infrastructure Support from the Victorian Government. M
   McGuinness is funded by an Australian Postgraduate Award and a
   studentship courtesy of Victorian Centre for Biostatistics (NHMRC:
   Centre of Research Excellence grant 1035261). JA Simpson is funded by an
   Australian National Health and Medical Research Council (NHMRC) Senior
   Research Fellowship 1104975 and RH Guymer is funded by an NHMRC
   principal research fellowship 1103013. This work was supported by
   infrastructure from the Cancer Council Victoria. The funding
   organizations had no role in study design or conduct of this research.
CR Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12
   Amor S, 2014, IMMUNOLOGY, V142, P151, DOI 10.1111/imm.12233
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chong EW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137322
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cole SR, 2002, INT J EPIDEMIOL, V31, P163, DOI 10.1093/ije/31.1.163
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2013, MED J AUSTRALIA, V198, P260, DOI 10.5694/mja12.11295
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Fogelholm M, 2006, MED SCI SPORT EXER, V38, P753, DOI 10.1249/01.mss.0000194075.16960.20
   Fratiglioni L, 2000, BEHAV BRAIN RES, V113, P117, DOI 10.1016/S0166-4328(00)00206-0
   Giles G G, 2002, IARC Sci Publ, V156, P69
   Golia E, 2014, CURR ATHEROSCLEROS R, V16, P7
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Ireland P, 1994, Asia Pac J Clin Nutr, V3, P19
   Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198-003-1490-4
   Jylhava J, 2009, EXP GERONTOL, V44, P297, DOI 10.1016/j.exger.2008.10.006
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Korn EL, 1997, AM J EPIDEMIOL, V145, P72
   Larson EB, 2004, ANN INTERN MED, V140, P501, DOI 10.7326/0003-4819-140-7-200404060-00008
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Lindekleiv H, 2013, EYE, V27, P1281, DOI 10.1038/eye.2013.181
   Magliano D, 2003, AUST NZ J PUBL HEAL, V27, P649, DOI 10.1111/j.1467-842X.2003.tb00615.x
   Mantovani A, 2008, CANCER LETT, V267, P180, DOI 10.1016/j.canlet.2008.05.003
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   Mitchell P, 2011, EYES FUTURE CLEAR OU
   Pandeya N, 2015, AUST NZ J PUBL HEAL, V39, P464, DOI 10.1111/1753-6405.12446
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Prins D, 2016, ACTA OPHTHALMOL, V94, P113, DOI 10.1111/aos.12825
   Raghunathan TE., 2001, SURV METHODOL, V27, P85, DOI DOI 10.1002/SIM.1186
   Schisterman EF, 2009, EPIDEMIOLOGY, V20, P488, DOI 10.1097/EDE.0b013e3181a819a1
   Scott LJ, 2015, EXPERT OPIN DRUG SAF, V14, P379, DOI 10.1517/14740338.2015.991712
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   SurgeonGeneral, 2014, HLTH CONSMOK 50 YE
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   Walser Tonya, 2008, Proc Am Thorac Soc, V5, P811, DOI 10.1513/pats.200809-100TH
   Whitcup SM, 2013, INT J INFLAM, V2013, P1
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Yu GW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134010
NR 65
TC 12
Z9 12
U1 1
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2017
VL 31
IS 9
SI SI
BP 1345
EP 1357
DI 10.1038/eye.2017.139
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA VI0JA
UT WOS:000458516100001
PM 28820184
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Nazari, H
   Zhang, L
   Zhu, DH
   Chader, GJ
   Falabella, P
   Stefanini, F
   Rowland, T
   Clegg, DO
   Kashani, AH
   Hinton, DR
   Humayun, MS
AF Nazari, Hossein
   Zhang, Li
   Zhu, Danhong
   Chader, Gerald J.
   Falabella, Paulo
   Stefanini, Francisco
   Rowland, Teisha
   Clegg, Dennis O.
   Kashani, Amir H.
   Hinton, David R.
   Humayun, Mark S.
TI Stem cell based therapies for age-related macular degeneration: The
   promises and the challenges
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Human embryonic stem cell-derived
   retinal pigment epithelium; Induced pluripotent stem cell-derived
   retinal pigment epithelium; Stem cell-derived retinal progenitor cell
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE PATTERNS; OPTICAL
   COHERENCE TOMOGRAPHY; PHOTORECEPTOR-LIKE CELLS; PARS-PLANA VITRECTOMY;
   FACTOR-H POLYMORPHISM; MARROW STROMAL CELLS; REGULATORY T-CELLS
AB Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in developed countries. AMD is classified as either neovascular (NV-AMD) or non-neovascular (NNV-AMD). Cumulative damage to the retinal pigment epithelium, Bruch's membrane, and choriocapillaris leads to dysfunction and loss of RPE cells. This causes degeneration of the overlying photoreceptors and consequential vision loss in advanced NNV-AMD (Geographic Atrophy). In NV-AMD, abnormal growth of capillaries under the retina and RPE, which leads to hemorrhage and fluid leakage, is the main cause of photoreceptor damage. Although a number of drugs (e.g., anti-VEGF) are in use for NV-AMD, there is currently no treatment for advanced NNV-AMD. However, replacing dead or dysfunctional RPE with healthy RPE has been shown to rescue dying photoreceptors and improve vision in animal models of retinal degeneration and possibly in AMD patients. Differentiation of RPE from human embryonic stem cells (hESC-RPE) and from induced pluripotent stem cells (iPSC-RPE) has created a potentially unlimited source for replacing dead or dying RPE. Such cells have been shown to incorporate into the degenerating retina and result in anatomic and functional improvement. However, major ethical, regulatory, safety, and technical challenges have yet to be overcome before stem cell-based therapies can be used in standard treatments. This review outlines the current knowledge surrounding the application of hESC-RPE and iPSC-RPE in AMD. Following an introduction on the pathogenesis and available treatments of AMD, methods to generate stem cell-derived RPE, immune reaction against such cells, and approaches to deliver desired cells into the eye will be explored along with broader issues of efficacy and safety. Lastly, strategies to improve these stem cell-based treatments will be discussed. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Nazari, Hossein; Zhang, Li; Zhu, Danhong; Chader, Gerald J.; Falabella, Paulo; Stefanini, Francisco; Kashani, Amir H.; Hinton, David R.] Univ So Calif, USC Eye Inst, Los Angeles, CA 90033 USA.
   [Rowland, Teisha] Univ Colorado, Cardiovasc Inst, Aurora, CO 80045 USA.
   [Rowland, Teisha] Univ Colorado, Adult Med Genet Program, Aurora, CO 80045 USA.
   [Clegg, Dennis O.] Univ Calif Santa Barbara, Ctr Stem Cell Biol & Engn Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
   [Humayun, Mark S.] Univ So Calif, USC Eye Inst, Inst Biomed Therapeut, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Colorado
   System; University of Colorado Anschutz Medical Campus; University of
   California System; University of California Santa Barbara; University of
   Southern California
RP Humayun, MS (通讯作者)，Univ So Calif, USC Eye Inst, Inst Biomed Therapeut, 1441 Eastlake Ave,NTT 4463, Los Angeles, CA 90033 USA.
EM h.nazari.k@gmail.com; drzhangli@hotmail.com; dzhu@med.usc.edu;
   gchader02040@gmail.com; paulofalabella@hotmail.com;
   frstefanini@gmail.com; teisha.rowland@ucdenver.edu;
   clegg@lifesci.ucsb.edu; ahkashan@med.usc.edu; dhinton@med.usc.edu;
   Humayun@med.usc.edu
RI Nazari, Hossein/GOK-8161-2022
OI Nazari, Hossein/0000-0002-8945-9680; Falabella,
   Paulo/0000-0001-8773-7168; Rowland, Teisha/0000-0001-5038-6763
FU California Institute for Regenerative Medicine [DR1-01444, TG2-01161];
   NIH Core Grant [EY03040]; Research to Prevent Blindness; Arnold and
   Mabel Beckman Foundation; NATIONAL EYE INSTITUTE [P30EY003040] Funding
   Source: NIH RePORTER
FX This work is supported by the California Institute for Regenerative
   Medicine DR1-01444 and TG2-01161 grants, NIH Core Grant EY03040,
   Research to Prevent Blindness, The Arnold and Mabel Beckman Foundation,
   and a generous gift from the Beatrice Apple Revocable Living Trust.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Afshari FT, 2010, BRAIN, V133, P448, DOI 10.1093/brain/awp319
   Aftab U, 2009, EXP EYE RES, V89, P301, DOI 10.1016/j.exer.2009.03.025
   Ahmad ZM, 2012, ARCH OPHTHALMOL-CHIC, V130, P908, DOI 10.1001/archophthalmol.2011.1425
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Akdis CA, 2001, IMMUNOLOGY, V103, P131, DOI 10.1046/j.1365-2567.2001.01235.x
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   Amae S, 1998, BIOCHEM BIOPH RES CO, V247, P710, DOI 10.1006/bbrc.1998.8838
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amirpour N, 2013, INT J PREVENTIVE MED, V4, P1243
   Amirpour N, 2012, STEM CELLS DEV, V21, P42, DOI 10.1089/scd.2011.0073
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arai S, 2004, EXP EYE RES, V79, P331, DOI 10.1016/j.exer.2004.05.013
   Araujo A, 2008, ARQ BRAS OFTALMOL, V71, P246, DOI 10.1590/S0004-27492008000200021
   Arnhold S, 2006, INVEST OPHTH VIS SCI, V47, P4121, DOI 10.1167/iovs.04-1501
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0
   Blenkinsop TA, 2012, REGEN MED, V7, P32, DOI [10.2217/RME.12.77, 10.2217/rme.12.77]
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Bolton EM, 2008, TRANSPLANTATION, V85, P667, DOI 10.1097/TP.0b013e3181664db3
   Bour-Jordan H, 2011, IMMUNOL REV, V241, P180, DOI 10.1111/j.1600-065X.2011.01011.x
   Brader HS, 2013, OPHTHALMOLOGY, V120, P1871, DOI 10.1016/j.ophtha.2013.01.049
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Burnett JC, 2011, BIOTECHNOL J, V6, P1130, DOI 10.1002/biot.201100054
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Caramoy A, 2010, BRIT J OPHTHALMOL, V94, P1040, DOI 10.1136/bjo.2009.161299
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJ, 2009, MOL VIS, V15, P283
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Casella AMB, 1999, EXP EYE RES, V68, P423, DOI 10.1006/exer.1998.0621
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chamberlain SJ, 2008, NEUROGENETICS, V9, P227, DOI 10.1007/s10048-008-0147-z
   CHANG CH, 1994, EUR J IMMUNOL, V24, P2889, DOI 10.1002/eji.1830241146
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cheng JW, 2011, NEW ENGL J MED, V364, P582, DOI 10.1056/NEJMc1013316
   Cho MS, 2012, STEM CELL RES, V9, P101, DOI 10.1016/j.scr.2012.05.002
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   COWEY A, 1979, EXP BRAIN RES, V35, P443
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   de Nie KF, 2013, GRAEF ARCH CLIN EXP, V251, P1373, DOI 10.1007/s00417-012-2205-3
   Del Priore LV, 2003, INVEST OPHTH VIS SCI, V44, P4044, DOI 10.1167/iovs.02-1175
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Drukker M, 2008, IMMUNOLOGICAL CONSID
   Duan P, 2013, CELL PHYSIOL BIOCHEM, V31, P601, DOI 10.1159/000350080
   Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eibl R, 2009, ADV BIOCHEM ENG BIOT, V112, P183, DOI [10.1007/10_2008_3, 10.1007/978-3-540-69357-4_8]
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   English K, 2011, CURR OPIN ORGAN TRAN, V16, P90, DOI 10.1097/MOT.0b013e3283424faa
   Enzmann V, 1998, OCUL IMMUNOL INFLAMM, V6, P145, DOI 10.1076/ocii.6.3.145.4043
   Enzmann V, 1999, OPHTHALMIC RES, V31, P256, DOI 10.1159/000055545
   Fang IM, 2009, EXP EYE RES, V88, P12, DOI 10.1016/j.exer.2008.09.019
   Feldmann M, 1987, Interferon, V9, P75
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Fox IJ, 2014, SCIENCE, V345, P889, DOI 10.1126/science.1247391
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Frasson M, 1999, INVEST OPHTH VIS SCI, V40, P2724
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fuhrmann S, 2000, DEVELOPMENT, V127, P4599
   Fujii Gildo Y, 2002, Ophthalmol Clin North Am, V15, P425, DOI 10.1016/S0896-1549(02)00046-9
   Fujikado T, 1998, AM J OPHTHALMOL, V126, P839, DOI 10.1016/S0002-9394(98)00201-3
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Gamm DM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000338
   Girman S, 2005, VISION RES, V45, P343, DOI 10.1016/j.visres.2004.08.023
   Girman SV, 2003, VISION RES, V43, P1817, DOI 10.1016/S0042-6989(03)00276-1
   Gong J, 2008, EXP EYE RES, V86, P957, DOI 10.1016/j.exer.2008.03.014
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   GOURAS P, 1984, AN ACAD BRAS CIENC, V56, P431
   Grafft CA, 2010, NEPHROL DIAL TRANSPL, V25, P307, DOI 10.1093/ndt/gfp526
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gregerson DS, 2007, INVEST OPHTH VIS SCI, V48, P4654, DOI 10.1167/iovs.07-0286
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Griffin MD, 2010, HUM GENE THER, V21, P1641, DOI 10.1089/hum.2010.156
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Guo Y, 2003, INVEST OPHTH VIS SCI, V44, P3194, DOI 10.1167/iovs.02-0875
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hambright D, 2012, MOL VIS, V18, P920
   Han L, 2013, INVEST OPHTH VIS SCI, V54, P4956, DOI 10.1167/iovs.13-11957
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Harvey RJ, 1997, VISION RES, V37, P1615, DOI 10.1016/S0042-6989(96)00292-1
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heller JP, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.4
   Herm RJ, 2008, NEW ENGL J MED, V359, P1735
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Hewitt Z, 2007, STEM CELLS, V25, P10, DOI 10.1634/stemcells.2005-0481
   Hippen KL, 2011, SEMIN IMMUNOL, V23, P462, DOI 10.1016/j.smim.2011.07.008
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hirano M, 2003, DEV DYNAM, V228, P664, DOI 10.1002/dvdy.10425
   Hirsch L, 2015, CYTOKINE, V71, P394, DOI 10.1016/j.cyto.2014.11.014
   Hollyfield JG, 1999, INVEST OPHTH VIS SCI, V40, P2767
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2015, GRAEF ARCH CLIN EXP, V253, P7, DOI 10.1007/s00417-014-2858-1
   Horie S, 2010, CLIN IMMUNOL, V136, P83, DOI 10.1016/j.clim.2010.03.001
   Howden SE, 2011, P NATL ACAD SCI USA, V108, P6537, DOI 10.1073/pnas.1103388108
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Hu QR, 2010, STEM CELLS, V28, P1981, DOI 10.1002/stem.531
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Huang LB, 2013, OCUL IMMUNOL INFLAMM, V21, P276, DOI 10.3109/09273948.2013.791925
   Huo JS, 2014, CURR OPIN GENET DEV, V28, P43, DOI 10.1016/j.gde.2014.09.008
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jeon CJ, 1998, J NEUROSCI, V18, P8936
   Jeon S, 2015, BMB REP, V48, P193, DOI 10.5483/BMBRep.2015.48.4.276
   JIANG LQ, 1994, EXP EYE RES, V58, P719, DOI 10.1006/exer.1994.1069
   JIANG LQ, 1994, INVEST OPHTH VIS SCI, V35, P4300
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Jin ZB, 2009, J GENET, V88, P417, DOI 10.1007/s12041-009-0063-5
   Joe AW, 2010, CURR EYE RES, V35, P941, DOI 10.3109/02713683.2010.516466
   John S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/465169
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kador KE, 2012, EXPERT REV OPHTHALMO, V7, P459, DOI 10.1586/EOP.12.56
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Kearns V, 2012, J MATER SCI-MATER M, V23, P2013, DOI 10.1007/s10856-012-4675-6
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Klassen H, 2001, EXP NEUROL, V169, P114, DOI 10.1006/exnr.2000.7617
   KLASSEN H, 1990, J NEUROSCI, V10, P578
   Klassen H, 2007, STEM CELLS, V25, P1222, DOI 10.1634/stemcells.2006-0541
   Klassen H, 2006, EXPERT OPIN BIOL TH, V6, P443, DOI 10.1517/14712598.6.5.443
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Klimanskaya I, 2006, NATURE, V444, P481, DOI 10.1038/nature05142
   Kohen L, 1997, OPHTHALMIC RES, V29, P298, DOI 10.1159/000268028
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Kundu J, 2014, DEV OPHTHALMOL, V53, P143, DOI 10.1159/000357369
   Kuroda T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037342
   Kwan ASL, 1999, EXP NEUROL, V159, P21, DOI 10.1006/exnr.1999.7157
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Lechler RI, 2005, NAT MED, V11, P605, DOI 10.1038/nm1251
   Lee G.Y., 2014, J TISSUE ENG REGEN M
   Levings MK, 2002, INT ARCH ALLERGY IMM, V129, P263, DOI 10.1159/000067596
   LI L, 1991, EXP EYE RES, V52, P669, DOI 10.1016/0014-4835(91)90019-B
   Li R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023148
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Li Yunping, 2012, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V37, P433, DOI 10.3969/j.issn.1672-7347.2012.05.001
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lipinski DM, 2013, PROG RETIN EYE RES, V32, P22, DOI 10.1016/j.preteyeres.2012.09.001
   Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Liu Y, 2013, TISSUE ENG PT A, V19, P135, DOI [10.1089/ten.tea.2012.0209, 10.1089/ten.TEA.2012.0209]
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Loewendorf A, 2013, STEM CELL TRANSL MED, V2, P136, DOI 10.5966/sctm.2012-0125
   LOPEZ R, 1987, INVEST OPHTH VIS SCI, V28, P1131
   Lu B, 2010, EXP EYE RES, V91, P449, DOI 10.1016/j.exer.2010.06.024
   Lu B, 2010, INVEST OPHTH VIS SCI, V51, P2269, DOI 10.1167/iovs.09-4526
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu B, 2014, DEV OPHTHALMOL, V53, P155, DOI 10.1159/000357375
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   Lu LC, 2001, BIOMATERIALS, V22, P291, DOI 10.1016/S0142-9612(00)00179-4
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   Luo J, 2014, J BIOL CHEM, V289, P6362, DOI 10.1074/jbc.M113.513713
   Lustremant C, 2013, CELL REPROGRAM, V15, P233, DOI 10.1089/cell.2012.0076
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Maehr R, 2009, P NATL ACAD SCI USA, V106, P15768, DOI 10.1073/pnas.0906894106
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Majji AB, 2000, GRAEF ARCH CLIN EXP, V238, P779, DOI 10.1007/s004170000132
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MCCONNELL DG, 1965, J CELL BIOL, V27, P459, DOI 10.1083/jcb.27.3.459
   MCGILL MG, 1988, VISION RES, V28, P761, DOI 10.1016/0042-6989(88)90022-3
   McGill TJ, 2004, INVEST OPHTH VIS SCI, V45, P932, DOI 10.1167/iovs.03-0964
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Melville H, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-53
   Merani R, 2007, AM J OPHTHALMOL, V144, P364, DOI 10.1016/j.ajo.2007.05.027
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mooney I, 2011, STEM CELLS CLONING, V4, P1, DOI 10.2147/SCCAA.S7674
   Murphy SP, 2011, IMMUNOL REV, V241, P39, DOI 10.1111/j.1600-065X.2011.01009.x
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Mylonas G, 2013, AM J OPHTHALMOL, V155, P253, DOI 10.1016/j.ajo.2012.07.013
   NABI IR, 1993, J CELL SCI, V104, P37
   Nadri S, 2013, MOL BIOL REP, V40, P3883, DOI 10.1007/s11033-012-2360-y
   Nadri S, 2013, NEUROSCI LETT, V541, P43, DOI 10.1016/j.neulet.2012.12.055
   Nakajima F, 2007, STEM CELLS, V25, P983, DOI 10.1634/stemcells.2006-0566
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nishida A, 2000, INVEST OPHTH VIS SCI, V41, P4268
   Nistor G, 2010, J NEUROSCI METH, V190, P63, DOI 10.1016/j.jneumeth.2010.04.025
   Okamura RM, 2007, J NEUROIMMUNOL, V192, P134, DOI 10.1016/j.jneuroim.2007.09.030
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Osusky R, 1997, OCUL IMMUNOL INFLAMM, V5, P43, DOI 10.3109/09273949709085049
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pan CK, 2013, EXPERT OPIN BIOL TH, V13, P1125, DOI 10.1517/14712598.2013.793304
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031
   Park Un Chul, 2011, Clin Exp Reprod Med, V38, P216, DOI 10.5653/cerm.2011.38.4.216
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   PERCOPO CM, 1990, J IMMUNOL, V145, P4101
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Pinilla I, 2005, VISION RES, V45, P635, DOI 10.1016/j.visres.2004.09.014
   Pinilla I, 2007, EXP EYE RES, V85, P381, DOI 10.1016/j.exer.2007.06.002
   Polosukhina A, 2012, NEURON, V75, P271, DOI 10.1016/j.neuron.2012.05.022
   Preynat-Seauve O, 2009, J CELL MOL MED, V13, P3556, DOI 10.1111/j.1582-4934.2009.00746.x
   Prusky GT, 2000, VISION RES, V40, P2201, DOI 10.1016/S0042-6989(00)00081-X
   Qiu GT, 2005, EXP EYE RES, V80, P515, DOI 10.1016/j.exer.2004.11.001
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Rashid ST, 2010, J CLIN INVEST, V120, P3127, DOI 10.1172/JCI43122
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Ribeiro RM, 2013, OSLI RETINA, V44, P380, DOI 10.3928/23258160-20130715-09
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5
   RIZZOLO LJ, 1990, EXP EYE RES, V51, P435, DOI 10.1016/0014-4835(90)90156-O
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rose JB, 2014, MATERIALS, V7, P3106, DOI 10.3390/ma7043106
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sauve Y, 2006, VISION RES, V46, P1459, DOI 10.1016/j.visres.2005.11.009
   Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seiler MJ, 2010, EUR J NEUROSCI, V31, P508, DOI 10.1111/j.1460-9568.2010.07085.x
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Sergijenko A, 2013, MOL THER, V21, P1938, DOI 10.1038/mt.2013.141
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Simara P, 2013, TRANSL RES, V161, P284, DOI 10.1016/j.trsl.2013.01.001
   SIMINOFF R, 1966, J COMP NEUROL, V127, P435, DOI 10.1002/cne.901270402
   SLOAN DJ, 1991, TRENDS NEUROSCI, V14, P341, DOI 10.1016/0166-2236(91)90159-R
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Stanga Paulo E., 2001, International Ophthalmology, V23, P297, DOI 10.1023/A:1014482025960
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Strauss O, 1998, ACTA ANAT, V162, P101
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Suga A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094556
   Sugino IK, 2014, DEV OPHTHALMOL, V53, P133, DOI 10.1159/000358531
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Sugita S, 2006, EXP EYE RES, V83, P1459, DOI 10.1016/j.exer.2006.08.005
   Sugita S, 2010, INVEST OPHTH VIS SCI, V51, P5783, DOI 10.1167/iovs.09-5098
   Sugita S, 2009, J IMMUNOL, V183, P5013, DOI 10.4049/jimmunol.0901623
   Sugita S, 2008, J IMMUNOL, V181, P7525, DOI 10.4049/jimmunol.181.11.7525
   Sugita S, 2009, INVEST OPHTH VIS SCI, V50, P2862, DOI 10.1167/iovs.08-2846
   Sun DM, 2003, J NEUROIMMUNOL, V144, P1, DOI 10.1016/S0165-5728(03)00248-0
   Sun K, 2007, MOL VIS, V13, P2310
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, MOL VIS, V5
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tan Y, 2014, CURR STEM CELL RES T, V9, P63
   Tang C, 2011, SEMIN IMMUNOPATHOL, V33, P563, DOI 10.1007/s00281-011-0269-5
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Taylor CJ, 2005, LANCET, V366, P2019, DOI 10.1016/S0140-6736(05)67813-0
   Tezcaner A, 2003, BIOMATERIALS, V24, P4573, DOI 10.1016/S0142-9612(03)00302-8
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thaung C, 2002, NEUROSCI LETT, V325, P21, DOI 10.1016/S0304-3940(02)00223-9
   Thomas BB, 2004, EXP EYE RES, V79, P29, DOI 10.1016/j.exer.2004.02.016
   Thomas BB, 2010, NEUROSCI LETT, V479, P92, DOI 10.1016/j.neulet.2010.05.031
   Thompson S, 2008, VISION RES, V48, P346, DOI 10.1016/j.visres.2007.07.020
   Thompson S, 2014, INVEST OPHTH VIS SCI, V55, P1859, DOI 10.1167/iovs.13-13661
   Thomson HA, 2010, J BIOMED MATER RES A, V95A, P1233, DOI 10.1002/jbm.a.32940
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Timmins NE, 2009, BIOTECHNOL BIOENG, V104, P832, DOI 10.1002/bit.22433
   Tochitsky I, 2014, NEURON, V81, P800, DOI 10.1016/j.neuron.2014.01.003
   Tolentino MJ, 2014, EXPERT OPIN INV DRUG, V22, P1
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Tomkins-Netzer O, 2014, OPHTHALMOLOGY, V121, P1649, DOI 10.1016/j.ophtha.2014.02.003
   Tomoda K, 2012, CELL STEM CELL, V11, P91, DOI 10.1016/j.stem.2012.05.019
   Treharne AJ, 2011, BRIT J OPHTHALMOL, V95, P768, DOI 10.1136/bjo.2010.184002
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Tucker BA, 2010, BIOMATERIALS, V31, P9, DOI 10.1016/j.biomaterials.2009.09.015
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Virgili G, 2007, COCHRANE DB SYST REV, V3
   Vugler A, 2007, MECH DEVELOP, V124, P807, DOI 10.1016/j.mod.2007.08.002
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P416, DOI 10.1167/iovs.07-0992
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
   Wang YD, 2003, J BIOMED MATER RES A, V66A, P192, DOI 10.1002/jbm.a.10534
   Warfvinge K, 2005, ARCH OPHTHALMOL-CHIC, V123, P1385, DOI 10.1001/archopht.123.10.1385
   Warfvinge K, 2006, CELL TRANSPLANT, V15, P603, DOI 10.3727/000000006783981594
   Webber A, 2011, TRANSPLANTATION, V91, P1057, DOI 10.1097/TP.0b013e3182145306
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Wenkel H, 1998, INVEST OPHTH VIS SCI, V39, P1823
   Whiteley SJO, 1996, EXP NEUROL, V140, P100, DOI 10.1006/exnr.1996.0120
   Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0
   Wright KL, 2006, TRENDS IMMUNOL, V27, P405, DOI 10.1016/j.it.2006.07.007
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Yang MM, 2008, MED HYPOTHESES, V70, P798, DOI 10.1016/j.mehy.2007.08.009
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zamiri P, 2006, INVEST OPHTH VIS SCI, V47, P3912, DOI 10.1167/iovs.05-1267
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhang K, 2011, NEW ENGL J MED, V365, P370, DOI 10.1056/NEJMcibr1105280
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhang L, 2015, NEUROSCI LETT, V585, P171, DOI 10.1016/j.neulet.2014.12.004
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
   Zhao JJ, 2014, J BIOL CHEM, V289, P11945, DOI 10.1074/jbc.M113.532671
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
   Zhu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054552
NR 374
TC 122
Z9 126
U1 0
U2 64
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2015
VL 48
BP 1
EP 39
DI 10.1016/j.preteyeres.2015.06.004
PG 39
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ8PE
UT WOS:000360869900001
PM 26113213
OA Green Published
DA 2022-11-30
ER

PT J
AU Fong, AHC
   Lai, TYY
AF Fong, Angie H. C.
   Lai, Timothy Y. Y.
TI Long-term effectiveness of ranibizumab for age-related macular
   degeneration and diabetic macular edema
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Review
DE ranibizumab; anti-VEGF therapy; age-related macular degeneration;
   diabetic macular edema; safety; diabetic retinopathy; cost-effectiveness
ID ENDOTHELIAL GROWTH-FACTOR; VISION-RELATED FUNCTION; PLUS PROMPT LASER;
   PHOTODYNAMIC THERAPY; COST-EFFECTIVENESS; DEFERRED LASER; RISK-FACTORS;
   CHOROIDAL NEOVASCULARIZATION; TRIAL; PHARMACOKINETICS
AB Neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) are major causes of visual impairment in the elderly population worldwide. With the aging population, the prevalence of neovascular AMD and DME has increased substantially over the recent years. Vascular endothelial growth factor (VEGF) has been implicated as playing an important role in the pathogenesis of both neovascular AMD and DME. Since its introduction in 2006, ranibizumab, a recombinant, humanized, monoclonal antibody fragment against all isoforms of VEGF-A, has revolutionized the treatment of neovascular AMD and DME. The efficacy and safety of ranibizumab in neovascular AMD has been demonstrated in the ANCHOR and MARINA trials. Further studies including the PIER, PrONTO, and SUSTAIN trials have also evaluated the optimal dosing regimen of ranibizumab in neovascular AMD. The CATT and IVAN trials compared the safety and efficacy of ranibizumab with off-label use of bevacizumab. Studies such as SUSTAIN and HORIZON have shown that ranibizumab has a good safety profile and is well tolerated for over 4 years with very few serious ocular and systemic adverse events. For DME, Phase II RESOLVE study and Phase III RISE and RIDE studies have demonstrated superiority of ranibizumab treatment in improving vision over placebo controls. Phase II READ and Phase III RESOLVE and REVEAL studies have shown that ranibizumab is more effective both as monotherapy and in combination with laser compared with laser monotherapy. The 3-year results from the DRCRnet protocol I study found that ranibizumab with deferred laser resulted in better long-term visual outcome compared with ranibizumab with prompt laser. This review summarizes various important clinical trials on the long-term efficacy and safety of ranibizumab in the treatment of neovascular AMD and DME. The pharmacological properties of ranibizumab, its cost effectiveness, and impact on quality of life will also be discussed.
C1 [Fong, Angie H. C.; Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
   [Lai, Timothy Y. Y.] 2010 Retina & Macula Ctr, Kowloon, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Lai, TYY (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk
RI Lai, Timothy Y Y/AAC-2120-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428
FU Allergan Inc; Bayer Healthcare; Heidelberg Engineering; Novartis
   Pharmaceutical Inc.
FX Dr Lai has received honorarium for consultancy and lecture fees from
   Allergan Inc, Bayer Healthcare, Heidelberg Engineering, and Novartis
   Pharmaceutical Inc. Dr Fong has no conflicts of interest in this work.
CR Bandello F, 2012, INVEST OPHTHALMOL VI, V53
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chaikitmongkol V, 2013, JAMA OPHTHALMOL, V131, P260, DOI 10.1001/jamaophthalmol.2013.1733
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Do DV, 2013, JAMA OPHTHALMOL, V131, P139, DOI 10.1001/2013.jamaophthalmol.91
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Elman MJ, 2012, OPHTHALMOLOGY, V119, P2312, DOI 10.1016/j.ophtha.2012.08.022
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   European Medicines Agency, 2012, EMA6462562012
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Frampton JE, 2012, DRUGS, V72, P509, DOI 10.2165/11208410-000000000-00000
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grover D, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005656.pub2
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Mitchell P, 2012, INVEST OPHTH VIS SCI, V53, P4667
   Mitchell P, 2012, BRIT J OPHTHALMOL, V96, P688, DOI 10.1136/bjophthalmol-2011-300726
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Ohji M, 2012, INVEST OPHTHALMOL VI, V53
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Presta LG, 1997, CANCER RES, V57, P4593
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 61
TC 28
Z9 29
U1 0
U2 17
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2013
VL 8
BP 467
EP 482
DI 10.2147/CIA.S36811
PG 16
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 133OT
UT WOS:000318148800001
PM 23766636
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, YM
   Kim, JH
   Koh, HJ
AF Kim, Yong Min
   Kim, Ji Hyun
   Koh, Hyoung Jun
TI Improvement of Photoreceptor Integrity and Associated Visual Outcome in
   Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL VEIN OCCLUSION; CENTRAL SEROUS
   CHORIORETINOPATHY; PHOTODYNAMIC THERAPY; OUTER SEGMENT; RANIBIZUMAB;
   ACUITY; LAYER; RESOLUTION; EDEMA
AB PURPOSE: To evaluate the association between improvement of photoreceptor integrity and visual acuity (VA) after anti vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (AMD).
   DESIGN: Retrospective, cross-sectional study.
   METHODS: Eighty-seven eyes of 84 patients who were newly diagnosed with neovascular AMD and treated with anti-VEGF injections were reviewed retrospectively. Using spectral-domain optical coherence tomography, the status of the inner segment/outer segment photoreceptor junction (IS/OS) was graded and classified into 3 groups at baseline and 1 and 2 months after 3 monthly injections. The proportion of the improved IS/OS line after treatment was analyzed and correlated with VA.
   RESULTS: The number of eyes in the IS/OS+ group, representing disrupted IS/OS line less than 200 mu m, was increased from 9 (10%) at baseline to 33 (38%) at 1 month. There was a significant difference in the ratio of IS/OS+ group between baseline and 1 month (P < .001). Those in the IS/OS+ group, showing focal disrupted IS/OS line between 200 and 800 mu m, decreased from 29 (33%) to 22 eyes (25%). Improvement of the IS/OS line at 1 month compared to baseline was noted in 43 eyes (49%) and correlated with better VA (P < .016). No increase of VA was observed in 44 eyes without definite improvement. There was no significant correlation between improvement of the IS/OS line and VA from 1 to 2 months.
   CONCLUSIONS: Assessing the change of the photoreceptor integrity before and after treatment would be a useful indicator to predict initial response to treatment and visual prognosis in patients with neovascular AMD. (Am J Ophthalmol 2012;154:164-173. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Kim, Yong Min; Koh, Hyoung Jun] Yonsei Univ, Dept Ophthalmol, Coll Med, Inst Vis Res, Seoul 120752, South Korea.
   [Kim, Ji Hyun] Siloam Eye Hosp, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Koh, HJ (通讯作者)，Yonsei Univ, Dept Ophthalmol, Coll Med, Inst Vis Res, 134 Shinchon Dong, Seoul 120752, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P417, DOI 10.1097/00006982-200506000-00004
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Ojima Y, 2010, JPN J OPHTHALMOL, V54, P55, DOI 10.1007/s10384-009-0766-4
   Ota M, 2008, RETINA-J RET VIT DIS, V28, P1502, DOI 10.1097/IAE.0b013e3181840b3c
   Ota M, 2007, BRIT J OPHTHALMOL, V91, P1644, DOI 10.1136/bjo.2007.118497
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakamoto A, 2009, GRAEF ARCH CLIN EXP, V247, P1325, DOI 10.1007/s00417-009-1107-5
   Sano M, 2009, AM J OPHTHALMOL, V147, P313, DOI 10.1016/j.ajo.2008.08.002
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Shimoda Y, 2010, AM J OPHTHALMOL, V149, P284, DOI 10.1016/j.ajo.2009.08.025
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P111, DOI 10.1016/j.ajo.2008.02.027
   Villate N, 2005, AM J OPHTHALMOL, V139, P280, DOI 10.1016/j.ajo.2004.09.029
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Yamaike N, 2008, OPHTHALMOLOGY, V115, P355, DOI 10.1016/j.ophtha.2007.04.052
NR 24
TC 20
Z9 22
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2012
VL 154
IS 1
BP 164
EP 173
DI 10.1016/j.ajo.2012.01.030
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 966XX
UT WOS:000305871800022
PM 22541932
DA 2022-11-30
ER

PT J
AU Wykoff, CC
   Brown, DM
   Chen, E
   Major, JC
   Croft, DE
   Mariani, A
   Wong, TP
AF Wykoff, Charles C.
   Brown, David M.
   Chen, Eric
   Major, James C.
   Croft, Daniel E.
   Mariani, Angeline
   Wong, Tien P.
CA Save Study Grp
TI SAVE (Super-dose Anti-VEGF) Trial: 2.0 mg Ranibizumab for Recalcitrant
   Neovascular Age-Related Macular Degeneration: 1-Year Results
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID TRAP-EYE
AB OBJECTIVES: To assess durability of visual and anatomic gains with 2.0 mg ranibizumab in recalcitrant neovascular age-related macular degeneration (AMD).
   METHODS: Phase I-II trial of 88 patients with recalcitrant neovascular AMD treated as needed every 4 (cohort A) or 6 weeks (cohort B) following three monthly doses. ETDRS refraction and spectral-domain OCT-guided as-needed re-treatments.
   RESULTS: Seventy-nine patients completed the 12-month endpoint and were given 11.6 (cohort A) and 8.6 (cohort B) mean treatments. Mean best corrected visual acuity gains of 4.1 letters following three monthly doses were sustained for 12 months for both cohorts. Anatomic improvements were sustained for 12 months for cohort A, but not for cohort B; cohort B demonstrated a gradual increase in mean central retinal thickness (P = .03).
   CONCLUSION: Visual and anatomic gains achieved with 2.0 mg ranibizumab in recalcitrant neovascular AMD were sustained for 1 year with monthly treatment. In comparison, anatomic gains were diminished with less than monthly treatment.
RP Wykoff, CC (通讯作者)，6560 Fannin St,Suite 750, Houston, TX 77030 USA.
EM ccwmd@houstonretina.com
FU Genentech
FX The authors received a research grant from Genentech. The funding
   organization had no role in the design or conduct of this research.
CR Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Busbee BG, 2013, OPHTHALMOLOGY, DOI [10.1016/j.oph-tha.2012.10.014, DOI 10.1016/J.0PH-THA.2012.10.014]
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
NR 15
TC 20
Z9 21
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2013
VL 44
IS 2
BP 121
EP 126
DI 10.3928/23258160-20130313-04
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 172PS
UT WOS:000321017200004
PM 23510037
DA 2022-11-30
ER

PT J
AU Nussenblatt, RB
   Lee, RWJ
   Chew, E
   Wei, L
   Liu, BY
   Sen, HN
   Dick, AD
   Ferris, FL
AF Nussenblatt, Robert B.
   Lee, Richard W. J.
   Chew, Emily
   Wei, Lai
   Liu, Baoying
   Sen, H. Nida
   Dick, Andrew D.
   Ferris, Frederick L.
TI Immune Responses in Age-Related Macular Degeneration and a Possible
   Long-term Therapeutic Strategy for Prevention
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID T-CELL; DOUBLE-BLIND; INFLAMMATION; ASSOCIATION; INVOLVEMENT;
   PREVALENCE; DISEASE
AB PURPOSE: To describe the immune alterations associated with age-related macular degeneration (AMD); and, based on these findings, to offer an approach to possibly prevent the expression of late disease.
   DESIGN: Perspective.
   METHODS: Review of the existing literature dealing with epidemiology, models, and immunologic findings in patients.
   RESULTS: Significant genetic associations have been identified and reported, but environmentally induced (including epigenetic) changes are also an important consideration. Immune alterations include a strong interleukin 17 family signature as well as marked expression of these molecules in the eye. Oxidative stress as well as other homeostatic altering mechanisms occur throughout life. With this immune dysregulation there is a rationale for considering immunotherapy. Indeed, immunotherapy has been shown to affect the late stages of AMD.
   CONCLUSION: Immune dysregulation appears to be an underlying alteration in AMD, as in other diseases thought to be degenerative and attributable to aging. Para-inflammation and immunosenescence may importantly contribute to the development of disease. The role of complement factor H still needs to be better defined, but in light of its association with ocular inflammatory conditions such as sarcoidosis, it does not appear to be unique to AMD but rather may be a marker for retinal pigment epithelium function. With the strong interleukin 17 family signature and the need to treat early on in the disease process, oral tolerance may be considered to prevent disease progression. Published by Elsevier Inc.
C1 [Nussenblatt, Robert B.; Chew, Emily; Wei, Lai; Liu, Baoying; Sen, H. Nida; Ferris, Frederick L.] NEI, NIH, Bethesda, MD 20892 USA.
   [Lee, Richard W. J.; Dick, Andrew D.] Moorfields Eye Hosp Natl Hlth Serv Fdn Trust, NIH, Res Biomed Res Ctr, Bristol, Avon, England.
   [Lee, Richard W. J.; Dick, Andrew D.] Univ Coll London, Inst Ophthalmol, Univ Hosp Bristol, Natl Hlth Serv,Fdn Trust, Bristol, Avon, England.
   [Lee, Richard W. J.; Dick, Andrew D.] Univ Bristol, Bristol, Avon, England.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; NHS Blood & Transplant (NHSBT);
   University of Bristol; University of London; University College London;
   University of Bristol
RP Nussenblatt, RB (通讯作者)，NEI, Immunol Lab, NIH, 10 Ctr Lane, Bethesda, MD 20892 USA.
EM DrBob@nei.nih.gov
RI Lee, Richard/A-3116-2017
OI Lee, Richard/0000-0002-9480-6843; Dick, Andrew/0000-0002-0742-3159;
   Ferris, Frederick/0000-0002-4933-0639
FU Novartis; Abbvie; Roche-Genentech; National Institute for Health
   Research Biomedical Research Centre based at Moorfields Eye Hospital NHS
   Foundation Trust and University College London Institute of
   Ophthalmology; NATIONAL EYE INSTITUTE [ZIAEY000278, ZIAEY000485,
   ZIAEY000501, ZIAEY000464] Funding Source: NIH RePORTER
FX A.D.D. is a consultant for Novartis and received payment for lectures
   from Abbvie. R.W.J.L. is a consultant for Roche-Genentech. Patents for
   A.D.D. and R.W.J.L. are through the University of Bristol and National
   Institutes of Health (NIH). Patents for R.B.N. are through the
   University of Bristol and NIH. Support for all the NIH authors came from
   intramural funds. For A.D.D. and R.W.J.L., this work was partly
   supported by the National Institute for Health Research Biomedical
   Research Centre based at Moorfields Eye Hospital NHS Foundation Trust
   and University College London Institute of Ophthalmology. The views
   expressed are those of the author(s) (R.W.J.L., ADD.) and not
   necessarily those of the National Health Service, the National Institute
   for Health Research, or the Department of Health. Contributions of
   authors: conception and design (R.B.N., F.F., H.N.S.); analysis and
   interpretation (R.B.N., F.L.F., E.C.); writing the article (R.B.N.,
   A.D.D., H.N.S., E.C., R.W.J.L., B.L., L.W.); critical revision of the
   article (R.B.N., R.W.J.L., F.L.F., E.C., H.N.S., A.D.D.); final approval
   of the article (R.B.N., A.D.D., H.N.S., E.C., R.W.J.L., B.L., L.W.,
   F.L.F.); data collection (R.B.N., F.L.F., H.N.S.); provision of
   materials, etc (R.B.N., F.L.F.); statistical expertise (F.L.F.);
   obtaining funding (R.B.N., F.L.F.); literature search (R.B.N., R.W.J.L.,
   F.L.F., H.N.S., A.D.D., L.W., B.L.); administrative support, etc
   (R.B.N., F.L.F.).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   [Anonymous], 2013, PLOS ONE, V8
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chou JP, 2013, CURR PHARM DESIGN, V19, P1680
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x
   FAUCI AS, 1979, J RETICULOENDOTH SOC, V26, P727
   Felinski EA, 2008, EXP EYE RES, V86, P867, DOI 10.1016/j.exer.2008.01.002
   Ferrara DC, 2008, ARCH OPHTHALMOL-CHIC, V126, P1562, DOI 10.1001/archopht.126.11.1562
   Fordham JB, 2012, SCI REP-UK, V2, DOI 10.1038/srep00512
   Forrester JV, 2013, EYE, V27, P340, DOI 10.1038/eye.2012.265
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geltzer A, 2013, COCHRANE DB SYST REV, V1
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kapp K, 2010, EUR J IMMUNOL, V40, P3128, DOI 10.1002/eji.201040701
   Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Koffeman EC, 2009, ARTHRITIS RHEUM-US, V60, P3207, DOI 10.1002/art.24916
   Lee RWJ, 2007, J IMMUNOL, V179, P7941, DOI 10.4049/jimmunol.179.11.7941
   Lee RWJ, 2009, INVEST OPHTH VIS SCI, V50, P4273, DOI 10.1167/iovs.08-3152
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Macaulay R, 2013, AGE, V35, P563, DOI 10.1007/s11357-012-9381-2
   Malaguarnera M, 2012, J CANCER RES THER, V8, P520, DOI 10.4103/0973-1482.106527
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Nussenblatt RB, 1997, AM J OPHTHALMOL, V123, P583, DOI 10.1016/S0002-9394(14)71070-0
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pawelec G, 2005, IMMUNOL REV, V205, P257, DOI 10.1111/j.0105-2896.2005.00271.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Postlethwaite AE, 2008, ARTHRITIS RHEUM-US, V58, P1810, DOI 10.1002/art.23501
   Riley JL, 2009, IMMUNITY, V30, P656, DOI 10.1016/j.immuni.2009.04.006
   Schmitt V, 2013, EXP GERONTOL, V48, P1379, DOI 10.1016/j.exger.2013.09.003
   Schwartz M, 2010, NAT REV NEUROL, V6, P405, DOI 10.1038/nrneurol.2010.71
   Thompson IA, 2013, AM J OPHTHALMOL, V155, P1068, DOI 10.1016/j.ajo.2013.01.019
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   United Nation, 2001, WORLD POP PROSP 2000
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   World Health Organization, 2012, PREV BLINDN VIS IMP
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
NR 53
TC 47
Z9 48
U1 0
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2014
VL 158
IS 1
BP 5
EP 11
DI 10.1016/j.ajo.2014.03.014
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK0IY
UT WOS:000338097300003
PM 24709810
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Azad, RV
   Khan, MA
   Chanana, B
   Azad, S
AF Azad, Raj Vardhan
   Khan, Mansur Ali
   Chanana, Bhuvan
   Azad, Shorya
TI Intravitreal bevacizumab for subfoveal choroidal neovascularization
   secondary to age-related macular degeneration in an Indian population
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization
ID AVASTIN; INJECTION; THERAPY; SAFETY
AB Purpose: To investigate the 6-month safety profile and clinical outcomes of intravitreal bevacizumab for treating subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
   Methods: We performed a prospective nonrandomized interventional study of 40 consecutive patients (40 eyes) with subfoveal CNV due to AMD. Patients underwent standard ophthalmic examination, optical coherence tomography, and fundus fluorescein angiography. All patients were administered one or more intravitreal injections of bevacizumab (1.25 mg) as primary therapy. Outcomes were also analyzed in subgroups based on lesion type (classic or occult) and lesion size (<= 3000 mu m or > 3000 mu m).
   Results: At the 6 months' follow-up, mean best-corrected visual acuity (BCVA) improved from 20/160 to 20/100 (P = 0.014), and the mean contrast sensitivity improved from 0.38 to 0.62 (P = 0.001). The mean greatest linear diameter and mean central macular thickness significantly decreased from 3.79 mm to 2.4 mm (P = 0.0001) and from 438.5 mu m to 363 mu m (P = 0.0001), respectively. Visual acuity gain of 15 letters or more was seen in 20% of patients, and the gain was more in the small-lesion subgroup (31.5%) than in the large-lesion subgroup (9.5%). No significant adverse effects were observed.
   Conclusions: Intravitreal bevacizumab is a safe and effective modality for treatment of CNV secondary to AMD. A significant improvement in BCVA with intravitreal bevacizumab was observed for all lesion types.
C1 [Azad, Raj Vardhan; Khan, Mansur Ali; Chanana, Bhuvan; Azad, Shorya] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Vitreo Retina Serv, New Delhi 110025, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences
RP Chanana, B (通讯作者)，All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Vitreo Retina Serv, 91 Pocket B,Sukhdev Vihar, New Delhi 110025, India.
EM bhuvan_chanana@rediffmail.com
OI Khan, Mansur/0000-0002-0289-156X
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Myint K, 2006, ACTA OPHTHALMOL SCAN, V84, P328, DOI 10.1111/j.1600-0420.2005.00623.x
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   RYAN SJ, 1980, GRAEFES ARCH CLIN EX, V215, P1
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   TEETERS VW, 1973, AM J OPHTHALMOL, V76, P1
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
NR 22
TC 19
Z9 21
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD FEB
PY 2008
VL 52
IS 1
BP 52
EP 56
DI 10.1007/s10384-007-0496-4
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 280PM
UT WOS:000254438700009
PM 18369701
DA 2022-11-30
ER

PT J
AU Lappas, A
   Foerster, AMH
   Weinberger, AWA
   Coburger, S
   Schrage, NF
   Kirchhof, B
AF Lappas, A
   Foerster, AMH
   Weinberger, AWA
   Coburger, S
   Schrage, NF
   Kirchhof, B
TI Translocation of iris pigment epithelium in patients with exudative
   age-related macular degeneration: long-term results
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULAR MEMBRANES; SURGICAL REMOVAL; GEOGRAPHIC ATROPHY;
   SUBFOVEAL NEOVASCULARIZATION; LASER PHOTOCOAGULATION; SUBMACULAR
   HEMORRHAGE; TRANSPLANTATION; SURGERY; CELLS; MANAGEMENT
AB Purpose: To report the practicability and efficacy of autologous iris pigment epithelium (IPE) translocation in exudative age-related macular degeneration (ARMD) over 1 year. Methods: The consecutive interventional case series included 56 patients with exudative ARMD. During vitrectomy the submacular neovascular membrane (CNV) was removed and IPE cells, harvested from a peripheral iridectomy, were injected into the submacular space. Included were patients with subfoveal occult CNV (11 eyes), classic CNV (10 eyes), mixed CNV (17 eyes), CNV with a pigment epithelial detachment (13 eyes) or CNV with a hemorrhage (5 eyes). Outcome measures were visual acuity, foveal fixation, size of CNV and rate of recurrence based on fluorescence angiographic imaging. Results: All patients underwent successful surgical removal of the CNV with consecutive subretinal IPE injection. Visual acuity was better than 20/100 in 19 patients preoperatively and in 18 patients postoperatively. A visual acuity of 20/100 or less was found in 37 patients preoperatively and in 38 patients postoperatively. Mean preoperative visual acuity (1.0+/-0.3 logMAR units) did not change significantly after 1 year (1.0+/-0.3 logMAR units). Ten eyes (18%) developed a recurrence. Fixation within the surgically denuded area could be demonstrated in 25 eyes (45%). Conclusions: Autologous IPE translocation for ARMD over one year can preserve foveal function on a low level, but cannot improve visual acuity. IPE translocation is technically feasible with a low rate of complications. Continued research seems justified to improve functional outcome.
C1 Univ Aachen, Dept Ophthalmol, D-52057 Aachen, Germany.
   Univ Cologne, Dept Ophthalmol, Cologne, Germany.
   Univ Cologne, Dept Med Stat Informat & Epidemiol, Cologne, Germany.
C3 RWTH Aachen University; University of Cologne; University of Cologne
RP Lappas, A (通讯作者)，Univ Aachen, Dept Ophthalmol, Pauwelsstr 30, D-52057 Aachen, Germany.
EM alappas2000@yahoo.com
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   HSU JK, 1995, RETINA-J RET VIT DIS, V15, P43, DOI 10.1097/00006982-199515010-00009
   HUDSON HL, 1995, BRIT J OPHTHALMOL, V79, P417, DOI 10.1136/bjo.79.5.417
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kociok N, 1998, EXP EYE RES, V67, P237, DOI 10.1006/exer.1998.0517
   LAMBERT HM, 1993, CURR OPIN OPHTHALMOL, V4, P19, DOI 10.1097/00055735-199306000-00004
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   Loewenstein A, 1998, AM J OPHTHALMOL, V125, P657, DOI 10.1016/S0002-9394(98)00014-2
   Machemer R, 1998, AM J OPHTHALMOL, V125, P698, DOI 10.1016/S0002-9394(98)00020-8
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   ORMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Rezai KA, 1997, EXP EYE RES, V65, P23, DOI 10.1006/exer.1997.0307
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P558, DOI 10.1007/BF00947084
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Schraermeyer U, 1999, INVEST OPHTH VIS SCI, V40, P1545
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thumann G, 1998, GRAEF ARCH CLIN EXP, V236, P753, DOI 10.1007/s004170050154
   Toonen F, 1995, Ger J Ophthalmol, V4, P311
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
NR 40
TC 33
Z9 36
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2004
VL 242
IS 8
BP 638
EP 647
DI 10.1007/s00417-003-0764-z
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 855EP
UT WOS:000223956300004
PM 15300442
OA Green Published
DA 2022-11-30
ER

PT J
AU Tanaka, K
   Oguchi, Y
   Omori, T
   Ishida, Y
   Shintake, H
   Tomita, R
   Kasai, A
   Ogasawara, M
   Sugano, Y
   Itagaki, K
   Ojima, A
   Machida, T
   Sekine, H
   Sekiryu, T
AF Tanaka, Keiichiro
   Oguchi, Yasuharu
   Omori, Tomoko
   Ishida, Yumi
   Shintake, Hiroaki
   Tomita, Ryutaro
   Kasai, Akihito
   Ogasawara, Masashi
   Sugano, Yukinori
   Itagaki, Kanako
   Ojima, Akira
   Machida, Takeshi
   Sekine, Hideharu
   Sekiryu, Tetsuju
TI Changes in complement activation products after anti-VEGF injection for
   choroidal neovascularization in age-related macular degeneration and
   pachychoroid disease
SO SCIENTIFIC REPORTS
LA English
DT Article
AB We evaluated changes in the complement system resulting from anti-vascular endothelial growth factor (VEGF) in eyes with age-related choroidal neovascularization (CNV) including neovascular age-related macular degeneration, pachychoroid neovasculopathy, and polypoidal choroidal neovasculopathy. We measured the concentrations of the complement activation products (C3a, C4a), VEGF, and monocyte chemotactic protein-1 in the aqueous humor during intravitreal anti-VEGF injections for CNV. The VEGF level decreased significantly (P<0.001), while the C3a and C4a levels increased significantly (P<0.001 for both comparisons) 1 month after two monthly anti-VEGF injections. The VEGF level was correlated with the C3a (R=0.328, P=0.007) and C4a (R=-0.237, P=0.055) levels at baseline, but the correlation between the VEGF and C3a levels (R=-0.148, P=0.242) changed significantly (P=0.028 by analysis of covariance) after anti-VEGF treatment. The C3a increase after anti-VEGF therapy did not change the visual outcomes in eyes with CNV for 1 year. Dysregulation of the complement system can be induced after anti-VEGF therapy.
C1 [Tanaka, Keiichiro; Oguchi, Yasuharu; Shintake, Hiroaki; Tomita, Ryutaro; Kasai, Akihito; Ogasawara, Masashi; Sugano, Yukinori; Itagaki, Kanako; Ojima, Akira; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima 9601295, Japan.
   [Omori, Tomoko; Ishida, Yumi; Machida, Takeshi; Sekine, Hideharu] Fukushima Med Univ, Dept Immunol, Fukushima 9601295, Japan.
C3 Fukushima Medical University; Fukushima Medical University
RP Sekiryu, T (通讯作者)，Fukushima Med Univ, Dept Ophthalmol, Fukushima 9601295, Japan.
EM sekiryu@fmu.ac.jp
FU JSPS KAKENHI [JP17K11427]
FX JSPS KAKENHI Grant Number JP17K11427 supported this work.
CR Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Greenberg JP, 2019, OPHTHALMOL RETINA, V3, P753, DOI 10.1016/j.oret.2019.04.006
   Hara C, 2019, GRAEF ARCH CLIN EXP, V257, P2559, DOI 10.1007/s00417-019-04456-2
   HUGLI T E, 1986, Complement, V3, P111
   Itagaki K, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01542-6
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koike N, 2019, CLIN OPHTHALMOL, V13, P1247, DOI 10.2147/OPTH.S206910
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Luo C, 2011, MOL VIS, V17, P1588
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maruko I, 2020, OPHTHALMOL RETINA, V4, P767, DOI 10.1016/j.oret.2020.03.010
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Omori T, 2020, OPHTHALMIC RES, V63, P252, DOI 10.1159/000503258
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Paraoan L, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100859
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Sato T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55191-x
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Takahashi H, 2016, INVEST OPHTH VIS SCI, V57, P462, DOI 10.1167/iovs.15-18245
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Vignesh P, 2017, CLIN CHIM ACTA, V465, P123, DOI 10.1016/j.cca.2016.12.017
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Williams PD, 2016, RETINA-J RET VIT DIS, V36, P909, DOI 10.1097/IAE.0000000000000801
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 40
TC 3
Z9 3
U1 0
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 19
PY 2021
VL 11
IS 1
AR 8464
DI 10.1038/s41598-021-87340-6
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA RQ7FC
UT WOS:000642579300001
PM 33875685
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kovacevic, D
   Misljenovic, T
   Njiric, S
   Mikulicic, M
   Vojnikovic, B
AF Kovacevic, Damir
   Misljenovic, Tamara
   Njiric, Sanja
   Mikulicic, Masa
   Vojnikovic, Bozidar
TI Appearance of Age Related Maculopathy after Cataract Surgery
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE pseudophakia; macular degeneration; lenses; intraocular; radiation;
   non-ionizing
ID MACULAR DEGENERATION; ULTRAVIOLET-RADIATION; RISK-FACTOR; EYE;
   PHACOEMULSIFICATION
AB The pathogenesis of age-related maculopathy (ARM), the most common cause of visual loss after the age of 60 years, involves a variety of hereditary and environmental factors. When the cataractous lens is removed and replaced by clear intraocular lens, a significant increase in ocular transmittance of optical radiation occurs. The aim of this study was to assess whether cataract surgery in older persons may increase the risk for development of ARM. This is a retrospective study. Medical records of 30 7 patients, aged 43 to 96 years, (163 male and 144 female) were randomly evaluated. They had undergone cataract extraction (phacoemulsification or extracapsular lens extraction) with clear intraocular lens implantation from January 2001 to December 2005 at the Department of Ophthalmology, University Hospital Rijeka. Patients were examined two weeks after surgery and followed Up for at least two years. Based on the exclusion criteria, only patients without any sign of AMD at the first postoperative check up were included. A total of 80 patients (26%) showed development of ARM at the last check up, which was at least 2 years after surgery. Our results indicate that pseudophakia is a risk factor for development of ARM.
C1 [Kovacevic, Damir; Misljenovic, Tamara; Mikulicic, Masa] Univ Hosp Rijeka, Dept Ophthalmol, Rijeka 51000, Croatia.
   [Misljenovic, Tamara; Njiric, Sanja; Mikulicic, Masa] Eye Polyclin Dr L Pavicevic, Rijeka, Croatia.
   [Vojnikovic, Bozidar] Eye Polyclin Dr B Vojnikovic, Rijeka, Croatia.
C3 University of Rijeka; University of Rijeka
RP Kovacevic, D (通讯作者)，Univ Hosp Rijeka, Dept Ophthalmol, Kresimirova 42, Rijeka 51000, Croatia.
EM damir.kovacevic@ri.t-com.hr
RI Vuceric, Tamara Misljenovic/AAF-4128-2020
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Barisic A, 2007, COLLEGIUM ANTROPOL, V31, P57
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   LERMAN S, 1988, NEW ENGL J MED, V319, P1475, DOI 10.1056/NEJM198812013192208
   Libre PE, 2003, AM J OPHTHALMOL, V136, P961, DOI 10.1016/S0002-9394(03)00906-1
   LUI IY, 1989, AM J PUBLIC HEALTH, V79, P765
   MAINSTER MA, 1983, OPHTHALMOLOGY, V90, P927
   Matsumura Y, 2004, TOXICOL APPL PHARM, V195, P298, DOI 10.1016/j.taap.2003.08.019
   Njiric S, 2007, COLLEGIUM ANTROPOL, V31, P107
   Pham TQ, 2007, EYE, V21, P512, DOI 10.1038/sj.eye.6702254
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Situm M, 2007, COLLEGIUM ANTROPOL, V31, P13
   Smith Bradley T, 2005, Curr Opin Ophthalmol, V16, P166, DOI 10.1097/01.icu.0000163030.33401.3d
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 22
TC 8
Z9 8
U1 0
U2 1
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD OCT
PY 2008
VL 32
SU 2
BP 9
EP 10
PG 2
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 380WK
UT WOS:000261496600004
PM 19140270
DA 2022-11-30
ER

PT J
AU Niazi, S
   Nielsen, MK
   Singh, A
   Sorensen, TL
   Subhi, Y
AF Niazi, Siar
   Krogh Nielsen, Marie
   Singh, Amardeep
   Sorensen, Torben Lykke
   Subhi, Yousif
TI Prevalence of Charles Bonnet syndrome in patients with age-related
   macular degeneration: systematic review and meta-analysis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; Charles Bonnet syndrome; prevalence;
   systematic review; visual hallucinations
ID VISUAL HALLUCINATIONS; LOW-VISION; INJECTION
AB Age-related macular degeneration (AMD) is the most common cause of visual impairment in the developed world. A number of patients experience complex lifelike visual experiences-Charles Bonnet syndrome (CBS). In this systematic review, our aim was to provide an overview of the CBS literature in relation to AMD, to determine the prevalence of CBS in patients with AMD and to provide an overview of associated demographical and clinical aspects. We searched the literature databases PubMed/MEDLINE, EMBASE, Web of Science, the Cochrane Central, and PsycINFO on 22 March 2019 for studies evaluating the prevalence of CBS in patients with AMD. Two independent authors extracted the data and evaluated risk of bias. Studies were reviewed qualitatively in the text and quantitatively in a meta-analysis including subgroup analyses for differences between demographic and clinical factors. We identified 18 studies with data on >4303 patients with AMD. We found an overall prevalence of CBS of 15.8% (95% confidence interval: 11.0%-21.2%). When looking at consecutively recruited patients with neovascular AMD from the clinic, prevalence of CBS was 7.2% (95% confidence interval: 4.3%-10.6%). Among visitors to visual rehabilitation centres, prevalence of CBS was 31.6% (95% confidence interval: 21.7%-42.3%). Taken together, we find that CBS is rather common in patients with AMD.
C1 [Niazi, Siar; Krogh Nielsen, Marie; Sorensen, Torben Lykke; Subhi, Yousif] Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Niazi, Siar; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Singh, Amardeep] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Ophthalmol, Lund, Sweden.
   [Subhi, Yousif] Rigshosp Glostrup, Dept Ophthalmol, Glostrup, Denmark.
C3 University of Copenhagen; Lund University; Skane University Hospital
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020; Singh, Amardeep/ABI-4544-2020
OI Subhi, Yousif/0000-0001-6620-5365; Krogh Nielsen,
   Marie/0000-0003-3804-7296
CR Abbou EJ, 2007, INVEST OPHTH VIS SCI, V48, P1416, DOI 10.1167/iovs.06-0942
   AGRON E, 2016, INVEST OPHTH VIS SCI, V57
   Alamri SH, 2018, NEUROPSYCH DIS TREAT, V14, P809, DOI 10.2147/NDT.S161124
   Anderson D, 2004, TOP GERIATR REHABIL, V20, P204
   Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104
   Billings F Tremaine, 2008, Trans Am Clin Climatol Assoc, V119, P225
   Bonnet C, 1769, ESSAI ANAL FACULTIES
   Boxerman H, 2014, BR J VIS IMPAIR, V22, P19, DOI DOI 10.1177/0264619614557529]
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   de Morsier G, 1967, ANN MED-PSYCHOL, V128, P677
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gilmour G, 2009, CAN J OPHTHALMOL, V44, P49, DOI 10.3129/i08-169
   Gordon KD, 2016, CAN J OPHTHALMOL, V51, P3, DOI 10.1016/j.jcjo.2015.10.006
   Hedges TR, 2007, SURV OPHTHALMOL, V52, P111, DOI 10.1016/j.survophthal.2006.10.007
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT., 2022, COCHRANE HDB SYSTEMA
   HOLROYD S, 1992, AM J PSYCHIAT, V149, P1701
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hou YB, 2012, GEN HOSP PSYCHIAT, V34, P566, DOI 10.1016/j.genhosppsych.2012.05.007
   Jacob A, 2004, BMJ-BRIT MED J, V328, P1552, DOI 10.1136/bmj.328.7455.1552
   Khan JC, 2008, OPHTHAL EPIDEMIOL, V15, P202, DOI 10.1080/09286580801939320
   Lang UE, 2007, J PSYCHOPHARMACOL, V21, P553, DOI 10.1177/0269881106075275
   Lannon SP, 2006, VIS IMPAIR RES, V8, P9, DOI DOI 10.1080/13882350600805761
   Leandro JE, 2017, INVEST OPHTH VIS SCI, V58, P4138, DOI 10.1167/iovs.16-21270
   Lewis S, 2001, BMJ-BRIT MED J, V322, P1479, DOI 10.1136/bmj.322.7300.1479
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Mitrut I, 2010, EYE, V24, P1825, DOI 10.1038/eye.2010.148
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Moja MC, 2005, NEUROL SCI, V26, P168, DOI 10.1007/s10072-005-0455-0
   Nalcaci S, 2016, OPHTHALMOLOGICA, V236, P48, DOI 10.1159/000446295
   Nixon PA, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.12.022
   Roh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196481
   Sedeh FB, 2017, DAN MED J, V64
   Singh A, 2011, BRIT J OPHTHALMOL, V95, P291, DOI 10.1136/bjo.2010.179465
   SINGH A, 2014, DAN MED J, V61
   Singh A, 2012, ACTA OPHTHALMOL, V90, P476, DOI 10.1111/j.1755-3768.2010.02051.x
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   Tan CSH, 2004, BRIT J OPHTHALMOL, V88, P1325, DOI 10.1136/bjo.2004.041947
   Terao T, 1998, HUM PSYCHOPHARM CLIN, V13, P451, DOI 10.1002/(SICI)1099-1077(199808)13:6<451::AID-HUP14>3.0.CO;2-V
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   Vlassoff C, 2007, J HEALTH POPUL NUTR, V25, P47
   Vojnikovic B, 2010, COLLEGIUM ANTROPOL, V34, P45
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
   Zhang H, 2012, ACTA OPHTHALMOL, V90, pe647, DOI 10.1111/j.1755-3768.2012.02421.x
NR 47
TC 12
Z9 12
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2020
VL 98
IS 2
BP 121
EP 131
DI 10.1111/aos.14287
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA KS3BI
UT WOS:000518184100004
PM 31654492
OA Bronze
DA 2022-11-30
ER

PT J
AU Jobling, AI
   Guymer, RH
   Vessey, KA
   Greferath, U
   Mills, SA
   Brassington, KH
   Luu, CD
   Aung, KZ
   Trogrlic, L
   Plunkett, M
   Fletcher, EL
AF Jobling, A. I.
   Guymer, R. H.
   Vessey, K. A.
   Greferath, U.
   Mills, S. A.
   Brassington, K. H.
   Luu, C. D.
   Aung, K. Z.
   Trogrlic, L.
   Plunkett, M.
   Fletcher, E. L.
TI Nanosecond laser therapy reverses pathologic and molecular changes in
   age-related macular degeneration without retinal damage
SO FASEB JOURNAL
LA English
DT Article
DE vision loss; drusen; Bruch's membrane; matrix metalloproteinase
ID BRUCHS MEMBRANE IMPLICATIONS; PIGMENT EPITHELIAL-CELLS; MATRIX
   METALLOPROTEINASES; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; MOUSE
   MODEL; CONVENTIONAL PHOTOCOAGULATOR; HYDRAULIC CONDUCTIVITY; GRID
   PHOTOCOAGULATION; GLIAL-CELL
AB Age-related macular degeneration (AMD) is a leading cause of vision loss, characterized by drusen deposits and thickened Bruch's membrane (BM). This study details the capacity of nanosecond laser treatment to reduce drusen and thin BM while maintaining retinal structure. Fifty patientswithAMDhad a single nanosecond laser treatment session and after 2 yr, change in drusen area was compared with an untreated cohort of patients. The retinal effect of the laser was determined in human and mouse eyes using immunohistochemistry and compared with untreated eyes. In a mouse with thickened BM (ApoEnull), the effect of laser treatment was quantified using electron microscopy and quantitative PCR. In patients with AMD, nanosecond laser treatment reduced drusen load at 2 yr. Retinal structurewas not compromised in human and mouse retina after laser treatment, with only a discrete retinal pigment epithelium (RPE) injury, and limited mononuclear cell response observed. BM was thinned in the ApoEnull mouse 3 mo after treatment (ApoEnull treated 683 +/- 38 nm, ApoEnull untreated 890 +/- 60 nm, C57Bl6J 606 +/- 43 nm), with the expression of matrix metalloproteinase-2 and -3 increased (> 260%). Nanosecond laser resolved drusen independent of retinal damage and improved BM structure, suggesting this treatment has the potential to reduceAMD progression.Jobling, A. I., Guymer, R. H., Vessey, K. A., Greferath, U., Mills, S. A., Brassington, K. H., Luu, C. D., Aung, K. Z., Trogrlic, L., Plunkett, M., Fletcher, E. L. Nanosecond laser therapy reverses pathologic andmolecular changes in agerelated macular degeneration without retinal damage.
C1 [Jobling, A. I.; Vessey, K. A.; Greferath, U.; Mills, S. A.; Trogrlic, L.; Fletcher, E. L.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3010, Australia.
   [Guymer, R. H.; Brassington, K. H.; Luu, C. D.; Aung, K. Z.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Parkville, Vic 3010, Australia.
   [Plunkett, M.] Ellex R&D Pty Ltd, Adelaide, SA, Australia.
C3 University of Melbourne; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne
RP Fletcher, EL (通讯作者)，Univ Melbourne, Dept Anat & Neurosci, Grattan St, Parkville, Vic 3010, Australia.
EM elf@unimelb.edu.au
RI Fletcher, Erica/E-6364-2012; Trogrlic, Lidia/C-8215-2015; Jobling,
   Andrew/C-8221-2015
OI Fletcher, Erica/0000-0001-9412-9523; Trogrlic,
   Lidia/0000-0002-2127-7979; Vessey, Kirstan/0000-0003-1031-1964; Guymer,
   Robyn/0000-0002-9441-4356; Luu, Chi/0000-0002-7604-7097; Jobling,
   Andrew/0000-0002-7827-3135
FU National Health and Medical Research Council of Australia [1038220,
   1061418, 1061419, 529905]; Victorian Science Agenda; Centre for Clinical
   Research Excellence Award [529923]; Victorian Government
FX This work was supported by the National Health and Medical Research
   Council of Australia (#1038220 to E.L.F.and M.P.; #1061418 to E.L.F. and
   A.I.J.; #1061419 to E.L.F.and K.A.V.), practitioner fellowship (#529905
   to R.H.G.) and the Victorian Science Agenda ( R.H.G., E.L.F., M.P.),
   Centre for Clinical Research Excellence Award (#529923 to R.H.G.). The
   Centre for Eye Research Australia receives Operational Infrastructure
   Support from the Victorian Government.At the time of this work, M.P. was
   employed by Ellex R&D Pty Ltd. All other authors declare no competing
   interests.
CR Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Barathi VA, 2014, INVEST OPHTH VIS SCI, V55, P460, DOI 10.1167/iovs.13-11636
   BIRNGRUBER R, 1983, HEALTH PHYS, V44, P519, DOI 10.1097/00004032-198305000-00006
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Chen J, 2007, J CLIN INVEST, V117, P2758, DOI 10.1172/JCI33513
   Chidlow G, 2013, INVEST OPHTH VIS SCI, V54, P2319, DOI 10.1167/iovs.12-11204
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DIAZARAYA CM, 1995, J COMP NEUROL, V363, P53, DOI 10.1002/cne.903630106
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Eliasieh K, 2007, INVEST OPHTH VIS SCI, V48, P2824, DOI 10.1167/iovs.06-1228
   Eter N, 2008, INVEST OPHTH VIS SCI, V49, P3649, DOI 10.1167/iovs.07-1322
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Fletcher EL, 2011, PROG MOL BIOL TRANSL, V100, P211, DOI 10.1016/B978-0-12-384878-9.00006-6
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Gullapalli VK, 2008, EXP EYE RES, V86, P189, DOI 10.1016/j.exer.2007.10.009
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Guymer RH, 2001, BRIT J OPHTHALMOL, V85, P40, DOI 10.1136/bjo.85.1.40
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Jobling AI, 2013, INVEST OPHTH VIS SCI, V54, P3350, DOI 10.1167/iovs.13-11831
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Kaur C, 2013, J NEUROIMMUNE PHARM, V8, P66, DOI 10.1007/s11481-012-9347-2
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Kumar A, 2010, INVEST OPHTH VIS SCI, V51, P2664, DOI 10.1167/iovs.09-4195
   Lanzetta P, 2008, OPHTHALMOLOGY, V115, P216, DOI 10.1016/j.ophtha.2007.08.007
   Lech M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/951390
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mojana F, 2011, RETINA-J RET VIT DIS, V31, P235, DOI 10.1097/IAE.0b013e3181ec80ad
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pauleikhoff D, 2000, OPHTHALMOLOGE, V97, P243, DOI 10.1007/s003470050520
   Pelosini L, 2013, RETINA-J RET VIT DIS, V33, P548, DOI 10.1097/IAE.0b013e3182670fea
   PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471
   Pollack JS, 1998, ARCH OPHTHALMOL-CHIC, V116, P1633, DOI 10.1001/archopht.116.12.1633
   Rhodes KM, 2009, CURR MED RES OPIN, V25, P787, DOI 10.1185/03007990902728316 
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Roider J., 1993, Ophthalmologe, V90, P274
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P1345, DOI 10.1167/iovs.10-6112
   Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Treumer F, 2012, EXP EYE RES, V97, P63, DOI 10.1016/j.exer.2012.02.011
   United Nations Department of Economic and Social Affairs Population Division (UN), 2013, ESAPWP228 UN DEP EC
   Vessey KA, 2011, J COMP NEUROL, V519, P506, DOI 10.1002/cne.22530
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   WALLOW IHL, 1973, AM J OPHTHALMOL, V75, P610, DOI 10.1016/0002-9394(73)90813-1
   Wood JPM, 2013, INVEST OPHTH VIS SCI, V54, P2305, DOI 10.1167/iovs.12-11203
   Wood JPM, 2011, LASER SURG MED, V43, P499, DOI 10.1002/lsm.21087
   Yamamoto C, 1996, GRAEF ARCH CLIN EXP, V234, P695, DOI 10.1007/BF00292356
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
NR 86
TC 61
Z9 61
U1 0
U2 18
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD FEB
PY 2015
VL 29
IS 2
BP 696
EP 710
DI 10.1096/fj.14-262444
PG 15
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA CB1ET
UT WOS:000349370400030
PM 25392267
DA 2022-11-30
ER

PT J
AU Gungor, ED
   Yulek, F
   Serkant, U
   Toklu, Y
   Hocaoglu, A
   Simsek, S
AF Gungor, Elif Damar
   Yulek, Fatma
   Serkant, Utku
   Toklu, Yasin
   Hocaoglu, Asim
   Simsek, Saban
TI Blood lead and cadmium in age related macular degeneration in a Turkish
   urban population
SO JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Lead; Cadmium; Age related macular degeneration; Smoking
ID OXIDATIVE-STRESS; EPITHELIAL-CELLS; EXPOSED WORKERS; URINARY CADMIUM;
   HYPERTENSION; PATHOGENESIS; METABOLISM; LIPOFUSCIN; PRESSURE; MARKERS
AB Purpose: To evaluate the blood lead (Pb) and cadmium (Cd) levels in age related macular degeneration (AMD) in a turkish urban population.
   Methods: Blood Pb and Cd levels of 31 AMD patients and 24 age and gender matched controls with no sign of AMD were measured using dual atomic absorption spectrophotometer system (AAS). History of hypertension, diabetes mellitus, cigarette smoking, myocardial infarction and stroke were obtained from all subjects. Degree of AMD was grade 4 according to the Age-Related Eye Disease Study grading system. Median blood Pb and Cd levels were compared by using Students' t-test.
   Results: Demographic properties like smoking status, presence of diabetes mellitus or hypertension, cerebrovascular occlusion history, serum cholesterol and lipid levels were not significantly different between groups except history of ischemic heart disease (3.22% vs 25% in AMD and control groups respectively, p =.022). Overall in AMD group blood Pb level was 2.83 +/- 0.15 mu g/l and it was 2.63 +/- 0.23 mu g/l in control group (p =.36). The Cd level was 3.25 +/- 0.20 mu g/l in AMD group and 3.11 +/- 0.25 mu g/l in control group (p =.67). The mean Pb (2.38 +/- 0.88 mu g/l vs 2.91 +/- 1.37 mu g/l for AMD vs control, p =.61) and Cd levels (3.06 +/- 1.34 mu g/l vs 3.35 +/- 1.26 mu g/l for AMD vs control, p =.56) in current and previous smokers with AMD were not significantly different from those of the current and previous smokers in control group.
   Conclusion: Blood Pb and Cd levels which reflect short term exposure were not significantly different in AMD patients and the control group. The difference was not significant either after involvement of previous or current smoker subjects.
C1 [Gungor, Elif Damar; Yulek, Fatma; Toklu, Yasin; Simsek, Saban] Yildirim Beyazit Univ, Ophthalmol Dept, Ataturk Training & Res Hosp, Ankara, Turkey.
   [Serkant, Utku] Minist Hlth, Ankara, Turkey.
   [Hocaoglu, Asim] Pharmaceut & Med Device Estab, Ankara, Turkey.
C3 Ankara Ataturk Training & Research Hospital; Yildirim Beyazit
   University; Ministry of Health - Turkey
RP Gungor, ED (通讯作者)，Kahramanmaras Necip Fazil Sehir Hastanesi, Yorukselim Ek Hizmet Binasi, Dulkadiroglu Kahramanmar, Turkey.
EM elif.damargungor@saglik.gov.tr; fyulek@ybu.edu.tr;
   utku.serkant@saglik.gov.tr; ytoklu@ybu.edu.tr;
   asim.hocaoglu@titck.gov.tr
RI serkant, utku/GVU-5152-2022
CR Adonaylo VN, 1999, TOXICOLOGY, V132, P19, DOI 10.1016/S0300-483X(98)00134-6
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alan H. B., 2005, CLIN GUIDE LAB TESTS, P658
   Barregard L, 2010, ENVIRON RES, V110, P47, DOI 10.1016/j.envres.2009.10.010
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Canfield RL, 2003, NEW ENGL J MED, V348, P1517, DOI 10.1056/NEJMoa022848
   Chiba M, 1996, TOHOKU J EXP MED, V178, P49, DOI 10.1620/tjem.178.49
   DESILVA PE, 1981, BRIT J IND MED, V38, P209
   Ercal Nuran, 2001, Current Topics in Medicinal Chemistry, V1, P529, DOI 10.2174/1568026013394831
   Erie JC, 2007, AM J OPHTHALMOL, V144, P414, DOI 10.1016/j.ajo.2007.05.020
   Erie JC, 2009, AM J OPHTHALMOL, V148, P890, DOI 10.1016/j.ajo.2009.07.001
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FOX DA, 1994, NEUROTOXICOLOGY, V15, P503
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   Gallagher CM, 2010, ENVIRON HEALTH PERSP, V118, P1676, DOI 10.1289/ehp.1002077
   Glasgow G P, 1991, Med Dosim, V16, P13
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Gurer-Orhan H, 2004, TOXICOLOGY, V195, P147, DOI 10.1016/j.tox.2003.09.009
   HERMESLIMA M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P57, DOI 10.1016/S0005-2728(05)80072-6
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   HSU JM, 1981, J NUTR, V111, P26, DOI 10.1093/jn/111.1.26
   ITO Y, 1985, INT ARCH OCC ENV HEA, V56, P119, DOI 10.1007/BF00379383
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kayaalti Z, 2011, TOXICOL APPL PHARM, V256, P1, DOI 10.1016/j.taap.2011.06.023
   KHALILMANESH F, 1993, AM J HYPERTENS, V6, P723, DOI 10.1093/ajh/6.9.723
   Khan Fahad, 2011, J Okla State Med Assoc, V104, P252
   Khan MI, 2010, ENVIRON SCI POLLUT R, V17, P1347, DOI 10.1007/s11356-010-0319-x
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Komarnicki GJK, 2005, ENVIRON POLLUT, V136, P47, DOI 10.1016/j.envpol.2004.12.006
   Lee DH, 2006, ENVIRON HEALTH PERSP, V114, P350, DOI 10.1289/ehp.8518
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Pandya C, 2012, ANDROLOGIA, V44, P813, DOI 10.1111/j.1439-0272.2010.01137.x
   Patra R C, 2011, Vet Med Int, V2011, P457327, DOI 10.4061/2011/457327
   Sanders Talia, 2009, Reviews on Environmental Health, V24, P15
   Satarug S, 2012, CURR DRUG METAB, V13, P257, DOI 10.2174/138920012799320446
   SCHWARTZ J, 1991, ENVIRON HEALTH PERSP, V91, P71, DOI 10.2307/3430985
   SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Surucu A. H., 2012, J FAM PRACTICE, V16, P61
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wang YD, 2004, FREE RADICAL BIO MED, V36, P1434, DOI 10.1016/j.freeradbiomed.2004.03.010
   Watanabe M, 2003, COMP BIOCHEM PHYS C, V134, P227, DOI 10.1016/S1532-0456(02)00253-3
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   Wills N. K., 2009, EXP EYE RES, V1
   Winkler BS, 1999, MOL VIS, V5
   Yilmaz O, 2002, INT J ENVIRON HEAL R, V12, P181, DOI 10.1080/09603120220129355
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 50
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0946-672X
J9 J TRACE ELEM MED BIO
JI J. Trace Elem. Med. Biol.
PY 2018
VL 48
BP 16
EP 19
DI 10.1016/j.jtemb.2018.02.019
PG 4
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA GM6ZE
UT WOS:000438326700003
PM 29773175
DA 2022-11-30
ER

PT J
AU Spencer, KL
   Hauser, MA
   Olson, LM
   Schnetz-Boutaud, N
   Scott, WK
   Schmidt, S
   Gallins, P
   Agarwal, A
   Postel, EA
   Pericak-Vance, MA
   Haines, JL
AF Spencer, Kylee L.
   Hauser, Michael A.
   Olson, Lana M.
   Schnetz-Boutaud, Nathalie
   Scott, William K.
   Schmidt, Silke
   Gallins, Paul
   Agarwal, Anita
   Postel, Eric A.
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI Haplotypes spanning the complement factor H gene are protective against
   age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BEAVER DAM EYE; JAPANESE POPULATION; FAMILIAL AGGREGATION; STRONG
   ASSOCIATION; MONOZYGOTIC TWINS; LINKAGE PHASE; MACULOPATHY; RISK;
   SUSCEPTIBILITY; POLYMORPHISM
AB PURPOSE. Age-related macular degeneration (AMD) is a devastating disorder that adversely affects the quality of life of nearly 2 million Americans who have advanced forms of the disease. Besides the well-known risk imparted by carrying the Y402H variant in the complement factor H (CFH) gene on chromosome 1, recent evidence of the existence of protective haplotypes spanning CFH has been reported.
   METHODS. The haplo.stats program was used to test for association of the protective haplotypes after adjusting for age in the dataset of 584 sporadic cases and 248 control samples. Logistic regression modeling and likelihood ratio tests were used to investigate an interaction between a particular haplotype and smoking status. The HBAT option of FBAT was used to confirm the associations in an independent dataset of 201 families.
   RESULTS. Two protective ( P) haplotypes in a family-based dataset (P1 = CAATTTAG, P = 0.021; and P2 = CGGCTTAG, P = 0.018) were identified for the first time. Age-adjusted score statistics provided support for these protective haplotypes in the case-control dataset ( P1 frequency in cases similar to 13%, in controls similar to 20%, P = 0.001; P2 frequency in cases similar to 5%, in controls similar to 8%, P = 0.077). There was also tentative evidence of an interaction between one of the protective haplotypes and cigarette smoking ( P = 0.04 likelihood ratio test for P2-smoking interaction).
   CONCLUSIONS. Replication of the association between the protective haplotypes and decreased AMD susceptibility provides increased evidence that these associations have biological meaning. The suggestion of a haplotype-smoking interaction adds to the growing body of evidence that smoking is an important environmental covariate in AMD that should be considered in genetic studies. Identification of the protective variant(s) carried within these haplotypes is critical for understanding the etiology of AMD.
C1 Vanderbilt Univ, Med Ctr, Ctr Human Genet res, Nashville, TN 37232 USA.
   Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC USA.
   Univ Miami, Miller Sch Med, Dept Med, Miami, FL USA.
   Univ Miami, Miller Sch Med, Inst Human Genom, Miami, FL 33152 USA.
C3 Vanderbilt University; Duke University; University of Miami; University
   of Miami
RP Haines, JL (通讯作者)，Vanderbilt Univ, Med Ctr, Ctr Human Genet res, 519 Light Hall, Nashville, TN 37232 USA.
EM jonathan@chgr.mc.vanderbilt.edu
RI Haines, Jonathan/C-3374-2012; Scott, William/A-7593-2009
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NCRR NIH HHS [M01 RR00095] Funding Source: Medline; NEI NIH HHS
   [EY12118, EY015216] Funding Source: Medline; NATIONAL CENTER FOR
   RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [R01EY012118, R03EY015216, U10EY012118] Funding Source:
   NIH RePORTER
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BERGER JW, 1999, AGE RELATED MACULAR
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180
   DERODRIGUEZ CS, 2004, MOL IMMUNOL, V41, P355
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KAZATCHKINE MD, 1979, J EXP MED, V150, P1202, DOI 10.1084/jem.150.5.1202
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MOLD C, 1984, J IMMUNOL, V133, P882
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Souied EH, 2005, MOL VIS, V11, P1135
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 47
TC 18
Z9 18
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2007
VL 48
IS 9
BP 4277
EP 4283
DI 10.1167/iovs.06-1427
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 204RO
UT WOS:000249061900052
PM 17724217
DA 2022-11-30
ER

PT J
AU Liu, Y
   Wen, F
   Li, JQ
   Zuo, CG
   Li, M
AF Liu, Yan
   Wen, Feng
   Li, Jiaqing
   Zuo, Chengguo
   Li, Meng
TI Transitions of multifocal electroretinography in patients with
   age-related macular degeneration after combination therapy with
   photodynamic therapy and intravitreal bevacizumab
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Photodynamic therapy; Bevacizumab;
   Choroidal neovascularization; Multifocal electroretinography
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; EPITHELIUM-DERIVED FACTOR;
   ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN THERAPY; RETINAL FUNCTION;
   AVASTIN; VASCULOPATHY; MACULOPATHY; EXPRESSION; INJECTION
AB To evaluate by multifocal electroretinograms (mfERG) the macular function before and after combined treatment with photodynamic therapy (PDT) and intravitreal bevacizumab in eyes suffering from choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). 15 eyes of 15 patients with subfoveal CNV were studied before and after the combined treatment. The post-treatment follow-up was 6 months. MfERG recordings were performed in each patient before and 1, 3, and 6 months after the treatment. The mean N1 response amplitudes tended to increase after the treatment, and ring 2 response amplitude was significantly increased at 3 and 6 months compared to baseline (P = 0.033, 0.005, respectively). For mean P1 response amplitudes, there was a significant increase in retinal response amplitudes in ring 1-3 at 6 months (P = 0.036, 0.013, 0.008, respectively). No statistically significant difference in both mean N1 and P1 latency was observed for any ring over the course of treatment. PDT combined with intravitreal bevacizumab can increase the response amplitudes of mfERG in neovascular AMD patients.
C1 [Wen, Feng; Li, Jiaqing; Zuo, Chengguo; Li, Meng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Liu, Yan] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200031, Peoples R China.
C3 Sun Yat Sen University; Fudan University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   Imai H, 2006, BRIT J OPHTHALMOL, V90, P1524, DOI 10.1136/bjo.2006.092783
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Mackay AM, 2007, DOC OPHTHALMOL, V115, P69, DOI 10.1007/s10633-007-9056-y
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Moschos MM, 2008, DOC OPHTHALMOL, V116, P147, DOI 10.1007/s10633-007-9110-9
   Moschos MM, 2004, J FR OPHTALMOL, V27, P1001, DOI 10.1016/S0181-5512(04)96255-9
   Roh MI, 2009, OPHTHALMOLOGY, V116, P80, DOI 10.1016/j.ophtha.2008.09.036
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
NR 20
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD DEC
PY 2009
VL 119
IS 3
BP 163
EP 169
DI 10.1007/s10633-009-9189-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 521TX
UT WOS:000271948400001
PM 20101800
DA 2022-11-30
ER

PT J
AU Chen, L
   Messinger, JD
   Sloan, KR
   Wong, J
   Roorda, A
   Duncan, JL
   Curcio, CA
AF Chen, Ling
   Messinger, Jeffrey D.
   Sloan, Kenneth R.
   Wong, Jessica
   Roorda, Austin
   Duncan, Jacque L.
   Curcio, Christine A.
TI ABUNDANCE AND MULTIMODAL VISIBILITY OF SOFT DRUSEN IN EARLY AGE-RELATED
   MACULAR DEGENERATION A Clinicopathologic Correlation
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; autofluorescence; basal linear
   deposit; clinicopathologic correlation; color fundus photography;
   drusen; histology; optical coherence tomography
ID RETINAL-PIGMENT EPITHELIUM; AUTOFLUORESCENCE; DEPOSITS
AB Purpose: To determine the abundance and multimodal visibility of drusen and basal linear deposit (BLinD) in early age-related macular degeneration. Methods: A 69-year-old white man was imaged by color fundus photography and red free photography, fundus autofluorescence, and optical coherence tomography. Fromen faceimages, we determined the drusen field, drusen area, and equivalent diameters of individual drusen. From high-resolution light-microscopic histology (6 months after the last clinic visit), we determined the area of drusen, BLinD, and pre-BLinD in a subretinal pigment epithelium-basal lamina lipid field. Results: In right and left eyes, respectively, BLinD covered 40% and 46% of the lipid field, versus 21% and 14% covered by drusen. The lipid field was covered 60% to 61% by Drusen + BLinD and 65% to 72% by BLinD + pre-BLinD. In the left eye, the drusen area on color fundus photography (0.18 mm(2)) and red free (0.28 mm(2)) was smaller than the drusen area on histology (1.16 mm(2)). Among drusen confirmed by optical coherence tomography, 55.1% and 56.6% were observed on red free and fundus autofluorescence, respectively. Conclusion: Basal linear deposit covered 1.9 and 3.4-fold more fundus area than soft drusen, silently increasing progression risk. Improved visualization of BLinD and readouts of the retinal pigment epithelium health over lipid will assist population surveillance, early detection, and trial outcome measures.
C1 [Chen, Ling; Messinger, Jeffrey D.; Sloan, Kenneth R.; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Sch Med, 1670 Univ Blvd Room 360, Birmingham, AL 35294 USA.
   [Chen, Ling] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Wong, Jessica; Duncan, Jacque L.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
   [Roorda, Austin] Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA.
   [Roorda, Austin] Univ Calif Berkeley, Vis Sci Grad Grp, Berkeley, CA 94720 USA.
C3 University of Alabama System; University of Alabama Birmingham; Sun Yat
   Sen University; University of California System; University of
   California San Francisco; University of California System; University of
   California Berkeley; University of California System; University of
   California Berkeley
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Sch Med, 1670 Univ Blvd Room 360, Birmingham, AL 35294 USA.; Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, EyeSight Fdn Alabama Vis Res Labs, 1670 Univ Blvd Room 360, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
OI Chen, Ling/0000-0002-5552-4667
FU Genentech/Hoffman LaRoche; Heidelberg Engineering; TheMacula Foundation,
   Inc, New York, NY; Research to Prevent Blindness, Inc; Foundation
   Fighting Blindness; The Beckman/Ryan Initiative for Macular Research;
   EyeSight Foundation of Alabama; National Eye Institute [R01EY023591];
   NIH/NEI [P30 EY002162]
FX Supported by Genentech/Hoffman LaRoche, Heidelberg Engineering,
   TheMacula Foundation, Inc, New York, NY; unrestricted funds to the
   Department of Ophthalmology and Visual Sciences (UAB and UCSF) from
   Research to Prevent Blindness, Inc, Foundation Fighting Blindness, The
   Beckman/Ryan Initiative for Macular Research and EyeSight Foundation of
   Alabama and the National Eye Institute R01EY023591 (JW) and NIH/NEI P30
   EY002162.
CR Chen L, 2018, INVEST OPHTH VIS SCI, V59, P5237, DOI 10.1167/iovs.18-25124
   Chong SP, 2018, BIOMED OPT EXPRESS, V9, P1477, DOI 10.1364/BOE.9.001477
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   Rudolf M, 2019, INVEST OPHTH VIS SCI, V60, P461, DOI 10.1167/iovs.18-25786
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   Vongkulsiri S, 2015, RETINA-J RET VIT DIS, V35, P1211, DOI 10.1097/IAE.0000000000000514
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 15
TC 12
Z9 12
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2020
VL 40
IS 8
BP 1644
EP 1648
DI 10.1097/IAE.0000000000002893
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NA3ZC
UT WOS:000559752400036
PM 32568988
DA 2022-11-30
ER

PT J
AU Yang, K
   Zhan, SY
   Liang, YB
   Duan, XR
   Wang, FH
   Wong, TY
   Sun, LP
   Wang, NL
AF Yang, Ke
   Zhan, Si Yan
   Liang, Yuan Bo
   Duan, Xinrong
   Wang, Fenghua
   Wong, Tien Yin
   Sun, Lan Ping
   Wang, Ning-Li
TI Association of dilated retinal arteriolar caliber with early age-related
   macular degeneration: the Handan Eye Study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Macular degeneration; Retinal vessels; Photography; Rural population;
   China
ID SINGAPORE MALAY EYE; BLUE MOUNTAINS EYE; VASCULAR CALIBER; GRADING
   SYSTEM; BEIJING EYE; PREVALENCE; MACULOPATHY; POPULATION; RISK; DISEASE
AB To identify factors associated with early age-related macular degeneration (AMD) in a rural Chinese population, with emphasis on retinal vessel caliber.
   The study population comprised the 6,830 participants of the Handan Eye Study. All participants underwent digital retinal photography of both eyes. Trained graders assessed the presence of AMD lesions. Arteriolar and venular diameters were measured with a specific computer-assisted program and were summarized as the central retinal arteriolar equivalent (CRAE) and central retinal venular equivalent (CRVE).
   The data for the 199 individuals with evaluable retinal photographs and early AMD and 400 age-matched individuals randomly selected from the group without AMD were analyzed. After adjusting for participants' age, sex, smoking status, hypertension, diabetes, BMI, and CRVE, the multivariate adjusted model showed that a higher CRAE was significantly associated with early AMD (OR = 1.34; 95% CI: 1.05-1.71; p = 0.020) and the presence of soft distinct drusen (OR = 1.32 (95% CI: 1.02-1.71, p = 0.037). There were no significant associations between CRVE and early AMD.
   Dilated retinal arteriolar caliber is associated with early AMD and soft distinct drusen in this population. We found no significant associations between CRAE and other characteristics of the retina related to AMD or between retinal venal caliber and early AMD. More research is needed to determine whether the difference between these results and those previously published stem from the rural living conditions of the participants or other factors.
C1 [Yang, Ke; Duan, Xinrong; Wang, Fenghua; Wang, Ning-Li] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China.
   [Zhan, Si Yan] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100871, Peoples R China.
   [Liang, Yuan Bo] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Liang, Yuan Bo] Shantou Univ, Joint Shantou Int Eye Ctr, Hong Kong, Hong Kong, Peoples R China.
   [Wong, Tien Yin] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117595, Singapore.
   [Sun, Lan Ping] Handan Eye Hosp, Handan, Hebei Province, Peoples R China.
C3 Capital Medical University; Peking University; Chinese University of
   Hong Kong; Shantou University; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; National
   University of Singapore; Singapore National Eye Center
RP Wang, NL (通讯作者)，Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dongjiao Min Xiang, Beijing 100730, Peoples R China.
EM wningli@vip.163.com
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; liang, Yuanbo/0000-0001-9685-7356
FU Ministry of Science and Technology of the P. R. China [2007CB512201];
   Program of Health Policy for blindness prevention from P. R. China;
   Bureau of Science and Technology of Handan City, P. R. China
   [2006-10903]; Beijing Tongren Hospital; Bureau of Health, Handan City,
   P. R. China
FX This work was supported by the National Basic Research Program of China
   (973 Program) (No. 2007CB512201) from the Ministry of Science and
   Technology of the P. R. China, and the Program of Health Policy for
   blindness prevention from P. R. China and was partially funded by the
   Key Technologies R& D Program (No. 2006-10903) from the Bureau of
   Science and Technology of Handan City, P. R. China with additional
   support from Beijing Tongren Hospital and key discipline fund of Bureau
   of Health, Handan City, P. R. China.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chakravarthy U, 2006, BMJ-BRIT MED J, V333, P869, DOI 10.1136/bmj.39009.366736.80
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CY, 2010, OPHTHALMOLOGY   1209
   Ikram MK, 2005, OPHTHALMOLOGY, V112, P548, DOI 10.1016/j.ophtha.2004.10.038
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Jenchitr W, 2011, OPHTHAL EPIDEMIOL, V18, P48, DOI 10.3109/09286586.2010.545502
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Leung H, 2003, CLIN EXP OPHTHALMOL, V31, P326, DOI 10.1046/j.1442-9071.2003.00661.x
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liang YB, 2009, OPHTHAL EPIDEMIOL, V16, P115, DOI 10.1080/09286580902738159
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   Liew G, 2008, CIRC-CARDIOVASC IMAG, V1, P156, DOI 10.1161/CIRCIMAGING.108.784876
   LOTFI K, 1991, INVEST OPHTH VIS SCI, V32, P3028
   McGeechan K, 2009, ANN INTERN MED, V151, P404, DOI 10.7326/0003-4819-151-6-200909150-00005
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nguyen TT, 2010, STROKE, V41, P1343, DOI 10.1161/STROKEAHA.110.581017
   Nguyen TT, 2009, CURR DIABETES REP, V9, P277, DOI 10.1007/s11892-009-0043-4
   Okuno T, 2002, JPN J OPHTHALMOL, V46, P170, DOI 10.1016/S0021-5155(01)00498-1
   Sun C, 2009, SURV OPHTHALMOL, V54, P74, DOI 10.1016/j.survophthal.2008.10.003
   Wieberdink RG, 2010, STROKE, V41, P2757, DOI 10.1161/STROKEAHA.110.599084
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
NR 29
TC 22
Z9 22
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2012
VL 250
IS 5
BP 741
EP 749
DI 10.1007/s00417-011-1824-4
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 933SB
UT WOS:000303381700014
PM 21971892
DA 2022-11-30
ER

PT J
AU Sturgill, GM
   Pauer, GJT
   Bala, E
   Simpson, E
   Yaniglos, SS
   Crabb, JW
   Hollyfield, JG
   Lewis, H
   Peachey, NS
   Hagstrom, SA
AF Sturgill, Gwen M.
   Pauer, Gayle J. T.
   Bala, Elisa
   Simpson, Ellen
   Yaniglos, Stacia S.
   Crabb, John W.
   Hollyfield, Joe G.
   Lewis, Hilel
   Peachey, Neal S.
   Hagstrom, Stephanie A.
TI Mutation screen of the cone-specific gene, CLUL1, in 376 patients with
   age-related macular degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE retinal degeneration; age-related macular degeneration; clusterin;
   mutation
ID FACTOR-H POLYMORPHISM; CLUSTERIN EXPRESSION; APOLIPOPROTEIN-J; APOPTOSIS
AB Clusterin is a secreted glycoprotein expressed ubiquitously in many tissues that appears to function as a molecular chaperone capable of protecting stressed proteins. It is upregulated in many different forms of neurodegeneration and is thought to represent a defense response against neuronal damage. Clusterin has been found to be a common protein identified in drusen preparations isolated from the retina of donor eyes of patients with age-related macular degeneration (AMD), the leading cause of blindness in the elderly population of developed countries. A retina-specific clusterin-like protein (CLUL1) showing nearly 25% identity to clusterin at the protein level was recently cloned and shown to be expressed specifically in cone photoreceptor cells. For these reasons, we investigated CLUL1 as a candidate gene for AMD. A mutation screen of the entire coding region of the CLUL1 gene in 376 unrelated patients with AMD uncovered three sequence variations, one isocoding change and two intronic changes. One intronic change appears significantly less frequent in patients with the more severe forms of AMD than in control subjects, suggesting that this variant may reduce the risk for AMD or may be linked to a nearby variant that may reduce AMD risk. Variant alleles of the CLUL1 gene were found; however, none are considered pathogenic. None of the variants identified are predicted to create or destroy splice donor or acceptor sites based on splice-site prediction software.
C1 Cleveland Clin Fdn, Cole Eye Inst, Ophthalm Res i31, Dept Ophthalmol Res, Cleveland, OH 44195 USA.
   Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, Cleveland, OH USA.
   Case Western Reserve Univ, Cleveland Clin Lerner Coll Med, Dept Ophthalmol, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Case Western Reserve University; Louis
   Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve
   University; Cleveland Clinic Foundation
RP Hagstrom, SA (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, Ophthalm Res i31, Dept Ophthalmol Res, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM hagstrs@ccf.org
RI Peachey, Neal/G-5533-2010
OI Peachey, Neal/0000-0002-4419-7226
FU NEI NIH HHS [R24 EY015638, R24 EY15638, R01 EY016072-04, R01 EY016072]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY016072,
   R24EY015638] Funding Source: NIH RePORTER
CR ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875
   JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4
   Jomary C, 1999, J NEUROCHEM, V72, P1923, DOI 10.1046/j.1471-4159.1999.0721923.x
   JONES SE, 1992, FEBS LETT, V300, P279, DOI 10.1016/0014-5793(92)80863-C
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   MORGAN T, 1999, NEUROSCI INTELL UNIT, V2, P109
   SMITH SB, 1995, INVEST OPHTH VIS SCI, V36, P2193
   TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064
   Wong P, 2001, CURR EYE RES, V23, P157, DOI 10.1076/ceyr.23.3.157.5463
   WONG P, 1994, BIOCHEM CELL BIOL, V72, P439, DOI 10.1139/o94-058
   Zhang Q, 2003, INVEST OPHTH VIS SCI, V44, P4542, DOI 10.1167/iovs.02-1202
   Zhang Q, 2000, GENE, V243, P151, DOI 10.1016/S0378-1119(99)00542-9
NR 20
TC 7
Z9 7
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD DEC
PY 2006
VL 27
IS 4
BP 151
EP 155
DI 10.1080/13816810600976871
PG 5
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 112WN
UT WOS:000242558600006
PM 17148042
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Martinez-Barricarte, R
   Recalde, S
   Fernandez-Robredo, P
   Millan, I
   Olavarrieta, L
   Vinuela, A
   Perez-Perez, J
   Garcia-Layana, A
   de Cordoba, SR
AF Martinez-Barricarte, Ruben
   Recalde, Sergio
   Fernandez-Robredo, Patricia
   Millan, Isabel
   Olavarrieta, Leticia
   Vinuela, Antonio
   Perez-Perez, Julian
   Garcia-Layana, Alfredo
   Rodriguez de Cordoba, Santiago
CA Spanish Multictr Grp AMD
TI Relevance of Complement Factor H-Related 1 (CFHR1) Genotypes in
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ALLOTYPIC VARIANT; INFLUENCES RISK; POLYMORPHISM; BINDING; GENES;
   SUSCEPTIBILITY; HAPLOTYPES; LOC387715; INCREASES; Y402H
AB PURPOSE. Age-related macular degeneration (AMD) has a strong genetic component with a major locus at 1q31, including the complement factor H (CFH) gene. Detailed analyses of this locus have demonstrated the existence of one SNP haplotype block, carrying the CFH 402His allele, which confers increased risk for AMD, and two protective SNP haplotypes, one of them carrying a deletion of the CFHR1 and CFHR3 genes (Delta(CFHR3-CFHR1)). The purpose of these studies was to evaluate the contribution of newly described CFHR1 alleles to the association of the 1q31 locus with AMD.
   METHODS. Two hundred fifty-nine patients and 191 age-matched controls of Spanish origin were included in a transversal case-control study using multivariate logistic regression analysis and ROC (receiver operating characteristic) statistics to generate and test models predictive of the development of AMD.
   RESULTS. This study showed for the first time that a particular CFHR1 allotype, CFHR1*A, is strongly associated with AMD (odds ratio, 2.08; 95% confidence interval, 1.59-2.73; P < 0.0001) and illustrate a peculiar genotype-phenotype correlation between the CFHR1 alleles and different diseases that may have important implications for understanding the pathophysiology of AMD. It also shows that CFHR1*A is in strong linkage disequilibrium with the CFH 402His allele, which provides additional candidate variants within the major risk haplotype at 1q31, promoting its association with AMD. Further, using the Spanish population as a model, the results showed that analysis of the CFHR1 genotypes provide sufficient information to delineate the individual risk of developing AMD.
   CONCLUSIONS. The results support a relevant role of CFHR1 in the pathogenesis of AMD. (Invest Ophthalmol Vis Sci. 2012;53: 1087-1094) DOI:10.1167/iovs.11-8709
C1 [Martinez-Barricarte, Ruben; Rodriguez de Cordoba, Santiago] Ctr Invest Biol CSIC, Dept Cellular & Mol Med, Madrid, Spain.
   [Martinez-Barricarte, Ruben; Rodriguez de Cordoba, Santiago] Ciber Enfermedades Raras CIBERER, Madrid, Spain.
   [Recalde, Sergio; Fernandez-Robredo, Patricia; Garcia-Layana, Alfredo] Univ Navarra, Dept Ophthalmol, Univ Clin, Navarra, Spain.
   [Millan, Isabel] Univ Autonoma Madrid, Dept Biostat, Hosp Univ Puerta Hierro, Madrid, Spain.
   [Olavarrieta, Leticia; Vinuela, Antonio; Perez-Perez, Julian] Secugen SL, Madrid, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de
   Investigaciones Biologicas (CIB); CIBER - Centro de Investigacion
   Biomedica en Red; CIBERER; University of Navarra; Autonomous University
   of Madrid; Hospital Puerta de Hierro-Majadahonda
RP de Cordoba, SR (通讯作者)，Ctr Invest Biol, Ramiro de Maeztu 9, Madrid 28040, Spain.
EM srdecordoba@cib.csic.es
RI Martin, Rosa Maria Coco/H-4511-2015; Gomez-Ramirez, Ana
   María/AAB-4677-2019; Viñuela, antonio/AAD-7599-2020; Viñuela,
   antonio/S-1128-2019; de Cordoba, Santiago Rodriguez/K-6727-2014;
   Olavarrieta, Leticia/GYQ-5751-2022; Recalde, Sergio/D-1815-2017;
   Barricarte, Ruben Martinez/W-8695-2019
OI Martin, Rosa Maria Coco/0000-0002-1811-1417; Gomez-Ramirez, Ana
   María/0000-0001-7953-7289; Viñuela, antonio/0000-0003-4306-1607;
   Viñuela, antonio/0000-0003-4306-1607; de Cordoba, Santiago
   Rodriguez/0000-0001-6401-1874; Recalde, Sergio/0000-0002-9328-9725;
   Barricarte, Ruben Martinez/0000-0001-7925-449X; Perez-Perez,
   Julian/0000-0001-6091-0012; Zapata, Miguel Angel/0000-0002-0096-4569;
   Ruiz-Moreno, Jose M/0000-0001-9636-0788
FU Spanish Ministerio de Ciencia e Innovacion [SAF2008-00226]; Ciber de
   Enfermedades Raras; Fundacion Renal Inigo Alvarez de Toledo (SRdeC);
   Instituto de Salud Carlos III [RTICS RD07/0062, FIS PI 08/1705, FIS
   11/00898]; Comunidad Autonoma de Madrid, Direccion General de Innovacion
   Tecnologica of the Consejeria Economa e Innovavion Tecnologica
FX Supported by Grant SAF2008-00226 from the Spanish Ministerio de Ciencia
   e Innovacion, the Ciber de Enfermedades Raras, and the Fundacion Renal
   Inigo Alvarez de Toledo (SRdeC); Grants RTICS RD07/0062, FIS PI 08/1705,
   and FIS 11/00898 from the Instituto de Salud Carlos III (AG-L); and
   Grant 35/2008 from the Comunidad Autonoma de Madrid, Direccion General
   de Innovacion Tecnologica of the Consejeria Economa e Innovavion
   Tecnologica (JP-P).
CR Abarrategui-Garrido C, 2009, BLOOD, V114, P4261, DOI 10.1182/blood-2009-05-223834
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gaunt TR, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-227
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 31
TC 35
Z9 35
U1 0
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2012
VL 53
IS 3
BP 1087
EP 1094
DI 10.1167/iovs.11-8709
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 925VT
UT WOS:000302790700002
PM 22247456
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Wu, J
   Cho, EY
   Giovannucci, EL
   Rosner, BA
   Sastry, SM
   Schaumberg, DA
   Willett, WC
AF Wu, Juan
   Cho, Eunyoung
   Giovannucci, Edward L.
   Rosner, Bernard A.
   Sastry, Srinivas M.
   Schaumberg, Debra A.
   Willett, Walter C.
TI Dietary intake of alpha-linolenic acid and risk of age-related macular
   degeneration
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE alpha-linolenic acid; omega-3 fatty acids; trans fat; age-related
   macular degeneration; prospective cohort study; food-frequency
   questionnaire
ID POLYUNSATURATED FATTY-ACIDS; GEOMETRICAL-ISOMERS; POSTMENOPAUSAL WOMEN;
   INFANT FORMULAS; PLASMA-LIPIDS; ASSOCIATION; PREVALENCE; DISEASE; BLOOD;
   CHAIN
AB Background: The relation between a-linolenic acid (ALA), a plant-derived omega-3 (n-3) fatty acid, and age-related macular degeneration (AMD) is unclear. European researchers reported that <= 40% of ALA can be present as trans forms.
   Objective: We aimed to evaluate the associations between intake of ALA and intermediate and advanced AMD.
   Design: Seventy-five thousand eight hundred eighty-nine women from the Nurses' Health Study and 38,961 men from Health Professionals Follow-Up Study were followed up from 1984 to 2012 and from 1986 to 2010, respectively. We assessed dietary intake by a validated food-frequency questionnaire at baseline and every 4 y thereafter. One thousand five hundred eighty-nine incident intermediate and 1356 advanced AMD cases (primarily neovascular AMD) were confirmed by medical record review.
   Results: The multivariable-adjusted HR for intermediate AMD comparing ALA intake at the top quintile to the bottom quintile was 1.28 (95% CI: 1.05, 1.56; P-trend = 0.01) in the analyses combining 2 cohorts. The HR in each cohort was in the positive direction but reached statistical significance only in the women. However, the positive association was apparent only in the pre-2002 era in each cohort and not afterward (P-time interaction = 0.003). ALA intake was not associated with advanced AMD in either time period. Using gas-liquid chromatography, we identified both cis ALA (mean +/- SD: 0.13% +/- 0.04%) and trans ALA isomers (0.05% +/- 0.01%) in 395 erythrocyte samples collected in 1989-1990. In stepwise regression models, mayonnaise was the leading predictor of erythrocyte concentrations of cis ALA and one isomer of trans ALA. We also found trans ALA in mayonnaise samples.
   Conclusions: A high intake of ALA was associated with an increased risk of intermediate AMD before 2002 but not afterward. The period before 2002 coincides with the same time period when trans ALA was found in food and participants' blood; this finding deserves further study.
C1 [Wu, Juan; Giovannucci, Edward L.; Willett, Walter C.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Giovannucci, Edward L.; Schaumberg, Debra A.; Willett, Walter C.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Rosner, Bernard A.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Cho, Eunyoung; Giovannucci, Edward L.; Rosner, Bernard A.; Willett, Walter C.] Brigham & Womens Hosp, Dept Med, Channing Div, Network Med, 75 Francis St, Boston, MA 02115 USA.
   [Cho, Eunyoung; Giovannucci, Edward L.; Rosner, Bernard A.; Willett, Walter C.] Harvard Med Sch, Boston, MA USA.
   [Schaumberg, Debra A.] Shire Pharmaceut, Global Med Affairs, Lexington, MA USA.
   [Cho, Eunyoung] Brown Univ, Dept Dermatol, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Cho, Eunyoung] Brown Sch Publ Hlth, Dept Epidemiol, Providence, RI USA.
   [Sastry, Srinivas M.] Bethesda Retina, Bethesda, MD USA.
   [Schaumberg, Debra A.] Univ Utah, Sch Med, John A Moran Eye Ctr, Ctr Translat Med, Salt Lake City, UT USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Brigham & Women's Hospital; Harvard University; Harvard
   Medical School; Shire Pharmaceuticals Limited; Brown University; Brown
   University; Utah System of Higher Education; University of Utah
RP Wu, J (通讯作者)，Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
EM juan.wu@mail.harvard.edu
RI Cho, Eunyoung/AAV-4469-2020
OI Cho, Eunyoung/0000-0001-6594-2582
FU NIH [EY017362, EY013834, EY000365, EY009611, EY021900, UM1 CA186107, UM1
   CA167552, R01 CA49449]
FX Supported by grants EY017362, EY013834, EY000365, EY009611, EY021900,
   UM1 CA186107, UM1 CA167552, and R01 CA49449 from NIH.
CR Abraham RA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/276174
   Acar N, 2002, J NUTR, V132, P3151, DOI 10.1093/jn/131.10.3151
   Acar N, 2006, REPROD NUTR DEV, V46, P515, DOI 10.1051/rnd:2006033
   Baylin A, 2005, AM J EPIDEMIOL, V162, P373, DOI 10.1093/aje/kwi213
   Burdge GC, 2002, BRIT J NUTR, V88, P411, DOI 10.1079/BJN2002689
   CHARDIGNY JM, 1995, EUR J CLIN NUTR, V49, P523
   Chardigny JM, 1996, J AM OIL CHEM SOC, V73, P1595, DOI 10.1007/BF02523531
   CHARDIGNY JM, 1993, NUTR RES, V13, P1105, DOI 10.1016/S0271-5317(05)80735-3
   CHEN ZY, 1995, LIPIDS, V30, P15, DOI 10.1007/BF02537037
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Eckel RH, 2007, CIRCULATION, V115, P2231, DOI 10.1161/CIRCULATIONAHA.106.181947
   Food and Drug Administration HHS, 2003, Fed Regist, V68, P41433
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hendrickson SJ, 2013, NUTRIENTS, V5, P4051, DOI 10.3390/nu5104051
   Honors MA, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001023
   Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849
   Jin Y, 2016, MENOPAUSE, V23, P1012, DOI 10.1097/GME.0000000000000667
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kotsopoulos J, 2010, CANCER EPIDEM BIOMAR, V19, P938, DOI 10.1158/1055-9965.EPI-09-1318
   Kris-Etherton PM, 2000, AM J CLIN NUTR, V71, p179S, DOI 10.1093/ajcn/71.1.179S
   Marshall J, 2015, CURR OPIN NEUROBIOL, V34, P86, DOI 10.1016/j.conb.2015.02.002
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   OTTOSSON UB, 1984, GYNECOL OBSTET INVES, V18, P296, DOI 10.1159/000299096
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Ratnayake WMN, 1997, J PEDIATR GASTR NUTR, V25, P400, DOI 10.1097/00005176-199710000-00007
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rosner B, 2008, AM J EPIDEMIOL, V167, P653, DOI 10.1093/aje/kwm348
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Schwenke DC, 2013, AM J CLIN NUTR, V97, P862, DOI 10.3945/ajcn.112.046508
   Sebedio JL, 2000, EUR J CLIN NUTR, V54, P104, DOI 10.1038/sj.ejcn.1600903
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sun Q, 2008, AM J CLIN NUTR, V88, P216, DOI 10.1093/ajcn/88.1.216
   Sun Q, 2007, AM J CLIN NUTR, V86, P74, DOI 10.1093/ajcn/86.1.74
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Vermunt SHF, 2001, BRIT J NUTR, V85, P387, DOI 10.1079/BJN2000270
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   WOLFF RL, 1993, J AM OIL CHEM SOC, V70, P219, DOI 10.1007/BF02545298
   WOLFF RL, 1993, J AM OIL CHEM SOC, V70, P425, DOI 10.1007/BF02552718
   WOLFF RL, 1991, J AM OIL CHEM SOC, V68, P719, DOI 10.1007/BF02662159
   WOLFF RL, 1992, J AM OIL CHEM SOC, V69, P106, DOI 10.1007/BF02540558
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Yuan CZ, 2017, AM J EPIDEMIOL, V185, P570, DOI 10.1093/aje/kww104
NR 50
TC 7
Z9 7
U1 2
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JUN 1
PY 2017
VL 105
IS 6
BP 1483
EP 1492
DI 10.3945/ajcn.116.143453
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA EW6IC
UT WOS:000402612200028
PM 28468892
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ronan, SM
   Yoganathan, P
   Chien, FY
   Corcostegui, IA
   Blumenkranz, MS
   Deramo, VA
   Elner, SG
   Fastenberg, DA
   Johnson, MW
   Lopez, M
   Mateo, C
   Moshfeghi, DM
   Navarro, R
   Rosenblatt, BJ
   Sanislo, SR
   Saxe, SJ
   Zacks, DN
AF Ronan, Shawn M.
   Yoganathan, Pradeepa
   Chien, Fred Y.
   Corcostegui, Inigo A.
   Blumenkranz, Mark S.
   Deramo, Vincent A.
   Elner, Susan G.
   Fastenberg, David A.
   Johnson, Mark W.
   Lopez, Mauricio
   Mateo, Carlos
   Moshfeghi, Darius M.
   Navarro, Rafael
   Rosenblatt, Brett J.
   Sanislo, Steven R.
   Saxe, Stephen J.
   Zacks, David N.
TI Retinal pigment epithelium tears after intravitreal injection of
   bevacizumab (Avastin) for neovascular age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; SAFETY
AB Background: Intravitreal bevacizumab (Avastin, Genentech, Inc., South San Francisco, CA) treatment of neovascular age-related macular degeneration (AMD) has become an important part of clinical retinal practice. We describe retinal pigment epithelium (RPE) tears that were noted after intravitreal injection of bevacizumab.
   Methods: In this multimember, retrospective case series, data on eyes that developed RIDE tears after intravitreal bevacizumab injection were collected and analyzed. Previous treatments, type of lesion, time to tear, and preinjection and final visual acuities were all compared. The total numbers of bevacizumab injections were available from all four institutions and compiled to estimate the incidence rate.
   Results: Four retina centers administered a total of 1,455 intravitreal 1.25-mg bevacizumab injections for neovascular AMD during the 9-month study period. Twelve patients presented with RPE tears within 4 days to 8 weeks of injection (mean +/- SID, 24.3 +/- 15.2 days from injection to tear). In each case, the RPE tear was preceded by an RPE detachment, and all had a component of serous sub-RPE fluid. On the basis of our collective data, we estimate an incidence rate of approximate to 0.8%.
   Conclusions: RPE tears can occur after intravitreal injection of bevacizumab. The low incidence of this adverse event should not preclude anti-vascular endothelial growth factor therapy counseling for patients with neovascular AMD, but eyes with serous RPE detachments appear to be most vulnerable to this adverse event.
C1 Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   N Shore Univ Hosp, Dept Ophthalmol, Manhasset, NY USA.
   Stanford Univ, Dept Ophthalmol, Palo Alto, CA 94304 USA.
   Inst Microcirugia Ocular, Barcelona, Spain.
C3 University of Michigan System; University of Michigan; Northwell Health;
   North Shore University Hospital; Stanford University
RP Zacks, DN (通讯作者)，Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM davzacks@med.umich.edu
RI Zacks, David/I-4394-2013
OI Johnson, Mark W/0000-0001-9720-8761; Zacks, David/0000-0001-8592-5165;
   Moshfeghi, Darius Mohammad/0000-0003-2254-292X
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   AVERY RL, 2006, RETINA, V26, P252
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P356, DOI 10.1097/00006982-200603000-00018
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   SPAIDE RF, 2006, RETINA, V26, P279
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   YOE JH, 1988, OPHTHALMOLOGY, V95, P8
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 22
TC 48
Z9 53
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2007
VL 27
IS 5
BP 535
EP 540
DI 10.1097/IAE.0b013e3180cc2645
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 178ZP
UT WOS:000247259400002
PM 17558313
DA 2022-11-30
ER

PT J
AU Venkatesh, R
   Mangla, R
   Mishra, P
   Nahata, H
   Yadav, NK
   Chhablani, J
AF Venkatesh, Ramesh
   Mangla, Rubble
   Mishra, Pranjal
   Nahata, Harshita
   Yadav, Naresh K.
   Chhablani, Jay
TI BRIDGE ARCH-SHAPED SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION Evolution and Outcomes
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bridge arch-shaped subretinal fluid;
   outcomes; pathogenesis; treatment
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; SEROUS RETINAL-DETACHMENT;
   INFLAMMATION
AB Purpose: To study factors leading to bridge arch-shaped subretinal fluid (SRF) on optical coherence tomography in wet age-related macular degeneration and evaluate its anatomical and functional outcomes. Methods: In this single-center, retrospective study, patients with bridge arch-shaped SRF and choroidal neovascular membrane (CNVM) were included. Results: Overall, 623 eyes in 431 patients with chronic CNVM were identified, and 24 eyes (4%) in 21 patients showed bridge arch-shaped SRF. Mean age of patients was 69.19 +/- 12.0 years. Type-1 CNVM was noted in 79% cases before development of bridge arch-shaped SRF. Mean early treatment diabetic retinopathy letters visual acuity was 53.93 +/- 32.19. Time interval to develop bridge arch-shaped SRF was 21.9 +/- 30.63 months. Mean number of intravitreal anti-vascular endothelial growth factor injections given before developing bridge arch-shaped SRF was 6.5 +/- 7.09. During the development of bridge arch-shaped SRF, visual acuity reduced by -20.57 +/- 31.13 letters (P = 0.033) and fibrotic Type-2 CNVM (n = 18, 75%) was noted. Retinal pigment epithelium tear was noted in 8 eyes (33%). At the final visit, further reduction in visual acuity of -7.136 +/- 13.73 early treatment diabetic retinopathy letters (P = 0.011) after developing bridge arch-shaped SRF was seen. Mean number of injections given after developing bridge arch-shaped SRF was 4.76 +/- 3.76. Conclusion: Bridge arch-shaped SRF is an uncommon finding seen in eyes with Type-2 chronic CNVMs. Presence of retinal pigment epithelium breach and tear and nonaggressive treatment regimen with intravitreal anti-vascular endothelial growth factor injections could be responsible for its pathogenesis. It is a marker of fibrotic enlargement, leading to poor visual outcomes despite showing favorable therapeutic response.
C1 [Venkatesh, Ramesh; Mangla, Rubble; Mishra, Pranjal; Nahata, Harshita; Yadav, Naresh K.] Narayana Nethralaya, Dept Retina & Vitreous, 121-C,1st R Block,Chord Rd, Bengaluru 560010, India.
   [Chhablani, Jay] Univ Pittsburgh, Sch Med, Med Retina & Vitreoretinal Surg, Pittsburgh, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Venkatesh, R (通讯作者)，Narayana Nethralaya, Dept Retina & Vitreous, 121-C,1st R Block,Chord Rd, Bengaluru 560010, India.
EM vramesh80@yahoo.com
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Fajnkuchen F, 2016, RETINA-J RET VIT DIS, V36, P476, DOI 10.1097/IAE.0000000000000746
   Fu B, 2017, INT J OPHTHALMOL-CHI, V10, P535, DOI 10.18240/ijo.2017.04.06
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jung JJ, 2021, RETINA-J RET VIT DIS, V41, P2106, DOI 10.1097/IAE.0000000000003153
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim Hyung Chan, 2012, Korean J Ophthalmol, V26, P347, DOI 10.3341/kjo.2012.26.5.347
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Martin DF, 2020, OPHTHALMOLOGY, V127, pS135, DOI 10.1016/j.ophtha.2020.01.029
   Metrangolo C, 2021, J OPHTHALMOL, V2021, DOI 10.1155/2021/9994098
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saenz-de-Viteri M, 2021, ACTA OPHTHALMOL, V99, P861, DOI 10.1111/aos.14786
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Taylor AW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.724601
   Tenbrock L, 2022, CELL TISSUE RES, V387, P361, DOI 10.1007/s00441-021-03514-8
   Venkatesh R, 2021, EUR J OPHTHALMOL, DOI 10.1177/11206721211064017
   Venkatesh R, 2022, CAN J OPHTHALMOL, V57, P328, DOI 10.1016/j.jcjo.2021.05.017
   Venkatesh R, 2021, OCUL IMMUNOL INFLAMM, DOI 10.1080/09273948.2021.1903934
   Wang FH, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/7530458
   Yamaguchi Y, 2007, AM J OPHTHALMOL, V144, P260, DOI 10.1016/j.ajo.2007.04.007
NR 30
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2022
VL 42
IS 6
BP 1012
EP 1019
DI 10.1097/IAE.0000000000003436
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1K9HA
UT WOS:000798904200005
PM 35152246
DA 2022-11-30
ER

PT J
AU Tao, Y
   Jonas, JB
AF Tao, Yong
   Jonas, Jost B.
TI Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone for
   Therapy-Resistant Exudative Age-Related Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION;
   COMBINATION THERAPY; RANIBIZUMAB; INJECTION; ACETONIDE; PREVALENCE;
   MEMBRANES; BLINDNESS; EFFICACY
AB Purpose: To investigate the effect of intravitreal bevacizumab (IVB) combined with intravitreal high-dose triamcinolone acetonide (IVTA) for therapy of exudative age-related macular degeneration (AMD) after unsuccessful IVB monotherapy.
   Methods: The prospective study included 29 White patients (31 eyes) who consecutively received IVB (1.5 mg) plus high-dose IVTA (20-25 mg) for exudative AMD, after they had received multiple IVB mono-injections without functional and anatomical success. Two additional IVB injections were given in intervals of 2 months after the combined injection. The main outcome parameters were best-corrected visual acuity (BCVA) and data measured by optic coherence tomography (OCT).
   Results: Mean BCVA (LogMAR) improved from 0.70 +/- 0.37 LogMAR at baseline to 0.59 +/- 0.38 LogMAR at 2 months after first follow-up (P = 0.004) and to 0.63 +/- 0.41 LogMAR (P = 0.04) at 4 months after baseline. It deteriorated to 0.68 +/- 0.41 at the end of the follow-up at 7 months after the combined injection, without a significant (P = 0.53) difference to the baseline visual acuity. The maximum macular thickness decreased significantly from 371 +/- 206 mu m at baseline to 322 +/- 90 mu m (P = 0.04) at the first follow-up and to 316 +/- 90 mu m (P = 0.03) at the second follow-up. It slightly increased toward the end of follow-up (333 +/- 133 mu m; P = 0.16). Intraocular pressure increased marginally significantly (P = 0.06) from 14.5 +/- 2.8 mm Hg to 15.7 +/- 3.3 mm Hg at the second follow-up.
   Conclusions: Patients with exudative AMD, in whom monotherapy with IVB was unsuccessful, may experience a temporary improvement in vision and reduction in macular thickness after a combined intravitreal injection of bevacizumab and triamcinolone.
C1 [Tao, Yong; Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
   [Tao, Yong] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
C3 Ruprecht Karls University Heidelberg; Peking University
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
OI Tao, Yong/0000-0003-1443-2667
FU German Academic Exchange Service (DAAD)
FX The work of Yong Tao was supported by K.C. Wong Fellowship from the
   German Academic Exchange Service (DAAD).
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Colucciello M, 2008, J OCUL PHARMACOL TH, V24, P15, DOI 10.1089/jop.2007.0080
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   Gopal Lekha, 2007, Indian Journal of Ophthalmology, V55, P431
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   JONAS JB, 2009, ACTA OPHTHALMOL 0427
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Jonas JB, 2006, OPHTHALMIC RES, V38, P324, DOI 10.1159/000096226
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P194, DOI 10.1089/jop.2006.22.194
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Nicolo M, 2005, EUR J OPHTHALMOL, V15, P415, DOI 10.1177/112067210501500318
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
NR 37
TC 14
Z9 15
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD APR
PY 2010
VL 26
IS 2
BP 207
EP 211
DI 10.1089/jop.2009.0131
PG 5
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 587KF
UT WOS:000276990000012
PM 20415625
DA 2022-11-30
ER

PT J
AU Ferrington, DA
   Sinha, D
   Kaarniranta, K
AF Ferrington, Deborah A.
   Sinha, Debasish
   Kaarniranta, Kai
TI Defects in retinal pigment epithelial cell proteolysis and the pathology
   associated with age-related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Autophagy; Proteasome; Proteostasis;
   Lysosome; Retinal pigment epithelium
ID OUTER-SEGMENT MEMBRANES; HUMAN RPE MELANOSOMES; COMPLEMENT ACTIVATION;
   OXIDATIVE STRESS; PHAGOSOME MATURATION; PHOTORECEPTOR PHAGOCYTOSIS;
   PROTEASOME SUBUNIT; NLRP3 INFLAMMASOME; PROGRESSIVE STAGES; DRUSEN
   FORMATION
AB Maintenance of protein homeostasis, also referred to as "Proteostasis", integrates multiple pathways that regulate protein synthesis, folding, translocation, and degradation. Failure in proteostasis may be one of the underlying mechanisms responsible for the cascade of events leading to age-related macular degeneration (AMD). This review covers the major degradative pathways (ubiquitin-proteasome and lysosomal involvement in phagocytosis and autophagy) in the retinal pigment epithelium (RPE) and summarizes evidence of their involvement in AMD. Degradation of damaged and misfolded proteins via the proteasome occurs in coordination with heat shock proteins. Evidence of increased content of proteasome and heat shock proteins in retinas from human donors with AMD is consistent with increased oxidative stress and extensive protein damage with AMD. Phagocytosis and autophagy share key molecules in phagosome maturation as well as degradation of their cargo following fusion with lysosomes. Phagocytosis and degradation of photoreceptor outer segments ensures functional integrity of the neural retina. Autophagy rids the cell of toxic protein aggregates and defective mitochondria. Evidence suggesting a decline in autophagic flux includes the accumulation of autophagic substrates and damaged mitochondria in RPE from AMD donors. An age-related decrease in lysosomal enzymatic activity inhibits autophagic clearance of outer segments, mitochondria, and protein aggregates, thereby accelerating the accumulation of lipofuscin. This cumulative damage over a person's lifetime tips the balance in RPE from a state of para-inflammation, which strives to restore cell homeostasis, to the chronic inflammation associated with AMD. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, 2001 6th St SE, Minneapolis, MN 55455 USA.
   [Sinha, Debasish] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Room M035 Robert & Clarice Smith Bldg, Baltimore, MD 21287 USA.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, POB 100, Kys 70029, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, POB 100, Kys 70029, Finland.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   Johns Hopkins University; Johns Hopkins Medicine; University of Eastern
   Finland; Kuopio University Hospital
RP Ferrington, DA (通讯作者)，Univ Minnesota, Dept Ophthalmol & Visual Neurosci, 2001 6th St SE, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu; debasish@jhmi.edu; kai.kaarniranta@uef.fi
OI Kaarniranta, Kai/0000-0003-2600-8679; Ferrington,
   Deborah/0000-0003-2561-7464
FU National Institutes of Health [EY019037, EY019037-S]; Finnish Eye
   Foundation; VTR grant [5503743]; Foundation Fighting Blindness
   [0613-0620-UMN]; Arnold and Mabel Beckman Initiative for Macular
   Research [1303]; Minnesota Lions Vision Foundation; Wilmer Eye Institute
   from the Research to Prevent Blindness; Elaine and Robert Larson Endowed
   Vision Research Chair; Bright-Focus Foundation; Research to Prevent
   Blindness; Department of Ophthalmology and Visual Neuroscience (U of
   MN); NATIONAL EYE INSTITUTE [R01EY019037] Funding Source: NIH RePORTER
FX The authors would like to acknowledge funding support from National
   Institutes of Health EY019037 (DS), EY019037-S (DS), The Finnish Eye
   Foundation (KK), The VTR grant (5503743) for Kuopio University Hospital
   (KK), Foundation Fighting Blindness (0613-0620-UMN, DF), Arnold and
   Mabel Beckman Initiative for Macular Research (1303, DF), an anonymous
   benefactor for AMD Research (DF), Minnesota Lions Vision Foundation
   (DF), and unrestricted grants to the Department of Ophthalmology and
   Visual Neuroscience (U of MN) and the Wilmer Eye Institute from the
   Research to Prevent Blindness.; DF is the recipient of the Elaine and
   Robert Larson Endowed Vision Research Chair. DS is a recipient of the
   Carolyn K. McGillvray Memorial Award for Macular Degeneration Research
   from Bright-Focus Foundation and the Sybil B. Harrington Special Scholar
   Award for Macular Degeneration from Research to Prevent Blindness.
CR Agarwal AK, 2010, AM J HUM GENET, V87, P866, DOI 10.1016/j.ajhg.2010.10.031
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arima K, 2011, P NATL ACAD SCI USA, V108, P14914, DOI 10.1073/pnas.1106015108
   Ban T, 2010, HUM MOL GENET, V19, P2113, DOI 10.1093/hmg/ddq088
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   BESHARSE JC, 1977, SCIENCE, V196, P536, DOI 10.1126/science.300504
   Birgisdottir AB, 2013, J CELL SCI, V126, P3237, DOI 10.1242/jcs.126128
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bobu C, 2009, INVEST OPHTH VIS SCI, V50, P3495, DOI 10.1167/iovs.08-3145
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Burke JM, 2007, PHOTOCHEM PHOTOBIOL, V83, P920, DOI 10.1111/j.1751-1097.2007.00081.x
   Burnside B., 1998, RETINAL PIGMENT EPIT, P41
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Caberoy NB, 2010, EMBO J, V29, P3898, DOI 10.1038/emboj.2010.265
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Ciechanover A, 2014, BBA-MOL CELL RES, V1843, P86, DOI 10.1016/j.bbamcr.2013.07.007
   Ciechanover A, 2012, BBA-PROTEINS PROTEOM, V1824, P3, DOI 10.1016/j.bbapap.2011.03.007
   Clausen TH, 2010, AUTOPHAGY, V6, P330, DOI 10.4161/auto.6.3.11226
   Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101
   Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Dahlmann B, 2000, J MOL BIOL, V303, P643, DOI 10.1006/jmbi.2000.4185
   Damek-Poprawa M, 2009, J BIOL CHEM, V284, P10877, DOI 10.1074/jbc.M808857200
   Daugaard M, 2007, CANCER RES, V67, P2559, DOI 10.1158/0008-5472.CAN-06-4121
   Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DEGUCHI J, 1994, INVEST OPHTH VIS SCI, V35, P568
   Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Durcan TM, 2015, GENE DEV, V29, P989, DOI 10.1101/gad.262758.115
   Ebermann I, 2007, HUM MUTAT, V28, P571, DOI 10.1002/humu.20478
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELDRED GE, 1993, NATURE, V364, P396
   Elliott MR, 2010, J CELL BIOL, V189, P1059, DOI 10.1083/jcb.201004096
   Eskelinen EL, 2008, INT REV CEL MOL BIO, V266, P207, DOI 10.1016/S1937-6448(07)66005-5
   Ethen CM, 2007, FEBS LETT, V581, P885, DOI 10.1016/j.febslet.2007.01.061
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferguson TA, 2014, AUTOPHAGY, V10, P165, DOI 10.4161/auto.26735
   Fernandes AF, 2008, J BIOL CHEM, V283, P20745, DOI 10.1074/jbc.M800268200
   Ferrington DA, 2008, J NEUROCHEM, V106, P158, DOI 10.1111/j.1471-4159.2008.05345.x
   Ferrington DA, 2012, PROG MOL BIOL TRANSL, V109, P75, DOI 10.1016/B978-0-12-397863-9.00003-1
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   FISHER SK, 1983, INVEST OPHTH VIS SCI, V24, P844
   Freeman GJ, 2010, IMMUNOL REV, V235, P172, DOI 10.1111/j.0105-2896.2010.00903.x
   Fricker M, 2012, J NEUROSCI, V32, P2657, DOI 10.1523/JNEUROSCI.4837-11.2012
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   Gregerson DS, 2006, INVEST OPHTH VIS SCI, V47, P5385, DOI 10.1167/iovs.06-0636
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haroon N, 2012, ARTHRITIS RHEUM-US, V64, P1119, DOI 10.1002/art.33430
   Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Hoppe G, 2004, CELL MOL LIFE SCI, V61, P1664, DOI 10.1007/s00018-004-4080-5
   Hussong SA, 2011, INVEST OPHTH VIS SCI, V52, P714, DOI 10.1167/iovs.10-6032
   Hussong SA, 2010, J NEUROCHEM, V113, P1481, DOI 10.1111/j.1471-4159.2010.06688.x
   Hyttinen JMT, 2014, AGEING RES REV, V18, P16, DOI 10.1016/j.arr.2014.07.002
   Hyttinen JMT, 2013, BBA-MOL CELL RES, V1833, P503, DOI 10.1016/j.bbamcr.2012.11.018
   IMMEL JH, 1985, CELL TISSUE RES, V239, P667
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jung T, 2014, REDOX BIOL, V2, P99, DOI 10.1016/j.redox.2013.12.008
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kay P, 2014, INVEST OPHTH VIS SCI, V55, P926, DOI 10.1167/iovs.13-13239
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kinchen JM, 2008, NAT REV MOL CELL BIO, V9, P781, DOI 10.1038/nrm2515
   Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363
   Kitamura A, 2011, J CLIN INVEST, V121, P4150, DOI 10.1172/JCI58414
   Kivinen N., 2014, J BIOCHEM, V2, P1
   Klare N, 2007, J MOL BIOL, V373, P1, DOI 10.1016/j.jmb.2007.07.038
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Knowles A, 2009, J NEUROSCI, V29, P1152, DOI 10.1523/JNEUROSCI.0429-08.2009
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Lai CM, 2000, MOL THER, V2, P476, DOI 10.1006/mthe.2000.0195
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   Li W, 2013, AGEING RES REV, V12, P1005, DOI 10.1016/j.arr.2013.05.006
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Liu Y, 2012, ARTHRITIS RHEUM-US, V64, P895, DOI 10.1002/art.33368
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Maldonado M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056187
   Marques FC, 2015, ANNU REV PATHOL-MECH, V10, P1, DOI 10.1146/annurev-pathol-012414-040508
   McCray BA, 2008, NEUROSIGNALS, V16, P75, DOI 10.1159/000109761
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mustafi D, 2011, FASEB J, V25, P3157, DOI 10.1096/fj.11-186767
   Nandrot EF, 2014, ADV EXP MED BIOL, V801, P77, DOI 10.1007/978-1-4614-3209-8_10
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   ODAY WT, 1978, J CELL BIOL, V76, P593, DOI 10.1083/jcb.76.3.593
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Paimela T, 2011, PHARMACOL RES, V64, P501, DOI 10.1016/j.phrs.2011.05.027
   Pallanck LJ, 2010, J CELL BIOL, V191, P1225, DOI 10.1083/jcb.201011068
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329
   Park SY, 2008, J BIOL CHEM, V283, P10593, DOI 10.1074/jbc.M709105200
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pierpaoli EV, 2005, ANN NY ACAD SCI, V1057, P206, DOI 10.1196/annals.1356.014
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Poon IKH, 2014, NAT REV IMMUNOL, V14, P166, DOI 10.1038/nri3607
   Pozdeyev N, 2006, J NEUROSCI, V26, P9153, DOI 10.1523/JNEUROSCI.1384-06.2006
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Ragauskaite L, 2001, PHOTOCHEM PHOTOBIOL, V74, P483, DOI 10.1562/0031-8655(2001)074<0483:EEOTPO>2.0.CO;2
   Rakoczy PE, 1997, BIOCHEM J, V324, P935, DOI 10.1042/bj3240935
   Rechsteiner M., 1999, TRENDS BIOCHEM SCI, V21, P267
   Reggiori F., 2012, INT J CELL BIOL
   Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637
   Reszka K, 1995, PHOTOCHEM PHOTOBIOL, V62, P1005
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   Rozanowski B, 2008, INVEST OPHTH VIS SCI, V49, P2838, DOI 10.1167/iovs.08-1700
   Rubinsztein DC, 2012, CURR BIOL, V22, pR29, DOI 10.1016/j.cub.2011.11.034
   Ruggiero L., 2014, SPRINGER SERIES VISI
   Ryhanen T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/798052
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schuld NJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126768
   Skaar JR, 2014, NAT REV DRUG DISCOV, V13, P889, DOI 10.1038/nrd4432
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stephenson LM, 2009, AUTOPHAGY, V5, P625, DOI 10.4161/auto.5.5.8133
   Su HB, 2011, TRENDS CARDIOVAS MED, V21, P224, DOI 10.1016/j.tcm.2012.05.015
   Subrizi A, 2015, PHARM RES-DORDR, V32, P211, DOI 10.1007/s11095-014-1456-6
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971
   Svenning S, 2013, ESSAYS BIOCHEM, V55, P79, DOI [10.1042/bse0550079, 10.1042/BSE0550079]
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tschernutter M, 2006, BRIT J OPHTHALMOL, V90, P718, DOI 10.1136/bjo.2005.084897
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viiri J, 2010, MOL VIS, V16, P1399
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   WILLIAMS DS, 1987, INVEST OPHTH VIS SCI, V28, P184
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Wong E., 2010, COLD SPRING HARB PER, V12
   Wu Y, 2006, TRENDS CELL BIOL, V16, P189, DOI 10.1016/j.tcb.2006.02.003
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1968, J CELL BIOL, V39, P169, DOI 10.1083/jcb.39.1.169
   YOUNG RW, 1977, J ULTRA MOL STRUCT R, V61, P172, DOI 10.1016/S0022-5320(77)80084-1
   YOUNG RW, 1978, INVEST OPHTH VIS SCI, V17, P105
   Zaiss DMW, 2011, J IMMUNOL, V187, P2302, DOI 10.4049/jimmunol.1101003
   Zhao H, 2013, INVEST OPHTH VIS SCI, V54, P5321, DOI 10.1167/iovs.13-12122
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zhou Z, 2008, TRENDS CELL BIOL, V18, P474, DOI 10.1016/j.tcb.2008.08.002
   Zigler JS, 2011, J CELL SCI, V124, P523, DOI 10.1242/jcs.078790
NR 189
TC 132
Z9 138
U1 1
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2016
VL 51
BP 69
EP 89
DI 10.1016/j.preteyeres.2015.09.002
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DG3AD
UT WOS:000371941000003
PM 26344735
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nittala, MG
   Corvi, F
   Maram, J
   Velaga, SB
   Haines, J
   Pericak-Vance, MA
   Stambolian, D
   Sadda, SR
AF Nittala, Muneeswar G.
   Corvi, Federico
   Maram, Jyotsna
   Velaga, Swetha B.
   Haines, Jonathan
   Pericak-Vance, Margaret A.
   Stambolian, Dwight
   Sadda, SriniVas R.
TI Risk Factors for Progression of Age-Related Macular Degeneration:
   Population-Based Amish Eye Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; Amish eye study; complete retinal
   pigment epithelial and outer retina atrophy; geographic atrophy; optical
   coherence tomography
ID RETICULAR PSEUDODRUSEN; DISEASE; ASSOCIATION
AB Objective: To evaluate the optical coherence tomography (OCT)-based risk factors for progression to late age-related macular degeneration (AMD) in a population-based study of elderly Amish. Methods: A total of 1332 eyes of 666 consecutive subjects who completed a 2-year follow-up visit were included in this multicenter, prospective, longitudinal, observational study. Imaging features were correlated with 2-year incidence of late AMD development. Odds ratios for imaging features were estimated from logistic regression. Baseline OCT images were reviewed for the presence of drusen volume >= 0.03 mm(3) in the central 3 mm ring, intraretinal hyperreflective foci (IHRF), hyporeflective drusen cores (hDC), subretinal drusenoid deposits (SDD), and drusenoid pigment epithelium detachment (PED). Subfoveal choroidal thickness, drusen area, and drusen volume within 3 and 5 mm circles centered on the fovea were also assessed. Results: Twenty-one (1.5%) of 1332 eyes progressed to late AMD by 2 years. The mean age of the study subjects was 65 +/- 10.17 (+/- SD) years and 410 subjects were female. Univariate logistic regression showed that drusen area and volume in both 3 mm and 5 mm circles, subfoveal choroidal thickness, drusen volume >= 0.03 mm(3) in the 3 mm ring, SDD, IHRF, and hDC were all associated with an increased risk for development of late AMD. The multivariate regression model identified that drusen volume in the 3 mm ring (OR: 2.59, p = 0.049) and presence of IHRF (OR: 57.06, p < 0.001) remained as independent and significant risk factors for progression to late AMD. Conclusions: This population-based study confirms previous findings from clinic-based studies that high central drusen volume and IHRF are associated with an increased risk of progression to late AMD. These findings may be of value in risk-stratifying patients in clinical practice or identifying subjects for early intervention clinical trials.
C1 [Nittala, Muneeswar G.; Corvi, Federico; Maram, Jyotsna; Velaga, Swetha B.; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
   [Haines, Jonathan] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Pericak-Vance, Margaret A.] Univ Miami, John P Hussman Inst Human Genom, Miller Sch Med, Miami, FL 33136 USA.
   [Stambolian, Dwight] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 Doheny Eye Institute; Case Western Reserve University; University of
   Miami; University of Pennsylvania; Pennsylvania Medicine; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.; Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
EM ssadda@doheny.org
OI Corvi, Federico/0000-0002-2661-5500
FU National Eye Institute, Bethesda, Maryland [RO1 EY023164]; Department of
   Ophthalmology at the Perelman School of Medicine, Univ. of Pennsylvania,
   Philadelphia, Pennsylvania; John P. Hussman Institute of Human Genomics
   at the University of Miami Miller School of Medicine, Miami, Florida;
   Institute for Computational Biology, Case Western Reserve University,
   Cleveland, Ohio; F.M. Kirby Foundation; Research to Prevent Blindness
FX Supported by the National Eye Institute, Bethesda, Maryland (grant #RO1
   EY023164), the Department of Ophthalmology at the Perelman School of
   Medicine, Univ. of Pennsylvania, Philadelphia, Pennsylvania, John P.
   Hussman Institute of Human Genomics at the University of Miami Miller
   School of Medicine, Miami, Florida and the Institute for Computational
   Biology, Case Western Reserve University, Cleveland, Ohio. Funds also
   were received from the F.M. Kirby Foundation and Research to Prevent
   Blindness.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Nittala MG, 2019, RETINA-J RET VIT DIS, V39, P1540, DOI 10.1097/IAE.0000000000002210
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 26
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2022
VL 11
IS 17
AR 5110
DI 10.3390/jcm11175110
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 4K3UH
UT WOS:000851878700001
PM 36079043
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhou, M
   Duan, PC
   Liang, JH
   Zhang, XF
   Pan, CW
AF Zhou, Miao
   Duan, Pei-Chen
   Liang, Jing-Hong
   Zhang, Xiao-Feng
   Pan, Chen-Wei
TI Geographic distributions of age-related macular degeneration incidence:
   a systematic review and meta-analysis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Epidemiology
ID 5-YEAR INCIDENCE; RISK-FACTORS; RACIAL-DIFFERENCES; VISUAL IMPAIRMENT;
   10-YEAR INCIDENCE; 6-YEAR INCIDENCE; FOLLOW-UP; MACULOPATHY;
   PROGRESSION; PREVALENCE
AB Purpose We performed a systematic review and meta-analysis to summarise the geographic distribution of age-related macular degeneration (AMD) incidence. Methods Databases including PubMed, Embase and Web of Science were searched for publications of early and late AMD before September 2019. Studies were included if they applied a standardised photographic assessment and classification system. The proportion of participants with AMD in each eligible study was combined to obtain a pooled incidence from all studies using a random effects model. We also assessed sources of potential heterogeneity in the incidence of AMD using meta-regression analyses for both late and early AMD. Results Twenty-four population-based studies (70 123 individuals aged 55 years or older) were included in the meta-analysis. The pooled global annual incidences of early and late AMD were 1.59% (95% CI 1.12% to 2.10%) and 0.19% (95% CI: 0.13% to 0.28%), respectively. Individuals of European descent had the highest annual incidence of both early (2.73%, 95% CI 1.63% to 4.57%) and late (0.36%, 95% CI 0.17% to 0.75%) AMD than other ethnic groups. Average age (p=0.001) at baseline, ethnicity (p=0.001), region (p=0.043) and gender (p=0.011) were predictors for incident late AMD, while only average age (p=0.01) at baseline and ethnicity (p=0.025) was associated with incidence of early AMD. Conclusions This meta-analysis offers an up-to-date overview of AMD globally, which may provide scientific guidance for the design and implementation of public health strategies such as screening programmes for AMD in both specific geographic locations and ethnic groups, as well as worldwide.
C1 [Zhou, Miao; Duan, Pei-Chen; Pan, Chen-Wei] Soochow Univ, Sch Publ Hlth, Med Coll, 199 Ren Rd, Suzhou 215123, Peoples R China.
   [Liang, Jing-Hong] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Peoples R China.
   [Zhang, Xiao-Feng] Soochow Univ, Dept Ophthalmol, Affiliated Hosp 1, 188 Shizi St, Suzhou 215000, Peoples R China.
C3 Soochow University - China; Sun Yat Sen University; Soochow University -
   China
RP Pan, CW (通讯作者)，Soochow Univ, Sch Publ Hlth, Med Coll, 199 Ren Rd, Suzhou 215123, Peoples R China.; Zhang, XF (通讯作者)，Soochow Univ, Dept Ophthalmol, Affiliated Hosp 1, 188 Shizi St, Suzhou 215000, Peoples R China.
EM zhangxiaofeng@suda.edu.cn; pcwonly@gmail.com
RI Liang, Jinghong/AAE-7171-2022
OI Zhou, Miao/0000-0002-6374-7334; Liang, Jinghong/0000-0001-9237-7291
FU Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD)
FX This study was supported by the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD).
CR Baker ML, 2008, STROKE, V39, P1371, DOI 10.1161/STROKEAHA.107.496091
   Bastawrous A, 2017, JAMA OPHTHALMOL, V135, P631, DOI 10.1001/jamaophthalmol.2017.1109
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Caramoy A, 2014, ACTA OPHTHALMOL, V92, P745, DOI 10.1111/aos.12437
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Foo VHX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27202-w
   Founti P., 2016, INVEST OPHTHALMOL VI, V57, P12, DOI [10.1167/iovs.16-19420, DOI 10.1167/IOVS.16-19420]
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoy D, 2012, J CLIN EPIDEMIOL, V65, P934, DOI 10.1016/j.jclinepi.2011.11.014
   Hussain RM, 2017, OSLI RETINA, V48, P780, DOI 10.3928/23258160-20170928-01
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kashiwagi K, 2005, JPN J OPHTHALMOL, V49, P36, DOI 10.1007/s10384-004-0143-2
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Farinha CVL, 2019, OPHTHALMIC RES, V61, P226, DOI 10.1159/000496393
   McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Patton WP, 1999, INVEST OPHTH VIS SCI, V40, P3268
   Petrea RE, 2009, STROKE, V40, P1032, DOI 10.1161/STROKEAHA.108.542894
   Phan K, 2015, INT J CARDIOL, V182, P213, DOI 10.1016/j.ijcard.2014.12.146
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sabanayagam C, 2019, LANCET DIABETES ENDO, V7, P140, DOI 10.1016/S2213-8587(18)30128-1
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tratsk KS, 2003, GRAEF ARCH CLIN EXP, V241, P852, DOI 10.1007/s00417-003-0747-0
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zhao B, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0498-z
NR 71
TC 7
Z9 7
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2021
VL 105
IS 10
BP 1427
EP 1434
DI 10.1136/bjophthalmol-2020-316820
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UZ8JS
UT WOS:000702446300021
PM 32907810
DA 2022-11-30
ER

PT J
AU Tiosano, L
   Byon, I
   Alagorie, AR
   Ji, YS
   Sadda, SR
AF Tiosano, Liran
   Byon, Iksoo
   Alagorie, Ahmed Roshdy
   Ji, Yong-Sok
   Sadda, Srinivas R.
TI Choriocapillaris flow deficit associated with intraretinal
   hyperreflective foci in intermediate age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Hyperreflective foci; Choriocapillaris flow deficit; Age-related macular
   degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; SWEPT-SOURCE; GEOGRAPHIC ATROPHY;
   ANGIOGRAPHY; DISEASE; MIGRATION; EYES; PROGRESSION; MECHANISMS
AB Purpose To evaluate the choriocapillaris (CC) flow deficit (FD) beneath drusen associated with overlying intraretinal hyperreflective foci (HRF). Methods Patients with intermediate age-related macular degeneration (AMD) who had structural spectral-domain optical coherence tomography (SD-OCT) and OCT angiography (OCTA) using the Cirrus HD-OCT with AngioPlex software were retrospectively evaluated. A 6 x 6-mm-volume scan was used for the SD-OCT and OCTA. Post-imaging processing steps included generation of drusen map, identification of HRF, and generation of a signal-compensated CC slab prior to binarization and CC FD computation. The CC OCTA image was aligned with the drusen + HRF map to define regions of interest for CC FD measurement. The CC was quantified below drusen with and without overlying HRF and within a 150-mu m-wide ring surrounding the drusen (unaffected by potential HRF-related shadowing), and across the entire 6 x 6 macular region. Results Fifty-three eyes with intermediate AMD were included, 25 eyes with HRF, and 28 eyes with no HRF. The mean +/- SD FD% over the whole 6 x 6 macular region was 41.1 +/- 3.4 in eyes with HRF compared with 39.5 +/- 3.5 in eyes without HRF (p = 0.001). The mean +/- SD CC FD% below drusen with HRF (54.4 +/- 9.3) was significantly greater than below drusen without HRF (49.6 +/- 9.5;p = 0.001). There was a strong positive correlation between the quantity of HRF and the extent of the CC FD (Pearson correlation = 0.81). Conclusion Choriocapillaris flow deficits appear to be more severe in eyes with HRF and in particular directly below HRF. As HRF are thought to represent a higher risk or more advanced feature of intermediate AMD, these findings highlight the relationship between the severity of CC FD and overall severity of AMD.
C1 [Tiosano, Liran; Byon, Iksoo; Alagorie, Ahmed Roshdy; Ji, Yong-Sok; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading & Res Lab, 1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
   [Tiosano, Liran; Byon, Iksoo; Alagorie, Ahmed Roshdy; Ji, Yong-Sok; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Tiosano, Liran] Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   [Tiosano, Liran] Hebrew Univ Jerusalem, Hadassah Sch Med, Jerusalem, Israel.
   [Byon, Iksoo] Pusan Natl Univ, Yangsan Hosp, Res Inst Convergence Biomed Sci & Technol, Dept Ophthalmol,Sch Med, Yangsan, South Korea.
   [Alagorie, Ahmed Roshdy] Tanta Univ, Fac Med, Dept Ophthalmol, Tanta, Egypt.
   [Ji, Yong-Sok] Chonnam Natl Univ, Dept Ophthalmol, Med Sch & Hosp, Gwangju, South Korea.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Hebrew University of
   Jerusalem; Hadassah University Medical Center; Hebrew University of
   Jerusalem; Pusan National University; Pusan National University
   Hospital; Egyptian Knowledge Bank (EKB); Tanta University; Chonnam
   National University
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading & Res Lab, 1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.; Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
EM Sadda@doheny.org
RI Alagorie, Ahmed/AAW-5304-2020
OI Alagorie, Ahmed/0000-0001-5489-0617
CR Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2019, RETINA-J RET VIT DIS, V39, P1216, DOI 10.1097/IAE.0000000000002123
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Eye TA, 2013, 8 AREDS, P119
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Jack LS, 2016, DEV OPHTHALMOL, V55, P302, DOI 10.1159/000438954
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lei JQ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36279-2
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Mitsuhiro MRKH, 2003, ACTA OPHTHALMOL SCAN, V81, P630, DOI 10.1111/j.1395-3907.2003.00170.x
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Muller PL, 2018, INVEST OPHTH VIS SCI, V59, pAMD122, DOI 10.1167/iovs.18-23819
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   THULLIEZ M, 2019, IMAGING OPHTHALMOL R, V3, P478, DOI DOI 10.1016/j.oret.2019.01.024
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 40
TC 13
Z9 13
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2020
VL 258
IS 11
BP 2353
EP 2362
DI 10.1007/s00417-020-04837-y
EA JUL 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH1OE
UT WOS:000548520000001
PM 32666252
DA 2022-11-30
ER

PT J
AU Pinna, A
   Zaccheddu, F
   Boscia, F
   Carru, C
   Solinas, G
AF Pinna, Antonio
   Zaccheddu, Francesco
   Boscia, Francesco
   Carru, Ciriaco
   Solinas, Giuliana
TI Homocysteine and risk of age-related macular degeneration: a systematic
   review and meta-analysis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; meta-analysis; random-effects model;
   systematic review; total plasma homocysteine
ID PLASMA HOMOCYSTEINE; CARDIOVASCULAR BIOMARKERS; INFLAMMATORY MARKERS;
   SERUM HOMOCYSTEINE; OXIDATIVE STRESS; FOLIC-ACID; ANTI-VEGF;
   POLYMORPHISM; FOLATE; DETERMINANTS
AB There is still no agreement on total plasma homocysteine (tHcy) role in age-related macular degeneration (AMD), the leading cause of new blindness in industrialized countries. We performed a systematic review and meta-analysis of the published data on the correlation between tHcy and AMD. MEDLINE/PubMed and ISI Web of Sciences searches were performed according to MOOSE guidelines. Case-control studies were eligible for inclusion. Participants and controls were AMD patients and subjects without AMD. The main outcome measure was wet AMD. Homocysteine level was the main exposure variable. Data were pooled using a random-effects model. Twelve case-control studies were identified: 10 assessed wet AMD, four dry AMD, one early AMD, one late AMD, and one any AMD. As for wet AMD, there was a total of 453 cases and 514 controls. Mean tHcy was on average 1.1mol/l (95% confidence interval [CI]=0.96-1.25) greater in wet AMD cases, but there was evidence of extreme between-study heterogeneity (p<0.001, I-2=91.8%). In a model homogenous for age, including six wet AMD studies (214 cases, 274 controls), mean tHcy was on average 0.58mol/l (95% CI=0.35-0.73) greater in the case group, a not statistically significant result (p=0.144) associated with moderate heterogeneity (I-2=39.2%). Our meta-analysis indicates that there is some weak evidence that increased tHcy might be associated with wet AMD; however, this result should be interpreted cautiously, because of a marked between-study heterogeneity and the possible effect of publication bias. Future studies, preferably of cohort design, are necessary before any firm conclusions on the putative role of increased tHcy on AMD can be drawn.
C1 [Pinna, Antonio; Zaccheddu, Francesco; Boscia, Francesco] Univ Sassari, Ophthalmol Unit, Dept Surg Microsurg & Med Sci, Sassari, Italy.
   [Pinna, Antonio; Boscia, Francesco; Carru, Ciriaco] Azienda Osped Univ Sassari, Sassari, Italy.
   [Carru, Ciriaco] Univ Sassari, Dept Biomed Sci, Clin Biochem Sect, Sassari, Italy.
   [Solinas, Giuliana] Univ Sassari, Dept Biomed Sci, Lab Epidemiol & Biostat, Sassari, Italy.
C3 University of Sassari; University of Sassari; University of Sassari;
   University of Sassari
RP Pinna, A (通讯作者)，Univ Sassari, Sect Ophthalmol, Dept Surg Microsurg & Med Sci, Viale San Pietro 43 A, I-07100 Sassari, Italy.
EM apinna@uniss.it
RI Carru, Ciriaco/AAI-9996-2021; Pinna, Antonio/H-5067-2018; Boscia,
   Francesco/AAC-7729-2022
OI Pinna, Antonio/0000-0003-3052-2662; Solinas,
   Giuliana/0000-0003-2174-0983; Carru, Ciriaco/0000-0002-6985-4907
CR Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bharathselvi M, 2013, ANN CLIN BIOCHEM, V50, P330, DOI 10.1177/0004563213492146
   Cahill MT, 2003, AM J OPHTHALMOL, V136, P1136, DOI 10.1016/S0002-9394(03)00571-3
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Christen WG, 2015, OPHTHAL EPIDEMIOL, V22, P85, DOI 10.3109/09286586.2015.1012272
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Evans J, 2013, AM J CLIN NUTR, V98, P4, DOI 10.3945/ajcn.113.064899
   FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Haidich AB, 2010, HIPPOKRATIA, V14, P29
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hozo S.P., 2005, BMC MED RES METHODOL, V5, DOI DOI 10.1186/1471-2288-5-13
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Javadzadeh A, 2012, RETINA-J RET VIT DIS, V32, P658, DOI 10.1097/IAE.0b013e31822529b1
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawada T, 2013, AM J CLIN NUTR, V98, P1144, DOI 10.3945/ajcn.113.071142
   Keles S, 2014, CLIN OPHTHALMOL, V8, P1573, DOI 10.2147/OPTH.S66160
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Manresa N, 2015, J NUTR HEALTH AGING, V19, P228, DOI 10.1007/s12603-014-0531-3
   Manresa N, 2015, RETINA-J RET VIT DIS, V35, P1765, DOI 10.1097/IAE.0000000000000552
   McCarty MF, 2000, MED HYPOTHESES, V55, P386, DOI 10.1054/mehy.2000.1075
   McGimpsey SJ, 2009, OPHTHALMOLOGY, V116, P1778, DOI 10.1016/j.ophtha.2009.02.033
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Mulero J, 2014, CLIN HEMORHEOL MICRO, V58, P447, DOI 10.3233/CH-141807
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Nowak Mariusz, 2004, Klin Oczna, V106, P429
   Nygard O, 1998, AM J CLIN NUTR, V67, P263, DOI 10.1093/ajcn/67.2.263
   Obeid R, 2013, CLIN CHEM LAB MED, V51, P657, DOI 10.1515/cclm-2012-0402
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Pinna A, 2006, INVEST OPHTH VIS SCI, V47, P4067, DOI 10.1167/iovs.06-0290
   Pinna A, 2016, CURR EYE RES, V41, P88, DOI 10.3109/02713683.2014.1002044
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Roybal CN, 2005, J BIOL CHEM, V280, P20331, DOI 10.1074/jbc.M411275200
   Saa J, 2014, ACTA OPHTHALMOL, V92, pe582, DOI 10.1111/aos.12357
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Woodside JV, 1998, AM J CLIN NUTR, V67, P858, DOI 10.1093/ajcn/67.5.858
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 57
TC 16
Z9 17
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2018
VL 96
IS 3
BP E269
EP E276
DI 10.1111/aos.13343
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GE0NY
UT WOS:000430912700001
PM 27966830
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Merle, BMJ
   Silver, RE
   Rosner, B
   Seddon, JM
AF Merle, Benedicte M. J.
   Silver, Rachel E.
   Rosner, Bernard
   Seddon, Johanna M.
TI Associations Between Vitamin D Intake and Progression to Incident
   Advanced Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE vitamin D; advanced age-related macular degeneration; epidemiology;
   nutrition; progression
ID 3RD NATIONAL-HEALTH; C-REACTIVE PROTEIN; GENETIC SUSCEPTIBILITY; DIETARY
   OMEGA-3-FATTY-ACIDS; GLAUCOMA PREVALENCE; FISH CONSUMPTION;
   BETA-CAROTENE; RISK-FACTORS; SUPPLEMENTATION; MACULOPATHY
AB PURPOSE. There is growing evidence of the importance of nutrition in age-related macular degeneration (AMD), but no prospective studies have explored the impact of vitamin D. We evaluated the association between vitamin D intake and progression to advanced AMD.
   METHODS. Among 2146 participants (3965 eyes), 541 (777 eyes) progressed from early or intermediate AMD to advanced disease (mean follow-up: 9.4 years) based on ocular imaging. Nutrients were log transformed and calorie adjusted. Survival analysis was used to assess associations between incident advanced disease and vitamin D intake. Neovascular disease (NV) and geographic atrophy (GA) were evaluated separately. Combined effects of dietary vitamin D and calcium were assessed based on high or low consumption of each nutrient.
   RESULTS. There was a lower risk of progression to advanced AMD in the highest versus lowest quintile of dietary vitamin D intake after adjustment for demographic, behavioral, ocular, and nutritional factors (hazard ratio [HR]: 0.60; 95% confidence interval [CI]: 0.43-0.83; P trend = 0.0007). Similar results were observed for NV (HR: 0.59; 95% CI: 0.39-0.89; P trend = 0.005) but not GA (HR: 0.83; 95% CI: 0.53-1.30; P trend = 0.35). A protective effect was observed for advanced AMD among participants with high vitamin D and low calcium compared to the group with low levels for each nutrient (HR: 0.67; 95% CI: 0.50-0.88; P = 0.005). When supplement use was considered, the effect was in the protective direction but was not significant.
   CONCLUSIONS. A diet rich in vitamin D may prevent or delay progression to advanced AMD, especially NV. Additional exploration is needed to elucidate the potential protective role of vitamin D and its contribution to reducing visual loss.
C1 [Merle, Benedicte M. J.] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Lifelong Exposures,Hlth & Aging, Bordeaux, France.
   [Silver, Rachel E.; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Rosner, Bernard] Harvard Univ, Harvard Med Sch, Channing Div Network Med, Boston, MA 02115 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; Tufts
   Medical Center; Harvard University; Harvard Medical School; Tufts
   University; Tufts University; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Merle, Benedicte MJ/AAQ-5021-2021; Merle, Benedicte MJ/F-1247-2015
OI Merle, Benedicte MJ/0000-0003-1332-0954; Merle, Benedicte
   MJ/0000-0003-1332-0954
FU National Institutes of Health [R01-EY011309, R01-EY022445];
   Massachusetts Lions Eye Research Fund, Inc., New Bedford, Massachusetts;
   Laboratoires Thea, Clermont-Ferrand, France; American Macular
   Degeneration Foundation, Northampton, MA; Age-Related Macular
   Degeneration Research Fund, Ophthalmic Epidemiology and Genetics
   Service, Tufts Medical Center, Tufts University School of Medicine,
   Boston, Massachusetts; NATIONAL EYE INSTITUTE [R01EY011309, R01EY022445]
   Funding Source: NIH RePORTER
FX Supported by Grants R01-EY011309 (JMS) and R01-EY022445 (BR) from the
   National Institutes of Health. JMS also received support from the
   Massachusetts Lions Eye Research Fund, Inc., New Bedford, Massachusetts;
   Laboratoires Thea, Clermont-Ferrand, France; American Macular
   Degeneration Foundation, Northampton, MA; and the Age-Related Macular
   Degeneration Research Fund, Ophthalmic Epidemiology and Genetics
   Service, Tufts Medical Center, Tufts University School of Medicine,
   Boston, Massachusetts. The funding sources had no role in relation to
   the following: design and conduct of the study; collection, management,
   analysis, and interpretation of the data; and preparation, review, or
   approval of the manuscript; and decision to submit the manuscript for
   publication.
CR AJANI UA, 1994, INVEST OPHTH VIS SCI, V35, P2725
   Annweiler C, 2016, MATURITAS, V88, P101, DOI 10.1016/j.maturitas.2016.04.002
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Feldman D, 2014, NAT REV CANCER, V14, P342, DOI 10.1038/nrc3691
   Glynn RJ, 2012, OPHTHAL EPIDEMIOL, V19, P159, DOI 10.3109/09286586.2012.674614
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Hewison M, 2010, ENDOCRIN METAB CLIN, V39, P365, DOI 10.1016/j.ecl.2010.02.010
   Institute of Medicine, 2011, DIETARY REFERENCE IN
   JOHNSON JA, 1995, CURR EYE RES, V14, P101, DOI 10.3109/02713689508999921
   Kakigi CLM, 2015, JAMA OPHTHALMOL, V133, P746, DOI 10.1001/jamaophthalmol.2015.0514
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Schleithoff SS, 2006, AM J CLIN NUTR, V83, P754, DOI 10.1093/ajcn/83.4.754
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Seddon JM, 2010, MOL VIS, V16, P2412
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Wang SY, 2013, CURR EYE RES, V38, P1049, DOI 10.3109/02713683.2013.803124
   Wang SY, 2012, INVEST OPHTH VIS SCI, V53, P725, DOI 10.1167/iovs.11-9038
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 47
TC 23
Z9 23
U1 1
U2 21
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2017
VL 58
IS 11
BP 4569
EP 4578
DI 10.1167/iovs.17-21673
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH2BS
UT WOS:000410944300016
PM 28892825
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Fernandez, AB
   Wong, TY
   Klein, R
   Collins, D
   Burke, G
   Cotch, MF
   Klein, B
   Sadeghi, MM
   Chen, J
AF Fernandez, Antonio B.
   Wong, Tien Y.
   Klein, Ronald
   Collins, Dorothea
   Burke, Gregory
   Cotch, Mary Frances
   Klein, Barbara
   Sadeghi, Mehran M.
   Chen, Jersey
TI Age-Related Macular Degeneration and Incident Cardiovascular Disease:
   The Multi-Ethnic Study of Atherosclerosis
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; MYOCARDIAL-INFARCTION; RISK; NEOVASCULARIZATION;
   INFLAMMATION; POLYMORPHISM; MACULOPATHY; PREVALENCE
AB Objective: To determine whether age-related macular degeneration (AMD) is a risk indicator for coronary heart disease (CHD) and cardiovascular disease (CVD) events independent of other known risk factors in a multi-ethnic cohort.
   Design: Population-based prospective cohort study.
   Participants: A diverse population sample of 6233 men and women aged 45 to 84 years without known CVD from the Multi-Ethnic Study of Atherosclerosis (MESA).
   Methods: Participants in the MESA had retinal photographs taken between 2002 and 2003. Photographs were evaluated for AMD. Incident CHD and CVD events were ascertained during clinical follow-up visits for up to 8 years after the retinal images were taken.
   Main Outcome Measures: Incident CHD and CVD events.
   Results: Of the 6814 persons at risk of CHD, there were 893 participants with early AMD (13.1%) and 27 patients (0.5%) at baseline. Over a mean follow-up period of 5.4 years, there was no statistically significant difference in incident CHD or CVD between the AMD and non-AMD groups (5.0% vs. 3.9%, P = 0.13 for CHD and 6.6% vs. 5.5%, P = 0.19 for CVD). In Cox regression models adjusting for CVD risk factors, there was no significant relationship between presence of any AMD and any CHD/CVD events (hazard ratio 0.99; 95% confidence interval, 0.74-1.33; P = 0.97). No significant association was found between subgroups of early AMD or late AMD and incident CHD/CVD events.
   Conclusions: In persons without a history of CVD, AMD was not associated with an increased risk of CHD or CVD.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:765-770 (C) 2012 by the American Academy of Ophthalmology.
C1 [Fernandez, Antonio B.] Brown Univ, Warren Alpert Sch Med, Div Cardiol, Providence, RI 02903 USA.
   [Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117595, Singapore.
   [Klein, Ronald; Klein, Barbara] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Collins, Dorothea; Sadeghi, Mehran M.] VA Connecticut Healthcare Syst, West Haven, CT USA.
   [Burke, Gregory] Wake Forest Univ, Bowman Gray Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Sadeghi, Mehran M.; Chen, Jersey] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA.
C3 Brown University; National University of Singapore; Singapore National
   Eye Center; University of Wisconsin System; University of Wisconsin
   Madison; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Connecticut Healthcare System; Wake Forest
   University; Wake Forest Baptist Medical Center; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); Yale University
RP Fernandez, AB (通讯作者)，Brown Univ, Sch Med, Rhode Isl Hosp, Dept Cardiol, 593 Eddy St, Providence, RI 02903 USA.
EM antoinefernandezt@hotmail.com
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cotch, Mary
   Frances/0000-0002-2046-4350; Klein, Ronald/0000-0002-4428-6237
FU National Heart, Lung, and Blood Institute [HL69979-03, N01-HC-95159,
   N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164,
   N01-HC-95165, N01-HC-95166]; Agency for Healthcare Research and Quality
   [1K08HS018781-01]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY
   [K08HS018781] Funding Source: NIH RePORTER; DIVISION OF EPIDEMIOLOGY AND
   CLINICAL APPLICATIONS [N01HC095159, N01HC095166] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [ZIAEY000403] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R13HL095166,
   R01HL069979] Funding Source: NIH RePORTER
FX This research was supported by Grant HL69979-03 to Dr. Klein and Dr.
   Wong and by contracts N01-HC-95159 to N01-HC-95166 from the National
   Heart, Lung, and Blood Institute. Dr. Chen is supported by an award from
   the Agency for Healthcare Research and Quality (1K08HS018781-01).
CR Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fleiner M, 2004, CIRCULATION, V110, P2843, DOI 10.1161/01.CIR.0000146787.16297.E8
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Hogg RE, 2007, OPHTHALMOLOGY, V115, P1046
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Kolodgie FD, 2007, J AM COLL CARDIOL, V49, P2093, DOI 10.1016/j.jacc.2006.10.083
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Moreno PR, 2006, CIRCULATION, V113, P2245, DOI 10.1161/CIRCULATIONAHA.105.578955
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Pulido JS, 2007, MAYO CLIN PROC, V82, P301, DOI 10.4065/82.3.301
   Sluimer JC, 2008, J AM COLL CARDIOL, V51, P1258, DOI 10.1016/j.jacc.2007.12.025
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Virmani R, 2005, ARTERIOSCL THROM VAS, V25, P2054, DOI 10.1161/01.ATV.0000178991.71605.18
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 31
TC 35
Z9 35
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2012
VL 119
IS 4
BP 765
EP 770
DI 10.1016/j.ophtha.2011.09.044
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 919UQ
UT WOS:000302355400015
PM 22197438
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Maugeri, A
   Barchitta, M
   Fallico, M
   Castellino, N
   Reibaldi, M
   Agodi, A
AF Maugeri, Andrea
   Barchitta, Martina
   Fallico, Matteo
   Castellino, Niccolo
   Reibaldi, Michele
   Agodi, Antonella
TI Characterization of SIRT1/DNMTs Functions and LINE-1 Methylation in
   Patients with Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE retinal degeneration; AMD; DNA methylation; DNMT; SIRT1; LINE-1
ID DNA METHYLATION; PERIPHERAL-BLOOD; ALZHEIMERS-DISEASE; GENE-EXPRESSION;
   IL17RC PROMOTER; SIRT1; HYPOMETHYLATION; DEMETHYLATION
AB Previous studies proposed the application of DNA methylation signatures as clinical biomarkers of age-related macular degeneration (AMD). However, the characterization of Long Interspersed Nuclear Element-1 (LINE-1) methylation levels-a surrogate marker of global DNA methylation-in AMD patients has not been investigated so far. In the present study, we first characterized DNA methyltransferases (DNMTs) and Sirtuin 1 (SIRT1) functions in blood samples of 40 AMD patients and 10 age- and sex-matched controls. Then, we evaluated whether changes in DNMTs functions were associated with different LINE-1 methylation levels in leukocyte DNA. We demonstrated that total DNMTs activity was 48% higher in AMD patients than in controls (p = 0.005). AMD patients also exhibited up-regulation of DNMT1 and DNMT3B expression (FC = 2.6; p = 0.003 and FC = 2.4; p = 0.018, respectively). In line with increased DNMTs functions, the LINE-1 methylation level was higher in AMD patients than in controls (mean = 69.10%; SE = 0.68 vs. mean = 65.73%; SE = 0.59; p = 0.020). All p-values were adjusted by Bonferroni correction. In AMD patients, LINE-1 methylation level was positively associated with total DNMTs activity (r = 0.694; p < 0.001), DNMT1 (r = 0.579; p < 0.001), and DNMT3B (r = 0.521; p = 0.001) expression. Our results encourage further large-size prospective research to understand the relationship between LINE-1 methylation and AMD aetiology, and its usefulness in the clinical setting.
C1 [Maugeri, Andrea; Barchitta, Martina; Agodi, Antonella] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, I-95123 Catania, Italy.
   [Fallico, Matteo; Castellino, Niccolo; Reibaldi, Michele] Univ Catania, Dept Ophthalmol, I-95123 Catania, Italy.
C3 University of Catania; University of Catania
RP Reibaldi, M (通讯作者)，Univ Catania, Dept Ophthalmol, I-95123 Catania, Italy.
EM andreamaugeri88@gmail.com; martina.barchitta@unict.it;
   matteofallico@hotmail.com; ncastellino7@gmail.com; mreibaldi@libero.it;
   agodia@unict.it
RI Barchitta, Martina/A-1362-2015; Reibaldi, Michele/AAL-1113-2021;
   Castellino, Niccolò/AAC-4717-2022; Agodi, Antonella/AIF-3938-2022;
   Fallico, Matteo/AAC-5284-2022; Maugeri, Andrea/K-1018-2017; Agodi,
   Antonella/B-3501-2011
OI Barchitta, Martina/0000-0002-0905-5003; Agodi,
   Antonella/0000-0002-4405-8162; Maugeri, Andrea/0000-0003-2655-8574;
   Agodi, Antonella/0000-0002-4405-8162; FALLICO,
   MATTEO/0000-0003-2639-1321
FU Department of Medical and Surgical Sciences and Advanced Technologies
   "GF Ingrassia", University of Catania (Piano Triennale di Sviluppo delle
   Attivita di Ricerca Scientifica del Dipartimento)
FX This research was partially funded by the Department of Medical and
   Surgical Sciences and Advanced Technologies "GF Ingrassia", University
   of Catania (Piano Triennale di Sviluppo delle Attivita di Ricerca
   Scientifica del Dipartimento-2016-2018).
CR Agodi A, 2015, GENES NUTR, V10, DOI 10.1007/s12263-015-0480-4
   Auclair G, 2012, BIOCHIMIE, V94, P2202, DOI 10.1016/j.biochi.2012.05.016
   Balaiya S, 2013, MOL VIS, V19, P2385
   Barchitta M, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00514
   Barchitta M, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3582-0
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   Barchitta M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109478
   Bollati V, 2011, BRAIN BEHAV IMMUN, V25, P1078, DOI 10.1016/j.bbi.2011.01.017
   Carreira PE, 2014, FEBS J, V281, P63, DOI 10.1111/febs.12601
   De Araujo ESS, 2015, MELANOMA RES, V25, P173, DOI 10.1097/CMR.0000000000000141
   Di Francesco A, 2015, BRAIN BEHAV IMMUN, V45, P139, DOI 10.1016/j.bbi.2014.11.002
   DUPONT WD, 1988, BIOMETRICS, V44, P1157, DOI 10.2307/2531743
   Fabris S, 2007, LEUKEMIA, V21, P1113, DOI 10.1038/sj.leu.2404616
   FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Halili MA, 2009, CURR TOP MED CHEM, V9, P309, DOI 10.2174/156802609788085250
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kang H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15560
   Katoh M, 2013, INT J MOL MED, V32, P763, DOI 10.3892/ijmm.2013.1444
   Liu RH, 2013, J FOOD SCI, V78, pA18, DOI 10.1111/1750-3841.12101
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maugeri A, 2019, ACTA OPHTHALMOL, V97, pE8, DOI 10.1111/aos.13849
   Maugeri A, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/5407482
   Maugeri A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072118
   Nusgen N, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0051-y
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Peng CH, 2011, BIOMATERIALS, V32, P9077, DOI 10.1016/j.biomaterials.2011.08.008
   Peng LR, 2011, MOL CELL BIOL, V31, P4720, DOI 10.1128/MCB.06147-11
   Pobsook T, 2011, CLIN CHIM ACTA, V412, P314, DOI 10.1016/j.cca.2010.10.030
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Rodic N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003402
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
NR 39
TC 18
Z9 18
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD FEB
PY 2019
VL 8
IS 2
AR 159
DI 10.3390/jcm8020159
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HN6KR
UT WOS:000460295400032
PM 30717113
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, KY
   Zhong, QL
   Chen, SY
   Guo, CX
   Xu, Y
   Liu, Y
   Sun, W
   Yan, YJ
   Zhao, PN
AF Zhang, Kaiyan
   Zhong, Qionglei
   Chen, Siying
   Guo, Chuanxian
   Xu, Yan
   Liu, Yang
   Sun, Wen
   Yan, Yijie
   Zhao, Puning
TI An epidemiological investigation of age-related macular degeneration in
   aged population in China: the Hainan study
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Aged population; Hainan Province; Risk
   factor
ID SINGAPORE MALAY EYE; CARDIOVASCULAR RISK-FACTORS; ANGELES LATINO EYE;
   5-YEAR INCIDENCE; ALCOHOL-CONSUMPTION; ADULT-POPULATION;
   CIGARETTE-SMOKE; BEIJING EYE; MACULOPATHY; DIETARY
AB Purpose The aim of this study was to investigate the prevalence of age-related macular degeneration (AMD) and the risk factors in the residents aged >= 50 years in Hainan Province.
   Methods Random sampling was carried out in four separated cities in Hainan Province in 2015. All the subjects accomplished the standard questionnaire and ocular examinations. The diagnosis of AMD was performed based on the criteria proposed by Beckman Initiative for Macular Research Classification Committee.
   Results Three hundred and fifty-seven subjects (15.6%) were diagnosed with AMD, including 267 (11.7%) of early AMD, 64 (2.80%) of intermediate AMD and 24 (1.1%) of late AMD, respectively. The factors associated with the prevalence of AMD included age, educational level, smoking, outdoor activities and diet. The prevalence of AMD increased with age, lower educational level, smoking or less outdoor activities. The prevalence of AMD in those with a diet of meat or eggs was higher compared with a diet of vegetables or fish. The prevalence of early, intermediate and late AMD in the aged population in Hainan Province was 11.7, 2.8 and 1.1%, respectively.
   Conclusions Age and smoking were the risk factors for AMD, while the educational level and outdoor activities were the protective factors. Early AMD mostly occurred in those aged 50-59 years and 60-69 years, while intermediate and late AMD occurred in 70-79 years and older than 80 years.
C1 [Zhang, Kaiyan; Zhong, Qionglei; Chen, Siying; Guo, Chuanxian; Xu, Yan; Liu, Yang; Sun, Wen; Yan, Yijie; Zhao, Puning] Hainan Prov Peoples Hosp, Dept Ophthalmol, Haikou 570311, Hainan, Peoples R China.
RP Zhang, KY (通讯作者)，Hainan Prov Peoples Hosp, Dept Ophthalmol, Haikou 570311, Hainan, Peoples R China.
EM zhangkaiyan0898@outlook.com
RI CHEN, SI/GZL-4800-2022
FU Hainan Provincial Social Development Special Fund for Science and
   Technology Grant [SF201412]; Hainan medical and health research project
   [14A200031]
FX This study was supported by the Hainan Provincial Social Development
   Special Fund for Science and Technology Grant (SF201412) and Hainan
   medical and health research project (14A200031).
CR Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Bingham SA, 2002, J NUTR, V132, p3522S, DOI 10.1093/jn/132.11.3522S
   Bingham SA, 1996, CARCINOGENESIS, V17, P515, DOI 10.1093/carcin/17.3.515
   Bourne R. R., 2013, LANCET GLOB HEALTH, V1, pe339
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   James WPT, 1997, BMJ-BRIT MED J, V314, P1545, DOI 10.1136/bmj.314.7093.1545
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   LOTFI K, 1991, INVEST OPHTH VIS SCI, V32, P3028
   Mathenge W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001393
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Nidhi B, 2013, INDIAN J OPHTHALMOL, V61, P722, DOI 10.4103/0301-4738.120218
   Njiric S, 2007, COLLEGIUM ANTROPOL, V31, P107
   Pham TQ, 2005, AM J OPHTHALMOL, V139, P536, DOI 10.1016/j.ajo.2004.08.070
   Pomp ER, 2008, THROMB HAEMOSTASIS, V99, P59, DOI 10.1160/TH07-07-0470
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shuker DEG, 1997, CANCER RES, V57, P366
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tomany SC, 2001, AM J OPHTHALMOL, V132, P271, DOI 10.1016/S0002-9394(01)00895-9
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wang A.L., 2009, PLOS ONE, V4
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 47
TC 5
Z9 5
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD AUG
PY 2018
VL 38
IS 4
BP 1659
EP 1667
DI 10.1007/s10792-017-0639-7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GN6EA
UT WOS:000439166500037
PM 28688024
OA Green Published
DA 2022-11-30
ER

PT J
AU Chang, AA
   Broadhead, GK
   Hong, T
   Joachim, N
   Syed, A
   Schlub, TE
   Toth, L
   Peto, T
   Zhu, MD
AF Chang, Andrew A.
   Broadhead, Geoffrey K.
   Hong, Thomas
   Joachim, Nichole
   Syed, Adil
   Schlub, Timothy E.
   Toth, Levente
   Peto, Tunde
   Zhu, Meidong
TI Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related
   Macular Degeneration: 12-Month Safety and Efficacy Outcomes
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Aflibercept; Treatment resistance; Intravitreal injection; Neovascular
   age-related macular degeneration
ID VEGF TRAP; RANIBIZUMAB; BEVACIZUMAB; THERAPY; ATROPHY; FLUID; EYE
AB Purpose: To prospectively assess the safety and efficacy of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration (nAMD). Methods: This prospective, non-randomized clinical trial included 49 patients with treatment-resistant nAMD who received 2 mg intravitreal aflibercept as 3 monthly loading doses, followed by injections every 2 months over 12 months. Inclusion criteria included active nAMD on fluorescein angiography at baseline and persistent intra-or subretinal fluid on optical coherence tomography (OCT) for >= 6 months prior to baseline with a minimum of 4 injections of bevacizumab and/or ranibizumab. Patients were assessed monthly for best-corrected visual acuity (BCVA), central retinal thickness (CRT) measured with OCT and occurrence of adverse events. Retinal pigment epithelium atrophy (RPEA) was assessed at baseline and at 12 months. Results: Mean BCVA improved by 4.7 letters (95% CI: 2.1-7.3, p < 0.001) and CRT decreased by 97.2 mu m (95% CI: 54.4-140.1, p < 0.001) at 12 months compared to baseline. Median RPEA area increased by 0.48 mm(2) (range = -0.1 to 19.9, p < 0.001). There was 1 arterial thromboembolic event and 2 cases of submacular haemorrhage. Conclusion: In this cohort of treatment-resistant nAMD patients, intravitreal aflibercept was effective in improving vision and reducing exudation. Early visual and anatomic outcomes may predict longer-term response to treatment, but further assessment is required. (c) 2015 S. Karger AG, Basel
C1 [Chang, Andrew A.; Broadhead, Geoffrey K.; Hong, Thomas; Joachim, Nichole; Syed, Adil; Zhu, Meidong] Univ Sydney, Sydney Inst Vis Sci, Sydney, NSW 2006, Australia.
   [Chang, Andrew A.; Broadhead, Geoffrey K.; Hong, Thomas; Joachim, Nichole; Syed, Adil; Zhu, Meidong] Univ Sydney, Sydney Retina Clin & Day Surg, Sydney, NSW 2006, Australia.
   [Chang, Andrew A.; Broadhead, Geoffrey K.; Zhu, Meidong] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Schlub, Timothy E.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [Toth, Levente; Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Toth, Levente; Peto, Tunde] UCL Inst Ophthalmol, London, England.
C3 University of Sydney; University of Sydney; University of Sydney;
   University of Sydney; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London
RP Chang, AA (通讯作者)，Sydney Retina Clin & Day Surg, Level 13,Pk House,187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
RI Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381; Schlub, Timothy/0000-0001-7746-9649
FU Bayer Corporation Global
FX Bayer Corporation Global provided financial support via an unrestricted
   research grant. The sponsor had no role in the design or conduct of this
   research.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Breslow NE, 1993, J AM STAT ASSOC, V88, P17
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   de Geus SJR, 2013, ACTA OPHTHALMOL, V91, pE411, DOI 10.1111/aos.12090
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 19
TC 14
Z9 14
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 55
IS 2
BP 84
EP 90
DI 10.1159/000440886
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA8SI
UT WOS:000368076000005
PM 26637166
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Flood, VM
   Louie, JCY
   Wang, JJ
   Burlutsky, G
   Rochtchina, E
   Mitchell, P
AF Gopinath, Bamini
   Flood, Victoria M.
   Louie, Jimmy C. Y.
   Wang, Jie Jin
   Burlutsky, George
   Rochtchina, Elena
   Mitchell, Paul
TI Consumption of dairy products and the 15-year incidence of age-related
   macular degeneration
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Age-related macular degeneration; Calcium; Dairy products; Blue
   Mountains Eye Study; Reduced fat foods
ID BLUE-MOUNTAINS-EYE; FOOD-FREQUENCY QUESTIONNAIRE; COMPLEMENT FACTOR-H;
   LONG-TERM INCIDENCE; RISK-FACTORS; 10-YEAR INCIDENCE; GLYCEMIC INDEX;
   COHORT; INFLAMMATION; MACULOPATHY
AB Habitual consumption of dairy products has been shown to play an important role in the prevention of several chronic diseases. We aimed to prospectively assess the relationship between the change in dairy product consumption (both regular fat and low/reduced fat) and the 15-year incidence of age-related macular degeneration (AMD). In the Blue Mountains Eye Study, 2037 participants aged 49 years or above at baseline were re-examined at follow-up in 1997-9, 2002-4 and/or 2007-9. AMD was assessed from retinal photographs. Dietary data were collected using a semi-quantitative FFQ, and servings of dairy product consumption calculated. Over the 15-year follow-up, there were 352, 268 and eighty-four incident cases of any, early and late AMD, respectively. After adjusting for age, sex, current smoking, white cell count and fish consumption, a significant linear trend (P for trend=0003) was observed with decreasing consumption of total dairy foods and the 15-year incidence of late AMD, comparing the lowest v. highest quintile of intake (OR 2.80, 95% CI 1.21, 3.04). Over the 15 years, decreased consumption of reduced-fat dairy foods was associated with an increased risk of incident late AMD, comparing the lowest to highest quintile of intake (OR 3.10, 95% CI 1.18, 8.14, P for trend=.004). Decreasing total dietary Ca intake over the 15 years was also associated with an increased risk of developing incident late AMD (multivariable-adjusted P for trend=0.03). A lower consumption of dairy products (regular and low fat) and Ca was independently associated with a higher risk of developing incident late AMD in the long term. Additional cohort studies are needed to confirm these findings.
C1 [Gopinath, Bamini; Wang, Jie Jin; Burlutsky, George; Rochtchina, Elena; Mitchell, Paul] Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   [Gopinath, Bamini; Wang, Jie Jin; Burlutsky, George; Rochtchina, Elena; Mitchell, Paul] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Flood, Victoria M.; Louie, Jimmy C. Y.] Univ Wollongong, Fac Hlth & Behav Sci, Sydney, NSW, Australia.
   [Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, Melbourne, Vic, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Wollongong; Centre for Eye Research
   Australia; University of Melbourne
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul.mitchell@sydney.edu.au
RI Flood, Victoria M/A-8732-2016; Gopinath, Bamini/K-4286-2019; wang,
   jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014; Mitchell,
   Paul/P-1498-2014; Louie, Jimmy Chun Yu/B-6754-2008
OI Flood, Victoria M/0000-0001-5310-7221; Gopinath,
   Bamini/0000-0003-3573-359X; Wang, Jie Jin/0000-0001-9491-4898; Louie,
   Jimmy Chun Yu/0000-0001-7736-605X
FU Australian National Health and Medical Research Council [974159, 991407,
   211069, 262120]; Westmead Millennium Institute; Macular Degeneration
   Foundation; Blackmores Dr Paul Beaumont Fellowship; Dairy Australia
FX The BMES was funded by the Australian National Health and Medical
   Research Council (grant no. 974159, 991407, 211069 and 262120), and
   Westmead Millennium Institute. B. G. was supported by a Macular
   Degeneration Foundation and Blackmores Dr Paul Beaumont Fellowship. P.
   M., J. C. Y. L., V. M. F. and G. B. previously received funding from
   Dairy Australia on other projects related to the BMES dataset. None of
   the funders had any role in the design, analysis or writing of this
   article.
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Barclay AW, 2008, PUBLIC HEALTH NUTR, V11, P573, DOI 10.1017/S1368980007001103
   Department of Community Services and Health, 1995, NUTTAB95 NUTR DAT TA
   Department of Community Services and Health, 1990, NUTTAB90 NUTR DAT TA
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Gibson RA, 2009, BRIT J NUTR, V102, P1267, DOI 10.1017/S0007114509371664
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   KLEIN BEK, 1989, INVEST OPHTH VIS SCI, V30, P304
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Lamarche B, 2008, J AM COLL NUTR, V27, p741S, DOI 10.1080/07315724.2008.10719752
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Louie JCY, 2013, NUTR METAB CARDIOVAS, V23, P816, DOI 10.1016/j.numecd.2012.08.004
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Malik VS, 2011, AM J CLIN NUTR, V94, P854, DOI 10.3945/ajcn.110.009621
   McLennan W, 1995, 48070 AUSTR BUR STAT
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mozaffarian D, 2010, ANN INTERN MED, V153, P790, DOI 10.7326/0003-4819-153-12-201012210-00005
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Schleithoff SS, 2006, AM J CLIN NUTR, V83, P754, DOI 10.1093/ajcn/83.4.754
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   ULM K, 1991, STAT MED, V10, P341, DOI 10.1002/sim.4780100306
   van Meijl LEC, 2011, NUTR METAB CARDIOVAS, V21, P355, DOI 10.1016/j.numecd.2009.10.008
   Verhaar MC, 1998, CIRCULATION, V97, P237, DOI 10.1161/01.CIR.97.3.237
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Zemel MB, 2008, J NUTR, V138, P1047, DOI 10.1093/jn/138.6.1047
   Zemel MB, 2009, PHYSICIAN SPORTSMED, V37, P29, DOI 10.3810/psm.2009.06.1707
   Zemel MB, 2010, AM J CLIN NUTR, V91, P16, DOI 10.3945/ajcn.2009.28468
NR 36
TC 25
Z9 25
U1 0
U2 12
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD MAY 14
PY 2014
VL 111
IS 9
BP 1673
EP 1679
DI 10.1017/S000711451300408X
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA AE2NT
UT WOS:000333810600015
PM 24502821
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Yeh, TC
   Luo, AC
   Deng, YS
   Lee, YH
   Chen, SJ
   Chang, PH
   Lin, CJ
   Tai, MC
   Chou, YB
AF Yeh, Tsai-Chu
   Luo, An-Chun
   Deng, Yu-Shan
   Lee, Yu-Hsien
   Chen, Shih-Jen
   Chang, Po-Han
   Lin, Chun-Ju
   Tai, Ming-Chi
   Chou, Yu-Bai
TI Prediction of treatment outcome in neovascular age-related macular
   degeneration using a novel convolutional neural network
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GEOGRAPHIC ATROPHY; IMAGING BIOMARKERS; VEGF; GROWTH
AB While prognosis and risk of progression are crucial in developing precise therapeutic strategy in neovascular age-related macular degeneration (nAMD), limited predictive tools are available. We proposed a novel deep convolutional neural network that enables feature extraction through image and non-image data integration to seize imperative information and achieve highly accurate outcome prediction. The Heterogeneous Data Fusion Net (HDF-Net) was designed to predict visual acuity (VA) outcome (improvement >= 2 line or not) at 12th months after anti-VEGF treatment. A set of pre-treatment optical coherence tomography (OCT) image and non-image demographic features were employed as input data and the corresponding 12th-month post-treatment VA as the target data to train, validate, and test the HDF-Net. This newly designed HDF-Net demonstrated an AUC of 0.989 (95% CI 0.970-0.999), accuracy of 0.936 [95% confidence interval (CI) 0.889-0.964], sensitivity of 0.933 (95% CI 0.841-0.974), and specificity of 0.938 (95% CI 0.877-0.969). By simulating the clinical decision process with mixed pre-treatment information from raw OCT images and numeric data, HDF-Net demonstrated promising performance in predicting individualized treatment outcome. The results highlight the potential of deep learning to simultaneously process a broad range of clinical data to weigh and leverage the complete information of the patient. This novel approach is an important step toward real-world personalized therapeutic strategy for typical nAMD.
C1 [Yeh, Tsai-Chu; Chen, Shih-Jen; Chou, Yu-Bai] Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sec 2,Shih Pai Rd, Taipei 11217, Taiwan.
   [Yeh, Tsai-Chu; Chen, Shih-Jen; Chou, Yu-Bai] Natl Yang Ming Chiao Tung Univ, Taipei, Taiwan.
   [Luo, An-Chun; Deng, Yu-Shan; Lee, Yu-Hsien; Chang, Po-Han; Lin, Chun-Ju; Tai, Ming-Chi] Ind Technol Res Inst, Hsinchu, Taiwan.
   [Tai, Ming-Chi] Natl Tsing Hua Univ, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; Industrial Technology Research Institute - Taiwan; National
   Tsing Hua University
RP Chou, YB (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sec 2,Shih Pai Rd, Taipei 11217, Taiwan.; Chou, YB (通讯作者)，Natl Yang Ming Chiao Tung Univ, Taipei, Taiwan.
EM suddenonset@gmail.com
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Boulesteix AL, 2012, WIRES DATA MIN KNOWL, V2, P493, DOI 10.1002/widm.1072
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gorin MB, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2019.107894
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   He K., 2016, P IEEE C COMPUTER VI, DOI DOI 10.1109/CVPR.2016.90
   Jaffe DH, 2018, J COMP EFFECT RES, V7, P1125, DOI 10.2217/cer-2018-0058
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Keenan TDL, 2021, OPHTHALMOLOGY, V128, P100, DOI [10.1016/j.opatha.2020.06.038, 10.1016/j.ophtha.2020.06.038]
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Li T, 2021, MED IMAGE ANAL, V69, DOI 10.1016/j.media.2021.101971
   Liu YT, 2020, BRIT J OPHTHALMOL, V104, P1735, DOI 10.1136/bjophthalmol-2019-315338
   Lv F, 2019, MATH PROBL ENG, V2019, DOI 10.1155/2019/3759607
   Rohm M, 2018, OPHTHALMOLOGY, V125, P1028, DOI 10.1016/j.ophtha.2017.12.034
   Schippert AC, 2018, GERONTOL GERIATR MED, V4, DOI 10.1177/2333721418801601
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Shen DG, 2017, ANNU REV BIOMED ENG, V19, P221, DOI [10.1146/annurev-bioeng-071516044442, 10.1146/annurev-bioeng-071516-044442]
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Yang J, 2021, EXPERT SYST APPL, V182, DOI 10.1016/j.eswa.2021.115068
NR 30
TC 1
Z9 1
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 7
PY 2022
VL 12
IS 1
AR 5871
DI 10.1038/s41598-022-09642-7
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 0I9YU
UT WOS:000779768200006
PM 35393449
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Semeraro, F
   Russo, A
   Delcassi, L
   Romano, MR
   Rinaldi, M
   Chiosi, F
   Costagliola, C
AF Semeraro, Francesco
   Russo, Andrea
   Delcassi, Luisa
   Romano, Mario R.
   Rinaldi, Michele
   Chiosi, Flavia
   Costagliola, Ciro
TI TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB
   COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; combination therapy; ketorolac eyedrops;
   photodynamic therapy; ranibizumab injections
ID RANDOMIZED CONTROLLED-TRIAL; CHOROIDAL NEOVASCULARIZATION; BROMFENAC
   0.09-PERCENT; NEPAFENAC 0.1-PERCENT; VERTEPORFIN; COMBINATION;
   PHACOEMULSIFICATION; 0.45-PERCENT; MONOTHERAPY; INHIBITION
AB Purpose:To evaluate whether ketorolac eyedrops plus intravitreal ranibizumab (IVR) or verteporfin photodynamic therapy plus IVR provides additional benefit over IVR monotherapy for treatment of choroidal neovascularization in age-related macular degeneration.Methods:This was a prospective, randomized, pilot study in 75 patients with naive choroidal neovascularization. Patients were randomized 1:1:1 into 3 groups: ranibizumab monotherapy (RM), ranibizumab plus ketorolac, or ranibizumab plus loading-phase reduced-fluence verteporfin photodynamic therapy (RV) groups.Results:At 12 months, all groups showed significant improvement in both best-corrected visual acuity and central retinal thickness. The mean best-corrected visual acuity change from baseline to 12 months was -0.14 0.52 logMAR (20/73 +/- 20/29), -0.25 +/- 0.60 logMAR (20/46 +/- 20/27), and -0.10 +/- 0.30 (20/97 +/- 20/40) logMAR in RM, ranibizumab plus ketorolac, and RV groups, respectively. The mean central retinal thickness change from baseline to 12 months was -125 +/- 15 m, -141 +/- 21 m, and -130 +/- 15 m in RM, ranibizumab plus ketorolac, and RV groups, respectively. Both ranibizumab plus ketorolac and RV groups required fewer IVR treatments than RM.Conclusion:Compared with RM and ranibizumab plus verteporfin photodynamic therapy, the combination of 0.45% ketorolac eyedrops 3 times a day and ranibizumab in patients with choroidal neovascularization provided superior best-corrected visual acuity and central retinal thickness outcomes. Both combination regimens required fewer IVR injections than RM during the 12-month follow-up period.
C1 [Semeraro, Francesco; Russo, Andrea; Delcassi, Luisa] Univ Brescia, Dept Neurol & Vis Sci, Eye Clin, I-125100 Brescia, Italy.
   [Romano, Mario R.] Humanitas Clin Inst, Milan, Italy.
   [Rinaldi, Michele] Univ Naples 2, Dept Ophthalmol, Naples, Italy.
   [Chiosi, Flavia; Costagliola, Ciro] Univ Molise, Dept Hlth Sci, Eye Clin, Campobasso, Italy.
C3 University of Brescia; Universita della Campania Vanvitelli; University
   of Molise
RP Russo, A (通讯作者)，Univ Brescia, Dept Neurol & Vis Sci, Eye Clin, Piazzale Spedale Civili, I-125100 Brescia, Italy.
EM dott.andrea.russo@gmail.com
RI Costagliola, Ciro/G-5707-2012; Semeraro, Francesco fs/K-8667-2016
OI Costagliola, Ciro/0000-0001-8477-6188; Semeraro, Francesco
   fs/0000-0002-2275-4917
CR Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Bashshur ZF, 2011, RETINA-J RET VIT DIS, V31, P636, DOI 10.1097/IAE.0b013e3181fe54ab
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bucci FA, 2011, ADV THER, V28, P1089, DOI 10.1007/s12325-011-0080-7
   Bucci FA, 2011, CURR MED RES OPIN, V27, P2235, DOI 10.1185/03007995.2011.626018
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Gallenga CE, 2014, INFLAMM RES, V63, P105, DOI 10.1007/s00011-013-0684-2
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Kim SJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P596, DOI 10.1001/archophthalmol.2010.69
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Parmeggiani F, 2010, OPHTHALMOLOGY, V117, P517, DOI 10.1016/j.ophtha.2009.08.028
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russo A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/476525
   Russo A, 2013, BRIT J OPHTHALMOL, V97, P1273, DOI 10.1136/bjophthalmol-2013-303417
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schoenberger SD, 2013, INT J INFLAM, V2013, P1
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Wittpenn JR, 2008, AM J OPHTHALMOL, V146, P554, DOI 10.1016/j.ajo.2008.04.036
   WORMALD R, 2007, COCHRANE DB SYST REV, V18
NR 33
TC 17
Z9 17
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2015
VL 35
IS 8
BP 1547
EP 1554
DI 10.1097/IAE.0000000000000525
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP4HX
UT WOS:000359843700007
PM 25784358
DA 2022-11-30
ER

PT J
AU Zhang, MX
   Zhao, XF
   Ren, YC
   Geng, TT
   Yang, H
   Feng, T
   Jin, TB
   Chen, C
AF Zhang, M. X.
   Zhao, X. F.
   Ren, Y. C.
   Geng, T. T.
   Yang, H.
   Feng, T.
   Jin, T. B.
   Chen, C.
TI Association between a functional genetic polymorphism (rs2230199) and
   age-related macular degeneration risk: a meta-analysis
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Polymorphism; Age-related macular degeneration; Rs2230199; Meta-analysis
ID COMPLEMENT-FACTOR-H; CHINESE POPULATION; VISUAL IMPAIRMENT; COMPONENT 3;
   C3; DISEASE; SUSCEPTIBILITY; PREVALENCE; ACTIVATION; VARIANTS
AB The association between the rs2230199 C>G single nucleotide polymorphism (SNP) in complement component 3 and age-related macular degeneration (AMD) risk has been examined extensively but the results are not consistent among studies. The aim of this study was to perform a meta-analysis of all available studies on this SNP in relation to AMD. The comprehensive databases of PubMed, Medline, Web of Knowledge, CNKI, and Google Scholar were searched for case-control studies investigating the association between the rs2230199 polymorphism and AMD susceptibility. ORs with 95% CIs were estimated to assess the association. Sensitivity analysis, test of heterogeneity, cumulative meta-analysis, and assessment of bias were also performed. A total of 15 published studies including 5593 cases and 5181 controls were used in this meta-analysis. Overall, the rs2230299 SNP was significantly associated with the risk of AMD in the overall population under the additive model (OR = 1.571, 95% CI = 1.414-1.745, P = 0.000), dominant model (OR = 1.681, 95% CI = 1.521-1.858, P = 0.000), and allelic model (OR = 1.597, 95% CI = 1.470-1.734, P = 0.000). In the subgroup analysis by ethnicity, the same results were found in Caucasian populations, while no significant correlations were found in Asian populations for all comparison models. In conclusion, our meta-analysis provides evidence that the rs2230199 polymorphism contributes to the development of AMD. Further large-scale multicenter epidemiological studies are warranted to confirm this finding.
C1 [Zhang, M. X.; Ren, Y. C.; Yang, H.; Jin, T. B.; Chen, C.] NW Univ Xian, Sch Life Sci, Xian 710069, Peoples R China.
   [Zhang, M. X.; Ren, Y. C.; Geng, T. T.; Yang, H.; Feng, T.; Jin, T. B.; Chen, C.] Natl Engn Res Ctr Miniaturized Detect Syst, Xian, Peoples R China.
   [Zhao, X. F.] Mil Area Gen Armed Police Hosp, Beijing, Peoples R China.
   [Jin, T. B.] Xizang Minzu Univ, Sch Med, Key Lab High Altitude Environm & Genes Related Di, Xianyang, Shaanxi, Peoples R China.
   [Geng, T. T.] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710049, Peoples R China.
C3 Northwest University Xi'an; Xizang Minzu University; Xi'an Jiaotong
   University
RP Jin, TB (通讯作者)，NW Univ Xian, Sch Life Sci, Xian 710069, Peoples R China.
EM tianbojin1975@163.com; cchen898@nwu.edu.cn
FU National 863 High-Technology Research and Development Program
   [2012AA02A519]; State Project for Essential Drug Research and
   Development [2012ZX09506001007]
FX Research supported by the National 863 High-Technology Research and
   Development Program (#2012AA02A519) and the State Project for Essential
   Drug Research and Development (Grant #2012ZX09506001007).
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mckay GJ, 2010, MOL VIS, V16, P194
   Mousavi M., 2013, J OPTOM, V6, P176, DOI [10.1016/j.optom.2013.07.002, DOI 10.1016/j.optom.2013.07.002]
   Munafo MR, 2004, TRENDS GENET, V20, P439, DOI 10.1016/j.tig.2004.06.014
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu LW, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-171
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 38
TC 12
Z9 12
U1 0
U2 4
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2015
VL 14
IS 4
BP 12567
EP 12576
DI 10.4238/2015.October.16.24
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CX7ZZ
UT WOS:000365922800093
PM 26505407
OA Bronze
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Liew, G
   Tang, DN
   Burlutsky, G
   Flood, VM
   Mitchell, P
AF Gopinath, Bamini
   Liew, Gerald
   Tang, Diana
   Burlutsky, George
   Flood, Victoria M.
   Mitchell, Paul
TI Consumption of eggs and the 15-year incidence of age-related macular
   degeneration
SO CLINICAL NUTRITION
LA English
DT Article
DE Age-related macular degeneration; Blue Mountains eye study; Eggs;
   Incidence
ID 10-YEAR INCIDENCE; CLINICAL-TRIAL; FATTY-ACIDS; VITAMIN-D;
   SUPPLEMENTATION; LUTEIN; MACULOPATHY; PREVALENCE; ZEAXANTHIN; AUSTRALIA
AB Background and aims: A naturally rich source of lutein and zeaxanthin are eggs. There is scarce epidemiological data on the temporal association between total egg consumption and age-related macular degeneration (AMD) incidence. We aimed to establish the prospective and independent association between consumption of eggs with the incidence of AMD over a 15-year follow-up.
   Methods: In this population-based cohort study of 3,654 participants aged 49 + years examined at baseline, 2034 participants had complete information on baseline egg consumption and AMD signs over 15 years. AMD was determined from retinal photographs. Egg consumption was assessed using a semi-quantitative food-frequency questionnaire. Total egg intake was calculated through summing up intakes in all forms e.g. boiled, poached, fried, scrambled and/or omelette. We summarized total egg consumption into the following categories: <= 1 egg/week; 2-4 eggs/week; 5-6 eggs/week; and >= 1 egg/day.
   Results: At baseline, participants who consumed 2-4 eggs/week compared to those who consumed <= 1 egg/week (reference group) had reduced risk of incident late-stage AMD after 15 years: multivariable-adjusted odds ratio, OR, 0.51 (95% confidence intervals, CI, 0.28-0.92). Participants who consumed 2 -4 eggs/week versus <= 1 egg/week at baseline had 62% reduced risk of developing neovascular AMD. Among those whose AMD onset was at or before the 10-year follow-up, consumption of 2-4 and 5-6 eggs/week was associated with 54% and 65% reduced risk of incident late AMD, respectively. When analyzed as a dichotomized variable, participants who consumed >1 egg/week versus <= 1 egg/week at baseline, had 46% reduced risk of developing late-stage AMD 15 years later: multivariable-adjusted OR 0.54 (95% CI 0.3-0.90). Non-significant associations were observed between egg consumption and incident early AMD.
   Conclusions: Our findings suggest that moderate consumption of eggs significantly reduces the risk of developing incident late-stage AMD over 15 years. (C) 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.
C1 [Gopinath, Bamini; Liew, Gerald; Tang, Diana; Burlutsky, George; Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
   [Flood, Victoria M.] Univ Sydney, Fac Hlth Sci, Sydney, NSW, Australia.
   [Flood, Victoria M.] Western Sydney Local Hlth Dist, Westmead Hosp, Westmead, NSW, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney; University of Sydney
RP Gopinath, B (通讯作者)，Westmead Hosp, Ctr Vis Res, Westmead, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Flood, Victoria M/A-8732-2016; Liew, Gerald/AAB-6870-2022
OI Flood, Victoria M/0000-0001-5310-7221; Tang, Diana/0000-0003-2007-9054
FU Australian National Health and Medical Research Council [974159, 991407,
   211069, 262120]; Westmead Institute for Medical Research
FX The Blue Mountains Eye Study was funded by the Australian National
   Health and Medical Research Council (Grant Nos. 974159, 991407, 211069,
   262120), and the Westmead Institute for Medical Research.
CR Annweiler C, 2016, MATURITAS, V88, P101, DOI 10.1016/j.maturitas.2016.04.002
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   COTTERILL OJ, 1977, POULTRY SCI, V56, P1927, DOI 10.3382/ps.0561927
   Flood VM, 2008, FOOD AUST, V60, P37
   Gopinath B, 2018, AM J CLIN NUTR, V108, P381, DOI 10.1093/ajcn/nqy114
   Gopinath B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122548
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly D, 2017, BRIT J NUTR, V117, P108, DOI 10.1017/S0007114516003895
   Kim JE, 2015, AM J CLIN NUTR, V102, P75, DOI 10.3945/ajcn.115.111062
   KLEIN BEK, 1989, INVEST OPHTH VIS SCI, V30, P304
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   McLennan W.A.S., 1995, NATL NUTR SURVEY CON
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   National Eye Institute National Institutes of Health, 2015, AG REL MAC DEG WHAT
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Ribaya-Mereado JD, 2004, J AM COLL NUTR, V23, p567S, DOI 10.1080/07315724.2004.10719427
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Smith Alison, 2016, Br J Community Nurs, V21, P305, DOI 10.12968/bjcn.2016.21.6.305
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 31
TC 11
Z9 12
U1 0
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0261-5614
EI 1532-1983
J9 CLIN NUTR
JI Clin. Nutr.
PD FEB
PY 2020
VL 39
IS 2
BP 580
EP 584
DI 10.1016/j.clnu.2019.03.009
PG 5
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA KO3DH
UT WOS:000515427600032
PM 30914217
DA 2022-11-30
ER

PT J
AU Kara, C
   Ozdal, PC
   Beyazyildiz, E
   Ozcan, NE
   Teke, MY
   Vural, G
   Ozturk, F
AF Kara, Caner
   Ozdal, Pinar C.
   Beyazyildiz, Emrullah
   Ozcan, Nurgul E.
   Teke, Mehmet Y.
   Vural, Gulden
   Ozturk, Faruk
TI Increased levels of circulating CD34+cells in neovascular age-related
   macular degeneration: relation with clinical and OCT features
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; CD34; Choroidal neovascularization;
   Optical coherence tomography; Stem cell
ID ENDOTHELIAL PROGENITOR CELLS; CHOROIDAL NEOVASCULARIZATION;
   RISK-FACTORS; STEM-CELLS; VASCULOGENESIS; MOBILIZATION; ISCHEMIA;
   THERAPY
AB Purpose: To investigate the levels of circulating CD34+ stem cells in patients with neovascular type age-related macular degeneration (AMD) and its relation with clinical and optical coherence tomography (OCT) findings.
   Methods: The study consisted of 55 patients: 28 patients (18 male and 10 female) with neovascular type AMD as a study group and 27 patients (12 male and 15 female) scheduled for cataract surgery as a control group. The level of CD34+ stem cells was measured by FLow cytometry. Demographic and clinical data were recorded.
   Results: The mean ages of patients in the study and control groups were 71 +/- 8 and 68 +/- 6 years, respectively. There was no statistically significant difference in terms of age, sex, or systemic disease association between study and control groups. However, smoking status was significantly higher in the study group (67.9% vs 37.0%; p = 0.02). Stem cell levels were significantly higher in the study group (1.5 +/- 0.9 vs 0.5 +/- 0.3; p<0.001), but there was no relation between stem cell levels and clinical and OCT findings.
   Conclusions: Increased circulating CD34+ stem cell levels were observed in patients with choroidal neovascular membrane associated with AMD, but no significant relation was found between cell levels and clinical and OCT findings.
C1 [Kara, Caner] Etlik Zubeyde Hanim Womens Hlth Educ & Res Hosp, Dept Ophthalmol, Yeni Etlik Caddesi 55, TR-06010 Ankara, Turkey.
   [Ozdal, Pinar C.; Teke, Mehmet Y.] Ulucanlar Eye Res & Training Hosp, Dept Retina & Vitreous Dis, Ankara, Turkey.
   [Beyazyildiz, Emrullah] Samsun Training & Res Hosp, Dept Ophthalmol, Samsun, Turkey.
   [Ozcan, Nurgul E.] Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Dept Biochem, Ankara, Turkey.
   [Vural, Gulden] Gazi Univ, Dept Hematol, Fac Med, Ankara, Turkey.
   [Ozturk, Faruk] Hacettepe Univ, Dept Ophthalmol, Fac Med, Ankara, Turkey.
C3 Etlik Zubeyde Hanim Gynecology Education & Research Hospital; Ankara
   Ulucanlar Eye Training & Research Hospital; Samsun Training & Research
   Hospital; Dr. Abdurrahman Yurtaslan Oncology Hospital; Gazi University;
   Hacettepe University
RP Kara, C (通讯作者)，Etlik Zubeyde Hanim Womens Hlth Educ & Res Hosp, Dept Ophthalmol, Yeni Etlik Caddesi 55, TR-06010 Ankara, Turkey.
EM canerkara@hotmail.com
RI Ozturk, Faruk/ABG-5457-2020; OZDAL, PINAR/ABD-9667-2020
OI Ozturk, Faruk/0000-0001-8441-2974; OZDAL, PINAR/0000-0002-5714-7172
CR Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397
   Kawamoto A, 2001, CIRCULATION, V103, P634
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498
   Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131
   Michaud SE, 2006, ATHEROSCLEROSIS, V187, P423, DOI 10.1016/j.atherosclerosis.2005.10.009
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Patel HR, 2015, OSLI RETINA, V46, P8, DOI 10.3928/23258160-20150101-01
   Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122
   Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9
   Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213
   Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434
   Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
NR 28
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2018
VL 28
IS 1
BP 80
EP 86
DI 10.5301/ejo.5001012
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC5BJ
UT WOS:000429800100015
PM 28777387
DA 2022-11-30
ER

PT J
AU Eperjesi, F
   Fowler, CW
   Evans, BJW
AF Eperjesi, F
   Fowler, CW
   Evans, BJW
TI Effect of light filters on reading speed in normal and low vision due to
   age-related macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; light filters; CPF450; Intuitive
   Colorimeter((R))
ID CHROMATIC ABERRATION; VISUAL FUNCTION; LENSES; SENSITIVITY;
   PSYCHOPHYSICS; PERFORMANCE; DISEASE
AB Purpose: To investigate the effects of light filters on reading speed in normal and low vision due to age-related macular degeneration (AMD).
   Methods: Reading speed was determined for 12 subjects with normal vision and 12 subjects with non-exudative AMD using stationary lowercase nonsensical print in Times Roman font and four light filters; a yellow Corning Photochromic Filter (CPF) 450, a grey neural density (ND) filter, an individual filter obtained using the Intuitive Colorimeter(R) and a clear filter.
   Results: There was no statistically significant light filter effect on reading speed for the normal subjects. The AMD group demonstrated a statistically significant 5% average improvement in reading speed with the CPF450 compared with the other filters although some AMD subjects had improvements of 10-15%.
   Conclusions: Light filters obtained using the Intuitive Colorimeter(R) performed poorly when compared with the CPF450, ND and clear filters for both the study groups. For the AMD group, average reading speed was statistically greater with the CPF450 than the other filters, however it is questionable whether the improvement (5%) would be clinically significant. As some of the subjects with AMD had greater improvements with the CPF450 we advocate clinical assessment of light filters using existing protocols on an individual basis.
C1 Aston Univ, Sch Life & Hlth Sci, Neurosci Res Inst, Birmingham B4 7ET, W Midlands, England.
   City Univ London, Dept Optometry & Visual Sci, London, England.
   Inst Optometry, London, England.
   Birmingham Focus Blindness, Low Vis Ctr, Birmingham, W Midlands, England.
C3 Aston University; City University London; University of London;
   University College London
RP Eperjesi, F (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Neurosci Res Inst, Birmingham B4 7ET, W Midlands, England.
EM f.eperjesi@aston.ac.uk
RI Eperjesi, Frank/A-9275-2013
OI Eperjesi, Frank/0000-0003-4358-0095
CR ABRAMOV I, 1977, J OPT SOC AM, V67, P195, DOI 10.1364/JOSA.67.000195
   AHN SJ, 1995, VISION RES, V35, P1939, DOI 10.1016/0042-6989(94)00294-V
   Armstrong RA, 2002, OPHTHAL PHYSL OPT, V22, P248, DOI 10.1046/j.1475-1313.2002.00020.x
   BAILEY I, 1978, LOW VISION ABSTR, V4, P2
   BEDFORD RE, 1957, J OPT SOC AM, V47, P564
   BENNETT AG, 1989, CLIN VISUAL OPTICS, P333
   Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   CAMPBELL FW, 1967, J PHYSIOL-LONDON, V192, P345, DOI 10.1113/jphysiol.1967.sp008304
   CHYLACK LT, 1988, ARCH OPHTHALMOL-CHIC, V106, P330
   DICKINSON C, 1998, LOW VISION PRINCIPLE, P35
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Eperjesi F, 2002, OPHTHAL PHYSL OPT, V22, P68, DOI 10.1046/j.1475-1313.2002.00004.x
   FRENNESSON IC, 1993, DOC OPHTHALMOL, V84, P135, DOI 10.1007/BF01206248
   Goodrich GL, 2000, VISION 99 VISION REH, P333
   GORMEZANO S, 2000, VISION 99 VISION REH, P206
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   HELLINGER G, 1983, J VISUAL IMPAIR BLIN, V77, P449
   HOEFT WW, 1981, AM J OPTOM PHYS OPT, V58, P841
   LEAT SJ, 1994, OPTOMETRY VISION SCI, V71, P199, DOI 10.1097/00006324-199403000-00009
   LEGGE GE, 1986, J OPT SOC AM A, V3, P40, DOI 10.1364/JOSAA.3.000040
   LEGGE GE, 1989, CLIN VISION SCI, V4, P51
   LEGUIRE LE, 1993, OPHTHAL PHYSL OPT, V13, P124, DOI 10.1111/j.1475-1313.1993.tb00440.x
   Lynch D, 1984, OPTOMETRIC MONTHLY, V75, P36
   Maino J H, 1986, J Am Optom Assoc, V57, P532
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   MORRISSETTE DL, 1984, AM J OPTOM PHYS OPT, V61, P704
   PENSYL CD, 1993, J VIS REHABIL, V7, P10
   Provines W F, 1997, J Am Optom Assoc, V68, P353
   Rosenblum YZ, 2000, OPHTHAL PHYSL OPT, V20, P335, DOI 10.1016/S0275-5408(00)00006-5
   TUPPER B, 1985, ANN OPHTHALMOL, V17, P67
   Wilkins A. J., 1993, SYSTEM PRECISION OPH
   Wilkins AJ, 1996, OPHTHAL PHYSL OPT, V16, P491, DOI 10.1016/0275-5408(96)00028-2
   WILKINS AJ, 1992, OPHTHAL PHYSL OPT, V12, P381, DOI 10.1016/0275-5408(92)90228-O
   Wolffsohn JS, 2002, OPHTHAL PHYSL OPT, V22, P300, DOI 10.1046/j.1475-1313.2002.00036.x
   ZIGMAN S, 1990, OPTOMETRY VISION SCI, V67, P100, DOI 10.1097/00006324-199002000-00007
NR 36
TC 9
Z9 9
U1 0
U2 8
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0275-5408
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JAN
PY 2004
VL 24
IS 1
BP 17
EP 25
DI 10.1046/j.1475-1313.2003.00157.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 769ZV
UT WOS:000188698900003
PM 14687197
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Meng, Y
   Liu, HW
   Sun, P
   Zhou, PP
   Wang, JJ
AF Meng, Yan
   Liu, Hong-wei
   Sun, Peng
   Zhou, Ping-ping
   Wang, Jian-jie
TI Omega-3 and ranibizumab for age-related macular degeneration A
   systematic review protocol
SO MEDICINE
LA English
DT Review
DE age-related macular degeneration; efficacy; Omega-3; ranibizumab;
   safety; systematic review
ID POLYUNSATURATED FATTY-ACIDS; OMEGA-3-FATTY-ACIDS; SUPPLEMENTATION;
   SAFETY
AB Background: Omega-3 and ranibizumab (O3R) has been reported to treat age-related macular degeneration (ARMD) effectively. However, up to the present, no systematic review specifically addressed the efficacy of O3R for the treatment of ARMD. Therefore, in this study, we will propose to assess the efficacy and safety of O3R for the treatment of ARMD.
   Methods: We will search PUMBED, EMBASE, CINAHI, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Cochrane Library, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, Wanfang Data, as well as the gray literature from inception up to the present. We will accept randomized controlled trials for assessing the efficacy and safety of O3R for ARMD. The primary outcomes include change in best corrected visual acuity and central retinal thickness. The secondary outcomes consist of changes in subfoveal choroidal thickness, macular atrophy, retinal average sensitivity, contrast sensitivity, glare disability, and quality of life. In addition, incidence and severity of adverse events will also be evaluated. Cochrane Collaboration tool will be used to assess the risk of bias for each included study. In addition, Grading of Recommendations Assessment, Development, and Evaluation tool will be utilized to assess the overall strength of the evidence. Two authors will independently carry out all procedures and any divergences will be solved through discussion with a third author. If it is possible, we will conduct meta-analysis and subgroup analysis concerning different interventions, risk of bias, and outcome measurements.
   Results: In this proposed study, we outline details of the aims and methods of efficacy and safety of O3R for the treatment of ARMD.
   Conclusion: The findings of this systematic review will summarize current evidence of O3R for the treatment of patients with ARMD.
   Dissemination and ethics: The results of the present study are expected to be published by peer-reviewed journals. This is a literature-based study. Thus, ethical approval is unnecessary for this study.
C1 [Meng, Yan; Liu, Hong-wei; Sun, Peng; Zhou, Ping-ping] Jiamusi Univ, Affiliated Hosp 1, Dept Ophthalmol, Jiamusi, Peoples R China.
   [Wang, Jian-jie] Jiamusi Univ, Dept Immunol, 148 Xuefu St, Jiamusi 154002, Peoples R China.
C3 Jiamusi University; Jiamusi University
RP Wang, JJ (通讯作者)，Jiamusi Univ, Dept Immunol, 148 Xuefu St, Jiamusi 154002, Peoples R China.
EM Jian-jieWang@outlook.com
FU Project of Jiamus University [13Z1201547]
FX This work was supported in part by the Project of Jiamus University
   (Grant number: 13Z1201547). The funders did not take part in the design,
   execution, or writing of the study.
CR Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Desmettre TJ, 2018, J FR OPHTALMOL, V41, pE407, DOI 10.1016/j.jfo.2018.09.001
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fong AHC, 2013, CLIN INTERV AGING, V8, P467, DOI 10.2147/CIA.S36811
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Gibson JM, 2014, EXPERT OPIN DRUG SAF, V13, P1259, DOI 10.1517/14740338.2014.939951
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson D, 2013, CURR OPIN OPHTHALMOL, V24, P205, DOI 10.1097/ICU.0b013e32835f8ec0
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lafuente M, 2017, RETINA-J RET VIT DIS, V37, P1277, DOI 10.1097/IAE.0000000000001363
   Li JQ, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/1425707
   Merle BMJ, 2017, ACTA OPHTHALMOL, V95, pe763, DOI 10.1111/aos.13408
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.i4086]
   Rasmussen A, 2014, CURR OPIN OPHTHALMOL, V25, P158, DOI 10.1097/ICU.0000000000000050
   Rezende FA, 2014, AM J OPHTHALMOL, V158, P1071, DOI 10.1016/j.ajo.2014.07.036
   SanGiovanni John Paul, 2008, Arch Ophthalmol, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wang LP, 2018, DRUG DES DEV THER, V12, P3625, DOI 10.2147/DDDT.S176021
   Wei Y, 2018, MEDICINE, V97, DOI DOI 10.1097/MD.0000000000010422
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
NR 27
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAR
PY 2019
VL 98
IS 13
AR e14516
DI 10.1097/MD.0000000000014516
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HX3UX
UT WOS:000467319800003
PM 30921177
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pauer, GJT
   Sturgill, GM
   Peachey, NS
   Hagstrom, SA
AF Pauer, Gayle J. T.
   Sturgill, Gwen M.
   Peachey, Neal S.
   Hagstrom, Stephanie A.
CA Clinical Genomic & Proteomic Amd S
TI Protective Effect of Paraoxonase 1 Gene Variant Gln192Arg in Age-Related
   Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; SERUM PARAOXONASE; OXIDATIVE STRESS;
   MOLECULAR-BASIS; RISK-FACTORS; PON1 GENE; ARYLESTERASE; ASSOCIATION;
   DISEASE
AB PURPOSE: Age-related macular degeneration (AMD) is the leading cause of blindness among older adults, in which oxidative damage may play a pivotal role. Paraoxonase 1 (PON 1) protects against oxidative damage and has been evaluated for its involvement in aging diseases including AMD. This study investigated whether PON1 gene polymorphisms associate with AMD.
   DESIGN: Case-control association study.
   METHODS: We studied 1037 individuals with AMD subcategorized using AREDS criteria and 370 control subjects without retinal disease. Participants were primarily Caucasian of European descent. All exons of PON1 were evaluated by single-strand conformation polymorphism and direct sequence analysis.
   RESULTS: Six missense changes (Leu55Met, Met127Arg, His155Arg, Gln192Arg, Gln192Glu, Ala252Gly) were identified in PON1. We observed a weak association of Leu55Met with an increased risk of wet AMD (P = .02), but not with dry AMD or when combining all patient categories. A significantly higher allele frequency for Gln192Arg was detected in controls than in the combined AMD patient population (P < .0001), and when category 2, 3, and 4 patients were separately considered (P = .004, P = .002, and P < .0001, respectively). For category 4 AMD, the Arg192 allele was significantly less prevalent in the wet form (P < .0001), but not in the dry form (P = .377).
   CONCLUSION: We report a weak association of PON1 Leu55Met with an increased risk of wet AMD, replicating previous reports. Our findings indicate a protective role for Gln192Arg, particularly for patients with the wet form. Gln192Glu warrants consideration, as this variant alters the same amino acid as Gln192Arg and was identified only in category 4 AMD patients. We believe that Met127Arg, His155Arg, and Ala252Gly play minor roles in AMD susceptibility because of their limited frequency and/or location within the PON1 gene. The functional and biological mechanism by which Gln192Arg is acting to decrease AMD susceptibility remains to be determined. (Am J Ophthalmol 2010;149:513-522. (C) 2010 Published by Elsevier Inc.)
C1 [Pauer, Gayle J. T.; Peachey, Neal S.; Hagstrom, Stephanie A.] Cleveland Clin, Cole Eye Inst, Dept Ophthalm Res, Cleveland, OH 44195 USA.
   [Sturgill, Gwen M.; Peachey, Neal S.] Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, Cleveland, OH USA.
   [Peachey, Neal S.; Hagstrom, Stephanie A.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
   [Clinical Genomic & Proteomic Amd S] Case Western Reserve Univ, Sch Med, Dept Ophthalmol, Cleveland, OH USA.
C3 Cleveland Clinic Foundation; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Case Western Reserve University; Louis
   Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve
   University; Cleveland Clinic Foundation; Case Western Reserve University
RP Hagstrom, SA (通讯作者)，Cleveland Clin, Cole Eye Inst, Dept Ophthalm Res, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM hagstrs@ccf.org
RI Peachey, Neal/G-5533-2010
OI Peachey, Neal/0000-0002-4419-7226
FU NEI NIH HHS [R01 EY016072, EY015638, EY016072, R24 EY015638, R01
   EY016072-04] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R24EY015638, R01EY016072] Funding Source: NIH RePORTER
CR ADKINS S, 1993, AM J HUM GENET, V52, P598
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhattacharyya T, 2008, JAMA-J AM MED ASSOC, V299, P1265, DOI 10.1001/jama.299.11.1265
   Brophy VH, 2001, AM J HUM GENET, V68, P1428, DOI 10.1086/320600
   Davies HG, 1996, NAT GENET, V14, P334, DOI 10.1038/ng1196-334
   Deakin S, 2003, BIOCHEM J, V372, P643, DOI 10.1042/BJ20021670
   Draganov DI, 2004, N-S ARCH PHARMACOL, V369, P78, DOI 10.1007/s00210-003-0833-1
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Ferrer-Costa C, 2005, BIOINFORMATICS, V21, P3176, DOI 10.1093/bioinformatics/bti486
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Furlong CE, 2002, HUM ECOL RISK ASSESS, V8, P31, DOI 10.1080/20028091056700
   Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HOLLMAN FW, 2003, METHODOLOGY ASSUMPTI, P1
   HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   ISELIUS L, 1982, J MED GENET, V19, P424, DOI 10.1136/jmg.19.6.424
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leviev I, 2000, ARTERIOSCL THROM VAS, V20, P516, DOI 10.1161/01.ATV.20.2.516
   Leviev I, 2001, J LIPID RES, V42, P528
   Marchegiani F, 2008, REJUV RES, V11, P113, DOI 10.1089/rej.2007.0582
   PrimoParmo SL, 1996, GENOMICS, V33, P498, DOI 10.1006/geno.1996.0225
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Richter RJ, 1999, PHARMACOGENETICS, V9, P745, DOI 10.1097/01213011-199912000-00009
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Stone EM, 2007, ANNU REV MED, V58, P477, DOI 10.1146/annurev.med.58.111405.133335
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Wheeler JG, 2004, LANCET, V363, P689, DOI 10.1016/S0140-6736(04)15642-0
   Winkler BS, 1999, MOL VIS, V5
   Xi QS, 2006, EXP EYE RES, V83, P569, DOI 10.1016/j.exer.2006.02.003
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 40
TC 21
Z9 21
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2010
VL 149
IS 3
BP 513
EP 522
DI 10.1016/j.ajo.2009.09.024
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 565MD
UT WOS:000275296400024
PM 20042177
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gudauskiene, G
   Povilaityte, I
   Sepetauskiene, E
   Zaliuniene, D
AF Gudauskiene, Gaile
   Povilaityte, Ieva
   Sepetauskiene, Egle
   Zaliuniene, Dalia
TI Phacoemulsification Induced Changes of Choroidal Thickness in Eyes with
   Age-Related Macular Degeneration
SO MEDICINA-LITHUANIA
LA English
DT Article
DE phacoemulsification; choroidal thickness; age-related macular
   degeneration
ID LONG-TERM INCREASE; OPTICAL COHERENCE TOMOGRAPHY; CATARACT-SURGERY;
   INTRAOCULAR-PRESSURE; SUBFOVEAL
AB Background and Objectives: Patients with cataract and age-related macular degeneration (AMD) may safely undergo cataract phacoemulsification to enhance visual acuity. Although it has not been proven that cataract surgery can cause AMD progression, different phacoemulsification effects are observed not only on retinal but also on choroidal tissues. The purpose of this study was to evaluate the effect of phacoemulsification on the choroidal thickness (CT) in eyes with and without AMD. Materials and Methods: In 32 eyes of 32 patients with senile cataract (No-AMD group) and in 32 eyes of 32 patients with cataract and dry AMD (AMD group), who had phacoemulsification without intraoperative complications and intraocular lens implantation, foveal retinal thickness (FRT) and CT were evaluated three times: at 1-2 post meridiem preoperatively, then 1 month and 3 months postoperatively, using 1050 nm swept source-optical coherence tomography (Topcon, Tokyo, Japan). Results: In both groups, a significant increase in FRT was observed after one month and a decrease after three months without reaching the baseline. One month after surgery, a sectorial CT increase was apparent in all sectors in both groups. A negative association between CT and age was disclosed in the No-AMD group almost for all regions at all time points. Furthermore, CT was significantly negatively associated with axial length (AL) in all sectors at all time points in the AMD group. Conclusion: Uneventful phacoemulsification may induce changes in the posterior eye segment. An increase in CT and FRT was observed in both groups one month after the surgery. However, three months after surgery, CT changes were different in both groups, while FRT decreased in both groups. CT changes negatively associated with age in the No-AMD group and with AL in the AMD eyes. These postoperative changes in the choroid and retina may not only lead to the late-onset pseudophakic cystoid macular edema but also to progression of AMD.
C1 [Gudauskiene, Gaile; Povilaityte, Ieva; Zaliuniene, Dalia] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, LT-50009 Kaunas, Lithuania.
   [Sepetauskiene, Egle] Lithuanian Univ Hlth Sci, Informat Technol Ctr, LT-50009 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Gudauskiene, G (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, LT-50009 Kaunas, Lithuania.
EM gaile.gudauskiene@lsmuni.lt; ieva.povilaityte@fc.lsmuni.lt;
   egle.sepetauskiene@lsmuni.lt; dalia.zaliuniene@lsmu.lt
CR Abdellatif MK, 2018, SEMIN OPHTHALMOL, V33, P719, DOI 10.1080/08820538.2017.1417453
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bille J.F., 2019, NEW FRONTIERS BIOMED, V1, P301
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Broadhead GK, 2017, OPHTHALMIC RES, V58, P27, DOI 10.1159/000464447
   Celik E, 2016, CLIN OPHTHALMOL, V10, P2171, DOI 10.2147/OPTH.S105992
   Cheong KX, 2015, AM J OPHTHALMOL, V159, P608, DOI 10.1016/j.ajo.2014.12.018
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Dong N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/126984
   Erkul SO, 2014, INT OPHTHALMOL, V34, P35, DOI 10.1007/s10792-013-9787-6
   Falcao MS, 2014, CLIN OPHTHALMOL, V8, P55, DOI 10.2147/OPTH.S53989
   Hau VS, 2016, OPHTHALMOL THER, V5, P21, DOI 10.1007/s40123-016-0047-5
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Ibrahim AM, 2018, SEMIN OPHTHALMOL, V33, P664, DOI 10.1080/08820538.2017.1416410
   Jiang HZ, 2018, OPHTHALMIC RES, V60, P243, DOI 10.1159/000480240
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim JH, 2013, EYE, V27, P809, DOI 10.1038/eye.2013.78
   Laurell CG, 2002, BRIT J OPHTHALMOL, V86, P1380, DOI 10.1136/bjo.86.12.1380
   Lee HD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36252-z
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Ngabou CGFN, 2017, J FR OPHTALMOL, V40, P397, DOI 10.1016/j.jfo.2016.12.011
   Ngo WK, 2016, BRIT J OPHTHALMOL, V100, P560, DOI 10.1136/bjophthalmol-2015-306713
   Noda Y, 2014, AM J OPHTHALMOL, V158, P455, DOI 10.1016/j.ajo.2014.05.016
   Ohsugi H, 2014, J CATARACT REFR SURG, V40, P184, DOI 10.1016/j.jcrs.2013.07.036
   Oyster C.W., 2000, OPHTHAL PHYSL OPT, V20, P349
   Pierru A, 2014, INVEST OPHTH VIS SCI, V55, P4967, DOI 10.1167/iovs.14-14172
   Quaranta L, 2013, SURV OPHTHALMOL, V58, P26, DOI 10.1016/j.survophthal.2012.05.003
   Shahzad R, 2018, CAN J OPHTHALMOL, V53, P60, DOI 10.1016/j.jcjo.2017.06.019
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P11, DOI 10.1007/978-3-319-95046-4_3
   Wan KH, 2018, JAMA OPHTHALMOL, V136, P866, DOI 10.1001/jamaophthalmol.2018.1627
   Wang W, 2014, AM J OPHTHALMOL, V158, P1362, DOI 10.1016/j.ajo.2014.09.025
   Yasin Alibhai A., 2018, CURR OPHTHALMOL REP, V6, P7, DOI DOI 10.1007/S40135-018-0158-3
   Yilmaz T, 2016, MED SCI MONITOR, V22, P1566
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zeng SX, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/2501325
NR 38
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD MAY
PY 2020
VL 56
IS 5
AR 252
DI 10.3390/medicina56050252
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LZ1YU
UT WOS:000541026200012
PM 32455884
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gillies, M
   Arnold, J
   Bhandari, S
   Essex, RW
   Young, S
   Squirrell, D
   Nguyen, V
   Barthelmes, D
AF Gillies, Mark
   Arnold, Jennifer
   Bhandari, Sanjeeb
   Essex, Rohan W.
   Young, Stephanie
   Squirrell, David
   Vuong Nguyen
   Barthelmes, Daniel
TI Ten-Year Treatment Outcomes of Neovascular Age-Related Macular
   Degeneration from Two Regions
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID LONG-TERM OUTCOMES; RANIBIZUMAB; THERAPY
AB PURPOSE: To report and compare 10-year treatment outcomes of vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD) from Australia and New Zealand (ANZ) and Switzerland.
   DESIGN: Retrospective, comparative, interventional case series.
   METHODS: We analyzed 712 treatment-naive eyes (ANZ, n = 474; Switzerland, n = 321) starting antiVEGF for nAMD in routine clinical practice between January 1, 2006, and December 31, 2008, tracked in the prospectively designed observational database, the Fight Retinal Blindness! registry. The primary outcome was mean change in visual acuity (VA [in logMAR letters]) in eyes that completed 10 years of treatment.
   RESULTS: The mean VA in 132 eyes (28%) from ANZ patients who completed 10 years of treatment dropped by 0.9 letters from baseline (95% confidence interval [CI], -4.9 to 3.1; P = 0.7) with 42% achieving >= 20/40, whereas the 37 eyes (12%) from Swiss subjects lost 14.9 letters (95% CI, -24 to -5.7; P < 0.001) with 35% achieving >= 20/40. Eyes from ANZ patients received more injections than eyes from Swiss subjects over 10 years (a median of 53 vs 42, respectively) from fewer visits with better disease control (proportion of visits with active disease: 38% vs 69%, respectively), suggesting a treat-and extend regimen versus a pro re nata regimen (treatment given only when the lesion is active). Macular atrophy and subretinal fibrosis were the main reasons for 10 letter loss in the subset of eyes analyzed retrospectively. The mean VA of eyes from both regions that discontinued treatment within 10 years had fallen below the baseline at their final visit.
   CONCLUSIONS: Eyes with nAMD may achieve satisfactory long-term visual outcomes if they receive adequate treatment. Central macular atrophy does not develop universally in eyes receiving long-term treatment with VEGF inhibitors as previously feared. Visual outcomes were better in eyes from ANZ patients, likely because they received more injections. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Gillies, Mark; Bhandari, Sanjeeb; Vuong Nguyen; Barthelmes, Daniel] Univ Sydney Hlth, Sydney Med Sch, Discipline Ophthalmol & Eye, Save Sight Inst, Sydney, NSW, Australia.
   [Arnold, Jennifer] Marsden Eye Specialists, Parramatta, NSW, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Acton, ACT, Australia.
   [Young, Stephanie] Gladesville Eye Specialists, Gladesville, NSW, Australia.
   [Squirrell, David] Univ Auckland, Dept Ophthalmol, Auckland, New Zealand.
   [Squirrell, David] Auckland Dist Hlth Board, Auckland, New Zealand.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; Australian National University; University of
   Auckland; Auckland District Health Board; University of Zurich;
   University Zurich Hospital
RP Bhandari, S (通讯作者)，Sydney Eye Hosp, Level 1,South Block,8 Macquarie St, Sydney, NSW 2000, Australia.
EM sbha5189@uni.sydney.edu.au
OI Essex, Rohan/0000-0001-5323-0334; Nguyen, Vuong/0000-0001-9070-9803;
   Gillies, mark/0000-0001-8580-0274; BHANDARI, SANJEEB/0000-0002-4110-4274
FU Royal Australian and New Zealand College of Ophthalmologists (RANZCO)
   Eye Foundation; National Health and Medical Research Council (NHMRC),
   Australia; Macular Disease Foundation, Australia; NHMRC practitioner
   fellowship; Walter Gertud Siegenthaler Foundation, Zurich, Switzerland;
   Swiss National Foundation
FX The Fight Retinal Blindness! Project was supported by a grant from the
   Royal Australian and New Zealand College of Ophthalmologists (RANZCO)
   Eye Foundation (2007-2009); a grant from the National Health and Medical
   Research Council (NHMRC), Australia (2010-2012); and a grant from the
   Macular Disease Foundation, Australia. Mark Gillies is a Sydney Medical
   Foundation Fellow and is supported by a NHMRC practitioner fellowship.
   Daniel Barthelmes was supported by the Walter Gertud Siegenthaler
   Foundation, Zurich, Switzerland, and by the Swiss National Foundation.
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chatfield MD, 2005, J CLIN EPIDEMIOL, V58, P13, DOI 10.1016/j.jclinepi.2004.05.006
   Gillies MC, 2017, OPHTHALMOLOGY, V124, pE31, DOI 10.1016/j.ophtha.2016.05.054
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Haddad WM, 2017, RETINA-J RET VIT DIS, V37, P951, DOI 10.1097/IAE.0000000000001282
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   R Team, 2010, R LANG ENV STAT COMP
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x
NR 19
TC 42
Z9 42
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2020
VL 210
BP 116
EP 124
DI 10.1016/j.ajo.2019.10.007
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KJ7CQ
UT WOS:000512216200015
PM 31606444
DA 2022-11-30
ER

PT J
AU Raman, R
   Pal, SS
   Ganesan, S
   Gella, L
   Vaitheeswaran, K
   Sharma, T
AF Raman, R.
   Pal, S. S.
   Ganesan, S.
   Gella, L.
   Vaitheeswaran, K.
   Sharma, T.
TI The prevalence and risk factors for age-related macular degeneration in
   rural-urban India, Sankara Nethralaya Rural-Urban Age-related Macular
   degeneration study, Report No. 1
SO EYE
LA English
DT Article
ID MACULOPATHY; POPULATION; EYE; ASSOCIATION; SMOKING; DISEASE
AB Purpose To report the age-and gender-adjusted prevalence rates of early and late age-related maculopathy (ARM) and associated risk factors in rural and urban Indian population.
   Methods A population-based cross-sectional study was carried out in South India between 2009 and 2011. Of the 6617 subjects >= 60 years enumerated ones, 5495 (83.04%) participated in the eye examination. A detailed history including data on demographic, socioeconomic, and ocular history was obtained. Participants underwent detailed ophthalmic evaluation including 30 degrees 3-field photograph as per Age-Related Eye Disease Study protocol. The ARM was graded according to the International ARM Epidemiological Study Group.
   Results Age-and gender-adjusted prevalence of early ARM was 20.91% (20.86-20.94) in the rural population and 16.37% (16.32-16.42) in the urban population. Similarly, the prevalence of late ARM was 2.26% (2.24-2.29) and 2.32% (2.29-2.34) in the rural and urban population, respectively. In both rural and urban populations, risk factors that were related to both early and late ARM were age, per year increase (OR, range 1.00-1.08); middle socioeconomic status (OR, range 1.05-1.83); and smokeless tobacco (OR, range 1.11-2.21). Protective factor in both was the presence of diabetes mellitus in all ARM (OR, range 0.34-0.83). Risk factors, only in the rural arm, were female gender (OR, range 1.06-1.64), past smoker (OR, 1.14), and serum low-density lipoprotein cholesterol level (OR, 1.03).
   Conclusions The study reports smokessless tobacco as a risk factor for both early and late ARM and identified a higher prevalence of early ARM in the rural population compared with urban population.
C1 [Raman, R.; Pal, S. S.; Ganesan, S.; Gella, L.; Sharma, T.] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Vis Res Fdn, 18 Coll Rd, Chennai 600006, Tamil Nadu, India.
   [Gella, L.] Elite Sch Optometry, Chennai, Tamil Nadu, India.
   [Vaitheeswaran, K.] Sankara Nethralaya, Dept Prevent Ophthalmol, Chennai, Tamil Nadu, India.
RP Sharma, T (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Vis Res Fdn, 18 Coll Rd, Chennai 600006, Tamil Nadu, India.
EM drtaruns@gmail.com
RI Raman, Rajiv/A-7234-2009
OI Raman, Rajiv/0000-0001-5842-0233
FU Jamshetji Tata trust, Mumbai
FX This work was funded by Jamshetji Tata trust, Mumbai.
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Agarwal S, 2005, OPHTHAL EPIDEMIOL, V12, P143, DOI 10.1080/09286580590932734
   [Anonymous], 2011, HDB STAT IND EC 2011, P395
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Census of India, 2001, POP PROJ IND STAT 20
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Dutta A, 2012, TOXICOL APPL PHARM, V261, P255, DOI 10.1016/j.taap.2012.04.004
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Irudaya RS, 2005, AGING INDIA PERSPECT, P11
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kim JH, 2012, INT J BIOCHEM CELL B, V44, P808, DOI 10.1016/j.biocel.2012.02.005
   Klein BEK, 2013, J ENVIRON SCI HEAL A, V48, P1757, DOI 10.1080/10934529.2013.823323
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Kumar SG, 2013, J CLIN DIAGN RES, V7, P1637, DOI 10.7860/JCDR/2013/5521.3216
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Sander B, 2001, INVEST OPHTH VIS SCI, V42, P433
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Thakur JS, 2013, ASIAN PAC J CANCER P, V14, P6965, DOI 10.7314/APJCP.2013.14.11.6965
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Varghese SB, 2011, INVEST OPHTH VIS SCI, V52, P9445, DOI 10.1167/iovs.11-7874
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   World Health Organisation, 2002, KEEP FIT LIF M NUTR
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Zhang XZ, 2012, AM J OPHTHALMOL, V154, pS53, DOI 10.1016/j.ajo.2011.08.045
NR 47
TC 21
Z9 22
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2016
VL 30
IS 5
BP 688
EP 697
DI 10.1038/eye.2016.14
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL5UL
UT WOS:000375702400007
PM 26915746
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Yoshida, M
   Oishi, A
   Miyake, M
   Ooto, S
   Tamura, H
   Miyata, M
   Takahashi, A
   Hata, M
   Yamashiro, K
   Tsujikawa, A
AF Yoshida, Miyo
   Oishi, Akio
   Miyake, Masahiro
   Ooto, Sotaro
   Tamura, Hiroshi
   Miyata, Manabu
   Takahashi, Ayako
   Hata, Masayuki
   Yamashiro, Kenji
   Tsujikawa, Akitaka
TI Rescue photodynamic therapy for age-related macular degeneration
   refractory to anti-vascular endothelial growth factor monotherapy
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Age-related macular degeneration; Anti-vascular endothelial growth
   factor; Macular atrophy; Photodynamic therapy; Pigment epithelium
   detachment; Subretinal hemorrhage
ID ATROPHY
AB Background: To evaluate the 3-year outcome in eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal anti-vascular endothelial growth factor monotherapy or rescue therapy using standard verteporfin photodynamic therapy (PDT), and corroborate efficacy of rescue PDT.
   Methods: Patients were administered aflibercept injections once a month for 3 months followed by once every 2 months in the first year. After year 1, treatment with aflibercept monotherapy as indicated or in combination with PDT at the retinal specialist's discretion. Only cases completing the three-year follow-up were included. Regression analysis with visual acuity and macular atrophy at year 3 was performed for the dependent variable.
   Results: Of the 292 eyes, 15 eyes underwent rescue PDT following year 1. The best-corrected visual acuity (logarithm of minimal angle of resolution, mean/Snellen equivalent +/- SD) was 0.35 (20/45) +/- 0.38, 0.23 (20/ 30) +/- 0.36, 0.26 (20/35) +/- 0.38, and 0.31 (20/40) +/- 0.42 at baseline, year 1, year 2, and year 3, respectively. Multiple regression analysis revealed that the rescue PDT was significantly associated with macular atrophy and poor visual outcome at year 3 (odds ratio = 1.2, p < 0.001; beta = 0.23, p = 0.0029, respectively).
   Conclusions: The visual outcome in eyes with nAMD retained baseline levels at year 3; however, patients treated with rescue PDT developed macular atrophy more frequently and poor visual outcomes.
C1 [Yoshida, Miyo; Oishi, Akio; Miyake, Masahiro; Ooto, Sotaro; Tamura, Hiroshi; Miyata, Manabu; Takahashi, Ayako; Yamashiro, Kenji; Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara Cho Shogoin, Kyoto 6068507, Japan.
   [Oishi, Akio] Nagasaki Univ, Dept Ophthalmol & Visual Sci, Sakamoto 1-7-1, Nagasaki 8528102, Japan.
   [Hata, Masayuki] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Ophthalmol, Res Ctr, Montreal, PQ H3T 1J4, Canada.
   [Hata, Masayuki] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Biochem & Mol Med, Res Ctr, Montreal, PQ H3T 1J4, Canada.
   [Yamashiro, Kenji] Japanese Red Cross Otsu Hosp, Dept Ophthalmol, 1 Chome 1-35 Nagara, Otsu, Shiga 5200046, Japan.
C3 Kyoto University; Nagasaki University; Universite de Montreal;
   Universite de Montreal
RP Oishi, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara Cho Shogoin, Kyoto 6068507, Japan.; Oishi, A (通讯作者)，Nagasaki Univ, Dept Ophthalmol & Visual Sci, Sakamoto 1-7-1, Nagasaki 8528102, Japan.
EM akio.oishi@nagasaki-u.ac.jp
RI Miyata, Manabu/U-9008-2018; TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Miyata, Manabu/0000-0002-7574-1749
FU Japan Society for the Promotion of Science, Tokyo, Japan [18K09444]
FX Acknowledgment Supported in part by a grant-in-aid for scientific
   research (No. 18K09444) from the Japan Society for the Promotion of
   Science, Tokyo, Japan. The funding body had no role in the design or
   conduct of the study, management, analysis, and interpretation of the
   data, or the preparation, review, or approval of the manuscript.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho HJ, 2016, RETINA-J RET VIT DIS, V36, P1851, DOI 10.1097/IAE.0000000000001009
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Hara C, 2019, BRIT J OPHTHALMOL, V103, P623, DOI 10.1136/bjophthalmol-2018-312275
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Joachim N, 2018, OPHTHALMOL RETINA, V2, P684, DOI 10.1016/j.oret.2017.10.019
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Miller Joan W, 2008, Trans Am Ophthalmol Soc, V106, P357
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Park UC, 2021, ACTA OPHTHALMOL, V99, pE899, DOI 10.1111/aos.14719
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
NR 26
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD JUN
PY 2022
VL 38
AR 102745
DI 10.1016/j.pdpdt.2022.102745
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 0N0VD
UT WOS:000782565200008
PM 35123015
DA 2022-11-30
ER

PT J
AU Oh, IH
   Choi, EY
   Park, JS
   Lee, CH
AF Oh, Il Hwan
   Choi, Eun Young
   Park, Joon-Sung
   Lee, Chang Hwa
TI Association of Serum Ferritin and Kidney Function with Age-Related
   Macular Degeneration in the General Population
SO PLOS ONE
LA English
DT Article
ID METABOLIC SYNDROME; RISK-FACTORS; IRON; PATHOGENESIS; DISEASE; HEALTH
AB Ferritin is considered to be a marker of the body's iron stores and has a potential relationship with the systemic manifestations of inflammatory reactions. Data on the association between increased levels of serum ferritin and ocular problems are limited, particularly in relation to age-related macular degeneration (AMD). Serum ferritin levels, as a possible clinical parameter for predicting AMD, were analyzed in anthropometric, biochemical, and ophthalmologic data from a nation-wide, population-based, case-control study (KNHNES IV and V). All native Koreans aged >= 20 years and who had no medical illness were eligible to participate. Among them, 2.9% had AMD, and its prevalence was found to increase in the higher ferritin quintile groups (P-trend < 0.0001). In multiple linear regression analysis, serum ferritin level was closely related to conventional risk factors for AMD. Comparison of early AMD with a control group showed that serum ferritin levels were closely associated with AMD (OR = 1.004, 95% CI = 1.002-1.006), and further adjustment for age, gender, serum iron, and kidney function did not reduce this association (OR = 1.003, 95% CI = 1.001-1.006). Furthermore, the relationship between ferritin quintile and early AMD was dose-dependent. Thus, an increased level of serum ferritin in a healthy person may be a useful indicator of neurodegenerative change in the macula. A large population-based prospective clinical study is needed to confirm these findings.
C1 [Oh, Il Hwan; Choi, Eun Young; Park, Joon-Sung; Lee, Chang Hwa] Hanyang Univ, Coll Med, Dept Internal Med, Seoul 133791, South Korea.
C3 Hanyang University
RP Park, JS; Lee, CH (通讯作者)，Hanyang Univ, Coll Med, Dept Internal Med, Seoul 133791, South Korea.
EM sjpjoon@hanyang.ac.kr; changhwa@hanyang.ac.kr
CR Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Batista-Nascimento L, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/128647
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Friedman A, 2011, PARKINSONISM RELAT D, V17, P423, DOI 10.1016/j.parkreldis.2011.03.016
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Ghosh A, 2007, EUR J CLIN NUTR, V61, P412, DOI 10.1038/sj.ejcn.1602534
   Gonzalez AS, 2006, EUR J CLIN NUTR, V60, P802, DOI 10.1038/sj.ejcn.1602384
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kell DB, 2014, METALLOMICS, V6, P748, DOI 10.1039/c3mt00347g
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Koorts A. M., 2007, Archives of Physiology and Biochemistry, V113, P30, DOI 10.1080/13813450701318583
   Krenn MA, 2015, FREE RADICAL BIO MED, V80, P48, DOI 10.1016/j.freeradbiomed.2014.12.007
   Lederman M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087751
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Lin SC, 2014, JAMA OPHTHALMOL, V132, P1414, DOI 10.1001/jamaophthalmol.2014.2876
   Loh A, 2009, BBA-GEN SUBJECTS, V1790, P637, DOI 10.1016/j.bbagen.2008.11.001
   Mainous AG, 2004, AM J CARDIOL, V93, P559, DOI 10.1016/j.amjcard.2003.11.018
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Moore C, 2013, JCR-J CLIN RHEUMATOL, V19, P324, DOI 10.1097/RHU.0b013e31829ce01f
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Richer Stuart, 2002, Am J Ther, V9, P25, DOI 10.1097/00045391-200201000-00006
   Schipper HM, 2012, BBA-MOL BASIS DIS, V1822, P350, DOI 10.1016/j.bbadis.2011.06.016
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
NR 30
TC 4
Z9 4
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 20
PY 2016
VL 11
IS 4
AR e0153624
DI 10.1371/journal.pone.0153624
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DJ9OU
UT WOS:000374543600046
PM 27096155
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU He, MS
   Chang, FL
   Lin, HZ
   Wu, JL
   Hsieh, TC
   Lee, YC
AF He, Ming-Shan
   Chang, Fang-Ling
   Lin, Hong-Zin
   Wu, Jung-Lun
   Hsieh, Tsung-Cheng
   Lee, Yuan-Chieh
TI The Association Between Diabetes and Age-Related Macular Degeneration
   Among the Elderly in Taiwan
SO DIABETES CARE
LA English
DT Article
ID RISK-FACTORS; 10-YEAR INCIDENCE; MACULOPATHY; EYE; SUSCEPTIBILITY;
   INFLAMMATION; RETINOPATHY; POPULATION; GLUCOSE; DISEASE
AB OBJECTIVE
   To investigate the relationship between diabetes and future development of age-related macular degeneration (AMD).
   RESEARCH DESIGN AND METHODS
   Longitudinal, retrospective cohort study data for the period between 1997 and 2012 were obtained from the Longitudinal Health Insurance Database (LHID) of Taiwan. The final available 71,904 patients with diabetes and 270,213 patients without diabetes >= 50 years of age were further matched by age, sex, and Charlson comorbidity index. In the end, 54,616 study subjects in each of the diabetes and nondiabetes groups were recruited. The stratified populations of patients with diabetes with diabetic retinopathy (DR) (n = 7,119) versus those with diabetes who do not have DR (n = 7,119) and populations of patients with proliferative DR (PDR) (n = 2,134) versus those with nonproliferative DR (NPDR) (n = 2,134) were also obtained. Competing risk regression models were used to assess the adjusted hazard ratio (HR) and 99% CI. The main outcome measures were the first-ever diagnosis of AMD during the observational period.
   RESULTS
   The incidences of nonexudative AMD (HR 1.23; P = 0.108) and exudative AMD (HR 1.37; P = 0.023) were not significantly associated with cohorts of persons with diabetes compared with cohorts without diabetes. The stratified analysis showed that nonexudative AMD (HR 3.89; P = 0.001) and exudative AMD (HR 3.42; P < 0.001) were significantly correlated to diabetes with DR cohorts, compared with diabetes without DR cohorts. The incidences of nonexudative AMD (HR 0.53; P = 0.277) and exudative AMD (HR 2.27; P = 0.058) were not significantly different between PDR cohorts compared with NPDR cohorts.
   CONCLUSIONS
   This study provides large-scale, population-based evidence that diabetes with retinopathy is independently associated with an increased risk of subsequent AMD development.
C1 [He, Ming-Shan; Chang, Fang-Ling; Lin, Hong-Zin; Lee, Yuan-Chieh] Buddhist Tzu Chi Gen Hosp, Dept Ophthalmol, Hualien, Taiwan.
   [He, Ming-Shan; Lee, Yuan-Chieh] Tzu Chi Univ, Dept Ophthalmol & Visual Sci, Hualien, Taiwan.
   [Wu, Jung-Lun; Hsieh, Tsung-Cheng; Lee, Yuan-Chieh] Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan.
C3 Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi
   University; Tzu Chi University
RP Lee, YC (通讯作者)，Buddhist Tzu Chi Gen Hosp, Dept Ophthalmol, Hualien, Taiwan.; Lee, YC (通讯作者)，Tzu Chi Univ, Dept Ophthalmol & Visual Sci, Hualien, Taiwan.; Lee, YC (通讯作者)，Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan.
EM yuanchieh.lee@gmail.com
OI he, mingshan/0000-0001-7873-0941
FU Buddhist Tzu Chi General Hospital, Hualien, Taiwan [TCRD103-48]
FX This study was supported by a research grant from Buddhist Tzu Chi
   General Hospital, Hualien, Taiwan (TCRD103-48).
CR Adamiec-Mroczek J, 2010, CYTOKINE, V49, P269, DOI 10.1016/j.cyto.2009.11.004
   ALGVERE P, 1985, BRIT J OPHTHALMOL, V69, P416, DOI 10.1136/bjo.69.6.416
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chen XX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085716, 10.1371/journal.pone.0091809, 10.1371/journal.pone.0103330, 10.1371/journal.pone.0115462, 10.1371/journal.pone.0087752, 10.1371/journal.pone.0091830]
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin M, 2001, RETINA-J RET VIT DIS, V21, P28, DOI 10.1097/00006982-200102000-00005
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   World Health Organization, 2016, GLOBAL REPORT DIABET
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zylbermann R, 1997, EYE, V11, P872, DOI 10.1038/eye.1997.224
NR 41
TC 25
Z9 30
U1 0
U2 4
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD OCT 1
PY 2018
VL 41
IS 10
BP 2202
EP 2211
DI 10.2337/dc18-0707
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA GU1WP
UT WOS:000445058200022
PM 30061321
DA 2022-11-30
ER

PT J
AU Hochberg, C
   Maul, E
   Chan, ES
   Van Landingham, S
   Ferrucci, L
   Friedman, DS
   Ramulu, PY
AF Hochberg, Chad
   Maul, Eugenio
   Chan, Emilie S.
   Van Landingham, Suzanne
   Ferrucci, Luigi
   Friedman, David S.
   Ramulu, Pradeep Y.
TI Association of Vision Loss in Glaucoma and Age-Related Macular
   Degeneration with IADL Disability
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SALISBURY EYE EVALUATION; QUALITY-OF-LIFE; VISUAL FUNCTION;
   OLDER-ADULTS; MOBILITY PERFORMANCE; EVALUATION PROJECT; READING SPEED;
   UNITED-STATES; SEE PROJECT; POPULATION
AB PURPOSE. To determine if glaucoma and/or age-related macular degeneration (AMD) are associated with disability in instrumental activities of daily living (IADLs).
   METHODS. Glaucoma subjects (n = 84) with bilateral visual field (VF) loss and AMD subjects (n = 47) with bilateral or severe unilateral visual acuity (VA) loss were compared with 60 subjects with normal vision (controls). Subjects completed a standard IADL disability questionnaire, with disability defined as an inability to perform one or more IADLs unassisted.
   RESULTS. Disability in one or more IADLs was present in 18.3% of controls as compared with 25.0% of glaucoma subjects (P = 0.34) and 44.7% of AMD subjects (P = 0.003). The specific IADL disabilities occurring more frequently in both AMD and glaucoma subjects were preparing meals, grocery shopping, and out-of-home travelling (P < 0.05 for both).
   In multivariate logistic regression models run adjusting for age, sex, mental status, comorbidity, and years of education, AMD (odds ratio [OR] = 3.4, P = 0.02) but not glaucoma (OR = 1.4, P = 0.45) was associated with IADL disability. However, among glaucoma and control patients, the odds of IADL disability increased 1.6-fold with every 5 dB of VF loss in the better-seeing eye (P = 0.001). Additionally, severe glaucoma subjects (better-eye MD worse than -13.5 dB) had higher odds of IADL disability (OR = 4.2, P = 0.02). Among AMD and control subjects, every Early Treatment of Diabetic Retinopathy Study line of worse acuity was associated with a greater likelihood of IADL disability (OR = 1.3).
   CONCLUSIONS. VA loss in AMD and severe VF loss in glaucoma are associated with self-reported difficulties with IADLs. These limitations become more likely with increasing magnitude of VA or VF loss. (Invest Ophthalmol Vis Sci. 2012;53:3201-3206) DOI:10.1167/iovs.12-9469
C1 [Hochberg, Chad; Maul, Eugenio; Chan, Emilie S.; Van Landingham, Suzanne; Friedman, David S.; Ramulu, Pradeep Y.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Ferrucci, Luigi] NIA, Longitudinal Studies Sect, Clin Res Branch, NIH, Bethesda, MD 20892 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; National Institutes of
   Health (NIH) - USA; NIH National Institute on Aging (NIA)
RP Ramulu, PY (通讯作者)，600 N Wolfe St,Maumenee B110, Baltimore, MD 21287 USA.
EM pramulu1@jhmi.edu
OI Friedman, David/0000-0002-2055-5797; Hochberg, Chad/0000-0002-4376-5754
FU Dennis W. Jahnigen Memorial Award; National Institutes of Health
   [EY018595]; Research to Prevent Blindness; National Institutes of
   Health, National Institute of Aging; NATIONAL EYE INSTITUTE
   [K23EY018595] Funding Source: NIH RePORTER
FX Supported by Dennis W. Jahnigen Memorial Award, National Institutes of
   Health Grant EY018595, the Research to Prevent Blindness Robert and
   Helen Schaub Special Scholar Award, and the Intramural Research Program
   of the National Institutes of Health, National Institute of Aging. All
   funding organizations had no role in the design or conduct of this
   research.
CR Altangerel U, 2006, OPHTHAL EPIDEMIOL, V13, P67, DOI 10.1080/09286580500428500
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Berger S, 2008, J AGING HEALTH, V20, P504, DOI 10.1177/0898264308317534
   Brennan M, 2005, GERONTOLOGIST, V45, P337, DOI 10.1093/geront/45.3.337
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   Deshpande N, 2008, J AM GERIATR SOC, V56, P615, DOI 10.1111/j.1532-5415.2007.01639.x
   Eberhard JW, 1998, GERIATRICS, V53, pS53
   Friedman B, 2005, J AM GERIATR SOC, V53, P1570, DOI 10.1111/j.1532-5415.2005.53461.x
   Friedman DS, 2007, OPHTHALMOLOGY, V114, P2232, DOI 10.1016/j.ophtha.2007.02.001
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman SM, 1999, INVEST OPHTH VIS SCI, V40, P858
   FURNER SE, 1995, GERONTOLOGIST, V35, P444, DOI 10.1093/geront/35.4.444
   Griffith L, 2010, AGE AGEING, V39, P738, DOI 10.1093/ageing/afq105
   GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141
   Gustavsson A, 2011, ALZHEIMERS DEMENT, V7, P318, DOI 10.1016/j.jalz.2010.09.001
   Hung WW, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-47
   Jampel HD, 2002, J GLAUCOMA, V11, P154, DOI 10.1097/00061198-200204000-00012
   Jette AM, 2006, PHYS THER, V86, P726, DOI 10.1093/ptj/86.5.726
   Keay L, 2009, INVEST OPHTH VIS SCI, V50, P107, DOI 10.1167/iovs.08-2367
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Knudtson MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P807, DOI 10.1001/archopht.123.6.807
   Kotecha A, 2009, INVEST OPHTH VIS SCI, V50, P203, DOI 10.1167/iovs.08-2496
   Laitinen A, 2007, OPHTHAL EPIDEMIOL, V14, P333, DOI 10.1080/01658100701473713
   Lamoureux EL, 2008, OPHTHAL EPIDEMIOL, V15, P105, DOI 10.1080/09286580701840354
   MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Owsley C, 2001, OPTOMETRY VISION SCI, V78, P350, DOI 10.1097/00006324-200105000-00019
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Ramulu P, 2009, CURR OPIN OPHTHALMOL, V20, P92, DOI 10.1097/ICU.0b013e32832401a9
   Ramulu PY, 2012, OPHTHALMOLOGY, V119, P1159, DOI 10.1016/j.ophtha.2012.01.013
   Ramulu PY, 2009, OPHTHALMOLOGY, V116, P1846, DOI 10.1016/j.ophtha.2009.03.033
   Ramulu PY, 2009, ARCH OPHTHALMOL-CHIC, V127, P82, DOI 10.1001/archophthalmol.2008.523
   Shumway-Cook A, 2007, J AM GERIATR SOC, V55, P58, DOI 10.1111/j.1532-5415.2006.00962.x
   Timberlake GT, 2011, INVEST OPHTH VIS SCI, V52, P2540, DOI 10.1167/iovs.10-6062
   Turano KA, 2004, OPTOMETRY VISION SCI, V81, P298, DOI 10.1097/01.opx.0000134903.13651.8e
   Turano KA, 1999, INVEST OPHTH VIS SCI, V40, P2803
   Warrian KJ, 2009, RETINA-J RET VIT DIS, V29, P80, DOI 10.1097/IAE.0b013e318187f160
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   Willis JR, 2012, ARCH OPHTHALMOL-CHIC, V130, P329, DOI 10.1001/archopthalmol.2011.1773
NR 40
TC 68
Z9 68
U1 0
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2012
VL 53
IS 6
BP 3201
EP 3206
DI 10.1167/iovs.12-9469
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 953JY
UT WOS:000304864600078
PM 22491415
OA Green Published
DA 2022-11-30
ER

PT J
AU Maguire, MG
   Alexander, J
   Fine, SL
AF Maguire, Maureen G.
   Alexander, Judith
   Fine, Stuart L.
CA Complications Of Age Related Macul
TI Characteristics of choroidal neovascularization in the Complications of
   Age-related Macular Degeneration Prevention Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID PHOTOCOAGULATION; PROGNOSIS; IMPACT
AB Objective: To describe the characteristics of incident choroidal neovascularization (CNV) in observed and treated eyes in the Complications of Age-related Macular Degeneration Prevention Trial (CAPT).
   Design: Cross-sectional descriptive study within a multicenter, randomized clinical trial.
   Participants: Patients who developed CNV during CAPT follow-up.
   Methods: Inclusion criteria for CAPT specified bilateral large drusen (>= 10 drusen at least 125 mu), visual acuity >= 20/40 in each eye, and age >= 50. Exclusion criteria included CNV and geographic atrophy >1 Macular Photocoagulation Study (MPS) disc area or within 500 mu of the foveal center. One eye of each person was selected randomly for low-intensity laser treatment and the contralateral eye was observed. Fluorescein angiography was performed at baseline, annually for >= 5 years, and whenever there were symptoms of CNV. Trained readers at the CAPT Photograph Reading Center assessed color stereo photographs and angiogram negatives to identify CNV.
   Main Outcome Measures: Choroidal neovascularization was classified by type (predominantly classic CNV, minimally classic CNV, occult only CNV, or scar), location, and area. Visual acuity was measured by certified examiners. Symmetry of characteristics between eyes of bilaterally affected patients was examined.
   Results: Choroidal neovascularization developed in 282 eyes of 225 patients. At the time of detection, 192 (68%) of the lesions were occult only, 153 (54%) were subfoveal, and 157 (56%) were <= 2 MPS disc areas. Visual acuity was >= 20/40 in 123 (69%) of 179 eyes with visual acuity measured at the time of detection. Choroidal neovascularization developed in both eyes in 57 patients (25%) during CAPT follow-up. Lesions in eyes of bilaterally affected patients were no more similar to each other than affected eyes in 2 different patients.
   Conclusions: When patients are monitored closely, many CNV lesions can be detected outside of the fovea and when they are relatively small. Early detection may lead to improved long-term visual acuity.
C1 [Maguire, Maureen G.; Alexander, Judith; Fine, Stuart L.; Complications Of Age Related Macul] Univ Penn, Sch Med, Dept Ophthalmol, CAPT Coordinating Ctr, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Maguire, MG (通讯作者)，Univ Penn, Sch Med, Dept Ophthalmol, CAPT Coordinating Ctr, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
OI Folk, James/0000-0002-6271-2906; Boldt, H. Culver/0000-0002-7292-2093;
   Russell, Stephen/0000-0003-3776-1367
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services. [EY012211, EY012261, EY012279]; NATIONAL EYE
   INSTITUTE [U10EY012279] Funding Source: NIH RePORTER
FX Supported by grants EY012211, EY012261, and EY012279, from the National
   Eye Institute, National Institutes of Health, Department of Health and
   Human Services.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BERKOW JW, 1984, AM J OPHTHALMOL, V97, P143, DOI 10.1016/S0002-9394(14)76083-0
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   DUFFY SW, 1989, AM J EPIDEMIOL, V130, P371, DOI 10.1093/oxfordjournals.aje.a115343
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gelfand YA, 1997, OPHTHALMIC SURG LAS, V28, P823
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREY RHB, 1979, BRIT J OPHTHALMOL, V63, P85, DOI 10.1136/bjo.63.2.85
   LAVIN MJ, 1991, BRIT J OPHTHALMOL, V75, P133, DOI 10.1136/bjo.75.3.133
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 22
TC 13
Z9 13
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2008
VL 115
IS 9
BP 1468
EP 1473
DI 10.1016/j.ophtha.2008.02.028
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 346LZ
UT WOS:000259071300005
PM 18486222
DA 2022-11-30
ER

PT J
AU Abu Asleh, S
   Chowers, I
AF Abu Asleh, Saleh
   Chowers, Itay
TI Ethnic background as a risk factor for advanced age-related macular
   degeneration in Israel
SO ISRAEL MEDICAL ASSOCIATION JOURNAL
LA English
DT Article
DE age-related macular degeneration; Arabs; ethnic background; Jews;
   blindness
ID CAUSE-SPECIFIC PREVALENCE; MACULOPATHY; POPULATION; EYE; BALTIMORE;
   HEALTH
AB Background: Age-related macular degeneration is the most common cause of legal blindness in the developed world including Israel. Ethnic background is a risk factor for advanced AMD in several populations, however the relative prevalence of this disease in different ethnic groups in the Middle East is unknown.
   Objectives: To compare the prevalence of advanced AMD in Arabs and Jews in Israel.
   Methods: We performed a retrospective analysis of two independent groups of patients: the first group comprised a sequential series of Jerusalem residents who underwent photodynamic therapy for neovascular AMD (PDT group), and the second group consisted of all individuals in Jerusalem who received a blind certificate due to AMD (legal blindness group). Control groups were assessed to exclude inherited ethnic associated bias in the two study groups.
   Results: The PDT group included 146 patients: 142 were Jews (97.3%) and 4 were Arabs (2.7%). The legal blindness group included 340 Jerusalem residents: 326 Jews (96%) and 14 Arabs (4%). The number of Arab AMD patients in the two groups was lower than expected based on the ethnic composition of the age-matched Jerusalem population (P = 0.0002 for the PDT group, and P < 0.0001 for the legal blindness group). By contrast, the number of non-AMD Arab patients who were treated in the same clinic and the number of Arabs who received a blind certificate for diabetic retinopathy was not different from expected based on their relative number in the Jerusalem population.
   Conclusions: Advanced AMD is less common in the Arab than the Jewish population of Jerusalem. Genetic and environmental factors may account for this difference. A population-based study is required to assess the overall prevalence of AMD in Jews and Arabs.
C1 Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@md.huji.ac.il
CR Baron-Epel O, 2004, EUR J PUBLIC HEALTH, V14, P384, DOI 10.1093/eurpub/14.4.384
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   HOSHINO M, 1984, OPHTHALMOLOGY, V28, P89
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Rennert G, 2001, ISR MED ASSOC J, V3, P404
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
NR 18
TC 11
Z9 11
U1 0
U2 0
PU ISRAEL MEDICAL ASSOC JOURNAL
PI RAMAT GAN
PA 2 TWIN TOWERS, 11TH FL, 35 JABOTINSKY ST, PO BOX 3604, RAMAT GAN 52136,
   ISRAEL
SN 1565-1088
J9 ISRAEL MED ASSOC J
JI Isr. Med. Assoc. J.
PD SEP
PY 2007
VL 9
IS 9
BP 656
EP 658
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 217PU
UT WOS:000249960600007
PM 17939627
DA 2022-11-30
ER

PT J
AU Lambooij, AC
   van Wely, KHM
   Lindenbergh-Kortleve, DJ
   Kuijpers, RWAM
   Kliffen, M
   Mooy, CM
AF Lambooij, AC
   van Wely, KHM
   Lindenbergh-Kortleve, DJ
   Kuijpers, RWAM
   Kliffen, M
   Mooy, CM
TI Insulin-like growth factor-I and its receptor in neovascular age-related
   macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; PROLIFERATIVE DIABETIC-RETINOPATHY; IGF-I;
   CHOROIDAL NEOVASCULARIZATION; BINDING-PROTEINS; MESSENGER-RNA; RETINAL
   NEOVASCULARIZATION; ENDOTHELIAL-CELLS; GENE-EXPRESSION; VITREOUS LEVELS
AB PURPOSE. The insulin-like growth factor (IGF)-I protein is a growth-promoting polypeptide that can act as an angiogenic agent in the eye. The purpose of the current study was to localize the expression of IGF-I and its receptor (IGF-IR) mRNA and IGF-IR protein in situ in the normal human eye and to examine the presence of expression in eyes with neovascular age-related macular degeneration (AMD).
   METHODS. Formalin-fixed, paraffin-embedded slides of 4 normal control eyes and 14 eyes with choroidal neovascularization (CNV) secondary to AMD were examined. Three eyes with proliferative diabetic retinopathy were studied as the positive control. IGF-I and IGF-IR mRNA was detected by in situ hybridization with digoxigenin-labeled RNA probes. IGF-IR protein was studied by immunohistochemistry.
   RESULTS. In the normal retina, IGF-I and IGF-IR mRNA expression was found throughout the neuroretinal layers, in the retinal pigment epithelium (RPE), and in some choriocapillary and retinal capillary endothelial cells. In eyes with CNV we found IGF and IGF-IR mRNA in capillary endothelial cells, some transdifferentiated RPE, and fibroblast-like cells. IGF-IR protein was found in normal eyes in all neuroretinal layers, in the RPE, and in the choroidal vessels. In eyes with CNV, IGF-IR protein was present in the RPE monolayer, in transdifferentiated RPE, and in newly formed vessels.
   CONCLUSIONS. The colocalization of protein and receptor indicates an autocrine function of IGF-I in the normal human retina. Because IGF-I participates in ocular neovascularization, synthesis of IGF-IR and IGF-I in endothelial cells, RPE cells, and fibroblast-like cells in CNV may point toward a role for this growth factor in the pathogenesis of neovascular AMD.
C1 Erasmus MC, Dept Ophthalmol, NL-3000 CA Rotterdam, Netherlands.
   Erasmus MC, Dept Expt Pathol, NL-3000 CA Rotterdam, Netherlands.
   Erasmus MC, Dept Pediat, NL-3000 CA Rotterdam, Netherlands.
   Erasmus MC, Dept Pathol, NL-3000 CA Rotterdam, Netherlands.
   Pathol Lab, Dordrecht, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University
   Rotterdam; Erasmus MC
RP Lambooij, AC (通讯作者)，Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM a.lambooij@erasmusmc.nl
RI kuijpers, robert/AAD-5194-2019
OI van Wely, Karel Hermanus Martinus/0000-0001-8431-8072
CR Boulton M, 1997, BRIT J OPHTHALMOL, V81, P228, DOI 10.1136/bjo.81.3.228
   Burgos R, 2000, DIABETES CARE, V23, P80, DOI 10.2337/diacare.23.1.80
   Burren CP, 1996, INVEST OPHTH VIS SCI, V37, P1459
   COLAS B, 1992, EUR J BIOCHEM, V207, P1017, DOI 10.1111/j.1432-1033.1992.tb17138.x
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Danis RP, 1997, OPHTHALMOLOGY, V104, P1661, DOI 10.1016/S0161-6420(97)30081-5
   GARTNER MH, 1992, J SURG RES, V52, P389, DOI 10.1016/0022-4804(92)90121-F
   Gerhardinger C, 2001, DIABETES, V50, P175, DOI 10.2337/diabetes.50.1.175
   GRANT M, 1986, DIABETES, V35, P416, DOI 10.2337/diabetes.35.4.416
   GRANT M, 1995, DIABETES REV, V3, P113
   GRANT MB, 1993, DIABETOLOGIA, V36, P282, DOI 10.1007/BF00400229
   GRANT MB, 1993, REGUL PEPTIDES, V48, P267, DOI 10.1016/0167-0115(93)90356-D
   HERNANDEZSANCHEZ C, 1995, P NATL ACAD SCI USA, V92, P9834, DOI 10.1073/pnas.92.21.9834
   JANSEN M, 1983, NATURE, V306, P609, DOI 10.1038/306609a0
   Kaven C, 2000, CURR EYE RES, V20, P480, DOI 10.1076/0271-3683(200006)20:6;1-Y;FT480
   Kermer P, 2000, J NEUROSCI, V20, P722, DOI 10.1523/JNEUROSCI.20-02-00722.2000
   KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Klisovic DD, 2001, INVEST OPHTH VIS SCI, V42, pS244
   Kociok N, 1998, EXP EYE RES, V67, P237, DOI 10.1006/exer.1998.0517
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lambooij AC, 2000, INVEST OPHTH VIS SCI, V41, P2329
   LEROITH D, 1992, ANN INTERN MED, V116, P854, DOI 10.7326/0003-4819-116-10-854
   LOWE WL, 1995, METABOLISM, V44, P1038, DOI 10.1016/0026-0495(95)90102-7
   MARTIN DM, 1992, MOL BRAIN RES, V12, P181, DOI 10.1016/0169-328X(92)90082-M
   MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877
   OCRANT I, 1989, ENDOCRINOLOGY, V125, P2407, DOI 10.1210/endo-125-5-2407
   Politi LE, 2001, J NEUROCHEM, V76, P1199, DOI 10.1046/j.1471-4159.2001.00128.x
   Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619
   Seigel G, 2000, MOL VIS, V6, P157
   Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963
   Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706
   Spoerri PE, 1998, GROWTH HORM IGF RES, V8, P125, DOI 10.1016/S1096-6374(98)80102-0
   Spranger J, 2000, HORM METAB RES, V32, P196, DOI 10.1055/s-2007-978621
   Spraul CW, 2000, OPHTHALMIC RES, V32, P244, DOI 10.1159/000055621
   Spraul CW, 2002, GRAEF ARCH CLIN EXP, V240, P227, DOI 10.1007/s00417-002-0441-7
   TAKAGI H, 1994, INVEST OPHTH VIS SCI, V35, P916
   Ulbig M W, 1995, Ger J Ophthalmol, V4, P264
   WALDBILLIG RJ, 1991, J NEUROCHEM, V57, P1522, DOI 10.1111/j.1471-4159.1991.tb06347.x
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 40
TC 61
Z9 66
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2003
VL 44
IS 5
BP 2192
EP 2198
DI 10.1167/iovs.02-0410
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672CQ
UT WOS:000182503700056
PM 12714661
DA 2022-11-30
ER

PT J
AU Ji, MH
   Callaway, NF
   Ludwig, CA
   Vail, D
   Al-Moujahed, A
   Rosenblatt, TR
   Leng, T
   Sanislo, SR
   Moshfeghi, DM
AF Ji, Marco H.
   Callaway, Natalia F.
   Ludwig, Cassie A.
   Vail, Daniel
   Al-Moujahed, Ahmad
   Rosenblatt, Tatiana R.
   Leng, Theodore
   Sanislo, Steven R.
   Moshfeghi, Darius M.
TI Visual acuity and progression of macular atrophy in patients receiving
   intravitreal anti-VEGF for age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; retina; medical therapies;
   retinal cell biology; retinal pathology; research
ID GEOGRAPHIC ATROPHY; PROLONGED BLOCKADE; OUTCOMES; DISEASE; GROWTH;
   RANIBIZUMAB; SECONDARY; HISTORY; DAMAGE; RISK
AB Purpose: Whether intravitreal anti-vascular endothelial growth factors (VEGFs) cause retinal atrophy is still a subject of debate. We reported 13 eyes that received several injections of anti-VEGF for wet age-related macular degeneration (AMD) with good visual acuity despite geographic atrophy on imaging. Methods: This is a case series study conducted at Byers Eye Institute at Stanford University. Patients of three retina specialists with wet AMD who received six or more intravitreal injection of anti-VEGFs with visual acuity of 20/60 or better and incomplete RPE and outer retina atrophy (iRORA) or complete RPE and outer retinal atrophy (cRORA) were enrolled in this case series. Different imaging modalities were reviewed by three retina specialists comparing the baseline with the most recent exam. Results: About 13 eyes of 10 patients met the selection criteria. Eleven eyes were classified as iRORA and 2 as cRORA. Despite the development of macular atrophy on imaging after an average of 38.1 injections, eyes maintained stable visual acuity. Conclusion: The discrepancy between structural and functional findings in this cohort suggests that patients treated by anti-VEGF drugs exhibit divergent clinical outcomes for currently unknown reasons. The authors propose anti-VEGF may affect melanosomes within RPE without disrupting RPE and photoreceptors function completely. This requires further investigation.
C1 [Ji, Marco H.; Callaway, Natalia F.; Ludwig, Cassie A.; Vail, Daniel; Al-Moujahed, Ahmad; Rosenblatt, Tatiana R.; Leng, Theodore; Sanislo, Steven R.; Moshfeghi, Darius M.] Stanford Univ, Sch Med, Dept Ophthalmol, Byers Eye Inst,Horngren Family Vitreoretinal Ctr, 2452 Watson Court, Palo Alto, CA 94303 USA.
   [Ji, Marco H.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Ludwig, Cassie A.] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Retina Serv, Boston, MA 02115 USA.
C3 Stanford University; Icahn School of Medicine at Mount Sinai; Harvard
   University; Harvard Medical School; Massachusetts Eye & Ear Infirmary
RP Moshfeghi, DM (通讯作者)，Stanford Univ, Sch Med, Dept Ophthalmol, Byers Eye Inst,Horngren Family Vitreoretinal Ctr, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM dariusm@stanford.edu
RI Ji, Marco H./Q-3807-2017
OI Ji, Marco H./0000-0002-7033-7763; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X; /0000-0002-5435-8804; Leng,
   Theodore/0000-0002-8461-3562
FU Heed Ophthalmic Foundation; Michels Fellowship Foundation; department of
   Ophthalmology at Stanford University School of Medicine by Research to
   Prevent Blindness; NEI [P30EY026877]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: This work
   was supported by the Heed Ophthalmic Foundation and Michels Fellowship
   Foundation awarded to Natalia F. Callaway, MD, MS, and the department of
   Ophthalmology at Stanford University School of Medicine by an
   unrestricted grant from Research to Prevent Blindness and NEI
   P30EY026877.
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2017, OPHTHALMOLOGY, V124, pE31, DOI 10.1016/j.ophtha.2016.05.054
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Horani M, 2019, OPHTHALMOL THER, V8, P235, DOI 10.1007/s40123-019-0177-7
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Long D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120231
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Miura M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39688-z
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Sitnilska V, 2019, OPHTHALMOLOGICA, V241, P154, DOI 10.1159/000492924
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 35
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP 429
EP 435
AR 11206721211001708
DI 10.1177/11206721211001708
EA MAR 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000678285300001
PM 33781106
DA 2022-11-30
ER

PT J
AU Hsia, Y
   Yang, CH
   Hsieh, YT
   Yang, CM
   Ho, TC
   Lai, TT
AF Hsia, Yun
   Yang, Chang-Hao
   Hsieh, Yi-Ting
   Yang, Chung-May
   Ho, Tzyy-Chang
   Lai, Tso-Ting
TI Hyperreflective foci in predicting the treatment outcome of antivascular
   endothelial growth factor in neovascular age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Antivascular endothelial growth factor; Hyperreflective foci;
   Neovascular age-related macular degeneration; Subretinal fluid
ID OPTICAL COHERENCE TOMOGRAPHY; OUTER RETINA; VISUAL OUTCOMES;
   PROGRESSION; BIOMARKERS; MICROGLIA
AB Purpose To describe the optical coherence tomographic findings of hyperreflective foci (HF) in neovascular age-related macular degeneration and evaluate the use of HF to predict visual outcome after antivascular endothelium growth factor (anti-VEGF) therapy. Methods This was a post-hoc analysis of a retrospective cohort study. Hyperreflective foci were localized in the inner retina, outer retina, or subretinal fluid (SRF) layer. The treatment response of HF was recorded. The association between HF and visual outcome was analyzed. Results We enrolled 126 eyes. Hyperreflective foci involving more than one layer were associated with poor initial visual acuity (P < 0.001). Hyperreflective foci in each layer at baseline were negatively correlated with baseline visual acuity. At 3 months posttreatment, HF in the SRF layer had decreased significantly (P = 0.003), which was faster compared with HF in other layers. Baseline HF status at each layer was not associated with final visual outcome. The eyes with reduced HF in the SRF at 3 months had better visual improvement at 12 months (P = 0.038). Conclusion Hyperreflective foci involving multiple layers were associated with poor initial visual acuity but not with final visual outcome. With anti-VEGF treatment, HF in the SRF layer resolved faster, which may predict better visual outcome.
C1 [Hsia, Yun; Yang, Chang-Hao; Hsieh, Yi-Ting; Yang, Chung-May; Ho, Tzyy-Chang; Lai, Tso-Ting] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Yang, Chang-Hao; Yang, Chung-May] Natl Taiwan Univ, Coll Med, Dept Ophthalmol, Taipei, Taiwan.
   [Lai, Tso-Ting] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University
RP Lai, TT (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.; Lai, TT (通讯作者)，Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan.
EM b91401005@ntu.edu.tw
RI Yang, Chang-Hao/AAR-3759-2021
OI Hsia, Yun/0000-0001-6972-7732; YANG, CHANG-HAO/0000-0002-4328-8716;
   YANG, CHUNG-MAY/0000-0003-4082-420X; Lai, Tso-Ting/0000-0002-8247-7018
CR Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Kang JW, 2016, RETINA-J RET VIT DIS, V36, P1630, DOI 10.1097/IAE.0000000000000995
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kuroda M, 2014, CLIN OPHTHALMOL, V8, P435, DOI 10.2147/OPTH.S58164
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P1372, DOI 10.1097/IAE.0000000000000929
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P465, DOI 10.1097/IAE.0000000000000645
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Mo B, 2017, INT J OPHTHALMOL-CHI, V10, P605, DOI 10.18240/ijo.2017.04.17
   Nishijima K, 2014, RETINA-J RET VIT DIS, V34, P732, DOI 10.1097/IAE.0000000000000005
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041
NR 27
TC 8
Z9 8
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2020
VL 258
IS 2
BP 273
EP 280
DI 10.1007/s00417-019-04546-1
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KJ3AA
UT WOS:000511928000007
PM 31828425
DA 2022-11-30
ER

PT J
AU Ayala-Haedo, JA
   Gallins, PJ
   Whitehead, PL
   Schwartz, SG
   Kovach, JL
   Postel, EA
   Agarwal, A
   Wang, GF
   Haines, JL
   Pericak-Vance, MA
   Scott, WK
AF Ayala-Haedo, Juan A.
   Gallins, Paul J.
   Whitehead, Patrice L.
   Schwartz, Stephen G.
   Kovach, Jaclyn L.
   Postel, Eric A.
   Agarwal, Anita
   Wang, Gaofeng
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
   Scott, William K.
TI Analysis of Single Nucleotide Polymorphisms in the NOS2A Gene and
   Interaction with Smoking in Age-Related Macular Degeneration
SO ANNALS OF HUMAN GENETICS
LA English
DT Article
DE Association; age-related macular degeneration; polymorphism;
   gene-environment interaction
ID NITRIC-OXIDE SYNTHASE; PIGMENTED EPITHELIAL-CELLS; CHOROIDAL
   NEOVASCULARIZATION; PARKINSONS-DISEASE; CIGARETTE-SMOKING;
   ENVIRONMENTAL-FACTORS; GROWTH-FACTOR; RISK-FACTORS; ASSOCIATION;
   SUSCEPTIBILITY
AB P>Age-related macular degeneration (AMD) is a complex degenerative retinal disease influenced by both genetic and environmental risk factors. We assessed whether single nucleotide polymorphisms (SNPs) in the NOS2A gene increase risk and modulate the effect of smoking in AMD. 998 Caucasian subjects (712 AMD cases and 286 controls) were genotyped for 17 SNPs in NOS2A. Multivariable logistic regression models containing SNP genotypes, age, sex, smoking status and genotype/smoking interaction were constructed. SNP rs8072199 was significantly associated with AMD (OR = 1.3; 95% CI : 1.02, 1.65; P = 0.035). A significant interaction with smoking was detected at rs2248814 (P = 0.037). Stratified data by genotypes demonstrated that the association between AMD and smoking was stronger in carriers of AA genotypes (OR = 35.98; 95% CI: 3.19, 405.98) than in carriers of the AG genotype (OR = 3.05; 95% CI: 1.36, 6.74) or GG genotype (OR = 2.1; 95% CI: 0.91, 4.84). The results suggest a possible synergistic interaction of AA genotype with smoking, although the result bears replication in larger samples. Our data suggests that SNPs in the NOS2A gene are associated with increased risk for AMD and might modulate the effect of smoking on AMD.
C1 [Ayala-Haedo, Juan A.; Gallins, Paul J.; Whitehead, Patrice L.; Wang, Gaofeng; Pericak-Vance, Margaret A.; Scott, William K.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Ayala-Haedo, Juan A.; Gallins, Paul J.; Whitehead, Patrice L.; Wang, Gaofeng; Pericak-Vance, Margaret A.; Scott, William K.] Univ Miami, Miller Sch Med, Dr John T Macdonald Fdn, Dept Human Genet, Miami, FL 33136 USA.
   [Schwartz, Stephen G.; Kovach, Jaclyn L.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Naples, FL 34102 USA.
   [Postel, Eric A.] Duke Univ, Duke Univ Eye Ctr, Durham, NC 27710 USA.
   [Agarwal, Anita] Vanderbilt Univ, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
   [Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN 37232 USA.
C3 University of Miami; University of Miami; Bascom Palmer Eye Institute;
   Duke University; Vanderbilt University; Vanderbilt University
RP Scott, WK (通讯作者)，Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, 1501 NW 10th Ave,BRB 414, Miami, FL 33136 USA.
EM bscott@med.miami.edu
RI Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU National Institutes of Health [EY12118]; NATIONAL EYE INSTITUTE
   [U10EY012118, R01EY012118] Funding Source: NIH RePORTER
FX This research was supported by National Institutes of Health grant
   EY12118 (to MP-V and JLH). A subset of the participants was ascertained
   while Margaret A. Pericak-Vance was a faculty member at Duke University.
CR Ando A, 2002, MOL PHARMACOL, V62, P539, DOI 10.1124/mol.62.3.539
   Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Fratiglioni L, 2000, BEHAV BRAIN RES, V113, P117, DOI 10.1016/S0166-4328(00)00206-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276
   Hague S, 2004, NEUROLOGY, V62, P635, DOI 10.1212/01.WNL.0000110191.38152.29
   Hancock DB, 2008, NEUROGENETICS, V9, P249, DOI 10.1007/s10048-008-0137-1
   Hancock DB, 2006, ANN NEUROL, V60, P366, DOI 10.1002/ana.20915
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   Hoyt JC, 2003, EXP LUNG RES, V29, P17, DOI 10.1080/01902140303759
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Ju WK, 2001, NEUROREPORT, V12, P4075, DOI 10.1097/00001756-200112210-00043
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Levecque C, 2003, HUM MOL GENET, V12, P79, DOI 10.1093/hmg/ddg009
   Lewis P.O., 2000, GENETIC DATA ANAL CO
   Mazzio EA, 2005, NEUROTOXICOLOGY, V26, P49, DOI 10.1016/j.neuro.2004.07.005
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006
   Osborne NN, 2004, INVEST OPHTH VIS SCI, V45, P3787, DOI 10.1167/iovs.04-0147
   Preux PM, 2000, NEUROEPIDEMIOLOGY, V19, P333, DOI 10.1159/000026273
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt S, 2000, MOL VIS, V6, P287
   She HC, 2007, INVEST OPHTH VIS SCI, V48, P2268, DOI 10.1167/iovs.06-0979
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 39
TC 17
Z9 17
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0003-4800
J9 ANN HUM GENET
JI Ann. Hum. Genet.
PD MAY
PY 2010
VL 74
BP 195
EP 201
DI 10.1111/j.1469-1809.2010.00570.x
PN 3
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 584TH
UT WOS:000276775500002
PM 20374233
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Feng, L
   Liao, X
   Zhang, Y
   Wang, F
AF Feng, Le
   Liao, Xin
   Zhang, Yao
   Wang, Fang
TI Protective Effects on Age-related Macular Degeneration by Activated
   Autophagy Induced by Amyloid-beta in Retinal Pigment Epithelial Cells
SO DISCOVERY MEDICINE
LA English
DT Article
ID POTENTIAL ROLE; ALZHEIMERS-DISEASE; PATHOGENESIS; RPE; DEGRADATION;
   SENESCENCE; EXPRESSION; SECRETION; PROGRESS; LC3
AB Amyloid-beta (A beta) accumulation has been reported in patients with age-related macular degeneration (AMD), and it has been demonstrated to play an important role in the development of AMD. This study was performed to detect the activation of autophagy in retinal pigment epithelial (RPE) cells treated with A beta, aiming to investigate the potential protective mechanism of RPE cells against A beta stress. Human ARPE-19 cells were treated with soluble A beta(1-42) oligomer. Transmission electron microscopy was used to assess the formation of autophagic compartments; immunofluorescence was used to detect the subcellular localization of LC3; and western blot was used to detect the conversion of LC3-I to LC3-II and the expression of p62. Activated autophagy in A beta-treated ARPE-19 cells was detected by three methodologies: 1) generation of autophagic compartments by transmission electron microscopy, 2) altered expression pattern of LC3 by immunofluorescence, and 3) elevated light-chain-3 II (LC3-II) and decreased p62 expression by western blot. These results suggest that A beta could induce autophagy in RPE cells, which provided a potential protective mechanism for the retina cells that encountered A beta deposition.
C1 [Feng, Le; Liao, Xin; Zhang, Yao; Wang, Fang] Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai 200072, Peoples R China.
C3 Tongji University
RP Wang, F (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai 200072, Peoples R China.
EM 1500015@tongji.edu.cn
FU Bethune Lang Mu Youth Ophthalmology Research Fund [BJ-LM2016006J];
   Shanghai Tenth People's Hospital Climbing Talent Program [2018SYPDRC036,
   2018SYPDRC029]; National Natural Key Research and Development Program of
   China [2017ZX09304010]; National Natural Science Foundation of China
   [81400417]; Shanghai Municipal Health and Family Planning Commission
   Research Fund [20144Y0149]
FX We thank the Biochemistry and Molecular Biology Institute of Shanghai
   Tenth People's Hospital for their technological support. This work was
   supported by Bethune Lang Mu Youth Ophthalmology Research Fund
   (BJ-LM2016006J), Shanghai Tenth People's Hospital Climbing Talent
   Program (2018SYPDRC036, 2018SYPDRC029), the National Natural Key
   Research and Development Program of China Grant (2017ZX09304010), the
   National Natural Science Foundation of China (81400417), and Shanghai
   Municipal Health and Family Planning Commission Research Fund
   (20144Y0149).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Cao LN, 2013, INT J MOL MED, V31, P1105, DOI 10.3892/ijmm.2013.1310
   Fan S, 2015, BIOMED RES INT, V2015
   Feng L, 2016, DISCOV MED, V21, P149
   Ferreira JO, 2008, ACTA OPHTHALMOL, V86, ps243
   Glabe CG, 2006, NEUROLOGY, V66, pS74, DOI 10.1212/01.wnl.0000192103.24796.42
   Goehe Rachel W, 2013, Methods Mol Biol, V962, P31, DOI 10.1007/978-1-62703-236-0_3
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hung SY, 2015, NEUROPHARMACOLOGY, V93, P243, DOI 10.1016/j.neuropharm.2015.02.003
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Korsnes MS, 2016, TOXICOL IN VITRO, V27, P1962
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li CP, 2013, BIOCHEM BIOPH RES CO, V438, P739, DOI 10.1016/j.bbrc.2013.07.097
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Nilsson P, 2014, BIOESSAYS, V36, P570, DOI 10.1002/bies.201400002
   SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989
   Tian Y, 2013, P NATL ACAD SCI USA, V110, P17071, DOI 10.1073/pnas.1315110110
   Tokarz P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060898
   Velez-Montoya R, 2014, RETINA, V33, P1487
   Wu MX, 2015, GUOJI YANKE ZAZHI, V15
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 31
TC 12
Z9 12
U1 0
U2 2
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD MAR
PY 2019
VL 27
IS 148
BP 153
EP 160
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IW5NF
UT WOS:000485024500002
PM 31095924
DA 2022-11-30
ER

PT J
AU Das, V
   Dandapat, S
   Bora, PK
AF Das, Vineeta
   Dandapat, Samarendra
   Bora, Prabin Kumar
TI Unsupervised Super-Resolution of OCT Images Using Generative Adversarial
   Network for Improved Age-Related Macular Degeneration Diagnosis
SO IEEE SENSORS JOURNAL
LA English
DT Article
DE Generative adversarial networks; Training; Retina; Image reconstruction;
   Gallium nitride; Age-related macular degeneration (AMD); generative
   adversarial network (GAN); optical coherence tomography (OCT);
   super-resolution
ID OPTICAL COHERENCE TOMOGRAPHY; MOTION ARTIFACTS; DRUSEN
AB Age-related macular degeneration (AMD) is the leading cause of progressive vision loss in the elderly. Optical coherence tomography (OCT) is a promising diagnostic tool for early detection and management of AMD. However, the speckle noise and low resolution (LR) of the OCT images affect its diagnostic viabilities. Therefore, denoising and super-resolution (SR) techniques present a potential solution to improve the quality of the OCT images. Recent methods rely on example-based approaches that require paired LR and high resolution (HR) images for training. However, the large scale acquisition of paired LR-HR images presents pertinent challenges in clinical settings. Therefore, this work proposes an unsupervised framework using the generative adversarial network (GAN) to perform fast and reliable SR without the requirement of aligned LR-HR pairs. We use adversarial learning with cycle consistency and identity mapping priors to preserve the spatial correlation, color and texture details in the generated clean HR images. Experimental results on clinical-grade OCT images show that the proposed method outperforms the existing methods both in terms of SR performance and computational time. Improved classification accuracy of 96.54% is obtained when the generated images are used for automated AMD diagnosis. The enhanced generalizability and faithful reconstruction attributes make the proposed method suitable for assisting ophthalmologists in better diagnosis and treatment planning.
C1 [Das, Vineeta; Dandapat, Samarendra; Bora, Prabin Kumar] Indian Inst Technol Guwahati, Dept Elect & Elect Engn, Gauhati 781039, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Guwahati
RP Das, V (通讯作者)，Indian Inst Technol Guwahati, Dept Elect & Elect Engn, Gauhati 781039, India.
EM vineetadas@iitg.ac.in; samaren@iitg.ac.in; prabin@iitg.ac.in
FU Department of Biotechnology, Government of India, through the North East
   Centre for Biological Sciences and Healthcare Engineering (NECBH)
   [BT/COE/34/SP28408/2018]
FX This work was supported by the Department of Biotechnology, Government
   of India, through the North East Centre for Biological Sciences and
   Healthcare Engineering (NECBH), under Project BT/COE/34/SP28408/2018.
CR Abbasi A, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.3.036011
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2018, PROC INT CONF EMERG
   Atry F, 2015, IEEE T BIO-MED ENG, V62, P766, DOI 10.1109/TBME.2014.2364816
   Baghaie A, 2017, MED IMAGE ANAL, V37, P129, DOI 10.1016/j.media.2017.02.002
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   de Kinkelder R, 2011, INVEST OPHTH VIS SCI, V52, P3908, DOI 10.1167/iovs.10-6738
   Drexler W, 2008, BIOL MED PHYS BIOMED, P1, DOI 10.1007/978-3-540-77550-8
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57, pOCT299, DOI 10.1167/iovs.15-18865
   Fang LY, 2017, IEEE T MED IMAGING, V36, P407, DOI 10.1109/TMI.2016.2611503
   Fang LY, 2013, IEEE T MED IMAGING, V32, P2034, DOI 10.1109/TMI.2013.2271904
   Fang LY, 2012, BIOMED OPT EXPRESS, V3, P927, DOI 10.1364/BOE.3.000927
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Fujimoto JG, 2000, NEOPLASIA, V2, P9, DOI 10.1038/sj.neo.7900071
   Gin TJ, 2017, INVEST OPHTH VIS SCI, V58, P2079, DOI 10.1167/iovs.16-20105
   Goodfellow IJ, 2014, ADV NEUR IN, V27, P2672
   HEE MR, 1995, IEEE ENG MED BIOL, V14, P67, DOI 10.1109/51.340751
   Huang YQ, 2019, OPT EXPRESS, V27, P12289, DOI 10.1364/OE.27.012289
   Isola P, 2017, PROC CVPR IEEE, P5967, DOI 10.1109/CVPR.2017.632
   Ledig C, 2017, PROC CVPR IEEE, P4681, DOI DOI 10.1109/CVPR.2017.19
   Li MXZ, 2017, BIOMED OPT EXPRESS, V8, P3903, DOI 10.1364/BOE.8.003903
   Madani A, 2018, NPJ DIGIT MED, V1, DOI [10.1038/s41746-018-0065-x, 10.1038/s41746-017-0013-1]
   Mao YX, 2011, IEEE T INSTRUM MEAS, V60, P3376, DOI 10.1109/TIM.2011.2126950
   Naqvi RZ, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.00055
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Plucinski J, 2008, B POL ACAD SCI-TECH, V56, P155
   Rasti R, 2018, IEEE T MED IMAGING, V37, P1024, DOI 10.1109/TMI.2017.2780115
   Schmitt JM, 1999, J BIOMED OPT, V4, P95, DOI 10.1117/1.429925
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shen K, 2017, BIOMED OPT EXPRESS, V8, P4887, DOI 10.1364/BOE.8.004887
   Struk P, 2015, IEEE SENS J, V15, P7061, DOI 10.1109/JSEN.2015.2469547
   Swillo R, 2008, IEEE SENS J, V8, P1138, DOI 10.1109/JSEN.2008.926180
   Ulyanov D., 2016, ARXIV160708022V3, P4
   Wang Q, 2020, IEEE T PATTERN ANAL, V42, P46, DOI 10.1109/TPAMI.2018.2875002
   Wang S, 2013, IEEE SENS J, V13, P4534, DOI 10.1109/JSEN.2013.2270008
   Wang XT, 2019, LECT NOTES COMPUT SC, V11133, P63, DOI 10.1007/978-3-030-11021-5_5
   Yuan Y., 2018, P IEEE C COMP VIS PA, P701
   Yun SH, 2004, OPT EXPRESS, V12, P2977, DOI 10.1364/OPEX.12.002977
   Zawadzki RJ, 2006, PROC SPIE, V6138, DOI 10.1117/12.647567
   Zhao R, 2017, BIOMED OPT EXPRESS, V8, P5049, DOI 10.1364/BOE.8.005049
   Zhu JY, 2017, IEEE I CONF COMP VIS, P2242, DOI 10.1109/ICCV.2017.244
NR 43
TC 14
Z9 14
U1 6
U2 22
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1530-437X
EI 1558-1748
J9 IEEE SENS J
JI IEEE Sens. J.
PD AUG.JAN
PY 2020
VL 20
IS 15
BP 8746
EP 8756
DI 10.1109/JSEN.2020.2985131
PG 11
WC Engineering, Electrical & Electronic; Instruments & Instrumentation;
   Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Instruments & Instrumentation; Physics
GA MG0IB
UT WOS:000545717900060
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Waldstein, SM
AF Schmidt-Erfurth, Ursula
   Waldstein, Sebastian M.
TI A paradigm shift in imaging biomarkers in neovascular age-related
   macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Optical
   coherence tomography; Intravitreal therapy; Intraretinal cystoid fluid;
   Subretinal fluid; Pigment-epithelial detachment; Antiangiogenic therapy;
   Prognostic factors; Predictive factors
ID OPTICAL-COHERENCE-TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT
   EPITHELIUM; ANTI-VEGF THERAPY; POSTERIOR VITREOUS DETACHMENT; SUBFOVEAL
   CHOROIDAL THICKNESS; INTRAVITREAL RANIBIZUMAB INJECTIONS; VERTEPORFIN
   PLUS RANIBIZUMAB; VISUAL-ACUITY; VITREOMACULAR ADHESION
AB Neovascular age-related macular degeneration (AMD) has undergone substantial break-throughs in diagnostic as well as therapeutic respect, with optical coherence tomography (OCT) allowing to identify disease morphology in great detail, and intravitreal anti-vascular endothelial growth factor therapy providing unprecedented benefit. However, these two paths have yet not been combined in an optimal way, real-world outcomes are inferior to expectations, and disease management is largely inefficient in the real-world setting. This dilemma can be solved by identification of valid biomarkers relevant for visual function, disease activity and prognosis, which can provide solid guidance for therapeutic management on an individual level as well as on the population base.
   Qualitative and quantitative morphological features obtained by advanced OCT provide novel insight into exudative and degenerative stages of neovascular AMD. However, conclusions from structure/function correlations evolve differently from previous paradigms. While central retinal thickness was used as biomarker for guiding retreatment management in clinical trials and practice, fluid localization in different compartments offers superior prognostic value: Intraretinal cystoid fluid has a negative impact on visual acuity and is considered as degenerative when persisting through the initial therapeutic interval. Subretinal fluid is associated with superior visual benefit and a lower rate of progression towards geographic atrophy. Detachment of the retinal pigment epithelium was identified as most pathognomonic biomarker, often irresponsive to therapy and responsible for visual decline during a pro-re-nata regimen. Alterations of neurosensory tissue are usually associated with irreversible loss of functional elements and a negative prognosis. Novel OCT technologies offer crucial insight into corresponding changes at the level of the photoreceptor retinal pigment epithelial - choriocapillary unit, identifying the biological limits of therapeutic interventions.
   To optimally benefit from high-resolution multi-modal imaging, an integrated analysis of all functional and structural features is required involving reliable automated algorithms and computational data analyses. Using innovative analysis methods, retinal biomarkers can be used to provide efficient personalized therapy for the individual patient, predictive disease- and population-based models for large-scale management and identifying promising targets for the development of novel therapeutic strategies. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Schmidt-Erfurth, Ursula; Waldstein, Sebastian M.] Med Univ Vienna, Dept Ophthalmol, Vienna Reading Ctr, Christian Doppler Lab Ophthalm Image Anal, Spitalgasse 23, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Waldstein,
   Sebastian/0000-0003-2899-6279
FU Austrian Federal Ministry of Science, Research, and Economy; National
   Foundation for Research, Technology, and Development
FX The financial support of the Austrian Federal Ministry of Science,
   Research, and Economy and the National Foundation for Research,
   Technology, and Development is gratefully acknowledged. The funding
   organizations had no role in the design or conduct of the study. The
   authors thank Dominika Podkowinski, MD for assistance in preparing the
   figures, and Jing Wu, PhD for language review.
CR AAO Retina/Vitreous PPP Panel, 2015, AG REL MAC DEG PREF
   Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Ahlers C, 2009, INVEST OPHTH VIS SCI, V50, P3417, DOI 10.1167/iovs.08-2759
   Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 1984, Am J Ophthalmol, V98, P376
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bogunovic H, 2015, INVEST OPHTH VIS SCI, V56, P259, DOI 10.1167/iovs.14-15885
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Chen XJ, 2012, INVEST OPHTH VIS SCI, V53, P8042, DOI 10.1167/iovs.12-10083
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dirani A., 2015, AM OPHTHALMOL, DOI [10.1016/j.ajo.2015.06.025. [Epub ahead of print], DOI 10.1016/J.AJO.2015.06.025]
   Dirani A, 2015, RETINA-J RET VIT DIS, V35, P1166, DOI 10.1097/IAE.0000000000000439
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   El-Emam S, 2013, RETINA-J RET VIT DIS, V33, P1249, DOI 10.1097/IAE.0b013e31827b6439
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481, DOI 10.1016/j.ajo.2011.08.018
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Felberer F, 2014, BIOMED OPT EXPRESS, V5, P439, DOI 10.1364/BOE.5.000439
   FERCHER AF, 1993, AM J OPHTHALMOL, V116, P113, DOI 10.1016/S0002-9394(14)71762-3
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   Filho CADG, 2013, OPHTHAL SURG LAS IM, V44, P204, DOI 10.3928/23258160-20130313-12
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gass, 1998, STEREOSCOPIC ATLAS M
   Geck U, 2013, GRAEF ARCH CLIN EXP, V251, P1691, DOI 10.1007/s00417-013-2266-y
   Gelman SK, 2014, RETINA-J RET VIT DIS, V34, P2088, DOI 10.1097/IAE.0000000000000207
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Giani A, 2011, RETINA-J RET VIT DIS, V31, P942, DOI 10.1097/IAE.0b013e31820a68cc
   Gianniou C., 2015, RETINA IN PRESS
   Gobel A.P., 2014, OPHTHALMOLOGE S1, V111, P1
   Goldenberg D.T., 2008, INVESTIG OPHTHALMOL, V49
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hawkes N, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3275
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Heimes B, 2011, OPHTHALMOLOGE, V108, P124, DOI 10.1007/s00347-010-2210-z
   Hemeida TS, 2010, BRIT J OPHTHALMOL, V94, P701, DOI 10.1136/bjo.2009.167627
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Ho J, 2009, OPHTHALMOLOGY, V116, P1960, DOI 10.1016/j.ophtha.2009.03.034
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hong YJ, 2014, INVEST OPHTH VIS SCI, V55, P5016, DOI 10.1167/iovs.14-14005
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Itakura H, 2013, JAMA OPHTHALMOL, V131, P1348, DOI 10.1001/jamaophthalmol.2013.4578
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Katz G, 2012, RETINA-J RET VIT DIS, V32, P293, DOI 10.1097/IAE.0b013e31821e20b0
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Krebs I, 2009, INVEST OPHTH VIS SCI, V50, P995, DOI 10.1167/iovs.08-2617
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Liu M., 2015, INVESTIG OPHTHALMOL
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   McDonnell EC, 2014, EUR J OPHTHALMOL, V24, P897, DOI 10.5301/ejo.5000509
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Mirza RG, 2007, SURV OPHTHALMOL, V52, P397, DOI 10.1016/j.survophthal.2007.04.007
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Modi YS, 2015, DRUG SAFETY, V38, P279, DOI 10.1007/s40264-015-0273-0
   Montuoro A, 2014, LECT NOTES COMPUT SC, V8674, P130, DOI 10.1007/978-3-319-10470-6_17
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Neudorfer M, 2012, INVEST OPHTH VIS SCI, V53, P3104, DOI 10.1167/iovs.11-8700
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Ouyang YL, 2011, INVEST OPHTH VIS SCI, V52, P7019, DOI 10.1167/iovs.11-8046
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Patel P.J., 2012, RETINA
   Pelosini L, 2011, INVEST OPHTH VIS SCI, V52, P2741, DOI 10.1167/iovs.09-4493
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Penha FM, 2012, AM J OPHTHALMOL, V153, P515, DOI 10.1016/j.ajo.2011.08.031
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Querques G, 2012, RETINA-J RET VIT DIS, V32, P458, DOI 10.1097/IAE.0b013e3182205960
   Querques G, 2011, AM J OPHTHALMOL, V152, P100, DOI 10.1016/j.ajo.2011.01.027
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rossi EA, 2013, BIOMED OPT EXPRESS, V4, P2527, DOI 10.1364/BOE.4.002527
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sato T, 2015, RETINA-J RET VIT DIS, V35, P1292, DOI 10.1097/IAE.0000000000000505
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schachat AP, 2015, OPHTHALMOLOGY, V122, P222, DOI 10.1016/j.ophtha.2014.09.015
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Shin J.Y., 2015, ACTA OPHTHALMOL
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singh RSJ, 2012, DRUG AGING, V29, P949, DOI 10.1007/s40266-012-0031-2
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sophie R, 2015, OPHTHALMOLOGY, V122, P1395, DOI 10.1016/j.ophtha.2015.02.036
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2014, AM J OPHTHALMOL, V158, P1267, DOI 10.1016/j.ajo.2014.08.035
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Takahashi H, 2015, BRIT J OPHTHALMOL, V99, P1065, DOI 10.1136/bjophthalmol-2014-306051
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Viola F, 2005, INVEST OPHTH VIS SCI, V46
   Vogl Wolf-Dieter, 2015, Inf Process Med Imaging, V24, P152, DOI 10.1007/978-3-319-19992-4_12
   Waldstein S.M., 2015, J OPHTHALMOL
   Waldstein S.M., 2015, JAMA OPHTHALMO UNPUB
   Waldstein S.M., 2015, PREDICTIVE IMP UNPUB
   Waldstein SM, 2015, BRIT J OPHTHALMOL, V99, P794, DOI 10.1136/bjophthalmol-2014-305573
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Waldstein SM, 2012, RETINA-J RET VIT DIS, V32, P424, DOI 10.1097/IAE.0b013e3182278b80
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wu J., 2014, OCEANS 2014 TAIPEI, P1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zhang L, 2014, INVEST OPHTH VIS SCI, V55, P2329, DOI 10.1167/iovs.13-13048
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 248
TC 198
Z9 206
U1 1
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2016
VL 50
BP 1
EP 24
DI 10.1016/j.preteyeres.2015.07.007
PG 24
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB9WN
UT WOS:000368868500001
PM 26307399
DA 2022-11-30
ER

PT J
AU Feher, J
   Papale, A
   Mannino, G
   Gualdi, L
   Gabrieli, CB
AF Feher, J
   Papale, A
   Mannino, G
   Gualdi, L
   Gabrieli, CB
TI Mitotropic compounds for the treatment of age-related macular
   degeneration - The metabolic approach and a pilot study
SO OPHTHALMOLOGICA
LA English
DT Article
DE acetyl-l-carnitine; polyunsaturated fatty acids; vitamin E; coenzyme
   Q(10); mitochondria; retina; age-related macular degeneration;
   photoreceptor
ID ESSENTIAL FATTY-ACIDS; BLUE MOUNTAINS EYE; COENZYME Q(10); DIETARY-FAT;
   L-CARNITINE; VITAMIN-E; DOCOSAHEXAENOIC ACID; LIPID-COMPOSITION;
   ALPHA-TOCOPHEROL; OXIDATIVE STRESS
AB Recent histopathologic studies have shown that mitochondria and peroxisomes of the retinal pigment epithelium may play a central role in the pathophysiology of age-related macular degeneration (AMD). We supposed that compounds which improve mitochondrial functions (mitotropic compounds) may show beneficial effects in preventing AMD. Fourteen patients affected by early AMD were treated with a mixture containing acetyl-L-carnitine (ALC), polyunsaturated fatty acids (PUFAs), coenzyme Q(10) (CoQ(10)) and vitamin E, while an equal number of age- and sex-matched patients affected by early AMD were treated with vitamin E only. Recovery time after macular photostress, foveal sensitivity and mean defect in the visual field as well as blood lipid levels were recorded at the beginning and after 3, 6, 9, 12 and 24 months of follow-up. In the treated group, all the visual functions showed slight improvement which was evident after 3 months of treatment and remained nearly stationary by the end of 24 months. The same tests in the control group showed slow worsening. The divergence between treated and control groups became more marked with time, but the difference was not significant at any time of the follow-up. These findings suggest that the blend of ALC, PUFA, CoQ(10) and vitamin E may improve retinal functions in early AMD. Copyright (C) 2003 S. Karger AG, Basel.
C1 Univ Roma La Sapienza, Ophthalm Neurosci Program, Inst Ophthalmol, Rome, Italy.
C3 Sapienza University Rome
RP Feher, J (通讯作者)，Via Lombardia 23-C, IT-00187 Rome, Italy.
CR Alagoz G, 2002, OPHTHALMOLOGICA, V216, P144, DOI 10.1159/000048315
   Ando S, 2001, J NEUROSCI RES, V66, P266, DOI 10.1002/jnr.1220
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Birch EE, 2000, DEV MED CHILD NEUROL, V42, P174, DOI 10.1017/S0012162200000311
   BIRD AC, 1992, AGE RELATED MACULAR, P63
   Blasi MA, 2001, OPHTHALMOLOGICA, V215, P51, DOI 10.1159/000050826
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   deTurco EBR, 1997, J BIOL CHEM, V272, P10491
   DETURCO EBR, 1990, J NEUROSCI RES, V17, P522
   FALSINI B, 1991, GRAEF ARCH CLIN EXP, V229, P262, DOI 10.1007/BF00167881
   Feher J., 1998, IOVS, V39, pS570
   Feher J, 2001, INVEST OPHTH VIS SCI, V42, pS222
   FEHER J, 1996, CLIN OCUL PATOL OCUL, V17, P31
   Ferdinandusse S, 2001, J LIPID RES, V42, P1987
   Froyland L, 1997, J LIPID RES, V38, P1851
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hoffman DR, 2000, J PEDIATR GASTR NUTR, V31, P540, DOI 10.1097/00005176-200011000-00016
   Ibrahim WH, 2000, J NUTR, V130, P2343, DOI 10.1093/jn/130.9.2343
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Jeffrey BG, 2002, INVEST OPHTH VIS SCI, V43, P2806
   Kang JX, 1996, P NATL ACAD SCI USA, V93, P3542, DOI 10.1073/pnas.93.8.3542
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KENNEDY CJ, 1995, EYE, V9, P262
   Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Lass A, 1999, FREE RADICAL BIO MED, V26, P1375, DOI 10.1016/S0891-5849(98)00330-X
   LITTARRU GP, 1994, ENERGY DEFENSE FACTS, P1
   LOWITT S, 1993, DIABETES, V42, P1115, DOI 10.2337/diabetes.42.8.1115
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mataix J., 1997, MOL ASPECTS MED, V18, P129
   Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892
   Nelson GJ, 1997, LIPIDS, V32, P1137, DOI 10.1007/s11745-997-0146-5
   Neuzil J, 1997, P NATL ACAD SCI USA, V94, P7885, DOI 10.1073/pnas.94.15.7885
   Olatunji-Bello I I, 1997, Afr J Med Med Sci, V26, P175
   REME CE, 1994, INVEST OPHTH VIS SCI, V35, P78
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Siegel D, 1997, MOL PHARMACOL, V52, P300, DOI 10.1124/mol.52.2.300
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   SNACHIS JIB, 2001, ARCH SOC ESP OFTALMO, V76, P13
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Sprecher H, 1999, PROSTAG LEUKOTR ESS, V60, P317, DOI 10.1016/S0952-3278(99)80006-4
   Suh M, 2000, PEDIATR RES, V48, P524, DOI 10.1203/00006450-200010000-00017
   Uauy R, 2000, AM J CLIN NUTR, V71, p245S, DOI 10.1093/ajcn/71.1.245S
   Uauy R, 2001, LIPIDS, V36, P885, DOI 10.1007/s11745-001-0798-1
   Uauy R, 2000, P NUTR SOC, V59, P3, DOI 10.1017/S0029665100000021
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VATASSERY GT, 1994, METHOD ENZYMOL, V234, P327
   Weisinger HS, 1999, INVEST OPHTH VIS SCI, V40, P327
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   WINKLER BS, 1999, MOL VIS, V3, P5
   WU G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1556, DOI 10.1001/archopht.1990.01070130058030
   Yamamura T, 2001, ANTIOXID REDOX SIGN, V3, P103, DOI 10.1089/152308601750100588
   Youdim KA, 2000, INT J DEV NEUROSCI, V18, P383, DOI 10.1016/S0736-5748(00)00013-7
NR 59
TC 30
Z9 37
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD SEP-OCT
PY 2003
VL 217
IS 5
BP 351
EP 357
DI 10.1159/000071351
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 717BB
UT WOS:000185064800009
PM 12913326
DA 2022-11-30
ER

PT J
AU Park, UC
   Shin, JY
   Kim, SJ
   Shin, ES
   Lee, JE
   McCarthy, LC
   Newcombe, PJ
   Xu, CF
   Chung, H
   Yu, HG
AF Park, Un Chul
   Shin, Joo Young
   Kim, Sang Jin
   Shin, Eun Soon
   Lee, Jong Eun
   McCarthy, Linda C.
   Newcombe, Paul J.
   Xu, Chun-Fang
   Chung, Hum
   Yu, Hyeong Gon
TI GENETIC FACTORS ASSOCIATED WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB IN
   KOREAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; pharmacogenetics; polymorphism;
   ranibizumab
ID COMPLEMENT-FACTOR-H; LOC387715 GENOTYPES; CHINESE POPULATION;
   RISK-FACTORS; POLYMORPHISM; AMD; VEGF; SUSCEPTIBILITY; BEVACIZUMAB;
   MACULOPATHY
AB Purpose: To investigate the association between genetic risk variants for age-related macular degeneration (AMD) and response to intravitreal ranibizumab in Korean patients with neovascular AMD.
   Methods: This prospective study included 273 treatment-naive patients (273 eyes) who underwent 5 monthly injections (Months 0, 1, 2, 3, and 4) of intravitreal ranibizumab for neovascular AMD. Patients were genotyped for 23 single-nucleotide polymorphisms within 12 AMD-relevant genes. For each polymorphism, genotypic association with good response at Month 5, predetermined as visual improvement of >= 8 Early Treatment Diabetic Retinopathy Study letters from baseline, was investigated with logistic regression analysis adjusted for age, gender, smoking, baseline Early Treatment Diabetic Retinopathy Study letter, central retinal thickness, lesion area, and type of choroidal neovascularization.
   Results: At Month 5, visual acuity improved by 9.1 +/- 17.6 letters from baseline, and 136 patients (49.8%) were classified as good responders. In logistic regression, no tested polymorphism showed statistically significant association with favorable visual outcome at Month 5. When unadjusted for multiple tests, AA genotype for VEGF rs699947 had an increased chance of good response compared with other genotypes (odds ratio, 3.61; 95% confidence interval, 1.42-9.18; P = 0.0071).
   Conclusion: In this Korean neovascular AMD cohort, there was no statistically significant effect of genotype on early visual outcome after ranibizumab treatment.
C1 [Park, Un Chul; Shin, Joo Young; Kim, Sang Jin; Chung, Hum; Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110799, South Korea.
   [Park, Un Chul] Natl Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Kim, Sang Jin] Sungkyunkwan Univ, Sch Med, Dept Ophthalmol, Samsung Med Ctr, Seoul, South Korea.
   [Shin, Eun Soon; Lee, Jong Eun] DNA Link Inc, Seoul, South Korea.
   [McCarthy, Linda C.; Newcombe, Paul J.; Xu, Chun-Fang] GlaxoSmithKline Med Res Ctr, Stevenage, Herts, England.
   [Yu, Hyeong Gon] Seoul Natl Univ, Sensory Organs Inst, Med Res Ctr, Seoul 110799, South Korea.
C3 Seoul National University (SNU); National Medical Center - Korea;
   Sungkyunkwan University (SKKU); Samsung Medical Center; DNA Link, Inc.;
   GlaxoSmithKline; Seoul National University (SNU)
RP Yu, HG (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, 103 Daehak Ro, Seoul 110799, South Korea.
EM hgonyu@snu.ac.kr
OI Yu, Hyeong Gon/0000-0002-1795-202X; Shin, Joo Young/0000-0001-5062-6392;
   Xu, Chun-Fang/0000-0002-8747-0683
FU GlaxoSmithKline Medicines Research Centre, Stevenage, United Kingdom
FX Supported by GlaxoSmithKline Medicines Research Centre, Stevenage,
   United Kingdom. The funding organization participated in part in the
   data management and analysis.
CR Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Kwon OW, 2012, GRAEF ARCH CLIN EXP, V250, P1467, DOI 10.1007/s00417-012-1970-3
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031243
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shahbazi M, 2002, J AM SOC NEPHROL, V13, P260, DOI 10.1681/ASN.V131260
   Szeto CC, 2004, KIDNEY INT, V65, P1947, DOI 10.1111/j.1523-1755.2004.00605.x
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 43
TC 26
Z9 33
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2014
VL 34
IS 2
BP 288
EP 297
DI 10.1097/IAE.0b013e3182979e1e
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6DF
UT WOS:000336959400012
PM 23842101
DA 2022-11-30
ER

PT J
AU Cheng, SY
   Malachi, A
   Cipi, J
   Ma, S
   Brush, RS
   Agbaga, MP
   Punzo, C
AF Cheng, Shun-Yun
   Malachi, Anneliese
   Cipi, Joris
   Ma, Shan
   Brush, Richard S.
   Agbaga, Martin-Paul
   Punzo, Claudio
TI HK2 Mediated Glycolytic Metabolism in Mouse Photoreceptors Is Not
   Required to Cause Late Stage Age-Related Macular Degeneration-Like
   Pathologies
SO BIOMOLECULES
LA English
DT Article
DE AMD; aerobic glycolysis; glycolytic metabolism; photoreceptors; GA; CNV;
   wet AMD; dry AMD
ID ACID BETA-OXIDATION; OUTER SEGMENTS; RETINITIS-PIGMENTOSA; GEOGRAPHIC
   ATROPHY; TSC1-TSC2 COMPLEX; CONE DEATH; MODEL; MTOR; ROD; CELLS
AB Age-related macular degeneration (AMD) is a multifactorial disease of unclear etiology. We previously proposed that metabolic adaptations in photoreceptors (PRs) play a role in disease progression. We mimicked these metabolic adaptations in mouse PRs through deletion of the tuberous sclerosis complex (TSC) protein TSC1. Here, we confirm our previous findings by deletion of the other complex protein, namely TSC2, in rod photoreceptors. Similar to deletion of Tsc1, mice with deletion of Tsc2 in rods develop AMD-like pathologies, including accumulation of apolipoproteins, migration of microglia, geographic atrophy, and neovascular pathologies. Subtle differences between the two mouse models, such as a significant increase in microglia activation with loss of Tsc2, were seen as well. To investigate the role of altered glucose metabolism in disease pathogenesis, we generated mice with simulation deletions of Tsc2 and hexokinase-2 (Hk2) in rods. Although retinal lactate levels returned to normal in mice with Tsc2-Hk2 deletion, AMD-like pathologies still developed. The data suggest that the metabolic adaptations in PRs that cause AMD-like pathologies are independent of HK2-mediated aerobic glycolysis.
C1 [Cheng, Shun-Yun; Malachi, Anneliese; Cipi, Joris; Ma, Shan; Punzo, Claudio] Univ Massachusetts, Med Sch, Dept Ophthalmol & Visual Sci, Worcester, MA 01655 USA.
   [Brush, Richard S.; Agbaga, Martin-Paul] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   [Brush, Richard S.; Agbaga, Martin-Paul] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
   [Brush, Richard S.; Agbaga, Martin-Paul] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Oklahoma City, OK 73104 USA.
   [Brush, Richard S.; Agbaga, Martin-Paul] Univ Oklahoma, Hlth Sci Ctr, Dean A McGee Eye Inst, Oklahoma City, OK 73104 USA.
   [Punzo, Claudio] Univ Massachusetts, Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01605 USA.
   [Punzo, Claudio] Univ Massachusetts, Med Sch, Li Weibo Inst Rare Dis Res, Worcester, MA 01605 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University of Oklahoma System; University of Oklahoma
   Health Sciences Center; University of Oklahoma System; University of
   Oklahoma Health Sciences Center; University of Oklahoma System;
   University of Oklahoma Health Sciences Center; University of
   Massachusetts System; University of Massachusetts Worcester; University
   of Massachusetts System; University of Massachusetts Worcester
RP Punzo, C (通讯作者)，Univ Massachusetts, Med Sch, Dept Ophthalmol & Visual Sci, Worcester, MA 01655 USA.; Punzo, C (通讯作者)，Univ Massachusetts, Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01605 USA.; Punzo, C (通讯作者)，Univ Massachusetts, Med Sch, Li Weibo Inst Rare Dis Res, Worcester, MA 01605 USA.
EM Shun-Yun.Cheng@umassmed.edu; Anneliese.Malachi@umassmed.edu;
   Joriscipi@gmail.com; labmashan@gmail.com; Richard-Brush@ouhsc.edu;
   Martin-Paul-Agbaga@ouhsc.edu; Claudio.Punzo@umassmed.edu
OI Punzo, Claudio/0000-0001-5207-0041
FU BrightFocus Foundation [M2017071]; National Eye Institute (NEI)
   [EY023570, R01: EY032461]; Oklahoma Center for Advancement of Science
   and Technology (OCAST); NEI [R01: EY030513]
FX This work was funded through grants from the BrightFocus Foundation
   (M2017071) and the National Eye Institute (NEI) (R01: EY023570; R01:
   EY032461) to C.P. and the Oklahoma Center for Advancement of Science and
   Technology (OCAST) and NEI (R01: EY030513) to M.-P.A.
CR Adijanto J, 2014, J BIOL CHEM, V289, P20570, DOI 10.1074/jbc.M114.565457
   Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2
   Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002
   BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9
   Busik JV, 2009, METHODS MOL BIOL, V579, P33, DOI 10.1007/978-1-60761-322-0_3
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Couturier A, 2014, MOL VIS, V20, P908
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fletcher EL, 2020, OPHTHAL PHYSL OPT, V40, P128, DOI 10.1111/opo.12671
   Forstreuter F, 2002, J NEUROIMMUNOL, V132, P93, DOI 10.1016/S0165-5728(02)00315-6
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gardner TW, 1999, DOC OPHTHALMOL, V97, P229, DOI 10.1023/A:1002140812979
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Goto J, 2011, P NATL ACAD SCI USA, V108, pE1070, DOI 10.1073/pnas.1106454108
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Grenell A, 2019, P NATL ACAD SCI USA, V116, P3530, DOI 10.1073/pnas.1812941116
   GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hernandez O, 2007, GENESIS, V45, P101, DOI 10.1002/dvg.20271
   Huang JC, 2019, THERANOSTICS, V9, P1170, DOI 10.7150/thno.26281
   Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08
   Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281
   Jones AC, 1997, HUM MOL GENET, V6, P2155, DOI 10.1093/hmg/6.12.2155
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   LAVAIL MM, 1980, INVEST OPHTH VIS SCI, V19, P407
   Law AL, 2009, MOL BIOL CELL, V20, P3896, DOI 10.1091/mbc.E08-12-1204
   Li S, 2005, GENESIS, V41, P73, DOI 10.1002/gene.20097
   LISMAN JE, 1977, J GEN PHYSIOL, V70, P621, DOI 10.1085/jgp.70.5.621
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Ma S, 2015, EXP EYE RES, V135, P1, DOI 10.1016/j.exer.2015.04.006
   Malsy J, 2020, ELIFE, V9, DOI 10.7554/eLife.60194
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mietzsch U, 2013, J COMP NEUROL, V521, P3817, DOI 10.1002/cne.23380
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pandi SPS, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108404
   Parker RO, 2010, EXP EYE RES, V91, P788, DOI 10.1016/j.exer.2010.08.013
   Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Petit L, 2018, CELL REP, V23, P2629, DOI 10.1016/j.celrep.2018.04.111
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Punzo C, 2007, INVEST OPHTH VIS SCI, V48, P849, DOI 10.1167/iovs.05-1555
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Rajala A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0296-4
   Reyes-Reveles J, 2017, J BIOL CHEM, V292, P8038, DOI 10.1074/jbc.M116.770784
   Ryu JK, 2009, J NEUROSCI, V29, P3, DOI 10.1523/JNEUROSCI.2888-08.2009
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   SCOTT BL, 1988, J NEUROSCI RES, V20, P202, DOI 10.1002/jnr.490200209
   Sinha T, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2018956118
   TOUT S, 1993, NEUROSCIENCE, V55, P291, DOI 10.1016/0306-4522(93)90473-S
   Tyni T, 2004, PEDIATR RES, V56, P744, DOI 10.1203/01.PDR.0000141967.52759.83
   Tyni T, 2002, PEDIATR RES, V52, P595, DOI 10.1203/01.PDR.0000030874.20888.2D
   Uehara H, 2015, AM J OPHTHALMOL, V159, P92, DOI 10.1016/j.ajo.2014.09.036
   Venkatesh A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.182
   Venkatesh A., 2013, Curr Protoc Microbiol, V28, DOI 10.1002/9780471729259.mc14d04s28
   Venkatesh A, 2015, J CLIN INVEST, V125, P1446, DOI 10.1172/JCI79766
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Whikehart D.R., 2003, BIOCH EYE, V2nd, P512
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   YOUNG RW, 1971, J CELL BIOL, V49, P303, DOI 10.1083/jcb.49.2.303
   YOUNG RW, 1971, J ULTRA MOL STRUCT R, V34, P190, DOI 10.1016/S0022-5320(71)90014-1
   Zeng LH, 2011, HUM MOL GENET, V20, P445, DOI 10.1093/hmg/ddq491
   Zieger M, 2016, ONCOTARGET, V7, P9620, DOI 10.18632/oncotarget.7330
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 77
TC 3
Z9 3
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD JUN
PY 2021
VL 11
IS 6
AR 871
DI 10.3390/biom11060871
PG 18
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA SX6GH
UT WOS:000665300500001
PM 34208233
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Suzuki, M
   Kamei, M
   Itabe, H
   Yoneda, K
   Bando, H
   Kume, N
   Tano, Y
AF Suzuki, Mihoko
   Kamei, Motohiro
   Itabe, Hiroyuki
   Yoneda, Kazuhito
   Bando, Hajime
   Kume, Noriaki
   Tano, Yasuo
TI Oxidized phospholipids in the macula increase with age and in eyes with
   age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; BRUCHS MEMBRANE; CHOROIDAL NEOVASCULARIZATION;
   MONOCLONAL-ANTIBODY; HUMAN RETINA; PHOSPHATIDYLCHOLINES;
   ATHEROSCLEROSIS; ACCUMULATION; PATHOGENESIS; EXPRESSION
AB PURPOSE: There is good evidence that oxidative stress is involved in the pathogenesis of age-related macular degeneration (AMD). Because AMD has risk factors and histopathology similar to with atherosclerosis, we hypothesized that oxidized phospholipids, which contribute to the pathogenesis of atherosclerosis, would accumulate in the eyes of AMD patients. To test this hypothesis, we investigated whether oxidized phospholipids were present in normal eyes and whether the level changed with increasing age. We then, we determined whether the levels of oxidized phospholipids were higher in eyes with AMD.
   METHODS: Twenty normal human donor eyes and six eyes with AMD were studied. Immunohistochemistry was performed on a tissue strip from the macular region using an antibody against oxidized phosphatidylcholine. Western blot analysis was also performed on proteins extracted from the posterior retina of donor eyes. The immunoreactivity of the specimens and the bands were quantified with NIH image software.
   RESULTS: Immunohistochemistry showed oxidized phosphatidylcholine was present in the photoreceptors and retinal pigment epithelium of the normal human macular area, and their levels increased with age. Eyes with AMD showed more intense immunoreactivity for oxidized phospholipids than age-matched normal eyes.
   CONCLUSIONS: These findings suggest that oxidative stress is involved in the pathogenesis of AMD possibly by oxidizing phospholipids in the photoreceptors as demonstrated in the arterial intima of patients with atherosclerosis. It is likely that controlling oxidation of phospholipids may be a potential treatment for AMD.
C1 Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
   Showa Univ, Sch Pharmaceut Sci, Dept Biol Chem, Tokyo 142, Japan.
   Kyoto Prefectural Univ, Dept Ophthalmol, Kyoto 606, Japan.
   Cleveland Clin Fdn, Cole Eye Inst, Ophthalm Res, Cleveland, OH 44195 USA.
   Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan.
C3 Osaka University; Showa University; Kyoto Prefectural University;
   Cleveland Clinic Foundation; Kyoto University
RP Suzuki, M (通讯作者)，Osaka Univ, Sch Med, Dept Ophthalmol, 2-2 Yamadaoka,E7, Suita, Osaka 5650871, Japan.
EM msuzuki@ophthal.med.osaka-u.ac.jp
RI 板部板部, 洋之/ABC-7746-2020
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Ehara S, 2001, CIRCULATION, V103, P1955, DOI 10.1161/01.cir.103.15.1955
   FEENEYBURNS L, 1987, INVEST OPHTH VIS SCI, V28, P1138
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Hoppe G, 2004, CELL MOL LIFE SCI, V61, P1664, DOI 10.1007/s00018-004-4080-5
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Itabe H, 1996, J BIOL CHEM, V271, P33208, DOI 10.1074/jbc.271.52.33208
   ITABE H, 1994, J BIOL CHEM, V269, P15274
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Leitinger N, 2005, MOL NUTR FOOD RES, V49, P1063, DOI 10.1002/mnfr.200500086
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Minami M, 2001, ARTERIOSCL THROM VAS, V21, P1796, DOI 10.1161/hq1001.096652
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nishi K, 2002, ARTERIOSCL THROM VAS, V22, P1649, DOI 10.1161/01.ATV.0000033829.14012.18
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Shimada K, 2004, ATHEROSCLEROSIS, V174, P343, DOI 10.1016/j.atherosclerosis.2004.01.029
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wihlmark U, 1996, APMIS, V104, P272, DOI 10.1111/j.1699-0463.1996.tb00717.x
   Winkler BS, 1999, MOL VIS, V5
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 36
TC 97
Z9 109
U1 1
U2 9
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAY 23
PY 2007
VL 13
IS 80-85
BP 772
EP 778
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 177HR
UT WOS:000247144700005
PM 17563727
DA 2022-11-30
ER

PT J
AU Trinh, M
   Kalloniatis, M
   Nivison-Smith, L
AF Trinh, Matt
   Kalloniatis, Michael
   Nivison-Smith, Lisa
TI Vascular Changes in Intermediate Age-Related Macular Degeneration
   Quantified Using Optical Coherence Tomography Angiography
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE optical coherence tomography; angiography; age-related macular
   degeneration; vascular density; retinal vasculature
ID FOVEAL AVASCULAR ZONE; GANGLION-CELL COMPLEX; RETICULAR PSEUDODRUSEN;
   COLLABORATIVE CARE; LAYER THICKNESSES; GLAUCOMA PATIENTS; DIABETIC EYES;
   BLOOD-FLOW; DENSITY; DISEASE
AB Purpose: To examine changes in retinal vasculature and ganglion cell layer (GCL) thickness in intermediate age-related macular degeneration (AMD) using optical coherence tomography angiography (OCTA).
   Methods: Zeiss Cirrus Angioplex OCTA 6 x 6 mm scans and a macula 512 x 128 cube scans of the central retina were taken of 63 eyes with intermediate AMD and 51 control eyes. For OCTA scans, the superficial and deep capillary plexus were automatically segmented and vascular density quantified as total number of pixels contributing to the blood flow signal detectable by OCTA. Images were then skeletonized and vessel length, diameter index, morphology, and branching complexity determined. Foveal avascular zone (FAZ) characteristics and GCL thickness were extracted from in-built Angioplex software.
   Results: Vascular density was significantly reduced in the superficial capillary plexus of AMD eyes compared with normal eyes, particularly in the superior quadrant (42.4% +/- 1.6% vs. 43.2% +/- 1.4%; P < 0.05). A nonsignificant reduction was also seen in the deep capillary plexus (P = 0.06). Total vessel length and average vessel diameter were all significantly decreased in AMD eyes suggesting density changes were related to decreased vessel number and caliber. Vascular complexity and number of branch points was significantly decreased in the deep capillary plexus (P < 0.05) suggesting loss or significantly reduced flow of vessels. Average GCL thickness was also significantly reduced in the AMD eyes (P < 0.05). No significant changes in FAZ parameters were observed in AMD eyes.
   Conclusions: This study suggests intermediate AMD affects both the quantity and morphology of inner retinal vasculature and may be associated with changes in inner retinal structure. This work builds upon the notion that AMD pathogenesis may extends beyond the outer retina.
   Translational Relevance: Better understanding of retinal vascular changes in AMD can provide insights in the development of treatment and prevention protocols for these diseases.
C1 [Trinh, Matt; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Trinh, Matt; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Nivison-Smith, L (通讯作者)，UNSW Australia, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
EM l.nivison-smith@unsw.edu.au
RI Trinh, Matt/AAV-1249-2021
OI Kalloniatis, Michael/0000-0002-5264-4639; Trinh,
   Matt/0000-0002-6184-0666
FU Guide Dogs NSW/ACT; Centre for Eye Health; UNSW Sydney
FX This work was supported in part by Guide Dogs NSW/ACT through support
   for LN-S and the Centre for Eye Health, a joint initiative with UNSW
   Sydney.
CR Ahn SM, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0866-3
   Al-Sheikh Mayss, 2017, Int J Retina Vitreous, V3, P13, DOI 10.1186/s40942-017-0068-9
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   Camacho P, 2017, OPHTHALMOLOGICA, V238, P31, DOI 10.1159/000468965
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Chatziralli I, 2018, OPHTHALMOL THER, V7, P101, DOI 10.1007/s40123-018-0119-9
   Chu ZD, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.066008
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Di G, 2016, GRAEF ARCH CLIN EXP, V254, P873, DOI 10.1007/s00417-015-3143-7
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freiberg FJ, 2016, GRAEF ARCH CLIN EXP, V254, P1051, DOI 10.1007/s00417-015-3148-2
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Jamous KF, 2015, CLIN EXP OPHTHALMOL, V43, P308, DOI 10.1111/ceo.12466
   Kim AY, 2016, INVEST OPHTH VIS SCI, V57, pOCT362, DOI 10.1167/iovs.15-18904
   Kim K, 2018, BRIT J OPHTHALMOL, V102, P1226, DOI 10.1136/bjophthalmol-2017-311149
   Krawitz BD, 2017, VISION RES, V139, P177, DOI 10.1016/j.visres.2016.09.019
   Kwon J, 2017, J GLAUCOMA, V26, P1120, DOI 10.1097/IJG.0000000000000800
   Kwon J, 2017, INVEST OPHTH VIS SCI, V58, P1637, DOI 10.1167/iovs.16-21079
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   Linderman R, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.16
   Linderman RE, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.20
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P632, DOI 10.1111/opo.12322
   Magrath GN, 2017, RETINA-J RET VIT DIS, V37, P2102, DOI 10.1097/IAE.0000000000001458
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Nivison-Smith L, 2018, OPHTHAL PHYSL OPT, V38, P584, DOI 10.1111/opo.12589
   Nivison-Smith L, 2018, OPTOMETRY VISION SCI, V95, P648, DOI 10.1097/OPX.0000000000001256
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Sampson DM, 2017, INVEST OPHTH VIS SCI, V58, P3065, DOI 10.1167/iovs.17-21551
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Takase N, 2015, RETINA-J RET VIT DIS, V35, P2377, DOI 10.1097/IAE.0000000000000849
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 50
TC 17
Z9 17
U1 1
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUL
PY 2019
VL 8
IS 4
AR 20
DI 10.1167/tvst.8.4.20
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ3BW
UT WOS:000480626600010
PM 31404428
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, YJ
   Yeung, L
   Sun, CC
   Huang, CC
   Chen, KS
   Lu, YH
AF Chen, Yi-Ju
   Yeung, Ling
   Sun, Chi-Chin
   Huang, Chien-Chieh
   Chen, Kuo-Su
   Lu, Yi-Hsuan
TI Age-Related Macular Degeneration in Chronic Kidney Disease: A
   Meta-Analysis of Observational Studies
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article
DE Age-related macular degeneration; Chronic kidney disease; Meta-analysis
ID RISK-FACTORS; PREVALENCE; GENDER; EYE; ASSOCIATIONS; PROGRESSION;
   IMPAIRMENT; SMOKING; BURDEN; HEALTH
AB Background: Age-related macular degeneration (AMD) is an important cause of blindness in aged people. Chronic kidney disease (CKD) was reported to be associated with a higher risk of AMD. However, supporting evidence was inconsistent between studies. This work intends to examine whether a positive association exists between CKD and AMD by systematic review and meta-analysis. Methods: A systematic search of electronic databases (Medline, PubMed, Cochrane and EMBASE) and reference lists on June 2017. The key inclusion criteria were controlled trials that investigated the relationship between AMD and CKD. The outcome measures included risk ratios and/or occurrence rates of AMD in CKD vs. non-CKD population. Data were pooled according to the type of AMD by random effect model. Results: Twelve observational studies (3 cohorts, 2 case controls, and 7 cross-sectionals) with a total 335,601 participants were included. Eleven studies reported risk ratios and 9 reported occurrence rates. Pooled prevalence for early, advanced, and any AMD were all higher in the CKD population than in the non-CKD population. The pooled multivariate adjusted OR of CKD vs. non-CKD was 1.49 (95% CI 1.11-2.02) for early, 1.55 (95% CI 1.05-2.27) for exudative, 1.58 (95% CI 1.12-2.23) for advanced, and 1.35 (95% CI 1.05-1.73) for any AMD. However, high statistical heterogeneity and methodological diversity existed. Moreover, results were inconsistent between different study designs. Conclusions: The overall results support a positive association between CKD and AMD, although some limitations exist. Given the risk that AMD is increased in CKD, regular eye screenings for the CKD population is recommended for an early detection and intervention.
C1 [Chen, Yi-Ju] Cathay Gen Hosp, Med Educ Dept, Taipei, Taiwan.
   [Yeung, Ling; Sun, Chi-Chin; Huang, Chien-Chieh] Chang Gung Mem Hosp, Dept Ophthalmol, 222 Mai Chin Rd, Keelung 20401, Taiwan.
   [Chen, Kuo-Su; Lu, Yi-Hsuan] Chang Gung Mem Hosp, Dept Nephrol, Keelung, Taiwan.
   [Yeung, Ling; Sun, Chi-Chin; Huang, Chien-Chieh; Chen, Kuo-Su; Lu, Yi-Hsuan] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
C3 Cathay General Hospital; Chang Gung Memorial Hospital; Chang Gung
   Memorial Hospital; Chang Gung University
RP Yeung, L (通讯作者)，Chang Gung Mem Hosp, Dept Ophthalmol, 222 Mai Chin Rd, Keelung 20401, Taiwan.
EM lingyeung@gmail.com
RI Chen, Kuo Su/N-5096-2018
OI Chen, Kuo Su/0000-0002-8358-7374; Chen, Yi-Ju/0000-0001-5692-2731
CR Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104
   Chen CY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006405
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Choi J, 2011, OPHTHAL EPIDEMIOL, V18, P259, DOI 10.3109/09286586.2011.602509
   Chong EW, 2014, OPTOMETRY VISION SCI, V91, P860, DOI 10.1097/OPX.0000000000000288
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Deva R, 2011, CLIN J AM SOC NEPHRO, V6, P1866, DOI 10.2215/CJN.10321110
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Elsayed EF, 2007, ARCH INTERN MED, V167, P1130, DOI 10.1001/archinte.167.11.1130
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Freedman BI, 2007, ARCH INTERN MED, V167, P1113, DOI 10.1001/archinte.167.11.1113
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gao BX, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-62
   Haag DG, 2017, J DENT RES, V96, P864, DOI 10.1177/0022034517709737
   Hsu CC, 2005, JAMA-J AM MED ASSOC, V293, P2892, DOI 10.1001/jama.293.23.2892
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Iseki K, 2008, KIDNEY INT, V74, P415, DOI 10.1038/ki.2008.261
   Izzedine H, 2003, J AM SOC NEPHROL, V14, P516, DOI 10.1097/01.ASN.0000051705.97966.AD
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MILLER JJ, 1978, AM STAT, V32, P138, DOI 10.2307/2682942
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Neugarten J, 2013, ADV CHRONIC KIDNEY D, V20, P390, DOI 10.1053/j.ackd.2013.05.004
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peres KG, 2015, ACTA PAEDIATR, V104, P54, DOI 10.1111/apa.13103
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rim TH, 2017, SEMIN OPHTHALMOL, V32, P466, DOI 10.3109/08820538.2015.1119861
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Taniguchi H, 2015, OPHTHALMOLOGICA, V233, P128, DOI 10.1159/000371716
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Vidt DG, 2006, AM J CARDIOL, V97, p20A, DOI 10.1016/j.amjcard.2005.11.012
   Wang IK, 2016, RETINA-J RET VIT DIS, V36, P1866, DOI 10.1097/IAE.0000000000001011
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Wells GA., NEWCASTLE OTTAWA SCA
   Wong CW, 2016, EBIOMEDICINE, V5, P193, DOI 10.1016/j.ebiom.2016.01.023
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ye J, 2014, INVEST OPHTH VIS SCI, V55, P2687, DOI 10.1167/iovs.13-13206
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 57
TC 5
Z9 5
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-8095
EI 1421-9670
J9 AM J NEPHROL
JI Am. J. Nephrol.
PY 2018
VL 48
IS 4
BP 278
EP 291
DI 10.1159/000493924
PG 14
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA GZ0SU
UT WOS:000449076100006
PM 30336463
DA 2022-11-30
ER

PT J
AU Oshima, H
   Iwase, T
   Ishikawa, K
   Yamamoto, K
   Terasaki, H
AF Oshima, Hisaaki
   Iwase, Takeshi
   Ishikawa, Kohei
   Yamamoto, Kentaro
   Terasaki, Hiroko
TI Long-term results after limited macular translocation surgery for wet
   age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; RETINAL
   SEPARATION; VISUAL FUNCTION; RETINOTOMY; MANAGEMENT; RELOCATION;
   SECONDARY; CELLS
AB Purpose
   To evaluate the long-term results of limited macular translocation (LMT) surgery with radial chorioscleral outfolding in patients with wet age-related macular degeneration (AMD) and subfoveal choroidal neovascularization (CNV). In addition, to identify the factors associated with the final best-corrected visual acuity (BCVA).
   Methods
   The medical records of 20 eyes of 20 consecutive patients (65.2 +/- 9.8 years) who had undergone LMT for the treatment of wet AMD and were followed for at least 5 years, were reviewed. The surgical outcomes including the BCVA, degree of foveal displacement, and complications were recorded.
   Results
   The mean foveal displacement was 1332 +/- 393 mu m after the LMT. The CNV was removed in 16 eyes and photocoagulated in 4 eyes. The mean preoperative VA was 0.83 +/- 0.33 logMAR units which significantly improved to 0.59 +/- 0.37 logMAR units at 1 year after the surgery (P = 0.015). This BCVA was maintained at 0.59 +/- 0.41 logMAR units on the final examination. The final BCVA was significantly correlated with that at 1 year after the surgery (r = 0.83, P<0.001). Multiple linear regression analysis showed that the final BCVA was significantly correlated with the BCVA at 1 year after the surgery (P<0.001), a recurrence of a CNV (P = 0.001), and the age (P = 0.022).
   Conclusions
   LMT improves the BCVA significantly at 1 year, and the improved BCVA lasted for at least 5 years. These results indicate that the impaired function of the sensory retina at the fovea can recover on the new RPE after the displacement for at least 5 years. The ability to maintain good retinal function on the new RPE for a long period is important for future treatments of CNVs such as the transplantation of RPE cells and stem cells.
C1 [Oshima, Hisaaki; Iwase, Takeshi; Ishikawa, Kohei; Yamamoto, Kentaro; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
C3 Nagoya University
RP Iwase, T (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
EM tiwase@med.nagoya-u.ac.jp
FU Grants-in-Aid for Scientific Research [17K11421] Funding Source: KAKEN
CR Benner JD, 2001, GRAEF ARCH CLIN EXP, V239, P815, DOI 10.1007/s004170100339
   Chang AA, 2003, CLIN EXP OPHTHALMOL, V31, P103, DOI 10.1046/j.1442-9071.2003.00614.x
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P244, DOI 10.1016/S0002-9394(00)00788-1
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   Fujikado T, 2001, AM J OPHTHALMOL, V131, P101, DOI 10.1016/S0002-9394(00)00770-4
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Glacet-Bernard A, 2007, AM J OPHTHALMOL, V143, P68, DOI 10.1016/j.ajo.2006.09.041
   Imai K, 1998, AM J OPHTHALMOL, V125, P627, DOI 10.1016/S0002-9394(98)00023-3
   Kadonosono K, 2001, AM J OPHTHALMOL, V132, P790, DOI 10.1016/S0002-9394(01)01140-0
   Kamei M, 2004, AM J OPHTHALMOL, V138, P574, DOI 10.1016/j.ajo.2004.05.029
   Kamei M, 2001, AM J OPHTHALMOL, V132, P149, DOI 10.1016/S0002-9394(01)01047-9
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Lewis H, 2001, AM J OPHTHALMOL, V132, P156, DOI 10.1016/S0002-9394(01)01088-1
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   Macular translocation, 2000, OPHTHALMOLOGY, V107, P1015
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mateo Carlos, 2004, Semin Ophthalmol, V19, P29, DOI 10.1080/08820530490520013
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Parameswaran S, 2010, STEM CELLS, V28, P695, DOI 10.1002/stem.320
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   QUIGLEY HA, 1990, ARCH OPHTHALMOL-CHIC, V108, P51, DOI 10.1001/archopht.1990.01070030057028
   Takeuchi K, 2012, EYE, V26, P52, DOI 10.1038/eye.2011.302
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 28
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 23
PY 2017
VL 12
IS 5
AR e0177241
DI 10.1371/journal.pone.0177241
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EV8UE
UT WOS:000402058800013
PM 28542257
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Agurto, C
   Barriga, ES
   Murray, V
   Nemeth, S
   Crammer, R
   Bauman, W
   Zamora, G
   Pattichis, MS
   Soliz, P
AF Agurto, Carla
   Barriga, E. Simon
   Murray, Victor
   Nemeth, Sheila
   Crammer, Robert
   Bauman, Wendall
   Zamora, Gilberto
   Pattichis, Marios S.
   Soliz, Peter
TI Automatic Detection of Diabetic Retinopathy and Age-Related Macular
   Degeneration in Digital Fundus Images
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PHOTOGRAPHY; EDEMA
AB PURPOSE. To describe and evaluate the performance of an algorithm that automatically classifies images with pathologic features commonly found in diabetic retinopathy (DR) and age-related macular degeneration (AMD).
   METHODS. Retinal digital photographs (N = 2247) of three fields of view (FOV) were obtained of the eyes of 822 patients at two centers: The Retina Institute of South Texas (RIST, San Antonio, TX) and The University of Texas Health Science Center San Antonio (UTHSCSA). Ground truth was provided for the presence of pathologic conditions, including microaneurysms, hemorrhages, exudates, neovascularization in the optic disc and elsewhere, drusen, abnormal pigmentation, and geographic atrophy. The algorithm was used to report on the presence or absence of disease. A detection threshold was applied to obtain different values of sensitivity and specificity with respect to ground truth and to construct a receiver operating characteristic (ROC) curve.
   RESULTS. The system achieved an average area under the ROC curve (AUC) of 0.89 for detection of DR and of 0.92 for detection of sight-threatening DR (STDR). With a fixed specificity of 0.50, the system's sensitivity ranged from 0.92 for all DR cases to 1.00 for clinically significant macular edema (CSME).
   CONCLUSIONS. A computer-aided algorithm was trained to detect different types of pathologic retinal conditions. The cases of hard exudates within 1 disc diameter (DD) of the fovea (surrogate for CSME) were detected with very high accuracy (sensitivity = 1, specificity = 0.50), whereas mild nonproliferative DR was the most challenging condition (sensitivity = 0.92, specificity = 0.50). The algorithm was also tested on images with signs of AMD, achieving a performance of AUC of 0.84 (sensitivity = 0.94, specificity = 0.50). (Invest Ophthalmol Vis Sci. 2011;52:5862-5871) DOI: 10.1167/iovs.10-7075
C1 [Agurto, Carla; Barriga, E. Simon; Murray, Victor; Pattichis, Marios S.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA.
   [Agurto, Carla; Barriga, E. Simon; Nemeth, Sheila; Crammer, Robert; Zamora, Gilberto; Soliz, Peter] VisionQuest Biomed LLC, Albuquerque, NM USA.
   [Crammer, Robert] New Mexico VA Hlth Care Syst, Albuquerque, NM USA.
   [Bauman, Wendall] Retinal Inst S Texas, San Antonio, TX USA.
   [Soliz, Peter] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
C3 University of New Mexico; University of Iowa
RP Agurto, C (通讯作者)，Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA.
EM capaagri@unm.edu
RI Pattichis, Marios/ABG-8325-2021; Murray, Victor/I-4418-2014; Agurto,
   Carla/AAH-1224-2019
OI Pattichis, Marios/0000-0002-1574-1827; Murray,
   Victor/0000-0002-6000-3380; Agurto, Carla/0000-0002-0617-4488
FU National Institutes of Health, National Eye Institute [EY018280,
   EY020015, RC3EY020749]; NATIONAL EYE INSTITUTE [R44EY018280,
   RC3EY020749, R43EY020015, R44EY020015] Funding Source: NIH RePORTER
FX Supported by National Institutes of Health, National Eye Institute
   Grants EY018280, EY020015, and RC3EY020749.
CR Abramoff MD, 2010, EXPERT REV MED DEVIC, V7, P287, DOI 10.1586/ERD.09.76
   Agurto C, 2010, PROC SPIE, V7624, DOI 10.1117/12.844431
   AGURTO C, 2008, 42 IEEE AS C SIGN SY, P659
   Agurto C, 2010, IEEE T MED IMAGING, V29, P502, DOI 10.1109/TMI.2009.2037146
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Barriga ES, 2010, I S BIOMED IMAGING, P1349, DOI 10.1109/ISBI.2010.5490247
   BARRIGA ES, 2009, IEEE INT S COMP BAS, P1
   Chaum E, 2008, RETINA-J RET VIT DIS, V28, P1463, DOI 10.1097/IAE.0b013e31818356dd
   Chen WJ, 2010, PROC SPIE, V7624, DOI 10.1117/12.844605
   Fleming AD, 2006, INVEST OPHTH VIS SCI, V47, P1120, DOI 10.1167/iovs.05-1155
   Fleming AD, 2010, BRIT J OPHTHALMOL, V94, P1606, DOI 10.1136/bjo.2009.176784
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Jelinek HF, 2010, AUTOMATED IMAGE DETECTION OF RETINAL PATHOLOGY, P1
   KINYOUN J, 1989, OPHTHALMOLOGY, V96, P746
   Larsen N, 2003, INVEST OPHTH VIS SCI, V44, P767, DOI 10.1167/iovs.02-0417
   Li HK, 2010, INVEST OPHTH VIS SCI, V51, P5846, DOI 10.1167/iovs.09-4803
   Murray V, 2010, IEEE T IMAGE PROCESS, V19, P1138, DOI 10.1109/TIP.2010.2040446
   MURRAYHERRERA VM, 2008, THESIS U NEW MEXICO
   Niemeijer M, 2009, IEEE T MED IMAGING, V28, P775, DOI 10.1109/TMI.2008.2012029
   Rudnisky CJ, 2006, CAN J OPHTHALMOL, V41, P727, DOI 10.1139/I06-066
   Scanlon PH, 2003, DIABETIC MED, V20, P467, DOI 10.1046/j.1464-5491.2003.00954.x
   Scotland GS, 2010, BRIT J OPHTHALMOL, V94, P712, DOI 10.1136/bjo.2008.151126
   Welty CJ, 2006, OPHTHAL SURG LAS IM, V37, P524, DOI 10.3928/15428877-20061101-17
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 24
TC 69
Z9 69
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2011
VL 52
IS 8
BP 5862
EP 5871
DI 10.1167/iovs.10-7075
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800QC
UT WOS:000293377400109
PM 21666234
OA Green Published
DA 2022-11-30
ER

PT J
AU Anderson, AJ
   Johnson, CA
   Werner, JS
AF Anderson, Andrew John
   Johnson, Chris A.
   Werner, John S.
TI Measuring Visual Function in Age-Related Macular Degeneration with
   Frequency-Doubling (Matrix) Perimetry
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; automated perimetry; visual field;
   psychophysics; frequency doubling; visual acuity; contrast
ID STANDARD AUTOMATED PERIMETRY; TECHNOLOGY PERIMETRY; FLICKER SENSITIVITY;
   CATARACT-EXTRACTION; HUMPHREY MATRIX; THRESHOLD; GLAUCOMA; FIELD;
   MACULOPATHY; VARIABILITY
AB Purpose. To determine the agreement between the Humphrey Matrix perimeter 10-2 test and the 10-2 Humphrey Field Analyzer (HFA) test when assessing visual function in patients with age-related macular degeneration (AMD).
   Methods. Forty-two eyes of 42 subjects with AMD (average 75.0 years, SD = 6.2: median visual acuity in logarithm of the minimum angle of resolution of 0.26, range, -0.12 to 1.04) were evaluated with the Matrix and HFA 10-2 visual field tests. Mean deviation (MD), pattern standard deviation, and test time were recorded. We calculated spatial concordance of individual test locations, being the proportion of spatially agreeing locations with identical classification (normal vs. abnormal, p < 5%) on the pattern deviation plot. As multiple HFA stimuli overlapped with some Matrix locations, several criteria for grouping HFA data into locations were investigated.
   Results. Both MD and pattern standard deviation were significantly correlated for the two devices (r(2) = 0.79 and r(2) = 0.80, respectively, p < 0.0001). Using our standard criterion for abnormal HFA locations (>= 50% stimuli abnormal), the median spatial concordance was 0.76, with 95% of tests giving a concordance of >= 0.59. A small, but significant, increase in concordance occurred when a stricter criterion (all stimuli abnormal at a location) was applied. Median fixation loss percentages were 7 and 0% for the HFA and Matrix, respectively. Visual acuity in logarithm of the minimum angle of resolution showed modest correlations with both defect depth (HFA MD: r(2) = 0.39, p < 0.0001) and size of defect (number of abnormal points on the HFA: r(2) = 0.24, p < 0.0001).
   Conclusions. Using a simple metric to calculate spatial concordance, the Matrix 10-2 test quantifies the spatial extent of significant depression of the central visual fields in AMD in a manner similar to the HFA 10-2. The spatial extent and depth of central visual field loss in AMD are only modestly predicted by visual acuity measurements. (Optom Vis Sci 2011; 88: 806-815)
C1 [Anderson, Andrew John] Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.
   [Johnson, Chris A.] Univ Iowa Hosp & Clin, Dept Ophthalmol & Vis Sci, Iowa City, IA 52242 USA.
   [Werner, John S.] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
C3 University of Melbourne; University of Iowa; University of California
   System; University of California Davis
RP Anderson, AJ (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.
EM aaj@unimelb.edu.au
OI Johnson, Chris/0000-0002-0090-630X; Anderson, Andrew/0000-0001-7015-0061
FU National Eye Institute [EY-03, 424]; Oregon Lions Sight and Hearing
   Foundation; National Institute on Aging [AG04058]; RPB Senior Scientist
   Award; Welch-Allyn; NATIONAL EYE INSTITUTE [R01EY003424] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON AGING [R23AG004058, R37AG004058,
   R01AG004058] Funding Source: NIH RePORTER
FX This work was supported by a National Eye Institute Research Grant
   EY-03,424, the Oregon Lions Sight and Hearing Foundation (to CAJ),
   National Institute on Aging Grant AG04058, RPB Senior Scientist Award
   (to JSW), and project support from Welch-Allyn (to AJA, CAJ, and JSW).
CR Anderson AJ, 2003, INVEST OPHTH VIS SCI, V44, P5043, DOI 10.1167/iovs.03-0058
   Anderson AJ, 2003, VISION RES, V43, P165, DOI 10.1016/S0042-6989(02)00396-6
   Anderson AJ, 2001, VISION RES, V41, P2449, DOI 10.1016/S0042-6989(01)00139-0
   Anderson AJ, 2000, VISION RES, V40, P2579, DOI 10.1016/S0042-6989(00)00121-8
   Anderson AJ, 2005, INVEST OPHTH VIS SCI, V46, P1540, DOI 10.1167/iovs.04-0968
   Anderson Andrew J, 2003, Ophthalmol Clin North Am, V16, P213, DOI 10.1016/S0896-1549(03)00011-7
   Anderson DR., 1999, AUTOMATED STATIC PER, V2
   Artes PH, 2009, INVEST OPHTH VIS SCI, V50, P4700, DOI 10.1167/iovs.09-3601
   Artes PH, 2005, INVEST OPHTH VIS SCI, V46, P2451, DOI 10.1167/iovs.05-0135
   Arvind H, 2005, CURR EYE RES, V30, P123, DOI 10.1080/02713680490904278
   BEECH DG, 1961, APPL STAT, V10, P14
   Burgansky-Eliash Z, 2007, BRIT J OPHTHALMOL, V91, P933, DOI 10.1136/bjo.2006.110437
   Cacho I, 2010, OPTOMETRY VISION SCI, V87, P344, DOI 10.1097/OPX.0b013e3181d9515c
   Carrillo MM, 2005, ARCH OPHTHALMOL-CHIC, V123, P929, DOI 10.1001/archopht.123.7.929
   Casson RJ, 2006, J GLAUCOMA, V15, P23, DOI 10.1097/01.ijg.0000197089.53354.6f
   HEIJL A, 1987, ARCH OPHTHALMOL-CHIC, V105, P1544
   HEIJL A, 1977, ACTA OPHTHALMOL, V55, P854
   Huang CQ, 2008, INVEST OPHTH VIS SCI, V49, P917, DOI 10.1167/iovs.07-0241
   Johnson CA, 1999, OPTOMETRY VISION SCI, V76, P571, DOI 10.1097/00006324-199908000-00026
   JOHNSON LN, 1993, OPHTHALMOLOGY, V100, P76
   Kook MS, 2004, AM J OPHTHALMOL, V138, P85, DOI 10.1016/j.ajo.2004.03.020
   Maier M, 2010, GRAEF ARCH CLIN EXP, V248, P409, DOI 10.1007/s00417-009-1270-8
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   PELI E, 1990, J OPT SOC AM A, V7, P2032, DOI 10.1364/JOSAA.7.002032
   Phipps JA, 1999, AUST NZ J OPHTHALMOL, V27, P265, DOI 10.1046/j.1440-1606.1999.00193.x
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Sakata LM, 2007, ARCH OPHTHALMOL-CHIC, V125, P340, DOI 10.1001/archopht.125.3.340
   Shapley R., 1984, PROG RETIN RES, V3, P263, DOI DOI 10.1016/0278-4327(84)90011-7
   Siddiqui MAR, 2005, BRIT J OPHTHALMOL, V89, P1569, DOI 10.1136/bjo.2005.080655
   Spry PGD, 2001, INVEST OPHTH VIS SCI, V42, P1404
   Spry PGD, 2005, BRIT J OPHTHALMOL, V89, P1031, DOI 10.1136/bjo.2004.057778
   Sun H, 2006, OPTOMETRY VISION SCI, V83, P455, DOI 10.1097/01.opx.0000225103.18087.5d
   Tanna AP, 2004, OPHTHALMOLOGY, V111, P1504, DOI 10.1016/j.ophtha.2004.01.035
   Taravati P, 2008, INVEST OPHTH VIS SCI, V49, P924, DOI 10.1167/iovs.07-0248
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Ueda T, 2006, AM J OPHTHALMOL, V142, P856, DOI 10.1016/j.ajo.2006.05.021
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
   Vingrys AJ, 1999, AUST NZ J OPHTHALMOL, V27, P109, DOI 10.1046/j.1440-1606.1999.00158.x
   WEST SK, 1988, INVEST OPHTH VIS SCI, V29, P73
   WESTHEIMER G, 1982, VISION RES, V22, P157, DOI 10.1016/0042-6989(82)90177-8
NR 46
TC 12
Z9 12
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JUL
PY 2011
VL 88
IS 7
BP 806
EP 815
DI 10.1097/OPX.0b013e31821861bd
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 784DP
UT WOS:000292134800005
PM 21478785
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Goldstein, M
   Loewenstein, A
   Barak, A
   Baruch, E
   Feitt, N
   Yair-Pur, G
   Pollack, A
   Bukelman, A
   Eisner, Z
   Gabby, A
   Katz, H
   Gelbart, Z
   Shleikman, E
   Springer, A
   Schachat, AP
   Bressler, NM
   Belt, J
   Bressler, SB
   Cain, D
   Cooney, MJ
   Doll, W
   Emmert, D
   Herring, M
   Falk, R
   McDonald, J
   Tian, Y
   Alster, Y
   Even-Chen, Z
   Leshno, M
   Rafaeli, O
   Malach, R
   Toaff, T
AF Goldstein, Michaela
   Loewenstein, Anat
   Barak, Adiel
   Baruch, Eli
   Feitt, Natan
   Yair-pur, Galit
   Pollack, Ayala
   Bukelman, Amir
   Eisner, Zipi
   Gabby, Avraham
   Katz, Haia
   Gelbart, Zvi
   Shleikman, Eliezer
   Springer, Amira
   Schachat, Andrew P.
   Bressler, Neil M.
   Belt, Judith
   Bressler, Susan B.
   Cain, Dennis
   Cooney, Michael J.
   Doll, Warren
   Emmert, David
   Herring, Mark
   Falk, Rachel
   McDonald, Jacquelyn
   Tian, Yen
   Alster, Yair
   Even-Chen, Zeev
   Leshno, Moshe
   Rafaeli, Omer
   Malach, Rafael
   Toaff, Techiya
CA PHP Res Grp
TI Results of a multicenter clinical trial to evaluate the preferential
   hyperacuity perimeter for detection of age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; drusen
ID CHOROIDAL NEOVASCULARIZATION; MEMBRANES; VISION; EYE
AB Purpose: To compare the preferential hyperacuity perimeter (PHP) with an Amsler grid in detection of age-related macular degeneration (AMD).
   Methods: Patients underwent refraction, visual acuity examination, PHP, Amsler grid examination, and macular photography.
   Results: One hundred fifty patients participated in the trial. Of 19 eyes with neovascular AMD, 19 (100%) were positive on the PHP, and 10 (53%), on the Amsler grid. Of 27 eyes with geographic atrophy, 26 (96%) were positive on the PHP, and 12 (44%), on the Amsler grid. Of 20 eyes with intermediate AMD, 14 (70%) were positive on the PHP, and 4 (20%), on the Amsler grid. Of 51 eyes with early AMD, 21 (41 %) were positive on the PHP, and 4 (8%), on the Amsler grid. Of 33 eyes with no AMD, 6 (18%) were positive on the PHP, and none, on the Amsler grid. Thus, 80 (68%) of 117 patients with AMD had a positive PHP, while 30 (26%) had positive results of Amsler grid examination (P < 0.001, McNemar test).
   Conclusion: The PHP had greater sensitivity, although with a relatively high rate of false-positive results for healthy individuals, than the Amsler grid in detecting AMD-related lesions.
C1 Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine
RP Loewenstein, A (通讯作者)，Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, 6 Weitzmann St, IL-64239 Tel Aviv, Israel.
EM anatlow@tasmc.health.gov.il
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   *AG REL EY DIS STU, 2001, ARCH OPHTHALMOL-CHIC, V117, P1417
   Altman DG., 1990, PRACTICAL STAT MED R, DOI [10.1201/9780429258589, DOI 10.1201/9780429258589]
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BARALDI P, 1986, INT OPHTHALMOL, V9, P173, DOI 10.1007/BF00159846
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   ENOCH JM, 1984, ARCH OPHTHALMOL-CHIC, V102, P1164, DOI 10.1001/archopht.1984.01040030942019
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   FINE SL, 1985, OPHTHALMOLOGY, V92, P603
   GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0
   KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LAKSHMINARAYANA.V, 1992, OPTOMETRY VISION SCI, V6, P423
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Parkes L, 2001, NAT NEUROSCI, V4, P739, DOI 10.1038/89532
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   ROY MS, 1985, OPHTHALMOLOGICA, V191, P215, DOI 10.1159/000309590
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   WALL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P520, DOI 10.1001/archopht.1986.01050160076015
   WESTHEIMER G, 1979, INVEST OPHTH VIS SCI, V18, P893
NR 28
TC 61
Z9 64
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR-MAY
PY 2005
VL 25
IS 3
BP 296
EP 303
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 100QT
UT WOS:000241684400008
PM 15805906
DA 2022-11-30
ER

PT J
AU Schmucker, C
   Ehlken, C
   Hansen, LL
   Antes, G
   Agostini, HT
   Lelgemann, M
AF Schmucker, Christine
   Ehlken, Christoph
   Hansen, Lutz L.
   Antes, Gerd
   Agostini, Hansjuergen T.
   Lelgemann, Monika
TI Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the
   treatment of age-related macular degeneration: a systematic review
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE bevacizumab; effectiveness; ranibizumab; safety
ID OCCULT CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL;
   VERTEPORFIN PHOTODYNAMIC THERAPY; PIGMENT EPITHELIAL TEARS;
   VISION-RELATED FUNCTION; TRIAMCINOLONE ACETONIDE; SUBGROUP ANALYSIS;
   VISUAL-ACUITY; SECONDARY; INJECTION
AB Purpose of review
   We conducted a systematic review to evaluate whether the existing evidence justifies the intravitreal use of bevacizumab in comparison to ranibizumab in age-related macular degeneration.
   Recent findings
   Compared with photodynamic therapy, bevacizumab shows a relative improvement in visual acuity that is of similar size as in the comparison of ranibizumab with photodynamic therapy (relative improvement from 30 to 35%). However, this finding is based on one randomized controlled trial including less than 50 patients treated with bevacizumab. Also, nothing is known about long-term (>12 months) improvements in visual acuity and optimal treatment intervals for bevacizumab. Regarding safety, the published literature indicates that ocular and systemic adverse effects are less frequent under bevacizumab than ranibizumab treatment. But the validity of this finding is strongly limited by inadequate reporting, an unsystematic evaluation of adverse effects and short follow-up times in studies evaluating bevacizumab.
   Summary
   Given the lack of controlled data, the widespread off-label use of bevacizumab is not justified in clinical practice. On the other hand, a major challenge in the management of patients who require repeated antivascular endothelial growth factor injections is the high cost of ranibizumab. This dilemma underlines the need for head-to-head studies comparing both vascular endothelial growth factor antibodies, or, at least, well conducted randomized controlled trials evaluating intravitreal bevacizumab.
C1 [Schmucker, Christine] Univ Med Ctr Freiburg, German Cochrane Ctr, Inst Med Biometry & Med Informat, Dept Med Biometry & Stat, D-79104 Freiburg, Germany.
   [Ehlken, Christoph; Hansen, Lutz L.; Agostini, Hansjuergen T.] Univ Eye Hosp, Freiburg, Germany.
   [Lelgemann, Monika] Univ Bremen, Hlth Technol Assessment Ctr, Bremen, Germany.
C3 University of Freiburg; University of Freiburg; University of Bremen
RP Schmucker, C (通讯作者)，Univ Med Ctr Freiburg, German Cochrane Ctr, Inst Med Biometry & Med Informat, Dept Med Biometry & Stat, Stefan Meier Str 26, D-79104 Freiburg, Germany.
EM schmucker@cochrane.de
RI Hansen, Lutz L/A-1390-2011
OI Schmucker, Christine/0000-0002-1188-3158
FU German health insurance fund
FX The authors declare that they have no competing interests. The review
   was commissioned and funded by the German health insurance fund.
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   [Anonymous], 2001, UND SYST REV RES EFF
   Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Azad RV, 2008, JPN J OPHTHALMOL, V52, P52, DOI 10.1007/s10384-007-0496-4
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   *CATT STUD, NCT00593450 CATT STU
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   *EQUAL STUD, NTR1331 EQUAL STUD
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Geitzenauer W, 2006, KLIN MONATSBL AUGENH, V223, P822, DOI 10.1055/s-2006-926875
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   *IVAN STUD, ISRCTN92166560 IVAN
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P240, DOI 10.1089/jop.2006.0146
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   LAZIC R, 2007, COLL ANTROPOL S1, V31, pS315
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Maier M, 2008, KLIN MONATSBL AUGENH, V225, P818, DOI 10.1055/s-2008-1027638
   Mangione CM., NATL EYE I 25 ITEM V
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   *VIBERA STUD, NCT00559715 VIBERA S
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 53
TC 42
Z9 43
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2010
VL 21
IS 3
BP 218
EP 226
DI 10.1097/ICU.0b013e3283386783
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 591NR
UT WOS:000277308300009
PM 20393293
DA 2022-11-30
ER

PT J
AU Androudi, S
   Dastiridou, A
   Pharmakakis, N
   Stefaniotou, M
   Kalogeropoulos, C
   Symeonidis, C
   Charonis, A
   Tsilimbaris, M
AF Androudi, Sofia
   Dastiridou, Anna
   Pharmakakis, Nikolaos
   Stefaniotou, Maria
   Kalogeropoulos, Christos
   Symeonidis, Chrysanthos
   Charonis, Alexandros
   Tsilimbaris, Miltiadis
TI Guidelines for the Management of Wet Age-Related Macular Degeneration:
   Recommendations from a Panel of Greek Experts
SO ADVANCES IN THERAPY
LA English
DT Review
DE Age-related macular degeneration; Consensus; Ophthalmology;
   Recommendations
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL
   NEOVASCULAR MEMBRANES; INTRAVITREAL RANIBIZUMAB; VISION OUTCOMES;
   VISUAL-ACUITY; AFLIBERCEPT; EYES; BEVACIZUMAB; MARINA
AB To propose guidelines for the management of patients with wet age-related macular degeneration (wAMD), taking into account the results of large multicenter studies and clinical experience of retina experts.
   A team of retina experts developed a consensus paper after three consecutive meetings. The group was focused on guidelines to help clinical decision-making around the definition of successful treatment and the definition of non-response to therapy.
   Parameters suggestive of a successful response to treatments included: any gain in best corrected visual acuity (BCVA) or vision loss that is less than 5-10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, reduction of central retinal thickness, partial or complete absorption of subretinal fluid (SRF), reduction of intraretinal fluid, reduction of pigment epithelial detachment or restoration of the anatomy of outer retinal layers. Non-response to current treatment was considered in the case of loss of BCVA greater than 10 ETDRS letters, increased retinal edema or increase of SRF as evidenced by optical coherence tomography or new bleeding in biomicroscopy.
   The introduction of anti-VEGF agents revolutionized the treatment of wAMD. Given the complexity of the disease, the emerging new agents and the difference of cases recruited in clinical trials compared to those appearing in every-day practice, it is essential to individualize treatment options taking into account the results of clinical trials.
C1 [Androudi, Sofia; Dastiridou, Anna] Univ Thessaly, Dept Ophthalmol, Larisa, Greece.
   [Pharmakakis, Nikolaos] Univ Patras, Dept Ophthalmol, Rion, Patras, Greece.
   [Stefaniotou, Maria; Kalogeropoulos, Christos] Univ Ioannina, Dept Ophthalmol, Epirus, Greece.
   [Symeonidis, Chrysanthos] Aristotle Univ Thessaloniki, Dept Ophthalmol 2, GR-54006 Thessaloniki, Greece.
   [Charonis, Alexandros] Athens Vis, Athens, Greece.
   [Tsilimbaris, Miltiadis] Univ Crete, Dept Ophthalmol, Iraklion, Greece.
C3 University of Thessaly; University of Patras; University of Ioannina;
   Aristotle University of Thessaloniki; University of Crete
RP Androudi, S (通讯作者)，Univ Thessaly, Dept Ophthalmol, Larisa, Greece.
EM androudi@otenet.gr
RI Androudi, Sofia/AAB-7618-2021; KALOGEROPOULOS, CHRIS/AAH-2898-2019;
   Symeonidis, Chrysanthos/I-8278-2019
OI Androudi, Sofia/0000-0002-5303-7793; Symeonidis,
   Chrysanthos/0000-0003-4104-3018; Tsilimbaris,
   Miltiadis/0000-0002-0130-1150; DASTIRIDOU, ANNA/0000-0002-2780-0062
FU Novartis Hellas
FX No funding or sponsorship was received for the publication of this
   article. The consensus discussion was finalized during an Advisory Board
   Meeting held in Athens, 22.5.2015, sponsored by Novartis Hellas. All
   named authors meet the International Committee of Medical Journal
   Editors (ICMJE) criteria for authorship for this manuscript, take
   responsibility for the integrity of the work as a whole, and have given
   final approval for the version to be published.
CR Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Aslankurt M, 2013, EUR J OPHTHALMOL, V23, P553, DOI 10.5301/ejo.5000268
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Geus SJR, 2013, ACTA OPHTHALMOL, V91, pE411, DOI 10.1111/aos.12090
   Eadie JA, 2014, OPHTHAL SURG LAS IM, V9, P1
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gharbiya M, 2014, RETINA-J RET VIT DIS, V34, P298, DOI 10.1097/IAE.0b013e3182979e62
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kang HM, 2014, AM J OPHTHALMOL, V157, pe1
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wolf S, 2011, BRIT J OPHTHALMOL, V95, P1713, DOI 10.1136/bjophthalmol-2011-300471
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 54
TC 10
Z9 10
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD MAY
PY 2016
VL 33
IS 5
BP 715
EP 726
DI 10.1007/s12325-016-0332-7
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DN2ZS
UT WOS:000376932400002
PM 27116423
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Arias, L
   Caminal, JM
   Casas, L
   Masuet, C
   Badia, MB
   Rubio, M
   Pujol, O
   Arruga, J
AF Arias, L.
   Caminal, J. M.
   Casas, L.
   Masuet, C.
   Badia, M. B.
   Rubio, M.
   Pujol, O.
   Arruga, J.
TI A study comparing two protocols of treatment with intravitreal
   bevacizumab (Avastin) for neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; COHERENCE TOMOGRAPHY FINDINGS;
   SHORT-TERM; RANIBIZUMAB; SECONDARY; INJECTION
AB Aims: The aim of this study was to compare two treatment options for choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD): (1) bevacizumab administered once a month for 3 months and thereafter as needed (loading dose (LD)); and (2) bevacizumab administered as needed, after the first injection (pro re nata (as needed) (PRN)).
   Methods: Fifty consecutive patients were enrolled in this prospective study. The first 25 patients were included in the LD group and the last 25 patients in the PRN group. In both groups, the need for re-treatment was based on the presence of persistent or recurrent macular oedema, subretinal fluid or pigment epithelial detachment on optical coherence tomography scans.
   Results: At the 6-month follow-up, mean visual acuity improved by 13.7 letters (p<0.001) in the LD group and 4.6 in the PRN group (p<0.001). Thirty-six per cent of patients in the LD group compared with 12% in the PRN group gained 15 or more letters (p = 0.04). Mean foveal thickness decreased by 91.3 mm (p<0.001) in the LD group and 48.2 mu m in the PRN group (p<0.001). No ocular or systemic side effects were observed.
   Conclusion: Patients with CNV secondary to AMD treated with a LD protocol had better results than patients treated with a PRN protocol with intravitreal bevacizumab.
C1 [Arias, L.; Caminal, J. M.; Rubio, M.; Pujol, O.; Arruga, J.] Hosp Univ Bellvitge, Dept Ophthalmol, Barcelona 08907, Spain.
   [Arias, L.] Ctr Med Teknon, Inst Macula & Retina, Barcelona, Spain.
   [Casas, L.; Masuet, C.] Hosp Univ Bellvitge, Dept Prevent Med, Barcelona 08907, Spain.
   [Badia, M. B.] Hosp Univ Bellvitge, Dept Pharm, Barcelona 08907, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge
   University Hospital; University of Barcelona; Institut d'Investigacio
   Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital;
   University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Bellvitge University Hospital; University of Barcelona
RP Arias, L (通讯作者)，Hosp Univ Bellvitge, Dept Ophthalmol, C Feixa Llarga Sn, Barcelona 08907, Spain.
EM luisarias@telefonica.net
RI Rubio Caso, Marcos Javier/L-6866-2013; Masuet-Aumatell,
   Cristina/E-5028-2017
OI Rubio Caso, Marcos Javier/0000-0002-7072-9855; Masuet-Aumatell,
   Cristina/0000-0001-7000-7345; Casas, Lidia/0000-0003-1820-8742; ARIAS,
   LUIS/0000-0001-7041-5576; Caminal, JM/0000-0001-9563-0344
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   EUGENE WM, 2005, CAN J OPHTHALMOL, V40, P352
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 20
TC 54
Z9 55
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2008
VL 92
IS 12
BP 1636
EP 1641
DI 10.1136/bjo.2008.141721
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 376ZW
UT WOS:000261222500015
PM 18782803
DA 2022-11-30
ER

PT J
AU Olivier, E
   Dutot, M
   Regazzetti, A
   Leguillier, T
   Dargere, D
   Auzeil, N
   Laprevote, O
   Rat, P
AF Olivier, Elodie
   Dutot, Melody
   Regazzetti, Anne
   Leguillier, Teddy
   Dargere, Delphine
   Auzeil, Nicolas
   Laprevote, Olivier
   Rat, Patrice
TI P2X7-pannexin-1 and amyloid beta-induced oxysterol input in human
   retinal cell: Role in age-related macular degeneration?
SO BIOCHIMIE
LA English
DT Article
DE Degenerative disease; Eye/retina; Lipids; Receptors; Toxicology
ID DEATH RECEPTOR ACTIVATION; PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS;
   ALZHEIMERS-DISEASE; P2X(7) RECEPTOR; NEURODEGENERATIVE DISEASES;
   INFLAMMATORY CYTOKINES; P2X7; APOPTOSIS; MODEL
AB Age-related macular degeneration (AMD) is the most common cause of severe vision loss worldwide. Amyloid beta involvement in degenerative diseases such as AMD is well known and its toxicity has been related to P2X7 receptor-pannexin-1. Recently, oxysterols (oxidized derivatives of cholesterol) have been implicated in AMD pathogenesis. The aim of our study was to highlight amyloid (beta/oxysterols relationship and to describe P2X7 receptor-pannexin-1 role in oxysterols toxicity. Using retinal epithelial cells, we first quantified sterols levels after amyloid beta incubation and second we investigated the cytotoxic effects induced by oxysterols. For the first time, our results showed that amyloid beta induced oxysterols formation in human retinal pigmented epithelial cells. We showed that oxysterol toxicity is mediated by P2X7 receptor activation. This activation was dependent on pannexin-1 with 25-hydroxycholesterol whereas P2X7 receptor signaling pathway was pannexin-1-independent for 7-ketocholesterol. Taken together our data suggest a pivotal role of P2X7 receptor-pannexin-1 in oxysterols toxicity in retinal cells which could be an important target to develop new treatments for AMD (C) 2016 Published by Elsevier B.V.
C1 [Olivier, Elodie; Dutot, Melody; Regazzetti, Anne; Leguillier, Teddy; Dargere, Delphine; Auzeil, Nicolas; Laprevote, Olivier; Rat, Patrice] Univ Paris 05, Sorbonne Paris Cite, Fac Pharm Paris, UMR CNRS Chim Toxicol Analyt & Cellulaire 8638, 4 Ave Observ, F-75006 Paris, France.
   [Olivier, Elodie] Soliance Givaudan, Route Bazancourt, F-51110 Pomacle, France.
   [Dutot, Melody] Yslab, Rech & Dev, Lab Evaluat Physiol, 2 Rue Felix Dantec, F-29000 Quimper, France.
C3 UDICE-French Research Universities; Universite Paris Cite
RP Rat, P (通讯作者)，Univ Paris 05, Sorbonne Paris Cite, Fac Pharm Paris, UMR CNRS Chim Toxicol Analyt & Cellulaire 8638, 4 Ave Observ, F-75006 Paris, France.
EM patrice.rat@parisdescartes.fr
RI Dutot, Mélody/ABC-7648-2020; DUTOT, Mélody/A-1796-2017; AUZEIL,
   Nicolas/A-1686-2017; Dargere, Delphine/G-5004-2013; OLIVIER,
   Elodie/A-5323-2017
OI Dutot, Mélody/0000-0003-0964-0664; DUTOT, Mélody/0000-0003-0964-0664;
   AUZEIL, Nicolas/0000-0003-2666-3526; OLIVIER, Elodie/0000-0002-6566-8170
CR Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Ayciriex S, 2012, ANAL BIOANAL CHEM, V404, P3049, DOI 10.1007/s00216-012-6396-6
   Bjorkhem I, 2009, MOL ASPECTS MED, V30, P171, DOI 10.1016/j.mam.2009.02.001
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding HT, 2015, CELL MOL NEUROBIOL, V35, P623, DOI 10.1007/s10571-015-0156-z
   Donnelly-Roberts DL, 2004, J PHARMACOL EXP THER, V308, P1053, DOI 10.1124/jpet.103.059600
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Dutot M, 2008, MOL VIS, V14, P889
   Dutot M, 2008, EUR J PHARM SCI, V33, P138, DOI 10.1016/j.ejps.2007.10.006
   Dutot M, 2006, INVEST OPHTH VIS SCI, V47, P2812, DOI 10.1167/iovs.06-0224
   Dutot M, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-39
   GSCHWIND M, 1995, J NEUROCHEM, V65, P292
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012
   LEGRAND C, 1992, J BIOTECHNOL, V25, P231, DOI 10.1016/0168-1656(92)90158-6
   Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2
   Leoni V, 2011, CHEM PHYS LIPIDS, V164, P515, DOI 10.1016/j.chemphyslip.2011.04.002
   Locovei S, 2007, FEBS LETT, V581, P483, DOI 10.1016/j.febslet.2006.12.056
   Luthra S, 2008, MICROVASC RES, V75, P343, DOI 10.1016/j.mvr.2007.10.003
   Malvitte L, 2008, CURR EYE RES, V33, P769, DOI 10.1080/02713680802337397
   McLarnon JG, 2006, J NEUROPATH EXP NEUR, V65, P1090, DOI 10.1097/01.jnen.0000240470.97295.d3
   NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Obulesu M, 2014, NEUROCHEM RES, V39, P2301, DOI 10.1007/s11064-014-1454-4
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Orellana JA, 2011, J NEUROCHEM, V118, P826, DOI 10.1111/j.1471-4159.2011.07210.x
   Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200
   Pelegrin P, 2007, J BIOL CHEM, V282, P2386, DOI 10.1074/jbc.M610351200
   Perini G, 2002, J EXP MED, V195, P907, DOI 10.1084/jem.20011797
   Phan HTT, 2013, BBA-BIOMEMBRANES, V1828, P2487, DOI 10.1016/j.bbamem.2013.06.021
   Poli G, 2013, REDOX BIOL, V1, P125, DOI 10.1016/j.redox.2012.12.001
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rissiek B, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00204
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Seeland S, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.123
   Silverman W, 2008, AM J PHYSIOL-CELL PH, V295, pC761, DOI 10.1152/ajpcell.00227.2008
   Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735
   Vejux A, 2009, MOL ASPECTS MED, V30, P153, DOI 10.1016/j.mam.2009.02.006
   Volonte C, 2012, CNS NEUROL DISORD-DR, V11, P705, DOI 10.2174/187152712803581137
   Wakx A., 2015, APPL BIOCH BIOTECH
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zarrouk A, 2014, AGEING RES REV, V18, P148, DOI 10.1016/j.arr.2014.09.006
NR 54
TC 28
Z9 30
U1 0
U2 13
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0300-9084
EI 1638-6183
J9 BIOCHIMIE
JI Biochimie
PD AUG
PY 2016
VL 127
BP 70
EP 78
DI 10.1016/j.biochi.2016.04.014
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DR7LZ
UT WOS:000380082500009
PM 27109381
DA 2022-11-30
ER

PT J
AU Martin, DF
   Maguire, MG
   Ying, GS
   Grunwald, JE
   Fine, SL
   Jaffe, GJ
AF Martin, Daniel F.
   Maguire, Maureen G.
   Ying, Gui-shuang
   Grunwald, Juan E.
   Fine, Stuart L.
   Jaffe, Glenn J.
CA CATT Res Grp
TI Ranibizumab and Bevacizumab for Neovascular Age-Related Macular
   Degeneration The CATT Research Group
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
AB Background
   Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data.
   Methods
   In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation. The primary outcome was the mean change in visual acuity at 1 year, with a noninferiority limit of 5 letters on the eye chart.
   Results
   Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive. The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 mu m) than in the other groups (152 to 168 mu m, P = 0.03 by analysis of variance). Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (P>0.20). The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern.
   Conclusions
   At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Differences in rates of serious adverse events require further study. (Funded by the National Eye Institute; ClinicalTrials. gov number, NCT00593450.)
C1 [Maguire, Maureen G.] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Fine, Stuart L.] Univ Colorado Denver, Aurora, CO USA.
   [Jaffe, Glenn J.] Duke Univ, Durham, NC USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Cleveland Clinic
   Foundation; Children's Hospital Colorado; University of Colorado System;
   University of Colorado Anschutz Medical Campus; Duke University
RP Maguire, MG (通讯作者)，Univ Penn, Scheie Eye Inst, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM maguirem@mail.med.upenn.edu
RI Barresi, Luca/B-4622-2013; Ciulla, Thomas/AAA-1299-2020
OI Barresi, Luca/0000-0002-3788-145X; Ciulla, Thomas/0000-0001-5557-6777;
   Pistilli, Maxwell/0000-0002-4266-4150; Vavvas,
   Demetrios/0000-0002-8622-6478; Stinnett, Sandra/0000-0001-7192-0195;
   Folk, James/0000-0002-6271-2906; Losordo, Douglas/0000-0002-6857-7506
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services [U10-EY017823, U10-EY017825, U10-EY017826,
   U10-EY017828]; Glaxo-SmithKline; Neurotech; SurModics; NATIONAL EYE
   INSTITUTE [U10EY017823, U10EY017825, U10EY017828, U10EY017826] Funding
   Source: NIH RePORTER
FX Supported by cooperative agreements (U10-EY017823, U10-EY017825,
   U10-EY017826, and U10-EY017828) from the National Eye Institute,
   National Institutes of Health, Department of Health and Human Services.;
   Dr. Grunwald reports receiving consulting fees from Glaxo-SmithKline;
   and Dr. Jaffe, consulting fees from Neurotech and SurModics. No other
   potential conflict of interest relevant to this article was reported.
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   [Anonymous], 2010, COMP AGERELATED MACU, P10
   [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   COX DR, 1972, J R STAT SOC B, V34, P187
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Genentech, AV LAB TEXT FDA APPR
   Martin DF, 2010, NEW ENGL J MED, V363, P105, DOI 10.1056/NEJMp1001201
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosner B, 2003, BIOMETRICS, V59, P1089, DOI 10.1111/j.0006-341X.2003.00125.x
   Rubin D, 2004, MULTIPLE IMPUTATION
   Schmidt-Erfurth U, 2010, OPHTHALMOLOGY   1209
   The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products (CPMP), 2000, CMPEWP48299 EUR AG E
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 23
TC 1929
Z9 1996
U1 0
U2 138
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 19
PY 2011
VL 364
IS 20
BP 1897
EP 1908
DI 10.1056/NEJMoa1102673
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 765PJ
UT WOS:000290720700005
PM 21526923
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yanagi, Y
AF Yanagi, Yasuo
TI Pachychoroid disease: a new perspective on exudative maculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Pachychoroid; Central serous chorioretinopathy; Polypoidal choroidal
   vasculopathy; Age-related macular degeneration
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; OPTICAL COHERENCE TOMOGRAPHY;
   INDOCYANINE GREEN VIDEOANGIOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; CLINICAL CHARACTERISTICS; SPECTRUM DISORDERS; FELLOW EYES;
   NEOVASCULARIZATION; CLASSIFICATION
AB Background Pachychoroid, or the structural and functional abnormalities of the choroid, is one of the most important causes of exudative maculopathies. The purpose of this article is to review the current definitions of pachychoroid and their potential consequences. Summary of findings Most publications are from Asian countries. Although no consensus diagnosis has been reached, pachychoroid is defined by thickened choroid and choroidal vascular hyperpermeability, pachyvessels with inner choroidal attenuation; it is closely linked to pachydrusen. Although some studies suggest choroidal congestion may play a role in its pathogenesis, the exact causes of this condition are still unknown. Pachychoroid is associated with exudative maculopathies including central serous chorioretinopathy, pachychoroid neovasculopathy and polypoidal choroidal vasculopathy (PCV). It is widely accepted that macular neovascular membranes may develop secondary to pachychoroid. Recent clinical observations illustrate the importance of pachychoroid in the etiology of macular neovascularization including neovascular age-related macular degeneration (nAMD). Conclusion Pachychoroid is an important cause of exudative maculopathies. Both drusen and pachychoroid are increasingly recognized as important causes of macular neovascularization, and eyes formally categorized as typical nAMD or PCV can be further sub-categorized based on the presence or absence of pachychoroid and drusen. There is a need to develop a consensus definition, which will greatly enhance our understanding of pachychoroid and facilitate the development of individual interventions in pachychoroid diseases.
C1 [Yanagi, Yasuo] Asahikawa Med Univ, Dept Ophthalmol, Asahikawa, Hokkaido, Japan.
   [Yanagi, Yasuo] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
C3 Asahikawa Medical College; National University of Singapore; Singapore
   National Eye Center
RP Yanagi, Y (通讯作者)，Asahikawa Med Univ, Dept Ophthalmol, Asahikawa, Hokkaido, Japan.; Yanagi, Y (通讯作者)，Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
EM yasuo.yanagi@snec.com.sg
RI Yanagi, Yasuo/AAA-5441-2022
CR Azuma K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212055
   Baek J, 2019, GRAEF ARCH CLIN EXP, V257, P1863, DOI 10.1007/s00417-019-04388-x
   Baek J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42052-w
   Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Baek J, 2019, EYE, V33, P419, DOI 10.1038/s41433-018-0228-7
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho HJ, 2019, J OCUL PHARMACOL TH, V35, P174, DOI 10.1089/jop.2018.0107
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Daizumoto E, 2017, BRIT J OPHTHALMOL, V101, P56, DOI 10.1136/bjophthalmol-2016-309694
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Demirel S, 2021, EUR J OPHTHALMOL, V31, P184, DOI 10.1177/1120672119887095
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P1668, DOI 10.1097/IAE.0000000000001773
   Ersoz MG, 2018, BRIT J OPHTHALMOL, V102, P473, DOI 10.1136/bjophthalmol-2017-310724
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P957, DOI 10.1097/IAE.0000000000001655
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Forte R, 2020, BRIT J OPHTHALMOL, V104, P1057, DOI 10.1136/bjophthalmol-2019-315189
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gal-Or O, 2018, RETINA-J RET VIT DIS, V38, P1984, DOI 10.1097/IAE.0000000000002051
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hara C, 2019, BRIT J OPHTHALMOL, V103, P623, DOI 10.1136/bjophthalmol-2018-312275
   Hariri A, 2013, INVEST OPHTH VIS SCI, V54, P8020, DOI 10.1167/iovs.13-12302
   Hata M, 2019, OPHTHALMOL RETINA, V3, P1016, DOI 10.1016/j.oret.2019.06.013
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   HAYASHI K, 1986, INT OPHTHALMOL, V9, P37
   Hiroe T, 2018, OPHTHALMOL RETINA, V2, P152, DOI 10.1016/j.oret.2017.05.013
   Hosoda Y, 2019, OPHTHALMOL RETINA, V3, P985, DOI 10.1016/j.oret.2019.05.025
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Hwang H, 2020, RETINA-J RET VIT DIS, V40, P1724, DOI 10.1097/IAE.0000000000002662
   Iida Tomohiro, 1995, Nippon Ganka Gakkai Zasshi, V99, P945
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jang JW, 2019, RETINA-J RET VIT DIS, V39, P1995, DOI 10.1097/IAE.0000000000002259
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Joachim N, 2014, INVEST OPHTH VIS SCI, V55, P4421, DOI 10.1167/iovs.14-14476
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Karacorlu M, 2018, GRAEF ARCH CLIN EXP, V256, P2319, DOI 10.1007/s00417-018-4144-0
   Kim K, 2020, OPHTHALMOLOGICA, V243, P172, DOI 10.1159/000501212
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lee JH, 2019, RETINA-J RET VIT DIS, V39, P1562, DOI 10.1097/IAE.0000000000002187
   Lee JH, 2016, OPHTHALMOLOGY, V123, P2066, DOI 10.1016/j.ophtha.2016.06.033
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Lee M, 2018, INVEST OPHTH VIS SCI, V59, P4896, DOI 10.1167/iovs.18-25018
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Mori K, 2004, OPHTHALMOLOGY, V111, P507, DOI 10.1016/j.ophtha.2003.06.009
   Nakayama M, 2012, RETINA-J RET VIT DIS, V32, P2061, DOI 10.1097/IAE.0b013e318256205a
   Nomura Y, 2015, CLIN OPHTHALMOL, V9, P297, DOI 10.2147/OPTH.S78210
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Pichi F, 2018, INT OPHTHALMOL, V38, P975, DOI 10.1007/s10792-017-0547-x
   Rochepeau C, 2018, AM J OPHTHALMOL, V194, P26, DOI 10.1016/j.ajo.2018.07.004
   Roy R, 2019, INDIAN J OPHTHALMOL, V67, P1678, DOI 10.4103/ijo.IJO_1481_18
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P657, DOI 10.1097/IAE.0000000000002635
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sheth J, 2018, INDIAN J OPHTHALMOL, V66, P1796, DOI 10.4103/ijo.IJO_377_18
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P1121, DOI 10.4103/ijo.IJO_1757_18
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P371, DOI 10.4103/ijo.IJO_1173_18
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P820, DOI 10.1097/00006982-200312000-00013
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Terao N, 2018, INVEST OPHTH VIS SCI, V59, P5924, DOI 10.1167/iovs.18-25517
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yanagi Y, 2019, EYE, V33, P34, DOI 10.1038/s41433-018-0225-x
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yoshimura Nagahisa, 2016, Nippon Ganka Gakkai Zasshi, V120, P163
   Yun C, 2019, GRAEF ARCH CLIN EXP, V257, P57, DOI 10.1007/s00417-018-4179-2
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 100
TC 33
Z9 34
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2020
VL 64
IS 4
BP 323
EP 337
DI 10.1007/s10384-020-00740-5
EA APR 2020
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MC1OL
UT WOS:000528091300001
PM 32318919
DA 2022-11-30
ER

PT J
AU Muether, PS
   Hermann, MM
   Droge, K
   Kirchhof, B
   Fauser, S
AF Muether, Philipp S.
   Hermann, Manuel M.
   Droege, Katharina
   Kirchhof, Bernd
   Fauser, Sascha
TI Long-term Stability of Vascular Endothelial Growth Factor Suppression
   Time Under Ranibizumab Treatment in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AQUEOUS-HUMOR LEVELS; VITREOUS LEVELS; BEVACIZUMAB; CYTOKINES
AB PURPOSE: To determine intra-individual long-term stability of vascular endothelial growth factor (VEGF) suppression time in eyes with neovascular age-related macular degeneration (AMD) treated with ranibizumab.
   DESIGN: Nonrandomized, prospective clinical study.
   METHODS: Eighty-three eyes of 83 patients with neovascular A.MD undergoing intravitreal ranibizumab injections were included in the study. A total of 859 aqueous humor specimens were taken before each intravitreal ranibizumab injection. Vascular endothelial growth factor A was measured by multiplex bead analysis.
   RESULTS: Ranibizumab resulted in complete VEGF suppression within a mean period of 36.4 days (standard deviation +/- 6.7 days; range, 26-69 days). Intra-individual suppression time was stable within a period of up to 3 years. Among 859 VEGF measurements, only 5 (0.58%) deviated from this pattern. Nonsuppressed VEGF levels did not differ significantly between baseline and recurrence (68.0 pg/mL vs 69.3 pg/mL) and did not correlate with choroidal neovascularization size and lesion type.
   CONCLUSIONS: Both the long-term stability and the broad range of individual suppression times after ranibizumab injections would allow and justify adjustment of continuous injections individually in order to achieve permanent VEGF suppression in patients. ((C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Muether, Philipp S.; Hermann, Manuel M.; Droege, Katharina; Kirchhof, Bernd; Fauser, Sascha] Univ Cologne, Dept Ophthalmol, D-50931 Cologne, Germany.
C3 University of Cologne
RP Fauser, S (通讯作者)，Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM sascha.fauser@uk-koeln.de
FU Gilen and Notting Foundations; Novartis; Bayer; Gilen and Nolting
   Foundations, Cologne, Germany
FX Sascha Fauser received grants from the Gilen and Notting Foundations,
   and from Novartis. He is a consultant to Novartis and Alimera and
   received payment for lectures from Bayer and Novartis. Philipp Muether
   reveived payment for lectures from Novartis, Heidelberg Engineering, and
   Bayer. Manuel Hermann is a consultant to Allergan. Bernd Kirchhof is a
   consultant to Bayer and Novartis and received payments for lectures and
   educational presentations from Bayer and Novartis. This study was
   supported by grants from the Gilen and Nolting Foundations, Cologne,
   Germany. The funding organizations had no role in the design or conduct
   of this research. Contributions of authors: Involved in conception and
   design (P.S.M., BK., S.F.); data analysis and interpretation (P.S.M.,
   M.M.H., K.D., S.F.); writing the article (P.S.M., S.F.); critical review
   of the article (P.S.M., M.M.H., K.D., B.K., S.F.); final approval of the
   article (P.S.M., M.M.H., K.D., B.K., S.F.); data collection (P.S.M.,
   K.D.); and statistical expertise (M.M.H., S.F.).
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether P, 2013, RETINA, DOI [10.1097/IAE.0b013e318285cd9e.2013.03.13, DOI 10.1097/1AE.0B013E318285CD9E.2013.03.13]
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
NR 11
TC 40
Z9 47
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2013
VL 156
IS 5
BP 989
EP 993
DI 10.1016/j.ajo.2013.06.020
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 250NJ
UT WOS:000326859200018
PM 23938122
DA 2022-11-30
ER

PT J
AU Gok, M
   Kapti, HB
AF Gok, Mustafa
   Kapti, Hasan Burhanettin
TI Effect of intravitreal aflibercept (Eylea((R))) on retrobulbar
   hemodynamics in patients with neovascular age-related macular
   degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Aflibercept; Color Doppler
   ultrasonography; Retrobulbar blood flow
ID ENDOTHELIAL GROWTH-FACTOR; VEGF TRAP-EYE; BLOOD-FLOW; BEVACIZUMAB
   AVASTIN(R); ULTRASOUND ASSESSMENT; VISUAL IMPAIRMENT; RETINAL-VESSELS;
   RANIBIZUMAB; INJECTION; PREVALENCE
AB Purpose To investigate the short-term effect of single intravitreal aflibercept injection on retrobulbar blood flow in patients with neovascular age-related macular degeneration (nAMD).
   Methods Twenty eyes of 20 patients with nAMD scheduled for single intravitreal aflibercept (Eylea((R))) injection and 20 fellow eyes (uninjected) were enrolled in this prospective interventional study. The hemodynamic parameters of the ophthalmic artery (OA), central retinal artery (CRA) and posterior ciliary artery (PCA) comprising peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index (RI) were measured by using color Doppler ultrasonography (CDU) in both injected and uninjected fellow eyes at baseline and 1 week after the injection.
   Results The measured first-week values of PSV and EDV in the CRA, OA and PCA showed a statistically significant reduction when comparing baseline values in both injected and uninjected fellow eyes (p = 0.0001). Also, it was found a significant increase in the post-injection RI values of all the CRA, OA, PCA in injected eye and OA in the uninjected eye (p = 0.0001). There was any significant difference between pre- and post-injection RI values of the CRA and PCA in the fellow eyes (p = 0.137, p = 0.736, respectively).
   Conclusion Single intravitreal administration of aflibercept alters retrobulbar blood flow velocities (BFVs) in both injected and uninjected fellow eyes in the short-term period.
C1 [Gok, Mustafa; Kapti, Hasan Burhanettin] Ordu Univ Res & Training Hosp, Dept Ophthalmol, Minist Hlth, TR-52200 Ordu, Turkey.
C3 Ministry of Health - Turkey
RP Gok, M (通讯作者)，Ordu Univ Res & Training Hosp, Dept Ophthalmol, Minist Hlth, TR-52200 Ordu, Turkey.
EM drmgok81@gmail.com
RI gök, mustafa/P-4983-2019; Kaptı, Hasan Burhanettin/AAD-6423-2022; gok,
   mustafa/V-6690-2017
OI gok, mustafa/0000-0002-7660-6557
CR Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bonnin P, 2014, ACTA OPHTHALMOL, V92, pE382, DOI 10.1111/aos.12356
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Facemire CS, 2009, HYPERTENSION, V54, P652, DOI 10.1161/HYPERTENSIONAHA.109.129973
   GUTHOFF RF, 1991, ARCH OPHTHALMOL-CHIC, V109, P532, DOI 10.1001/archopht.1991.01080040100037
   Harris A, 1996, BRIT J OPHTHALMOL, V80, P1055, DOI 10.1136/bjo.80.12.1055
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hosseini H, 2012, RETINA-J RET VIT DIS, V32, P967, DOI 10.1097/IAE.0b013e31822c28d6
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Krohne TU, 2014, OPHTHALMOLOGE, V111, P113, DOI 10.1007/s00347-013-2932-9
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   Lovasik JV, 2003, INVEST OPHTH VIS SCI, V44, P2126, DOI 10.1167/iovs.02-0825
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   ROBINSON F, 1986, INVEST OPHTH VIS SCI, V27, P722
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Toklu Y, 2011, ACTA OPHTHALMOL, V89, pE41, DOI 10.1111/j.1755-3768.2010.02075.x
   Tschulakow A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113701
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Williamson TH, 1996, SURV OPHTHALMOL, V40, P255, DOI 10.1016/S0039-6257(96)82001-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Yuksel K, 2013, J OCUL PHARMACOL TH, V29, P723, DOI 10.1089/jop.2013.0051
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
NR 34
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD APR
PY 2018
VL 38
IS 2
BP 713
EP 719
DI 10.1007/s10792-017-0522-6
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GE6AD
UT WOS:000431304900033
PM 28421399
DA 2022-11-30
ER

PT J
AU Golan, S
   Shalev, V
   Goldstein, M
   Treister, G
   Chodick, G
   Loewenstein, A
AF Golan, Shani
   Shalev, Varda
   Goldstein, Michaela
   Treister, Giora
   Chodick, Gabriel
   Loewenstein, Anat
TI The rate of myocardial infarction events among patients with age-related
   macular degeneration: a population-based study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Arterial thromboembolic events-ATEs; Myocardial infarctions-MIs; Health
   maintenance organization-HMO
ID BEAVER DAM EYE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; DIETARY-FAT;
   MACULOPATHY; ATHEROSCLEROSIS; HYPERTENSION; RANIBIZUMAB; ASSOCIATION;
   STROKE
AB To examine the association between age-related macular degeneration (AMD) and the risk of myocardial infarctions (MIs) in a large health maintenance organization.
   A retrospective cohort study carried out at Maccabi Healthcare Services (MHS).
   A total of 6,546 patients aged a parts per thousand yen65 years who were diagnosed with AMD between April 18 1996 and June 6 2008, and 61,672 non-AMD patients frequency-matched for age and gender.
   Participants were retrospectively followed to the day of leaving the MHS, to undergoing an MI, or to closure of the study on July 1 2008, whichever came earlier. The relative risk of MI associated with AMD was estimated using the Cox proportional hazard model.
   Incident myocardial infarction events.
   During the study period, there were 159 (5.1 per 1,000 person years [PY]) and 2,997 (4.2 per 1,000 PY) MIs respecively in the AMD and non-AMD patient groups. The age- and gender-adjusted hazard ratio (HR) of MI among AMD patients was 1.01 (95%CI: 0.85-1.20). Baseline medical characteristics associated with increased risk of mortality included diabetes mellitus, hypertension, older age, and male gender. The fully adjusted HR associated with AMD was 1.03 (95%CI: 0.87-1.22).
   Despite the shared risk factors associated with AMD and MIs, we found no increased risk of MI in AMD patients.
C1 [Golan, Shani; Goldstein, Michaela; Loewenstein, Anat] Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
   [Shalev, Varda; Treister, Giora; Chodick, Gabriel] Maccabi Hlth Care Serv, Tel Aviv, Israel.
   [Golan, Shani; Shalev, Varda; Goldstein, Michaela; Treister, Giora; Chodick, Gabriel; Loewenstein, Anat] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center; Tel Aviv University; Sackler Faculty of Medicine
RP Golan, S (通讯作者)，Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, 6 Weizman St, IL-64239 Tel Aviv, Israel.
EM shanigol2@walla.com
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BARRON H, IMPORTANT DRUG WARNI
   Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   COX DR, 1972, J R STAT SOC B, V34, P187
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 27
TC 10
Z9 10
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2011
VL 249
IS 2
BP 179
EP 182
DI 10.1007/s00417-010-1489-4
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 723ML
UT WOS:000287510600004
PM 21337041
DA 2022-11-30
ER

PT J
AU Serini, S
   Piccioni, E
   Calviello, G
AF Serini, S.
   Piccioni, E.
   Calviello, G.
TI Dietary n-3 PUFA Vascular Targeting and the Prevention of Tumor Growth
   and Age-Related Macular Degeneration
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE n-3 PUFAs; EPA; DHA; angiogenesis; age-related macular degeneration;
   cancer
ID POLYUNSATURATED FATTY-ACIDS; ALPHA-LINOLENIC ACID; PROTEIN-KINASE-C;
   NF-KAPPA-B; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; ENDOTHELIAL
   DYSFUNCTION; CANCER CELLS; MATRIX METALLOPROTEINASES; ARACHIDONIC-ACID
AB The protective role of dietary n-3 polyunsaturated fatty acids (PUFAs) against cardiovascular diseases has been partly related to their ability to modulate the risk condition known as "endothelial dysfunction", by reverting the endothelial alterations associated to it (reduced vascular reactivity, the proinflammatory state, and the prothrombotic properties). Moreover, vasculature represents the target for inhibition of pathologic neo-angiogenesis by n-3 PUFAs. This effect is believed to contribute to the beneficial action of these fatty acids against disorders which recognize neovascularization as a crucial pathogenetic step for their development, such as cancer and age-related macular degeneration (AMD). Many epidemiological studies have been conducted to evaluate the association between the intake of these fatty acids and the risk of developing cancer or AMD, even though contrasting and not definitive results have been obtained. Conversely, plenty of preclinical and in vitro experimental studies have provided evidence for the anti-angiogenic effects of n-3 PUFAs, mainly studying neo-angiogenesis in general (using normal endothelial cells in vitro) or as a step of cancer growth. The main aim of this review is to critically review the current evidence for the inhibition of the neo-angiogenic process exerted by n-3 PUFAs in cancer and AMD, and to identify possible molecular mechanisms that might contribute to their beneficial effects.
C1 [Serini, S.; Piccioni, E.; Calviello, G.] Catholic Univ, Inst Gen Pathol, I-00168 Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Calviello, G (通讯作者)，Catholic Univ, Inst Gen Pathol, Lgo F Vito 1, I-00168 Rome, Italy.
EM g.calviello@rm.unicatt.it
OI CALVIELLO, Gabriella/0000-0002-2117-5534; SERINI,
   Simona/0000-0002-6894-1443
FU Catholic University of Sacred Hearth [D1 2008]
FX This work was supported in part by grant D1 2008 to G. C. from the
   Catholic University of Sacred Hearth within its program of promotion and
   diffusion of scientific research.
CR Al Suwaidi J, 2000, CIRCULATION, V101, P948, DOI 10.1161/01.CIR.101.9.948
   Albini A, 2007, CLIN CANCER RES, V13, P4320, DOI 10.1158/1078-0432.CCR-07-0069
   Allt G, 2001, CELLS TISSUES ORGANS, V169, P1, DOI 10.1159/000047855
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   ARENBERG DA, 1999, INFLAMMATION BASIC P, P851
   Arita M, 2005, BIOCHEM BIOPH RES CO, V338, P149, DOI 10.1016/j.bbrc.2005.07.181
   Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031
   Armah CK, 2008, CLIN SCI, V114, P679, DOI 10.1042/CS20070277
   Arroyo AG, 2007, CURR PHARM DESIGN, V13, P1787, DOI 10.2174/138161207780831284
   Astrof S, 2009, ANGIOGENESIS, V12, P165, DOI 10.1007/s10456-009-9136-6
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   BANG HO, 1971, LANCET, V1, P1143, DOI 10.1016/S0140-6736(71)91658-8
   Bays Harold E, 2008, Expert Rev Cardiovasc Ther, V6, P391, DOI 10.1586/14779072.6.3.391
   BAZAN NG, 1986, PROG LIPID RES, V25, P595, DOI 10.1016/0163-7827(86)90122-0
   Blondeau N, 2002, NEUROSCIENCE, V109, P231, DOI 10.1016/S0306-4522(01)00473-0
   Blondeau N, 2007, CIRC RES, V101, P176, DOI 10.1161/CIRCRESAHA.107.154443
   Bonnet CS, 2005, RHEUMATOLOGY, V44, P7, DOI 10.1093/rheumatology/keh344
   Bouzan C, 2005, AM J PREV MED, V29, P347, DOI 10.1016/j.amepre.2005.07.002
   Brantley-Sieders D, 2004, CURR PHARM DESIGN, V10, P3431, DOI 10.2174/1381612043383160
   Breier G, 2000, PLACENTA, V21, pS11, DOI 10.1053/plac.1999.0525
   Brenna JT, 2007, PROSTAG LEUKOTR ESS, V77, P247, DOI 10.1016/j.plefa.2007.10.016
   Burdge G, 2004, CURR OPIN CLIN NUTR, V7, P137, DOI 10.1097/00075197-200403000-00006
   BURR ML, 1989, LANCET, V2, P757
   Calder PC, 2008, MOL NUTR FOOD RES, V52, P885, DOI 10.1002/mnfr.200700289
   Calviello G, 2007, CURR MED CHEM, V14, P3059, DOI 10.2174/092986707782793934
   Calviello G, 1997, LIPIDS, V32, P1075, DOI 10.1007/s11745-997-0139-4
   Calviello G, 2004, CARCINOGENESIS, V25, P2303, DOI 10.1093/carcin/bgh265
   Calviello G, 2009, NUTR CANCER, V61, P287, DOI 10.1080/01635580802582777
   Calviello G, 2008, CURR SIGNAL TRANSD T, V3, P152, DOI 10.2174/157436208785699659
   Calviello G, 2006, CURR SIGNAL TRANSD T, V1, P255, DOI 10.2174/157436206778226923
   Calviello G, 2007, CARCINOGENESIS, V28, P1202, DOI 10.1093/carcin/bgl254
   Cantile M, 2008, NUTR METAB CARDIOVAS, V18, P651, DOI 10.1016/j.numecd.2008.08.001
   Cao YH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.259re1
   Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3
   CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F
   Chapkin RS, 2008, BRIT J NUTR, V100, P1152, DOI 10.1017/S0007114508992576
   CHEN LY, 1994, THROMB RES, V76, P317, DOI 10.1016/0049-3848(94)90160-0
   Cheresh DA, 2008, ONCOGENE, V27, P6285, DOI 10.1038/onc.2008.304
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   De Caterina R, 2005, J MEMBRANE BIOL, V206, P103, DOI 10.1007/s00232-005-0783-2
   De Maria G, 2008, AGRO FOOD IND HI TEC, V19, P4
   DECATERINA R, 1994, ARTERIOSCLER THROMB, V14, P1829, DOI 10.1161/01.ATV.14.11.1829
   DECATERINA R, 1995, PROSTAG LEUKOTR ESS, V52, P191, DOI 10.1016/0952-3278(95)90021-7
   deGraffenried LA, 2003, ANN ONCOL, V14, P1051, DOI 10.1093/annonc/mdg291
   Delbosc S, 2008, AM J PATHOL, V172, P1430, DOI 10.2353/ajpath.2008.070951
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Denys A, 2005, J LIPID RES, V46, P752, DOI 10.1194/jlr.M400444-JLR200
   Easwaran V, 2003, CANCER RES, V63, P3145
   Endemann DH, 2004, J AM SOC NEPHROL, V15, P1983, DOI 10.1097/01.ASN.0000132474.50966.DA
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FALLON S, 2001, TRIPPING LIGHTLY DOW
   Feletou M, 2008, FRONT BIOSCI-LANDMRK, V13, P4198, DOI 10.2741/3000
   Ferguson TA, 2008, SEMIN IMMUNOPATHOL, V30, P111, DOI 10.1007/s00281-008-0113-8
   Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297
   Firth JA, 2002, J ANAT, V200, P541, DOI 10.1046/j.1469-7580.2002.00059.x
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0
   FORM DM, 1983, P SOC EXP BIOL MED, V172, P214
   Fukuda R, 2003, CANCER RES, V63, P2330
   Garry A, 2007, EMBO REP, V8, P354, DOI 10.1038/sj.embor.7400916
   Ghersi G, 2008, FRONT BIOSCI-LANDMRK, V13, P2335, DOI 10.2741/2848
   GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Guebre-Egziabher F, 2008, EUR J CLIN NUTR, V62, P1287, DOI 10.1038/sj.ejcn.1602857
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hansen RA, 2008, J NUTR BIOCHEM, V19, P101, DOI 10.1016/j.jnutbio.2007.01.008
   Hardman WE, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-12
   Hardman WE, 2004, J NUTR, V134, p3427S, DOI 10.1093/jn/134.12.3427S
   HARDY SC, 1994, J PEDIATR-US, V125, pS69, DOI 10.1016/S0022-3476(06)80739-0
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Heurteaux C, 2004, EMBO J, V23, P2684, DOI 10.1038/sj.emboj.7600234
   Heurteaux C, 2006, NEUROSCIENCE, V137, P241, DOI 10.1016/j.neuroscience.2005.08.083
   Higashi Y, 2009, CIRC J, V73, P411, DOI 10.1253/circj.CJ-08-1102
   Hites RA, 2004, ENVIRON SCI TECHNOL, V38, P4945, DOI 10.1021/es049548m
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200
   Hynes RO, 2007, J THROMB HAEMOST, V5, P32, DOI 10.1111/j.1538-7836.2007.02569.x
   IGNARRO L J, 1988, P427
   Inuzuka T, 2009, BIOCHEM BIOPH RES CO, V379, P510, DOI 10.1016/j.bbrc.2008.12.101
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   James MJ, 2003, PROSTAG LEUKOTR ESS, V68, P399, DOI 10.1016/S0952-3278(03)00064-4
   Jung YD, 1999, CANCER RES, V59, P4804
   Kakar P, 2008, CURR ATHEROSCLER REP, V10, P79, DOI 10.1007/s11883-008-0012-4
   KANAYASU T, 1991, LIPIDS, V26, P271, DOI 10.1007/BF02537136
   Karamysheva AF, 2008, BIOCHEMISTRY-MOSCOW+, V73, P751, DOI 10.1134/S0006297908070031
   Kim HJ, 2007, MOL CANCER RES, V5, P321, DOI 10.1158/1541-7786.MCR-06-0218
   Kimura Y, 2005, CANCER SCI, V96, P441, DOI 10.1111/j.1349-7006.2005.00067.x
   Kimura Y, 2002, J NUTR, V132, P2069, DOI 10.1093/jn/132.7.2069
   Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D
   Komatsu M, 2005, NAT MED, V11, P1346, DOI 10.1038/nm1324
   Kopp HG, 2006, CURR OPIN HEMATOL, V13, P175, DOI 10.1097/01.moh.0000219664.26528.da
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   KROMANN N, 1980, ACTA MED SCAND, V208, P401
   Kuijper S, 2007, TRENDS CARDIOVAS MED, V17, P145, DOI 10.1016/j.tcm.2007.03.003
   Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009
   Landmesser U, 2004, CIRCULATION, V109, P27, DOI 10.1161/01.CIR.0000129501.88485.1f
   Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784
   LAWSON DL, 1991, EICOSANOIDS, V4, P217
   LICKENS S, 2001, BIOCHEM PHARMACOL, V61, P253
   Madri JA, 1997, TRANSPL IMMUNOL, V5, P179, DOI 10.1016/S0966-3274(97)80035-4
   MAKRIDES M, 1994, AM J CLIN NUTR, V60, P189, DOI 10.1093/ajcn/60.2.189
   Mannini A, 2009, BRIT J NUTR, V101, P688, DOI 10.1017/S0007114508043791
   Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Marti Hugo H., 1999, Thrombosis and Haemostasis, V82, P44
   Massaro M, 2006, P NATL ACAD SCI USA, V103, P15184, DOI 10.1073/pnas.0510086103
   Massaro M, 2008, PROSTAG LEUKOTR ESS, V79, P109, DOI 10.1016/j.plefa.2008.09.009
   Matsumoto T, 2009, J PHARMACOL EXP THER, V329, P324, DOI 10.1124/jpet.108.148718
   McCabe AJ, 2005, J NUTR BIOCHEM, V16, P17, DOI 10.1016/j.jnutbio.2004.07.006
   McCarty MF, 1996, MED HYPOTHESES, V46, P107, DOI 10.1016/S0306-9877(96)90009-2
   Menakuru SR, 2008, BRIT J CANCER, V99, P1961, DOI 10.1038/sj.bjc.6604733
   MENGEAUD V, 1992, PROSTAG LEUKOTR ESS, V47, P313, DOI 10.1016/0952-3278(92)90204-V
   Meuillet EJ, 1999, BBA-MOL BASIS DIS, V1454, P38, DOI 10.1016/S0925-4439(99)00023-X
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Morgan DR, 2006, AM J CARDIOL, V97, P547, DOI 10.1016/j.amjcard.2005.08.075
   Mori H, 2004, MUTAT RES-REV MUTAT, V566, P191, DOI 10.1016/j.mrrev.2003.08.002
   Morris MC, 2006, ARCH NEUROL-CHICAGO, V63, P1527, DOI 10.1001/archneur.63.11.1527
   Mozaffarian D, 2007, J CARDIOVASC MED, V8, pS23, DOI 10.2459/01.JCM.0000289279.95427.e2
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Mukutmoni-Norris M, 2000, CANCER LETT, V150, P101, DOI 10.1016/S0304-3835(99)00380-8
   Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960
   Mundel TM, 2008, INT J CANCER, V122, P1738, DOI 10.1002/ijc.23269
   Murakami M, 2008, CARDIOVASC RES, V78, P223, DOI 10.1093/cvr/cvm086
   Murota SI, 2000, ANN NY ACAD SCI, V902, P208
   Narayanan BA, 2003, CANCER RES, V63, P972
   NELSON GJ, 2000, EFFECTS DIETARY FATT, P481
   Nestel P, 2002, AM J CLIN NUTR, V76, P326, DOI 10.1093/ajcn/76.2.326
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Okumura T, 2002, AM J MED SCI, V324, P247, DOI 10.1097/00000441-200211000-00003
   Onguchi T, 2009, AM J PATHOL, V174, P1564, DOI 10.2353/ajpath.2009.080452
   Patan S, 2000, J NEURO-ONCOL, V50, P1, DOI 10.1023/A:1006493130855
   Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8
   Politi LE, 2001, INVEST OPHTH VIS SCI, V42, P3008
   Pollet I, 2003, BLOOD, V102, P1740, DOI 10.1182/blood-2003-01-0288
   Priante G, 2009, J NEPHROL, V22, P137
   Pulz O, 2004, APPL MICROBIOL BIOT, V65, P635, DOI 10.1007/s00253-004-1647-x
   Raffaelli L, 2008, INT J IMMUNOPATH PH, V21, P261, DOI 10.1177/039463200802100202
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21
   Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Rose DP, 1999, INT J ONCOL, V15, P1011
   ROSE DP, 1997, BREAST CANC, V4, P7
   Rotstein NP, 1997, J NEUROCHEM, V69, P504
   Rotstein NP, 1996, J NEUROCHEM, V66, P1851
   Rotstein NP, 1998, INVEST OPHTH VIS SCI, V39, P2750
   Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x
   Russo GL, 2009, BIOCHEM PHARMACOL, V77, P937, DOI 10.1016/j.bcp.2008.10.020
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Saugstad Letten F., 2006, Nutrition and Health (Bicester), V18, P89
   Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1
   SEPPANENLAAKSO T, 1992, BRIT J NUTR, V68, P639, DOI 10.1079/BJN19920122
   Serhan CN, 2008, BRIT J PHARMACOL, V153, pS200, DOI 10.1038/sj.bjp.0707489
   Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760
   Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197
   SERINI S, 2009, J FOOD COMP IN PRESS
   Sethi G, 2008, EXP BIOL MED, V233, P21, DOI 10.3181/0707-MR-196
   Sha G, 2007, HUM REPROD, V22, P3159, DOI 10.1093/humrep/dem266
   Shawber CJ, 2007, J CLIN INVEST, V117, P3369, DOI 10.1172/JCI24311
   Sheehan KM, 2004, EUR J GASTROEN HEPAT, V16, P619, DOI 10.1097/00042737-200406000-00017
   Shimokawa H, 1999, J MOL CELL CARDIOL, V31, P23, DOI 10.1006/jmcc.1998.0841
   Sijtsma L, 2004, APPL MICROBIOL BIOT, V64, P146, DOI 10.1007/s00253-003-1525-y
   Silva R, 2008, ARTERIOSCL THROM VAS, V28, P1703, DOI 10.1161/ATVBAHA.108.172015
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   Simopoulos AP, 2006, BIOMED PHARMACOTHER, V60, P502, DOI 10.1016/j.biopha.2006.07.080
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Sprecher H, 1995, J LIPID RES, V36, P2471
   Sprecher H, 1996, NUTRITION, V12, pS5
   Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200
   Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200
   Suzuki I, 1997, INT J CANCER, V73, P607, DOI 10.1002/(SICI)1097-0215(19971114)73:4<607::AID-IJC24>3.0.CO;2-4
   SWANSON JE, 1988, BRIT J NUTR, V59, P535, DOI 10.1079/BJN19880062
   Szymczak M, 2008, BLOOD, V111, P3514, DOI 10.1182/blood-2007-08-109934
   Tagawa H, 1999, J CARDIOVASC PHARM, V33, P633, DOI 10.1097/00005344-199904000-00017
   TAKAHASHI Y, 1995, CANCER RES, V55, P3964
   Tevar R, 2002, JPEN-PARENTER ENTER, V26, P285, DOI 10.1177/0148607102026005285
   Thurston G, 2008, BRIT J CANCER, V99, P1204, DOI 10.1038/sj.bjc.6604484
   Tjonahen E, 2006, CHEM BIOL, V13, P1193, DOI 10.1016/j.chembiol.2006.09.011
   TREEN M, 1992, ARCH BIOCHEM BIOPHYS, V294, P564, DOI 10.1016/0003-9861(92)90726-D
   Tsuji M, 2003, PROSTAG LEUKOTR ESS, V68, P337, DOI 10.1016/S0952-3278(03)00025-5
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tsuzuki T, 2004, J NUTR, V134, P1162, DOI 10.1093/jn/134.5.1162
   Tsuzuki T, 2007, BIOSCI BIOTECH BIOCH, V71, P1902, DOI 10.1271/bbb.70114
   Tsuzuki T, 2007, J NUTR, V137, P641, DOI 10.1093/jn/137.3.641
   Uauy R, 2001, LIPIDS, V36, P885, DOI 10.1007/s11745-001-0798-1
   Valentine RC, 2004, PROG LIPID RES, V43, P383, DOI 10.1016/j.plipres.2004.05.004
   Vanhoutte PM, 2009, ACTA PHYSIOL, V196, P193, DOI 10.1111/j.1748-1716.2009.01964.x
   Vanhoutte PM, 2009, CIRC J, V73, P595, DOI 10.1253/circj.CJ-08-1169
   Vanhoutte PM, 2008, J PHYSIOL-LONDON, V586, P5295, DOI 10.1113/jphysiol.2008.161430
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   von Schacky C, 2006, VASC HEALTH RISK MAN, V2, P251, DOI 10.2147/vhrm.2006.2.3.251
   Walser B, 2006, EUR J APPL PHYSIOL, V97, P347, DOI 10.1007/s00421-006-0190-0
   Walsh DA, 1999, RHEUMATOLOGY, V38, P103, DOI 10.1093/rheumatology/38.2.103
   Weis SM, 2007, BLOOD, V109, P1962, DOI 10.1182/blood-2005-10-038893
   Wen B, 2003, BRIT J CANCER, V89, P1102, DOI 10.1038/sj.bjc.6601136
   Wu KT, 2007, CHINESE J PHYSIOL, V50, P164
   Xiao YF, 2005, J MEMBRANE BIOL, V206, P141, DOI 10.1007/S00232-005-0786-Z
   Yang SP, 1998, J CELL PHYSIOL, V176, P342, DOI 10.1002/(SICI)1097-4652(199808)176:2<342::AID-JCP12>3.0.CO;2-5
   Yokoyama M, 2007, LANCET, V369, P1090, DOI 10.1016/S0140-6736(07)60527-3
   Yu HG, 2004, INT J COLORECTAL DIS, V19, P18, DOI 10.1007/s00384-003-0494-z
   Zachary I, 2003, BIOCHEM SOC T, V31, P1171
NR 214
TC 8
Z9 10
U1 0
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD DEC
PY 2009
VL 16
IS 34
BP 4511
EP 4526
DI 10.2174/092986709789760788
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 514GR
UT WOS:000271382900003
PM 19903153
DA 2022-11-30
ER

PT J
AU Singh, A
   Sorensen, TL
AF Singh, Amardeep
   Sorensen, Torben L.
TI The prevalence and clinical characteristics of Charles Bonnet Syndrome
   in Danish patients with neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; Charles Bonnet syndrome; geographic
   atrophy; low vision; visual hallucinations
ID VISUAL HALLUCINATIONS; DISEASE
AB . Purpose: To investigate the prevalence and clinical characteristics of the Charles Bonnet Syndrome (CBS) in a group of Danish patients with neovascular age-related macular degeneration (AMD) and to study whether CBS is associated with a specific retinal morphology. Methods: Three-hundred consecutive patients with neovascular AMD attending assessment consultations following variable series of ranibizumab therapy were actively asked whether they had symptoms of CBS. If they responded positively, a detailed questionnaire was orally administered to inquire into the details of the symptoms. Detailed optical coherence tomography and autofluorescence was performed. A comparison was made between retinal morphology of a randomly selected equal number of patients without CBS to patients with CBS. Results: Twenty-five (8.3%) patients of 300 had hallucinations attributable to CBS. The median lesion size measured as total area with increased autofluorescence in the CBS group (median 14.2 mm2) was not significantly different from the non-CBS group (median 16.2 mm2); however, the patients with CBS had significantly larger areas of geographic atrophy (median 2 mm2) compared to patients without CBS (median 0.3 mm2) (p = 0.002). Conclusion: CBS is not uncommon in an unselected population with neovascular AMD, and symptoms of CBS may be associated with larger areas of geographic atrophy.
C1 [Singh, Amardeep; Sorensen, Torben L.] Copenhagen Univ Hosp, Dept Ophthalmol, DK-4000 Roskilde, Denmark.
C3 University of Copenhagen
RP Singh, A (通讯作者)，Copenhagen Univ Hosp, Dept Ophthalmol, DK-4000 Roskilde, Denmark.
EM asingh@dadlnet.dk
RI Sørensen, Torben Lykke L/N-1417-2014; Singh, Amardeep/ABI-4544-2020
OI Sørensen, Torben Lykke L/0000-0002-6790-0199; 
CR Abbou EJ, 2007, INVEST OPHTH VIS SCI, V48, P1416, DOI 10.1167/iovs.06-0942
   D'Aleo G, 2007, FUNCT NEUROL, V22, P81
   Ffytche DH, 2009, CURR OPIN NEUROL, V22, P28, DOI 10.1097/WCO.0b013e32831f1b3f
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   HOLROYD S, 1992, AM J PSYCHIAT, V149, P1701
   Khan JC, 2008, OPHTHAL EPIDEMIOL, V15, P202, DOI 10.1080/09286580801939320
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Schadlu AP, 2009, CURR OPIN OPHTHALMOL, V20, P219, DOI 10.1097/ICU.0b013e328329b643
   Shiraishi Y, 2004, J PSYCHIATR RES, V38, P207, DOI 10.1016/S0022-3956(03)00090-6
   Stofler PM, 2004, J AM GERIATR SOC, V52, P646, DOI 10.1111/j.1532-5415.2004.52178_5.x
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   Tan CSH, 2004, BRIT J OPHTHALMOL, V88, P1325, DOI 10.1136/bjo.2004.041947
   TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254
   Vukicevic M, 2008, CLIN EXP OPHTHALMOL, V36, P659, DOI [10.1111/j.1442-9071.2008.01814.x, 10.1111/j.1442-9071.2008.01864.x]
NR 15
TC 25
Z9 25
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2012
VL 90
IS 5
BP 476
EP 480
DI 10.1111/j.1755-3768.2010.02051.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 980OV
UT WOS:000306903600039
PM 21106047
OA Bronze
DA 2022-11-30
ER

PT J
AU Yang, SQ
   Li, T
   Jia, HX
   Gao, M
   Li, YM
   Wan, XL
   Huang, Z
   Li, M
   Zhai, YQ
   Li, XM
   Yang, XT
   Wang, T
   Liang, J
   Gu, Q
   Luo, XT
   Qian, L
   Lu, SJ
   Liu, JJ
   Song, YP
   Wang, FH
   Sun, XD
   Yu, DC
AF Yang, Shiqi
   Li, Tong
   Jia, Huixun
   Gao, Min
   Li, Yiming
   Wan, Xiaoling
   Huang, Zhen
   Li, Min
   Zhai, Yuanqi
   Li, Xiaomeng
   Yang, Xiaotong
   Wang, Tao
   Liang, Jian
   Gu, Qing
   Luo, Xueting
   Qian, Lei
   Lu, Shujie
   Liu, Junjian
   Song, Yanping
   Wang, Fenghua
   Sun, Xiaodong
   Yu, Dechao
TI Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized
   for neovascular age-related macular degeneration therapy
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; INDUCED CHOROIDAL
   NEOVASCULARIZATION; MEMBRANE-ATTACK-COMPLEX; GEOGRAPHIC ATROPHY;
   ALTERNATIVE PATHWAY; MOUSE MODEL; FACTOR-B; ACTIVATION; INHIBITOR
AB Antiangiogenesis therapies targeting vascular endothelial growth factor (VEGF) have revolutionized the treatment of neovascular ocular diseases, including neovascular age-related macular degeneration (nAMD). Compelling evidence has implicated the vital role of complement system dysregulation in AMD pathogenesis, implying it as a potential therapeutic strategy for geographic atrophy in dry AMD and to enhance the efficacy of anti-VEGF monotherapies in nAMD. This study reports the preclinical assessment and phase 1 clinical outcomes of a bispecific fusion protein, efdamrofusp alfa (code: IBI302), which is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa showed superior efficacy over anti-VEGF monotherapy in a mouse laser-induced choroidal neovascularization (CNV) model after intravitreal delivery. Dual inhibition of VEGF and the complement activation was found to further inhibit macrophage infiltration and M2 macrophage polarization. Intravitreal efdamrofusp alfa demonstrated favorable safety profiles and exhibited antiangiogenetic efficacy in a nonhuman primate laser-induced CNV model. A phase 1 dose-escalating clinical trial (NCT03814291) was thus conducted on the basis of the preclinical data. Preliminary results showed that efdamrofusp alfa was well tolerated in patients with nAMD. These data suggest that efdamrofusp alfa might be effective for treating nAMD and possibly other complement-related ocular conditions.
C1 [Yang, Shiqi; Li, Tong; Jia, Huixun; Gao, Min; Wan, Xiaoling; Li, Min; Zhai, Yuanqi; Li, Xiaomeng; Yang, Xiaotong; Wang, Tao; Liang, Jian; Gu, Qing; Luo, Xueting; Wang, Fenghua; Sun, Xiaodong] Shanghai Jiao Tong Univ Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai 200080, Peoples R China.
   [Yang, Shiqi; Li, Tong; Jia, Huixun; Li, Xiaomeng; Yang, Xiaotong; Wang, Fenghua; Sun, Xiaodong] Natl Clin Res Ctr Ophthalm Dis, Shanghai 200080, Peoples R China.
   [Jia, Huixun; Wang, Fenghua; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai 200080, Peoples R China.
   [Li, Yiming; Qian, Lei; Lu, Shujie; Liu, Junjian; Yu, Dechao] Innovent Biol Inc, Suzhou 215000, Peoples R China.
   [Wan, Xiaoling; Li, Min; Zhai, Yuanqi; Wang, Tao; Liang, Jian; Gu, Qing; Luo, Xueting; Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai 200080, Peoples R China.
   [Huang, Zhen; Song, Yanping] Wuhan Gen Hosp Guangzhou Mil Reg, Dept Ophthalmol, Wuhan 430070, Peoples R China.
C3 Shanghai Jiao Tong University
RP Wang, FH; Sun, XD (通讯作者)，Shanghai Jiao Tong Univ Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai 200080, Peoples R China.; Wang, FH; Sun, XD (通讯作者)，Natl Clin Res Ctr Ophthalm Dis, Shanghai 200080, Peoples R China.; Wang, FH; Sun, XD (通讯作者)，Shanghai Engn Ctr Visual Sci & Photomed, Shanghai 200080, Peoples R China.; Sun, XD (通讯作者)，Shanghai Key Lab Fundus Dis, Shanghai 200080, Peoples R China.
EM shretina@sjtu.edu.cn; xdsun@sjtu.edu.cn
RI Qian, Lei/I-8763-2019; Yang, Shiqi/CAI-7690-2022
OI Qian, Lei/0000-0001-8720-7140; Sun, Xiaodong/0000-0001-5015-0945; Wan,
   Xiaoling/0000-0003-4583-8686; Yang, Shiqi/0000-0003-1314-951X
FU National Major Scientific and Technological Special Project for
   "Significant New Drugs Development" [2019ZX09301113]; National Natural
   Science Foundation of China [81730026, 82000882]; National Key RD
   Program [2017YFA0105301]; Science and Technology Commission of Shanghai
   Municipality [19YF1439800]; Shanghai Hospital Development Center
   [SHDC2020CR2040B]; Innovent Biologics Inc.
FX This work was supported by the National Major Scientific and
   Technological Special Project for "Significant New Drugs Development"
   (2019ZX09301113 to X.S.), the National Natural Science Foundation of
   China [81730026 (to X.S.) and 82000882 (to S.Y.)], National Key R&D
   Program (2017YFA0105301 to X.S.), Science and Technology Commission of
   Shanghai Municipality (19YF1439800 to T.L.), and Shanghai Hospital
   Development Center (SHDC2020CR2040B to X.S.). Innovent Biologics Inc.
   provided funding sources for the phase 1 trial.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2021, AP ANN 3 OR PRES PHA
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Ding K, 2017, MABS-AUSTIN, V9, P269, DOI 10.1080/19420862.2016.1268305
   Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fahey E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01426
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grunert U, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100844
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   He LZ, 2014, J BIOL CHEM, V289, P8019, DOI 10.1074/jbc.M113.535765
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kim HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32548
   Kim SJ, 2013, BRIT J OPHTHALMOL, V97, P367, DOI 10.1136/bjophthalmol-2012-302307
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee CH, 2021, ANN NUCL MED, V35, P639, DOI 10.1007/s12149-021-01607-6
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Liu J, 2011, J BIOL CHEM, V286, P20991, DOI 10.1074/jbc.M111.226266
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mastellos DC, 2019, NAT REV DRUG DISCOV, V18, P707, DOI 10.1038/s41573-019-0031-6
   Matsumoto H, 2014, INVEST OPHTH VIS SCI, V55, P4165, DOI 10.1167/iovs.14-14238
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Ren XY, 2016, EXP EYE RES, V145, P352, DOI 10.1016/j.exer.2016.02.004
   Richards A, 2006, VISUAL NEUROSCI, V23, P91, DOI 10.1017/S0952523806231080
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rohrer B, 2012, J OCUL PHARMACOL TH, V28, P402, DOI 10.1089/jop.2011.0212
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Schmitz R, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25745-7
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Song J, 2018, INVEST OPHTH VIS SCI, V59, P3747, DOI 10.1167/iovs.18-23892
   Sulaiman RS, 2015, J OCUL PHARMACOL TH, V31, P447, DOI 10.1089/jop.2015.0049
   Toomey DP, 2009, SURG-J R COLL SURG E, V7, P174, DOI 10.1016/S1479-666X(09)80042-5
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Xu Y, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12660
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 83
TC 2
Z9 3
U1 7
U2 7
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JUN 1
PY 2022
VL 14
IS 647
AR eabj2177
DI 10.1126/scitranslmed.abj2177
PG 19
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 1Y3MZ
UT WOS:000808048700004
PM 35648811
DA 2022-11-30
ER

PT J
AU Gharbiya, M
   Cruciani, F
   Mariotti, C
   Grandinetti, F
   Marenco, M
   Cacace, V
AF Gharbiya, Magda
   Cruciani, Filippo
   Mariotti, Cesare
   Grandinetti, Francesca
   Marenco, Marco
   Cacace, Vittorio
TI Choroidal Thickness Changes After Intravitreal Antivascular Endothelial
   Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab
   Versus Aflibercept
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID INDOCYANINE GREEN ANGIOGRAPHY; PHOTODYNAMIC THERAPY; VEGF-TRAP;
   BEVACIZUMAB; INJECTION; CHORIOCAPILLARIS
AB Purpose: To compare the changes in subfoveal choroidal thickness (CT) in eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal ranibizumab or aflibercept. Methods: In this retrospective case series, the medical records of 28 patients with nAMD treated with at least 3 consecutive monthly injections of ranibizumab (0.5mg/0.05mL) or aflibercept (2mg/0.05mL) between December 2013 and June 2014 and who were followed up for at least 3 months were reviewed. Subfoveal choroidal thickness was measured using enhanced depth imaging optical coherence tomography. Results: Choroidal thickness decreased over time in the aflibercept group, but was unchanged throughout the study in the ranibizumab group. At each time point, the decrease was significantly greater in aflibercept-treated eyes compared with ranibizumab-treated eyes (P<0.05). No significant change in best-corrected visual acuity (BCVA) was seen in either group during follow-up. There was no correlation between change in choroidal thickness and age, sex, duration of previous antivascular endothelial growth factor treatment, number of previous injections, spherical equivalent, baseline choroidal thickness, and the BCVA outcome in either group. Conclusions: Subfoveal choroidal thickness appeared to decrease significantly in eyes with nAMD during 3 months of aflibercept treatment. No corresponding decrease in choroidal thickness occurred in ranibizumab-treated eyes.
C1 [Gharbiya, Magda; Cruciani, Filippo; Grandinetti, Francesca; Marenco, Marco; Cacace, Vittorio] Univ Roma La Sapienza, Umberto Univ Hosp 1, Dept Ophthalmol, I-00161 Rome, Italy.
   [Mariotti, Cesare] Polytech Univ Marche, Dept Ophthalmol, Ancona, Italy.
C3 Sapienza University Rome; University Hospital Sapienza Rome; Marche
   Polytechnic University
RP Gharbiya, M (通讯作者)，Univ Roma La Sapienza, Umberto Univ Hosp 1, Dept Ophthalmol, Viale Policlin 155, I-00161 Rome, Italy.
EM magda.gharbiya@tiscali.it
RI Gharbiya, Magda/AAS-1182-2021
OI Marenco, Marco/0000-0002-6978-3790; Gharbiya, Magda/0000-0002-4991-9689
FU Novartis Farma, Italy
FX Financial support for medical editorial assistance was provided by
   Novartis Farma, Italy.
CR Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   GIOVANNINI A, 1994, OPHTHALMOLOGICA, V208, P185, DOI 10.1159/000310483
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McDonnell EC, 2014, EUR J OPHTHALMOL, V24, P897, DOI 10.5301/ejo.5000509
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mori K, 2005, RETINA-J RET VIT DIS, V25, P430, DOI 10.1097/00006982-200506000-00006
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Schraermeyer U, 2013, EXPERT OPIN BIOL TH, V13, P157, DOI 10.1517/14712598.2012.748741
   Schraermeyer U, 2012, GRAEF ARCH CLIN EXP, V250, P1303, DOI 10.1007/s00417-012-2055-z
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 23
TC 40
Z9 40
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUL 1
PY 2015
VL 31
IS 6
BP 357
EP 362
DI 10.1089/jop.2014.0160
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA CV0JD
UT WOS:000363936100009
PM 26133059
DA 2022-11-30
ER

PT J
AU Furino, C
   Ferrara, A
   Cardascia, N
   Besozzi, G
   Alessio, G
   Sborgia, L
   Boscia, F
AF Furino, Claudio
   Ferrara, Andrea
   Cardascia, Nicola
   Besozzi, Gianluca
   Alessio, Giovanni
   Sborgia, Luigi
   Boscia, Francesco
TI Combined cataract extraction and intravitreal bevacizumab in eyes with
   choroidal neovascularization resulting from age-related macular
   degeneration
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID LENS OPACITIES; RISK-FACTORS; SURGERY; MACULOPATHY; PHACOEMULSIFICATION;
   AVASTIN; INJECTION; EXPOSURE; THERAPY
AB PURPOSE: To evaluate the safety and efficacy of phacoemulsification, intraocular lens (IOL) implantation, and a single intravitreal injection of bevacizumab in patients with coexisting visually significant cataract and subfoveal neovascularization due to age-related macular degeneration.
   SETTING: Department of Ophthalmology, University of Bari, Bari, Italy.
   METHODS: Eyes with predominantly classic subfoveal neovascularization and cataract had phacoemulsification, IOL implantation, and a 1.25 mg intravitreal injection of bevacizumab. One month after combined surgery, corrected distance visual acuity (CDVA), anterior chamber reaction, and intraocular pressure were evaluated and central foveal thickness was measured by optical coherence tomography.
   RESULTS: Twenty eyes of 20 patients were evaluated. One month postoperatively, the mean CDVA improved significantly, from 20/100 (range 20/160 to 20/80) at baseline to 20/63 (range 20/125 to 20/50) (P<.0001). The mean central foveal thickness decreased significantly, from 353.75 mu m +/- 12.50 (SD) (range 334 to 375 mu m) at baseline to 275.7 +/- 17.3 mu m (range 255 to 323 mu m) at 1 month (P<.0001). Intraocular pressure did not change significantly, and anterior chamber reaction was absent. No ocular or systemic adverse events were observed.
   CONCLUSION: Combined phacoemulsification, IOL implantation, and intravitreal bevacizumab was a safe and efficacious treatment in patients with visually significant cataract and active subfoveal neovascularization.
C1 [Furino, Claudio; Ferrara, Andrea; Cardascia, Nicola; Besozzi, Gianluca; Alessio, Giovanni; Sborgia, Luigi; Boscia, Francesco] Univ Bari, Dept Ophthalmol, I-70124 Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro
RP Boscia, F (通讯作者)，Univ Bari, Dipartimento Oftalmol & Otorinolaringoiatria, Piazza Giulio Cesare 11, I-70124 Bari, Italy.
EM francescoboscia@hotmail.com
RI Boscia, Francesco/AAC-7729-2022; Cardascia, Nicola/AAC-3306-2019
OI Boscia, Francesco/0000-0002-5478-060X; Alessio,
   Giovanni/0000-0001-8313-4159; Sborgia, Luigi/0000-0003-4433-9527
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Biro Z, 2008, EYE, V22, P8, DOI 10.1038/sj.eye.6702460
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Estafanous MFG, 2001, AM J OPHTHALMOL, V131, P620, DOI 10.1016/S0002-9394(00)00909-0
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Grewing R, 2000, OPHTHALMIC SURG LAS, V31, P215
   HOGAN MJ, 1959, AM J OPHTHALMOL, V47, P155, DOI 10.1016/S0002-9394(14)78239-X
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P329, DOI 10.1177/112067210501500303
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miyake K, 2002, SURV OPHTHALMOL, V47, pS203, DOI 10.1016/S0039-6257(02)00294-1
   Pham TQ, 2007, EYE, V21, P512, DOI 10.1038/sj.eye.6702254
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SENGER DR, 1990, CANCER RES, V50, P1774
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 37
TC 20
Z9 20
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD SEP
PY 2009
VL 35
IS 9
BP 1518
EP 1522
DI 10.1016/j.jcrs.2009.04.032
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 496HQ
UT WOS:000269961400008
PM 19683147
DA 2022-11-30
ER

PT J
AU Joussen, AM
   Wolf, S
   Kaiser, PK
   Boyer, D
   Schmelter, T
   Sandbrink, R
   Zeitz, O
   Deeg, G
   Richter, A
   Zimmermann, T
   Hoechel, J
   Buetehorn, U
   Schmitt, W
   Stemper, B
   Boettger, MK
AF Joussen, Antonia M.
   Wolf, Sebastian
   Kaiser, Peter K.
   Boyer, David
   Schmelter, Thomas
   Sandbrink, Rupert
   Zeitz, Oliver
   Deeg, Gesa
   Richter, Annett
   Zimmermann, Torsten
   Hoechel, Joachim
   Buetehorn, Ulf
   Schmitt, Walter
   Stemper, Brigitte
   Boettger, Michael K.
TI The Developing Regorafenib Eye drops for neovascular Age-related Macular
   degeneration (DREAM) study: an open-label phase II trial
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE drug development; clinical trials; pharmacometrics; ophthalmology
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR;
   DOSE-ESCALATION; VEGF TRAP; IN-VITRO; RANIBIZUMAB; EXPRESSION;
   VERTEPORFIN; PENETRATION; PAZOPANIB
AB Aims This programme investigated topical regorafenib, a multikinase inhibitor, in patients with neovascular age-related macular degeneration (nAMD). Methods Topical regorafenib was investigated in an open-label, phase IIa/b study in which patients with choroidal neovascularization (CNV) secondary to nAMD received regorafenib (25 mu l, 30 mg ml(-1)) three times a day for 12 weeks. The primary endpoint of the phase II/a/b study was mean change in best-corrected visual acuity (BCVA) from baseline to weeks 4 and 12. Results In nAMD patients (N = 51), mean changes in BCVA were +1.2 [90% confidence interval (CI) -0.61, 2.97] and -2.4 (90% CI -4.18, -0.54) letters at weeks 4 and 12, respectively. Ocular treatment-emergent adverse events (TEAEs) (study eye) were reported in 21 patients by week 12. There was one serious ocular TEAE (visual acuity reduced) that was not drug related. Twenty patients required rescue (intravitreal ranibizumab). Conclusions The programme was terminated after phase IIa ended because efficacy was lower than with current nAMD treatments. According to elaborate post hoc analyses, the most likely reason was insufficient exposure in the target compartment (back of the eye).
C1 [Joussen, Antonia M.; Zeitz, Oliver] Charite Univ Med Berlin, Dept Ophthalmol, Berlin, Germany.
   [Wolf, Sebastian] Univ Bern, Univ Hosp, Inselspital, Bern Photog Reading Ctr, Bern, Switzerland.
   [Wolf, Sebastian] Univ Bern, Univ Hosp, Inselspital, Dept Ophthalmol, Bern, Switzerland.
   [Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH USA.
   [Boyer, David] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Boyer, David] USC Keck Sch Med, Los Angeles, CA USA.
   [Schmelter, Thomas; Sandbrink, Rupert; Zeitz, Oliver; Deeg, Gesa; Richter, Annett; Zimmermann, Torsten; Hoechel, Joachim; Buetehorn, Ulf; Schmitt, Walter; Stemper, Brigitte; Boettger, Michael K.] Bayer AG, Div Pharma, Berlin, Germany.
   [Schmelter, Thomas; Sandbrink, Rupert; Zeitz, Oliver; Deeg, Gesa; Richter, Annett; Zimmermann, Torsten; Hoechel, Joachim; Buetehorn, Ulf; Schmitt, Walter; Stemper, Brigitte; Boettger, Michael K.] Bayer AG, Div Pharma, Wuppertal, Germany.
   [Sandbrink, Rupert] Heinrich Heine Univ, Dept Neurol, Dusseldorf, Germany.
   [Stemper, Brigitte] Univ Erlangen Nurnberg, Dept Neurol, Erlangen, Germany.
   [Boettger, Michael K.] Berg Univ Gesamthsch Wuppertal, Dept Sports Med, Wuppertal, Germany.
   [Sandbrink, Rupert] Topas Therapeut GmbH, Hamburg, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; University of Bern; University Hospital of
   Bern; University of Bern; University Hospital of Bern; Retina Vitreous
   Associates Medical Group; University of Southern California; Bayer AG;
   Bayer AG; Heinrich Heine University Dusseldorf; University of Erlangen
   Nuremberg; University of Wuppertal
RP Boettger, MK (通讯作者)，Bayer AG, Div Pharma, Forschungszentrum Elberfeld, Aprather Weg 18a, D-42113 Wuppertal, Germany.
EM michael.boettger@bayer.com
RI Schmelter, Thomas/AAS-3728-2021; Zeitz, Oliver/AAJ-9728-2021; Joussen,
   Antonia/AAA-6901-2022; Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Schmelter,
   Thomas/0000-0003-1358-3172; Schmitt, Walter/0000-0001-6983-6525
FU Bayer AG, Pharmaceuticals; Bayer AG, Division Pharma, Leverkusen,
   Germany
FX A.M.J. is a consultant for Bayer AG, Division Pharma, Novartis, and
   OD-DS. S.W. declares financial support from Alcon, Allergan, Bayer AG,
   Division Pharma and Novartis, and nonfinancial support from Heidelberg
   Engineering, Optos and Zeiss. P.K.K. is a consultant for Alcon,
   Allergan, Bayer AG, Division Pharma, Genentech, Kanghong, Neurotech,
   Novartis, Ohr, Ophthotech and Regeneron. D.B. is a consultant for Alcon,
   Allergan, Bayer AG, Division Pharma, Genentech, Neurotech, Novartis, Ohr
   and Roche. T.S., R.S., O.Z., G.D., J.H., U.B., A.R., T.Z., W.S., B.S.
   and M.K.B. were employees of Bayer AG, Division Pharma at the time the
   study was performed and hold shares in Bayer. Editorial assistance for a
   previous version of the manuscript was provided by PAREXEL, and funded
   by Bayer AG, Pharmaceuticals. All studies were funded by Bayer AG,
   Division Pharma, Leverkusen, Germany. The sponsor participated in the
   study design and conduct, data collection, data management, data
   analysis, data interpretation, and preparation, review and approval of
   the manuscript.
CR Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS225, DOI 10.1111/bph.13876
   ARAIE M, 1982, JPN J OPHTHALMOL, V26, P248
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Boettger MK, 2015, ARVO 2015 ANN M 3 7
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   CHANG SC, 1987, INVEST OPHTH VIS SCI, V28, P487
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho QT, 2007, INT J BIOCHEM CELL B, V39, P1349, DOI 10.1016/j.biocel.2007.04.010
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Klar J, 2015, ARVO 2015 ANN M 3 7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Miller JW, 1997, AM J PATHOL, V151, P13
   Mross K, 2012, CLIN CANCER RES, V18, P2658, DOI 10.1158/1078-0432.CCR-11-1900
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121
   Sakanaka K, 2008, BIOL PHARM BULL, V31, P970, DOI 10.1248/bpb.31.970
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmitt W, 2008, TOXICOL IN VITRO, V22, P457, DOI 10.1016/j.tiv.2007.09.010
   Thiele S, 2013, KLIN MONATSBL AUGENH, V230, P247, DOI 10.1055/s-0032-1328161
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Witmer AN, 2002, INVEST OPHTH VIS SCI, V43, P849
   Zimmermann T, 2018, BRIT J CLIN PHARMACO, V84, P865, DOI 10.1111/bcp.13502
NR 34
TC 19
Z9 19
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD FEB
PY 2019
VL 85
IS 2
BP 347
EP 355
DI 10.1111/bcp.13794
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HI1BK
UT WOS:000456178500004
PM 30341774
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ren, XT
   Gu, H
   Han, X
   Zhang, JY
   Li, X
   Yang, XF
   Xu, J
   Snellingen, T
   Liu, XP
   Wang, NL
   Liu, NP
AF Ren, Xue-Tao
   Gu, Hong
   Han, Xu
   Zhang, Jun-Yan
   Li, Xue
   Yang, Xiu-Fen
   Xu, Jun
   Snellingen, Torkel
   Liu, Xi-Pu
   Wang, Ning-Li
   Liu, Ning-Pu
TI Measurement of macular pigment optical density among healthy Chinese
   people and patients with early-stage age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; diets; foveal architecture; macular
   pigment optical density
ID EYE DISEASE; LUTEIN; ZEAXANTHIN; CAROTENOIDS; MACULOPATHY; POPULATION;
   ANCILLARY; ASSOCIATION; PREVALENCE; THICKNESS
AB AIM: To measure the macular pigment optical density (MPOD) in healthy Chinese people and patients with early age-related macular degeneration (AMD).
   METHODS: Cross -sectional population based study. Demographic and lifestyle characteristics were ascertained by questionnaire. A food frequency questionnaire was completed for all participants. Participants underwent general physical and ophthalmic examinations and MPOD was measured by heterochromatic flicker photometry. Foveal architecture was measured by optical coherence tomography.
   RESULTS: MPOD of 225 participants (122 healthy and 103 early AMD) was 0.48 +/- 0.18. Patients with early AMD (0.52 +/- 0.19) tended to have higher MPOD levels than healthy people (0.47 +/- 0.17), but the difference was not statistically significant (P=0.06). Participants with carrot or corn oil intake every week tended to have higher levels of MPOD (P=0.002 and 0.008 respectively) while those with corn intake had relatively lower level of MPOD (P=0.01). MPOD increased with the center foveal thickness (P=0.01).
   CONCLUSION: Our findings show that there is no statistically significant association between MPOD and early AMD in the studied population. MPOD is related to center foveal thickness and diets would influence MPOD levels.
C1 [Ren, Xue-Tao; Gu, Hong; Han, Xu; Zhang, Jun-Yan; Li, Xue; Yang, Xiu-Fen; Xu, Jun; Wang, Ning-Li; Liu, Ning-Pu] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China.
   [Snellingen, Torkel] Sekwa Eye Hosp, Beijing 100088, Peoples R China.
   [Liu, Xi-Pu] Tsinghua Univ, Hosp 1, Dept Ophthalmol, Beijing 100016, Peoples R China.
C3 Capital Medical University; Tsinghua University
RP Liu, NP (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM nliu001@gmail.com
FU National Natural Science Foundation of China [81070734]; National Key
   Basic Research Program of China (973 Program) [2007CB512201]
FX Supported by the National Natural Science Foundation of China (No.
   81070734); National Key Basic Research Program of China (973 Program,
   No. 2007CB512201).
CR Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Gupta A, 2012, EYE, V26, P260, DOI 10.1038/eye.2011.328
   Gupta OP, 2007, CURR OPIN OPHTHALMOL, V18, P201, DOI 10.1097/ICU.0b013e32810c8df4
   Hammond CJ, 2012, INVEST OPHTH VIS SCI, V53, P4963, DOI 10.1167/iovs.12-9618
   Iannaccone A, 2007, INVEST OPHTH VIS SCI, V48, P1458, DOI 10.1167/iovs.06-0438
   Koushan K, 2013, NUTRIENTS, V5, P1823, DOI 10.3390/nu5051823
   Lam RF, 2005, CURR EYE RES, V30, P799, DOI 10.1080/02713680590968439
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liew SHM, 2006, EXP EYE RES, V82, P915, DOI 10.1016/j.exer.2005.10.014
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Moeller SM, 2009, J NUTR, V139, P1692, DOI 10.3945/jn.109.107748
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   O'Connell E, 2006, ANN ACAD MED SINGAP, V35, P821
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Raman R, 2012, EYE, V26, P950, DOI 10.1038/eye.2012.69
   Raman R, 2011, INVEST OPHTH VIS SCI, V52, P7910, DOI 10.1167/iovs.11-7636
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Sandberg MA, 2010, INVEST OPHTH VIS SCI, V51, P1086, DOI 10.1167/iovs.09-3396
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   Tang CY, 2004, OPHTHAL PHYSL OPT, V24, P586, DOI 10.1111/j.1475-1313.2004.00242.x
   Wisniewska A, 2003, CELL MOL BIOL LETT, V8, P147
   Wolf-Schnurrbusch UEK, 2007, INVEST OPHTH VIS SCI, V48, P3783, DOI 10.1167/iovs.06-1218
   Yu J, 2012, INVEST OPHTH VIS SCI, V53, P2106, DOI 10.1167/iovs.11-8518
   Zheng WJ, 2013, CURR EYE RES, V38, P168, DOI 10.3109/02713683.2012.713150
NR 36
TC 3
Z9 3
U1 0
U2 12
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD DEC 18
PY 2015
VL 8
IS 6
BP 1190
EP 1195
DI 10.3980/j.issn.2222-3959.2015.06.20
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CW1DQ
UT WOS:000364730200020
PM 26682171
DA 2022-11-30
ER

PT J
AU Fang, K
   Gao, P
   Tian, J
   Qin, XY
   Yu, WZ
   Li, J
   Chen, Q
   Huang, LZ
   Chen, DF
   Hu, YH
   Li, XX
AF Fang, Kai
   Gao, Pei
   Tian, Jun
   Qin, Xueying
   Yu, Wenzhen
   Li, Juan
   Chen, Qing
   Huang, Lvzhen
   Chen, Dafang
   Hu, Yonghua
   Li, Xiaoxin
TI Joint Effect of CFH and ARMS2/HTRA1 Polymorphisms on Neovascular
   Age-Related Macular Degeneration in Chinese Population
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; VISUAL IMPAIRMENT; RISK ALLELES; ASSOCIATION;
   LOC387715; SMOKING; GENES; SUSCEPTIBILITY; PREVALENCE; BLINDNESS
AB Purpose. The etiology of neovascular age-related macular degeneration (nAMD) cannot be completely explained by identified environmental risk factors or single-locus gene variants. This study was to explore the potential interactions among gene variants on nAMD in Chinese population. Methods. 43 SNPs located in different genes were genotyped in 932 Chinese individuals (464 nAMD patients and 468 controls). We explored the potential interactions among gene variants using generalized multifactor dimensionality reduction (GMDR) algorithm and the method to measure the departure from the additivity model. Results. The joint effect that involved CFH rs1061170 and HTRA1 rs3793917 was shown statistically significant (P < 0.001) with the highest cross-validation consistency (10/10) and the best testing balanced accuracy (64.50%). In addition, based on the method to measure the departure from the additivity model, the synergy index (S) was 2.63 (1.09-6.38) and the attributable proportion due to interaction (AP) was 55.7% (21.4%-89.9%), which suggested that a common pathway may exist for these genes for nAMD. Those who carried CC for rs3793917 and TC/CC for rs1061170 were at the highest risk of nAMD (OR: 9.76, 95% CI: 4.65-20.51). Conclusions. Evidence that the joint effect that involved CFH and ARMS2/HTRA1 may contribute to the risk of neovascular AMD in Chinese population was obtained.
C1 [Fang, Kai; Gao, Pei; Tian, Jun; Qin, Xueying; Chen, Dafang; Hu, Yonghua] Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China.
   [Yu, Wenzhen; Huang, Lvzhen; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Yu, Wenzhen; Huang, Lvzhen; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing 100044, Peoples R China.
   [Li, Juan] Beijing Ctr Dis Control & Prevent, Beijing 100013, Peoples R China.
   [Chen, Qing] Third Mil Med Univ, Dept Hyg Toxicol, Prevent Med Coll, Chongqing 400038, Peoples R China.
C3 Peking University; Peking University; Army Medical University
RP Hu, YH (通讯作者)，Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China.
EM yhhu@bjmu.edu.cn; dr_lixiaoxin@163.com
RI 陈, 卿/Q-5601-2019
OI 陈, 卿/0000-0003-4108-7977; Qin, Xueying/0000-0003-3271-8618
FU Ministry of Science and Technology of the People's Republic of China,
   Beijing, China [2006BAI02B05]
FX The authors would like to acknowledge the participants in this study and
   the experts in the 16 clinical centers for their support in recruiting
   participants. This study is supported by the National Key Technology
   Research and Development Program in the 11th Five-Year Plan from The
   Ministry of Science and Technology of the People's Republic of China,
   Beijing, China (2006BAI02B05).
CR Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Greene CS, 2009, BIODATA MIN, V2, DOI 10.1186/1756-0381-2-5
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Huang Xiao-bo, 2009, Zhonghua Yan Ke Za Zhi, V45, P786
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lee SJ, 2010, CLIN EXP OPHTHALMOL, V38, P698, DOI 10.1111/j.1442-9071.2010.02316.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Lou XY, 2007, AM J HUM GENET, V80, P1125, DOI 10.1086/518312
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rothman K, 2002, EPIDEMIOLOGY INTRO
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seitsonen S, 2006, MOL VIS, V12, P796
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088324
   Wu LC, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-10
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yang ZF, 2010, PROCEDIA ENVIRON SCI, V2, P1, DOI 10.1016/j.proenv.2010.10.001
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 48
TC 7
Z9 7
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 821918
DI 10.1155/2015/821918
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CF2PP
UT WOS:000352389800001
PM 25883802
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Rencova, E
   Blaha, M
   Studnicka, J
   Blaha, V
   Lanska, M
   Renc, O
   Stepanov, A
   Kratochvilova, V
   Langrova, H
AF Rencova, Eva
   Blaha, Milan
   Studnicka, Jan
   Blaha, Vladimir
   Lanska, Miriam
   Renc, Ondrej
   Stepanov, Alexander
   Kratochvilova, Vera
   Langrova, Hana
TI Preservation of the Photoreceptor Inner/Outer Segment Junction in Dry
   Age-Related Macular Degeneration Treated by Rheohemapheresis
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE IMAGES; VISUAL RECOVERY; RHEOPHERESIS; GUIDELINES;
   FORM; DETACHMENT; EFFICACY; FEATURES; THERAPY; LINE
AB Aim. To evaluate the long-term effect of rheohemapheresis (RHF) treatment of age-related macular degeneration (AMD) on photoreceptor IS/OS junction status. Methods. In our study, we followed 24 patients with dry AMD and drusenoid retinal pigment epithelium detachment (DPED) for a period of more than 2.5 years. Twelve patients (22 eyes) were treated by RHF and 12 controls (18 eyes) were randomized. The treated group underwent 8 RHF standardized procedures. We evaluated best-corrected visual acuity, IS/OS junction status (SD OCT), and macular function (multifocal electroretinography) at baseline and at 2.5-year follow-up. Results. RHF caused a decrease of whole-blood viscosity/plasma viscosity at about 15/12%. BCVA of treated patients increased insignificantly (P = 0.187) from median 74.0 letters (56.2 to 81.3 letters) to median 79.0 letters (57.3 to 83.4 letters), but it decreased significantly from 74.0 letters (25.2 to 82.6 letters) to 72.5 letters (23.4 to 83.1 letters) in the control group (P = 0.041). The mfERG responses in the region of eccentricity between 1.8 degrees and 7 degrees were significantly higher in treated patients (P = 0.04). Conclusions. RHF contributed to sparing of photoreceptor IS/OS junction integrity in the fovea, which is assumed to be a predictive factor for preservation of visual acuity.
C1 [Rencova, Eva; Studnicka, Jan; Stepanov, Alexander; Kratochvilova, Vera; Langrova, Hana] Fak Nemocnice, Lekarska Fak, Dept Ophthalmol, Hradec Kralove 50009, Czech Republic.
   [Blaha, Milan; Lanska, Miriam] Fak Nemocnice, Lekarska Fak, Dept Internal Med Hematol 4, Hradec Kralove 50009, Czech Republic.
   [Blaha, Vladimir] Fak Nemocnice, Dept Gerontol & Metab Care, Lekarsk Fak, Hradec Kralove 50009, Czech Republic.
   [Renc, Ondrej] Fak Nemocnice, Lekarska Fak, Dept Radiol, Hradec Kralove 50009, Czech Republic.
C3 Charles University Prague; Charles University Prague; Charles University
   Prague
RP Blaha, M (通讯作者)，Fak Nemocnice, Lekarska Fak, Dept Internal Med Hematol 4, Sokolska 581, Hradec Kralove 50009, Czech Republic.
EM blaham@email.cz
RI Stepanov, Alexandr/N-9961-2017; Studnička, Jan/AAC-4127-2022; Renc,
   Ondrej/N-2574-2017; Studnicka, Jan/K-2875-2017; Blaha,
   Vladimir/C-1151-2016; Blaha, Milan/H-8955-2016
OI Stepanov, Alexandr/0000-0002-8462-8756; Renc,
   Ondrej/0000-0002-2123-2447; Studnicka, Jan/0000-0002-9911-4379; Blaha,
   Vladimir/0000-0001-8088-9919; Blaha, Milan/0000-0003-2330-5838;
   Langrova, Hana/0000-0001-8488-7208
FU Ministry of Health, Czech Republic [NT14037-3/2013]
FX This research was supported by the grant of the Ministry of Health,
   Czech Republic, no. NT14037-3/2013.
CR Aizawa S, 2010, CLIN EXP OPHTHALMOL, V38, P597, DOI 10.1111/j.1442-9071.2010.02321.x
   Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baba T, 2008, RETINA-J RET VIT DIS, V28, P453, DOI 10.1097/IAE.0b013e3181571398
   Blaha M, 2013, ATHEROSCLEROSIS SUPP, V14, P179, DOI 10.1016/j.atherosclerosissup.2012.10.023
   Blaha M, 2012, CLIN HEMORHEOL MICRO, V50, P245, DOI 10.3233/CH-2011-1431
   Blaha M, 2009, THER APHER DIAL, V13, P453, DOI 10.1111/j.1744-9987.2009.00752.x
   Borberg H, 2009, TRANSFUS APHER SCI, V41, P49, DOI 10.1016/j.transci.2009.05.013
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Friberg TR, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.02.048
   Fujimoto JG., 2004, OPTICAL COHERENCE TO, V2nd
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   Iannetti L, 2012, OPHTHALMOLOGICA, V228, P13, DOI 10.1159/000337234
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Klingel R, 2010, THER APHER DIAL, V14, P276, DOI 10.1111/j.1744-9987.2010.00807.x
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Kousal B, 2014, Cesk Slov Oftalmol, V70, P228
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   Mitamura Y, 2009, BRIT J OPHTHALMOL, V93, P171, DOI 10.1136/bjo.2008.146381
   Pulido J, 2005, J CLIN APHERESIS, V20, P185, DOI 10.1002/jca.20047
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Rencova E, 2012, Cesk Slov Oftalmol, V68, P84
   Rencova E, 2011, ACTA OPHTHALMOL, V89, P463, DOI 10.1111/j.1755-3768.2009.01710.x
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Schwartz J, 2013, J CLIN APHERESIS, V28, P145, DOI 10.1002/jca.21276
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
   Studnicka J, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/135798
NR 28
TC 6
Z9 6
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 359747
DI 10.1155/2015/359747
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ2XQ
UT WOS:000360466200001
PM 26351571
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Moon, SW
   Oh, J
   Yu, HG
   Cho, HY
   Song, SJ
AF Moon, Sang Woong
   Oh, Jaeryung
   Yu, Hyeong Gon
   Cho, Hee Yoon
   Song, Su Jeong
TI Incidence and Risk Factors for Macular Hemorrhage Following Intravitreal
   Ranibizumab Injection for Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID THERAPY; COMPLICATIONS; EFFICACY; SAFETY
AB Purpose: To analyze the incidence of and risk factors for newly developed or increased macular hemorrhage after intravitreal ranibizumab injection (IVR) for neovascular age-related macular degeneration (AMD).
   Methods: We performed a retrospective chart review of 220 subjects (220 eyes) from 5 hospitals who received IVRs for neovascular AMD between 1 June 2009 and 30 June 2010. Systemic conditions (age, sex, presence of diabetes, hypertension, cardiovascular disease, smoking, and use of anticoagulation agent) and presence of hemorrhage at the initial exam were evaluated. The primary study outcome was the incidence of newly developed or increased macular hemorrhage during the 1-month postinjection period.
   Results: The incidence of newly developed or increased macular hemorrhage including vitreous hemorrhage was 8% (18/220). Presence of diabetes was found to be a risk factor for macular hemorrhage [odds ratios (OR): 2.16, 95% confidence intervals (CI): 1.07-8.13]. When subjects had both diabetes and hypertension, the risk of macular hemorrhage after injection increased 4.8-fold (OR: 4.84, CI: 1.24-18.85).
   Conclusion: The systemic condition of subjects was found to be an important risk factor for newly developed or increased macular hemorrhage after IVR for neovascular AMD. More consideration should be given to the status of diabetes and hypertension in subjects who receive ranibizumab for neovascular AMD.
C1 [Moon, Sang Woong] Kyung Hee Univ, Sch Med, Dept Ophthalmol, Seoul, South Korea.
   [Oh, Jaeryung] Korea Univ, Coll Med, Dept Ophthalmol, Seoul 136705, South Korea.
   [Yu, Hyeong Gon] Hanyang Univ, Coll Med, Dept Ophthalmol, Seoul 133791, South Korea.
   [Cho, Hee Yoon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Song, Su Jeong] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Ophthalmol, Seoul 110746, South Korea.
C3 Kyung Hee University; Korea University; Korea University Medicine (KU
   Medicine); Hanyang University; Seoul National University (SNU);
   Sungkyunkwan University (SKKU); Samsung Medical Center
RP Song, SJ (通讯作者)，Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Ophthalmol, Seoul 110746, South Korea.
EM ssjeye@yahoo.co.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562
FU Novartis Korea, Seoul, Korea [R1005961]
FX This study was supported by funding (R1005961) from Novartis Korea,
   Seoul, Korea.
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Levine JP, 2009, RETINA-J RET VIT DIS, V29, P1074, DOI 10.1097/IAE.0b013e3181b09443
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Mason JO, 2010, RETINA-J RET VIT DIS, V30, P1386, DOI 10.1097/IAE.0b013e3181e09739
   O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Pezzini A, 2011, J NEUROL, V258, P634, DOI 10.1007/s00415-010-5813-z
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
NR 18
TC 10
Z9 10
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUL-AUG
PY 2013
VL 29
IS 6
BP 556
EP 559
DI 10.1089/jop.2012.0148
PG 4
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 180SJ
UT WOS:000321616400008
PM 23480269
DA 2022-11-30
ER

PT J
AU Ennis, S
   Goverdhan, S
   Cree, A
   Hoh, J
   Collins, A
   Lotery, A
AF Ennis, Sarah
   Goverdhan, Srini
   Cree, Angela
   Hoh, Josephine
   Collins, Andrew
   Lotery, Andrew
TI Fine-scale linkage disequilibrium mapping of age-related macular
   degeneration in the complement factor H gene region
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID STRONG ASSOCIATION; POLYMORPHISM; VARIANT; SUSCEPTIBILITY; GENOME; DNA
AB Aim: To present results from a nested association study of the complement factor H ( CFH) gene region using a novel methodology that uses a high- resolution genetic linkage disequilibrium map to estimate a point location for a causal mutation.
   Method: Age- related macular degeneration ( AMD) case - control data from a genomewide single- nucleotide polymorphism ( SNP) panel were used to identify the target interval to be genotyped at higher density in a second independent panel. The pattern of linkage disequilibrium ( LD) and segmental duplications across this region are described in detail.
   Result: Data were consistent with other studies in that strong association between the Y402H variant and AMD is observed. However, composite likelihood analysis, which combines association data from all SNPs in the region, and uses genetic locations on a high- resolution LD map, gave a point location for a causal variant between exons 1 and 2 of the CFH gene.
   Conclusion: The findings are consistent with evidence that, in addition to the widely described Y402H variant, there is at least one and, most probably, several other mutations in the CFH gene which determine disease manifestation in AMD. A genetic model in which multiple mutations contribute to a varying degree to disease aetiology has been previously well described in ophthalmic genetics, and is typified by the COL2A1 and ABCA4 genes.
C1 Southampton Gen Hosp, Clin Neurosci Div, Southampton SO16 6YD, Hants, England.
   Southampton Gen Hosp, Div Human Genet, Genet Epidemiol & Bioinformat Grp, Southampton SO16 6YD, Hants, England.
   Southampton Gen Hosp, Southampton Eye Unit, Southampton SO16 6YD, Hants, England.
   Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA.
C3 University of Southampton; University of Southampton; University of
   Southampton; Yale University
RP Lotery, A (通讯作者)，Southampton Gen Hosp, Clin Neurosci Div, Mailpoint 806, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
RI Collins, Andrew/S-2196-2019; Collins, Andrew/A-6595-2010
OI Collins, Andrew/0000-0001-7108-0771; Collins,
   Andrew/0000-0001-7108-0771; Lotery, Andrew/0000-0001-5541-4305; Cree,
   Angela/0000-0002-1987-8900
FU Wellcome Trust [076169] Funding Source: Medline
CR Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Bell PA, 2002, BIOTECHNIQUES, P70
   Chen LJ, 2006, MOL VIS, V12, P1536
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maniatis N, 2005, HUM MOL GENET, V14, P145, DOI 10.1093/hmg/ddi019
   Maniatis N, 2004, AM J HUM GENET, V74, P846, DOI 10.1086/383589
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Morris AP, 2003, P NATL ACAD SCI USA, V100, P13442, DOI 10.1073/pnas.2235031100
   Morton N, 2007, AM J HUM GENET, V80, P19, DOI 10.1086/510401
   Neumann R, 2006, HUM MOL GENET, V15, P1401, DOI 10.1093/hmg/ddl063
   REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4
   She XW, 2004, NATURE, V431, P927, DOI 10.1038/nature03062
   SIMON M, 1976, DIABETES METAB, V2, P149
   Snead MP, 1999, J MED GENET, V36, P353
   Tapper W, 2005, P NATL ACAD SCI USA, V102, P11835, DOI 10.1073/pnas.0505262102
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6
NR 28
TC 13
Z9 14
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2007
VL 91
IS 7
BP 966
EP 970
DI 10.1136/bjo.2007.114090
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 180FK
UT WOS:000247347700032
PM 17314151
OA Green Published
DA 2022-11-30
ER

PT J
AU Dasari, B
   Prasanthi, JRP
   Marwarha, G
   Singh, BB
   Ghribi, O
AF Dasari, Bhanu
   Prasanthi, Jaya R. P.
   Marwarha, Gurdeep
   Singh, Brij B.
   Ghribi, Othman
TI Cholesterol-enriched diet causes age-related macular degeneration-like
   pathology in rabbit retina
SO BMC OPHTHALMOLOGY
LA English
DT Article
ID INSULIN-DEGRADING ENZYME; ENDOPLASMIC-RETICULUM STRESS; FIBRILLARY
   ACIDIC PROTEIN; PHOTORECEPTOR CELL-DEATH; ALZHEIMERS-DISEASE; PIGMENT
   EPITHELIUM; HEME OXYGENASE-1; BASAL DEPOSITS; AMYLOID-BETA; MULLER CELL
AB Background: Alzheimer's disease (AD) and age-related macular degeneration (AMD) share several pathological hallmarks including beta amyloid (A beta) accumulation, oxidative stress, and apoptotic cell death. The causes of AD and AMD are likely multi-factorial with several factors such as diet, environment, and genetic susceptibility participating in the pathogenesis of these diseases. Epidemiological studies correlated high plasma cholesterol levels with high incidence of AD, and feeding rabbits with a diet rich in cholesterol has been shown to induce AD-like pathology in rabbit brain. High intake of cholesterol and saturated fat were also long been suspected to increase the risk for AMD. However, the extent to which cholesterol-enriched diet may also cause AMD-like features in rabbit retinas is not well known.
   Methods: Male New Zealand white rabbits were fed normal chow or a 2% cholesterol-enriched diet for 12 weeks. At necropsy, animals were perfused with Dulbecco's phosphate-buffered saline and the eyes were promptly removed. One eye of each animal was used for immunohistochemistry and retina dissected from the other eye was used for Western blot, ELISA assays, spectrophotometry and mass spectrometry analyses.
   Results: Increased levels of A beta, decreased levels of the anti-apoptotic protein Bcl-2, increased levels of the proapoptotic Bax and gadd153 proteins, emergence of TUNEL-positive cells, and increased generation of reactive oxygen species were found in retinas from cholesterol-fed compared to normal chow-fed rabbits. Additionally, astrogliosis, drusen-like debris and cholesterol accumulations in retinas from cholesterol-fed rabbits were observed. As several lines of evidence suggest that oxidized cholesterol metabolites (oxysterols) may be the link by which cholesterol contributes to the pathogenesis of AMD, we determined levels of oxysterols and found a dramatic increase in levels of oxysterols in retinas from cholesterol-fed rabbits.
   Conclusions: Our results suggest that cholesterol-enriched diets cause retinal degeneration that is relevant to AMD. Furthermore, our data suggests high cholesterol levels and subsequent increase in the cholesterol metabolites as potential culprits to AMD.
C1 [Dasari, Bhanu; Prasanthi, Jaya R. P.; Marwarha, Gurdeep; Ghribi, Othman] Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA.
   [Singh, Brij B.] Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58202 USA.
C3 University of North Dakota Grand Forks; University of North Dakota Grand
   Forks
RP Ghribi, O (通讯作者)，Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA.
EM othman.ghribi@med.und.edu
OI Singh, Brij/0000-0003-0535-5997; MARWARHA, GURDEEP/0000-0001-5556-0003
FU NIEHS/NIH [R01ES014826]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL
   RESEARCH [R01DE017102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF ENVIRONMENTAL HEALTH SCIENCES [R01ES014826] Funding Source: NIH
   RePORTER
FX Supported by a grant from NIEHS/NIH to OG (R01ES014826). The authors
   thank Dr. David Russell (University of Texas South Western Medical
   Center) for measurements of oxysterols with mass spectrometry. The
   authors also thank Dr. Byron Grove and Sarah Rolling (Department of
   Anatomy and Cell Biology, School of Medicine & Health Sciences,
   University of North Dakota) for their technical assistance in confocal
   microscopy.
CR Abler AS, 1996, RES COMMUN MOL PATH, V92, P177
   Age related eye disease study research group, 2001, ARCH OPHTHALMOL, V119, P1439
   Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7
   Berisha F, 2007, INVEST OPHTH VIS SCI, V48, P2285, DOI 10.1167/iovs.06-1029
   Dorfman VB, 2010, NEUROBIOL AGING, V31, P1743, DOI 10.1016/j.neurobiolaging.2008.09.016
   BIGNAMI A, 1979, EXP EYE RES, V28, P63
   Bjorkhem I, 2009, MOL ASPECTS MED, V30, P171, DOI 10.1016/j.mam.2009.02.001
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Butterfield DA, 2002, J ALZHEIMERS DIS, V4, P193, DOI 10.3233/JAD-2002-4309
   Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013
   Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cook DG, 2003, AM J PATHOL, V162, P313, DOI 10.1016/S0002-9440(10)63822-9
   Cordeiro MF, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.3
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
   Deng GM, 1999, EXP NEUROL, V159, P309, DOI 10.1006/exnr.1999.7145
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Dyer MA, 2000, NAT NEUROSCI, V3, P873, DOI 10.1038/78774
   EISENFELD AJ, 1984, INVEST OPHTH VIS SCI, V25, P1321
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Frank R N, 1998, Trans Am Ophthalmol Soc, V96, P635
   GHRIBI O, 2009, ALZHEIMERS DEMENT, V5, P180
   Ghribi O, 2006, EXP NEUROL, V200, P460, DOI 10.1016/j.expneurol.2006.03.019
   Ghribi O, 2006, J NEUROCHEM, V99, P438, DOI 10.1111/j.1471-4159.2006.04079.x
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Guo L, 2010, CURR ALZHEIMER RES, V7, P3, DOI 10.2174/156720510790274491
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Javitt NB, 2007, CURR OPIN LIPIDOL, V18, P283, DOI 10.1097/MOL.0b013e328133851e
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS
   Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014
   MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   McDonald JG, 2007, METHOD ENZYMOL, V432, P145, DOI 10.1016/S0076-6879(07)32006-5
   Miners JS, 2009, J NEUROPATH EXP NEUR, V68, P902, DOI 10.1097/NEN.0b013e3181afe475
   Mizutani M, 1998, DIABETES, V47, P445, DOI 10.2337/diabetes.47.3.445
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0
   Nishiyama T, 2000, TOHOKU J EXP MED, V191, P221, DOI 10.1620/tjem.191.221
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   OKADA M, 1990, GRAEF ARCH CLIN EXP, V228, P467, DOI 10.1007/BF00927264
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160
   PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974
   Prasanthi JRP, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-1
   Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3
   QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   SADUN AA, 1987, AM J OPHTHALMOL, V104, P113, DOI 10.1016/0002-9394(87)90001-8
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Schipper HM, 2006, NEUROBIOL AGING, V27, P252, DOI 10.1016/j.neurobiolaging.2005.01.016
   SCHIPPER HM, 1995, ANN NEUROL, V37, P758, DOI 10.1002/ana.410370609
   SMITH MA, 1994, AM J PATHOL, V145, P42
   Solomon A, 2009, DEMENT GERIATR COGN, V28, P75, DOI 10.1159/000231980
   TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748
   Trivino A, 2006, EXP EYE RES, V83, P357, DOI 10.1016/j.exer.2005.12.020
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Vejux A, 2008, BRAZ J MED BIOL RES, V41, P545, DOI 10.1590/S0100-879X2008000700001
   Vepsalainen S, 2008, NEUROSCI LETT, V438, P216, DOI 10.1016/j.neulet.2008.04.025
   Wang X, 2000, EXP BRAIN RES, V132, P476, DOI 10.1007/s002210000360
   Wellington CL, 2004, CLIN GENET, V66, P1, DOI 10.1111/j.0009-9163.2004.00280.x
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
NR 85
TC 52
Z9 52
U1 1
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 18
PY 2011
VL 11
AR 22
DI 10.1186/1471-2415-11-22
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 818PV
UT WOS:000294767200001
PM 21851605
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Waldstein, SM
   Vogl, WD
   Bogunovic, H
   Sadeghipour, A
   Riedl, S
   Schmidt-Erfurth, U
AF Waldstein, Sebastian M.
   Vogl, Wolf-Dieter
   Bogunovic, Hrvoje
   Sadeghipour, Amir
   Riedl, Sophie
   Schmidt-Erfurth, Ursula
TI Characterization of Drusen and Hyperreflective Foci as Biomarkers for
   Disease Progression in Age-Related Macular Degeneration Using Artificial
   Intelligence in Optical Coherence Tomography
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; NEOVASCULARIZATION; ATROPHY; LAYER
AB IMPORTANCE The morphologic changes and their pathognomonic distribution in progressing age-related macular degeneration (AMD) are not well understood.
   OBJECTIVES To characterize the pathognomonic distribution and time course of morphologic patterns in AMD and to quantify changes distinctive for progression to macular neovascularization (MNV) and macular atrophy (MA).
   DESIGN, SETTING, AND PARTICIPANTS This cohort study included optical coherence tomography (OCT) volumes from study participants with early or intermediate AMD in the fellow eye in the HARBOR (A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration) trial. Patients underwent imaging monthly for 2 years (July 1, 2009, to August 31, 2012) following a standardized protocol. Data analysis was performed from June 1, 2018, to January 21, 2020.
   MAIN OUTCOMES AND MEASURES To obtain topographic correspondence between patients and over time, all scans were mapped into a joint reference frame. The time of progression to MNV and MA was established, and drusen volumes and hyperreflective foci (HRF) volumes were automatically segmented in 3 dimensions using validated artificial intelligence algorithms. Topographically resolved population means of these markers were constructed by averaging quantified drusen and HRF maps in the patient subgroups.
   RESULTS Of 1097 patients enrolled in HARBOR, 518 (mean [SD] age, 78.1 [8.2] years; 309 [59.7%] female) had early or intermediate AMD in the fellow eye at baseline. During the 24-month follow-up period, 135 (26%) eyes developed MNV, 50 eyes (10%) developed MA, and 333 (64%) eyes did not progress to advanced AMD. Drusen and HRF had distinct topographic patterns. Mean drusen thickness at the fovea was 29.6 mu m (95% CI, 20.2-39.0 mu m) for eyes progressing to MNV, 17.2 mu m (95% CI, 9.8-24.6 mu m) for eyes progressing to MA, and 17.1 mu m (95% CI, 12.5-21.7 mu m) for eyes without disease progression. At 0.5-mm eccentricity, mean drusen thickness was 25.8 mu m (95% CI, 19.1-32.5 mu m) for eyes progressing to MNV, 21.7 mu m (95% CI, 14.6-28.8 mu m) for eyes progressing to MA, and 14.4 mu m (95% CI, 11.2-17.6 mu m) for eyes without disease progression. The mean HRF thickness at the foveal center was 0.072 mu m (95% CI, 0-0.152 mu m) for eyes progressing to MNV, 0.059 mu m (95% CI, 0-0.126 mu m) for eyes progressing to MA, and 0.044 mu m (95% CI, 0.007-0.081) for eyes without disease progression. At 0.5-mm eccentricity, the largest mean HRF thickness was seen in eyes progressing to MA (0.227 mu m; 95% CI, 0.104-0.349 mu m) followed by eyes progressing to MNV (0.161 mu m; 95% CI, 0.101-0.221 mu m) and eyes without disease progression (0.085 mu m; 95% CI, 0.058-0.112 mu m).
   CONCLUSIONS AND RELEVANCE In this study, drusen and HRF represented imaging biomarkers of disease progression in AMD, demonstrating distinct topographic patterns over time that differed between eyes progressing to MNV, eyes progressing to MA, or eyes without disease progression. Automated localization and precise quantification of these factors may help to develop reliable methods of predicting future disease progression.
C1 [Waldstein, Sebastian M.; Vogl, Wolf-Dieter; Bogunovic, Hrvoje; Sadeghipour, Amir; Riedl, Sophie; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Christian Doppler Lab Ophthalm Image Anal, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Christian Doppler Lab Ophthalm Image Anal, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
FU Bayer; Christian Doppler Research Association; Austrian Federal Ministry
   for Digital and Economic Affairs; National Foundation for Research,
   Technology, and Development; Austrian Science Fund; Genentech
FX This study was in part supported by Bayer and Genentech by research
   grants (DrWaldstein) and by the Christian Doppler Research Association,
   the Austrian Federal Ministry for Digital and Economic Affairs, the
   National Foundation for Research, Technology, and Development, and the
   Austrian Science Fund (Dr Schmidt-Erfurth).
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Rizopoulos D, 2016, J STAT SOFTW, V72, P1, DOI 10.18637/jss.v072.i07
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schlegl T., 2018, ARXIV180503278
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041
   Vogl WD, 2017, IEEE T MED IMAGING, V36, P1773, DOI 10.1109/TMI.2017.2700213
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [DOI 10.1001/JAMA.2013.281053, 10.1001/jama.2013.281053]
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
NR 32
TC 43
Z9 44
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2020
VL 138
IS 7
BP 740
EP 747
DI 10.1001/jamaophthalmol.2020.1376
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MP3OT
UT WOS:000552116800004
PM 32379287
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kim, J
   Kwak, HW
   Lee, WK
   Kim, HK
AF Kim, Jinhyun
   Kwak, Hyung Woo
   Lee, Won Ki
   Kim, Ha Kyoung
TI Impact of photodynamic therapy on quality of life of patients with
   age-related macular degeneration in Korea
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; photodynamic therapy; quality of life;
   verteporfin; visual function
ID HEALTH-STATUS; MACULOPATHY
AB To assess quality of life (QOL) changes in patients with age-related macular degeneration (AMD) before and after treatment with photodynamic therapy (PDT).
   In 625 patients with AMD, the EuroQol Health Questionnaire (EQ-5D) for general health status and the Visual Function Questionnaire (VF-4D) for vision-related reading ability, independence, and fear for the future were used and the results compared between within 1 week before PDT and 1 year after PDT. Subscale QOL changes were also scored with the Korean versions of EQ-5D and VF-4D.
   EQ-5D scores of male patients were higher than those of female patients (P < 0.05), and scores of unilateral patients were higher than those of bilateral patients (P < 0.001). Among all patients, 41.2% had a higher EQ-5D score after PDT. The mean differences between before and after treatment, estimated by three different models, the Korean model, the UK model, and the Japanese model, were all statistically significant (P < 0.001). Utility measured by the VF-4D score after PDT increased by 16.1% (P < 0.001), and subscale utilities indicated significant improvements in fear for the future (21.1%), reading ability (16.6%-14.5%), and independence (11.6%).
   PDT for patients with AMD improved both general health-related QOL and vision-related QOL, as well as subscale scores, as evaluated by EQ-5D and VF-4D.
C1 [Kim, Ha Kyoung] Hallym Univ, Kangnam Sacred Heart Hosp, Dept Ophthalmol, Sch Med, Seoul 150950, South Korea.
   [Kim, Jinhyun] Seoul Natl Univ, Coll Nursing, Seoul, South Korea.
   [Kwak, Hyung Woo] Kyung Hee Univ, Kyung Hee Univ Hosp, Dept Ophthalmol, Sch Med, Seoul, South Korea.
   [Lee, Won Ki] Catholic Univ, Seoul St Marys Hosp, Sch Med, Dept Ophthalmol, Seoul, South Korea.
C3 Hallym University; Seoul National University (SNU); Kyung Hee
   University; Kyung Hee University Hospital; Catholic University of Korea;
   Seoul St. Mary's Hospital
RP Kim, HK (通讯作者)，Hallym Univ, Kangnam Sacred Heart Hosp, Dept Ophthalmol, Sch Med, 948-1 Daerim Dong, Seoul 150950, South Korea.
EM ophkim@hallym.or.kr
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bradley C, 2001, LANCET, V357, P7, DOI 10.1016/S0140-6736(00)03562-5
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   BUSH JW, 1984, ASSESSMENT QUALITY L
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Hewitt AW, 2006, GRAEF ARCH CLIN EXP, V244, P972, DOI 10.1007/s00417-005-0218-x
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   JOYCE CRB, 1994, QUALITY LIFE FOLLOWI, P43
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   KIM JH, 2007, 98 ANN C KOR RET SOC
   KIM JH, 2007, COST UTILITY ANAL RA
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kyo Tetsuhiro, 2007, Nippon Ganka Gakkai Zasshi, V111, P315
   Kyo Tetsuhiro, 2006, Nippon Ganka Gakkai Zasshi, V110, P710
   Laouar K, 2007, J FR OPHTALMOL, V30, P233, DOI 10.1016/S0181-5512(07)89583-0
   LEE DW, 2004, J KOREAN OPHTHALMOL, V45, P736
   Luke M, 2007, GRAEF ARCH CLIN EXP, V245, P1831, DOI 10.1007/s00417-007-0558-9
   MCGEE HM, 1991, PSYCHOL MED, V21, P749, DOI 10.1017/S0033291700022388
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Tano Y, 2008, JPN J OPHTHALMOL, V52, P99, DOI 10.1007/s10384-008-0512-3
   WHO, 2004, MAGN CAUS VIS IMP
   Yamashiro K, 2007, JPN J OPHTHALMOL, V51, P368, DOI 10.1007/s10384-007-0465-y
NR 31
TC 8
Z9 10
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2010
VL 54
IS 4
BP 325
EP 330
DI 10.1007/s10384-010-0825-x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 637IS
UT WOS:000280811400012
PM 20700801
DA 2022-11-30
ER

PT J
AU Van Hove, I
   Hu, TT
   Beets, K
   Van Bergen, T
   Etienne, I
   Stitt, AW
   Vermassen, E
   Feyen, JHM
AF Van Hove, Inge
   Hu, Tjing-Tjing
   Beets, Karen
   Van Bergen, Tine
   Etienne, Isabelle
   Stitt, Alan W.
   Vermassen, Elke
   Feyen, Jean H. M.
TI Targeting RGD-binding integrins as an integrative therapy for diabetic
   retinopathy and neovascular age-related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE RGD-binding integrin; Diabetic retinopathy; Neovascular age-related
   macular degeneration; Retina
ID ENDOTHELIAL GROWTH-FACTOR; ANGIOPOIETIN-LIKE PROTEIN-2; NF-KAPPA-B;
   FOCAL ADHESION KINASE; LATENT-TGF-BETA; SUPPRESSES CHOROIDAL
   NEOVASCULARIZATION; PATHOLOGICAL RETINAL ANGIOGENESIS;
   NECROSIS-FACTOR-ALPHA; ROD OUTER SEGMENTS; ACUTE LUNG INJURY
AB Integrins are a class of transmembrane receptors that are involved in a wide range of biological functions. Dysregulation of integrins has been implicated in many pathological processes and consequently, they are attractive therapeutic targets. In the ophthalmology arena, there is extensive evidence suggesting that integrins play an important role in diabetic retinopathy (DR), age-related macular degeneration (AMD), glaucoma, dry eye disease and retinal vein occlusion. For example, there is extensive evidence that arginyl-glycyl-aspartic acid (ArgGly-Asp; RGD)-binding integrins are involved in key disease hallmarks of DR and neovascular AMD (nvAMD), specifically inflammation, vascular leakage, angiogenesis and fibrosis. Based on such evidence, drugs that engage integrin-linked pathways have received attention for their potential to block all these vision-threatening pathways. This review focuses on the pathophysiological role that RGD-binding integrins can have in complex multifactorial retinal disorders like DR, diabetic macular edema (DME) and nvAMD, which are leading causes of blindness in developed countries. Special emphasis will be given on how RGD-binding integrins can modulate the intricate molecular pathways and regulate the underlying pathological mechanisms. For instance, the interplay between integrins and key molecular players such as growth factors, cytokines and enzymes will be summarized. In addition, recent clinical advances linked to targeting RGD-binding integrins in the context of DME and nvAMD will be discussed alongside future potential for limiting progression of these diseases.
C1 [Van Hove, Inge; Hu, Tjing-Tjing; Beets, Karen; Van Bergen, Tine; Etienne, Isabelle; Stitt, Alan W.; Vermassen, Elke; Feyen, Jean H. M.] Oxurion NV, Gaston Geenslaan 1, B-3001 Heverlee, Belgium.
   [Stitt, Alan W.] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland.
C3 Queens University Belfast
RP Stitt, AW (通讯作者)，Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, McCauley Chair Expt Ophthalmol, 97 Lisburn Rd, Belfast BT9 7AE, Antrim, North Ireland.
EM Inge.VanHove@oxurion.com; Tjing-Tjing.Hu@oxurion.com;
   Karen.Beets@oxurion.com; Tine.VanBergen@oxurion.com;
   Isabelle.Etienne@oxurion.com; a.stitt@qub.ac.uk;
   Elke.Vermassen@oxurion.com; Jean.Feyen@oxurion.com
OI , Elke/0000-0002-1217-8020; Van Hove, Inge/0000-0002-3125-0438; Stitt,
   Alan/0000-0002-8647-9918
CR Abdollahi A, 2005, CLIN CANCER RES, V11, P6270, DOI 10.1158/1078-0432.CCR-04-1223
   Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Aidoudi S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002657
   Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567
   Akwii RG, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050471
   ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109
   Alexander RA, 2012, CARDIOVASC RES, V94, P125, DOI 10.1093/cvr/cvs017
   Alghisi GC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004449
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   ANDERSON DH, 1990, INVEST OPHTH VIS SCI, V31, P81
   Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229
   [Anonymous], 2017, EYEWIRENEWS
   Antonov AS, 2011, J CELL PHYSIOL, V226, P469, DOI 10.1002/jcp.22356
   Aoi J, 2011, CANCER RES, V71, P7502, DOI 10.1158/0008-5472.CAN-11-1758
   AOTA S, 1994, J BIOL CHEM, V269, P24756
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Araya J, 2006, AM J PATHOL, V169, P405, DOI 10.2353/ajpath.2006.060049
   Arnold TD, 2012, J NEUROSCI, V32, P1197, DOI 10.1523/JNEUROSCI.5648-11.2012
   Asano Y, 2005, ARTHRITIS RHEUM-US, V52, P2897, DOI 10.1002/art.21246
   AsclepiX Therapeutics, ASCLEPIX THER PIP
   Askew BC, 2018, J PHARMACOL EXP THER, V366, P244, DOI 10.1124/jpet.118.248427
   AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907
   Avery R.L., 2020, RETIN PHYS
   Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353
   Azmy R, 2012, APPL CLIN GENET, V5, P55, DOI 10.2147/TACG.S31979
   Balcioglu HE, 2015, J CELL SCI, V128, P1316, DOI 10.1242/jcs.156950
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Banno A, 2008, BIOCHEM SOC T, V36, P229, DOI 10.1042/BST0360229
   Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153
   Basta J, 2020, PHYSIOL REP, V8, DOI 10.14814/phy2.14329
   Bax DV, 2004, J BIOL CHEM, V279, P22377, DOI 10.1074/jbc.M400180200
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Bedke J, 2007, AM J PATHOL, V171, P1127, DOI 10.2353/ajpath.2007.070329
   Bhatwadekar AD, 2020, EXPERT OPIN INV DRUG, V29, P935, DOI 10.1080/13543784.2020.1795639
   Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200
   Bian ZM, 2018, EXP EYE RES, V170, P29, DOI 10.1016/j.exer.2018.02.014
   Biernacka A, 2011, GROWTH FACTORS, V29, P196, DOI 10.3109/08977194.2011.595714
   Bifulco K, 2013, MOL CANCER THER, V12, P1981, DOI 10.1158/1535-7163.MCT-13-0077
   Biswas S, 2017, AM J PATHOL, V187, P2112, DOI 10.1016/j.ajpath.2017.05.016
   Bouvard D, 2013, NAT REV MOL CELL BIO, V14, P430, DOI 10.1038/nrm3599
   Boyer D., 2012, INTEGRIN PEPTIDE THE
   Brandt K, 2015, GROWTH HORM IGF RES, V25, P34, DOI 10.1016/j.ghir.2014.11.001
   BREM RB, 1994, INVEST OPHTH VIS SCI, V35, P3466
   Brezinschek RI, 1996, AM J PATHOL, V149, P1651
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6
   Cabrera AP, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010216
   Campochiaro PA, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100921
   Cao YA, 2014, INVEST OPHTH VIS SCI, V55, P7321, DOI 10.1167/iovs.14-15167
   Capone Jr A., 2009, INVEST OPHTH VIS SCI, V50, P1259
   Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200
   Cascone I, 2005, J CELL BIOL, V170, P993, DOI 10.1083/jcb.200507082
   Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140
   Cepeda-Nieto AC, 2015, EXP THER MED, V10, P435, DOI 10.3892/etm.2015.2520
   Chatterjee S, 2012, CELL ADHES MIGR, V6, P157, DOI 10.4161/cam.20252
   Chaurasia SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21198-z
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Chen BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/sj.bjp.0704334
   Chen NY, 2004, J BIOL CHEM, V279, P44166, DOI 10.1074/jbc.M406813200
   Cho CH, 2006, P NATL ACAD SCI USA, V103, P4946, DOI 10.1073/pnas.0506352103
   Christenheit A., 2016, GLOBAL J CANC THERAP, V2, DOI DOI 10.17352/XXXX-XXXX.000008
   CHU PG, 1991, INVEST OPHTH VIS SCI, V32, P1757
   Cohen K, 2014, ONCOTARGET, V5, P6312, DOI 10.18632/oncotarget.2205
   Conroy KP, 2016, CELL TISSUE RES, V365, P511, DOI 10.1007/s00441-016-2407-9
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Crisp JL, 2014, MOL CANCER THER, V13, P1514, DOI 10.1158/1535-7163.MCT-13-1067
   Cui Jing, 2009, J Ocul Biol Dis Infor, V2, P12, DOI 10.1007/s12177-009-9015-9
   Curtis TM, 2009, EYE, V23, P1496, DOI 10.1038/eye.2009.108
   D'Onofrio PM, 2019, INVEST OPHTH VIS SCI, V60, P634, DOI 10.1167/iovs.18-25257
   Dallabrida SM, 2008, FASEB J, V22, P3010, DOI 10.1096/fj.07-100966
   Dalton AC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163732
   Daly C, 2006, P NATL ACAD SCI USA, V103, P15491, DOI 10.1073/pnas.0607538103
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Danilucci TM, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0339-1
   Dardik R, 2016, MOL VIS, V22, P548
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396
   De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding Q, 2003, J BIOL CHEM, V278, P39882, DOI 10.1074/jbc.M304685200
   Ding XB, 2015, SHOCK, V43, P352, DOI 10.1097/SHK.0000000000000313
   Dong YY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0795-5
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   DRAKE CJ, 1995, J CELL SCI, V108, P2655
   Dudiki T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14787-y
   Dugel P.U., 2019, RETINA TODAY
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Edwards DN, 2020, J CEREBR BLOOD F MET, V40, P1695, DOI 10.1177/0271678X19880161
   Edwards DN, 2019, AM J PHYSIOL-CELL PH, V316, pC252, DOI 10.1152/ajpcell.00151.2018
   EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x
   Eklund L, 2017, CLIN SCI, V131, P87, DOI 10.1042/CS20160129
   Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084
   Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255
   Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079
   Elner SG, 1996, INVEST OPHTH VIS SCI, V37, P696
   Evans RA, 2003, EXP CELL RES, V282, P90, DOI 10.1016/S0014-4827(02)00015-0
   Fanelli R, 2014, VASC CELL, V6, DOI 10.1186/2045-824X-6-11
   Felcht M, 2012, J CLIN INVEST, V122, P1991, DOI 10.1172/JCI58832
   Feng NP, 2015, J MOL NEUROSCI, V57, P426, DOI 10.1007/s12031-015-0589-3
   Feramda Biopharmaceutical, MOLECULES
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Filla MS, 2017, EXP EYE RES, V158, P124, DOI 10.1016/j.exer.2016.05.011
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Finnson KW, 2020, SEMIN CELL DEV BIOL, V101, P115, DOI 10.1016/j.semcdb.2019.11.013
   Fischer AJ, 2010, MOL NEUROBIOL, V42, P199, DOI 10.1007/s12035-010-8152-2
   Ford JA, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002269
   FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Fu YL, 2007, INVEST OPHTH VIS SCI, V48, P5184, DOI 10.1167/iovs.07-0469
   Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026
   Ganter MT, 2008, CIRC RES, V102, P804, DOI 10.1161/CIRCRESAHA.107.161067
   Gao BB, 2008, J PROTEOME RES, V7, P2516, DOI 10.1021/pr800112g
   Gao R, 2006, GUT, V55, P856, DOI 10.1136/gut.2005.079178
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Garmy-Susini B, 2005, J CLIN INVEST, V115, P1542, DOI 10.1172/JCI23445
   Gaublomme D, 2014, J NEUROCHEM, V129, P966, DOI 10.1111/jnc.12703
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Georges-Labouesse E, 1998, CURR BIOL, V8, P983, DOI 10.1016/S0960-9822(98)70402-6
   Goda S, 2000, J IMMUNOL, V164, P4313, DOI 10.4049/jimmunol.164.8.4313
   Gong JY, 2015, CURR EYE RES, V40, P476, DOI 10.3109/02713683.2014.932386
   Gonzalez AL, 2007, J LEUKOCYTE BIOL, V81, P686, DOI 10.1189/jlb.0906553
   Grosche A, 2016, MOL CELL PROTEOMICS, V15, P462, DOI 10.1074/mcp.M115.052183
   Guenther SR, 2019, CURR EYE RES, V44, P341, DOI 10.1080/02713683.2018.1542006
   Guerrero Paola A, 2018, Adv Pharmacol, V81, P129, DOI 10.1016/bs.apha.2017.08.011
   Guidry C, 2003, INVEST OPHTH VIS SCI, V44, P1355, DOI 10.1167/iovs.02-0046
   Gustavsson C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012699
   Hakanpaa L, 2018, P NATL ACAD SCI USA, V115, pE6467, DOI 10.1073/pnas.1722317115
   Hakanpaa L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6962
   Hammes HP, 2011, DIABETES, V60, P9, DOI 10.2337/db10-0454
   Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529
   Han S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/268486
   Hauck SM, 2003, GLIA, V44, P251, DOI 10.1002/glia.10292
   Hennig R, 2016, J DRUG TARGET, V24, P952, DOI 10.3109/1061186X.2016.1163709
   HERSHKOVIZ R, 1994, INVEST OPHTH VIS SCI, V35, P2585
   Hirasawa M, 2016, J BIOL CHEM, V291, P7373, DOI 10.1074/jbc.M115.710186
   Hirota S, 2011, DEVELOPMENT, V138, P5157, DOI 10.1242/dev.069153
   Hoffmann DC, 2013, J BIOL CHEM, V288, P17976, DOI 10.1074/jbc.M113.451831
   Honda E, 2010, TOHOKU J EXP MED, V220, P319, DOI 10.1620/tjem.220.319
   Horan GS, 2008, AM J RESP CRIT CARE, V177, P56, DOI 10.1164/rccm.200706-805OC
   Hsu CC, 2011, J THROMB HAEMOST, V9, P593, DOI 10.1111/j.1538-7836.2010.04163.x
   Hu TT, 2019, EXP EYE RES, V180, P43, DOI 10.1016/j.exer.2018.11.022
   Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921
   HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867
   Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098
   HUNTER DD, 1992, NEURON, V8, P399, DOI 10.1016/0896-6273(92)90269-J
   Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje
   Imanishi Y, 2007, CANCER RES, V67, P4254, DOI 10.1158/0008-5472.CAN-06-4100
   Imhof BA, 1997, EUR J IMMUNOL, V27, P3242, DOI 10.1002/eji.1830271223
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Jang JW, 2016, CURR EYE RES, V41, P689, DOI 10.3109/02713683.2015.1050737
   Jester JV, 2002, EXP EYE RES, V75, P645, DOI 10.1006/exer.2002.2066
   Jin H, 2006, CANCER RES, V66, P2146, DOI 10.1158/0008-5472.CAN-05-2704
   Jo DH, 2016, MOL CELL PROTEOMICS, V15, P1681, DOI 10.1074/mcp.M115.053249
   Johansson Mats W, 2013, Front Pharmacol, V4, P33, DOI 10.3389/fphar.2013.00033
   JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553
   Jun HK, 2012, IMMUNITY, V36, P755, DOI 10.1016/j.immuni.2012.05.002
   Kaiser P, 2013, INVEST OPHTH VIS SCI, V54
   Kanda A, 2012, LAB INVEST, V92, P1553, DOI 10.1038/labinvest.2012.111
   Kanda S, 2000, ARTERIOSCL THROM VAS, V20, P998, DOI 10.1161/01.ATV.20.4.998
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268
   Kiwanuka E, 2013, EXP CELL RES, V319, P2938, DOI 10.1016/j.yexcr.2013.08.021
   Klapholz B, 2017, J CELL SCI, V130, P2435, DOI 10.1242/jcs.190991
   Koch AE, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2187
   Kornberg LJ, 2004, INVEST OPHTH VIS SCI, V45, P4463, DOI 10.1167/iovs.03-1201
   Kronenwett R, 2002, CANCER GENE THER, V9, P587, DOI 10.1038/sj.cgt.7700474
   Kubota Y, 2009, TRENDS CARDIOVAS MED, V19, P38, DOI 10.1016/j.tcm.2009.04.004
   Kuppermann BD, 2010, INVEST OPHTH VIS SCI, V51
   Kurihara Y, 2011, CELL IMMUNOL, V270, P25, DOI 10.1016/j.cellimm.2011.03.017
   Labus J, 2018, EXP CELL RES, V373, P99, DOI 10.1016/j.yexcr.2018.10.002
   Lacy-Hulbert A, 2007, AM J TRANSPLANT, V7, P1080, DOI 10.1111/j.1600-6143.2007.01757.x
   LaFoya B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020449
   Lagos-Cabre R, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0968-5
   Larsen M, 2006, CURR OPIN CELL BIOL, V18, P463, DOI 10.1016/j.ceb.2006.08.009
   Laurens N, 2009, ANGIOGENESIS, V12, P275, DOI 10.1007/s10456-009-9150-8
   Lawrence DA, 2001, MOL CELL BIOCHEM, V219, P163, DOI 10.1023/A:1010819716023
   Lebrun P, 2000, J BIOL CHEM, V275, P38371, DOI 10.1074/jbc.M006162200
   Lee HS, 2007, J IMMUNOL, V179, P7001, DOI 10.4049/jimmunol.179.10.7001
   Lee HS, 2014, J BIOL CHEM, V289, P31330, DOI 10.1074/jbc.M114.572594
   Lee JH, 2014, NEUROMOL MED, V16, P292, DOI 10.1007/s12017-013-8277-3
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Lee J, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006666
   Lee SJ, 2018, J CLIN INVEST, V128, P5018, DOI 10.1172/JCI99659
   Lee TH, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0529-6
   Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1
   Li C, 2013, INFLAMM BOWEL DIS, V19, P2829, DOI 10.1097/MIB.0b013e3182a8452e
   Li R, 2009, INVEST OPHTH VIS SCI, V50, P5988, DOI 10.1167/iovs.09-3591
   Li Y, 2016, BBA-GEN SUBJECTS, V1860, P2137, DOI 10.1016/j.bbagen.2016.05.031
   Li YJ, 2014, EXP EYE RES, V129, P119, DOI 10.1016/j.exer.2014.11.004
   Li ZL, 2020, J CLIN INVEST, V130, P1977, DOI 10.1172/JCI130308
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Silva RLE, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8030
   Lin H, 1998, INVEST OPHTH VIS SCI, V39, P1703
   Lipson KE, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-S1-S24
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Liu GZ, 2001, J CELL BIOCHEM, V83, P129, DOI 10.1002/jcb.1208
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Liu WM, 2020, FOLIA MICROBIOL, V65, P329, DOI 10.1007/s12223-019-00728-w
   Lorenc VE, 2015, INVEST OPHTH VIS SCI, V56, P6948, DOI 10.1167/iovs.15-17496
   Lv Z, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01420
   Lygoe KA, 2004, WOUND REPAIR REGEN, V12, P461, DOI 10.1111/j.1067-1927.2004.12402.x
   Lyu Y, 2018, INT J OPHTHALMOL-CHI, V11, P726, DOI 10.18240/ijo.2018.05.04
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Mahabeleshwar GH, 2007, CIRC RES, V101, P570, DOI 10.1161/CIRCRESAHA.107.155655
   Maier AKB, 2007, CURR EYE RES, V32, P801, DOI 10.1080/02713680701553052
   Malan D, 2010, DEVELOPMENT, V137, P993, DOI 10.1242/dev.045377
   Matsubara Y, 2000, BLOOD, V95, P1560, DOI 10.1182/blood.V95.5.1560.005k43_1560_1564
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Meerovitch K, 2003, VASC PHARMACOL, V40, P77, DOI 10.1016/S1537-1891(02)00339-7
   Meller J, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93002
   Midani F, 2019, SEMIN OPHTHALMOL, V34, P365, DOI 10.1080/08820538.2019.1632354
   Miller CG, 2017, EXP BIOL MED, V242, P1, DOI 10.1177/1535370216675245
   Milner R, 2003, J IMMUNOL, V170, P3850, DOI 10.4049/jimmunol.170.7.3850
   Milner R, 1999, J CELL SCI, V112, P4271
   Milner R, 2002, J NEUROSCI, V22, P1562, DOI 10.1523/JNEUROSCI.22-05-01562.2002
   Milner R, 2007, J IMMUNOL, V178, P8158, DOI 10.4049/jimmunol.178.12.8158
   Mirando AC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145142
   Mirando AC, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122043
   Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011
   Mitroulis I, 2015, PHARMACOL THERAPEUT, V147, P123, DOI 10.1016/j.pharmthera.2014.11.008
   MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Monick MM, 2002, AM J PHYSIOL-LUNG C, V283, pL390, DOI 10.1152/ajplung.00437.2001
   Montassar F, 2017, FASEB J, V31, P1107, DOI 10.1096/fj.201600351R
   Moon C, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-18
   Moradian S, 2008, GRAEF ARCH CLIN EXP, V246, P1699, DOI 10.1007/s00417-008-0914-4
   Morales SA, 2007, EXP EYE RES, V85, P790, DOI 10.1016/j.exer.2007.08.014
   Moreno-Layseca P, 2014, MATRIX BIOL, V34, P144, DOI 10.1016/j.matbio.2013.10.011
   Mori S, 2008, J BIOL CHEM, V283, P18066, DOI 10.1074/jbc.M801213200
   Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622
   Morrison John C, 2006, Trans Am Ophthalmol Soc, V104, P453
   Moser M, 2009, SCIENCE, V324, P895, DOI 10.1126/science.1163865
   Motegi S, 2011, ARTERIOSCL THROM VAS, V31, P2653, DOI 10.1161/ATVBAHA.111.233619
   Motta C, 2016, INVEST OPHTH VIS SCI, V57, P5723, DOI 10.1167/iovs.16-19909
   Moulisova V, 2017, BIOMATERIALS, V126, P61, DOI 10.1016/j.biomaterials.2017.02.024
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100
   Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0
   Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0
   Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627
   Nagy JA, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006544
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Nandrot EE, 2006, ADV EXP MED BIOL, V572, P119
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Neumann C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092762
   Nisato RE, 2005, CANCER RES, V65, P9377, DOI 10.1158/0008-5472.CAN-05-1512
   Ocugen, OCU200
   Ogawara K, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1885
   Orecchia A, 2003, J CELL SCI, V116, P3479, DOI 10.1242/jcs.00673
   Oxurion, 2020, OX NV REP POS TOPL D
   Pan L, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2502-0
   Pan LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104335
   Pang DF, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0145-7
   Park SW, 2014, DIABETES, V63, P3057, DOI 10.2337/db13-1942
   Peach CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041264
   Peng Q, 2005, J IMMUNOL, V174, P2258, DOI 10.4049/jimmunol.174.4.2258
   Perdiguero EG, 2016, J PATHOL, V240, P461, DOI 10.1002/path.4805
   Perruzzi CA, 2003, J INVEST DERMATOL, V120, P1100, DOI 10.1046/j.1523-1747.2003.12236.x
   Petrovic MG, 2003, J HUM GENET, V48, P457, DOI 10.1007/s10038-003-0060-0
   PHILP NJ, 1987, INVEST OPHTH VIS SCI, V28, P1275
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   Pilorget A, 2007, J CELL PHYSIOL, V211, P307, DOI 10.1002/jcp.20935
   Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72
   Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0
   Priscakova P, 2016, MOL BIOL REP, V43, P1327, DOI 10.1007/s11033-016-4075-y
   Puthawala K, 2008, AM J RESP CRIT CARE, V177, P82, DOI 10.1164/rccm.200706-806OC
   Qin SF, 2012, EXP EYE RES, V94, P63, DOI 10.1016/j.exer.2011.11.007
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Quiroz-Mercado H., 2013, RETINA TODAY
   Ramakrishnan V, 2006, J EXP THER ONCOL, V5, P273
   Reed NI, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa5094
   Rifkin DB, 2005, J BIOL CHEM, V280, P7409, DOI 10.1074/jbc.R400029200
   ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3475
   Robel S, 2009, GLIA, V57, P1630, DOI 10.1002/glia.20876
   Roberts J, 2017, J CEREBR BLOOD F MET, V37, P85, DOI 10.1177/0271678X15616979
   Robinson SD, 2004, ARTERIOSCL THROM VAS, V24, P2108, DOI 10.1161/01.ATV.0000143857.27408.de
   Roggia MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134870
   Rossi E, 2013, BLOOD, V121, P403, DOI 10.1182/blood-2012-06-435347
   Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087
   Roy S, 2016, EXP EYE RES, V142, P71, DOI 10.1016/j.exer.2015.04.004
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697
   Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449
   Saharinen P, 2017, NAT REV DRUG DISCOV, V16, P635, DOI 10.1038/nrd.2016.278
   Samy E, 2017, ARTHRITIS RHEUMATOL, V69
   Santos ARC, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0036243, 10.1371/journal.pone.0048332]
   Santulli RJ, 2008, J PHARMACOL EXP THER, V324, P894, DOI 10.1124/jpet.107.131656
   Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083
   Scheppke L, 2008, J CLIN INVEST, V118, P2337, DOI [10.1172/JCI33361, 10.1172/JC133361]
   Scheppke L, 2012, BLOOD, V119, P2149, DOI 10.1182/blood-2011-04-348706
   Schneider JG, 2007, ARTERIOSCL THROM VAS, V27, P2699, DOI 10.1161/ATVBAHA.107.153650
   Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600
   Schwartz MA, 2001, J CELL SCI, V114, P2553
   Seo S, 2017, MOL VIS, V23, P823
   Sergeys J, 2020, EXP EYE RES, V197, DOI 10.1016/j.exer.2020.108108
   Shattil SJ, 2005, TRENDS CELL BIOL, V15, P399, DOI 10.1016/j.tcb.2005.06.005
   Shaw LT, 2020, EXPERT OPIN INV DRUG, V29, P547, DOI 10.1080/13543784.2020.1763953
   Shi S, 2015, KIDNEY INT, V88, P479, DOI 10.1038/ki.2015.103
   Shibata K, 1997, CANCER RES, V57, P5416
   Shimamura N, 2006, STROKE, V37, P1902, DOI 10.1161/01.STR.0000226991.27540.f2
   Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298
   Silva R, 2008, ARTERIOSCL THROM VAS, V28, P1703, DOI 10.1161/ATVBAHA.108.172015
   Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87
   Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485
   Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002
   Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882
   Somanath PR, 2009, ANGIOGENESIS, V12, P177, DOI 10.1007/s10456-009-9141-9
   Song KH, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.10.33
   Stanton H, 1998, J CELL SCI, V111, P2789
   Stenzel D, 2011, DEVELOPMENT, V138, P4451, DOI 10.1242/dev.071381
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Stitt AW, 2013, CLIN SCI, V125, P1, DOI 10.1042/CS20120588
   Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808
   Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070
   Su G, 2013, CRIT CARE MED, V41, P546, DOI 10.1097/CCM.0b013e3182711b1e
   Su G, 2012, AM J RESP CRIT CARE, V185, P58, DOI 10.1164/rccm.201108-1381OC
   Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100
   Sui AL, 2018, MED SCI MONITOR, V24, P5860, DOI 10.12659/MSM.907446
   Sui AL, 2018, GRAEF ARCH CLIN EXP, V256, P951, DOI 10.1007/s00417-018-3940-x
   Sun JX, 2018, ANGIOGENESIS, V21, P635, DOI 10.1007/s10456-018-9614-9
   Suzuki Y, 2010, J BIOL CHEM, V285, P18443, DOI 10.1074/jbc.M110.114645
   Tabakci BN, 2017, TURK OFTALMOL DERG, V47, P156, DOI 10.4274/tjo.56338
   Tabata M, 2009, CELL METAB, V10, P178, DOI 10.1016/j.cmet.2009.08.003
   TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171
   Takada YK, 2017, J BIOL CHEM, V292, P20067, DOI 10.1074/jbc.M117.818302
   Takano M, 2021, CARTILAGE, V13, p885S, DOI 10.1177/1947603519878242
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0
   Tang CH, 2008, CELL MOL LIFE SCI, V65, P1916, DOI 10.1007/s00018-008-7573-9
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Taylor AW, 2009, J LEUKOCYTE BIOL, V85, P29, DOI 10.1189/jlb.0708415
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Thibault G, 2001, AM J PHYSIOL-CELL PH, V281, pC1457, DOI 10.1152/ajpcell.2001.281.5.C1457
   Thomas M, 2010, J BIOL CHEM, V285, P23842, DOI 10.1074/jbc.M109.097543
   Thorin-Trescases N, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1096385
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tigges U, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-33
   Tolentino MS, 2016, EXPERT OPIN INV DRUG, V25, P1011, DOI 10.1080/13543784.2016.1201062
   Toutounchian JJ, 2017, MOL PHARMACOL, V91, P1, DOI 10.1124/mol.116.105031
   Tsotridou Eleni, 2020, Med Hypothesis Discov Innov Ophthalmol, V9, P91
   Tsou R, 2001, MOL CELL BIOCHEM, V224, P81, DOI 10.1023/A:1011947301849
   Tzoumas N, 2021, SURV OPHTHALMOL, V66, P378, DOI 10.1016/j.survophthal.2020.10.008
   Uhrin P, 2013, CELL ADHES MIGR, V7, P23, DOI 10.4161/cam.22124
   Ulbrich S, 2011, CELLS TISSUES ORGANS, V194, P443, DOI 10.1159/000323653
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   Umikawa M, 2015, BIOCHEM BIOPH RES CO, V467, P235, DOI 10.1016/j.bbrc.2015.09.183
   Van Bergen T, 2019, PROG RETIN EYE RES, V69, P116, DOI 10.1016/j.preteyeres.2018.10.006
   Van Bergen T, 2016, INVEST OPHTH VIS SCI, V57, P6428, DOI 10.1167/iovs.16-19751
   van Hinsbergh VWM, 2001, ANN NY ACAD SCI, V936, P426
   Van Hove I, 2020, DIABETOLOGIA, V63, P2235, DOI 10.1007/s00125-020-05218-0
   Vecino E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125250
   Vella F, 2003, J BIOL CHEM, V278, P19834, DOI 10.1074/jbc.M301470200
   Wan YY, 2007, IMMUNOL REV, V220, P199, DOI 10.1111/j.1600-065X.2007.00565.x
   Wang AZ, 1997, ARTHRITIS RHEUM, V40, P1298, DOI 10.1002/art.15
   Wang B, 2007, HEPATOLOGY, V46, P1404, DOI 10.1002/hep.21849
   Wang DJ, 2020, THERANOSTICS, V10, P231, DOI 10.7150/thno.37142
   Wang GK, 2006, J BIOL CHEM, V281, P14085, DOI 10.1074/jbc.M513686200
   Wang J, 2006, J NEUROCHEM, V96, P148, DOI 10.1111/j.1471-4159.2005.03521.x
   Wang L, 2019, EXP NEUROL, V321, DOI 10.1016/j.expneurol.2019.113042
   Wang WS, 2018, CELL PHYSIOL BIOCHEM, V49, P985, DOI 10.1159/000493229
   Wang WQ, 2016, MOL PHARMACEUT, V13, P2881, DOI 10.1021/acs.molpharmaceut.6b00056
   Wang WQ, 2011, INVEST OPHTH VIS SCI, V52, P7213, DOI 10.1167/iovs.10-7097
   Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595
   Weng S, 2003, P NATL ACAD SCI USA, V100, P6730, DOI 10.1073/pnas.1137612100
   Wilkinson-Berka JL, 2006, INVEST OPHTH VIS SCI, V47, P1600, DOI 10.1167/iovs.05-1314
   Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042
   Woodard AS, 1998, J CELL SCI, V111, P469
   Wu WJ, 2019, EXP EYE RES, V180, P23, DOI 10.1016/j.exer.2018.11.027
   Wu X, 2012, PHARMACOL THERAPEUT, V134, P68, DOI 10.1016/j.pharmthera.2011.12.008
   Xie B, 1998, J BIOL CHEM, V273, P11583, DOI 10.1074/jbc.273.19.11583
   Yamamoto H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7429
   Yamamoto T, 2003, AM J OPHTHALMOL, V135, P14, DOI 10.1016/S0002-9394(02)01819-6
   Yang CH, 1996, INVEST OPHTH VIS SCI, V37, P843
   Yang HM, 2012, INT J ONCOL, V41, P589, DOI 10.3892/ijo.2012.1484
   Yang R, 2007, ANN NY ACAD SCI, V1103, P196, DOI 10.1196/annals.1394.000
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZW, 2007, J CELL BIOL, V176, P787, DOI 10.1083/jcb.200611044
   Yasukawa T, 2004, CURR EYE RES, V28, P359, DOI 10.1076/ceyr.28.5.359.28678
   Yeh YC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14932-6
   Yoshida T, 2012, EXP EYE RES, V94, P41, DOI 10.1016/j.exer.2011.11.003
   Yossipof TE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00979
   You JJ, 2014, CELL SIGNAL, V26, P133, DOI 10.1016/j.cellsig.2013.08.026
   Yue J, 2012, CANCER MICROENVIRON, V5, P275, DOI 10.1007/s12307-012-0101-3
   Yun JH, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.347
   Zahn G, 2010, INVEST OPHTH VIS SCI, V51, P1028, DOI 10.1167/iovs.09-3575
   Zahn G, 2009, ARCH OPHTHALMOL-CHIC, V127, P1329, DOI 10.1001/archophthalmol.2009.265
   ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853
   Zaveri TD, 2014, BIOMATERIALS, V35, P3504, DOI 10.1016/j.biomaterials.2014.01.007
   Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997
   Zhu P, 1998, BIOCHEM J, V330, P975, DOI 10.1042/bj3300975
NR 401
TC 13
Z9 13
U1 6
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2021
VL 85
AR 100966
DI 10.1016/j.preteyeres.2021.100966
EA NOV 2021
PG 29
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WZ7GE
UT WOS:000720131700001
PM 33775825
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Ye, FX
   Kaneko, H
   Hayashi, Y
   Takayama, K
   Hwang, SJ
   Nishizawa, Y
   Kimoto, R
   Nagasaka, Y
   Tsunekawa, T
   Matsuura, T
   Yasukawa, T
   Kondo, T
   Terasaki, H
AF Ye, Fuxiang
   Kaneko, Hiroki
   Hayashi, Yumi
   Takayama, Kei
   Hwang, Shiang-Jyi
   Nishizawa, Yuji
   Kimoto, Reona
   Nagasaka, Yosuke
   Tsunekawa, Taichi
   Matsuura, Toshiyuki
   Yasukawa, Tsutomu
   Kondo, Takaaki
   Terasaki, Hiroko
TI Malondialdehyde induces autophagy dysfunction and VEGF secretion in the
   retinal pigment epithelium in age-related macular degeneration
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Age-related macular degeneration; Lipid peroxidation; Malondialdehyde;
   Autophagy; Linoleic acid
ID ENDOTHELIAL GROWTH-FACTOR; LIPID-PEROXIDATION PRODUCTS; CHOROIDAL
   NEOVASCULARIZATION; THERAPEUTIC TARGET; OXIDATIVE STRESS; LINOLEIC-ACID;
   FATTY-ACIDS; CELLS; RANIBIZUMAB; ACTIVATION
AB Age-related macular degeneration (AMD) is a major cause of blindness in developed countries and is closely related to oxidative stress, which leads to lipid peroxidation. Malondialdehyde (MDA) is a major byproduct of polyunsaturated fatty acid (PUFA) peroxidation. Increased levels of MDA have been reported in eyes of AMD patients. However, little is known about the direct relationship between MDA and AMD. Here we show the biological importance of MDA in AMD pathogenesis. We first confirmed that MDA levels were significantly increased in eyes of AMD patients. In ARPE-19 cells, a human retinal pigment epithelial cell line, MDA treatment induced vascular endothelial growth factor (VEGF) expression alternation, cell junction disruption, and autophagy dysfunction that was also observed in eyes of AMD patients. The MDA-induced VEGF increase was inhibited by autophagy-lysosomal inhibitors. Intravitreal MDA injection in mice increased laser-induced choroidal neovascularization (laser-CNV) volumes. In a mouse model fed a high-linoleic acid diet for 3 months, we found a significant increase in MDA levels, autophagic activity, and laser-CNV volumes. Our study revealed an important role of MDA, which acts not only as a marker but also as a causative factor of AMD pathogenesis-related autophagy dysfunction. Furthermore, higher dietary intake of linoleic acid promoted CNV progression in mice with increased MDA levels. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Ye, Fuxiang; Kaneko, Hiroki; Takayama, Kei; Hwang, Shiang-Jyi; Kimoto, Reona; Nagasaka, Yosuke; Tsunekawa, Taichi; Matsuura, Toshiyuki; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
   [Hayashi, Yumi; Kondo, Takaaki] Nagoya Univ, Grad Sch Med, Dept Radiol & Med Lab Sci, Nagoya, Aichi 4618673, Japan.
   [Hayashi, Yumi] Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648601, Japan.
   [Hwang, Shiang-Jyi] Nagoya Univ, Grad Sch Med, Dept Obstet & Gynecol Collaborat Res, Lab Bell Res Ctr, Nagoya, Aichi 4668550, Japan.
   [Nishizawa, Yuji] Chubu Univ, Dept Biomed Sci, Kasugai, Aichi 4878501, Japan.
   [Yasukawa, Tsutomu] Nagoya City Univ, Sch Med, Dept Ophthalmol, Nagoya, Aichi 4678601, Japan.
C3 Nagoya University; Nagoya University; Nagoya University; Nagoya
   University; Chubu University; Nagoya City University
RP Kaneko, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM h-kaneko@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/AHA-2461-2022
OI Kaneko, Hiroki/0000-0003-0731-6465; Ye, Fuxiang/0000-0003-2550-2173;
   Takayama, Kei/0000-0002-1477-9014
FU Japan Society for the Promotion of Science, Takeda Medical Research
   Foundation [15H04994, 25713056]; Takeda Science Foundation; Japan
   Intractable Diseases Research Foundation; Yokoyama Foundation for
   Clinical Pharmacology [YRY1411]; Uehara Memorial Foundation; Hori
   Science and Arts Foundation; Mishima Saiichi Memorial Ophthalmic
   Research International Foundation; Grants-in-Aid for Scientific Research
   [25713056] Funding Source: KAKEN
FX The authors thank Chisato Ishizuka for her technical assistance. This
   work was partially supported by Grants-in-Aid for Scientific Research B
   (H.T.; 15H04994) and for Young Scientists A (H.K.; 25713056) from Japan
   Society for the Promotion of Science, Takeda Medical Research Foundation
   (H.K.), Takeda Science Foundation (H.K.), Japan Intractable Diseases
   Research Foundation (H.K.), Yokoyama Foundation for Clinical
   Pharmacology (YRY1411, H.K.), The Uehara Memorial Foundation (H.K.),
   Hori Science and Arts Foundation (F.Y.), and Mishima Saiichi Memorial
   Ophthalmic Research International Foundation (F.Y.).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438
   Ayalasomayajula SP, 2002, EUR J PHARMACOL, V449, P213, DOI 10.1016/S0014-2999(02)02043-5
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergmann M, 2011, GRAEF ARCH CLIN EXP, V249, P1477, DOI 10.1007/s00417-011-1682-0
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brzek P, 2014, J EXP BIOL, V217, P1504, DOI 10.1242/jeb.100073
   Cai ZY, 2015, NEUROPSYCH DIS TREAT, V11, P1015, DOI 10.2147/NDT.S75717
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Del Rio D, 2005, NUTR METAB CARDIOVAS, V15, P316, DOI 10.1016/j.numecd.2005.05.003
   Ding WX, 2011, EXP BIOL MED, V236, P546, DOI 10.1258/ebm.2011.010360
   Dodson M, 2013, FREE RADICAL BIO MED, V63, P207, DOI 10.1016/j.freeradbiomed.2013.05.014
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Elali A, 2011, STROKE, V42, P3238, DOI 10.1161/STROKEAHA.111.615559
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Farvid MS, 2014, CIRCULATION, V130, P1568, DOI 10.1161/CIRCULATIONAHA.114.010236
   Gibson RA, 2011, MATERN CHILD NUTR, V7, P17, DOI 10.1111/j.1740-8709.2011.00299.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hohn A, 2013, J PROTEOMICS, V92, P132, DOI 10.1016/j.jprot.2013.01.004
   Ijima R, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.6
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   IMAI H, 1991, BUNSEKI KAGAKU, V40, P143
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kaneko H, 2014, BRIT J PHARMACOL, V171, P3754, DOI 10.1111/bph.12737
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kawano Y, 2010, ARCH BIOCHEM BIOPHYS, V504, P221, DOI 10.1016/j.abb.2010.09.001
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   KWON TW, 1963, J FOOD SCI, V28, P627, DOI 10.1111/j.1365-2621.1963.tb01666.x
   Lebrun-Julien F, 2010, P NATL ACAD SCI USA, V107, P3817, DOI 10.1073/pnas.0909276107
   Liang CM, 2011, ACTA OPHTHALMOL, V89, pE505, DOI 10.1111/j.1755-3768.2011.02147.x
   LUNG CC, 1990, J IMMUNOL METHODS, V128, P127, DOI 10.1016/0022-1759(90)90471-7
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Matsui A, 2016, OPHTHALMIC RES, V55, P37, DOI 10.1159/000440885
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Muhlfeld C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020424
   Niedernhofer LJ, 2003, J BIOL CHEM, V278, P31426, DOI 10.1074/jbc.M212549200
   Njie-Mbye YF, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00366
   Okuyama H, 1996, PROG LIPID RES, V35, P409, DOI 10.1016/S0163-7827(96)00012-4
   Pizzimenti S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00242
   RAMSDEN CE, 2013, BMJ-BRIT MED J, V346, P94477, DOI DOI 10.1136/BMJ.E8707
   REMTULLA S, 1985, VISION RES, V25, P21, DOI 10.1016/0042-6989(85)90076-8
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Saadat KASM, 2014, FEBS OPEN BIO, V4, P1007, DOI 10.1016/j.fob.2014.11.003
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Sharma S, 2005, VISUAL NEUROSCI, V22, P631, DOI 10.1017/S0952523805225129
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Shirasawa M, 2013, EXP EYE RES, V110, P59, DOI 10.1016/j.exer.2013.02.012
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Terasaki H, 2015, CURR EYE RES, V40, P936, DOI 10.3109/02713683.2014.964417
   Tomida D, 2011, INVEST OPHTH VIS SCI, V52, P3193, DOI 10.1167/iovs.10-6737
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Vatsyayan R, 2012, BIOCHEM BIOPH RES CO, V417, P346, DOI 10.1016/j.bbrc.2011.11.113
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Ye FX, 2015, SCI REP-UK, V5, DOI 10.1038/srep07705
   Yildirim O, 2004, OPHTHALMOLOGICA, V218, P202, DOI 10.1159/000076845
   Yu DY, 2006, INVEST OPHTH VIS SCI, V47, P1109, DOI 10.1167/iovs.05-1118
   Zaitsu K, 2015, LIFE SCI, V137, P49, DOI 10.1016/j.lfs.2015.05.013
   Zhao H, 2015, MOL MED REP, V12, P2771, DOI 10.3892/mmr.2015.3781
NR 70
TC 37
Z9 37
U1 2
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD MAY
PY 2016
VL 94
BP 121
EP 134
DI 10.1016/j.freeradbiomed.2016.02.027
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA DK1AK
UT WOS:000374644100012
PM 26923802
DA 2022-11-30
ER

PT J
AU Mohamed, R
   Gadhvi, K
   Mensah, E
AF Mohamed, Ryian
   Gadhvi, Kunal
   Mensah, Evelyn
TI What Effect Does Ethnicity Have on the Response to Ranibizumab in the
   Treatment of Wet Age-Related Macular Degeneration?
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Anti-vascular endothelial growth
   factor; Ethnicity
ID INTRAVITREAL RANIBIZUMAB; PREVALENCE; BEVACIZUMAB; POPULATION; OUTCOMES;
   DISEASE; BURDEN
AB Aims: To compare, in a single urban population, the visual outcomes of ranibizumab monotherapy in "White" (W) and "Non-White" (NW) patients with wet age-related macular degeneration (AMD). Procedures: Prospective data was collected from 434 eyes of 217 patients with wet AMD patients receiving intravitreal ranibizumab. Baseline and monthly LogMAR visual acuities were obtained. All patients received treatment under a "treat and extend policy" consisting of three monthly injections of ranibizumab, followed by individualised sequentially lengthening follow-up intervals when stable. Results: At 24 months, the percentage of eyes that maintained or improved vision was 91% in W patients and 83% in NW patients. Correspondingly, at 24 months, the percentage of visual loss was 9% for W patients and 17% of NW patients. We found that whilst W patients required fewer overall injections (14.1) they gained an average 4 LogMAR letters of visual acuity. However, NW patients required more injections (14.6) to gain 0.5 LogMAR letters of visual acuity over the same 24 months of treatment. Conclusions: Individualised ranibizumab monotherapy is more effective in preserving vision for W compared to NW patients with wet AMD. (C) 2018 S. Karger AG, Basel
C1 [Mohamed, Ryian] Luton & Dunstable Hosp, London, England.
   [Gadhvi, Kunal; Mensah, Evelyn] London North West Univ NHS Trust, Cent Middlesex Hosp, Dept Ophthalmol, London, England.
C3 Imperial College London
RP Mohamed, R (通讯作者)，L&D Hosp NHS Fdn Trust, Lewsey Rd, Luton LU4 0DZ, Beds, England.
EM m0601207@gmail.com
RI Mohamed, Ryian/L-9132-2019
OI Mohamed, Ryian/0000-0001-8555-4659
CR Basheer K, 2015, CLIN OPHTHALMOL, V9, P959, DOI 10.2147/OPTH.S76754
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Feng XF, 2011, INT J OPHTHALMOL-CHI, V4, P85, DOI 10.3980/j.issn.2222-3959.2011.01.20
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, P47
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Kundu RV, 2013, AM FAM PHYSICIAN, V87, P859
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   National Institute for Health and Care Excellence (NICE), 2008, RAN PEG TREATM AG RE
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Royal College of Ophthalmologists, AG REL MAC DEG GUID
   Russell SB, 2010, J INVEST DERMATOL, V130, P2489, DOI 10.1038/jid.2010.162
   Vemala R, 2010, CLIN OPHTHALMOL, V4, P913
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 17
TC 3
Z9 3
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 240
IS 3
BP 157
EP 162
DI 10.1159/000486403
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GW3OG
UT WOS:000446814000006
PM 29847823
DA 2022-11-30
ER

PT J
AU Arnon, R
   Pikkel, J
   Yahalomi, T
   Stanescu, N
   Wood, K
   Leshno, A
   Achiron, A
   Hilely, A
AF Arnon, Roee
   Pikkel, Joseph
   Yahalomi, Tal
   Stanescu, Nir
   Wood, Keren
   Leshno, Ari
   Achiron, Asaf
   Hilely, Assaf
TI The negative impact of COVID-19 pandemic on age-related macular
   degeneration patients treated with intravitreal bevacizumab injections
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; COVID-19; Bevacizumab; Injection; Loss of follow-up
ID OPTICAL COHERENCE TOMOGRAPHY; BASE-LINE PREDICTORS; VISUAL-ACUITY;
   RANIBIZUMAB; EXTEND; OUTCOMES; REGIMEN; TRIAL; RISK
AB Purpose COVID-19 emerged in the end of 2019 and was declared a worldwide pandemic shortly after. Social distancing and lockdowns resulted in lower compliance in intravitreal injections and office visits. We aimed to assess clinical outcomes among patients who missed these visits compared to those who arrived as planned. Methods Patients who missed or were late to office visits or intravitreal injections were defined as non-adherent and were compared to adherent patients. Our main outcomes were the need for subsequent injections, mean change in best-corrected visual acuity (BCVA), and central macular thickness (CMT). Results This study included 77 patients (24 adherent and 53 non-adherent). The mean BCVA remained stable during the study period for the adherent group (p = 0.159) and worsened in the non-adherent group (p < 0.001). Changes in CMT and maximum thickness were not significant for either group. A higher proportion of patients in the non-adherent group needed subsequent intravitreal injections (49% vs 20%, p = 0.014). Conclusion The findings demonstrate the negative implications of the COVID-19 pandemic and the effect of deferring bevacizumab injections among individuals with age-related macular degeneration. This emphasizes the importance of a scheduled follow-up, also during a pandemic.
C1 [Arnon, Roee; Pikkel, Joseph; Yahalomi, Tal; Stanescu, Nir; Wood, Keren] Assuta Samson Med Ctr, Ophthalmol Dept, Ashdod, Israel.
   [Pikkel, Joseph] Ben Gurion Univ Negev, Sch Med, Beer Sheva, Israel.
   [Leshno, Ari; Achiron, Asaf; Hilely, Assaf] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Leshno, Ari] Sheba Med Ctr, Goldschleger Eye Inst, Tel Hashomer, Israel.
   [Achiron, Asaf; Hilely, Assaf] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel.
C3 Ben Gurion University; Tel Aviv University; Sackler Faculty of Medicine;
   Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of
   Medicine; Tel Aviv Sourasky Medical Center
RP Arnon, R (通讯作者)，Assuta Samson Med Ctr, Ophthalmol Dept, Ashdod, Israel.
EM roee.arnon@gmail.com
OI Arnon, Roee/0000-0001-9995-8574
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Achiron A, 2015, ACTA OPHTHALMOL, V93, pE649, DOI 10.1111/aos.12735
   Agarwal D, 2020, INDIAN J OPHTHALMOL, V68, P1216, DOI 10.4103/ijo.IJO_1391_20
   Rodriguez-Fernandez CA, 2021, J CLIN MED, V10, DOI 10.3390/jcm10184087
   Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Ashkenazy N, 2021, CLIN OPHTHALMOL, V15, P413, DOI 10.2147/OPTH.S296345
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2655, DOI 10.1007/s00417-020-04858-7
   Campos A, 2020, CLIN OPHTHALMOL, V14, P2625, DOI 10.2147/OPTH.S267427
   Carnevali A, 2021, EUR J OPHTHALMOL, V31, P10, DOI 10.1177/1120672120962032
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hanhart J, 2022, GRAEF ARCH CLIN EXP, V260, P1907, DOI 10.1007/s00417-021-05505-5
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Huemer J, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2020-000560
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Krivosic V, 2017, J FR OPHTALMOL, V40, P642, DOI 10.1016/j.jfo.2017.03.005
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nahen K, 2020, KLIN MONATSBL AUGENH, V237, P1410, DOI 10.1055/a-1271-6834
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Safadi K, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2020-000487
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Shah N, 2016, BRIT J OPHTHALMOL, V100, P1346, DOI 10.1136/bjophthalmol-2015-307375
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sobolewska B, 2021, CLIN OPHTHALMOL, V15, P4317, DOI 10.2147/OPTH.S325763
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wasser Lauren M, 2020, SN Compr Clin Med, V2, P2546, DOI 10.1007/s42399-020-00614-4
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
NR 46
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD NOV
PY 2022
VL 42
IS 11
BP 3387
EP 3395
DI 10.1007/s10792-022-02337-y
EA MAY 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5M6UX
UT WOS:000800970800003
PM 35604624
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Finger, RP
   Schmitz-Valckenberg, S
   Schmid, M
   Rubin, GS
   Dunbar, H
   Tufail, A
   Crabb, DP
   Binns, A
   Sanchez, CI
   Margaron, P
   Normand, G
   Durbin, MK
   Luhmann, UFO
   Zamiri, P
   Cunha-Vaz, J
   Asmus, F
   Holz, FG
   Berger, M
   Bohner, J
   Bottger, M
   Brazier, JE
   Butt, T
   Carapezzi, C
   Carlton, J
   Costa, M
   Ferrao, A
   Hoyng, C
   Kersten, F
   Kratzschmar, J
   Luning, A
   Martinho, C
   Rowen, D
   Sahel, J
   Fernandes, DS
   Skelly, A
   Wojek, C
AF Finger, Robert P.
   Schmitz-Valckenberg, Steffen
   Schmid, Matthias
   Rubin, Gary S.
   Dunbar, Hannah
   Tufail, Adnan
   Crabb, David P.
   Binns, Alison
   Sanchez, Clara I.
   Margaron, Philippe
   Normand, Guillaume
   Durbin, Mary K.
   Luhmann, Ulrich F. O.
   Zamiri, Parisa
   Cunha-Vaz, Jose
   Asmus, Friedrich
   Holz, Frank G.
   Berger, M.
   Bohner, J.
   Bottger, M.
   Brazier, J. E.
   Butt, T.
   Carapezzi, C.
   Carlton, J.
   Costa, M.
   Ferrao, A.
   Hoyng, C.
   Kersten, F.
   Kratzschmar, J.
   Luning, A.
   Martinho, C.
   Rowen, D.
   Sahel, J.
   Fernandes, D. Sanches
   Skelly, A.
   Wojek, C.
CA MACUSTAR Consortium
TI MACUSTAR: Development and Clinical Validation of Functional, Structural,
   and Patient-Reported Endpoints in Intermediate Age-Related Macular
   Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Intermediate age-related macular degeneration; Disease progression;
   Clinical endpoint; Patient-reported outcomes; Structure-function
   correlation
ID MEDIATED DARK-ADAPTATION; VISUAL-ACUITY LOSS; QUALITY-OF-LIFE;
   GEOGRAPHIC ATROPHY; IMPAIRMENT; MICROPERIMETRY; CLASSIFICATION;
   DYSFUNCTION; PROGRESSION; PREVALENCE
AB Purpose: Currently, no outcome measures are clinically validated and accepted as clinical endpoints by regulatory agencies for drug development in intermediate age-related macular degeneration (iAMD). The MACUSTAR Consortium, a public-private research group funded by the European Innovative Medicines Initiative intends to close this gap. Procedures: Development of study protocol and statistical analysis plan including predictive modelling of multimodal endpoints based on a review of the literature and expert consensus. Results: This observational study consists of a cross-sectional and a longitudinal part. Functional outcome measures assessed under low contrast and low luminance have the potential to detect progression of visual deficit within iAMD and to late AMD. Structural outcome measures will be multimodal and investigate topographical relationships with function. Current patient-reported outcome measures (PROMs) are not acceptable to regulators and may not capture the functional deficit specific to iAMD with needed precision, justifying development of novel PROMs for iAMD. The total sample size will be n = 750, consisting mainly of subjects with iAMD (n = 600). Conclusions: As clinical endpoints currently accepted by regulators cannot detect functional loss or patient-relevant impact in iAMD, we will clinically validate novel candidate endpoints for iAMD. (C) 2018 The Author(s) Published by S. Karger AG, Basel
C1 [Finger, Robert P.; Schmitz-Valckenberg, Steffen; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
   [Schmid, Matthias] Univ Hosp Bonn, Inst Med Biometry Epidemiol & Informat, Bonn, Germany.
   [Rubin, Gary S.; Dunbar, Hannah] UCL, Inst Ophthalmol, London, England.
   [Tufail, Adnan] Moorfields Eye Hosp, London, England.
   [Crabb, David P.; Binns, Alison] City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, London, England.
   [Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Diagnost Image Anal Grp, Nijmegen, Netherlands.
   [Margaron, Philippe; Normand, Guillaume] Novartis Pharma AG, Basel, Switzerland.
   [Durbin, Mary K.] Carl Zeiss Meditec AG, Dublin, CA USA.
   [Luhmann, Ulrich F. O.] Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Translat Med Ophthalmol, Roche Pharmaceut Res & Early Dev, Basel, Switzerland.
   [Cunha-Vaz, Jose] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Asmus, Friedrich] Bayer AG, Therapeut Areas PAO, Dev Pharmaceut, Berlin, Germany.
C3 University of Bonn; University of Bonn; University of London; University
   College London; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; City University London;
   Radboud University Nijmegen; Novartis; Carl Zeiss AG; Roche Holding;
   Universidade de Coimbra; Bayer AG
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
EM robert.finger@ukbonn.de
RI brazier, john e/B-1936-2008; Carlton, Jill/E-6673-2010; Butt,
   Thomas/AAH-7882-2019
OI Carlton, Jill/0000-0002-9373-7663; Butt, Thomas/0000-0002-0387-4550;
   Schmid, Matthias/0000-0002-0788-0317; Cunha-Vaz,
   Jose/0000-0002-0947-9850; Luhmann, Ulrich F.O./0000-0002-1993-1951;
   Finger, Robert P/0000-0003-4253-7597; Tufail, Adnan/0000-0001-6131-7640;
   Crabb, David/0000-0001-8754-3902; Normand,
   Guillaume/0000-0003-1228-3813; Brazier, John/0000-0001-8645-4780
FU Innovative Medicines Initiative 2 Joint Undertaking [116076]; European
   Union; EFPIA; Carl Zeiss Meditec AG
FX This project has received funding from the Innovative Medicines
   Initiative 2 Joint Undertaking under grant agreement No. 116076. This
   Joint Undertaking receives support from the European Union's Horizon
   2020 research and innovation program and EFPIA and Carl Zeiss Meditec
   AG.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Collins GS, 2015, J CLIN EPIDEMIOL, V68, P112, DOI [10.1002/bjs.9736, 10.1038/bjc.2014.639, 10.7326/M14-0697, 10.1016/j.jclinepi.2014.11.010, 10.1161/CIRCULATIONAHA.114.014508, 10.1136/bmj.g7594, 10.1016/j.eururo.2014.11.025, 10.1186/s12916-014-0241-z]
   Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Frost C, 2004, STAT MED, V23, P3275, DOI 10.1002/sim.1909
   Harvey DJ, 2003, J ALZHEIMERS DIS, V5, P357, DOI 10.3233/JAD-2003-5502
   Haymes SA, 2002, OPHTHAL PHYSL OPT, V22, P79, DOI 10.1046/j.1475-1313.2002.00016.x
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Kim JH, 2009, COMPUT STAT DATA AN, V53, P3735, DOI 10.1016/j.csda.2009.04.009
   Laske C, 2014, NEW ENGL J MED, V370, P1459, DOI 10.1056/NEJMc1402193
   Liefers B, 2017, BIOMED OPT EXPRESS, V8, P5160, DOI 10.1364/BOE.8.005160
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Longworth L, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18090
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Nadeau C, 2003, MACH LEARN, V52, P239, DOI 10.1023/A:1024068626366
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pfau M, 2018, BRIT J OPHTHALMOL, V102, P1054, DOI 10.1136/bjophthalmol-2017-311012
   Rentz AM, 2014, JAMA OPHTHALMOL, V132, P310, DOI 10.1001/jamaophthalmol.2013.7639
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P794, DOI 10.1016/j.ophtha.2018.02.027
   Rubin GS, 2013, VISION RES, V90, P43, DOI 10.1016/j.visres.2013.02.015
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   Russell RA, 2012, INVEST OPHTH VIS SCI, V53, P2760, DOI 10.1167/iovs.11-7976
   Sanchez CI, 2015, INVEST OPHTH VIS SCI, V56
   Schott JM, 2006, J NEUROL, V253, P1147, DOI 10.1007/s00415-006-0173-4
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Shah N, 2016, BRIT J OPHTHALMOL, V100, P1346, DOI 10.1136/bjophthalmol-2015-307375
   Shah N, 2011, OPHTHAL PHYSL OPT, V31, P17, DOI 10.1111/j.1475-1313.2010.00806.x
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   Steinberg JS, 2016, RETINA-J RET VIT DIS, V36, P1548, DOI 10.1097/IAE.0000000000000951
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tosh J, 2012, VALUE HEALTH, V15, P118, DOI 10.1016/j.jval.2011.08.002
   van der Ploeg T, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-137
   van Grinsven MJJP, 2015, INVEST OPHTH VIS SCI, V56, P633, DOI 10.1167/iovs.14-15019
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   Venhuizen FG, 2017, BIOMED OPT EXPRESS, V8, P3292, DOI 10.1364/BOE.8.003292
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Weingessel B, 2009, EYE, V23, P1052, DOI 10.1038/eye.2008.237
   Wintergerst MWM, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.10
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
   Zhu HG, 2014, BIOMED OPT EXPRESS, V5, P2215, DOI 10.1364/BOE.5.002215
   Zhu HG, 2010, INVEST OPHTH VIS SCI, V51, P5657, DOI 10.1167/iovs.10-5239
   Zou GY, 2012, STAT MED, V31, P3972, DOI 10.1002/sim.5466
NR 54
TC 42
Z9 42
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2019
VL 241
IS 2
BP 61
EP 72
DI 10.1159/000491402
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HM5LS
UT WOS:000459517800001
PM 30153664
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Minami, S
   Nagai, N
   Suzuki, M
   Kurihara, T
   Sonobe, H
   Kamoshita, M
   Uchida, A
   Shinoda, H
   Takagi, H
   Sonoda, S
   Sakamoto, T
   Tsubota, K
   Ozawa, Y
AF Minami, Sakiko
   Nagai, Norihiro
   Suzuki, Misa
   Kurihara, Toshihide
   Sonobe, Hideki
   Kamoshita, Mamoru
   Uchida, Atsuro
   Shinoda, Hajime
   Takagi, Hitoshi
   Sonoda, Shozo
   Sakamoto, Taiji
   Tsubota, Kazuo
   Ozawa, Yoko
TI Benefits of aflibercept treatment for age-related macular degeneration
   patients with good best-corrected visual acuity at baseline
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RANIBIZUMAB; EYE; BINARIZATION; PEGAPTANIB; THERAPY
AB Currently, age-related macular degeneration (AMD) is treated while patients exhibit good best-corrected visual acuity (BCVA). However, previous clinical trials only include patients with poor BCVA. We prospectively analyzed the benefits of intravitreal aflibercept (IVA) treatment for AMD patients exhibiting good BCVA at baseline. Twenty-nine treatment-naive AMD patients (29 eyes) with BCVA better than 0.6 (74 letters in ETDRS chart) were treated with IVA once a month for 3 months and every 2 months thereafter with no additional treatments. Improvement in mean BCVA, measured using the conventional Landolt C chart, contrast VA chart, and functional VA (FVA) system, and reductions in mean central retinal thickness (CRT), central choroidal thickness, macular volume (MV), and choroidal area on optical coherence tomography images were observed at 6 and 12 months. Improvements in contrast VA and FVA scores, in contrast to conventional BCVA, correlated with MV reduction; no VA scores correlated with a reduced CRT. The MV correlated with choroidal area after IVA. No severe adverse events occurred. IVA improved visual function, retinal condition, and quality of life evaluated by Visual Function Questionnaire, and was beneficial in these patients. The contrast VA and FVA scores and MVs, which detect subtle changes, helped demonstrate the benefits.
C1 [Minami, Sakiko; Nagai, Norihiro; Suzuki, Misa; Kurihara, Toshihide; Sonobe, Hideki; Kamoshita, Mamoru; Uchida, Atsuro; Shinoda, Hajime; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Minami, Sakiko; Takagi, Hitoshi] St Marianna Univ, Sch Med, Dept Ophthalmol, Kawasaki, Kanagawa, Japan.
   [Minami, Sakiko] Inagi Municipal Hosp, Tokyo, Japan.
   [Sonoda, Shozo; Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima, Japan.
   [Nagai, Norihiro; Suzuki, Misa; Kamoshita, Mamoru; Ozawa, Yoko] Keio Univ, Lab Retinal Cell Biol, Sch Med, Tokyo, Japan.
C3 Keio University; Saint Marianna University; Kagoshima University; Keio
   University
RP Ozawa, Y (通讯作者)，Keio Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.; Ozawa, Y (通讯作者)，Keio Univ, Lab Retinal Cell Biol, Sch Med, Tokyo, Japan.
EM ozawa@a5.keio.jp
RI Uchida, Atsuro/GVT-8593-2022; Ozawa, Yoko/AAH-9888-2020; Kurihara,
   Toshihide/ABA-7058-2020; Tsubota, Kazuo/M-1915-2013
OI Kurihara, Toshihide/0000-0002-5457-2720; Uchida,
   Atsuro/0000-0002-1378-7151; Tsubota, Kazuo/0000-0002-8874-7111
CR Abdelfattah NS, 2014, INT J OPHTHALMOL-CHI, V7, P891, DOI 10.3980/j.issn.2222-3959.2014.05.27
   Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   Balcer LJ, 2017, MULT SCLER J, V23, P734, DOI 10.1177/1352458517690822
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Camparini M, 2001, INVEST OPHTH VIS SCI, V42, P1226
   Chan CWS, 2009, BRIT J OPHTHALMOL, V93, P1431, DOI 10.1136/bjo.2009.158428
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Goto E, 2006, OCUL SURF, V4, P207, DOI 10.1016/S1542-0124(12)70167-2
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho V.Y., 2013, AM J OPHTHALMOL, V156
   Kaido M, 2011, JPN J OPHTHALMOL, V55, P451, DOI 10.1007/s10384-011-0049-8
   Kaido M, 2006, AM J OPHTHALMOL, V142, P917, DOI 10.1016/j.ajo.2006.07.055
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Nishi Y, 2013, ACTA OPHTHALMOL, V91, pE353, DOI 10.1111/aos.12060
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Suzuki M, 2016, AM J OPHTHALMOL, V166, P52, DOI 10.1016/j.ajo.2016.03.024
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Szczupak L, 2016, CURR OPIN NEUROBIOL, V41, P99, DOI 10.1016/j.conb.2016.08.005
   Tomita Y, 2016, OPTOMETRY VISION SCI, V93, P70, DOI 10.1097/OPX.0000000000000755
   TSUBOTA K, 1993, NEW ENGL J MED, V328, P584, DOI 10.1056/NEJM199302253280817
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Yamamoto A., 2017, OPHTHALMOLOGICA J IN
   Zhang L, 2014, INVEST OPHTH VIS SCI, V55, P2329, DOI 10.1167/iovs.13-13048
NR 32
TC 6
Z9 6
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 8
PY 2018
VL 8
AR 58
DI 10.1038/s41598-017-18255-4
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FS0CP
UT WOS:000419441800011
PM 29311612
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Montes, T
   Tortajada, A
   Morgan, BP
   de Cordoba, SR
   Harris, CL
AF Montes, Tamara
   Tortajada, Agustin
   Morgan, B. Paul
   Rodriguez de Cordoba, Santiago
   Harris, Claire L.
TI Functional basis of protection against age-related macular degeneration
   conferred by a common polymorphism in complement factor B
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE alternative pathway; AMD
ID FACTOR-H POLYMORPHISM; ALTERNATIVE PATHWAY; INFLAMMATION; GENES; RISK;
   ACTIVATION; VARIANT; HLA; C2; PATHOGENESIS
AB Mutations and polymorphisms in complement genes have been linked with numerous rare and prevalent disorders, implicating dysregulation of complement in pathogenesis. The 3 common alleles of factor B (fB) encode Arg (fB(32R)), Gln (fB(32Q)), or Trp (fB(32W)) at position 32 in the Ba domain. The fB(32Q) allele is protective for age-related macular degeneration, the commonest cause of blindness in developed countries. Factor B variants were purified from plasma of homozygous individuals and were tested in hemolysis assays. The protective variant fB(32Q) had decreased activity compared with fB(32R). Biacore comparison revealed markedly different proenzyme formation; fB(32R) bound C3b with 4-fold higher affinity, and formation of activated convertase was enhanced. Binding and functional differences were confirmed with recombinant fB(32R) and fB(32Q); an intermediate affinity was revealed for fB(32W). To confirm contribution of Ba to binding, affinity of Ba for C3b was determined. Ba-fB(32R) had 3-fold higher affinity compared with Ba-fB(32Q). We demonstrate that the disease-protective effect of fB(32Q) is consequent on decreased potential to form convertase and amplify complement activation. Knowledge of the functional consequences of polymorphisms in complement activators and regulators will aid disease prediction and inform targeting of diagnostics and therapeutics.
C1 [Morgan, B. Paul; Harris, Claire L.] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales.
   [Montes, Tamara; Tortajada, Agustin; Rodriguez de Cordoba, Santiago] Ctr Invest Biomed Red Enfermedades Raras, CSIC, Ctr Invest Biol, Madrid 28040, Spain.
   [Montes, Tamara; Tortajada, Agustin; Rodriguez de Cordoba, Santiago] Fdn Renal Inigo Alvarez de Toledo, Madrid 28040, Spain.
C3 Cardiff University; CIBER - Centro de Investigacion Biomedica en Red;
   CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC -
   Centro de Investigaciones Biologicas (CIB)
RP Harris, CL (通讯作者)，Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Henry Wellcome Bldg,Heath Pk, Cardiff CF14 4XN, S Glam, Wales.
EM harriscl@cardiff.ac.uk
RI Tortajada, Agustín/H-2857-2015; de Cordoba, Santiago
   Rodriguez/K-6727-2014
OI Tortajada, Agustín/0000-0002-2131-2594; de Cordoba, Santiago
   Rodriguez/0000-0001-6401-1874; Morgan, Paul/0000-0003-4075-7676
FU Wellcome Trust [068823, 06850]; Medical Research Council [84908];
   Ministerio de Ciencia e Innovacio [SAF 2008-00226]; Centro de
   Investigacion Biome medica en Red de Enfermedades Raras; Fundacion Renal
   Inigo Alvarez de Toledo; MRC [G0701298] Funding Source: UKRI; Medical
   Research Council [G0701298] Funding Source: researchfish
FX We thank the blood donors for their invaluable contribution to the
   project. This work was supported by Wellcome Trust University Award
   068823 (to C. L. H.), Medical Research Council Project Grant 84908 (to
   C. L. H. and B. P. M.), Ministerio de Ciencia e Innovacio Grant SAF
   2008-00226 (to S. R. d. C.), and the Centro de Investigacion Biome
   medica en Red de Enfermedades Raras and Fundacion Renal Inigo Alvarez de
   Toledo (to S. R. d. C.). B. P. M. was funded by a Wellcome Trust Program
   Grant (06850).
CR ABBAL M, 1985, HUM GENET, V69, P181, DOI 10.1007/BF00293294
   Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   ALPER CA, 1972, J EXP MED, V135, P68, DOI 10.1084/jem.135.1.68
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Atkinson JP, 2005, ANN NY ACAD SCI, V1056, P144, DOI 10.1196/annals.1352.032
   DAVRINCHE C, 1990, IMMUNOGENETICS, V32, P309
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAGGLOF B, 1986, HUM HERED, V36, P201, DOI 10.1159/000153627
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Harris CL, 2005, J BIOL CHEM, V280, P2569, DOI 10.1074/jbc.M410179200
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HORIUCHI T, 1993, MOL IMMUNOL, V30, P1587
   JAHN I, 1994, EUR J IMMUNOGENET, V21, P415, DOI 10.1111/j.1744-313X.1994.tb00214.x
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LACHMANN PJ, 1984, SPRINGER SEMIN IMMUN, V7, P143, DOI 10.1007/BF01893018
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MAUFF G, 1980, IMMUNOBIOLOGY, V158, P86, DOI 10.1016/S0171-2985(80)80045-3
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Messias-Reason IJ, 2003, TISSUE ANTIGENS, V62, P308, DOI 10.1034/j.1399-0039.2003.00101.x
   Milder FJ, 2007, NAT STRUCT MOL BIOL, V14, P224, DOI 10.1038/nsmb1210
   Morgan B P, 2000, Methods Mol Biol, V150, P1
   Morgan B. P., 1999, COMPLEMENT REGULATOR
   MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366
   MORTENSEN JP, 1981, IMMUNOLOGY, V42, P505
   PAPIHA SS, 1991, HUM HERED, V41, P397, DOI 10.1159/000154033
   PRYZDIAL ELG, 1987, J BIOL CHEM, V262, P1519
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 43
TC 86
Z9 97
U1 0
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 17
PY 2009
VL 106
IS 11
BP 4366
EP 4371
DI 10.1073/pnas.0812584106
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 420HD
UT WOS:000264278800057
PM 19255449
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Thakkinstian, A
   Han, P
   McEvoy, M
   Smith, W
   Hoh, J
   Magnusson, K
   Zhang, K
   Attia, J
AF Thakkinstian, Ammarin
   Han, Pearline
   McEvoy, Mark
   Smith, Wayne
   Hoh, Josephine
   Magnusson, Kristinn
   Zhang, Kang
   Attia, John
TI Systematic review and meta-analysis of the association between
   complementary factor HY402H polymorphisms and age-related macular
   degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Review
ID FACTOR-H POLYMORPHISM; BEAVER DAM EYE; APOLIPOPROTEIN-E GENOTYPE;
   MOLECULAR ASSOCIATION; SUSCEPTIBILITY LOCI; GENOMEWIDE-SCAN; DISEASE
   ASSOCIATIONS; FAMILIAL AGGREGATION; GENE POLYMORPHISMS; EXTENDED
   FAMILIES
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and complement factor H (CFH) polymorphism has been found to associated with the AMD. We performed a meta-analysis to estimate the magnitude of the gene effect and the possible mode of action. A meta-analysis of eight studies assessing association between the CFH Y402H polymorphism and AMD was performed. Data extraction and study quality assessment were performed in duplicate, and heterogeneity and publication bias were explored. There was strong evidence for association between CFH and AMD, with those having CC and TC genotypes being roughly six and 2.5 times more likely to have AMD than patients with TT genotype, suggesting a co-dominant, multiplicative genetic model. The population attributable risk for the CC/TC genotype is 58.9%, i.e. the CFH polymorphism is involved in over half of all AMD. This meta-analysis summarizes the strong evidence for an association between CFH and AMD and indicates a multiplicative model with each C allele increasing the odds of AMD by similar to 2.5-fold. This result is at least as important at the population level as ApoE4 and Alzheimer's disease, playing a role in almost 60% of AMD at the population level.
C1 Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
   Univ Newcastle, Clin Pharmacol Unit, Sch Med Practice & Populat Hlth, Newcastle, NSW 2308, Australia.
   Mahidol Univ, Ramathibodi Hosp, Fac Med, Clin Epidemiol Unit, Bangkok 10400, Thailand.
   Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT USA.
   deCODE Genet Inc, Reykjavik, Iceland.
   Univ Utah, Eccles Inst Human Genet, Salt Lake City, UT USA.
C3 University of Newcastle; University of Newcastle; Mahidol University;
   Yale University; Utah System of Higher Education; University of Utah
RP Thakkinstian, A (通讯作者)，Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
EM ammarin.thakkinstian@newcastle.edu.au
RI Thakkinstian, Ammarin/J-4788-2019; Attia, John R/F-5376-2013; Magnusson,
   Kristinn P Pétur/X-4907-2019; Zhang, Kang/Y-2740-2019; Magnusson,
   Kristinn/A-6479-2011
OI Attia, John R/0000-0001-9800-1308; Magnusson, Kristinn P
   Pétur/0000-0003-4528-6826; Zhang, Kang/0000-0002-4549-1697; Magnusson,
   Kristinn/0000-0003-4528-6826; McEvoy, Mark/0000-0002-5505-5557
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   EGGER M, 2001, SYSTEMATIC REV HLTH
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gorin MB, 1999, MOL VIS, V5, pU31
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hayden KM, 2005, J AM GERIATR SOC, V53, P935, DOI 10.1111/j.1532-5415.2005.53301.x
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HERNANDEZ JL, 1989, BIOMETRICS, V45, P53, DOI 10.2307/2532034
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Minelli C, 2005, INT J EPIDEMIOL, V34, P1319, DOI 10.1093/ije/dyi169
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Pang CP, 2002, HUM MUTAT, V19, P189, DOI 10.1002/humu.10053
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rossman MD, 2003, AM J HUM GENET, V73, P720, DOI 10.1086/378097
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Souied EH, 2005, MOL VIS, V11, P1135
   Spiegelhalter D., 2003, WINBUGS USER MANUAL
   *STAT CORP, 2005, STAT STAT SOFTW REL
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thakkinstian A, 2004, J BONE MINER RES, V19, P419, DOI 10.1359/JBMR.0301265
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Thompson SG, 1997, STAT MED, V16, P2741, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2741::AID-SIM703>3.0.CO;2-0
   THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trikalinos TA, 2006, AM J EPIDEMIOL, V163, P300, DOI 10.1093/aje/kwj046
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 60
TC 176
Z9 183
U1 0
U2 22
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD SEP 15
PY 2006
VL 15
IS 18
BP 2784
EP 2790
DI 10.1093/hmg/ddl220
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 085FZ
UT WOS:000240590400013
PM 16905558
DA 2022-11-30
ER

PT J
AU Potilinski, MC
   Tate, PS
   Lorenc, VE
   Gallo, JE
AF Constanza Potilinski, Maria
   Tate, Pablo S.
   Lorenc, Valeria E.
   Gallo, Juan E.
TI New insights into oxidative stress and immune mechanisms involved in
   age-related macular degeneration tackled by novel therapies
SO NEUROPHARMACOLOGY
LA English
DT Review
DE Age-related macular degeneration; Oxidative stress; Signaling; Innate
   immunity; Adaptative immunity; Alpha-1 antitrypsin
ID PIGMENT EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; ACID PHENETHYL
   ESTER; PROTECTS RPE CELLS; UP-REGULATION; GENE-THERAPY; VEGF-TRAP;
   HYDROXYTYROSOL PROTECTS; RETINAL DEGENERATION; SIGNALING PATHWAYS
AB The prevalence of age-related macular degeneration (AMD) has increased in the last years. Although anti-VEGF agents have improved the prognosis of exudative AMD, dry AMD has still devastating effects on elderly people vision. Oxidative stress and inflammation are mechanisms involved in AMD pathogenesis and its progression. Molecular pathways involving epidermal growth factor receptor (EGFR), bone morphogenetic protein (BMP4) and the nuclear erythroid related factor 2 (Nrf2) are behind oxidative stress in AMD due to their participation in antioxidant cellular pathways. As a consequence of the disbalance produced in the antioxidant mechanisms, there is an activation of innate and adaptative immune response with cell recruitment, changes in complement factors expression, and modification of cellular milieu. Different therapies are being studied to treat dry AMD based on the possible effects on antioxidant molecular pathways or their action on the immune response. There is a wide range of treatments presented in this review, from natural antioxidant compounds to cell and gene therapy, based on their mechanisms. Finally, we hypothesize that alpha-1-antitrypsin (AAT), an antiinflammatory and immunomodulatory molecule that can also modulate antioxidant cellular defenses, could be a good candidate for testing in AMD.
   This article is part of the special ssue on 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.
C1 [Constanza Potilinski, Maria; Lorenc, Valeria E.; Gallo, Juan E.] Univ Austral, Inst Invest Med Translac, Nanomed & Vis Lab, CONICET, JD Peron 1500, Pilar, Buenos Aires, Argentina.
   [Tate, Pablo S.] Univ Austral, Inst Invest Med Translac, Lab Enfermedades Neurodegenerat, CONICET, Pilar, Buenos Aires, Argentina.
   [Gallo, Juan E.] Hosp Univ Austral, Dept Oftalmol, Pilar, Buenos Aires, Argentina.
C3 Austral University; Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET); Austral University; Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET); Austral University;
   Hospital Universitario Austral
RP Gallo, JE (通讯作者)，Univ Austral, Inst Invest Med Translac, Nanomed & Vis Lab, CONICET, JD Peron 1500, Pilar, Buenos Aires, Argentina.
EM jgallo@cas.austral.edu.ar
OI Potilinski, Constanza/0000-0003-4116-5875
FU Agencia Nacional de Promocion Cientifica y Tecnologica [PICTO
   2016-0105]; Universidad Austral [O05-PDISR073]
FX This work was funded by Agencia Nacional de Promocion Cientifica y
   Tecnologica, JEG, MCP (PICTO 2016-0105), and Universidad Austral, MCP
   (grant number O05-PDISR073). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Ambreen F, 2015, MOL VIS, V21, P985
   [Anonymous], 2019, OXID MED CELL LONGEV, DOI DOI 10.1155/2019/
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Arroba AI, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00203
   Askou AL, 2018, METHODS MOL BIOL, V1715, P47, DOI 10.1007/978-1-4939-7522-8_4
   Bals R, 2010, BEST PRACT RES CL GA, V24, P629, DOI 10.1016/j.bpg.2010.08.006
   Baraldo S, 2016, RESPIRATION, V91, P380, DOI 10.1159/000445692
   Barben M, 2018, CELL DEATH DIFFER, V25, P2071, DOI 10.1038/s41418-018-0094-7
   Batabyal S, 2019, CURR GENE THER, V19, P318, DOI 10.2174/1566523219666191017114044
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Biswal MR, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21272
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Bouchecareilh M, 2012, CURR MOL MED, V12, P815, DOI 10.2174/156652412801318782
   Brilliant MH, 2016, AM J MED, V129, P292, DOI 10.1016/j.amjmed.2015.10.015
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Campbell JP, 2014, OCUL IMMUNOL INFLAMM, V22, P161, DOI 10.3109/09273948.2013.831907
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Cashman SM, 2015, J GENE MED, V17, P229, DOI 10.1002/jgm.2865
   Chen S, 2018, MOL CELL BIOCHEM, V448, P225, DOI 10.1007/s11010-018-3328-6
   Chen XD, 2017, INT J OPHTHALMOL-CHI, V10, P507, DOI 10.18240/ijo.2017.04.02
   Cheng LB, 2014, INT J MOL SCI, V15, P18762, DOI 10.3390/ijms151018762
   Childs BG, 2017, NAT REV DRUG DISCOV, V16, P718, DOI 10.1038/nrd.2017.116
   Chistyakov DV, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030704
   Cho C, 2019, ADV EXP MED BIOL, V1185, P557, DOI 10.1007/978-3-030-27378-1_91
   Choudhary M, 2019, ADV EXP MED BIOL, V1185, P9, DOI 10.1007/978-3-030-27378-1_2
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Potilinski MC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228895
   Cui RZ, 2020, OPHTHALMIC RES, V63, P404, DOI 10.1159/000504891
   Cui YT, 2020, FREE RADICAL BIO MED, V148, P52, DOI 10.1016/j.freeradbiomed.2019.12.033
   Dierich M.P., 1979, IMMUNOBIOLOGY, V156
   Dimeloe S, 2019, J STEROID BIOCHEM, V189, P1, DOI 10.1016/j.jsbmb.2019.01.014
   Dinc E, 2017, CURR EYE RES, V42, P1659, DOI 10.1080/02713683.2017.1368085
   Ding DM, 2018, BIOCHEM BIOPH RES CO, V503, P2742, DOI 10.1016/j.bbrc.2018.08.034
   Dong X, 2011, MOL VIS, V17, P2040
   Ebrahimi T, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1319-x
   Ehlers MR, 2014, BIOL CHEM, V395, P1187, DOI 10.1515/hsz-2014-0161
   Elbaz-Hayoun S, 2019, MOL VIS, V25, P479
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21018
   FDA Center for Drug Evaluation and Research, 2019, 212306 FDA XPOVIO ND
   Fei SK, 2019, MED SCI MONITOR, V25, P7694, DOI 10.12659/MSM.919148
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Feng YL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173711
   Feng YL, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00176
   Feng ZH, 2010, J NUTR BIOCHEM, V21, P1222, DOI 10.1016/j.jnutbio.2009.10.010
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Forrester JV, 2018, AM J OPHTHALMOL, V189, P77, DOI 10.1016/j.ajo.2018.02.019
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hanus J, 2015, INVEST OPHTH VIS SCI, V56, P5048, DOI 10.1167/iovs.15-16401
   He HJ, 2019, J CELL MOL MED, V23, P3495, DOI 10.1111/jcmm.14246
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Huang SY, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080380
   Hughes CP, 2019, MOL THER-METH CLIN D, V13, P86, DOI 10.1016/j.omtm.2018.11.005
   Hyttinen JMT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225800
   Ildefonso CJ, 2016, INVEST OPHTH VIS SCI, V57, P372, DOI 10.1167/iovs.15-17703
   Jack LS, 2016, DEV OPHTHALMOL, V55, P302, DOI 10.1159/000438954
   Jadeja RN, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101336
   Jain A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05489-7
   Jana M, 2007, J IMMUNOL, V179, P4142, DOI 10.4049/jimmunol.179.6.4142
   Janciauskiene S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00341
   Jang H, 2015, MOL NUTR FOOD RES, V59, P1918, DOI 10.1002/mnfr.201400897
   Jang H, 2014, J AGR FOOD CHEM, V62, P182, DOI 10.1021/jf404285v
   Jiang JJ, 2021, FUND CLIN PHARMACOL, V35, P4, DOI 10.1111/fcp.12561
   Jiao HH, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0278-0
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Jordan SC, 2020, AM J TRANSPLANT, V20, P2581, DOI 10.1111/ajt.15922
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kim M, 2018, ANN PEDIATR ENDOCRIN, V23, P131, DOI 10.6065/apem.2018.23.3.131
   Kim SH, 2019, FREE RADICAL RES, V53, P865, DOI 10.1080/10715762.2019.1637862
   Klein R, 2020, OPHTHALMOLOGY, V127, pS122, DOI 10.1016/j.ophtha.2020.01.033
   Kolosova NG, 2018, AGING-US, V10, P2136, DOI 10.18632/aging.101537
   Koskela A, 2014, MOL VIS, V20, P760
   Kubota R, 2019, INVEST OPHTH VIS SCI, V60, P4924, DOI 10.1167/iovs.19-28194
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Landa G, 2011, J OCUL PHARMACOL TH, V27, P77, DOI 10.1089/jop.2010.0109
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lashkari K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195751
   Lee SHS, 2019, MOL THER-METH CLIN D, V14, P171, DOI 10.1016/j.omtm.2019.06.004
   Lee SHS, 2018, INVEST OPHTH VIS SCI, V59, P5398, DOI 10.1167/iovs.18-24926
   Lee YY, 2013, INT J MOL SCI, V14, P9820, DOI 10.3390/ijms14059820
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Li YH, 2013, INT J FLOW CONTROL, V4, P1
   Li Y, 2013, TOXICOL APPL PHARM, V272, P726, DOI 10.1016/j.taap.2013.07.029
   Li ZR, 2013, MOL VIS, V19, P1656
   Liang KJ, 2017, MOL THER, V25, P765, DOI 10.1016/j.ymthe.2016.12.016
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu XB, 2016, REDOX BIOL, V8, P98, DOI 10.1016/j.redox.2015.12.005
   Liu ZB, 2007, J NEUROCHEM, V103, P2690, DOI 10.1111/j.1471-4159.2007.04954.x
   Liutkeviciene R, 2019, GENE, V686, P8, DOI 10.1016/j.gene.2018.11.004
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Marquioni-Ramella MD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1560, DOI 10.1039/c5pp00188a
   Maugeri A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7532507
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   Mimouni M, 2018, JPN J OPHTHALMOL, V62, P652, DOI 10.1007/s10384-018-0619-0
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   MOD A, 1981, IMMUNOBIOLOGY, V158, P338, DOI 10.1016/S0171-2985(81)80005-8
   Nakamura S, 2019, INVEST OPHTH VIS SCI, V60, P1943, DOI 10.1167/iovs.18-25745
   National Eye Institute, 2019, AG REL MAC DEG AMD D
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Ni TM, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190689
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Nielsen MK, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0100-9
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   O'Brien ME, 2020, THORAX, V75, P321, DOI 10.1136/thoraxjnl-2019-214076
   Ortiz G, 2018, EXP EYE RES, V174, P29, DOI 10.1016/j.exer.2018.05.013
   Ortiz G, 2014, BIOL RES, V47, DOI 10.1186/0717-6287-47-58
   Paeng SH, 2015, INT J MOL MED, V35, P1419, DOI 10.3892/ijmm.2015.2116
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park GB, 2018, MOL MED REP, V17, P3563, DOI 10.3892/mmr.2017.8355
   Pechan P, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017335
   Pitha-Rowe I, 2009, INVEST OPHTH VIS SCI, V50, P5339, DOI 10.1167/iovs.09-3648
   Potilinski MC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072351
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Ramos EM, 2014, AM J MED GENET C, V166, P93, DOI 10.1002/ajmg.c.31386
   Ratnapriya R, 2020, HUM MOL GENET, V29, P2022, DOI 10.1093/hmg/ddaa057
   Rezaie T, 2012, INVEST OPHTH VIS SCI, V53, P7847, DOI 10.1167/iovs.12-10793
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sarabhai T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177450
   Sato T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55191-x
   Schnabolk G, 2018, MOL THER-METH CLIN D, V9, P1, DOI 10.1016/j.omtm.2017.11.003
   Shao Y, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1479571
   Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Shaw LT, 2020, EXPERT OPIN INV DRUG, V29, P547, DOI 10.1080/13543784.2020.1763953
   Sheu SJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213932
   Shiragami C, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006422
   Siebers K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00877
   Slusarczyk J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071965
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Tamura K, 2015, REPROD SCI, V22, P1088, DOI 10.1177/1933719115570901
   Tate PS, 2020, J FUNCT FOODS, V67, DOI 10.1016/j.jff.2020.103833
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Vu KT, 2017, EXP EYE RES, V164, P31, DOI 10.1016/j.exer.2017.08.001
   Wang BW, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0122-1
   Wang HB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52163-z
   Wang K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51151-7
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wei YL, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010422
   Willermain F, 2012, PROG RETIN EYE RES, V31, P182, DOI 10.1016/j.preteyeres.2011.11.004
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2018, PRIOR EYE DIS
   Xiaokaiti Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep11494
   Xie XB, 2017, MOL VIS, V23, P520
   Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y
   Xu J, 2011, FASEB J, V25, P2221, DOI 10.1096/fj.10-178350
   Xu XZ, 2019, FREE RADICAL BIO MED, V143, P387, DOI 10.1016/j.freeradbiomed.2019.08.024
   Xu Y, 2012, MOL ONCOL, V6, P405, DOI 10.1016/j.molonc.2012.03.005
   Yang PM, 2016, LIFE SCI, V155, P94, DOI 10.1016/j.lfs.2016.05.006
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
   Zhang JY, 2015, J CLIN INVEST, V125, P2781, DOI 10.1172/JCI80950
   Zhao HL, 2019, INT J MOL MED, V43, P936, DOI 10.3892/ijmm.2018.4027
   Zhao S, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014645
   Zhao XW, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0192-6
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01202
   Zhou YQ, 2019, CURR MOL MED, V19, P172, DOI 10.2174/1566524019666190424131704
   Zhu C, 2015, NEUROSCIENCE, V304, P328, DOI 10.1016/j.neuroscience.2015.07.057
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
   Zhu L, 2010, J NUTR BIOCHEM, V21, P1089, DOI 10.1016/j.jnutbio.2009.09.006
   Zhu Q, 2019, ARTIF CELL NANOMED B, V47, P2010, DOI 10.1080/21691401.2019.1608217
   Zou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.190
NR 195
TC 5
Z9 5
U1 4
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD MAY 1
PY 2021
VL 188
AR 108513
DI 10.1016/j.neuropharm.2021.108513
EA MAR 2021
PG 13
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA RS1SF
UT WOS:000643563300009
PM 33662390
DA 2022-11-30
ER

PT J
AU Xu, YS
   Lu, B
   Zhou, YN
   Ren, SX
   Pang, GM
   Deng, AJ
AF Xu, Yunsheng
   Lu, Bo
   Zhou, Yana
   Ren, Shuxia
   Pang, Guoming
   Deng, Aijun
TI Is dietary fat associated with the risk of age-related macular
   degeneration? Protocol for a systematic review and meta-analysis
SO MEDICINE
LA English
DT Review
DE age-related macular degeneration; dietary fat; meta-analysis; protocol;
   systematic review
ID CORONARY-HEART-DISEASE; PREVALENCE; PROGRESSION; ACIDS
AB Previous studies evaluating the association of dietary fat and risk of age-related macular degeneration (AMD) yield discrepant results. The objective of this systematic review (SR) and meta-analysis is to establish whether an association exists between dietary fat and AMD. This protocol was developed in line with the quality requirements of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement. PubMed and EMBASE will be searched for randomized controlled trials (RCTs), non-randomized trials (NRTs), cross-sectional studies, cohort studies, and case-control studies that evaluate the total incidence of AMD. The data extraction content and quantitative analysis will be carried out systematically. Newcastle-Ottawa Scale (NOS), the Cochrane risk of bias tool, and quality assessment tools will be used for quality assessment. This SR will synthesize evidence to determine if there is an association between dietary fat and AMD. The evidence would provide rationale for future research and serve as a basis for the development of future guidelines. Results are expected to be publicly available in mid 2020. PROSPERO registration number: CRD42019137086.
C1 [Xu, Yunsheng] Shandong Univ Tradit Chinese Med, Affiliated Hosp 2, Jinan, Shandong, Peoples R China.
   [Lu, Bo] Shaanxi Tradit Chinese Med Hosp, Xian, Shaanxi, Peoples R China.
   [Zhou, Yana] Hubei Prov Hosp Tradit Chinese Med, Wuhan, Hubei, Peoples R China.
   [Ren, Shuxia] Tianjin Polytech Univ, Sch Comp Sci & Technol, Tianjin, Peoples R China.
   [Pang, Guoming] Kaifeng Hosp Tradit Chinese Med, Kaifeng 475000, Henan, Peoples R China.
   [Deng, Aijun] Weifang Med Univ, Affiliated Hosp, Dept Ophthalmol, Weifang 261031, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Tiangong
   University; Weifang Medical University
RP Pang, GM (通讯作者)，Kaifeng Hosp Tradit Chinese Med, Kaifeng 475000, Henan, Peoples R China.; Deng, AJ (通讯作者)，Weifang Med Univ, Affiliated Hosp, Dept Ophthalmol, Weifang 261031, Shandong, Peoples R China.
EM kfszyypgm@163.com; 15966077166@163.com
FU National Key Research and Development Program of China [2017YFC1703502]
FX This study is supported by National Key Research and Development Program
   of China (No.2017YFC1703502).
CR Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   de Roos B, 2009, BRIT J PHARMACOL, V158, P413, DOI 10.1111/j.1476-5381.2009.00189.x
   Demaison L, 2002, CELL MOL LIFE SCI, V59, P463, DOI 10.1007/s00018-002-8439-1
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Li YP, 2015, J AM COLL CARDIOL, V66, P1538, DOI 10.1016/j.jacc.2015.07.055
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Mance TC, 2011, COLLEGIUM ANTROPOL, V35, P307
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.i4086]
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Tarsilla M, 2008, COCHRANE HDB SYSTEMA
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Welch VA, 2017, J CLIN EPIDEMIOL, V90, P59, DOI 10.1016/j.jclinepi.2017.01.014
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 22
TC 1
Z9 1
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD APR
PY 2020
VL 99
IS 17
AR e19081
DI 10.1097/MD.0000000000019081
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ME5SP
UT WOS:000544715800006
PM 32332595
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Son, Y
   Lim, D
   Park, S
   Song, IS
   Kim, JH
   Shin, S
   Jang, H
   Liu, KH
   Yuseok, O
   Song, GY
   Kang, W
   Cho, YS
   Na, M
   Chung, H
   Oh, S
AF Son, Younglim
   Lim, Daehan
   Park, Seoyoung
   Song, Im-Sook
   Kim, Joo-Hyun
   Shin, Sora
   Jang, Hoik
   Liu, Kwang-Hyeon
   Yuseok, O.
   Song, Gyu-Yong
   Kang, Wonku
   Cho, Yun-Seok
   Na, MinKyun
   Chung, Hyewon
   Oh, Sangtaek
TI Ilimaquinone inhibits neovascular age-related macular degeneration
   through modulation of Wnt/beta-catenin and p53 pathways
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Neovascular age-related macular degeneration; Ilimaquinone;
   Wnt/beta-catenin pathway; p53 pathway
ID TYROSINE KINASE INHIBITOR; MARINE SPONGE METABOLITES; WNT SIGNALING
   PATHWAY; BETA-CATENIN; CHOROIDAL NEOVASCULARIZATION; PATHOGENIC ROLE;
   ACTIVATION; ANGIOGENESIS; CELLS; RECEPTOR
AB Neovascular age-related macular degeneration (nAMD) is a common cause of irreversible vision loss in the elderly. Anti-vascular endothelial growth factor has been effective in treating pathological ocular neovascularization, but it has limitations including the need for repeated intraocular injections for the maintenance of therapeutic effects in most patients and poor or non-response to this agent in some patients. in vitro cellular studies were conducted using retinal pigment epithelial cell lines (ARPE-19 and hTERT-RPE1), human umbilical vein endothelial cells (HUVECs), and human umbilical vein smooth muscle cells (HUVSMCs). in vivo efficacy of ilimaquinone (IQ) was tested in laser-induced choroidal neovascularization mouse and rabbit models. Tissue distribution study was performed in male C57BL6/J mice. IQ, 4,9-friedodrimane-type sesquiterpenoid isolated from the marine sponge, repressed the expression of angiogenic/inflammatory factors and restored the expression of E-cadherin in retinal pigment epithelial cells by inhibiting the Wnt/beta-catenin pathway. In addition, it selectively inhibited proliferation and tube formation of HUVECs by activating the p53 pathway. Topical and intraperitoneal administration of IQ significantly reduced choroidal neovascularization in rabbits and mice with laser-induced choroidal neovascularization. Notably, IQ by the oral route of exposure was highly permeable to the eyes and suppressed abnormal vascular leakage by downregulation of beta-catenin and stabilization of p53 in vivo. Our findings demonstrate that IQ functions through regulation of p53 and Wnt/beta-catenin pathways with conceivable advantages over existing cytokine-targeted anti-angiogenic therapies.
C1 [Son, Younglim; Park, Seoyoung; Kim, Joo-Hyun; Shin, Sora; Oh, Sangtaek] Kookmin Univ, Dept Bio & Fermentat Convergence Technol, Seoul 02707, South Korea.
   [Lim, Daehan; Jang, Hoik; Chung, Hyewon] Konkuk Univ, Dept Ophthalmol, Sch Med, Seoul 05030, South Korea.
   [Song, Im-Sook; Liu, Kwang-Hyeon] Kyungpook Natl Univ, Coll Pharm, Daegu 41566, South Korea.
   [Song, Im-Sook; Liu, Kwang-Hyeon] Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu 41566, South Korea.
   [Yuseok, O.; Song, Gyu-Yong; Na, MinKyun] Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea.
   [Kang, Wonku] Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea.
   [Cho, Yun-Seok] Hanlim Pharm Co Ltd, R&D Ctr, Seoul 06634, South Korea.
C3 Kookmin University; Konkuk University; Konkuk University Medical Center;
   Kyungpook National University; Kyungpook National University; Chungnam
   National University; Chung Ang University
RP Oh, S (通讯作者)，Kookmin Univ, Dept Bio & Fermentat Convergence Technol, Seoul 02707, South Korea.; Chung, H (通讯作者)，Konkuk Univ, Dept Ophthalmol, Sch Med, Seoul 05030, South Korea.; Na, M (通讯作者)，Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea.
EM mkna@cnu.ac.kr; hchung@kuh.ac.kr; ohsa@kookmin.ac.kr
FU National Research Foundation of Korea (NRF) - Korean Government
   [2017R1E1A1A01073964, 2020R1A2B5B01002415, 2020R1A2C1010109]
FX This work was supported by the Fundamental Technology Program
   (2017R1E1A1A01073964,2020R1A2B5B01002415, 2020R1A2C1010109) through the
   National Research Foundation of Korea (NRF) funded by the Korean
   Government.
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Baek A, 2017, AUTOPHAGY, V13, P248, DOI 10.1080/15548627.2016.1256932
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543
   Chavala SH, 2013, J CLIN INVEST, V123, P4170, DOI 10.1172/JCI67315
   Chen HC, 2012, LAB INVEST, V92, P676, DOI 10.1038/labinvest.2011.201
   Chen SW, 2015, DEVELOPMENT, V142, P1180, DOI 10.1242/dev.113506
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   del Amo EM, 2015, EXP EYE RES, V137, P111, DOI 10.1016/j.exer.2015.05.003
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Elice F, 2012, THROMB RES, V129, pS50, DOI 10.1016/S0049-3848(12)70016-6
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gu QH, 2015, PHARMACOL RES, V97, P70, DOI 10.1016/j.phrs.2015.04.004
   Guo QY, 2019, PHARMACOL RES, V144, P151, DOI 10.1016/j.phrs.2019.03.022
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q
   Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kang S, 2013, EXP EYE RES, V112, P125, DOI 10.1016/j.exer.2013.05.006
   Kappers MHW, 2009, J HYPERTENS, V27, P2297, DOI 10.1097/HJH.0b013e3283309b59
   Kim JH, 2015, BMB REP, V48, P525, DOI 10.5483/BMBRep.2015.48.9.140
   Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744
   Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200
   Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee HY, 2015, MAR DRUGS, V13, P543, DOI 10.3390/md13010543
   Li H, 2014, BIOCHEM BIOPH RES CO, V446, P347, DOI 10.1016/j.bbrc.2014.02.119
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Lu PH, 2007, EUR J PHARMACOL, V556, P45, DOI 10.1016/j.ejphar.2006.10.061
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Park S, 2006, MOL PHARMACOL, V70, P960, DOI 10.1124/mol.106.024729
   Park S, 2014, MAR DRUGS, V12, P3231, DOI 10.3390/md12063231
   Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606
   Pop C, 2009, J BIOL CHEM, V284, P21777, DOI 10.1074/jbc.R800084200
   Prasad PS, 2010, MATURITAS, V66, P46, DOI 10.1016/j.maturitas.2010.02.006
   Radeke HS, 1999, CHEM BIOL, V6, P639, DOI 10.1016/S1074-5521(99)80115-X
   Ravi R, 2000, GENE DEV, V14, P34
   Sherif ZA, 2001, CANCER GENE THER, V8, P771, DOI 10.1038/sj.cgt.7700361
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Sidman RL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4882
   Speidel D, 2010, TRENDS CELL BIOL, V20, P14, DOI 10.1016/j.tcb.2009.10.002
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Yafai Y, 2011, EUR J PHARMACOL, V666, P12, DOI 10.1016/j.ejphar.2011.05.016
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 55
TC 2
Z9 2
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
EI 1096-1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD NOV
PY 2020
VL 161
AR 105146
DI 10.1016/j.phrs.2020.105146
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA PI3JG
UT WOS:000600990100040
PM 32814173
DA 2022-11-30
ER

PT J
AU Owsley, C
   Clark, ME
   McGwin, G
AF Owsley, Cynthia
   Clark, Mark E.
   McGwin, Gerald, Jr.
TI Natural History of Rod-Mediated Dark Adaptation over 2 Years in
   Intermediate Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; endpoint; dark adaptation
ID SUBRETINAL DRUSENOID DEPOSITS; RETINAL-PIGMENT EPITHELIUM; RETICULAR
   PSEUDODRUSEN; VISUAL FUNCTION; MACULOPATHY; SMOKING; OLDER; EYES
AB Purpose: To characterize the natural history of rod-mediated dark adaptation (RMDA) over 2 years in eyes with intermediate age-related macular degeneration (AMD). This information will be useful in understanding the potential of RMDA to serve as a functional endpoint in proof-of-concept studies and clinical trials on intermediate AMD.
   Methods: RMDA was measured in eyes with intermediate AMD at baseline and follow-up visits over 2 years at 6, 12, 18, and 24 months. A computerized dark adaptometer measured sensitivity for targets centered at 11 degrees on the superior vertical meridian of the retina. Rod intercept time (RIT) characterized the speed of dark adaptation and was defined as the duration (in minutes) required for sensitivity to reach a criterion level of 3.0 log units of attenuation of the stimulus.
   Results: Mean change in RIT over 24 months for 30 eyes was 10.5 minutes (standard deviation 19.4), p < 0.0001; 73.3% of eyes had a RIT increase > 1 minute, 56.7% had an increase > 3 minutes, and 36.7% had an increase > 6 minutes; for 26.7% RIT was unchanged (0- to 1-minute increase) or decreased. Greater increase in RIT over 24 months was associated with smoking.
   Conclusions: RMDA slows in intermediate AMD over 2 years in most eyes. There was wide variability in RIT at both baseline and in the extent to which it increased over 24 months. A major risk factor for AMD, smoking, exacerbated RMDA slowing.
C1 [Owsley, Cynthia; Clark, Mark E.; McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
FU National Institutes of Health [R01-AG04212]; EyeSight Foundation of
   Alabama; Dorsett Davis Discovery Fund; Alfreda J. Schueler Trust;
   Research to Prevent Blindness, Inc.; NATIONAL INSTITUTE ON AGING
   [R01AG004212] Funding Source: NIH RePORTER
FX Supported by grants from Genentech, the National Institutes of Health
   (R01-AG04212),the EyeSight Foundation of Alabama, the Dorsett Davis
   Discovery Fund, the Alfreda J. Schueler Trust, and Research to Prevent
   Blindness, Inc.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Barlow H. B., 1972, HDB SENSORY PHYSL, P1
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   McGwin G, 1999, BEHAV RES METH INS C, V31, P712, DOI 10.3758/BF03200752
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Neely D, RETINA IN PRESS
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P413, DOI 10.1113/jphysiol.1975.sp010982
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 39
TC 25
Z9 25
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAY
PY 2017
VL 6
IS 3
AR 15
DI 10.1167/tvst.6.3.15
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH2GT
UT WOS:000410957800015
PM 28593103
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shimazawa, M
   Masuda, T
   Nakamura, S
   Miwa, M
   Nakamura, K
   Hara, H
AF Shimazawa, Masamitsu
   Masuda, Tomomi
   Nakamura, Shinsuke
   Miwa, Miki
   Nakamura, Katsuki
   Hara, Hideaki
TI An Experimental Model for Exudative Age-related Macular Degeneration
   with Choroidal Neovascularization Using the Common Marmoset
SO CURRENT NEUROVASCULAR RESEARCH
LA English
DT Article
DE Age related macular degeneration; common marmoset; choroidal
   neovascularization; fluorescein angiograms; placental growth factor;
   vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; CELL-DEATH; VEGF
   TRAP; BEVACIZUMAB; ANGIOGENESIS; RANIBIZUMAB; PREVENTION; MACROPHAGE
AB This study aimed to establish an experimental exudative age-related macular degeneration (AMD) model in the common marmoset (Callithrix jacchus), which is a small New World monkey. Choroidal neovascularization (CNV) was induced by laser irradiation on the left eye of each animal under anesthesia. Eight laser spots were applied around the macular area using the image-guided laser system (532 nm) attached with Micron III at 650 mW-2,000 mW power. Laser pulse duration and spot size were fixed at 100 ms and 50 mu m, respectively. At 14 days after laser irradiation, fluorescein angiograms were observed. At 21 days after laser irradiation, the fluorescein angiograms were transcardially perfused to the bilateral common carotid arteries with 4% paraformaldehyde for the transverse section or with fluorescein-conjugated dextran (MW = 2,000 kDa) for the retinal pigment epithelia (RPE)-choroidal flatmount. At 14 days after laser irradiation, late hyperfluorescence and leakage within or beyond the lesion borders were observed in a laser power-dependent manner. In the RPE-choroidal flatmount, the mean size of the CNV lesions at 1,500 mW was 1.34 +/- 0.49 x 10(5) mu m(2) (Mean +/- S. D., n = 29), and the coefficient of variation for each CNV area was 36.5% (n = 29). In conclusion, we succeeded in producing an experimental exudative type of AMD model in the common marmoset. This model may be useful in elucidating the pathophysiological mechanism and screening of new candidates for exudative AMD.
C1 [Shimazawa, Masamitsu; Masuda, Tomomi; Nakamura, Shinsuke; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, Gifu 5011196, Japan.
   [Nakamura, Shinsuke] Novartis Pharma KK, Tokyo, Japan.
   [Miwa, Miki; Nakamura, Katsuki] Kyoto Univ, Primate Res Inst, Dept Behav & Brain Sci, Inuyama, Aichi 484, Japan.
C3 Gifu Pharmaceutical University; Novartis; Kyoto University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM hidehara@gifu-pu.ac.jp
OI Hara, Hideaki/0000-0003-2046-9001
FU Cooperative Research Program of Primate Research Institute, Kyoto
   University; Novartis Pharma K.K. (Tokyo, Japan)
FX This study was supported in part by the Cooperative Research Program of
   Primate Research Institute, Kyoto University (2012 and 2013), and
   Novartis Pharma K.K. (Tokyo, Japan).
CR Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Goody RJ, 2011, EXP EYE RES, V92, P464, DOI 10.1016/j.exer.2011.03.006
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hashimoto A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023359
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hollanders K, 2015, INVEST OPHTHALMOL VI
   INGRAM J C, 1975, Laboratory Animals (London), V9, P249, DOI 10.1258/002367775780957205
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Layne DG, 2003, COMPARATIVE MED, V53, P351
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Lu F, 2009, GRAEF ARCH CLIN EXP, V247, P171, DOI 10.1007/s00417-008-0936-y
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Oliner JD, 2012, INVEST OPHTH VIS SCI, V53, P2170, DOI 10.1167/iovs.11-7381
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sasaki E, 2009, NATURE, V459, P523, DOI 10.1038/nature08090
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Su DF, 2013, EXP THER MED, V5, P1226, DOI 10.3892/etm.2013.962
   Tan X, 2015, EXP EYE RES, V131, P77, DOI 10.1016/j.exer.2015.01.005
   Yu LL, 2008, INVEST OPHTH VIS SCI, V49, P522, DOI 10.1167/iovs.07-1175
   Yuzawa M, 2014, OPHTHALMOLOGY
   Zhang M, 2008, MOL VIS, V14, P37
   Zuhlke U, 2003, Toxicol Pathol, V31 Suppl, P123, DOI 10.1080/01926230309767
NR 29
TC 5
Z9 6
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2026
EI 1875-5739
J9 CURR NEUROVASC RES
JI Curr. Neurovasc. Res.
PY 2015
VL 12
IS 2
BP 128
EP 134
DI 10.2174/1567202612666150311105814
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CE5JD
UT WOS:000351867500004
PM 25760220
DA 2022-11-30
ER

PT J
AU Patel, PJ
   Chen, FK
   Ikeji, F
   Tufail, A
AF Patel, Praveen J.
   Chen, Fred K.
   Ikeji, Felicia
   Tufail, Adnan
TI Intersession repeatability of optical coherence tomography measures of
   retinal thickness in early age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; clinical methods; optical coherence
   tomography; reproducibility of results
ID REPRODUCIBILITY
AB Purpose:
   To determine the intersession repeatability of Stratus optical coherence tomography (OCT) measures of retinal thickness in patients with age-related macular degeneration (AMD).
   Methods:
   Measurement of retinal thickness was performed over four sessions over 12 weeks using a standardized OCT protocol with the fast macular thickness map in 67 non-treated eyes of 67 patients with AMD enrolled in a clinical trial. The intrapatient standard deviation (S(w)) and 95% coefficient of repeatability (CR) (<file type="gif" name="aos_1659_mu1.gif"/>), expressed in mu m and as a percentage of mean retinal thickness, were calculated to estimate intersession repeatability.
   Results:
   The CR was 32 mu m for the average retinal thickness in the central 1 mm A1 subfield [95% confidence interval (CI) 31-33 mu m] and 53 mu m (95% CI 51-55 mu m) for the centre-point thickness (CPT). When expressed as a percentage, the CR was 15% (95% CI 14-16) for the central 1 mm A1 subfield and 29% (95% CI 27-30) for the CPT measure.
   Conclusion:
   The average central 1 mm (A1) subfield retinal thickness measure shows good intersession repeatability in patients with stable, early AMD with poorer repeatability for the CPT measure. The results suggest that a change in Stratus OCT retinal thickness of more than 32 mu m in the central A1 subfield is more indicative of true clinical change in these patients.
C1 [Patel, Praveen J.; Chen, Fred K.; Ikeji, Felicia; Tufail, Adnan] Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM praveenjpatel@yahoo.co.uk
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Tufail, Adnan/0000-0001-6131-7640
FU Special Trustees of Moorfields Eye Hospital
FX Financial support came from the Special Trustees of Moorfields Eye
   Hospital.
CR Bland JM, 1996, BRIT MED J, V313, P744
   Bland JM, 2004, WHAT IS STANDARD ERR
   Browning DJ, 2004, AM J OPHTHALMOL, V138, P477, DOI 10.1016/j.ajo.2004.03.014
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Danis RP, 2008, ARCH OPHTHALMOL-CHIC, V126, P45, DOI 10.1001/archopht.126.1.45
   Eriksson U, 2008, ACTA OPHTHALMOL
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hammer DX, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1896967
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Polito A, 2005, ARCH OPHTHALMOL-CHIC, V123, P1330, DOI 10.1001/archopht.123.10.1330
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
NR 15
TC 9
Z9 9
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2011
VL 89
IS 3
BP 229
EP 234
DI 10.1111/j.1755-3768.2009.01659.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 751TR
UT WOS:000289641000008
PM 19845557
DA 2022-11-30
ER

PT J
AU Liu, XC
   Guo, XH
   Chen, X
   Yao, Y
AF Liu, Xiao-Cui
   Guo, Xiao-Hui
   Chen, Xiang
   Yao, Yi
TI Toll-like receptor 4 gene polymorphisms rs4986790 and rs4986791 and
   age-related macular degeneration susceptibility: a meta-analysis
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Toll-like receptor 4; polymorphism; age-related macular degeneration;
   meta-analysis
ID TLR4 POLYMORPHISMS; LIPOPOLYSACCHARIDE; INFLAMMATION
AB Background: Several studies have investigated two single nucleotide polymorphisms (SNPs) (rs4986790 and rs4986791) of toll-like receptor 4 (TLR4) and age-related macular degeneration (AMD) susceptibility. However, their results varied. Here, we performed a systematic review and meta-analysis to investigate the association between these two SNPs and AMD susceptibility. Materials and Methods: We searched the PubMed and Web of Science databases for articles indexed up to July 20, 2019. Studies investigating the association between TLR4 polymorphisms rs4986790 (Asp299Gly) and rs4986791 (Thr399Ile) and AMD susceptibility were included in this systematic review. The results of the included studies were pooled with allele contrast, recessive, dominant and overdominant models. The quality of the included studies was assessed using the Newcastle-Ottawa Scale. Egger's test was used to evaluate publication bias. Results: Six studies with 9 cohorts were included in this systematic review and meta-analysis. The recessive and overdominant models showed that rs4986790 was significantly associated with AMD susceptibility, with odds ratios (ORs) of 0.73 and 1.41, respectively. By contrast, rs4986791 was not associated with AMD susceptibility. No publication bias was observed for either rs4986791 or rs4986790. Conclusion: The current evidence supports the hypothesis that rs4986790 but not rs4986791 is associated with AMD susceptibility.
C1 [Liu, Xiao-Cui; Guo, Xiao-Hui; Chen, Xiang; Yao, Yi] Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Med Ctr 1, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Yao, Y (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Med Ctr 1, Beijing 100853, Peoples R China.
EM yaoyi301@sina.cn
CR Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6
   Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048
   Balistreri CR, 2009, J CLIN IMMUNOL, V29, P406, DOI 10.1007/s10875-009-9297-5
   Chen L, 2016, MOL MED REP, V13, P3249, DOI 10.3892/mmr.2016.4890
   Cho Y, 2010, INVEST OPHTH VIS SCI, V51
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elner SG, 2005, INVEST OPHTH VIS SCI, V46, P4627, DOI 10.1167/iovs.05-0658
   Ferwerda B, 2008, MOL MED, V14, P346, DOI 10.2119/2007-00135.Ferwerda
   Ferwerda B, 2007, P NATL ACAD SCI USA, V104, P16645, DOI 10.1073/pnas.0704828104
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Guven M, 2016, CURR EYE RES, V41, P856, DOI 10.3109/02713683.2015.1067326
   Jin GM, 2019, CLIN EXP OPHTHALMOL, V47, P1019, DOI 10.1111/ceo.13580
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Lee YH, 2015, ANN LAB MED, V35, P283, DOI 10.3343/alm.2015.35.3.283
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Liaunardy-Jopeace A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00473
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ling Y, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015583
   Liu XC, 2015, CURR EYE RES, V40, P676, DOI 10.3109/02713683.2014.957325
   Long HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093550
   Martorell-Marugan J, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1990-4
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Rallabhandi P, 2006, J IMMUNOL, V177, P322, DOI 10.4049/jimmunol.177.1.322
   Sarli A, 2017, CLIN OPHTHALMOL, V11, P1347, DOI 10.2147/OPTH.S134538
   Schmitt C, 2002, CLIN CHEM, V48, P1661
   Sergejeva O, 2016, MEDICINA-LITHUANIA, V52, P79, DOI 10.1016/j.medici.2016.02.004
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zhu Y, 2015, MOL VIS, V21, P1122
NR 32
TC 2
Z9 2
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD JAN 2
PY 2020
VL 41
IS 1
BP 31
EP 35
DI 10.1080/13816810.2020.1723117
EA FEB 2020
PG 5
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA MG1TR
UT WOS:000517037900001
PM 32102594
DA 2022-11-30
ER

PT J
AU Empeslidis, T
   Storey, M
   Giannopoulos, T
   Konidaris, V
   Tranos, PG
   Panagiotou, ES
   Voudouragkaki, IC
   Konstas, AG
AF Empeslidis, Theodoros
   Storey, Matthew
   Giannopoulos, Theodoros
   Konidaris, Vassileios
   Tranos, Paris G.
   Panagiotou, Evangelia S.
   Voudouragkaki, Irini C.
   Konstas, Anastasios G.
TI How Successful is Switching from Bevacizumab or Ranibizumab to
   Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
SO ADVANCES IN THERAPY
LA English
DT Review
DE Aflibercept; Anti-VEGF; Bevacizumab; Macular degeneration; Ranibizumab
ID QUALITY-OF-LIFE; INTRAVITREAL AFLIBERCEPT; CHOROIDAL NEOVASCULARIZATION;
   ANATOMICAL OUTCOMES; EYES; AMD; INJECTION; CONVERSION; THERAPY; REGIMEN
AB Emerging anti-vascular endothelial growth factor (anti-VEGF) therapies for neovascular age-related macular degeneration (nAMD) have revolutionised medical retina practice and the management and eventual outcome of nAMD. Recent research has focused on evaluating and comparing the efficacy of the two most widely employed anti-VEGF agents, bevacizumab and ranibizumab; however, a subgroup of patients with nAMD demonstrates a suboptimal response to standard therapy. We have therefore conducted a review of pertinent studies published until August 2018 which have documented the clinical efficacy when switching to a different anti-VEGF. Evidence on baseline disease characteristics, injection frequency and disease outcome has been obtained for patients treated with ranibizumab 0.5mg and/or bevacizumab 1.25mg and were switched to aflibercept 2mg. Our review identified 45 studies investigating switching to aflibercept. Our review showed a clear anatomical benefit after the switch in terms of central retinal thickness and pigment epithelium detachment characteristics, whereas the functional outcomes were variable. Remarkable heterogeneity was documented among the relevant studies with regard to several factors including the baseline characteristics of the cohorts, the non-response definition and previous treatment protocols. Larger prospective trials with appropriate control arms are therefore required to elucidate the potential benefit when switching between anti-VEGF agents in refractory nAMD.
C1 [Empeslidis, Theodoros; Storey, Matthew; Konidaris, Vassileios] Univ Hosp Leicester, Med Retina Dept, Leicester Royal Infirm, Leicester, Leics, England.
   [Giannopoulos, Theodoros; Panagiotou, Evangelia S.; Voudouragkaki, Irini C.] Aristotle Univ Thessaloniki, Dept Ophthalmol 1, Thessaloniki, Greece.
   [Tranos, Paris G.] Ophthalm Eye Inst, Thessaloniki, Greece.
   [Konstas, Anastasios G.] Aristotle Univ Thessaloniki, Univ Dept Ophthalmol 1, Thessaloniki, Greece.
   [Konstas, Anastasios G.] Aristotle Univ Thessaloniki, Univ Dept Ophthalmol 3, Thessaloniki, Greece.
C3 University Hospitals of Leicester NHS Trust; University of Leicester;
   Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki; Aristotle University of Thessaloniki
RP Konstas, AG (通讯作者)，Aristotle Univ Thessaloniki, Univ Dept Ophthalmol 1, Thessaloniki, Greece.; Konstas, AG (通讯作者)，Aristotle Univ Thessaloniki, Univ Dept Ophthalmol 3, Thessaloniki, Greece.
EM konstas@med.auth.gr
CR Abou-Ltaif S, 2016, SAUDI J OPHTHALMOL, V30, P227, DOI 10.1016/j.sjopt.2016.10.008
   Aghdam KA, 2016, LASER SURG MED, V48, P668, DOI 10.1002/lsm.22531
   Aghdam KA, 2016, EUR J OPHTHALMOL, V26, P473, DOI 10.5301/ejo.5000757
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Blanco-Garavito R, 2017, RETINA, V00, P1
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Cardoso PN, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/6835782
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chang AA, 2016, OPHTHALMIC RES, V55, P84, DOI 10.1159/000440886
   Chatziralli I, 2016, OPHTHALMOLOGY, V123, P1762, DOI 10.1016/j.ophtha.2016.05.002
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Curry B, 2017, ASIA-PAC J OPHTHALMO, V6, P481, DOI 10.22608/APO.2017364
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Dirani A, 2018, CLIN OPHTHALMOL, V12, P593, DOI 10.2147/OPTH.S160367
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Hall LB, 2014, J OCUL PHARMACOL TH, V30, P346, DOI 10.1089/jop.2013.0188
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   Hirakata T, 2016, CLIN OPHTHALMOL, V10, P969, DOI 10.2147/OPTH.S101596
   Homer N, 2015, EYE, V29, P1152, DOI 10.1038/eye.2015.87
   Husler S, 2013, KLIN MONATSBL AUGENH, V230, P1251, DOI 10.1055/s-0033-1351029
   Jorstad OK, 2017, ACTA OPHTHALMOL, V95, P460, DOI 10.1111/aos.13480
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kim K, 2017, RETINA, V1, P1
   Kocak I, 2017, INT OPHTHALMOL, V37, P531, DOI 10.1007/s10792-016-0294-4
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lee CH, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.16.00007
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JC, 2012, J FORMOS MED ASSOC, V111, P572, DOI 10.1016/j.jfma.2011.09.021
   Lores-Motta L, 2018, MOL DIAGN THER, V22, P315, DOI 10.1007/s40291-018-0332-1
   Mantel I, 2016, RETINA-J RET VIT DIS, V36, P53, DOI 10.1097/IAE.0000000000000664
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Moon Da Ru Chi, 2015, Korean J Ophthalmol, V29, P226, DOI 10.3341/kjo.2015.29.4.226
   Muftuoglu IK, 2016, AM J OPHTHALMOL, V167, P1, DOI 10.1016/j.ajo.2016.03.038
   Narayan DS, 2015, INDIAN J OPHTHALMOL, V63, P832, DOI 10.4103/0301-4738.171964
   Nomura Y, 2015, JPN J OPHTHALMOL, V59, P261, DOI 10.1007/s10384-015-0387-z
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Ricci F, 2016, EYE, V30, P1077, DOI 10.1038/eye.2016.95
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sarao V, 2016, RETINA-J RET VIT DIS, V36, P770, DOI 10.1097/IAE.0000000000000751
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Tiosano L, 2017, EYE, V31, P890, DOI 10.1038/eye.2017.7
   Tyagi P, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0824-0
   Van Lancker L, 2017, EUR J OPHTHALMOL, V27, P342, DOI 10.5301/ejo.5000861
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Waizel M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0471-x
   Warwick AN, 2016, INT J OPHTHALMOL-CHI, V9, P1156, DOI 10.18240/ijo.2016.08.12
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   You QS, 2018, RETINA-J RET VIT DIS, V38, P1156, DOI 10.1097/IAE.0000000000001726
   Zhang XY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9640131
   Zhu MD, 2017, GRAEF ARCH CLIN EXP, V255, P475, DOI 10.1007/s00417-016-3477-9
NR 65
TC 12
Z9 12
U1 2
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD JUL
PY 2019
VL 36
IS 7
BP 1532
EP 1548
DI 10.1007/s12325-019-00971-0
PG 17
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA IH2VA
UT WOS:000474351400003
PM 31102206
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Sekeroglu, HT
   Kadayifcilar, S
   Eldem, B
AF Sekeroglu, Hande Taylan
   Kadayifcilar, Sibel
   Eldem, Bora
TI QUALITY OF LIFE IN THE ELDERLY POPULATION: EFFECTS OF AGE RELATED
   MACULAR DEGENERATION ON NEI-VFQ 25 SCORES
SO TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI
LA English
DT Article
DE Macular Degeneration; Quality of Life; Photochemotherapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; BLUE MOUNTAINS EYE; PHOTODYNAMIC
   THERAPY; VISUAL FUNCTION; IMPACT; QUESTIONNAIRE; ACUITY
AB Introduction: To investigate and to evaluate the quality of life of the patients with exudative age-related macular degeneration (AMD) by using National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ 25) before and after the photodynamic therapy (PDT).
   Materials and Method: Forty-five patients with exudative AMD who were candidate for PDT were enrolled in the study. Main outcome measures were visual acuity, lesion size on fundus fluorescein angiography (FFA) and central foveal thickness on optical coherence tomography (OCT), and the quality of life scores by using NEI-VFQ 25.
   Results: The mean age of the patients was 72.2 +/- 7.1 years. The mean follow-up duration was 9.1 +/- 4.5 months. The visual acuity was maintained within +3 lines in 71% of the patients. The treatment caused no significant change on the quality of life scores.
   Conclusions: PDT was one of the most effective treatment strategies of exudative AMD before the era of vascular endothelial growth factor antibodies. PDT was found to be safe and effective in preservation of vision and in reducing the probability of severe vision loss due to exudative AMD, but it was found to be inadequate to provide an increase in vision, and in life quality.
C1 [Sekeroglu, Hande Taylan; Kadayifcilar, Sibel; Eldem, Bora] Hacettepe Univ, Tip Fak, Goz Hastaliklan Anabilim Dali, Ankara, Turkey.
C3 Hacettepe University
RP Sekeroglu, HT (通讯作者)，Hacettepe Univ, Tip Fak, Goz Hastaliklan Anabilim Dali, Ankara, Turkey.
EM h_taylan@yahoo.com
CR Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chakravarthy Usha, 2005, Curr Opin Ophthalmol, V16, P179, DOI 10.1097/01.icu.0000163035.37957.c2
   Chia EM, 2006, OPHTHAL EPIDEMIOL, V13, P371, DOI 10.1080/09286580600864794
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Forte R, 2011, ACTA OPHTHALMOL, V89, pE373, DOI 10.1111/j.1755-3768.2010.01991.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Kim J, 2010, JPN J OPHTHALMOL, V54, P325, DOI 10.1007/s10384-010-0825-x
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Owen CG, 2006, BMC OPHTHALMOL, V9, P24
   Reeves BC, 2009, OPHTHALMOLOGY, V116, P2463, DOI 10.1016/j.ophtha.2009.10.031
   Sahni J, 2007, CLIN EXP OPHTHALMOL, V35, P13, DOI 10.1111/j.1442-9071.2006.01385.x
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 2001, AM J OPHTHALMOL, V131, P584, DOI 10.1016/S0002-9394(01)00832-7
   Sharma Sanjay, 2004, Curr Opin Ophthalmol, V15, P227, DOI 10.1097/01.icu.0000124082.88389.cf
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Stein Joshua D, 2004, Curr Opin Ophthalmol, V15, P238, DOI 10.1097/01.icu.0000120712.35941.ad
   Toprak AB, 2005, OPHTHAL EPIDEMIOL, V12, P259, DOI 10.1080/09286580590967763
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
NR 25
TC 1
Z9 1
U1 0
U2 4
PU GUNES KITABEVI LTD STI
PI ANKARA
PA M RAUF INAN SOK NO 3, ANKARA, SIHHIYE 06410, TURKEY
SN 1304-2947
EI 1307-9948
J9 TURK J GERIATR
JI Turk. J. Geriatr.
PY 2012
VL 15
IS 2
BP 134
EP 141
PG 8
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 979NH
UT WOS:000306826200003
DA 2022-11-30
ER

PT J
AU Yamashiro, K
   Mori, K
   Honda, S
   Kano, M
   Yanagi, Y
   Obana, A
   Sakurada, Y
   Sato, T
   Nagai, Y
   Hikichi, T
   Kataoka, Y
   Hara, C
   Koyama, Y
   Koizumi, H
   Yoshikawa, M
   Miyake, M
   Nakata, I
   Tsuchihashi, T
   Horie-Inoue, K
   Matsumiya, W
   Ogasawara, M
   Obata, R
   Yoneyama, S
   Matsumoto, H
   Ohnaka, M
   Kitamei, H
   Sayanagi, K
   Ooto, S
   Tamura, H
   Oishi, A
   Kabasawa, S
   Ueyama, K
   Miki, A
   Kondo, N
   Bessho, H
   Saito, M
   Takahashi, H
   Tan, X
   Azuma, K
   Kikushima, W
   Mukai, R
   Ohira, A
   Gomi, F
   Miyata, K
   Takahashi, K
   Kishi, S
   Iijima, H
   Sekiryu, T
   Iida, T
   Awata, T
   Inoue, S
   Yamada, R
   Matsuda, F
   Tsujikawa, A
   Negi, A
   Yoneya, S
   Iwata, T
   Yoshimura, N
AF Yamashiro, Kenji
   Mori, Keisuke
   Honda, Shigeru
   Kano, Mariko
   Yanagi, Yasuo
   Obana, Akira
   Sakurada, Yoichi
   Sato, Taku
   Nagai, Yoshimi
   Hikichi, Taiichi
   Kataoka, Yasushi
   Hara, Chikako
   Koyama, Yasurou
   Koizumi, Hideki
   Yoshikawa, Munemitsu
   Miyake, Masahiro
   Nakata, Isao
   Tsuchihashi, Takashi
   Horie-Inoue, Kuniko
   Matsumiya, Wataru
   Ogasawara, Masashi
   Obata, Ryo
   Yoneyama, Seigo
   Matsumoto, Hidetaka
   Ohnaka, Masayuki
   Kitamei, Hirokuni
   Sayanagi, Kaori
   Ooto, Sotaro
   Tamura, Hiroshi
   Oishi, Akio
   Kabasawa, Sho
   Ueyama, Kazuhiro
   Miki, Akiko
   Kondo, Naoshi
   Bessho, Hiroaki
   Saito, Masaaki
   Takahashi, Hidenori
   Tan, Xue
   Azuma, Keiko
   Kikushima, Wataru
   Mukai, Ryo
   Ohira, Akihiro
   Gomi, Fumi
   Miyata, Kazunori
   Takahashi, Kanji
   Kishi, Shoji
   Iijima, Hiroyuki
   Sekiryu, Tetsuju
   Iida, Tomohiro
   Awata, Takuya
   Inoue, Satoshi
   Yamada, Ryo
   Matsuda, Fumihiko
   Tsujikawa, Akitaka
   Negi, Akira
   Yoneya, Shin
   Iwata, Takeshi
   Yoshimura, Nagahisa
TI A prospective multicenter study on genome wide associations to
   ranibizumab treatment outcome for age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMPLEMENT FACTOR-H; GROWTH-FACTOR TREATMENT; ANTI-VEGF THERAPY;
   INTRAVITREAL RANIBIZUMAB; PHOTODYNAMIC THERAPY; LOC387715 GENOTYPES;
   GEOGRAPHIC ATROPHY; Y402H POLYMORPHISM; GENETIC-FACTORS; RISK
AB We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF treatment for exudative age-related macular degeneration (AMD) in a prospective cohort. Four hundred and sixtyone treatment-naive AMD patients were recruited at 13 clinical centers and all patients were treated with 3 monthly injections of ranibizumab followed by pro re nata regimen treatment for one year. Genomic DNA was collected from all patients for a 2-stage GWAS on achieving dry macula after the initial treatment, the requirement for an additional treatment, and visual acuity changes during the 12-month observation period. In addition, we evaluated 9 single-nucleotide polymorphisms (SNPs) in 8 previously reported AMD-related genes for their associations with treatment outcome. The discovery stage with 256 patients evaluated 8,480,849 SNPs, but no SNPs showed genome-wide level significance in association with treatment outcomes. Although SNPs with P-values of < 5 x 10(-6) were evaluated in replication samples of 205 patients, no SNP was significantly associated with treatment outcomes. Among AMD-susceptibility genes, rs10490924 in ARMS2/HTRA1 was significantly associated with additional treatment requirement in the discovery stage (P = 0.0023), and pooled analysis with the replication stage further confirmed this association (P = 0.0013). ARMS2/HTRA1 polymorphism might be able to predict the frequency of injection after initial ranibizumab treatment.
C1 [Yamashiro, Kenji; Yoshikawa, Munemitsu; Miyake, Masahiro; Nakata, Isao; Ooto, Sotaro; Tamura, Hiroshi; Oishi, Akio; Tsujikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo, Kyoto 6068507, Japan.
   [Yamashiro, Kenji; Nakata, Isao] Otsu Red Cross Hosp, Dept Ophthalmol, Otsu, Shiga 5208511, Japan.
   [Mori, Keisuke; Tsuchihashi, Takashi; Kabasawa, Sho; Ueyama, Kazuhiro; Yoneya, Shin] Saitama Med Univ, Dept Ophthalmol, Iruma, Saitama 3500495, Japan.
   [Mori, Keisuke] Int Univ Hlth & Welf, Dept Ophthalmol, Nasushiobara, Tochigi 3292763, Japan.
   [Honda, Shigeru; Matsumiya, Wataru; Miki, Akiko; Kondo, Naoshi; Bessho, Hiroaki; Negi, Akira] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 6500017, Japan.
   [Kano, Mariko; Ogasawara, Masashi; Saito, Masaaki; Sekiryu, Tetsuju] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima 9601247, Japan.
   [Kano, Mariko] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Ophthalmol, Chiba 2760046, Japan.
   [Yanagi, Yasuo; Obata, Ryo; Takahashi, Hidenori; Tan, Xue; Azuma, Keiko] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1130033, Japan.
   [Yanagi, Yasuo; Obata, Ryo; Takahashi, Hidenori; Tan, Xue; Azuma, Keiko] Univ Tokyo, Fac Med, Tokyo 1130033, Japan.
   [Yanagi, Yasuo] Natl Univ Singapore, Duke NUS Med Sch, Ophthalmol & Visual Sci Program, Singapore 119077, Singapore.
   [Yanagi, Yasuo] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Obana, Akira] Seirei Hamamatsu Gen Hosp, Dept Ophthalmol, Shizuoka 4308558, Japan.
   [Sakurada, Yoichi; Yoneyama, Seigo; Kikushima, Wataru; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo, Yamanashi 4093898, Japan.
   [Sato, Taku; Matsumoto, Hidetaka; Mukai, Ryo; Kishi, Shoji] Gunma Univ, Sch Med, Dept Ophthalmol, Gunma 3710034, Japan.
   [Sato, Taku] Takasaki Sato Eye Clin, Gunma 3700036, Japan.
   [Nagai, Yoshimi; Ohnaka, Masayuki; Takahashi, Kanji] Kansai Med Univ, Dept Ophthalmol, Osaka 5731191, Japan.
   [Hikichi, Taiichi; Kitamei, Hirokuni] Ohtsuka Eye Hosp, Sapporo, Hokkaido 0010016, Japan.
   [Hikichi, Taiichi; Sayanagi, Kaori] Hikichi Eye Clin, Sapporo, Hokkaido 0600807, Japan.
   [Koyama, Yasurou; Miyata, Kazunori] Miyata Ophthalm Hosp, Miyazaki 8850051, Japan.
   [Hara, Chikako; Gomi, Fumi] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Osaka 5650871, Japan.
   [Koyama, Yasurou; Ohira, Akihiro] Shimane Univ, Fac Med, Dept Ophthalmol, Shimane 6930021, Japan.
   [Koizumi, Hideki; Iida, Tomohiro] Tokyo Womens Med Univ, Sch Med, Dept Ophthalmol, Tokyo 1628666, Japan.
   [Horie-Inoue, Kuniko; Inoue, Satoshi] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Hidaka, Saitama 3501241, Japan.
   [Saito, Masaaki] Akita Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Akita 0108543, Japan.
   [Takahashi, Hidenori] Jichi Med Univ, Dept Ophthalmol, Shimotsuke, Tochigi, Japan.
   [Gomi, Fumi] Hyogo Coll Med, Dept Ophthalmol, Nishinomiya, Hyogo, Japan.
   [Kishi, Shoji] Maebashi Cent Eye Clin, Gunma 3710031, Japan.
   [Awata, Takuya] Int Univ, Hlth & Welf Hosp, Dept Diabet Endocrinol & Metab, 537-3 Iguchi, Nasushiobara, Tochigi 3292763, Japan.
   [Yamada, Ryo; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto 6068507, Japan.
   [Tsujikawa, Akitaka] Kagawa Univ, Fac Med, Dept Ophthalmol, Miki, Kagawa 7610793, Japan.
   [Iwata, Takeshi] Natl Hosp Org, Natl Inst Sensory Organs, Tokyo Med Ctr, Div Mol & Cellular Biol, Tokyo 1528902, Japan.
C3 Kyoto University; Saitama Medical University; International University
   of Health & Welfare; Kobe University; Fukushima Medical University;
   Tokyo Women's Medical University; University of Tokyo; University of
   Tokyo; National University of Singapore; National University of
   Singapore; Singapore National Eye Center; University of Yamanashi; Gunma
   University; Kansai Medical University; Osaka University; Shimane
   University; Tokyo Women's Medical University; Saitama Medical
   University; Akita University; Jichi Medical University; Hyogo College of
   Medicine; International University of Health & Welfare; Kyoto
   University; Kagawa University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo, Kyoto 6068507, Japan.; Yamashiro, K (通讯作者)，Otsu Red Cross Hosp, Dept Ophthalmol, Otsu, Shiga 5208511, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Saito, Masaaki/ABI-2783-2020; Takahashi, Hidenori/H-2945-2019; Miyake,
   Masahiro/V-1261-2019; TAMURA, Hiroshi/H-1855-2011; Oishi,
   Akio/AAE-9996-2020; Honda, Shigeru/W-4761-2019; Yanagi,
   Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020
OI Saito, Masaaki/0000-0003-1494-6350; Takahashi,
   Hidenori/0000-0001-5331-4730; Miyake, Masahiro/0000-0001-7410-3764;
   TAMURA, Hiroshi/0000-0002-7740-2732; Oishi, Akio/0000-0002-0977-9458;
   Gomi, Fumi/0000-0003-0807-8817; Sekiryu, Tetsuju/0000-0001-8042-2729;
   Yanagi, Yasuo/0000-0002-0362-7285; Yamada, Ryo/0000-0002-1587-630X;
   Tsujikawa, Akitaka/0000-0003-0779-7799; Kondo,
   Naoshi/0000-0001-6025-3876; Awata, Takuya/0000-0003-2622-8129; Mori,
   Keisuke/0000-0001-6671-7192; Yamashiro, Kenji/0000-0001-9354-8558
FU Ministry of Health, Labour and Welfare of Japan, Tokyo, Japan
FX This work was supported by grant from the Ministry of Health, Labour and
   Welfare of Japan, Tokyo, Japan. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chang W, 2013, MOL VIS, V19, P702
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Habibi I, 2013, OPHTHALMIC RES, V49, P177, DOI 10.1159/000345068
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hautamaki A, 2014, OPHTHALMOLOGY, V121, P973, DOI 10.1016/j.ophtha.2013.11.035
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Kang Haeng Ku, 2012, Korean J Ophthalmol, V26, P414, DOI 10.3341/kjo.2012.26.6.414
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wecker T, BR J OPHTHA IN PRESS
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yuan DQ, 2013, OPHTHALMOLOGICA, V230, P227, DOI 10.1159/000355068
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
NR 49
TC 21
Z9 24
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 23
PY 2017
VL 7
AR 9196
DI 10.1038/s41598-017-09632-0
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FE5NF
UT WOS:000408257500001
PM 28835685
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chiam, PJ
   Ho, VW
   Hickley, NM
   Kotamarthi, V
AF Chiam, Patrick J.
   Ho, Vivian W.
   Hickley, Nicholas M.
   Kotamarthi, Venkat
TI 6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular
   age-related macular degeneration: a 2-year outcome
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE bevacizumab; ranibizumab; neovascular age-related macular degeneration;
   treatment on as required basis
ID SINGLE INTRAVITREAL INJECTION; INTRAOCULAR PHARMACOKINETICS; AVASTIN;
   HUMANS; TRIAL
AB AIM: To compare visual acuity and central macular thickness (CMT) changes in neovascular age-related macular degeneration patients treated with either 6 weekly bevacizumab regimen or 4 weekly ranibizumab on an as required basis.
   METHODS: Patients made an informed choice between bevacizumab 1.25 mg or ranibizumab 0.5 mg. The selected treatment was administered in the first 3 visits. Bevacizumab patients were followed-up 6 weekly and ranibizumab 4 weekly. Retreatment criteria was based on the reduction of >5 letters in the best-corrected visual acuity (BCVA), the presence of retinal fluid on optical coherence tomography (OCT) or new retinal haemorrhage.
   RESULTS: Visual acuity at 2y bevacizumab patients gained 7.0 letters and ranibizumab 9.2 (P=0.31, 95% CI -6.4 to 2.0). At 2y 86% of bevacizumab and 94% ranibizumab patients had not lost 15 letters or more (P=0.13). Mean CMT decreased at 2y bevacizumab by 146 mu M, ranibizumab 160 mu m(P=0.72). Mean number of injections was at 2y bevacizumzb 11.9, ranibizumab 10.3 (P=0.023).
   CONCLUSION: Bevacizumab 6 weekly on an as required basis was not demonstrably non-inferior to ranibizumab 4 weekly pro re nata (pm) in terms of BCVA and change in CMT. In the bevacizumab group, one more injection was required in the second year compared to the ranibizumab group.
C1 [Chiam, Patrick J.; Ho, Vivian W.; Hickley, Nicholas M.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England.
   [Chiam, Patrick J.; Ho, Vivian W.; Hickley, Nicholas M.; Kotamarthi, Venkat] Leighton Hosp, Eye Care Ctr, Crewe CW1 4QJ, England.
   [Chiam, Patrick J.] Leicester Royal Infirm, Eye Dept, Leicester LE1 5WW, Leics, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Leicester
RP Chiam, PJ (通讯作者)，Leicester Royal Infirm, Eye Dept, Leicester LE1 5WW, Leics, England.
EM pjtchiam@yahoo.com
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Berg K., 2013, RET SUBSP DAY AM AC
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Conrad PW, 2008, CLIN OPHTHALMOL, V2, P727
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Ghazi NG, 2010, CLIN OPHTHALMOL, V4, P307
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Sonmez K, 2011, RETINA-J RET VIT DIS, V31, P645, DOI 10.1097/IAE.0b013e3182012d18
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
NR 20
TC 1
Z9 1
U1 0
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2016
VL 9
IS 4
BP 551
EP 555
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DJ5UW
UT WOS:000374276600012
PM 27162727
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Martinez-Velasco, A
   Perez-Ortiz, AC
   Antonio-Aguirre, B
   Martinez-Villasenor, L
   Lira-Romero, E
   Palacio-Pastrana, C
   Zenteno, JC
   Ramirez, I
   Zepeda-Palacio, C
   Mendoza-Velasquez, C
   Camacho-Ordonez, A
   Bibriesca, DMO
   Estrada-Mena, FJ
AF Martinez-Velasco, Antonieta
   Perez-Ortiz, Andric C.
   Antonio-Aguirre, Bani
   Martinez-Villasenor, Lourdes
   Lira-Romero, Esmeralda
   Palacio-Pastrana, Claudia
   Zenteno, Juan Carlos
   Ramirez, Israel
   Zepeda-Palacio, Claudia
   Mendoza-Velasquez, Cristina
   Camacho-Ordonez, Azyadeh
   Ortiz Bibriesca, Daniela Michelle
   Estrada-Mena, F. Javier
TI Assessment of CFH and HTRA1 polymorphisms in age-related macular
   degeneration using classic and machine-learning approaches
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; complement factor H; high-temperature
   requirement A serine peptidase 1; genetic association study;
   machine-learning
ID GENE POLYMORPHISMS; ASSOCIATION; SUSCEPTIBILITY; PREVALENCE; VARIANT;
   HAPLOTYPES
AB Background: CFH and HTRA1 are pivotal genes driving increased risk for age-related macular degeneration (AMD) among several populations. Here, we performed a hospital-based case-control study to evaluate the effects of three single nucleotide polymorphisms (SNPs) among Hispanics from Mexico.
   Materials and methods: 122 cases and 249 controls were genotyped using Taqman probes. Experienced ophthalmologists diagnosed AMD following the American Association of Ophthalmology guidelines. We studied CFH (rs1329428, rs203687) and HTRA1 (rs11200638) SNPs thoroughly by logistic regression models (assuming different modes of inheritance) and machine learning-based methods (ML).
   Results: HTRA1 rs11200638 is the most significant polymorphism associated with AMD in our studied population. In a multivariate regression model adjusted for clinically and statistically meaningful covariates, the A/G and A/A genotypes increased the odds of disease by a factor of 2.32 and 7.81, respectively (P < .05) suggesting a multiplicative effect of the polymorphic A allele. Furthermore, this observation remains statistically meaningful in the allelic, dominant, and recessive models, and ML algorithms. When stratifying by phenotype, this polymorphism was significantly associated with increased odds for geographic atrophy (GA) in a recessive mode of inheritance (12.4, p < .05).
   Conclusions: In sum, this work supports a strong association between HTRA1 genetic variants and AMD in Hispanics from Mexico, especially with GA. Moreover, ML was able to replicate the results of conventional biostatistics methods unbiasedly.
C1 [Martinez-Velasco, Antonieta; Martinez-Villasenor, Lourdes; Ortiz Bibriesca, Daniela Michelle] Univ Panamer, Fac Ingn, Mexico City, DF, Mexico.
   [Perez-Ortiz, Andric C.; Antonio-Aguirre, Bani; Lira-Romero, Esmeralda; Ramirez, Israel; Estrada-Mena, F. Javier] Univ Panamer, Fac Ciencias Salud, Mexico City, DF, Mexico.
   [Perez-Ortiz, Andric C.] Massachusetts Gen Hosp, Div Surg, Transplant Ctr, Boston, MA 02114 USA.
   [Palacio-Pastrana, Claudia; Zepeda-Palacio, Claudia; Mendoza-Velasquez, Cristina; Camacho-Ordonez, Azyadeh] Fdn Hosp Nuestra Senora La Luz, Dept Microsurg Anterior Segment, IAP, Mexico City, DF, Mexico.
   [Palacio-Pastrana, Claudia] Clin Oftalmol Salauno Salud, Dept Microsurg Anterior Segment, Mexico City, DF, Mexico.
   [Zenteno, Juan Carlos] Univ Nacl Autonoma Mexico, Dept Biochem, Fac Med, Mexico City, DF, Mexico.
C3 Universidad Panamericana - Ciudad de Mexico; Universidad Panamericana -
   Ciudad de Mexico; Harvard University; Massachusetts General Hospital;
   Universidad Nacional Autonoma de Mexico
RP Estrada-Mena, FJ (通讯作者)，Univ Panamer, Escuela Med, Mexico City 03920, DF, Mexico.
EM festrada@up.edu.mx
RI Antonio-Aguirre, Bani/AAS-2450-2020
OI Antonio-Aguirre, Bani/0000-0003-2393-1097; Camacho-Ordonez,
   Azyadeh/0000-0002-6531-9288; MARTINEZ-VELASCO,
   ANTONIETA/0000-0001-6535-1440; Zenteno, Juan Carlos/0000-0002-9716-8146;
   Lira, Esmeralda/0000-0002-9838-1731
FU Universidad Panamericana, Facultad de Ingenieria
FX We are grateful to Universidad Panamericana, Facultad de Ingenieria for
   providing partial financial support.
CR Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   [Anonymous], 2015, PREF PRACT PATT GUID, P12, DOI [10.1002/14651858.CD005137.pub3, DOI 10.1002/14651858.CD005137.PUB3]
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Perez-Ortiz AC, 2018, GENES-BASEL, V9, DOI 10.3390/genes9100467
   Contreras AV, 2014, MOL VIS, V20, P105
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fourgeux C, 2012, INVEST OPHTH VIS SCI, V53, P7026, DOI 10.1167/iovs.12-9652
   Fraccaro P, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-10
   Gil Y, 2019, PROCEEDINGS OF IUI 2019, P614, DOI 10.1145/3301275.3302324
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kourou K, 2015, COMPUT STRUCT BIOTEC, V13, P8, DOI 10.1016/j.csbj.2014.11.005
   Leisch F, 2013, WARN MG R PACK GEN V
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Lu FT, 2018, GENET TEST MOL BIOMA, V22, P526, DOI 10.1089/gtmb.2018.0110
   Martinez-Velasco A, 2016, LECT NOTES COMPUT SC, V10070, P28, DOI 10.1007/978-3-319-48799-1_4
   Ming C, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1158-4
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Perez-Ortiz AC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215480
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qi Y, 2019, GWAS BASED MACHINE L, DOI [10.1101/19006155, DOI 10.1101/19006155]
   R Core Team, 2021, LANG ENV STAT COMP
   Ryu E, 2010, MOL VIS, V16, P2811
   SAS Institute Inc, 2014, SAS 94 SOFTWARE
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Taninaga J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48769-y
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tong Y, 2010, MOL VIS, V16, P1958
   Wojcik GL, 2019, NATURE, V570, P514, DOI 10.1038/s41586-019-1310-4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
NR 40
TC 2
Z9 2
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD NOV 1
PY 2020
VL 41
IS 6
BP 539
EP 547
DI 10.1080/13816810.2020.1804945
EA AUG 2020
PG 9
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA OU3ES
UT WOS:000562227800001
PM 32838591
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Zhang, M
   Chu, Y
   Mowery, J
   Konkel, B
   Galli, S
   Theos, AC
   Golestaneh, N
AF Zhang, Meng
   Chu, Yi
   Mowery, Joseph
   Konkel, Brandon
   Galli, Susana
   Theos, Alexander C.
   Golestaneh, Nady
TI Pgc-1 alpha repression and high-fat diet induce age-related macular
   degeneration-like phenotypes in mice
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE RPE; AMD; Retinal degeneration; PGC-1 alpha; High-fat diet;
   Mitochondria; Autophagy
ID RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS; RPE CELLS; AUTOPHAGY;
   DRUSEN; PROTEIN; MODEL; MITOCHONDRIA; REGULATOR; DEPOSITS
AB Age-related macular degeneration (AMD) is the major cause of blindness in the elderly in developed countries and its prevalence is increasing with the aging population. AMD initially affects the retinal pigment epithelium (RPE) and gradually leads to secondary photoreceptor degeneration. Recent studies have associated mitochondrial damage with AMD, and we have observed mitochondrial and autophagic dysfunction and repressed peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha; also known as Ppargc1 alpha) in native RPE from AMD donor eyes and their respective induced pluripotent stem cell-derived RPE. To further investigate the effect of PGC-1 alpha repression, we have established a mouse model by feeding Pgc-1 alpha(+/-). mice with a high-fat diet (HFD) and investigated RPE and retinal health. We show that when mice expressing lower levels of Pgc-1 alpha are exposed to HFD, they present AMD like abnormalities in RPE and retinal morphology and function. These abnormalities include basal laminar deposits, thickening of Bruch's membrane with drusen marker-containing deposits, RPE and photoreceptor degeneration, decreased mitochondrial activity, increased levels of reactive oxygen species, decreased autophagy dynamics/flux, and increased inflammatory response in the RPE and retina. Our study shows that Pgc-1 alpha is important in outer retina biology and that Pgc-1 alpha(+/-) mice fed with HFD provide a promising model to study AMD, opening doors for novel treatment strategies.
C1 [Zhang, Meng; Chu, Yi; Golestaneh, Nady] Georgetown Univ, Dept Ophthalmol, Med Ctr, Washington, DC 20057 USA.
   [Mowery, Joseph] USDA ARS, Electron & Confocal Microscopy Unit, Beltsville, MD 20705 USA.
   [Konkel, Brandon; Galli, Susana; Golestaneh, Nady] Georgetown Univ, Dept Biochem & Mol & Cellular Biol, Med Ctr, Washington, DC 20057 USA.
   [Theos, Alexander C.] Georgetown Univ, Dept Human Sci, Washington, DC 20057 USA.
   [Golestaneh, Nady] Georgetown Univ, Dept Neurol, Med Ctr, Washington, DC 20057 USA.
C3 Georgetown University; United States Department of Agriculture (USDA);
   Georgetown University; Georgetown University; Georgetown University
RP Golestaneh, N (通讯作者)，Georgetown Univ, Dept Ophthalmol, Med Ctr, Washington, DC 20057 USA.; Golestaneh, N (通讯作者)，Georgetown Univ, Dept Biochem & Mol & Cellular Biol, Med Ctr, Washington, DC 20057 USA.; Golestaneh, N (通讯作者)，Georgetown Univ, Dept Neurol, Med Ctr, Washington, DC 20057 USA.
EM ncg8@georgetown.edu
OI Theos, Alexander/0000-0002-1826-8705; Golestaneh,
   Nady/0000-0001-7573-0962
FU BrightFocus Foundation [M2014039]; International Agency for the
   Prevention of Blindness
FX This study was partially supported by the BrightFocus Foundation
   (M2014039) and the International Agency for the Prevention of Blindness.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Austin S, 2011, FREE RADICAL BIO MED, V51, P2243, DOI 10.1016/j.freeradbiomed.2011.08.036
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Chang RCA, 2015, INVEST OPHTH VIS SCI, V56, P2367, DOI 10.1167/iovs.14-16143
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   COHEN AH, 1976, AM J CLIN PATHOL, V65, P631
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   DE DUVE CHRISTIAN, 1963, SCI AMER, V208, P64
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   Finn PF, 2006, NUTRITION, V22, P830, DOI 10.1016/j.nut.2006.04.008
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Halling JF, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12698
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jarrett Stuart G, 2013, Methods Mol Biol, V935, P227, DOI 10.1007/978-1-62703-080-9_16
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li S, 2008, CELL METAB, V8, P105, DOI 10.1016/j.cmet.2008.06.013
   Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   NikoliA N., 2012, BIOCHEM RES INT, V2012
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Petrukhin Konstantin, 2013, Drug Discov Today Ther Strateg, V10, pe11
   Rabin DM, 2013, AGING-US, V5, P51
   Rajagopal R, 2016, DIABETES, V65, P1072, DOI 10.2337/db15-1255
   Saint-Geniez M, 2013, AM J PATHOL, V182, P255, DOI 10.1016/j.ajpath.2012.09.003
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053155
   Sen D, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.066002
   St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Vainshtein A, 2015, AM J PHYSIOL-CELL PH, V308, pC710, DOI 10.1152/ajpcell.00380.2014
   Valle I, 2005, CARDIOVASC RES, V66, P562, DOI 10.1016/j.cardiores.2005.01.026
   Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000
   Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003
   Wei H, 2016, EXP EYE RES, V145, P450, DOI 10.1016/j.exer.2015.09.015
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
NR 52
TC 27
Z9 28
U1 0
U2 2
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754-8403
EI 1754-8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD SEP
PY 2018
VL 11
IS 9
AR dmm032698
DI 10.1242/dmm.032698
PG 10
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA GV4TO
UT WOS:000446093700004
PM 29925537
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kaszubski, PA
   Ben Ami, T
   Saade, C
   Nabati, C
   Kumar, V
   Santos, AR
   Silva, R
   Cachulo, ML
   Cunha-Vaz, JG
   Smith, RT
AF Kaszubski, Patrick A.
   Ben Ami, Tal
   Saade, Celine
   Nabati, Camellia
   Kumar, Vivek
   Santos, Ana Rita
   Silva, Rufino
   Cachulo, Maria Luz
   Cunha-Vaz, Jose G.
   Theodore Smith, R.
TI Changes in reticular pseudodrusen area in eyes that progressed from
   early to late age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Reticular pseudodrusen; Choroidal neovascularization; Geographic
   atrophy; Age-related macular degeneration
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY;
   GEOGRAPHIC-ATROPHY; CHOROIDAL NEOVASCULARIZATION; RISK-FACTOR;
   PREVALENCE; DISEASE; MACULOPATHY
AB Objective This retrospective cohort study utilized 3 imaging modalities to analyze quantitatively reticular pseudodrusen (RPD) area changes in eyes that progressed from early to late age-related macular degeneration (AMD).
   Methods Subjects with AMD, unilateral choroidal neovascularization (CNV), and early AMD with RPD in the fellow eye (the study eye) were included. The study eyes underwent indocyanine green angiography (ICGA), near-infrared reflectance (NIR-R), and shortwavelength autofluorescence (AF) imaging of the macula at baseline and at follow-up. Study eyes were analyzed for RPD and for the development of late AMD-CNV and/or geographic atrophy (GA). RPD area was measured at baseline and at follow-up as a percentage of the 30-degree field.
   Results During the study period (mean follow-up time 23.5 +/- 5.0 months), 12/31 study eyes developed CNV and 4/31 developed GA. In the eyes that developed CNV, there was a statistically significant decrease in mean RPD area over the follow-up period as seen on AF (P < 0.01) and NIR-R (P = 0.01), and the decrease in mean RPD area approached statistical significance on ICGA (P = 0.08).
   Conclusion Using 3 en face imaging techniques, we demonstrate that RPD undergo dynamic spatiotemporal changes in eyes that progress from early AMD to CNV, namely a decrease in the area of lesions detected.
C1 [Kaszubski, Patrick A.; Ben Ami, Tal; Saade, Celine; Nabati, Camellia; Kumar, Vivek; Theodore Smith, R.] NYU, Sch Med, Dept Ophthalmol, 462 First Ave NBV 5N18, New York, NY 10016 USA.
   [Santos, Ana Rita; Silva, Rufino; Cachulo, Maria Luz; Cunha-Vaz, Jose G.] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Silva, Rufino] Ctr Hosp & Univ Coimbra, Coimbra, Portugal.
   [Cachulo, Maria Luz] Coimbra Univ Hosp, Dept Ophthalmol, Coimbra, Portugal.
C3 New York University; Universidade de Coimbra; Universidade de Coimbra;
   Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de
   Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC)
RP Smith, RT (通讯作者)，NYU, Sch Med, Dept Ophthalmol, 462 First Ave NBV 5N18, New York, NY 10016 USA.
EM roland.smith@nyumc.org
RI Silva, Rufino M/J-2817-2012; santos, ana/GWV-5678-2022
OI Silva, Rufino M/0000-0001-8676-0833; Cunha-Vaz,
   Jose/0000-0002-0947-9850; Cachulo, Maria Luz/0000-0002-0900-4548; smith,
   theodore/0000-0002-1693-943X; B M Santos, Ana Rita/0000-0003-3761-3292
FU Foundation Fighting Blindness (RTS); National Institutes of
   Health/National Eye Institute [R01 EY015520]; Research to Prevent
   Blindness; NATIONAL EYE INSTITUTE [R01EY015520] Funding Source: NIH
   RePORTER
FX This work was supported by an individual investigator research award
   from the Foundation Fighting Blindness (RTS), National Institutes of
   Health/National Eye Institute Grant R01 EY015520 (RTS), and unrestricted
   funds from Research to Prevent Blindness (RTS). The funding
   organizations had no role in the study design; in the collection,
   analysis, and interpretation of the data; in the writing of the report;
   or in the decision to submit for publication.
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 25
TC 4
Z9 4
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD APR
PY 2018
VL 38
IS 2
BP 503
EP 511
DI 10.1007/s10792-017-0485-7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GE6AD
UT WOS:000431304900011
PM 28265823
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Muniraju, R
   Ramu, J
   Sivaprasad, S
AF Muniraju, Ramu
   Ramu, Jayashree
   Sivaprasad, Sobha
TI Three-Year Visual Outcome and Injection Frequency of Intravitreal
   Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Neovascular age-related macular degeneration; Ranibizumab; Visual
   acuity; Injection frequency
ID SUBGROUP ANALYSIS; REGIMEN; ANCHOR
AB Background: To assess the 3-year visual outcome and injection frequency for patients on ranibizumab for neovascular age-related macular degeneration (NV-AMD). Methods: Retrospective case-note review of 174 treatment-naive eyes of 156 patients with NV-AMD with 3-year follow-up was done at specific time points closest to 12, 24 and 36 months. Results: The median baseline visual acuity (VA) of 50 Early Treatment Diabetic Retinopathy Study letters (mean 48.2 +/- 16.9) improved significantly to 55 (mean 51.2 +/- 18.7) by the end of 12 months (p = 0.04). At 24 months, the median letter score remained unchanged at 55 (mean 50.4 +/- 20.8; p = 0.14 as compared to baseline) and at 36 months, the median VA was 54 letters (mean 49.1 +/- 21.7; p = 0.34 compared to baseline). The mean numbers of injections were 4.8 +/- 2.2 at 1 year, 7.8 +/- 4.2 at 2 years (2.9 in the second year) and 10.2 +/- 6.2 at the end of the third year (2.4 in the third year). Conclusion: Our study demonstrates the efficacy of a variable dosing regimen of ranibizumab for the treatment of NV-AMD. The mean gain in VA is inversely proportional to the baseline VA and did not correlate with the number of injections. Copyright (C) 20135. Karger AG, Basel
C1 [Muniraju, Ramu; Ramu, Jayashree; Sivaprasad, Sobha] Kings Coll Hosp London, Dept Ophthalmol, Laser & Retinal Res Unit, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
FU Novartis; Pfizer; Allergan; Alimera Services; Bayer
FX Sobha Sivaprasad has received research grants, travel grants and
   participated in advisory boards of Novartis, Pfizer, Allergan, Alimera
   Services and Bayer.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   National Institute for Clinical Excellence, 2008, RAN PEG TREATM AG RE
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
NR 20
TC 16
Z9 17
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 230
IS 1
BP 27
EP 33
DI 10.1159/000350238
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 178RW
UT WOS:000321466100004
PM 23635665
DA 2022-11-30
ER

PT J
AU Venza, I
   Visalli, M
   Oteri, R
   Teti, D
   Venza, M
AF Venza, Isabella
   Visalli, Maria
   Oteri, Rosaria
   Teti, Diana
   Venza, Mario
TI Combined effects of cigarette smoking and alcohol consumption on
   antioxidant/oxidant balance in age-related macular degeneration
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Age-related macular degeneration; smoking; alcohol consumption;
   antioxidant enzymes; DNA damage
AB Background and aims: To investigate the single and joint effects of chronic cigarette smoking and alcohol consumption on oxidative stress in age-related macular degeneration (ARMD). Methods: Superoxide dismutase (SOD), glutathione peroxidase (GSHPx), and catalase (CAT) activities; malondialdehyde (MDA) levels; and DNA damage were measured in patients with early ARMD (n=211) and late ARMD (n=205), and control persons (n=262). Results: When compared with healthy controls, early-and late-ARMD patients showed significant decreases in the activities of SOD and GSHPx, but not CAT, along with marked enhancements of MDA levels and tail parameters (p<0.01). No notable differences were observed in the early-vs the late-ARMD group for each of the above mentioned dependent variables. Multiple regression analysis revealed that in healthy subjects chronic smoking had the strongest impact on SOD and GSHPx activities, MDA levels, and amount of DNA damage, whereas in ARMD patients, the combination of smoking and drinking habits was the greatest predictor of oxidative stress. Conclusions: The combination of chronic cigarette smoking and alcohol consumption appears to be an aggravating factor that contribute to serious oxidative imbalance and DNA damage in ARMD. Thus, combined smoking/drinking by persons with this pathological condition should be considered harmful. Identification of factors exacerbating ARMD-associated oxidative stress can facilitate development and adoption of effective preventative measures for this disease. (C) 2012, Editrice Kurtis
C1 [Venza, Isabella; Venza, Mario] Univ Messina, Azienda Osped Univ G Martino, Dipartimento Sci Sperimentali Med Chirurg Special, Messina, Italy.
   [Visalli, Maria; Oteri, Rosaria; Teti, Diana] Univ Messina, Azienda Osped Univ G Martino, Dipartimento Med Clin & Sperimentale, Messina, Italy.
C3 AOU Policlinico Gaetano Martino; University of Messina; AOU Policlinico
   Gaetano Martino; University of Messina
RP Teti, D (通讯作者)，Azienda Osped Univ, Dipartimento Med Clin & Sperimentale, Via Consolare Valeria 1 Gazzi, I-98125 Messina, Italy.
EM dteti@unime.it
FU Progetto di Ricerca di Ateneo, University of Messina; PhD research on
   the "Pathology of Cellular Proliferation and Differentiation",
   University of Messina
FX The work described in this paper was supported by grants from the
   Progetto di Ricerca di Ateneo, University of Messina (to Isabella
   Venza), and the PhD research on the "Pathology of Cellular Proliferation
   and Differentiation", University of Messina (to Diana Teti).
CR Babizhayev MA, 2011, FUND CLIN PHARMACOL, V25, P425, DOI 10.1111/j.1472-8206.2010.00866.x
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Bergamini CM, 2004, CURR PHARM DESIGN, V10, P1611, DOI 10.2174/1381612043384664
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Galan P, 2005, EUR J CLIN NUTR, V59, P1181, DOI 10.1038/sj.ejcn.1602230
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Marnett LJ, 1999, MUTAT RES-FUND MOL M, V424, P83, DOI 10.1016/S0027-5107(99)00010-X
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Zima T, 2001, J BIOMED SCI, V8, P59, DOI 10.1007/BF02255972
   1992, ARCH OPHTHALMOL, V110, P1701
NR 25
TC 23
Z9 23
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1594-0667
EI 1720-8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD OCT
PY 2012
VL 24
IS 5
BP 530
EP 536
DI 10.3275/8477
PG 7
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA V30WV
UT WOS:000208847000018
PM 22732472
DA 2022-11-30
ER

PT J
AU Luo, D
   Deng, H
   Zhang, YH
   Deng, TT
   Yuan, W
   Wang, ZJ
   Jin, M
AF Luo Dan
   Deng Hui
   Zhang Youhua
   Deng Tingting
   Yuan Wei
   Wang Zhijun
   Jin Ming
TI Chinese medicine formula HB01 for treating exudative age-related macular
   degeneration: a 6 consecutive months of clinical observation study
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE Macular degeneration; Visual acuity; Chinese medicine formula; HB01
ID PANAX-NOTOGINSENG SAPONINS; RETINAL-PIGMENT EPITHELIUM; CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; ANGELICA SINENSIS; BLOOD-FLOW;
   PREVALENCE; PROGRESS
AB OBJECTIVE: To evaluate the clinical efficacy of Chinese medicine formula HB01 on exudative age-related macular degeneration (AMD) patients who received HB01 for 6 months by analyzing relative indexes.
   METHODS: From July 2006 to August 2015, 139 eligible exudative AMD patients (183 eyes) were enrolled into this study and received aqueous extract from herbs of HB01 by oral twice a day (100 mL for once) for 6 months. The best corrected visual acuity, center macular thickness (CMT), hemorrhage area, fluorescein leakage area as the main outcomes were estimated and compared before and after treatment.
   RESULTS: After 3 and 6 months of treatment, visual acuity obtained a greater improvement (P < 0.01). After 1, 3 and 6 months of treatment, CMT obviously decreased (P < 0.05). After 3 and 6 months of treatment, the hemorrhage area and fluorescein leakage area also significantly narrowed (P < 0.01). During treatment, no significant adverse events relating to HB01 treatment were elucidated.
   CONCLUSION: On the basis of these results, HB01 could improve visual acuity, and reduce hemorrhage and fluorescein leakage of patients with exudative AMD, which may be an effective alternative and supportive treatment for exudative AMD. (C) 2017 JTCM. All rights reserved.
C1 [Luo Dan; Deng Hui; Zhang Youhua; Deng Tingting; Yuan Wei; Wang Zhijun; Jin Ming] China Japan Friendship Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China.
   [Luo Dan] Beijing Univ Chinese Med, Dept Grad Sch, Beijing 100029, Peoples R China.
C3 China-Japan Friendship Hospital; Beijing University of Chinese Medicine
RP Jin, M (通讯作者)，China Japan Friendship Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China.
EM jinming57@163.com
FU National Natural Science Foundation of China: Mechanism Study of
   Age-related Macular Degeneration Based on IL-17RC Methylation
   [81373693]; Beijing Natural Science Foundation: Molecular Mechanism
   Underlying the Treatment of Age-related Macular Degeneration by Chinese
   Herbal Medicine YQTXHT Decotion Based on New Biomarker IL-17RC [7132196]
FX Supported by the Grant from the National Natural Science Foundation of
   China: Mechanism Study of Age-related Macular Degeneration Based on
   IL-17RC Methylation (No. 81373693) and Beijing Natural Science
   Foundation: Molecular Mechanism Underlying the Treatment of Age-related
   Macular Degeneration by Chinese Herbal Medicine YQTXHT Decotion Based on
   New Biomarker IL-17RC (No. 7132196)
CR [Anonymous], 1997, CLIN RES GUID PRINC, V3, P205
   Arnold JJ., 2016, BMJ CLIN EVID, V2016
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen YQ, 2014, MOL MED REP, V10, P1400, DOI 10.3892/mmr.2014.2328
   Cheng LB, 2014, INT J MOL SCI, V15, P18762, DOI 10.3390/ijms151018762
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Gao Dong, 2005, Zhongguo Zhong Xi Yi Jie He Za Zhi, V25, P912
   Ge J, 2013, OPHTHALMOLOGY, P314
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Han CC, 2012, INFLAMMATION, V35, P913, DOI 10.1007/s10753-011-9393-6
   HENKIND P, 1983, T OPHTHAL SOC UK, V103, P444
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-118
   Jin Ming, 2009, Zhongguo Zhong Xi Yi Jie He Za Zhi, V29, P540
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Li XX, 2014, MOLECULES, V19, P18850, DOI 10.3390/molecules191118850
   Ohkura N, 2012, BLOOD COAGUL FIBRIN, V23, P254, DOI 10.1097/MBC.0b013e3283504148
   Ohkura N, 2011, BLOOD COAGUL FIBRIN, V22, P631, DOI 10.1097/MBC.0b013e328349a22c
   Potter MJ, 2007, BRIT J OPHTHALMOL, V91, P753, DOI 10.1136/bjo.2006.110239
   Russo A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/476525
   Shi Xu-qin, 2012, Yaoxue Xuebao, V47, P1375
   Sodi A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/281010
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Ventrice P, 2013, J PHARMACOL PHARMACO, V4, pS38, DOI 10.4103/0976-500X.120947
   Wang HY, 2013, INT J OPHTHALMOL-CHI, V6, P600, DOI 10.3980/j.issn.2222-3959.2013.05.09
   Yang XC, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/204840
   Yang XB, 2007, BIOL PHARM BULL, V30, P1884, DOI 10.1248/bpb.30.1884
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Zhang M, 2004, CHIN J OCUL FUNDUS, V20, P5
   Zhou NN, 2014, PHYTOMEDICINE, V21, P1189, DOI 10.1016/j.phymed.2014.05.004
   杨立, 2012, [中国老年学杂志, Chinese Journal of Gerontology], V32, P4569
NR 34
TC 0
Z9 1
U1 0
U2 6
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD DEC
PY 2017
VL 37
IS 6
BP 767
EP 773
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA FT9UK
UT WOS:000423497600005
PM 32188185
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Tomany, SC
   Danforth, LG
   Cruickshanks, KJ
AF Klein, R
   Klein, BEK
   Tomany, SC
   Danforth, LG
   Cruickshanks, KJ
TI Relation of statin use to the 5-year incidence and progression of
   age-related maculopathy
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM-EYE; MACULAR DEGENERATION; VISUAL-ACUITY; CLINICAL-TRIALS;
   CHOLESTEROL; RISK; STUDY/; POPULATION
AB Objective: To examine the association of hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) with the 5-year incidence of age-related maculopathy (ARM).
   Design: Population-based cohort study. Participants included persons 48 to 91 years old examined March 1, 1993, through June 14, 1995, living in Beaver Dam, Wis (N = 3684), of whom 2780 participated in a follow-up 5 years later.
   Methods: Standardized procedures were used for physical examinations, blood sample collection, and questionnaire administration. Age-related maculopathy was determined by grading images of the posterior pole using a standard protocol. Standard univariate and multivariate analyses were performed.
   Main Outcome Measures: Incidence and progression of ARM was measured over the 5-year interval.
   Results: While controlling for age and sex, statin use was not found to be associated with the 5-year incidence of early ARM (odds ratio [OR], 1.12; 95% confidence interval [CI], 0.47-2.67), progression of ARM (OR, 1.22; 95% CI, 0.54-2.76), or incidence of late ARM (OR, 0.41; 95% CI, 0.12-1.45).
   Conclusions: These findings do not suggest an association between statin use and incident ARM over a 5-year period. Further investigation of these relationships in larger studies over a longer period is needed.
C1 Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Univ Wisconsin, Sch Med, Dept Populat Hlth Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
OI Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR ALLAIN CC, 1974, CLIN CHEM, V20, P470
   *AM SOC HLTH SYST, 2000, AM HOSP FORM SERV DR
   [Anonymous], 1976, Prev Med, V5, P207
   [Anonymous], 1999, SAS STAT US GUID VER
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1995, 95273827 PB NAT TECH
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   KLEIN R, 1991, 91149823 PB NAT TECH
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   van Leeuwen R, 2001, BRIT MED J, V323, P1308, DOI 10.1136/bmj.323.7324.1308a
NR 30
TC 71
Z9 73
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2003
VL 121
IS 8
BP 1151
EP 1155
DI 10.1001/archopht.121.8.1151
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 709HR
UT WOS:000184620200010
PM 12912693
OA Bronze
DA 2022-11-30
ER

PT J
AU Ross, RJ
   Bojanowski, CM
   Wang, JJ
   Chew, EY
   Rochtchina, E
   Ferris, FL
   Mitchell, P
   Chan, CC
   Tuo, J
AF Ross, Robert J.
   Bojanowski, Christine M.
   Wang, Jie Jin
   Chew, Emily Y.
   Rochtchina, Elena
   Ferris, Frederick L., III
   Mitchell, Paul
   Chan, Chi-Chao
   Tuo, Jingsheng
TI The LOC387715 polymorphism and age-related macular degeneration:
   Replication in three case-control samples
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOMEWIDE-SCAN; GENETIC ASSOCIATION;
   APOLIPOPROTEIN-E; COMMON VARIANTS; VISUAL-LOSS; SUSCEPTIBILITY;
   MACULOPATHY; RISK; CFH
AB PURPOSE. Age-related macular degeneration (AMD) is a multifactorial blinding disease in the elderly. LOC387715 harbors single-nucleotide polymorphism that has an association with AMD. This study was conducted to confirm the association between LOC387715 and AMD and to refine estimates of the impact of this gene variation in using samples from three studies: an Australian population-based study and two U.S. clinic-based case-control studies.
   METHODS. Cases and controls were collected from a National Eye Institute (NEI) clinical protocol (n = 240), the Age-Related Eye Disease Study (AREDS; n = 488), and the Blue Mountains Eye Study (BMES; n = 851). After DNA extraction, subjects were genotyped for the LOC387715 Ala69Ser polymorphism (rs10490924).
   RESULTS. The combined NEI and AREDS samples yielded odds ratios (ORs) of 2.61 (95% CI 1.89-3.61, P = 1.42 X 10(-9)) and 8.59 (95% CI 4.49-16.5, P = 3.56 x 10(-13)) for the heterozygous and homozygous risk alleles, respectively. The corresponding odds ratios in the BMES sample were 1.69 (95% CI: 1.25-2.28, P = 0.0007) and 2.20 (95% CI: 1.05-4.62, P = 0.038) for the heterozygous and homozygous groups. Neither set of samples showed statistically significant interaction with smoking, although there appeared to be a trend of interaction between smoking and LOC387715 for risk of advanced AMD.
   CONCLUSIONS. Although these data from three case-control samples support an AMD genetic risk marker harbored within LOC387715, the nested case-control data from the population-based BMES samples showed lower estimates than from the clinic-based samples. This may be because the BMES samples consisted of largely early AMD cases while the clinic-based AMD samples consisted exclusively of advanced cases.
C1 NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
   Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); University of Sydney; University of Sydney; Westmead
   Institute for Medical Research
RP Tuo, J (通讯作者)，NEI, Immunol Lab, NIH, 10-10N103,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM tuoj@nei.nih.gov
RI wang, jie/GRS-0942-2022; Mitchell, Paul/P-1498-2014; Wang, Jie
   Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898; Ferris,
   Frederick/0000-0002-4933-0639; Tuo, Jingsheng/0000-0002-1372-7810
FU Intramural NIH HHS [Z99 EY999999, ZIA EY000489-01, Z01 EY000418-04]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000418] Funding
   Source: NIH RePORTER
CR Allam A, 2005, IMMUNOL LETT, V97, P7, DOI 10.1016/j.imlet.2004.09.019
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hogan A, 2004, J BIOL CHEM, V279, P53717, DOI 10.1074/jbc.M410654200
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Shastry BS, 2006, OPHTHALMOLOGICA, V220, P291, DOI 10.1159/000094617
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 43
TC 55
Z9 55
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2007
VL 48
IS 3
BP 1128
EP 1132
DI 10.1167/iovs.06-0999
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 142YF
UT WOS:000244686500025
PM 17325155
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chen, HX
   Deng, H
   Zou, XB
   Zhao, JQ
AF Chen, Hongxia
   Deng, Hong
   Zou, Xianbiao
   Zhao, Jingquan
TI Hypocrellin B Encapsulated in Triphenyl Phosphonium-Modified Cationic
   Liposomes for Photodynamic Treatment of Exudative Age-Related Macular
   Degeneration
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Photodynamic Therapy; Hypocrellin B; Triphenyl-Phosphonium Modified
   Cationic Liposomes; Exudative Age-Related Macular Degeneration;
   Neovascular Targeting; Internalization
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   ENDOTHELIAL GROWTH-FACTOR; LONG-TERM OUTCOMES; DRUG-DELIVERY; IN-VITRO;
   THERAPY; ANGIOGENESIS; TARGET; PHOTOSENSITIZERS
AB Verteporfin photodynamic therapy (PDT) has been approved for the treatment of exudative age-related macular degeneration (AMD) for over a decade. However, its extensive application has been impeded by inevitably collateral tissue damage and immediate induction of angiogenesis, in addition to the need of multiple treatments. In order to develop prospective photosensitizers for clinical use, a triphenyl phosphonium-modified cationic liposomal hypocrellin B (TPP cationic LHB) for angiogenic targeting and endothelial internalization was constructed. With optimal PDT parameters, TPP cationic LHB can lead to death of choroid-retinal vascular endothelial cells while cause negligible damage to collateral retinal pigment epithelium cells. This is likely due to the mitochondria targeting and effective intracellular singlet oxygen generation of TPP cationic LHB in vascular endothelial cells. Additionally, in vivo chick chorioallantoic membrane assay indicated the elevated neovessel-targeting ability and photo-induced anti-angiogenic activity of TPP cationic LHB. Furthermore, TPP cationic LHB PDT is able to maintain neovessel occlusion for an extended period of time compared with verteporfin PDT, without inducing significant increased expression of some angiogenic factors, such as vascular endothelial growth factor and integrin alpha(v)beta(3). This study describes a facile strategy that may be useful for developing new-generation photosensitizers to circumvent the limitations of PDT treatment of exudative AMD.
C1 [Chen, Hongxia; Zou, Xianbiao] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 4, Dept Dermatol, Beijing 100037, Peoples R China.
   [Deng, Hong; Zhao, Jingquan] Chinese Acad Sci, Inst Chem, Key Lab Photochem, BNLMS, Beijing 100190, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese Academy of
   Sciences; Institute of Chemistry, CAS
RP Zou, XB (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Med Ctr 4, Dept Dermatol, Beijing 100037, Peoples R China.; Deng, H (通讯作者)，Chinese Acad Sci, Inst Chem, Key Lab Photochem, BNLMS, Beijing 100190, Peoples R China.
EM denghong010@iccas.ac.cn; xbz@126.com
FU National Natural Science Foundation of China [61308117, 21303223]
FX This work was financially supported by the National Natural Science
   Foundation of China [grant numbers 61308117, 21303223].
CR Ashkenazi A, 2015, J CLIN INVEST, V125, P487, DOI 10.1172/JCI80420
   Bhuvaneswari R, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-56
   Biswas S, 2012, J CONTROL RELEASE, V159, P393, DOI 10.1016/j.jconrel.2012.01.009
   BORN GVR, 1985, BRIT J EXP PATHOL, V66, P543
   Breukink MB, 2016, ACTA OPHTHALMOL, V94, P187, DOI 10.1111/aos.12938
   Chen HJ, 2016, THERANOSTICS, V6, P78, DOI 10.7150/thno.13242
   Dang L, 2007, AM J CHINESE MED, V35, P713, DOI 10.1142/S0192415X0700520X
   Dashnyam K, 2017, BIOMATERIALS, V116, P145, DOI 10.1016/j.biomaterials.2016.11.053
   Deng H, 2015, J INNOV OPT HEAL SCI, V8, DOI 10.1142/S1793545815300037
   Deng H, 2013, DYES PIGMENTS, V99, P930, DOI 10.1016/j.dyepig.2013.06.037
   Deng H, 2012, J MED CHEM, V55, P1910, DOI 10.1021/jm2017368
   Dicheva BM, 2013, NANO LETT, V13, P2324, DOI 10.1021/nl3014154
   Doyle J, 2018, INT J OPHTHALMOL-CHI, V11, P333, DOI 10.18240/ijo.2018.02.25
   Friedman JR, 2014, NATURE, V505, P335, DOI 10.1038/nature12985
   Gouras P, 2016, GRAEF ARCH CLIN EXP, V254, P1221, DOI 10.1007/s00417-016-3342-x
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hunter R.J., 2013, ZETA POTENTIAL COLLO
   Kaihong Z., 1989, CHINESE J ORG CHEM, V9, P252
   Karewicz A, 2013, COLLOID SURFACE B, V109, P307, DOI 10.1016/j.colsurfb.2013.03.059
   Kazerounian S, 2018, J CELL COMMUN SIGNAL, V12, P171, DOI 10.1007/s12079-017-0433-3
   Knoll JD, 2015, COORDIN CHEM REV, V282, P110, DOI 10.1016/j.ccr.2014.05.018
   Lange N, 2001, INVEST OPHTH VIS SCI, V42, P38
   Li TH, 2015, PHOTOCH PHOTOBIO SCI, V14, P972, DOI 10.1039/c4pp00412d
   Li WQ, 2017, ACS APPL MATER INTER, V9, P16794, DOI 10.1021/acsami.7b01540
   Lim SH, 2010, PHOTOCHEM PHOTOBIOL, V86, P397, DOI 10.1111/j.1751-1097.2009.00684.x
   Meszaros M, 2018, EUR J PHARM SCI, V123, P228, DOI 10.1016/j.ejps.2018.07.042
   Miyaji A, 2016, BIOCHEM BIOPH RES CO, V471, P450, DOI 10.1016/j.bbrc.2016.02.056
   Muchowicz A, 2017, EUR J CANCER, V83, P19, DOI 10.1016/j.ejca.2017.06.004
   Naeye B, 2013, BIOMATERIALS, V34, P2350, DOI 10.1016/j.biomaterials.2012.11.058
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Nowak-Sliwinska P, 2012, J CELL MOL MED, V16, P1553, DOI 10.1111/j.1582-4934.2011.01440.x
   Nowak-Sliwinska P, 2010, ANGIOGENESIS, V13, P281, DOI 10.1007/s10456-010-9185-x
   Pasha SPBS, 2018, J PHARMACOL EXP THER, V367, P108, DOI 10.1124/jpet.118.248088
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Ribatti D, 2016, MECH DEVELOP, V141, P70, DOI 10.1016/j.mod.2016.05.003
   Salomao GHA, 2018, BIOORG MED CHEM LETT, V28, P1870, DOI 10.1016/j.bmcl.2018.04.007
   Saraf S, 2016, CRIT REV THER DRUG, V33, P401, DOI 10.1615/CritRevTherDrugCarrierSyst.2016015926
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sun XL, 2017, THERANOSTICS, V7, P319, DOI 10.7150/thno.18078
   Tangutoori S, 2016, NANOMED-NANOTECHNOL, V12, P223, DOI 10.1016/j.nano.2015.08.007
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Varano M, 2014, OPHTHALMOLOGICA, V231, P204, DOI 10.1159/000357504
   Wainwright M, 2017, LANCET INFECT DIS, V17, pE49, DOI 10.1016/S1473-3099(16)30268-7
   Wang JD, 2013, J BIOMED NANOTECHNOL, V9, P1882, DOI 10.1166/jbn.2013.1691
   Weijer R, 2015, J PHOTOCH PHOTOBIO C, V23, P103, DOI 10.1016/j.jphotochemrev.2015.05.002
   Weiss A, 2012, BBA-REV CANCER, V1826, P53, DOI 10.1016/j.bbcan.2012.03.003
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Xavier LL, 2005, BRAIN RES PROTOC, V16, P58, DOI 10.1016/j.brainresprot.2005.10.002
   Xia YQ, 2016, BIOMATERIALS, V79, P56, DOI 10.1016/j.biomaterials.2015.11.056
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yu YM, 2018, J BIOMED NANOTECHNOL, V14, P1568, DOI 10.1166/jbn.2018.2609
   Zhang JY, 2017, APOPTOSIS, V22, P777, DOI 10.1007/s10495-017-1374-2
   Zhang Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep18398
   Zhao JQ, 2010, MINI-REV MED CHEM, V10, P332, DOI 10.2174/138955710791330963
   Zheng Z, 2018, ACS NANO, V12, P8145, DOI 10.1021/acsnano.8b03138
   Zhong YN, 2016, BIOMATERIALS, V84, P250, DOI 10.1016/j.biomaterials.2016.01.049
NR 59
TC 2
Z9 2
U1 0
U2 33
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD DEC
PY 2019
VL 15
IS 12
BP 2305
EP 2320
DI 10.1166/jbn.2019.2861
PG 16
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA JP1HS
UT WOS:000498023900002
PM 31748013
DA 2022-11-30
ER

PT J
AU Strafella, C
   Errichiello, V
   Caputo, V
   Aloe, G
   Ricci, F
   Cusumano, A
   Novelli, G
   Giardina, E
   Cascella, R
AF Strafella, Claudia
   Errichiello, Valeria
   Caputo, Valerio
   Aloe, Gianluca
   Ricci, Federico
   Cusumano, Andrea
   Novelli, Giuseppe
   Giardina, Emiliano
   Cascella, Raffaella
TI The Interplay between miRNA-Related Variants and Age-Related Macular
   Degeneration: EVIDENCE of Association of MIR146A and MIR27A
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE AMD; miRNAs; epigenetics; susceptibility; inflammation; choroidal
   neovascularization; neurodegeneration
ID SINGLE-NUCLEOTIDE POLYMORPHISM; PIGMENT EPITHELIAL-CELLS; PRECISION
   MEDICINE; MICRORNA-146A; MIR-146A; GENE; MIR-27A; ARMS2; RISK
AB The complex interplay among genetic, epigenetic, and environmental variables is the basis for the multifactorial origin of age-related macular degeneration (AMD). Previous results highlighted that single nucleotide polymorphisms (SNPs) of CFH, ARMS2, IL-8, TIMP3, SLC16A8, RAD51B, VEGFA, and COL8A1 were significantly associated with the risk of AMD in the Italian population. Given these data, this study aimed to investigate the impact of SNPs in genes coding for MIR146A, MIR31, MIR23A, MIR27A, MIR20A, and MIR150 on their susceptibility to AMD. Nine-hundred and seventy-six patients with exudative AMD and 1000 controls were subjected to an epigenotyping analysis through real-time PCR and direct sequencing. Biostatistical and bioinformatic analysis was performed to evaluate the association with susceptibility to AMD. These analyses reported that the SNPs rs11671784 (MIR27A, G/A) and rs2910164 (MIR146A, C/G) were significantly associated with AMD risk. Interestingly, the bioinformatic analysis showed that MIR27A and MIR146A take part in the angiogenic and inflammatory pathways underlying AMD etiopathogenesis. Thus, polymorphisms within the pre-miRNA sequences are likely to affect their functional activity, especially the interaction with specific targets. Therefore, our study represents a step forward in the comprehension of the mechanisms leading to AMD onset and progression, which certainly include the involvement of epigenetic modifications.
C1 [Strafella, Claudia; Errichiello, Valeria; Caputo, Valerio; Giardina, Emiliano; Cascella, Raffaella] Santa Lucia Fdn, Mol Genet Lab UILDM, I-00142 Rome, Italy.
   [Strafella, Claudia; Novelli, Giuseppe; Giardina, Emiliano] Tor Vergata Univ, Dept Biomed & Prevent, I-00133 Rome, Italy.
   [Aloe, Gianluca; Ricci, Federico; Cusumano, Andrea] Tor Vergata Univ, UOSD Retinal Pathol PTV Fdn Policlin, I-00133 Rome, Italy.
   [Cascella, Raffaella] Catholic Univ Our Lady Good Counsel, Dept Biomed Sci, Tirana 1000, Albania.
C3 IRCCS Santa Lucia; University of Rome Tor Vergata; University of Rome
   Tor Vergata
RP Strafella, C (通讯作者)，Santa Lucia Fdn, Mol Genet Lab UILDM, I-00142 Rome, Italy.; Strafella, C (通讯作者)，Tor Vergata Univ, Dept Biomed & Prevent, I-00133 Rome, Italy.
EM claudia.strafella@gmail.com; valeriaerrichiello@hotmail.it;
   v.caputo91@gmail.com; gianluca.aloe@alice.it; rccfrc00@gmail.com;
   cusumano@tin.it; novelli@med.uniroma2.it; emiliano.giardina@uniroma2.it;
   raffaellacascella@virgilio.it
RI Giardina, Emiliano/J-1965-2012; Novelli, Giuseppe/T-8822-2019;
   Strafella, Claudia/AAA-5929-2019; ricci, federico/AAC-3836-2020;
   Cascella, Raffaella/G-9040-2019; Novelli, Giuseppe/A-5195-2013; Novelli,
   Giuseppe/GQB-3329-2022; Caputo, Valerio/AAB-6481-2019
OI Strafella, Claudia/0000-0003-1334-0920; ricci,
   federico/0000-0002-4224-9280; Cascella, Raffaella/0000-0002-2148-0758;
   Novelli, Giuseppe/0000-0002-7781-602X; Novelli,
   Giuseppe/0000-0002-7781-602X; Caputo, Valerio/0000-0002-3503-3318; Aloe,
   Gianluca/0000-0002-7624-1041
FU National Health Ministry (General Board of Medical Devices and of
   Pharmaceutical Service) [E83C17000920001]
FX This research was founded by the National Health Ministry (General Board
   of Medical Devices and of Pharmaceutical Service, grant number:
   E83C17000920001).
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Bailey JNC, 2014, GENES-BASEL, V5, P518, DOI 10.3390/genes5030518
   Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90
   Bhattacharya A, 2014, NUCLEIC ACIDS RES, V42, pD86, DOI 10.1093/nar/gkt1028
   Bhaumik D, 2009, AGING-US, V1, P402, DOI 10.18632/aging.100042
   Cascella R, 2018, EYE, V32, P446, DOI 10.1038/eye.2017.192
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Cascella R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/321291
   Chakraborti S., 2017, PROTEASES PHYSL PATH, P325
   Chatzikyriakidou A, 2010, SCAND J IMMUNOL, V71, P382, DOI 10.1111/j.1365-3083.2010.02381.x
   Chhabra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-232
   Cusumano Andrea, 2019, J Med Case Rep, V13, P5, DOI 10.1186/s13256-018-1935-1
   Ding XY, 2009, INVEST OPHTH VIS SCI, V50, P4957, DOI 10.1167/iovs.09-3381
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Giri M, 2017, BIOMED REP, V7, P105, DOI 10.3892/br.2017.927
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Kaidonis G, 2016, ACTA DIABETOL, V53, P643, DOI 10.1007/s00592-016-0850-4
   Kozomara A, 2019, NUCLEIC ACIDS RES, V47, pD155, DOI 10.1093/nar/gky1141
   Kutty RK, 2013, MOL VIS, V19, P737
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lepre T, 2011, AM J OPHTHALMOL, V152, P325, DOI 10.1016/j.ajo.2011.04.021
   Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-26
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Ramkaran P, 2014, CELL BIOCHEM BIOPHYS, V68, P259, DOI 10.1007/s12013-013-9704-7
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   SanGiovanni JP, 2017, CLIN CHEM LAB MED, V55, P763, DOI 10.1515/cclm-2016-0898
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Strafella C, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00701
   Sun QM, 2010, CANCER SCI, V101, P2241, DOI 10.1111/j.1349-7006.2010.01667.x
   Vallee A, 2017, LIFE SCI, V188, P123, DOI 10.1016/j.lfs.2017.09.008
   Van der Heide C.J., 2018, 23 BIENN M INT SOC E
   Yang Q, 2014, ONCOGENE, V33, P193, DOI 10.1038/onc.2012.569
   Zhang WG, 2014, J CELL MOL MED, V18, P2225, DOI 10.1111/jcmm.12359
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 42
TC 13
Z9 13
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2019
VL 20
IS 7
AR 1578
DI 10.3390/ijms20071578
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HU4PM
UT WOS:000465258100009
PM 30934838
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Holz, FG
   Tadayoni, R
   Beatty, S
   Berger, A
   Cereda, MG
   Cortez, R
   Hoyng, CB
   Hykin, P
   Staurenghi, G
   Heldner, S
   Bogumil, T
   Heah, T
   Sivaprasad, S
AF Holz, Frank G.
   Tadayoni, Ramin
   Beatty, Stephen
   Berger, Alan
   Cereda, Matteo G.
   Cortez, Rafael
   Hoyng, Carel B.
   Hykin, Philip
   Staurenghi, Giovanni
   Heldner, Stephanie
   Bogumil, Timon
   Heah, Theresa
   Sivaprasad, Sobha
TI Multi-country real-life experience of anti-vascular endothelial growth
   factor therapy for wet age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; RANIBIZUMAB TREATMENT; VISUAL-ACUITY; EFFICACY;
   OUTCOMES; REGIMEN; SAFETY
AB Background/aims Real-life anti-vascular endothelial growth factor (VEGF) therapy use in patients with wet age-related macular degeneration (wAMD) was assessed in a retrospective, observational study in Canada, France, Germany, Ireland, Italy, the Netherlands, UK and Venezuela.
   Methods Medical records of patients with wAMD, who started ranibizumab treatment between 1 January 2009 and 31 August 2009, were evaluated. Data were collected until the end of treatment and/or monitoring or until 31 August 2011.
   Results 2227 patients who received >= 1 anti-VEGF injection with a baseline visual acuity assessment and >= 1 postbaseline visual acuity assessment for the treated eye were evaluated. Visual acuity improved until about day 120; thereafter, visual acuity gains were not maintained. Mean change in visual acuity score from baseline to years 1 and 2 was +2.4 and +0.6 letters, respectively. Patients received a mean of 5.0 and 2.2 injections in the first and second year, respectively. There were substantial differences in visual outcomes and injection frequency between countries. More frequent visits and injections were associated with greater improvements in visual acuity.
   Conclusions In clinical practice, fewer injections are administered than in clinical trials. Anti-VEGF treatment resulted in an initial improvement in visual acuity; however, this was not maintained over time.
C1 [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Tadayoni, Ramin] Univ Paris 07, Hop Lariboisiere, AP HP, Dept Ophthalmol,Sorbonne Paris Cite, F-75221 Paris 05, France.
   [Beatty, Stephen] Inst Eye Surg, Dept Ophthalmol, Waterford, Ireland.
   [Berger, Alan] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Berger, Alan] St Michaels Hosp, Toronto, ON M5B 1W8, Canada.
   [Cereda, Matteo G.; Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Cortez, Rafael] Ctr Cirugia Oftalmol, Caracas, Venezuela.
   [Hoyng, Carel B.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Hykin, Philip; Sivaprasad, Sobha] Moorfields Eye Hosp, NIHR Biomed Ctr Res Ophthalmol, London, England.
   [Heldner, Stephanie] Bayer HealthCare Pharmaceut, Berlin, Germany.
   [Bogumil, Timon; Heah, Theresa] Bayer HealthCare Pharmaceut, Montville, NJ USA.
   [Sivaprasad, Sobha] Kings Coll Hosp London, London SE5 9RS, England.
C3 University of Bonn; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research
   Universities; Universite Paris Cite; University of Toronto; University
   of Toronto; University Toronto Affiliates; Saint Michaels Hospital
   Toronto; University of Milan; Luigi Sacco Hospital; Radboud University
   Nijmegen; University of London; University College London; Moorfields
   Eye Hospital NHS Foundation Trust; Bayer AG; Bayer Healthcare
   Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals; King's
   College Hospital NHS Foundation Trust; King's College Hospital
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Sivaprasad, S./D-6876-2015; Hoyng, C.B./H-8050-2014; Staurenghi,
   Giovanni/K-4388-2017
OI Sivaprasad, S./0000-0001-8952-0659; Staurenghi,
   Giovanni/0000-0002-2299-5251
FU Bayer HealthCare Pharmaceuticals AG, Leverkusen, Germany
FX The AURA study was funded by Bayer HealthCare Pharmaceuticals AG,
   Leverkusen, Germany. The funding organisation participated in the design
   and conduct of the study, analysis of the data and preparation of the
   manuscript.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], LUCENTIS RAN INJ
   [Anonymous], 2013, LUC SUMM PROD CHAR
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Finger RP, 2012, OPHTHALMOLOGE, V109, P474, DOI 10.1007/s00347-012-2554-7
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
NR 20
TC 373
Z9 390
U1 2
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2015
VL 99
IS 2
BP 220
EP 226
DI 10.1136/bjophthalmol-2014-305327
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ5UG
UT WOS:000348285500016
PM 25193672
OA Green Published, hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Liu, MM
   Chan, CC
   Tuo, JS
AF Liu, Melissa M.
   Chan, Chi-Chao
   Tuo, Jingsheng
TI Genetic mechanisms and age-related macular degeneration: common
   variants, rare variants, copy number variations, epigenetics, and
   mitochondrial genetics
SO HUMAN GENOMICS
LA English
DT Review
DE Age-related macular degeneration; Copy number variation; Genetics;
   Epigenetics; Mitochondria
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; S-TRANSFERASE M1; PIGMENT
   EPITHELIAL-CELLS; REAL-TIME PCR; DNA-DAMAGE; OXIDATIVE STRESS;
   HUMAN-DISEASE; POLYMORPHISM; RISK
AB Age-related macular degeneration (AMD) is a complex and multifaceted disease involving contributions from both genetic and environmental influences. Previous work exploring the genetic contributions of AMD has implicated numerous genomic regions and a variety of candidate genes as modulators of AMD susceptibility. Nevertheless, much of this work has revolved around single-nucleotide polymorphisms (SNPs), and it is apparent that a significant portion of the heritability of AMD cannot be explained through these mechanisms. In this review, we consider the role of common variants, rare variants, copy number variations, epigenetics, microRNAs, and mitochondrial genetics in AMD. Copy number variations in regulators of complement activation genes (CFHR1 and CFHR3) and glutathione S transferase genes (GSTM1 and GSTT1) have been associated with AMD, and several additional loci have been identified as regions of potential interest but require further evaluation. MicroRNA dysregulation has been linked to the retinal pigment epithelium degeneration in geographic atrophy, ocular neovascularization, and oxidative stress, all of which are hallmarks in the pathogenesis of AMD. Certain mitochondrial DNA haplogroups and SNPs in mitochondrially encoded NADH dehydrogenase genes have also been associated with AMD. The role of these additional mechanisms remains only partly understood, but the importance of their further investigation is clear to elucidate more completely the genetic basis of AMD.
C1 [Liu, Melissa M.; Chan, Chi-Chao; Tuo, Jingsheng] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Liu, Melissa M.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Johns Hopkins University
RP Tuo, J (通讯作者)，NEI, Immunol Lab, NIH, 10-10 N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM tuoj@nei.nih.gov
OI Tuo, Jingsheng/0000-0002-1372-7810
FU NEI NIH HHS [T32 EY007143] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [T32EY007143] Funding Source: NIH RePORTER
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1291, DOI 10.2741/3789
   Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003
   Brasch-Andersen C, 2004, HUM MUTAT, V24, P208, DOI 10.1002/humu.20074
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Centre for Applied Genomics, DAT GEN VAR
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cipriani V, HUM MOL GEN IN PRESS
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fanciulli M, 2010, CLIN GENET, V77, P201, DOI 10.1111/j.1399-0004.2009.01342.x
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Frova C, 2006, BIOMOL ENG, V23, P149, DOI 10.1016/j.bioeng.2006.05.020
   Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gredilla R, 2010, EXP GERONTOL, V45, P478, DOI 10.1016/j.exger.2010.01.017
   Green W R, 1999, Mol Vis, V5, P27
   Gu Wenli, 2008, Pathogenetics, V1, P4, DOI 10.1186/1755-8417-1-4
   Guven M, 2011, OPHTHALMIC RES, V46, P31, DOI 10.1159/000321940
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollox EJ, 2008, NAT GENET, V40, P23, DOI 10.1038/ng.2007.48
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu MM, 2011, INVEST OPHTH VIS SCI, V52, P3129, DOI 10.1167/iovs.10-6735
   Liu SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015778
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Lupski JR, 2005, PLOS GENET, V1, P627, DOI 10.1371/journal.pgen.0010049
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708
   Olson JH, 2011, SEMIN OPHTHALMOL, V26, P131, DOI 10.3109/08820538.2011.577131
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Ptacek T, 2008, CYTOGENET GENOME RES, V123, P142, DOI 10.1159/000184701
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rose-Zerilli MJ, 2009, CLIN CHEM, V55, P1680, DOI 10.1373/clinchem.2008.120105
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Sawitzke J, 2011, OPHTHALMOLOGY, V118, P2442, DOI 10.1016/j.ophtha.2011.05.027
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Wang AL, 2008, MOL VIS, V14, P644
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zhang F, 2009, ANNU REV GENOM HUM G, V10, P451, DOI 10.1146/annurev.genom.9.081307.164217
   Zhou J, 2010, INVEST OPHTH VIS SCI, V51, P3924, DOI 10.1167/iovs.10-5240
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 92
TC 55
Z9 55
U1 0
U2 24
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1473-9542
EI 1479-7364
J9 HUM GENOMICS
JI Hum. Genomics
PD AUG 31
PY 2012
VL 6
AR 13
DI 10.1186/1479-7364-6-13
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 121DK
UT WOS:000317222800001
PM 23244519
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Heier, JS
   Brown, DM
   Shah, SP
   Saroj, N
   Dang, S
   Waheed, NK
   Wykoff, CC
   Prenner, JL
   Boyer, DS
AF Heier, Jeffrey S.
   Brown, David M.
   Shah, Sumit P.
   Saroj, Namrata
   Dang, Sabin
   Waheed, Nadia K.
   Wykoff, Charles C.
   Prenner, Jonathan L.
   Boyer, David S.
TI Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against
   Conversion to Exudative Age-Related Macular Degeneration in High-risk
   Eyes A Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
AB Question Can intravitreal aflibercept injection (IAI) be used as a prophylactic treatment against conversion to exudative age-related macular degeneration (eAMD) in high-risk eyes? Findings In a randomized, single-masked clinical trial of 128 patients at high risk for eAMD, there was no difference in the proportion of eyes converting to eAMD between the IAI (6 patients [9.5%]) and sham (7 patients [10.9%]) groups at month 24. Patients with eAMD for longer than 2 years in their fellow eye at baseline showed a lower conversion rate in the study eye compared with those with eAMD for no longer than 2 years in the fellow eye. Meaning Although these findings do not support IAI as a prophylactic against conversion to eAMD, such prophylaxis is needed.
   This randomized clinical trial evaluates the use of intravitreal aflibercept as prophylaxis against conversion to exudative age-related macular degeneration (AMD) in patients with dry AMD and high risk for conversion.
   Importance Anti-vascular endothelial growth factor (VEGF) agents may provide a prophylactic effect in high-risk eyes with intermediate dry age-related macular degeneration (AMD) against conversion to exudative AMD (eAMD), lowering the risk of vision loss. Objective To evaluate intravitreal aflibercept injection (IAI) as prophylaxis against the conversion to eAMD in high-risk eyes at 24 months. Design, Setting, and Participants This single-masked, sham-controlled, randomized clinical trial performed at 4 US clinical sites enrolled patients with intermediate AMD in 1 eye (study eye), defined as presence of more than 10 medium drusen (>= 63 to <125 mu m), at least 1 large druse (>= 125 mu m), and/or retinal pigmentary changes, and eAMD in the fellow eye. Patients were treated from June 23, 2015, to March 13, 2019. Interventions Intravitreal aflibercept injection (2 mg) or sham quarterly injection for 24 months (1:1 randomization). Main Outcomes and Measures The primary end point was the proportion of patients with conversion to eAMD at month 24 characterized by development of choroidal neovascularization, as assessed by leakage on fluorescein angiography and fluid on spectral-domain optical coherence tomography by an independent masked reading center. Results Of 128 patients enrolled, 127 (63 in the IAI group and 64 in the sham group) were included in the primary analysis (68 men [53.5%]; mean [SD] age, 76.5 [8.1] years). Baseline demographic and clinical characteristics were balanced between the groups. By month 24, 6 patients (9.5%) in the IAI group and 7 (10.9%) in the sham group developed eAMD (P = .98). Patients with a history of eAMD for longer than 2 years in their fellow eye at baseline showed a lower rate of conversion to eAMD in the study eye compared with those with a history of eAMD for 2 years or less in the fellow eye. Safety was consistent with previous studies involving intravitreal anti-VEGF injections. Conclusions and Relevance In this evaluation of quarterly anti-VEGF exposure as prophylaxis to reduce conversion of eyes with high-risk dry AMD to eAMD, the rates of conversion were not lower in the IAI group compared with the sham treatment group at month 24. Understanding the mechanism of conversion to eAMD and therapies that could prevent this event remains an important unmet need.
C1 [Heier, Jeffrey S.] Ophthalm Consultants Boston, 50 Staniford St,Ste 600, Boston, MA 02114 USA.
   [Brown, David M.] Retina Consultants Houston, Houston, TX USA.
   [Shah, Sumit P.] New Jersey Retina, New Brunswick, NJ USA.
   [Saroj, Namrata] All Eyes Consulting LLC, New York, NY USA.
   [Dang, Sabin] Retina Inst, St Louis, MO USA.
   [Waheed, Nadia K.] Tufts Med Ctr, Boston Image Reading Ctr, Boston, MA 02111 USA.
   [Wykoff, Charles C.] Houston Methodist Hosp, Weill Cornell Med Coll, Blanton Eye Inst, Retina Consultants Amer,Retina Consultants Housto, Houston, TX 77030 USA.
   [Prenner, Jonathan L.] Rutgers Robert Wood Johnson Med Sch, Dept Ophthalmol, New Brunswick, NJ USA.
   [Boyer, David S.] Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
C3 Ophthalmic Consultants of Boston; Tufts Medical Center; Cornell
   University; The Methodist Hospital System; The Methodist Hospital -
   Houston; Rutgers State University New Brunswick; Rutgers State
   University Medical Center; Retina Vitreous Associates Medical Group
RP Heier, JS (通讯作者)，Ophthalm Consultants Boston, 50 Staniford St,Ste 600, Boston, MA 02114 USA.
EM jsheier@eyeboston.com
FU Regeneron Pharmaceuticals, Inc.
FX This study was supported by Regeneron Pharmaceuticals, Inc.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bailey ST, 2019, OPHTHALMOL RETINA, V3, P629, DOI 10.1016/j.oret.2019.03.008
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Heiferman MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217805
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lujan BJZL., 2012, 2012 JOINT M AM AC O
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Parikh R, 2019, JAMA OPHTHALMOL, V137, P914, DOI 10.1001/jamaophthalmol.2019.1947
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
   Yang J, 2019, AM J OPHTHALMOL, V208, P1, DOI 10.1016/j.ajo.2019.06.017
NR 12
TC 6
Z9 7
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2021
VL 139
IS 5
BP 542
EP 547
DI 10.1001/jamaophthalmol.2021.0221
EA MAR 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SF2VX
UT WOS:000630525200003
PM 33734306
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ng, TK
   Chen, LJ
   Liu, DTL
   Tam, POS
   Chan, WM
   Liu, K
   Hu, YJ
   Chong, KKL
   Lau, CSL
   Chiang, SWY
   Lam, DSC
   Pang, CP
AF Ng, Tsz Kin
   Chen, Li Jia
   Liu, David T. L.
   Tam, Pancy O. S.
   Chan, Wai Man
   Liu, Ke
   Hu, Yi Jun
   Chong, Kelvin K. L.
   Lau, Charles S. L.
   Chiang, Sylvia W. Y.
   Lam, Dennis S. C.
   Pang, Chi Pui
TI Multiple gene polymorphisms in the complement factor H gene are
   associated with exudative age-related macular degeneration in chinese
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID HTRA1 PROMOTER POLYMORPHISM; JAPANESE POPULATION; GEOGRAPHIC ATROPHY;
   VARIANT; RISK; Y402H; SUSCEPTIBILITY; CFH; INCREASES; HAPLOTYPE
AB PURPOSE. Variants in the complement factor H (CFH) gene have been shown to be strongly associated with age-related macular degeneration (AMD). In this study, sequence alterations in CFH were investigated in 163 Chinese patients with exudative AMD and 155 unrelated Chinese control subjects.
   METHODS. All the 22 CFH exons, intron-exon boundaries, and promoter sequences were screened by polymerase chain reaction and DNA sequencing.
   RESULTS. Fifty-eight sequence changes, 42 of them novel, were identified. Six SNPs with an allele frequency >30% were significantly associated with exudative AMD. SNP rs3753396 was novel; the rest had been reported: rs3753394, rs551397, rs800292, rs2274700, and rs1329428. Two haplotype blocks were constructed. The TG haplotype for rs551397 and rs800292 was the major haplotype that conferred a significantly increased susceptibility to exudative AMD (P(corr) = 0.0001, OR = 1.91, 95% CI = 1.36-2.68).
   CONCLUSIONS. The findings support prior evidence that the CFH gene is one of the AMD-associated genes. There is a different distribution pattern of CFH variants in the Chinese compared with other populations. Individual SNP and haplotype analyses revealed that the ancient alleles at the 5' end of CFH contribute to an increased susceptibility to exudative AMD.
C1 [Ng, Tsz Kin; Chen, Li Jia; Liu, David T. L.; Tam, Pancy O. S.; Chan, Wai Man; Liu, Ke; Hu, Yi Jun; Chong, Kelvin K. L.; Lau, Charles S. L.; Chiang, Sylvia W. Y.; Lam, Dennis S. C.; Pang, Chi Pui] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
   [Hu, Yi Jun] Shantou Univ Med Coll, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
C3 Chinese University of Hong Kong
RP Pang, CP (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM pang@cuhk.edu.hk
RI Hu, Yijun/J-4044-2016; Ng, Tsz Kin/I-8061-2014; Chong, Kelvin
   Kam-Lung/K-4929-2016; Pang, Chi P/I-5388-2014; Lam,
   Dennis/AAL-1211-2020; Chen, Li Jia/I-5078-2014
OI Ng, Tsz Kin/0000-0001-7863-7229; Chen, Li Jia/0000-0003-3500-5840;
   CHONG, Kelvin Kam-lung/0000-0003-2587-1323
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bylsma Guy W, 2005, Clin Exp Optom, V88, P322
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen LJ, 2006, MOL VIS, V12, P1536
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2007, BRIT J OPHTHALMOL, V91, P966, DOI 10.1136/bjo.2007.114090
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Xu L, 2006, OPHTHALMOLOGY, V113, pe1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 39
TC 71
Z9 76
U1 3
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2008
VL 49
IS 8
BP 3312
EP 3317
DI 10.1167/iovs.07-1517
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 330NW
UT WOS:000257951100008
PM 18421087
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Harsch, S
   Brandl, C
   Kiel, C
   Nurnberg, P
   Toliat, MR
   Fleckenstein, M
   Pfau, M
   Schmitz-Valckenberg, S
   Holz, FG
   Chew, EY
   Swaroop, A
   Ratnapriya, R
   Klein, ML
   Mulyukov, Z
   Zamiri, P
   Weber, BHF
AF Grassmann, Felix
   Harsch, Sebastian
   Brandl, Caroline
   Kiel, Christina
   Nuernberg, Peter
   Toliat, Mohammad R.
   Fleckenstein, Monika
   Pfau, Maximilian
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   Chew, Emily Y.
   Swaroop, Anand
   Ratnapriya, Rinki
   Klein, Michael L.
   Mulyukov, Zufar
   Zamiri, Parisa
   Weber, Bernhard H. F.
TI Assessment of Novel Genome-Wide Significant Gene Loci and Lesion Growth
   in Geographic Atrophy Secondary to Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID NATURAL-HISTORY; EYE DISEASE; ASSOCIATION; EXPRESSION; DISCOVERY;
   DATABASE; RARE; AREA
AB Importance
   Age-related macular degeneration (AMD) is a common threat to vision loss in individuals older than 50 years. While neovascular complications in AMD are treatable, there is currently no therapy for geographic atrophy secondary to AMD. Geographic atrophy lesion progression over time shows considerable interindividual variability, but little is known about prognostic factors.
   Objective
   To elucidate the contribution of common genetic variants to geographic atrophy lesion growth.
   Design, Setting, and Participants
   This pooled analysis combined 4 independent studies: the Fundus Autofluorescence Imaging in Age-Related Macular Degeneration (FAM) study, the Directional Spread in Geographic Atrophy (DSGA) study, the Age-Related Eye Disease Study (AREDS), and the Geographic Atrophy Treatment Evaluation (GATE) study. Each provided data for geographic atrophy lesion growth in specific designs. Patients with geographic atrophy secondary to AMD were recruited to these studies. Genotypes were retrieved through the database of Genotypes and Phenotypes (for AREDS) or generated at the Cologne Center for Genomics (for FAM, DSGA, and GATE).
   Main Outcomes
   The correlation between square root-transformed geographic atrophy growth rate and 7596219 genetic variants passing quality control was estimated using linear regression. The calculations were adjusted for known factors influencing geographic atrophy growth, such as the presence of bilateral geographic atrophy as well as the number of lesion spots and follow-up times.
   Main Outcomes and Measures
   Slopes per allele, 95% CIs, and P values of genetic variants correlated with geographic atrophy lesion growth.
   Results
   A total of 935 patients (mean [SD] age, 74.7 [7.8] years; 547 female participants [59.0%]) were included. Two gene loci with conservative genome-wide significance were identified. Each minor allele of the genome-wide associated variants increased the geographic atrophy growth rate by a mean of about 15% or 0.05 mm per year. Gene prioritization within each locus suggests the protein arginine methyltransferase 6 gene (PRMT6; chromosome 1; slope, 0.046 [95% CI, 0.026-0.066]; P=4.09x10(-8)) and the lanosterol synthase gene (LSS; chromosome 21; slope, 0.105 [95% CI, 0.068-0.143]; P=4.07x10(-7)) as the most likely progression-associated genes.
   Conclusions and Relevance
   These data provide further insight into the genetic architecture of geographic atrophy lesion growth. Geographic atrophy is a clinical outcome with a high medical need for effective therapy. The genes PRMT6 and LSS are promising candidates for future studies aimed at understanding functional aspects of geographic atrophy progression and also for designing novel and targeted treatment options.
C1 [Grassmann, Felix; Harsch, Sebastian; Brandl, Caroline; Kiel, Christina; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
   [Grassmann, Felix] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [Brandl, Caroline] Univ Klinikum Regensburg, Klin & Poliklin Augenheilkunde, Regensburg, Germany.
   [Nuernberg, Peter; Toliat, Mohammad R.] Univ Cologne, Cologne Ctr Genom, Cologne, Germany.
   [Nuernberg, Peter] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany.
   [Fleckenstein, Monika; Pfau, Maximilian; Schmitz-Valckenberg, Steffen; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, Clin Trials Branch, NIH, Bethesda, MD 20892 USA.
   [Swaroop, Anand; Ratnapriya, Rinki] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Mulyukov, Zufar] Novartis Pharmaceut Inc, Basel, Switzerland.
   [Zamiri, Parisa] Novartis Pharmaceut Inc, Cambridge, MA USA.
C3 University of Regensburg; Karolinska Institutet; University of
   Regensburg; University of Cologne; University of Cologne; University of
   Bonn; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); Oregon Health & Science University; Novartis;
   Novartis
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
OI Kiel, Christina/0000-0003-3154-4847; Grassmann,
   Felix/0000-0003-1390-7528; Brandl, Caroline/0000-0001-8223-6137;
   Ratnapriya, Rinki/0000-0002-0469-4631
FU National Eye Institute [N01-EY0-2127]; Alcon, a Novartis company; German
   Research Foundation (Deutsche Forschungsgemeinschaft) [SPP 1088,
   FL-658/4-1, FL-658/4-2]; institutional funds of the Institute of Human
   Genetics, Regensburg [77]; Academy of Sciences Leopoldina [LPSD2018-06];
   NATIONAL EYE INSTITUTE [ZIAEY000546, ZIAEY000489] Funding Source: NIH
   RePORTER
FX Funding for the Age-Related Eye Disease Study was provided by the
   National Eye Institute (grant N01-EY0-2127). The Geographic Atrophy
   Treatment Evaluation study was supported by Alcon, a Novartis company.
   Funding support for the Fundus Autofluorescence Imaging in Age-Related
   Macular Degeneration study (grant SPP 1088) and Directional Spread in
   Geographic Atrophy study (grants FL-658/4-1 and FL-658/4-2) was provided
   by the German Research Foundation (Deutsche Forschungsgemeinschaft). The
   genome-wide association study analysis was financially supported by
   institutional funds of the Institute of Human Genetics, Regensburg
   (Titel 77). Dr Grassmann is a Leopoldina Postdoctoral Fellow (grant
   LPSD2018-06) funded by the Academy of Sciences Leopoldina.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   [Anonymous], 2015, SAMTOOLS BCFTOOLS
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   [Anonymous], 2014, QCTOOL V2 TOOL QUALI
   Aulchenko YS, 2007, BIOINFORMATICS, V23, P1294, DOI 10.1093/bioinformatics/btm108
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Benjamini Y, 2001, ANN STAT, V29, P1165
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Dickinson ME, 2016, NATURE, V537, P508, DOI 10.1038/nature19356
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkx1132, 10.1093/nar/gkz1031]
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Flutre T, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003486
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Goh L, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-415
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grassmann F, 2015, ANNU REV VIS SCI, V1, P73, DOI 10.1146/annurev-vision-082114-035609
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Heier JS, 2017, AM AC OPHTH ANN M NO
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Kitsios GD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013782
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Lamparter D, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004714
   Lee S, 2013, SKAT SNP SET SEQUENC
   Li JQ, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/1425707
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Machiela MJ, 2018, BIOINFORMATICS, V34, P887, DOI 10.1093/bioinformatics/btx561
   Maller JB, 2012, NAT GENET, V44, P1294, DOI 10.1038/ng.2435
   Neault M, 2012, NUCLEIC ACIDS RES, V40, P9513, DOI 10.1093/nar/gks764
   O'Connell J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004234
   Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095
   Reimand J, 2016, NUCLEIC ACIDS RES, V44, pW83, DOI 10.1093/nar/gkw199
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Tasman W, 2006, DUANES OPHTHALMOLOGY, P614
   Thavikulwat AT, 2017, OPHTHALMOL RETINA, V1, P34, DOI 10.1016/j.oret.2016.09.005
   Tryka KA, 2014, NUCLEIC ACIDS RES, V42, pD975, DOI 10.1093/nar/gkt1211
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Zhan XW, 2016, BIOINFORMATICS, V32, P1423, DOI 10.1093/bioinformatics/btw079
   Zheng J, 2017, BIOINFORMATICS, V33, P272, DOI 10.1093/bioinformatics/btw613
NR 52
TC 14
Z9 14
U1 1
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2019
VL 137
IS 8
BP 867
EP 876
DI 10.1001/jamaophthalmol.2019.1318
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IP8JE
UT WOS:000480291900001
PM 31120506
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Pawlowska, E
   Szczepanska, J
   Kaarniranta, K
AF Blasiak, Janusz
   Pawlowska, Elzbieta
   Szczepanska, Joanna
   Kaarniranta, Kai
TI Interplay between Autophagy and the Ubiquitin-Proteasome System and Its
   Role in the Pathogenesis of Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; autophagy; mitophagy;
   ubiquitin-proteasome system; cellular waste elimination; proteostasis
ID RETINAL-PIGMENT EPITHELIUM; ENDOPLASMIC-RETICULUM STRESS;
   PROTEIN-HOMOLOGOUS PROTEIN; FREE-RADICAL THEORY; OXIDATIVE-STRESS;
   CIGARETTE-SMOKE; CONJUGATING ENZYMES; SEQUESTOSOME 1/P62; RPE;
   DEGRADATION
AB Age-related macular degeneration (AMD) is a complex eye disease with many pathogenesis factors, including defective cellular waste management in retinal pigment epithelium (RPE). Main cellular waste in AMD are: all-trans retinal, drusen and lipofuscin, containing unfolded, damaged and unneeded proteins, which are degraded and recycled in RPE cells by two main machineries-the ubiquitin-proteasome system (UPS) and autophagy. Recent findings show that these systems can act together with a significant role of the EI24 (etoposide-induced protein 2.4 homolog) ubiquitin ligase in their action. On the other hand, E3 ligases are essential in both systems, but E3 is degraded by autophagy. The interplay between UPS and autophagy was targeted in several diseases, including Alzheimer disease. Therefore, cellular waste clearing in AMD should be considered in the context of such interplay rather than either of these systems singly. Aging and oxidative stress, two major AMD risk factors, reduce both UPS and autophagy. In conclusion, molecular mechanisms of UPS and autophagy can be considered as a target in AMD prevention and therapeutic perspective. Further work is needed to identify molecules and effects important for the coordination of action of these two cellular waste management systems.
C1 [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, PL-92216 Lodz, Poland.
   [Szczepanska, Joanna] Med Univ Lodz, Dept Pediat Dent, PL-92216 Lodz, Poland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
C3 University of Lodz; Medical University Lodz; Medical University Lodz;
   University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.; Kaarniranta, K (通讯作者)，Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
EM janusz.blasiak@biol.uni.lodz.pl; elzbieta.pawlowska@umed.lodz.pl;
   joanna.szczepanska@umed.lodz.pl; kai.kaarniranta@kuh.fi
OI Blasiak, Janusz/0000-0001-9539-9584; Szczepanska,
   JOANNA/0000-0001-9912-5345; Pawlowska, Elzbieta/0000-0002-5373-4783
FU National Science Centre, Poland [2017/27/B/NZ3/00872]
FX This work was supported by National Science Centre, Poland grant number
   2017/27/B/NZ3/00872.
CR Ando Ryo, 2014, Invest Ophthalmol Vis Sci, V55, P4682, DOI 10.1167/iovs.13-13272
   Asai M, 2009, J MOL CELL CARDIOL, V46, P452, DOI 10.1016/j.yjmcc.2008.11.001
   Baek A, 2017, AUTOPHAGY, V13, P248, DOI 10.1080/15548627.2016.1256932
   Baixauli F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00403
   Baranov Vladislav S, 2017, Curr Aging Sci, V10, P6
   Bazi Ali, 2016, Iranian Biomedical Journal, V20, P63, DOI 10.7508/ibj.2016.01.009
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benavides SH, 2002, ARCH GERONTOL GERIAT, V34, P219, DOI 10.1016/S0167-4943(01)00223-0
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Bulteau AL, 2001, J BIOL CHEM, V276, P45662, DOI 10.1074/jbc.M105374200
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Cherra SJ, 2010, NEUROPATH APPL NEURO, V36, P125, DOI [10.1111/j.1365-2990.2010.01062.x, 10.1111/j.1365-2990.2009.01062.x]
   Choi CH, 2012, BIOCHEM BIOPH RES CO, V418, P759, DOI 10.1016/j.bbrc.2012.01.095
   Chondrogianni N, 2010, ADV EXP MED BIOL, V694, P38
   Crowe E, 2009, MECH AGEING DEV, V130, P793, DOI 10.1016/j.mad.2009.10.005
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Daugaard M, 2007, FEBS LETT, V581, P3702, DOI [10.1016/j.febslet.2007.05.039, 10.1016/j.febsiet.2007.05.039]
   de Carvalho JER, 2018, BIOCHEM BIOPHYS REP, V13, P83, DOI 10.1016/j.bbrep.2018.01.005
   Di Rita A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05722-3
   Ding QX, 2006, FASEB J, V20, P1055, DOI 10.1096/fj.05-5495com
   Ding QX, 2006, ANTIOXID REDOX SIGN, V8, P163, DOI 10.1089/ars.2006.8.163
   Ding W, 2008, P NATL ACAD SCI USA, V105, P13433, DOI 10.1073/pnas.0806298105
   Ding WX, 2008, AUTOPHAGY, V4, P141, DOI 10.4161/auto.5190
   Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119
   Diot A, 2016, MAMM GENOME, V27, P381, DOI 10.1007/s00335-016-9651-x
   Djakovic SN, 2009, J BIOL CHEM, V284, P26655, DOI 10.1074/jbc.M109.021956
   Elshelmani H, 2017, METHODS MOL BIOL, V1509, P93, DOI 10.1007/978-1-4939-6524-3_10
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feng YJ, 2018, BIOCHEM BIOPH RES CO, V496, P1148, DOI 10.1016/j.bbrc.2018.01.159
   Ferrington DA, 2005, FASEB J, V19, P664, DOI 10.1096/fj.04-2578fje
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Gal J, 2009, J NEUROCHEM, V111, P1062, DOI 10.1111/j.1471-4159.2009.06388.x
   Gao J, 2016, AUTOPHAGY, V12, P632, DOI 10.1080/15548627.2016.1147667
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Gidalevitz T, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a009704
   Gladyshev VN, 2014, ANTIOXID REDOX SIGN, V20, P727, DOI 10.1089/ars.2013.5228
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Goloubinoff P, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14306
   Gouras P, 2016, GRAEF ARCH CLIN EXP, V254, P1221, DOI 10.1007/s00417-016-3342-x
   Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020
   Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064
   Harnett MM, 2017, BIOMED J, V40, P9, DOI 10.1016/j.bj.2016.12.004
   He YL, 2018, J CELL BIOL, V217, P315, DOI 10.1083/jcb.201701049
   He Yuan, 2010, J Ocul Biol Dis Infor, V3, P92, DOI 10.1007/s12177-011-9061-y
   He Y, 2010, ADV EXP MED BIOL, V664, P165, DOI 10.1007/978-1-4419-1399-9_20
   Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6
   Hohn A, 2011, FREE RADICAL BIO MED, V50, P585, DOI 10.1016/j.freeradbiomed.2010.12.011
   Hohn A, 2010, FREE RADICAL BIO MED, V48, P1100, DOI 10.1016/j.freeradbiomed.2010.01.030
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Hong M, 2004, J CELL BIOCHEM, V92, P723, DOI 10.1002/jcb.20118
   Hong M, 2004, J BIOL CHEM, V279, P11354, DOI 10.1074/jbc.M309804200
   Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x
   Huang CX, 2015, J BIOL CHEM, V290, P5367, DOI 10.1074/jbc.M114.603738
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Hwang JW, 2018, TRENDS BIOCHEM SCI, V43, P593, DOI 10.1016/j.tibs.2018.06.005
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218
   JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Keil E, 2013, CELL DEATH DIFFER, V20, P321, DOI 10.1038/cdd.2012.129
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Klein R, 2015, J CLIN MED, V4, P425, DOI 10.3390/jcm4030425
   Klingeborn M, 2018, ADV EXP MED BIOL, V1074, P539, DOI 10.1007/978-3-319-75402-4_65
   Klionsky DJ, 2008, AUTOPHAGY, V4, P740, DOI 10.4161/auto.6398
   Konig J, 2017, REDOX BIOL, V11, P673, DOI 10.1016/j.redox.2017.01.017
   Kondapalli C, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120080
   Korovila I, 2017, REDOX BIOL, V13, P550, DOI 10.1016/j.redox.2017.07.008
   Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002
   Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793
   Lee SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.266
   Li X, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01272-2
   Lim J, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004987
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Liu QS, 2006, CELL, V127, P1223, DOI 10.1016/j.cell.2006.10.037
   Liu Y, 2014, GERIATR GERONTOL INT, V14, P740, DOI 10.1111/ggi.12296
   Liu ZZ, 2014, ADV EXP MED BIOL, V801, P237, DOI 10.1007/978-1-4614-3209-8_31
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Marchesi N, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4956080
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   Matsumoto G, 2011, MOL CELL, V44, P279, DOI 10.1016/j.molcel.2011.07.039
   Mattern MR, 2012, BBA-MOL CELL RES, V1823, P2014, DOI 10.1016/j.bbamcr.2012.05.005
   Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6
   McCaffrey K, 2016, ESSAYS BIOCHEM, V60, P227, DOI 10.1042/EBC20160003
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Myeku N, 2011, J BIOL CHEM, V286, P22426, DOI 10.1074/jbc.M110.149252
   Nam T, 2017, MOL CELLS, V40, P897, DOI 10.14348/molcells.2017.0226
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Orellana-Rios J, 2018, OSLI RETINA, V49, pS34, DOI 10.3928/23258160-20180814-06
   Pandey UB, 2007, AUTOPHAGY, V3, P643, DOI 10.4161/auto.5050
   Perusek L, 2013, NUTRIENTS, V5, P2646, DOI 10.3390/nu5072646
   Pickering AM, 2010, BIOCHEM J, V432, P585, DOI 10.1042/BJ20100878
   Qin TY, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5392432
   Rashed MH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030538
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Ruan HB, 2017, GENE DEV, V31, P1655, DOI 10.1101/gad.305441.117
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Saadat KASM, 2014, FEBS OPEN BIO, V4, P1007, DOI 10.1016/j.fob.2014.11.003
   Schilders G, 2006, INT REV CYTOL, V251, P159, DOI 10.1016/S0074-7696(06)51005-8
   Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004
   Shiba-Fukushima K, 2012, SCI REP-UK, V2, DOI 10.1038/srep01002
   Song CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171940
   Subrizi A, 2015, PHARM RES-DORDR, V32, P211, DOI 10.1007/s11095-014-1456-6
   Tagawa Y, 2008, FREE RADICAL BIO MED, V45, P50, DOI 10.1016/j.freeradbiomed.2008.03.003
   Tagawa Y, 2011, TOXICOLOGY, V287, P105, DOI 10.1016/j.tox.2011.06.005
   Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013
   Tanaka K, 2009, P JPN ACAD B-PHYS, V85, P12, DOI [10.2183/pjab.85.12, 10.2183/pjab/85.12]
   Tang BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103364
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Tong Y, 2016, MED HYPOTHESES, V97, P98, DOI 10.1016/j.mehy.2016.10.027
   Tyedmers J, 2010, NAT REV MOL CELL BIO, V11, P777, DOI 10.1038/nrm2993
   van Rijt SH, 2012, AM J PHYSIOL-LUNG C, V303, pL814, DOI 10.1152/ajplung.00128.2012
   Vernace VA, 2007, FASEB J, V21, P2672, DOI 10.1096/fj.06-6751com
   Vernace VA, 2007, AGING CELL, V6, P599, DOI 10.1111/j.1474-9726.2007.00329.x
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viiri J, 2010, MOL VIS, V16, P1399
   vonZglinicki T, 1995, GERONTOLOGY, V41, P95
   Waizel M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0471-x
   Wang AL, 2008, MOL VIS, V14, P644
   Wang AL, 2010, NEUROBIOL AGING, V31, P2002, DOI 10.1016/j.neurobiolaging.2008.10.019
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang XR, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001232
   Warburton S, 2007, MOL VIS, V13, P318
   Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200
   Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yu B, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aag3315
   Zhan J, 2016, CURR MOL MED, V16, P487, DOI 10.2174/1566524016666160429121606
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang W, 2018, ACTA PHARMACOL SIN, V39, P1, DOI 10.1038/aps.2017.77
   Zhang Y, 2017, MOL VIS, V23, P228
   Zhao YG, 2012, J BIOL CHEM, V287, P42053, DOI 10.1074/jbc.M112.415968
   Zhou JH, 2006, P NATL ACAD SCI USA, V103, P14343, DOI 10.1073/pnas.0606480103
NR 151
TC 56
Z9 57
U1 3
U2 14
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN 1
PY 2019
VL 20
IS 1
AR 210
DI 10.3390/ijms20010210
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HM8RD
UT WOS:000459747700210
PM 30626110
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Jacobo, SMP
   DeAngelis, MM
   Kim, IK
   Kazlauskas, A
AF Jacobo, Sarah Melissa P.
   DeAngelis, Margaret M.
   Kim, Ivana K.
   Kazlauskas, Andrius
TI Age-Related Macular Degeneration-Associated Silent Polymorphisms in
   HtrA1 Impair Its Ability To Antagonize Insulin-Like Growth Factor 1
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; SERINE-PROTEASE HTRA1; MESSENGER-RNA; FACTOR-I;
   PULSE PROTEOLYSIS; ENDOTHELIAL-CELLS; EXPRESSION; GENE; BINDING;
   RECEPTOR
AB Synonymous single nucleotide polymorphisms (SNPs) within a transcript's coding region produce no change in the amino acid sequence of the protein product and are therefore intuitively assumed to have a neutral effect on protein function. We report that two common variants of high-temperature requirement A1 (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and Gly36 to less frequently used codons. The frequent-to-rare codon conversion reduced the mRNA translation rate and appeared to compromise HtrA1's conformation and function. The protein product generated from the SNP-containing cDNA displayed enhanced susceptibility to proteolysis and a reduced affinity for an anti-HtrA1 antibody. The NvAMD-associated synonymous polymorphisms lie within HtrA1's putative insulin-like growth factor 1 (IGF-1) binding domain. They reduced HtrA1's abilities to associate with IGF-1 and to ameliorate IGF-1-stimulated signaling events and cellular responses. These observations highlight the relevance of synonymous codon usage to protein function and implicate homeostatic protein quality control mechanisms that may go awry in NvAMD.
C1 [Jacobo, Sarah Melissa P.; Kazlauskas, Andrius] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA.
   [Jacobo, Sarah Melissa P.; Kazlauskas, Andrius] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [DeAngelis, Margaret M.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Kim, Ivana K.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Schepens Eye Research
   Institute; Harvard University; Massachusetts Eye & Ear Infirmary; Utah
   System of Higher Education; University of Utah; Harvard University;
   Harvard Medical School; Massachusetts Eye & Ear Infirmary
RP Kazlauskas, A (通讯作者)，Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA.
EM andrius_kazlauskas@meei.harvard.edu
RI DeAngelis, e/J-7863-2015
OI Kim, Ivana/0000-0003-0310-6129; Jacobo, Sarah
   Melissa/0000-0002-1341-7222
FU AMD Center for Excellence; Thome Memorial Foundation Bank of America; 
   [EY014458]; NATIONAL EYE INSTITUTE [R01EY014458, P30EY014800] Funding
   Source: NIH RePORTER
FX The AMD Center for Excellence provided support for this project, as did
   EY014458 and Thome Memorial Foundation Bank of America grants to M.M.D.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   BAR RS, 1988, AM J MED, V85, P59, DOI 10.1016/0002-9343(88)90398-1
   Bartoszewski RA, 2010, J BIOL CHEM, V285, P28741, DOI 10.1074/jbc.M110.154575
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bjorndahl M, 2005, P NATL ACAD SCI USA, V102, P15593, DOI 10.1073/pnas.0507865102
   Brest P, 2011, NAT GENET, V43, P242, DOI 10.1038/ng.762
   Cannarrozzi G, 2010, CELL, V141, P355, DOI 10.1016/j.cell.2010.02.036
   Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290
   CASCIERI MA, 1988, BIOCHEMISTRY-US, V27, P3229, DOI 10.1021/bi00409a016
   Chamary JV, 2009, SCI AM, V300, P46, DOI 10.1038/scientificamerican0609-46
   Chamary JV, 2006, NAT REV GENET, V7, P98, DOI 10.1038/nrg1770
   Cohen E, 2009, CELL, V139, P1157, DOI 10.1016/j.cell.2009.11.014
   De Luca A, 2004, J HISTOCHEM CYTOCHEM, V52, P1609, DOI 10.1369/jhc.4A6330.2004
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055
   Eigenbrot C, 2012, STRUCTURE, V20, P1040, DOI 10.1016/j.str.2012.03.021
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fowlkes JL, 1996, J BIOL CHEM, V271, P14676, DOI 10.1074/jbc.271.25.14676
   FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298
   Hou J, 2005, J CELL BIOCHEM, V94, P470, DOI 10.1002/jcb.20328
   Hou S, 2007, DEV CELL, V13, P226, DOI 10.1016/j.devcel.2007.07.001
   Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406
   Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761
   Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jiang J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046058
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0
   Kim MS, 2009, PROTEIN SCI, V18, P1051, DOI 10.1002/pro.115
   Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308
   Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905
   Komar AA, 1999, FEBS LETT, V462, P387, DOI 10.1016/S0014-5793(99)01566-5
   Kondo T, 2003, J CLIN INVEST, V111, P1835, DOI 10.1172/JCI200317455
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Lampson BL, 2013, CURR BIOL, V23, P70, DOI 10.1016/j.cub.2012.11.031
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lofqvist C, 2009, INVEST OPHTH VIS SCI, V50, P1831, DOI 10.1167/iovs.08-2903
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   Makeyev EV, 1996, FEBS LETT, V378, P166, DOI 10.1016/0014-5793(95)01438-1
   Mauney J, 2010, MATRIX BIOL, V29, P657, DOI 10.1016/j.matbio.2010.08.008
   Mendioroz M, 2010, NEUROLOGY, V75, P2033, DOI 10.1212/WNL.0b013e3181ff96ac
   Na YR, 2009, PROTEIN SCI, V18, P268, DOI 10.1002/pro.29
   Nackley AG, 2006, SCIENCE, V314, P1930, DOI 10.1126/science.1131262
   NAKAOHAYASHI J, 1992, ATHEROSCLEROSIS, V92, P141, DOI 10.1016/0021-9150(92)90273-J
   Nishimoto Y, 2011, NEUROLOGY, V76, P1353, DOI 10.1212/WNL.0b013e318215281d
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Park CW, 2005, NAT METHODS, V2, P207, DOI 10.1038/NMETH740
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ruberte J, 2004, J CLIN INVEST, V113, P1149, DOI 10.1172/JCI200419478
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Sauer T, 2008, EXPERT REV OPHTHALMO, V3, P29, DOI 10.1586/17469899.3.1.29
   SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P5125, DOI 10.1093/nar/14.13.5125
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Sitar T, 2006, P NATL ACAD SCI USA, V103, P13028, DOI 10.1073/pnas.0605652103
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tennstaedt A, 2012, J BIOL CHEM, V287, P20931, DOI 10.1074/jbc.M111.316232
   Tsuchiya A, 2005, BONE, V37, P323, DOI 10.1016/j.bone.2005.03.015
   Tuller T, 2010, CELL, V141, P344, DOI 10.1016/j.cell.2010.03.031
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180
   Zhang FL, 2010, SCIENCE, V329, P1534, DOI 10.1126/science.1191701
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
NR 80
TC 20
Z9 23
U1 1
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD MAY
PY 2013
VL 33
IS 10
BP 1976
EP 1990
DI 10.1128/MCB.01283-12
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 130ZN
UT WOS:000317959900009
PM 23478260
OA Green Published
DA 2022-11-30
ER

EF